U.S. patent application number 12/834707 was filed with the patent office on 2010-11-04 for binding constructs and methods for use thereof.
This patent application is currently assigned to TRUBION PHARMACEUTICALS, INC.. Invention is credited to MARTHA SUSAN HAYDEN-LEDBETTER, JEFFREY A. LEDBETTER, PETER AMSTRONG THOMPSON.
Application Number | 20100279932 12/834707 |
Document ID | / |
Family ID | 34193490 |
Filed Date | 2010-11-04 |
United States Patent
Application |
20100279932 |
Kind Code |
A1 |
LEDBETTER; JEFFREY A. ; et
al. |
November 4, 2010 |
BINDING CONSTRUCTS AND METHODS FOR USE THEREOF
Abstract
The invention relates to novel binding domain-immunoglobulin
fusion proteins that feature a binding domain for a cognate
structure such as an antigen, a counterreceptor or the like, a
wild-type IgG1, IGA or IgE hinge-acting region, i.e., IgE CH2,
region polypeptide or a mutant IgG1 hinge region polypeptide having
either zero, one or two cysteine residues, and immunoglobulin CH2
and CH3 domains, and that are capable of ADCC and/or CDC while
occurring predominantly as polypeptides that are compromised in
their ability to form disulfide-linked multimers. The fusion
proteins can be recombinantly produced at high expression levels.
Also provided are related compositions and methods, including cell
surface forms of the fusion proteins and immunotherapeutic
applications of the fusion proteins and of polynucleotides encoding
such fusion proteins.
Inventors: |
LEDBETTER; JEFFREY A.;
(SHORELINE, WA) ; HAYDEN-LEDBETTER; MARTHA SUSAN;
(SHORELINE, WA) ; THOMPSON; PETER AMSTRONG;
(BELLEVUE, WA) |
Correspondence
Address: |
SEED INTELLECTUAL PROPERTY LAW GROUP PLLC
701 FIFTH AVE, SUITE 5400
SEATTLE
WA
98104
US
|
Assignee: |
TRUBION PHARMACEUTICALS,
INC.
SEATTLE
WA
|
Family ID: |
34193490 |
Appl. No.: |
12/834707 |
Filed: |
July 12, 2010 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10566409 |
Aug 24, 2006 |
7754209 |
|
|
PCT/US03/41600 |
Dec 24, 2003 |
|
|
|
12834707 |
|
|
|
|
10627556 |
Jul 26, 2003 |
|
|
|
10566409 |
|
|
|
|
Current U.S.
Class: |
514/7.3 ;
514/13.2; 514/16.6; 514/17.9; 514/18.6; 514/19.6 |
Current CPC
Class: |
A61P 35/00 20180101;
C07K 2317/22 20130101; A61P 1/04 20180101; A61P 17/06 20180101;
C07K 16/2878 20130101; C07K 16/464 20130101; C07K 2317/732
20130101; C07K 2319/30 20130101; A61P 43/00 20180101; C07K 2317/64
20130101; C07K 2317/24 20130101; A61P 21/04 20180101; C07K 2319/00
20130101; C07K 16/462 20130101; A61P 7/04 20180101; A61K 2039/505
20130101; C07K 16/2809 20130101; A61P 19/02 20180101; C07K 16/2896
20130101; C07K 2317/56 20130101; A61P 25/00 20180101; C07K 2317/53
20130101; A61P 37/00 20180101; C07K 2317/622 20130101; A61P 3/10
20180101; C07K 2317/734 20130101; C07K 16/2818 20130101; A61P 35/02
20180101; A61P 29/00 20180101 |
Class at
Publication: |
514/7.3 ;
514/19.6; 514/16.6; 514/18.6; 514/17.9; 514/13.2 |
International
Class: |
A61K 38/17 20060101
A61K038/17; A61P 1/04 20060101 A61P001/04; A61P 3/10 20060101
A61P003/10; A61P 17/06 20060101 A61P017/06; A61P 19/02 20060101
A61P019/02; A61P 25/00 20060101 A61P025/00; A61P 35/02 20060101
A61P035/02 |
Claims
1.-413. (canceled)
414. A method of treating a B-cell disorder, comprising
administering to a patient a therapeutically effective amount of a
fusion protein that binds CD20 and comprises an amino acid sequence
as set forth in: SEQ ID NO:135 (2H7 scFv (CSS--S)H WCH2 WCH3),
wherein proline at position 283 is substituted with serine; SEQ ID
NO:137 (2H7 scFv (SCS--S)H WCH2 WCH3), wherein proline at position
283 is substituted with serine; SEQ ID NO:166 (2H7 scFv (CSC--S)H
WCH2 WCH3), wherein proline at position 283 is substituted with
serine; SEQ ID NO:372 (2H7 scFv VHL11S(CSS--S)H WCH2 WCH3); SEQ ID
NO:246 (2H7 scFv VH L11S(CSC--S)H WCH2 WCH3); SEQ ID NO:370 (2H7
scFv VH L11S(SSS--S)H WCH2 WCH3); SEQ ID NO:268 (2H7 scFv VH
L11S(CSS--S)H K322S CH2 WCH3); or SEQ ID NO:276 (2H7 scFv VH
L11S(CSS--S)H P331S CH2 WCH3).
415. The method of claim 414, wherein the B-cell disorder is a
B-cell lymphoma or chronic lymphocytic leukemia.
416. The method of claim 414, wherein the B-cell disorder is
selected from the group consisting of rheumatoid arthritis,
systemic lupus erythematosus, type I diabetes mellitus, multiple
sclerosis, immune thrombocytopenic purpura, psoriasis, inflammatory
bowel disease, Crohn's disease, and ulcerative colitis.
417. A method of treating a B-cell disorder, comprising
administering to a patient a therapeutically effective amount of a
fusion protein that binds CD20 and consists essentially of an amino
acid sequence as set forth in SEQ ID NO:135 (2H7 scFv (CSS--S)H
WCH2 WCH3) wherein proline at position 283 is substituted with
serine, SEQ ID NO:166 (2H7 scFv (CSC--S)H WCH2 WCH3) wherein
proline at position 283 is substituted with serine, SEQ ID NO:372
(2H7 scFv VHL11S(CSS--S)H WCH2 WCH3), or SEQ ID NO:246 (2H7 scFv VH
L11S(CSC--S)H WCH2 WCH3).
418. The method of claim 417, wherein the B-cell disorder is a
B-cell lymphoma or chronic lymphocytic leukemia.
419. The method of claim 417, wherein the B-cell disorder is
selected from the group consisting of rheumatoid arthritis,
systemic lupus erythematosus, type I diabetes mellitus, multiple
sclerosis, immune thrombocytopenic purpura, psoriasis, inflammatory
bowel disease, Crohn's disease, and ulcerative colitis.
420. A method of treating a B-cell disorder, comprising
administering to a patient a therapeutically effective amount of a
fusion protein that comprises from amino-terminus to
carboxy-terminus: (i) an scFv binding domain polypeptide that binds
CD20, wherein the scFv comprises amino acids 23-265 of SEQ ID
NO:246; (ii) an immunoglobulin hinge polypeptide consisting of
amino acids 269-283 as set forth in SEQ ID NO:246; and (iii) an
amino-terminally truncated immunoglobulin heavy chain constant
region polypeptide consisting of amino acids 284-500 as set forth
in SEQ ID NO:246.
421. The method of claim 420 wherein the B-cell disorder is a
B-cell lymphoma or chronic lymphocytic leukemia.
422. The method of claim 420 wherein the B-cell disorder is
selected from the group consisting of rheumatoid arthritis,
systemic lupus erythematosus, type I diabetes mellitus, multiple
sclerosis, immune thrombocytopenic purpura, psoriasis, inflammatory
bowel disease, Crohn's disease, and ulcerative colitis.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a divisional of U.S. patent application
Ser. No. 10/566,409, filed Aug. 24, 2006, now issued U.S. Pat. No.
7,754,209, which application is a national stage conversion of
PCT/US2003/041600, file Dec. 24, 2003, which is a
continuation-in-part of U.S. patent application Ser. No.
10/627,556, filed Jul. 26, 2003, which applications are
incorporated herein by reference in their entireties.
STATEMENT REGARDING SEQUENCE LISTING
[0002] The Sequence Listing associated with this application is
provided in text format in lieu of a paper copy, and is hereby
incorporated by reference into the specification. The name of the
text file containing the Sequence Listing is
910180.sub.--40102D1_SEQUENCE_LISTING.txt. The text file is 1304
KB, was created on Jul. 12, 2010, and is being submitted
electronically via EFS-Web.
FIELD OF THE INVENTION
[0003] The present invention relates generally to compounds having
various utilities including uses for research, diagnostics, and
therapy, for example, immunotherapy. Compounds of the invention
include immunologically active proteins and protein conjugates.
Such proteins include recombinant or engineered binding proteins
such as, for example, binding domain-immunoglobulin fusion
proteins, which may include single chain Fv-immunoglobulin fusion
proteins and compounds containing single chain Fv-immunoglobulins.
The present invention also relates to compositions and methods for
treating conditions, diseases and disorders that would improved,
eased, or lessened from the administration of, for example,
polypeptide and/or nucleic acid constructs of the invention,
including, for example, malignant conditions and B cell disorders,
including diseases characterized by autoantibody production and/or
inflammation.
BACKGROUND OF THE INVENTION
[0004] The immune system is one of the most complex of the body's
many intricate systems. A vast and complicated arrangement made up
of many different types of cells and involving many different kinds
of molecules, the human immune system allows the body to respond to
foreign invaders such as bacteria, viruses, and other infectious
agents, as well as foreign material such as pollen. In general, the
human immune system is divided into two main parts,
antibody-mediated immunity (also called "humoral" or "circulating"
immunity) and cell-mediated immunity, both of which are managed by
lymphocytes. Lymphocytes are one of the five kinds of white blood
cells (leukocytes) circulating in the blood. There are several
kinds of lymphocytes, each with different functions to perform. The
most common types of lymphocytes are B lymphocytes (B cells), which
are responsible for making antibodies, and T lymphocytes (T cells).
Cells of the immune system not only include T cells and B cells,
but also Natural Killer Cells, granulocytes (or polymorphonuclear
(PMN) leukocytes), macrophages, and dendritic cells. The humoral
system is managed by B cells with help from T cells and deals with
infectious agents in the blood and tissues of the body. The
cell-mediated system is managed by T cells and deals with cells of
the body that have been infected.
[0005] An antigen is a substance, usually macromolecular, that
stimulates or induces an immune response. Because of its complex
macromolecular structure, a single microorganism consists of
multiple antigens (e.g., surface structures such as cell wall
components, fimbriae, flagella, etc., or extracellular proteins,
such as toxins or enzymes produced by the microorganism). The coat
proteins and some of the envelope proteins of animal viruses are
also usually antigenic. A host is generally able to respond
specifically to antigens that come into contact with components of
its immune system. Both the antibody-mediated immunity and
cell-mediated immunity systems involve complex interrelationships
that allow them to mount immune reactions to almost any antigen. In
other words, the immune system is able to recognize foreign
substances (antigens) that stimulate the system to produce
antibody-mediated immunity, cell-mediated immunity, or both.
[0006] The immune system complex is constituted by a variety of
different cell types and organs disseminated throughout the body.
These include the primary and secondary lymphoid organs. The
primary lymphoid organs are the bone marrow and the thymus. All the
cells of the immune system are initially derived from the bone
marrow in a process called hematopoiesis. During hematopoiesis bone
marrow-derived stem cells differentiate into either mature cells of
the immune system ("B" cells) or into precursors of cells that
migrate out of the bone marrow to mature in the thymus ("T" cells).
In addition to red blood cells, platelets, and B cells, the bone
marrow also produces Natural Killer cells, granulocytes, and
immature thymocytes. The function of the thymus is to produce
mature T cells. Immature thymocytes, also known as prothymocytes,
leave the bone marrow and migrate into the thymus where they mature
and are then released into the bloodstream. The immune system
complex also includes secondary lymphoid organs, e.g., the spleen,
the lymph nodes, etc., as well as a circulatory system that is
separate from blood vessels.
[0007] The spleen, made up of B cells, T cells, macrophages,
dendritic cells, Natural Killer cells, and red blood cells, is an
immunologic filter of the blood. Migratory macrophages and
dendritic cells capture antigens from blood that passes through the
spleen. Migratory macrophages and dendritic cells also bring
antigens to the spleen via the bloodstream. An immune response is
initiated in the spleen when macrophages or dendritic cells present
the antigen to the appropriate B or T cells, and B cells become
activated and produce large amounts of antibody.
[0008] Lymphatic vessels and lymph nodes are the parts of a special
circulatory system that carries lymph. Lymph is a transparent fluid
containing white blood cells, chiefly lymphocytes. Lymph bathes the
tissues of the body, and is then collected in lymphatic vessels.
Lymph nodes dot a network of lymphatic vessels and, when afferent
lymph ducts bring lymph-containing antigens into the node, function
as an immunologic filter for lymph. Composed mostly of T cells, B
cells, dendritic cells, and macrophages, the lymph nodes drain
fluid from most tissues. Antigens are filtered out of the lymph in
the lymph node before the lymph is returned to the circulation.
Macrophages and dendritic cells that capture antigens also present
these foreign materials to T and B cells in the lymph nodes,
resulting in the stimulation of B cells to develop there into
antibody-secreting plasma cells. Antibodies leave the lymph node by
the efferent ducts that empty into the blood stream. Lymphocytes
can also leave the node by the efferent duct and travel to other
sites in the lymphatic system or enter into the blood circulation.
A single lymphocyte completes a circuit through the circulating
blood and lymphatic systems once every 24 hours.
[0009] Tonsils, adenoids, Peyer's patches, and the appendix are
also lymphoid tissues. Peyer's patches (masses of lymphocytes) are
similar to the tonsils and are found throughout the body,
especially in the mucous linings of the digestive and respiratory
tracts. It is the function of the phagocytic cells found in Peyer's
patches and other lymphatic aggregate follicles to defend the body
against, for example, inadequately digested food particles crossing
the gut wall and entering the blood, and to attack unwanted foreign
invaders while they are still in the bowel.
[0010] The major function of B cells is the production of
antibodies in response to foreign proteins of bacteria, viruses,
and tumor cells. T cells are usually divided into two major groups,
namely, the cytotoxic T lymphocytes ("Tc" cells or CTLs) and the
helper T cells ("Th" cells or T helper cells). Th cells, also
referred to as CD4+ T cells, function to augment or potentiate
immune responses by the secretion of specialized factors that
activate other white blood cells to fight off infection. They
enhance the production of antibodies by B cells. Tc cells, also
called CD8+ T cells, can directly kill certain tumor cells,
viral-infected cells, and sometimes parasites. Tc cells are also
important in down-regulation of immune responses. Both types of T
cells often depend on the secondary lymphoid organs (the lymph
nodes and spleen) as sites where activation occurs, but they are
also found in other tissues of the body, including the liver, lung,
blood, and intestinal and reproductive tracts.
[0011] Natural Killer cells, often referred to as NK cells,
represent another type of lymphocyte and are similar to the Tc cell
subset. They function as effector cells that directly kill certain
tumors such as melanomas and lymphomas, and viral-infected cells.
They are called "natural" killers because, unlike cytotoxic T
cells, they do not need to recognize a specific antigen before
carrying out their function. While NK cells, unlike the Tc cells,
kill their targets without prior activation in the lymphoid organs,
NK cells activated by Th cell secretions will kill tumor or
viral-infected targets more effectively. NK cells target tumor
cells and protect against a wide variety of infectious microbes. In
several immunodeficiency diseases, including AIDS, Natural Killer
cell function is abnormal. Natural Killer cells may also contribute
to immunoregulation by secreting high levels of influential
lymphokines.
[0012] Some NK cells have surface receptors (Fc.gamma.RIII, also
called CD16) for the Fc portion of the IgG antibody. They bind to
target cells through receptors for the Fc portion of an antibody
that has reacted with antigen on a target cell. This type of
cell-mediated immunity is called antibody-dependent cell-mediated
cytotoxicity (ADCC). NK cells may also have receptors for the C3
component of complement, another immune defense system, and
therefore recognize cells that are coated with C3 as targets. ADCC
is thought to be an important defense against a variety of
parasitic infections caused, for example, by protozoa and
helminths.
[0013] Although small lymphocytes look identical, they can be
distinguished by molecules carried on their cell surface. Not only
do such markers distinguish between B cells and T cells, they
distinguish among various subsets of cells that behave differently.
Every mature T cell, for instance, carries a marker known as T3 (or
CD3). In addition, most helper T cells carry a T4 (CD4) marker, a
molecule that recognizes Class II major histocompatibility complex
("MHC") antigens. A molecule known as T8 (CD8), which recognizes
Class I MHC antigens, is found on many suppressor/cytotoxic T
cells.
[0014] Another group of white blood cells collectively referred to
as granulocytes, or polymorphonuclear leukocytes (PMNs), is
composed of three cell types. These cells, neutrophils,
eosinophils, and basophils are important in the removal of bacteria
and parasites from the body. Neutrophils migrate through capillary
walls and into infected tissue where they kill invaders (e.g.,
bacteria) and then engulf the remnants by phagocytosis. Eosinophils
are cytotoxic, releasing the contents of their granules on an
invader. Basophils leave the blood and accumulate at the site of an
infection or other inflammation and discharge the contents of their
granules, releasing a variety of mediators such as histamine,
serotonin, prostaglandins and leukotrienes that, for example,
increase blood flow to the area. Mediators released by basophils
also play an important part in some allergic responses such as hay
fever and anaphylactic responses to insect stings.
[0015] Monocytes are large phagocytic white blood cells released
from the bone marrow into the blood circulation. When a monocyte
enters tissue, it develops into a macrophage. Macrophages are also
large, phagocytic cells that engulf foreign material (antigens)
that enter the body, as well as dead and dying cells of the body.
Macrophages are important in the regulation of immune responses,
and are often referred to as scavengers, or antigen-presenting
cells (APCs) because they pick up and ingest foreign materials and
present these antigens to other cells of the immune system such as
T cells and B cells. This is one of the important first steps in
the initiation of an immune response. Stimulated macrophages
exhibit increased levels of phagocytosis and also secrete
Interleukin-1 (IL-1), a product that helps to activate B cells and
T cells.
[0016] Dendritic cells also originate in the bone marrow and
function as APCs. They are usually found in the structural
compartment of lymphoid organs such as the thymus, lymph nodes and
spleen, but are also found in the bloodstream and other tissues. It
is believed that dendritic cells capture antigen or bring it to the
lymphoid organs where an immune response is initiated.
[0017] Important features of the immunological system relevant to
host defense and/or immunity to pathogenic microorganisms include
specificity, memory, and tolerance. It is understood, for example,
that an antibody or reactive T cell will react specifically with
the antigen that induced its formation; it will not react with
other antigens. Generally, this specificity is of the same order as
that of enzyme-substrate specificity or receptor-ligand
specificity, although cross-reactivity is possible. The specificity
of the immune response is explained by clonal selection. During the
primary immune response, a specific antigen selects a pre-existing
clone of specific lymphocytes and stimulates its activation,
proliferation and differentiation. It is also understood that once
the immune system has responded to produce a specific type of
antibody or reactive T cell, it is capable of producing more of the
antibody or activated T cell more rapidly and in larger amounts;
this is called the secondary (or memory) response. It is also
recognized that an animal generally does not undergo an
immunological response to its own (potentially-antigenic)
components. The animal is said to be tolerant, or unable to react
to its own potentially antigenic components. This ensures that
under normal conditions, an immune response to "self" antigens
(called an autoimmune response) does not occur. Tolerance is
brought about in a number of ways, but in essence the immune system
is able to distinguish "self" components from "non-self' (foreign)
antigens; it will respond to "non-self" but not to "self".
Sometimes in an animal, tolerance can be "broken", which may result
in an autoimmune disease.
[0018] The biological activities of the antibody-mediated and
cell-mediated immune responses are different and vary from one type
of infection to another. There are several classes or types of
antibodies (and subclasses of various types) involved in
antibody-mediated immunity. All of the classes of antibodies that
are produced in response to a specific antigen react
stereochemically with that antigen and not with other (different)
antigens. The host has the genetic capacity to produce specific
antibodies to thousands of different antigens, but does not do so
until there is an appropriate (specific) antigenic stimulus. Due to
clonal selection, the host produces only the homologous antibodies
that will react with that antigen which, as noted above, are found
in blood (plasma), lymph, and many extravascular tissues. Once the
antibody-mediated immunity response occurs following interaction of
B lymphocytes with antigen and their differentiation into
antibody-secreting plasma cells, the secreted antibody binds to the
antigen which, in turn, results in its neutralization or
elimination from the body.
[0019] Cell-mediated immunity, on the other hand, is mediated by
specific subpopulations of T-lymphocytes called effector T cells
that exist in precursor form as "resting T cells" (pT cells). These
cells bear receptors for specific antigens and recognize these
antigens on the surfaces of other cells. Stimulation with that
antigen results in T cell activation. T cells enlarge, enter into a
mitotic cycle, reproduce and develop into effector T cells whose
activities are responsible for this type of immunity. They also
develop into clones of identical reactive T cells called memory T
cells. As noted above, most of the T cells in the body belong to
one of two subsets and are distinguished by the presence on their
surface of one or the other of two glycoproteins designated CD4 and
CD8. Which of these molecules is present determines the types of
cells to which the T cell can bind. T cells bearing CD8 (CD8' T
cells) always recognize antigen in association with Class I MHC
proteins and typically function as cytotoxic T cells. Almost all
the cells of the body express Class I MHC molecules. T cells
bearing CD4 (CD4' T cells) always recognize antigens in association
with Class II MHC proteins on the surfaces of other cells. Only
specialized antigen-presenting cells express Class II MHC
molecules, including dendritic cells, phagocytic cells such as
macrophages, and B cells. CD4' T lymphocytes generally function as
T helper cells.
[0020] T helper cells, which include Th1 cells and Th2 cells,
respond to antigen with the production of lymphokines Th1 and Th2
cells can be distinguished based on their lymphokine profiles. Like
all T cells, Th cells arise in the thymus. When they are presented
with an antigen by antigen-presenting dendritic cells they begin to
proliferate and become activated. There are two kinds of dendritic
cell, DC1 cells (descended from monocytes) and DC2 cells (which
appear to be derived from lymphocytes).
[0021] Th1 cells (inflammatory Th1 cells involved in the
elimination of pathogens residing intracellularly in vesicular
compartments) are produced when DC1-type dendritic cells present
antigen to the T cell receptor for antigen (TCR) and secrete
Interleukin 12 (IL-12). This paracrine stimulation activates Th1
cells to secrete their own lymphokines, in particular,
Tumor-Necrosis Factor-beta (TNF-.beta.) (also known as lymphotoxin)
and Interferon-gamma (IFN-.gamma.). These lymphokines stimulate
macrophages to kill bacteria they have engulfed by phagocytosis and
they recruit other leukocytes to the site producing inflammation.
Th1 cells are essential for cell-mediated immunity and for
controlling intracellular pathogens such as, for example, Listeria
and Mycobacterium tuberculosis.
[0022] Th2 cells ("true" helper Th2 cells, which are required for
antibody production by B cells) are produced when DC2-type
dendritic cells present antigen to the T cell receptor for antigen
and, presumably, one or more paracrine stimulants. The major
lymphokines secreted by Th2 cells are Interleukin 4 (IL-4), which
stimulates class-switching in B cells and promotes their synthesis
of IgE antibodies, acts as a positive-feedback device promoting
more pre-Th cells to enter the Th2 pathway, and blocks expression
of the IL-12 receptor thereby inhibiting pre-Th cells in the thymus
from entering the Th1 pathway. IL-4 also causes B cells to
proliferate and differentiate into antibody-secreting plasma cells
and memory B cells. IL-4 activates only B cells in the vicinity
which themselves have bound the antigen, and not others, so as to
sustain the specificity of the immune response. Th2 cells also
produce Interleukin 5 (IL-5, which attracts and activates
eosinophils), Interleukin 10 (IL-10, which inhibits IL-12
production by DCs and prevents maturation of pre-Th cells to Th1
cells), and Interleukin 13 (IL-13, which also promotes the
synthesis of IgE antibodies).
[0023] Activation of the Th2 cell also causes it to begin to
produce Interleukin 2 (IL-2), and to express a membrane receptor
for IL-2. The secreted IL-2 autostimulates proliferation of Th2
cells. For example, IL-2 binds to IL-2 receptors on other T cells
(which have bound the antigen) and stimulates their proliferation.
In addition to IL-2, stimulated Th2 cells also produce IFN-.gamma.
and Interleukin 6 (IL-6), which mediate various aspects of the
immune response. IFN-.gamma. activates Natural Killer cells to
their full cytolytic potential, and is an activator of macrophages
and thus increases their antitumor activities. If the macrophages
are infected by intracellular parasites, it activates macrophages,
which in turn destroy the parasites. IFN-.gamma. also reinforces
the antitumor activities of the cytotoxic lymphocytes, increases
the nonspecific activities of NK-cells, and is one of the factors
that controls the differentiation of B cells and increases the
secretion of immunoglobins. IL-6 stimulates several types of
leukocytes, as well as the production of Acute Phase Proteins in
the liver. It is particularly important in inducing B cells to
differentiate into antibody forming (plasma) cells. Thus, Th2 cells
provide help for B cells and are essential for antibody-mediated
immunity.
[0024] Cytotoxic T lymphocytes are able to kill cells that show a
new or foreign antigen on their surface (for example,
virus-infected cells, or tumor cells, or transplanted tissue
cells). The CD8.sup.+ CTLs also come in two subsets: Tc1 that, like
Th1 cells, secrete IFN-.gamma., and Tc2 that, like Th2 cells,
secrete IL-4.
[0025] The cell-mediated immunity response also plays a role in
destruction of tumor cells and in rejection of tissue transplants
in animals. A major problem in tissue transplantation is rejection,
which is often based on cell-mediated immunity response to
"foreign" cells (because they are not a perfect antigenic match).
Because tumor cells contain specific antigens not seen on normal
cells they also may be recognized as foreign and destroyed by the
forces of cell-mediated immunity. If tumor cells develop on a
regular basis in animals, it may be cell-mediated immunity that
eliminates them or holds them in check. The increase in the
incidence of many types of cancer (tumors) in humans with
advancement of age may be correlated with a decline in the peak
efficiency of the immune system that occurs about 25 years of
age.
[0026] A summary of the types of cells involved in the expression
of cell-mediated immunity follows. Tc lymphocytes kill cells
bearing foreign antigen on surface in association with Class I MHC
and can kill cells that are harboring intracellular parasites
(either bacteria or viruses) as long as the infected cell is
displaying a microbial antigen on its surface. Tc cells kill tumor
cells and account for rejection of transplanted cells. Tc cells
recognize antigen-Class I MHC complexes on target cells, contact
them, and release the contents of granules directly into the target
cell membrane that lyses the cell. Th lymphocytes produce
lymphokines that are "helper" factors for development of B cells
into antibody-secreting plasma cells. They also produce certain
lymphokines that stimulate the differentiation of effector T
lymphocytes and the activity of macrophages. Th1 cells recognize
antigen on macrophages in association with Class II MHC and become
activated (by IL-1) to produce lymphokines including IFN-.gamma.
that activates macrophages and NK cells. These cells mediate
various aspects of the cell-mediated immunity response including
delayed-type hypersensitivity reactions. Th2 cells recognize
antigen in association with Class II MHC on an APC and then produce
interleukins and other substances that stimulate specific B cell
and T cell proliferation and activity. Macrophages are important as
antigen-presenting cells that initiate T cell interactions,
development, and proliferation. Macrophages are also involved in
expression of cell-mediated immunity because they become activated
by IFN-.gamma. produced in a cell-mediated immunity response.
Activated macrophages have increased phagocytic potential and
release soluble substances that cause inflammation and destroy many
bacteria and other cells. Natural Killer cells are cytotoxic cells
that lyse cells bearing new antigen regardless of their MHC type
and even lyse some cells that bear no MHC proteins. NK cells are
defined by their ability to kill cells displaying a foreign antigen
(e.g., tumor cells) regardless of MHC type and regardless of
previous sensitization (exposure) to the antigen. NK cells can be
activated by IL-2 and IFN-.gamma., and lyse cells in the same
manner as cytotoxic T lymphocytes. Some NK cells have receptors for
the Fc domain of the IgG antibody and are thus able to bind to the
Fc portion of IgG on the surface of a target cell and release
cytolytic components that kill the target cell via
antibody-dependent cell-mediated cytotoxicity.
[0027] Extracellular factors that affect cell proliferation and
differentiation have been defined as cytokines. These include the
lymphokines, which are proteins produced by T-lymphocytes that have
effects on the differentiation, proliferation, and activity of
various cells involved in the expression of cell-mediated immunity.
In general, lymphokines function by (1) focusing circulating
leukocytes and lymphocytes into the site of immunological
encounter; (2) stimulating the development and proliferation of B
cells and T cells; (3) stimulating and preparing macrophages for
their phagocytic tasks; (4) stimulating Natural Killer cells; and
(5) providing antiviral cover and activity. A summary of various
important lymphokines follows. Initially referred to as lymphocyte
activation factor, IL-1 is mainly a product of macrophages, and has
a variety of effects on various types of cells. It acts as a growth
regulator of T cells and B cells, and it induces other cells such
as hepatocytes to produce proteins relevant to host defense. IL-1
forms a chemotactic gradient for neutrophils and serves as an
endogenous pyrogen that produces fever. Thus, IL-1 plays an
important role in both the immune responses and in the inflammatory
response. IL-2 stimulates the proliferation of T cells and
activates NK cells. IL-3 regulates the proliferation of stem cells
and the differentiation of mast cells. IL-4 causes B cell
proliferation and enhanced antibody synthesis. IL-6 (also referred
to as Interferon-beta2, hybridoma growth factor, B-cell
differentiation factor, and hepatocyte stimulatory factor) has
effects on B cell differentiation and on antibody production and on
T cell activation, growth, and differentiation, and probably has a
major role in the mediation of the inflammatory and immune
responses initiated by infection or injury. IL-8 is a chemotactic
attractant for neutrophils. IL-13 shares many of the properties of
IL-4, and is a potent regulator of inflammatory and immune
responses. IFN-.gamma. is produced by T cells and may be considered
a lymphokine It is sometimes called "immune interferon"
(Interferon-alpha being referred to as "leukocyte interferon" and
Interferon-beta being referred to as "fibroblast interferon").
IFN-.gamma. has several antiviral effects including inhibition of
viral protein synthesis in infected cells. It also activates
macrophages and NK cells, and stimulates IL-1, IL-2, and antibody
production. Lymphotoxins include the Tumor Necrosis Factors. T
cells produce TNF-beta, while TNF-alpha is produced by T cells as
well as other types of cells. TNFs function to kill cells,
including tumor cells (at a distance). There are several Colony
Stimulating Factors (CSFs), including granulocyte macrophage colony
stimulating factor (GMCSF), which cause phagocytic white cells of
all types to differentiate and divide.
[0028] The nature of the membrane receptors for antigen on B cells
and T cells is fairly well understood. Each B cell has
approximately 10.sup.5 membrane-bound antibody molecules (IgD or
IgM) that correspond in specificity to the antibody the cell is
programmed to produce (these receptors being referred to as BCRs).
CD32 (Fc.gamma.RII) on B cells are receptors for the Fc region of
IgG. CD21 and CD35 on B cells are receptors for complement
components. Each T cell has about 10.sup.5 molecules of a specific
antigen-binding T cell receptor (a TCR) exposed on its surface. The
TCR is similar, but not identical, to an antibody. There are two
types of T cells that differ in their TCRs, alpha/beta
(.alpha..beta.) T cells and gamma/delta (.gamma..epsilon.) T cells.
The TCR of alpha/beta T cells binds a bimolecular complex displayed
by a Class I MHC molecule at the surface of an antigen-presenting
cell. As noted above, most Th cells express CD4, whereas most Tc
cells express CD8.
[0029] Both BCRs and TCRs are similar in that they are integral
membrane proteins, they are present in thousands of identical
copies exposed at the cell surface, they are made before the cell
ever encounters an antigen, they are encoded by genes assembled by
the recombination of segments of DNA, they have a unique binding
site that binds through non-covalent forces to a portion of the
antigen called an epitope (or antigenic determinant) that depends
on complementarity of the surface of the receptor and the surface
of the epitope, and successful binding of the antigen receptor to
the epitope, if accompanied by additional signals, results in
stimulation of the cell to leave G.sub.0 and enter the cell cycle
and repeated mitosis that leads to the development of a clone of
cells bearing the same antigen receptor, i.e., a clone of cells of
the identical specificity. BCRs and TCRs differ in their structure,
the genes that encode them, and the type of epitope to which they
bind.
[0030] Induction of a primary immune response begins when an
antigen penetrates epithelial surfaces. It will eventually come
into contact with macrophages or certain other classes of antigen
presenting cells, including B cells, monocytes, dendritic cells,
Langerhans cells, and endothelial cells. Antigens, such as
bacterial cells, are internalized by endocytosis and "processed" by
APCs, then "presented" to immunocompetent lymphocytes to initiate
the early steps of the immunological response. Processing by a
macrophage (for example) results in attaching antigenic materials
to the surface of the membrane in association with Class II MHC
molecules on the surface of the cell. The antigen-class II MHC
complex is presented to a T-helper (Th2) cell, which is able to
recognize processed antigen associated with a Class II MHC molecule
on the membrane of the macrophage. This interaction, together with
stimulation by IL-1 from secreted by the macrophage, will activate
the Th2 cell.
[0031] As indicated above, B cells themselves behave as APCs.
Cross-linked antigens bound to antibody receptors on the surface of
a B cell cause internalization of some of the antigen and
expression on the B cell membrane together with Class II MHC
molecules. The Th2 cell recognizes the antigen together with the
Class II MHC molecules, and secretes the various lymphokines that
activate the B cells to become antibody-secreting plasma cells and
memory B cells. Even if the antigen cannot cross-link the receptor,
it may be endocytosed by the B cell, processed, and returned to the
surface in association with Class II MHC where it can be recognized
by specific Th2 cells which will become activated to initiate B
cell differentiation and proliferation. In any case, the overall B
cell response leads to antibody-mediated immunity.
[0032] The antigen receptors on B cell surfaces are thought to be
the specific types of antibodies that they are genetically
programmed to produce. Hence, there are thousands of
sub-populations of B cells distinguished by their ability to
produce a unique antibody molecule. B cells can also react with a
homologous antigen on the surface of the macrophage, or with
soluble antigens. When a B cell is bound to antigen, and
simultaneously is stimulated by IL-4 produced by a nearby Th2 cell,
the B cell is stimulated to grow and divide to form a clone of
identical B cells, each capable of producing identical antibody
molecules. The activated B cells further differentiate into plasma
cells which synthesize and secrete large amounts of antibody, and
into memory B cells. The antibodies produced and secreted by the
plasma cells will react specifically with the homologous antigen
that induced their formation. Many of these reactions lead to host
defense and to prevention of reinfection by pathogens. Memory cells
play a role in secondary immune responses. Plasma cells are
relatively short-lived (about one week) but produce large amounts
of antibody during this period. Memory cells, on the other hand,
are relatively long-lived and upon subsequent exposure to antigen
they become quickly transformed into antibody-producing plasma
cells.
[0033] Generation of cell mediated immunity begins when, for
example, a cytotoxic T cell recognizes a processed antigen
associated with Class I MHC on the membrane of a cell (usually an
altered self cell, but possibly a transplanted tissue cell, or a
eukaryotic parasite). Under stimulation by IL-2 produced by Th2
cells, the Tc cell becomes activated to become a cytotoxic T
lymphocyte capable of lysing the cell which is showing the new
foreign antigen on its surface, a primary manifestation of
cell-mediated immunity. The interaction between an
antigen-presenting macrophage and a Th cell stimulates the
macrophage to produce and secrete a Interleukin-1 that acts locally
on the Th cell, stimulating the Th-cell to differentiate and
produce its own cytokines (which may here be called lymphokines
because they arise from a lymphocyte). These lymphokines have
various functions. IL-4 has an immediate effect on nearby B cells.
IL-2 has an immediate effect on T cells as described above.
[0034] Leucocytes also express adhesion-promoting receptors that
mediate cell-cell and cell-matrix interactions. These adhesive
interactions are crucial to the regulation of haemopoiesis and
thymocyte maturation, the direction and control of leucocyte
traffic and migration through tissues, and the development of
immune and non-immune inflammatory responses. Several families of
adhesion receptors have been identified. The leucocyte integrin
family comprises three alpha-beta heterodimeric membrane
glycoproteins that share a common beta subunit, designated CD18.
The alpha subunits of each of the three members, lymphocyte
function associated antigen-1 (LFA-1), macrophage antigen-1 (Mac-1)
and p150, are designated CD11a, b, and c respectively. These
adhesion molecules play a critical part in the immune and
inflammatory responses of leucocytes. The leucocyte integrin family
is, in turn, part of the integrin superfamily, members of which are
evolutionally, structurally and functionally related. Another
integrin subfamily found on leucocytes is the VLA group, so-called
because the "very late activation antigens" VLA-1 and VLA-2 were
originally found to appear late in T-cell activation. Members of
this family function mainly as extracellular matrix adhesion
receptors and are found both on haemopoietic and non-haemopoietic
cells. They play a part in diverse cellular functions including
tissue organization, lymphocyte recirculation and T-cell immune
responses. Another integrin subfamily, the cytoadhesins, are
receptors on platelets and endothelial cells that bind
extracellular matrix proteins. A second family of adhesion
receptors is the immunoglobulin superfamily, members of which
include CD2, LFA-3, and ICAM-1, which participate in T-cell
adhesive interactions, and the antigen-specific receptors of T and
B cells, CD4, CD8, and the MHC Class I and II molecules. Another
recognized family of adhesion receptors is the selectins,
characterized by a common lectin domain. Leucocyte adhesion
molecule-1 (LAM-1), which is the human homologue of the murine
homing receptor, MEL-14, is expressed on leucocytes, while
endothelial leucocyte adhesion molecule-1 (ELAM-1) and granule
membrane protein (GMP-140) are expressed on stimulated endothelial
cells and activated platelets.
[0035] Activation of an immune response requires physical cell-cell
contact in addition to cytokines. Thus, for example, development of
B and T cell precursors require intimate contact with stromal
cells. At least three critical cell-cell contact events are
required for the generation of immune responses. The first is
initial contact of a specific antigen with a naive T cell. Because
of the requirement for MHC presentation, this is an obligate cell
contact event. In normal situations the critical antigen presenting
cell is the dendritic cell. In addition to the MHC/peptide-TCR
interaction there are other non-antigen specific membrane bound
ligand-receptor pairs that are important for the dendritic cell-T
cell interaction. The principal one is the association of the CD28
molecule on the T cell with either of two ligands, B7.1 (CD80) and
B7.2 (CD86), on the dendritic cell. These molecules are termed
accessory molecules and it is understood that the CD28 molecule
delivers an essential second signal to the T cell without which the
T cell does not become activated.
[0036] A second essential cell-cell contact is between the
activated T cell and an antigen-specific B cell. Most antigens are
T cell-dependent, that is, an antibody response to the antigen
absolutely requires T cell help. This help is delivered both by
cytokines and by cell-cell contact. Cells bind specific antigen via
surface Ig, then internalize, process, and present it on Class II
MHC molecules. This enables them to be recognized by T cells
specific for helper epitopes from the specific antigen. This
cell-cell interaction also requires CD28 binding to B7 on the B
cell. In addition, a molecule called CD40 ligand or CD154, the
expression of which is induced upon T cell activation, binds to
CD40 on B cells. CD40 crosslinking promotes B cell proliferation,
prevents apoptosis of germinal-center B cells, and promotes
immunoglobulin isotype switching. The CD28-B7 and CD40-CD40L
receptor ligand interactions are both essential for the dialogue
between B and T cells that causes their mutual activation.
[0037] A third cell-cell interaction that is essential in immune
responses is the binding of activated B cells (which have migrated
into a specialized structure in lymphoid organs called germinal
centers) to follicular dendritic cells (FDCs). FDCs are specialized
stromal cells that hold intact, i.e., unprocessed, antigen on their
surface in the form of long-lived immune complexes. Among other
molecules, FDCs express CD23, which binds to germinal center B
cells via a CR2 receptor and stimulates differentiation to plasma
cells.
[0038] Time is required before a primary immune response is
effective as a host defense. Antigens have to be recognized, taken
up, digested, processed, and presented by APCs. A few select Th
cells must react with antigen and respond; preexisting B or T
lymphocytes must encounter the antigen and proliferate and
differentiate into effector cells (plasma cells or Tc cells). In
the case of antibody-mediated immunity, antibody level has to build
up to an effective physiological concentration to render its host
resistant. It may take several days or weeks to reach a level of
effective immunity, even though this immunity may persist for many
months, or years, or even a lifetime, due to the presence of the
antibodies. In natural infections, the inoculum is small, and even
though the antigenic stimulus increases during microbial
replication, only small amounts of antibody are formed within the
first few days, and circulating antibody is not detectable until
about a week after infection.
[0039] With regard to induction of a secondary immune response, it
is understood that on re-exposure to microbial antigens (secondary
exposure to antigen), there is an accelerated immunological
response, i.e., the secondary or memory response. Larger amounts of
antibodies are formed in only 1-2 days. This is due to the
activities of specific memory B cells or memory T cells which were
formed during the primary immune response. These memory cells, when
stimulated by homologous antigen, "remember" having previously seen
the antigen, and are able to rapidly divide and differentiate into
effector cells. Stimulating memory cells to rapidly produce very
high (effective) levels of persistent circulating antibodies is the
basis for giving "booster"-type vaccinations to humans and pets.
Thus, following the first exposure to an antigen the immune
response (as evidenced by following the concentration of specific
antibody in the serum) develops gradually over a period of days,
reaches a low plateau within 2-3 weeks, and usually begins to
decline in a relatively short period of time. When the antigen is
encountered a second time, a secondary (memory) response causes a
rapid rise in the concentration of antibody, reaching a much higher
level in the serum, which may persist for a relatively long period
of time. A protective level of antibody may be reached by primary
exposure alone, but usually to ensure a high level of protective
antibody that persists over a long period of time, it is necessary
to have repeated antigenic stimulation of the immune system.
[0040] An immunoglobulin molecule (abbreviated Ig), is a multimeric
protein composed of two identical light chain polypeptides and two
identical heavy chain polypeptides (H.sub.2L.sub.2) that are joined
into a macromolecular complex by interchain disulfide bonds, i.e.,
covalent bonds between the sulfhydryl groups of neighboring
cysteine residues. There are various classes of human antibody
proteins, each of which is produced by a specific clone of plasma
cells. Five human immunoglobulin classes are defined on the basis
of their heavy chain composition, and are named IgG, IgM, IgA, IgE,
and IgD. The IgG-class and IgA-class antibodies are further divided
into subclasses, namely, IgG1, IgG2, IgG3, and IgG4, and IgA1 and
IgA2. Intrachain disulfide bonds join different areas of the same
polypeptide chain, which results in the formation of loops that,
along with adjacent amino acids, constitute the immunoglobulin
domains. At the amino-terminal portion (also called the
"NH.sub.2-terminus" or the "N-terminus"), each light chain and each
heavy chain has a single variable region that shows considerable
variation in amino acid composition from one antibody to another.
The light chain variable region, V.sub.L, associates with the
variable region of a heavy chain, V.sub.H, to form the antigen
binding site of the immunoglobulin, called the Fv.
[0041] In addition to variable regions, each of the antibody chains
has one or more constant regions. Light chains have a single
constant region domain. Thus, light chains have one variable region
and one constant region. Heavy chains have several constant region
domains. The heavy chains in IgG, IgA, and IgD antibodies have
three constant region domains, which are designated CH.sub.1,
CH.sub.2, and CH.sub.3, and the heavy chains in IgM and IgE
antibodies have four constant region domains, CH1, CH2, CH3 and
CH4. Thus, heavy chains have one variable region and three or four
constant regions. Immunoglobulin structure and function are
reviewed, for example, in Harlow et al., Eds., Antibodies: A
Laboratory Manual, Chapter 14, Cold Spring Harbor Laboratory, Cold
Spring Harbor (1988).
[0042] The heavy chains of immunoglobulins can also be divided into
three functional regions: the Fd region (a fragment comprising
V.sub.H and CH1, i.e., the two N-terminal domains of the heavy
chain), the hinge region, and the Fc region (the "fragment
crystallizable" region, derived from constant regions and formed
after pepsin digestion). The Fd region in combination with the
light chain forms an Fab (the "fragment antigen-binding"). Because
an antigen will react stereochemically with the antigen-binding
region at the amino terminus of each Fab the IgG molecule is
divalent, i.e., it can bind to two antigen molecules. The Fc
contains the domains that interact with immunoglobulin receptors on
cells and with the initial elements of the complement cascade.
Thus, the Fc fragment is generally considered responsible for the
effector functions of an immunoglobulin, such as complement
fixation and binding to Fc receptors. Pepsin sometimes also cleaves
before the third constant domain (CH3) of the heavy chain to give a
large fragment F(abc) and a small fragment pFcb. These terms are
also used for analogous regions of the other immunoglobulins. The
hinge region, found in IgG, IgA, and IgD class antibodies, acts as
a flexible spacer, allowing the Fab portion to move freely in
space. In contrast to the constant regions, the hinge domains are
structurally diverse, varying in both sequence and length among
immunoglobulin classes and subclasses.
[0043] For example, the length and flexibility of the hinge region
varies among the IgG subclasses. The hinge region of IgG1
reportedly encompasses amino acids 216-231 and because it is freely
flexible, the Fab fragments can rotate about their axes of symmetry
and move within a sphere centered at the first of two inter-heavy
chain disulfide bridges. IgG2 has a shorter hinge than IgG1,
reportedly 12 amino acid residues and four disulfide bridges. The
hinge region of IgG2 lacks a glycine residue, it is relatively
short and contains a rigid poly-proline double helix, stabilised by
extra inter-heavy chain disulfide bridges. These properties
restrict the flexibility of the IgG2 molecule. IgG3 differs from
the other subclasses by its unique extended hinge region (about
four times as long as the IgG1 hinge), and is reported to contain
62 amino acids (including 21 prolines and 11 cysteines), forming an
inflexible poly-proline double helix. In IgG3 the Fab fragments are
relatively far away from the Fc fragment, giving the molecule a
greater flexibility. The elongated hinge in IgG3 is also
responsible for its higher molecular weight compared to the other
subclasses. The hinge region of IgG4 is shorter than that of IgG1
and its flexibility is intermediate between that of IgG1 and IgG2.
The flexibility of the hinge region reportedly decreases in the
order IgG3>IgG1>IgG4>IgG2. The four IgG subclasses also
differ from each other with respect to their effector functions.
This difference is related to differences in structure, including
with respect to the interaction between the variable region, Fab
fragments, and the constant Fc fragment. Nevertheless, aside from
glycosylation within the CH2 region, for example, and in spite of
this knowledge there are no set rules or conventions regarding
means or methods to change features, including sequences, of these
subclasses of molecule to change, control, add, or remove different
functions, for example, ADCC, CDC, and other functions.
[0044] According to crystallographic studies, the immunoglobulin
hinge region can be further subdivided functionally into three
regions: the upper hinge region, the core region, and the lower
hinge region. Shin et al., 1992 Immunological Reviews 130:87. The
upper hinge region includes amino acids from the carboxyl end of
CH1 to the first residue in the hinge that restricts motion,
generally the first cysteine residue that forms an interchain
disulfide bond between the two heavy chains. The length of the
upper hinge region correlates with the segmental flexibility of the
antibody. The core hinge region contains the inter-heavy chain
disulfide bridges, and the lower hinge region joins the amino
terminal end of the CH2 domain and includes residues in CH2. Id.
The core hinge region of human IgG1 contains the sequence
Cys-Pro-Pro-Cys (SEQ ID NO:515) which, when dimerized by disulfide
bond formation, results in a cyclic octapeptide believed to act as
a pivot, thus conferring flexibility. The hinge region may also
contain one or more glycosylation sites, which include a number of
structurally distinct types of sites for carbohydrate attachment.
For example, IgA1 contains five glycosylation sites within a 17
amino acid segment of the hinge region, conferring resistance of
the hinge region polypeptide to intestinal proteases, considered an
advantageous property for a secretory immunoglobulin.
[0045] Conformational changes permitted by the structure and
flexibility of the immunoglobulin hinge region polypeptide sequence
may also affect the effector functions of the Fc portion of the
antibody. Three general categories of effector functions associated
with the Fc region include (1) activation of the classical
complement cascade, (2) interaction with effector cells, and (3)
compartmentalization of immunoglobulins. The different human IgG
subclasses vary in the relative efficacies with which they fix
complement, or activate and amplify the steps of the complement
cascade. See, e.g., Kirschfink, 2001 Immunol. Rev. 180:177;
Chakraborti et al., 2000 Cell Signal 12:607; Kohl et al., 1999 Mol.
Immunol. 36:893; Marsh et al., 1999 Curr. Opin. Nephrol. Hypertens.
8:557; Speth et al., 1999 Wien Klin. Wochenschr. 111:378.
[0046] Complement-dependent cytotoxicity (CDC) is believed to be a
significant mechanism for clearance of specific target cells such
as tumor cells. CDC is a stream of events that consists of a series
of enzymes that become activated by each other in a cascade
fashion. Complement has an important role in clearing antigen,
accomplished by its four major functions: (1) local vasodilation;
(2) attraction of immune cells, especially phagocytes (chemotaxis);
(3) tagging of foreign organisms for phagocytosis (opsonization);
and (4) destruction of invading organisms by the membrane attack
complex (MAC attack). The central molecule is the C3 protein. It is
an enzyme that is split into two fragments by components of either
the classical pathway or the alternative pathway. Antibodies,
especially IgG and IgM, induce the classical pathway while the
alternative pathway is nonspecifically stimulated by bacterial
products like lipopolysaccharide (LPS). Briefly, the products of
the C3 split include a small peptide C3a that is chemotactic for
phagocytic immune cells and results in local vasodilation by
causing the release of C5a fragment from C5. The other part of C3,
C3b coats antigens on the surface of foreign organisms and acts to
opsonize the organism for destruction. C3b also reacts with other
components of the complement system to form an MAC consisting of
C5b, C6, C7, C8 and C9.
[0047] In general, IgG1 and IgG3 most effectively fix complement,
IgG2 is less effective, and IgG4 does not activate complement.
Complement activation is initiated by binding of Clq, a subunit of
the first component C1 in the cascade, to an antigen-antibody
complex. Even though the binding site for Clq is located in the CH2
domain of the antibody, the hinge region influences the ability of
the antibody to activate the cascade. For example, recombinant
immunoglobulins lacking a hinge region are reportedly unable to
activate complement. Shin et al., 1992. Without the flexibility
conferred by the hinge region, the Fab portion of the antibody
bound to the antigen may not be able to adopt the conformation
required to permit Clq to bind to CH2. See id. Hinge length and
segmental flexibility have been reported to correlate with
complement activation; however, the correlation is not absolute.
Human IgG3 molecules with altered hinge regions that are as rigid
as IgG4, for example, can still effectively activate the
cascade.
[0048] The absence of a hinge region, or a lack of a functional
hinge region, can also affect the ability of certain human IgG
immunoglobulins to bind Fc receptors on immune effector cells.
Binding of an immunoglobulin to an Fc receptor facilitates
antibody-dependent cell-mediated cytotoxicity, which as noted above
is presumed to be an important mechanism for the elimination of
tumor cells. The human IgG Fc receptor (FcR) family is divided into
three groups, Fc.gamma.RI (CD64), which is capable of binding IgG
with high affinity, and Fc.gamma.RII (CD32) and Fc.gamma.RIII
(CD16), both of which are lower affinity receptors. The molecular
interaction between each of the three receptors and an
immunoglobulin has not been defined precisely, but experimental
evidence indicates that residues in the hinge proximal region of
the CH2 domain may be important to the specificity of the
interaction between the antibody and the Fc receptor. IgG1 myeloma
proteins and recombinant IgG3 chimeric antibodies that lack a hinge
region are reportedly unable to bind Fc.gamma.RI, perhaps because
accessibility to CH2 is decreased. Shin et al., 1993 Intern. Rev.
Immunol. 10:177, 178-79.
[0049] Unusual and apparently evolutionarily unrelated exceptions
to the H.sub.2L.sub.2 structure of conventional antibodies occur in
some isotypes of the immunoglobulins found in camelids (camels,
dromedaries and llamas; Hamers-Casterman et al., 1993 Nature
363:446; Nguyen et al., 1998 J. Mol. Biol. 275:413), nurse sharks
(Roux et al., 1998 Proc. Nat. Acad. Sci. USA 95:11804), and in the
spotted ratfish (Nguyen, et al., "Heavy-chain antibodies in
Camelidae; a case of evolutionary innovation," 2002 Immunogenetics
54(1):39-47). These antibodies can apparently form antigen-binding
regions using only heavy chain variable region, i.e., these
functional antibodies are homodimers of heavy chains only (referred
to as "heavy-chain antibodies" or "HCAbs"). In both species, these
variable regions often contain an extended third complementarity
determining region (CDR3) that may help compensate for the lack of
a light chain variable region, and there are frequent disulfide
bonds between CDR regions that presumably help to stabilize the
binding site. Muyldermans et al., 1994 Prot. Engineer. 7:1129; Roux
et al., 1998. However, the precise function of the heavy chain-only
"antibodies" is unknown, and the evolutionary pressure leading to
their formation has not been identified. See, e.g., Nguyen, et al.,
2002, supra. Camelids, including camels, llamas, and alpacas, also
express conventional H.sub.2L.sub.2 antibodies, and the heavy
chain-only antibodies thus do not appear to be present in these
animals simply as an alternative antibody structure.
[0050] Variable regions (V.sub.HH) of the camelid heavy chain-only
immunoglobulins and conventional (H.sub.2L.sub.2) heavy chain
variable regions contain amino acid differences, including
differences at several positions that may be involved in the
interface between conventional V.sub.H and V.sub.L domains. Nguyen
et al., 1998 J. Mol. Biol. 275:413; Muyldermans et al., 1994 Prot.
Engineer. 7:1129. Camelid V.sub.HH reportedly recombines with IgG2
and IgG3 constant regions that contain hinge, CH2, and CH3 domains
and lack a CH1 domain. Hamers-Casterman et al., 1993 Nature
363:446. Interestingly, V.sub.HH are encoded by a chromosomal locus
distinct from the V.sub.H locus (Nguyen et al., 1998, supra),
indicating that camelid B cells have evolved complex mechanisms of
antigen recognition and differentiation. Thus, for example, llama
IgG1 is a conventional (H.sub.2L.sub.2) antibody isotype in which
V.sub.H recombines with a constant region that contains hinge, CH1,
CH2 and CH3 domains, whereas the llama IgG2 and IgG3 are heavy
chain-only isotypes that lack CH1 domains and that contain no light
chains.
[0051] The classes of immunoglobulins have different physical and
chemical characteristics and they exhibit unique biological
properties. Their synthesis occurs at different stages and rates
during an immune response and/or during the course of an infection.
Their importance and functions in host resistance (immunity) are
different.
[0052] Immunoglobulin G (IgG), a protein with a molecular weight of
about 150,000 daltons (150 kD), is the predominant Ig in the serum.
It makes up about 80% of the total antibody found in an animal at
any given time, being 75% of the total serum antibody. It can
diffuse out of the blood stream into the extravascular spaces and
it is the most common Ig found there. Its concentration in tissue
fluids is increased during inflammation, and it is particularly
effective at the neutralization of bacterial extracellular toxins
and viruses. It also has opsonizing ability and complement-fixing
ability. The polypeptide composition of the Fc region of all IgG1
antibody molecules is relatively constant regardless of antibody
specificity; however, as noted above, the Fab regions always differ
in their exact amino acid sequences depending upon their antigenic
specificity. Specific amino acid regions of the Fc portion of the
molecule are recognized by receptors on phagocytes and certain
other cells, and the Fc domain contains a peptide region that will
bind to and activate complement, which is often required for the
manifestation of antibody-mediated immunity. Because the IgG
molecule is divalent, it can cross-link antigen molecules, which
may lead to precipitation or agglutination of antigens; if IgG is
bound to antigen on a microbial cell or surface, its Fc region may
provide an extrinsic ligand that will be recognized by specific
receptors on phagocytes. Microbial cells or viruses coated with IgG
molecules are opsonized for phagocytosis, and opsonized pathogens
are taken up and destroyed much more readily by phagocytes than
their non-opsonized counterparts. IgG, as well as IgM and IgA, will
neutralize the activity of toxins, including bacterial exotoxins.
Furthermore, cross-linked IgG molecules on the surface of a cell
can bind and activate complement from the serum and set off a
cascade of reactions that can lead to destruction of the cell.
[0053] IgM is the first immunoglobulin to appear in the blood
stream during the course of an infection. It is mainly confined to
the bloodstream and provides protection against blood-borne
pathogens. IgM makes up about 10% serum immunoglobulins, and is
arranged to resemble a pentamer of five immunoglobulin molecules
(having a molecular weight of about 900 kD) tethered together at by
their Fc domains. In addition to covalent linkages between the
monomeric subunits, the pentamer is stabilized by a 15 kd
polypeptide called J chain. IgM, therefore, has a theoretical
"valence" of ten (i.e., it has ten exposed Fab domains). Probably,
the most important role of IgM is its ability to function early in
the immune responses against blood-borne pathogens given its
efficiency in agglutinating particulate antigens. IgM binds also
complement strongly and IgM antibodies bound to a microbial surface
act as opsonins, rendering the microbe more susceptible to
phagocytosis. In the presence of complement and IgM whole microbial
cells may be killed and lysed. As noted above, IgM also appears on
the surfaces of mature B cells as a transmembranous monomer where
it functions as an antigen receptor, capable of activating B cells
when bound to antigen.
[0054] Gene rearrangement at the immunoglobulin loci during
lymphoid development generates a repertoire of B lymphocytes that
express a diversity of antigen receptors. The gene rearrangement,
which is catalysed by the rearrangement-activating gene ("RAG")
recombinase, integrates the immunoglobulin V, D and J gene segments
to yield productively rearranged immunoglobulin genes that encode
the heavy and light chains of IgM antibodies. The diversity of IgM
antibodies in this primary repertoire is achieved through
combinatorial mechanisms (the choice of V, D and J gene segments
utilized in a particular antibody), as well as junctional
diversity. The joining of V, D and J gene segments is somewhat
imprecise, and nucleotides may be inserted at the junction in a
non-templated manner. There is therefore a very high degree of
resultant diversity at the V-D-J borders. This contributes in a
major way to the structural diversity of the third complementarity
determining region of the antibody, a region that often plays a
critical role in antigen recognition. This primary repertoire of
IgM antibodies comprises a few million different structures. The
size of this repertoire means that any incoming antigen is likely
to encounter an antibody that recognizes it with acceptable
affinity. A high-affinity binding site is unlikely to be available
for most incoming antigens (the repertoire is not large enough),
but the affinity of the available IgM antibodies in the primary
repertoire will vary from antigen to antigen. If an epitope is
re-iterated at high density on the surface of the antigen (e.g., a
repeated structure on the surface of a virus or bacterium), then an
IgM antibody may nevertheless be effective in mediating clearance
of the organism, despite the low affinity of the individual
interaction between antigenic epitope and immunoglobulin combining
site. The density of the epitopes may allow multivalent
interactions with IgM, leading to a high-avidity interaction,
providing that a suitable spacing of antigenic epitopes can occur.
Nevertheless, to ensure an effective and specific response,
especially when the concentration of antigen is low (as may occur
when the body is faced with a very small number of infecting viral
particles), it would be preferable if high-affinity antibodies were
available for neutralizing, for example, an infecting organism. The
size of the primary repertoire militates against the likelihood of
such high-affinity antibodies being present in this repertoire. The
immune system therefore operates using a two-stage strategy. The
primary repertoire of IgM antibodies is generated by a process of
gene rearrangement and takes place prior to antigen encounter
during early lymphocyte development. However, once foreign antigen
has been encountered, those B cells in the primary repertoire that
encode suitable (albeit low-affinity) antibodies are selectively
expanded and subjected to an iterative alternation of directed
hypermutation and antigen-mediated selection. This allows a
significant maturation in affinity of the antigen-specific
antibodies that are produced. Antigen triggering also drives
isotype switch recombination. Thus, in the absence of external
antigen stimulation and any maternally derived immunoglobulin, the
serum will only contain a diversity of unmutated IgM molecules that
have been generated by gene rearrangement. This repertoire shifts
with age as a result of continuous antigen exposure, such that the
majority of the serum immunoglobulin in older animals is composed
of mutated IgG (and IgA) molecules whose specificities have
developed as a consequence of antigen selection.
[0055] IgA exists as a H.sub.2L.sub.2 monomer of about 160 kD in
serum and, in secretions, as a dimer of the H.sub.2L.sub.2 monomer
of about 400 kD. As with IgM, polymerization (dimerization) is via
a J-chain. IgA has two subclasses based on different heavy chains,
IgA1 and IgA2. IgA1 is produced in bone marrow and makes up most of
the serum IgA. Both IgA1 and IgA2 are synthesized in GALT (gut
associated lymphoid tissues) to be secreted onto the mucosal
surfaces. Because IgA may be synthesized locally and secreted in
the seromucous secretions of the body, it is sometimes referred to
as secretory antibody or sIgA. Quantitatively, IgA is synthesized
in amounts greater than IgG, but it has a short half life in serum
(6 days), and it is lost in secretory products. The concentration
of IgA in serum is about 15% of the total antibody. Secretion of
dimeric IgA is mediated by a 100 kD glycoprotein called secretory
component. It is the addition of the secretory piece to IgA
molecules that accounts for their ability to exit the body to
mucosal surfaces via the exocrine glands. IgM can be transported
similarly and makes up a small proportion of secretory antibodies.
Secretory IgA is the predominant immunoglobulin present in
gastrointestinal fluids, nasal secretions, saliva, tears and other
mucous secretions of the body. IgA antibodies are important in
resistance to infection of the mucosal surfaces of the body,
particularly the respiratory, intestinal and urogenital tracts. IgA
acts as a protective coating for the mucous surfaces against
microbial adherence or initial colonization. It can also neutralize
toxin activity on mucosal surfaces. Fc receptors for IgA-coated
microorganisms found on monocytes and neutrophils derived from the
respiratory mucosa suggest that IgA may have a role in the lung, at
least, in opsonization of pathogens. Secretory IgA is also
transferred via the milk, i.e., the colostrum, from a nursing
mother to a newborn, which provides passive immunity to many
pathogens, especially those that enter by way of the GI tract.
[0056] IgE is an immunoglobulin of about 190 kD that accounts for
about 0.002% of the total serum immunoglobulins. It is produced by
plasma cells below the respiratory and intestinal epithelia. The
majority of IgE is bound to tissue cells, especially mast cells. If
an infectious agent succeeds in penetrating the IgA barrier, it
comes up against the next line of defense, the MALT
(mucosa-associated lymphoid tissues) system that is managed by IgE.
IgE is bound very firmly to specific IgE Fc receptors on mast
cells. Contact with antigen leads to release of mediators of
inflammation from the mast cells, which effectively recruits
various agents of the immune response including complement,
chemotactic factors for phagocytes, T cells, etc. Although a
well-known manifestation of this reaction is a type of immediate
hypersensitivity reaction called atopic allergy (e.g., hives,
asthma, hay fever, etc.), the MALT responses act as a defense
mechanism because they amplify the inflammatory response and may
facilitate rejection of a pathogen.
[0057] IgD is a molecule of about 175 kd that resembles IgG in its
monomeric form. IgD antibodies are found for the most part on the
surfaces of B lymphocytes. The same cells may also carry IgM
antibody. As noted above, it is thought that IgD and IgM function
as mutually interacting antigen receptors for control of B cell
activation and suppression. Hence, IgD may have an immunoregulatory
function.
[0058] In addition to opsonization, activation of complement, and
ADCC, antibodies have other functions in host defense including
steric hindrance, toxin neutralization, agglutination, and
precipitation. With regard to steric hindrance, it is understood
that antibodies combine with the surfaces of microorganisms and may
block or prevent their attachment to susceptible cells or mucosal
surfaces. Antibody against a viral component can block attachment
of the virus to susceptible host cells and thereby reduce
infectivity. Secretory IgA can block attachment of pathogens to
mucosal surfaces. Toxin-neutralizing antibodies (antitoxins) can
also react with a soluble bacterial toxin and block the interaction
of the toxin with its specific target cell or substrate. Antibodies
can also combine with the surfaces of microorganisms or soluble
antigens and cause them to agglutinate or precipitate. This reduces
the number of separate infectious units and makes them more readily
phagocytosed because the clump of particles is larger in size.
Phagocytes may remove floccules or aggregates of neutralized
toxin.
[0059] Antibodies have been proposed for use in therapy. Animals,
including humans and mice have the ability to make antibodies able
to recognize (by binding to) virtually any antigenic determinant
and to discriminate between similar epitopes. Not only does this
provide the basis for protection against disease organisms, but it
also makes antibodies attractive candidates to target other types
of molecules found in the body, such as receptors or other proteins
present on the surface of normal cells and molecules present
uniquely on the surface of cancer cells. Thus the remarkable
specificity of antibodies makes them promising agents for human
therapy.
[0060] Initial antibody preparations available for use, such as
intravenous gammaglobulins, included animal and human antisera that
were used in vivo to destroy bacteria (tetanus, pneumococcus) and
neutralize virus (hepatitis A and B, rabies, cytomegalovirus, and
varicella zoster) in the blood of infected individuals. Possibly
the most important early application was the use of endotoxins.
However, there are problems associated with the use of antibodies
in human therapy because the response of the immune system to any
antigen, even the simplest, is "polyclonal," i.e., the system
manufactures antibodies of a great range of structures both in
their binding regions as well as in their effector regions.
Polyclonal antibody treatment was also associated with unwanted
side effects. In addition to the polyclonal nature of these
antibody preparations, there was the risk of infection from
contaminating viruses. Serum sickness and anaphylaxis were also
considered limiting factors. Furthermore, even if one were to
isolate a single antibody-secreting cell, and place it in culture,
it would die out after a few generations because of the limited
growth potential of all normal somatic cells.
[0061] Until the late 1970s, polyclonal antibodies obtained from
the blood serum of immunized animals provided the only source of
antibodies for research or treatment of disease. Isolation of
specific antibodies was essentially impossible until Kohler and
Milstein discovered how to make "monoclonal antibodies" that would
have a single specificity, that would all be alike due to
manufacture by a single clone of plasma cells and that could be
grown indefinitely. This technique was described in a 1975
publication (Nature 256:495-97), and Kohler and Milstein received
the 1984 Nobel Prize in Medicine for their work.
[0062] The first step in Kohler and Milstein's technique for
production of monoclonal antibodies involves immunizing an
experimental animal with the antigen of interest. In most of their
experiments, Kohler and Milstein injected a mouse with sheep red
blood cells. The mouse's body initiates an immune response and
begins producing antibodies specific to the antigen. The mouse's
spleen is then removed and B cells producing the antibody of
interest are isolated. Tumor-producing cells that have been grown
in culture are then fused with the B lymphocytes using polyethylene
glycol in order to produce a "hybridoma." Only hybridomas resulting
from the fusion will survive. The spleen lymphocyte has a limited
life span, so any B cells that did not fuse with a myeloma will die
in the culture. Additionally, those cells that lack the
antibody-producing aspect of the B cell will not secrete the enzyme
HGPRT, which is required for growth in the
hypoxathine-aminopterinthymidine (HAT) medium. The HAT medium, on
which the cells are grown, inhibits the pathway for nucleotide
synthesis. Cells that produce HGPRT can bypass this pathway and
continue to grow. By placing the fused cells in a HAT medium, true
hybridomas can be isolated. The isolated hybridoma cells are then
screened for specificity to the desired antigen. Because each
hybridoma descends from one B cell, it makes copies of only one
antibody. The hybridoma that produces the antibody of interest is
grown in culture to produce large amounts of monoclonal antibodies,
which are then isolated for further use. The technique is called
somatic cell hybridization, and the resulting hybridoma (selected
for both immortality and production of the specific antibody of
interest) may be cultured indefinitely, i.e., it is a potenially
immortal cell line.
[0063] Monoclonal antibodies are now widely used as diagnostic and
research reagents. However, their introduction into human therapy
has been much slower. One principal difficulty is that mouse
antibodies are "seen" by the human immune system as foreign. The
human patient mounts an immune response against them, producing
HAMA ("human anti-mouse antibodies"). These not only cause the
therapeutic antibodies to be quickly eliminated from the host, but
also form immune complexes that cause damage to the kidneys.
[0064] Two approaches have been used in an attempt to reduce the
problem of HAMA. The first is the production of chimeric antibodies
in which the antigen-binding part (variable regions) of a mouse
monoclonal antibody is fused to the effector part (constant region)
of a human antibody using genetic engineering. In a second
approach, rodent antibodies have been altered through a technique
known as complementarity determining region (CDR) grafting or
"humanization." In this process, the antigen binding sites, which
are formed by three CDRs of the heavy chain and three CDRs of the
light chain, are excised from cells secreting rodent mAb and
grafted into the DNA coding for the framework of the human
antibody. Because only the antigen-binding site CDRs, rather than
the entire variable domain of the rodent antibody are transplanted,
the resulting humanized antibody (a second generation or
"hyperchimeric" antibody) is reportedly less immunogenic than a
first generation chimeric antibody. This process has been further
improved to include changes referred to as "reshaping" (Verhoeyen,
et al., "Reshaping human antibodies: grafting an anti-lysozyme
activity," 1988 Science 239:1534-1536; Riechmann, et al.,
"Reshaping human antibodies for therapy," 1988 Nature 332:323-337;
Tempest, et al., "Reshaping human monoclonal antibody to inhibit
respiratory syncitial virus infection in vivo," Bio/Technol 1991
9:266-271), "hyperchimerization" (Queen, et al., "A humanized
antibody that binds to the human interleukin 2 receptor," 1989 Proc
Natl Acad Sci USA 86:10029-10033; Co, et al., "Humanized antibodies
for antiviral therapy," 1991 Proc Natl Acad Sci USA
88:2869.+-.2873; Co, et al., "Chimeric and humanized antibodies
with specificity for the CD33 antigen," 1992 J Immunol
148:1149-1154), and "veneering" (Mark, et al., "Derivation of
therapeutically active humanized and veneered anti-CD18 antibodies.
In: Metcalf B W, Dalton B J, eds. Cellular adhesion: molecular
definition to therapeutic potential. New York: Plenum Press,
1994:291-312).
[0065] In the reshaping process on the basis of homology, the
rodent variable region is compared with the consensus sequence of
the protein sequence subgroup to which it belongs. Similarly, the
selected human constant region accepting framework is compared with
its family consensus sequence. Gussowal, et al., "Humanization of
monoclonal antibodies," 1991 Meth Enzymol 203:99-121. The sequence
analyses identify residues, which may have undergone mutation
during the affinity maturation procedure and may therefore be
idiosyncratic. Inclusion of the more common human residues is said
to lessen immunogenicity problems by replacing human acceptor
idiosyncratic residues. Further, the reshaping process is said to
allow comparison of human and rodent consensus sequences to
identify any systematic "species" differences. RSV19 antibodies
were humanized by employing this procedure. Taylor et al.,
"Humanized monoclonal antibody to respiratory syncitial virus,"
1991 Lancet 337:1411-1412; Tempest, et al., "Reshaping a human
monoclonal antibody to inhibit human respiratory syncitial virus
infection in vivo," 1991 Bio/Technol 9:266-271.
[0066] Hyperchimerization is an alternative method of identifying
residues outside CDR regions that are likely to be involved in the
reconstitution of binding activity. In this method, the human
sequences are compared with murine variable region sequences and
the one with highest homology is selected as the acceptor
framework. As in the reshaping procedure, the "idiosyncratic"
residues are replaced by more commonly occurring human residues.
The non-CDR residues that may be interacting with the CDR sequences
are identified. Finally, it is determined which one of these
residues is to be included in the variable region framework.
Humanized antibodies against CD33 antigen were reportedly developed
by this method. Co, et al., "Chimeric and humanized antibodies with
specificity for the CD33 antigen," 1992 J Immunol 148:1149-154. See
also Carter, et al., "Humanization of an anti-p185 HER2 antibody
for human cancer therapy," 1992 Proc Natl Acad Sci USA
89:4285-4289.
[0067] The displayed surface of the protein is the primary
determinant of its immunogenicity. A humanized murine antibody can
thus be made less immunogenic by replacing exposed residues that
differ from those commonly found in human antibodies. This method
of humanization is referred to as "veneering." Appropriate
replacement of the outer residues may have little or no impact on
the inner domains or interdomain framework. Veneering is a two-step
process. In the first step, the most homologous human variable
regions are selected and compared by each single residue to the
corresponding mouse variable regions. In the second step, the
residues present in the human homologue replace the mouse framework
residues, which differ from its human homologue. This replacement
involves only those residues that are on the surface and at least
partially exposed.
[0068] Nevertheless, it took more than a quarter century of
research for monoclonal antibody technology and genetic engineering
methods to result in the development of immunoglobulin molecules
for treatment of human diseases. Indeed, it was not until the past
five years that monoclonal antibodies became an expanding class of
therapeutics. See Glennie M J and van de Winkel J G, Drug Discov
Today 2003 Jun. 1; 8(11):503-10; Souriau C and Hudson P J,
"Recombinant antibodies for cancer diagnosis and therapy," 2003
Expert Opin Biol Ther. 3(2):305-18. See also Pendley C, et al.,
"Immunogenicity of therapeutic monoclonal antibodies," 2003 Curr
Opin Mol. Ther. 5(2):172-9.
[0069] All the same, an average of less than one therapeutic
antibody per year has been introduced to the market beginning in
1986, eleven years after the publication of monoclonal antibodies.
Five murine monoclonal antibodies were introduced into human
medicine over a ten year period from 1986-1995, including
"muromonab-CD3" (OrthoClone OKT3.RTM.), which binds to a molecule
on the surface of T cells and was launched in 1986 to prevent acute
rejection of organ transplants; "edrecolomab" (Panorex.RTM.),
launched in 1995 for treatment of colorectal cancer; "odulimomab"
(Antilfa.RTM.), launched in 1997 for use in transplant rejection;
and, "ibritumomab" (Zevalin.RTM. yiuxetan), launched in 2002 for
use in non-Hodgkin's lymphoma. Additionally, one monoclonal Fab,
"abciximab" (ReoPro.RTM.), was launched in 1995. It inhibits the
clumping of platelets by binding the receptors on their surface
that normally are linked by fibrinogen and may be helpful in
preventing reclogging of the coronary arteries in patients who have
undergone angioplasty. Three chimeric monoclonal antibodies were
also launched: "rituximab" (Rituxan.RTM.), in 1997, which binds to
the CD20 molecule found on most B cells and is used to treat B cell
lymphomas; "basiliximab" (Simulect.RTM.), in 1998 for transplant
rejection; and "infliximab" (Remicade.RTM.) which binds to tumor
necrosis factor-alpha (TNF-a), in 1998 for treatment of rheumatoid
arthritis and Crohn's disease. Additionally, "abciximab"
(ReoPro.RTM.), a 47.6 kD Fab fragment of the chimeric human-murine
monoclonal antibody 7E3 that binds to the glycoprotein (GP)
IIb/IIIa receptor of human platelets, was launched in 1995 as an
adjunct to percutaneous coronary intervention for the prevention of
cardiac ischemic complications in patients undergoing percutaneous
coronary intervention. Finally, seven "humanized" monoclonals were
launched from 1997-2003: "daclizumab" (Zenapax.RTM.) in 1997, which
binds to part of the IL-2 receptor produced at the surface of
activated T cells and is used to prevent acute rejection of
transplanted kidneys; "palivizumab" (Synagis.RTM.) in 1998 for RSV;
"trastuzumab" (Herceptin.RTM.) in 1998, which binds HER-2, a growth
factor receptor found on breast cancers cells; "gemtuzumab"
(Mylotarg.RTM.) in 2000, which is a conjugate of a monoclonal
antibody that binds CD33, a cell-surface molecule expressed by the
cancerous cells in acute myelogenous leukemia (AML) but not found
on the normal stem cells needed to repopulate the bone marrow; and
"alemtuzumab" (MabCampath.RTM.) in 2001, which binds to CD52, a
molecule found on white blood cells and has produced temporary
remission of chronic lymphocytic leukemia; "adalimumab"
(Humira.RTM. (D2E7)), a human anti-TNF monoclonal containing
human-derived heavy chain and light chain variable regions and
human IgG:.kappa. constant regions was launched in 2002 for the
treatment of rheumatoid arthritis; and, "omalizumab" (Xolair.RTM.),
which binds to IgE and prevents it from binding to mast cells was
approved in 2003 for the treatment of adults and adolescents over
12 years of age with moderate to severe persistent asthma who have
a positive skin test or in vitro reactivity to a perennial
aeroallergen and whose symptoms are inadequately controlled with
inhaled corticosteroids.
[0070] Thus, protein engineering has been applied in an effort to
diminish problems related to immunogenicity of administered
recombinant immunoglobulin polypeptides and to try to alter
antibody effector functions. However, problems remain. For example,
the majority of cancer patients treated with rituximab relapse,
generally within about 6-12 months, and fatal infusion reactions
within 24 hours of rituximab infusion have been reported. These
fatal reactions followed an infusion reaction complex that included
hypoxia, pulmonary infiltrates, acute respiratory distress
syndrome, myocardial infarction, ventricular fibrillation or
cardiogenic shock. Acute renal failure requiring dialysis with
instances of fatal outcome has also been reported in the setting of
tumor lysis syndrome following treatment with rituximab, as have
severe mucocutaneous reactions, some with fatal outcome.
Additionally, high doses of rituximab are required for intravenous
injection because the molecule is large, approximately 150 kDa, and
diffusion is limited into the lymphoid tissues where many tumor
cells reside.
[0071] Trastuzumab administration can result in the development of
ventricular dysfunction and congestive heart failure, and the
incidence and severity of cardiac dysfunction has been reported to
be particularly high in patients who received trastuzumab in
combination with anthracyclines and cyclophosphamide. Trastuzumab
administration can also result in severe hypersensitivity reactions
(including anaphylaxis), infusion reactions, and pulmonary
events.
[0072] Patients receiving daclizumab immunosuppressive therapy are
at increased risk for developing lymphoproliferative disorders and
opportunistic infections, and it is not known whether daclizumab
use will have a long-term effect on the ability of the immune
system to respond to antigens first encountered during
daclizumab-induced immunosuppression.
[0073] Hepatotoxicity, including severe hepatic veno-occlusive
disease (VOD), has also been reported in association with the use
of gemtuzumab as a single agent, as part of a combination
chemotherapy regimen, and in patients without a history of liver
disease or hematopoietic stem-cell transplant (HSCT). Patients who
receive gemtuzumab either before or after HSCT, patients with
underlying hepatic disease or abnormal liver function, and patients
receiving gemtuzumab in combinations with other chemotherapy may be
at increased risk for developing severe VOD. Death from liver
failure and from VOD has been reported in patients who received
gemtuzumab, and it has been cautioned that even careful monitoring
may not identify all patients at risk or prevent the complications
of hepatotoxicity.
[0074] Hepatotoxicity was also reported in patients receiving
alemtuzumab. Serious and, in some rare instances fatal,
pancytopenia/marrow hypoplasia, autoimmune idiopathic
thrombocytopenia, and autoimmune hemolytic anemia have occurred in
patients receiving alemtuzumab therapy. Alemtuzumab can also result
in serious infusion reactions as well as opportunistic
infections.
[0075] In patients treated with adalimumab, serious infections and
sepsis, including fatalities, have been reported, as has the
exacerbation of clinical symptoms and/or radiographic evidence of
demyelinating disease, and patients treated with adalimumab in
clinical trials had a higher incidence of lymphoma than the
expected rate in the general population.
[0076] Serious adverse reactions in clinical studies with
omalizumab have included malignancies and anaphylaxis, in which the
observed incidence of malignancy among omalizumab-treated patients
(0.5%) was numerically higher than among patients in control groups
(0.2%).
[0077] Smaller immunoglobulin molecules have been constructed in an
effort to overcome various problems associated with whole
immunoglobulin therapy. Single chain immunoglobulin variable region
fragment polypeptides (scFvs) are made of an immunoglobulin heavy
chain variable domain joined via a short linker peptide to an
immunoglobulin light chain variable domain. Huston et al., 1988
Proc. Natl. Acad. Sci. USA, 85:5879-83. It has been suggested that
the smaller size of scFv molecules may lead to more rapid clearance
from plasma and more effective penetration into tissues than whole
immunoglobulins. See, e.g., Jain, 1990 Cancer Res. 50:814s-819s. An
anti-tumor scFv was reported to show more rapid tumor penetration
and more even distribution through the tumor mass than the
corresponding chimeric antibody. Yokota et al., Cancer Res.
52:3402-08 (1992).
[0078] Despite advantages that scFv molecules may have with regard
to serotherapy, drawbacks to this therapeutic approach also exist.
For example, rapid clearance of scFv may prevent delivery of a
minimum effective dose to the target tissue. Additionally,
manufacturing adequate amounts of scFv for administration to
patients has been challenging due to difficulties in expression and
isolation of scFv that adversely affect yields. During expression,
scFv molecules lack stability and often aggregate due to pairing of
variable regions from different molecules. Furthermore, production
levels of scFv molecules in mammalian expression systems are
reportedly low, which may limit the potential for efficient
manufacturing of scFv molecules for therapy. Davis et al., 1990 J.
Biol. Chem. 265:10410-18; Traunecker et al., 1991 EMBO J.
10:3655-59. Strategies for means to improve production have been
explored, and reportedly include the addition of glycosylation
sites to variable regions. See, e.g., U.S. Pat. No. 5,888,773; Jost
et al., 1994 J. Biol. Chem. 269:26267-73. Another disadvantage to
the use of scFvs for therapy is the lack of effector function. An
scFv that lacks the cytolytic functions, ADCC, and complement
dependent-cytotoxicity may be less effective or ineffective for
treating disease. Even though development of scFv technology began
over 12 years ago, there are currently no scFv products approved
for therapy.
[0079] Alternatively, it has been proposed that fusion of an scFv
to another molecule, such as a toxin, could take advantage of the
specific antigen-binding activity and the small size of an scFv to
deliver the toxin to a target tissue. Chaudary et al., 1989 Nature
339:394; Batra et al., 1991 Mol. Cell. Biol. 11:2200. Conjugation
or fusion of toxins to scFvs has thus been offered as an
alternative strategy to provide potent, antigen-specific molecules,
but dosing with such conjugates or chimeras can be limited by
excessive and/or non-specific toxicity due to the toxin moiety of
such preparations. Toxic effects may include supraphysiological
elevation of liver enzymes and vascular leak syndrome, and other
undesired effects. In addition, immunotoxins are themselves highly
immunogenic upon administration to a host, and host antibodies
generated against the immunotoxin limit potential usefulness for
repeated therapeutic treatments of an individual.
[0080] Fusion proteins in which immunoglobulin constant region
polypeptide sequences are present and nonimmunoglobulin sequences
are substituted for the antibody variable regions have also been
investigated. For example, CD4, the T cell surface protein
recognized by HIV, was recombinantly fused to an immunoglobulin Fc
effector domain, and an IL-2-IgG1 fusion protein reportedly
effected complement-mediated lysis of IL-2 receptor-bearing cells.
See Sensel et al., Chem. Immunol. 65:129-158 (1997). An extensive
introduction as well as detailed information about all aspects of
recombinant antibody technology can be found in the textbook
"Recombinant Antibodies" (John Wiley & Sons, NY, 1999). A
comprehensive collection of detailed antibody engineering lab
Protocols can be found in R. Kontermann and S. Dubel (eds.), "The
Antibody Engineering Lab Manual" (Springer Verlag, Heidelberg/New
York, 2000).
[0081] Diseases and disorders thought to be amenable to some type
of immunoglobulin therapy include cancer and immune system
disorders. Cancer includes a broad range of diseases, affecting
approximately one in four individuals worldwide. Rapid and
unregulated proliferation of malignant cells is a hallmark of many
types of cancer, including hematological malignancies. Although
patients with a hematologic malignant condition have benefited from
advances in cancer therapy in the past two decades, Multani et al.,
1998 J. Clin. Oncology 16:3691-3710, and remission times have
increased, most patients still relapse and succumb to their
disease. Barriers to cure with cytotoxic drugs include, for
example, tumor cell resistance and the high toxicity of
chemotherapy, which prevents optimal dosing in many patients.
[0082] Nevertheless, patients have been treated with
immunotherapeutics that target malignant cells, i.e., to antigens
expressed on tumor cells. With regard to the selection of tumor
cell surface antigens suitable for use as immunotherapy targets, it
is preferable that such a target antigen is not expressed by normal
tissues, particularly where the preservation of such tissue is
important to host survival. In the case of hematologic malignancy,
malignant cells express many antigens that are not expressed on the
surfaces of stem cells or other essential cells. Treatment of a
hematologic malignant condition using a therapeutic regimen that
depletes both normal and malignant cells of hematological origin
has been acceptable where regeneration of normal cells from
progenitors can occur after therapy has ended. Additionally, the
target antigen is desirably expressed on all or virtually all
clonogenic populations of tumor cells, and it is best that
expression persists despite selective pressure from immunoglobulin
therapy. Strategies that employ selection of a cell surface
idiotype (e.g., a particular idiotope) as a target for therapy of B
cell malignancy have been limited by the outgrowth of tumor cell
variants with altered surface idiotype expression, even where the
antigen exhibits a high degree of tumor selectivity. Meeker et al.,
1985 N. Engl. J. Med. 312:1658-65. The selected antigen should also
traffic properly after an immunoglobulin binds to it. Shedding or
internalization of a cell surface target antigen after an
immunoglobulin binds to the antigen may allow tumor cells to escape
destruction, thus limiting the effectiveness of serotherapy.
Finally, binding of an immunoglobulin to cell surface target
antigens that transmit or transduce cellular activation signals may
result in improved functional responses to immunotherapy in tumor
cells, and can lead to growth arrest and/or apoptosis. While all of
these properties are important, the triggering of apoptosis after
an immunoglobulin binds to the target antigen may also be a
critical factor in achieving successful serotherapy.
[0083] Antigens that have been tested as targets for serotherapy of
B and T cell malignancies include Ig idiotype (Brown et al., 1989
Blood 73:651-61), CD19 (Hekman et al., 1991 Cancer Immunol.
Immunother. 32:364-72), Vlasveld et al., 1995 Cancer Immunol.
Immunother. 40:37-47), CD20 (Press et al., 1987 Blood 69: 584-91),
Maloney et al., 1997 J. Clin. Oncol. 15:3266-74), CD21 (Scheinberg
et al., 1990 J. Clin. Oncol. 8:792-803), CD5 (Dillman et al., 1986
J. Biol. Respn. Mod. 5:394-410), and CD52 (CAMPATH) (Pawson et al.,
1997 J. Clin. Oncol. 15:2667-72). Of these, greater benefit for
therapy of B cell lymphomas has been obtained using molecules that
target CD20. Other targets have been limited by biological
properties of the antigen. For example, surface idiotype can be
altered through somatic mutation, allowing tumor cell escape. CD5,
CD21, and CD19 are rapidly internalized after monoclonal antibody
binding, allowing tumor cells to escape destruction unless
monoclonal antibodies are conjugated with toxin molecules. CD22 is
expressed on only a subset of B cell lymphomas, thereby limiting
its usefulness, while CD52 is expressed on both T cells and B cells
and may therefore generate counterproductive immunosuppression by
depletion.
[0084] Treatment of patients with low grade or follicular B cell
lymphoma using a chimeric CD20 monoclonal antibody has been
reported to induce partial or complete responses in patients.
McLaughlin et al., 1996 Blood 88:90a (abstract, suppl. 1); Maloney
et al., 1997 Blood 90:2188-95. However, as noted above, tumor
relapse commonly occurs within six months to one year. Further
improvements in serotherapy are needed to induce more durable
responses, for example, in low grade B cell lymphoma, and to allow
effective treatment of high-grade lymphoma and other B cell
diseases.
[0085] Another approach has been to target radioisotopes to B cell
lymphomas using monoclonal antibodies specific for CD20. While the
effectiveness of therapy is reportedly increased, associated
toxicity from the long in vivo half-life of the radioactive
antibody increases also, sometimes requiring that the patient
undergo stem cell rescue. Press et al., 1993 N. Eng. J. Med.
329:1219-1224; Kaminski et al., 1993 N. Eng. J. Med. 329:459-65.
Monoclonal antibodies to CD20 have also been cleaved with proteases
to yield F(ab').sub.2 or Fab fragments prior to attachment of
radioisotope. This has been reported to improve penetration of the
radioisotope conjugate into the tumor and to shorten the in vivo
half-life, thus reducing the toxicity to normal tissues. However,
these molecules lack effector functions, including complement
fixation and/or ADCC.
[0086] CD20 was the first human B cell lineage-specific surface
molecule identified by a monoclonal antibody. It is a
non-glycosylated, hydrophobic 35 kDa B cell transmembrane
phosphoprotein that has both amino and carboxy ends situated in the
cytoplasm. Einfeld et al., 1988 EMBO J. 7:711-17. CD20 is expressed
by all normal mature B cells, but is not expressed by precursor B
cells. Natural ligands for CD20 have not been identified, and the
function of CD20 in B cell biology is still incompletely
understood.
[0087] Anti-CD20 monoclonal antibodies affect the viability and
growth and growth of B cells. Clark et al., 1986 Proc. Natl. Acad.
Sci. USA 83:4494-98. Extensive cross-linking of CD20 can induce
apoptosis in B lymphoma cell lines, Shan et al., 1998 Blood
91:1644-52, and cross-linking of CD20 on the cell surface has been
reported to increase the magnitude and enhance the kinetics of
signal transduction, for example, as detected by measuring tyrosine
phosphorylation of cellular substrates. Deans et al., 1993 J.
Immunol. 146:846-53. Therefore, in addition to cellular depletion
by complement and ADCC mechanisms, Fc-receptor binding by CD20
monoclonal antibodies in vivo may promote apoptosis of malignant B
cells by CD20 cross-linking, consistent with the theory that
effectiveness of CD20 therapy of human lymphoma in a SCID mouse
model may be dependent upon Fc-receptor binding by the CD20
monoclonal antibody. Funakoshi et al., 1996 J. Immunotherapy
19:93-101. The presence of multiple membrane spanning domains in
the CD20 polypeptide (Einfeld et al., 1988 EMBO J. 7:711-17;
Stamenkovic et al., 1988 J. Exp. Med. 167:1975-80; Tedder et al.,
1988 J. Immunol. 141:4388-4394), prevent CD20 internalization after
antibody binding, and this was recognized as an important feature
for therapy of B cell malignancies when a murine CD20 monoclonal
antibody, 1F5, was injected into patients with B cell lymphoma,
resulting in significant depletion of malignant cells and partial
clinical responses. Press et al., 1987 Blood 69:584-91.
[0088] Because normal mature B cells also express CD20, normal B
cells are depleted by anti-CD20 antibody therapy. Reff, M. E. et
al., 1994 Blood 83:435-445. After treatment is completed, however,
normal B cells can be regenerated from CD20 negative B cell
precursors; therefore, patients treated with anti-CD20 therapy do
not experience significant immunosuppression. Depletion of normal B
cells may also be beneficial in diseases that involve inappropriate
production of autoantibodies or other diseases where B cells may
play a role. A chimeric monoclonal antibody specific for CD20,
consisting of heavy and light chain variable regions of mouse
origin fused to human IgG1 heavy chain and human kappa light chain
constant regions, reportedly retained binding to CD20 and the
ability to mediate ADCC and to fix complement. Liu et al., 1987 J.
Immunol. 139:3521-26. The mechanism of anti-tumor activity of
rituximab, discussed above, is thought to be a combination of
several activities, including ADCC, complement fixation, and
triggering of signals that promote apoptosis in malignant B cells,
although the large size of rituximab prevents optimal diffusion of
the molecule into lymphoid tissues that contain malignant B cells,
thereby limiting these anti-tumor activities. Autoimmune diseases
include autoimmune thyroid diseases, which include Graves' disease
and Hashimoto's thyroiditis. In the United States alone, there are
about 20 million people who have some form of autoimmune thyroid
disease. Autoimmune thyroid disease results from the production of
autoantibodies that either stimulate the thyroid to cause
hyperthyroidism (Graves' disease) or destroy the thyroid to cause
hypothyroidism (Hashimoto's thyroiditis). Stimulation of the
thyroid is caused by autoantibodies that bind and activate the
thyroid stimulating hormone (TSH) receptor. Destruction of the
thyroid is caused by autoantibodies that react with other thyroid
antigens. Current therapy for Graves' disease includes surgery,
radioactive iodine, or antithyroid drug therapy. Radioactive iodine
is widely used, since antithyroid medications have significant side
effects and disease recurrence is high. Surgery is reserved for
patients with large goiters or where there is a need for very rapid
normalization of thyroid function. There are no therapies that
target the production of autoantibodies responsible for stimulating
the TSH receptor. Current therapy for Hashimoto's thyroiditis is
levothyroxine sodium, and therapy is usually lifelong because of
the low likelihood of remission. Suppressive therapy has been shown
to shrink goiters in Hashimoto's thryoiditis, but no therapies that
reduce autoantibody production to target the disease mechanism are
known.
[0089] Rheumatoid arthritis (RA) is a chronic disease characterized
by inflamation of the joints, leading to swelling, pain, and loss
of function. RA affects an estimated 2.5 million people in the
United States. RA is caused by a combination of events including an
initial infection or injury, an abnormal immune response, and
genetic factors. While autoreactive T cells and B cells are present
in RA, the detection of high levels of antibodies that collect in
the joints, called rheumatoid factor, is used in the diagnosis of
RA. Current therapy for RA includes many medications for managing
pain and slowing the progression of the disease. No therapy has
been found that can cure the disease. Medications include
nonsteroidal antiinflamatory drugs (NSAIDS), and disease modifying
antirheumatic drugs (DMARDS). NSAIDS are useful in benign disease,
but fail to prevent the progression to joint destruction and
debility in severe RA. Both NSAIDS and DMARDS are associated with
signficant side effects. Only one new DMARD, Leflunomide, has been
approved in over 10 years. Leflunomide blocks production of
autoantibodies, reduces inflamation, and slows progression of RA.
However, this drug also causes severe side effects including
nausea, diarrhea, hair loss, rash, and liver injury.
[0090] Systemic Lupus Erythematosus (SLE) is an autoimmune disease
caused by recurrent injuries to blood vessels in multiple organs,
including the kidney, skin, and joints. SLE is estimated to affect
over 500,000 people in the United States. In patients with SLE, a
faulty interaction between T cells and B cells results in the
production of autoantibodies that attack the cell nucleus. These
include anti-double stranded DNA and anti-Sm antibodies.
Autoantibodies that bind phospholipids are also found in about half
of SLE patients, and are responsible for blood vessel damage and
low blood counts. Immune complexes accumulate the kidneys, blood
vessels, and joints of SLE patients, where they cause inflamation
and tissue damage. No treatment for SLE has been found to cure the
disease. NSAIDS and DMARDS are used for therapy depending upon the
severity of the disease. Plasmapheresis with plasma exchange to
remove autoantibodies can cause temporary improvement in SLE
patients. There is general agreement that autoantibodies are
responsible for SLE, so new therapies that deplete the B cell
lineage, allowing the immune system to reset as new B cells are
generated from precursors, would offer hope for long lasting
benefit in SLE patients.
[0091] Sjogren's syndrome is an autoimmune disease characterized by
destruction of the body's moisture-producing glands. Sjogren's
syndrome is one of the most prevelant autoimmune disorders,
striking up to an estimated 4 million people in the United States.
About half of people stricken with Sjogren's syndrome also have a
connective tissue disease, such as RA, while the other half have
primary Sjogren's syndrome with no other concurrent autoimmune
disease. Autoantibodies, including anti-nuclear antibodies,
rheumatoid factor, anti-fodrin, and anti-muscarinic receptor are
often present in patients with Sjogren's syndrome. Conventional
therapy includes corticosteroids, and additional more effective
therapies would be of benefit.
[0092] Immune thrombocytopenic purpura (ITP) is caused by
autoantibodies that bind to blood platelets and cause their
destruction. Drugs cause some cases of ITP, and others are
associated with infection, pregnancy, or autoimmune disease such as
SLE. About half of all cases are classified as "idiopathic",
meaning the cause is unknown. The treatment of ITP is determined by
the severity of the symptoms. In some cases, no therapy is needed
although in most cases immunosuppressive drugs, including
corticosteroids or intravenous infusions of immune globulin to
deplete T cells, are provided. Another treatment that usually
results in an increased number of platelets is removal of the
spleen, the organ that destroys antibody-coated platelets. More
potent immunosuppressive drugs, including cyclosporine,
cyclophosphamide, or azathioprine are used for patients with severe
cases. Removal of autoantibodies by passage of patients' plasma
over a Protein A column is used as a second line treatment in
patients with severe disease. Additional more effective therapies
are desired.
[0093] Multiple sclerosis (MS) is also an autoimmune disease. It is
characterized by inflamation of the central nervous system and
destruction of myelin, which insulates nerve cell fibers in the
brain, spinal cord, and body. Although the cause of MS is unknown,
it is widely believed that autoimmune T cells are primary
contributors to the pathogenesis of the disease. However, high
levels of antibodies are present in the cerebral spinal fluid of
patients with MS, and some theories predict that the B cell
response leading to antibody production is important for mediating
the disease. No B cell depletion therapies have been studies in
patients with MS, and there is no cure for MS. Current therapy is
corticosteroids, which can reduce the duration and severity of
attacks, but do not affect the course of MS over time. New
biotechnology interferon (IFN) therapies for MS have recently been
approved but additional more effectiver therapies are desired.
[0094] Myasthenia Gravis (MG) is a chronic autoimmune neuromuscular
disorder that is characterized by weakness of the voluntary muscle
groups. MG effects about 40,000 people in the united states. MG is
caused by autoantibodies that bind to acetylcholine receptors
expressed at neuromuscular junctions. The autoantibodies reduce or
block acetylcholine receptors, preventing the transmission of
signals from nerves to muscles. There is no known cure for mg.
Common treatments include immunosuppression with corticosteroids,
cyclosporine, cyclophosphamide, or azathioprine. Surgical removal
of the thymus is often used to blunt the autoimmune response.
Plasmapheresis, used to reduce autoantibody levels in the blood, is
effective in mg, but is short-lived because the production of
autoantibodies continues. Plasmapheresis is usually reserved for
severe muscle weakness prior to surgery. New and effective
therapies would be of benefit.
[0095] Psoriasis affects approximately five million people, and is
characterized by autoimmune inflammation in the skin. Psoriasis is
also associated with arthritis in 30% (psoriatic arthritis). Many
treatments, including steroids, uv light retenoids, vitamin d
derivatives, cyclosporine, methotrexate have been used but it is
also plain that psoriasis would benefit from new and effective
therapies. Scleroderma is a chronic autoimmune disease of the
connective tissue that is also known as systemic sclerosis.
Scleroderma is characterized by an overproduction of collagen,
resulting in a thickening of the skin, and approximately 300,000
people in the United States have scleroderma, which would also
benefit from new and effective therapies.
[0096] There is a clear need for improved compositions and methods
to treat malignacies, including B cell malignancies and disorders
including autoimmune diseases, disorders, and conditions, as well
as other diseases, disorders, and conditions. The compositions and
methods of the present invention described and claimed herein
provide such improved compositions and methods as well as other
advantages.
SUMMARY OF THE INVENTION
[0097] It is an aspect of the present invention to provide a
binding domain-immunoglobulin fusion protein, comprising a binding
domain polypeptide that is fused or otherwise connected to an
immunoglobulin hinge or hinge-acting region polypeptide, which in
turn is fused or otherwise connected to a region comprising one or
more native or engineered constant regions from an immunoglobulin
heavy chain, other than CH1, for example, the CH2 and CH3 regions
of IgG and IgA, or the CH3 and CH4 regions of IgE. The binding
domain-immunoglobulin fusion protein further comprises a region
that comprises, consists essentially of, or consists of, a native
or engineered immunoglobulin heavy chain CH2 constant region
polypeptide (or CH3 in the case of a construct derived in whole or
in part from IgE) that is fused or otherwise connected to the hinge
region polypeptide and a native or engineered immunoglobulin heavy
chain CH3 constant region polypeptide (or CH4 in the case of a
construct derived in whole or in part from IgE) that is fused or
otherwise connected to the CH2 constant region polypeptide (or CH3
in the case of a construct derived in whole or in part from IgE).
Such binding domain-immunoglobulin fusion proteins are capable of
at least one immunological activity selected from the group
consisting of antibody dependent cell-mediated cytotoxicity and
complement fixation. Such binding domain polypeptides are also
capable of binding or specifically binding to a target, for
example, a target antigen.
[0098] In certain embodiments, for example, the binding domain
polypeptide comprises at least one immunoglobulin variable region
polypeptide that is selected from a native or engineered
immunoglobulin light chain variable region polypeptide and/or a
native or engineered immunoglobulin heavy chain variable region
polypeptide. In certain further embodiments the binding
domain-immunoglobulin fusion protein comprises a native or
engineered immunoglobulin heavy chain variable region polypeptide,
wherein the heavy chain variable region polypeptide is an
engineered human immunoglobulin heavy chain variable region
polypeptide (or an engineered immunoglobulin heavy chain variable
region polypeptide from a non-human species) comprising a mutation,
substitution, or deletion of an amino acid(s) at a location
corresponding to any one or more of amino acid positions 9, 10, 11,
12, 108, 110, and/or 112. Mutations, substitutions, or deletions of
an amino acid(s) at a location corresponding to any one or more of
amino acid positions 9, 10, 11, 12, 108, 110, and/or 112 in a heavy
chain variable region may be included within a construct such as
the construct corresponding to, for example, SEQ ID NO:212. In
certain embodiments the immunoglobulin variable region polypeptide
is derived from, for example, a human immunoglobulin, and in
certain other embodiments the immunoglobulin variable region
polypeptide comprises a humanized immunoglobulin polypeptide
sequence. In certain embodiments the immunoglobulin variable region
polypeptide, whether or not humanized, is derived from a murine
immunoglobulin, or is derived from an immunoglobulin from another
species, including, for example a rat, a pig, a monkey, or a
camelid.
[0099] According to certain embodiments of the present invention,
the binding domain polypeptide comprises, consists essentially of,
or consists of, (a) at least one native or engineered
immunoglobulin light chain variable region polypeptide; (b) at
least one native or engineered immunoglobulin heavy chain variable
region polypeptide; and (c) at least one linker polypeptide that is
fused or otherwise connected to the polypeptide of (a) and to the
polypeptide of (b). In certain further embodiments the native or
engineered immunoglobulin light chain variable region and heavy
chain variable region polypeptides are derived or constructed from
human immunoglobulins, and in certain other further embodiments the
linker polypeptide comprises at least one polypeptide including or
having as an amino acid sequence Gly-Gly-Gly-Gly-Ser [SEQ ID
NO:516]. In other embodiments the linker polypeptide comprises at
least two or three repeats of a polypeptide having as an amino acid
sequence Gly-Gly-Gly-Gly-Ser [SEQ ID NO:516]. In other embodiments
the linker comprises a glycosylation site, which in certain further
embodiments is an asparagine-linked glycosylation site, an O-linked
glycosylation site, a C-mannosylation site, a glypiation site or a
phosphoglycation site. In another embodiment at least one of a
native or engineered immunoglobulin heavy chain CH2 constant region
polypeptide and a native or engineered immunoglobulin heavy chain
CH3 constant region polypeptide is derived from an IgG or IgA human
immunoglobulin heavy chain. In another embodiment at least one of a
native or engineered immunoglobulin heavy chain CH3 constant region
polypeptide and a native or engineered immunoglobulin heavy chain
CH4 constant region polypeptide is derived from an IgE human
immunoglobulin heavy chain.
[0100] An immunoglobulin hinge region polypeptide may comprise,
consist essentially or, or consist of, for example, any of (1) any
hinge or hinge-acting peptide or polypeptide that occurs naturally
for example, a human immunoglobulin hinge region polypeptide
including, for example, a wild-type human IgG hinge or a portion
thereof, a wild-type human IgA hinge or a portion thereof, a
wild-type human IgD hinge or a portion thereof, or a wild-type
human IgE hinge-acting region, i.e., IgE CH2, or a portion thereof,
a wild-type camelid hinge region or a portion thereof (including a
IgG1 llama hinge region or portion thereof, a IgG2 llama hinge
region or portion thereof, and a IgG3 llama hinge region or portion
thereof), a nurse shark hinge region or portion thereof, and/or a
spotted ratfish hinge region or a portion thereof; (2) a mutated or
otherwise altered or engineered hinge region polypeptide that
contains no cysteine residues and that is derived or constructed
from a wild-type immunoglobulin hinge region polypeptide having one
or more cysteine residues; (3) a mutated or otherwise altered or
engineered hinge region polypeptide that contains one cysteine
residue and that is derived from a wild-type immunoglobulin hinge
region polypeptide having one or more cysteine residues; (4) a
hinge region polypeptide that has been mutated or otherwise altered
or engineered to contain or add one or more glycosylation sites,
for example, an asparagine-linked glycosylation site, an O-linked
glycosylation site, a C-mannosylation site, a glypiation site or a
phosphoglycation site; (5) a mutated or otherwise altered or
engineered hinge region polypeptide in which the number of cysteine
residues is reduced by amino acid substitution or deletion, for
example, a mutated or otherwise altered or engineered IgG1 or IgG4
hinge region containing for example zero, one, or two cysteine
residues, a mutated or otherwise altered or engineered IgG2 hinge
region containing for example zero, one, two or three cysteine
residues, a mutated or otherwise altered or engineered IgG3 hinge
region containing for example zero, one, two, three, or from four
to ten cysteine residues, or a mutated or otherwise altered or
engineered human IgA1 or IgA2 hinge region polypeptide that
contains zero or only one or two cysteine residues (e.g., an "SCC"
hinge), a mutated or otherwise altered or engineered IgD hinge
region containing no cysteine residues, or a mutated or otherwise
altered or engineered human IgE hinge-acting region, i.e., IgE CH2
region polypeptide that contains zero or only one, two, three or
four cysteine residues; or (6) any other connecting region molecule
described or referenced herein or otherwise known or later
discovered as useful for connecting adjoining immunoglobulin
domains such as, for example, a CH1 domain and a CH2 domain. For
example, a hinge region polypeptide may be selected from the group
consisting of (i) a wild-type human IgG1 immunoglobulin hinge
region polypeptide, for example, (ii) a mutated or otherwise
altered or engineered human IgG1 or other immunoglobulin hinge
region polypeptide that is derived or constructed from a wild-type
immunoglobulin hinge region polypeptide having three or more
cysteine residues, wherein said mutated human IgG1 or other
immunoglobulin hinge region polypeptide contains two cysteine
residues and wherein a first cysteine of the wild-type hinge region
is not mutated, (iii) a mutated or otherwise altered or engineered
human IgG1 or other immunoglobulin hinge region polypeptide that is
derived from a wild-type immunoglobulin hinge region polypeptide
having three or more cysteine residues, wherein said mutated human
IgG1 or other immunoglobulin hinge region polypeptide contains no
more than one cysteine residue, and (iv) a mutated or otherwise
altered or engineered human IgG1 or other immunoglobulin hinge
region polypeptide that is derived from a wild-type immunoglobulin
hinge region polypeptide having three or more cysteine residues,
wherein said mutated or otherwise altered or engineered human IgG1
or other immunoglobulin hinge region polypeptide contains no
cysteine residues. In certain embodiments, for example, the
immunoglobulin hinge region polypeptide is a mutated or otherwise
altered or engineered hinge region polypeptide and exhibits a
reduced ability to dimerize, relative to a wild-type human
immunoglobulin G or other wild type hinge region or hinge-acting
polypeptide.
[0101] The immunoglobulin heavy chain constant region polypeptides
may be, for example, native or engineered CH2 and CH3 domains of an
isotype that is human IgG or human IgA. The immunoglobulin heavy
chain constant region polypeptides may also be, for example, native
or engineered immunoglobulin heavy chain constant region CH3 and
CH4 polypeptides of an isotype that is human IgE.
[0102] In certain other embodiments the target or target antigen
may be, for example, CD19 (B-lymphocyte antigen CD19, also referred
to as B-lymphocyte surface antigen B4, or Leu-12), CD20
(B-lymphocyte antigen 20, also referred to as B-lymphocyte surface
antigen B1, Leu-16, or Bp35), CD22 (B-cell receptor CD22, also
referred to as Leu-14, B-lymphocyte cell adhesion molecule, or
BL-CAM), CD37 (leukocyte antigen CD37), CD40 (B-cell surface
antigen CD40, also referred to as Tumor Necrosis Factor receptor
superfamily member 5, CD40L receptor, or Bp50), CD80 (T lymphocyte
activation antigen CD80, also referred to as Activation B7-1
antigen, B7, B7-1, or BB1), CD86 (T lymphocyte activation antigen
CD86, also referred to as Activation B7-2 antigen, B70, FUN-1, or
BU63), CD137 (also referred to as Tumor Necrosis Factor receptor
superfamily member 9), CD152 (also referred to as cytotoxic
T-lymphocyte protein 4 or CTLA-4), CD45 (Leukocyte common antigen,
also referred to as L-CA, T200, and EC 3.1.3.48), CD45RA (an
isoform of CD45, and an antigen expressed on naive or immature
lymphocytes), CD45RB (an isoform of CD45), CD45RO (an isoform of
CD45, and a common leukocyte antigen expressed on memory B and T
cells), L6 (Tumor-associated antigen L6, also referred to as
Transmembrane 4 superfamily member 1, Membrane component surface
marker 1, or M3S1), CD2 (T-cell surface antigen CD2, also referred
to as T-cell surface antigen T11/Leu-5, LFA-2, LFA-3 receptor,
Erythrocyte receptor, or Rosette receptor), CD28 (T-cell-specific
homodimer surface protein CD28, also referred to as Tp44), CD30
(lymphocyte activation antigen CD30, also referred to as Tumor
Necrosis Factor receptor superfamily member 8, CD30L receptor, or
Ki-1), LD50 (also referred to as Intercellular adhesion molecule-3
(ICAM3), or ICAM-R), CD54 (also referred to as Intercellular
adhesion molecule-1 (ICAM1), or Major group rhinovirus receptor),
B7-H1 (ligand for an immunoinhibitory receptor expressed by
activated T cells, B cells, and myeloid cells, also referred to as
PD-L1; see Dong, et al., "B7-H1, a third member of the B7 family,
co-stimulates T-cell proliferation and interleukin-10 secretion,"
1999 Nat. Med. 5:1365-1369), CD134 (also referred to as Tumor
Necrosis Factor receptor superfamily member 4,OX40, OX40L receptor,
ACT35 antigen, or TAX-transcriptionally activated glycoprotein 1
receptor), 41 BB (4-1 BB ligand receptor, T-cell antigen 4-1BB, or
T-cell antigen ILA), CD153 (also referred to as Tumor Necrosis
Factor ligand superfamily member 8, CD30 ligand, or CD30-L), CD154
(also referred to as Tumor Necrosis Factor ligand superfamily
member 5, CD40 ligand, CD40-L, TNF-related activation protein,
TRAP, or T cell antigen Gp39), ICOS (Inducible Costimulator), CD3
(one or more of the delta, epsilon, gamma, eta and/or zeta chains,
alone or in combination), CD4 (T-cell surface glycoprotein CD4,
also referred to as T-cell surface antigen T4/Leu-3), CD25 (also
referred to as Interleukin-2 receptor alpha chain, IL-2 receptor
alpha subunit, p55, or Tac antigen), CD8a (T-cell surface
glycoprotein CD8 alpha chain, also referred to as T-lymphocyte
differentiation antigen, T8/Leu-2, and Lyt-2), CD11b (also referred
to as Integrin alpha-M, Cell surface glycoprotein MAC-1 alpha
subunit, CR-3 alpha chain, Leukocyte adhesion receptor Mol, or
Neutrophil adherence receptor), CD14 (Monocyte differentiation
antigen CD14, also referred to as Myeloid cell-specific
leucine-rich glycoprotein or LPS receptor), CD56 (also referred to
as Neural cell adhesion molecule 1), or CD69 (also referred to as
Early T-cell activation antigen p60, Gp32/28, Leu-23, MLR-3,
Activation inducer molecule, or AIM), and TNF factors (for example
TNF-.alpha.). The above list of construct targets and/or target
antigens is exemplary only and is not exhaustive.
[0103] In another aspect, the invention includes a binding
construct (or a polynucleotide encoding such a construct) that
comprises a CD154 extracellular domain, or desired functional
portion thereof. In one embodiment of this aspect of the invention,
for example, the binding construct comprises a CD154 extracellular
domain fused or otherwise connected to a second binding domain. The
second binding domain, for example, may comprise, consist
essentially of, or consist of at least one immunoglobulin variable
region polypeptide. The at least one immunoglobulin variable region
polypeptide may be a native or engineered scFv. The native or
engineered scFv may be a native or engineered scFv disclosed or
described herein. The second binding domain, including a native or
engineered scFv, may be one that binds, for example, to any of the
targets, including target antigens, disclosed or described herein,
including but not limited to, for example, any of B7-H1, ICOS, L6,
CD2, CD3, CD8, CD4, CD11b, CD14, CD19, CD20, CD22, CD25, CD28,
CD30, CD37, CD40, CD45, CD50, CD54, CD56, CD69, CD80, CD86, CD134,
CD137, CD152, CD153, or CD154.
[0104] In another embodiment the binding domain polypeptide
comprises a CTLA-4 extracellular domain, or desired functional
portion thereof, and in further embodiments at least one of the
immunoglobulin heavy chain constant region polypeptides selected
from a CH2 constant region polypeptide and a CH3 constant region
polypeptide is a human IgG1 constant region polypeptide, either
native or engineered.
[0105] In another further embodiment at least one of the
immunoglobulin heavy chain constant region polypeptides selected
from a CH2 constant region polypeptide and a CH3 constant region
polypeptide is a human IgA constant region polypeptide, either
native or engineered.
[0106] In another further embodiment at least one of the
immunoglobulin heavy chain constant region polypeptides selected
from a CH3 constant region polypeptide and a CH4 constant region
polypeptide is a human IgE constant region polypeptide, either
native or engineered.
[0107] Turning to another embodiment, the present invention
provides a binding domain-immunoglobulin fusion protein,
comprising, consisting essentially of, or consisting of, (a) a
binding domain polypeptide that is fused or otherwise connected to
an immunoglobulin hinge region polypeptide; (b) a native or
engineered immunoglobulin heavy chain CH2 (or IgE Ch3) constant
region polypeptide that is fused or otherwise connected to the
hinge region polypeptide; and (c) a native or engineered
immunoglobulin heavy chain CH3 (or IgE CH4) constant region
polypeptide that is fused or otherwise connected to the CH2 (or IgE
CH3) constant region polypeptide, wherein (1) the binding domain
polypeptide comprises a CTLA-4 extracellular domain, or a portion
thereof, that is capable of binding or specifically binding to at
least one CTLA-4 ligand selected from the group consisting of CD80
and CD86, (2) the immunoglobulin hinge region polypeptide may be as
described above or herein, and may comprise, consist essentially
of, or consist of, for example, a polypeptide that is selected from
the group consisting of a native or engineered human IgA hinge
region polypeptide, a native or engineered human IgG1 hinge region
polypeptide, and a native or engineered human IgE CH2 region
polypeptide (3) a immunoglobulin heavy chain constant region
polypeptide that comprises, consists essentially of, or consists
of, a polypeptide that is selected from the group consisting of a
native or engineered human IgA heavy chain CH2 constant region
polypeptide, a native or engineered human IgG1 heavy chain CH2
constant region polypeptide, and a native or engineered human IgE
heavy chain CH3 constant region polypeptide (4) a immunoglobulin
heavy chain constant region polypeptide that comprises, consists
essentially of, or consists of, a polypeptide that is selected from
the group consisting of a native or engineered human IgA heavy
chain CH3 constant region polypeptide, a native or engineered human
IgG1 heavy chain CH3 constant region polypeptide, and a native or
engineered human IgE heavy chain CH4 constant region polypeptide,
and (5) the binding domain-immunoglobulin fusion protein is capable
of inducing at least one immunological activity selected from the
group consisting of antibody dependent cell-mediated cytotoxicity,
CDC, and complement fixation. In a further embodiment, the binding
domain-immunoglobulin fusion protein is capable of inducing two
immunological activities selected from the group consisting of
antibody dependent cell-mediated cytotoxicity, CDC, and complement
fixation.
[0108] In another embodiment the present invention provides a
binding domain-immunoglobulin fusion protein, comprising,
consisting essentially of, or consisting of (a) a binding domain
polypeptide that is fused or otherwise connected to an
immunoglobulin hinge region polypeptide, wherein said hinge region
polypeptide may be as described above or herein, and may comprise,
consist essentially of, or consist of, for example, a native or
engineered human IgE hinge-acting region, i.e., a IgE CH2 region
polypeptide; (b) a first native or engineered immunoglobulin heavy
chain constant region polypeptide that is fused or otherwise
connected to the hinge region polypeptide, wherein said native or
engineered constant region polypeptide comprises, consists
essentially of, or consists of, a native or engineered human IgE
CH3 constant region polypeptide; and (c) a second native or
engineered immunoglobulin heavy chain constant region polypeptide
that is fused or otherwise connected to the first native or
engineered constant region polypeptide, wherein said native or
engineered second constant region polypeptide comprises, consists
essentially of, or consists of, a native or engineered human IgE
CH4 constant region polypeptide and wherein (1) the binding
domain-immunoglobulin fusion protein is capable of inducing at
least one immunological activity selected from antibody dependent
cell-mediated cytotoxicity and induction of an allergic response
mechanism, and (2) the binding domain polypeptide is capable of
binding or specifically binding to an antigen. In a further
embodiment the antigen is a tumor antigen.
[0109] In certain other embodiments the present invention provides
a binding domain-immunoglobulin fusion protein, comprising,
consisting essentially of, or consisting of, (a) a binding domain
polypeptide that is fused or otherwise connected to an
immunoglobulin hinge region polypeptide, wherein the binding domain
polypeptide is capable of binding or specifically binding to at
least one antigen that is present on an immune effector cell and
wherein the hinge region polypeptide may be as described above or
herein, and may comprise, consist essentially of, or consist of,
for example, a polypeptide selected from the group consisting of a
native or engineered human IgA hinge region polypeptide, a native
or engineered human IgG hinge region polypeptide, and a native or
engineered human IgE hinge-acting region, i.e., IgE CH2 region
polypeptide; (b) a first native or engineered immunoglobulin heavy
chain constant region polypeptide that is fused or otherwise
connected to the hinge region polypeptide, wherein said first
native or engineered constant region polypeptide comprises,
consists essentially of, or consists of, a polypeptide selected
from the group consisting of a native or engineered human IgA CH2
constant region polypeptide, a native or engineered human IgG CH2
constant region polypeptide, and a native or engineered human IgE
CH3 constant region polypeptide; (c) a second native or engineered
immunoglobulin heavy chain constant region polypeptide that is
fused or otherwise connected to the first constant region
polypeptide, wherein said second constant region polypeptide
comprises, consists essentially of, or consists of, a polypeptide
selected from the group consisting of a native or engineered human
IgA CH3 constant region polypeptide, a native or engineered human
IgG CH3 constant region polypeptide, and a native or engineered
human IgE CH4 constant region polypeptide; and (d) a native or
engineered plasma membrane anchor domain polypeptide. In one
example of this embodiment, the plasma membrane anchor domain
polypeptide links to a membrane via a native or engineered
glycosyl-phosphatidylinositol-linkage. In a further embodiment the
plasma membrane anchor domain polypeptide comprises, consists
essentially of, or consists of, a native or engineered
transmembrane domain polypeptide. In another further embodiment the
membrane anchor domain polypeptide comprises, consists essentially
of, or consists of, a native or engineered transmembrane domain
polypeptide and a native or engineered cytoplasmic tail
polypeptide. In a still further embodiment the cytoplasmic tail
polypeptide comprises, consists essentially of, or consists of, a
native or engineered apoptosis signaling polypeptide sequence,
which in a still further embodiment is derived or constructed from
a native or engineered receptor death domain polypeptide, a death
domain, or a functional portion of either. In a further embodiment
the native or engineered death domain polypeptide comprises,
consists essentially of, or consists of, for example, a native or
engineered polypeptide selected from an ITIM domain (immunoreceptor
Tyr-based inhibition motif), an ITAM domain (immunoreceptor
Tyr-based activation motif), TRAF, RIP, CRADD, FADD (Fas-associated
death domain), TRADD (Tumor Necrosis Factor receptor type 1
associated DEATH domain protein), RAIDD (also referred to as RAID),
CD95 (Tumor Necrosis Factor receptor superfamily member 6, also
referred to as FASL receptor, Apoptosis-mediating surface antigen
FAS, FAS and Apo-1 antigen), TNFR1, and/or DR5 (death receptor-5).
In another embodiment the native or engineered apoptosis signaling
polypeptide sequence comprises, consists essentially of, or
consists of, for example, a polypeptide sequence derived from a
native or engineered caspase polypeptide that is caspase-3 or
caspase-8 or caspase-10, including caspase 8/FLICE/MACH/Mch5 and
caspase 10/Flice2/Mch4. In another embodiment the plasma membrane
anchor domain polypeptide comprises, consists essentially of, or
consists of, for example, a native or engineered
glycosyl-phosphatidylinositol-linkage polypeptide sequence. In
another embodiment the antigen that is present on an immune
effector cell is, for example, CD2, CD16, CD28, CD30, CD32, CD40,
CD50, CD54, CD64, CD80, CD86, B7-H1, CD134, CD137, CD152, CD153,
CD154, ICOS, CD19, CD20, CD22, CD37, L6, CD3, CD4, CD25, CD8,
CD11b, CD14, CD56, or CD69. In another embodiment the human IgG is
a native or engineered human IgG1. These binding
domain-immunoglobulin fusion proteins may be capable of inducing,
for example, at least one immunological activity selected from
antibody dependent cell-mediated cytotoxicity and/or complement
fixation and/or CDC, and are capable of binding or specifically
binding to a target, including, for example, a target antigen. In
other embodiments, the binding domain-immunoglobulin fusion
proteins may be capable of inducing, for example, two immunological
activities selected from antibody dependent cell-mediated
cytotoxicity and/or complement fixation and/or CDC, and are capable
of binding or specifically binding to a target. Immune effector
cells include, for example, granulocytes, mast cells, monocytes,
macrophages, dendritic cells, neutrophils, eosinophils, basophils,
NK cells, T cells (including Th1 cells, Th2 cells, Tc cells, memory
T cells, null cells, and large granular lymphocytes, etc.), and B
cells. This embodiment of the invention further includes the use of
such proteins for therapy, and, for example, the use of such
vectors for in vivo and ex vivo gene therapy. The above lists of
construct components and targets are not exhaustive and may include
any desired target or component that may function as, or be useful
for the purposes, described herein.
[0110] In another embodiment, the invention provides a protein
having a first protein motif that comprises, consists essentially
of, or consists of, (1) a native or engineered immunoglobulin hinge
region or hinge-acting region (e.g., IgE CH2) polypeptide that is
fused or otherwise connected to (2) a native or engineered CH2
constant region polypeptide (or native or engineered IgE CH3
constant region polypeptide). Said first protein motif may be fused
or otherwise connected to one or more other such first protein
motifs to form a second protein motif, the second protein motif
being fused or otherwise connected to (3) a native or engineered
CH3 constant region (or a native or engineered IgE CH4 constant
region) to form a third protein motif. Said first, second or third
protein motifs may be fused or otherwise connected to one or more
of the herein-described native or engineered plasma membrane anchor
domain polypeptides, including, for example, a native or engineered
transmembrane domain polypeptide, and a native or engineered
transmembrane domain polypeptide and a native or engineered
cytoplasmic tail polypeptide, such as for example, a native or
engineered apoptosis signaling polypeptide sequence, which may be
derived or constructed from a native or engineered receptor death
domain polypeptide, a death domain, or a functional portion of
either. Thus, a protein or polynucleiotide within this aspect of
the invention may be, for example, a
Hinge-CH2-CH3-TransmembraneDomain-DeathDomain construct. It may
also be, for example, a
(Hinge-CH2).sub.x--CH3-TransmembraneDomain-DeathDomain construct,
where X is from 2 to about 5, or such other number as may be needed
to achieve a desired length or Fc receptor binding and/or
complement fixation function(s). This embodiment of the invention
also includes polynucleotides encoding such proteins, vectors
including such polynucleotides, and host cells containing such
polynucleotides and vectors. This embodiment of the invention
further includes the use of such proteins for therapy, and, for
example, the use of such polynuceotides and/or vectors for in vivo
and ex vivo gene therapy. The invention provides, in another
embodiment, a binding domain-immunoglobulin fusion protein,
comprising, consisting essentially of, or consisting of, (a) a
binding domain polypeptide that is fused or otherwise connected to
an immunoglobulin hinge region polypeptide, wherein the binding
domain polypeptide is capable of binding or specifically binding to
at least one antigen that is present on a cancer cell surface and
wherein the hinge region polypeptide may be as described above or
herein, and may comprise, consist essentially of, or consist of,
for example, a polypeptide selected from the group consisting of a
native or engineered human IgA hinge region polypeptide, a native
or engineered human IgG hinge region polypeptide, and a native or
engineered human IgE hinge-acting region, i.e., IgE CH2, region
polypeptide; (b) a first native or engineered immunoglobulin heavy
chain constant region polypeptide that is fused or otherwise
connected to the hinge region polypeptide, wherein the first
constant region polypeptide comprises, consists essentially of, or
consists of, a polypeptide that is a native or engineered human IgA
CH2 constant region polypeptide, a native or engineered human IgG
CH2 constant region polypeptide, or a native or engineered human
IgE CH3 constant region polypeptide; and (c) a second native or
engineered immunoglobulin heavy chain constant region polypeptide
that is fused or otherwise connected to the first constant region
polypeptide, wherein the second constant region polypeptide
comprises, consists essentially of, or consists of, a polypeptide
that is a native or engineered human IgA CH3 constant region
polypeptide, a native or engineered human IgG CH3 constant region
polypeptide, or a native or engineered human IgE CH4 constant
region polypeptide. In a further embodiment the human IgG
polypepdides are native or engineered human IgG1 polypeptides.
[0111] In another embodiment the present invention provides a
binding domain-immunoglobulin fusion protein, comprising,
consisting essentially of, or consisting of, (a) a binding domain
polypeptide that is fused or otherwise connected to an
immunoglobulin hinge region polypeptide, wherein said hinge region
polypeptide may be as described above or herein, and may comprises,
consist essentially of, or consist of, for example, a wild-type or
engineered human IgA hinge region polypeptide; (b) a native or
engineered immunoglobulin heavy chain CH2 constant region
polypeptide that is fused or otherwise connected to the hinge
region polypeptide, wherein said native or engineered CH2 constant
region polypeptide comprises, consists essentially of, or consists
of, a native or engineered human IgA CH2 constant region
polypeptide; and (c) a native or engineered immunoglobulin heavy
chain CH3 constant region polypeptide that is fused or otherwise
connected to the native or engineered CH2 constant region
polypeptide, wherein the native or engineered CH3 constant region
polypeptide comprises, consists essentially of, or consists of, a
polypeptide that is (i) a wild-type human IgA CH3 constant region
polypeptide or other IgA region, preferably human or humanized,
that is capable of associating with J Chain, (ii) a mutated,
altered or otherwise engineered human IgA CH3 constant region
polypeptide that is, for example, incapable of associating with a J
chain, wherein (1) the binding domain-immunoglobulin fusion protein
is capable of at least one immunological activity selected from the
group consisting of antibody dependent cell-mediated cytotoxicity,
CDC, and complement fixation, and (2) the binding domain
polypeptide is capable of binding or specifically binding to a
target such as, for example, an antigen. In certain further
embodiments the mutated human IgA CH3 constant region polypeptide
that is incapable of associating with a J chain is (i) a
polypeptide comprising, consisting essentially of, or consisting
of, an amino acid sequence as set forth in SEQ ID NO:69 or (ii) a
polypeptide comprising, consisting essentially of, or consisting
of, an amino acid sequence as set forth in SEQ ID NO:74. In other
embodiments, the IgA hinge region polypeptide is a native or
engineered IgA1 hinge region polypeptide or a native or engineered
IgA2 hinge region polypeptide. In still other embodiments, the IgA
hinge region polypeptide is different from a wild-type IgA1 or IgA2
hinge region polypeptide by, for example, the alteration,
substitution, or deltion of one or more of the cysteine residues
within said wild-type hinge region.
[0112] In certain other embodiments the present invention provides
a binding domain-immunoglobulin fusion protein, comprising,
consisting essentially of, or consisting of (a) a binding domain
polypeptide that is fused or otherwise connected to an
immunoglobulin hinge region polypeptide; (b) a native or engineered
immunoglobulin heavy chain CH2 constant region polypeptide that is
fused or otherwise connected to the hinge region polypeptide,
wherein the native or engineered CH2 constant region polypeptide
comprises, consists essentially of, or consists of, a native or
engineered llama CH2 constant region polypeptide that is a native
or engineered llama IgG1 CH2 constant region polypeptide, a native
or engineered llama IgG2 CH2 constant region polypeptide, or a
native or engineered llama IgG3 CH2 constant region polypeptide;
and (c) a native or engineered immunoglobulin heavy chain CH3
constant region polypeptide that is fused or otherwise connected to
the native or engineered CH2 constant region polypeptide, wherein
said native or engineered CH3 constant region polypeptide
comprises, consists essentially of, or consists of, a native or
engineered llama CH3 constant region polypeptide that is selected
from the group consisting of a native or engineered llama IgG1 CH3
constant region polypeptide, a native or engineered llama IgG2 CH3
constant region polypeptide and a native or engineered llama IgG3
CH3 constant region polypeptide wherein (1) the binding
domain-immunoglobulin fusion protein is capable of at least one
immunological activity selected from the group consisting of
antibody dependent cell-mediated cytotoxicity, fixation of
complement and CDC, and (2) the binding domain polypeptide is
capable of binding or specifically binding to a target, for example
a target antigen. In a further embodiment the immunoglobulin hinge
region polypeptide, the native or engineered llama CH2 constant
region polypeptide and the native or engineered llama CH3 constant
region polypeptide comprise sequences derived from a native or
engineered llama IgG1 polypeptide and the fusion protein does not
include a native or engineered llama IgG1 CH1 domain. In certain
embodiments the invention provides any of the above described
binding domain-immunoglobulin fusion proteins wherein the hinge
region polypeptide is mutated, engineered, or otherwise altered to
contain a glycosylation site, which in certain further embodiments
is an asparagine-linked glycosylation site, an O-linked
glycosylation site, a C-mannosylation site, a glypiation site or a
phosphoglycation site.
[0113] In certain embodiments the invention, there are provided any
of the above or herein described binding constructs, including
binding domain-immunoglobulin fusion proteins, wherein a binding
region or binding domain polypeptide comprises two or more binding
domain polypeptide sequences wherein each of the binding domain
polypeptide sequences is capable of binding or specifically binding
to a target(s) such as an antigen(s), which target(s) or antigen(s)
may be the same or may be different. A native, for more preferably
an engineered, IgD hinge is a desired connecting region between
binding domains of a bispecific molecule of the invention, i.e.,
one with two or more binding domains, preferably two. The wild type
human IgD hinge has one cysteine that forms a disulfide bond with
the light chain in the native IgD structure. It is desirable to
mutate or delete this cysteine in the human IgD hinge for use as a
connecting region between binding domains of, for example, a
bispecific molecule. Other amino acid changes or deletions or
alterations in an IgD hinge that do not result in undesired hinge
inflexibility are within the scope of the invention. Native or
engineered IgD hinge regions from other species are also within the
scope of the invention, as are humanized native or engineered IgD
hinges from non-human species. The present invention also provides,
in certain embodiments, a binding domain-immunoglobulin fusion
protein, comprising, consisting essentially of, or consisting of
(a) a binding domain polypeptide that is fused or otherwise
connected to an immunoglobulin hinge region polypeptide, wherein
the hinge region polypeptide may be as described above or herein,
and may comprise, consist essentially of, or consist of, for
example, an alternative hinge region polypeptide sequence; (b) a
first native or engineered immunoglobulin heavy chain constant
region, such as an IgG or IgA CH2 constant region polypeptide (or
an IgE CH3 constant region polypeptide) that is fused or otherwise
connected to the hinge region polypeptide; and (c) a second native
or engineered immunoglobulin heavy chain constant region, such as
an IgG or IgA CH3 constant region polypeptide (or an IgE CH4
constant region polypeptide) that is fused or otherwise connected
to the first constant region polypeptide, wherein: (1) the binding
domain-immunoglobulin fusion protein is capable of at least one
immunological activity selected from the group consisting of
antibody dependent cell-mediated cytotoxicity, CDC, and complement
fixation, and (2) the binding domain polypeptide is capable of
binding or specifically binding to a target, such as an
antigen.
[0114] Turning to another embodiment there is provided a binding
domain-immunoglobulin fusion protein, comprising, consisting
essentially of, or consisting of (a) a binding domain polypeptide
that is fused or otherwise connected to an immunoglobulin hinge
region polypeptide, wherein the binding domain polypeptide is
capable of binding or specifically binding to at least one target,
such as an antigen, that is present on a cancer cell surface and
wherein the hinge region polypeptide may be as described above or
herein, and may comprise, consist essentially of, or consist of,
for example, an alternative hinge region polypeptide sequence; (b)
a first native or engineered immunoglobulin heavy chain constant
region polypeptide that is fused or otherwise connected to the
hinge region polypeptide, wherein said native or engineered
constant region polypeptide comprises, consists essentially of, or
consists of, a polypeptide selected from the group consisting of a
native or engineered human IgA CH2 constant region polypeptide, a
native or engineered human IgG CH2 constant region polypeptide, and
a native or engineered human IgE CH3 constant region polypeptide;
and (c) a second immunoglobulin heavy chain constant region
polypeptide that is fused or otherwise connected to the first
constant region polypeptide, wherein the second constant region
polypeptide comprises, consists essentially of, or consists of, a
polypeptide that is a native or engineered human IgA CH3 constant
region polypeptide, a native or engineered human IgG CH3 constant
region polypeptide, or a native or engineered human IgE CH4
constant region polypeptide. In certain further embodiments the
alternative hinge region polypeptide sequence comprises, consists
essentially of, or consists of, a polypeptide sequence of at least
ten continuous amino acids of an Ig hinge region in any one of the
constructs set out herein.
[0115] In certain embodiments the present invention provides
polynucleotides or vectors (including cloning vectors and
expression vectors) or transformed or transfected cells, including
isolated or purified or pure polynucleotides, vectors, and isolated
transformed or transfected cells, encoding or containing any one of
the above or herein described polypeptide or protein constructs of
the invention, for example, including binding domain-immunoglobulin
fusion proteins. Thus, in various embodiments the invention
provides a recombinant cloning or expression construct comprising
any such polynucleotide that is operably linked to a promoter.
[0116] In other embodiments there is provided a host cell
transformed or transfected with, or otherwise containing, any such
recombinant cloning or expression construct. Host cells include the
cells of a subject undergoing ex vivo cell therapy including, for
example, ex vivo gene therapy.
[0117] In a related embodiment there is provided a method of
producing a polypeptide or protein or other construct of the
invention, for example, including a binding domain-immunoglobulin
fusion protein, comprising the steps of (a) culturing a host cell
as described or provided for herein under conditions that permit
expression of the construct, for example, a binding
domain-immunoglobulin fusion protein; and (b) isolating the
construct, for example, the binding domain-immunoglobulin fusion
protein from the host cell or host cell culture.
[0118] In another embodiment there is provided a pharmaceutical
composition comprising any one of the above or herein described
polypeptide or protein or other constructs of the invention, for
example (including, for example, binding domain-immunoglobulin
fusion proteins), in combination with a physiologically acceptable
carrier.
[0119] In another embodiment the invention provides a
pharmaceutical composition comprising, for example, an isolated,
purified, or pure polynucleotide encoding any one of the
polypeptide or protein constructs of the invention, for example
(including, for example, binding domain-immunoglobulin fusion
proteins), in combination with a physiologically acceptable
carrier, or for example, in combination with, or in, a gene therapy
delivery vehicle or vector.
[0120] In another embodiment the invention provides a method of
treating a subject having or suspected of having a malignant
condition or a B cell disorder, comprising administering to a
patient a therapeutically effective amount of any of the
pharmaceutical compositions described or claimed herein.
[0121] In certain further embodiments the malignant condition or B
cell disorder is a B cell lymphoma or B cell leukemia, or a disease
characterized by autoantibody production, and in certain other
further embodiments the B cell disorder is, for example, rheumatoid
arthritis, myasthenia gravis, Grave's disease, type I diabetes
mellitus, multiple sclerosis or an autoimmune disease. In certain
other embodiments the malignant condition is, for example,
melanoma, myeloma, glioma, astrocytoma, lymphoma, leukemia,
carcinoma, or sarcoma, and so on.
[0122] It is another aspect of the present invention to provide a
binding domain-immunoglobulin fusion protein, comprising,
consisting essentially or, or consisting of, (a) a binding domain
polypeptide that is fused or otherwise connected to an
immunoglobulin hinge region polypeptide, wherein said hinge region
polypeptide is as described herein, and may be selected from the
group consisting of (i) a mutated, engineered or otherwise altered
hinge region polypeptide that contains no cysteine residues and
that is derived from a wild-type immunoglobulin hinge region
polypeptide having one or more cysteine residues, (ii) a mutated,
engineered or otherwise altered hinge region polypeptide that
contains one cysteine residue and that is derived from a wild-type
immunoglobulin hinge region polypeptide having two or more cysteine
residues, (iii) a wild-type human IgA hinge region polypeptide,
(iv) a mutated, engineered or otherwise altered human IgA hinge
region polypeptide that contains no cysteine residues, (v) a
mutated, engineered or otherwise altered human IgA hinge region
polypeptide that contains one cysteine residue and (vi) a mutated,
engineered or otherwise altered human IgA hinge region polypeptide
that contains two cysteine residues; (b) a native or engineered
immunoglobulin heavy chain CH2 constant region polypeptide that is
fused or otherwise connected to the hinge region polypeptide; and
(c) a native or engineered immunoglobulin heavy chain CH3 constant
region polypeptide that is fused or otherwise connected to the CH2
constant region polypeptide, wherein: (1) the binding
domain-immunoglobulin fusion protein is capable of at least one
immunological activity selected from the group consisting of
antibody dependent cell-mediated cytotoxicity and complement
fixation, and (2) the binding domain polypeptide is capable of
binding or specifically binding to an antigen. In one embodiment
the immunoglobulin hinge region polypeptide is a mutated hinge
region polypeptide, for example, and the resulting construct
exhibits a reduced ability to dimerize, relative to a construct
containing a wild-type human immunoglobulin G hinge region
polypeptide. In another embodiment the binding domain polypeptide
comprises, consists essentially of, or consists of, at least one
native or engineered immunoglobulin variable region polypeptide
that is a native or engineered immunoglobulin light chain variable
region polypeptide and/or a native or engineered immunoglobulin
heavy chain variable region polypeptide. In a further embodiment
the native or engineered immunoglobulin variable region polypeptide
is derived from a human immunoglobulin and, for example, may be
humanized.
[0123] In another embodiment, the invention provides a binding
domain-immunoglobulin fusion protein includes a binding domain
polypeptide that comprises, consists essentially of, or consists
of, (a) at least one native or engineered immunoglobulin light
chain variable region polypeptide; (b) at least one native or
engineered immunoglobulin heavy chain variable region polypeptide;
and (c) at least one linker peptide that is fused or otherwise
connected to the polypeptide of (a) and to the polypeptide of (b).
In a further embodiment the native or engineered immunoglobulin
light chain variable region and the native or engineered heavy
chain variable region polypeptides are derived from human
immunoglobulins and may, for example, be humanized.
[0124] In another embodiment at least one of the native or
engineered immunoglobulin heavy chain CH2 (or IgE CH3) constant
region polypeptide and the native or engineered immunoglobulin
heavy chain CH3 (or IgE CH4) constant region polypeptide is derived
or constructed from a human immunoglobulin heavy chain. In another
embodiment the native or engineered immunoglobulin heavy chain
constant region CH2 and CH3 polypeptides are of, or are derived or
otherwise prepared or constructed from, an isotype selected from
human IgG and human IgA. In another embodiment the target, for
example, the target antigen is selected from the group consisting
of CD16, CD19, CD20, CD37, CD40, CD45RO, CD80, CD86, CD137, CD152,
and L6. In certain further embodiments of the above described
fusion protein construct, the binding domain comprises, consists
essentially of, or consists of, an scFv and the scFv contains a
linker polypeptide that comprises, consists essentially of, or
consists of, at least one polypeptide comprising or having as an
amino acid sequence Gly-Gly-Gly-Gly-Ser [SEQ ID NO:516], and in
certain other embodiments the linker polypeptide comprises,
consists essentially of, or consists of, at least three repeats of
a polypeptide having as an amino acid sequence Gly-Gly-Gly-Gly-Ser
[SEQ ID NO:516]. In certain embodiments the immunoglobulin hinge
region polypeptide comprises, consists essentially of, or consists
of, a native or engineered human IdG, IgA, IgD hinge region
polypeptide, or a native or engineered IgE CH2 region polypeptide.
In certain embodiments the binding domain polypeptide comprises,
consists essentially of, or consists of, a native or engineered
CD154 extracellular domain. In certain embodiments the binding
domain polypeptide comprises, consists essentially of, or consists
of, a native or engineered CD154 extracellular domain and at least
one a native or engineered immunoglobulin variable region
polypeptide.
[0125] In other embodiments the invention provides an isolated
polynucleotide encoding any of the constructs of the invention, for
example, protein or polypeptide constructs of the invention
including binding domain-immunoglobulin fusion proteins, and in
related embodiments the invention provides a recombinant expression
construct comprising such a polynucleotide, and in certain further
embodiments the invention provides a host cell transformed or
transfected with, or otherwise containing, such a recombinant
expression construct. In another embodiment the invention provides
a method of producing a construct of the invention, for example, a
protein or polypeptide construct of the invention such as a binding
domain-immunoglobulin fusion protein, comprising the steps of (a)
culturing a host cell that has been transformed or transfected
with, or otherwise made to contain, a polynucleotide construct of
the invention under conditions that permit expression of the
construct, for example, a construct encoding a binding
domain-immunoglobulin fusion protein; and (b) isolating the
construct, for example, the binding domain-immunoglobulin fusion
protein, from the host cell culture.
[0126] The inventions described and claimed herein include novel
molecules useful, for example, as therapeutics and other purposes
including diagnostic and research purposes. Such molecules have,
for example, antigen binding or other binding function(s) and one
or more effector functions. DNA constructs of the invention are
useful in, for example, gene therapies, including in vivo and ex
vivo gene therapies.
[0127] In one aspect, various constructs of the molecules of the
invention include molecules comprising a "binding region", a "tail"
region, and a "connecting" region that joins a binding region and a
tail region.
[0128] Binding regions within the molecules of the invention may
comprise, for example, binding domains for desired targets,
including antigen-binding targets. Binding domains for
antigen-binding targets may comprise, for example, single chain Fvs
and scFv domains. In certain embodiments, molecules of the
invention may comprise a binding region having at least one
immunoglobulin variable region polypeptide, which may be a light
chain or a heavy chain variable region polypeptide. In certain
embodiments, molecules of the invention may comprise at least one
such light chain V-region and one such heavy chain V-region and at
least one linker peptide that connects the V-regions. ScFvs useful
in the invention also include those with chimeric binding or other
domains or sequences. Other ScFvs useful in the invention also
include those with humanized binding or other domains or sequences.
In such embodiments, all or a portion of an immunoglobulin binding
or other sequence that is derived from a non-human source may be
"humanized" according to recognized procedures for generating
humanized antibodies, i.e., immunoglobulin sequences into which
human Ig sequences are introduced to reduce the degree to which a
human immune system would perceive such proteins as foreign.
[0129] Example of scFvs useful in the invention, whether included
as murine or other scFvs (including human scFvs), chimeric scFvs,
or humanized scFvs, in whole or in part, include anti-human CD20
scFvs (for example, "2H7" scFvs), anti-human CD37 scFvs (for
example, "G28-1" scFvs), anti-human CD40 scFvs (for example,
"G28-5" scFvs and "40.2.220" scFvs), anti-carcinoma-associated
antigen scFvs (for example, "L6" scFvs), anti-CTLA-4 (CD152) scFvs
(for example, "10A8" scFvs), anti-human CD28 scFvs (for example,
"2E12" scFvs), anti-murine CD3 scFvs (for example, "500A2" scFvs),
anti-human CD3 scFvs (for example, G19-4 scFvs), anti-murine 4-1BB
scFvs (for example, "1D8" scFvs), anti-human 4-1BB scFvs (for
example, "5B9" scFvs), anti-human CD45RO (for example, "UCHL-1"
scFvs), and anti-human CD16 (for example, "Fc2" scFvs).
[0130] scFvs useful in the invention also include scFvs, including
chimeric and humanized scFvs, having one or more amino acid
substitutions. A preferred amino acid substitution is at amino acid
position 11 in the variable heavy chain (the V.sub.H). Such a
substitution may be referred to herein as "XxxV.sub.H11Zxx". Thus,
for example, where the normally occurring amino acid at position
V.sub.H11 is a Leucine, and a Serine amino acid residue is
substituted therefore, the substitution is identified as "L
V.sub.H11S" or "Leu V.sub.H11Ser." Other preferred embodiments of
the invention include molecules containing scFvs wherein the amino
acid residue normally found at position V.sub.H11 is deleted. Still
other preferred embodiments of the invention include molecules
containing scFvs wherein the amino acid residues normally found at
positions V.sub.H10 and/or V.sub.H11 and/or V.sub.H12 are
substituted or deleted.
[0131] Other binding regions within the molecules of the invention
may include domains that comprise sites for glycosylation, for
example, covalent attachment of carbohydrate moieties such as
monosaccharides or oligosaccharides.
[0132] Still other binding regions within molecules of the
invention include polypeptides that may comprise proteins or
portions thereof that retain the ability to specifically bind
another molecule, including an antigen. Thus, binding regions may
comprise or be derived from hormones, cytokines, chemokines, and
the like; cell surface or soluble receptors for such polypeptide
ligands; lectins; intercellular adhesion receptors such as specific
leukocyte integrins, selectins, immunoglobulin gene superfamily
members, intercellular adhesion molecules (ICAM-1, -2, -3) and the
like; histocompatibility antigens; and so on. Binding regions
derived from such molecules generally will include thoss portions
of the molecules necessary or desired for binding to a target.
[0133] Certain constructs include binding regions that comprise
receptor or receptor-binding domains. Receptor domains useful for
binding to a target include, for example, a CD154 extracellular
domain, or a CTLA-4 extracellular domain. In another example, the
binding domain may include a first portion comprising, consisting
essentially or, or consisting of, a CD154 extracellular domain and
a second portion comprising, consisting essentially or, or
consisting of, at least one immunoglobulin variable region
polypeptide, said second portion including, for example, an scFv or
a V.sub.H. Examples of other cell surface receptors that may
comprise, consist essentially or, or consist of, or a portion of
which may provide, a binding region or binding domain polypeptide,
include, for example, HER1, HER2, HER3, HER4, epidermal growth
factor receptor (EGFR), vascular endothelial cell growth factor,
vascular endothelial cell growth factor receptor, insulin-like
growth factor-I, insulin-like growth factor-II, transferrin
receptor, estrogen receptor, progesterone receptor, follicle
stimulating hormone receptor (FSH-R), retinoic acid receptor,
MUC-1, NY-ESO-1, Melan-A/MART-1, tyrosinase, Gp-100, MAGE, BAGE,
GAGE, any of the CTA class of receptors including in particular
HOM-MEL-40 antigen encoded by the SSX2 gene, carcinoembyonic
antigen (CEA), and PyLT. Additional cell surface receptors that may
be sources of binding regions or binding domain polypeptides
include, for example, CD2, 4-1BB, 4-1BB ligand, CD5, CD10, CD27,
CD28, CD152/CTLA-4, CD40, interferon-.gamma. (IFN-.gamma.),
interleukin-4 (IL-4), interleukin-17 (IL-17) and interleukin-17
receptor (IL-17R). Still other cell surface receptors that may be
sources of binding regions and/or binding domain polypeptides
include, for example, CD59, CD48, CD58/LFA-3, CD72, CD70,
CD80/B7.1, CD86/B7.2, B7-H1/B7-DC, IL-17, CD43, ICOS, CD3 (e.g.,
gamma subunit, epsilon subunit, delta subunit), CD4, CD25, CD8,
CD11b, CD14, CD56, CD69 and VLA-4 (.alpha..sub.4.beta..sub.7). The
following cell surface receptors are typically associated with B
cells: CD19, CD20, CD22, CD30, CD153 (CD30 ligand), CD37, LD50
(ICAM-3), CD106 (VCAM-1), CD54 (ICAM-1), interleukin-12, CD134
(OX40), CD137 (41BB), CD83, and DEC-205. These lists are not
exhaustive. Binding regions such as those set forth above may be
connected, for example, by a native or engineered IgD hinge region
polypeptide, preferably a human or humanized native or engineered
IgD hinge region polypeptide. The invention thus further provides
constructs that comprise, consist essentially of, or consist of,
two binding regions, for example, an scFv and a cell surface
receptor (or portion thereof), connected by a third molecule, for
example, an IgD hinge region polypeptide as described herein.
[0134] Various molecules of the invention described and claimed
herein include a connecting region joining one end of the molecule
to another end. Such connecting regions may comprise, for example,
immunoglobulin hinge region polypeptides, including any hinge
peptide or polypeptide that occurs naturally. A connecting region
may also include, for example, any artificial peptide or other
molecule (including, for example, non-peptide molecules, partial
peptide molecules, and peptidomimetics, etc.) useful for joining
the tail region and the binding region. These may include, for
example, alterations of molecules situated in an immunoglobulin
heavy chain polypeptide between the amino acid residues responsible
for forming intrachain immunoglobulin-domain disulfide bonds in CH1
and CH2 regions. Naturally occurring hinge regions include those
located between the constant region domains, CH1 and CH2, of an
immunoglobulin. Useful immunoglobulin hinge region polypeptides
include, for example, human immunoglobulin hinge region
polypeptides and llama or other camelid immunoglobulin hinge region
polypeptides. Other useful immunoglobulin hinge region polypeptides
include, for example, nurse shark and spotted ratfish
immunoglobulin hinge region polypeptides. Human immunoglobulin
hinge region polypeptides include, for example, wild type IgG
hinges including wild-type human IgG1 hinges, human IgG-derived
immunoglobulin hinge region polypeptides, a portion of a human IgG
hinge or IgG-derived immunoglobulin hinge region, wild-type human
IgA hinge region polypeptides, human IgA-derived immunoglobulin
hinge region polypeptides, a portion of a human IgA hinge region
polypeptide or IgA-derived immunoglobulin hinge region polypeptide,
wild-type human IgD hinge region polypeptides, human Ig-D derived
immunoglobulin hinge region polypeptides, a portion of a human IgD
hinge region polypeptide or IgD-derived immunoglobulin hinge region
polypeptide, wild-type human IgE hinge-acting region, i.e., IgE CH2
region polypeptides (which generally have 5 cysteine residues),
human IgE-derived immunoglobulin hinge region polypeptides, a
portion of a human IgE hinge-acting region, i.e., IgE CH2 region
polypeptide or IgE-derived immunoglobulin hinge region polypeptide,
and so on. A polypeptide "derived from" or that is "a portion or
fragment of" an immunoglobulin polypeptide chain region regarded as
having hinge function has one or more amino acids in peptide
linkage, for example 15-115 amino acids, preferably 95-110, 80-94,
60-80, or 5-65 amino acids, preferably 10-50, more preferably
15-35, still more preferably 18-32, still more preferably 20-30,
still more preferably 21, 22, 23, 24, 25, 26, 27, 28 or 29 amino
acids. Llama immunoglobulin hinge region polypeptides include, for
example, an IgG1 llama hinge. The connecting region may comprise a
stretch of consecutive amino acids from an immunoglobulin hinge
region. For example, the connecting region can comprise at least
five consecutive hinge region amino acids, at least ten consecutive
hinge region amino acids, at least fifteen consecutive hinge region
amino acids, at least 20 consecutive hinge region amino acids, and
at least twenty five or more consecutive hinge region amino acids
from human IgG hinge, human IgA hinge, human IgE hinge, camelid
hinge region, IgG1 llama hinge region, nurse shark hinge region,
and spotted ratfish hinge region, including for example an
IgG.sub.1 hinge region, a IgG.sub.2 hinge region, a IgG.sub.3 hinge
region, an IgG.sub.3 hinge region, and an IgG.sub.4 hinge
region.
[0135] Such connecting regions also include, for example, mutated
or otherwise altered or engineered immunoglobulin hinge region
polypeptides. A mutated or otherwise altered or engineered
immunoglobulin hinge region polypeptide may comprise, consist
essentially of, or consist of, a hinge region that has its origin
in an immunoglobulin of a species, of an immunoglobulin isotype or
class, or of an immunoglobulin subclass that is the same or
different from that of any included native or engineered CH2 and
CH3 domains. Mutated or otherwise altered or engineered
immunoglobulin hinge region polypeptides include those derived or
constructed from, for example, a wild-type immunoglobulin hinge
region that contains one or more cysteine residues, for example, a
wild-type human IgG or IgA hinge region that naturally comprises
three cysteines. In such polypeptides the number of cysteine
residues may be reduced by amino acid substitution or deletion or
truncation, for example. These polypeptides include, for example,
mutated human or other IgG1 or IgG4 hinge region polypeptides
containing zero, one, or two cysteine residues, and mutated human
or other IgA1 or IgA2 hinge region polypeptides that contain zero,
one, or two cysteine residues. Mutated or otherwise altered or
engineered immunoglobulin hinge region polypeptides include those
derived or constructed from, for example, a wild-type
immunoglobulin hinge region that contains three or more cysteine
residues, for example, a wild-type human IgG2 hinge region (which
has 4 cysteines) or IgG4 hinge region (which has 11 cysteines).
Mutated or otherwise altered or engineered immunoglobulin hinge
region polypeptides include those derived or constructed from, for
example, an IgE CH2 wild-type immunoglobulin region that generally
contains five cysteine residues. In such polypeptides the number of
cysteine residues may be reduced by one or more cysteine residues
by amino acid substitution or deletion or truncation, for example.
Also included are altered hinge region polypeptides in which
cysteine residues in the hinge region are substituted with serine
or one or more other amino acids that are less polar, less
hydrophobic, more hydrophilic, and/or neutral. Such mutated
immunoglobulin hinge region polypeptides include, for example,
mutated hinge region polypeptides that contain one cysteine residue
and that are derived from a wild-type immunoglobulin hinge region
polypeptide having two or more cysteine residues, such as a mutated
human IgG or IgA hinge region polypeptide that contains one
cysteine residue and that is derived from a wild-type human IgG or
IgA region polypeptide. Connecting region polypeptides include
immunoglobulin hinge region polypeptides that are compromised in
their ability to form interchain, homodimeric disulfide bonds.
[0136] Mutated immunoglobulin hinge region polypeptides also
include mutated hinge region polypeptides that exhibit a reduced
ability to dimerize, relative to a wild-type human immunoglobulin G
hinge region polypeptide, and mutated hinge region polypeptides
that allow expression of a mixture of monomeric and dimeric
molecules. Mutated immunoglobulin hinge region polypeptides also
include hinge region polypeptides engineered to contain a
glycosylation site. Glycosylation sites include, for example, an
asparagine-linked glycosylation site, an O-linked glycosylation
site, a C-mannosylation site, a glypiation site, and a
phosphoglycation site.
[0137] Specific connecting regions useful in molecules of the
invention described and claimed herein include, for example, the
following 18 amino acid sequences, DQEPKSCDKTHTCPPCPA (SEQ ID
NO:10), DQEPKSSDKTHTSPPSPA (SEQ ID NO:18), and DLEPKSCDKTHTCPPCPA
(SEQ ID NO:12). Other specific connecting regions include, for
example, the mutant hinges within the sequences referred to herein
as "2H7 scFv (SSS-S)H WCH2 WCH3" and "2H7 scFv (CSS)H WCH2 WCH3",
and the human IgA-derived hinge referred to herein as "2H7 scFv
IgAH WCH2 WCH3".
[0138] Tail regions within the molecules of the invention may
include heavy chain constant region immunoglobulin sequences. Tail
regions may thus include, for example, a polypeptide having at
least one of an immunoglobulin heavy chain CH2 constant region
polypeptide and an immunoglobulin heavy chain CH3 constant region
polypeptide. At least one of the immunoglobulin heavy chain CH2
constant region polypeptide and the immunoglobulin heavy chain CH3
constant region polypeptide may be derived from a human
immunoglobulin heavy chain. Thus, for example, CH2 and/or CH3
polypeptides may be derived from human IgG, human IgA, or human IgD
molecules. Tail regions may also include, for example, a
polypeptide having at least one of an immunoglobulin heavy chain
CH3 constant region polypeptide and an immunoglobulin heavy chain
CH4 constant region polypeptide. At least one of the immunoglobulin
heavy chain CH3 constant region polypeptide and the immunoglobulin
heavy chain CH4 constant region polypeptide may be derived from a
human immunoglobulin heavy chain. Thus, for example, CH3 and/or CH4
polypeptides may be derived from human IgE. An immunoglobulin heavy
chain CH2 region polypeptide included within a molecule of the
invention may, for example, be from the IgG1, IgG2, IgG3 and/or
IgG4 subclasses. An immunoglobulin heavy chain CH3 region
polypeptide included within a molecule of the invention may also,
for example, be from the IgG1, IgG2, IgG3 and/or IgG4 subclasses.
Additionally, both the immunoglobulin heavy chain CH2 region
polypeptide and the immunoglobulin heavy chain CH2 region
polypeptide included within a molecule of the invention may, for
example, be from the IgG1, IgG2, IgG3 and/or IgG4 subclasses. In
other molecules of the invention at least one of the immunoglobulin
heavy chain constant region polypeptides selected from a CH2
constant region polypeptide and a CH3 constant region polypeptide
is a human IgA constant region polypeptide. An immunoglobulin heavy
chain CH2 region polypeptide included within a molecule of the
invention may, for example, be from the IgA1 and/or IgA2
subclasses. An immunoglobulin heavy chain CH3 region polypeptide
included within a molecule of the invention may also, for example,
be from the IgA1 and/or IgA2 subclasses. Additionally, both the
immunoglobulin heavy chain CH2 region polypeptide and the
immunoglobulin heavy chain CH2 region polypeptide included within a
molecule of the invention may, for example, be from the IgA1 and/or
IgA2 subclasses. In still other molecules of the invention, the
tail region may comprise or consist essentially of a CH2 and/or CH3
constant region polypeptide comprising a polypeptide from human IgA
and/or human IgE. In other embodiments, for example, the tail
region within a molecule of the invention may include an
immunoglobulin heavy chain CH2 and/or CH3 constant region
polypeptide that is a mutated (for example, a mutated IgA CH3
constant region polypeptide that is incapable of associating with a
J chain in which, for example, the IgA CH3 constant region
polypeptide is of human origin). The tail region may also comprise,
consist essentially of, or consist of an extracellular portion of a
protein from the TNF superfamily, for example, CD154.
[0139] For molecules of the invention intended for use in humans,
these regions will typically be substantially or completely human
to minimize potential human immune responses against the molecules
and to provide appropriate effector functions. In certain
embodiments of the invention, for example, the tail region includes
a human IgG1 CH3 region sequence, a wild-type IgA heavy chain
constant region polypeptide sequence that is capable or incapable
of associating with J chain.
[0140] In preferred embodiments of the invention, a CH1 domain is
not included in the tail region of the molecule, and the carboxyl
end of the binding region is joined to the amino terminus of a CH2
portion of a tail region either directly or indirectly. A binding
region may be indirectly joined to a tail region, for example via a
connecting region polypeptide or other connecting molecule.
[0141] The invention also includes molecules that have mutated CH2
and/or CH3 sequences within a tail region. For example, a molecule
of the invention may include a mutated Fc domain that has one or
more mutations introduced into the CH2, CH3 and/or CH4 domains. In
certain embodiments of the invention, molecules may include an IgA
CH3 constant region polypeptide such as a human IgA CH3 constant
region polypeptide in which two or more residues from the
C-terminus have been deleted to yield a truncated CH3 constant
region polypeptide. In other embodiments of the invention,
molecules include a mutated human IgA CH3 constant region
polypeptide that is incapable of associating with a J chain that
comprises a C-terminal deletion of either four or 18 amino acids.
However, the invention need not be so limited, such that molecules
containing the mutated IgA CH3 constant region polypeptide may
comprise a deletion of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,
15, 16, 17, 18, 19, 20, 21-25, 26-30 or more amino acids, so long
as the fusion protein is capable of specifically binding an antigen
and capable of at least one immunological activity such as ADCC,
CDC or complement fixation. The invention also includes molecules
containing a tail region that comprises a mutated IgA CH3 constant
region polypeptide that is incapable of associating with a J chain
by virtue of replacement of the penultimate cysteine, or by
chemical modification of that amino acid residue, in a manner that
prevents interchain disulfide bond formation.
[0142] Various molecules of the invention include, for example, a
binding domain scFv-fusion protein having a binding domain
polypeptide comprising, consisting essentially of, or consisting
of, (a) at least one immunoglobulin light chain variable region
polypeptide, (b) at least one immunoglobulin heavy chain variable
region polypeptide, and at least one linker peptide that joins the
polypeptide of (a) and the polypeptide of (b). Such polypeptides
may, for example, be derived from human immunoglobulins or
non-human immunoglobulins.
[0143] Thus, in one aspect, the invention includes a non-naturally
occurring single chain protein and/or V.sub.H protein and/or
V.sub.L protein, or a desired portion of any of the above,
including a first polypeptide comprising a binding domain
polypeptide capable of binding to a target molecule, a second
polypeptide comprising a flexible or other desired linker attached
to said first polypeptide, a third polypeptide comprising a tail
region, for example, an N-terminally truncated immunoglobulin heavy
chain constant region polypeptide (or desired portion thereof)
attached to the second polypeptide. The flexible linker may
comprise, consist essentially of, or consist of, an immunoglobulin
hinge region or portion thereof that has been mutated or otherwise
altered or engineered, for example, one that contains a number of
cysteine residues that is less than the number of cysteine residues
present in the wild type immunoglobulin hinge region or portion
(for example, zero, one, or two cysteines in the case of IgG1 or
IgG4), and wherein said non-naturally occurring single-chain
protein is capable of at least one immunological activity, for
example, ADCC, CDC, and/or complement fixation. The single chain
protein may be capable of two immunological activities including,
for example, ADCC, CDC, and/or complement fixation. This protein
may include a binding domain polypeptide that is a single chain Fv.
Additionally, this protein may include a binding domain polypeptide
that is a single chain Fv wherein the heavy chain variable region
of the single chain Fv has an amino acid deletion or substitution
at one or more of amino acid positions 9, 10, 11, 12, 108, 110, and
112. The protein may also include a binding domain polypeptide that
is a single chain Fv wherein the light chain variable region of the
single chain Fv has an amino acid deletion or substitution at one
or more of amino acid positions 12, 80, 81, 83, 105, 106, and
107.
[0144] In another aspect, the invention includes a non-naturally
occurring V.sub.H protein, or a desired portion thereof, that
comprises, consists essentially of, or consists of, alone or in
combination with any other molecule or construct, a V.sub.H region
or portion thereof that has an amino acid deletion or substitution
at one or more of amino acid positions 9, 10, 11, 12, 108, 110, and
112 of said V.sub.H region. Amino acids may be substituted with
either naturally occurring or non-naturally occurring amino acids,
or any other desired useful molecule.
[0145] Also described and claimed are uses of V.sub.H proteins, or
desired portions thereof, that comprise, consist essentially of, or
consist of, alone or in combination with any other molecule or
construct, a V.sub.H region or portion thereof that has an amino
acid deletion or substitution at one or more of amino acid
positions 9, 10, 11, 12, 108, 110, and 112 of said V.sub.H region.
Such uses include uses in phage display, yeast display, and
ribosome display systems and methods.
[0146] In yet another aspect, the invention includes a
non-naturally occurring V.sub.L protein, or a desired portion
thereof, that comprises, consists essentially of, or consists of,
alone or in combination with any other molecule, a V.sub.L region
or portion thereof that has an amino acid deletion or substitution
at one or more of amino acid positions 12, 80, 81, 83, 105, 106,
and 107 of said V.sub.L region. Amino acids may be substituted with
either naturally occurring or non-naturally occurring amino acids,
or any other desired useful molecule.
[0147] Also described and claimed are uses of V.sub.L proteins, or
desired portions thereof, that comprises, consists essentially of,
or consists of, alone or in combination with any other molecule, a
V.sub.L region or portion thereof that has an amino acid deletion
or substitution at one or more of amino acid positions 12, 80, 81,
83, 105, 106, and 107 of said V.sub.L region. Such uses include
uses in phage display, yeast display, and ribosome display systems
and methods.
[0148] In yet another aspect, the invention includes a molecule
comprising, consisting essentially of, or consisting of, (1) a
V.sub.H protein, or a desired portion thereof, wherein the V.sub.H
protein or portion thereof has an amino acid deletion or
substitution at one or more of amino acid positions 9, 10, 11, 12,
108, 110, and 112, and (2) a non-naturally occurring V.sub.L
protein, or a desired portion thereof, alone or in combination with
any other molecule, wherein the V.sub.L protein or portion thereof
has an amino acid deletion or substitution at one or more of amino
acid positions 12, 80, 81, 83, 105, 106, and 107. Amino acids may
be substituted with either naturally occurring or non-naturally
occurring amino acids, or any other desired useful molecule.
[0149] Also described and claimed are uses of a molecule
comprising, consisting essentially of, or consisting of, (1) a
V.sub.H protein, or a desired portion thereof, wherein the V.sub.H
protein or portion thereof has an amino acid deletion or
substitution at one or more of amino acid positions 9, 10, 11, 12,
108, 110, and 112, and (2) a non-naturally occurring V.sub.L
protein, or a desired portion thereof, alone or in combination with
any other molecule, wherein the V.sub.L protein or portion thereof
has an amino acid deletion or substitution at one or more of amino
acid positions 12, 80, 81, 83, 105, 106, and 107. Such uses include
uses in phage display, yeast display, and ribosome display systems
and methods.
[0150] The invention also includes molecular constructs wherein the
binding domain is a single chain Fv and the heavy chain variable
region of said single chain Fv has an amino acid substitution at
amino acid position 11. The amino acid substituted for the amino
acid at position of 11 of the single chain Fv heavy chain variable
region may be selected from the group consisting of serine,
threonine, tyrosine, asparagine, glutamine, aspartic acid, glutamic
acid, lysine, arginine, and histidine. The invention thus includes,
for example, a construct wherein the binding domain is a single
chain Fv and the heavy chain variable region of said single chain
Fv has a serine amino acid substitution at amino acid position 11.
Other amino acid position changes, substitutions, and deletions,
are noted herein.
[0151] The invention also includes, for example, a construct
wherein the binding domain is a single chain Fv and the amino acid
at position 10 and/or 11 of the heavy chain variable region of said
single chain Fv has been deleted.
[0152] In another aspect, the invention includes constructs wherein
the binding region binds to a tumor or tumor-associated antigen.
The binding region of a construct of the invention may bind, for
example, to a cancer cell antigen. Cancer cell antigens to which
constructs of the invention bind include cancer cell surface
antigens and intracellular cancer cell antigens.
[0153] In yet another aspect, the invention includes a construct
wherein the binding region binds to an antigen on an immune
effector cell.
[0154] In another aspect, the invention includes a construct
wherein the binding region binds to a B cell antigen including, for
example, a B cell antigen selected from the group consisting of
CD19, CD20, CD22, CD37, CD40, CD80, and CD86. Constructs of the
invention that bind to such B cell antigens include, for example,
binding regions comprising an single chain Fv. Examples of such
single chain Fv binding regions include molecules comprising or
consisting essentially of single chain Fvs selected from the group
consisting of HD37 single chain Fv, 2H7 single chain Fv, G28-1
single chain Fv, and 4.4.220 single chain Fv. Other examples
include a binding region comprising, consisting essentially of, or
consisting of, an extracellular domain of CTLA-4.
[0155] In another aspect, the invention includes a construct
wherein the binding region binds to a B cell differentiation
antigen. B cell differentiation antigens include, for example,
CD19, CD20, CD21, CD22, CD23, CD37, CD40, CD45RO, CD80, CD86, and
HLA class II.
[0156] In another aspect, the invention includes a construct
wherein the binding region binds to a target selected from the
group consisting of CD2, CD3, CD4, CD5, CD6, CD8, CD10, CD11b,
CD14, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD28, CD30, CD37,
CD40, CD43, CD50 (ICAM3), CD54 (ICAM1), CD56, CD69, CD80, CD86,
CD134 (OX40), CD137 (41BB), CD152 (CTLA-4), CD153 (CD30 ligand),
CD154 (CD40 ligand), ICOS, L6, B7-H1, and HLA class II.
[0157] The invention also includes protein constructs having a
binding region, a tail region, and a connecting region, wherein the
protein construct is capable of existing in solution as a monomer
or in substantially monomeric form.
[0158] The invention also includes protein constructs having a
binding region, a tail region, and a connecting region, wherein the
protein construct is capable of forming a complex comprising two or
more of said protein constructs including, for example, wherein
said complex is a dimer.
[0159] In another aspect, constructs of the invention are capable
of participating in or inducing or eliciting or helping to induce
or elicit, directly or indirectly, at least one immunological
activity selected from the group consisting of antibody dependent
cell-mediated cytotoxicity, complement-dependent cytotoxicity (or
complement-mediated lysis), complement fixation, induction of
apoptosis, induction of one or more biologically active signals,
induction of one or more immune effector cells, activation of
cellular differentiation, cellular activation, release of one or
more biologically active molecules, and neutralization of an
infectious agent or toxin.
[0160] In another aspect, binding constructs of the invention are
capable of induction of biologically active signals by activation
or inhibition of one or more molecules selected from the group
consisting of protein kinases, protein phosphatases, G-proteins,
cyclic nucleotides or other second messengers, ion channels, and
secretory pathway components. Such biologically active molecules
are, for example, proteases. Other biologically active molecules
are, for example, cytokines, including by way of example monokines,
lymphokines, chemokines, growth factors, colony stimulating
factors, interferons, and interleukins.
[0161] In another aspect, constructs of the invention are capable
of induction, or participation in the induction, of one or more
immune effector cells selected from the group consisting of NK
cells, monocytes, macrophages, B cells, T cells, mast cells,
neutrophils, eosinophils, and basophils.
[0162] In another aspect, constructs of the invention are capable
of induction, or participation in the induction, of one or more
immune effector cells that results in antibody dependent
cell-mediated cytotoxicity or the release of one or more
biologically active molecules.
[0163] In another aspect, constructs of the invention are capable
of participating in and/or initiating apopotosis within target
cells, for example, by activating one or more signalling mechanisms
or molecules.
[0164] In another aspect, constructs of the invention are capable
of induction, or participation in the induction, of cellular
activation, wherein said activation leads to changes in cellular
transcriptional activity. In one embodiment, cellular
transcriptional activity is increased. In another embodiment,
cellular transcriptional activity is decreased.
[0165] In another aspect, constructs of the invention having tail
regions comprising, consisting essentially of, or consisting of,
constant regions from IgA or IgE molecules, are capable of
induction, or participation in the induction, of degranulation of
neutrophils and/or mast cells.
[0166] In another aspect, constructs of the invention are capable
of promotion, or participation in the promotion, of neutralization
of an infectious agent, wherein said infectious agent is, for
example, a bacterium, a virus, a parasite, or a fungus.
[0167] In another aspect, constructs of the invention are capable
of promoting, or participating in the promotion of, neutralization
of a toxin, wherein said toxin is selected from the group
consisting of endotoxins and exotoxins. Such toxins include, for
example, exotoxins selected from the group consisting of anthrax
toxin, cholera toxin, diphtheria toxin, pertussis toxin, E. coli
heat-labile toxin LT, E. coli heat stable toxin ST, shiga toxin
Pseudomonas Exotoxin A, botulinum toxin, tetanus toxin, Bordetella
pertussis AC toxin, and Bacillus anthracis EF toxin. Other toxins
include, for example, saxitoxins, tetrodotoxin, mushroom toxins
(amatoxins, gyromitrin, orellanine, etc.), aflatoxins,
pyrrolizidine alkaloids, phytohemagglutinins, and
grayanotoxins.
[0168] In another aspect, constructs of the invention are capable
of binding to an intracellular target to, for example, effect (or
participate in effecting) a cellular function. Such constructs
include, for example, constructs that include a tail region
comprising, consisting essentially of, or consisting of, a native
or engineered IgA CH2 domain region and a native or engineered IgA
CH3 domain region, said tail region being capapble of binding J
chain. Such a tail region is found, for example, in the 2H7 scFv
IgAH WlgACH2 WCH3+JChain construct. Thus, the invention includes
constructs having, for example, an "Anti-Intracellular Target"
binding domain (for example, and "Anti-Intracellular Target" scFv),
a connecting region, and a native or engineered IgA constant region
capable of binding J chain (for example, WlgACH2 WCH3).
[0169] In still another aspect, constructs of the invention include
a molecule wherein an N-terminally immunoglobulin heavy chain
constant region polypeptide comprises an IgG CH2 constant region
polypeptide attached to an immunoglobulin heavy chain IgG CH3
constant region polypeptide.
[0170] In yet another aspect, the invention includes a method of
reducing a target cell population in a subject comprising
administering to said subject a therapeutically effective amount of
a protein molecule that is less than about 120 kK, or less than
about 150 kD, as measured, for example, by HPLC and non-reducing
gels and consists essentially of (a) a first protein or peptide
molecule that is capable of binding to cells within said target
cell population, and (b) a second protein or peptide molecule that
is capable of (i) binding to an Fc receptor and/or (ii) inducing
target cell apoptosis, and/or (iii) fixing complement, wherein said
first protein or peptide molecule is directly connected to said
second protein or peptide molecule, or, optionally, said first
protein or peptide molecule and said second protein or peptide
molecule are linked by a third protein or peptide molecule, wherein
said protein molecule is not an antibody, a member of the TNF
family or the TNF receptor family, and is not conjugated with a
bacterial toxin, a cytotoxic drug, or a radioisotope.
[0171] In another aspect, the invention also includes single chain
proteins comprising, consisting essentially of, or consisting of,
(i) a first polypeptide having a binding domain polypeptide capable
of binding to a target molecule; (ii) a second polypeptide
comprising a connecting region attached to the C-terminus of said
first polypeptide; and (iii) a third polypeptide comprising an
N-terminally truncated immunoglobulin heavy chain constant region
polypeptide attached to the C-terminus of said second polypeptide,
wherein said single-chain protein is capable of at least one
immunological activity, and provided that (a) when the connecting
region polypeptide comprises an IgG hinge region polypeptide having
no cysteine residues, the binding domain polypeptide target is not
CD20 or L6, or (b) when the connecting region polypeptide comprises
an IgG hinge region polypeptide having no cysteine residues, the
single chain protein is not a 1F5 scFv capable of binding to CD20.
The invention also includes single chain proteins comprising,
consisting essentially of, or consisting of, (i) a first
polypeptide having a binding domain polypeptide capable of binding
to a target molecule; (ii) a second polypeptide comprising a
connecting region attached to the C-terminus of said first
polypeptide; and (iii) a third polypeptide comprising an
N-terminally truncated immunoglobulin heavy chain constant region
polypeptide attached to the C-terminus of said second polypeptide,
wherein said single-chain protein is capable of binding to a target
molecule on or in a target cell and decreasing the number of target
cells in vivo and/or depleting a population of target cells in
vivo. The invention also includes single chain proteins comprising,
consisting essentially of, or consisting of, (i) a first
polypeptide having a binding domain polypeptide capable of binding
to a target molecule; (ii) a second polypeptide comprising a
connecting region attached to the C-terminus of said first
polypeptide; and (iii) a third polypeptide comprising an
N-terminally truncated immunoglobulin heavy chain constant region
polypeptide attached to the C-terminus of said second polypeptide,
wherein said single-chain protein is capable of inducing
antibody-dependent cell-mediated cytotoxicity and complement
fixation. The invention also includes single chain proteins
comprising, consisting essentially of, or consisting of, (i) a
first polypeptide having a binding domain polypeptide capable of
binding to a target molecule; (ii) a second polypeptide comprising
a connecting region attached to the C-terminus of said first
polypeptide; and (iii) a third polypeptide comprising an
N-terminally truncated immunoglobulin heavy chain constant region
polypeptide attached to the C-terminus of said second polypeptide,
wherein said single-chain protein is capable of (1) inducing
antibody-dependent cell-mediated cytotoxicity and complement
fixation, and (2) binding to a target molecule on or in a target
cell and decreasing the number of target cells in vivo and/or
depleting a population of target cells in vivo. The invention also
includes single chain proteins comprising, consisting essentially
of, or consisting of, (i) a first polypeptide having a binding
domain polypeptide capable of binding to a target molecule; (ii) a
second polypeptide comprising a connecting region attached to the
C-terminus of said first polypeptide; and (iii) a third polypeptide
comprising an N-terminally truncated immunoglobulin heavy chain
constant region polypeptide attached to the C-terminus of said
second polypeptide, wherein when said connecting region comprises
an IgG hinge region polypeptide having at least first, second, and
third cysteine residues, said first cysteine being N-terminal to
said second cysteine and said second cysteine being N-terminal to
said third cysteine, one or both of said second and third cysteine
residues is substituted or deleted, and wherein said single-chain
protein is capable of at least one immunological activity. The
invention also includes single chain proteins comprising,
consisting essentially of, or consisting of, (i) a first
polypeptide having a binding domain polypeptide capable of binding
to a target molecule; (ii) a second polypeptide comprising a
connecting region attached to the C-terminus of said first
polypeptide; and (iii) a third polypeptide comprising an
N-terminally truncated immunoglobulin heavy chain constant region
polypeptide attached to the C-terminus of said second polypeptide,
wherein when said connecting region comprises an IgG hinge region
polypeptide having at least first, second, and third cysteine
residues, said first cysteine being N-terminal to said second
cysteine and said second cysteine being N-terminal to said third
cysteine, one or both of said second and third cysteine residues is
substituted or deleted, and wherein said single-chain protein is
capable of inducing at least one immunological activity selected
from (a) antibody-dependent cell-mediated cytotoxicity and (b)
complement fixation. The invention also includes single chain
proteins comprising, consisting essentially of, or consisting of,
(i) a first polypeptide having a binding domain polypeptide capable
of binding to a target molecule; (ii) a second polypeptide
comprising a connecting region attached to the C-terminus of said
first polypeptide; and (iii) a third polypeptide comprising an
N-terminally truncated immunoglobulin heavy chain constant region
polypeptide attached to the C-terminus of said second polypeptide,
wherein when said connecting region comprises an IgG hinge region
polypeptide having at least first, second, and third cysteine
residues, said first cysteine being N-terminal to said second
cysteine and said second cysteine being N-terminal to said third
cysteine, one or both of said second and third cysteine residues is
substituted or deleted, and wherein said single-chain protein is
capable of antibody-dependent cell-mediated cytotoxicity and
complement fixation. The invention also includes single chain
proteins comprising, consisting essentially of, or consisting of,
(i) a first polypeptide having a binding domain polypeptide capable
of binding to a target molecule; (ii) a second polypeptide
comprising a connecting region attached to the C-terminus of said
first polypeptide; and (iii) a third polypeptide comprising an
N-terminally truncated immunoglobulin heavy chain constant region
polypeptide attached to the C-terminus of said second polypeptide,
wherein when said connecting region comprises an IgG hinge region
polypeptide having at least first, second, and third cysteine
residues, said first cysteine being N-terminal to said second
cysteine and said second cysteine being N-terminal to said third
cysteine, one or both of said second and third cysteine residues is
substituted or deleted, and wherein said single-chain protein is
capable of binding to a target molecule on or in a target cell and
decreasing the number of target cells in vivo and/or depleting a
population of target cells in vivo. The invention also includes
single chain proteins comprising, consisting essentially of, or
consisting of, (i) a first polypeptide having a binding domain
polypeptide capable of binding to a target molecule; (ii) a second
polypeptide comprising a connecting region attached to the
C-terminus of said first polypeptide; and (iii) a third polypeptide
comprising an N-terminally truncated immunoglobulin heavy chain
constant region polypeptide attached to the C-terminus of said
second polypeptide, wherein when said connecting region comprises
an IgG hinge region polypeptide having at least first, second, and
third cysteine residues, said first cysteine being N-terminal to
said second cysteine and said second cysteine being N-terminal to
said third cysteine, one or both of said second and third cysteine
residues is substituted or deleted, and wherein said single-chain
protein is capable of inducing at least one immunological activity
selected from antibody-dependent cell-mediated cytotoxicity and
complement fixation, and wherein said single-chain protein is
capable of binding to a target molecule on or in a target cell and
decreasing the number of target cells in vivo and/or depleting a
population of target cells in vivo. The invention also includes
single chain proteins comprising, consisting essentially of, or
consisting of, (i) a first polypeptide having a binding domain
polypeptide capable of binding to a target molecule; (ii) a second
polypeptide comprising a connecting region attached to the
C-terminus of said first polypeptide; and (iii) a third polypeptide
comprising an N-terminally truncated immunoglobulin heavy chain
constant region polypeptide attached to the C-terminus of said
second polypeptide, wherein when said connecting region comprises
an IgG hinge region polypeptide having at least first, second, and
third cysteine residues, said first cysteine being N-terminal to
said second cysteine and said second cysteine being N-terminal to
said third cysteine, one or both of said second and third cysteine
residues is substituted or deleted, and wherein said single-chain
protein is capable of inducing antibody-dependent cell-mediated
cytotoxicity and complement fixation, and wherein said single-chain
protein is capable of binding to a target molecule on or in a
target cell and decreasing the number of target cells in vivo
and/or depleting a population of target cells in vivo. The
invention also includes single chain proteins comprising,
consisting essentially of, or consisting of, (i) a first
polypeptide having a binding domain polypeptide capable of binding
to a target molecule, said binding domain polypeptide comprising a
heavy chain variable region wherein leucine at position 11 in the
first framework region of the heavy chain variable region is
deleted or substituted with another amino acid; (ii) a second
polypeptide comprising a connecting region attached to the
C-terminus of said first polypeptide; and (iii) a third polypeptide
comprising an N-terminally truncated immunoglobulin heavy chain
constant region polypeptide attached to the C-terminus of said
second polypeptide, wherein said single-chain protein is capable of
at least one immunological activity, and provided that when the
binding domain polypeptide is capable of binding to CD20 said
connecting region comprises three cysteine residues wherein one or
two of said three cysteine residues is substituted or replaced with
another amino acid. The invention also includes single chain
proteins comprising, consisting essentially of, or consisting of,
(i) a first polypeptide having a binding domain polypeptide capable
of binding to a target molecule, said binding domain polypeptide
comprising a heavy chain variable region wherein leucine at
position 11 in the first framework region of the heavy chain
variable region is deleted or substituted with another amino acid,
(ii) a second polypeptide comprising a connecting region attached
to the C-terminus of said first polypeptide; and (iii) a third
polypeptide comprising an N-terminally truncated immunoglobulin
heavy chain constant region polypeptide attached to the C-terminus
of said second polypeptide, wherein said single-chain protein is
capable of inducing at least one immunological activity, provided
that when binding domain polypeptide is a 2H7 scFv capable of
binding to CD20 and said connecting region comprises an IgG hinge
region polypeptide having at least first, second, and third
cysteine residues, said first cysteine being N-terminal to said
second cysteine and said second cysteine being N-terminal to said
third cysteine, one or two of said cysteine residues is substituted
or deleted. The invention also includes single chain proteins
comprising, consisting essentially of, or consisting of, (i) a
first polypeptide having a binding domain polypeptide capable of
binding to a target molecule on or in a target cell, said binding
domain polypeptide comprising a heavy chain variable region wherein
leucine at position 11 in the first framework region of the heavy
chain variable region is deleted or substituted with another amino
acid; (ii) a second polypeptide comprising a connecting region
attached to said first polypeptide; and (iii) a third polypeptide
comprising an N-terminally truncated immunoglobulin heavy chain
constant region polypeptide attached to the second polypeptide,
wherein said single-chain protein is capable of at least one
immunological activity, provided that said single chain protein
does not comprise, or consist essentially of, a binding domain
polypeptide capable of binding to CD20 and a connecting region that
comprises (a) an IgG hinge having three cysteine residues or (b) an
IgG hinge comprising three serine (or like amino acid) residues
that have been substituted for cysteine residues. There are many
possible variations and variants of these single chain proteins.
For example, the binding domain polypeptide may be a single chain
antibody or scFv including naturally occurring and/or non-naturally
occurring V.sub.H and V.sub.L polypeptides, and the binding domain
polypeptide may bind any of a number of targets. Non-naturally
occurring V.sub.H polypeptides include, by way of example and not
limitation, human heavy chain variable region polypeptide
comprising a mutation, substitution, or deletion of an amino
acid(s) at a location corresponding to any one or more of amino
acid positions 9, 10, 11, 12, 108, 110, and/or 112. Non-naturally
occurring V.sub.L polypeptides include, by way of example and not
limitation, human light chain variable region polypeptides
comprising a mutation, substitution, or deletion of an amino
acid(s) at a location corresponding to any one or more of amino
acid positions 12, 80, 81, 83, 105, 106, and 107. Targets include,
by way of example and not limitation, CD19, CD20, CD28, CD30, CD37,
CD40, L6, HER2, epidermal growth factor receptors (EGFRs), vascular
endothelial cell growth factors (VEGFs), tumor necrosis factors
(e.g., TNF-alpha), as well as other targets described or referred
to herein or otherwise useful, whether now known or later
discovered. Additionally, the connecting region polypeptide may be
any of a number of molecules, both naturally occurring and
non-naturally occurring. Connecting region polypeptides include, by
way of example and not limitation, naturally occurring and
non-naturally occurring immunoglobulin hinge region polypeptides.
Naturally occurring immunoglobulin hinge region polypeptides
include wild-type immunoglobulin hinge region polypeptides such as,
by way of example and not limitation, human IgG1 hinge region
polypeptides, human IgA hinge region polypeptides, human IgD hinge
region polypeptides, human IgE hinge-acting regions (e.g., IgE
CH2), camelid immunoglobulin hinge regions, or any other naturally
occurring hinge region peptides described or referred to herein or
otherwise useful useful, whether now known or later discovered.
Non-naturally occurring immunoglobulin hinge region polypeptides
include, by way of example and not limitation, mutated naturally
occurring immunoglobulin hinges, including immunoglobulin hinge
region polypeptides that contain less than the wild-type number of
cysteines, for example, mutated naturally occurring immunoglobulin
hinge region polypeptides that contain zero, one, or two cysteines,
and any other connecting region molecule described or referenced
herein or otherwise useful or now known or later discovered as
useful for connecting joining, for example, immunoglobulin domains
such as a CH1 domain and a CH2 domain. N-terminally truncated
immunoglobulin heavy chain constant region polypeptides include
naturally occurring and non-naturally occurring N-terminally
truncated immunoglobulin heavy chain constant region polypeptides
that, with or without other portions of the single chain protein,
provide one or more effector functions such as those described
herein. Naturally occurring N-terminally truncated immunoglobulin
heavy chain constant region polypeptides include, by way of example
and not limitation, CH2CH3 constant region polypeptides, including
CH2CH3 constant region polypeptides taken, separately or together,
from human IgGs, human IgAs, and human IgE, and any other
immunoglobulin heavy chain constant region polypeptide described or
referenced herein or otherwise now known or later discovered to be
useful. Non-naturally occurring N-terminally truncated
immunoglobulin heavy chain constant region polypeptides include, by
way of example and not limitation, any mutated naturally occurring
heavy chain constant region polypeptide described or referred to
herein or otherwise now known or later discovered to be useful.
[0172] Various specific constructs of the invention include, by way
of example only, the following: [0173] 1. 2H7 scFv VH L11S (CSC-S)
H WCH2 WCH3 [0174] 2. 2H7 scFv VH L11S IgE CH2 CH3 CH4 [0175] 3.
2H7 scFv VH L11S mIgE CH2 CH3 CH4 [0176] 4. 2H7 scFv VH L11S mIgAH
WIgACH2 T4-CH3 [0177] 5. 2H7 scFv VH L11S (SSS-S) H K322S CH2 WCH3
[0178] 6. 2H7 scFv VH L11S (CSS-S) H K322S CH2 WCH3 [0179] 7. 2H7
scFv VH L11S (SSS-S) H P331S CH2 WCH3 [0180] 8. 2HU scFv VH L11S
(CSS-S) H P331S CH2 WCH3 [0181] 9. 2H7 scFv VH L11S (SSS-S) H T256N
CH2 WCH3 [0182] 10. 2H7 scFv VH L11S (SSS-S) H RTPE/QNAK (255-258)
CH2 WCH3 [0183] 11. 2H7 scFv VH L11S (SSS-S) H K290Q CH2 WCH3
[0184] 12. 2H7 scFv VH L11S (SSS-S) H A339P CH2 WCH3 [0185] 13.
G28-1 scFv (SSS-S) H WCH2 WCH3 [0186] 14. G28-1 scFv IgAH WCH2 WCH3
[0187] 15. G28-1 scFv VH L11S (SSS-S) H WCH2 WCH3 [0188] 16. G28-1
scFv VH L11S (CSS-S) H WCH2 WCH3 [0189] 17. G28-1 scFv VH
L11S(CSC-S) H WCH2 WCH3 [0190] 18. G28-1 scFv VH L11S (SSC-P) H
WCH2 WCH3 [0191] 19. CTLA4 (SSS-S) H P238SCH2 WCH32 [0192] 20.
CTLA4 (CCC-P) WH WCH2 WCH3 [0193] 21. FC2-2 scFv (SSS-S) H WCH2
WCH3 [0194] 22. FC2-2 scFv VHL11S (SSS-S) H WCH2 WCH3 [0195] 23.
UCHL-1 scFv (SSS-S) H WCH2 WCH3 [0196] 24. UCHL-1 scFv VHL11S
(SSS-S) H WCH2 WCH3 [0197] 25. 5B9 scFv (SSS-S) H WCH2 WCH3 [0198]
26. 5B9 scFv VHL11S (SSS-S) H WCH2 WCH3 [0199] 27. 2H7 scFv (SSS-S)
H WCH2 WCH3 [0200] 28. 2H7 scFv (SSS-S) H P238SCH2 WCH3 [0201] 29.
2H7 scFv IgAH WCH2 WCH3 [0202] 30. 2H7 scFv IgAH WIgACH2 T4-CH3
[0203] 31. 2H7 scFv IgAH WlgACH2 WCH3+JChain [0204] 32. 2H7 scFv
(CCC-P) WH WCH2 WCH3 [0205] 33. 2H7 scFv (SSS-S) H WCH2 F405YCH3
[0206] 34. 2H7 scFv (SSS-S) H WCH2 F405ACH3 [0207] 35. 2H7 scFv
(SSS-S) H WCH2 Y407ACH3 [0208] 36. 2H4 scFv (SSS-S) HWCH2 F405A,
Y407ACH3 [0209] 37. 2H7 scFv (CSS-S) H WCH2 WCH3 [0210] 38. 2H7
scFv (SCS-S) H WCH2 WCH3 [0211] 39. 2H7 scFv (SSC-P) H WCH2 WCH3
[0212] 40. 2H7 scFv (CSC-S) H WCH2 WCH3 [0213] 41. 2H7 scFv (CCS-P)
H WCH2 WCH3 [0214] 42. 2H7 scFv (SCC-P) H WCH2 WCH3 [0215] 43. 2H7
scFv VH L11S (SSS-S) H WCH2 WCH3 [0216] 44. 2H7 scFv VH L11S
(CSS-S) H WCH2 WCH3 [0217] 45. G28-1 scFv VH L11S (SCS-S) H WCH2
WCH3 [0218] 46. G28-1 scFv VH L11S(CCS-P) H WCH2 WCH3 [0219] 47.
G28-1 scFv VH L11S (SCC-P) H WCH2 WCH3 [0220] 48. G28-1 scFv VH
L11S mlgE CH2 CH3 CH4 [0221] 49. G28-1 scFv VH L11S mIgAH WIgACH2
T4CH3 [0222] 50. G28-1 scFv VH L11S hIgE CH2 CH3 CH4 [0223] 51.
G28-1 scFv VH L11S hIgAH WIgACH2 T4CH3 [0224] 52. HD37 scFv IgAH
WCH2 WCH3 [0225] 53. HD37 scFv (SSS-S) H WCH2 WCH3 [0226] 54. HD37
scFv VH L11S (SSS-S) H WCH2 WCH3 [0227] 55. L6 scFv lgAH WCH2 WCH3
[0228] 56. L6 scFv VHL11S (SSS-S) H WCH2 WCH3 [0229] 57. 2H7
scFv-llama IgG1 [0230] 58. 2H7 scFv-llama IgG2 [0231] 59. 2H7
scFv-llama IgG3 [0232] 60. CD16-6 low (ED)(SSS-S) H P238SCH2 WCH3
[0233] 61. CD16-9 high (ED)(SSS-S) H P238SCH2 WCH3 [0234] 62. 2e12
scFv (SSS-s)H P238SCH2 WCH3-hCD80TM/CT [0235] 63. 10A8 scFv
(SSS-s)H P238SCH2 WCH3-hCD80TM/CT [0236] 64. 40.2.36 scFv (SSS-s)H
P238SCH2 WCH3-hCD80TM/CT [0237] 65. 2H7 scFv (SSS-s)H P238SCH2
WCH3-hCD80TM/CT [0238] 66. G19-4 scFv (SSS-s)H P238SCH2
WCH3-hCD80TM/CT [0239] 67. 2e12 scFv (SSS-s)H WCH2 WCH3-hCD80TM/CT
[0240] 68. 2e12 scFv IgAH IgACH2 T4CH3-hCD80TM/CT [0241] 69. 2e12
scFv IgE CH2CH3CH4-hCD80TM/CT [0242] 70. 2e12 scFv (SSS-s)H
P238SCH2 WCH3-mFADD-TM/CT [0243] 71. 2e12 scFv (SSS-s)H WCH2
WCH3-mFADD-TM/CT [0244] 72. 2e12 scFv (SSS-s)H WCH2
WCH3-mcasp3-TM/CT [0245] 73. 2e12 scFv (SSS-s)H P238SCH2
WCH3-mcasp3-TM/CT [0246] 74. 2e12 scFv (SSS-s)H WCH2
WCH3-mcasp8-TM/CT [0247] 75. 2e12 scFv (SSS-s)H P238SCH2
WCH3-mcasp-8-TM/CT [0248] 76. 2e12 scFv (SSS-s)H WCH2
WCH3-hcasp3-TM/CT [0249] 77. 2e12 scFv (SSS-s)H P238SCH2
WCH3-hcasp3-TM/CT [0250] 78. 2e12 scFv (SSS-s)H WCH2
WCH3-hcasp8-TM/CT [0251] 79. 2e12 scFv (SSS-s)H P238SCH2
WCH3-hcasp8-TM/CT [0252] 80. 1D8 scFv-hIgG1 (SSS-s)H P238SCH2
WCH3-hCD80TM/CT [0253] 81. 1D8 scFv-hIgG1 (SSS-s)H WCH2
WCH3-hCD80TM/CT [0254] 82. 1D8 scFv-mIgAT4-hCD80TM/CT [0255] 83.
1D8 scFv-hIgE-hCD80TM/CT [0256] 84. 1D8 scFv-hIgG1 (SSS-s)H
P238SCH2 WCH3-mFADD-TM/CT [0257] 85. 1D8 scFv-hIgG1 (SSS-s)H WCH2
WCH3-mFADD-TM/CT [0258] 86. 1D8 scFv-hIgG1 (SSS-s)H WCH2
WCH3-mcasp3-TM/CT [0259] 87. 1D8 scFv-hIgG1 (SSS-s)H P238SCH2
WCH3-mcasp3-TM/CT [0260] 88. 1D8 scFv-hIgG1 (SSS-s)H WCH2
WCH3-mcasp8-TM/CT [0261] 89. 1D8 scFv-hIgG1 (SSS-s)H P238SCH2
WCH3-mcasp8-TM/CT [0262] 90. 1D8 scFv-hIgG1 (SSS-s)H WCH2
WCH3-hcasp3-TM/CT [0263] 91. 1D8 scFv-hIgG1 (SSS-s)H P238SCH2
WCH3-hcasp3-TM/CT [0264] 92. 1D8 scFv-hIgG1 (SSS-s)H WCH2
WCH3-hcasp8-TM/CT [0265] 93. 1D8 scFv-hIgG1 (SSS-s)H P238SCH2
WCH3-hcasp8-TM/CT L6 scFv (SSS-S) H WCH2 WCH3 [0266] 94. 2H7 scFv
CD154 (L2) [0267] 95. 2H7 scFv CD154 (S4) [0268] 96. CTLA4 IgAH
IGACH2CH3 [0269] 97. CTLA4 IgAH IgACH2 T4CH3 [0270] 98. 2H7 scFv
IgAH IgACH2CH3 [0271] 99. 2H7 scFv IgAH IgAHCH2 T18CH3 [0272] 100.
2H&-40.2.220 scFv (SSS-S) H WCH2 WCH3 (bispecific
anti-ccd20-anti-cd40) [0273] 101. 2H7 scFv IgAH IgACH2 T4CH3-hCD89
TM/CT [0274] 102. G19-4 scFv (CCC-P) WH WCH2 WCH3-hCD89 TM/CT
[0275] 103. 2e12 scFv (CCC-P) WH WCH2 WCH3-hCD89 TM/CT
[0276] These and other aspects of the present invention will become
further apparent upon reference to the following detailed
description and attached drawings. As noted herein, all referenced
patents, articles, documents, and other materials disclosed or
identified herein are hereby incorporated by reference in their
entireties as if each was incorporated individually.
BRIEF DESCRIPTION OF THE DRAWINGS
[0277] FIG. 1 shows DNA and deduced amino acid sequences [SEQ ID
NOS:688 and 689] of 2H7 scFv-Ig, a binding domain-immunoglobulin
fusion protein capable of specifically binding CD20.
[0278] FIG. 2 shows production levels of 2H7 scFv-Ig by
transfected, stable CHO lines and generation of a standard curve by
binding of purified 2H7 scFv-Ig to CHO cells expressing CD20.
[0279] FIG. 3 shows SDS-PAGE analysis of multiple preparations of
isolated 2H7scFv-Ig protein.
[0280] FIG. 4 shows complement fixation (FIG. 4A) and mediation of
antibody-dependent cellular cytotoxicity (FIG. 4B) by
2H7scFv-Ig.
[0281] FIG. 5 shows the effect of simultaneous ligation of CD20 and
CD40 on growth of normal B cells.
[0282] FIG. 6 shows the effect of simultaneous ligation of CD20 and
CD40 on CD95 expression and induction of apoptosis in a B
lymphoblastoid cell line.
[0283] FIG. 7 shows DNA and deduced amino acid sequences of
2H7scFv-CD154 L2 (FIG. 7A, SEQ ID NOS:690 and 691) and
2H7scFv-CD154 S4 (FIG. 7B, SEQ ID NOS:692 and 693) binding
domain-immunoglobulin fusion proteins capable of specifically
binding CD20 and CD40.
[0284] FIG. 8 shows binding of 2H7scFv-CD154 binding
domain-immunoglobulin fusion proteins to CD20+CHO cells by flow
immunocytofluorimetry.
[0285] FIG. 9 shows binding of Annexin V to B cell lines Ramos,
BJAB, and T51 after binding of 2H7scFv-CD154 binding
domain-immunoglobulin fusion protein to cells.
[0286] FIG. 10 shows effects on proliferation of B cell line T51
following binding of 2H7scFv-CD154 binding domain-immunoglobulin
fusion protein.
[0287] FIG. 11 depicts schematic representations of the structures
of 2H7ScFv-Ig fusion proteins referred to as CytoxB or CytoxB
derivatives: CytoxB-MHWTG1C (2H7 ScFv, mutant hinge, wild-type
human IgG1 Fc domain), CytoxB-MHMG1C (2H7 ScFv, mutant hinge,
mutated human IgG1 Fc domain) and CytoxB-IgAHWTHG1C (2H7 ScFv,
human IgA-derived hinge [SEQ ID NO:41], wild-type human IgG1 Fc
domain). Arrows indicate position numbers of amino acid residues
believed to contribute to FcR binding and ADCC activity (heavy
arrows), and to complement fixation (light arrows). Note absence of
interchain disulfide bonds. Also shown are a peptide linker (SEQ ID
NO:682) and a portion of the human IgA hinge (SEQ ID NO:683).
[0288] FIG. 12 shows SDS-PAGE analysis of isolated CytoxB and
2H7scFv-CD154 binding domain-immunoglobulin fusion proteins.
[0289] FIG. 13 shows antibody dependent cell-mediated cytotoxicity
activity of CytoxB derivatives.
[0290] FIG. 14 shows complement dependent cytotoxicity of CytoxB
derivatives.
[0291] FIG. 15 shows serum half-life determinations of
CytoxB-MHWTG1C in macaque blood samples.
[0292] FIG. 16 shows effects of CytoxB-MHWTG1C on levels of
circulating CD40+B cells in macaque blood samples.
[0293] FIG. 17 shows production levels of HD37 (CD19-specific)
ScFv-Ig by transfected mammalian cell lines and generation of a
standard curve by binding of purified HD37 ScFv-Ig to cells
expressing CD19.
[0294] FIG. 18 shows production levels of L6 (carcinoma antigen)
ScFv-Ig by transfected, stable CHO lines and generation of a
standard curve by binding of purified L6 ScFv-Ig to cells
expressing L6 antigen.
[0295] FIG. 19 shows antibody dependent cell-mediated cytotoxicity
activity of binding domain-immunoglobulin fusion proteins 2H7
ScFv-Ig, HD37 ScFv-Ig and G28-1 (CD37-specific) ScFv-Ig.
[0296] FIG. 20 shows antibody dependent cell-mediated cytotoxicity
activity of L6 ScFv-Ig fusion proteins.
[0297] FIG. 21 shows SDS-PAGE analysis of L6 ScFv-Ig and 2H7
ScFv-Ig fusion proteins.
[0298] FIG. 22 shows SDS-PAGE analysis of G28-1 ScFv-Ig and HD37
ScFv-Ig fusion proteins.
[0299] FIG. 23 presents a sequence alignment of immunoglobulin
hinge and CH2 domains of human IgG1 (SEQ ID NO:684) with the hinge
and CH2 domains of llama IgG1 (SEQ ID NO:685), IgG2 (SEQ ID
NO:686), and IgG3 (SEQ ID NO:687).
[0300] FIG. 24 illustrates migration of purified 2H7 scFv llama IgG
fusion proteins in a 10% SDS polyacrylamide gel. Purified fusion
proteins (5 .mu.g per sample) were prepared in non-reducing sample
buffer (lanes 2-5) and in reducing sample buffer (lanes 6-9). Lane
1: molecular weight markers (non-reduced); lanes 2 and 6: 2H7
scFv-llama IgG1 (SEQ ID NOS:21 and 22); Lanes 3 and 7: 2H7
scFv-llama IgG2 (SEQ ID NOS:23 and 24): lanes 4 and 8: 2H7
scFv-llama IgG3 (SEQ ID NOS:25 and 26); and Lanes 5 and 9:
Rituximab (chimeric anti-CD20 antibody (human IgG1 constant
region)).
[0301] FIG. 25 shows binding of 2H7 scFv-llama IgG1 (SEQ ID NOS:21
and 22), 2H7 scFv-llama IgG2 (SEQ ID NOS:23 and 24), and 2H7
scFv-llama IgG3 (SEQ ID NOS:25 and 26) to CD20+CHO cells detected
by flow immunocytofluorimetry.
[0302] FIG. 26 depicts CDC activity of 2H7 scFv llama IgG fusion
proteins, 2H7 scFv-llama IgG1 (SEQ ID NO:22), 2H7 scFv-llama IgG2
(SEQ ID NO:24), and 2H7 scFv-llama IgG3 (SEQ ID NO:26), and 2H7
scFv human IgG1 (2H7 scFv IgG WTH WTCH2CH3) (SEQ ID NO:28) against
BJAB cells in the presence of rabbit complement. Rituximab was
included as a control.
[0303] FIG. 27 shows antibody dependent cell-mediated cytotoxicity
activity of 2H7 scFv llama IgG fusion proteins, 2H7 scFv-llama IgG1
(SEQ ID NO:22), 2H7 scFv-llama IgG2 (SEQ ID NO:24), and 2H7
scFv-llama IgG3 (SEQ ID NO:26). Effector cells (human PBMC) were
combined with target cells (BJAB cells) at three different ratios,
1:25, 1:50, and 1:100. Rituximab was included as a control. Each
data point represents three separate measurements.
[0304] FIG. 28 shows antibody dependent cell-mediated cytotoxicity
activity of 2H7 scFv llama IgG fusion proteins, 2H7 scFv-llama IgG1
(SEQ ID NO:22), 2H7 scFv-llama IgG2 (SEQ ID NO:24), and 2H7
scFv-llama IgG3 (SEQ ID NO:26). Effector cells (llama PBMC) were
combined with target cells (BJAB cells) at three different ratios,
1:25, 1:50, and 1:100. Rituximab was included as a control. Each
data point represents three separate measurements.
[0305] FIG. 29 depicts complement dependent cytotoxicity activity
of Reh cells (acute lymphocytic leukemia) expressing scFv-Ig fusion
proteins on the cell surface. Reh cells were transfected with
constructs encoding scFv antibodies specific for human
costimulatory molecules, CD152, CD28, CD40, and CD20, fused to
human IgG1 wild-type hinge-CH2-CH3, which was fused to human CD80
transmembrane and cytoplasmic tail domains. Complement dependent
cytotoxicity activity was measured in the presence and absence of
rabbit complement (plus C' and no C', respectively). The data
represent the average of duplicate samples. Reh anti-hCD152 scFvIg:
Reh cells transfected with polynucleotide 10A8 scFv IgG MTH (SSS)
MT CH2CH3 (SEQ ID NO:53); Reh anti-hCD28scFvIg: 2E12 scFv IgG MTH
(SSS) MT CH2CH3 (SEQ ID NO:51); Reh anti-hCD40scFvIg: 4.2.220 scFv
IgG MTH (SSS) MT CH2CH3 (SEQ ID NO:49); and Reh anti-hCD20scFvIg:
2H7 scFv IgG MTH (SSS) MT CH2CH3 (SEQ ID NOS:57 and 29).
[0306] FIG. 30 presents antibody dependent cell-mediated
cytotoxicity activity of Reh cells that were transfected with
constructs encoding scFv antibodies specific for human
costimulatory molecules, CD152, CD28, CD40, and CD20, as described
for FIG. 29, and for murine CD3, fused to human mutant IgG1 hinge
and mutant CH2 and wild type CH3 (Reh anti-mCD3scFv designating Reh
cells transfected with polynucleotide 500A2 scFv IgG MTH (SSS)
MTCH2WTCH3 SEQ ID NO:55)), which was fused to human CD80
transmembrane and cytoplasmic tail domains. The data represent the
average of quadruplicate samples.
[0307] FIG. 31 lists immunoglobulin constant region constructs that
were used in experiments illustrated in subsequent figures.
[0308] FIG. 32 depicts complement dependent cytotoxicity activity
of CTLA-4 Ig fusion proteins, CTLA-4 IgG WTH (CCC) WTCH2CH3 (SEQ ID
NO:_) (2 .mu.g/ml) and CTLA-4 IgG MTH MTCH2WTCH3 (SEQ ID NO:_) (2
.mu.g/ml), in the presence and absence of rabbit complement (plus
C' and no C', respectively). The target cells were Reh cells and
Reh cells transfected with CD80 (Reh CD80.10).
[0309] FIG. 33 shows antibody dependent cell-mediated cytotoxicity
activity of CTLA-4 Ig fusion proteins, CTLA-4 IgG WTH (CCC)
WTCH2CH3 (SEQ ID NO:78) (2 .mu.g/ml) and CTLA-4 IgG MTH MTCH2WTCH3
(SEQ ID NOS:530 and 86) (2 .mu.g/ml). Effector cells, human PBMC,
were added to target cells, Reh or Reh CD80.1, at the ratios
indicated. FIG. 33A presents the level of natural killing in Reh
CD80.1 cells in the absence of any Ig fusion protein. FIG. 33B
presents antibody dependent cell-mediated cytotoxicity mediated by
CTLA-4 IgG MTH MTCH2WTCH3, and FIG. 33C presents antibody dependent
cell-mediated cytotoxicity mediated by CTLA-4 IgG WTH (CCC)
WTCH2CH3. Each data point represents the average percent specific
killing measured in four sample wells.
[0310] FIG. 34 illustrates binding of 2H7 (anti-CD20) scFv Ig
fusion proteins to (CD20+) CHO cells by flow
immunocytofluorimetry.
[0311] FIG. 35 presents an immunoblot of 2H7 scFv IgG and IgA
fusion proteins. COS cells were transiently transfected with
various 2H7 scFv Ig fusion protein constructs. The expressed
polypeptides were immune precipitated with protein A, separated in
a non-reducing SDS polyacrylamide gel, and then transferred to a
polyvinyl fluoride membrane. Proteins were detected using an
anti-human IgG (Fc specific) horseradish peroxidase conjugate. Lane
1: vector only; lane 2: 2H7 scFv IgG WTH (CCC) WTCH2CH3 (SEQ ID
NO:28); lane 3: 2H7 scFv IgG MTH (CSS) WTCH2CH3 (SEQ ID NO:135);
lane 4: 2H7 scFv IgG MTH (SCS) WTCH2CH3 (SEQ ID NO:137); lane 5:
2H7 scFv IgAH IgG WTCH2CH3 (SEQ ID NO:60); and lane 6: 2H7 scFv IgG
MTH (SSS) WTCH2CH3 (SEQ ID NO:50).
[0312] FIG. 36 illustrates binding of 2H7 scFv IgAH IgACH2CH3
polypeptide (SEQ ID NO:62) and 2H7 scFv IgAH IgAT4 (SEQ ID NO:71)
to (CD20+) CHO cells by flow immunocytofluorimetry. The source of
the polypeptides was culture supernatants from transiently
transfected COS cells. COS cells transfected with a plasmid
comprising a sequence encoding 2H7 scFv IgAH IgACH2CH3 were
co-transfected with a plasmid containing nucleotide sequence
encoding human J chain.
[0313] FIG. 37 illustrates antibody dependent cell-mediated
cytotoxicity activity of anti-CD20 (2H7) scFv Ig fusion proteins
against BJAB target cells using whole blood as the source of
effector cells. Purified 2H7 scFv Ig fusion proteins were titrated
and combined with .sup.51Cr-labeled BJAB cells (5.times.10.sup.4)
and whole blood (1:4 final dilution). Each data point represents
the average percent specific killing measured in four sample
wells.
[0314] FIG. 38 demonstrates antibody dependent cell-mediated
cytotoxicity activity of 2H7 scFv Ig fusion proteins (5 .mu.g/ml)
against .sup.51Cr-labeled BJAB cells at 0.25, 0.125, and 0.625
dilutions of whole blood. Each data point represents the average
percent specific killing measured in four sample wells.
[0315] FIG. 39 shows a comparison of antibody dependent
cell-mediated cytotoxicity activity of 2H7 scFv IgG MTH (SSS)
WTCH2CH3 (5 .mu.g/ml) and 2H7 scFv IgAH IgACH2CH3 (5 .mu.g/ml) when
human PBMC are the source of effector cells (FIG. 39A) and when
human whole blood is the source of effector cells (FIG. 39B).
[0316] FIG. 40 presents an immunoblot of 2H7 scFv IgG fusion
proteins. COS cells were transiently transfected with various 2H7
scFv Ig fusion protein constructs. Culture supernatants containing
the expressed polypeptides were separated in a non-reducing SDS
polyacrylamide gel, and then were transferred to a polyvinyl
fluoride membrane. Proteins were detected using an anti-human IgG
(Fc specific) horseradish peroxidase conjugate. Lanes 1-5: purified
2H7 scFv IgG MTH (SSS) WTCH2CH3 at 40 ng, 20 ng, 10 ng/5 ng, and
2.5 ng per lane, respectively. Culture supernatants were separated
in lanes 6-9. Lane 6: 2H7 scFv IgG WTH (CCC) WTCH2CH3; lane 7: 2H7
scFv IgG MTH (CSS) WTCH2CH3; lane 8: 2H7 scFv IgG MTH (SCS)
WTCH2CH3; and lane 9: 2H7 scFv VHSER11 IgG MTH (SSS) WTCH2CH3. The
molecular weight (kDal) of marker proteins is indicated on the left
side of the immunoblot.
[0317] FIG. 41 illustrates cell surface expression of 1D8
(anti-murine 4-1BB) scFv IgG WTH WTCH2CH3-CD80 fusion protein on
K1735 melanoma cells by flow immunofluorimetry (FIG. 41A). The scFv
fusion protein was detected with phycoerythrin-conjugated
F(ab').sub.2 goat anti-human IgG. FIG. 41B depicts growth of tumors
in naive C3H mice transplanted by subcutaneous injection with wild
type K1735 melanoma cells (K1735-WT) or with K1735 cells
transfected with 1D8 scFv IgG WTH WTCH2CH3-CD80 (K1735-1D8). Tumor
growth was monitored by measuring the size of the tumor. FIG. 41C
demonstrates the kinetics of tumor growth in naive C3H mice
injected intraperitoneally with monoclonal antibodies to remove
CD8.sup.+, CD4.sup.+, or both CD4.sup.+ and CD8.sup.+ T cells prior
to transplantation of the animals with K1735-1D8 cells.
[0318] FIG. 42 demonstrates therapy of established K1735-WT tumors
using K1735-1D8 as an immunogen. Six days after mice were
transplanted with K1735-WT tumors, one group (five animals) was
injected subcutaneously with K1735-1D8 cells (open circles) or
irradiated K1735-WT cells (solid squares) on the contralateral
side. A control group of mice received PBS (open squares).
Treatments were repeated on the days indicated by the arrows.
[0319] FIG. 43 shows the growth of tumors in animals that were
injected subcutaneously with 2.times.10.sup.6 K1735-WT cells (solid
squares) and the growth of tumors in animals that were injected
subcutaneously with 2.times.10.sup.6 K1735-WT cells plus
2.times.10.sup.5 K1735-1D8 cells (open triangles).
[0320] FIG. 44 presents a flow cytometry analysis of antigen104
murine sarcoma tumor cells transfected with 1D8 scFv IgG WTH
WTCH2CH3-CD80 isolated after repeated rounds of panning against
anti-human IgG. Transfected cells expressing 1D8 scFv IgG WTH
WTCH2CH3-CD80 were detected with fluoroisothiocyanate
(FITC)-conjugated goat anti-human IgG (depicted in black).
Untransfected cells are shown in gray.
[0321] FIG. 45 illustrates migration of various 2H7 scFv Ig fusion
proteins in a 10% SDS-PAGE gel. 2H7 was the anti-CD20 scFv and
40.2.220 was the anti-CD40 scFv. Lane 1: Bio-Rad prestained
molecular weight standards; lane 2: anti-CD20 scFv IgG MTH (SSS)
MTCH2WTCH3; lane 3: anti-CD20 scFv IgG MTH (SSS) WTCH2CH3; lane 4:
2H7 scFv IgAH IgG WTCH2CH3; lane 5: anti-CD20-anti-CD40 scFv IgG
MTH (SSS) MTCH2WTCH3; lane 6: Rituximab; lane 7: Novex
Multimark.RTM. molecular weight standards.
[0322] FIG. 46 illustrates effector function as measured in an
antibody dependent cell-mediated cytotoxicity assay of 2H7 Ig
fusion proteins that contain a mutant CH2 domain or wild type CH2
domain. The percent specific killing of BJAB target cells in the
presence of human PBMC effector cells by 2H7 scFv IgG MTH (SSS)
MTCH2WTCH3 (diamonds) was compared to 2H7 scFv IgG MTH (SSS)
WTCH2CH3 (squares) and 2H7 scFv IgAH IgG WTCH2CH3 (triangles) and
Rituximab (circles).
[0323] FIG. 47 shows cell surface expression of an anti-human CD3
scFv IgG WTH WTCH2CH3-CD80 (SEQ ID NO:413) fusion protein on Reh
cells (FIG. 47A) and T51 lymphoblastoid cells (FIG. 47B) by
measuring the linear fluorecent equivalent (LFE) using flow
immunocytofluorimetry.
[0324] FIG. 48 presents the percent specific killing of
untransfected Reh and T51 cells and the percent specific killing of
Reh cells (Reh anti-hCD3) (FIG. 48A) and T51 cells (T51 anti-hCD3)
(FIG. 48B) that were transfected with a construct encoding scFv
antibodies specific for human CD3, fused to human IgG1 wild-type
hinge-CH2-CH3, which was fused to human CD80 transmembrane and
cytoplasmic tail domains (anti-human CD3 scFv IgG WTH WTCH2CH3-CD80
(SEQ ID NO:29). Human PBMC (effector cells) were combined with BJAB
target cells at the ratios indicated.
[0325] FIG. 49 illustrates binding of 5B9, an anti-murine CD137
(4-1BB) monoclonal antibody, and a 5B9 scFv IgG fusion protein (5B9
scFv IgG MTH (SSS) WTCH2CH3 (SEQ ID NO:133) to stimulated human
PBMC. Binding of the 5B9 scFv IgG fusion protein was detected by
flow immunocytofluorimetry using FITC conjugated goat anti-human
IgG. Binding of the 5B9 monoclonal antibody was detected with FITC
conjugated goat anti-mouse IgG.
[0326] FIG. 50 illustrates the effect of the LV.sub.H11S mutation
on the expression of 2H7 LV.sub.H11S scFv WCH2 WCH3 ("CytoxB scFv
Ig"; SEQ ID NO:369) in CHO cell lines.
[0327] FIG. 51 shows a semi-quantitative SDS-PAGE analysis
examining the expression of 2H7 LV.sub.H11S scFv WCH2 WCH3 (SEQ ID
NO:369) when transiently transfected in CHO cells. Lanes 2-5 are
various amounts of 2H7 LV.sub.H11S scFv WCH2 WCH3. Lanes 6-10 are
10 .mu.l samples from five different clones expressing 2H7
LV.sub.H11S scFv WCH2 WCH3.
[0328] FIG. 52 shows differences in binding capacity between a
G28-1 LV.sub.H11S scFv Ig construct (SEQ ID NO:324) and a G28-1
wild type scFv Ig binding domain fusion protein construct (SEQ ID
NO:320), both obtained from transiently transfected COS cells.
Binding to Ramos cells was determined using flow cytometry. The
data illustrates a significant increase in binding of the
V.sub.H11S protein to CD37+Ramos cells.
[0329] FIG. 53 illustrates increased levels of expression of a
G28-1 LV.sub.H11S scFv Ig construct (SEQ ID NO:324) compared to a
G28-1 wild type scFv Ig construct in COS. Protein levels were
compared using immunoblot analysis. Both immunoblot gels have
quantitated amounts of purified a G28-1 scFv Ig (SSS-S) H WCH2 WCH3
contruct of the invention in lanes 1-4. Lanes 5-9 of the first
immunoblot represent five different clones each transfected with
G28-1 scFv (SSS-S) H WCH2 WCH3, while lanes 5-9 of the second
immunoblot represent five different clones transfected with G28-1
LV.sub.H11S scFv (SSS-S) H WCH2 WCH3. The immunoblots illustrate
that the LV.sub.H11S form causes the G28-1 scFv Ig construct to
express at very high levels.
[0330] FIG. 54 illustrates the binding of 2H7 scFv Ig derivatives
with altered hinges) to CHO cells expressing CD20 (CD20+CHO) by
flow cytometry, and indicates that these altered connecting region
hinge constructs (including (SSS-S), (CSS-S), (SCS-S) and (CSC-S)
hinge regions) retain binding function to CD20.
[0331] FIG. 55 shows the ability to mediate antibody dependent
cell-mediated cytotoxicity of various constructs against Bjab
targets: (A) 2H7 scFv Ig constructs of the invention that contain
connecting regions comprising (CSS-S), (SCS-S), (CSC-S), and
(SSS-S) hinges and (B) 2H7 scFv constructs of the invention with
various connecting regions and tail regions. Percent specific
killing is compared to total killing induced by a detergent. The
controls are natural killing in target cells with effectors added
and a 2H7 construct with an IgA hinge connecting region and
IgA-derived tail region that does not bind PBMC effectors.
[0332] FIG. 56 illustrates the ability of various 2H7 scFv Ig
constructs of the invention that include connecting regions having
various hinge regions (e.g., (CSC-S), (SSS-S), (SCS-S), and
(CSS-S)) to mediate complement activity in Ramos cells. Percent
specific killing is measured against the control of complement
only, and 100% killing was determined by exposure of cells to
detergent.
[0333] FIG. 57 illustrates the shows the binding of 2H7 scFv Ig
constructs of the invention containing different tail regions to
CD20+CHO using immunocytofluoroimetry. The different proteins were
detected using FITC conjugated to anti-IgG, anti-IgA, and
anti-IgE.
[0334] FIG. 58A shows the binding of 2H7 V.sub.H L11S scFv
IgECH2CH3CH4, purified using Hydrophobic charge induction
chromatography (HCIC) and eluted at different pHs 4.0 and 3.5, in
CD20+CHO cells by flow cytometry, indicating that the proteins
bound CD20 whether eluted at pH 4.0 or 3.5. FIG. 58B is a data
graph indicating the ability of these 2H7 VH L11S scFv IgE
constructs of the invention to mediate, for example, ADCC in Bjab
target cells.
[0335] FIG. 59 shows the binding capacity of G28-1 VH L11S
mIgECH2CH3CH4 (A) to Bjab and Ramos target cells and (B) to
CD20+CHO cells by flow cytometry.
[0336] FIG. 60 shows the High Performance Liquid Chromatography
(HPLC) profiles of various protein constructs of the invention (A)
2H7 scFv (SSS-S) H (P238S)CH2 WCH3 (B) 2H7 scFv (CSS-S) H WCH2
WCH3, (C) 2H7 scFv (SCS-S) H WCH2 WCH3, and (D) 2H7 scFv (SSS-S) H
WCH2 (Y407A)CH3, indicating that construct A has apparent molecular
weight forms of 100 kD and 75 kD and that, by introducing certain
changes a predominant 75 kD molecular weight form is obtained, as
seen in constructs B, C, and D. See Example 40.
[0337] FIG. 61 shows the HPLC profiles of various protein
constructs of the invention (A) 2H7 scFv (SSS-S) H WCH2 WCH3, (B)
2H7 scFv (CSC-S) H WCH2 WCH3, (C) 2H7 scFv (CCC-P) H WCH2 WCH3, and
(D) 2H7 scFv IgAH WCH2 WCH3, indicating that construct A has
apparent molecular weight forms of 100 kD and 75 kD and that, by
introducing certain changes a predominant 75 kD molecular weight
form is obtained, as seen in constructs B and C, while construct D
(which has an IgA tail regaion) has an apparent molecular weight of
150 kD. See Example 40.
[0338] FIG. 62 shows the HPLC profiles of various protein
constructs of the invention (A) 2H7 scFv (SSS-S) H WCH2 WCH3, (B)
2H7 scFv (SCS-S) H WCH2 WCH3, (C) 2H7 scFv IgA 3TCH2 WCH3, and (D)
2H7 scFv (SSS-S) H WCH2 (F405A Y407A)CH3, indicating that construct
A has two forms with apparent molecular weights at 100 kD and 75
kD, construct B has a predominant form with an apparent molecular
weight of 75 kD, while construct C with a T4 mutation leads to
three forms with apparent molecular weights near 600 kD and
construct D with a double point mutation in the CH3 region leads to
a predominant form having an apparent molecular weight less than 44
kD. A T4 mutation here refers to a truncation of four amino acids
from a CH3 region. See Example 40.
[0339] FIG. 63 compares the effect on binding CD20+CHO cells by 2H7
V.sub.H L11S scFv Ig constructs, with and without F405A and Y407A
alterations in the CH3 region, by flow cytometry, indicating a loss
of binding capability with this double amino acid change. See
Example 41.
[0340] FIG. 64 shows the binding capacity of FITC conjugated 2H7
V.sub.H L11S scFv Ig derivatives to CH20+CHO cells by flow
cytometry, indicating that these constructs do not lose binding
capacity when conjugated to a florescent marker. See Example
41.
[0341] FIG. 65 shows a nonreducing SDS-PAGE analysis examining 10
.mu.g (per lane) of various purified 2H7 V.sub.H L11S scFv Ig
constructs of the invention, indicating an apparent molecular
weight for each construct in reference to a standard molecular
weight marker in lane 1. See Example 41.
[0342] FIG. 66 compares the CH2 domain sequences of four different
human IgG regions, hIgG1, hIgG2, hIgG3, hIgG4, hIgG4, and one rat
region, rIgG2b (SEQ ID NOs:694-698). Point mutations affecting ADCC
and CDC are labeled with arrows. See Example 52.
[0343] FIG. 67 demonstrates the ability of various 2H7 V.sub.H L11S
scFv Ig constructs to mediate ADCC in CHO and Lec13 CHO transiently
transfected cells, indicating that constructs expressed in Lec 13
CHO cells had a 20% increase in specific killing over the same
construct expressed in regular CHO cells. See Example 42.
[0344] FIG. 68 shows SDS-PAGE analysis, both reduced and
nonreduced, of high and low affinity alleles of soluble CD 16(ED)
(SSS-S)H P283S CH2 WCH3 (SEQ ID NOs:422 and 426). See Example
43.
[0345] FIG. 69 demonstrates the different binding capabilities of
the high and low affinity CD16 fusion proteins to 2H7 V.sub.H L11S
scFv (CSC-S) WCH2 WCH3 or 2H7 V.sub.H L11S scFv (SSS-S) WCH2 WCH3,
and indicates a loss of high and low affinity allele binding using
P238S CH2 constructs. See Example 43.
[0346] FIG. 70 shows a diagram of (A) an assay used to detect
changes in Fc receptor binding using FITC conjugated CD16
extracellular domain Ig fusion protein with a mutated tail, which
eliminates self-association and B) a mammalian display system using
cell surface expression of constructs. See Example 44.
[0347] FIG. 71 shows the induction of apoptosis in Bjab and Ramos
cells by various mAbs and scFvIg constructs of the invention. See
Example 45.
[0348] FIG. 72 illustrates the ability of 2H7 scFv (SSS-S) H WCH2
WCH3 and 2H7 scFv (SSS-S) H P238CH2 WCH3 constructs to induce
apoptosis in Ramos cells that is mediated by activation of caspase
3. The results indicate that under these conditions, both
constructs bind CD20 and induced apoptosis.
[0349] FIG. 73 illustrates the ability of 2H7 scFv (SSS-S) H WCH2
WCH3 and 2H7 scFv (SSS-S) H P238CH2 WCH3 constructs to mediate CDC
activity in CD20 positive Bjab target cells. The results indicate
both constructs had the ability to mediate CDC.
[0350] FIG. 74 compares the ability of 2H7 scFv (SSS-S) H WCH2 WCH3
and 2H7 scFv (SSS-S) H P238CH2 WCH3 constructs to mediate ADCC in
Bjab target cells. The results indicate the 2H7 scFv (SSS-S) H WCH2
WCH3 construct was very effective and induced high levels of
specific killing, while the of 2H7 scFv (SSS-S) H P238CH2 WCH3
construct was not effective in mediating ADCC.
[0351] FIG. 75 compares the ability of 2H7 scFv (SSS-S) H WCH2 WCH3
and 2H7 scFv (SSS-S) H P238CH2 WCH3 constructs to bind soluble CD16
(high affinity and low affinity forms) in CD20 positive CHO cells.
Results indicate that 2H7 scFv (SSS-S) H WCH2 WCH3 was able to bind
CD16 (both forms), while 2H7 scFv (SSS-S) H P238CH2 WCH3 was not
able to bind CD16 (either form).
[0352] FIG. 76 compares the ability of 2H7 scFv (SSS-S) H WCH2 WCH3
and 2H7 scFv (SSS-S) H P238CH2 WCH3 constructs to bind CD64
positive U937 cells. The results indicate that both constructs had
high affinity for Fc.gamma.RI, and that the P238S mutation
selectively reduced binding to Fc.gamma.RIII.
[0353] FIG. 77 illustrates an in vivo experiment in macaques to
measure the effect of where 2H7 scFv (SSS-S) H WCH2 WCH3 and 2H7
scFv (SSS-S) H P238CH2 WCH3 constructs on B cell depletion. The
constructs were administered one week apart and B cells were
measures on days -7, 0, 1, 3, 7, 8, 10, 14, 28 and 43 using
complete blood counts and two-color flow cytometry. The results
indicate that the 2H7 scFv (SSS-S) H WCH2 WCH3 construct resulted
in rapid and complete depletion of B cells, which lasted up to 28
days after the second injection. Conversely the 2H7 scFv (SSS-S) H
P238CH2 WCH3 construct resulted in a slow reduction in B cells to
about 50% in the first 2 weeks; however, B cells rapidly began to
return to regular level shortly after this. This suggests that ADCC
mediated by CD16 interaction is likely necessary for rapid and
sustained B cell depletion.
[0354] FIG. 78 illustrates the SEC profiles of G28-1 VL11S scFv
(SSS) H WCH2 WCH3 and G28-1 VL11S scFv (SSC) H WCH2 WCH3
constructs. The construct with an SSS hinge generated a single
uniform peak at approximately 75-100 Kd, while the construct with a
SSC hinge generated a smaller form and other heterogeneous forms,
including one at greater than 200 Kd.
[0355] FIG. 79 illustrates the binding ability of G28-1 VL11S scFv
(SSS) H WCH2 WCH3 and G28-1 VL11S scFv (SSC) H WCH2 WCH3 constructs
in B cell lymphoma cells: Bjab, Ramos, WIL-2, Namalwa and Raji. The
results in (a) indicate that G28-1 VL11S scFv (SSS) H WCH2 WCH3
bound to Bjab and Ramos cells, and moderately to WIL-2 cells, and
at lower levels to Namalwa and Raji cells. The results in (b)
indicate the G28-1 VL11S scFv (SSC) H WCH2 WCH3 bound to Bjab
cells, and moderately to and Ramos and WIL-2 cells, and at lower
levels to Namalwa and Raji cells.
[0356] FIG. 80 illustrates annexin and v-propidium iodide binding
in Ramos cells incubated with G28-1 VL11S scFv (SSS) H WCH2 WCH3
and G28-1 VL11S scFv (SSC) H WCH2 WCH3 constructs overnight. The
results indicate that both constructs induced apoptosis; however,
the construct with the (SSC) hinge induced more apoptosis than the
construct with the (SSS) hinge.
[0357] FIG. 81 illustrates the ability of G28-1 VL11S scFv (SSS) H
WCH2 WCH3 and G28-1 VL11S scFv (SSC) H WCH2 WCH3 constructs to
inhibit proliferation of Ramos cells. The results indicate that
both constructs inhibited proliferation.
[0358] FIG. 82 illustrates the ability of G28-1 VL11S scFv (SSS) H
WCH2 WCH3 and G28-1 VL11S scFv (SSC) H WCH2 WCH3 and 2H7 scFv (CSS)
H WCH2 WCH3 constructs to induce apoptosis in Ramos B cells, alone
and in different combinations. The results shown in this experiment
indicate that the both G28-1 constructs were more efficient than
the 2H7 construct. The results also indicate that the G28-1 VL11S
scFv (SSS) H WCH2 WCH3 construct was more efficient than the G28-1
VL11S scFv (SSC) H WCH2 WCH3 construct. However, the amount of
apoptosis was greatest when the 2H7 and the G28-1 constructs were
used in combination.
[0359] FIG. 83 compares the ability of G28-1 VL11S scFv (SSS) H
WCH2 WCH3, G28-1 VL11S scFv (SSC) H WCH2 WCH3 and 2H7 scFv (CSS) H
WCH2 WCH3 constructs to mediate CDC in Ramos B cells. The results
indicate that all the constructs mediated CDC. The 2H7 construct
was the most efficient, followed by G28-1 VL11S scFv (SSC) H WCH2
WCH3, then G28-1 VL11S scFv (SSS) H WCH2 WCH3.
[0360] FIG. 84 compares the ability of the G28-1 VL11S scFv (SSS) H
WCH2 WCH3, G28-1 VL11S scFv (SSC) H WCH2 WCH3 and 2H7 scFv (CSS) H
WCH2 WCH3 constructs to mediate ADCC in Ramos B cells. The results
indicate that the G28-1 VL11S scFv (SSS) H WCH2 WCH3 and G28-1
VL11S scFv (SSC) H WCH2 WCH3 constructs were able to mediate ADCC,
while the 2H7 scFv (CSS) H WCH2 WCH3 construct ability to mediate
ADCC was lower, but still higher than the level of natural
killing.
DETAILED DESCRIPTION OF THE INVENTION
[0361] The present invention is directed to novel molecules useful,
for example, as therapeutics, as well as for other purposes
including diagnostic and research purposes. Such molecules have,
for example, antigen binding or other binding function(s) and, for
example, one or more effector functions. The invention includes
molecular constructs, including binding domain-immunoglobulin
fusion proteins, and related compositions and methods, which will
be useful in immunotherapeutic and immunodiagnostic applications,
and in research methods, and which offer certain advantages over
antigen-specific compounds and polypeptides of the prior art. The
constructs, including fusion proteins, of the present invention are
preferably single polypeptide chains that comprise, in pertinent
part, the following fused or otherwise connected domains or
regions: a binding region construct, such as a binding domain or
polypeptide, a connecting region construct including, for example,
a native or engineered immunoglobulin hinge region polypeptide, and
a tail region construct, including, for example, a construct that
may comprise, consist essentially of, or consist of, a native or
engineered immunoglobulin heavy chain CH2 constant region
polypeptide and a native or engineered immunoglobulin heavy chain
CH3 constant region polypeptide. According to certain embodiments
that are particularly useful for gene therapy, the constructs,
including fusion proteins, of the present invention may further
comprise a native or engineered plasma membrane anchor domain.
According to certain other preferred embodiments the constructs,
including fusion proteins, of the present invention may further
include a tail region having a native or engineered immunoglobulin
heavy chain CH4 constant region polypeptide. In particularly
preferred embodiments, the binding regions, such as polypeptide
domains, of which the constructs, including binding
domain-immunoglobulin fusion proteins, are comprised are, or are
derived from, polypeptides that are the products of human gene
sequences, but the invention need not be so limited and may in fact
relate to constructs, including binding domain-immunoglobulin
fusion proteins, as provided herein that are derived from any
natural or artificial source, including genetically engineered
and/or mutated polypeptides.
[0362] The present invention relates in part to the surprising
observation that the novel constructs, including binding
domain-immunoglobulin fusion proteins, described herein are capable
of immunological activity. More specifically, these proteins retain
the ability to participate in well known immunological effector
activities including, for example, antibody dependent cell mediated
cytotoxicity (e.g., subsequent to antigen binding on a cell
surface, engagement and induction of cytotoxic effector cells
bearing appropriate Fc receptors, such as Natural Killer cells
bearing FcR.gamma.III, under appropriate conditions) and/or
complement fixation in complement dependent cytotoxicity (e.g.,
subsequent to antigen binding on a cell surface, recruitment and
activation of cytolytic proteins that are components of the blood
complement cascade) despite having structures not be expected to be
capable of promoting such effector activities or to promtion of
such activities as described herein. For reviews of ADCC and CDC
see, e.g., Carter, 2001 Nat. Rev. Canc. 1:118; Sulica et al., 2001
Int. Rev. Immunol. 20:371; Maloney et al., 2002 Semin. Oncol. 29:2;
Sondel et al., 2001 Hematol Oncol Clin North Am 15(4):703-21;
Maloney 2001 Anticanc. Drugs 12 Suppl.2:1-4. IgA activation of
complement by the alternative pathway is described, for example, in
Schneiderman et al., 1990 J. Immunol. 145:233. As described in
greater detail below, ADCC, complement fixation, and CDC are
unexpected functions for constructs, including fusion proteins,
comprising for example immunoglobulin heavy chain regions and
having the structures described herein, and in particular for
immunoglobulin fusion proteins comprising, for example,
immunoglobulin hinge region polypeptides that are compromised in
their ability to form interchain, homodimeric disulfide bonds.
[0363] Another advantage afforded by the present invention is
constructs, including binding domain-immunoglobulin fusion
polypeptides, of the invention that can be produced in substantial
quantities that are typically greater than those routinely attained
with single-chain antibody constructs of the prior art, for
example. In preferred embodiments, constructs, including the
binding domain-immunoglobulin fusion polypeptides, of the present
invention are recombinantly expressed in mammalian or other desired
and useful expression systems, which offer the advantage of
providing polypeptides that are stable in vivo (e.g., under
physiological conditions). According to non-limiting theory, such
stability may derive in part from posttranslational modifications,
and specifically glycosylation. Production of the constructs,
including binding domain-immunoglobulin fusion protein constructs,
of the invention via recombinant mammalian expression has been
attained in static cell cultures at a level of greater than 50 mg
protein per liter culture supernatant and has been routinely
observed in such cultures at 10-50 mg/liter, such that preferably
at least 10-50 mg/liter may be produced under static culture
conditions; also contemplated are enhanced production, in whole or
in part, of the protein constructs of the invention using
art-accepted scale-up methodologies such as "fed batch" (i.e.,
non-static) production, where yields of at least 5-500 mg/l, and in
some instances at least 0.5-1 gm/l, depending on the particular
protein product, are obtained.
[0364] A construct, including a binding domain polypeptide,
according to the present invention may be, for example, any
polypeptide that possesses the ability to specifically recognize
and bind to a cognate biological molecule or complex of more than
one molecule or assembly or aggregate, whether stable or transient,
of such a molecule. Such molecules include proteins, polypeptides,
peptides, amino acids, or derivatives thereof; lipids, fatty acids
or the like, or derivatives thereof; carbohydrates, saccharides or
the like or derivatives thereof; nucleic acids, nucleotides,
nucleosides, purines, pyrimidines or related molecules, or
derivatives thereof, or the like; or any combination thereof such
as, for example, glycoproteins, glycopeptides, glycolipids,
lipoproteins, proteolipids; or any other biological molecule that
may be present in a biological sample. Biological samples may be
provided, for example, by obtaining a blood sample, biopsy
specimen, tissue explant, organ culture, biological fluid or any
other tissue or cell or other preparation from a subject or a
biological source. The subject or biological source may, for
example, be a human or non-human animal, a primary cell culture or
culture adapted cell line including but not limited to genetically
engineered cell lines that may contain chromosomally integrated or
episomal recombinant nucleic acid sequences, immortalized or
immortalizable cell lines, somatic cell hybrid cell lines,
differentiated or differentiatable cell lines, transformed cell
lines and the like, etc. In certain preferred embodiments of the
invention, the subject or biological source may be suspected of
having or being at risk for having a disease, disorder or
condition, including a malignant disease, disorder or condition or
a B cell disorder, which in certain further embodiments may be an
autoimmune disease, and in certain other embodiments of the
invention the subject or biological source may be known to be free
of a risk or presence of such disease, disorder or condition.
[0365] A binding region, including a binding domain polypeptide,
for example, may be any naturally occurring, synthetic,
semi-synthetic, and/or recombinantly produced binding partner for a
biological or other molecule that is a target structure of
interest, herein sometimes referred to as an "antigen" but intended
according to the present disclosure to encompass any target
biological or other molecule to which it is desirable to have the
subject invention, for example, a fusion protein, bind or
specifically bind. Constructs of the invention, including binding
domain-immunoglobulin fusion proteins, are defined to be
"immunospecific" or capable of binding to a desired degree,
including specifically binding, if they bind a desired target
molecule such as an antigen as provided herein, at a desired level,
for example, with a K.sub.a of greater than or equal to about
10.sup.4 M.sup.-1, preferably of greater than or equal to about
10.sup.5 M.sup.-1, more preferably of greater than or equal to
about 10.sup.6 M.sup.-1 and still more preferably of greater than
or equal to about 10.sup.7 M.sup.-1. Affinities of even greater
than about 10.sup.7 M.sup.-1 are still more preferred, such as
affinities equal to or greater than about 10.sup.7 M.sup.-1, about
10.sup.8 M.sup.-1, and about 10.sup.9 M.sup.-1, and about 10.sup.10
M.sup.-1. Affinities of binding domain-immunoglobulin fusion
proteins according to the present invention can be readily
determined using conventional techniques, for example those
described by Scatchard et al., 1949 Ann. N.Y. Acad. Sci. 51:660.
Such determination of fusion protein binding to target antigens of
interest can also be performed using any of a number of known
methods for identifying and obtaining proteins that specifically
interact with other proteins or polypeptides, for example, a yeast
two-hybrid screening system such as that described in U.S. Pat. No.
5,283,173 and U.S. Pat. No. 5,468,614, or the equivalent.
[0366] Preferred embodiments of the subject invention constructs,
for example, binding domain-immunoglobulin fusion proteins,
comprise binding regions or binding domains that may include, for
example, at least one native or engineered immunoglobulin variable
region polypeptide, such as all or a portion or fragment of a
native or engineered heavy chain and/or a native or engineered
light chain V-region, provided it is capable of binding or
specifically binding an antigen or other desired target structure
of interest at a desired level of binding and selectivity. In other
preferred embodiments the binding region or binding domain
comprises, consists essentially of, or consists of, a single chain
immunoglobulin-derived Fv product, for example, and scFv, which may
include all or a portion of at least one native or engineered
immunoglobulin light chain V-region and all or a portion of at
least one native or engineered immunoglobulin heavy chain V-region,
and a linker fused or otherwise connected to the V-regions;
preparation and testing such constructs are described in greater
detail herein. Other preparation and testing methods are well known
in the art.
[0367] As described herein and known in the art, immunoglobulins
comprise products of a gene family the members of which exhibit a
high degree of sequence conservation. Amino acid sequences of two
or more immunoglobulins or immunoglobulin domains or regions or
portions thereof (e.g., V.sub.H domains, V.sub.L domains, hinge
regions, CH2 constant regions, CH3 constant regions) may be aligned
and analyzed. Portions of sequences that correspond to one another
may be identified, for instance, by sequence homology.
Determination of sequence homology may be determined with any of a
number of sequence alignment and analysis tools, including computer
algorithms well known to those of ordinary skill in the art, such
as Align or the BLAST algorithm (Altschul, 1991 J. Mol. Biol.
219:555-565; Henikoff and Henikoff, 1992 Proc. Natl. Acad. Sci. USA
89:10915-10919), which is available at the NCBI website
(http://www/ncbi.nlm.nih.gov/cgi-bin/BLAST). Default parameters may
be used.
[0368] Portions, for example, of a particular immunoglobulin
reference sequence and of any one or more additional immunoglobulin
sequences of interest that may be compared to a reference sequence.
"Corresponding" sequences, regions, fragments or the like, may be
identified based on the convention for numbering immunoglobulin
amino acid positions according to Kabat, Sequences of Proteins of
Immunological Interest, (5.sup.th ed. Bethesda, Md.: Public Health
Service, National Institutes of Health (1991)). For example,
according to this convention, the immunoglobulin family to which an
immunoglobulin sequence of interest belongs is determined based on
conservation of variable region polypeptide sequence invariant
amino acid residues, to identify a particular numbering system for
the immunoglobulin family, and the sequence(s) of interest can then
be aligned to assign sequence position numbers to the individual
amino acids which comprise such sequence(s). Preferably at least
about 70%, more preferably at least about 80%-85% or about 86%-89%,
and still more preferably at least about 90%, about 92%, about 94%,
about 96%, about 98% or about 99% of the amino acids in a given
amino acid sequence of at least about 1000, more preferably about
700-950, more preferably about 350-700, still more preferably about
100-350, still more preferably about 80-100, about 70-80, about
60-70, about 50-60, about 40-50 or about 30-40 consecutive amino
acids of a sequence, are identical to the amino acids located at
corresponding positions in a reference sequence such as those
disclosed by Kabat (1991) or in a similar compendium of related
immunoglobulin sequences, such as may be generated from public
databases (e.g., Genbank, SwissProt, etc.) using sequence alignment
tools such as, for example, those described above. In certain
preferred embodiments, an immunoglobulin sequence of interest or a
region, portion, derivative or fragment thereof is greater than
about 95% identical to a corresponding reference sequence, and in
certain preferred embodiments such a sequence of interest may
differ from a corresponding reference at no more than about 1, 2,
3, 4, 5, 6, 7, 8, 9 or 10 amino acid positions.
[0369] For example, in certain embodiments the present invention is
directed to a construct, including a binding domain-immunoglobulin
fusion protein, comprising in pertinent part a human or other
species immunoglobulin heavy chain variable region polypeptide
comprising a mutation, alteration or deletion at an amino acid at a
location or locations corresponding to one or more of amino acid
positions 9, 10, 11, 12, 108, 110, 111, and 112 in, for example,
SEQ ID NO:212, which comprises, for example, a murine
V.sub.H-derived sequence. At a relatively limited number of
immunoglobulin V.sub.H sequence positions, for example, including
position 11, amino acid conservation is observed in the
overwhelming majority of V.sub.H sequences analyzed across
mammalian species lines (e.g., Leull, Va137, Gly44, Leu45, Trp47;
Nguyen et al., 1998 J. Mol. Biol. 275:413). Various such amino acid
residues, and hence their side chains, are located at the surface
of the variable domain (V.sub.H). They may contact residues of the
C.sub.H1 (e.g., Leu11) and the V.sub.L domains (e.g., Va137, Gly44,
Leu45, and Trp47) and may, in the absence of light chains,
contribute to stability and solubility of the protein (see, e.g.,
Chothia et al., 1985 J. Mol. Biol. 186:651; Muyldermans et al.,
1994 Prot. Engineer. 7:1129; Desmyter et al., 1996 Nat. Struct.
Biol. 3:803; Davies et al., 1994 FEES Lett. 339:285). In certain
embodiments, for example, the present invention is also directed to
a construct, including a binding domain-immunoglobulin fusion
protein, comprising in pertinent part a human immunoglobulin light
chain variable region polypeptide, or an immunoglobulin light chain
variable region polypeptide from another species, comprising a
mutation, alteration or deletion at an amino acid at a location or
locations corresponding to one or more of amino acid positions 12,
80, 81, 82, 83, 105, 106, 107 and 108. In still other certain
embodiments, for example, the present invention is directed to a
construct, including a binding domain-immunoglobulin fusion
protein, comprising in pertinent part (1) a human immunoglobulin
heavy chain variable region polypeptide, or an immunoglobulin light
chain variable region polypeptide from another species, comprising,
consisting essentially of, or consisting of, said heavy chain
sequence having a mutation, alteration or deletion at a location or
locations corresponding to one or more of amino acid positions 9,
10, 11, 12, 108, 110, 111, and 112, and (2) a human immunoglobulin
light chain variable region polypeptide, or an immunoglobulin light
chain variable region polypeptide from another species, comprising,
consisting essentially of, or consisting of, said light chain
sequence having a mutation, alteration or deletion at a location or
locations corresponding to one or more of amino acid positions 12,
80, 81, 82, 83, 105, 106, 107 and 108.
[0370] As another example, by reference to immunoglobulin sequence
compendia and databases such as those cited above, for example, the
relatedness of two or more immunoglobulin sequences to each other
can readily and without undue experimentation be established in a
manner that permits identification of the animal species of origin,
the class and subclass (e.g., isotype) of a particular
immunoglobulin or immunoglobulin region polypeptide sequence. Any
immunoglobulin variable region polypeptide sequence, including
native or engineered V.sub.H and/or V.sub.L and/or single-chain
variable region (sFv) sequences or other native or engineered V
region-derived sequences or the like, may be used as a binding
region or binding domain. Engineered sequences includes
immunoglobulin sequences from any species, preferably human or
mouse, for example, that include, for example, a mutation,
alteration or deletion at an amino acid at a location or locations
corresponding to one or more of amino acid positions 9, 10, 11, 12,
108, 110, 111, and 112 in a heavy chain variable region sequence or
an scFv, and/or a mutation, alteration or deletion at a location or
locations corresponding to one or more of amino acid positions 12,
80, 81, 82, 83, 105, 106, 107 and 108 in a light chain variable
region sequence or an scFv.
[0371] Various preferred embodiments include, for example, native
or engineered immunoglobulin V region polypeptide sequences
derived, for example, from antibodies including monoclonal
antibodies such as murine or other rodent antibodies, or antibodies
or monoclonal antibodies derived from other sources such as goat,
rabbit, equine, bovine, camelid or other species, including
transgenic animals, and also including human or humanized
antibodies or monoclonal antibodies. Non-limiting examples include
variable region polypeptide sequences derived from monoclonal
antibodies such as those referenced herein and/or described in
greater detail in the Examples below, for instance, CD20-binding or
specific murine monoclonal antibodies (e.g., 2H7), other
CD20-binding or specific murine monoclonal antibodies that are not
1F5 antibodies, monoclonal antibody L6 (specific for a
carbohydrate-defined epitope and available from American Type
Culture Collection, Manassas, Va., as hybridoma HB8677), and
monoclonal antibodies that bind to or are specific for CD28 (e.g.,
monoclonal antibody 2E12), CD40, CD80, CD137 (e.g., monoclonal
antibody 5B9 or monoclonal antibody 1D8 which recognizes the murine
homologue of CD137, 41BB) and CD152 (CTLA-4).
[0372] Other binding regions, including binding domain
polypeptides, may comprise any protein or portion thereof that
retains the ability to bind or specifically bind to an antigen as
provided herein, including non-immunoglobulins. Accordingly the
invention contemplates constructs, including fusion proteins,
comprising binding region or binding domain polypeptides that are
derived from polypeptide ligands such as hormones, cytokines,
chemokines, and the like; cell surface or soluble receptors for
such polypeptide ligands; lectins; intercellular adhesion receptors
such as specific leukocyte integrins, selectins, immunoglobulin
gene superfamily members, intercellular adhesion molecules (ICAM-1,
-2, -3) and the like; histocompatibility antigens; etc.
[0373] Examples of cell surface receptors useful in the preparation
of, or as, binding regions, or that may provide a binding domain
polypeptide, and that may also be selected as a target molecule or
antigen to which a construct, including for example, a binding
domain-Ig fusion protein of the present invention desirably binds,
include the following, or the like: HER1 (e.g., GenBank Accession
Nos. U48722, SEG_HEGFREXS, KO03193), HER2 (Yoshino et al., 1994 J.
Immunol. 152:2393; Disis et al., 1994 Canc. Res. 54:16; see also,
e.g., GenBank Acc. Nos. X03363, M17730, SEG_HUMHER20), HER3 (e.g.,
GenBank Acc. Nos. U29339, M34309), HER4 (Plowman et al., 1993
Nature 366:473; see also e.g., GenBank Acc. Nos. L07868, T64105),
epidermal growth factor receptor (EGFR) (e.g., GenBank Acc. Nos.
U48722, SEG_HEGFREXS, K03193), vascular endothelial cell growth
factor (e.g., GenBank No. M32977), vascular endothelial cell growth
factor receptor (VEGF) (e.g., GenBank Acc. Nos. AF022375, 1680143,
U48801, X62568), insulin-like growth factor-I (e.g., GenBank Acc.
Nos. X00173, X56774, X56773, X06043, see also European Patent No.
GB 2241703), insulin-like growth factor-II (e.g., GenBank Acc. Nos.
X03562, X00910, SEG_HUMGFIA, SEG_HUMGFI2, M17863, M17862),
transferrin receptor (Trowbridge and Omary, 1981 Proc. Nat. Acad.
USA 78:3039; see also e.g., GenBank Acc. Nos. X01060, M11507),
estrogen receptor (e.g., GenBank Acc. Nos. M38651, X03635, X99101,
U47678, M12674), progesterone receptor (e.g., GenBank Acc. Nos.
X51730, X69068, M15716), follicle stimulating hormone receptor
(FSH-R) (e.g., GenBank Acc. Nos. Z34260, M65085), retinoic acid
receptor (e.g., GenBank Acc. Nos. L12060, M60909, X77664, X57280,
X07282, X06538), MUC-1 (Barnes et al., 1989 Proc. Nat. Acad. Sci.
USA 86:7159; see also e.g., GenBank Acc. Nos. SEG_MUSMUCIO, M65132,
M64928) NY-ESO-1 (e.g., GenBank Acc. Nos. AJ003149, U87459), NA
17-A (e.g., European Patent No. WO 96/40039), Melan-A/MART-1
(Kawakami et al., 1994 Proc. Nat. Acad. Sci. USA 91:3515; see also
e.g., GenBank Acc. Nos. U06654, U06452), tyrosinase (Topalian et
al., 1994 Proc. Nat. Acad. Sci. USA 91:9461; see also e.g., GenBank
Acc. Nos. M26729, SEG_HUMTYR0, see also Weber et al., J. Clin.
Invest (1998) 102:1258), Gp-100 (Kawakami et al., 1994 Proc. Nat.
Acad. Sci. USA 91:3515; see also e.g., GenBank Acc. No. S73003, see
also European Patent No. EP 668350; Adema et al., 1994 J. Biol.
Chem. 269:20126), MAGE (van den Bruggen et al., 1991 Science
254:1643; see also e.g, GenBank Acc. Nos. U93163, AF064589, U66083,
D32077, D32076, D32075, U10694, U10693, U10691, U10690, U10689,
U10688, U10687, U10686, U10685, L18877, U10340, U10339, L18920,
U03735, M77481), BAGE (e.g., GenBank Acc. No. U19180; see also U.S.
Pat. Nos. 5,683,886 and 5,571,711), GAGE (e.g., GenBank Acc. Nos.
AF055475, AF055474, AF055473, U19147, U19146, U19145, U19144,
U19143, U19142), any of the CTA class of receptors including in
particular HOM-MEL-40 antigen encoded by the SSX2 gene (e.g.,
GenBank Acc. Nos. X86175, U90842, U90841, X86174), carcinoembyonic
antigen (CEA, Gold and Freedman, 1985 J. Exp. Med. 121:439; see
also e.g., GenBank Acc. Nos. SEG_HUMCEA, M59710, M59255, M29540),
and PyLT (e.g., GenBank Acc. Nos. J02289, J02038).
[0374] Additional cell surface receptors that may be sources of
binding region or binding domain polypeptides or portions thereof,
or that may be targets, including target antigens, include the
following, or the like: CD2 (e.g., GenBank Acc. Nos. Y00023,
SEG_HUMCD2, M16336, M16445, SEG_MUSCD2, M14362), 4-1BB (CDw137,
Kwon et al., 1989 Proc. Nat. Acad. Sci. USA 86:1963, 4-1BB ligand
(Goodwin et al., 1993 Eur. J. Immunol. 23:2361; Melero et al., 1998
Eur. J. Immunol. 3:116), CD5 (e.g., GenBank Acc. Nos. X78985,
X89405), CD10 (e.g., GenBank Acc. Nos. M81591, X76732) CD27 (e.g.,
GenBank Acc. Nos. M63928, L24495, L08096), CD28 (June et al., 1990
Immunol. Today 11:211; see also, e.g., GenBank Acc. Nos. J02988,
SEG_HUMCD28, M34563), CD152/CTLA-4 (e.g., GenBank Acc. Nos. L15006,
X05719, SEG_HUMIGCTL), CD40 (e.g., GenBank Acc. Nos. M83312,
SEG_MUSC040A0, Y10507, X67878, X96710, U15637, L07414),
interferon-.gamma. (IFN-.gamma.; see, e.g., Farrar et al. 1993 Ann.
Rev. Immunol. 11:571 and references cited therein, Gray et al. 1982
Nature 295:503, Rinderknecht et al. 1984 J. Biol. Chem. 259:6790,
DeGrado et al. 1982 Nature 300:379), interleukin-4 (IL-4; see,
e.g., 53.sup.rd Forum in Immunology, 1993 Research in Immunol.
144:553-643; Banchereau et al., 1994 in The Cytokine Handbook,
2.sup.nd ed., A. Thomson, ed., Academic Press, NY, p. 99; Keegan et
al., 1994 J. Leukocyt. Biol. 55:272, and references cited therein),
interleukin-17 (IL-17) (e.g., GenBank Acc. Nos. U32659, U43088) and
interleukin-17 receptor (IL-17R) (e.g., GenBank Acc. Nos. U31993,
U58917). Notwithstanding the foregoing, the present invention
expressly does not encompass any immunoglobulin fusion protein that
is disclosed in U.S. Pat. No. 5,807,734, or U.S. Pat. No.
5,795,572.
[0375] Additional cell surface receptors that may be sources of
binding region or binding domain polypeptides or portions thereof,
or that may serve as targets including target antigens or binding
sites include the following, or the like: CD59 (e.g., GenBank Acc.
Nos. SEG_HUMCD590, M95708, M34671), CD48 (e.g., GenBank Acc. Nos.
M59904), CD58/LFA-3 (e.g., GenBank Acc. No. A25933, Y00636, E12817;
see also JP 1997075090-A), CD72 (e.g., GenBank Acc. Nos. AA311036,
540777, L35772), CD70 (e.g., GenBank Acc. Nos. Y13636, S69339),
CD80/B7.1 (Freeman et al., 1989 J. Immunol. 43:2714; Freeman et
al., 1991 J. Exp. Med. 174:625; see also e.g., GenBank Acc. Nos.
U33208, 1683379), CD86/B7.2 (Freeman et al., 1993 J. Exp. Med.
178:2185, Boriello et al., 1995 J. Immunol. 155:5490; see also,
e.g., GenBank Acc. Nos. AF099105, SEG_MMB72G, U39466, U04343,
SEG_HSB725, L25606, L25259), B7-H1/B7-DC (e.g., Genbank Acc. Nos.
NM.sub.--014143, AF177937, AF317088; Dong et al., 2002 Nat. Med.
June 24 [epub ahead of print], PMID 12091876; Tseng et al., 2001 J.
Exp. Med. 193:839; Tamura et al., 2001 Blood 97:1809; Dong et al.,
1999 Nat. Med. 5:1365), CD40 ligand (e.g., GenBank Acc. Nos.
SEG_HUMCD40L, X67878, X65453, L07414), IL-17 (e.g., GenBank Acc.
Nos. U32659, U43088), CD43 (e.g., GenBank Acc. Nos. X52075,
J04536), ICOS (e.g., Genbank Acc. No. AH011568), CD3 (e.g., Genbank
Acc. Nos. NM.sub.--000073 (gamma subunit), NM.sub.--000733 (epsilon
subunit), X73617 (delta subunit)), CD4 (e.g., Genbank Acc. No.
NM.sub.--000616), CD25 (e.g., Genbank Acc. No. NM.sub.--000417),
CD8 (e.g., Genbank Acc. No.M12828), CD11b (e.g., Genbank Acc. No.
J03925), CD14 (e.g., Genbank Acc. No. XM.sub.--039364), CD56 (e.g.,
Genbank Acc. No.U63041), CD69 (e.g., Genbank Acc.
No.NM.sub.--001781) and VLA-4 (.alpha..sub.4.beta..sub.7) (e.g.,
GenBank Acc. Nos. L12002, X16983, L20788, U97031, L24913, M68892,
M95632). The following cell surface receptors are typically
associated with B cells: CD19 (e.g., GenBank Acc. Nos.
SEG_HUMCD19W0, M84371, SEG_MUSCD19W, M62542), CD20 (e.g., GenBank
Acc. Nos. SEG_HUMCD20, M62541), CD22 (e.g., GenBank Acc. Nos.
1680629, Y10210, X59350, U62631, X52782, L16928), CD30 (e.g.,
Genbank Acc. Nos. M83554, D86042), CD153 (CD30 ligand, e.g.,
GenBank Acc. Nos. L09753, M83554), CD37 (e.g., GenBank Acc. Nos.
SEG_MMCD37X, X14046, X53517), CD50 (ICAM-3, e.g., GenBank Acc. No.
NM.sub.--002162), CD106 (VCAM-1) (e.g., GenBank Acc. Nos. X53051,
X67783, SEG_MMVCAM1C, see also U.S. Pat. No. 5,596,090), CD54
(ICAM-1) (e.g., GenBank Acc. Nos. X84737, 582847, X06990, J03132,
SEG_MUSICAMO), interleukin-12 (see, e.g., Reiter et al, 1993 Crit.
Rev. Immunol. 13:1, and references cited therein), CD134 (OX40,
e.g., GenBank Acc. No. AJ277151), CD137 (41BB, e.g., GenBank Acc.
No. L12964, NM.sub.--001561), CD83 (e.g., GenBank Acc. Nos.
AF001036, AL021918), DEC-205 (e.g., GenBank Acc. Nos. AF011333,
U19271).
[0376] Constructs, including binding domain-immunoglobulin fusion
proteins, of the present invention comprise, for example, a binding
domain, such as a binding domain polypeptide that, according to
certain particularly preferred embodiments, is capable of binding
or specifically binding at least one target, for example, a target
antigen or other binding site that is present on an immune effector
cell. According to non-limiting theory, such constructs, including
for example binding domain-immunoglobulin fusion proteins, may
advantageously recruit desired immune effector cell function(s) in
a therapeutic context, where it is well known that immune effector
cells having different specialized immune functions can be
identified or distinguished from one another on the basis of their
differential expression of a wide variety of cell surface antigens,
including many of the antigens described herein to which constructs
of the invention including binding domain polypeptides can
specifically bind. As noted herein, immune effector cells include
any cell that is capable of directly mediating an activity that is
a component of immune system function, including cells having such
capability naturally or as a result of genetic engineering.
[0377] In certain embodiments an immune effector cell comprises a
cell surface receptor for an immunoglobulin or other peptide
binding molecule, such as a receptor for an immunoglobulin constant
region and including the class of receptors commonly referred to as
"Fc receptors" ("FcR"s). A number of FcRs have been structurally
and/or functionally characterized and are well known in the art,
including FcR having specific abilities to interact with a
restricted subset of immunoglobulin heavy chain isotypes, or that
interact with Fc domains with varying affinities, and/or which may
be expressed on restricted subsets of immune effector cells under
certain conditions (e.g., Kijimoto-Ochichai et al., 2002 Cell Mol.
Life. Sci. 59:648; Davis et al., 2002 Curr. Top. Microbiol.
Immunol. 266:85; Pawankar, 2001 Curr. Opin. Allerg. Clin. Immunol.
1:3; Radaev et al., 2002 Mol. Immunol. 38:1073; Wurzburg et al.,
2002 Mol. Immunol. 38:1063; Sulica et al., 2001 Int. Rev. Immunol.
20:371; Underhill et al., 2002 Ann. Rev. Immunol. 20:825;
Coggeshall, 2002 Curr. Dir. Autoimm. 5:1; Mimura et al., 2001 Adv.
Exp. Med. Biol. 495:49; Baumann et al., 2001 Adv. Exp. Med. Biol.
495:219; Santoso et al., 2001 Ital. Heart J. 2:811; Novak et al.,
2001 Curr. Opin. Immunol. 13:721; Fossati et al., 2001 Eur. J.
Clin. Invest. 31:821).
[0378] Cells that are capable of mediating ADCC are preferred
examples of immune effector cells according to the present
invention. Other preferred examples include Natural Killer cells,
tumor-infiltrating T lymphocytes (TILs), cytotoxic T lymphocytes,
and granulocytic cells such as cells that comprise allergic
response mechanisms. Immune effector cells thus include, but are
not limited to, cells of hematopoietic origins including cells at
various stages of differentiation within myeloid and lymphoid
lineages and which may (but need not) express one or more types of
functional cell surface FcR, such as T lymphocytes, B lymphocytes,
NK cells, monocytes, macrophages, dendritic cells, neutrophils,
basophils, eosinophils, mast cells, platelets, erythrocytes, and
precursors, progenitors (e.g., hematopoietic stem cells), as well
as quiescent, activated, and mature forms of such cells. Other
immune effector cells may include cells of non-hematopoietic origin
that are capable of mediating immune functions, for example,
endothelial cells, keratinocytes, fibroblasts, osteoclasts,
epithelial cells, and other cells. Immune effector cells may also
include cells that mediate cytotoxic or cytostatic events, or
endocytic, phagocytic, or pinocytotic events, or that effect
induction of apoptosis, or that effect microbial immunity or
neutralization of microbial infection, or cells that mediate
allergic, inflammatory, hypersensitivity and/or autoimmune
reactions.
[0379] Allergic response mechanisms are well known in the art and
include an antigen (e.g., allergen)-specific component such as an
immunoglobulin (e.g., IgE), as well as the cells and mediators
which comprise sequelae to allergen-immunoglobulin (e.g., IgE)
encounters (e.g., Ott et al., 2000 J. Allerg. Clin. Immunol.
106:429; Barnes, 2000 J. Allerg. Clin. Immunol. 106:5; Togias, 2000
J. Allerg. Clin. Immunol. 105:S599; Akdis et al., 2000 Int. Arch.
Allerg. Immunol. 121:261; Beach, 2000 Occup. Med. 15:455).
Particularly with regard to constructs, including binding
domain-immunoglobulin fusion proteins, of the present invention
that interact with FcR, certain embodiments of the present
invention contemplate constructs including fusion proteins that
comprise one or more IgE-derived domains including, for example,
those that are capable of inducing an allergic response mechanism
that comprises IgE-specific FcR, or portions thereof, which
IgE-specific FcRs include those noted above and described or
identified in the cited articles. Without wishing to be bound by
particular theory or mechanism, and as disclosed herein,
constructs, including fusion proteins, of the present invention may
comprise portions of IgE heavy chain Fc domain polypeptides, for
example, native or engineered IgE CH3 and CH4 domains, whether
provided or expressed as cell surface proteins (e.g., with a plasma
membrane anchor domain) or as soluble or otherwise not cell-bound
proteins (e.g., without a plasma membrane anchor domain). Further
according to non-limiting theory, recruitment and induction of an
allergic response mechanism (e.g., an FcR-epsilon expressing immune
effector cell) may proceed as the result of either or both of the
presence of an IgE Fc domain or portion thereof as described herein
(e.g., one that is capable of triggering an allergic mechanism by
FcR crosslinking) and the presence of a target such as a antigen to
which the binding region, for example a binding domain, binds or
specifically binds. The present invention therefore exploits
induction of allergic response mechanisms in heretofore
unappreciated contexts, such as treatment of a malignant condition
or a B cell disorder, including those described or referenced
herein.
[0380] An immunoglobulin hinge region polypeptide includes any
hinge peptide or polypeptide that occurs naturally, as an
artificial peptide or as the result of genetic engineering and that
is situated, for example, in an immunoglobulin heavy chain
polypeptide between the amino acid residues responsible for forming
intrachain immunoglobulin-domain disulfide bonds in CH1 and CH2
regions. Hinge region polypeptides for use in the present invention
may also include a mutated or otherwise alterd hinge region
polypeptide. Accordingly, for example, an immunoglobulin hinge
region polypeptide may be derived from, or may be a portion or
fragment of (i.e., one or more amino acids in peptide linkage,
typically about 15-115 amino acids, preferably about 95-110, about
80-94, about 60-80, or about 5-65 amino acids, preferably about
10-50, more preferably about 15-35, still more preferably about
18-32, still more preferably about 20-30, still more preferably
about 21, 22, 23, 24, 25, 26, 27, 28 or 29 amino acids) an
immunoglobulin polypeptide chain region classically regarded as
having hinge function, including those described herein, but a
hinge region polypeptide for use in the instant invention need not
be so restricted and may include one or more amino acids situated
(according to structural criteria for assigning a particular
residue to a particular domain that may vary, as known in the art)
in an adjoining immunoglobulin domain such as a CH1 domain and/or a
CH2 domain in the cases of IgG, IgA and IgD (or in an adjoining
immunoglobulin domain such as a CH1 domain and/or a CH3 domain in
the case of IgE), or in the case of certain artificially engineered
immunoglobulin constructs, an immunoglobulin variable region
domain.
[0381] Wild-type immunoglobulin hinge region polypeptides include
any known or later-discovered naturally occurring hinge region that
is located between the constant region domains, CH1 and CH2, of an
immunoglobulin, for example, a human immunoglobulin (or between the
CH1 and CH3 regions of certain types of immunoglobulins, such as
IgE). For use in constructing one type of connecting region, the
wild-type immunoglobulin hinge region polypeptide is preferably a
human immunoglobulin hinge region polypeptide, preferably
comprising a hinge region from a human IgG, IgA, or IgD
immunoglobulin (or the CH2 region of an IgE immunoglobulin), and
more preferably, for example, a hinge region polypeptide from a
wild-type or mutated human IgG1 isotype as described herein.
[0382] As is known to the art, despite the tremendous overall
diversity in immunoglobulin amino acid sequences, immunoglobulin
primary structure exhibits a high degree of sequence conservation
in particular portions of immunoglobulin polypeptide chains,
notably with regard to the occurrence of cysteine residues which,
by virtue of their sulfyhydryl groups, offer the potential for
disulfide bond formation with other available sulfydryl groups.
Accordingly, in the context of the present invention wild-type
immunoglobulin hinge region polypeptides for use as connecting
regions include those that feature one or more highly conserved
(e.g., prevalent in a population in a statistically significant
manner) cysteine residues, and in certain preferred embodiments a
connecting region may comprise, or consist essentially of, or
consist of, a mutated hinge region polypeptide may be selected that
contains less than the number of naturally-occurring cysteines, for
example, zero or one or two cysteine residue(s) in the case of IgG1
and IgG4 hinge regions, and that is derived or constructed from (or
using) such a wild-type hinge region sequence.
[0383] In certain preferred embodiments wherein the connecting
region is a hinge region polypeptide and the hinge region
polypeptide is a mutated, engineered or otherwise altered human
IgG1 immunoglobulin hinge region polypeptide that is derived or
constructed from (or using) a wild-type hinge region sequence, it
is noted that the wild-type human IgG1 hinge region polypeptide
sequence comprises three non-adjacent cysteine residues, referred
to as a first cysteine of the wild-type hinge region, a second
cysteine of the wild-type hinge region and a third cysteine of the
wild-type hinge region, respectively, proceeding along the hinge
region sequence from the polypeptide N-terminus toward the
C-terminus. This can be referred to herein as a "CCC" hinge (or a
"WTH", i.e., a wild-type hinge). Examples of mutated or engineered
hinge regions include those with no cysteines, which may be
referred to herein as an "XXX" hinge (or, for example, as "MH-XXX,"
referring to a mutant or engineered hinge with three amino acids or
other molecules in place of naturally occurring cysteines, such as,
for example, "MH-SSS", which refers to a mutant hinge with three
serine residues in place of the naturally occurring cysteine
residues. It will be understood that the term "mutant" refers only
to the fact that a different molecule or molecules is present, or
no molecule, at the position of a naturally occurring residue and
does not refer to any particular method by which such substitution,
alteration, or deletion has been carried out. Accordingly, in
certain embodiments of the present invention, the connecting region
may be a hinge region polypeptide and the hinge region polypeptide
is a mutated human IgG1 immunoglobulin hinge region polypeptide
that contains two cysteine residues and in which the first cysteine
of the wild-type hinge region has not changed or deleted, for
example. This can be referred to as a "MH-CXX" hinge, for example,
a "MH-CSC" hinge, in which case the cysteine residue has been
replaced with a serine residue. In certain other embodiments of the
present invention the mutated human IgG1 immunoglobulin hinge
region polypeptide contains no more than one cysteine residue and
include, for example, a "MH-CSS" hinge or a "MH-SSC" hinge or a
"MH-CSC" hinge, and in certain other embodiments the mutated human
IgG1 immunoglobulin hinge region polypeptide contains no cysteine
residues such as, for example, a "MH-SSS" hinge.
[0384] The constructs, including binding domain-immunoglobulin
fusion proteins, of the present invention expressly do not
contemplate any fusion protein that is disclosed in U.S. Pat. No.
5,892,019. U.S. Pat. No. 5,892,019 refers to a human IgG1 hinge
region in which the first IgG1 hinge region cysteine residue has
been changed or deleted, but retains both of the second and third
IgG1 hinge region cysteine residues that correspond to the second
and third cysteines of the wild-type IgG1 hinge region sequence.
The patent states that the first cysteine residue of the wild-type
IgG1 hinge region is replaced to prevent interference by the first
cysteine residue with proper assembly of the polypeptide described
therein into a dimer. The patent requires that the second and third
cysteines of the IgG1 hinge region be retained to provide
interchain disulfide linkage between two heavy chain constant
regions to promote dimer formation so that the molecule contains
has effector function such as the ability to mediate ADCC.
[0385] By contrast and as described herein, the constructs,
including the binding domain-immunogloblin fusion proteins, of the
present invention, various of which are capable of ADCC, CDC and/or
complement fixation, for example, are not so limited and may
comprise, in pertinent part, for example, (i) a wild-type
immunoglobulin hinge region polypeptide, such as a wild-type human
immunoglobulin hinge region polypeptide, for example, a human IgG1
immunoglobulin hinge region polypeptide, (ii) a mutated or
otherwise altered immunoglobulin hinge region polypeptide, such as
a mutated or otherwise altered human immunoglobulin hinge region
polypeptide, for example, a mutated or otherwise altered human IgG1
immunoglobulin hinge region polypeptide that, for example, is or
has been derived or constructed from (or using) a wild-type
immunoglobulin hinge region polypeptide or nucleic acid sequence
having three or more cysteine residues, wherein the mutated or
otherwise altered human IgG1 immunoglobulin hinge region
polypeptide contains two cysteine residues and wherein a first
cysteine of the wild-type hinge region is not mutated or deleted,
(iii) a mutated or otherwise altered immunoglobulin hinge region
polypeptide, such as a mutated or otherwise altered human
immunoglobulin hinge region polypeptide, for example, a mutated or
otherwise altered human IgG1 immunoglobulin hinge region
polypeptide that, for example, is or has been derived or
constructed from (or using) a wild-type immunoglobulin hinge region
polypeptide or nucleic acid sequence having three or more cysteine
residues, wherein the mutated or otherwise altered human IgG1
immunoglobulin hinge region polypeptide contains no more than one
cysteine residue, or (iv) a mutated or otherwise altered
immunoglobulin hinge region polypeptide, such as a mutated or
otherwise altered human immunoglobulin hinge region polypeptide,
for example, a mutated or otherwise altered human IgG1
immunoglobulin hinge region polypeptide that is or has been derived
or constructed from (or using) a wild-type immunoglobulin hinge
region polypeptide or nucleic acid sequence having three or more
cysteine residues, wherein the mutated or otherwise altered (for
example, by amino acid change or deletion) human IgG1
immunoglobulin hinge region polypeptide contains no cysteine
residues. The present invention offers unexpected advantages
associated with retention by the constructs, including the fusion
proteins, described herein of the ability to mediate ADCC and/or
CDC and/or complement fixation notwithstanding that the ability to
dimerize via IgG1 hinge region interchain disulfide bonds is
ablated or compromised by the removal or replacement of one, two or
three hinge region cysteine residues, and even in constructs where
the first cysteine of an IgG1 hinge region, for example, is not
mutated or otherwise altered or deleted.
[0386] A connecting region may comprise a mutated or otherwise
altered immunoglobulin hinge region polypeptide, which itself may
comprise a hinge region that has its origin in an immunoglobulin of
a species, of an immunoglobulin isotype or class, or of an
immunoglobulin subclass that is different from that of the tail
region, for example, a tail region comprising, or consisting
essentially or, or consisting of, CH2 and CH3 domains (or IgE CH3
and CH4 domains). For instance, in certain embodiments of the
invention, a construct, for example, a binding
domain-immunoglobulin fusion protein, may comprise a binding region
such as a binding domain polypeptide that is fused or otherwise
connected to an immunoglobulin hinge region polypeptide comprising,
or consisting essentially of, or consisting of, a wild-type human
IgA hinge region polypeptide, or a mutated or otherwise altered
human IgA hinge region polypeptide that contains zero or only one
or more cysteine residues (but less than the wild-type number of
cysteines), as described herein, or a wild-type human IgG hinge,
such as an IgG1 hinge, region polypeptide, or a wild-type human IgE
hinge-acting region, i.e., IgE CH2 region polypeptide, or a mutated
or otherwise altered human IgG hinge, such as an IgG1 hinge, region
polypeptide that is or has been mutated or otherwise altered to
contain zero, one or two cysteine residues wherein the first
cysteine of the wild-type hinge region is not mutated or altered or
deleted, as also described herein. Such a hinge region polypeptide
may be fused or otherwise connected to, for example, a tail region
comprising, or consisting essentially of, or consisting of, an
immunoglobulin heavy chain CH2 region polypeptide from a different
Ig isotype or class, for example an IgA or an IgD or an IgG
subclass (or a CH3 region from an IgE subclass), which in certain
preferred embodiments will be the IgG1 or IgA or IgE subclass and
in certain other preferred embodiments may be any one of the IgG2,
IgG3 or IgG4 subclasses.
[0387] For example, and as described in greater detail herein, in
certain embodiments of the present invention a connecting region
may be selected to be an immunoglobulin hinge region polypeptide,
which is or has been derived from a wild-type human IgA hinge
region that naturally comprises three cysteines, where the selected
hinge region polypeptide is truncated or otherwise altered or
substituted relative to the complete and/or naturally-occurring
hinge region such that only one or two of the cysteine residues
remain (e.g., SEQ ID NOS:35-36). Similarly, in certain other
embodiments of the invention, the construct may be binding
domain-immunoglobulin fusion protein comprising a binding domain
polypeptide that is fused or otherwise connected to an
immunoglobulin hinge region polypeptide comprising a mutated or
otherwise altered hinge region polypeptide in which the number of
cysteine residues is reduced by amino acid substitution or
deletion, for example a mutated or otherwise altered IgG1 hinge
region containing zero, one or two cysteine residues as described
herein, or an IgD hinge region containing zero cysteine
residues.
[0388] A mutated or otherwise altered hinge region polypeptide may
thus be derived or constructed from (or using) a wild-type
immunoglobulin hinge region that contains one or more cysteine
residues. In certain embodiments, a mutated or otherwise altered
hinge region polypeptide may contain zero or only one cysteine
residue, wherein the mutated or otherwise altered hinge region
polypeptide is or has been derived from a wild type immunoglobulin
hinge region that contains, respectively, one or more or two or
more cysteine residues. In the mutated or otherwise altered hinge
region polypeptide, the cysteine residues of the wild-type
immunoglobulin hinge region are preferably deleted or substituted
with amino acids that are incapable of forming a disulfide bond. In
one embodiment of the invention, a mutated or otherwise altered
hinge region polypeptide is or has been derived from a human IgG
wild-type hinge region polypeptide, which may include any of the
four human IgG isotype subclasses, IgG1, IgG2, IgG3 or IgG4. In
certain preferred embodiments, the mutated or otherwise altered
hinge region polypeptide is or has been derived from (or using) a
human IgA or IgD wild-type hinge region polypeptide. By way of
example, a mutated or otherwise altered hinge region polypeptide
that is or has been derived from a human IgG1 or IgA wild-type
hinge region polypeptide may comprise mutations, alterations, or
deletions at two of the three cysteine residues in the wild-type
immunoglobulin hinge region, or mutations, alterations, or
deletions at all three cysteine residues.
[0389] The cysteine residues that are present in a wild-type
immunoglobulin hinge region and that are removed or altered by
mutagenesis or any other techniques according to particularly
preferred embodiments of the present invention include cysteine
residues that form, or that are capable of forming, interchain
disulfide bonds. Without wishing to be bound by particular theory
or mechanism of action, the present invention contemplates that
mutation, deletion, or other alteration of such hinge region
cysteine residues, which are believed to be involved in formation
of interchain disulfide bridges, reduces the ability of the subject
invention binding domain-immunoglobulin fusion protein to dimerize
(or form higher oligomers) via interchain disulfide bond formation,
while surprisingly not ablating or undesireably compromising the
ability of a fusion protein or other construct to promote ADCC,
and/or CDC and/or to fix complement. In particular, the Fc
receptors that mediate ADCC (e.g., FcRIII, CD16) exhibit low
affinity for immunoglobulin Fc domains, supporting the idea that
functional binding of Fc to FcR requires avidity stabilization of
the Fc-FcR complex by virtue of the dimeric structure of heavy
chains in a conventional antibody, and/or FcR aggregation and
cross-linking by a conventional antibody Fc structure. Sonderman et
al., 2000 Nature 406:267; Radaev et al., 2001 J. Biol. Chem.
276:16469; Radaev et al., 2001 J. Biol. Chem. 276:16478; Koolwijk
et al., 1989 J. Immunol. 143:1656; Kato et al., 2000 Immunol. Today
21:310. Hence, the constructs, including for example binding
domain-immunoglobulin fusion proteins, of the present invention
provide the advantages associated with single-chain constructs
including singe-chain immunoglobulin fusion proteins while also
unexpectedly retaining one or more immunological activities.
Similarly, the ability to fix complement is typically associated
with immunoglobulins that are dimeric with respect to heavy chain
constant regions such as those that comprise Fc, while various
constructs, including binding domain-immunoglobulin fusion
proteins, of the present invention, which may, due to the
replacement or deletion of hinge region cysteine residues or due to
other structural modifications as described herein, for example,
have compromised or ablated abilities to form interchain disulfide
bonds, exhibit the unexpected ability to fix complement.
Additionally, according to certain embodiments of the present
invention wherein a construct, including, for example, a binding
domain-immunoglobulin fusion protein, may comprise a connecting
region and tail region comprising, or consisting essentially of, or
consisting of, one or more of a human IgE hinge-acting region,
i.e., a IgE CH2 region polypeptide, a human IgE CH3 constant region
polypeptide, and a human IgE CH4 constant region polypeptide, the
invention constructs including fusion proteins unexpectedly retain
the immunological activity of mediating ADCC and/or of inducing an
allergic response mechanism.
[0390] Selection of an immunoglobulin hinge region polypeptide as a
connecting region according to certain embodiments of the subject
invention constructs, such as binding domain-immunoglobulin fusion
proteins, may relate to the use of an "alternative hinge region"
polypeptide sequence, which includes a polypeptide sequence that is
not necessarily derived from any immunoglobulin hinge region
sequence per se. Instead, an alternative hinge region refers to a
hinge region polypeptide that comprises an amino acid sequence, or
other molecular sequence, of at least about ten consecutive amino
acids or molecules, and in certain embodiments at least about 11,
12, 13, 14, 15, 16, 17, 18, 19, 20, 21-25, 26-30, 31-50, 51-60,
71-80, 81-90, or 91-110 amino acids or molecules that is present in
a sequence disclosed herein, for example a polypeptide sequence
that is or has been derived from a region located between
intrachain disulfide-generated immunoglobulin-like loop domains of
immunoglobulin gene superfamily members such as CD2 (e.g., Genbank
Acc. No. NM.sub.--001767), CD4 (e.g., Genbank Acc. No.
NM.sub.--000616), CD5 (e.g., Genbank Acc. No. BCO27901), CD6 (e.g.,
Genbank Acc. No. NM.sub.--006725), CD7 (e.g., Genbank Acc. Nos.
XM.sub.--046782, BC009293, NM.sub.--006137) or CD8 (e.g., Genbank
Acc. No. M12828), or other Ig superfamily members. By way of
non-limiting example, an alternative hinge region used as a
connecting region, for example, may provide a glycosylation site as
provided herein, or may provide a human gene-derived polypeptide
sequence for purposes of enhancing the degree of "humanization" of
a fusion protein, or may comprise, or consist essentially of, or
consist of, an amino acid sequence that eliminates or reduces the
ability of a construct of the invention, such as a fusion protein,
to form multimers or oligomers or aggregates or the like. Certain
alternative hinge region polypeptide sequences, including those
described herein, may be derived or constructed from (or using) the
polypeptide sequences of immunoglobulin gene superfamily members
that are not actual immunoglobulins per se. For instance and
according to non-limiting theory, certain polypeptide sequences
that are situated between intrachain disulfide-generated
immunoglobulin loop domain of immunoglobulin gene super-family
member proteins may be used in whole or in part as alternative
hinge region polypeptides as provided herein, or may be further
modified for such use.
[0391] As noted above, the constructs of the invention, including
binding domain-immunoglobulin fusion proteins, are believed,
according to non-limiting theory, to be compromised in their
ability to dimerize via interchain disulfide bond formation, and
further according to theory, this property is a consequence, in
whole or in part, of a reduction in the number of cysteine residues
that are present in an immunoglobulin hinge region polypeptide
selected for inclusion in the construction of the construct, such
as a fusion protein construct. Determination of the relative
ability of a polypeptide to dimerize is well within the knowledge
of the relevant art, where any of a number of established
methodologies may be applied to detect protein dimerization (see,
e.g., Scopes, Protein Purification: Principles and Practice, 1987
Springer-Verlag, New York). For example, biochemical separation
techniques for resolving proteins on the basis of molecular size
(e.g., gel electrophoresis, gel filtration chromatography,
analytical ultracentrifugation, etc.), and/or comparison of protein
physicochemical properties before and after introduction of
sulfhydryl-active (e.g., iodoacetamide, N-ethylmaleimide) or
disulfide-reducing (e.g., 2-mercaptoethanol, dithiothreitol)
agents, or other equivalent methodologies, may all be employed for
determining a degree of polypeptide dimerization or
oligomerization, and for determining possible contribution of
disulfide bonds to such potential quarternary structure. In certain
embodiments, the invention relates to a construct, for example a
binding domain-immunoglobulin fusion protein, that exhibits a
reduced (i.e., in a statistically significant manner relative to an
appropriate IgG-derived control, for example) ability to dimerize,
relative to a wild-type human immunoglobulin G hinge region
polypeptide as provided herein. Those familiar with the art will be
able readily to determine whether a particular fusion protein
displays such reduced ability to dimerize.
[0392] Compositions and methods for preparation of immunoglobulin
fusion proteins, for example, are well known in the art. See, e.g.,
U.S. Pat. No. 5,892,019, which reports recombinant proteins that
are the product of a single encoding polynucleotide but which are
not constructs, including binding domain-immunoglobulin fusion
proteins, according to the present invention.
[0393] For a construct, for example, in an immunoglobulin fusion
protein of the invention that is intended for use in humans, any
included Ig constant regions will typically be of human sequence
origin, or humanized, to minimize a potential anti-human immune
response and to provide appropriate and/or desired effector
functions. Manipulation of sequences encoding antibody constant
regions is referenced in the PCT publication of Morrison and Oi, WO
89/07142. In particularly preferred embodiments, a tail region is
prepared from an immunoglobulin heavy chain constant region in
which the CH1 domain is or has been deleted (the CH1 and CH2
regions in the case of IgE) and the carboxyl end of the binding
domain, or where the binding domain comprises two immunoglobulin
variable region polypeptides, the second (i.e., more proximal to
the C-terminus) variable region is joined to the amino terminus of
CH2 through one or more connecting regions, such as a hinge or
altered region. A schematic diagram depicting the structures of two
exemplary binding domain-immunoglobulin fusion proteins is shown in
FIG. 11. In particularly preferred embodiments no interchain
disulfide bonds are present, and in other embodiments a restricted
number of interchain disulfide bonds may be present relative to the
number of such bonds that would be present if wild-type hinge
region polypeptides were instead present. In other embodiments a
construct of the invention, such as for example, a fusion protein,
comprises, or consists essentially of, or consists of, a mutated or
otherwise altered hinge region polypeptide that exhibits a reduced
ability to dimerize, relative to a wild-type human IgG hinge region
polypeptide. Thus, an isolated polynucleotide molecule coding for
such a single chain construct, such as an immunoglobulin fusion
protein, has a binding region, for example, a domain that provides
specific or otherwise desired binding affinity and selectivity for
a target, such as a target antigen.
[0394] The invention also contemplates, for example, in certain
embodiments, constructs including binding domain-immunoglobulin
fusion proteins that comprise fused or otherwise connected
polypeptide sequences or portions thereof derived or prepared from
a plurality of genetic sources, for example, according to molecular
"domain swapping" paradigms. Those having familiarity with the art
will appreciate that selection of such polypeptide sequences for
assembly into a construct, such as a binding domain-immunoglobulin
fusion protein, for example, may involve determination of
appropriate portions of each component polypeptide sequence, for
example, based on structural and/or functional properties of each
such sequence (see, e.g., Carayannopoulos et al., 1996 J. Exp. Med.
183:1579; Harlow et al., Eds., Antibodies: A Laboratory Manual,
Cold Spring Harbor Laboratory, Cold Spring Harbor (1988)). The
component polypeptide sequences of which the construct, such as a
fusion protein, is comprised or prepared may therefore comprise
intact or full-length binding domain, immunoglobulin, linker and/or
plasma membrane anchor domain polypeptide sequences, or truncated
versions or variants thereof such as those provided herein.
According to these and related embodiments of the invention, any
two or more of the candidate component polypeptides of which the
subject invention constructs, for example, fusion proteins, may be
comprised will be derived or prepared from independent sources,
such as from immunoglobulin sequences of differing allotype,
isotype, subclass, class, or species of origin (e.g., xenotype).
Thus, as a non-limiting example, a binding domain polypeptide (or
its constituent polypeptides such as one or more variable region
polypeptides and/or a linker polypeptide), a hinge region
polypeptide, immunoglobulin heavy chain CH2 and CH3 constant region
polypeptides and optionally an immunoglobulin heavy chain CH4
constant region polypeptide as may be obtained from an IgM or IgE
heavy chain, and a plasma membrane anchor domain polypeptide may
all be separately obtained from distinct genetic sources and
engineered into a chimeric or fusion protein using well known
techniques and according to methodologies described herein, for
example.
[0395] Accordingly, a construct of the invention, for example a
binding domain-immunoglobulin fusion protein according to certain
embodiments of the present invention, may also therefore comprise
in pertinent part an immunoglobulin heavy chain CH3 constant region
polypeptide that is a wild-type IgA CH3 constant region
polypeptide, or alternatively, that is a mutated or otherwise
altered or substituted or truncated IgA CH3 constant region
polypeptide that is incapable of associating with a J chain, or
that will not associate to an undesired degree with a J chain;
preferably the IgA CH3 constant region polypeptides used in a tail
region portion of a construct are of human origin or are humanized.
By way of brief background, IgA molecules are known to be released
into secretory fluids by a mechanism that involves association of
IgA into disulfide-linked polymers (e.g., dimers) via a J chain
polypeptide (e.g., Genbank Acc. Nos. XM.sub.--059628, M12378,
M12759; Johansen et al., 1999 Eur. J. Immunol. 29:1701) and
interaction of the complex so formed with another protein that acts
as a receptor for polymeric immunoglobulin, and which is known as
transmembrane secretory component (SC; Johansen et al., 2000 Sc. J.
Immunol. 52:240; see also, e.g., Sorensen et al., 2000 Int.
Immunol. 12:19; Yoo et al., 1999 J. Biol. Chem. 274:33771; Yoo et
al., 2002 J. Immunol. Meth. 261:1; Corthesy, 2002 Trends
Biotechnol. 20:65; Symersky et al., 2000 Mol. Immunol. 37:133;
Crottet et al., 1999 Biochem. J. 341:299). Interchain disulfide
bond formation between IgA Fc domains and J chain is mediated
through a penultimate cysteine residue in an 18-amino acid
C-terminal extension that forms part of the IgA heavy chain
constant region CH3 domain polypeptide (Yoo et al., 1999; Sorensen
et al., 2000). Certain embodiments of the subject invention
constructs, including for example, fusion proteins, therefore
contemplate inclusion of the wild-type IgA heavy chain constant
region polypeptide sequence, which is capable of associating with J
chain. Certain other embodiments of the invention, however,
contemplate fusion proteins that comprise a mutated or otherwise
altered, substituted, or truncated IgA CH3 constant region
polypeptide that is incapable of associating with a J chain.
According to such embodiments, for example, two or more residues
from the C-terminus of an IgA CH3 constant region polypeptide such
as a human IgA CH3 constant region polypeptide may be deleted to
yield a truncated CH3 constant region polypeptide as provided
herein. In preferred embodiments and as described in greater detail
herein, a mutated human IgA CH3 constant region polypeptide that is
incapable of associating with a J chain comprises such a C-terminal
deletion of either four or 18 amino acids. However, the invention
need not be so limited, such that the mutated IgA CH3 constant
region polypeptide may comprise a deletion of about 2, 3, 4, 5, 6,
7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21-25, 26-30
or more amino acids, so long as the construct, for example, the
fusion protein, is capable of specifically binding an antigen and
of at least one immunological activity as provided herein.
Alternatively, the invention also contemplates constructs, for
example, fusion proteins, having a tail region that comprises a
mutated IgA CH3 constant region polypeptide that is incapable of
associating with a J chain by virtue of replacement of the
penultimate cysteine, or by chemical modification of that amino
acid residue, in a manner that prevents, or inhibits an undesired
level of, interchain disulfide bond or multimer formation. Methods
for determining whether a construct, for example a fusion protein,
can associate with a J chain will be known to those having
familiarity with the art and are described or referenced
herein.
[0396] As also described herein and according to procedures known
in the art, the construct, for example a fusion protein, may
further be tested routinely for immunological activity, for
instance, in ADCC or CDC assays. As an illustrative example, a
construct, for example a fusion protein, according to such an
embodiment may comprise a binding domain polypeptide derived or
constructed from (or using) a native or engineered human heavy
chain variable region polypeptide sequence, a native or engineered
human IgA-derived immunoglobulin hinge region polypeptide sequence,
a native or engineered human IgG1 immunoglobulin heavy chain CH2
constant region polypeptide sequence, a native or engineered human
IgG2 immunoglobulin heavy chain CH3 constant region polypeptide
sequence, and optionally a native or engineered human IgE
immunoglobulin heavy chain CH4 constant region polypeptide sequence
and/or a native or engineered human TNF-.alpha. receptor type 1
(TNFR1) plasma membrane anchor domain polypeptide sequence that
comprises a cytoplasmic tail polypeptide which is capable of
apoptotic signaling or otherwise promoting apoptosis. The invention
therefore contemplates these and other embodiments according to the
present invention in which two or more polypeptide sequences that
are present in a construct, for example a fusion protein, have
independent genetic origins.
[0397] As noted above, in certain embodiments the construct, for
example a binding protein-immunoglobulin fusion protein, comprises
at least one native or engineered immunoglobulin variable region
polypeptide, which may be a native or engineered light chain or a
native or engineered heavy chain variable region polypeptide, and
in certain embodiments the fusion protein comprises at least one
such native or engineered light chain V-region and one such native
or engineered heavy chain V-region and at least one linker peptide
that is fused or otherwise connected to to each of the native or
engineered V-regions. Construction of such binding domains, for
example single chain Fv domains, is known in the art and is
described in greater detail in the Examples below, and has been
described, for example, in various documents cited herein;
selection and assembly of single-chain variable regions and of
linker polypeptides that may be fused or otherwise connected to
each of a heavy chain-derived and a light chain-derived V region
(e.g., to generate a binding region, such as a binding domain that
comprises a single-chain Fv polypeptide) is also known to the art
and described herein. See, e.g., U.S. Pat. Nos. 5,869,620,
4,704,692, and 4,946,778. In certain embodiments all or a portion
or portions of an immunoglobulin sequence that is derived from a
non-human source may be "humanized" according to recognized
procedures for generating humanized antibodies, i.e.,
immunoglobulin sequences into which human Ig sequences are
introduced to reduce the degree to which a human immune system
would perceive such proteins as foreign (see, e.g., U.S. Pat. Nos.
5,693,762; 5,585,089; 4,816,567; 5,225,539; 5,530,101; and
documents cited therein).
[0398] Constructs of the invention, including binding
domain-immunoglobulin fusion proteins, as described herein may,
according to certain embodiments, desirably comprise sites for
glycosylation, e.g., covalent attachment of carbohydrate moieties
such as, for example, monosaccharides or oligosaccharides.
Incorporation of amino acid sequences that provide substrates for
polypeptide glycosylation is within the scope of the relevant art,
including, for example, the use of genetic engineering or protein
engineering methodologies to obtain a polypeptide sequence
containing, for example, the classic Asn-X-Ser/Thr site for
N-(asparagine)-linked glycosylation, or a sequence containing Ser
or Thr residues that are suitable substrates for O-linked
glycosylation, or sequences amenable to C-mannosylation,
glypiation/glycosylphosphatidylinositol modification, or
phosphoglycation, all of which can be identified according to
art-established criteria (e.g., Spiro, 2002 Glybiology 12:43R).
Without wishing to be bound by any particular theory or mechanism,
glycosylated constructs such as fusion proteins having particular
amino acid sequences may beneficially possess attributes associated
with one or more of improved solubility, enhanced stability in
solution, enhanced physiological stability, improved
bioavailability including in vivo biodistribution, and superior
resistance to proteases, all in a statistically significant manner,
relative to constructs, including fusion proteins, having the same
or highly similar amino acid sequences but lacking glycosyl
moieties. In certain preferred embodiments the subject invention
constructs, such as fusion protein constructs, may comprise a
glycosylation site that is present in a linker as provided herein,
and in certain other preferred embodiments the subject invention
construct, for example, a fusion protein, comprises a glycosylation
site that is present in a connecting region, such as a hinge region
polypeptide sequence as provided herein.
[0399] In certain preferred embodiments of the present invention,
such as those useful for gene therapy applications or in display
systems or assays, such as screening assays (including library
display systems and library screening assays), the construct, for
example, a binding domain-immunoglobulin fusion protein, is a
protein or glycoprotein that is capable of being expressed by a
host cell such that it localizes to the cell surface. Constructs,
such as binding domain-immunoglobulin fusion proteins, that
localize to the cell surface may do so by virtue of having
naturally present or artificially introduced structural features
that direct the fusion protein to the cell surface (e.g., Nelson et
al. 2001 Trends Cell Biol. 11:483; Ammon et al., 2002 Arch.
Physiol. Biochem. 110:137; Kasai et al., 2001 J. Cell Sci.
114:3115; Watson et al., 2001 Am. J. Physiol. Cell Physiol.
281:C215; Chatterjee et al., 200 J. Biol. Chem. 275:24013)
including by way of illustration and not limitation, secretory
signal sequences, leader sequences, plasma membrane anchor domain
polypeptides and transmembrane domains such as hydrophobic
transmembrane domains (e.g., Heuck et al., 2002 Cell Biochem.
Biophys. 36:89; Sadlish et al., 2002 Biochem J. 364:777; Phoenix et
al., 2002 Mol. Membr. Biol. 19:1; Minke et al., 2002 Physiol. Rev.
82:429) or glycosylphosphatidylinositol attachment sites
("glypiation" sites, e.g., Chatterjee et al., 2001 Cell Mol. Life.
Sci. 58:1969; Hooper, 2001 Proteomics 1:748; Spiro, 2002 Glycobiol.
12:43R), cell surface receptor binding domains, extracellular
matrix binding domains, or any other structural feature that causes
at least a desired portion of the fusion protein population to
localize, in whole or in part, to the cell surface. Particularly
preferred are fusion protein constructs that comprise a plasma
membrane anchor domain which includes a transmembrane polypeptide
domain, typically comprising a membrane spanning domain which
includes a hydrophobic region capable of energetically favorable
interaction with the phospholipid fatty acyl tails that form the
interior of the plasma membrane bilayer. Such features are known to
those of ordinary skill in the art, who will further be familiar
with methods for introducing nucleic acid sequences encoding these
features into the subject expression constructs by genetic
engineering, and with routine testing of such constructs to verify
cell surface localization of the product.
[0400] According to certain further embodiments, a plasma membrane
anchor domain polypeptide comprises such a transmembrane domain
polypeptide and also comprises a cytoplasmic tail polypeptide,
which refers to a region or portion of the polypeptide sequence
that contacts the cytoplasmic face of the plasma membrane and/or is
in contact with the cytosol or other cytoplasmic components. A
large number of cytoplasmic tail polypeptides are known that
comprise the intracellular portions of plasma membrane
transmembrane proteins, and discrete functions have been identified
for many such polypeptides, including biological signal
transduction (e.g., activation or inhibition of protein kinases,
protein phosphatases, G-proteins, cyclic nucleotides and other
second messengers, ion channels, secretory pathways), biologically
active mediator release, stable or dynamic association with one or
more cytoskeletal components, cellular differentiation, cellular
activation, mitogenesis, cytostasis, apoptosis and the like (e.g.,
Maher et al., 2002 Immunol. Cell Biol. 80:131; El Far et al., 2002
Biochem J. 365:329; Teng et al., 2002 Genome Biol. 2REVIEWS:3012;
Simons et al., 2001 Cell Signal 13:855; Furie et al., 2001 Thromb.
Haemost. 86:214; Gaffen, 2001 Cytokine 14:63; Dittel, 2000 Arch.
Immunol. Ther. Exp. (Warsz.) 48:381; Parnes et al., 2000 Immunol.
Rev. 176:75; Moretta et al., 2000 Semin. Immunol. 12:129; Ben
Ze'ev, 1999 Ann. N.Y. Acad. Sci. 886:37; Marsters et al., Recent
Prog. Horm. Res. 54:225).
[0401] FIG. 70 illustrates the binding, for example, of
fluorceine-conjugated FcRIII (CD16) soluble fusion proteins to 2H7
scFv-binding domain constructs that are attached to CD20 expressed
by cells, CHO cells in this example. CD16 binding to a construct of
the invention, for example, scFv-binding domain construct, provides
one example of a screening tool that may be used to detect and/or
quantitate changes in CD16 binding to altered constructs of the
invention, including scFv-binding domain constructs, that contains
targeted or site-specific mutations, substitutions, deletions, or
other alterations. Changes in CD16 binding properties may be
reflected, for example, by changes in binding of either CD16 high
affinity protein (158V) or CD16 low affinity protein (158 F) or
both.
[0402] A schematic representation of one example of such a
screening process is diagrammed in the second drawing in FIG. 70,
in which scFv-binding domain constructs are displayed on the cell
surface of mammalian cells. scFv-binding domain molecules in this
example are displayed on the cell surface through a molecule that
serves as a transmembrane domain anchor. These molecules may
represent, for example, a single scFv-binding domain construct or
may be introduced into a population of mammalian cells as a library
of such molecules. Transfected cells with altered binding
properties can then, for example, be panned, sorted, or otherwise
isolated from other cells by altering the stringency of the
selection conditions and using CD16 fusion proteins as a binding
probe. Cells that express scFv-Ig molecules with altered binding to
either CD16 high affinity allele (158V) or CD16 low affinity allele
(158F) or both, for example, can be isolated.
[0403] This display system can be used, for example, to create a
library of constructs of the invention with mutated or otherwise
altered tail regions with short stretches of CH2 sequence replaced
with randomized oligonucleotides or, for example, randomization of
a single residue with all possible amino acid substitutions,
natural or unnatural, including synthetic amino acids. Once such a
library is constructed, it can be transfected into appropriate
cells, for example, COS cells, by methods known in the art.
Transfectants can then be bound to, for example, labeled CD16
constructs, and panned or sorted based on their relative or desired
binding properties to multiple allelotypes/isoforms. Desired cells
may be harvested, and the DNA, for example, plasmid DNA, isolated
and then transformed into, for example, bacteria. This process may
be repeated iteratively multiple times until desire single clones
are isolated from the mammalian host cells. See Seed B and Aruffo
A, Pro. Nat'l Acad Sci USA 1987 84:3365-3369; Aruffo A and Seed B,
Pro. Nat'l Acad Sci USA 1987 84:8573-8577.
[0404] One such use of this type of screening system, for example,
is for the identification and/or isolation of constructs of the
invention having tail regions, or tail regions, that bind equally
well to both the high and low affinity alleles of CD16 with the
goal of improving effector functions mediated by scFv-binding
domain constructs in multiple subpopulations of patients.
Constructs of the invention having tail regions, or tail regions
with altered binding properties to other Fc receptors can also be
selected using such a display system, for example, the display
system described. Other display systems that do not glycosylate
proteins, for example, those that use bacteriophage or yeast, are
not generally desired for selection of constructs of the invention
having Ig-based tail regions, or Ig-based tail regions, with
altered FcR binding properties. Most non-mammalian systems, for
example, do not glycosylate proteins.
[0405] Expression of constructs of the invention, for example,
scFv-binding domain constructs, expressd on the surface of a
mammalian cell by incorporation of an appropriate molecule into the
construct, for example, by incorporation of a transmembrane domain
or a GPI anchor signal, also have utility in other display systems
that are useful, for example, for selection of constructs of the
invention, for example, altered scFv-binding domain molecules that
will be produced at higher or other desired levels. In one such an
embodiment, cells that are useful in the production of glycosylated
proteins, for example, mammalian cells such as COS cells, are
transfected with a library of scFv-binding domain constructs in a
plasmid that directs their expression to the cell surface. Cells,
such as COS cells, that express the highest or other desired level
of the scFv-binding domain molecules are selected by techniques
known in the art (for example panning, sterile cell sorting,
magnetic bead separation, etc.), and DNA, for example, plasmid DNA,
is isolated for transformation into other cells, for example,
bacteria. After one or more rounds of selection single clones are
isolated that encode scFv-binding domain molecules capable of a
high or other desired level of expression. The isolated clones may
then be altered to remove the membrane anchor and expressed in an
appropriate cells system, for example, a mammalian cell system,
wherein the scFv-binding domain constructs will be produced, for
example, by secretion into the culture fluid at desired levels.
Without being bound by any particular mechanism or theory, this is
believed to result from the common requirement of secreted
glycoproteins and cell surface glycoproteins for a signal peptide
and processing through the golgi for expression. Thus, selection
for a molecule that shows an improvement expression levels on a
cell surface will also result in the identification of a molecule
having an improvement in levels of secreted protein.
[0406] These display systems utilizing a construct of the invention
may also be used for screening and/or identifying and/or isolating
affinity variants of the binding domain within a construct.
[0407] Particularly preferred are such display and/or screening
systems, for example, that include or use constructs that include
(1) an immunoglobulin variable region polypeptide sequence,
including native or engineered V.sub.H and/or V.sub.L and/or
single-chain variable region (sFv) sequences, and which include,
for example, a mutation, alteration or deletion at an amino acid at
a location or locations corresponding to one or more of amino acid
positions 9, 10, 11, 12, 108, 110, 111, and 112, in a V.sub.H
region sequence (including in a V.sub.H region sequence within an
scFv or other construct), and/or (2) an immunoglobulin variable
region polypeptide sequence, including native or engineered V.sub.H
and/or V.sub.L and/or single-chain variable region (sFv) sequences,
and which include, for example, a mutation, alteration or deletion
at a location or locations corresponding to one or more of amino
acid positions 12, 80, 81, 82, 83, 105, 106, 107 and 108 in a light
chain variable region sequence (including in a V.sub.L region
sequence within an scFv or other construct). Especially preferred
are such display and/or screening systems that include or use
constructs that include an engineered V.sub.H sequence (whether or
not associated with one or more other sequences, including
immunoglobulin-derived and other sequences contained, for example,
within an sFv or scFv-containing construct), which includes a
mutation, alteration or deletion at an amino acid at a location or
locations corresponding to amino acid position 11. The V.sub.H11
amino acid, if substituted, may be substituted with another amino
acid as described herein, or by another molecule as desired.
[0408] In the context of other methods of using constructs of the
invention, including binding domain-immunoglobulin fusion proteins,
for the treatment of a malignant condition or a B cell disorder(s)
as provided herein, including, for example, by one or more of a
number of gene therapy methods and related construct delivery
techniques, the present invention also contemplates certain
embodiments wherein a construct, for example, a binding
domain-immunoglobulin fusion protein that comprises a plasma
membrane anchor domain polypeptide is expressed (or capable or
expression) at a cell surface and may further comprise a
cytoplasmic tail polypeptide which comprises an apoptosis signaling
polypeptide sequence. A number of apoptosis signaling polypeptide
sequences are known to the art, as reviewed, for example, in When
Cells Die: A Comprehensive Evaluation of Apoptosis and Programmed
Cell Death (R. A. Lockshin et al., Eds., 1998 John Wiley &
Sons, New York; see also, e.g., Green et al., 1998 Science 281:1309
and references cited therein; Ferreira et al., 2002 Clin. Canc.
Res. 8:2024; Gurumurthy et al., 2001 Cancer Metastas. Rev. 20:225;
Kanduc et al., 2002 Int. J. Oncol. 21:165). Typically an apoptosis
signaling polypeptide sequence comprises all or a portion of, or is
derived or constructed from, a receptor death domain polypeptide,
for instance, FADD (e.g., Genbank Acc. Nos. U24231, U43184,
AF009616, AF009617, NM.sub.--012115), TRADD (e.g., Genbank Acc. No.
NM.sub.--003789), RAIDD (e.g., Genbank Acc. No. U87229), CD95
(FAS/Apo-1; e.g., Genbank Acc. Nos. X89101, NM.sub.--003824,
AF344850, AF344856), TNF-.alpha.-receptor-1 (TNFR1, e.g., Genbank
Acc. Nos. 563368, AF040257), DR5 (e.g., Genbank Acc. No. AF020501,
AF016268, AF012535), an ITIM domain (e.g., Genbank Acc. Nos.
AF081675, BC015731, NM.sub.--006840, NM.sub.--006844,
NM.sub.--006847, XM.sub.--017977; see, e.g., Billadeau et al., 2002
J. Clin. Invest. 109:161), an ITAM domain (e.g., Genbank Acc. Nos.
NM.sub.--005843, NM.sub.--003473, BC030586; see, e.g., Billadeau et
al., 2002), or other apoptosis-associated receptor death domain
polypeptides known to the art, for example, TNFR2 (e.g., Genbank
Acc. No. L49431, L49432), caspase/procaspase-3 (e.g., Genbank Acc.
No. XM.sub.--54686), caspase/procaspase-8 (e.g., AF380342,
NM.sub.--004208, NM.sub.--001228, NM.sub.--033355, NM.sub.--033356,
NM.sub.--033357, NM.sub.--033358), caspase/procaspase-2 (e.g.,
Genbank Acc. No. AF314174, AF314175), etc.
[0409] Cells in biological samples that are suspected of undergoing
apoptosis may be examined for morphological, permeability or other
changes that are indicative of an apoptotic state. For example by
way of illustration and not limitation, apoptosis in many cell
types may cause altered morphological appearance such as plasma
membrane blebbing, cell shape change, loss of substrate adhesion
properties or other morphological changes that can be readily
detected by a person having ordinary skill in the art, for example
by using light microscopy. As another example, cells undergoing
apoptosis may exhibit fragmentation and disintegration of
chromosomes, which may be apparent by microscopy and/or through the
use of DNA-specific or chromatin-specific dyes that are known in
the art, including fluorescent dyes. Such cells may also exhibit
altered plasma membrane permeability properties as may be readily
detected through the use of vital dyes (e.g., propidium iodide,
trypan blue) or by the detection of lactate dehydrogenase leakage
into the extracellular milieu. These and other means for detecting
apoptotic cells by morphologic criteria, altered plasma membrane
permeability, and related changes will be apparent to those
familiar with the art.
[0410] In another embodiment of the invention wherein a construct,
such as a binding domain-immunoglobulin fusion protein, that is
expressed at a cell surface comprises a plasma membrane anchor
domain having a transmembrane domain and a cytoplasmic tail that
comprises an apoptosis signaling polypeptide, cells in a biological
sample may be assayed for translocation of cell membrane
phosphatidylserine (PS) from the inner to the outer leaflet of the
plasma membrane, which may be detected, for example, by measuring
outer leaflet binding by the PS-specific protein annexin. Martin et
al., J. Exp. Med. 182:1545, 1995; Fadok et al., J. Immunol.
148:2207, 1992. In still other related embodiments of the
invention, including embodiments wherein a construct, such as a
binding domain-immunoglobulin fusion protein, is expressed at the
cell surface and comprises a plasma membrane anchor domain having
an apoptosis signaling polypeptide and also including embodiments
wherein the construct, such as a binding domain-immunoglobulin
fusion protein, is a soluble protein that lacks a membrane anchor
domain and that is capable of inducing apoptosis, a cellular
response to an apoptogen is determined by an assay for induction of
specific protease activity in any member of a family of
apoptosis-activated proteases known as the caspases (see, e.g.,
Green et al., 1998 Science 281:1309). Those having ordinary skill
in the art will be readily familiar with methods for determining
caspase activity, for example by determination of caspase-mediated
cleavage of specifically recognized protein substrates. These
substrates may include, for example, poly-(ADP-ribose) polymerase
(PARP) or other naturally occurring or synthetic peptides and
proteins cleaved by caspases that are known in the art (see, e.g.,
Ellerby et al., 1997 J. Neurosci. 17:6165). The synthetic peptide
Z-Tyr-Val-Ala-Asp-AFC (SEQ ID NO:528;), wherein "Z" indicates a
benzoyl carbonyl moiety and AFC indicates
7-amino-4-trifluoromethylcoumarin (Kluck et al., 1997 Science
275:1132; Nicholson et al., 1995 Nature 376:37), is one such
substrate. Other non-limiting examples of substrates include
nuclear proteins such as U1-70 kDa and DNA-PKcs (Rosen and
Casciola-Rosen, 1997 J. Cell. Biochem. 64:50; Cohen, 1997 Biochem.
J. 326:1). Cellular apoptosis may also be detected by determination
of cytochrome c that has escaped from mitochondria in apoptotic
cells (e.g., Liu et al., Cell 86:147, 1996). Such detection of
cytochrome c may be performed spectrophotometrically,
immunochemically or by other well established methods for
determining the presence of a specific protein. Persons having
ordinary skill in the art will readily appreciate that there may be
other suitable techniques for quantifying apoptosis.
[0411] Particularly preferred embodiments of constructs useful for
gene therapy applications, including those constructs that include
a plasma membrane anchor domain and/or cytoplasmic tail polypeptide
(including, for example, an apoptosis signaling sequence), are such
constructs that include (1) an immunoglobulin variable region
polypeptide sequence, including native or engineered V.sub.H and/or
V.sub.L and/or single-chain variable region (sFv) sequences, and
which include, for example, a mutation, alteration or deletion at
an amino acid at a location or locations corresponding to one or
more of amino acid positions 9, 10, 11, 12, 108, 110, 111, and 112,
in a V.sub.H region sequence (including in a V.sub.H region
sequence within an scFv or other construct), and/or (2) an
immunoglobulin variable region polypeptide sequence, including
native or engineered V.sub.H and/or V.sub.L and/or single-chain
variable region (sFv) sequences, and which include, for example, a
mutation, alteration or deletion at a location or locations
corresponding to one or more of amino acid positions 12, 80, 81,
82, 83, 105, 106, 107 and 108 in a light chain variable region
sequence (including in a V.sub.L region sequence within an scFv or
other construct). Especially preferred are constructs that include
an engineered V.sub.H sequence (whether or not associated with one
or more other sequences, including immunoglobulin-derived and other
sequences contained, for example, within an sFv or scFv-containing
construct), which includes a mutation, alteration or deletion at an
amino acid at a location or locations corresponding to amino acid
position 11. The V.sub.H11 amino acid, if substituted, may be
substituted with another amino acid as described herein, or by
another molecule as desired.
[0412] Once a construct, such as for example a binding
domain-immunoglobulin fusion protein, as provided herein has been
designed, polynucleotides including DNAs encoding the construct,
where it or a relevant portion of it is a polypeptide, may be
synthesized in whole or in part via oligonucleotide synthesis as
described, for example, in Sinha et al., Nucleic Acids Res.,
12:4539-4557 (1984); assembled via PCR as described, for example in
Innis, Ed., PCR Protocols, Academic Press (1990) and also in Better
et al. J. Biol. Chem. 267:16712-16118 (1992); cloned and expressed
via standard procedures as described, for example, in Ausubel et
al., Eds., Current Protocols in Molecular Biology, John Wiley &
Sons, New York (1989) and also in Robinson et al., Hum. Antibod.
Hybridomas, 2:84-93 (1991); and tested for desired activity, for
example, binding to a target, or specific antigen binding activity,
as described, for example, in Harlow et al., Eds., Antibodies: A
Laboratory Manual, Chapter 14, Cold Spring Harbor Laboratory, Cold
Spring Harbor (1988) and Munson et al., Anal. Biochem., 107:220-239
(1980).
[0413] The preparation of single polypeptide chain binding
molecules of the Fv region, single-chain Fv molecules, is known in
the art. See, e.g., U.S. Pat. No. 4,946,778. In the present
invention, single-chain Fv-like molecules that may be included in
constructs of the invention may be synthesized by encoding a first
variable region of the heavy or light chain, followed by one or
more linkers to the variable region of the corresponding light or
heavy chain, respectively. The selection of various appropriate
linker(s) between the two variable regions is described in U.S.
Pat. No. 4,946,778 (see also, e.g., Huston et al., 1993 Int. Rev.
Immunol. 10:195). An exemplary linker described herein is
(Gly-Gly-Gly-Gly-Ser).sub.3 (SEQ ID NO:529), but may be of any
desired length. The linker is used to convert the naturally
aggregated but chemically separate heavy and light chains into the
amino terminal antigen binding portion of a single polypeptide
chain, for example, wherein this antigen binding portion will fold
into a structure similar to the original structure made of two
polypeptide chains, or that otherwise has the ability to bind to a
target, for example a target antigen. For those constructs that
include an scFv as a binding region, a native or engineered
immunoglobulin hinge as a connecting region, and one or more native
or engineered heavy chain constant regions as a binding region,
nucleotide sequences encoding the variable regions of native or
engineered heavy and light chains, joined by a sequence encoding a
linker, are joined to a nucleotide sequence encoding native or
engineeredantibody constant regions, as desired. The constant
regions may be those that permit the resulting polypeptide to form
interchain disulfide bonds to form a dimer, and which contain
desired effector functions, such as the ability to mediate ADCC,
CDC, or fix complement, although native or engineered constant
regions that do not favor dimer or other multimer fomation or
aggregation are preferred. For a construct, such as an
immunoglobulin-like molecule, of the invention that is intended for
use in humans, the included sequences having constant regions
and/or desired constant regions function(s) will typically be human
or substantially human or humanized to minimize a potential
anti-human immune response and to provide appropriate or desired
effector functions. Manipulation of sequences encoding antibody
constant regions is referenced in the PCT publication of Morrison
and Oi, WO 89/07142. In preferred embodiments, the CH1 domain is
deleted in whole or in part from a tail region that includes, or
consists essentially of, or consists of, a native or engineered
immunoglobulin constant region(s) (for example, native or
engineered CH2 and/or CH3 constant region(s), or native or
engineered CH2 and/or CH3 and/or CH4 constant region(s)), and the
carboxyl end of the binding region, for example, a binding domain
polypeptide such as an immunoglobulin variable region polypeptide,
is joined to the amino terminus of, for example, a CH2 via a
connecting region, for example, a native or engineered hinge region
polypeptide as provided herein.
[0414] As described above, the present invention provides
recombinant expression constructs capable of directing the
expression of constructs of the invention, including binding
domain-immunoglobulin fusion proteins, as provided herein. The
amino acids, which occur in the various amino acid sequences
referred to herein, are identified according to their well known
three-letter or single-letter abbreviations. The nucleotides, which
occur in the various DNA sequences or fragments thereof referred
herein, are designated with the standard single letter designations
used routinely in the art. A given amino acid sequence may also
encompass similar but changed amino acid sequences, such as those
having only minor changes, for example by way of illustration and
not limitation, covalent chemical modifications, insertions,
deletions and substitutions, which may further include conservative
substitutions or substitutions with non-naturally-occurring amino
acids. Amino acid sequences that are similar to one another may
share substantial regions of sequence homology. In like fashion,
nucleotide sequences may encompass substantially similar nucleotide
sequences having only minor changes, for example by way of
illustration and not limitation, covalent chemical modifications,
insertions, deletions and substitutions, which may further include
silent mutations owing to degeneracy of the genetic code.
Nucleotide sequences that are similar to one another may share
substantial regions of sequence homology.
[0415] The presence of a malignant condition in a subject refers to
the presence of dysplastic, cancerous, and/or transformed cells in
the subject, including, for example, neoplastic, tumor, non-contact
inhibited, or oncogenically transformed cells, or the like (e.g.,
melanoma, carcinomas such as adenocarcinoma, squamous cell
carcinoma, small cell carcinoma, oat cell carcinoma, etc., sarcomas
such as chondrosarcoma, osteosarcoma, etc.) which are known to the
art and for which criteria for diagnosis and classification are
established. In preferred embodiments contemplated by the present
invention, for example, such cancer cells are malignant
hematopoietic cells, such as transformed cells of lymphoid lineage
and in particular, B cell lymphomas and the like; cancer cells may
in certain preferred embodiments also be epithelial cells such as
carcinoma cells. The invention also contemplates B cell disorders,
which may include certain malignant conditions that affect B cells
(e.g., B cell lymphoma) but which is not intended to be so limited,
and which is also intended to encompass autoimmune diseases and in
particular, diseases, disorders and conditions that are
characterized by autoantibody production, for example.
[0416] Autoantibodies are antibodies that react with self-antigens.
Autoantibodies are detected in several autoimmune diseases (i.e., a
disease, disorder or condition wherein a host immune system
generates an inappropriate anti-"self" immune reaction) where they
are involved in disease activity. Current treatments for various
autoimmune diseases include immunosuppressive drugs that require
continuing administration, lack specificity, and cause significant
side effects. New approaches that can eliminate autoantibody
production with minimal toxicity will address an unmet medical need
for a spectrum of diseases that affect many people. Constructs of
the subject invention, including binding domain-immunoglobulin
fusion proteins, are designed, for example, for improved
penetration into lymphoid tissues. Depletion of B lymphocytes
interrupts the autoantibody production cycle, and allows the immune
system to reset as new B lymphocytes are produced from precursors
in the bone marrow.
[0417] A number of diseases, disorders, and conditions have been
identified for which beneficial effects are believed, according to
non-limiting theory, to result from B cell depletion therapy. Such
diseases disorders, and conditions include, but are not limited to,
Grave's disease, Hashimoto's disease, rheumatoid arthritis,
systemic lupus erythematosus, Sjogrens Syndrome Immune
Thrombocytopenic purpura, multiple sclerosis, myasthenia gravis,
scleroderma, psoriasis, Inflamatory Bowel Disease including Crohn's
disease and ulcerative colitis. Inflamatory Bowel Disease including
Crohn's disease and Ulcerative colitis, are autoimmune diseases of
the digestive system.
[0418] The present invention further relates to nucleotide
constructs encoding constructs of the invention, for example,
binding domain-immunoglobulin fusion proteins, and in particular to
methods for administering recombinant constructs encoding such
proteins for gene therapy applications that may be expressed, for
example, as fragments, analogs and derivatives of such
polypeptides.
[0419] The terms "fragment," "derivative" and "analog" when
referring to constructs of the invention including, for example,
binding domain-immunoglobulin fusion polypeptides or fusion
proteins, refers to any construct, such as a binding
domain-immunoglobulin fusion polypeptide or fusion protein, that
retains essentially the same biological function or activity as
such polypeptide. Thus, an analog includes a pro- or prepro-form of
a construct, for example, a pro-protein that can be activated by
cleavage of the pro-protein portion to produce an active construct,
such as a binding domain-immunoglobulin fusion polypeptide.
[0420] A fragment, derivative or analog of a construct of the
invention, for example, a binding domain-immunoglobulin fusion
polypeptide or fusion protein, including binding
domain-immunoglobulin fusion polypeptides or fusion proteins
encoded by the cDNAs referred to herein, may be (i) one in which
one or more of the amino acid residues are substituted with a
conserved or non-conserved amino acid residue (preferably a
conserved amino acid residue) and such substituted amino acid
residue may or may not be one encoded by the genetic code, or (ii)
one in which one or more of the amino acid residues includes a
substituent group, or (iii) one in which additional amino acids are
fused or otherwise connected to the construct, e.g., a binding
domain-immunoglobulin fusion polypeptide, including amino acids
that are employed for detection or specific functional alteration
of the construct, inlcuding such constructs as a binding
domain-immunoglobulin fusion polypeptide or a proprotein sequence.
Such fragments, derivatives and analogs are deemed to be within the
scope of those skilled in the art from the teachings herein.
[0421] The constructs, including polypeptide constructs, of the
present invention include, for example, binding
domain-immunoglobulin fusion polypeptides and fusion proteins
having binding regions such as binding domain polypeptide amino
acid sequences that are identical or similar to sequences known in
the art, or fragments or portions thereof. For example by way of
additional illustration and not limitation, a human CD154 molecule
extracellular domain is contemplated for use according to the
instant invention, as are portions of such polypeptides and/or
polypeptides having at least about 70% similarity (preferably
greater than a 70% identity) and more preferably about 90%
similarity (more preferably greater than a 90% identity) to the
reported polypeptide and still more preferably about 95% similarity
(still more preferably greater than a 95% identity) to the reported
polypeptides and to portions of such polypeptides, wherein such
portions of a binding domain-immunoglobulin fusion polypeptide, for
example, generally contain at least about 30 amino acids and more
preferably at least about 50 amino acids. Extracellular domains
include, for example, portions of a cell surface molecule, and in
particularly preferred embodiments cell surface molecules that are
integral membrane proteins or that comprise a plasma membrane
spanning transmembrane domain, that are constructed to extend
beyond the outer leaflet of the plasma membrane phospholipid
bilayer when the molecule is expressed at a cell surface,
preferably in a manner that exposes the extracellular domain
portion of such a molecule to the external environment of the cell,
also known as the extracellular milieu. Methods for determining
whether a portion of a cell surface molecule comprises an
extracellular domain are well known to the art and include, for
example, experimental determination (e.g., direct or indirect
labeling of the molecule, evaluation of whether the molecule can be
structurally altered by agents to which the plasma membrane is not
permeable such as proteolytic or lipolytic enzymes) or topological
prediction based on the structure of the molecule (e.g., analysis
of the amino acid sequence of a polypeptide) or other
methodologies.
[0422] As used herein, an "amino acid" is a molecule having the
structure wherein a central carbon atom (the alpha (.alpha.)-carbon
atom) is linked to a hydrogen atom, a carboxylic acid group (the
carbon atom of which is referred to herein as a "carboxylcarbon
atom"), an amino group (the nitrogen atom of which is referred to
herein as an "amino nitrogen atom"), and a side chain group, R.
When incorporated into a peptide, polypeptide, or protein, an amino
acid loses one or more atoms of its amino and carboxylic groups in
the dehydration reaction that links one amino acid to another. As a
result, when incorporated into a protein, an amino acid may also be
referred to as an "amino acid residue." In the case of naturally
occurring proteins, an amino acid residue's R group differentiates
the 20 amino acids from which proteins are typically synthesized,
although one or more amino acid residues in a protein may be
derivatized or modified following incorporation into protein in
biological systems (e.g., by glycosylation and/or by the formation
of cystine through the oxidation of the thiol side chains of two
non-adjacent cysteine amino acid residues, resulting in a disulfide
covalent bond that frequently plays an important role in
stabilizing the folded conformation of a protein, etc.). As those
in the art will appreciate, non-naturally occurring amino acids can
also be incorporated into proteins, particularly those produced by
synthetic methods, including solid state and other automated
synthesis methods. Examples of such amino acids include, without
limitation, .alpha.-amino isobutyric acid, 4-amino butyric acid,
L-amino butyric acid, 6-amino hexanoic acid, 2-amino isobutyric
acid, 3-amino propionic acid, ornithine, norlensine, norvaline,
hydroxproline, sarcosine, citralline, cysteic acid, t-butylglyine,
t-butylalanine, phenylylycine, cyclohexylalanine, 13-alanine,
fluoro-amino acids, designer amino acids (e.g., .beta.-methyl amino
acids, .alpha.-methyl amino acids, N.alpha.-methyl amino acids) and
amino acid analogs in general. In addition, when an .alpha.-carbon
atom has four different groups (as is the case with the 20 amino
acids used by biological systems to synthesize proteins, except for
glycine, which has two hydrogen atoms bonded to the .alpha. carbon
atom), two different enantiomeric forms of each amino acid exist,
designated D and L. In mammals, only L-amino acids are incorporated
into naturally occurring polypeptides. The instant invention
envisions proteins incorporating one or more D- and L-amino acids,
as well as proteins comprised of just D- or L-amino acid
residues.
[0423] Herein, the following abbreviations may be used for the
following amino acids (and residues thereof): alanine (Ala, A);
arginine (Arg, R); asparagine (Asn, N); aspartic acid (Asp, D);
cyteine (Cys, C); glycine (Gly, G); glutamic acid (Glu, E);
glutamine (Gln, Q); histidine (His, H); isoleucine (Ile, I);
leucine (Leu, L); lysine (Lys, K); methionine (Met, M);
phenylalanine (Phe, F); proline (Pro, P); serine (Ser, S);
threonine (Thr, T); tryptophan (Trp, W); tyrosine (Tyr, Y); and
valine (Val, V). Non-polar (hydrophobic) amino acids include
alanine, leucine, isoleucine, valine, proline, phenylalanine,
tryptophan, and methionines. Neutral amino acids include glycine,
serine, threonine, cysteine, tyrosine, esparagine, and glutamine.
Positively charged (basic amino acids include arginine, lysine and
histidine. Negatively charged (acidic) amino acids include aspartic
acid and glutamic acid.
[0424] "Protein" refers to any polymer of two or more individual
amino acids (whether or not naturally occurring) linked via a
peptide bond, and occurs when the carboxylcarbon atom of the
carboxylic acid group bonded to the .alpha.-carbon of one amino
acid (or amino acid residue) becomes covalently bound to the amino
nitrogen atom of amino group bonded to the .alpha.-carbon of an
adjacent amino acid. The term "protein" is understood to include
the terms "polypeptide" and "peptide" (which, at times, may be used
interchangeably herein) within its meaning In addition, proteins
comprising multiple polypeptide subunits or other components will
also be understood to be included within the meaning of "protein"
as used herein. Similarly, fragments of proteins, peptides, and
polypeptides are also within the scope of the invention and may be
referred to herein as "proteins."
[0425] In biological systems (be they in vivo or in vitro,
including cell-free, systems), the particular amino acid sequence
of a given protein (i.e., the polypeptide's "primary structure,"
when written from the amino-terminus to carboxy-terminus) is
determined by the nucleotide sequence of the coding portion of a
mRNA, which is in turn specified by genetic information, typically
genomic DNA (which, for purposes of this invention, is understood
to include organelle DNA, for example, mitochondrial DNA and
chloroplast DNA). Of course, any type of nucleic acid which
constitutes the genome of a particular organism (e.g.,
double-stranded DNA in the case of most animals and plants, single
or double-stranded RNA in the case of some viruses, etc.) is
understood to code for the gene product(s) of the particular
organism. Messenger RNA is translated on a ribosome, which
catalyzes the polymerization of a free amino acid, the particular
identity of which is specified by the particular codon (with
respect to mRNA, three adjacent A, G, C, or U ribonucleotides in
the mRNA's coding region) of the mRNA then being translated, to a
nascent polypeptide. Recombinant DNA techniques have enabled the
large-scale synthesis of proteins and polypeptides (e.g., human
insulin, human growth hormone, erythropoietin, granulocyte colony
stimulating factor, etc.) having the same primary sequence as when
produced naturally in living organisms. In addition, such
technology has allowed the synthesis of analogs of these and other
proteins, which analogs may contain one or more amino acid
deletions, insertions, and/or substitutions as compared to the
native proteins. Recombinant DNA technology also enables the
synthesis of entirely novel proteins.
[0426] In non-biological systems (e.g., those employing solid state
synthesis), the primary structure of a protein (which also includes
disulfide (cystine) bond locations) can be determined by the user.
As a result, polypeptides having a primary structure that
duplicates that of a biologically produced protein can be achieved,
as can analogs of such proteins. In addition, completely novel
polypeptides can also be synthesized, as can protein incorporating
non-naturally occurring amino acids.
[0427] As is known in the art, "similarity" between two
polypeptides may be determined by comparing the amino acid sequence
(including conserved amino acid substitutes therein) of one
polypeptide to the sequence of a second polypeptide. Fragments or
portions of the nucleic acids encoding polypeptides of the present
invention may be used to synthesize full-length nucleic acids of
the present invention. As used herein, "% identity" refers to the
percentage of identical amino acids situated at corresponding amino
acid residue positions when two or more polypeptide are aligned and
their sequences analyzed using, for example, a gapped BLAST
algorithm (e.g., Altschul et al., 1997 Nucl. Ac. Res. 25:3389;
Altschul et al., 1990 J. Mol. Biol., 215:403-410) which weights
sequence gaps and sequence mismatches according to the default
weightings provided by the National Institutes of Health/NCBI
database (Bethesda, Md.; see
www.ncbi.nlm.nih.gov/cgi-bin/BLAST/nph-newblast). Other alignment
methods include BLITZ (MPsrch) (Sturrock & Collins, 1993), and
FASTA (Pearson and Lipman, 1988 Proc. Natl. Acad. Sci. USA.
85:2444-2448).
[0428] The term "isolated" means, in the case of a naturally
occurring material, that the material is or has been removed from,
or is no longer associated with, its natural or original
environment. For example, a naturally occurring nucleic acid or
protein or polypeptide present in a living animal is not isolated,
but the same nucleic acid or polypeptide, separated from some or
all of the co-existing materials in the natural system, is
isolated. Such nucleic acids could be part of a vector and/or such
nucleic acids or polypeptides could be part of a composition, and
still be isolated in that such vector or composition is not part of
its natural environment. The term "isolated", in the case of
non-naturally occurring material, such as a recombinantly
manufactured construct of the invention, includes material that is
substantially or essentially free from components which normally
accompany it during manufacture, such as, for example, proteins and
peptides that have been purified to a desired degree, preferably,
for example, so that they are at least about 80% pure, more
preferably at least about 90%, and still more preferably at least
about 95% as measured by techniques known in the art.
[0429] The term "gene" means a segment of DNA involved in producing
a polypeptide chain; it may also include regions preceding and
following a polypeptide coding region, for example, a "leader and
trailer" as well as intervening sequences (introns) between
relevant individual coding segments (exons).
[0430] As described herein, the invention provides constructs,
including binding domain-immunoglobulin fusion proteins, that may
be encoded in whole or in part by nucleic acids that have a binding
region coding sequence such as, for example, a binding domain
coding sequence fused or otherwise connected in frame to an
additional native or engineered immunoglobulin domain encoding
sequence to provide for expression of, for example, a binding
domain polypeptide sequence fused or otherwise connected to an
additional functional polypeptide sequence that permits, for
example by way of illustration and not limitation, detection,
functional alteration, isolation and/or purification of the fusion
protein. Such fusion proteins may permit functional alteration of a
binding domain by containing additional immunoglobulin-derived
polypeptide sequences that influence behavior of the fusion
product, for example (and as described above) by reducing the
availability of sufhydryl groups for participation in disulfide
bond formation, and by conferring the ability to potentiate ADCC
and/or CDC and/or fix complement.
[0431] Modification of a polypeptide may be effected by any means
known to those of skill in this art. The preferred methods herein
rely on modification of DNA encoding, for example, a fusion protein
and expression of the modified DNA. DNA encoding one of the
constructs of the invention, for example, one of the binding
domain-immunoglobulin fusions discussed herein, for example, may be
altered or mutagenized using standard methodologies, including
those described below. For example, cysteine residues that may
otherwise facilitate multimer formation or promote particular
molecular conformations can be deleted from a polypeptide or
replaced, e.g., cysteine residues that are responsible for or
participate in aggregate formation. If necessary, for example, the
identity of cysteine residues that contribute to aggregate
formation may be determined empirically, by deleting and/or
replacing a cysteine residue and ascertaining whether the resulting
protein aggregates in solutions containing physiologically
acceptable buffers and salts. In addition, fragments of, for
example, binding domain-immunoglobulin fusions may be constructed
and used. As noted above, counterreceptor/ligand binding domains
for many candidate binding domain-immunoglobulin fusion have been
delineated, such that one having ordinary skill in the art may
readily select appropriate polypeptide domains for inclusion in
encoded products of the instant expression constructs.
[0432] Conservative substitutions of amino acids are well known and
may be made generally without altering the biological activity of
the resulting binding domain-immunoglobulin fusion protein
molecule. For example, such substitutions are generally made by
interchanging within the groups of polar residues, charged
residues, hydrophobic residues, small residues, and the like. If
necessary, such substitutions may be determined empirically merely
by testing the resulting modified protein for the ability to bind
to the appropriate cell surface receptors in in vitro biological
assays, or to bind to appropriate antigens or desired target
molecules.
[0433] The present invention further relates to nucleic acids which
hybridize to constructs of the invention, including for example,
binding domain-immunoglobulin fusion protein encoding
polynucleotide sequences as provided herein, or their complements,
as will be readily apparent to those familiar with the art, if
there is at least about 70%, preferably at least about 80-85%, more
preferably at least about 90%, and still more preferably at least
about 95%, 96%, 97%, 98% or 99% identity between the sequences.
[0434] The present invention particularly relates to nucleic acids
that hybridize under stringent conditions to, for example, the
binding domain-immunoglobulin fusion encoding nucleic acids
referred to herein. As used herein, to "hybridize" under conditions
of a specified stringency is used to describe the stability of
hybrids formed between two single-stranded nucleic acid molecules.
Stringency of hybridization is typically expressed in conditions of
ionic strength and temperature at which such hybrids are annealed
and washed. The term "stringent conditions" refers to conditions
that permit hybridization between polynucleotides. Stringent
conditions can be defined by salt concentration, the concentration
of organic solvent (e.g., formamide), temperature, and other
conditions well known in the art. In particular, stringency can be
increased by reducing the concentration of salt, increasing the
concentration of organic solvents (e.g., formamide), or raising the
hybridization temperature. For example, stringent salt
concentration will ordinarily be less than about 750 mM NaCl and 75
mM trisodium citrate, preferably less than about 500 mM NaCl and 50
mM trisodium citrate, and most preferably less than about 250 mM
NaCl and 25 mM trisodium citrate. Low stringency hybridization can
be obtained in the absence of organic solvent, e.g., formamide,
while high stringency hybridization can be obtained in the presence
of an organic solvent (e.g., at least about 35% formamide, most
preferably at least about 50% formamide). Stringent temperature
conditions will ordinarily include temperatures of at least about
30.degree. C., more preferably of at least about 37.degree. C., and
most preferably of at least about 42.degree. C. Varying additional
parameters, for example, hybridization time, the concentration of
detergent, e.g., sodium dodecyl sulfate (SDS), and the inclusion or
exclusion of carrier DNA, are well known to those skilled in the
art. Various levels of stringency are accomplished by combining
these various conditions as needed, and are within the skill in the
art. Other typical "high", "medium" and "low" stringency encompass
the following conditions or equivalent conditions thereto: high
stringency: 0.1.times.SSPE or SSC, 0.1% SDS, 65.degree. C.; medium
stringency: 0.2.times.SSPE or SSC, 0.1% SDS, 50.degree. C.; and low
stringency: 1.0.times.SSPE or SSC, 0.1% SDS, 50.degree. C. As known
to those having ordinary skill in the art, variations in stringency
of hybridization conditions may be achieved by altering the time,
temperature and/or concentration of the solutions used for
prehybridization, hybridization and wash steps, and suitable
conditions may also depend in part on the particular nucleotide
sequences of the probe used, and of the blotted, proband nucleic
acid sample. Accordingly, it will be appreciated that suitably
stringent conditions can be readily selected without undue
experimentation where a desired selectivity of the probe is
identified, based on its ability to hybridize to one or more
certain proband sequences while not hybridizing to certain other
proband sequences.
[0435] As used herein, preferred "stringent conditions" generally
refer to hybridization that will occur only if there is at least
about 90-95% and more preferably at least about 97% identity
between the sequences. The nucleic acid constructs which hybridize
to, for example, binding domain-immunoglobulin fusion encoding
nucleic acids referred to herein, in preferred embodiments, encode
polypeptides which retain substantially the same biological
function or activity as, for example, the binding
domain-immunoglobulin fusion polypeptides encoded by the cDNAs.
[0436] The nucleic acids of the present invention, also referred to
herein as polynucleotides, may be in the form of RNA, for example,
mRNA, or in the form of DNA, which DNA includes cDNA (also called
"complementary DNA", which is a DNA molecule that is complementary
to a specific messenger RNA), genomic DNA, and synthetic DNA. The
DNA may be double-stranded or single-stranded, and if single
stranded may be the coding strand or non-coding (anti-sense)
strand. A coding sequence which encodes a construct of the
invention, for example, a binding domain-immunoglobulin fusion
polypeptide for use according to the invention may contain portions
that are identical to the coding sequence known in the art or
described herein for portions thereof, or may be a different coding
sequence, which, as a result of the redundancy or degeneracy of the
genetic code, encodes the same construct or portion thereof,
including all or a portion of a binding domain-immunoglobulin
fusion polypeptide.
[0437] The nucleic acids which encode constructs of the invention,
for example, binding domain-immunoglobulin fusion polypeptides, for
use according to the invention may include, but are not limited to:
only the coding sequence for the construct, such as a binding
domain-immunoglobulin fusion polypeptide; the coding sequence for
the construct, such as a binding domain-immunoglobulin fusion
polypeptide and additional coding sequence; the coding sequence for
the construct, such as a binding domain-immunoglobulin fusion
polypeptide (and optionally additional coding sequence) and
non-coding sequence, such as introns or non-coding sequences 5'
and/or 3' of the coding sequence for the binding
domain-immunoglobulin fusion polypeptide or a portion(s) thereof,
which for example may further include but need not be limited to
one or more regulatory nucleic acid sequences that may be a
regulated or regulatable promoter, enhancer, other transcription
regulatory sequence, repressor binding sequence, translation
regulatory sequence or any other regulatory nucleic acid sequence.
Thus, the term "nucleic acid encoding" or "polynucleotide encoding"
a construct, for example, a binding domain-immunoglobulin fusion
protein, encompasses a nucleic acid which includes only coding
sequence for, for example, a binding domain-immunoglobulin fusion
polypeptide as well as a nucleic acid which includes additional
coding and/or non-coding sequence(s).
[0438] Nucleic acids and oligonucleotides for use as described
herein can be synthesized by any method known to those of skill in
this art (see, e.g., WO 93/01286, U.S. application Ser. No.
07/723,454; U.S. Pat. No. 5,218,088; U.S. Pat. No. 5,175,269; U.S.
Pat. No. 5,109,124). Identification of various oligonucleotides and
nucleic acid sequences also involves methods known in the art. For
example, the desirable properties, lengths and other
characteristics of oligonucleotides useful for cloning are well
known. In certain embodiments, synthetic oligonucleotides and
nucleic acid sequences may be designed that resist degradation by
endogenous host cell nucleolytic enzymes by containing such
linkages as: phosphorothioate, methylphosphonate, sulfone, sulfate,
ketyl, phosphorodithioate, phosphoramidate, phosphate esters, and
other such linkages that have proven useful in antisense
applications. See, e.g., Agrwal et al., Tetrehedron Lett.
28:3539-3542 (1987); Miller et al., J. Am. Chem. Soc. 93:6657-6665
(1971); Stec et al., Tetrehedron Lett. 26:2191-2194 (1985); Moody
et al., Nucl. Acids Res. 12:4769-4782 (1989); Uznanski et al.,
Nucl. Acids Res. (1989); Letsinger et al., Tetrahedron 40:137-143
(1984); Eckstein, Annu. Rev. Biochem. 54:367-402 (1985); Eckstein,
Trends Biol. Sci. 14:97-100 (1989); Stein In:
Oligodeoxynucleotides. Antisense Inhibitors of Gene Expression,
Cohen, Ed, Macmillan Press, London, pp. 97-117 (1989); Jager et
al., Biochemistry 27:7237-7246 (1988).
[0439] In one embodiment, the present invention provides truncated
components (e.g., binding domain polypeptide, hinge region
polypeptide, linker, etc.) for use in a construct of the invention,
for example, a binding domain-immunoglobulin fusion protein. In
another embodiment the invention provides nucleic acids encoding a
construct of the invention, for example, a binding
domain-immunoglobulin fusion protein having such truncated
components. A truncated molecule may be any molecule that comprises
less than a full length version of the molecule of interest.
Truncated molecules provided by the present invention may include
truncated biological polymers, and in preferred embodiments of the
invention such truncated molecules may be truncated nucleic acid
molecules or truncated polypeptides. Truncated nucleic acid
molecules have less than the full length nucleotide sequence of a
known or described nucleic acid molecule, where such a known or
described nucleic acid molecule may be a naturally occurring, a
synthetic, or a recombinant nucleic acid molecule, so long as one
skilled in the art would regard it as a full length molecule. Thus,
for example, truncated nucleic acid molecules that correspond to a
gene sequence contain less than the full length gene where the gene
comprises coding and non-coding sequences, promoters, enhancers and
other regulatory sequences, flanking sequences and the like, and
other functional and non-functional sequences that are recognized
as part of the gene. In another example, truncated nucleic acid
molecules that correspond to a mRNA sequence contain less than the
full length mRNA transcript, which may include various translated
and non-translated regions as well as other functional and
non-functional sequences.
[0440] In other preferred embodiments, truncated molecules are
polypeptides that comprise less than the full-length amino acid
sequence of a particular protein or polypeptide component. As used
herein "deletion" has its common meaning as understood by those
familiar with the art, and may refer to molecules that lack one or
more portions of a sequence from either terminus or from a
non-terminal region, relative to a corresponding full length
molecule, for example, as in the case of truncated molecules
provided herein. Truncated molecules that are linear biological
polymers such as nucleic acid molecules or polypeptides may have
one or more of a deletion from either terminus of the molecule
and/or one or more deletions from a non-terminal region of the
molecule, where such deletions may be deletions of from about
1-1500 contiguous nucleotide or amino acid residues, preferably
about 1-500 contiguous nucleotide or amino acid residues and more
preferably about 1-300 contiguous nucleotide or amino acid
residues, including deletions of about 1, 2, 3, 4, 5, 6, 7, 8, 9,
10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26,
27, 28, 29, 30, 31-40, 41-50, 51-74, 75-100, 101-150, 151-200,
201-250 or 251-299 contiguous nucleotide or amino acid residues. In
certain particularly preferred embodiments truncated nucleic acid
molecules may have a deletion of about 270-330 contiguous
nucleotides. In certain more preferred embodiments, truncated
polypeptide molecules may have a deletion, for example, of about
80-140 contiguous amino acids.
[0441] The present invention further relates to variants of the
herein referenced nucleic acids that encode fragments, analogs
and/or derivatives of a construct of the invention, for example, a
binding domain-immunoglobulin fusion polypeptide. The variants of
the nucleic acids encoding constructs of the invention, for
example, binding domain-immunoglobulin fusion proteins, may be
naturally occurring allelic variants of one or more portions of the
nucleic acid sequences included therein, or non-naturally occurring
variants of such sequences or portions or sequences, including
sequences varied by molecular engineering using, for example,
methods know in the art for varying sequence. As is known in the
art, an allelic variant is an alternate form of a nucleic acid
sequence which may have at least one of a substitution, a deletion
or an addition of one or more nucleotides, any of which does not
substantially or undesireably alter the function of the encoded
binding domain-immunoglobulin fusion polypeptide.
[0442] Variants and derivatives of constructs of the invention, for
example, binding domain-immunoglobulin fusion proteins, may be
obtained by mutations of nucleotide sequences encoding, for
example, binding domain-immunoglobulin fusion polypeptides or any
portion thereof. Alterations of the native amino acid sequence may
be accomplished by any of a number of conventional methods.
Mutations can be introduced at particular loci, for example, by
synthesizing oligonucleotides containing a mutant sequence, flanked
by restriction sites enabling ligation to fragments of the native
sequence. Following ligation, the resulting reconstructed sequence
encodes an analog having the desired amino acid insertion,
substitution, or deletion.
[0443] Alternatively, for example, oligonucleotide-directed
site-specific mutagenesis procedures can be employed to provide an
altered gene wherein predetermined codons can be altered by
substitution, deletion or insertion. Exemplary methods of making
such alterations are disclosed by Walder et al., 1986 Gene 42:133;
Bauer et al., 1985 Gene 37:73; Craik, January 1985 BioTechniques
12-19; Smith et al., January 1985 Genetic Engineering: Principles
and Methods BioTechniques 12-19; Costa G L, et al., "Site-directed
mutagenesis using a rapid PCR-based method," 1996 Methods Mol.
Biol. 57:239-48; Rashtchian A., "Novel methods for cloning and
engineering genes using the polymerase chain reaction," 1995 Curr
Opin Biotechnol. 6(1):30-6; Sharon J, et al.,
"Oligonucleotide-directed mutagenesis of antibody combining sites,"
1993 Int Rev Immunol. 10(2-3):113-27; Kunkel, 1985 Proc. Natl.
Acad. Sci. USA 82:488; Kunkel et al., 1987 Methods in Enzymol.
154:367; and, U.S. Pat. Nos. 4,518,584 and 4,737,462.
[0444] As an example, modification of DNA may be performed by
site-directed mutagenesis of DNA encoding a protein combined with
the use of DNA amplification methods using primers to introduce and
amplify alterations in the DNA template, such as PCR splicing by
overlap extension (SOE). Site-directed mutagenesis is typically
effected using a phage vector that has single- and double-stranded
forms, such as M13 phage vectors, which are well known and
commercially available. Other suitable vectors that contain a
single-stranded phage origin of replication may be used. See, e.g.,
Veira et al., 1987 Meth. Enzymol. 15:3. In general, site-directed
mutagenesis is performed by preparing a single-stranded vector that
encodes the protein of interest (e.g., all or a component portion
of a given binding domain-immunoglobulin fusion protein). An
oligonucleotide primer that contains the desired mutation within a
region of homology to the DNA in the single-stranded vector is
annealed to the vector followed by addition of a DNA polymerase,
such as E. coli DNA polymerase I (Klenow fragment), which uses the
double stranded region as a primer to produce a heteroduplex in
which one strand encodes the altered sequence and the other the
original sequence. The heteroduplex is introduced into appropriate
bacterial cells and clones that include the desired mutation are
selected. The resulting altered DNA molecules may be expressed
recombinantly in appropriate host cells to produce the modified
protein.
[0445] Equivalent DNA constructs that include code for additions or
substitutions of amino acid residues or sequences, or deletions of
terminal or internal residues or sequences not needed or desired
for biological activity, for example, are also encompassed by the
invention. For example, and as discussed above, sequences encoding
Cys residues that are not desirable or essential for biological
activity can be altered to cause the Cys residues to be deleted or
replaced with other amino acids, for example, thus preventing
formation of incorrect or undesired intramolecular disulfide
bridges upon synthesis or renaturation.
[0446] A "host cell" or "recombinant host cell" is a cell that
contains a vector, e.g., an expression vector, or a cell that has
otherwise been manipulated by recombinant techniques to express a
protein of interest. Host organisms include those organisms in
which recombinant production of constructs of the invention, for
example, binding domain-immunoglobulin fusion products encoded by
the recombinant constructs of the present invention may occur, such
as bacteria (for example, E. coli), yeast (for example,
Saccharomyces cerevisiae and Pichia pastoris), insect cells, and
mammalian cells, including in vitro and in vivo expression. Host
organisms thus may include organisms for the construction,
propagation, expression or other steps in the production of the
compositions provided herein. Hosts include subjects in which
immune responses take place, as described herein. Presently
preferred host organisms for production of constructs of the
invention that produce glycosylated proteins are mammalian cells or
other cells systems that pemit the expression and recovery of
glycosylated proteins. Other cell lines include inbred murine
strains and murine cell lines, and human cellsand cell lines.
[0447] A DNA construct encoding a desired construct of the
invention, for example, a binding domain-immunoglobulin fusion
protein is introduced into a vector, for example, a plasmid, for
expression in an appropriate host. In preferred embodiments, the
host is a mammalian host, for example, a mammalian cell line. The
sequence encoding the ligand or nucleic acid binding domain is
preferably codon-optimized for expression in the particular host.
Thus, for example, if a construct, for example, is a human binding
domain-immunoglobulin fusion and is expressed in bacteria, the
codons may be optimized for bacterial usage. For small coding
regions, the gene can be synthesized as a single oligonucleotide.
For larger proteins, splicing of multiple oligonucleotides,
mutagenesis, or other techniques known to those in the art may be
used. The sequences of nucleotides in plasmids or other vectors
that are regulatory regions, such as promoters and operators, are
operationally associated with one another for transcription. The
sequence of nucleotides encoding a binding domain-immunoglobulin
fusion protein may also include DNA encoding a secretion signal,
whereby the resulting peptide is a precursor protein. The resulting
processed protein may be recovered from the periplasmic space or
the fermentation medium.
[0448] In preferred embodiments, the DNA plasmids may also include
a transcription terminator sequence. As used herein, a
"transcription terminator region" is a sequence that signals
transcription termination. The entire transcription terminator may
be obtained from a protein-encoding gene, which may be the same or
different from the inserted binding domain-immunoglobulin fusion
encoding gene or the source of the promoter. Transcription
terminators are optional components of the expression systems
herein, but are employed in preferred embodiments.
[0449] The plasmids or other vectors used herein include a promoter
in operative association with the DNA encoding the protein or
polypeptide of interest and are designed for expression of proteins
in a suitable host as described above (e.g., bacterial, murine, or
human) depending upon the desired use of the plasmid (e.g.,
administration of a vaccine containing binding
domain-immunoglobulin fusion encoding sequences). Suitable
promoters for expression of proteins and polypeptides herein are
widely available and are well known in the art. Inducible promoters
or constitutive promoters that are linked to regulatory regions are
preferred. Such promoters include, for example, but are not limited
to, the T7 phage promoter and other T7-like phage promoters, such
as the T3, T5 and SP6 promoters, the trp, lpp, and lac promoters,
such as the lacUV5, from E. coli; the P10 or polyhedrin gene
promoter of baculovirus/insect cell expression systems (see, e.g.,
U.S. Pat. Nos. 5,243,041, 5,242,687, 5,266,317, 4,745,051, and
5,169,784) and inducible promoters from other eukaryotic expression
systems. For expression of the proteins such promoters are inserted
in a plasmid in operative linkage with a control region such as the
lac operon.
[0450] Preferred promoter regions are those that are inducible and
functional in mammalian cells, for example. Examples of suitable
inducible promoters and promoter regions for bacterial expression
include, but are not limited to: the E. coli lac operator
responsive to isopropyl .beta.-D-thiogalactopyranoside (IPTG; see
Nakamura et al., 1979 Cell 18:1109-1117); the metallothionein
promoter metal-regulatory-elements responsive to heavy-metal (e.g.,
zinc) induction (see, e.g., U.S. Pat. No. 4,870,009); the phage
T7lac promoter responsive to IPTG (see, e.g., U.S. Pat. No.
4,952,496; and Studier et al., 1990 Meth. Enzymol. 185:60-89) and
the TAC promoter. Depending on the expression host system to be
used, plasmids may optionally include a selectable marker gene or
genes that are functional in the host. Thus, for example, a
selectable marker gene includes any gene that confers a phenotype
on bacteria that allows transformed bacterial cells to be
identified and selectively grown from among a vast majority of
untransformed cells. Suitable selectable marker genes for bacterial
hosts, for example, include the ampicillin resistance gene
(Amp.sup.r), tetracycline resistance gene (Tc.sup.r) and the
kanamycin resistance gene (Kan.sup.r). The kanamycin resistance
gene is presently preferred for bacterial expression.
[0451] In various expression systems, plasmids or other vectors may
also include DNA encoding a signal for secretion of the operably
linked protein. Secretion signals suitable for use are widely
available and are well known in the art. Prokaryotic and eukaryotic
secretion signals functional in E. coli may be employed. Depending
on the expression systems, presently preferred secretion signals
may include, but are not limited to, those encoded by the following
E. coli genes: ompA, ompT, ompF, ompC, beta-lactamase, and alkaline
phosphatase, and the like (von Heijne, J. Mol. Biol. 184:99-105,
1985). In addition, the bacterial pelB gene secretion signal (Lei
et al., J. Bacteriol. 169:4379, 1987), the phoA secretion signal,
and the cek2 functional in insect cell may be employed. The most
preferred secretion signal for certain expression systems is the E.
coli ompA secretion signal. Other prokaryotic and eukaryotic
secretion signals known to those of skill in the art may also be
employed (see, e.g., von Heijne, J. Mol. Biol. 184:99-105, 1985).
Using the methods described herein, one of skill in the art can
substitute secretion signals that are functional, for example, in
yeast, insect or mammalian cells to secrete proteins from those
cells.
[0452] Preferred plasmids for transformation of E. coli cells
include the pET expression vectors (e.g., pET-11a, pET-12a-c,
pET-15b; see U.S. Pat. No. 4,952,496; available from Novagen,
Madison, Wis.). Other preferred plasmids include the pKK plasmids,
particularly pKK 223-3, which contains the tac promoter (Brosius et
al., 1984 Proc. Natl. Acad. Sci. 81:6929; Ausubel et al., Current
Protocols in Molecular Biology; U.S. Pat. Nos. 5,122,463,
5,173,403, 5,187,153, 5,204,254, 5,212,058, 5,212,286, 5,215,907,
5,220,013, 5,223,483, and 5,229,279). Plasmid pKK has been modified
by replacement of the ampicillin resistance gene with a kanamycin
resistance gene. (Available from Pharmacia; obtained from pUC4K,
see, e.g., Vieira et al. (1982 Gene 19:259-268; and U.S. Pat. No.
4,719,179.) Baculovirus vectors, such as pBlueBac (also called
pJVETL and derivatives thereof), particularly pBlueBac III (see,
e.g., U.S. Pat. Nos. 5,278,050, 5,244,805, 5,243,041, 5,242,687,
5,266,317, 4,745,051, and 5,169,784; available from Invitrogen, San
Diego) may also be used for expression of the polypeptides in
insect cells. Other plasmids include the pIN-IIIompA plasmids (see
U.S. Pat. No. 4,575,013; see also Duffaud et al., Meth. Enz.
153:492-507, 1987), such as pIN-IIIompA2.
[0453] Preferably, if one or more DNA molecules is replicated in
bacterial cells, the preferred host is E. coli. The preferred DNA
molecule is such a system also includes a bacterial origin of
replication, to ensure the maintenance of the DNA molecule from
generation to generation of the bacteria. In this way, large
quantities of the DNA molecule can be produced by replication in
bacteria. In such expression systems, preferred bacterial origins
of replication include, but are not limited to, the fl-ori and col
E1 origins of replication. Preferred hosts for such systems contain
chromosomal copies of DNA encoding T7 RNA polymerase operably
linked to an inducible promoter, such as the lacUV promoter (see
U.S. Pat. No. 4,952,496). Such hosts include, but are not limited
to, lysogens E. coli strains HMS174(DE3)pLysS, BL21(DE3)pLysS,
HMS174(DE3) and BL21(DE3). Strain BL21(DE3) is preferred. The pLys
strains provide low levels of T7 lysozyme, a natural inhibitor of
T7 RNA polymerase.
[0454] The DNA molecules provided may also contain a gene coding
for a repressor protein. The repressor protein is capable of
repressing the transcription of a promoter that contains sequences
of nucleotides to which the repressor protein binds. The promoter
can be derepressed by altering the physiological conditions of the
cell. For example, the alteration can be accomplished by adding to
the growth medium a molecule that inhibits the ability to interact
with the operator or with regulatory proteins or other regions of
the DNA or by altering the temperature of the growth media.
Preferred repressor proteins include, but are not limited to the E.
coli lad repressor responsive to IPTG induction, the temperature
sensitive .lamda. cI857 repressor, and the like. The E. coli lad
repressor is preferred.
[0455] In general, recombinant constructs of the subject invention
will also contain elements necessary for transcription and
translation. In particular, such elements are preferred where the
recombinant expression construct containing nucleic acid sequences
encoding binding domain-immunoglobulin fusion proteins is intended
for expression in a host cell or organism. In certain embodiments
of the present invention, cell type preferred or cell type specific
expression of a cell binding domain-immunoglobulin fusion encoding
gene may be achieved by placing the gene under regulation of a
promoter. The choice of the promoter will depend upon the cell type
to be transformed and the degree or type of control desired.
Promoters can be constitutive or active and may further be cell
type specific, tissue specific, individual cell specific, event
specific, temporally specific or inducible. Cell-type specific
promoters and event type specific promoters are preferred. Examples
of constitutive or nonspecific promoters include the SV40 early
promoter (U.S. Pat. No. 5,118,627), the SV40 late promoter (U.S.
Pat. No. 5,118,627), CMV early gene promoter (U.S. Pat. No.
5,168,062), and adenovirus promoter. In addition to viral
promoters, cellular promoters are also amenable within the context
of this invention. In particular, cellular promoters for the
so-called housekeeping genes are useful. Viral promoters are
preferred, because generally they are stronger promoters than
cellular promoters. Promoter regions have been identified in the
genes of many eukaryotes including higher eukaryotes, such that
suitable promoters for use in a particular host can be readily
selected by those skilled in the art.
[0456] Inducible promoters may also be used. These promoters
include MMTV LTR (PCT WO 91/13160), inducible by dexamethasone;
metallothionein promoter, inducible by heavy metals; and promoters
with cAMP response elements, inducible by cAMP. By using an
inducible promoter, the nucleic acid sequence encoding a binding
domain-immunoglobulin fusion protein may be delivered to a cell by
the subject invention expression construct and will remain
quiescent until the addition of the inducer. This allows further
control on the timing of production of the gene product.
[0457] Event-type specific promoters are active or up regulated
only upon the occurrence of an event, such as tumorigenicity or
viral infection. The HIV LTR is a well-known example of an
event-specific promoter. The promoter is inactive unless the tat
gene product is present, which occurs upon viral infection. Some
event-type promoters are also tissue-specific.
[0458] Additionally, promoters that are coordinately regulated with
a particular cellular gene may be used. For example, promoters of
genes that are coordinately expressed may be used when expression
of a particular binding construct of the invention, for example, a
binding domain-immunoglobulin fusion protein-encoding gene is
desired in concert with expression of one or more additional
endogenous or exogenously introduced genes. This type of promoter
is especially useful when one knows the pattern of gene expression
relevant to induction of an immune response in a particular tissue
of the immune system, so that specific immunocompetent cells within
that tissue may be activated or otherwise recruited to participate
in the immune response.
[0459] In addition to the promoter, repressor sequences, negative
regulators, or tissue-specific silencers may be inserted to reduce
non-specific expression of binding domain-immunoglobulin fusion
protein encoding genes in certain situations, such as, for example,
a host that is transiently immunocompromised as part of a
therapeutic strategy. Multiple repressor elements may be inserted
in the promoter region. Repression of transcription is independent
on the orientation of repressor elements or distance from the
promoter. One type of repressor sequence is an insulator sequence.
Such sequences inhibit transcription (Dunaway et al., 1997 Mol Cell
Biol 17: 182-9; Gdula et al., 1996 Proc Natl Acad Sci USA
93:9378-83, Chan et al., 1996 J Virol 70: 5312-28; Scott and Geyer,
1995 EMBO J. 14:6258-67; Kalos and Fournier, 1995 Mol Cell Biol
15:198-207; Chung et al., 1993 Cell 74: 505-14) and will silence
undesired background transcription.
[0460] Repressor elements have also been identified in the promoter
regions of the genes for type II (cartilage) collagen, choline
acetyltransferase, albumin (Hu et al., 1992 J. Cell Growth Differ.
3(9):577-588), phosphoglycerate kinase (PGK-2) (Misuno et al., 1992
Gene 119(2):293-297), and in the
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene.
(Lemaigre et al., Mol. Cell. Biol. 11(2):1099-1106). Furthermore,
the negative regulatory element Tse-1 has been identified in a
number of liver specific genes, and has been shown to block cAMP
response element(CRE)-mediated induction of gene activation in
hepatocytes. (Boshart et al., 1990 Cell 61(5):905-916,).
[0461] In preferred embodiments, elements that increase the
expression of the desired product are incorporated into the
construct. Such elements include internal ribosome binding sites
(IRES; Wang and Siddiqui, 1995 Curr. Top. Microbiol. Immunol
203:99; Ehrenfeld and Semler, 1995 Curr. Top. Microbiol. Immunol.
203:65; Rees et al., 1996 Biotechniques 20:102; Sugimoto et al.,
1994 Biotechnology 12:694). IRES increase translation efficiency.
As well, other sequences may enhance expression. For some genes,
sequences especially at the 5' end inhibit transcription and/or
translation. These sequences are usually palindromes that can form
hairpin structures. Any such sequences in the nucleic acid to be
delivered are generally deleted. Expression levels of the
transcript or translated product are assayed to confirm or
ascertain which sequences affect expression. Transcript levels may
be assayed by any known method, including Northern blot
hybridization, RNase probe protection and the like. Protein levels
may be assayed by any known method, including ELISA, western blot,
immunocytochemistry or other well-known techniques.
[0462] Other elements may be incorporated into the constructs of
the invention, for example, into binding domain-immunoglobulin
fusion protein encoding constructs of the present invention. In
preferred embodiments, the construct includes a transcription
terminator sequence, including a polyadenylation sequence, splice
donor and acceptor sites, and an enhancer. Other elements useful
for expression and maintenance of the construct in mammalian cells
or other eukaryotic cells may also be incorporated (e.g., origin of
replication). Because the constructs are conveniently produced in
bacterial cells, elements that are necessary for, or that enhance,
propagation in bacteria are incorporated. Such elements include an
origin of replication, a selectable marker and the like.
[0463] As provided herein, an additional level of controlling the
expression of nucleic acids encoding constructs of the invention,
for example, binding domain-immunoglobulin fusion proteins,
delivered to cells for gene therapy, for example, may be provided
by simultaneously delivering two or more differentially regulated
nucleic acid constructs. The use of such a multiple nucleic acid
construct approach may permit coordinated regulation of an immune
response such as, for example, spatiotemporal coordination that
depends on the cell type and/or presence of another expressed
encoded component. Those familiar with the art will appreciate that
multiple levels of regulated gene expression may be achieved in a
similar manner by selection of suitable regulatory sequences,
including but not limited to promoters, enhancers and other well
known gene regulatory elements.
[0464] The present invention also relates to vectors, and to
constructs prepared from known vectors that include nucleic acids
of the present invention, and in particular to "recombinant
expression constructs", including any of various known constructs,
including delivery constructs, useful for gene therapy, that
include any nucleic acids encoding, for example, binding
domain-immunoglobulin fusion proteins and polypeptides according to
the invention as provided herein; to host cells which are
genetically engineered with vectors and/or other constructs of the
invention and to methods of administering expression or other
constructs comprising nucleic acid sequences encoding, for example,
binding domain-immunoglobulin fusion polypeptides and fusion
proteins of the invention, or fragments or variants thereof, by
recombinant techniques.
[0465] Various constructs of the invention, including for example,
binding domain-immunoglobulin fusion proteins, can be expressed in
virtually any host cell, including in vivo host cells in the case
of use for gene therapy, under the control of appropriate
promoters, depending on the nature of the construct (e.g., type of
promoter, as described above), and on the nature of the desired
host cell (e.g., whether postmitotic terminally differentiated or
actively dividing; e.g., whether the expression construct occurs in
host cell as an episome or is integrated into host cell
genome).
[0466] Appropriate cloning and expression vectors for use with
prokaryotic and eukaryotic hosts are described, for example, by
Sambrook, et al., Molecular Cloning: A Laboratory Manual, Second
Edition, Cold Spring Harbor, N.Y., (1989); as noted herein, in
particularly preferred embodiments of the invention, recombinant
expression is conducted in mammalian cells that have been
transfected or transformed with the subject invention recombinant
expression construct. See also, for example, Machida, Calif.,
"Viral Vectors for Gene Therapy Methods and Protocols"; Wolff, J A,
"Gene Therapeutics: Methods and Applications of Direct Gene
Transfer" (Birkhauser 1994); Stein, U and Walther, W (eds. P, "Gene
Therapy of Cancer: Methods and Protocols" (Humana Press 2000);
Robbins, PD (ed.), "Gene Therapy Protocols" (Humana Press 1997);
Morgan, J R (ed.), "Gene Therapy Protocols" (Humana Press 2002);
Meager, A (ed.), "Gene Therapy Technologies, Applications and
Regulations: From Laboratory to Clinic" (John Wiley & Sons Inc.
1999); MacHida, C A and Constant, J G, "Viral Vectors for Gene
Therapy: Methods and Protocols" (Humana Press 2002); "New Methods
Of Gene Therapy For Genetic Metabolic Diseases NIH Guide," Volume
22, Number 35, Oct. 1, 1993. See also recent U.S. patents relating
to gene therapy, including vaccines, which include U.S. Pat. Nos.
6,384,210 ("Solvent for biopolymer synthesis, solvent microdroplets
and methods of use"); 6,384,203 ("Family of immunoregulators
designated leukocyte immunoglobulin-like receptors (LIR)");
6,384,202 ("Cell-specific active compounds regulated by the cell
cycle"); 6,384,018 ("Polynucleotide tuberculosis vaccine");
6,383,814 ("Cationic amphiphiles for intracellular delivery of
therapeutic molecules"); 6,383,811 ("Polyampholytes for delivering
polyions to a cell"); 6,383,795 ("Efficient purification of
adenovirus"); 6,383,794 ("Methods of producing high titer
recombinant adeno-associated virus"); 6,383,785 ("Self-enhancing,
pharmacologically controllable expression systems"); 6,383,753
("Yeast mammalian regulators of cell proliferation"); 6,383,746
("Functional promoter for CCR5"); 6,383,743 ("Method for serial
analysis of gene expression"); 6,383,738 ("Herpes simplex virus ORF
P is a repressor of viral protein synthesis"); 6,383,737 ("Human
oxalyl-CoA Decarboxylase"); 6,383,733 ("Methods of screening for
pharmacologically active compounds for the treatment of tumour
diseases"); 6,383,522 ("Toxicity reduced composition containing an
anti-neoplastic agent and a shark cartilage extract"); 6,383,512
("Vesicular complexes and methods of making and using the same");
6,383,481 ("Method for transplantation of hemopoietic stem cells");
6,383,478 ("Polymeric encapsulation system promoting
angiogenesis"); 6,383,138 ("Method for transdermal sampling of
analytes"); 6,380,382 ("Gene encoding a protein having diagnostic,
preventive, therapeutic, and other uses"); 6,380,371 ("Endoglycan:
a novel protein having selectin ligand and chemokine presentation
activity"); 6,380,369 ("Human DNA mismatch repair proteins");
6,380,362 ("Polynucleotides, polypeptides expressed by the
polynucleotides and methods for their use"); 6,380,170 ("Nucleic
acid construct for the cell cycle regulated expression of
structural genes"); 6,380,169 ("Metal complex containing
oligonucleoside cleavage compounds and therapies"); 6,379,967
("Herpesvirus saimiri as viral vector"); 6,379,966 ("Intravascular
delivery of non-viral nucleic acid protease proteins, and uses
thereof").
[0467] Typically, for example, expression constructs are derived
from plasmid vectors. One preferred construct is a modified pNASS
vector (Clontech, Palo Alto, Calif.), which has nucleic acid
sequences encoding an ampicillin resistance gene, a polyadenylation
signal and a T7 promoter site. Other suitable mammalian expression
vectors are well known (see, e.g., Ausubel et al., 1995; Sambrook
et al., supra; see also, e.g., catalogues from Invitrogen, San
Diego, Calif.; Novagen, Madison, Wis.; Pharmacia, Piscataway, N.J.;
and others). Presently preferred constructs may be prepared that
include a dihydrofolate reductase (DHFR) encoding sequence under
suitable regulatory control, for promoting enhanced production
levels of the binding domain-immunoglobulin fusion protei, which
levels result from gene amplification following application of an
appropriate selection agent (e.g., methetrexate).
[0468] Generally, recombinant expression vectors will include
origins of replication and selectable markers permitting
transformation of the host cell, and a promoter derived from a
highly-expressed gene to direct transcription of a downstream
structural sequence, as described above. The heterologous
structural sequence is assembled in appropriate phase with
translation initiation and termination sequences. Thus, for
example, the binding domain-immunoglobulin fusion protein encoding
nucleic acids as provided herein may be included in any one of a
variety of expression vector constructs as a recombinant expression
construct for expressing a binding domain-immunoglobulin fusion
polypeptide in a host cell. In certain preferred embodiments the
constructs are included in formulations that are administered in
vivo. Such vectors and constructs include chromosomal,
nonchromosomal and synthetic DNA sequences, e.g., derivatives of
SV40; bacterial plasmids; phage DNA; yeast plasmids; vectors
derived from combinations of plasmids and phage DNA, viral DNA,
such as vaccinia, adenovirus, fowl pox virus, and pseudorabies, or
replication deficient retroviruses as described below. However, any
other vector may be used for preparation of a recombinant
expression construct, and in preferred embodiments such a vector
will be replicable and viable in the host.
[0469] The appropriate DNA sequence(s) may be inserted into a
vector, for example, by a variety of procedures. In general, a DNA
sequence is inserted into an appropriate restriction endonuclease
site(s) by procedures known in the art. Standard techniques for
cloning, DNA isolation, amplification and purification, for
enzymatic reactions involving DNA ligase, DNA polymerase,
restriction endonucleases and the like, and various separation
techniques are those known and commonly employed by those skilled
in the art. A number of standard techniques are described, for
example, in Ausubel et al. (1993 Current Protocols in Molecular
Biology, Greene Publ. Assoc. Inc. & John Wiley & Sons,
Inc., Boston, Mass.); Sambrook et al. (1989 Molecular Cloning,
Second Ed., Cold Spring Harbor Laboratory, Plainview, N.Y.);
Maniatis et al. (1982 Molecular Cloning, Cold Spring Harbor
Laboratory, Plainview, N.Y.); Glover (Ed.) (1985 DNA Cloning Vol. I
and II, IRL Press, Oxford, UK); Hames and Higgins (Eds.), (1985
Nucleic Acid Hybridization, IRL Press, Oxford, UK); and
elsewhere.
[0470] The DNA sequence in the expression vector is operatively
linked to at least one appropriate expression control sequence(s)
(e.g., a constitutive promoter or a regulated promoter) to direct
mRNA synthesis. Representative examples of such expression control
sequences include promoters of eukaryotic cells or their viruses,
as described above. Promoter regions can be selected from any
desired gene using CAT (chloramphenicol transferase) vectors or
other vectors with selectable markers. Eukaryotic promoters include
CMV immediate early, HSV thymidine kinase, early and late SV40,
LTRs from retrovirus, and mouse metallothionein-I. Selection of the
appropriate vector and promoter is well within the level of
ordinary skill in the art, and preparation of certain particularly
preferred recombinant expression constructs comprising at least one
promoter or regulated promoter operably linked to a nucleic acid
encoding an binding domain-immunoglobulin fusion polypeptide is
described herein.
[0471] Transcription of the DNA encoding proteins and polypeptides
included within the present invention by higher eukaryotes may be
increased by inserting an enhancer sequence into the vector.
Enhancers are cis-acting elements of DNA, usually about from 10 to
300 by that act on a promoter to increase its transcription.
Examples including the SV40 enhancer on the late side of the
replication origin by 100 to 270, a cytomegalovirus early promoter
enhancer, the polyoma enhancer on the late side of the replication
origin, and adenovirus enhancers.
[0472] Gene therapy is the use of genetic material to treat
disease. It comprises strategies to replace defective genes or add
new genes to cells and/or tissues, and is being developed for
application in the treatment of cancer, the correction of metabolic
disorders and in the field of immunotherapy. Gene therapies of the
invention include the use of various constructs of the invention,
with or without a separate carrier or delivery vehicle or
constructs, for treatment of the diseases, disorders, and/or
conditions noted herein. Such constructs may also be used as
vaccines for treatment or prevention of the diseases, disorders,
and/or conditions noted herein. DNA vaccines, for example, make use
of polynucleotides encoding immunogenic protein and nucleic acid
determinants to stimulate the immune system against pathogens or
tumor cells. Such strategies can stimulate either acquired or
innate immunity or can involve the modification of immune function
through cytokine expression. In vivo gene therapy involves the
direct injection of genetic material into a patient or animal model
of human disease. Vaccines and immune modulation are systemic
therapies. With tissue-specific in vivo therapies, such as those
that aim to treat cancer, localized gene delivery and/or
expression/targeting systems are preferred. Diverse gene therapy
vectors have been designed to target specific tissues, and
procedures have been developed to physically target specific
tissues, for example, using catheter-based technologies, all of
which are contemplated herein. Ex vivo approaches to gene therapy
are also contemplated herein and involve the removal, genetic
modification, expansion and re-administration of a patient's own
cells. Examples include bone marrow transplantation for cancer
treatment or the genetic modivation of lymphoid progenitor cells.
Ex vivo gene therapy is preferably applied to the treatment of
cells that are easily accessible and can survive in culture during
the gene transfer process (such as blood or skin cells).
[0473] Useful gene therapy vectors include adenoviral vectors,
lentiviral vectors, Adeno-associated virus (AAV) vectors, Herpes
Simplex Virus (Hsv) vectors, and retroviral vectors. Gene therapies
may also be carried out using "naked DNA," lipsome-based delivery,
lipid-based delivery (including DNA attached to positively charged
lipids), and electroporation.
[0474] As provided herein, in certain embodiments, including but
not limited to gene therapy embodiments, the vector may be a viral
vector such as, for example, a retroviral vector. Miller et al.,
1989 BioTechniques 7:980; Coffin and Varmus, 1996 Retroviruses,
Cold Spring Harbor Laboratory Press, NY. For example, retroviruses
from which the retroviral plasmid vectors may be derived include,
but are not limited to, Moloney Murine Leukemia Virus, spleen
necrosis virus, retroviruses such as Rous Sarcoma Virus, Harvey
Sarcoma virus, avian leukosis virus, gibbon ape leukemia virus,
human immunodeficiency virus, adenovirus, Myeloproliferative
Sarcoma Virus, and mammary tumor virus.
[0475] Retroviruses are RNA viruses that can replicate and
integrate into the genome of a host cell via a DNA intermediate.
This DNA intermediate, or provirus, may be stably integrated into
the host cell DNA. According to certain embodiments of the present
invention, an expression construct may comprise a retrovirus into
which a foreign gene that encodes a foreign protein is incorporated
in place of normal retroviral RNA. When retroviral RNA enters a
host cell coincident with infection, the foreign gene is also
introduced into the cell, and may then be integrated into host cell
DNA as if it were part of the retroviral genome. Expression of this
foreign gene within the host results in expression of the foreign
protein.
[0476] Most retroviral vector systems that have been developed for
gene therapy are based on murine retroviruses. Such retroviruses
exist in two forms, as free viral particles referred to as virions,
or as proviruses integrated into host cell DNA. The virion form of
the virus contains the structural and enzymatic proteins of the
retrovirus (including the enzyme reverse transcriptase), two RNA
copies of the viral genome, and portions of the source cell plasma
membrane containing viral envelope glycoprotein. The retroviral
genome is organized into four main regions: the Long Terminal
Repeat (LTR), which contains cis-acting elements necessary for the
initiation and termination of transcription and is situated both 5'
and 3' of the coding genes, and the three coding genes gag, pol,
and env. These three genes gag, pol, and env encode, respectively,
internal viral structures, enzymatic proteins (such as integrase),
and the envelope glycoprotein (designated gp70 and p15e) which
confers infectivity and host range specificity of the virus, as
well as the "R" peptide of undetermined function.
[0477] Separate packaging cell lines and vector producing cell
lines have been developed because of safety concerns regarding the
uses of retroviruses, including their use in expression constructs
as provided by the present invention. Briefly, this methodology
employs the use of two components, a retroviral vector and a
packaging cell line (PCL). The retroviral vector contains long
terminal repeats (LTRs), the foreign DNA to be transferred and a
packaging sequence (y). This retroviral vector will not reproduce
by itself because the genes that encode structural and envelope
proteins are not included within the vector genome. The PCL
contains genes encoding the gag, pol, and env proteins, but does
not contain the packaging signal "y". Thus, a PCL can only form
empty virion particles by itself. Within this general method, the
retroviral vector is introduced into the PCL, thereby creating a
vector-producing cell line (VCL). This VCL manufactures virion
particles containing only the retroviral vector's (foreign) genome,
and therefore has previously been considered to be a safe
retrovirus vector for therapeutic use.
[0478] "Retroviral vector construct" refers to an assembly that is,
within preferred embodiments of the invention, capable of directing
the expression of a sequence(s) or gene(s) of interest, such as
binding domain-immunoglobulin fusion encoding nucleic acid
sequences. Briefly, the retroviral vector construct must include a
5' LTR, a tRNA binding site, a packaging signal, an origin of
second strand DNA synthesis and a 3' LTR. A wide variety of
heterologous sequences may be included within the vector construct,
including for example, sequences which encode a protein (e.g.,
cytotoxic protein, disease-associated antigen, immune accessory
molecule, or replacement gene), or which are useful as a molecule
itself (e.g., as a ribozyme or antisense sequence).
[0479] Retroviral vector constructs of the present invention may be
readily constructed from a wide variety of retroviruses, including
for example, B, C, and D type retroviruses as well as spumaviruses
and lentiviruses (see, e.g., RNA Tumor Viruses, Second Edition,
Cold Spring Harbor Laboratory, 1985). Such retroviruses may be
readily obtained from depositories or collections such as the
American Type Culture Collection ("ATCC"; Rockville, Md.), or
isolated from known sources using commonly available techniques.
Any of the above retroviruses may be readily utilized in order to
assemble or construct retroviral vector constructs, packaging
cells, or producer cells of the present invention given the
disclosure provided herein, and standard recombinant techniques
(e.g., Sambrook et al, Molecular Cloning: A Laboratory Manual, 2d
ed., Cold Spring Harbor Laboratory Press, 1989; Kunkle, 1985 PNAS
82:488).
[0480] Suitable promoters for use in viral vectors generally may
include, but are not limited to, the retroviral LTR; the SV40
promoter; and the human cytomegalovirus (CMV) promoter described in
Miller, et al., 1989 Biotechniques 7:980-990, or any other promoter
(e.g., cellular promoters such as eukaryotic cellular promoters
including, but not limited to, the histone, pol III, and
.beta.-actin promoters). Other viral promoters that may be employed
include, but are not limited to, adenovirus promoters, thymidine
kinase (TK) promoters, and B19 parvovirus promoters. The selection
of a suitable promoter will be apparent to those skilled in the art
from the teachings contained herein, and may be from among either
regulated promoters or promoters as described above.
[0481] As described above, the retroviral plasmid vector is
employed to transduce packaging cell lines to form producer cell
lines. Examples of packaging cells which may be transfected
include, but are not limited to, the PE501, PA317, .psi.-2,
.psi.-AM, PA12, T19-14X, VT-19-17-H2, .psi.CRE, .psi.CRIP, GP+E-86,
GP+envAm12, and DAN cell lines as described in Miller, Human Gene
Therapy, 1:5-14 (1990). The vector may transduce the packaging
cells through any means known in the art. Such means include, but
are not limited to, electroporation, the use of liposomes, and
CaPO.sub.4 precipitation. In one alternative, the retroviral
plasmid vector may be encapsulated into a liposome, or coupled to a
lipid, and then administered to a host.
[0482] The producer cell line generates infectious retroviral
vector particles that include the nucleic acid sequence(s) encoding
the binding domain-immunoglobulin fusion polypeptides or fusion
proteins. Such retroviral vector particles then may be employed, to
transduce eukaryotic cells, either in vitro or in vivo. The
transduced eukaryotic cells will express the nucleic acid
sequence(s) encoding the binding domain-immunoglobulin fusion
polypeptide or fusion protein. Eukaryotic cells which may be
transduced include, but are not limited to, embryonic stem cells,
as well as hematopoietic stem cells, hepatocytes, fibroblasts,
circulating peripheral blood mononuclear and polymorphonuclear
cells including myelomonocytic cells, lymphocytes, myoblasts,
tissue macrophages, dendritic cells, Kupffer cells, lymphoid and
reticuloendothelia cells of the lymph nodes and spleen,
keratinocytes, endothelial cells, and bronchial epithelial
cells.
[0483] As another example of an embodiment of the invention in
which a viral vector is used to prepare, for example, a recombinant
binding domain-immunoglobulin fusion expression construct, in one
preferred embodiment, host cells transduced by a recombinant viral
construct directing the expression of binding domain-immunoglobulin
fusion polypeptides or fusion proteins may produce viral particles
containing expressed binding domain-immunoglobulin fusion
polypeptides or fusion proteins that are derived from portions of a
host cell membrane incorporated by the viral particles during viral
budding.
[0484] In another aspect, the present invention relates to host
cells containing the herein described nucleic acid constructs, such
as, for example, recombinant binding domain-immunoglobulin fusion
expression constructs. Host cells are genetically engineered
(transduced, transformed or transfected) with the vectors and/or
expression constructs of this invention that may be, for example, a
cloning vector, a shuttle vector, or an expression construct. The
vector or construct may be, for example, in the form of a plasmid,
a viral particle, a phage, etc. The engineered host cells can be
cultured in conventional nutrient media modified as appropriate for
activating promoters, selecting transformants or amplifying
particular genes such as genes encoding binding
domain-immunoglobulin fusion polypeptides or binding
domain-immunoglobulin fusion fusion proteins. The culture
conditions for particular host cells selected for expression, such
as temperature, pH and the like, will be readily apparent to the
ordinarily skilled artisan.
[0485] The host cell for production or expression of a construct of
the invention, for example, can be a higher eukaryotic cell, such
as a mammalian cell, or a lower eukaryotic cell, such as a yeast
cell, or the host cell can be a prokaryotic cell, such as a
bacterial cell. Representative examples of appropriate host cells
according to the present invention include, but need not be limited
to, bacterial cells, such as E. coli, Streptomyces, Salmonella
tvphimurium; fungal cells, such as yeast; insect cells, such as
Drosophila S2 and Spodoptera Sf9; animal cells, such as CHO, COS or
293 cells; adenoviruses; plant cells, or any suitable cell already
adapted to in vitro propagation or so established de novo. The
selection of an appropriate host is deemed to be within the scope
of those skilled in the art from the teachings herein.
[0486] Various mammalian cell culture systems can also be employed
to express recombinant protein. Examples of mammalian expression
systems include the COS-7 lines of monkey kidney fibroblasts,
described by Gluzman, 1981 Cell 23:175, and other cell lines
capable of expressing a compatible vector, for example, the C127,
3T3, CHO, HeLa and BHK cell lines. Mammalian expression vectors
will comprise an origin of replication, a suitable promoter and
enhancer, and also any necessary ribosome binding sites,
polyadenylation site, splice donor and acceptor sites,
transcriptional termination sequences, and 5' flanking
nontranscribed sequences, for example as described herein regarding
the preparation of binding domain-immunoglobulin fusion expression
constructs. DNA sequences derived from the SV40 splice, and
polyadenylation sites may be used to provide the required
nontranscribed genetic elements. Introduction of the construct into
the host cell can be effected by a variety of methods with which
those skilled in the art will be familiar, including but not
limited to, for example, calcium phosphate transfection,
DEAE-Dextran mediated transfection, or electroporation (Davis et
al., 1986 Basic Methods in Molecular Biology).
[0487] The present invention constructs, for example, binding
domain-immunoglobulin fusion proteins, or compositions comprising
one or more polynucleotides encoding same as described herein (for
example, to be administered under conditions and for a time
sufficient to permit expression of a binding domain-immunoglobulin
fusion protein in a host cell in vivo or in vitro, for gene
therapy, for example, among other things), may be formulated into
pharmaceutical compositions for administration according to well
known methodologies. Pharmaceutical compositions generally comprise
one or more recombinant expression constructs, and/or expression
products of such constructs, in combination with a pharmaceutically
acceptable carrier, excipient or diluent. Such carriers will be
nontoxic to recipients at the dosages and concentrations employed.
For nucleic acid-based formulations, or for formulations comprising
expression products of the subject invention recombinant
constructs, about 0.01 .mu.g/kg to about 100 mg/kg body weight will
be adminstered, for example, typically by the intradermal,
subcutaneous, intramuscular or intravenous route, or by other
routes. A preferred dosage, for example, is about 1 .mu.g/kg to
about 1 mg/kg, with about 5 .mu.g/kg to about 200 .mu.g/kg
particularly preferred. It will be evident to those skilled in the
art that the number and frequency of administration will be
dependent upon the response of the host. "Pharmaceutically
acceptable carriers" for therapeutic use are well known in the
pharmaceutical art, and are described, for example, in Remingtons
Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro edit.
1985). For example, sterile saline and phosphate-buffered saline at
physiological pH may be used. Preservatives, stabilizers, dyes and
even flavoring agents may be provided in the pharmaceutical
composition. For example, sodium benzoate, sorbic acid and esters
of p-hydroxybenzoic acid may be added as preservatives. Id. at
1449. In addition, antioxidants and suspending agents may be used.
Id.
[0488] "Pharmaceutically acceptable salt" refers to salts of the
compounds of the present invention derived from the combination of
such compounds and an organic or inorganic acid (acid addition
salts) or an organic or inorganic base (base addition salts). The
compounds of the present invention may be used in either the free
base or salt forms, with both forms being considered as being
within the scope of the present invention.
[0489] The pharmaceutical compositions that contain one or more
nucleic acid constructs of the invention, for example, binding
domain-immunoglobulin fusion protein encoding constructs (or their
expressed products) may be in any form that allows for the
composition to be administered to a patient. For example, the
composition may be in the form of a solid, liquid or gas (aerosol).
Typical routes of administration include, without limitation, oral,
topical, parenteral (e.g., sublingually or buccally), sublingual,
rectal, vaginal, and intranasal. The term parenteral as used herein
includes subcutaneous injections, intravenous, intramuscular,
intrasternal, intracavernous, intrathecal, intrameatal,
intraurethral injection or infusion techniques. The pharmaceutical
composition is formulated so as to allow the active ingredients
contained therein to be bioavailable upon administration of the
composition to a patient. Compositions that will be administered to
a patient take the form of one or more dosage units, where for
example, a tablet may be a single dosage unit, and a container of
one or more compounds of the invention in aerosol form may hold a
plurality of dosage units.
[0490] For oral administration, an excipient and/or binder may be
present. Examples are sucrose, kaolin, glycerin, starch dextrins,
sodium alginate, carboxymethylcellulose and ethyl cellulose.
Coloring and/or flavoring agents may be present. A coating shell
may be employed.
[0491] The composition may be in the form of a liquid, e.g., an
elixir, syrup, solution, emulsion or suspension. The liquid may be
for oral administration or for delivery by injection, as two
examples. When intended for oral administration, preferred
compositions contain, in addition to one or more binding
domain-immunoglobulin fusion construct or expressed product, one or
more of a sweetening agent, preservatives, dye/colorant and flavor
enhancer. In a composition to be administered by injection, one or
more of a surfactant, preservative, wetting agent, dispersing
agent, suspending agent, buffer, stabilizer and isotonic agent, for
example, may be included.
[0492] A liquid pharmaceutical composition as used herein, whether
in the form of a solution, suspension or other like form, may
include one or more of the following adjuvants: sterile diluents
such as water for injection, saline solution, preferably
physiological saline, Ringer's solution, isotonic sodium chloride,
fixed oils such as synthetic mono or digylcerides which may serve
as the solvent or suspending medium, polyethylene glycols,
glycerin, propylene glycol or other solvents; antibacterial agents
such as benzyl alcohol or methyl paraben; antioxidants such as
ascorbic acid or sodium bisulfite; chelating agents such as
ethylenediaminetetraacetic acid; buffers such as acetates, citrates
or phosphates and agents for the adjustment of tonicity such as
sodium chloride or dextrose. The parenteral preparation can be
enclosed in ampoules, disposable syringes or multiple dose vials
made of glass or plastic. Physiological saline is a preferred
adjuvant. An injectable pharmaceutical composition is preferably
sterile.
[0493] It may also be desirable to include other components in the
preparation, such as delivery vehicles including but not limited to
aluminum salts, water-in-oil emulsions, biodegradable oil vehicles,
oil-in-water emulsions, biodegradable microcapsules, and liposomes.
Examples of immunostimulatory substances (adjuvants) for use in
such vehicles include N-acetylmuramyl-L-alanine-D-isoglutamine
(MDP), lipopoly-saccharides (LPS), glucan, IL-12, GM-CSF, gamma
interferon and IL-15.
[0494] While any suitable carrier known to those of ordinary skill
in the art may be employed in the pharmaceutical compositions of
this invention, the type of carrier will vary depending on the mode
of administration and whether a sustained release is desired. For
parenteral administration, such as subcutaneous injection, the
carrier preferably comprises water, saline, alcohol, a fat, a wax
or a buffer. For oral administration, any of the above carriers or
a solid carrier, such as mannitol, lactose, starch, magnesium
stearate, sodium saccharine, talcum, cellulose, glucose, sucrose,
and magnesium carbonate, may be employed. Biodegradable
microspheres (e.g., polylactic galactide) may also be employed as
carriers for the pharmaceutical compositions of this invention.
Suitable biodegradable microspheres are disclosed, for example, in
U.S. Pat. Nos. 4,897,268 and 5,075,109. In this regard, it is
preferable that the microsphere be larger than approximately 25
microns.
[0495] Pharmaceutical compositions may also contain diluents such
as buffers, antioxidants such as ascorbic acid, low molecular
weight (less than about 10 residues) polypeptides, proteins, amino
acids, carbohydrates including glucose, sucrose or dextrins,
chelating agents such as EDTA, glutathione and other stabilizers
and excipients. Neutral buffered saline or saline mixed with
nonspecific serum albumin are exemplary appropriate diluents.
Preferably, product is formulated as a lyophilizate using
appropriate excipient solutions (e.g., sucrose) as diluents.
[0496] As described above, the subject invention includes
compositions capable of delivering nucleic acid molecules encoding
binding domain-immunoglobulin fusion proteins. Such compositions
include recombinant viral vectors (e.g., retroviruses (see WO
90/07936, WO 91/02805, WO 93/25234, WO 93/25698, and WO 94/03622),
adenovirus (see Berkner, 1988 Biotechniques 6:616-627; L1 et al.,
1993 Hum. Gene Ther. 4:403-409; Vincent et al., Nat. Genet.
5:130-134; and Kolls et al., 1994 Proc. Natl. Acad. Sci. USA
91:215-219), pox virus (see U.S. Pat. No. 4,769,330; U.S. Pat. No.
5,017,487; and WO 89/01973)), recombinant expression construct
nucleic acid molecules complexed to a polycationic molecule (see WO
93/03709), and nucleic acids associated with liposomes (see Wang et
al., 1987 Proc. Natl. Acad. Sci. USA 84:7851). In certain
embodiments, the DNA may be linked to killed or inactivated
adenovirus (see Curiel et al., 1992 Hum. Gene Ther. 3:147-154;
Cotton et al., 1992 Proc. Natl. Acad. Sci. USA 89:6094). Other
suitable compositions include DNA-ligand (see Wu et al., 1989 J.
Biol. Chem. 264:16985-16987) and lipid-DNA combinations (see
Felgner et al., 1989 Proc. Natl. Acad. Sci. USA 84:7413-7417).
[0497] In addition to direct in vivo procedures, ex vivo procedures
may be used in which cells are removed from a host, modified, and
placed into the same or another host animal. It will be evident
that one can utilize any of the compositions noted above for
introduction of constructs of the invention, for example, binding
domain-immunoglobulin fusion proteins or of binding
domain-immunoglobulin fusion protein encoding nucleic acid
molecules into tissue cells in an ex vivo context. Protocols for
viral, physical and chemical methods of uptake are well known in
the art.
[0498] Accordingly, the present invention is useful for treating a
patient having a B cell disorder or a malignant condition, or for
treating a cell culture derived from such a patient. As used
herein, the term "patient" refers to any warm-blooded animal,
preferably a human. A patient may be afflicted with cancer or a
malignant condition, such as B cell lymphoma, or may be normal
(i.e., free of detectable disease and infection). A "cell culture"
includes any preparation amenable to ex vivo treatment, for example
a preparation containing immunocompetent cells or isolated cells of
the immune system (including, but not limited to, T cells,
macrophages, monocytes, B cells and dendritic cells). Such cells
may be isolated by any of a variety of techniques well known to
those of ordinary skill in the art (e.g., Ficoll-hypaque density
centrifugation). The cells may (but need not) have been isolated
from a patient afflicted with a B cell disorder or a malignant
condition, and may be reintroduced into a patient after
treatment.
[0499] A liquid composition intended for either parenteral or oral
administration should contain an amount of a construct of the
invention, for example, a binding domain-immunoglobulin fusion
protein encoding construct or expressed product, such that a
suitable dosage will be obtained. Typically, this amount is at
least 0.01 wt % of a binding domain-immunoglobulin fusion construct
or expressed product in the composition. When intended for oral
administration, this amount may be varied to be between 0.1 and
about 70% of the weight of the composition. Preferred oral
compositions contain between about 4% and about 50% of binding
domain-immunoglobulin fusion construct or expressed product(s).
Preferred compositions and preparations are prepared so that, for
example, a parenteral dosage unit contains between 0.01 to 1% by
weight of active compound.
[0500] The pharmaceutical composition may be intended for topical
administration, in which case the carrier may suitably comprise a
solution, emulsion, ointment, or gel base. The base, for example,
may comprise one or more of the following: petrolatum, lanolin,
polyethylene glycols, beeswax, mineral oil, diluents such as water
and alcohol, and emulsifiers and stabilizers. Thickening agents may
be present in a pharmaceutical composition for topical
administration. If intended for transdermal administration, the
composition may include a transdermal patch or iontophoresis
device. Topical formulations may contain a concentration of a
construct of the invention, for example, a binding
domain-immunoglobulin fusion construct or expressed product, of
from about 0.1 to about 10% w/v (weight per unit volume).
[0501] The composition may be intended for rectal administration,
in the form, e.g., of a suppository that will melt in the rectum
and release the drug. The composition for rectal administration may
contain an oleaginous base as a suitable nonirritating excipient.
Such bases include, without limitation, lanolin, cocoa butter and
polyethylene glycol.
[0502] In the methods of the invention, a construct of the
invention, for example, a binding domain-immunoglobulin fusion
encoding constructs or expressed product(s), may be administered
through use of insert(s), bead(s), timed-release formulation(s),
patch(es) or fast-release formulation(s).
[0503] Constructs of the invention, for example, antigen-binding
constructs of the invention, may be administered or co-administered
to an animal or patient in combination with, or at the same or
about the same time, as other compounds. In one aspect, one or more
constructs, including for example one or more antigen-binding
constructs, are administered to an animal or patient in conjunction
with one or more chemotheraputic compounds such as alkylating
agents, nucleoside analogues, and the like. The administration or
co-administration of one or more constructs, including one or more
antigen-binding constructs, of the invention and one or more
chemotheraputic agents can be used for the treatment of tumors or
cancer in an animal or patient. Exemplary cancers include, but are
not limited to, head and neck cancer, breast cancer, colorectal
cancer, gastric cancer, hepatic cancer, bladder cancer, cervical
cancer, endometrial cancer, lung cancer (non-small cell), ovarian
cancer, pancreatic cancer, prostate cancer; choriocarcinoma (lung
cancer); hairy cell leukemia, chronic lymphotic leukemia, acute
lymphocytic leukemia (breast & bladder), acute myelogenous
leukemia, meningeal leukemia, chronic myelogenous leukemia,
erythroleukemia. More commonly the cancers treated include
non-Hodgkin's lymphoma (osteogenic sarcoma, adult soft tissue
sarcoma), T-cell lymphoma, chronic lymphocytic leukaemia, slowly
growing non-Hodgkin's lymphomas, Hodgkin's lymphoma and ovarian
cancer.
[0504] Examples of an alkylating agents that can be co-administered
with one or more constructs, including one or more antigen-binding
constructs, of the invention include mechlorethamine, chlorambucil,
ifosfamide, melphalan, busulfan, carmustine, lomustine,
procarbazine, dacardazine, cisplatin, carboplatin, mitomycin C,
cyclophosphamide, ifosfamide, thiotepa, and dacarbazine, and
analogues thereof. See for example U.S. Pat. No. 3,046,301
describing the synthesis of chlorambucil, U.S. Pat. No. 3,732,340
describing the synthesis of ifosfamide, U.S. Pat. No. 3,018,302 for
the synthesis of cyclophosphamide, U.S. Pat. No. 3,032,584
describing the synthesis of melphalan, and Braunwald et al.,
"Harrison's Principles of Internal Medicine," 15th Ed.,
McGraw-Hill, New York, N.Y., pp. 536-544 (2001) for clinical
aspects of cyclophosphamide, chlorambucil, melphalan, ifosfamide,
procarbazine, hexamethylmelamine, cisplatin, and carboplatin.
Examples of nucleoside analogues, include, but are not limited to,
fludarabine pentostatin, methotrexate, fluorouracil,
fluorodeoxyuridine, CB3717, azacitidine, cytarabine, floxuridine,
mercaptopurine, 6-thioguanine, cladribine, and analogues thereof.
One example is the combination of constructs, including
antigen-binding constructs that bind CD20. This construct acts as a
chemosensitising agent and works together with chemotherapeutic
agents, such that less chemotherapeutic agents are necessary to
achieve anti-tumor or anti-cancer effects. For example, U.S. Pat.
No. 3,923,785 describing the synthesis of pentostatin, U.S. Pat.
No. 4,080,325 describing the synthesis of methotrexate, U.S. Pat.
No. 2,802,005 describing the synthesis of fluorouracil, and
Braunwald et al., "Harrison's Principles of Internal Medicine,"
15th Ed., McGraw-Hill, New York, N.Y., pp. 536-544 (2001) for
clinical aspects of methotrexate, 5-fluorouracil, cytosine
arabinoside, 6-mercaptopurine, 6-thioguanine, and fludarabine
phosphate.
[0505] In another aspect, one or more constructs, including one or
more antigen-binding constructs, of the invention can be
administered or co-administered compounds that inhibit
topoisomerase II or compounds that otherwise interact with nucleic
acids in cells. Such compounds include, for example, doxorubicin,
epirubicin, etoposide, teniposide, mitoxantrone, and analogues
thereof. In one example, this combination is used in treatment to
reduce tumor cell contamination of peripheral blood progenitor
cells (PBSC) in conjunction with high-dose chemotherapy and
autologous stem cell support (HDC-ASCT). See U.S. Pat. No.
6,586,428 to Geroni et al.
[0506] In anther aspect, one or more constructs, including one or
more antigen-binding constructs, of the invention can be
administered or co-adminstered with therapeutic drugs. For example,
Virulizin (Lorus Therapeutics), which is believed to stimulate the
release of tumour necrosis factor, TNF-alpha, by tumour cells in
vitro and stilumalate activiation of macrophage cells. This can be
used in combination with one or more constructs, including one or
more antigen-binding constructs, of the invention to increase
cancer cell apoptosis and treat various types of cancers including
Pancreatic Cancer, Malignant Melanoma, Kaposi's Sarcoma (KS), Lung
Cancer, Breast Cancer, Uterine, Ovarian and Cervical Cancer.
Another example is CpG 7909 (Coley Pharmaceutical Group), which is
believed to activate NK cells and monocytes and enhance ADCC. This
drug can be used in combination with cancer or tumor specific
constructs, including antigen-binding constructs, of the invention,
such as an anti-CD20 construct, to treat non-Hodgkin's lymphoma and
other cancers.
[0507] One or more constructs, including one or more
antigen-binding constructs, of the invention can also be combined
with angiogensis inhibitors to increase anti-tumor effects.
Angiogenisis is the growth of new blood vessels. This process
allows tumors to grow and metastasize. Inhibiting angiogeneisis can
help prevent metastasis, and stop the spread of tumors cells.
Angiogenisis inhibitors include, but are not limited to,
angiostatin, endostatin, thrombospondin, platelet factor 4,
Cartilage-derived inhibitor (CDI), retinoids, Interleukin-12,
tissue inhibitor of metalloproteinase 1, 2 and 3 (TIMP-1, TIMP-2,
and TIMP-3) and proteins that block the angiogensis signaling
cascade, such as anti-VEGF (Vascular Endothelial Growth Factor) and
IFN-alpha. Angiogenesis inhibitors can be administered or
co-administered with tumor specific constructs, including
antigen-binding constructs capable of mediating, for example, ADCC
and/or complement fixation or chemotherapy-conjugated
antigen-binding of the invention to combat various types of
cancers, for example, solid tumor cancers such as lung and breast
cancer.
[0508] In another aspect, one or more constructs, including one or
more antigen-binding constructs, of the invention can be
administered or co-administered with disease modifying
anti-rheumatic agents (DMAR agents) for the treatment of rheumatoid
arthritis, psoriasis, ulcerative colitus, systemic lupus
erythematosus (SLE), Crohn's disease, ankylosing spondylitis, and
various inflammatory disease processes. In such treatment, the
constructs, for example, antigen-binding constructs, of the
invention are commonly administered in conjunction with compounds
such as azathioprine, cyclosporin, gold, hydroxychloroquine,
methotrexate, penicallamine, sulphasalazine, and the like.
[0509] In another aspect, one or more constructs, including one or
more antigen-binding constructs, of the invention can be
administered or co-administered with agents or compounds that
counteract the biological effects of interleukin-1, including for
example interleukin-1 inhibitors and interleukin-1 receptor
antagonist. It is thought that interleukin-1 has a role in the
generation of rheumatoid arthritis (RA), inflammation, and the
destruction of joints. IL-1 inhibitors can also be used in
conjunction with the constructs, including antigen-binding
constructs, of the invention to treat arthritis, inflammatory bowel
disease, sepsis and septic shock, ischemic injury, reperfusion,
ischemic brain injury such as cerebral palsy and multiple
sclerosis. See U.S. Pat. No. 6,159,460 to Thompson et al. In
another aspect, for example, one or more constructs, including one
or more antigen-binding constructs, of the invention can be
administered or co-administered to an animal or patient in
conjunction with one or more glucocorticoids for example,
methylprednisilone, dexamethasone, hydrocortisone, and the like.
Glucocorticoids have been used to induce apoptosis and inhibit
growth, independent of ADCC and CDC. These compounds can be
combined with constructs, including antigen-binding constructs, of
the invention capable of inducing apoptosis in cancer cells. In one
example is the anti-CD20, and anti-CD40 antigen-binding constructs,
which can be used to induce apoptosis in B-cells, are combined with
glutcocorticoids to treat B-cell non-Hodgkin's lymphoma (NHL).
[0510] In another aspect, one or more constructs, including one or
more antigen-binding constructs, of the invention can be
administered or co-administered with p38 inhibitors or antagonists.
The p38 mitogen-activated protein kinase pathway is involved in a
number of cellular processes instrumental to the development of
rheumatoid arthritis. For example, the activation and infiltration
of leukocytes as well as the production of inflammatory cytokines
are p38-dependent processes.
[0511] In another aspect, one or more constructs, including one or
more antigen-binding constructs, of the invention are administered
or co-administered with compounds that promote the differentiation
and proliferation of B-cells. Cytokines such as \ interleukin-4
(IL-4) and interleukin-6 (IL-6), in additional to other biological
activities, have been shown to stimulate antibody synthesis and
secretion by activated B lympocytes. In a particular aspect of the
invention, constructs, including antigen-binding constructs that
recognize and bind CD20 are co-administered with one or more of
interleukin-4 (IL-4) and interleukin-6 (IL-6).
[0512] In another aspect one or more constructs, including one or
more antigen-binding constructs, of the invention can be
administered or co-administered with Interleukin-2 (IL-2).
Interleukin 2 (IL-2) is a lymphokine that increases production of
effector cells, such as CD4+ T-helper cells, CD8 cytotoxic cells,
antibody producing B cells, natural killer cells (NK), and
monocytes/macrophages. IL-2 helps produce T-cells, which in turn
secrete more of the IL-2 (an "autocrine loop"). IL-2 can be used to
augment antibody-dependent cell-mediated cytotoxicity (ADCC) and
immunotherapies associated with constructs of the invention. In one
example, an anti-CD20 construct of the invention and IL-2 are used
to treat patients with relapsed or refractory follicular
non-Hodgkin's lymphoma. In another example IL-2 is administered or
co-administered with HIV immunotherapies to help with T cell
recovery.
[0513] In another aspect one or more constructs, including one or
more antigen-binding constructs, of the invention can be
administered or co-administered with Interleukin-12 (IL-12). IL-12
is know to enhance cytolytic T-cell responses, promote the
development of helper T cells, enhance the activity of natural
killer (NK) cells, and induces the secretion of IFN-.gamma. in T
and NK cells. IL-12 also increases many helper and effector cells
that mediate apoptosis. In another aspect of the invention, one or
more constructs, including one or more antigen-binding constructs,
are administered or co-administeredwith IL-12 in the treatment of
an animal or patient with a tumor or cancer. For example, a
construct, including an antigen-binding construct, of the invention
that binds CD20 combined with IL-2 for thetreatment of a patient
with B-cell non-Hodgkin's lymphoma (NHL).
[0514] One or more constructs, including one or more
antigen-binding constructs, of the invention can also be combined
with immunomodulators to boost the efficacy of the antigen-binding
constructs of the invention. Immunomodulators include, but are not
limited to, Colony Stimulating Factors (CSF), Tumor necrosis
Factors (TNF), and Interferons (IFN).
[0515] CSFs can include granulocyte-macrophage CSF (GM-CSF),
granulocyte-CSF (G-CSF), and macrophage CSF (M-CSF). GM-CSF is
thought to regulate the development of neutrophils, macrophages,
monocytes and eosinophils. G-CSF has been shown to induce
neutrophil production, and M-CSF production. M-CSF has been shown
to stimulate macrophages and monocytes. The use of CSFs to treat
neutropenia in cancer patients has been long established. In one
example, constructs, including antigen-binding constructs, of the
invention can be combined with GM-CSF, G-CSF or combinations
thereof in order to accelerate recovery from neutropenia in
patients after bone marrow trans-plantation and chemotherapy.
Neutrophils play a major role in fighting microbes such as
bacterial, fungi and parasites. Patients with neutropenia are
particularly susceptible to bacterial and wide spread fungal
infections. In another example, a construct, including an antigen
binding construct, of the invention can be combined with
GM-CSF-treated neutrophils, monocytes and macrophages to increase
activity against bacteria, fungi, etc, including the dreaded
Pneumocystis carinii.
[0516] An example of an IFN is interferon alpha (IFN-.alpha.).
IFN-.alpha. is made naturally by some types of white blood cell as
part of the immune response when the body reacts to cancers or
viral infections. It has two main modes of attack, interfering with
growth and proliferation of cancer cells and it boosting the
production of killer T cells and other cells that attack cancer
cells. Interferon is also thought to facilitate cancer cells to put
out chemical signals that make them better targets for the immune
system, and has been used in recent years for several different
types of cancer, particularly kidney cancer, melanoma, multiple
myeloma, and some types of leukemia. It is also used to treat viral
infections such as hepatitis. Interferon-alpha2a, for example,
enhances ADCC and can be combined with one or more constructs,
including antigen-binding constructs, of the invention to increase
the efficiency of ADCC activity associated with the construct. In
another example, one or more constructs, including one or more
antigen-binding constructs of the invention are administered or
co-administered to an animal or patient with interferon-gamma
(IFN-.gamma.), which has been show to increase the number of
anti-CD20 antigens on B cells and bone marrow plasma cells (BMPC).
This is particularly useful for the treatment of patients with
multiple myelomas, which have a reduced expression of CD20 in their
B cells and bone marrow plasma cells (BMPC). Accordingly, the
treatment of multiple myeloma patients with constructs, including
antigen-binding constructs of the invention, in particular
constructs that bind CD20, may be usefully co-administered in
conjunction with IFN-.gamma. TNF is a class of natural chemicals
with anticancer properties. One example of a TNF is TNF-alpha.
TNF-alpha has also been shown to have synergistic effects with
IFN-gamma and IL-12. In another example, TNF can be administered or
co-administered with one or more tumor specific constructs,
including one or more antigen-binding constructs, of the invention,
and include chemotherapy-conjugated antigen binding constructs of
the invention, together with IFN-gamma, IL-12 or various
combinations thereof. TNF is also known to be an inflammatory
regulation molecule. TNF-alpha antibodies or antagonist(s) can be
combined with anti-T cell constructs, including antigen-binding
constructs, of the invention to treat patients with rheumatoid
arthritis, psoriasis, ulcerative colitus, systemic lupus
erythematosus (SLE), Crohn's disease, ankylosing spondylitis, and
various inflammatory disease processes.
[0517] In another aspect, one or more constructs, including one or
more antigen-binding constructs, of the invention can be
administered or co-administered with another antibody or
antigen-binding construct of the invention. One example is a
construct, for example, an antigen-binding construct of the
invention capable of binding CD20 combined with a construct capable
of binding CD22, CD19 or combinations thereof. This combination is
effective as a treatment for indolent and aggressive forms of
B-cell lymphomas, and acute and chronic forms of lymphatic
leukemias. See U.S. Pat. No. 6,306,393 to Goldberg. In another
example, constructs, including antigen-binding constructs, of the
invention are co-administered with other constructs such as
antigen-binding constructs of the invention that aid in mediating
apoptosis. For example, a combination of one or more constructs,
including one or more antigen-binding constructs of the invention
capable of binding CD28, CD3, CD20 or a combination thereof. The
combination of anti-CD28 and CD3 provides a method for prolonged
proliferation of T-cells. See U.S. Pat. No. 6,352,694 to June et
al. This prolonged T-cell proliferation increases the efficiency
immune dependent cytotoxicity, particularly those associated with
anti-CD20.
[0518] In another aspect, constructs, including antigen-binding
constructs, of the invention can be administered or co-administered
with one or more T-cell regulatory molecules. One example is a
combination with interleukin-12 (IL-12). The IL-12 cytokine
stimulates cell-mediated immunity, has angiostatic activity, and
possesses significant anti-tumor effects in a variety of tumor
models. IL-12 has also been shown to stimulate the production of
interferon-gamma (IFN-.gamma.). Accordingly, the treatment of
multiple myeloma patients with one or more constructs, including
one or more antigen-binding constructs, of the invention, in
particular those that bind CD20, is expected to be more efficacious
when co-administered in conjunction with IL-12. In another example,
one or more constructs, including one or more antigen-binding
constructs, of the invention can be administered or co-administered
with a binding-domain construct of the invention other protein
capable of binding CTLA-4 to enhance the anti-tumor immune
response, by inhibiting the downregulation of T-cell
activation.
[0519] In another aspect, one or more constructs, including one or
more antigen-binding constructs, of the invention can be combined
with gene therapies. In one example, a chemotherapy-conjugated
construct of the invention is administered or co-administered with
the Bcl-2 antisense oligonucleotide. Bcl-2 is associated with tumor
resistance to anti-cancer therapies, and its believed to blocking
chemotherapy-induced cell death. In another example one or more
constructs, including one or more antigen-binding constructs, of
the invention is administered or co-administered with an adenovirus
for delivery of a "suicide gene." The adenovirus inserts the gene
directly into the tumor cells, which makes these cells sensitive to
an otherwise ineffective drug. Drug treatment then destroys the
tumor cells, while leaving healthy cells untouched. However, once
therapy is complete stray cancer cells that escaped therapy can
reestablish and metastasize. Combining gene therapy with one or
more constructs, including one or more antigen-binding constructs,
will help kill stray cancer cells and minimize cancer
reoccurrence.
[0520] A similar combination can be used with palliative
(non-radical) operations to surgically remove tumors. In this
example one or more constructs, including one or more
antigen-binding constructs, of the invention can be administered
before and after surgical extractions of tumors in order to
increase the immune response and reduce the likelihood of
reoccurrence by killing any cancer cells that were not removed
during the surgery.
[0521] Another aspect combines a cancer or antigen vaccine and
T-cell regulator molecules. For example, the binding portion, for
example, an antigen-binding portion, of a construct can be specific
for a cancer cell or antigen, or a protein fragment from a cancer
cell or antigen. This can help mediate an immune response against a
particular tumor or antigen. Such constructs can be combined with
T-cell regulators to increase the efficiency of the immune
response.
[0522] In another example, one or more constructs, including one or
more antigen-binding constructs, of the invention is administered
or co-administered with retinoids. Retinoids include Vitamin A and
its derivatives, which have the ability to stop cells from dividing
and cause them to differentiate. Vitamin A is combined with an
anti-cancer construct(s), including antigen-binding construct(s),
of the invention to combat various forms of cancer.
[0523] The terms "binding construct" and "antigen-binding
construct" as used herein may refer to, for example, engineered
polypeptides, recombinant polypeptides, synthetic, semi-synthetic
or other fusion proteins that are capable of binding a target, for
example, an antigen. Antigen-binding constructs of the invention
may be used in various applications, including those within the
variety of uses to which antibodies or related immunoglobulin-type
constructs may be put. Constructs, including antigen-binding
constructs of the invention can be used in in vivo and in vitro
experiments for therapeutic, diagnostic, research, and other
purposes. Such uses include, for example, the following.
[0524] Constructs, including antigen-binding constructs of the
invention may be used for immunohistochemistry applications. For
example, they may be used for immunolocalization of a particular
antigen or group of antigens in a tissue. Tissue can be fixed and
incubated with antigen-binding constructs of interest. These
constructs can then be localized using a secondary antibody or
binding construct of the invention coupled to a label, for example,
to a gold particle or an enzyme that gives a chemical reaction,
like horseradish peroxidase or beta-galactosidase. A secondary
antibody or binding construct is frequently made that is reactive
against, for example, a portion of the primary binding construct.
Thus, for example, if the primary binding construct has a human
tail portion, the secondary antibody or binding construct could be,
for example, a rabbit anti-mouse antibody or antigen-binding
construct that has been linked to beta-galactosidase. Alternatively
the antibody or binding construct of the invention can be purified
and then conjugated to another molecule to produce a fluorescent
antibody or binding construct.
[0525] Constructs, including antigen-binding contracts of the
invention can also be used to detect the location of an antigen or
antigens on the surface of cells or to detect the location of
intracellular materials using, for example, Immunoelectron
Microscopy. Electron dense materials such as ferritin or colloidal
gold, for example, can be conjugated to an antigen-binding
construct. Scanning electron microscopy can be used to detect the
localization of the antigen/binding construct complex.
[0526] Constructs, including antigen-binding constructs of the
invention may also be used to quantitate the presence of an antigen
or antigens using one of a variety of immunoassay formats, for
example, a radioimmunoassay (RIA) format or an enzyme-linked
immunosorbent assay (ELISA) format. There are many variants of
these approaches, but those are based on a similar idea. For
example, if an antigen can be bound to a solid support or surface,
or is in solution, it can be detected by reacting it with a
specific antigen-binding construct of the invention. The presence
or amount of the construct can then be detected or quantitated by
reacting it with, for example, either a secondary antibody or a
second antigen-binding construct of the invention by incorporating
a label directly into the primary antibody. Alternatively, for
example, an antigen-binding polypeptide of the invention can be
bound to a solid surface and the antigen added. A second antibody
or antigen-binding polypeptide(s) of the invention that recognizes
a distinct epitope on the antigen can then be added and detected.
This technique is commonly referred to as a "sandwich assay", which
is frequently used to avoid problems of high background or
non-specific reactions, among other reasons.
[0527] Because the binding constructs of the invention can have
high affinity/affinities and/or selectivity/selectivities for a
particular epitope or epitopes, they can also be used as affinity
reagents, for example, in protein or antigen purification. In one
example of such a process, antigen-binding constructs of the
invention are immobilized on a suitable support, for example,
Sephadex resin or filter paper. The immobilized construct is
exposed to a sample containing, or suspected of containing, a
target protein(s) or antigen(s). The support is rinsed with a
suitable buffer that will remove unwanted materials. The support is
washed with another buffer that will release the bound protein(s)
or antigen(s).
[0528] Because particular binding constructs of the invention can
bind to proteins or other antigens with high affinity and
selectivity they can also be used as a criterion for the importance
of a particular enzyme or other macromolecule in a particular
reaction. If an antigen-binding construct of the invention can
interfere with a reaction in a solution, this will indicate that
the construct may be binding specifically to a protein or other
antigenic material involved in that reaction.
[0529] Constructs, including antigen-binding constructs of the
invention can also be used as receptor blockers or inhibitors or
antagonists.
[0530] Constructs, including antigen-binding constructs of the
invention can also be used in identifying and studying the
function(s) of proteins. If an antigen-binding construct of the
invention reacts with a specific protein, for example, that protein
can subsequently be precipitated from solution, for example.
Precipitation is typically performed by using a secondary antibody
or antigen-binding construct of the invention that links primary
complexes together. Alternatively, the complex can be removed by
reacting the solution with either protein A or, for example,
depending on the construct, an anti-Fc antibody, for example, which
has been attached to beads, for example, so that can be easily
removed form the solution.
[0531] Constructs, including antigen-binding constructs of the
invention can also be used in conjunction with gel-shift
experiments to identify specific nucleic acid-binding proteins such
as DNA-binding proteins. For example, DNA-binding proteins can be
assayed by their ability to bind with high affinity to a particular
oligonucleotide. The mobility of an oligonucleotide associated with
the protein is far different than the mobility of a free
oligonucleotide and results in a gel migration pattern and signal
that is commonly referred to as a gel shift. The addition of the
construct to the binding assay can have either of two effects. If
the construct binds to a region of a protein not involved in DNA
binding it can result in a complex that has even a slower mobility
and is detected as a greater shift in mobility (a super-shift).
Alternatively, if the construct binds to a region of the protein
involved in recognizing the DNA then it can disrupt the binding and
eliminate the shift. In either case, the data from these
experiments can serve as a criterion to identify a DNA-binding
protein, for example.
[0532] It is also possible to use constructs, including
antigen-binding constructs of the invention to detect a protein by
western blotting after fractionation by SDS-PAGE, for example. Once
fractionated proteins are transferred to a membrane such as a
nitrocellulose sheet, they are exposed to a particular
antigen-binding construct of the invention that specifically
recognizes, or recognizes to a desired degree of selectivity,
proteins immobilized to the blot. This allows particular proteins
to be identified. This approach is particularly useful if the
mobility of the protein changes during an experiment. For example,
incorporation of a phosphate or a carbohydrate, or cleavage of the
protein, results in a change in mobility that can be followed in
straightforward manner by western analysis. With appropriate
controls, this approach can be used to measure the abundance of a
protein in response to experimental manipulations.
[0533] The combination of SDS gels and immunoprecipitation can also
be extremely effective. If a particular protein can be
immunoprecipitated in a solution, both supernatant and precipitated
fractions can be separated on an SDS gel and studied using an
antigen-binding construct(s) of the invention.
[0534] Sometimes a binding construct of the invention directed
against one protein will also precipitate a second protein that
interacts with the first protein. The second protein, as well as
the first, can then be seen by staining the gel or by
autoradiography. This relationship is frequently the first
indication that a protein functions as part of a complex and it can
also be used to demonstrate a physical interaction of two proteins
that are hypothesized to interact on the basis of other evidence
(e.g., a two hybrid screen or a supressor mutation). This approach
can be combined with western blotting analysis in several extremely
effective ways.
[0535] Thus, for example, antigen-binding constructs of the
invention can be used in a combination of immunoprecipitation and
western analysis in the study, for example, of signal transduction
and protein processing. For example, an immunoprecipitated protein
can be subsequently studied by western analysis using a different
antibody or antigen-binding construct of the invention that binds
to the protein. The most useful of are those that are directed
against particular structural determinants that may be present in a
protein. Thus, an antibody or antigen-binding construct of the
invention directed against a region of the protein that undergoes
proteolytic processing can be useful to follow proteolytic
processing. Additionally, a construct of the invention or a mixture
of antigen-binding constructs of the invention that recognize
phosphorylated peptides (e.g., anti PY (phosphorylated tyrosine)
can be used to follow the extent of phosphorylation of a protein
(using western analysis) after it is precipitated, or visa versa.
Glycosylation reactions can also be followed by antigen-binding
constructs of the invention directed against a carbohydrate epitope
(or by lectins, i.e., proteins that recognize carbohydrates).
Likewise, some antigen-binding constructs of the invention can be
made that specifically recognize a phosphorylated epitope, for
example, that will recognize a tyrosine or a serine residue after
phosphorylation, but will not bind (or detectably bind) the epitope
in the absence of phosphate. This approach can be used to determine
the phosphorylation state of a particular protein. For example, the
phosphorylation of CREB (the cAMP response element binding protein)
can be followed by an antibody that specifically recognizes an
epitope in a way that is dependent on the phosphorylation of serine
133.
[0536] Constructs, including antigen-binding constructs of the
invention can also be used to screen expression libraries to
isolate candidate polynucleotides that express or present a
particular epitope, or that have a particular affinity or
expression characteristic.
[0537] Constructs, including antigen-binding constructs of the
invention that bind to a cell surface can also be used as a marker
to quantitate the fraction of cells expressing that marker using
flow cytometry. If different antigen binding constructs of the
invention/fluorescent dye combinations are used, for example, the
fraction of cells expressing several antigens can be
determined.
[0538] Constructs, including antigen-binding constructs of the
invention that function like anti-idiotype antibodies, i.e.,
antibodies against the binding domain of another antibody, can be
used in any of a number of methods in which is would be desirable
or useful to mimic the structure of an antigen. Such uses include,
for example, uses as cancer vaccines (including antigen-binding
constructs of the invention that incorporate a molecular adjuvant),
as probes for receptors, as receptor agonists, as receptor
antagonists, as receptor blockers or inhibitors, and so on.
[0539] In another aspect, constructs, including antigen-binding
constructs of the invention may bispecific and thus capable of
binding to two distinct epitopes, which may be present on the same
or different cell types.
[0540] In vivo uses of constructs of the invention, including
antigen-binding constructs, include therapy, alone or in
combination with one or more other therapies, for various diseases
including cancers as well as B-cell disorders including autoimmune
diseases. In some cases the constructs of the invention are
administered to a patient. In other cases, the construct may be
coupled to another molecule by techniques known in the art, for
example, a fluorescent molecule to aid in imaging a target, or a
therapeutic drug and/or a toxin to aid in killing a target.
[0541] For example, a labeling molecule or atom can be conjugated
or otherwise linked to the antigen-binding construct of the
invention to aid in imaging or as a diagnostic agent. These
include, but are not limited to enzymatic labels, radioisotopes or
radioactive compounds or elements, fluorescent compounds or metals,
chemiluminescent compounds and bioluminescent compounds. Thus,
binding contructs or antigen-binding constructs of the invention
can be conjugated to a drug, which allows specific drug targeting
and increased efficiency once the drug reaches the target. This
facilitates drug therapy while reducing systemic toxicity and side
effects. This allows use of drugs that would otherwise be
unacceptable when administered systemically. Dosage will depend on
the potency of the drug and the efficiency of the carrier
construct. Other examples of in vivo uses include the use of
binding constructs or antigen-binding constructs of the invention
in which a toxin is chemically linked or conjugated to an
polypeptide of the invention to form, for example, molecules that
may be termed "immunoconjugates" or "immunotoxins." Typically, for
example, such a toxin may include one or more radioisotopes (for
example, Iodine-131, Yttrium-90, Rhenium-186, Copper-67, and/or
Bishmuth-212), natural toxins, chemotherapy agents, biological
response modifiers, or any other substance that is capable of
assisting in damaging or killing a target cell, inhibiting target
cell replication, or is effective in disrupting a desired cellular
function in a target cell.
[0542] The toxin portion of the immunotoxin can be derived form
various sources. Toxins are commonly derived from plants or
bacteria, but toxins of human origin or synthetic toxins can be
used as well, for example. Examples of toxins derived from bacteria
or plants include, but are not limited to, abrin, .alpha.-sarcin,
diptheria toxin, ricin, saporin, and pseudomonas exotoxin. Examples
of mammalian enzymes include, but are not limited to, ribonucleases
(RNAse) and deoxyribonucleases. Numerous immunotoxins that may be
used with one or more constructs of the invention have been
described in the art. See, for example, U.S. Pat. No. 4,753,894 to
Frankel et al.; U.S. Pat. No. 6,099,842 to Pastan et al.; Nevelle,
et al., 1982 Immunol Rev. 62:75-91; Pastan et al., 1992 Ann Rev
Biochem 61:331-354; Chaudary et al., 1989 Nature 339:394; and Batra
et al., 1991 Mol. Cell. Biol. 11:2200. Modified toxins described
herein and those described in the various publications are also
within the scope of the instant invention.
[0543] Generally, the immunotoxins and other therapeutic agents of
this invention are administered at a concentration that is
therapeutically effective to treat or prevent a particular disease,
disorder, or condition, such as for the treatment of tumors and
malignancies, the treatment of autoimmune diseases, allergies and
inflammation, etc. This effective dosage and mode of administration
will depend on the animal or patient being treated, the disease or
condition being treated, the strength of the immunoconjugates or
immunotoxins and the efficiency of the conjugate. To accomplish
this goal, the immunotoxins may be formulated using a variety of
acceptable formulations and excipients known in the art. Typically,
for example, the immunotoxins are administered by injection, either
intravenously or intraperitoneally. Methods to accomplish this
administration are known to those of ordinary skill in the art. It
another aspect, the invention includes topically or orally
administered compositions such as an aerosol or cream or patch that
may be capable of transmission across mucous membranes.
[0544] Formulants may be added to an immunoconjugates or
immunotoxins of the invention before administration to a patients
being treated. A liquid formulation is most common, but other
formulations are within the scope of the invention. The formulants
may include for example oils, polymers, vitamins, carbohydrates,
amino acids, salts, buffers, albumin, surfactants, or bulking
agents. Carbohydrates can include sugar or sugar alcohols such as
mono, di, or polysaccharides, or water-soluble glucans. The
saccharides or glucans can include for example fructose, dextrose,
lactose, glucose, mannose, sorbose, xylose, maltose, sucrose,
dextran, pullulan, dextrin, alpha and beta cyclodextrin, soluble
starch, hydroxethyl starch and carboxymethylcellulose, or mixtures
thereof "Sugar alcohol" may be defined as a C.sub.4 to C.sub.8
hydrocarbon having an --OH group and includes, for example,
galactitol, inositol, mannitol, xylitol, sorbitol, glycerol, and
arabitol. These sugars or sugar alcohols mentioned above may be
used individually or in combination. There is no fixed limit to the
amount used as long as the sugar or sugar alcohol is soluble in the
aqueous preparation. In one aspect, the sugar or sugar alcohol
concentration is between 0.5 w/v % and 15 w/v %, typically between
1.0 w/v % and 7.0 w/v %, more typically between 2.0 and 6.0 w/v
%.
[0545] Exemplary amino acids include levorotary (L) forms of
camitine, arginine, and betaine; however, other amino acids may be
added. Commonly used polymers include polyvinylpyrrolidone (PVP)
with an average molecular weight between 2,000 and 3,000, for
example, or polyethylene glycol (PEG) with an average molecular
weight between 3,000 and 5,000, for example. A buffer can be used
in the composition to minimize pH changes in the solution before
lyophilization or after reconstitution. Any physiological buffer
may be used, but citrate, phosphate, succinate, and glutamate
buffers or mixtures thereof are more commonly utilized. The
concentration can be, for example, from 0.01 to 0.3 molar. Higher
or lower concentrations may be used.
[0546] Immunotoxins of the invention can be chemically modified by
covalent conjugation to a polymer to increase their circulating
half-life, for example. Exemplary polymers and methods to attach
them to peptides are referenced in U.S. Pat. Nos. 4,766,106 to
Katre et al.; 4,179,337 to Davis et al.; 4,495,285 to Shimizu et
al.; and 4,609,546 to Hiratani.
[0547] The following Examples are offered by way of illustration
and not by way of limitation.
Example 1
Cloning of the 2H7 Variable Regions and Construction and Sequencing
of 2H7scFv-Ig
[0548] This Example illustrates the cloning of cDNA molecules that
encode the heavy chain and light chain variable regions of the
monoclonal antibody 2H7. This Example also demonstrates the
construction, sequencing, and expression of 2H7scFv-Ig.
[0549] Prior to harvesting, cells expressing 2H7 monoclonal
antibody that specifically bound to CD20 were kept in log phase
growth for several days in RPMI 1640 media Invitrogen/Life
Technologies, Gaithersburg, Md.) supplemented with glutamine,
pyruvate, DMEM non-essential amino acids, and
penicillin-streptomycin. Cells were pelleted by centrifugation from
the culture medium, and 2.times.10.sup.7 cells were used to prepare
RNA. RNA was isolated from the 2H7-producing hybridoma cells using
the Pharmingen (San Diego, Calif.) total RNA isolation kit (Catalog
#45520K) according to the manufacturer's instructions accompanying
the kit. One microgram (1 .mu.g) of total RNA was used as template
to prepare cDNA by reverse transcription. The RNA and 300 ng random
primers were combined and denatured at 72.degree. C. for 10 minutes
prior to addition of enzyme. Superscript II reverse transcriptase
(Life Technologies) was added to the RNA plus primer mixture in a
total volume of 25 .mu.l in the presence of 5.times. second strand
buffer and 0.1 M DTT provided with the enzyme. The reverse
transcription reaction was allowed to proceed at 42.degree. C. for
one hour.
[0550] The 2H7 cDNA generated in the randomly primed reverse
transcriptase reaction and V region specific primers were used to
amplify by PCR the variable regions for the light and heavy chain
of the 2H7 antibody. The V region specific primers were designed
using the published sequence (Genbank accession numbers M17954 for
V.sub.L and M17953 for V.sub.H) as a guide. The two variable chains
were designed with compatible end sequences so that an scFv could
be assembled by ligation of the two V regions after amplification
and restriction enzyme digestion.
[0551] A (Gly.sub.4Ser).sub.3 peptide linker to be inserted between
the two V regions was incorporated by adding the extra nucleotides
to the antisense primer for the V.sub.L of 2H7. A Sac I restriction
site was also introduced at the junction between the two V regions.
The sense primer used to amplify the 2H7 V.sub.L, that included a
HindIII restriction site and the light chain leader peptide was
5'-gtc aag ctt gcc gcc atg gat ttt caa gtg cag att ttt cag c-3'
(SEQ ID NO:530). The antisense primer was 5'-gtc gtc gag ctc cca
cct cct cca gat cca cca ccg ccc gag cca ccg cca cct ttc agc tcc agc
ttg gtc cc-3' (SEQ ID NO:531). The reading frame of the V region is
indicated as a bold, underlined codon. The Hind III and Sad sites
are indicated by underlined italicized sequences.
[0552] The V.sub.H domain was amplified without a leader peptide,
but included a 5' Sad restriction site for fusion to the V.sub.L
and a BclI restriction site at the 3' end for fusion to various
tails, including the human IgG1 Fc domain and the truncated forms
of CD40 ligand, CD154. The sense primer was 5'-gct get gag ctc tca
ggc tta tct aca gca agt ctg g-3' (SEQ ID NO:532). The SacI site is
indicated in italicized and underlined font, and the reading frame
of the codon for the first amino acid of the V.sub.H domain is
indicated in bold, underlined type. The antisense primer was 5'-gtt
gtc tga tca gag acg gtg acc gtg gtc cc-3' (SEQ ID NO:533). The BclI
site is indicated in italicized, underlined type, and the last
serine of the V.sub.H domain sequence is indicated in bold,
underlined type.
[0553] The scFv-Ig was assembled by inserting the 2H7 scFv
HindIII-BclI fragment into pUC19 containing the human IgG1 hinge,
CH2, and CH3 regions, which was digested with restriction enzymes,
HindIII and BclI. After ligation, the ligation products were
transformed into DH5a bacteria. Positive clones were screened for
the properly inserted fragments using the Sad site at the
V.sub.L-V.sub.H junction of 2H7 as a diagnostic site. The
2H7scFv-Ig cDNA was subjected to cycle sequencing on a PE 9700
thermocycler using a 25-cycle program by denaturing at 96.degree.
C. for 10 seconds, annealing at 50.degree. C. for 30 seconds, and
extending at 72.degree. C. for 4 minutes. The sequencing primers
were pUC forward and reverse primers and an internal primer that
annealed to the CH2 domain human in the IgG constant region
portion. Sequencing reactions were performed using the Big Dye
Terminator Ready Sequencing Mix (PE-Applied Biosystems, Foster
City, Calif.) according to the manufacturer's instructions. Samples
were subsequently purified using Centrisep columns (Catalog
#CS-901, Princeton Separations, Adelphia, N.J.), the eluates dried
in a Savant vacuum dryer, denatured in Template Suppression Reagent
(PE-ABI), and analyzed on an ABI 310 Genetic Analyzer (PE-Applied
Biosystems). The sequence was edited, translated, and analyzed
using Vector Nti version 6.0 (Informax, North Bethesda, Md.). FIG.
1 shows the cDNA and predicted amino acid sequence of the
2H7scFv-Ig construct.
Example 2
Expression of 2H7 ScFv-Ig in Stable CHO Cell Lines
[0554] This Example illustrates expression of 2H7scFv-Ig in a
eukaryotic cell line and characterization of the expressed
2H7scFv-Ig by SDS-PAGE and by functional assays, including ADCC and
complement fixation.
[0555] The 2H7scFv-Ig HindIII-XbaI (.about.1.6 kb) fragment with
correct sequence was inserted into the mammalian expression vector
pD18, and DNA from positive clones was amplified using QIAGEN
plasmid preparation kits (QIAGEN, Valencia, Calif.). The
recombinant plasmid DNA (100 .mu.g) was then linearized in a
nonessential region by digestion with AscI, purified by phenol
extraction, and resuspended in tissue culture media, Excell 302
(Catalog #14312-79P, JRH Biosciences, Lenexa, Kans.). Cells for
transfection, CHO DG44 cells, were kept in logarithmic growth, and
10.sup.7 cells harvested for each transfection reaction. Linearized
DNA was added to the CHO cells in a total volume of 0.8 ml for
electroporation.
[0556] Stable production of the 2H7 scFv-Ig fusion protein (SEQ. ID
NO:10) was achieved by electroporation of a selectable, amplifiable
plasmid, pD18, containing the 2H7 scFv-Ig cDNA under the control of
the CMV promoter, into Chinese Hamster Ovary (CHO) cells (all cell
lines from American Type Culture Collection, Manassas, Va., unless
otherwise noted). The 2H7 expression cassette was subcloned
downstream of the CMV promoter into the vector multiple cloning
site as a .about.1.6 kb HindIII-XbaI fragment. The pD18 vector is a
modified version of pcDNA3 encoding the DHFR selectable marker with
an attenuated promoter to increase selection pressure for the
plasmid. Plasmid DNA was prepared using Qiagen maxiprep kits, and
purified plasmid was linearized at a unique AscI site prior to
phenol extraction and ethanol precipitation. Salmon sperm DNA
(Sigma-Aldrich, St. Louis, Mo.) was added as carrier DNA, and 100
.mu.g each of plasmid and carrier DNA was used to transfect
10.sup.7 CHO DG44 cells by electroporation. Cells were grown to
logarithmic phase in Excell 302 media (JRH Biosciences) containing
glutamine (4 mM), pyruvate, recombinant insulin,
penicillin-streptomycin, and 2.times.DMEM nonessential amino acids
(all from Life Technologies, Gaithersburg, Md.), hereafter referred
to as "Excell 302 complete" media. Media for untransfected cells
also contained HT (diluted from a 100.times. solution of
hypoxanthine and thymidine) (Invitrogen/Life Technologies). Media
for transfections under selection contained varying levels of
methotrexate (Sigma-Aldrich) as selective agent, ranging from 50 nM
to 5 .mu.M. Electroporations were performed at 275 volts, 950
.mu.F. Transfected cells were allowed to recover overnight in
non-selective media prior to selective plating in 96 well flat
bottom plates (Costar) at varying serial dilutions ranging from 125
cells/well to 2000 cells/well. Culture media for cell cloning was
Excell 302 complete, containing 100 nM methotrexate. Once clonal
outgrowth was sufficient, serial dilutions of culture supernatants
from master wells were screened for binding to CD20-CHO transfected
cells. The clones with the highest production of the fusion protein
were expanded into T25 and then T75 flasks to provide adequate
numbers of cells for freezing and for scaling up production of the
2H7scFvIg. Production levels were further increased in cultures
from three clones by progressive amplification in methotrexate
containing culture media. At each successive passage of cells, the
Excell 302 complete media contained an increased concentration of
methotrexate, such that only the cells that amplified the DHFR
plasmid could survive.
[0557] Supernatants were collected from CHO cells expressing the
2H7scFv-Ig, filtered through 0.2 .mu.m PES express filters
(Nalgene, Rochester, N.Y.) and were passed over a Protein A-agarose
(IPA 300 crosslinked agarose) column (Repligen, Needham, Mass.).
The column was washed with PBS, and then bound protein was eluted
using 0.1 M citrate buffer, pH 3.0. Fractions were collected and
eluted protein was neutralized using 1M Tris, pH 8.0, prior to
dialysis overnight in PBS. Concentration of the purified 2H7scFv-Ig
was determined by absorption at 280 nm. An extinction coefficient
of 1.77 was determined using the protein analysis tools in the
Vector Nti Version 6.0 Software package (Informax, North Bethesda,
Md.). This program uses the amino acid composition data to
calculate extinction coefficients.
[0558] Production levels of 2H7scFv-Ig by transfected, stable CHO
cells were analyzed by flow cytometry. Purified 2H7scFv-Ig to CHO
cells was allowed to bind to CHO cells that expressed CD20 (CD20
CHO) and analyzed by flow cytometry using a fluorescein-conjugated
anti-human IgG second step reagent (Catalog Numbers H10101 and
H10501, CalTag, Burlingame, Calif.). FIG. 2 (top) shows a standard
curve generated by titration of 2H7scFv-Ig binding to CD20 CHO. At
each concentration of 2H7scFv-Ig, the mean brightness of the
fluorescein signal in linear units is shown. Supernatants collected
from T flasks containing stable CHO cell clones expressing
2H7scFv-Ig were then allowed to bind to CD20 CHO and the binding
was analyzed by flow cytometry. The fluorescein signal generated by
2H7scFv-Ig contained in the supernatants was measured and the
2H7scFv-Ig concentration in the supernatants was calculated from
the standard curve (FIG. 2, bottom).
[0559] Purified 2H7scFv-Ig was analyzed by electrophoresis on
SDS-Polyacrylamide gels. Samples of 2H7scFv-Ig, purified by
independent Protein A Agarose column runs, were boiled in SDS
sample buffer without reduction of disulfide bonds and applied to
SDS 10% Tris-BIS gels (Catalog #NP0301, Novex, Carlsbad, Calif.).
Twenty micrograms of each purified batch was loaded on the gels.
The proteins were visualized after electrophoresis by Coomassie
Blue staining (Pierce Gel Code Blue Stain Reagent, Catalog #24590,
Pierce, Rockford, Ill.), and destaining in distilled water.
Molecular weight markers were included on the same gel
(Kaleidoscope Prestained Standards, Catalog #161-0324, Bio-Rad,
Hercules, Calif.). The results are presented in FIG. 3. The numbers
above the lanes designate independent purification batches. The
molecular weights in kilodaltons of the size markers are indicated
on the left side of the figure. Further experiments with
alternative sample preparation conditions indicated that reduction
of disulfide bonds by boiling the protein in SDS sample buffer
containing DTT or 2-mercaptoethanol caused the 2H7scFv-Ig to
aggregate.
[0560] Any number of other immunological parameters may be
monitored using routine assays that are well known in the art.
These may include, for example, antibody dependent cell-mediated
cytotoxicity (ADCC) assays, secondary in vitro antibody responses,
flow immunocytofluorimetric analysis of various peripheral blood or
lymphoid mononuclear cell subpopulations using well established
marker antigen systems, immunohistochemistry or other relevant
assays. These and other assays may be found, for example, in Rose
et al. (Eds.), Manual of Clinical Laboratory Immunology, 5.sup.th
Ed., a 1997 American Society of Microbiology, Washington, D.C.
[0561] The ability of 2H7scFv-Ig to kill CD20 positive cells in the
presence of complement was tested using B cell lines Ramos and
Bjab. Rabbit complement (Pel-Freez, Rogers, Ak.) was used in the
assay at a final dilution of 1/10. Purified 2H7scFv-Ig was
incubated with B cells and complement for 45 minutes at 37.degree.
C., followed by counting of live and dead cells by trypan blue
exclusion. The results in FIG. 4A show that in the presence of
rabbit complement, 2H7scFv-Ig lysed B cells expressing CD20.
[0562] The ability of 2H7scFv-Ig to kill CD20 positive cells in the
presence of peripheral blood mononuclear cells (PBMC) was tested by
measuring the release of .sup.51Cr from labeled Bjab cells in a
4-hour assay using a 100:1 ratio of PBMC to Bjab cells. The results
shown in FIG. 4B indicated that 2H7scFv-Ig can mediate antibody
dependent cellular cytotoxicity (ADCC) because the release of
.sup.51Cr was higher in the presence of both PBMC and 2H7scFv-Ig
than in the presence of either PBMC or 2H7scFv-Ig alone.
Example 3
Effect of Simultaneous Ligation of CD20 and CD40 on Growth of
Normal B Cells, and on CD95 Expression, and Induction of
Apoptosis
[0563] This Example illustrates the effect on cell proliferation of
cross-linking of CD20 and CD40 expressed on the cell surface.
[0564] Dense resting B cells were isolated from human tonsil by a
Percoll step gradient and T cells were removed by E-rosetting.
Proliferation of resting, dense tonsillar B cells was measured by
uptake of .sup.3[H]-thymidine during the last 12 hours of a 4-day
experiment. Proliferation was measured in quadruplicate cultures
with means and standard deviations as shown. Murine anti-human CD20
monoclonal antibody 1F5 (anti-CD20) was used alone or was
cross-linked with anti-murine .kappa. monoclonal antibody 187.1
(anti-CD20XL). CD40 activation was accomplished using soluble human
CD154 fused with murine CD8 (CD154) (Hollenbaugh et al., EMBO J.
11: 4212-21 (1992)), and CD40 cross-linking was accomplished using
anti-murine CD8 monoclonal antibody 53-6 (CD154XL). This procedure
allowed simultaneous cross-linking of CD20 and CD40 on the cell
surface. The results are presented in FIG. 5.
[0565] The effect of CD20 and CD40 cross-linking on Ramos cells, a
B lymphoma cell line, was examined. Ramos cells were analyzed for
CD95 (Fas) expression and percent apoptosis eighteen hours after
treatment (no goat anti-mouse IgG (GAM)) and/or cross-linking
(+GAM) using murine monoclonal antibodies that specifically bind
CD20 (1F5) and CD40 (G28-5). Control cells were treated with a
non-binding isotype control (64.1) specific for CD3.
[0566] Treated Ramos cells were harvested, incubated with
FITC-anti-CD95, and analyzed by flow cytometry to determine the
relative expression level of Fas on the cell surface after CD20 or
CD40 cross-linking. Data is plotted as mean fluorescence of cells
after treatment with the stimuli indicated (FIG. 6A).
[0567] Treated Ramos cells from the same experiment were harvested
and binding of annexin V was measured to indicate the percentage
apoptosis in the treated cultures. Apoptosis was measured by
binding of Annexin V 18 hours after cross-linking of CD20 and CD40
using 1F5 and G28-5 followed by cross-linking with GAM. Binding of
Annexin V was measured using a FITC-Annexin V kit (Catalog
#PN-IM2376, Immunotech, Marseille, France,). Annexin V binding is
known to be an early event in progression of cells into apoptosis.
Apoptosis, or programmed cell death, is a process characterized by
a cascade of catabolic reactions leading to cell death by suicide.
In the early phase of apoptosis, before cells change morphology and
hydrolyze DNA, the integrity of the cell membrane is maintained but
cells lose the asymmetry of their membrane phospholipids, exposing
negatively charged phospholipids, such as phosphatidylserine, at
the cell surface. Annexin V, a calcium and phopholipid binding
protein, binds preferentially and with high affinity to
phosphatidylserine. Results demonstrating the effect of
cross-linking both CD20 and CD40 on expression of the FAS receptor
(CD95) are presented in FIG. 6B. The effect of cross-linking of
both CD20 and CD40 on Annexin V binding to cells is shown in FIG.
6B.
Example 4
Construction and Characterization of 2H7 ScFv-CD154 Fusion
Proteins
[0568] To construct a molecule capable of binding to both CD20 and
CD40, cDNA encoding the 2H7 scFv was fused with cDNA encoding
CD154, the CD40 ligand. The 2H7 scFv cDNA encoded on the
HindIII-BclI fragment was removed from the 2H7 scFvIg construct,
and inserted into a pD18 vector along with a BamHI-XbaI cDNA
fragment encoding the extracellular domain of human CD154. The
extracellular domain is encoded at the carboxy terminus of CD154,
similar to other type II membrane proteins.
[0569] The extracellular domain of human CD154 was PCR amplified
using cDNA generated with random primers and RNA from human T
lymphocytes activated with PHA (phytohemagglutinin). The primer
sets included two different 5' or sense primers that created fusion
junctions at two different positions within the extracellular
domain of CD154. Two different fusion junctions were designed that
resulted in a short or truncated form (form S4) including amino
acids 108 (Glu)-261 (Leu)+(Glu), and a long or complete form (form
L2) including amino acids 48 (Arg)-261 (Leu)+(Glu), of the
extracellular domain of CD154, both constructed as BamHI-XbaI
fragments. The sense primer that fuses the two different truncated
extracellular domains to the 2H7scFv includes a BamHI site for
cloning. The sense primer for the S4 form of the CD154 cDNA is
designated SEQUENCE ID NO: 535 or CD154BAM108 and encodes a 34 mer
with the following sequence: 5'-gtt gtc gga tcc aga aaa cag ctt tga
aat gca a-3', while the antisense primer is designated SEQUENCE ID
NO: 536 or CD154XBA and encodes a 44 mer with the following
sequence: 5'-gtt gtt tct aga tta tca ctc gag ttt gag taa gcc aaa
gga cg-3' (SEQ ID NO:536).
[0570] The oligonucleotide primers used in amplifying the long form
(L2) of the CD154 extracellular domain encoding amino acids 48
(Arg)-261 (Leu)+(Glu), were as follows: The sense primer designated
CD154 BAM48 (SEQUENCE ID NO:537) encoded a 35-mer with the
following sequence: 5'-gtt gtc gga tcc aag aag gtt gga caa gat aga
ag-3'. The antisense primer designated or CD154XBA (SEQUENCE ID
NO:538) encoded the 44-mer: 5'-gtt gtt tct aga tta tca ctc gag ttt
gag taa gcc aaa gga cg-3'. Other PCR reaction conditions were
identical to those used for amplifying the 2H7 scFv (see Example
1). PCR fragments were purified by PCR quick kits (QIAGEN, San
Diego, Calif.), eluted in 30 .mu.l ddH.sub.2O, and digested with
BamHI and XbaI (Roche) restriction endonucleases in a 40 .mu.l
reaction volume at 37.degree. C. for 3 hours. Fragments were gel
purified, purified using QIAEX kits according to the manufacturer's
instructions (QIAGEN), and ligated along with the 2H7 HindIII-BclI
fragment into the pD18 expression vector digested with
HindIII+XbaI. Ligation reactions were transformed into DH5-alpha
chemically competent bacteria and plated onto LB plates containing
100 .mu.g/ml ampicillin. Transformants were grown overnight at
37.degree. C., and isolated colonies used to inoculate 3 ml liquid
cultures in Luria Broth containing 100 .mu.g/ml ampicillin. Clones
were screened after mini-plasmid preparations (QIAGEN) for
insertion of both the 2H7 scFv and the CD154 extracellular domain
fragments.
[0571] The 2H7scFv-CD154 construct cDNAs were subjected to cycle
sequencing on a PE 9700 thermocycler using a 25-cycle program that
included denaturating at 96.degree. C., 10 seconds, annealing at
50.degree. C. for 5 seconds, and extension at 60.degree. C., for 4
minutes. The sequencing primers used were pD18 forward (SEQ ID
NO:539: 5'-gtctatataagcagagctctggc-3') and pD18 reverse (SEQ ID
NO:540: 5'-cgaggctgatcagcgagctctagca-3') primers. In addition, an
internal primer was used that had homology to the human CD154
sequence (SEQ ID NO:541: 5'-ccgcaatttgaggattctgatcacc-3').
Sequencing reactions included primers at 3.2 pmol, approximately
200 ng DNA template, and 8 .mu.l sequencing mix. Sequencing
reactions were performed using the Big Dye Terminator Ready
Sequencing Mix (PE-Applied Biosystems, Foster City, Calif.)
according to the manufacturer's instructions. Samples were
subsequently purified using Centrisep columns (Princeton
Separations, Adelphia, N.J.). The eluates were dried in a Savant
speed-vacuum dryer, denatured in 20 .mu.l template Suppression
Reagent (ABI) at 95.degree. C. for 2 minutes, and analyzed on an
ABI 310 Genetic Analyzer (PE-Applied Biosystems). The sequence was
edited, translated, and analyzed using Vector Nti version 6.0
(Informax, North Bethesda, Md.). The 2H7scFv-CD154 L2 cDNA sequence
and predicted amino acid sequence is presented in FIG. 7A, and
2H7scFv-CD154 S4 cDNA sequence and predicted amino acid sequence is
presented in FIG. 7B.
[0572] The binding activity of the 2H7 scFv-CD154 fusion proteins
(SEQ. ID NOs: 691 and 693) to CD20 and CD40 simultaneously was
determined by flow cytometry. The assay used CHO cell targets that
express CD20. After a 45-minute incubation of CD20 CHO cells with
supernatants from cells transfected with the 2H7 scFv-CD 154
expression plasmid, the CD20 CHO cells were washed twice and
incubated with biotin-conjugated CD40-Ig fusion protein in PBS/2%
FBS. After 45 min, cells were washed twice and incubated with
phycoerythrin (PE)-labeled strepavidin at 1:100 in PBS/2% FBS
(Molecular Probes, Eugene Oreg.). After an additional 30 min
incubation, cells were washed 2.times. and were analyzed by flow
cytometry. The results show that the 2H7 scFv-CD154 molecule was
able to bind to CD20 on the cell surface and to capture
biotin-conjugated CD40 from solution (FIG. 8).
[0573] To determine the effect of the 2H7scFv-CD 154 on growth and
viability of B lymphoma and lymphoblastoid cell lines, cells were
incubated with 2H7scFv-CD154 L2 (SEQ. ID NO:691) for 12 hours and
then examined for binding of Annexin V. Binding of Annexin V was
measured using a FITC-Annexin V kit (Immunotech, Marseille, France,
Catalog #PN-IM2376). B cell lines were incubated in 1 ml cultures
with dilutions of concentrated, dialyzed supernatants from cells
expressing secreted forms of the 2H7scFv-CD154 fusion proteins. The
results are presented in FIG. 9.
[0574] The growth rate of the Ramos B lymphoma cell line in the
presence of 2H7scFv-CD154 was examined by uptake of
.sup.3H-thymidine for the last 6 hours of a 24-hour culture. The
effect of 2H7scFv-CD154 on cell proliferation is shown in FIG.
10.
Example 5
Construction and Characterization of CytoxB Antibody
Derivatives
[0575] CytoxB antibodies were prepared using 2H7 scFv-IgG
polypeptide. The 2H7 scFv (see Example 1) was linked to the human
IgG1 Fc domain via an altered hinge domain (see FIG. 11). Cysteine
residues in the hinge region were substituted with serine residues
by site-directed mutagenesis and other methods known in the art.
The mutant hinge was fused either to a wild-type Fc domain to
create one construct, designated CytoxB-MHWTG1C, or was fused to a
mutated Fc domain (CytoxB-MHMG1C) that had additional mutations
introduced into the CH2 domain. Amino acid residues in CH2 that are
implicated in effector function are illustrated in FIG. 11.
Mutations of one or more of these residues may reduce FcR binding
and mediation of effector functions. In this Example, the leucine
residue 234 known in the art to be important to Fc receptor
binding, was mutated in the 2H7 scFv fusion protein,
CytoxB-[MG1H/MG1C]. In another construct, the human IgG1 hinge
region was substituted with a portion of the human IgA hinge, which
was fused to wild-type human Fc domain (CytoxB-IgAHWTHG1C). (See
FIG. 11). This mutated hinge region allows expression of a mixture
of monomeric and dimeric molecules that retain functional
properties of the human IgG1 CH2 and CH3 domains. Synthetic,
recombinant cDNA expression cassettes for these molecules were
constructed and polypeptides were expressed in CHODG44 cells
according to methods described in Example 2.
[0576] Purified fusion protein derivatives of CytoxB-scFvIg
molecules were analyzed by SDS-PAGE according to the methods
described in Example 2. Polyacrylamide gels were run under
non-reducing and reducing conditions. Two different molecule weight
marker sets, BioRad prestained markers, (BioRad, Hercules, Calif.)
and Novex Multimark molecular weight markers were loaded onto each
gel. The migration patterns of the different constructs and of
Rituximab.TM. are presented in FIG. 12.
[0577] The ability of the different derivatives of CytoxB-scFvIg
molecules to mediate ADCC was measured using the Bjab B lymphoma
cells as the target and freshly prepared human PBMCs as effector
cells. (See Example 2). Effector to target ratios were varied as
follows: 70:1, 35:1, and 18:1, with the number of Bjab cells per
well remaining constant but the number of PBMCs were varied. Bjab
cells were labeled for 2 hours with .sup.51Cr and aliquoted at a
cell density of 5.times.10.sup.4 cells/well to each well of
flat-bottom 96 well plates. Purified fusion proteins or rituximab
were added at a concentration of 10 .mu.g/ml to the various
dilutions of PBMCs. Spontaneous release was measured without
addition of PBMC or fusion protein, and maximal release was
measured by the addition of detergent (1% NP-40) to the appropriate
wells. Reactions were incubated for 4 hours, and 100 .mu.l of
culture supernatant was harvested to a Lumaplate (Packard
Instruments) and allowed to dry overnight prior to counting cpm
released. The results are presented in FIG. 13.
[0578] Complement dependent cytotoxicity (CDC) activity of the
CytoxB derivatives was also measured. Reactions were performed
essentially as described in Example 2. The results are presented in
FIG. 14 as percent of dead cells to total cells for each
concentration of fusion protein.
Example 6
In Vivo Studies in Macaques
[0579] Initial in vivo studies with CytoxB derivatives have been
performed in nonhuman primates. FIG. 15 shows data characterizing
the serum half-life of CytoxB in monkeys. Measurements were
performed on serum samples obtained from two different macaques
(J99231 and K99334) after doses of 6 mg/kg were administered to
each monkey on the days indicated by arrows. For each sample, the
level of 2H7scFvIg present was estimated by comparison to a
standard curve generated by binding of purified CytoxB-(MHWTG1C)-Ig
fusion protein to CD20 CHO cells (see Example 2). The data are
tabulated in the bottom panel of the FIG. 15.
[0580] The effect of CytoxB-(MHWTG1C)Ig fusion protein on levels of
circulating CD40+ cells in macaques was investigated. Complete
blood counts were performed at each of the days indicated in FIG.
16. In addition, FACS (fluorescence activated cell sorter) assays
were performed on peripheral blood lymphocytes using a
CD40-specific fluorescein conjugated antibody to detect B cells
among the cell population. The percentage of positive cells was
then used to calculate the number of B cells in the original
samples. The data are graphed as thousands of B cells per
microliter of blood measured at the days indicated after injection
(FIG. 16).
Example 7
Construction and Expression of an Anti-CD19 scFv-Ig Fusion
Protein
[0581] An anti-CD19 scFv-Ig fusion protein was constructed,
transfected into eukaryotic cells, and expressed according to
methods presented in Examples 1, 2, and 5 and standard in the art.
The variable heavy chain regions and variable light chain regions
were cloned from RNA isolated from hybridoma cells producing
antibody HD37, which specifically binds to CD19. Expression levels
of a HD37scFv-IgAHWTG1C and a HD37scFv-IgMHWTG1C were measured and
compared to a standard curve generated using purified HD37 scFvIg.
The results are presented in FIG. 17.
Example 8
Construction and Expression of an Anti-L6 scFv-Ig Fusion
Protein
[0582] An scFv-Ig fusion protein was constructed using variable
regions derived from an anti-carcinoma monoclonal antibody, L6. The
fusion protein was constructed, transfected into eukaryotic cells,
and expressed according to methods presented in Examples 1, 2, and
5 and standard in the art. Expression levels of L6 scFv-IgAH WCH2
CH3 and L6 scFv-(SSS-S)H WCH2 WCH3 were measured and compared to a
standard curve generated using purified L6 scFvIg. The results are
presented in FIG. 18.
Example 9
Characterization of Various scFv-Ig Fusion Proteins
[0583] In addition to the scFv-Ig fusion protein already described,
G28-1 (anti-CD37) scFv-Ig fusion proteins were prepared essentially
as described in Examples 1 and 5. The variable regions of the heavy
and light chains were cloned according to methods known in the art.
ADCC activity of 2H7-MHWTG1C, 2H7-IgAHWTG1C, G28-1-MHWTG1C, G28-1
IgAHWTG1C, HD37-MHWTG1C, and HD37-IgAHWTG1C was determined
according to methods described above (see Example 2). Results are
presented in FIG. 19. ADCC activity of L6scFv-IgAHWTG1C and
L6scFv-IgMHWTG1C was measured using the 2981 human lung carcinoma
cell line. The results are presented in FIG. 20. The murine L6
monoclonal antibody is known not to exhibit ADCC activity.
[0584] The purified proteins were analyzed by SDS-PAGE under
reducing and non-reducing conditions. Samples were prepared and
gels run essentially as described in Examples 2 and 5. The results
for the L6 and 2H7 scFv-Ig fusion proteins are presented in FIG. 21
and the results for the G28-1 and HD37 scFv-Ig fusion proteins are
presented in FIG. 22.
Example 10
Construction and Expression of Anti-CD20 scFv-Llama Ig Fusion
Proteins
[0585] This Example illustrates the cloning of llama IgG1, IgG2,
and IgG3 constant region domains and the construction of
immunoglobulin fusion proteins with each of the three constant
regions and anti-CD20 scFv.
[0586] The constant regions of llama IgG1, IgG2, and IgG3
immunoglobulins were cloned and inserted into mammalian vector
constructs containing an anti-CD20 single chain Fv, 2H7 scFv. Total
RNA was isolated from peripheral blood mononuclear cells (PBMC)
from llama blood (Triple J Farms, Bellingham, Wash.) by lysing the
lymphocytes in TRIzol.RTM. (Invitrogen Life Technologies, Carlsbad,
Calif.) according to the manufacturer's instructions. One microgram
(1 .mu.g) of total RNA was used as template to prepare cDNA by
reverse transcription. The RNA and 200 ng random primers were
combined and denatured at 72.degree. C. for 10 minutes prior to
addition of enzyme. Superscript II reverse transcriptase
(Invitrogen Life Technologies) was added to the RNA plus primer
mixture in a total volume of 25 .mu.l in the presence of 5.times.
second strand buffer and 0.1 M DTT provided with the enzyme. The
reverse transcription reaction was allowed to proceed at 42.degree.
C. for one hour. The cDNA was amplified by PCR using sequence
specific primers. The 5' primers were designed according to
published sequences for the V.sub.HH and V.sub.H domains of
camelids. The 3' primer, which was used to amplify all three
isotypes, was designed using mammalian CH3 domain sequences as a
guide. The following specific primers were used. The Bcl and XbaI
sites are indicated by underlined italicized sequences.
TABLE-US-00001 5' primer for llama IgG1 constant region (SEQ ID NO:
542) LLG1-5'bgl: 5'-gtt gtt gat caa gaa cca cat gga gga tgc acg
tg-3' 5' primer for llama IgG2 constant region (SEQ ID NO: 543)
LLG2-5'bgl: 5'-gtt gtt gat caa gaa ccc aag aca cca aaa cc-3' 5'
primer for llama IgG3 constant region (SEQ ID NO: 544) LLG3-5'bgl:
5'-gtt gtt gat caa gcg cac cac agc gaa gac ccc-3' 3' primer for
llama IgG1, IgG2, and IgG3 constant regions (SEQ ID NO: 545)
LLG123-3'X: 5'-gtt gtt tct aga tta cta ttt acc cga aga ctg ggt gat
gga-3'
[0587] PCR fragments of the expected size were cloned into
TOPO.RTM. cloning vectors (Invitrogen Life Technologies) and then
were sequenced. The sense sequencing primer, LLseqsense, had the
sequence 5'-ctg aga tcg agt tca gct g-3' (SEQ ID NO:546), and the
antisense primer, LLseqAS, had the sequence 5'-cct cct ttg gct ttg
tct c-3' (SEQ ID NO:547). Sequencing was performed as described in
Example 1. FIG. 23 compares the amino acid sequence of the three
isotype llama constant regions containing the hinge, CH2, and CH3
domains with the amino acid sequence of human IgG1 hinge, CH2, and
CH3 domains.
[0588] After verifying the sequence, the amplified PCR products
were digested with restriction enzymes BclI and Xba1 to create
compatible restriction sites. The digested fragments were then
gel-purified, and the DNA was eluted using a QIAquick Gel
Extraction Kit (QIAGEN, Valencia, Calif.). The 2H7scFv-Ig pD18
mammalian expression vector construct (see Example 2) was digested
with BclI and XbaI to remove the human IgG hinge, CH2, and CH3
domains. The pD18 vector is a modified derivative of pcDNA3 that
contains an attenuated DHFR gene, which serves as a selectable
marker for mammalian expression (Hayden et al., Tissue Antigens
48:242-54 (1996)). The purified llama IgG1, IgG2, and IgG3 constant
region PCR products were ligated by T4 DNA ligase (Roche Molecular
Biochemicals, Indianapolis, Ind.) into the double-digested 2H7
scFv-pD18 vector at room temperature overnight according to the
manufacturer's instructions. After ligation, the ligation products
were transformed into E. coli DH5a bacteria (BD Biosciences, Palo
Alto, Calif.) and plated according to standard molecular biology
procedures and manufacturer's instructions. Isolated colonies were
chosen to screen for transformants containing the correct
inserts.
[0589] For expression of the encoded polypeptides, plasmid DNA from
positive clones was transiently transfected into COS-7 cells using
DEAE-dextran (Hayden et al., Ther Immunol. 1:3-15 (1994)). COS-7
cells were seeded at approximately 3.times.10.sup.6 cells per 150
mm plate and grown overnight until the cells were about 75%
confluent. Cells were then washed once with serum-free DMEM
(Invitrogen Life Technologies, Grand Island, N.Y.). Transfection
supernatant (10 ml) containing 400 .mu.g/ml DEAE-dextran, 0.1 mM
chloroquine, and 5 .mu.g/ml of the DNA constructs were added to the
cells, which were then incubated at 37.degree. C. for 3-4 hrs.
After incubation, cells were pulsed with 10 ml of 10% dimethyl
sulfoxide (DMSO) in 1.times.PBS at room temperature for 2 minutes.
Cells were then placed back into fully supplemented DMEM/10% FBS
(1% L-glutamine, 1% penicillin/streptomycin, 1% sodium pyruvate, 1%
MEM essential amino acids) (Invitrogen Life Technologies). After 24
hours, the media was replaced with serum-free fully supplemented
DMEM (Invitrogen Life Technologies), and the cells were maintained
up to 21 days with media changes every 3-4 days.
[0590] Ig-fusion proteins were purified by passing COS cell culture
supernatants through Protein A Agarose (Repligen, Cambridge, Mass.)
columns. After application of the culture supernatant, the Protein
A columns were then washed with 1.times.PBS (Invitrogen Life
Technologies). Bound Ig-fusion proteins were eluted with 0.1 M
citric acid (pH 2.8), and the collected fractions were immediately
neutralized with Tris base (pH 10.85). The fractions containing
protein were identified by measuring the optical density
(A.sub.280) and then were pooled, dialyzed against 1.times.PBS,
(Invitrogen Life Technologies) and filtered through a 0.2 .mu.m
filter.
[0591] The purified Ig-fusion proteins were analyzed by SDS-PAGE.
Aliquots of 2H7 scFv-llama IgG1, 2H7 scFv-llama IgG2, 2H7
scFv-llama IgG3, and Rituxan.RTM. (Rituximab, anti-CD20 antibody,
Genentech, Inc. and IDEC Pharmaceuticals Corp.) (5 .mu.g protein)
were combined with 25 .mu.l 2.times. NuPAGE.RTM. SDS Sample Buffer
(Invitrogen Life Technologies) (non-reduced samples). Samples of
each protein were also prepared in reducing sample buffer
containing 5% 2-mercaptoethanol (Sigma-Aldrich, St. Louis, Mo.).
Molecular weight markers (Invitrogen Life Technologies) were
applied to the gels in non-reducing buffer only. The proteins were
fractionated on NuPAGE.RTM. 10% Bis-Tris gels (Invitrogen Life
Technologies). After electrophoresis (approximately 1 hour), the
gels were washed three times, five minutes each, with Distilled
Water (Invitrogen Life Technologies) and then stained in 50 ml
Bio-Safe Coommassie Stain (BioRad, Hercules, Calif.) overnight at
room temperature. After a wash in Distilled Water, the gels were
photographed. The migration pattern of each Ig-fusion protein is
presented in FIG. 24.
[0592] The ability of the 2H7 scFv-llama Ig fusion proteins to bind
to cells expressing CD20 was demonstrated by flow cytometry. Serial
dilutions starting at 25 .mu.g/ml of purified 2H7 scFv-llama IgG1,
2H7 scFv-llama IgG2, and 2H7 scFv-llama IgG3 were prepared and
incubated with CD20-transfected (CD20+) CHO cells (from the
laboratory of Dr. S. Skov, Institute of Medical Microbiology and
Immunology, Copenhagen Denmark in 1% FBS 1.times.PBS media
(Invitrogen Life Technologies) for one hour on ice. After the
incubation, the cells were then centrifuged and washed with 1% FBS
in 1.times.PBS. To detect bound 2H7 scFv-llama Ig, the cells were
incubated for one hour on ice with fluorescein-conjugated goat
anti-camelid IgG (heavy and light chain) (1:100) (Triple J Farms).
The cells were then centrifuged and resuspended in 1%
FBS-1.times.PBS and analyzed using a Coulter Epics XL cell sorter
(Beckman Coulter, Miami, Fla.). The data (percent of maximum
brightness) are presented in FIG. 25.
Example 11
Effector Function of Anti-CD20 scFv-Llama Ig Fusion Proteins
[0593] This Example demonstrates the ability of anti-CD20 llama
IgG1, IgG2, and IgG3 fusion proteins to mediate complement
dependent cytotoxicity (CDC) and antibody dependent cell-mediated
cytotoxicity (ADCC).
[0594] The ability of the 2H7 scFv-llama IgG fusion proteins to
kill CD20 positive cells in the presence of complement was tested
using the BJAB human B cell line. Rabbit complement was obtained
from 3-4 week old rabbits (Pel-Freez, Brown Deer, Wis.). BJAB cells
(2.times.10.sup.6 cells/ml) were combined with rabbit complement
(final dilution 1:10) and purified 2H7 Ig fusion proteins. 2H7
scFv-llama IgG1, 2H7 scFv-llama IgG2, 2H7 scFv-llama IgG3, and 2H7
scFv-human IgG1 wild type hinge-CH2-CH3) (Example 1) were added at
1:3 serial dilutions beginning at a concentration of 30 .mu.g/ml.
After one hour at 37.degree. C., cell viability was determined by
counting live and dead cells by trypan blue exclusion (0.4%)
(Invitrogen Life Technologies) using a hemacytometer (Bright-line,
Horsham, Pa.). The percent killing was calculated by dividing the
number of dead cells by the number of total cells (dead+live
cells). The data presented in FIG. 26 show that all Ig fusion
proteins had CDC activity.
[0595] The ADCC activity of the 2H7 scFv-llama IgG fusion proteins
was determined using BJAB cells as target cells and human or llama
peripheral blood mononuclear cells (PBMC) as effector cells. BJAB
cells were pre-incubated for approximately 2 hours with .sup.51Cr
(100 .mu.Ci) (Amersham Biosciences, Piscataway, N.J.) in fully
supplemented IMDM (Invitrogen Life Technologies) containing 15%
FBS. The cells were mixed intermittently during the pre-incubation
period. Fresh, resting human PBMC were purified from whole blood
using Lymphocyte Separation Media (LSM) (ICN Pharmaceuticals, New
York, N.Y.). PBMC were combined with labeled BJAB cells
(5.times.10.sup.4 cells per well of 96 well tissue culture plate)
at ratios of 25:1, 50:1, and 100:1. To each combination was added
10 .mu.g/ml of purified 2H7 scFv-llama IgG1, 2H7 scFv-llama IgG2,
2H7 scFv-llama IgG3, Rituximab, or no anti-CD20 antibody. The
mixtures were incubated for 6 hours at 37.degree. C. Supernatant
from each reaction containing .sup.51Cr released from lysed cells
was collected onto a LumaPlate-96 filter plate (Packard, Meriden,
Conn.), which was dried overnight. The amount of .sup.51Cr was
measured by a TopCount NXT plate reader (Packard). FIG. 27 shows
that the 2H7 scFv-llama IgG2 fusion protein was the most effective
llama fusion protein in mediating ADCC. Each data point represents
the average measurement of triplicate wells.
[0596] ADCC activity was affected by the source of effector cells.
Llama PBMC were isolated from llama blood (Triple J Farms) using
LSM. Llama effector cells were added at the same ratios to BJAB
target cells as described for the ADCC assay using human effector
cells. The cells were combined with 10 .mu.g/ml of purified 2H7
scFv-llama IgG1, 2H7 scFv-llama IgG2, 2H7 scFv-llama IgG3,
Rituximab, or no anti-CD20 antibody. The results are presented in
FIG. 28.
Example 12
Construction and Characterization of scFv Ig Fusion Proteins
Expressed on the Cell Surface
[0597] This Example describes a retroviral transfection system for
ectopic surface expression of genetically engineered cell surface
receptors composed of scFvs that bind costimulatory receptors. The
Example also demonstrates the effector function of these various
scFv Ig fusion proteins expressed on the surface of target
cells.
[0598] The heavy and light chain variable regions were cloned from
murine monoclonal antibodies specific for various costimulatory
receptors, and single chain Fv constructs were prepared essentially
as described in Example 1. Antibodies included 2H7, anti-human
CD20; 40.2.220, anti-human CD40; 2E12, anti-human CD28; 10A8,
anti-human CD152 (anti-CTLA-4); and 500A2, anti-murine CD3. The
heavy chain and light chain variable regions of each antibody were
cloned according to standard methods for cloning immunoglobulin
genes and as described in Example 1. Single chain Fv constructs
were prepared as described in Example 1 by inserting a nucleotide
sequence encoding a (gly.sub.4ser).sub.3 (SEQ ID NO:529) peptide
linker between the VL region nucleotide sequence of 40.2.220, 2E12,
10A8, and 500A2, respectively (SEQ ID NOs:31, 37 and 43,
respectively) and the VH region nucleotide sequence of 40.2.220,
2E12, 10A8, and 500A2, respectively (SEQ ID NOs:33, 39 and 45,
respectively). The polypeptide sequence for VL of 40.2.220, 2E12,
10A8, and 500A2 are set forth in SEQ ID NOs:32, 38 and 44,
respectively, and the polypeptide sequence for VH of 40.2.220,
2E12, 10A8, and 500A2 are set forth in SEQ ID NOs:30, 40 and 46,
respectively. Each scFv polynucleotide (SEQ ID NOs:36, 42 and 47
for 40.2.220, 2E12, 10A8, and 500A2, respectively) was then fused
to human IgG1 mutant hinge (CCC.fwdarw.SSS) and mutant CH2 (proline
to serine mutation at residue 238 (238 numbering according to EU
nomenclature, Ward et al., 1995 Therap. Immunol. 2:77-94; residue
251 according to Kabat et al.) and wild type CH3 domains according
to the methods described in Example 5 and 11. Each scFv mutant IgG1
fusion polynucleotide sequence was then fused in frame to sequences
encoding the transmembrane domain and cytoplasmic tail of human
CD80 (SEQ ID NO:29), such that when the fusion protein was
expressed in the transfected cell, CD80 provided an anchor for
surface expression of the scFv Ig fusion protein. cDNAs encoding
the scFv-IgG-CD80 fusion proteins (SEQ ID NOs:49, 51, 53 and 55 for
40.2.220-, 2E12-, 10A8-, and 500A2-scFv-IgG-CD80, respectively)
were inserted into the retroviral vector pLNCX (BD Biosciences
Clontech, Palo Alto, Calif.) according to standard molecular
biology procedures and vendor instructions. The scFv-Ig-CD80 cDNA
was inserted between the 5'LTR-neomycin resistance gene-CMV
promoter sequences and the 3'LTR sequence. The retroviral
constructs were transfected into Reh, an acute lymphocytic leukemia
cell line (ATCC CRL-8286). Transfected cells were screened to
select clones that were expressing scFv-Ig fusion proteins on the
cell surface.
[0599] CDC and ADCC assays were performed with the transfected Reh
cells to determine if expression of the scFv-Ig polypeptides on the
cell surface augmented effector cell function. Reh cells expressing
anti-human CD152 scFv-mutant IgG-CD80 (SEQ ID NO:56); Reh
anti-human CD28 scFv-mutant IgG-CD80 (SEQ ID NO:52);; Reh
anti-human CD40 scFv-mutant IgG-CD80 (SEQ ID NO50:); Reh anti-human
CD20 scFv-mutant IgG-CD80 (SEQ ID NO:_) were combined with human
PBMC (see Example 11) and rabbit complement (10 .mu.g/ml) for one
hour at 37.degree. C. Untransfected Reh cells were included as a
control. Viability of the cells was determined by trypan blue
exclusion, and the percent of killed cells was calculated (see
Example 11). FIG. 29 shows the effectiveness of the scFv-IgG-CD80
fusion proteins when expressed on the cell surface of tumor cells
to mediate complement dependent cytotoxicity.
[0600] The same transfected Reh cells tested in the CDC assay plus
Reh cells transfected with the polynucleotide construct that
encodes anti-murine CD3-scFv-Ig-CD80 (SEQ ID NO:110) were analyzed
for ADCC activity (see Example 11). Untransfected and transfected
Reh cells were pre-labeled with .sup.51Cr (100 .mu.Ci) (Amersham)
for two hours at 37.degree. C. Human PBMC served as effector cells
and were added to the Reh target cells (5.times.10.sup.4 cells per
well of 96 well plate) at ratios of 5:1, 2.5:1, and 1.25:1. After
five hours at 37.degree. C., culture supernatants were harvested
and analyzed as described in Example 11. Percent specific killing
was calculated according to the following equation: ((experiment
release minus spontaneous release)/(maximum release minus
spontaneous release)).times.100. The data are presented in FIG. 30.
Each data point represents the average of quadruplicate
samples.
[0601] Using the same procedures described above, the same results
with other binding domains were obtained using the following
monoclonal antibodies monoclonal antibodies as sources of sFv: for
CD20, 1F5 (Genbank AY 058907 and AY058906); for CD40, 2.36 and
G28.5; for CD28, 9.3.
[0602] Cell surface expression of antibody binding domains is
accomplished by fusing antibody scFvs to IgA hinge and constant
regions and IgE hinge-acting region, i.e., IgE CH2, and constant
regions. Polynucleotides encoding an anti-4-1BB scFv, 5B9
(anti-human 4-1BB) scFv, and 2e12 (anti-human CD40) fused to IgAH
IgA T4 (four terminal CH3 residues deleted) fused to the CD80
transmembrane and cytoplasmic domains and IgE Fc regions are shown
in SEQ ID NOs:177, 181, 179 and 183. The encoded polypeptides are
shown in SEQ ID NOs:178, 182, 180 and 184.
Example 13
Construction and Sequence of Human Ig Hinge-CH2-CH3 Mutants and 2H7
Variable Region Mutants
[0603] This Example describes construction of scFv fusion proteins
containing mutant human IgG1 and IgA constant regions. This Example
also describes construction of a 2H7 scFv mutant with a single
point mutation in the variable heavy chain region. Mutations were
introduced into variable and constant region domains according to
methods described herein and known in the molecular biology arts.
FIG. 31 presents nomenclature for the Ig constant region
constructs.
[0604] The human IgG1 hinge region of the 2H7 scFv human IgG1
hinge-CH2-CH3 fusion proteins was mutated to substitute cysteine
residues that in a whole immunoglobulin are involved in forming
disulfide bonds between two heavy chain molecules. One mutant, 2H7
scFv fused to a human IgG1 hinge region in which all three cysteine
residues were mutated to serine residues (MTH (SSS)), was prepared
as described in Example 5 (designated in Example 5 as
CytoxB-MHWTG1C (includes wild type IgG1 CH2 and CH3 domains)) (now
referred to as 2H7 scFv MTH (SSS) WTCH2CH3) and comprises the
polynucleotide sequence SEQ ID NO:57 encoding the polypeptide as
set forth in SEQ ID NO:58. The polynucleotide sequence encoding
this mutant (SEQ ID NO:57) was used as a template to create mutant
hinge regions in which the first two cysteine residues were
substituted with serine residues (IgG MTH (SSC)). An
oligonucleotide was designed to substitute the third serine residue
with a cysteine and had the following sequence: 5'-gtt gtt gat cag
gag ccc aaa tct tct gac aaa act cac aca tct cca ccg tgc cca gca cct
g-3' (HuIgGMHncs3, SEQ ID NO:548). A second mutant was prepared in
which the mutant hinge had serine residues substituting the first
and third cysteine residues (IgG MTH (SCS)). The sequence of the
oligonucleotide to create this mutant was as follows: 5'-gtt gtt
gat cag gag ccc aaa tct tct gac aaa act cac aca tgc cca ccg-3'
(HuIgGMHncs2, SEQ ID NO:549). A third mutant was prepared with
cysteine residues substituted at the second and third positions
(IgG MTH (CSS)), also using the IgG MTH (SSS) mutant as template,
and an oligonucleotide having the sequence, 5'-gtt gtt gat cag gag
ccc aaa tct tgt gac aaa act cac-3' (HuIgGMHncs1, SEQ ID
NO:550).
[0605] The oligonucleotides introducing the mutations into the
hinge region were combined with template and a 3' oligonucleotide
containing an XbaI site (underlined and italicized) (5'-gtt gtt tct
aga tca ttt acc cgg aga cag gga gag get ctt ctg cgt gta g-3' (SEQ
ID NO:551)) to amplify the mutant hinge-wild type (WT)-CH2-CH3
sequences by PCR. The IgG MTH CSS and IgG MTH SCS mutant sequences
were amplified for 25 cycles with a denaturation profile of
94.degree. C., annealing at 52.degree. C. for 30 seconds, and
extension at 72.degree. C. for 30 seconds. The IgG MTH SSC mutant
sequence was amplified under slightly different conditions:
denaturation profile of 94.degree. C., annealing at 45.degree. C.
for 30 seconds, and extension at 72.degree. C. for 45 seconds. The
amplified polynucleotides were inserted into the TOPO.RTM. cloning
vector (Invitrogen Life Technologies) and then were sequenced as
described in Example 1 to confirm the presence of the mutation.
pD18 vector containing 2H7 scFv was digested to remove the constant
region sequences essentially as described in Example 10. The mutant
hinge-wild type CH2-CH3 regions were inserted in frame into the
digested vector DNA to obtain vectors comprising 2H7 scFv MTH (CSS)
WTCH2CH3 encoding DNA (SEQ ID NO:134); 2H7 scFv MTH (SCS) WTCH2CH3
encoding DNA (SEQ ID NO:136); and 2H7 scFv MTH (SSC) WTCH2CH3
encoding DNA (SEQ ID NO:138).
[0606] A mutation of leucine to serine at position 11 in the first
framework region of the heavy chain variable region (numbering
according to Kabat et al., Sequences of Proteins of Immunological
Interest, 5.sup.th ed. Bethesda, Md.: Public Health Service,
National Institutes of Health (1991)) was introduced into the 2H7
scFv MTH (SSS) WTCH2CH3 fusion protein (SEQ ID NO:58). The wild
type leucine residue was substituted with serine by site-directed
mutagenesis using the oligonucleotide Vhser11: 5'-gga ggt ggg agc
tct cag gct tat cta cag cag tct ggg gct gag tcg gtg agg cc-3' (SEQ
ID NO:552)(this sequence, or an amino acid sequence that it
encodes, may be optionally excluded from particular claimed
embodiments of the instant invention). The 3'-primer for PCR was
huIgG1-3' having the sequence 5'-gtc tct aga cta tca ttt acc cgg
aga cag-3' (SEQ ID NO:553) (XbaI site underlined and italicized).
After PCR amplification, the fragments were inserted into the
TOPO.RTM. cloning vector and sequenced to confirm the presence of
the VH11 leucine to serine mutation. The 2H7 scFv-IgG MTH (SSS)
WTCH2CH3 encoding DNA was shuttled into the PSL1180 cloning vector
(Pharmacia Biotech, Inc., Piscataway, N.J.). The construct
PSL1180-2H7 scFv-IgG MTH (SSS) WTCH2CH3 was digested with Sac and
XbaI to remove the wild type VH domain and the hinge and CH2 and
CH3 domains. The PCR product comprising the VH11 mutant was
digested with Sac and XbaI and then inserted into the digested
PSL1180 construct according to standard molecular biology
procedures. The construct was then digested with Hind III and XbaI,
and inserted into the mammalian expression vector pD18 (see methods
described in Example 1 and Example 10). The mutant is designated
2H7 scFv VH11SER IgG MTH (SSS) WTCH2CH3 (FIG. 31). The
polynucleotide sequence is provided in SEQ ID NO:369, and the
encoded polypeptide sequence is provided in SEQ ID NO:370 (these
sequences may be optionally excluded from particular claimed
embodiments of the instant invention).
[0607] Four constructs containing IgA constant region domains were
prepared. One construct contained wild type IgA hinge fused to
human IgG1 CH2 and CH3 (IgAH IgG WTCH2CH3) (FIG. 31). Sequential
PCR amplifications were performed to substitute the human IgG1
hinge of the 2H7 scFv construct with nucleotide sequences encoding
the IgA hinge. The 5' oligonucleotide primer (huIgA/Gchim5) for the
first PCR reaction had the sequence, 5'-cca tct ccc tca act cca cct
acc cca tct ccc tca tgc gca cct gaa ctc ctg-3' (SEQ ID NO:554). The
primer (huIgAhg-5') for the second PCR reaction to add more IgA
specific hinge sequence and add a BclI restriction enzyme site
(italicized and underlined) had the sequence, 5'-gtt gat cag cca
gtt ccc tca act cca cct acc cca tct ccc caa ct-3' (SEQ ID NO:555).
The 3' primer for both amplification steps was huIgG1-3' having the
sequence, 5'-gtc tct aga cta tca ttt acc cgg aga cag-3' (SEQ ID
NO:556). The sequence of the PCR product was confirmed by TOPO.RTM.
cloning as described above. The gel-purified fragment was digested
with BclI and XbaI and then inserted into the 2H7 scFv-pD18 vector
that had been digested BclI and XbaI to remove all the IgG1
constant region domains. Ligation was performed as described in
Example 10 to provide a mammalian expression vector comprising the
nucleotide sequence (SEQ ID NO:59) encoding a 2H7 scFv IgA
hinge-IgG1 CH2-CH3 polypeptide (SEQ ID NO:60).
[0608] A second pD18 mammalian expression vector was constructed
that had a polynucleotide sequence (SEQ ID NO:61) that encoded a
2H7 scFv fused to wild type IgA hinge, CH2, and CH3 domains (SEQ ID
NO:62). Human IgA constant regions sequences were obtained by using
random primers to reverse transcribe total RNA isolated from human
tonsil followed by PCR amplification of the cDNA using sequence
specific primers, essentially as described in Example 10. Human IgA
hinge-CH2-CH3 nucleotide sequence (SEQ ID NO:63) encoding the
IgA-CH2-CH3 polypeptide (IgAH IgACH2CH3, FIG. 31) (SEQ ID NO:64)
was amplified using the 5' oligonucleotide huIgAhg-5' (SEQ ID
NO:555 and a 3' oligonucleotide huIgA3' having the sequence, 5'-gtt
gtt tct aga tta tca gta gca ggt gcc gtc cac ctc cgc cat gac aac-3'
(SEQ ID NO:557). Secretion of a 2H7-IgA hinge-IgA CH2-CH3
polypeptide from transfected mammalian cells required co-expression
of human J chain that covalently binds to two IgA CH3 domains via
disulfide bonds. Total RNA was isolated from tonsil B cells and was
reversed transcribed to generate cDNA as described above. PCR
amplification of the nucleotide sequence encoding the J chain was
performed with J chain specific primers. The 5' PCR primer,
HUJCH5n1, had the sequence, 5'-gtt gtt aga tct caa gaa gat gaa agg
att gtt ctt-3' (SEQ ID NO:558), and sequence of the 3' primer,
HUJCH3, was 5'-gtt gtt tct aga tta gtc agg ata gca ggc atc tgg-3'
(SEQ ID NO:559). The cDNA was cloned into TOPO.RTM. for sequencing
as described in Example 10. J chain encoding cDNA (SEQ ID NO:65)
was then inserted into pD18 and pcDNA3-Hygro (+) (Invitrogen Life
Technology) vectors for co-transfection with 2H7 scFv IgA
hinge-CH2-CH3 constructs. The J chain has the predicted amino acid
sequence set forth in SEQ ID NO:66.
[0609] Secretion of an scFv IgA constant region construct in the
absence of J chain was accomplished by engineering a truncated CH3
domain with a deletion of the four carboxy terminal amino acids
(GTCY, SEQ ID NO:67) (IgAH IgA-T4, FIG. 31), which include a
cysteine residue that forms a disulfide bond with the J chain. The
IgA hinge-CH2-CH3 nucleotide sequence containing the deletion in
CH3 (SEQ ID NO:68) was prepared using a 5' PCR primer (huIgAhg-5')
having the sequence 5'-gtt gtt gat cag cca gtt ccc tca act cca cct
acc cca tct ccc tca act-3' (SEQ ID NO:561) (BclI site is underlined
and italicized), and a 3' PCR primer (HUIGA3T1) having the sequence
5'-gtt gtt tct aga tta tca gtc cac ctc cgc cat gac aac aga cac-3'
(SEQ ID NO:562). This mutated IgA constant region nucleotide
sequence was inserted into a 2H7 scFv pD18 vector as described for
the generation of the previous 2H7 scFv-Ig constructs (see Example
1 and this Example) that comprises the polynucleotide sequence (SEQ
ID NO:70) encoding a 2H7 IgAH IgA-T4 polynucleotide (SEQ ID
NO:71).
[0610] A fourth construct was prepared that encoded a 2H7 scFv-IgA
constant region fusion protein with a deletion of 14 additional
amino acids, most of which are hydrophobic residues, from the
carboxy terminus of IgA CH3. The 2H7 scFv-IgAH IgA-T4 encoding
polynucleotide was used as template to engineer a deletion of the
nucleotide sequence encoding PTHVNVSVVMAEVD (SEQ ID NO:72). The 5'
oligonucleotide primer had the sequence 5'-gtt gtt gat cag cca gtt
ccc tca act cca cct acc cca tct ccc tca act-3' (SEQ ID NO:564)
(BclI site shown as underlined and italicized). The 3'
oligonucleotide sequence was 5'-gtt gtt tct aga tta tca ttt acc cgc
caa gcg gtc gat ggt ctt-3' (SEQ ID NO:565). The deleted IgA CH3
region was amplified by using the above oligonucleotides to amplify
the IgA constant region from RNA isolated from human tonsil such
that the cDNA contained the deleted carboxyl terminal encoding
region for the 18 amino acids. The IgAH IgA-T18 constant region was
inserted into a 2H7 scFv pD18 vector that comprises the
polynucleotide sequence (SEQ ID NO:75) encoding a 2H7 IgAH IgA-T18
polynucleotide (SEQ ID NO:76) as described above.
Example 14
Effector Function of CTLA-4 IgG Fusion Proteins
[0611] The Example compares the effector functions of CTLA-4 Ig
fusion proteins in CDC and ADCC assays.
[0612] Two CTLA-4 IgG fusion proteins were constructed. One fusion
protein comprises the extracellular domain of CTLA-4 fused to human
IgG1 wild type hinge, CH2, and CH3 domains and is designated CTLA-4
IgG WTH (CCC) WTCH2CH3 (SEQ ID NO78). A pD18 mammalian expression
vector comprising a polynucleotide sequence encoding CTLA-4 IgG WTH
(CCC) WTCH2CH3 (SEQ ID NO:77) was prepared by fusing in frame the
nucleotide sequence encoding the extracellular domain of CTLA-4
(SEQ ID NO:83) (see U.S. Pat. No. 5,844,095) to the nucleotide
sequence encoding IgG WTH (CCC) WTCH2CH3 (SEQ ID NO:1) according to
the methods described in Examples 1 and 10. The extracellular
domain nucleotide sequence also comprises a BclI restriction enzyme
site at the 3' end, and a leader peptide nucleotide sequence (SEQ
ID NO:79) that encodes an oncoM leader peptide (SEQ ID NO:80). A
second CTLA-4 IgG fusion protein, designated CTLA-4 IgG MTH (SSS)
MTCH2WTCH3, contained the extracellular domain of CTLA-4 (plus the
oncoM leader peptide sequence) fused to a mutant IgG hinge in which
all three cysteine residues were replaced with serine residues. The
hinge region was fused to a mutant IgG1 CH2 domain that had a
mutation at isotype position 238 (EU numbering, Ward et al., supra,
(position 251 using numbering according to Kabat et al., supra;
position 209 where numbering commences with first residue of IgG1
CH1; i.e., PAPELLDGPS (SEQ ID NO:566) of wild type IgG1 CH2 is
modified to PAPELLDGSS (SEQ ID NO:567)), which was fused to IgG1
wild type CH3 (U.S. Pat. No. 5,844,095). The CTLA-4 IgG MTH (SSS)
MTCH2WTCH3 polynucleotide comprises the nucleotide sequence in SEQ
ID NO:85 and the deduced amino acid sequence comprises the sequence
provided in SEQ ID NO:86. CTLA-4 fusion proteins were also prepared
using CTLA-4 extracellular membrane encoding sequences without the
leader peptide (SEQ ID NO:84).
[0613] To measure CDC activity, purified CTLA-4 IgG WTH (CCC)
WTCH2CH3 (2 .mu.g/ml) or CTLA-4 IgG MTH (SSS) MTCH2WTCH3 (2
.mu.g/ml) was added to Reh cells (see Example 12) and to Reh cells
transfected with the costimulatory molecule CD80 such that CD80 was
expressed on the cell surface (Reh CD80.10; see Doty et al., 1998
J. Immunol. 161:2700; Doty et al., 1996 J. Immunol. 157:3270), in
the presence or absence of rabbit complement (10 .mu.g/ml).
Purified CTLA Ig fusion proteins were prepared from culture
supernatants of transiently transfected COS cells according to
methods described in Example 10. The assays were performed
essentially as described in Example 11 and 12. The data presented
in FIG. 32 show that only CD80-transfected Reh cells were killed in
the presence of complement and CTLA-4 IgG WTH (CCC) WTCH2CH3 fusion
protein.
[0614] The purified CTLA-4 Ig fusion proteins were also tested in
ADCC assays. Human PBMC, serving as effector cells, were added to
Reh or Reh CD80.1 target cells at a ratio of 1.25:1, 2.5:1, 5.0:1,
and 10:1. Cells were labeled and the assays performed essentially
as described in Examples 11 and 12. The results are presented in
FIG. 33. Each data point represents the average of four independent
culture wells at each effector:target cell ratio. The data show
that only CTLA-4 IgG WTH (CCC) WTCH2CH3 mediated significant ADCC
of Reh CD80.10 cells.
Example 15
Effector Function of CTLA-4 IgA Fusion Proteins
[0615] CTLA-4 IgA fusion proteins are prepared as described for the
IgG fusion proteins (see Examples 1, 13, and 14). CTLA-4
extracellular domain nucleotide sequence (SEQ ID NO:84) is fused in
open reading frame to nucleotides encoding IgAH IgACH2CH3 (SEQ ID
NO:63) to provide the nucleotide sequence (SEQ ID NO:87) encoding a
CTLA-4 IgAH IgACH2CH3 fusion protein (SEQ ID NO:88). The fusion
protein is transiently expressed in COS cells (see Example 10) or
stably expressed in CHO cells (see Example 1). Secretion of the
CTLA-4 IgAH IgACH2CH3 fusion protein requires co-transfection with
a construct containing a polynucleotide sequence (SEQ ID NO:65)
that encodes human J chain (SEQ ID NO:66). The CTLA-4 IgAH
IgACH2CH3 fusion protein is isolated as described in Examples 10
and 14. To express a CTLA-4 IgA construct without the presence of J
chain, a CTLA-4 IgAH IgA-T4 construct is prepared and transfected
into mammalian cells. In a similar manner as described for the
CTLA-4 extracellular fragment fused to wild type IgA hinge-CH2CH3,
the CTLA-4 extracellular domain nucleotide sequence (SEQ ID NO:84)
is fused in open reading frame to a nucleotide sequence (SEQ ID
NO:68) encoding a IgAH IgA-T4 polypeptide (SEQ ID NO:69) to provide
a nucleotide sequence comprising SEQ ID NO:89 encoding a CTLA-4
IgAH IgA-T4 polypeptide (SEQ ID NO:90). Effector function of each
construct is evaluated by CDC and ADCC as described in Example
14.
Example 16
Binding of Anti-CD20 scFv Human Ig Fusion Proteins to CHO Cells
Expressing CD20
[0616] This Example describes binding of 2H7 scFv Ig fusion
proteins to CHO cells that express CD20. The analysis was performed
by flow cytometry. Culture supernatants were collected from
transiently transfected COS cells expressing 2H7 scFv IgG WTH (CCC)
WTCH2CH3 (SEQ ID NO:28); 2H7 scFv IgG MTH (CSS) WTCH2CH3 (SEQ ID
NO:135); 2H7 scFv IgG MTH (SCS) WTCH2CH3 (SEQ ID NO:137); and 2H7
scFv VHSER11 WTH WTCH2CH3, and two-fold serial dilutions were
prepared. Serial two-fold dilutions of purified 2H7 scFv IgG MTH
(SSC) WTCH2CH3 (SEQ ID NO:139) were prepared starting at a
concentration of 5 .mu.g/ml. The culture supernatants and purified
fusion protein samples were incubated with (CD20+) CHO cells for
one hour on ice. The cells were washed twice and then incubated
with 1:100 FITC-conjugated goat anti-human IgG (CalTag) for 40
minutes. The unbound conjugate was then removed by washing the
cells and flow cytometry analysis was performed using a Coulter
Epics XL cell sorter. Results are presented in FIG. 34.
Example 17
Immunoblot Analysis of Anti-CD20 scFv Human IgG and IgA Fusion
Proteins
[0617] This Example describes immunoblot analysis of 2H7 scFv IgG
and 2H7 scFv IgA fusion proteins that were immunoprecipitated from
transfected cell culture supernants.
[0618] COS cells were transiently transfected with plasmids
comprising nucleotide sequences for 2H7 scFv IgG WTH (CCC) WTCH2CH3
(SEQ ID NO:28); 2H7 scFv IgG MTH (CSS) WTCH2CH3 (SEQ ID NO:135);
2H7 scFv IgG MTH (SCS) WTCH2CH3 (SEQ ID NO:137); 2H7 scFv IgA H IgG
WTCH2CH3 (SEQ ID NO:60); and scFv IgG MTH (SSS) WTCH2CH3 (SEQ ID
NO:58) essentially according to the method described in Example 10.
Cells were also transfected with vector only. After 48-72 hours at
37.degree. C., cell culture supernatants were harvested and
combined with protein A-agarose beads (Repligen) for one hour at
4.degree. C. The beads were centrifuged and washed several times in
TNEN [20 mM Tris base, 100 mM NaCl, 1 mM EDTA, and 0.05% NP-40, pH
8.0). The immunoprecipitates were combined with 25 .mu.l 2.times.
NuPAGE.RTM. SDS Sample Buffer (Invitrogen Life Technologies)
(non-reduced samples). The proteins were fractionated on
NuPAGE.RTM. 10% Bis-Tris gels (Invitrogen Life Technologies). After
electrophoresis (approximately 1 hour), the proteins were
transferred from the gel onto a Immobilon P polyvinylidene fluoride
(PVDF) membrane (Millipore, Bedford, Mass.) using a semi-dry
blotter (Ellard Instrumentation, Monroe, Wash.). The PVDF membrane
was blocked in PBS containing 5% nonfat milk and then probed with
HRP-conjugated goat anti-human IgG (Fc specific) (CalTag). After
washing the immunoblot several times in PBS, the blot was developed
using ECL (Amersham Biosciences). The results are shown in FIG.
35.
Example 18
Binding of Anti-CD20 scFv Human IgA Fusion Proteins to CD20+CHO
Cells
[0619] This Example describes flow immunocytofluorimetry analysis
of binding of 2H7 scFv IgAH IgACH2CH3 (SEQ ID NO:62) and 2H7 scFv
IgAH IgAT4 (SEQ ID NO:70) fusion proteins to (CD20+) CHO cells.
[0620] COS cells were transiently co-transfected as described in
Example 10 with plasmid DNA comprising a polynucleotide sequence
(SEQ ID NO:61) encoding 2H7 scFv IgAH IgACH2CH3 polypeptide (SEQ ID
NO:62) and with a separate plasmid comprising a polynucleotide
sequence (SEQ ID NO:65) encoding a human J chain polypeptide (SEQ
ID NO:66). COS cells were also transfected with a polynucleotide
sequence (SEQ ID NO:70) encoding a 2H7 scFv IgA fusion protein that
had a deletion of four amino acids at the carboxy terminus of CH3
(2H7 scFv IgAH IgA-T4, SEQ ID NO:71). The transfections were
performed as described in Example 10. Culture supernatants from
transfected COS cells were combined with (CD20+) CHO cells (see
Example 1) and incubated for one hour on ice. The cells were washed
twice with PBS-2% FBS and then combined with FITC-conjugated goat
anti-human IgA chain (CalTag) (1:100) for 40 minutes. The cells
were again washed and then analyzed by flow cytometry using a
Coulter Epics XL cell sorter. FIG. 36 shows that co-transfection
with J chain was not required for secretion of 2H7 scFv IgAH IgAT4,
the 2H7 IgA fusion protein with the truncated CH3 carboxy end (SEQ
ID NO:71).
Example 19
Effector Function of Anti-CD20 scFv Human IgA Fusion Proteins
[0621] This Example illustrates ADCC activity of 2H7 IgG and IgA
fusion proteins against cells that express CD20. BJAB cells were
prelabeled with .sup.51Cr (100 .mu.Ci) (Amersham) for two hours at
37.degree. C. Effector cells were obtained from fresh, resting
human whole blood, which was diluted in an equal volume of
Alsever's solution to prevent coagulation. 2H7 scFv IgG MTH (SSS)
WTCH2CH3 (SEQ ID NO:58); 2H7 scFv IgG MTH (SCS) WTCH2CH3 (SEQ ID
NO:137); 2H7 scFv IgG WTH (CCC) WTCH2CH3 (SEQ ID NO:28); and 2H7
scFv IgAH IgACH2CH3 (SEQ ID NO:62) fusion proteins were purified
from transiently transfected COS cell supernatants (100-200 ml) by
protein A chromatography as described in Example 10. COS cells
transfected with the plasmid encoding 2H7 scFv IgAH IgACH2CH3 were
co-transfected with a plasmid encoding human J chain as described
in Example 18. Two-fold serial dilutions of the purified 2H7 Ig
fusion proteins starting at 5 .mu.g/ml were added to the labeled
BJAB cells (5.times.10.sup.4 cells per well of 96 well tissue
culture plate) in the presence of whole blood (100 .mu.l of whole
blood diluted 1:1 in Alsever's solution, final dilution 1:4) and
incubated for five hours at 37.degree. C. Culture supernatants were
harvested and analyzed as described in Example 11. Percent specific
killing was calculated according to the following equation:
((experiment release minus spontaneous release)/(maximum release
minus spontaneous release)).times.100. The data are presented in
FIG. 37. Each data point represents the average of quadruplicate
samples.
[0622] In a second ADCC assay, the number of labeled BJAB target
cells was held constant in each sample, and whole blood was added
at dilutions of 0.25, 0.125, and 0.0625. Purified 2H7 IgG and IgA
fusion proteins were added at a concentration of 5 .mu.g/ml. The
BJAB cells, whole blood, and fusion proteins were incubated, the
supernatants harvested, and the percent specific killing was
calculated as described above. Percent specific killing for each of
the 2H7 fusion proteins is presented in FIG. 38.
[0623] The ADCC activity of purified 2H7 scFv IgG MTH (SSS)
WTCH2CH3 (5 .mu.g/ml) and of purified 2H7 scFv IgAH IgACH2CH3 (5
.mu.g/ml) was compared in the presence of different effector cell
populations. PBMC were isolated from whole blood as described in
Examples 11 and 12. PBMC were combined with labeled BJAB target
cells (5.times.10.sup.4 per well of 96 well tissue culture plate)
at ratios of 50:1, 25:1, and 12.5:1. The assay was performed and
the data analyzed as described above. FIG. 39A shows that only the
2H7 scFv IgG MTH (SSS) WTCH2CH3 fusion protein had ADCC activity
when PBMC served as the effector cells. FIG. 39B shows that both
2H7 scFv IgG MTH (SSS) WTCH2CH3 and 2H7 scFv IgAH IgACH2CH3 exhibit
ADCC activity when whole blood was the source of effector cells (as
illustrated in FIG. 38).
Example 20
Expression Level of 2H7 scFv VH11ser IgG MTH (SSS) WTCH2CH3 Fusion
Protein
[0624] This Example compares the expression level of 2H7 scFv
VH11Ser IgG MTH (SSS) WTCH2CH3 fusion protein (SEQ ID NO:370) with
other 2H7 scFv IgG constructs that do not contain the mutation in
the variable heavy chain domain. The mammalian expression vector
pD18 comprising nucleotide sequences 2H7 scFv IgG MTH (SSS)
WTCH2CH3 (SEQ ID NO:370); 2H7 scFv IgG MTH (CSS) WTCH2CH3 (SEQ ID
NO:372); 2H7 scFv IgG MTH (SCS) WTCH2CH3 (SEQ ID NO:137); 2H7 scFv
IgG WTH (CCC) WTCH2CH3 (SEQ ID NO:28); and 2H7 scFv VHSER11 IgG MTH
(SSS) WTCH2CH3 (see Examples 1 and 13) were transiently transfected
into COS cells as described in Example 10. After 72 hours at
37.degree. C., culture supernatants were harvested, and 1 .mu.l of
each supernatant was combined with non-reducing sample buffer (see
method described in Example 10). The culture supernatant samples
and aliquots of purified 2H7 scFv IgG MTH (SSS) WTCH2CH3 (40 ng, 20
ng, 10 ng/5 ng, and 2.5 ng) were fractionated on 10% Bis-Tris
(MOPS) NuPAGE.RTM. gels (Invitrogen Life Technologies).
Multimark.RTM. protein standards (Invitrogen Life Technologies)
were also separated on the gel. The proteins were transferred to a
PDVF membrane and immunoblotted as described in Example 17. The
immunoblot is presented in FIG. 40. The amounts of the fusion
proteins were quantified by densitometry analysis of the blots
using the ScionImage for Windows software and comparison with the
standard curve. The 2H7 scFv IgG WTH (CCC) WTCH2CH3 construct
produced approximately 12 ng/ul or 12 micrograms/ml, the 2H7 scFv
IgG MTH (CSS) WTCH2CH3 produced approximately 10 ng/ul or 10
micrograms/ml, the 2H7 scFv IgG MTH (SCS) WTCH2CH3 construct
produced approximately 1 ng/ul or 1 microgram/ml, and the 2H7 scFv
VHSER11 IgG MTH (SSS) WTCH2CH3 construct produced approximately 30
ng/ml or 30 micrograms/ml. In particular claimed embodiments the
instant invention, an amino acid sequence of 2H7 scFv VHSER11 IgG
MTH (SSS) WTCH2CH3, or a polynucleotide sequence that encodes 2H7
scFv VHSER11 IgG MTH (SSS) WTCH2CH3 may be optionally excluded from
the instant invention. Similarly, an amino acid sequence of 2H7
scFv VHSER11 IgG WTH (CCC) WTCH2CH3, or a polynucleotide sequence
that encodes 2H7 scFv VHSER11 IgG WTH (CCC) WTCH2CH3 may be
optionally excluded from particular claimed embodiments of the
instant invention. Additionally, an amino acid substitution of a
leucine at position 11 to serine in the variable heavy chain
domain, or polynucleotides that encode an amino acid substitution
of a leucine at position 11 to serine in the variable heavy chain
domain, may be optionally excluded from particular claimed
embodiments of the instant invention.
Example 21
Construction of a 2H7 scFv IgG Fusion Protein with a Mutant CH3
Domain
[0625] Amino acid mutations were introduced into the CH3 domain of
a 2H7 IgG fusion protein. The pD18 vector comprising 2H7 scFv IgG
MTH (SSS) WTCH2CH3 (SEQ ID NO:135) was digested with BclI and XbaI
to remove the MTH WTCH2CH3 fragment, which was then subcloned into
pShuttle vector (BD Biosciences Clontech, Palo Alto, Calif.) that
was double-digested with BclI and XbaI. Subcloning was performed in
a kanamycin resistant vector because the ampicillin resistance gene
has an XmnI site, which is required for this cloning procedure.
Five constructs were prepared with the following substitutions: (1)
a phenylalanine residue at position 405 (numbering according to
Kabat et al. supra) was substituted with tyrosine using the
oligonucleotide CH3Y405; (2) the phenylalanine position at 405 was
substituted with an alanine residue using the oligonucleotide
CH3A405; (3) the tyrosine residue at position 407 was substituted
with an alanine using the oligonucleotide CH3A407; (4) both wild
type amino acids at positions 405 and 407 were substituted with
tyrosine and alanine, respectively using the oligonucleotide
CH3Y405A407; and (5) both wild type amino acids at positions 405
and 407 were substituted with alanine using the oligonucleotide
CH3A405A407. The oligonucleotides were the 3' primers for PCR
amplification of a portion of the CH3 domain. The nucleotide
sequences for each 3' oligonucleotide were as follows.
TABLE-US-00002 (SEQ ID NO: 568) CH3Y405: 5'-gtt gtt gaa gac gtt ccc
ctg ctg cca cct gct ctt gtc cac ggt gag ctt gct gta gag gta gaa gga
gcc-3' (SEQ ID NO: 569) CH3A405: 5'-gtt gtt gaa gac gtt ccc ctg ctg
cca cct gct ctt gtc cac ggt gag ctt gct gta gag ggc gaa gga gcc-3'
(SEQ ID NO: 570) CH3A407: 5'-gtt gtt gaa gac gtt ccc ctg ctg cca
cct gct ctt gtc cac ggt gag ctt gct ggc gag gaa gaa gga gcc-3' (SEQ
ID NO: 571) CH3Y405A407: 5'-gtt gtt gaa gac gtt ccc ctg ctg cca cct
gct ctt gtc cac ggt gag ctt gct ggc gag gta gaa gga gcc-3' (SEQ ID
NO: 572) CH3A405A407: 5'-gtt gtt gaa gac gtt ccc ctg ctg cca cct
gct ctt gtc cac ggt gag ctt gct ggc gag ggc gaa gga gcc-3'
[0626] The template was the mutant hinge MHWTCH2CH3 human IgG1. The
5' PCR oligonucleotide primer was huIgGMHWC. The amplified products
were TOPO.RTM. cloned and sequenced as described in Examples 1 and
10. DNA from the clones with the correct sequence was digested with
BclI and XmnI and transferred to pShuttle containing the MTH
WTCH2CH3 sequence, which was also digested with the same
restriction enzymes. The mutated IgG sequences were then removed by
digestion with BclI and XbaI and inserted into a pD18 vector
containing 2H7 scFv that was also digested with BclI and XbaI. The
polynucleotide sequences for mutated the CH3 domains, MTCH3 Y405,
MTCH3 A405, MTCH3 A407, MTCH3 Y405A407, and MTCH3 A405A407 are
shown in SEQ ID NOs:143, 145, 147 and 149, respectively, and the
polypeptide sequences for each are shown in SEQ ID NOs:144, 146,
148 and 150, respectively. The polynucleotide sequences for the 2H7
scFv MTH WTCH2 MTCH3 Y405, 2H7 scFv MTH WTCH2 MTCH3 A405, scFv MTH
WTCH2 MTCH3 A407, scFv MTH WTCH2 MTCH3 Y405A407, and scFv MTH WTCH2
MTCH3 A405A407, respectively, and the deduced amino acid sequences
are shown in SEQ ID NOs:154, 156, 158, 160 and 162, and the deduced
nucleotide sequences are shown in SEQ ID NOs: 153, 155, 157, 159,
161, respectively, respectively.
Example 22
Construction of 2H7 scFv IgG Fusion Proteins with Hinge
Mutations
[0627] A 2H7 scFv IgG fusion protein was constructed with the third
cysteine residue in the IgG1 hinge region substituted with a serine
residue. The template for introduction of the mutations was a
polynucleotide encoding 2H7 scFv WTH WTCH2CH3 (SEQ ID NO:28). The
oligonucleotide introducing the mutations was a 5' PCR primer
oligonucleotide HIgGMHcys3 having the sequence 5'-gtt gtt gat cag
gag ccc aaa tct tgt gac aaa act cac aca tgt cca ccg tcc cca gca
cct-3' (SEQ ID NO:573). The oligonucleotide introducing the
mutation into the hinge region was combined with template and a 3'
oligonucleotide containing an XbaI site (underlined and italicized)
(5'-gtt gtt tct aga tca ttt acc cgg aga cag gga gag get ctt ctg cgt
gta g-3' (SEQ ID NO:574)) to amplify the mutant hinge-wild type
(WT)-CH2-CH3 sequences by PCR. The IgG MTH CCS mutant sequence was
amplified for 30 cycles with a denaturation profile of 94.degree.
C., annealing at 50.degree. C. for 30 seconds, and extension at
72.degree. C. for 30 seconds. The amplified polynucleotides were
inserted into the TOPO.RTM. cloning vector (Invitrogen Life
Technologies) and then were sequenced as described in Example 1 to
confirm the presence of the mutation. pD18 vector containing 2H7
scFv was digested to remove the constant region sequences
essentially as described in Example 10. The mutant hinge-wild type
CH2-CH3 regions were inserted in frame into the digested vector DNA
to obtain vectors comprising 2H7 scFv MTH (CCS) WTCH2CH3 encoding
DNA (SEQ ID NO:167). The deduced polypeptide sequence is shown in
SEQ ID NO:168.
Example 23
Construction of Anti-CD20 IgE Fusion Proteins
[0628] A binding domain is fused to IgE constant region sequences
such that the expressed polypeptide is capable of inducing an
allergic response mechanism. The single chain Fv nucleotide
sequence of 40.2.220 (SEQ ID NO:35), an anti-CD40 antibody, is
fused to IgE CH2-CH3-CH4 according to methods described for other
scFv immunoglobulin constant region constructs (see Examples 1, 5,
10, and 13). To PCR amplify the IgE CH2-CH3-CH4 domains, a 5'
oligonucleotide primer, hIgE5Bcl, having the sequence 5'-gtt gtt
gat cac gtc tgc tcc agg gac ttc acc cc-3' (SEQ ID NO:575), and a 3'
oligonucleotide primer, hIgE3stop, having the sequence 5'-gtt gtt
tct aga tta act ttt acc ggg att tac aga cac cgc tcg ctg g-3' (SEQ
ID NO:576) are used.
[0629] The retroviral transfection system for ectopic surface
expression of genetically engineered cell surface receptors
composed of scFvs that bind costimulatory receptors described in
Example 12 is used to construct a 40.2.220 scFv IgE-CD80 fusion
protein. The 40.2.220 scFv IgE fusion polynucleotide sequence is
fused in frame to sequences encoding the transmembrane domain and
cytoplasmic tail of human CD80 (SEQ ID NO:30), such that when the
fusion protein is expressed in the transfected cell, CD80 provided
an anchor for surface expression of the scFv Ig fusion protein.
cDNA encoding the anti-CD40 scFv-IgE-CD80 fusion proteins is
inserted into the retroviral vector pLNCX (BD Biosciences Clontech)
according to standard molecular biology procedures and vendor
instructions. The 40.2.220 scFv-Ig-CD80 cDNA is inserted between
the 5'LTR-neomycin resistance gene-CMV promoter sequences and the
3'LTR sequence. The retroviral constructs are transfected into a
carcinoma cell line, and transfected cells are screened to select
clones that are expressing the 40.2.220 scFv-Ig-CD80 fusion protein
on the cell surface.
Example 24
Construction of IgA-T4 Mutants that are Expressed on the Cell
Surface
[0630] The retroviral transfection system for ectopic surface
expression of genetically engineered cell surface receptors
composed of scFvs that bind costimulatory receptors described in
Example 12 is used to construct a 2H7 scFv IgA hinge IgA-T4-CD80
fusion protein. The 2H7 scFv IgAH IgA-T4 fusion polynucleotide
sequence (SEQ ID NO:70) is fused in frame to sequences encoding the
transmembrane domain and cytoplasmic tail of human CD80 (SEQ ID
NO:29), such that when the fusion protein is expressed in the
transfected cell, CD80 provided an anchor for surface expression of
the scFv Ig fusion protein. cDNA encoding the 2H7 scFv IgAH
IgA-T4-CD80 fusion protein is inserted into the retroviral vector
pLNCX (BD Biosciences Clontech) according to standard molecular
biology procedures and vendor instructions. The 2H7 scFv IgAH
IgA-T4-CD80 cDNA is inserted between the 5'LTR-neomycin resistance
gene-CMV promoter sequences and the 3'LTR sequence. The retroviral
construct is transfected into Reh, an acute lymphocytic leukemia
cell line (ATCC CRL-8286). Transfected cells are screened to select
clones that are expressing 2H7 scFv-Ig fusion proteins on the cell
surface.
Example 25
Characterization of an Anti-4-1BB scFv Ig-CD80 Fusion Protein
Expressed on the Cell Surface of Tumor Cells and Growth of the
Tumor Cells In Vivo
[0631] This Example describes construction of an anti-murine 4-1BB
(CD137) scFv fusion protein that has an IgG wild type hinge and CH2
and CH3 domains that is fused to the CD80 transmembrane and
cytoplasmic domains. The Example also illustrates the effect of the
cell surface expression of the anti-4-1BB scFv IgG CD80 polypeptide
when the transfected tumor cells are transplanted into mice.
[0632] The heavy and light chain variable regions of a rat
anti-4-1BB (CD137) monoclonal antibody (1D8) were cloned, and a
single chain Fv construct was prepared essentially as described in
Example 1. The heavy chain and light chain variable regions of each
antibody were cloned according to standard methods for cloning
immunoglobulin genes and as described in Example 1. Aingle chain Fv
construct was prepared as described in Example 1 by inserting a
nucleotide sequence encoding a (gly.sub.4ser).sub.3 (SEQ ID NO:529)
peptide linker between the VL region nucleotide sequence of 1D8
(SEQ ID NO:102) and the VH region nucleotide sequence of 1D8 (SEQ
ID NO:100). The polypeptide sequence for 1D8 VL is shown in SEQ ID
NO:103, and the polypeptide sequence for the VH domain is shown in
SEQ ID NO:101. The scFv polynucleotide (SEQ ID NO:104) was then
fused to human IgG1 wild-type hinge-CH2-CH3 domains according to
the methods described in Example 1. The scFv IgG1 fusion
polynucleotide sequence was then fused in frame to sequences
encoding the transmembrane domain and cytoplasmic tail of human
CD80 (SEQ ID NO:29) essentially as described in Example 12, such
that when the fusion protein was expressed in the transfected cell,
CD80 provided an anchor for surface expression of the scFv Ig
fusion protein. cDNA encoding the scFv-IgG-CD80 fusion protein (SEQ
ID NO:110) was inserted into the retroviral vector pLNCX (BD
Biosciences Clontech) according to standard molecular biology
procedures and vendor instructions. The scFv-Ig-CD80 cDNA was
inserted between the 5'LTR-neomycin resistance gene-CMV promoter
sequences and the 3'LTR sequence.
[0633] The retroviral constructs were transfected into the
metastatic M2 clone of K1735, a melanoma cell line, provided by Dr.
I. Hellstrom, PNRI, Seattle, Wash. Transfected cells were screened
to select clones that were expressing scFv-Ig fusion proteins on
the cell surface. To demonstrate that the 1D8 scFv IgG-CD80
construct was expressed on the cell surface of the tumor cells, the
transfected cells were analyzed by flow immunocytofluorimetry.
Transfected cells (K1735-1D8) were incubated for one hour on ice in
phycoerythrin-conjugated F(ab').sub.2 goat anti-human IgG. The
unbound conjugate was then removed by washing the cells and flow
cytometry analysis was performed using a Coulter Epics XL cell
sorter. Results are presented in FIG. 41A.
[0634] The growth of K1735-1D8 transfected cells was examined in
vivo. K1735-WT cells grew progressively when transplanted
subcutaneously (s.c.) in naive C3H mice. Although the same dose of
K1735-1D8 cells initially formed tumors of an approximately 30
mm.sup.2 surface area, the tumors started to regress around day 7
and had disappeared by day 20 as shown in FIG. 41B. Tumor cells
that were transfected with a similarly constructed vector encoding
a non-binding scFv, a human anti-CD28 scFv construct, grew as well
as tumor cells that had not been transfected. The presence of a
foreign protein, that is, human IgG1 constant domains or rat
variable regions, did not make transfected K1735-WT cells
immunogenic; the growth of the K1735-1D8 cells in C3H mice was
identical to that of K1735-WT cells (untransfected).
[0635] To investigate the roles of CD4.sup.+ and CD8.sup.+ T
lymphocytes and NK cells in the regression of K1735-1D8 tumors,
naive mice were injected intraperitoneally (i.p.) with monoclonal
antibodies (monoclonal antibodies, typically 50 .mu.g in a volume
0.1 ml) to remove CD8.sup.+, CD4.sup.+ or both CD4.sup.+ and
CD8.sup.+ T cells, or were injected with anti-asialo-GM1 rabbit
antibodies to remove NK cells. Twelve days later, when flow
cytometry analysis of spleen cells from identically treated mice
showed that the targeted T cell populations were depleted,
K1735-1D8 cells were transplanted s.c to each T cell-depleted
group. K1735-1D8 had similar growth kinetics in mice that had been
injected with the anti-CD8 MAb or control rat IgG while removal of
CD4' T cells resulted in the growth of K1735-1D8 with the same
kinetics as K1735-WT. This failure to inhibit tumor growth after
CD4+ T cell removal was observed regardless of the presence or
absence of CD8+ T cells. K1735-1D8 grew in all NK-depleted mice,
although more slowly than in the CD4-depleted group. The results
are presented in FIG. 41C.
Example 26
Therapeutic Effect of Tumor Cells Expressing Anti-4-1BB scFv
IgG-CD80 Fusion Protein
[0636] This Example examines the ability of K1735-1D8 transfected
tumor cells expressing an anti-CD137 scFv on the cell surface to
generate a sufficient immune response in mice to mediate rejection
of established, untransfected wild type tumors. C3H mice were
transplanted with K1735-WT tumors (2.times.10.sup.6 cells/animal)
and grown for approximately six days. Experiments were performed
using mice with established K1735-WT tumors of 30 mm.sup.2 surface
area. Mice were vaccinated by s.c. injection of K1735-1D8 or
irradiated K1735-WT cells on the contralateral side. Identical
injections were repeated at the time points indicated in FIG. 42.
One group of animals was given four weekly injections of K1735-1D8
cells. According to the same schedule, another group was given
irradiated (12,000 rads) K1735-WT cells, and a third group was
injected with PBS. The data are plotted in FIG. 42. The WT tumors
grew progressively in all control mice and in all mice that
received irradiated K1735-WT cells. In contrast, the tumors
regressed in 4 of the 5 mice treated by immunization with
K1735-1D8. The animals remained tumor-free and without signs of
toxicity when the experiment was terminated 3 months later. In the
fifth mouse, the tumor nodule decreased in size as long as the
mouse received K1735-1D8 cells, but the tumor grew back after
therapy was terminated.
[0637] In another experiment with 5 mice/group, mice were injected
intravenously (i.v.) with 3.times.10.sup.5 K1735-WT cells to
initiate lung metastases. Three days later, K1735-1D8 cells were
transplanted s.c. This procedure was repeated once weekly for a
month; control mice were injected with PBS. The experiment was
terminated when one mouse in the control group died, 37 days after
receiving the K1735-WT cells. At that time, lungs of the control
mice each had >500 metastatic foci. In contrast, less than 10
metastatic foci were present in the lungs of the immunized
mice.
[0638] In a third experiment, mixtures of K1735-WT cells and
K1735-1D8 cells were injected into immunocompetent syngeneic C3H
mice. Mice were injected subcutaneously with K7135-WT cells alone
or with a mixture of 2.times.10.sup.6 K1735-WT cells and
2.times.10.sup.5 K1735-1D8 cells. Tumor growth was monitored at
5-day intervals.
Example 27
Expression of Anti-4-1BB scFv IgG-CD80 Fusion Protein on the Cell
Surface of Sarcoma Cells
[0639] This Example demonstrates expression of an anti-CD137 scFv
on the cell surface of a second type of tumor cell by transfecting
a murine sarcoma cell line with an anti-CD137 scFv IgG-CD80
construct.
[0640] The 1D8 scFv IgG WTH WTCH2CH3-CD80 polynucleotide (SEQ ID
NO:110) was transferred from the pLNCX vector into pcDNA3-hygro
vector using restriction enzyme digestion and ligation steps
according to standard molecular biology methods. The constuct was
cut with HindIII+Cla1 and thesFv fragment was filled in with Klenow
(Roche) and the blunt-ended fragment was ligated into EcoR5 site of
pcDNA3. Ag104 murine sarcoma tumor cells were transfected with the
pcDNA3-hygro vector containing the 1D8 scFv IgG CD80 fusion
protein. Hygromycin-resistant clones were screened by flow
cytometry using a FITC anti-human IgG antibody to detect expression
of the transgene. Only approximately 15% of the resistant clones
had detectable fusion protein initially. Positive cells identified
by flow cytometry were repeatedly panned on flasks coated with
immobilized anti-human IgG (10 .mu.g/ml) according to standard
methods. Panning was performed by incubating cells on the coated
plates for 30 min at 37 C; the plates were then washed 2-3.times.
in versene or PBS. After each round, cells were tested for IgG
expression by FACS. The histogram in FIG. 44 shows the staining
pattern after four rounds of panning against anti-human IgG
(black). Untransfected cells were stained and are indicated in
gray. All of the cells in the population were positive.
Example 28
Construction and Characterization of a Bispecific scFv Ig Fusion
Protein and scFv Ig Fusion Proteins with a Mutation in the IgG1 CH2
Domain
[0641] An anti-CD20 (2H7) scFv IgG fusion protein was constructed
that had a mutant hinge (MT (SSS)) and a mutant CH2 domain in which
the proline at residue (position number 238 according to Ward et
al., supra) was substituted with a serine. The 2H7 scFv IgG MTH
(SSS) MTCH2WTCH3 encoding polynucleotide (SEQ ID NO:130) was
constructed essentially according to methods described in Examples
1, 5, and 13. The IgG mutant hinge-mutant CH2-wild type CH3 domains
were also fused to an anti-CD20 (2H7)-anti-CD40 (40.2.220)
bispecific scFv. The anti-CD20-anti-CD40 scFv IgG MTH (SSS)
MTCH2WTCH3 encoding polynucleotide sequence is shown in SEQ ID
NO:114 and the encoded polypeptide is shown in SEQ ID NO:115.
[0642] COS cells were transiently transfected with vectors
comprising the polynucleotide sequences encoding 2H7 scFv IgG MTH
(SSS) MTCH2WTCH3 (SEQ ID NO:131); anti-CD20-anti-CD40 scFv IgG MTH
(SSS) MTCH2WTCH3 (SEQ ID NO:114); 2H7 scFv IgG MTH (SSS) WTCH2CH3
(SEQ ID NO:58); and 2H7 scFv IgAH IgG WTCH2CH3 (SEQ ID NO:60) as
described in Example 10. Culture supernatants were collected and
the fusion proteins were purified by protein A chromatography (see
Example 10). The purified polypeptides were fractionated by
SDS-PAGE according to the method described in Example 10. Rituximab
(anti-CD20 monoclonal antibody), and Bio-Rad prestained molecular
weight standards (Bio-Rad, Hercules, Calif.), and Multimark.RTM.
molecular weight standards (Invitrogen Life Technologies were also
applied to the gel. The results are presented in FIG. 45.
[0643] The 2H7 scFv Ig fusion protein that contains a mutation in
the CH2 domain was compared to fusion proteins that have the wild
type CH2 domain in an ADCC assay. The assays were performed
essentially as described in Examples 11 and 19. Fresh resting PBMC
(effector cells) were added to .sup.51Cr-labeled BJAB cells (target
cells) at the ratios indicated in FIG. 46. Purified 2H7 scFv IgG
MTH (SSS) MTCH2WTCH3, 2H7 scFv IgG MTH (SSS) WTCH2CH3, 2H7 scFv
IgAH IgG WTCH2CH3, and Rituximab, each at 10 .mu.g/ml were added to
the effector/target cell mixtures and incubated for five hours at
37.degree. C. Supernatants were harvested and the amount of
chromium released was determined as described in Examples 11 and
19. Percent specific killing by each fusion protein is presented in
FIG. 46.
Example 29
Tumor Cell Surface Expression of an Anti-Human CD3 scFv IgG Fusion
Protein
[0644] An anti-human CD3 scFv Ig CD80 fusion protein was prepared
essentially as described in Examples 1 and 12. The fusion protein
comprised an anti-human CD3 scFv fused to wild type IgG1 hinge (SEQ
ID NO:12) and wild type CH2 (SEQ ID NO:13) and CH3 (SEQ ID NO:15)
domains, fused to CD80 transmembrane and cytoplasmic domains (SEQ
ID NO:29) to enable cell surface expression of the anti-CD3 scFv.
The anti-human CD3 scFv IgG WTH WTCH2CH3-CD80 polynucleotide (SEQ
ID NO:110) encoding the polypeptide (SEQ ID NO:111) was transfected
in Reh cells and into T51 cells (lymphoblastoid cell line).
Expression of the anti-human CD3 scFv IgG fusion protein was
detected by flow cytometry using FITC conjugated goat anti-human
IgG (see methods in Examples 4, 10, 16, 18). FIG. 47A illustrates
expression of the anti-human CD3 fusion protein on the cell surface
of Reh cells, and FIG. 47B shows expression of the fusion protein
on T41 cells.
[0645] ADCC assays were performed with the transfected Reh and T51
cells to determine if expression of the scFv-Ig polypeptides on the
cell surface augmented effector cell function. Untransfected and
transfected Reh cells and untransfected and transfected T51 cells
were pre-labeled with .sup.51Cr (100 .mu.Ci) (Amersham) for two
hours at 37.degree. C. Human PBMC served as effector cells and were
added to the target cells (5.times.10.sup.4 cells per well of 96
well plate) at ratios of 20:1, 10:1, 5:1, and 2.5:1. After four
hours at 37.degree. C., culture supernatants were harvested and
analyzed as described in Examples 11 and 12. Percent specific
killing was calculated as described in Example 12. The results are
presented in FIG. 48.
Example 30
Induction of Cytokine Expression in Tumor Cells Expressing
Anti-CD28 scFv on the Cell Surface
[0646] This Example describes the effect of cell surface expressed
scFv on cytokine mRNA induction in stimulated lymphocytes
co-cultured with tumor cells transfected with an anti-human CD28
scFv IgG-CD80 fusion protein.
[0647] Real time PCR analysis was performed on RNA samples from
human PBMC stimulated with Reh, Reh-anti-CD28 (2e12) (see Example
12 for construction of 2e12 scFv IgG WTH WHTCH3CH2-CD80 and
transfection of Reh cells), and Reh-CD80 (see Example 14) in order
to measure the effects of the surface expressed scFv on cytokine
production by the PBMC effector cells. For the real-time PCR assay,
SYBR Green (QIAGEN) (Morrison et al., Biotechniques 24:954-8, 960,
962 (1998)) was used and measured by an ABI PRISM.RTM. 7000
Sequence Detection System (Applied Biosystems, Foster City, Calif.)
that measures the formation of PCR product after each amplification
cycle. Cells were harvested from cultures and total RNA prepared
using QIAGEN RNA kits, including a QIA shredder column purification
system to homogenize cell lysates, and RNeasy.RTM. mini-columns for
purification of RNA. cDNA was reverse transcribed using equal
amounts of RNA from each cell type and Superscript II Reverse
Transcriptase (Life Technologies). SYBR Green real-time PCR
analysis was then performed using the prepared cDNA as template and
primer pairs specific for cytokine gene products. The average
length of the PCR products that were amplified ranged from 150-250
base pairs. The cDNA levels for many activation response molecules
including IFN.gamma., TNF.alpha., GM-CSF, IL-4, IL-5, IL-6, IL-8,
IL-10, IL-12, IL-15, ICOSL, CD80 and CD86 were assayed. Control
reference cDNAs for constitutively expressed genes, including
GAPDH, .beta.-actin, and CD3.epsilon. were measured in each assay.
The most significant induction of specific mRNA was observed for
IFN-.gamma., and more modest induction was observed for CTLA-4 and
ICOS.
Example 31
Cloning of an Anti-Human 4-1BB Antibody and Construction of an
Anti-Human 4-1BB scFv Ig Fusion Protein
[0648] A hybridoma cell line expressing a mouse anti-human
monoclonal antibody (designated 5B9) was obtained from Dr. Robert
Mittler, Emory University Vaccine Center, Atlanta, Ga. The variable
heavy and light chain regions were cloned according to known
methods for cloning of immunoglobulin genes and as described
herein. Cells were grown in IMDM/15% FBS (Invitrogen Life
Technologies) media for several days. Cells in logarithmic growth
were harvested from cultures and total RNA prepared using QIAGEN
RNA kits, including a QIA shredder column purification system to
homogenize cell lysates, and RNeasy.RTM. mini-columns for
purification of RNA according to manufacturer's instructions. cDNA
was reverse transcribed using random hexamer primers and
Superscript II Reverse Transcriptase (Invitrogen Life
Technologies).
[0649] cDNA was anchor-tailed using terminal transferase and dGTP.
PCR was then performed using an anchor-tail complementary primer
and a primer that annealed specifically to the antisense strand of
the constant region of either mouse Ck (for amplifcation of VL) or
the appropriate isotype mouse CH1 (for amplification of VH). The
amplified variable region fragments were TOPO.RTM. cloned
(Invitrogen Life Technologies), and clones with inserts of the
correct size were then sequenced. Consensus sequence for each
variable domain was determined from sequence of at least four
independent clones. The 5B9 VL and VH polynucleotide sequences are
shown in SEQ ID NOs:120 and 116, respectively, and the deduced
amino acid sequences are shown in SEQ ID NOs:121 and 118. The scFv
was constructed by a sewing PCR method using overlapping primers
containing a synthetic (Gly.sub.4Ser).sub.3 (SEQ ID NO:529) linker
domain inserted between the light and heavy chain variable regions
(see Example 1). The 5B9 scFv polypeptide (SEQ ID NO:123) is
encoded by the polynucleotide sequence comprising SEQ ID
NO:122.
[0650] 5B9 scFv polynucleotide sequence was fused in frame to the
polynucleotide sequence encoding the human IgG1 mutant hinge and
wild type CH2 and CH3 (MTH (SSS) WTCH2CH3, according to methods
described in Examples 5, 10, and 13. COS cells were transiently
transfected with a vector comprising the 5B9 scFv IgG MTH (SSS)
WTCH2CH3 polynucleotide sequence (SEQ ID NO:132). Supernatant was
collected and binding of the 5B9 scFv IgG MTH (SSS) WTCH2CH3
polypeptide (SEQ ID NO:133) was measured by flow
immunocytofluorimetry essentially as described in Examples 4, 10,
16, and 18. Culture supernatant from the 5B9 hybridoma cell line
was also included in the binding assay. Fresh human PBMC were
incubated in the presence of immobilized anti-CD3 for four days
prior to the binding experiment to induce expression of CD137 on
the surface of activated T cells. Stimulated PBMC were washed and
incubated with COS or hybridoma culture supernatant containing the
5B9 scFv IgG fusion protein or 5B9 murine monoclonal antibody,
respectively, for 1 hour on ice. Binding of 5B9 scFv IgG fusion
protein or 5B9 murine monoclonal antibody was detected with FITC
conjugated anti-human IgG or anti-mouse IgG, respectively. The
results are presented in FIG. 49.
Example 32
Construction of 2H7 scFv IgG Fusion Proteins with Hinge
Mutations
[0651] 2H7 scFv IgG fusion proteins are constructed with the first
cysteine residue and the second cystein in the IgG1 hinge region
substituted with a serine residue to provide MTH (SCC) and MTH
(CSC). The template for introduction of the mutations is a
polynucleotide encoding 2H7 scFv WTH WTCH2CH3. The oligonucleotide
introducing the mutations are 5' PCR primer oligonucleotides
HIgGMHcys1 (SEQ ID NO:140) and HIgGMHcys2 (SEQ ID NO:141). The
constructs are prepared as described previously. The encoding
polynucleotides of the mutants are presented in SEQ ID NOs:163 and
165) and the polypeptide sequences are provided in SEQ ID NO:164
and 166).
Example 33
Construction of 2H7 V.sub.HL11S scFv (SSS-S) H WCH2 WCH3
[0652] A change from leucine to serine at position 11 in the heavy
chain variable region (numbering according to Kabat et al.,
Sequences of Proteins of Immunological Interest, 5.sup.th ed.
Bethesda, Md.: Public Health Service, National Institutes of Health
(1991)) was introduced into the 2H7 scFv MTH (SSS) WTCH2CH3 fusion
protein (SEQ ID NO:58). The wild type leucine residue was
substituted with serine by site-directed mutagenesis using the
oligonucleotide Vhser11: 5'-gga ggt ggg agc tct cag gct tat cta cag
cag tct ggg gct gag tcg gtg agg cc-3' (SEQ ID NO:577). The
3'-primer for PCR was huIgG1-3' having the sequence 5'-gtc tct aga
cta tca ttt acc cgg aga cag-3' (SEQ ID NO:578) (XbaI site
underlined and italicized). After PCR amplification, the fragments
were inserted into the TOPO.RTM. cloning vector and sequenced to
confirm the presence of the VH11 leucine to serine mutation. The
2H7 scFv-IgG (SSS-S) H WCH2 WCH3 encoding DNA was shuttled into the
PSL1180 cloning vector (Pharmacia Biotech, Inc., Piscataway, N.J.).
The construct PSL1180-2H7 scFv-IgG (SSS-S) H WCH2 WCH3 was digested
with Sac and XbaI to remove the wild type VH domain and the
connecting region and CH2 and CH3 domains. The PCR product
comprising the VH11 mutant was digested with Sac and XbaI and then
inserted into the digested PSL1180 construct according to standard
molecular biology procedures. The construct was then digested with
Hind III and XbaI, and inserted into the mammalian expression
vector pD18 (see methods described in Example 1 and Example 10).
The mutant is designated 2H7 scFv VH L11S IgG (SSS-S) H WCH2 WCH3.
The polynucleotide sequence is provided in SEQ ID NO:369, and the
encoded polypeptide sequence is provided in SEQ ID NO:370.
Example 34
Expression and of 2H7 scFv VH L11S (SSS-S) H WCH2 WCH3 in Stable
CHO Lines
[0653] CHO DG44 cells were transfected by electroporation with
approximately 150 micrograms of linearized expression plasmid
encoding the 2H7 VH L 11S scFv (SSS-S) H WCH2 WCH3. Cultures were
plated in selection media containing 100 nM methotrexate, in 96
well, flat bottom tissue culture plates at various numbers of
cells/well, ranging from 125 to 2000. Methotrexate resistant clones
were selected and culture supernatants were screened for the
highest expressors of the fusion protein using a CD20CHO binding
assay similar to that described for FIG. 1. Clones were amplified
after the initial selection in gradually increasing doses of
methotrexate. Cells were passaged for two passages in the higher
concentration prior to adjusting the concentration to the next
higher dose. Clones were amplified to a final concentration of 1
micromolar methotrexate.
[0654] FIG. 50B illustrates the production levels of 2H7 VH L11S
scFv (SSS-S) H WCH2 WCH3. Spent supernatants from amplified CHO
cells expressing this molecule and growing in stationary T25 flasks
were tested for quantitative binding to CD20 CHO cells by flow
cytometry. The activity was converted to protein concentration by
generation of a standard curve using the same molecule purified
from supernatants with Protein A affinity chromatography (FIG.
50A). The concentration of the purified protein was determined by
A280 using an extinction coefficient provided by the amino acid
composition of the recombinant protein (Vector NTI). Although
levels of production varied between clones tested, multiple clones
produced over 1 mg/ml. This level of protein expression is over
10-fold higher than the identical molecule except for the amino
acid change in V.sub.H.
[0655] FIG. 51 illustrates the production levels of 2H7 VH L11S
scFv (SSS-S) H WCH2 WCH3 by semi-quantitative analysis on SDS-PAGE.
Ten microliters of spent supernatant from amplified CHO cells
expressing this molecule and growing in stationary T25 flasks were
mixed with 10 microliters 2.times. non-reducing SDS sample buffer,
run on SDS-PAGE gels, and stained with coomassie blue.
Example 35
Construction and Binding Capacity of G28-1 scFv Ig Constructs
[0656] Contrstruction of the G28-1 (anti-CD37) scFv was performed
using total RNA isolated from the G28-1 hybridoma using Trizol
(Invitrogen) reagent according to manufacturer's instructions. cDNA
was prepared using random primers and the protocol described
previously for 2H7 cloning in Example 1. The variable domains of
the scFv was cloned using one of two methods: the first method used
a family of degenerate 5' oligonucleotides specific for each V
region gene family and a single 3' primer specific for the constant
region of either the light or heavy chain using methods and primers
described in (Ig-Prime Kit Mouse Ig-Primer Set, Novagen). The
second approach used the anchor-tailing methods and primers
described in (Gilliland L K et al, Tissue Antigens 47: 1-20 (1995).
In either case, PCR amplified products were cloned into the TOPO
cloning vector (Invitrogen). The clones were digested with EcoRI
and screened for inserts of the proper size. Positive clones were
sequenced as previously described in Example 1.
[0657] Specific primers were then designed for each V region, one
with the leader sequence and one without. Primers were also
designed to include desired linkers and/or restriction sites at the
primer ends. PCR reactions were performed on the TOPO cloned DNA
using a 25 cycle program with the following profile: 94 C, 30 sec;
55 C, 30 sec; 72 C, 30 sec, followed by a final extension at 72 C
for 8 minutes. PCR products were gel purified and fragments
recovered using a QIAQUICK gel extraction kit (QIAGEN, Valencia,
Calif.). Fragments were diluted 1:50 and 1 microliter used for
SEWING PCR reactions according to the methods described in Example
1. The following oligonucleotides were used for the secondary PCR
reactions of the V.sub.L domain for the G28-1 scFv:
TABLE-US-00003 (SEQ ID NO: 579) 5' primers with SalI site without
leader: 5'-GTTGTTGTCGACATCCAGATGACTCAGTCTCCA-3' (SEQ ID NO: 580) 5'
primer with HindIII site and leader sequence:
5'-GTCAAGCTTGCCGCCATGGTATCCA CAGCTCAGTTCCTTGG-3' (SEQ ID NO: 581)
3' primer: 5'-GCCACCCGACCCACCACC GCCCGAGCCACCGCCACCTTTGATCTCCA
GTTCGGTG CC-3'
[0658] The primers used for the V.sub.H domain are shown below:
TABLE-US-00004 (SEQ ID NO: 582) 5' sense primer:
TCGGGCGGTGGTGGGTCGGGTGGCGGCGGAT CGTCAGCGGTCCAGCTGCAGCAGTCTGGA-3'
(SEQ ID NO: 583). 3' antisense primer with BclI site: 5'-TCAGTGC
TGATCAGAAGAGACGGTGACTGAGGTTCCTTG-3'
[0659] A change from leucine to serine at position 11 in the heavy
chain variable region (Kabat numbering) was introduced in into the
G28-1 scFv by site-directed mutagenesis. The wild type form of the
G28-1 scFv was initially constructed by sewing/overlap PCR to
insert a (gly4ser)3 (SEQ ID NO:529) linker between the VL and VH
domains as described above. However, no Sac I site was introduced
as a part of this fusion of the variable domains, so alternative,
nearby restriction sites (HaeII and PvuII) near leucine 11 were
used to synthesize the VL+mutated VH domain. Primers were designed
to contain one of these sites and the DNA sequence including the L
to S change, followed by 12 wild type base pairs. Several attempts
at this strategy failed, so an alternative strategy using the
Genetailor (Invitrogen) method of site directed mutagenesis was
used to introduce the desired mutation. The mutagenesis was carried
out according to manufacturer's instructions. Briefly the procedure
involves methylation of the plasmid DNA with DNA methylase,
amplification of the DNA in a mutagenesis reaction with two
overlapping primers, one of which contains the target muations,
trasformation of the plasmid into wild type E. coli which digests
all methylated DNA and leaves only the unmethylated, mutated
amplification product. Both primers are approximately 30
nucleotides in length (not including the mutation site on the
mutagenic primer, with an overlapping region at the 5' ends of
15-20 nucleotides, for efficient end joining of the mutagenesis
product. The template for the mutagenesis reaction was 100 ng of a
plasmid containing the wild type G28-1 scFvIg construct, and the
primers used for the G28-1 VH mutagenesis are as follows:
TABLE-US-00005 (SEQ ID NO: 584) Forward primer:
5'-GCAGCAGTCTGGACCTGAGTCGGAAAAG CCTG-3' (SEQ ID NO: 585) Reverse
Primer: 5'-CTCAGGTCCAGACTGCTGCAGCTGGACC GC-3'
[0660] PCR reactions were performed using the 15 ng methylated
template, the primers above, and the usual reaction components as
previously described. A 20 cycle program with the following profile
was used for amplification: 94 C, 30 sec; 55 C, 30 sec; 68 C, 8
min, followed by a final 68 C extension step for 10 minutes. PCR
products were transformed into wild type bacteria, and colonies
screened by sequencing. Clones with only the desired mutation were
isolated and plasmid prepared as previously described Example 33.
The mutant is designated G28-1 scFv VH L11S (SSS-S)H WCH2 WCH3. The
polynucleotide sequence is provided in SEQ ID NO:323, and the
encoded polypeptide sequence is provided in SEQ ID NO:324.
[0661] The expression level of G28-1 fusion proteins was confirmed
using Immunblot analysis according to the methods described in
Example 17. FIG. 53 illustrates a large increase in protein
expression in the VH L11S mutant G28-1 fusion proteins compared to
the G28-1 fusion protein without the mutation.
[0662] The G28-1 scFv Ig fusion proteins were transiently
transfected and expressed in COS cells according to methods
described in Example 10. FIG. 52 illustrates the capacity of the
G28-1 scFv Ig fusion proteins from the COS supernatants to bind
CD37. Ramos and BJAB cells both express human CD37, and were
therefore used to screen the G28-1 supernatants for functional
activity. Binding of G28-1 scFv (SSS-S) H WCH2 WCH3 and G28-1 scFv
VH L11S (SSS-S) H WCH2 WCH3 to CD37+ Ramos cells was measured by
flow cytometry according to methods described in Example 2. Each
point on the graph represents the mean of five replicate
transfections. The graph illustrates that the G28-1 scFv VH L11S
(SSS-S) H WCH2 WCH3 is able to bind CD37+ Ramos cells.
[0663] Addition constructs were made with different connecting
regions. The pD18 G28-1 scFv VHL11S (SSS-S) H WCH2 WCH3 vector was
digested with BclI and XbaI to remove the connecting region, CH2
and CH3. Theses were replaced with each different connecting
region, CH2 and CH3 according to the methods described in Example
13. The new constructs were designated: G28-1 scFv VHL11S (CSS-S) H
WH2 WH3 (SEQ ID NO:325), G28-1 scFv VHL11S (CSC-S) H WH2 WH3 (SEQ
ID NO:327), G28-1 scFv VHL11S (SSC-P) H WH2 WH3 (SEQ ID NO:329),
G28-1 scFv VHL11S (SCS-S) H WH2 WH3 (SEQ ID NO:373), G28-1 scFv
VHL11S (CCS-P) H WH2 WH3 (SEQ ID NO:375), and G28-1 scFv VHL11S
(SCC-P) H WH2 WH3 (SEQ ID NO:377).
[0664] The G28-1 scFv was also attached to an IgA connecting
region, CH2, CH3 and an IgE CH2, CH3, CH4. The pD18 G28-1 scFv
VHL11S (SSS-S) H WCH2 WCH3 plasmid was digested using methods above
to remove the connecting region CH2, and CH3. The IgA regions were
inserted using methods described in Example 13. The construct was
designated G28-1 scFv VHL11S IgAH IgACH2 T4CH3 (SEQ ID NO:381). The
IgE CH2 CH3 CH4 region was inserted into the digested pD18 vector
above using methods described in Example 39. The construct was
designated G28-1 scFv VHL11S IgECH2 CH3 CH4 (SEQ ID NOs:379 and
383).
Example 36
Characterization of 2H7 scFv Ig Mutant Fusion Proteins
[0665] FIG. 54 illustrates the binding capacity of purified 2H7
scFv Ig constructs to CD20+CHO cells. The proteins were transfected
into stable CHO cells according to methods described in Example 2.
Binding was determined using flow cytometry according to the
methods described in Example 2. The graph in FIG. 54 illustrates
that these proteins retain binding function to CD20 with altered
connecting regions. Comparative results were obtained in each of
the 2H7 scFv VHL11S mutants with each type of altered connecting
region (results omitted).
[0666] The ability of 2H7scFv-Ig constructs with mutated connecting
regions to kill CD20 positive cells in the presence of peripheral
blood mononuclear cells (PBMC) through ADCC was tested by measuring
the release of .sup.51Cr from labeled BJAB cells in a 4 hr. assay
using 100:1 ratio of PBMC to BJAB cells. The results shown in FIG.
55 indicate that 2H7scFv-Ig mutants can mediate antibody dependent
cellular cytotoxicity (ADCC), since the release of .sup.51Cr was
significantly higher in the presence of both PBMC and 2H7scFv-Ig
than in the presence of either PBMC or 2H7scFv-Ig alone.
Comparative results were obtained in each of the 2H7 scFv VHL11S
mutants with each type of altered connecting region (results
omitted).
[0667] The ability of 2H7scFv-Ig mutant fusion proteins to kill
CD20 positive cells in the presence of complement was tested using
B cell lines Ramos target cells. Rabbit complement was purchased
from Pel-Freez (Rogers, Ak.), and was used in the assay at a final
concentration of 1/10. Purified 2H7scFv-Ig was incubated with B
cells and complement for 45 minutes at 37.degree. C., followed by
counting of live and dead cells by trypan blue exclusion. The
results in FIG. 56 show that 2H7scFv-Ig mutants in the presence of
rabbit complement lysed B cells expressing CD20.
Example 37
Comparative Binding of IgA, IgG, and IgE 2H7 scFv Constructs
[0668] Binding capacity of Ig constructs IgA, IgG and IgE were
measured using flow cytrometry according to the methods described
in Example 2, using a commercially available (Caltag) second step
specific for each Ig tail. The results in FIG. 57 show that all the
IgE constructs were able to bind CD20+CHO cells comparable to the
binding abilities of IgG and IgA. These results also demonstrate
that the IgE constructs were detected with the IgE second step, but
not the IgA or IgG second step.
Example 38
Construction and Characterization of 2H7 VH L11S IgE Constructs
[0669] IgE tail RNA was isolated from SKO-007 cells(ATCC) using
QIAGEN QIAshredder homogenization and RNA minikits Random-primed
cDNA was generated according to the usual protocol, with 4
microliters RNA eluted from the QIAGEN columns. Human IgE from the
beginning of CH1 through CH4 (approximately 1.2 kb) was isolated by
PCR amplification of 5 microliters cDNA, with an amplification
profile of 94 C, 60 sec; 72 C, 2 minutes for 35 cycles, and the
following primers:
TABLE-US-00006 (SEQ ID NO: 586) 5' primer:
5'-ggatccacccgctgctgcaaaaacattccctcc aatgccacctccgtgac-3' (SEQ ID
NO: 587) 3' primer: 5'-tcatttaccgggatttacagacaccgctcgctgga
cggtctgtgaggggctcgctgc-3'
[0670] PCR fragments were ligated into PCR 2.1-TOPO vector, and
transformants screened for inserts of the correct size by digestion
with EcoRI according to the methods described in Example 1. One of
the clones with the correct sequence from was used as template to
amplify the CH2-CH4 domains with appropriate restriction sites
attached for subcloning as soluble or cell surface (ORF) forms. The
following primers were used with an amplification profile of 94 C,
60 sec; 55 C, 60 sec; 72 C, 2 min; for 35 cycles to amplify a
fragment of approximately 950 bp:
TABLE-US-00007 5' primer: (attaches BclI site to 5' end of CH2
domain of IgE) (SEQ ID NO: 588)
5'-gttgttgatcacgtctgctccagggacttcacc-3' 3' primer: (attaches stop
codon and XbaI site to 3' end of CH4 of IgE) (SEQ ID NO: 589)
5'-gttgtttctagattatcatttaccaggatttacagacaccgctcg ctg-3' 3' primer:
(attaches SfuI and BamHI to 3' end of CH4 without a stop codon)
(SEQ ID NO: 590) 5'-gttgttttcgaaggatccgctttaccagatttacagacac
cgctcgctg-3'
[0671] The IgE CH2CH3CH4 tail with a stop codon was digested with
BclI and XbaI and inserted into a pD18 vector that contains 2H7
VHL11S scFv. This construct was designated 2H7 IgECH2CH3CH4. The
polynucleotide sequence is provided in SEQ ID NO:128, and the
encoded polypeptide sequence is provided in SEQ ID NO:96. The IgE
CH2CH3CH4 tail with no stop codon (ORF) was digested with BclI and
SfuI and inserted in into a pD18 vector that contains 2H7 VHL11S
scFv. This construct was designated 2H7 IgECH2CH3CH4(ORF).
[0672] The human IgE was also amplified as a fragment missing both
CH1 and CH2 domains, with only the CH3 and CH4 domains attached to
the human IgG1 hinge. Sequential PCR reactions using overlapping 5'
oligonucleotides were used to attach the IgG1 hinge to the CH3
domain of human IgE. Primers for the first step of the PCR
reaction:
TABLE-US-00008 5' Primer: (SEQ ID NO: 591)
5'-actcacacatccccaccgtccccagcatccaacccgagaggggtgag c-3'
[0673] Primers for the second step of the PCR reaction:
TABLE-US-00009 5' primer: (SEQ ID NO: 592)
5'-tctgatcaggagcccaaatcttctgacaaaactcac acatccccaccg-3' 3' primer:
(SEQ ID NO: 593) 5'-gttgtttctagattatcatttaccaggatttacaga
caccgctcgctg-3'
[0674] The PCR product was digested with EcoRI and sequenced
according to the methods described in Example 1. Positive clones
were inserted into pD18 plasmid containing 2H7 VHL11S scFv (SSS-S)
H. The construct was designated 2H7 VHL11S scFv (SSS-S) H IgE
CH3CH4. The polynucleotide sequence is provided in SEQ ID NO:227,
and the encoded polypeptide sequence is provided in SEQ ID
NO:228.
[0675] Binding capacity of 2H7 scFv VH L 11S IgECH2 CH3 CH4, was
measured using flow cytometry, essentially according to Example 2.
The protein was purified using MEP HyperCel, (Cipergen, Catalog
#12035-010, Lot#200920/0271) chromatography resin and Hydrophobic
Charge Induction Chromatography (HCIC). HCIC absorbent is a high
capacity, high selectivity, absorbent designed for capture and
purification of monoclonal and polyclonal antibodies from various
sources including cell culture supernatants. Columns were packed
with a 10 ml bead volume of MEP Hypercel, and equilibrated with
PBS, pH 7.4 containing 0.1% NaN3. Approximately 1 liter of 2H7 scFv
VHL11S IgE CH2CH3CH4 CHO culture supernatant was then run over the
column. A series of citrate buffers ranging from pH 3-6 were
prepared for elution of the fusion protein. The column was washed
in PBS. Protein was eluted in fifteen 1 ml fractions at pH6, 5, and
4. A final 15 ml fraction was collected at pH 3.5. Aliquots from
each fraction were analyzed for A280 and were also subjected to
SDS-PAGE, loading roughly 10 micrograms/well based on the A280
reading. The results of these two analyses indicated that the bulk
of the protein did not elute in citrate buffers at the higher pH,
but eluted at pH4, and the post elution wash at pH3.5 also
contained significant amounts of protein.
[0676] The ability of these 2H7 VH L11S IgE purified proteins to
bind CD20+CHO cells was determined using flow cytometry according
to the methods described in Example 2 using FITC-conjugated
goat-anti-human IgE. FIG. 58A illustrates that both purified
proteins are able to bind CD20+CHO cells.
[0677] The ability of these 2H7 VH L11S IgE purified proteins to
mediate ADCC against BJAB target cells with PBMC effectors was
measured according to the methods described in Example 2. FIG. 58B
illustrates that both proteins were able to mediate ADCC at similar
levels.
Example 39
Construction and Binding Capacity of scFv VH L11S Mutants with
Mouse IgA and IgE Tail Regions
[0678] Murine IgA was cloned from murine spleen RNA using
essentially the same methods used to clone the human IgE tails in
Example 38. The PCR reactions were performed with a 94 C 60 sec; 52
C 60 sec; 72 C 2 min amplification profile for 35 cycles. The PCR
primers used to clone CH1-CH4 regions were:
TABLE-US-00010 (SEQ ID NO: 594) 5' primer:
5'-atctgttctcctcctactactcctcctccacct-3' (SEQ ID NO: 595) 3' primer:
5'-tcagtagcagatgccatctccctctgacatgatgac agacacgct-3'
PCR primers used to delete the CH1 region:
TABLE-US-00011 5' primer: (SEQ ID NO: 596)
5'-gttgttgatcacatctgttctcctcctactactcct cctccacct-3' 3' primer with
a stop codon, XbaI site at end of Ig tail, and the T4 mutation in
CH3 region: (SEQ ID NO: 597)
5'-gttgtttctagattatcaatctccctctgacatgatgacaga cac-3' 3' primer for
the ORF, a SfuI and BamHI sites, and T4 mutation in the CH3 region:
(SEQ ID NO: 598) 5'-gttcttcgaaggatccgcatctccctctgacatgatgac-3'
[0679] The mouse IgACH2 T4-CH3 tail with a stop codon was digested
with BclI and XbaI and inserted into a pD18 vector that contains
2H7 VHL11S scFv and the IgAH. This construct was designated 2H7
VHL11S scFv IgAH mIgACH2 T4-CH3. The polynucleotide sequence is
provided in SEQ ID NO:253, and the encoded polypeptide sequence is
provided in SEQ ID NO:25.
[0680] The mouse IgACH2 T4-CH3 tail with no stop codon (ORF) was
digested with BclI and SfuI and inserted in into a pD18 vector that
contains 2H7 VHL11S scFv and IgAH. This construct was designated
2H7 VHL11S scFv IgAH mIgACH2 T4-CH3 (ORF). The polynucleotide
sequence is provided in SEQ ID NO:255, and the encoded polypeptide
sequence is provided in SEQ ID NO:256.
[0681] Murine IgE was cloned murine IgE La2 (ATCC) RNA essentially
according the methods described in Example 38. The PCR reactions
were performed with a 94 C 60 sec; 52 C 60 sec; 72 C 2 min
amplification profile for 35 cycles. Initial PCR primers used to
clone the CH1-CH4:
TABLE-US-00012 5' primer: (SEQ ID NO: 599)
5'-tctatcaggaaccctcagctctaccccttgaagcc ctg-3' 3' primer: (SEQ ID
NO: 600) 5'-gttgtttctagattatcaggatggacggagggaggt
gttaccaaggct-3'
PCR primers to remove the CH1 region:
TABLE-US-00013 (SEQ ID NO: 601) 5' primer:
5'-gttgttgatcacgttcgacctgtcaacatcactgag cccacc-3' (SEQ ID NO: 602)
3' primer with stop codon and XbaI site: 5'-gttgtt
tctagattatcaggatggacggagggaggtgttaccaaggct-3' (SEQ ID NO: 603) 3'
primer ORF, SfuI and Bam HI: 5'-gttgttttcgaagga
tccgcggatggacggagggaggtgtta-3'
[0682] The mouse IgE CH2CH3CH4 tail with a stop codon was digested
with BclI and XbaI and inserted into a pD18 vector that contains
2H7 VHL11S scFv. This construct was designated 2H7 VHL11S
mIgECH2CH3CH4. The polynucleotide sequence is provided in SEQ ID
NO:249, and the encoded polypeptide sequence is provided in SEQ ID
NO:250.
[0683] The mouse IgE CH2CH3CH4 tail with no stop codon (ORF) was
digested with BclI and SfuI and inserted in into a pD18 vector that
contains 2H7 VHL11S scFv. This construct was designated 2H7 VHL11S
scFv mIgECH2CH3CH4(ORF). The polynucleotide sequence is provided in
SEQ ID NO:249, and the encoded polypeptide sequence is provided in
SEQ ID NO:250.
[0684] Binding capacity of 2H7 VH L11S mIgE and mIgA (with mouse
tail regions) to CD20+CHO cells were also measured by flow
cytometry according to the methods described in Example 2 using
commercially available IgE or IgA second step reagents (Caltag).
Each point in FIG. 59 represents the mean of a population with
brightness corrected by subtracting the binding of the second step
alone. This figure illustrates that these constructs have the
ability to bind CD20+CHO cells.
Example 40
HPLC Profiles of 2H7 scFv Ig Mutant Fusion Proteins
[0685] HPLC analysis of purified 2H7 scFv-Ig mutant fusion proteins
with altered connecting and CH3 regions. Each protein was purified
by Protein A affinity chromatography from supernatants of
transfected COS or CHO cells. Twenty-five to fifty micrograms of
each sample was run at 1 ml/min in PBS on a TSK-GEL G3000SW.sub.XL
30 cm column (Tosoh Biosep, Stuttgart, Germany). The arrow near the
beginning of each profile represents the sample injection point.
Gel filtration standards (Bio-Rad) included thryoglobulin (670
kDa), gamma globulin (158 kDa), ovalbumin (44 kDa), myoglobin (12.5
kDa), and vitamin B-12 (1.35 kDa). Standards were run at the
beginning and end of each experiment. Migration positions of
standards are shown and did not vary between experiments. (FIGS.
60-62)
Example 41
Binding Capacity of 2H7 VH L11S Mutant Fusion Proteins
[0686] Binding effects of the CH3 mutant were compared to the
non-mutated CH3 fusion protein. The constructs were transfected
into COS cells and purified from the supernatant using protein A
column purification techniques described in Example 2. FIG. 63
illustrates the differential effects of CH3 mutations on binding
using flow cytometry according to the methods described in Example
2. This figure illustrates that some binding ability is lost when
the double point mutation is introduced in the CH3 region.
[0687] Binding of fluorescein isothiocyanate (FITC) conjugated 2H7
VH L11S mutant fusion proteins was determined using flow cytometry.
A 1 mg/ml solution of FITC was prepared in DMSO. Fusion proteins
were dialyzed in pH 9.3 bicarbonate buffer overnight at 4 C in a
volume of 2 liters. Concentration of the protein was adjusted to
1-5 mg/ml prior to conjugation. A series of Falcon 5 ml tubes was
set up with varying FITC to protein ratios, ranging from 15-60, but
minimally ratios of 20 and 40. Conjugation reactions were incubated
at 37 C for 30 minutes protected from light. Fluoresceing labeled
protein was separated from free fluorescein on a 2 ml Sephadex G-25
column equilibrated with PBS, 0.5 M NaCl, and 1% NaN3. The
fluorescein labeled protein eluted from the column first and was
collected in a 5 ml tube. The degree of labeling was determined by
measuring the absorbance of the diluted conjugate at 280 and 494
nm, and utilizing the formulas provided by technical services at
Molecular Probes (Eugene, Oreg.). Data has been corrected for FITC:
protein ratio. FIG. 64 illustrates that these constructs do not
lose binding capacity when conjugated to a fluorescent marker.
[0688] Purified 2H7 VH L11S constructs were run on a non-reducing
SDS gel according to the methods described in Example 2. The
migration patterns are presented in FIG. 65.
Example 42
Characterization of 2H7 scFv VH L11S (CSC-S) H WCH2 WCH3 in Lec13
CHO Cells
[0689] 2H7 scFv VH L11S (CSC-S) H WCH2 WCH3 were transiently
transfected and expressed in Lec13 CHO cells. Lec13CHO cells were
used as the mammalian cell hosts for either the 2H7 scFv VHS11
hIgG1 (CSS-S) H WCH2 WCH3 and (CSC-S) H WCH2 WCH3 expressing
plasmids in side-by-side transfections. All transfections were
performed in 100 mm tissue culture dishes. Cells were transfected
when approximately 90% confluent using lipofectamine 2000
(Invitrogen, Catalog #: 11668-027, 0.75 ml), following
manufacturer's instructions. Both cell lines were grown in the
presence of serum to promote and maintain adherence to the cell
culture dishes, simplifying transfection manipulations, washes, and
supernatant harvests. DNA: lipofectamine complexes were allowed to
form in the absence of serum and antibiotics, following the
suggested protocol/conditions recorded in the product insert.
Culture supernatants were harvested 72 hours after transfection,
and then again 72 hours after the first harvest. Fusion protein
from the two CHO sources was isolated by protein A purification as
previously described and used in CD20 binding and ADCC assays.
[0690] The ability of mutated fusion protein to mediate ADCC in
CD20 positive cells was determined using the methods described in
Example 2. Constructs expressed in Lec13 CHO cells exhibited better
binding to CD20 CHO target cells and also showed significantly
improved activity in ADCC assays relative to the CHO DG44 derived
proteins at equivalent concentrations as illustrated in FIG.
67.
Example 43
Construction of High and Low Affinity CD16 Alleles
[0691] The low(V) and high(F) affinity alleles at position 158 of
the human CD16 extracellular domain were cloned from cDNA derived
from human PBMC using PCR assay. PCR reactions used random primed
cDNA made from PBMC stimulated for 3 days with immobilized anti-CD3
antibody (64.1) prior to harvest. PCR reactions included 2, 4, 6 or
8 microliters of cDNA, each primer at 25 pmol, and an amplification
profile of 94 C 60 sec; 55 C 60 sec; 72 C 2 min, for 35 cycles. The
PCR primers are listed below:
TABLE-US-00014 (SEQ ID NO: 604) 3' primer-no leader peptide:
5'-GTTGTTACCGGTGCAATG CGGACTGAAGATCTCCCAAAGGCTGTG-3' (SEQ ID NO:
605) 3' antisense primer: 5'-GTTGTTTGATCAGCCAAACCTTGAGT
GATGGTGATGTTCACA-3'
[0692] Positive clones were sequenced, and inserted into a vector
containing an efficient leader peptide and the (SSS-S)H P238SCH2
WCH3 human IgG tail. Two different versions of the CD16 ED fusion
proteins were expressed. The first contained the F158 (high
affinity) and the second contained the V158 (low affinity) allele.
Constructs were cloned into a (SSS-S)H P238S CH2 WCH3 pD18 plasmid
and expressed in COS and CHO cells as previously described in
examples 1 and 10. CHO clones were screened for expression using an
IgG sandwich ELISA to determine relative expression levels of the
fusion proteins in the culture supernatant using the following
protocol: Immulon 1V plates were coated at 4 C with 0.4
microgram/ml goat anti-human IgG (mouse Adsorbed), (CalTag, Catalog
#H10500) in PBS buffer. Plates were then blocked in PBS/1.5% nonfat
milk at 4 C overnight. Plates were washed three times in PBS/0.1%
Tween 20, then incubated with 100 microliters dilution series from
CHO clone culture supernatants at room temperature for 3 hours.
Four dilutions per clone were added to successive wells, diluting
in 5 fold increments from 1:5 to 1:375. In addition a standard
curve was derived using CTLA4 hIgG1 (SSS-S)H P238SCH2 WCH3 as a
concentration standard. The dilution series utilized 5 fold
dilutions starting at 0.5 micrograms/ml; a second set of 8 wells
was used to make a 2-fold dilution series starting at 0.34
micrograms/ml. Plates were washed 3 times in PBS/0.1% Tween 20, and
incubated with goat anti-human IgG, conjugated to horseradish
peroxidase (GAH IgG-HRP) at 1:5000, in PBS/0.5% BSA for 1 hour.
Plates were washed four times with PBS/0.1% Tween 20, then TMB
chromagen substrate (BD-Pharmingen) was added for 10 minutes, and
reactions stopped by addition of 100 microlites 1N sulfuric acid.
Plates were then read at 415 nm on a SpectraCount plate reader.
Concentrations of fusion protein were estimated by comparison of
the ODs in the linear range to the CTLA4Ig standard curve run on
each plate.
[0693] Proteins were purified using Protein A purification and were
directly conjugated to fluorescein isothiocyanate (FITC) as
described in Example 42. These proteins were run out on SDS gels
under reduced and nonreduced conditions according to the methods
described in Example 2. The migration of these proteins is
presented in FIG. 68.
[0694] The ability of the high and low CD16 alleles to bind 2H7
VH111S(CSC-S) H WCH2 WCH3 or bind 2H7 VH111S (SSS-S) H (P238S)CH2
WCH3 expressed on the cell surface of CD20+CHO target cell is
determined using flow cytometry according to the methods described
in Example 2. The results in FIG. 69 demonstrate both the high and
low affinity alleles were able to bind 2H7 VHL11S (CSC-S)H WCH2
WCH3 (SEQ ID NO:246) and lost some binding capabilities when the
P238S mutation was introduced into the CH2 region of the construct
(SEQ ID NOs:417 and 418).
Example 44
Mammalian Display System
[0695] FIG. 70A diagrams how FITC conjugates of FcRIII (CD16)
Soluble Fusion proteins bind to 2H7 scFv-Ig constructs that are
attached to CD20 expressed by CHO cells. The CD16 binding to a
scFv-Ig provides a screening tool for detecting changes in CD16
binding to an altered scFv-Ig constructs containing targeted or
site-specific mutations. Changes in CD16 binding properties may be
changes in binding of either CD16 high affinity protein (158 F) or
CD16 low affinity protein (158 V) or both.
[0696] A schematic representation of such a screening process is
diagrammed in FIG. 70B, where scFv-Ig constructs are displayed on
the cell surface of mammalian cells. The scFv-Ig molecules in this
Example are displayed on the cell surface because they contain a
transmembrane domain anchor. These molecules may represent a single
scFv-Ig construct or may be introduced into a population of
mammalian cells as a library of such molecules. Transfected cells
with altered binding properties can then be panned, sorted, or
otherwise isolated from other cells by altering the stringency of
the selection conditions and using CD16 fusion proteins as the
binding probe. Cells that express scFv-Ig molecules with altered
binding to either CD16 high affinity allele (158 F) or CD16 low
affinity allele (158V) or both can be isolated. For example, this
display system can be used to create a library of mutated Ig tails
with short stretches of CH2 sequence replaced with randomized
oligonucleotides or possibly randomization of a single residue with
all possible amino acid substitutions, including synthetic amino
acids. Once such a library is constructed, it can be transfected
into COS cells by methods well known in the art. Transfectants can
then be bound to the labeled CD16 constructs, and panned or sorted
based on their relative binding properties to multiple
allelotypes/isoforms. Panned cells are harvested, and the plasmid
DNA is isolated and then transformed into bacteria. This process
may be repeated iteratively multiple times until single clones are
isolated from the mammalian host cells (see Seed B and Aruffo A,
PNAS 84:3365-3369 (1987) and Aruffo A and Seed B, PNAS 84:
8573-8577 (1987)). One such use of this type of screening system
would be to isolate Ig tails which bind equally well to both the
high and low affinity alleles of CD16 with the goal of improving
effector functions mediated by scFv-Ig constructs in multiple
subpopulations of patients. Ig tails with altered binding
properties to other Fc receptors can also be selected using the
display system described. Other display systems for example those
that use bacteriophage or yeast are not suitable for selection of
Ig tails with altered FcR binding properties because of the
requirement for glycosylation in the Ig CH2 domain that would not
occur in non-mammalian systems.
[0697] This system is also useful for selection of altered scFv-Ig
molecules that will be produced at higher levels. In this Example,
mammalian cells such as COS cells can be transfected with a library
of scFv-Ig constructs in a plasmid that directs their expression to
the cell surface. COS cells that express the highest levels of the
scFv-Ig molecules can be selected by techniques well known in the
art (for example panning, sterile cell sorting, magnetic bead
separation, etc), and plasmid DNA is isolated for transformation
into bacteria. After several rounds of selection single clones are
isolated that encode scFv-Ig molecules capable of high level
expression. When the isolated clones are altered to remove the
membrane anchor and then expressed in mammalian cells, the scFv-Ig
constructs will be secreted into the culture fluid in high levels.
This reflects the common requirement of secreted glycoproteins and
cell surface glycoproteins for a signal peptide and processing
through the golgi for expression, so that selection for a molecule
that illustrates an improvement in expression levels on the cell
surface will also select for a molecule that illustrates an
improvement in levels of secreted protein.
Example 45
Characterization of G28-1 mAbs and scFvs
[0698] Ability of G28-1 mAbs and scFvs to induce apoptosis was
measured by binding Annexin V, using the methods described in
Example 3. The results in FIG. 71 demonstrate that the Annexin V
binding of G28-1 antibodies and scFv is increased when treated
together with 2H7 antibodies and scFv constructs.
Example 46
Construction of FC2-2 scFv Constructs
[0699] Contrstruction of the FC2-2 (anti-CD16) scFv was performed
using total RNA isolated from the FC2-2 hybridoma and cloned using
methods described in Example 35. The polynucleotide sequence is
provided in SEQ ID NO:337, and the encoded polypeptide sequence is
provided in SEQ ID NO:338. The specific primers for the secondary
PCR reaction are listed bellow. The following are primers for the
light chain variable region:
TABLE-US-00015 (SEQ ID NO: 606) 5' primer with HindIII site with no
leader: 5'-GTT GTTAAGCTTGCCGCCATGGATTCACAGGCCCAGGTTCTT-3' (SEQ ID
NO: 607) 5' primer with SalI site and leader: 5'-GTTGTTGTCG
ACATTGTGATGTCACAGTCTCCATCCTCCCTA-3' (SEQ ID NO: 608) 3' primer:
5'-TCAGTGCTGATCATGAGGAGACGGTGACTGAGGTTC CTT-3'
[0700] The following are primers for the heavy chain variable
region:
TABLE-US-00016 (SEQ ID NO: 609) 5' primer:
5'-TCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCGTCA CAGGTGCAGTTGAAGGAGTCAGGA-3'
(SEQ ID NO: 610) 3' primer: 5'-ACCCGACCCACCACCGCCCGAGCCACCGCCACCTTT
TATTTCCAGCTTGGTGCCACCTCCGAA-3'
[0701] A change from leucine to serine at position 11 in the heavy
chain variable region (Kabat numbering) was introduced in into the
FC2-2 scFv by site-directed mutagenesis according to the methods
described in Example 33. The scFv was attached to the (SSS-S) H
WCH2 WCH3 IgG tail according to methods described in Example 33.
The mutant is designated FC2-2 scFv VH L11S (SSS-S) H WCH2 WCH3.
The polynucleotide sequence is provided in SEQ ID NO:345, and the
encoded polypeptide sequence is provided in SEQ ID NO:346.
Example 47
Construction of 5B9 scFv Constructs
[0702] Contrstruction of the 5B9 (anti-CD137) scFv was performed
using total RNA isolated from the 5B9 hybridoma and cloned using
methods described in Example 35. The polynucleotide sequence is
provided in SEQ ID NO:361, and the encoded polypeptide sequence is
provided in SEQ ID NO:362. The specific primers for the secondary
PCR reaction are listed bellow. The following are primers for the
light chain variable region:
TABLE-US-00017 (SEQ ID NO: 611) 5' primer with HindIII site with no
leader: 5'-GTT GTTAAGCTTGCCGCCATGAGGTTCTCTGCTCAGCTTCTG-3' ((SEQ ID
NO: 612) 5' primer with SalI site and leader: 5'-GTTGTTGTCG
ACATTTGTGATGACGCAGGCTGCATTCTCCAATT-3' ((SEQ ID NO: 613) 3' primer:
5'-TCAGTGCTGATCAGAGGAGGACGGTGACTGAGGTT CCTTG-3'
[0703] The following are primers for the heavy chain variable
region:
TABLE-US-00018 (SEQ ID NO: 614) 5' primer:
5'-CGGGCGGTGGTGGGTCGGGTGGCGGCGGATCGTCAC AGGTGCAGCTGAAGCAGTCAGGA-3'
(SEQ ID NO: 615) 3' primer: 5'-CCCGACCCACCACCGCCCGAGCCACCGCCACCCTTC
AGCTCCAGCTTGGTGCCAGCACC-3'
[0704] A change from leucine to serine at position 11 in the heavy
chain variable region (Kabat numbering) was introduced in into the
5B9 scFv by site-directed mutagenesis and attached to (SSS-S) H
WCH2 WCH3 according to the methods described in Example 33. This
construct was designated 5B9 scFv VHL11S (SSS-S) H WCH2 WCH3. The
polynucleotide sequence is provided in SEQ ID NO:365, and the
encoded polypeptide sequence is provided in SEQ ID NO:366.
Example 48
Construction of UCHL1 scFv Constructs
[0705] Contrstruction of the UCHL1 (anti-CD45RO) scFv was performed
using total RNA isolated from the UCHL1 hybridoma and cloned using
methods described in Example 35 The polynucleotide sequence is
provided in SEQ ID NO:351, and the encoded polypeptide sequence is
provided in SEQ ID NO:352. The following are primers for the light
chain variable region:
TABLE-US-00019 (SEQ ID NO: 616) 5' primer with HindIII site:
5'-GTTGTTAAGCTTGCCGCC ATGAAGTTGCCTGTTAGGCTGTTGGTGCTG-3' (SEQ ID NO:
617) 3' primer with Sac site: 5'-AGAGCTCCCACCTCCTCCAGAT
CCACCACCGCCCGAGCCACCGCCATCTTTGATTTCCAGCTTGGT-3'
[0706] The following are primers for the heavy chain variable
region:
TABLE-US-00020 (SEQ ID NO: 618) 5' primer:
5'-TTTCAGAGTAATCTGAGAGCTCCCACCTCCTCCAGA TCCACCACCGCCCGA-3' (SEQ ID
NO: 619) 3' primer: 5'-TCAGTGCTGATCATGCAGAGAGACAGTGACCAGAGT
CCC-3'
[0707] A change from leucine to serine at position 11 in the heavy
chain variable region (Kabat numbering) was introduced in into the
5B9 scFv by site-directed mutagenesis and connected to a (SSS-S)
HWCH2 WCH3 according to the methods described in Example 33. The
mutant is designated UCHL1 scFv VH L11S (SSS-S) H WCH2 WCH3. The
polynucleotide sequence is provided in SEQ ID NO:359, and the
encoded polypeptide sequence is provided in SEQ ID NO:360.
Example 49
L6 VHL11S scFv (SSS-S) H WCH2 WCH3
[0708] A change from leucine to serine at position 11 in the heavy
chain variable region (Kabat numbering) was introduced in into the
L6 scFv (SSS-S) H WCH2 WCH3 (constructed according to methods
described in Example 106) by site-directed mutagenesis according to
the methods described in Example 33. The L6scFvIg (SSS-S) H WCH2
WCH3 pD18 plasmid was used as template. Positive clones were
inserted into the pD18 plasmid containing (SSS-S) H WCH2 WCH3
according to methods described in Example 33. The mutant is
designated L6 scFv VH L11S (SSS-S) H WCH2 WCH3. The polynucleotide
sequence is provided in SEQ ID NO:415, and the encoded polypeptide
sequence is provided in SEQ ID NO:416. PCR primers are listed
bellow:
TABLE-US-00021 5' Primer with PstI restriction site: (SEQ ID NO:
620) 5'-ggcggatctctgcagatccagttggtgcagtctggacctgagtcgaa
gaagcctggagag-3' 3'Primer: (SEQ ID NO: 621)
5'-ggacagtgggagtggcacc-3'
Example 50
Construction of HD37 scFv VHL11S Construct
[0709] A change from leucine to serine at position 11 in the heavy
chain variable region (Kabat numbering) was introduced in into the
HD37 scFv by site-directed mutagenesis according to the methods
described in Example 33. The HD37 scFv (SSS-S)H WCH2 WCH3 pD18
plasmid was used as a template. Positive clones were inserted into
the pD18 plasmid containing (SSS-S) H WCH2 WCH3 according to
methods described in Example 33. The mutant is designated HD37 scFv
VH L11S (SSS-S) H WCH2 WCH3. The polynucleotide sequence is
provided in SEQ ID NO:401, and the encoded polypeptide sequence is
provided in SEQ ID NO:402. PCR primers are listed bellow:
TABLE-US-00022 (SEQ ID NO: 622) 5' primer:
5'-caggttcagctgcagcagtctggggctgagtcggtg aggcctgg-3' (SEQ ID NO:
623) 3' primer: 5'-ggaggattcgtctgcagtcagagtggc-3'
Example 51
2H7 scFv VHL11S Constructs
[0710] Additional 2H7 VHL11S constructs were made with different
connecting regions. The pD18 2H7 scFv VHL11S (SSS-S) H WCH2 WCH3
vector was digested with BclI and XbaI to remove the connecting
region, CH2 and CH3. Theses were replaced with each different
connecting region, CH2 and CH3 according to the methods described
in Example 13. The new constructs were designated: 2H7scFv VHL11S
(CSS-S) H WH2 WH3 (SEQ ID NO:371), 2H7scFv VHL11S (CSC-S) H WH2 WH3
(SEQ ID NO:245). 2H7 scFv VHL11S was also attached to an IgA
connecting region, CH2, CH3 and an IgE CH2, CH3, CH4. The pD18 2H7
scFv VHL11S (SSS-S) H WCH2 WCH3 plasmid was digested using methods
above to remove the connecting region CH2, and CH3. The IgA regions
were inserted using methods described in Example 13. The construct
was designated 2H7 scFv VHL11S IgAH IgACH2 T4CH3 (SEQ ID NOs:251
and 253). The IgE CH2 CH3 CH4 region was inserted into the digested
pD18 vector above using methods described in Example 39. The
construct was designated 2H7 scFv VHL11S IgECH2 CH3 CH4 (SEQ ID
NO:247).
Example 52
2H7 scFv VH L11S (CSC-S) H WCH2 WCH3
[0711] This construct has a 2H7 (anti-CD20) single chain Fv binding
region with a point mutation at amino acid residue 11 in the heavy
chain variable region, where the leucine has been changed to a
serine, as described in Example 33. This binding region is
connected to a human IgG1 connecting region, CH2 and CH3 region,
where in the second cysteine and the proline in the connecting
region have been changed to serines (SSS-S) as described in Example
32. The polynucleotide sequence is provided in SEQ ID NO:245, and
the encoded polypeptide sequence is provided in SEQ ID NO:246.
Example 53
2H7 scFv VH L11S IgE CH2 CH3 CH4
[0712] This construct has a 2H7 (anti-CD20) single chain Fv binding
region with a point mutation at amino acid residue 11 in the heavy
chain variable region, where the leucine has been changed to a
serine, as described in Example 33. This binding region is attached
to a human IgE constant region containing CH2, CH3 and CH4 as
described in Example 38. The polynucleotide sequence is provided in
SEQ ID NO:247, and the encoded polypeptide sequence is provided in
SEQ ID NO:248.
Example 54
2H7 scFv VH L11S mIgE CH2 CH3 CH4
[0713] This construct has a 2H7 (anti-CD20) single chain Fv binding
region with a point mutation at amino acid residue 11 in the heavy
chain variable region, where the leucine has been changed to a
serine, as described in Example 33. This binding region is attached
to a mouse IgE constant region containing CH2, CH3 and CH4 as
described in Example 39. The polynucleotide sequence is provided in
SEQ ID NO:249, and the encoded polypeptide sequence is provided in
SEQ ID NO:250.
Example 55
2H7 scFv VH L11S mIgAH WIgACH2 T4CH3
[0714] This construct has a 2H7 (anti-CD20) single chain Fv binding
region with a point mutation at amino acid residue 11 in the heavy
chain variable region, where the leucine has been changed to a
serine, as described in Example 33. This binding region is attached
to a connecting region from human IgA as described in Example 5.
This connecting region is attached to a mouse IgA constant region
consisting of a wild type CH2 region and a mutated CH3 region where
there is a truncation of 4 amino acid residues prior to the 3' stop
codon as described in Example 39. The polynucleotide sequence is
provided in SEQ ID NO:253, and the encoded polypeptide sequence is
provided in SEQ ID NO:254.
Example 56
2H7 scFv VH L11S (SSS-S) H K322S CH2 WCH3
[0715] This construct has a 2H7 (anti-CD20) single chain Fv binding
region with a point mutation at amino acid residue 11 in the heavy
chain variable region, where the leucine has been changed to a
serine, as described in Example 33. This binding region is
connected to a mutated human IgG connecting region where all of the
cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. The connecting region
is attached to a mutated IgG CH2 region and a wild type IgG CH3
region. The K322S mutation in the CH2 region is at a residue 322,
where a Lysine has been changed to a serine using overlapping PCR
assay. An (SSS-S) H WCH2 WCH3 IgG1 template in the pD18 vector was
used for PCR amplification, to create (SSS-S) H derivatives
containing these CH2 mutations. PCR reactions used a cycling
profile of 94 C, 30 sec; 55 C, 30 sec; 72 C, 30 sec, for 37 cycles
to complete the reactions. This IgG1 derivative was constructed by
using sequential PCR reactions with overlapping oligonucleotides in
the primary and secondary reactions. The primary amplification
primers introduced the mutation(s), but deleted one end of the Fc
domain. Secondary reaction primers reattached these ends using
overlapping primers. The first overlapping primer was added at the
beginning of the PCR, the reactions allowed to proceed for 12
cycles, paused and then the second overlapping primer added to the
reactions followed by 25 more cycles to complete the overlap
extension PCR reactions.
Primers for the first PCR reaction:
TABLE-US-00023 (SEQ ID NO: 624) 5' Primer:
5'-ggagatggttttctcgatgggggctgggagggcttt
gttggagaccgagcacttgtactcc-3' (SEQ ID NO: 625) 3' primer:
5'-ggacagtgggagtggcacc-3'
[0716] PCR products were cloned into TOPO vector and sequenced for
verification. Positive vectors were used as templates for the
second overlapping PCR reaction.
TABLE-US-00024 (SEQ ID NO: 626) 5' primer:
5'ccgtctctgatcaggagcccaaatcttctgacaaaac tcacacatccccaccgtccccagc-3'
(SEQ ID NO: 627) 5' primer overlapping primer: 5'-tccccaccgtccccagc
acctgaactcctggggggatcgtcagtcttcctcttccccccaaaacc- 3' (SEQ ID NO:
628) 3' primer: 5'-caggaaacagctatgac-3'
[0717] PCR product was cloned into TOPO vector and sequenced. The
polynucleotide sequence is provided in SEQ ID NO:263, and the
encoded polypeptide sequence is provided in SEQ ID NO:264.
Example 57
2H7 scFv V11 L11S (CSS-S) H K322S CH2 WCH3
[0718] This construct has a 2H7 (anti-CD20) single chain Fv binding
region with a point mutation at amino acid residue 11 in the heavy
chain variable region, where the leucine has been changed to a
serine, as described in Example 33. This binding region is attached
to a mutant IgG connecting region, where the second and third
cysteines have been changed to serines and the proline has been
changed to serine (CSS-S), according to methods described in
Example 13. The connecting region is attached to a mutated IgG CH2
region and a wild type IgG CH3 region. The K322S mutation in the
CH2 region is at a residue 322, where a Lysine has been changed to
a serine using overlapping PCR assay. region is attached to a
mutated IgG CH2 region and a wild type IgG CH3 region. The mutation
in the CH2 region was added by overlapping PCR reaction essentially
according to Example 57, with (CSS-S) H WCH2 WHC3 IgG1 pD18 vector
as a template in the first PCR reaction and different primers in
the second PCR reaction, which are listed below.
TABLE-US-00025 (SEQ ID NO: 629) 5' primer:
5'-ccgtctctgatcaggaccccaaatcttgtgacaaaa
ctcacacatccccaccgtccccagc-3' (SEQ ID NO: 630) 5' overlapping
primer: 5'-tccccaccgtccccagcacctgaa
ctcctggggggatcgtcagtcttcctcttccccccaaaacc-3' (SEQ ID NO: 628) 3'
primer: 5'-caggaaacagctatgac-3'
[0719] PCR products were cloned into the TOPO vector and sequenced.
The polynucleotide sequence is provided in SEQ ID NO:267, and the
encoded polypeptide sequence is provided in SEQ ID NO:268.
Example 58
2H7 scFv VH L11S (SSS-S) H P331S CH2 WCH3
[0720] This construct has a 2H7 (anti-CD20) single chain Fv binding
region with a point mutation at amino acid residue 11 in the heavy
chain variable region, where the leucine has been changed to a
serine, as described in Example 33. This binding region is
connected to a mutated human IgG1 connecting region where all of
the cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. The connecting region
is attached to a mutated IgG1 CH2 region and a wild type IgG1 CH3
region. The mutation P331S mutation in the CH2 region, where the
proline at residue 331 has been changed to a serine, was
incorporated using a single PCR reaction, using a (SSS-S) H WCH2
WCH3 pD18 template and a cycling profile of 94 C, 30 sec; 55 C, 30
sec; 72 C, 30 sec, for 37 cycles. The specific primers for reaction
are listed below.
TABLE-US-00026 (SEQ ID NO: 631) 5' primer:
5'-ccgtctctgatcaggagcccaaatcttctgacaaaa
ctcacacatccccaccgtccccagc-3' (SEQ ID NO: 632) 3' Primers:
5'-gcagggtgtacacctgtggttctcggggctgccct
ttggctttggagatggttttctcgatggaggctgggagg-3'
[0721] The polynucleotide sequence is provided in SEQ ID NO:273,
and the encoded polypeptide sequence is provided in SEQ ID
NO:274.
Example 59
2H7 scFv V11 L11S (CSS-S) H P331S CH2 WCH3
[0722] This binding region is attached to a mutant IgG connecting
region, where the second and third cysteines have been changed to
serines and the proline has been changed to serine (CSS-S),
according to methods described in Example 13. The connecting region
is attached to a mutated IgG CH2 region and a wild type IgG CH3
region. The mutation P331S mutation in the CH2 region, where the
proline at residue 331 has been changed to a serine, was
incorporated using a single PCR reaction, using a (CSS-S) H WCH2
WCH3 pD18 template and a cycling profile of 94 C, 30 sec; 55 C, 30
sec; 72 C, 30 sec, for 37 cycles. The specific primers for reaction
are listed below.
TABLE-US-00027 (SEQ ID NO: 633) 5' primer:
5'-ccgtctctgatcaggaccccaaatcttgtgacaaaa
ctcacacatccccaccgtccccagc-3' (SEQ ID NO: 634) 3' Primer:
5'-gcagggtgtacacctgtggttctcggggctgccctt
tggctttggagatggttttctcgatggaggctgggagg-3'
[0723] The polynucleotide sequence is provided in SEQ ID NO:275,
and the encoded polypeptide sequence is provided in SEQ ID
NO:276.
Example 60
2H7 scFv VH L11S (SSS-S) H T256N CH2 WCH3
[0724] This construct has a 2H7 (anti-CD20) single chain Fv binding
region with a point mutation at amino acid residue 11 in the heavy
chain variable region, where the leucine has been changed to a
serine, as described in Example 33. This binding region is
connected to a mutated human IgG connecting region where all of the
cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. The connecting region
is attached to a mutated IgG CH2 region and a wild type IgG CH3
region. The T256N mutation in the CH2 region, the threonine at
residue 256 has been changed to an asparagine, using the
overlapping PCR methods described in Example 56. The specific
primers are listed below.
[0725] Primers for the first PCR reaction:
TABLE-US-00028 5' primer: (SEQ ID NO: 635)
5'ttcctcttccccccaaaacccaaggacaccctcatgatctcccggaac cctgaggtcac-3'
3' primer: (SEQ ID NO: 636) 5'-ggacagtgggagtggcacc-3'
[0726] PCR product cloned into TOPO vector and sequenced. This
product was used as the template in the second PCR reaction.
Primers for the second PCR reaction:
TABLE-US-00029 5' primer: (SEQ ID NO: 637)
5'ccgtctctgatcaggagcccaaatcttctgacaaaactcacacatcc ccaccgtccccagc-3'
5' overlapping primer: (SEQ ID NO: 638)
5'-tccccaccgtccccagcacctgaactcctggggggatcgtcagtct
tcctcttccccccaaaacc-3' 3' primer: (SEQ ID NO: 628)
5'-caggaaacagctatgac-3'
[0727] The polynucleotide sequence is provided in SEQ ID NO:281,
and the encoded polypeptide sequence is provided in SEQ ID
NO:282.
Example 61
2H7 scFv VH L11S (SSS-S) H RTPE/QNAK (255-258) CH2 WCH3
[0728] This construct has a 2H7 (anti-CD20) single chain Fv binding
region with a point mutation at amino acid residue 11 in the heavy
chain variable region, where the leucine has been changed to a
serine, as described in Example 33. This binding region is
connected to a mutated human IgG connecting region where all of the
cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. The connecting region
is attached to a mutated IgG CH2 region and a wild type IgG CH3
region. The RTPE/QNAK mutation in the CH2 region, where residues
255-258 have been mutated from arginine, threonine, proline,
glutamic acid to glutamine, asparagines, alanine and lysine,
respectively, using the overlapping PCR reactions described in
Example 56. The specific primers are listed below.
PCR primers for the first PCR reaction:
TABLE-US-00030 5' primer: (SEQ ID NO: 641)
5'-ttcctcttccccccaaaacccaaggacaccctcatgatctcccaga
acgctaaggtcacatgc-3' 3' primer: (SEQ ID NO: 636)
5'-ggacagtgggagtggcacc-3'
[0729] The PCR product was cloned into TOPO vector, sequenced and
used as a template for the second PCR reaction. The primers for the
second PCR reaction:
TABLE-US-00031 5 primer: (SEQ ID NO: 637)
5'ccgtctctgatcaggagcccaaatcttctgacaaaactcacacatcc ccaccgtccccagc-3'
5' overlapping primer: (SEQ ID NO: 638)
5'-tccccaccgtccccagcacctgaactcctggggggatcgtcagtct
tcctcttccccccaaaacc-3' 3' primer: (SEQ ID NO: 628)
5'-caggaaacagctatgac-3'
[0730] The polynucleotide sequence is provided in SEQ ID NO:289,
and the encoded polypeptide sequence is provided in SEQ ID
NO:290.
Example 62
2H7 scFv VH L11S (SSS-S) H K290Q CH2 WCH3
[0731] This construct has a 2H7 (anti-CD20) single chain Fv binding
region with a point mutation at amino acid residue 11 in the heavy
chain variable region, where the leucine has been changed to a
serine, as described in Example 33. This binding region is
connected to a mutated human IgG1 connecting region where all of
the cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. The connecting region
is attached to a mutated human IgG1 CH2 region and a wild type
human IgG1 CH3 region. The K290Q mutation in the CH2 region, where
the Lysine at residue 290 has been changed to a Glutamine, using a
single PCR reaction according to the methods described in Example
58. The specific primers used in this reaction are listed
below.
TABLE-US-00032 5' primer: (SEQ ID NO: 642)
5'ccgtctctgatcaggagcccaaatcttctgacaaaactcacacatcc ccaccgtccccagc-3'
3' primer: (SEQ ID NO: 645) 5'-gctcccgcggctgtgtcttggc-3'
[0732] PCR products were cloned into TOPO and sequenced. The
polynucleotide sequence is provided in SEQ ID NO:297, and the
encoded polypeptide sequence is provided in SEQ ID NO:298.
Example 63
2H7 scFv VH L11S (SSS-S) H A339P CH2 WCH3
[0733] This construct has a 2H7 (anti-CD20) single chain Fv binding
region with a point mutation at amino acid residue 11 in the heavy
chain variable region, where the leucine has been changed to a
serine, as described in Example 33. This binding region is
connected to a mutated human IgG1 connecting region where all of
the cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. The connecting region
is attached to a mutated human IgG1 CH2 region and a wild type
human IgG1 CH3 region. The A339P mutation in the CH2 region, where
the alanine at residue 339 has been changed to a proline, using a
single PCR reaction according to the methods described in Example
58. The specific primers used in this reaction are listed
below.
TABLE-US-00033 5' primer: (SEQ ID NO: 644)
5'ccgtctctgatcaggagcccaaatcttctgacaaaactcacacatcc ccaccgtccccagc-3'
3' Primer: (SEQ ID NO: 647)
5'-ggaggtgggcagggtgtacacctgtggttctcggggctgccctttg
ggtttggagatgg-3'
[0734] PCR products were cloned into TOPO and sequenced. The
polynucleotide sequence is provided in SEQ ID NO:305, and the
encoded polypeptide sequence is provided in SEQ ID NO:306.
Example 64
G28-1 scFv (SSS-S) H WCH2 WCH3
[0735] This construct has a G28-1 (anti-CD37) single chain Fv
binding region made according to methods described in Example 35.
This binding region is connected to a mutated human IgG1 connecting
region where all of the cysteines and one proline have been changed
to serines (SSS-S) according to methods described in Example 5.
This connecting region is connected to a wild type human IgG1 CH2
and CH3 region as described in Example 1. This construct has
previously been referred to as G28-1-MHWTG1C and G28-1 scFv Ig,
both have the same sequence as the abouve construct. The
polynucleotide sequence is provided in SEQ ID NO:319, and the
encoded polypeptide sequence is provided in SEQ ID NO:320.
Example 65
G28-1 scFv IgAH WCH2 WCH3
[0736] This construct has a G28-1 (anti-CD37) single chain Fv
binding region made according to methods described in Example 35.
This binding region is connected to a human IgA connecting region
and wild type human IgG CH2 and CH3 constant regions as described
in Example 5. This construct has previously been referred to as:
G28-1-IgAHWTG1C. The polynucleotide sequence is provided in SEQ ID
NO:321, and the encoded polypeptide sequence is provided in SEQ ID
NO:322.
Example 66
G28-1 scFv VH L11S (SSS-S) H WCH2 WCH3
[0737] This construct has a G28-1 (anti-CD37) single chain Fv
binding region with a point mutation at amino acid residue 11 in
the heavy chain variable region, where the leucine has been changed
to a serine as described in Example 35. This binding region is
connected to a mutated human IgG1 connecting region where all of
the cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This connecting region
is attached to wild type human IgG1 CH2 and CH3 region as described
in Example 1. The polynucleotide sequence is provided in SEQ ID
NO:323, and the encoded polypeptide sequence is provided in SEQ ID
NO:324.
Example 67
G28-1 scFv VH L11S(CSS-S) H WCH2 WCH3
[0738] This construct has a G28-1 (anti-CD37) single chain Fv
binding region with a point mutation at amino acid residue 11 in
the heavy chain variable region, where the leucine has been changed
to a serine as described in Example 35. This binding region is
attached to a mutant human IgG1 connecting region, where the second
and third cysteines have been changed to serines and the proline
has been changed to serine (CSS-S), according to methods described
in Example 13. This connecting region is attached to wild type
human IgG1 CH2 and CH3 region as described in Example 1. The
polynucleotide sequence is provided in SEQ ID NO:325, and the
encoded polypeptide sequence is provided in SEQ ID NO:326.
Example 68
G28-1 scFv VH L11S (CSC-S) H WCH2 WCH3
[0739] This construct has a G28-1 (anti-CD37) single chain Fv
binding region with a point mutation at amino acid residue 11 in
the heavy chain variable region, where the leucine has been changed
to a serine as described in Example 35. This binding region is
attached to a mutant human IgG1 connecting region, where the second
cysteine and the proline has been changed to serine (CSC-S),
according to methods described in Example 32. This connecting
region is attached to wild type human IgG1 CH2 and CH3 region as
described in Example 1. The polynucleotide sequence is provided in
SEQ ID NO:327, and the encoded polypeptide sequence is provided in
SEQ ID NO:328.
Example 69
G28-1 scFv VH L11S (SSC-P) H WCH2 WCH3
[0740] This construct has a G28-1 (anti-CD37) single chain Fv
binding region with a point mutation at amino acid residue 11 in
the heavy chain variable region, where the leucine has been changed
to a serine as described in Example 35. This binding region is
attached to a mutant human IgG1 connecting region, where the first
and second cysteines have been changed to serines (SSC-P),
according to methods described in Example 13. This connecting
region is connected to a wild type human IgG1 CH2 and CH3 region as
described in Example 1. The polynucleotide sequence is provided in
SEQ ID NO:329, and the encoded polypeptide sequence is provided in
SEQ ID NO:330.
Example 70
CTLA4 (SSS-S) H P238SCH2 WCH3
[0741] This construct has the extra cellular CTLA-4 binding region
as described in Example 14. This binding region is connected to a
mutated human IgG1 connecting region where all of the cysteines and
one proline have been changed to serines (SSS-S) according to
methods described in Example 5. This hinge region is attached to a
mutated human IgG1 CH2 region and a wild type human IgG1 CH3
region. The P238S mutation, where a proline at residue 238 was
changed to a serine, was introduced using a PCR assay. PCR
reactions were performed using random primed cDNA prepared from
human tonsil B cell RNA. PCR amplifications used an amplification
profile of 94 C 4 min; [94 C 1 min; 55 C 1 min; 72 C 1 min; for 30
cycles followed by a final extension step for 6 minutes at 72 C.
PCR fragments were TOPO cloned and clones with EcoRI inserts of
approximately 800 bp were sequenced as described in Example 1. The
primers used for the PCR are listed below:
TABLE-US-00034 5' primer: (SEQ ID NO: 648)
5'-gttgttgatcaggagcccaaatcttctgacaaaactcacacatctcc
accgtccccagcacctgaactcctgggtggaccgtcagtcttcc-3' 3' primer: (SEQ ID
NO: 649) 5'gttgtttctagattatcatttacccggagacag-3'
[0742] This construct has previously been referred to as CTLA-4 IgG
MTH (SSS) MTCH2WTCH3, which has the same sequence as the above
construct. The polynucleotide sequence is provided in SEQ ID
NO:331, and the encoded polypeptide sequence is provided in SEQ ID
NO:332.
Example 71
CTLA4 (CCC-P) WH WCH2 WCH3
[0743] This construct has a CTLA-4 binding region as described in
Example 14. This binding region is attached to a wild type human
IgG1 connecting region (CCC-P) as described in Example 1. This
connecting region is connected to a wild type human IgG1 CH2 and
CH3 region as described in Example 1. This construct has previously
been referred to as CTLA-4 IgG WTH (CCC) WTCH2CH3, which has the
same sequence as the above construct. The polynucleotide sequence
is provided in SEQ ID NO:47, and the encoded polypeptide sequence
is provided in SEQ ID NO:78.
Example 72
FC2-2 scFv (SSS-S) H WCH2 WCH3
[0744] This construct has a FC2-2 (anti-CD16) single chain Fv made
according to methods described in Example 46. This binding region
is connected to a mutated human IgG1 connecting region where all of
the cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This connecting region
is connected to a wild type human IgG1 CH2 and CH3 region as
described in Example 1. The polynucleotide sequence is provided in
SEQ ID NO:343, and the encoded polypeptide sequence is provided in
SEQ ID NO:344.
Example 73
FC2-2 scFv VHL11S (SSS-S) H WCH2 WCH3
[0745] This construct has a FC2-2 (anti-CD16) single chain Fv with
a point mutation at amino acid residue 11 in the heavy chain
variable region, where the leucine has been changed to a serine as
described in Example 46. This binding region is connected to a
mutated human IgG1 connecting region where all of the cysteines and
one proline have been changed to serines (SSS-S) according to
methods described in Example 5. This connecting region is connected
to a wild type human IgG1 CH2 and CH3 region as described in
Example 1. The polynucleotide sequence is provided in SEQ ID
NO:345, and the encoded polypeptide sequence is provided in SEQ ID
NO:346.
Example 74
UCHL-1 scFv (SSS-S) H WCH2 WCH3
[0746] This construct has a UCHL-1 (anti-CD45RO) single chain Fv
made according to methods described in Example 48. This binding
region is connected to a mutated human IgG1 connecting region where
all of the cysteines and one proline have been changed to serines
(SSS-S) according to methods described in Example 5. This
connecting region is connected to a wild type human IgG1 CH2 and
CH3 region as described in Example 1. The polynucleotide sequence
is provided in SEQ ID NO:357, and the encoded polypeptide sequence
is provided in SEQ ID NO:358.
Example 75
UCHL-1 scFv VHL11S (SSS-S) H WCH2 WCH3
[0747] This construct has a UCHL-1 (anti-CD45RO) single chain Fv
with a point mutation at amino acid residue 11 in the heavy chain
variable region, where the leucine has been changed to a serine as
described in Example 48. This binding region is connected to a
mutated human IgG1 connecting region where all of the cysteines and
one proline have been changed to serines (SSS-S) according to
methods described in Example 5. This connecting region is connected
to a wild type human IgG1 CH2 and CH3 constant region as described
in Example 1. The polynucleotide sequence is provided in SEQ ID
NO:359, and the encoded polypeptide sequence is provided in SEQ ID
NO:360.
Example 76
5B9 scFv (SSS-S) H WCH2 WCH3
[0748] This construct has a 5B9 (anti-CD137) single chain Fv made
according to methods described in Example 47. This binding region
is connected to a mutated human IgG1 connecting region where all of
the cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This connecting region
is connected to a wild type human IgG1 CH2 and CH3 constant region
as described in Example 1. This construct has previously been
referred to as 5B9 scFv IgG MTH (SSS) WTCH2CH3, which has the same
sequence as the above construct. The polynucleotide sequence is
provided in SEQ ID NO:132, and the encoded polypeptide sequence is
provided in SEQ ID NO:133.
Example 77
5B9 scFv VHL11S (SSS-S) H WCH2 WCH3
[0749] This construct has a 5B9 (anti-CD137) single chain Fv with a
point mutation at amino acid residue 11 in the heavy chain variable
region, where the leucine has been changed to a serine as described
in Example 47. This binding region is connected to a mutated human
IgG1 connecting region where all of the cysteines and one proline
have been changed to serines (SSS-S) according to methods described
in Example 5. This connecting region is connected to a wild type
human IgG1 CH2 and CH3 constant region as described in Example 1.
The polynucleotide sequence is provided in SEQ ID NO:365, and the
encoded polypeptide sequence is provided in SEQ ID NO:366.
Example 78
2H7 scFv (SSS-S) H WCH2 WCH3
[0750] This construct has a 2H7 (anti-CD20) single chain Fv binding
region as described in Example 1. This binding region is connected
to a mutated human IgG1 connecting region where all of the
cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This connecting region
is connected to a wild type IgG1 CH2 and CH3 constant region as
described in Example 1. This construct has previously been referred
to as 2H7-MHWTG1C, CytoxB-(MHWTG1C)--Ig, anti-CD20 scFv IgG MTH
(SSS) WTCH2CH3, CytoxB-MHWTG1C, 2H7 scFv-human IgG1 wild type
hinge-CH2-CH3, and 2H7 scFv IgG MTH (SSS) WTCH2CH3, which all have
the same sequence as the above construct. The polynucleotide
sequence is provided in SEQ ID NO:57, and the encoded polypeptide
sequence is provided in SEQ ID NO:58.
Example 79
2H7 scFv (SSS-S) H P238SCH2 WCH3
[0751] This construct has a 2H7 (anti-CD20) single chain Fv binding
region as described in Example 1. This binding region is connected
to a mutated human IgG1 connecting region where all of the
cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This binding region is
connected to a mutated human IgG1 connecting region where all of
the cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This hinge region is
attached to a mutated human IgG1 CH2 region and a wild type human
IgG1 CH3 region. The P238S mutation, where a proline at residue 238
was changed to a serine, was introduced according to methods
described in Example 70. This construct has previously been
referred to as 2H7 scFv IgG MTH (SSS) MTCH2WTCH3, anti-CD20 scFv
IgG MTH (SSS) MTCH2CH3, and CytoxB-MHMG1C which all have the same
sequence as the above construct. The polynucleotide sequence is
provided in SEQ ID NO:419, and the encoded polypeptide sequence is
provided in SEQ ID NO:420.
Example 80
2H7 scFv IgAH WCH2 WCH3
[0752] This construct has a 2H7 (anti-CD20) single chain Fv binding
region as described in Example 1. This binding region is connected
to a human IgA connecting region and wild type human IgG1 CH2 and
CH3 constant regions as described in Example 5. This construct has
previously been referred to as 2H7 scFv IgAH IgG WTCH2CH3, 2H7 scFv
IgA hinge-IgG1 CH2-CH3, and CytoxB-IgAHWTHG1C, which all have the
same sequence as the above construct. The polynucleotide sequence
is provided in SEQ ID NO:59, and the encoded polypeptide sequence
is provided in SEQ ID NO:60.
Example 81
2H7 scFv IgAH WIgACH2 T4CH3
[0753] This construct has a 2H7 (anti-CD20) single chain Fv binding
region as described in Example 1. This binding region is attached
to a connecting region from human IgA as described in Example 5.
This connecting region is attached to a human IgA constant region
consisting of a wild type CH2 region and a mutated CH3 region where
there is a truncation of 4 amino acid residues prior to the 3' stop
codon as described in Example 13. This construct has previously
been referred to as 2H7 scFv IgAH IgAT4, which has the same
sequence as the above construct. The polynucleotide sequence is
provided in SEQ ID NO:70, and the encoded polypeptide sequence is
provided in SEQ ID NO:71.
Example 82
2H7 scFv IgAH WIgACH2 WCH3+Jchain
[0754] This construct has a 2H7 (anti-CD20) single chain Fv binding
region as described in Example 1. This binding region is attached
to a wild type human IgA connecting region as described in Example
5. This connecting region is attached to a wild type human IgA CH2
and CH3 constant region according to methods described in Example
13. This constant region is attached to a J-chain region as
described in Example 13. The polynucleotide sequence is provided in
SEQ ID NO:61, and the encoded polypeptide sequence is provided in
SEQ ID NO:62.
Example 83
2H7 scFv (CCC-P) WH WCH2 WCH3
[0755] This construct has a 2H7 (anti-CD20) single chain Fv binding
region as described in Example 1. This binding region is attached
to a wild type human IgG1 connecting region (CCC-P) as described in
Example 1. This connecting region is attached to wild type human
IgG1 CH2 and CH3 constant regions as described in Example 1. This
construct has previously been referred to as 2H7 scFv Ig WTH (CCC)
WTCH2CH3, 2H7 scFv IgG WTH WTCH2CH3, and 2H7 scFv-Ig, which both
have the same sequence as the above construct. The polynucleotide
sequence is provided in SEQ ID NO:688, and the encoded polypeptide
sequence is provided in SEQ ID NO:689.
Example 84
2H7 scFv (SSS-S) H WCH2 F405YCH3
[0756] This construct has a 2H7 (anti-CD20) single chain Fv binding
region as described in Example 1. This binding region is connected
to a mutated human IgG1 connecting region where all of the
cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This connecting region
is attached to a wild type human IgG1 CH2 and a mutated human IgG1
CH3 region. The F405Y mutation, where the phenylalanine at residue
405 has been changed to a tyrosine, was introduced according to
methods described in Example 21. This construct has previously been
referred to as 2H7 scFv MTH WTCH2 MTCH3 Y405, which has the same
sequence as the above construct. The polynucleotide sequence is
provided in SEQ ID NO:153, and the encoded polypeptide sequence is
provided in SEQ ID NO:154.
Example 85
2H7 scFv (SSS-S) H WCH2 F405ACH3
[0757] This construct has a 2H7 (anti-CD20) single chain Fv binding
region as described in Example 1. This binding region is connected
to a mutated human IgG1 connecting region where all of the
cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This connecting region
is attached to a wild type human IgG1 CH2 and a mutated human IgG1
CH3 region. The F405A mutation, where the phenylalanine at residue
405 has been changed to an alanine, was introduced according to
methods described in Example 21. This construct has previously been
referred to as 2H7 scFv MTH WTCH2 MTCH3 A405, which has the same
sequence as the above construct. The polynucleotide sequence is
provided in SEQ ID NO:155, and the encoded polypeptide sequence is
provided in SEQ ID NO:156.
Example 86
2H7 scFv (SSS-S) H WCH2 Y407ACH3
[0758] This construct has a 2H7 (anti-CD20) single chain Fv binding
region as described in Example 1. This binding region is connected
to a mutated human IgG1 connecting region where all of the
cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This connecting region
is attached to a wild type human IgG1 CH2 and a mutated human IgG1
CH3 region. The Y407A mutation, where the tyrosine at residue 407
has been changed to an alanine, was introduced according to methods
described in Example 21. This construct has previously been
referred to as scFv MTH WTCH2 MTCH3 A407, which has the same
sequence as the above construct. The polynucleotide sequence is
provided in SEQ ID NO:157, and the encoded polypeptide sequence is
provided in SEQ ID NO:158.
Example 87
2H7 scFv (SSS-S) HWCH2 F405A, Y407ACH3
[0759] This construct has a 2H7 (anti-CD20) single chain Fv binding
region as described in Example 1. This binding region is connected
to a mutated human IgG1 connecting region where all of the
cysteines and one proline have been changed to serines (SSS-S),
according to methods described in Example 5. This connecting region
is attached to a wild type human IgG1 CH2 and a mutated human IgG1
CH3 region. The F405A and Y407A mutation, where the phenylalanine
at residue 405 has been changed to an alanine and the tyrosine at
residue 407 has been changed to an alanine, was introduced
according to methods described in Example 21. This construct has
previously been referred to as scFv MTH WTCH2 MTCH3 A405A407, which
has the same sequence as the above construct. The polynucleotide
sequence is provided in SEQ ID NO:161, and the encoded polypeptide
sequence is provided in SEQ ID NO:162.
Example 88
2H7 scFv (CSS-S) H WCH2 WCH3
[0760] This construct has a 2H7 (anti-CD20) single chain Fv binding
region as described in Example 1. This binding region is attached
to a mutant human IgG1 connecting region, where the second and
third cysteines have been changed to serines and the proline has
been changed to serine (CSS-S), according to methods described in
Example 13. This connecting region is attached to wild type human
IgG1 CH2 and CH3 constant regions as described in Example 1. This
construct has previously been referred to as 2H7 scFv MTH (CSS)
WTCH2CH3, which has the same sequence as the above construct. The
polynucleotide sequence is provided in SEQ ID NO:134, and the
encoded polypeptide sequence is provided in SEQ ID NO:135.
Example 89
2H7 scFv (SCS-S) H WCH2 WCH3
[0761] This construct has a 2H7 (anti-CD20) single chain Fv binding
region as described in Example 1. This binding region is attached
to a mutant human IgG1 connecting region, where the first and third
cysteines have been changed to serines and the proline has been
changed to serine (SCS-S), according to methods described in
Example 13. This connecting region is attached to wild type human
IgG1 CH2 and CH3 constant regions as described in Example 1. This
construct has previously been referred to as 2H7 scFv IgG MTH (SCS)
WTCH2CH3, which has the same sequence as the above construct. The
polynucleotide sequence is provided in SEQ ID NO:136, and the
encoded polypeptide sequence is provided in SEQ ID NO:137.
Example 90
2H7 scFv (SSC-P) H WCH2 WCH3
[0762] This construct has a 2H7 (anti-CD20) single chain Fv binding
region as described in Example 1. This binding region is attached
to a mutant human IgG1 connecting region, where the first and
second cysteines have been changed to serines (SSC-P), according to
methods described in Example 13. This connecting region is attached
to wild type human IgG1 CH2 and CH3 constant regions as described
in Example 1. This construct has previously been referred to as 2H7
scFv MTH (SSC) WTCH2CH3, which has the same sequence as the above
construct. The polynucleotide sequence is provided in SEQ ID
NO:138, and the encoded polypeptide sequence is provided in SEQ ID
NO:139.
Example 91
2H7 scFv (CSC-S) H WCH2 WCH3
[0763] This construct has a 2H7 (anti-CD20) single chain Fv binding
region as described in Example 1. This binding region is attached
to a mutant human IgG1 connecting region, where the second cysteine
and the proline has been changed to serine (CSC-S), according to
methods described in Example 32. This connecting region is attached
to wild type human IgG1 CH2 and CH3 constant regions as described
in Example 1. This construct has previously been referred to as 2H7
scFv MTH (CSC) WTCH2CH3, which has the same sequence as the above
construct. The polynucleotide sequence is provided in SEQ ID
NO:165, and the encoded polypeptide sequence is provided in SEQ ID
NO:166.
Example 92
2H7 scFv (CCS-P) H WCH2 WCH3
[0764] This construct has a 2H7 (anti-CD20) single chain Fv binding
region as described in Example 1. This binding region is attached
to a mutant human IgG1 connecting region, where third cysteine has
been changed to a serine (CCS-P), according to methods described in
Example 22. This connecting region is attached to wild type human
IgG1 CH2 and CH3 constant regions as described in Example 1. This
construct has previously been referred to as 2H7 scFv MTH (CCS)
WTCH2CH3, which has the same sequence as the above construct. The
polynucleotide sequence is provided in SEQ ID NO:167, and the
encoded polypeptide sequence is provided in SEQ ID NO:168.
Example 93
2H7 scFv (SCC-P) H WCH2 WCH3
[0765] This construct has a 2H7 (anti-CD20) single chain Fv binding
region as described in Example 1. This binding region is attached
to a mutant human IgG1 connecting region, where first cysteine has
been changed to a serine (SCC-P), according to methods described in
Example 32. This connecting region is attached to wild type human
IgG1 CH2 and CH3 constant regions as described in Example 1. This
construct has previously been referred to as 2H7 scFv MTH (SCC)
WTCH2CH3, which has the same sequence as the above construct. The
polynucleotide sequence is provided in SEQ ID NO:163, and the
encoded polypeptide sequence is provided in SEQ ID NO:164.
Example 94
2H7 scFv VH L11S (SSS-S) H WCH2 WCH3
[0766] This construct has a 2H7 (anti-CD20) single chain Fv binding
region with a point mutation at amino acid residue 11 in the heavy
chain variable region, where the leucine has been changed to a
serine as described in Example 33. This binding region is connected
to a mutated human IgG1 connecting region where all of the
cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This connecting region
is attached to wild type human IgG1 CH2 and CH3 constant regions as
described in Example 1. This construct has previously been referred
to as 2H7 scFv VH11SER IgG MTH (SSS) WTCH2CH3 and 2H7 scFv VHSER11
WTH WTCH2CH3, which both have the same sequence as the above
construct. The polynucleotide sequence is provided in SEQ ID
NO:369, and the encoded polypeptide sequence is provided in SEQ ID
NO:370.
Example 95
2H7 scFv VH L11S (CSS-S) H WCH2 WCH3
[0767] This construct has a 2H7 (anti-CD20) single chain Fv binding
region with a point mutation at amino acid residue 11 in the heavy
chain variable region, where the leucine has been changed to a
serine as described in Example 33. This binding region is attached
to a mutant human IgG1 connecting region, where the second and
third cysteines have been changed to serines and the proline has
been changed to serine (CSS-S), according to methods described in
Example 13. This connecting region is attached to wild type human
IgG1 CH2 and CH3 constant regions as described in Example 1. The
polynucleotide sequence is provided in SEQ ID NO:371, and the
encoded polypeptide sequence is provided in SEQ ID NO:372.
Example 96
G28-1 scFv VH L11S (SCS-S) H WCH2 WCH3
[0768] This construct has a G28-1 (anti-CD37) single chain Fv
binding region with a point mutation at amino acid residue 11 in
the heavy chain variable region, where the leucine has been changed
to a serine as described in Example 35. This binding region is
attached to a mutant human IgG1 connecting region, where the first
and third cysteines have been changed to serines and the proline
has been changed to serine (SCS-S), according to methods described
in Example 13. This connecting region is attached to wild type
human IgG1 CH2 and CH3 constant regions as described in Example 1.
The polynucleotide sequence is provided in SEQ ID NO:373, and the
encoded polypeptide sequence is provided in SEQ ID NO:374.
Example 97
G28-1 scFv V11 L11S(CCS-P) H WCH2 WCH3
[0769] This construct has a G28-1 (anti-CD37) single chain Fv
binding region with a point mutation at amino acid residue 11 in
the heavy chain variable region, where the leucine has been changed
to a serine as described in Example 35. This binding region is
attached to a mutant human IgG1 connecting region, where third
cysteine has been changed to a serine (CCS-P), according to methods
described in Example 22. This connecting region is attached to wild
type human IgG1 CH2 and CH3 constant regions as described in
Example 1. The polynucleotide sequence is provided in SEQ ID
NO:375, and the encoded polypeptide sequence is provided in SEQ ID
NO:376.
Example 98
G28-1 scFv VH L11S (SCC-P) H WCH2 WCH3
[0770] This construct has a G28-1 (anti-CD37) single chain Fv
binding region with a point mutation at amino acid residue 11 in
the heavy chain variable region, where the leucine has been changed
to a serine as described in Example 35. This binding region is
attached to a mutant human IgG1 connecting region, where first
cysteine has been changed to a serine (SCC-P), according to methods
described in Example 32. This connecting region is attached to wild
type human IgG1 CH2 and CH3 constant regions as described in
Example 1. The polynucleotide sequence is provided in SEQ ID
NO:377, and the encoded polypeptide sequence is provided in SEQ ID
NO:378.
Example 99
G28-1 scFv VH L11S mIgE CH2 CH3 CH4
[0771] This construct has a G28-1 (anti-CD37) single chain Fv
binding region with a point mutation at amino acid residue 11 in
the heavy chain variable region, where the leucine has been changed
to a serine as described in Example 35. This binding region is
attached to a wilt type mouse IgE CH2 CH3 and CH4 region using
methods described in Example 39. The polynucleotide sequence is
provided in SEQ ID NO:379, and the encoded polypeptide sequence is
provided in SEQ ID NO:380.
Example 100
G28-1 scFv V11 L11S mIgAH WIgACH2 T4CH3
[0772] This construct has a G28-1 (anti-CD37) single chain Fv
binding region with a point mutation at amino acid residue 11 in
the heavy chain variable region, where the leucine has been changed
to a serine as described in Example 35. This binding region is
attached to a connecting region from mouse IgA as described in
Example 39. This connecting region is attached to a mouse IgA
constant region consisting of a wild type CH2 region and a mutated
CH3 region where there is a 4 amino acid truncation at residues as
described in Example 39. The polynucleotide sequence is provided in
SEQ ID NO:381, and the encoded polypeptide sequence is provided in
SEQ ID NO:382.
Example 101
G28-1 scFv VH L11S hIgE CH2 CH3 CH4
[0773] This construct has a G28-1 (anti-CD37) single chain Fv
binding region with a point mutation at amino acid residue 11 in
the heavy chain variable region, where the leucine has been changed
to a serine as described in Example 35. This binding region is
attached to a wild type human IgE constant region containing CH2,
CH3 and CH4 as described in Example 38. The polynucleotide sequence
is provided in SEQ ID NO:383, and the encoded polypeptide sequence
is provided in SEQ ID NO:384.
Example 102
G28-1 scFv VH L118 hIgAH WIgACH2 T4CH3
[0774] This construct has a G28-1 (anti-CD37) single chain Fv
binding region with a point mutation at amino acid residue 11 in
the heavy chain variable region, where the leucine has been changed
to a serine as described in Example 35. This binding region is
attached to a connecting region from human IgA as described in
Example 5. This connecting region is attached to a human IgA
constant region consisting of a wild type CH2 region and a mutated
CH3 region where there is a truncation of 4 amino acid residues
prior to the 3' stop codon as described in Example 13. The
polynucleotide sequence is provided in SEQ ID NO:385, and the
encoded polypeptide sequence is provided in SEQ ID NO:386.
Example 103
HD37 scFv IgAH WCH2 WCH3
[0775] The HD37 scFv was cloned from the HD37 hybridoma using the
Novagen -Ig family primer sets, TOPO cloning and sequencing and
sewing PCR assay. For the initial PCR reactions prior to sewing,
the TOPO clone templates HD37 VH C-1 and HD37 KVL B-9 were used at
1:100 with an amplification profile of 94 C 30 sec; 55 C, 30 sec;
72 C, 30 seconds for 25 cycles. To provide templates for the
secondary SEWING PCR reactions, primary reaction products were gel
purified, QIAQUICK purified, and the eluates diluted 50 fold. One
microliter each VL and VH overlapping templates were added to PCR
reactions with the following amplification profile: 94 C, 60 sec;
55 C, 60 sec; 72 C, 60 sec; for 30 cycles. After two cycles, the
machine was paused, and the flanking 5'VL and 3'VH primers were
added to the reactions at 25 pmol each, and the PCR reactions
resumed. PCR products were checked on a gel for the presence of an
750-800 by fragment, and the reactions products QIAQUICK purified
and digested with the appropriate restriction enzymes for insertion
into pD18 Ig expression vectors.
[0776] PCR of VL domain with native leader peptide and part of
glyser linker:
TABLE-US-00035 5' primer: (SEQ ID NO: 650)
5'-gttgttaagcttgccgccatggagacagacacactcctgctatgg- 3' 3' primer:
(SEQ ID NO: 651) 5'gccacccgacccaccaccgcccgagccaccgccacctttgatttccag
cttggtgcctcc-3'
[0777] PCR of VL domain without leader peptide (SalI site) and part
of glyser linker:
TABLE-US-00036 5' primer: (SEQ ID NO: 652)
5'-gttgttgtcgacattgtgctgacccaatctcca-3' 3' priemr: (SEQ ID NO: 651)
5'-gccacccgacccaccaccgcccgagccaccgccacctttgatttcca
gcttggtgcctcc-3'
[0778] PCR of VH domain with part of glyser linker and BclI site
for fusion to -Ig tails.
TABLE-US-00037 5'primer: (SEQ ID NO: 653)
5'-tcgggcggtggtgggtcgggtggcggcggatcgtcacaggttcagc tgcagcagtctgg-3'
3' primer: (SEQ ID NO: 654)
5'-tcagtgctgatcagaggagacggtgactgaggttccttg-3'
[0779] This binding region is connected to a wild type human IgA
connecting region and wild type human IgG CH2 and CH3 constant
regions as described in Example 5. This connecting region is
attached to wild type human IgG1 CH2 and CH3 constant regions as
described in Example 1. This construct has previously been referred
to as HD37 scFv-IgAHWTG1C and HD37-IgAHWTG1C, which both have the
same sequence as the above construct. The polynucleotide sequence
is provided in SEQ ID NO:397, and the encoded polypeptide sequence
is provided in SEQ ID NO:398.
Example 104
HD37 scFv (SSS-S) H WCH2 WCH3
[0780] This construct has a HD 37 single chain Fv as described in
Example 103. This binding region is connected to a mutated human
IgG1 connecting region where all of the cysteines and one proline
have been changed to serines (SSS-S) according to methods described
in Example 5. This connecting region is attached to wild type human
IgG1 CH2 and CH3 constant regions as described in Example 1. This
construct has previously been referred to as HD37-MHWTG1C and HD37
scFv-IgMHWTG1C, which both have the same sequence as the above
construct. The polynucleotide sequence is provided in SEQ ID
NO:399, and the encoded polypeptide sequence is provided in SEQ ID
NO:400.
Example 105
[0781] HD37 scFv VH L11S (SSS-S) H WCH2 WCH3
[0782] This construct has a HD 37 single chain Fv with a mutation
in the heavy chain variable region at amino acid residue 11, where
leucine has been changed to serine according to the methods
described in Example 50. This binding region is connected to a
mutated human IgG1 connecting region where all of the cysteines and
one proline have been changed to serines (SSS-S) according to
methods described in Example 5. This connecting region is attached
to wild type human IgG1 CH2 and CH3 constant regions as described
in Example 1. The polynucleotide sequence is provided in SEQ ID
NO:401, and the encoded polypeptide sequence is provided in SEQ ID
NO:402.
Example 106
L6 scFv IgAH WCH2 WCH3
[0783] The L6 scFv was cloned from the L6 hybridoma (1Hellstrom)
using the anchor-tailing method described in the Tissue Antigens
Paper from 1996. The PCR profile was 94 C, 1 min; 50 C, 2 min; 72
C, 2 min; for 35 cycles. Once consensus sequence was obtained for
VL and VH regions from at least 4 TOPO clones, primers were ordered
for PCR reactions prior to SEWING PCR reactions as follows: For the
initial PCR reactions prior to sewing, the TOPO cloned templates
L6VK and L6VH were used at 1:100 with an amplification profile of
94 C 30 sec; 55 C, 30 sec; 72 C, 30 seconds for 25 cycles. To
provide templates for the secondary SEWING PCR reactions, primary
reaction products were gel purified, QIAQUICK purified, and the
eluates diluted 50 fold. One microliter each VL and VH overlapping
templates were added to PCR reactions with the following
amplification profile: 94 C, 60 sec; 55 C, 60 sec; 72 C, 60 sec;
for 30 cycles. After two cycles, the machine was paused, and the
flanking 5'VL and 3'VH primers were added to the reactions at 25
pmol each, and the PCR reactions resumed. PCR products were checked
on a gel for the presence of an 750-800 by fragment, and the
reactions products QIAQUICK purified and digested with the
appropriate restriction enzymes for insertion into pD18 Ig
expression vectors.
[0784] PCR of VL domain with native leader peptide and part of
glyser linker:
TABLE-US-00038 L6VLHindIII: (SEQ ID NO: 655)
5'-gttgttaagcttgccgccatggattttcaagtgcagattttcagctt c-3' L6VLLK3:
(SEQ ID NO: 656) 5'-gccacccgacccaccaccgcccgagccaccgccaccagagagctctt
tcagctccagcttggt-3'
[0785] PCR of VL domain without leader peptide (SalI site) and part
of glyser linker:
TABLE-US-00039 5' primer: (SEQ ID NO: 657)
5'-gttgttgtcgacattgttctctcccagtctccagcaatcctgtctg- 3' 3' primer:
(SEQ ID NO: 656) 5'-gccacccgacccaccaccgcccgagccaccgccaccagagagct
ctttcagctccagcttggt-3'
[0786] PCR of VH domain with part of glyser linker and BclI site
for fusion to -Ig tails.
TABLE-US-00040 5': (SEQ ID NO: 658)
5'-tcgggcggtggtgggtcgggtggcggcggatctctgcagatcc agttggtgcagtct-3'
3'Bcl: (SEQ ID NO: 659)
5'-tcagtgctgatcagaggagactgtgagagtggtgccttg-3'
[0787] This binding region is connected to a human IgA connecting
region and wild type human IgG1 CH2 and CH3 constant regions as
described in Example 5. This connecting region is attached to wild
type human IgG1 CH2 and CH3 constant regions as described in
Example 1. This construct has previously been referred to as L6
scFv-IgAHWTG1C, which HAS the same sequence as the above construct.
The polynucleotide sequence is provided in SEQ ID NO:413, and the
encoded polypeptide sequence is provided in SEQ ID NO:414.
Example 107
L6 scFv VHL11S (SSS-S) H WCH2 WCH3
[0788] This construct has a L6 single chain Fv with a mutation in
the heavy chain variable region at amino acid residue 11, where
leucine has been changed to serine according to the methods
described in Example 49. This binding region is connected to a
mutated human IgG1 connecting region where all of the cysteines and
one proline have been changed to serines (SSS-S) according to
methods described in Example 5. This connecting region is attached
to wild type human IgG1 CH2 and CH3 constant regions as described
in Example 1. The polynucleotide sequence is provided in SEQ ID
NO:415, and the encoded polypeptide sequence is provided in SEQ ID
NO:416.
Example 108
2H7 scFv-Llama IgG1
[0789] This construct has a 2H7 (anti-CD20) single chain Fv binding
region as described in Example 1. This binding region is attached
to a llama IgG1 hinge, CH2 and CH3 regions according to the methods
described in Example 10. The polynucleotide sequence is provided in
SEQ ID NO:21, and the encoded polypeptide sequence is provided in
SEQ ID NO:22.
Example 109
2H7 scFv-Llama IgG2
[0790] This construct has a 2H7 (anti-CD20) single chain Fv binding
region as described in Example 1. This binding region is attached
to a llama IgG2 hinge, CH2 and CH3 regions according to the methods
described in Example 10. The polynucleotide sequence is provided in
SEQ ID NO:23, and the encoded polypeptide sequence is provided in
SEQ ID NO:24.
Example 110
2H7 scFv-Llama IgG3
[0791] This construct has a 2H7 (anti-CD20) single chain Fv binding
region as described in Example 1. This binding region is attached
to a llama IgG3 hinge, CH2 and CH3 regions according to the methods
described in Example 10. The polynucleotide sequence is provided in
SEQ ID NO:25, and the encoded polypeptide sequence is provided in
SEQ ID NO:26.
Example 111
CD16 Low (ED)(SSS-S) H P238SCH2 WCH3
[0792] This construct has the extra cellular, CD16 low affinity
allele binding domain as described in Example 43. This binding
region is connected to a mutated human IgG1 connecting region where
all of the cysteines and one proline have been changed to serines
(SSS-S) according to methods described in Example 5. This hinge
region is attached to a mutated human IgG1 CH2 region and a wild
type human IgG1 CH3 region. The P238S mutation, where a proline at
residue 238 was changed to a serine, was introduced according to
methods described in Example 70. The polynucleotide sequence is
provided in SEQ ID NO:421, and the encoded polypeptide sequence is
provided in SEQ ID NO:422.
Example 112
CD16-9 High (ED)(SSS-S) H P238SCH2 WCH3
[0793] This construct has the extra cellular, CD16 high affinity
allele binding domain as described in Example 43. This binding
region is connected to a mutated human IgG1 connecting region where
all of the cysteines and one proline have been changed to serines
(SSS-S) according to methods described in Example 5. This hinge
region is attached to a mutated human IgG1 CH2 region and a wild
type human IgG1 CH3 region. The P238S mutation, where a proline at
residue 238 was changed to a serine, was introduced according to
methods described in Example 70. The polynucleotide sequence is
provided in SEQ ID NO:425, and the encoded polypeptide sequence is
provided in SEQ ID NO:426.
Example 113
2e12 scFv (SSS-S)H P238SCH2 WCH3-hCD80TM/CT
[0794] This construct has a 2e12 (anti-CD28) single chain Fv
binding region described in Example 12. This binding region is
connected to a mutated human IgG1 connecting region where all of
the cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This connecting region
is attached to a mutated human IgG1 CH2 region and a wild type
human IgG1 CH3 region. The P238S mutation, where a proline at
residue 238 was changed to a serine, was introduced according to
methods described in Example 70. The CH3 region is attached to a
human CD80 transmembrane and cytoplasmic tail region (hCD80 TM/CT).
The hCD80 TM/CT was cloned using random primed cDNA derived from
the BJAB cell line according to methods described in Example 12.
This TM/CT region was attached to a Ig CH3 region with an open
reading frame (ORF). Open reading frame versions of scFvIg
constructs of interest were created by replacement of the soluble
versions of each -Ig tail with ORF (open reading frame versions) of
these tails. PCR primers were designed for the existing clones of
soluble -Ig tails which delete the stop codon and add one or more
restriction sites to the 3' end of the new -Ig cassettes. The
desired transmembrane and cytoplasmic tail sequences can then be
subcloned downstream of these new -Ig cassettes. Each construct
utilized the existing available 5' BCLI oligonucleotide used in
amplifying the soluble version of the tails for the PCR reactions.
The 3' oligonucleotides replace the stop codon with out of frame
restriction sites fused to the coding region for protein domains
involved in regulation of apoptosis.
[0795] The PCR amplifications were carried out with 25 pmol of each
primer, standard PCR reagents, and varying volumes of either cloned
domains or cDNA obtained from PBMC, spleen, or thymus RNA. The
reactions used a cycling profile of 94 C, 60sec; 55 C, 60 sec; 72
C, 2 min, for 35 cycles. The primers for the IgG ORF are listed
below.
TABLE-US-00041 5' primer: (SEQ ID NO: 660)
5'-gttgtagatcaggagcccaaatcttctgacaaaactcacacatctcc
accgtccccagcacctgaactcctgggggaccgtcagtcttcc-3' 3' primer: (SEQ ID
NO: 661) 5'-gttgttttcgaaggatccgctttacccgggagcagggagaggctct
tctgcgtgtagtg-3'
[0796] The polynucleotide sequence is provided in SEQ ID NO:437,
and the encoded polypeptide sequence is provided in SEQ ID
NO:438.
Example 114
10A8 scFv (SSS-S)H P238SCH2 WCH3-hCD80TM/CT
[0797] This construct has a 10A8 (anti-CD2152) single chain Fv
binding region described in Example 12. This binding region is
connected to a mutated human IgG1 connecting region where all of
the cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This hinge region is
attached to a mutated human IgG1 CH2 region and a wild type human
IgG1 CH3 region. The P238S mutation, where a proline at residue 238
was changed to a serine, was introduced according to methods
described in Example 70. This CH3 region is attached to a hCD80
TM/CT according to methods described in Example 113. The
polynucleotide sequence is provided in SEQ ID NO:439, and the
encoded polypeptide sequence is provided in SEQ ID NO:440.
Example 115
40.2.220 scFv (SSS-S)H P238SCH2 WCH3-hCD80TM/CT
[0798] This construct has a 40.2.220 (anti-CD40) single chain Fv
binding region described in Example 12. This binding region is
connected to a mutated human IgG1 connecting region where all of
the cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This hinge region is
attached to a mutated human IgG1 CH2 region and a wild type human
IgG1 CH3 region. The P238S mutation, where a proline at residue 238
was changed to a serine, was introduced according to methods
described in Example 70. This CH3 region is attached to a hCD80
TM/CT according to methods described in Example 113.
Example 116
2H7 scFv (SSS-S)H P238SCH2 WCH3-hCD80TM/CT
[0799] This construct has a 2H7 (anti-CD20) single chain Fv binding
region as described in Example 1. This binding region is connected
to a mutated human IgG1 connecting region where all of the
cysteines and one proline have been changed to serines (SSS-S),
according to methods described in Example 5. This hinge region is
attached to a mutated human IgG1 CH2 region and a wild type human
IgG1 CH3 region. The P238S mutation, where a proline at residue 238
was changed to a serine, was introduced according to methods
described in Example 70. This CH3 region is attached to a hCD80
TM/CT according to methods described in Example 113. This construct
has previously been referred to as: The polynucleotide sequence is
provided in SEQ ID NO:441, and the encoded polypeptide sequence is
provided in SEQ ID NO:442.
Example 117
G19-4 scFv (SSS-S)H P238SCH2 WCH3-hCD80TM/CT
[0800] This construct has a G19 (anti-CD3) single chain Fv binding
region described in Example 29. This binding region is connected to
a mutated human IgG1 connecting region where all of the cysteines
and one proline have been changed to serines (SSS-S) according to
methods described in Example 5. This hinge region is attached to a
mutated human IgG1 CH2 region and a wild type human IgG1 CH3
region. The P238S mutation, where a proline at residue 238 was
changed to a serine, was introduced according to methods described
in Example 70. This CH3 region is attached to a hCD80 TM/CT
according to methods described in Example 113. The polynucleotide
sequence is provided in SEQ ID NO:443, and the encoded polypeptide
sequence is provided in SEQ ID NO:444.
Example 118
2E12 scFv (SSS-S)H WCH2 WCH3-hCD80TM/CT
[0801] This construct has a 2e12 (anti-CD28) single chain Fv
binding region described in Example 12. This binding region is
connected to a mutated human IgG1 connecting region where all of
the cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This connecting region
is attached to wild type human IgG1 CH2 and CH3 constant regions as
described in Example 1. This CH3 region is attached to a hCD80
TM/CT according to methods described in Example 113. This construct
has previously been referred to as 2e12 scFv IgG WTH
WHTCH3CH2-CD80, which has the same sequence as the above construct.
The polynucleotide sequence is provided in SEQ ID NO:126, and the
encoded polypeptide sequence is provided in SEQ ID NO:127.
Example 119
2E12 scFv IgAH IgACH2 T4CH3-hCD80TM/CT
[0802] This construct has a 2e12 (anti-CD28) single chain Fv
binding region described in Example 12. This binding region is
attached to a connecting region from human IgA as described in
Example 5. This connecting region is attached to a human IgA
constant region consisting of a wild type CH2 region and a mutated
CH3 region where there is a truncation of 4 amino acid residues
prior to the 3' stop codon as described in Example 13. This CH3
region is attached to a hCD80 TM/CT according to methods described
in Example 113. The specific primers used to create an IgA ORF are
listed below.
TABLE-US-00042 5'primer: (SEQ ID NO: 662)
5'-gttgttgatcagccagttccctcaactccacctacc-3' 3' primer: (SEQ ID NO:
663) 5'-gttgttttcgaaggatccgcgtccacctccgccatgacaacaga
[0803] The polynucleotide sequence is provided in SEQ ID NO:445,
and the encoded polypeptide sequence is provided in SEQ ID
NO:446.
Example 120
2E12 scFv IgE CH2CH3CH4-hCD80TM/CT
[0804] This construct has a 2e12 (anti-CD28) single chain Fv
binding region described in Example 12. This binding region is
attached to a human IgE constant region containing CH2, CH3 and CH4
as described in Example 38. This CH4 region is attached to a hCD80
TM/CT essentially according to methods described in Example 113.
The specific primers used to create an IgE ORF are listed
below.
TABLE-US-00043 5' primer: (SEQ ID NO: 664)
5'-gttgttgatcacgtctgctccagggacttcacc-3' 3'primer: (SEQ ID NO: 665)
5'-gttgttttcgaaggatccgctttaccagatttacagacaccgctcgc tg-3'
[0805] The polynucleotide sequence is provided in SEQ ID NO:183,
and the encoded polypeptide sequence is provided in SEQ ID
NO:184.
Example 121
2E12 scFv (SSS-S)H P238SCH2 WCH3-mFADD-TM/CT
[0806] This construct has a 2e12 (anti-CD28) single chain Fv
binding region described in Example 12. This binding region is
connected to a mutated human IgG1 connecting region where all of
the cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This hinge region is
attached to a mutated human IgG1 CH2 region and a wild type human
IgG1 CH3 region. The P238S mutation, where a proline at residue 238
was changed to a serine, was introduced according to methods
described in Example 70. The CH3 region is attached to a mouse FADD
transmembrane ans cytoplasmic tail region (mFADD TM/CT). This
region is cloned using essentially the same methods described in
Example 113. The domain was PCR amplified from randomly primed cDNA
from mouse spleen RNA. The specific primers are listed below.
TABLE-US-00044 5' primer: (SEQ ID NO: 666)
5'-gttgtggatccttcgaacccattcctggtgctgctgcactcgctg- 3' 3' primer:
(SEQ ID NO: 667) 5'-gttgttatcgatctcgagtcagggtgtttctgaggaagacacagt-
3'
[0807] The specific primers used to create a mouse IgG ORF are
listed below.
TABLE-US-00045 5'primer: (SEQ ID NO: 668)
5'-gttgtagatctggagcccagagggcccacaatcaagc cctctcctccaagcaaaagccca-3'
3'primer: (SEQ ID NO: 669) 5'-gttgttttcgaaggatccgctttacccggagtccggg
agaag-3'
[0808] The polynucleotide sequence is provided in SEQ ID NO:447,
and the encoded polypeptide sequence is provided in SEQ ID
NO:448.
Example 122
2E12 scFv (SSS-S)H WCH2 WCH3-mFADD-TM/CT
[0809] This construct has a 2e12 (anti-CD28) single chain Fv
binding region described in Example 12. This binding region is
connected to a mutated human IgG1 connecting region where all of
the cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This connecting region
is attached to wild type human IgG1 CH2 and CH3 constant regions as
described in Example 1. The CH3 region was attached to a mFADD
TM/TM region according to methods described in Example 113 and 121.
The polynucleotide sequence is provided in SEQ ID NO:449, and the
encoded polypeptide sequence is provided in SEQ ID NO:450.
Example 123
2E12 scFv (SSS-S)H WCH2 WCH3-mcasp3-TM/CT
[0810] This construct has a 2e12 (anti-CD28) single chain Fv
binding region described in Example 12. This binding region is
connected to a mutated human IgG1 connecting region where all of
the cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This connecting region
is attached to wild type human IgG1 CH2 and CH3 constant regions as
described in Example 1. The CH3 region is attached to a mouse casp3
transmembrane and ctyoplasmic tail region according to methods
described in Examples 113 and 121. The specific primers used to
isolate the mcasp3 TM/CT region are listed below:
TABLE-US-00046 5' primer: (SEQ ID NO: 670)
5'-gttgttggatccttcgaacatggagaacaacaaaacctcagtggatt ca-3' 3' primer:
(SEQ ID NO: 671) 5'-gttgttatcgatctcgagctagtgataaaagtacagttctttcgt-
3'
[0811] The polynucleotide sequence is provided in SEQ ID NO:453,
and the encoded polypeptide sequence is provided in SEQ ID
NO:454.
Example 124
2E12 scFv (SSS-S)H P238SCH2 WCH3-mcasp3-TM/CT
[0812] This construct has a 2e12 (anti-CD28) single chain Fv
binding region described in Example 12. This binding region is
connected to a mutated human IgG1 connecting region where all of
the cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This hinge region is
attached to a mutated human IgG1 CH2 region and a wild type human
IgG1 CH3 region. The P238S mutation, where a proline at residue 238
was changed to a serine, was introduced according to methods
described in Example 70. The CH3 region is connected to a mcasp3
TM/CT region according to methods described in Examples 113, 121
and 123. The polynucleotide sequence is provided in SEQ ID NO:455,
and the encoded polypeptide sequence is provided in SEQ ID
NO:456.
Example 125
2E12 scFv (SSS-S)H WCH2 WCH3-mcasp8-TM/CT
[0813] This construct has a 2e12 (anti-CD28) single chain Fv
binding region described in Example 12. This binding region is
connected to a mutated human IgG1 connecting region where all of
the cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This connecting region
is attached to wild type human IgG1 CH2 and CH3 constant regions as
described in Example 1. The CH3 region is attached to a mouse casp8
transmemebrane and cytoplasmic tail region (mcasp8 TM/CT)
essentially according to methods described in Example 113 and 121.
The specific primers used to clone the mcasp8 TM/CT region are
listed below.
TABLE-US-00047 5' primer: (SEQ ID NO: 672)
5'-gttgtttcgaacatggatttccagagttgtctttatgctattgctg- 3' 3' primer:
(SEQ ID NO: 673) 5'-gttgttatcgatctcgagtcattagggagggaagaagagcttcttcc
g-3'
[0814] The polynucleotide sequence is provided in SEQ ID NO:459,
and the encoded polypeptide sequence is provided in SEQ ID
NO:460.
Example 126
2E12 scFv (SSS-S)H P238SCH2 WCH3-mcasp8-TM/CT
[0815] This construct has a 2e12 (anti-CD28) single chain Fv
binding region described in Example 12. This binding region is
connected to a mutated human IgG1 connecting region where all of
the cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This hinge region is
attached to a mutated human IgG1 CH2 region and a wild type human
IgG1 CH3 region. The P238S mutation, where a proline at residue 238
was changed to a serine, was introduced according to methods
described in Example 70. The CH3 region was attached to a mcasp8
TM/CT region according to methods described in Examples 113, 121
and 125. The polynucleotide sequence is provided in SEQ ID NO:461,
and the encoded polypeptide sequence is provided in SEQ ID
NO:462.
Example 127
2E12 scFv (SSS-S)H WCH2 WCH3-Hcasp3-TM/CT
[0816] This construct has a 2e12 (anti-CD28) single chain Fv
binding region described in Example 12. This binding region is
connected to a mutated human IgG1 connecting region where all of
the cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This connecting region
is attached to wild type human IgG1 CH2 and CH3 constant regions as
described in Example 1. The CH3 region was attached to a human
casp3 transmembrane and cytoplasmic tail region (hcasp3 TM/CT)
essentially according to methods describe in Examples 113. The
specific primers used to clone the hcasp3 TM/CT region are listed
below.
TABLE-US-00048 5' Primer: (SEQ ID NO: 674)
5'-gttgtggatccttcgaacatggagaacactgaaaactcagtggat- 3' 3' Primer:
(SEQ ID NO: 675) 5'-gttgttatcgatctcgagttagtgataaaaatagagttcttttgtga
g-3'
[0817] The polynucleotide sequence is provided in SEQ ID NO:465,
and the encoded polypeptide sequence is provided in SEQ ID
NO:466.
Example 128
2E12 scFv (SSS-S)H P238SCH2 WCH3-hcasp3-TM/CT
[0818] This construct has a 2e12 (anti-CD28) single chain Fv
binding region described in Example 12. This binding region is
connected to a mutated human IgG1 connecting region where all of
the cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This hinge region is
attached to a mutated human IgG1 CH2 region and a wild type human
IgG1 CH3 region. The P238S mutation, where a proline at residue 238
was changed to a serine, was introduced according to methods
described in Example 70. The CH3 region is attached to a hcasp3
TM/CT region according to methods described in Examples 113 and
127. The polynucleotide sequence is provided in SEQ ID NO:467, and
the encoded polypeptide sequence is provided in SEQ ID NO:468.
Example 129
2E12 scFv (SSS-S)H WCH2 WCH3-hcasp8-TM/CT
[0819] This construct has a 2e12 (anti-CD28) single chain Fv
binding region described in Example 12. This binding region is
connected to a mutated human IgG1 connecting region where all of
the cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This connecting region
is attached to wild type human IgG1 CH2 and CH3 constant regions as
described in Example 1. The CH3 region is attached to a human casp8
transmembrane and cytoplasmic tail region (hcasp8 TM/CT) according
to methods described in Example 133. The specific primers used to
clone the hcasp8 TM/CT region are listed below.
TABLE-US-00049 5' Primer: (SEQ ID NO: 676)
5'-gttgtggatccttcgaacatggacttcagcagaaatctttatgat- 3' 3' Primer:
(SEQ ID NO: 677) 5'-gttgttatcgatgcatgctcaatcagaagggaagacaagtttttttc
t-3'
[0820] The polynucleotide sequence is provided in SEQ ID NO:473,
and the encoded polypeptide sequence is provided in SEQ ID
NO:474.
Example 130
2E12 scFv (SSS-S)H P238SCH2 WCH3-hcasp8-TM/CT
[0821] This construct has a 2e12 (anti-CD28) single chain Fv
binding region described in Example 12. This binding region is
connected to a mutated human IgG1 connecting region where all of
the cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This hinge region is
attached to a mutated human IgG1 CH2 region and a wild type human
IgG1 CH3 region. The P238S mutation, where a proline at residue 238
was changed to a serine, was introduced according to methods
described in Example 70. The CH3 region is attached to a hcasp8
TM/CT according to methods described in Examples 113 and 129. The
polynucleotide sequence is provided in SEQ ID NO:475, and the
encoded polypeptide sequence is provided in SEQ ID NO:476.
Example 131
1D8 scFv (SSS-S)H P238SCH2 WCH3-HCD80TM/CT
[0822] This construct has a 1D8 (anti-4-1BB) single chain Fv
binding region described in Example 25. This binding region is
connected to a mutated human IgG1 connecting region where all of
the cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This hinge region is
attached to a mutated human IgG1 CH2 region and a wild type human
IgG1 CH3 region. The P238S mutation, where a proline at residue 238
was changed to a serine, was introduced according to methods
described in Example 70. The CH3 region is attached to a hCD80
TM/CT region according to methods described in Example 113. The
polynucleotide sequence is provided in SEQ ID NO:108, and the
encoded polypeptide sequence is provided in SEQ ID NO:109.
Example 132
1D8 scFv (SSS-S)H WCH2 WCH3-hCD80TM/CT
[0823] This construct has a 1D8 (anti-4-1BB) single chain Fv
binding region described in Example 25. This binding region is
connected to a mutated human IgG1 connecting region where all of
the cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This connecting region
is attached to wild type human IgG1 CH2 and CH3 constant regions as
described in Example 1. The CH3 region is attached to a hCD80 TM/CT
region according to methods described in Example 113. This
construct has previously been referred to as 1D8 scFv IgG WTH
WTCH2CH3-CD80, which has the same sequence as the above construct.
The polynucleotide sequence is provided in SEQ ID NO:481, and the
encoded polypeptide sequence is provided in SEQ ID NO:482.
Example 133
1D8 scFv-mIgAH WIgA CH2 T4CH3-hCD80TM/CT
[0824] This construct has a 1D8 (anti-4-1BB) single chain Fv
binding region described in Example 25. This binding region is
attached to a connecting region from human IgA as described in
Example 5. This connecting region is attached to a mouse IgA
constant region consisting of a wild type CH2 region and a mutated
CH3 region where there is a truncation of 4 amino acid residues
prior to the 3' stop codon as described in Example 39. The CH3
region can be attached to a hCD80 TM/CT region according to methods
described in Examples 113 using primers that create an IgA ORF (SEQ
ID NOs: 483 and 484).
Example 134
1D8 scFv IgE CH2CH3CH4-HCD80TM/CT
[0825] This construct has a 1D8 (anti-4-1BB) single chain Fv
binding region described in Example 25. This binding region is
attached to a human IgE constant region containing CH2, CH3 and CH4
as described in Example 38. The CH4 region is attached to a hCD80
TM/CT according to methods described in Examples 113 and 120. The
polynucleotide sequence is provided in SEQ ID NO:175, and the
encoded polypeptide sequence is provided in SEQ ID NO:176.
Example 135
1D8 scFv (SSS-S)H P238SCH2 WCH3-mFADD-TM/CT
[0826] This construct has a 1D8 (anti-4-1BB) single chain Fv
binding region described in Example 25. This binding region is
connected to a mutated human IgG1 connecting region where all of
the cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This hinge region is
attached to a mutated human IgG1 CH2 region and a wild type human
IgG1 CH3 region. The P238S mutation, where a proline at residue 238
was changed to a serine, was introduced according to methods
described in Example 70. The CH3 region was attached to a mFADD
TM/TM region according to methods described in Example 113 and 121.
The polynucleotide sequence is provided in SEQ ID NO:487, and the
encoded polypeptide sequence is provided in SEQ ID NO:488.
Example 136
1D8 scFv (SSS-S)H WCH2 WCH3-mFADD-TM/CT
[0827] This construct has a 1D8 (anti-4-1BB) single chain Fv
binding region described in Example 25. This binding region is
connected to a mutated human IgG1 connecting region where all of
the cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This connecting region
is attached to wild type human IgG1 CH2 and CH3 constant regions as
described in Example 1. The CH3 region was attached to a mFADD
TM/TM region according to methods described in Example 113 and 121.
The polynucleotide sequence is provided in SEQ ID NO:485, and the
encoded polypeptide sequence is provided in SEQ ID NO:486.
Example 137
1D8 scFv (SSS-S)H WCH2 WCH3-mcasp3-TM/CT
[0828] This construct has a 1D8 (anti-4-1BB) single chain Fv
binding region described in Example 25. This binding region is
connected to a mutated human IgG1 connecting region where all of
the cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This connecting region
is attached to wild type human IgG1 CH2 and CH3 constant regions as
described in Example 1. The CH3 region was attached to a mcasp3
TM/TM region according to methods described in Example 113, 121 and
123. The polynucleotide sequence is provided in SEQ ID NO:489, and
the encoded polypeptide sequence is provided in SEQ ID NO:490.
Example 138
1D8 scFv (SSS-S)H P238SCH2 WCH3-mcasp3-TM/CT
[0829] This construct has a 1D8 (anti-4-1BB) single chain Fv
binding region described in Example 25. This binding region is
connected to a mutated human IgG1 connecting region where all of
the cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This hinge region is
attached to a mutated human IgG1 CH2 region and a wild type human
IgG1 CH3 region. The P238S mutation, where a proline at residue 238
was changed to a serine, was introduced according to methods
described in Example 70. The CH3 region was attached to a mcasp3
TM/TM region according to methods described in Example 113, 121 and
123. The polynucleotide sequence is provided in SEQ ID NO:491, and
the encoded polypeptide sequence is provided in SEQ ID NO:492.
Example 139
1D8 scFv (SSS-S)H WCH2 WCH3-mcasp8-TM/CT
[0830] This construct has a 1D8 (anti-4-1BB) single chain Fv
binding region described in Example 25. This binding region is
connected to a mutated human IgG1 connecting region where all of
the cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This connecting region
is attached to wild type human IgG1 CH2 and CH3 constant regions as
described in Example 1. The CH3 region was attached to a mcasp8
TM/TM region according to methods described in Example 113, 121 and
125. The polynucleotide sequence is provided in SEQ ID NO:493, and
the encoded polypeptide sequence is provided in SEQ ID NO:494.
Example 140
1D8 scFv (SSS-S)H P238SCH2 WCH3-mcasp8-TM/CT
[0831] This construct has a 1D8 (anti-4-1BB) single chain Fv
binding region described in Example 25. This binding region is
connected to a mutated human IgG1 connecting region where all of
the cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This hinge region is
attached to a mutated human IgG1 CH2 region and a wild type human
IgG1 CH3 region. The P238S mutation, where a proline at residue 238
was changed to a serine, was introduced according to methods
described in Example 70. The CH3 region was attached to a mcasp8
TM/TM region according to methods described in Example 113, 121 and
125. The polynucleotide sequence is provided in SEQ ID NO:495, and
the encoded polypeptide sequence is provided in SEQ ID NO:496.
Example 141
1D8 scFv (SSS-S)H WCH2 WCH3-hcasp3-TM/CT
[0832] This construct has a 1D8 (anti-4-1BB) single chain Fv
binding region described in Example 25. This binding region is
connected to a mutated human IgG1 connecting region where all of
the cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This connecting region
is attached to wild type human IgG1 CH2 and CH3 constant regions as
described in Example 1. The CH3 region is attached to a hcasp3
TM/CT according to methods described in Examples 113 and 127. The
polynucleotide sequence is provided in SEQ ID NO:497, and the
encoded polypeptide sequence is provided in SEQ ID NO:498.
Example 142
1D8 scFv (SSS-S)H P238SCH2 WCH3-hcasp3-TM/CT
[0833] This construct has a 1D8 (anti-4-1BB) single chain Fv
binding region described in Example 25. This binding region is
connected to a mutated human IgG1 connecting region where all of
the cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This hinge region is
attached to a mutated human IgG1 CH2 region and a wild type human
IgG1 CH3 region. The P238S mutation, where a proline at residue 238
was changed to a serine, was introduced according to methods
described in Example 70. The CH3 region is attached to a hcasp3
TM/CT according to methods described in Examples 113 and 127. The
polynucleotide sequence is provided in SEQ ID NO:499, and the
encoded polypeptide sequence is provided in SEQ ID NO:500.
Example 143
1D8 scFv (SSS-S)H WCH2 WCH3-hcasp8-TM/CT
[0834] This construct has a 1D8 (anti-4-1BB) single chain Fv
binding region described in Example 25. This binding region is
connected to a mutated human IgG1 connecting region where all of
the cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This connecting region
is attached to wild type human IgG1 CH2 and CH3 constant regions as
described in Example 1. The CH3 region is attached to a hcasp8
TM/CT according to methods described in Examples 113 and 129. The
polynucleotide sequence is provided in SEQ ID NO:501, and the
encoded polypeptide sequence is provided in SEQ ID NO:502.
Example 144
1D8 scFv (SSS-s)H P238SCH2 WCH3-hcasp8-TM/CT
[0835] This construct has a 1D8 (anti-4-1BB) single chain Fv
binding region described in Example 25. This binding region is
connected to a mutated human IgG1 connecting region where all of
the cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This hinge region is
attached to a mutated human IgG1 CH2 region and a wild type human
IgG1 CH3 region. The P238S mutation, where a proline at residue 238
was changed to a serine, was introduced according to methods
described in Example 70. The CH3 region is attached to a hcasp8
TM/CT according to methods described in Examples 113 and 129. The
polynucleotide sequence is provided in SEQ ID NO:503, and the
encoded polypeptide sequence is provided in SEQ ID NO:504.
Example 145
L6 scFv (SSS-S) H WCH2 WCH3
[0836] This construct has a L6 scFv binding domain as described in
Example 105. This binding region is connected to a mutated human
IgG1 connecting region where all of the cysteines and one proline
have been changed to serines (SSS-S) according to methods described
in Example 5. This connecting region is attached to wild type human
IgG1 CH2 and CH3 constant regions as described in Example 1. This
construct has previously been referred to as L6 scFv-IgMHWTG1C,
which has the same sequence as the above construct. The
polynucleotide sequence is provided in SEQ ID NO:415, and the
encoded polypeptide sequence is provided in SEQ ID NO:416.
Example 146
2H7 scFv CD154 (L2)
[0837] This construct has a 2H7 (anti-CD20) single chain Fv binding
region as described in Example 1. This binding region has been
attached to CD154 extracellular domain according to methods
described in Example 4. The polynucleotide sequence is provided in
SEQ ID NO:690, and the encoded polypeptide sequence is provided in
SEQ ID NO:691.
Example 147
2H7 scFv CD154 (S4)
[0838] This construct has a 2H7 (anti-CD20) single chain Fv binding
region as described in Example 1. This binding region has been
attached to CD154 extracellular domain according to methods
described in Example 4, such that methods of attachment resulted in
a truncated version compared to the construct describe in Example
146. The polynucleotide sequence is provided in SEQ ID NO:692, and
the encoded polypeptide sequence is provided in SEQ ID NO:693.
Example 148
CTLA4 IgAH IgACH2CH3
[0839] This construct has the extra cellular CTLA-4 binding region
as described in Example 14. This binding region is attached to a
wild type human IgA connecting region as described in Example 5.
This connecting region is attached to a wild type human IgA CH2 and
CH3 constant region according to methods described in Example 13.
This constant region is attached to a J-chain region as described
in Example 13. This construct has previously been referred to as
CTLA-4 IgAH IgACH2CH3, which has the same sequence as the above
construct. The polynucleotide sequence is provided in SEQ ID
NO:505, and the encoded polypeptide sequence is provided in SEQ ID
NO:506.
Example 149
CTLA4 IgAH IgACH2 T4-CH3
[0840] This construct has the extra cellular CTLA-4 binding region
as described in Example 14. This binding region is attached to a
connecting region from human IgA as described in Example 5. This
connecting region is attached to a human IgA constant region
consisting of a wild type CH2 region and a mutated CH3 region where
there is a truncation of 4 amino acid residues prior to the 3' stop
codon as described in Example 13. This construct has previously
been referred to as CTLA-4 IgAH IgA-T4, which has the same sequence
as the above construct. The polynucleotide sequence is provided in
SEQ ID NO:507, and the encoded polypeptide sequence is provided in
SEQ ID NO:508.
Example 150
2H7 scFv IgAH IgACH2CH3
[0841] This construct has a 2H7 (anti-CD20) single chain Fv binding
region as described in Example 1. This binding region is attached
to a wild type human IgA connecting region as described in Example
5. This connecting region is attached to a wild type human IgA CH2
and CH3 constant region according to methods described in Example
13. The polynucleotide sequence is provided in SEQ ID NO:61, and
the encoded polypeptide sequence is provided in SEQ ID NO:62.
Example 151
2H7 scFv IgAH IgAHCH2 T18CH3
[0842] This construct has a 2H7 (anti-CD20) single chain Fv binding
region as described in Example 1. This binding region is attached
to a connecting region from human IgA as described in Example 5.
This connecting region is attached to a human IgA constant region
consisting of a wild type CH2 region and a mutated CH3 region where
there is a truncation of 18 amino acid residues prior to the 3'
stop codon as described in Example 13. The polynucleotide sequence
is provided in SEQ ID NO:509, and the encoded polypeptide sequence
is provided in SEQ ID NO:510.
Example 152
2H7-40.2.220 scFv (SSS-S) H WCH2 WCH3
[0843] A bispecific fusion protein was constructed between 2H7 scFv
(anti-CD20) and 40.2.220 (anti-CD40), which both target B cell
receptors. The 2H7 scFv hIgG1 (SSS-S)H WCH2 WCH3 construct in the
expression vector pD18 was passaged through dam.sup.- bacteria in
order to permit cleavage at the BclI site. Cleaved plasmid was
treated with alkaline phosphatase prior to ligation to a BclI cut
linker-CD40 scFv fragment. This fragment was synthesized from the
existing 40.2.220 scFv by successive PCR reactions with overlapping
primers. The linker attached is a previously patented (BMS patent
issued) helical type linker with a high number of lysine and
glutamic acid residues. The scFv for CD40 was PCR amplified without
the leader peptide as a SalI-BclI fragment, but with the hinge type
linker substituted at the amino terminus as a BclI-SalI fragment,
to mediate insertion of the linker-scFv cassette as a BclI fragment
between the scFv and -Ig tail included in an existing scFvIg
construct for CD20 (2H7 scFv hIgG1 constructs). The 3' end was
similar to the other scFv VH molecules with an out of frame BclI
site fused to the VTVSS type sequence at the end of the VH
domain.
PCR oligos: 40.2.220 scFv:
TABLE-US-00050 5' primer--40.2.220S5: (SEQ ID NO: 678)
5'-gttgttgtcgacattgttctgactcagtctccagccaccctgtc-3' 3'
primer--40.2.220Bcl3: (SEQ ID NO: 679)
5'-gttgttgatcagagacagtgaccagtgtcccttgg-3'
Linker Primers:
[0844] BclI-SalI fragment created by annealing complementary
oligonucleotides. This fragment is then ligated into BclI digested
vector along with a SalI-BclI scFv to create the (linker-scFv) BclI
fragment desired for shuttling.
TABLE-US-00051 5' primer: (SEQ ID NO: 560)
5'-gatcaatccaactctgaagaagcaaagaaagaggaggccaaaaagga
ggaagccaagaaatctaacagcg-3' 3' primer: (SEQ ID NO: 563)
5'-tcgacgctgttagatttcttggcttcctcctttttggcctcctcttt
ctttgcttcttcagagttggatt-3'
[0845] This BclI fragment was then ligated downstream of the 2H7
scFv in pD18-Ig. Transformants were screened for the presence of a
2.4 kb HindIII-Xba insert and positive clones sequenced prior to
further studies. COS cell transient transfections were performed
with this construct and culture supernatants screened for the
presence of protein of the predicted size and for binding to CD20
and to CD40 transfected CHO cells.
[0846] New bispecific constructs can be created by designing hinge
type linkers which incorporate one or preferably two restriction
sites at either end of the linker, facilitating asymmetric digests
and transfer of (linker-scFv) or (scFv-linker) cassettes between
different constructs. These constructs will also incorporate the VH
L11S and other V region substitutions, which presumably facilitate
proper folding and result in increased expression of the molecules
in which they are inserted.
This binding region is connected to a mutated human IgG1 connecting
region where all of the cysteines and one proline have been changed
to serines (SSS-S) according to methods described in Example 5.
This connecting region is attached to wild type human IgG1 CH2 and
CH3 constant regions as described in Example 1. This construct has
previously been referred to as anti-CD20-anti-CD40 scFv IgG MTH
(SSS) MTCH2WTCH3, which has the same sequence as the above
construct. The polynucleotide sequence is provided in SEQ ID
NO:114, and the encoded polypeptide sequence is provided in SEQ ID
NO:115.
Example 153
2H7 scFv IgAH IgACH2 T4-CH3-hCD80 TM/CT
[0847] This construct has a 2H7 (anti-CD20) single chain Fv binding
region as described in Example 1. This binding region is attached
to a connecting region from human IgA as described in Example 5.
This connecting region is attached to a human IgA constant region
consisting of a wild type CH2 region and a mutated CH3 region where
there is a truncation of 4 amino acid residues prior to the 3' stop
codon as described in Example 13. This CH3 region is attached to a
hCD80 TM/CT according to the methods described in Examples 113 and
119. This construct has previously been referred to as 2H7 scFv IgA
hinge IgA-T4-CD80 and 2H7 scFv IgAH IgA-T4-CD80, which both have
the same sequence as the above construct. The polynucleotide
sequence is provided in SEQ ID NOs:70 and 29, and the encoded
polypeptide sequence is provided in SEQ ID NOs:71 and 30.
Example 154
G19-4 scFv (CCC-P) WH WCH2 WCH3-hCD80 TM/CT
[0848] This construct has a G19 (anti-CD3) single chain Fv binding
region described in Example 29. This binding region is attached to
a wild type human IgG1 connecting region (CCC-P) as described in
Example 1. This connecting region is attached to wild type human
IgG1 CH2 and CH3 constant regions as described in Example 1. This
CH3 region is attached to a hCD80 TM/CT according to the methods
described in Examples 113. The polynucleotide sequence is provided
in SEQ ID NOs:112 and 29, and the encoded polypeptide sequence is
provided in SEQ ID NOs:113 and 30.
Example 155
2E12 scFv (CCC-P) WH WCH2 WCH3-HCD80 TM/CT
[0849] This construct has a 2e12 (anti-CD28) single chain Fv
binding region described in Example 12. This binding region is
attached to a wild type human IgG1 connecting region (CCC-P) as
described in Example 1. This connecting region is attached to wild
type human IgG1 CH2 and CH3 constant regions as described in
Example 1. This CH3 region is attached to a hCD80 TM/CT according
to the methods described in Examples 113. The polynucleotide
sequence is provided in SEQ ID NO:126, and the encoded polypeptide
sequence is provided in SEQ ID NO:127.
Example 156
2H7 VHL11S scFv (SSS-S) IgECH3CH4
[0850] This construct has a 2H7 (anti-CD20) single chain Fv binding
region with a point mutation at amino acid residue 11 in the heavy
chain variable region, where the leucine has been changed to a
serine as described in Example 33. This binding region is connected
to a mutated human IgG1 connecting region where all of the
cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. This connecting region
is attached to human IgE CH3 and CH4 constant region. This
truncated constant region was created according to the methods
described in Example 38. The polynucleotide sequence is provided in
SEQ ID NO:227, and the encoded polypeptide sequence is provided in
SEQ ID NO:228.
Example 157
IgD Hinge
[0851] An alternative hinge region can be isolated from human IgD
immunoglobulin hinge region by using PCR assay to isolate the
desired region. The PCR reaction is the same used in Example 1.
This hinge was truncated by 6 amino acid residues at the 3' end.
The primers used in this PCR reaction are listed below.
TABLE-US-00052 5'' Primer: (SEQ ID NO: 534)
5'-GTGGATCCAGGTTCGAAGTCTCCAAAGGCACAGGCC-3' 3' primer: (SEQ ID NO:
517) 5'-GTTGTCGACTGCACCGGTCTTTGTCTCTCTCTCTTC-3'
[0852] The polynucleotide sequence is provided in SEQ ID NO:237,
and the encoded polypeptide sequence is provided in SEQ ID
NO:238.
Example 158
hCD28 TM/CT
[0853] For some of the cell surface ORF constructs, the
transmembrane domain of CD80 was substituted with the transmembrane
domain of human CD28 because it forms a dimer on the cell surface
rather than a monomer as the CD80 does. Several of the molecules
which drive the apoptotic program require
oligomerization/trimerization to form a signaling complex;
therefore, it is important to be able to control initiation of
signaling by controlling the degree of oligomerization of these
recombinant receptors on the cell surface.
The primers used in PCR amplification of the CD28 tail are given
below:
TABLE-US-00053 5' Primer: (SEQ ID NO: 518)
5'-gttgtggatccttcgaaccccttttgggtgctggtggtggttggtgg a-3' 3' primer:
(SEQ ID NO: 519)
5'-gttgttatcgatctcgagtcaggagcgataggctgcgaagtc-3'
Example 159
2H7 scFv VH L11S (SSS-S) H K322L CH2 WCH3
[0854] This construct has a 2H7 (anti-CD20) single chain Fv binding
region with a point mutation at amino acid residue 11 in the heavy
chain variable region, where the leucine has been changed to a
serine. as described in Example 33. This binding region is
connected to a mutated human IgG connecting region where all of the
cysteines and one proline have been changed to serines (SSS-S)
according to methods described in Example 5. The connecting region
is attached to a mutated IgG CH2 region and a wild type IgG CH3
region. The K322L mutation in the CH2 region is at a residue 322,
where a Lysine has been changed to a leucine using overlapping PCR
described in Example 56, but with different primers for the first
PCR reaction, which are listed below.
TABLE-US-00054 5' primer: (SEQ ID NO: 635)
5'ttcctcttccccccaaaacccaaggacaccctcatgatctcccggaac cctgaggtcac-3'
3' primer: (SEQ ID NO: 621) 5'-ggacagtgggagtggcacc-3'
[0855] PCR product was cloned into TOPO vector and sequenced. The
polynucleotide sequence is provided in SEQ ID NO:265, and the
encoded polypeptide sequence is provided in SEQ ID NO:266.
Example 160
2H7 scFv VH L11S(CSS-S) H K322L CH2 WCH3
[0856] This construct has a 2H7 (anti-CD20) single chain Fv binding
region with a point mutation at amino acid residue 11 in the heavy
chain variable region, where the leucine has been changed to a
serine, as described in Example 33. This binding region is attached
to a mutant IgG connecting region, where the second and third
cysteines have been changed to serines and the proline has been
changed to serine (CSS-S), according to methods described in
Example 13. The connecting region is attached to a mutated IgG CH2
region and a wild type IgG CH3 region. The K322L mutation in the
CH2 region is at a residue 322, where a Lysine has been changed to
a leucine using overlapping PCR described in Example 56, using
primers from Example 159 in the first PCR reaction and primers from
Example 57 for the second PCR reaction.
[0857] PCR products were cloned into the TOPO vector and sequenced.
The polynucleotide sequence is provided in SEQ ID NO:261, and the
encoded polypeptide sequence is provided in SEQ ID NO:262.
Example 161
In Vivo B Cell Depletion by 2H7 scFv (SSS-S) H WCH2 WCH3 and 2H7
scFv (SSS-S) H P238SCH2 WCH3
[0858] This Example describes experiments relating to ADCC effector
mechanisms in the depletion of B cells through comparison of the
activities of an anti-CD20 construct (2H7 scFv (SSS-S) H WCH2 WCH3)
and a anti-CD20 construct with a proline to serine amino acid
substitution in the CH2 domain (2H7 scFv (SSS-S) H P238SCH2 WCH3).
FIG. 72 shows the results of an experiment on apoptosis induction
by these constructs. The results indicated that both molecules bind
CD20 and induce apoptosis that is mediated by activation of caspase
3.
[0859] FIG. 73 illustrates that anti-CD20 constructs mediate CDC
activity towards CD20 positive target cells. A 2H7 scFv (SSS-S) H
WCH2 WCH3 construct, a 2H7 scFv (SSS-S) H P238SCH2 WCH3 construct,
or Rituximab were incubated at increasing concentrations with
10.sup.4 Bjab Target Cells and a 1:10 dilution of rabbit complement
(PelFreez) in a volume of 100 microliters for sixty minutes.
Aliquots were stained with trypan blue (Invitrogen), and counted
using a hemacytometer to determine the percentage of the cell
population killed during treatment. Negative controls with cells
and only one reagent were also included. FIG. 74 illustrates that
the 2H7 scFv (SSS-S) H WCH2 WCH3 construct was effective in ADCC
with peripheral blood mononuclear cells. ADCC activity of 2H7 scFv
(SSS-S) H WCH2 WCH3 or Rituximab was measured in vitro against BJAB
B lymphoma cell line as the target cells, and using fresh human
PBMC as effector cells. Effector to target ratios were varied as
follows: 100:1, 50:1, and 25:1, with the number of BJAB cells per
well remaining constant but varying the number of PBMC. BJAB cells
were labeled for 2 hours with .sup.51Cr and aliquoted at a cell
density of 5.times.10.sup.4 cells/well to each well of flat-bottom
96 well plates. Purified fusion proteins or Rituximab were added at
a concentration of 10 .mu.g/ml, and PBMC were added at
1.25.times.10.sup.6 cells/well (25:1), 2.5.times.10.sup.6
cells/well (50:1), or 5.times.10.sup.6 cells/well (100:1), in a
final volume of 200 .mu.l. Natural killing was measured at each
effector:target ratio by omission of the construct or MAb.
Spontaneous release was measured without addition of PBMC or fusion
protein, and maximal release was measured by the addition of
detergent (1% NP-40) to the appropriate wells. Reactions were
incubated for 5 hours, and 100 .mu.l culture supernatant harvested
to a Lumaplate (Packard Instruments) and allowed to dry overnight
prior to counting cpm released on a Packard Top Count NXT
Microplate Scintillation Counter. FIG. 75 illustrates that the 2H7
scFv (SSS-S) H WCH2 WCH3 construct bound soluble CD16 fusion
protein (constructed from either high or low affinity alleles
(158V/F)), while the 2H7 scFv (SSS-S) H P238SCH2 WCH3 construct did
not show detectable binding. CD20 CHO cells (106) were incubated
with saturating amounts of 2H7 scFv (SSS-S) H WCH2 WCH3 or 2H7 scFv
(SSS-S) H P238SCH2 WCH3 (10 ug/ml) for one hour on ice in PBS/2%
FBS. Cells were washed in PBS/2% FBS and incubated with serial
dilutions of 0.5 mg/ml FITC-CD16 for one hour on ice. Cells were
washed and specific binding measured by flow cytometry using a
Beckman-Coulter Epics C machine. Results were analyzed using Expo
analysis software and normalized fluorescence units graphed as a
function of concentration. FIG. 76 illustrates an experiment on the
ability of 2H7 scFv (SSS-S) H WCH2 WCH3 and 2H7 scFv (SSS-S) H
P238SCH2 WCH3 constructs to bind U937 cells. U937 cells (106)
expressing CD64 were incubated in PBS/2% FBS for one hour on ice
with 2H7 scFv (SSS-S) H WCH2 WCH3 or 2H7 scFv (SSS-S) H P238SCH2
WCH3. Cells were washed and incubated for one hour on ice with
FITC-goat anti-human IgG1 (Fc specific) (Caltag) at a final
dilution of 1:100. Cells were washed and fluorescence analyzed on a
Beckman-Coulter EpicsC flow cytometer. Data was analyzed using Expo
analysis software, and fluorescence intensity graphed as a function
of the concentration of 2H7 scFv (SSS-S) H WCH2 WCH3 or 2H7 scFv
(SSS-S) H P238SCH2 WCH3. This figure shows that both the 2H7 scFv
(SSS-S) H WCH2 WCH3 construct and the 2H7 scFv (SSS-S) H P238SCH2
WCH3 construct bound to U937 cells with equivalent titration
curves. The results indicated that the 2H7 scFv (SSS-S) H P238SCH2
WCH3 construct was not impaired in its binding to the high affinity
Fc receptor Fc.gamma.RI (CD64). The fact that binding to high
affinity Fc.gamma.RI on U937 cells was similar for the two
molecules in this experiment indicated that the P238S amino acid
change selectively reduced the binding to Fc.gamma.RIII. FIG. 77
illustrates B cell depletion in macaques mediated by a anti-CD20
construct (2H7 scFv (SSS-S) H WCH2 WCH3) and a anti-CD20) scFv with
a CH2 domain mutation. 2H7 scFv (SSS-S) H WCH2 WCH3 or 2H7 scFv
(SSS-S) H P238SCH2 WCH3 were administered to macaques (M.
fasicularis) by intravenous injection at 6 mg/kg, with two
infusions given one week apart. The effect on circulating B cells
was measured by detection of CD40 positive B cells in peripheral
blood. Blood samples were drawn from injected animals at days 7, 0,
1, 3, 7, 8, 10, 14, 28, and 43. B cell depletion was estimated by
performing CBC (complete blood counts) and two-color flow cytometry
analysis on monkey blood. FITC or PE conjugates of antibodies
against CD40, CD19, CD20, IgG, CD3, CD8 were used in various
combinations. Data are plotted as the number of CD40 positive blood
B cells tabulated in thousands of cells per microliter over time
relative to the initial pre-injection time point level of B cells
(maximum). This experiment showed that 2H7 scFv (SSS-S) H WCH2 WCH3
scFv injection resulted in rapid and complete depletion of
circulating B cells that lasted longer than 28 days following the
second injection. Injection of 2H7 scFv (SSS-S) H P238SCH2 WCH3
scFv did not completely deplete B cells even though CD20 epitopes
were saturated. A slow reduction in B cells to approximately 50% of
initial levels was observed during the first 2 weeks, but B cells
rapidly returned to starting levels in these animals. These results
indicate that the ability to bind high affinity Fc.gamma.RI and to
mediate complement dependent cytotoxicity is not sufficient for a
CytoxB20G molecule to completely deplete circulating B cells, and
that ADCC mediated by interaction with CD16 is likely necessary for
rapid and sustained B cell depletion.
[0860] These experiments indicated that the 2H7 scFv (SSS-S) H WCH2
WCH3 scFvs are able to trigger B cell depletion functions through
three different mechanisms of action (1) induction of apoptosis,
(2) CDC effector mechanisms, and (3) ADCC effector mechanisms. All
three of these mechanisms probably contribute to depletion of B
cells in vivo. The data indicate that complete and sustained
depletion of B cells requires intact ADCC effector mechanisms.
However, the partial depletion obtained with an ADCC negative
mutant also indicates that apoptosis and CDC mechanisms contribute
to mediating a portion of the total B cell depletion effects. The
results support the use of 2H7 scFv (SSS-S) H WCH2 WCH3 scFv in
patients with a CD20 positive B cell malignancy or autoimmune
disease.
Example 162
Induction of Apoptosis in B Cells by Anti-CD37 GS-1 VL11S scFv
(SSS) H WCH2WCH3 Constructs
[0861] In this Example, anti-CD37 GS-1 VL11S scFv (SSS) H WCH2WCH3
constructs were evaluated for their ability to bind target cells
and for their ability to induce apoptosis. The constructs were also
physically characterized by size-exclusion chromatography (SEC).
FIG. 78 illustrates the SEC profile of G28-1 (anti-CD37) constructs
having SSC hinge domain forms (GS-1 VL11S scFv (SSC) H WCH2WCH3).
G28-1 (anti-CD37) constructs were purified from CHO culture
supernatants by Protein A affinity chromatography. Purified
aliquots of 10-25 mg were subjected to HPLC over a Tosoh Biosep,
Inc. TSK 3000 SWXL HPLC column, pore size 5 mm. The flow rate was 1
ml/min, in PBS, pH 7.2 running buffer. Migration rates of molecular
weight standards are indicated below the tracing. The GS-1 VL11S
scFv (SSS) H WCH2WCH3 construct is indicated in blue, while the
GS-1 VL11S scFv (SSC) H WCH2WCH3 construct is indicated in red. The
GS-1 VL11S scFv (SSS) H WCH2WCH3 construct generated a uniform peak
of approximately 75-100 kDa, while the GS-1 VL11S scFv (SSC) H
WCH2WCH3 construct generated a smaller form and other heterogeneous
forms, including a high molecular weight form greater than 200 kDa.
FIG. 79 illustrates the binding of G28-1 (anti-CD37) constructs to
B cell lymphoma cell lines. Serial dilutions of purified GS-1 VL11S
scFv (SSS) H WCH2WCH3 or GS-1 VL11S scFv (SSC) H WCH2WCH3 were
incubated with 10.sup.6 cells of each cell type for 60 minutes on
ice in PBS/2% FBS. Samples were washed twice, and incubated with a
mixture of FITC goat anti-human IgG and FITC goat anti-human IgG
F(ab').sub.2 (CalTag) at 1:100 each, on ice for 45 minutes. Samples
were washed and analyzed by flow cytometry using a FACsCalibur
(Becton-Dickinson). The results of this experiment show that both
GS-1 VL11S scFv (SSS) H WCH2WCH3 and GS-1 VL11S scFv (SSC) H
WCH2WCH3 constructs bound to BJAB and Ramos cells, and moderately
to WIL-2 cells. G28-1 (anti-CD37) (SSS) H G scFv or G28-1 (SSC) H G
scFv constructs molecules bound Raji and Namalwa cells at lower
levels in these experiments. Binding to all lines was significant
because background fluorescence has been subtracted from the data
shown in FIG. 79. FIG. 80 illustrates the binding of annexin and
v-propidium iodide to Ramous cells after overnight incubation with
GS-1 VL11S scFv (SSS) H WCH2WCH3 or GS-1 VL11S scFv (SSC) H
WCH2WCH3 forms of scFvs. AnnexinV-PI staining of Ramos Cells
incubated for 24 hours with G28-1 (anti-CD37) scFvs. Ramos B cells
at 10.sup.6 cells/ml were incubated in 12 well dishes for 24 hours
with G28-1 (anti-CD37) scFvs at 10 mg/ml, in a total volume of 2
ml. Cells were stained with annexinV and propidium iodide with a
kit obtained from Immunotech, according to manufacturer's
instructions. Samples were analyzed by two-color flow cytometry
using a FACsCalibur flow cytometer (Becton-Dickinson). The % of the
total cells in each quadrant is indicated next to each dot plot.
FIG. 83 shows the binding of Annexin V-Propidium Iodide to cells
after overnight incubation with GS-1 VL11S scFv (SSS) H WCH2WCH3 or
GS-1 VL11S scFv (SSC) H WCH2WCH3. The results indicated that both
GS-1 VL11S scFv (SSS) H WCH2WCH3 and GS-1 VL11S scFv (SSC) H
WCH2WCH3 constructs were able to induce apoptosis, but that the SSC
form induced more apoptosis than the SSS form. FIG. 81 illustrates
the inhibition of proliferation of Ramos cells grown in the
presence of G28-1 (anti-CD37) constructs. Ramos B cells were
incubated with serial dilutions of purified G28-1 (anti-CD37)
constructs containing either the IgG1 hinge identified as (SSS) H
or (SSC) H. Cultures were incubated in 96 well flat bottom tissue
culture dishes (Costar) at 37.degree. C., 5% CO.sub.2 for 36 hours
prior to pulsing with 3H-thymidine for the last 12 hours of a 48
hour incubation (0.75 mCi/well). Cells were harvested onto 96-well
GFC plates using a Packard harvester, dried, and 25 ml Microscint
scintillation fluid added to each well prior to counting on a
TopCount NXT microplate (Packard) scintillation counter. Data are
plotted as cpm incorporated versus protein concentration. Each
construct showed increasing inhibition of proliferation with
increasing protein concentration. FIG. 82 illustrates the induction
of apoptosis in Ramos B cells cultured in the presence of and 2H7
(anti-CD20) and G28-1 (anti-CD37) constructs. Ramos B cells were
incubated with CD20 and/or CD37 targeted constructs (10 mg/ml) in
solution for 20 hours. The cells were then harvested, washed, and
incubated in annexinV and propidium iodide using a staining kit
from Immunotech prior to two color flow cytometry using a
FACsCalibur flow cytometer (Becton-Dickinson). The graph shows the
percentage of annexin V positive cells identified by their staining
in the right quadrants of the dot plots. The results of this
experiment indicate that the both G28-1 constructs were more
efficient than the 2H7 construct and that the G28-1 VL11S scFv
(SSS) H WCH2 WCH3 construct was more efficient than the G28-1 VL11S
scFv (SSC) H WCH2 WCH3 construct. However, the amount of apoptosis
of Ramos cells was greatest when the 2H7 and the G28-1 constructs
were used in combination. FIG. 83 illustrates the killing of Ramos
cells by complement dependent cytotoxicity (CDC) induced by 2H7
(anti-CD20) constructs and G28-1 (anti-CD37) constructs with hinge
region mutations. 2H7 scFv (CSS-S) H WCH2 WCH3 (anti-CD20), G28-1
scFv (SSS) H G, G28-1 (SCS)H (anti-CD37-scFv), G28-1 (CSS)H
(anti-CD37-scFv), or G28-1 (SSC) H (anti-CD37-scFv) were incubated
at 10 mg/ml with 10.sup.4 Ramos Target Cells and a 1:10 dilution of
rabbit complement (PelFreez) in a volume of 150 ml for 90 minutes.
Aliquots were stained with trypan blue (Invitrogen), and counted
using a hemacytometer to determine the percentage of the cell
population killed during treatment. Negative controls with cells
and only one reagent were also included. Both G28-1 (SSS)
(anti-CD37 scFv) and G28-1 (SSC) (anti-CD37 scFv) rapidly killed
Ramos cells in the presence of rabbit complement in this
experiment. The activity of G28-1 (SSC) (anti-CD37 scFv) was higher
than that of G28-1 (SSS) (anti-CD37 scFv), and was nearly as potent
in this assay as the CD20-directed 2H7 scFv (CSS-S)H WCH2 WCH3 scFv
molecule. FIG. 84 illustrates the induction of ADCC of Ramos cells
incubated with G28-1 (anti-CD37) scFvs. G28-1 (anti-CD37)
constructs at 10 mg/ml were incubated in flat-bottom 96 well plates
with 10.sup.4 51Cr-labeled Ramos cells and resting human PBMCs at
different effector:target ratios ranging from 0 to 100. All
incubations were performed in triplicate at each effector:target
ratio. Natural killing was measured at each effector:target ratio
by omission of the constructs. Spontaneous release was measured
without addition of PBMC or fusion protein, and maximal release was
measured by the addition of detergent (1% NP-40) to the appropriate
wells. Reactions were incubated for 6 hours, and 100 ml culture
supernatant harvested to a Lumaplate (Packard Instruments) and
allowed to dry overnight prior to counting cpm released on a
Packard Top Count NXT Microplate Scintillation Counter. Results
from these experiments indicated that the G28-1 (anti-CD37)
constructs bind to target cells, that they induce apoptosis in the
B cell lines, and that they mediate effector functions including
CDC and ADCC.
[0862] Additional non-limiting representative constructs or
sequences within, or useful within, the present inventions are as
follows:
TABLE-US-00055 HuIgG1 wild type hinge, CH2, CH3 (nucleotide
sequence) (SEQ ID NO: 1)
tctgatcaggagcccaaatcttgtgacaaaactcacacatgcccaccgtgcccagcacctgaactcctgggggg-
accgtcagtcttcctctt
ccccccaaaacccaaggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagcc-
acgaagaccctgagg
tcaagttcaactggtacgtggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaac-
agcacgtaccgtgtg
gtcagcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagc-
cctcccagcccccatc
gagaaaacaatctccaaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatga-
gctgaccaagaacc
aggtcagcctgacctgcctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcag-
ccggagaacaactac
aagaccacgcctcccgtgctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcag-
gtggcagcaggggaa
cgtcttctcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgg-
gtaaatgatctaga HuIgG1 wild type hinge, CH2, CH3 (amino acid
sequence) (SEQ ID NO: 2)
SDQEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPE
VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL
PAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPE
NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Llama
IgG1 hinge, CH2, CH3 (nucleotide sequence) (SEQ ID NO: 3)
tgatcaagaaccacatggaggatgcacgtgcccncagtgcccncaatgcccngcnccngaactnccaggaggcc-
cttctgtctttgtcttc
cccccgaaacccaaggacgtcctctccatttttggaggccgagtcacgtgcgttgtagtggacgtcggaaagaa-
agaccccgaggtcaatt
tcaactggtatattgatggcgttgaggtgcgaacggccaatacgaagccaaaagaggaacagttcaacagcacg-
taccgcgtggtcagcg
tcctgcccatccagcaccaggactggctgacggggaaggaattcaagtgcaaggtcaacaacaaagctctcccg-
gcccccatcgagagg
accatctccaaggccaaagggcagacccgggagccgcaggtgtacaccctggccccacaccgggaagaactggc-
caaggacaccgtg
agcgtaacatgcctggtcaaaggcttctacccagctgacatcaacgttgagtggcagaggaacggtcagccgga-
gtcagagggcacctac
gccaacacgccgccacagctggacaacgacgggacctacttcctctacagcaagctctcggtgggaaagaacac-
gtggcagcggggag
aaaccttaacctgtgtggtgatgcatgaggccctgcacaaccactacacccagaaatccatcacccagtcttcg-
ggtaaatagtaatctaga Llama IgG1 hinge, CH2, CH3 (in FIG. 23 as Llama
IgG1) (amino acid sequence) (SEQ ID NO: 4)
EPHGGCTCPQCPAPELPGGPSVFVFPPKPKDVLSISGRPEVTCVVVDVGKEDPEVNFNW
YIDGVEVRTANTKPKEEQFNSTYRVVSVLPIQHQDWLTGKEFKCKVNNKALPAPIERTIS
KAKGQTREPQVYTLAPHREELAKDTVSVTCLVKGFYPADINVEWQRNGQPESEGTYAN
TPPQLDNDGTYFLYSRLSVGKNTWQRGETLTGVVMHEALHNHYTQKSITQSSGK Llama IgG2
(nucleotide sequence) (SEQ ID NO: 5)
tgatcaagaacccaagacaccaaaaccacaaccacaaccacaaccacaacccaatcctacaacagaatccaagt-
gtcccaaatgtccagc
ccctgagctcctgggagggccctcagtcttcatcttccccccgaaacccaaggacgtcctctccatttctggga-
ggcccgaggtcacgtgc
gttgtggtagacgtgggccaggaagaccccgaggtcagtttcaactggtacattgatggcgctgaggtgcgaac-
ggccaacacgaggcc
aaaagaggaacagttcaacagcacgtaccgcgtggtcagcgtcctgcccatccagcaccaggactggctgacgg-
ggaaggaattcaagt
gcaaggtcaacaacaaagctctcccggcccccatcgagaagaccatctccaaggccaaagggcagacccgggag-
ccgcaggtgtaca
ccctggccccacaccgggaagagctggccaaggacaccgtgagcgtaacatgcctggtcaaaggcttctaccca-
cctgatatcaacgttg
agtggcagaggaatgggcagccggagtcagagggcacytacgccaccacgccaccccagctggacaacgacggg-
acctacttcctcta
cagcaagctctcggtgggaaagaacacgtggcagcagggagaaaccttcacctgtgtggtgatgcacgaggccc-
tgcacaaccactaca cccagaaatccatcacccagtcttcgggtaaatagtaatctaga Llama
IgG2 (amino acid sequence) (SEQ ID NO: 6)
DQEPKTPKPQPQPQPQPNPTTESKCPKCPAPELLGGPSVFIFPPKPKDVLSISGRPEVTCVV
VDVGQEDPEVSFNWYIDGAEVRTANTRPKEEQFNSTYRVVSVLPIQHQDWLTGKEFKC
KVNNKALPAPIEKTISKAKGQTREPQVYTLAPHREELAKDTVSVTCLVKGFYPPDINVE
WQRNGQPESEGTYATTPPQLDNDGTYFLYSKLSVGKNTWQQGETFTCVVMHEALHNH
YTQKSITQSSGK Llama IgG3 Fc (nucleotide sequence)_(SEQ ID NO: 7)
tgatcaagcgcaccacagcgaagaccccagctccaagtgtcccaaatgcccaggccctgaactccttggagggc-
ccacggtcttcatcttc
cccccgaaagccaaggacgtcctctccatcacccgaaaacctgaggtcacgtgcttgtggtggacgtgggtaaa-
gaagaccctgagatcg
agttcaagctggtccgtggatgacacagaggtacacacggctgagacaaagccaaaggaggaacagttcaacag-
cacgtaccgcgtggt
cagcgtcctgcccatccagcaccaggactggctgacggggaaggaattcaagtgcaaggtcaacaacaaagctc-
tcccagcccccatcg
agaggaccatctccaaggccaaagggcagacccgggagccgcaggtgtacaccctggccccacaccgggaagag-
ctggccaaggac
accgtgagcgtaacctgcctggtcaaaggcttcttcccagctgacatcaacgttgagtggcagaggaatgggca-
gccggagtcagagggc
acctacgccaacacgccgccacagctggacaacgacgggacctacttcctctacagcaaactctccgtgggaaa-
gaacacgtggcagca
gggagaagtcttcacctgtgtggtgatgcacgaggctctacacaatcactccacccagaaatccatcacccagt-
cttcgggtaaatagtaatc tagagggccc Llama IgG3 Fc (amino acid sequence)
(SEQ ID NO: 8)
DQAHHSEDPSSKCPKCPGPELLGGPTVFIFPPKAKDVLSITRKPEVTCLWWTWVKKTLR
SSSSWSVDDTEVHTAETKPKEEQFNSTYRVVSVLPIQHQDWLTGKEFKCKVNNKALPAP
IERTISKAKGQTREPQVYTLAPHREELAKDTVSVTCLVKGFFPADINVEWQRNGQPESEG
TYANTPPQLDNDGTYFLYSKLSVGKNTWQQGEVFTCVVMHEALHNHSTQKSITQSSGK HuIgG1
wild type hinge (nucleotide sequence) (SEQ ID NO: 9)
gatcaggagcccaaatcttgtgacaaaactcacacatgcccaccgtgcccagca HuIgG1 wild
type hinge (amino acid sequence) (SEQ ID NO: 10) DQEPKSCDKTHTCPPCPA
HuIgG1 H2, wild type hinge with leu at second position (nucleotide
sequence) (SEQ ID NO: 11)
gatctggagcccaaatcttgtgacaaaactcacacatgcccaccgtgcccagca HuIgG1 H2,
wild type hinge with leu at second position (amino acid sequence)
(SEQ ID NO: 12) DLEPKSCDKTHTCPPCPA NTHuIgG1 wild type CH2
(nucleotide sequence) (SEQ ID NO: 13)
cctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggac-
ccctgaggtcacatgcgt
ggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatg-
ccaagacaaagccgc
gggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggc-
aaggagtacaagtgc
aaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaa HuIgG1
wild type CH2(amino acid sequence) (SEQ ID NO: 14)
PELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK HuIgG1 wild type
CH3 (nucleotide sequence) (SEQ ID NO: 15)
gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggaggagatgaccaagaaccaggtcagcct-
gacctgcctggtca
aaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacg-
cctcccgtgctgga
ctccgacggctccttcttcctctatagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttct-
catgctccgtgatgcatg
aggctctgcacaaccactacacgcagaagagcctctccctgtccccgggtaaatga HuIgG1
wild type CH3 (amino acid sequence) (SEQ ID NO: 16)
GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD
SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK HuIgG1 mutated
hinge (C-C-C.fwdarw.S-S-S) (nucleotide sequence) (SEQ ID NO: 17)
gatcaggagcccaaatcttctgacaaaactcacacatccccaccgtccccagca HuIgG1
mutated hinge (C-C-C.fwdarw.S-S-S) (amino acid sequence) (SEQ ID
NO: 18) DQEPKSSDKTHTSPPSPA HIgG1MTH WTCH2CH3 (mutant hinge with
wild type CH2 and CH3 (reads from the hinge + Ig tail) (nucleotide
sequence) (SEQ ID NO: 19)
tgatcaccccaaatcttctgacaaaactcacacatctccaccgtcctcagcacctgaactcctgggtggaccgt-
cagtcttcctcttcccccca
aaacccaaggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaaga-
ccctgaggtcaagttc
aactggtacgtggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgta-
ccgtgtggtcagcg
tcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctccca-
gcccccatcgagaaaa
caatctccaaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgacc-
aagaaccaggtcag
cctgacctgcctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggaga-
acaactacaagacca
cgcctcccgtgctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcag-
caggggaacgtcttctc
atgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgat-
aatctaga Mutant hinge, but wild type CH2 and CH3 (amino acid
sequence) (SEQ ID NO: 20)
DHPKSSDKTHTSPPSSAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF
NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPI
EKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY
KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 2H7 scFv
llama IgG1 (nucleotide sequence) (SEQ ID NO: 21)
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagctggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaagaaccacatggaggat
gcacgtgcccncagtgcccncaatgcccngcnccngaactnccaggaggcccttctgtctttgtcttccccccg-
aaacccaaggacgtcc
tctccatttttggaggccgagtcacgtgcgttgtagtggacgtcggaaagaaagaccccgaggtcaatttcaac-
tggtatattgatggcgttga
ggtgcgaacggccaatacgaagccaaaagaggaacagttcaacagcacgtaccgcgtggtcagcgtcctgccca-
tccagcaccaggac
tggctgacggggaaggaattcaagtgcaaggtcaacaacaaagctctcccggcccccatcgagaggaccatctc-
caaggccaaagggc
agacccgggagccgcaggtgtacaccctggccccacaccgggaagaactggccaaggacaccgtgagcgtaaca-
tgcctggtcaaag
gcttctacccagctgacatcaacgttgagtggcagaggaacggtcagccggagtcagagggcacctacgccaac-
acgccgccacagctg
gacaacgacgggacctacttcctctacagcaagctctcggtgggaaagaacacgtggcagcggggagaaacctt-
aacctgtgtggtgatg
catgaggccctgcacaaccactacacccagaaatccatcacccagtcttcgggtaaatagtaatctaga
2H7 scFv llama IgG1 (amino acid sequence) (SEQ ID NO: 22)
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAELVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQEPHGGCTCPQCPAPELPGGPSVFVFP
PKPKDVLSIFGGRVTCVVVDVGKKDPEVNFNWYIDGVEVRTANTKPKEEQFNSTYRVV
SVLPIQHQDWLTGKEFKCKVNNKALPAPIERTISKAKGQTREPQVYTLAPHREELAKDT
VSVTCLVKGFYPADINVEWQRNGQPESEGTYANTPPQLDNDGTYFLYSKLSVGKNTWQ
RGETLTCVVMHEALHNHYTQKSITQSSGK 2H7 scFv llama IgG2 (nucleotide
sequence) (SEQ ID NO: 23)
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagctggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaagaacccaagacacca
aaaccacaaccacaaccacaaccacaacccaatcctacaacagaatccaagtgtcccaaatgtccagcccctga-
gctcctgggagggcc
ctcagtcttcatcttccccccgaaacccaaggacgtcctctccatttctgggaggcccgaggtcacgtgcgttg-
tggtagacgtgggccagg
aagaccccgaggtcagtttcaactggtacattgatggcgctgaggtgcgaacggccaacacgaggccaaaagag-
gaacagttcaacagc
acgtaccgcgtggtcagcgtcctgcccatccagcaccaggactggctgacggggaaggaattcaagtgcaaggt-
caacaacaaagctct
cccggcccccatcgagaagaccatctccaaggccaaagggcagacccgggagccgcaggtgtacaccctggccc-
cacaccgggaag
agctggccaaggacaccgtgagcgtaacatgcctggtcaaaggcttctacccacctgatatcaacgttgagtgg-
cagaggaatgggcagc
cggagtcagagggcacytacgccaccacgccaccccagctggacaacgacgggacctacttcctctacagcaag-
ctctcggtgggaaa
gaacacgtggcagcagggagaaaccttcacctgtgtggtgatgcacgaggccctgcacaaccactacacccaga-
aatccatcacccagtc ttcgggtaaatagtaatctaga AA2H7 scFv llama IgG2
(amino acid sequence) (SEQ ID NO: 24)
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAELVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQEPKTPKPQPQPQPQPNPTTESKCPKC
PAPELLGGPSVFIFPPKPKDVLSISGRPEVTCVVVDVGQEDPEVSFNWYIDGAEVRTANT
RPKEEQFNSTYRVVSVLPIQHQDWLTGKEFKCKVNNKALPAPIEKTISKAKGQTREPQV
YTLAPHREELAKDTVSVTCLVKGFYPPDINVEWQRNGQPESEGTYATTPPQLDNDGTYF
LYSKLSVGKNTWQQGETFTCVVMHEALHNHYTQKSITQSSGK NT2H7 scFv llama IgG3
(nucleotide sequence) (SEQ ID NO: 25)
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagctggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaagcgaaccacagcgaa
gaccccagctccaagtgtcccaaatgcccaggccctgaactccttggagggcccacggtcttcatcttcccccc-
gaaagccaaggacgtc
ctctccatcacccgaaaacctgaggtcacgtgcttgtggtggacgtgggtaaagaagaccctgagatcgagttc-
aagctggtccgtggatg
acacagaggtacacacggctgagacaaagccaaaggaggaacagttcaacagcacgtaccgcgtggtcagcgtc-
ctgcccatccagca
ccaggactggctgacggggaaggaattcaagtgcaaggtcaacaacaaagctctcccagcccccatcgagagga-
ccatctccaaggcca
aagggcagacccgggagccgcaggtgtacaccctggccccacaccgggaagagctggccaaggacaccgtgagc-
gtaacctgcctgg
tcaaaggcttcttcccagctgacatcaacgttgagtggcagaggaatgggcagccggagtcagagggcacctac-
gccaacacgccgcca
cagctggacaacgacgggacctacttcctctacagcaaactctccgtgggaaagaacacgtggcagcagggaga-
agtcttcacctgtgtg
gtgatgcacgaggctctacacaatcactccacccagaaatccatcacccagtcttcgggtaaatagtaatctag-
agggccc 2H7 scFv llama IgG3 (amino acid sequence) (SEQ ID NO: 26)
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAELVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQAHSHSEDPSSKCPKCPGPELLGGPTV
FIFPPKAKDVLSITRKPEVTCLWWTWVKKTLRSSSSWSVDDTEVHTAETKPKEEQFNST
YRVVSVLPIQHQDWLTGKEFKCKVNNKALPAPIERTISKAKGQTREPQVYTLAPHREEL
AKDTVSVTCLVKGFFPADINVEWQRNGQPESEGTYANTPPQLDNDGTYFLYSKLSVGK
NTWQQGEVFTCVVMHEALHNHSTQKSITQSSGK 2H7 scFv WTH WTCH2CH3 (nucleotide
sequence) (SEQ ID NO: 27)
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagctggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaggagcccaaatcttgtg
acaaaactcacacatgcccaccgtgcccagcacctgaactcctggggggaccgtcagtcttcctcttcccccca-
aaacccaaggacaccct
catgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttca-
actggtacgtggacgg
cgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcc-
tcaccgtcctgcacc
aggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaca-
atctccaaagccaaa
gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcct-
gacctgcctggtca
aaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacg-
cctcccgtgctgga
ctccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttct-
catgctccgtgatgcatg
aggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga 2H7
scFv WTH WTCH2CH3 (amino acid sequence) (SEQ ID NO: 28)
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAELVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQEPKSCDKTHTCPPCPAPELLGGPSVF
LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST
YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL
TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW
QQGNVFSCSVMHEALHNHYTQKSLSLSPGK NTCD80 transmembrane domain and
cytoplasmic tail (+restriction sites) (nucleotide sequence) (SEQ ID
NO: 29)
gcggatccttcgaacctgctcccatcctgggccattaccttaatctcagtaaatggaatttttgtgatatgctg-
cctgacctactgctttgcccca
agatgcagagagagaaggaggaatgagagattgagaagggaaagtgtacgccctgtataaatcgat
CD80 transmembrane domain and cytoplasmic tail (amino acid
sequence) (SEQ ID NO: 30)
ADPSNLLPSWAITLISVNGIFVICCLTYCFAPRCRERRRNERLRRESVRPV 40.2.220 VL
(anti-human CD40 scFv #1--VL) (nucleotide sequence) (SEQ ID NO: 31)
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgttctgactcagtctc
cagccaccctgtctgtgactccaggagatagagtctctctttcctgcagggccagccagagtattagcgactac-
ttacactggtatcaacaaa
aatcacatgagtctccaaggcttctcatcaaatatgcttcccattccatctctgggatcccctccaggttcagt-
ggcagtggatcagggtcagat
ttcactctcagtatcaacagtgtggaacctgaagatgttggaatttattactgtcaacatggtcacagattccg-
tggacgttcggtggaggcac caagctggaaatcaaacgg 40.2.220 VL (anti-human
CD40 scFv #1--VL) (amino acid sequence) (SEQ ID NO: 32)
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPATLSVTPGDRVSLSCRASQSISDYLHWYQQ
KSHESPRLLIKYASHSISGIPSRFSGSGSGSDFTLSINSVEPEDVGIYYCQHGHSFPWTFGG
GTKLEIKR 40.2.220 VH (for anti-human CD40 scFv #1--VH) (nucleotide
sequence) (SEQ ID NO: 33)
cagatccagttggtgcaatctggacctgagctgaagaagcctggagagacagtcaggatctcctgcaaggcttc-
tgggtatgccttcacaac
tactggaatgcagtgggtgcaagagatgccaggaaagggtttgaagtggattggctggataaacaccccactct-
ggagtgccaaaatatgt
agaagacttcaaggacggtttgccttctctttggaaacctctgccaacactgcatatttacagataagcaacct-
caaagatgaggacacggct
acgtatttctgtgtgagatccgggaatggtaactatgacctggcctactttgcttactggggccaagggacact-
ggtcactgtctctgatca 40.2.220 VH (for anti-human CD40 scFv #1--VH)
(amino acid sequence) (SEQ ID NO: 34)
QIQLVQSGPELKKPGETVRISCKASGYAFTTTGMQWVQEMPGKGLKWIGWINTPLWSA
KICRRLQGRFAFSLETSANTAYLQISNLKDEDTATYFCVRSGNGNYDLAYFAYWGQGTL VTVS
40.2.220 scFv (anti-human CD40 scFv #1) (nucleotide sequence) (SEQ
ID NO: 35)
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgttctgactcagtctc
cagccaccctgtctgtgactccaggagatagagtctctctttcctgcagggccagccagagtattagcgactac-
ttacactggtatcaacaaa
aatcacatgagtctccaaggcttctcatcaaatatgcttcccattccatctctgggatcccctccaggttcagt-
ggcagtggatcagggtcagat
ttcactctcagtatcaacagtgtggaacctgaagatgttggaatttattactgtcaacatggtcacagctttcc-
gtggacgttcggtggaggcac
caagctggaaatcaaacggggtggcggtggctcgggcggaggtgggtcgggtggcggcggatctcagatccagt-
tggtgcaatctgga
cctgagctgaagaagcctggagagacagtcaggatctcctgcaaggcttctgggtatgccttcacaactactgg-
aatgcagtgggtgcaag
agatgccaggaaagggtttgaagtggattggctggataaacaccccactctggagtgccaaaatatgtagaaga-
cttcaaggacggtttgc
cttctctttggaaacctctgccaacactgcatatttacagataagcaacctcaaagatgaggacacggctacgt-
atttctgtgtgagatccggg
aatggtaactatgacctggcctactttgcttactggggccaagggacactggtcactgtctctgatca
40.2.220 scFv (anti-human CD40 scFv #1) (amino acid sequence) (SEQ
ID NO: 36)
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPATLSVTPGDRVSLSCRASQSISDYLHWYQQ
KSHESPRLLIKYASHSISGIPSRFSGSGSGSDFTLSINSVEPEDVGIYYCQHGHSFPWTFGG
GTKLEIKRGGGGSGGGGSGGGGSQIQLVQSGPELKKPGETVRISCKASGYAFTTTGMQW
VQEMPGKGLKWIGWINTPLWSAKICRRLQGRFAFSLETSANTAYLQISNLKDEDTATYF
CVRSGNGNYDLAYFAYWGQGTLVTVS 2e12 VL (with L6 VK leader peptide)
(nucleotide sequence) (SEQ ID NO: 37)
atggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagtcgacat-
tgtgctcacccaatctccagctt
ctttggctgtgtctctaggtcagagagccaccatctcctgcagagccagtgaaagtgttgaatattatgtcaca-
agtttaatgcagtggtaccaa
cagaaaccaggacagccacccaaactcctcatctctgctgcatccaacgtagaatctggggtccctgccaggtt-
tagtggcagtgggtctg
ggacagacttcagcctcaacatccatcctgtggaggaggatgatattgcaatgtatttctgtcagcaaagtagg-
aaggttccttggacgttcg gtggaggcaccaagctggaaatcaaacgg 2e12 VL (with L6
VK leader peptide) (amino acid sequence) (SEQ ID NO: 38)
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPASLAVSLGQRATISCRASESVEYYVTSLMQ
WYQQKPGQPPKLLISAASNVESGVPARFSGSGSGTDFSLNIHPVEEDDIAMYFCQQSRKV
PWTFGGGTKLEIKR 2e12 VH (no leader peptide) (nucleotide sequence)
(SEQ ID NO: 39)
caggtgcagctgaaggagtcaggacctggcctggtggcgccctcacagagcctgtccatcacatgcaccgtctc-
agggttctcattaaccg
gctatggtgtaaactgggttcgccagcctccaggaaagggtctggagtggctgggaatgatatggggtgatgga-
agcacagactataattc
agctctcaaatccagactgagcatcaccaaggacaactccaagagccaagttttcttaaaaatgaacagtctgc-
aaactgatgacacagcca
gatactactgtgccagagatggttatagtaactttcattactatgttatggactactggggtcaaggaacctca-
gtcaccgtctcctca(gatctg) 2e12 VH (amino acid sequence) (SEQ ID NO:
40) QVQLKESGPGLVAPSQSLSITCTVSGFSLTGYGVNWVRQPPGKGLEWLGMIWGDGSTD
YNSALKSRLSITKDNSKSQVFLKMNSLQTDDTARYYCARDGYSNFHYYVMDYWGQGT SVTVSS
2e12scFv(+Restriction sites) (nucleotide sequence) (SEQ ID NO: 41)
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcacccaatctc
cagcttctttggctgtgtctctaggtcagagagccaccatctcctgcagagccagtgaaagtgttgaatattat-
gtcacaagtttaatgcagtgg
taccaacagaaaccaggacagccacccaaactcctcatctctgctgcatccaacgtagaatctggggtccctgc-
caggtttagtggcagtg
ggtctgggacagacttcagcctcaacatccatcctgtggaggaggatgatattgcaatgtatttctgtcagcaa-
agtaggaaggttccttgga
cgttcggtggaggcaccaagctggaaatcaaacggggtggcggtggctcgggcggaggtgggtcgggtggcggc-
ggatctcaggtgc
agctgaaggagtcaggacctggcctggtggcgccctcacagagcctgtccatcacatgcaccgtctcagggttc-
tcattaaccggctatggt
gtaaactgggttcgccagcctccaggaaagggtctggagtggctgggaatgatatggggtgatggaagcacaga-
ctataattcagctctca
aatccagactgagcatcaccaaggacaactccaagagccaagttttcttaaaaatgaacagtctgcaaactgat-
gacacagccagatactac
tgtgccagagatggttatagtaactttcattactatgttatggactactggggtcaaggaacctcagtcaccgt-
ctcctct(gatcag) 2e12scFv (amino acid sequence) (SEQ ID NO: 42)
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPASLAVSLGQRATISCRASESVEYYVTSLMQ
WYQQKPGQPPKLLISAASNVESGVPARFSGSGSGTDFSLNIHPVEEDDIAMYFCQQSRKV
PWTFGGGTKLEIKRGGGGSGGGGSGGGGSQVQLKESGPGLVAPSQSLSITCTVSGFSLT
GYGVNWVRQPPGKGLEWLGMIWGDGSTDYNSALKSRLSITKDNSKSQVFLKMNSLQT
DDTARYYCARDGYSNFHYYVMDYWGQGTSVTVSS 10A8 is anti-CD152 (CTLA-4) 10A8
VL (with L6 VK leader peptide) (nucleotide sequence) (SEQ ID NO:
43)
atggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagtcgacat-
ccagatgacacagtctccatc
ctcactgtctgcatctctgggaggcaaagtcaccatcacttgcaaggcaagccaagacattaagaagtatatag-
gttggtaccaacacaagc
ctggaaaaggtcccaggctgctcatatattacacatctacattacagccaggcatcccatcaaggttcagtgga-
agtgggtctgggagagatt
attccctcagcatcagaaacctggagcctgaagatattgcaacttattattgtcaacagtatgataatcttcca-
ttgacgttcggctcggggaca aagttggaaataaaacgg 10A8 VL (amino acid
sequence) (SEQ ID NO: 44)
MDFQVQIFSFLLISASVIMSRGVDIQMTQSPSSLSASLGGKVTITCKASQDIKKYIGWYQH
KPGKGPRLLIYYTSTLQPGIPSRFSGSGSGRDYSLSIRNLEPEDIATYYCQQYDNLPLTFGS
GTKLEIKR 10A8 VH (no leader peptide) (nucleotide sequence) (SEQ ID
NO: 45)
gatgtacagcttcaggagtcaggacctggcctcgtgaaaccttctcagtctctgtctctcacctgctctgtcac-
tggctactccatcaccagtg
gtttctactggaactggatccgacagtttccgggaaacaaactggaatggatgggccacataagccacgacggt-
aggaataactacaaccc
atctctcataaatcgaatctccatcactcgtgacacatctaagaaccagtttttcctgaagttgagttctgtga-
ctactgaggacacagctacata
tttctgtgcaagacactacggtagtagcggagctatggactactggggtcaaggaacctcagtcaccgtctcct-
ctgatca 10A8 VH (amino acid sequence) (SEQ ID NO: 46)
DVQLQESGPGLVKPSQSLSLTCSVTGYSITSGFYWNWIRQFPGNKLEWMGHISHDGRNN
YNPSLINRISITRDTSKNQFFLKLSSVTTEDTATYFCARHYGSSGAMDYWGQGTSVTVSS 10A8
SCFV (nucleotide sequence) (SEQ ID NO: 47)
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacatccagatgacacagtct
ccatcctcactgtctgcatctctgggaggcaaagtcaccatcacttgcaaggcaagccaagacattaagaagta-
tataggttggtaccaaca
caagcctggaaaaggtcccaggctgctcatatattacacatctacattacagccaggcatcccatcaaggttca-
gtggaagtgggtctggga
gagattattccctcagcatcagaaacctggagcctgaagatattgcaacttattattgtcaacagtatgataat-
cttccattgacgttcggctcgg
ggacaaagttggaaataaaacggggtggcggtggctcgggcggtggtgggtcgggtggcggcggatctgatgta-
cagcttcaggagtca
ggacctggcctcgtgaaaccttctcagtctctgtctctcacctgctctgtcactggctactccatcaccagtgg-
tttctactggaactggatccg
acagtttccgggaaacaaactggaatggatgggccacataagccacgacggtaggaataactacaacccatctc-
tcataaatcgaatctcc
atcactcgtgacacatctaagaaccagtttttcctgaagttgagttctgtgactactgaggacacagctacata-
tttctgtgcaagacactacgg
tagtagcggagctatggactactggggtcaaggaacctcagtcaccgtctcctctgatca 10A8
SCFV (amino acid sequence) (SEQ ID NO: 48)
MDFQVQIFSFLLISASVIMSRGVDIQMTQSPSSLSASLGGKVTITCKASQDIKKYIGWYQH
KPGKGPRLLIYYTSTLQPGIPSRFSGSGSGRDYSLSIRNLEPEDIATYYCQQYDNLPLTFGS
GTKLEIKRGGGGSGGGGSGGGGSDVQLQESGPGLVKPSQSLSLTCSVTGYSITSGFYWN
WIRQFPGNKLEWMGHISHDGRNNYNPSLINRISITRDTSKNQFFLKLSSVTTEDTATYFC
ARHYGSSGAMDYWGQGTSVTVSSD 40.2.220-hmtIgG1-hCD80 (nucleotide
sequence) (SEQ ID NO: 49)
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgttctgactcagtctc
cagccaccctgtctgtgactccaggagatagagtctctctttcctgcagggccagccagagtattagcgactac-
ttacactggtatcaacaaa
aatcacatgagtctccaaggcttctcatcaaatatgcttcccattccatctctgggatcccctccaggttcagt-
ggcagtggatcagggtcagat
ttcactctcagtatcaacagtgtggaacctgaagatgttggaatttattactgtcaacatggtcacagctttcc-
gtggacgttcggtggaggcac
caagctggaaatcaaacggggtggcggtggctcgggcggaggtgggtcgggtggcggcggatctcagatccagt-
tggtgcaatctgga
cctgagctgaagaagcctggagagacagtcaggatctcctgcaaggcttctgggtatgccttcacaactactgg-
aatgcagtgggtgcaag
agatgccaggaaagggtttgaagtggattggctggataaacaccccactctggagtgccaaaatatgtagaaga-
cttcaaggacggtttgc
cttctctttggaaacctctgccaacactgcatatttacagataagcaacctcaaagatgaggacacggctacgt-
atttctgtgtgagatccggg
aatggtaactatgacctggcctactttgcttactggggccaagggacactggtcactgtctctgatctggagcc-
caaatcttctgacaaaactc
acacatccccaccgtccccagcacctgaactcctggggggatcgtcagtcttcctcttccccccaaaacccaag-
gacaccctcatgatctcc
cggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgt-
ggacggcgtggaggt
gcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcc-
tgcaccaggactggc
tgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaa-
gccaaagggcagccc
cgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcct-
ggtcaaaggcttctat
cccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgct-
ggactccgacggct
ccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtg-
atgcatgaggctctgcac
aaccactacacgcagaagagcctctccctgtctccgggtaaagcggatccttcgaacctgctcccatcctgggc-
cattaccttaatctcagta
aatggaatttttgtgatatgctgcctgacctactgctttgccccaagatgcagagagagaaggaggaatgagag-
attgagaagggaaagtgt acgccctgtataaatcgat 40.2.220-hmtIgG1-hCD80
(amino acid sequence) (SEQ ID NO: 50)
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPATLSVTPGDRVSLSCRASQSISDYLHWYQQ
KSHESPRLLIKYASHSISGIPSRFSGSGSGSDFTLSINSVEPEDVGIYYCQHGHSFPWTFGG
GTKLEIKRGGGGSGGGGSGGGGSQIQLVQSGPELKKPGETVRISCKASGYAFTTTGMQW
VQEMPGKGLKWIGWINTPLWSAKICRRLQGRFAFSLETSANTAYLQISNLKDEDTATYF
CVRSGNGNYDLAYFAYWGQGTLVTVSDLEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKP
KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVS
VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQV
SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV
FSCSVMHEALHNHYTQKSLSLSPGKADPSNLLPSWAITLISVNGIFVICCLTYCFAPRCRE
RRRNERLRRESVRPV 2e12scFv-hmtIgG1-CD80 fusion protein (nucleotide
sequence) (SEQ ID NO: 51)
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcacccaatctc
cagcttctttggctgtgtctctaggtcagagagccaccatctcctgcagagccagtgaaagtgttgaatattat-
gtcacaagtttaatgcagtgg
taccaacagaaaccaggacagccacccaaactcctcatctctgctgcatccaacgtagaatctggggtccctgc-
caggtttagtggcagtg
ggtctgggacagacttcagcctcaacatccatcctgtggaggaggatgatattgcaatgtatttctgtcagcaa-
agtaggaaggttccttgga
cgttcggtggaggcaccaagctggaaatcaaacggggtggcggtggctcgggcggaggtgggtcgggtggcggc-
ggatctcaggtgc
agctgaaggagtcaggacctggcctggtggcgccctcacagagcctgtccatcacatgcaccgtctcagggttc-
tcattaaccggctatggt
gtaaactgggttcgccagcctccaggaaagggtctggagtggctgggaatgatatggggtgatggaagcacaga-
ctataattcagctctca
aatccagactgagcatcaccaaggacaactccaagagccaagttttcttaaaaatgaacagtctgcaaactgat-
gacacagccagatactac
tgtgccagagatggttatagtaactttcattactatgttatggactactggggtcaaggaacctcagtcaccgt-
ctcctcagatctggagcccaa
atcttctgacaaaactcacacatccccaccgtccccagcacctgaactcctggggggatcgtcagtcttcctct-
tccccccaaaacccaagg
acaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtc-
aagttcaactggtacgt
ggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtca-
gcgtcctcaccgtc
ctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcga-
gaaaaccatctccaa
agccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccagg-
tcagcctgacctgc
ctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaa-
gaccacgcctcccgt
gctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacg-
tcttctcatgctccgtg
atgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaagcggatccttcgaa-
cctgctcccatcctggg
ccattaccttaatctcagtaaatggaatttttgtgatatgctgcctgacctactgattgccccaagatgcagag-
agagaaggaggaatgagag attgagaagggaaagtgtacgccctgtataaatcgat
2e12scFv-hmtIgG1-CD80 fusion protein (amino acid sequence) (SEQ ID
NO: 52)
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPASLAVSLGQRATISCRASESVEYYVTSLMQ
WYQQKPGQPPKLLISAASNVESGVPARFSGSGSGTDFSLNIHPVEEDDIAMYFCQQSRKV
PWTFGGGTKLEIKRGGGGSGGGGSGGGGSQVQLKESGPGLVAPSQSLSITCTVSGFSLT
GYGVNWVRQPPGKGLEWLGMIWGDGSTDYNSALKSRLSITKDNSKSQVFLKMNSLQT
DDTARYYCARDGYSNFHYYVMDYWGQGTSVTVSSDLEPKSSDKTHTSPPSPAPELLGG
SSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKADPSNLLPSWAITLISVNGIFVICCLT
YCFAPRCRERRRNERLRRESVRPV 10A8 scFv-hmtIgG1-CD80 (nucleotide
sequence) (SEQ ID NO: 53)
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacatccagatgacacagtct
ccatcctcactgtctgcatctctgggaggcaaagtcaccatcacttgcaaggcaagccaagacattaagaagta-
tataggttggtaccaaca
caagcctggaaaaggtcccaggctgctcatatattacacatctacattacagccaggcatcccatcaaggttca-
gtggaagtgggtctggga
gagattattccctcagcatcagaaacctggagcctgaagatattgcaacttattattgtcaacagtatgataat-
cttccattgacgttcggctcgg
ggacaaagttggaaataaaacggggtggcggtggctcgggcggtggtgggtcgggtggcggcggatctgatgta-
cagcttcaggagtca
ggacctggcctcgtgaaaccttctcagtctctgtctctcacctgctctgtcactggctactccatcaccagtgg-
tttctactggaactggatccg
acagtttccgggaaacaaactggaatggatgggccacataagccacgacggtaggaataactacaacccatctc-
tcataaatcgaatctcc
atcactcgtgacacatctaagaaccagtttttcctgaagttgagttctgtgactactgaggacacagctacata-
tttctgtgcaagacactacgg
tagtagcggagctatggactactggggtcaaggaacctcagtcaccgtctcctctgatctggagcccaaatctt-
ctgacaaaactcacacatc
cccaccgtccccagcacctgaactcctggggggatcgtcagtcttcctcttccccccaaaacccaaggacaccc-
tcatgatctcccggacc
cctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacgg-
cgtggaggtgcataat
gccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcacca-
ggactggctgaatg
gcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaa-
gggcagccccgaga
accacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtca-
aaggcttctatcccag
cgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggact-
ccgacggctccttct
tcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcat-
gaggctctgcacaacca
ctacacgcagaagagcctctccctgtctccgggtaaagcggatccttcgaacctgctcccatcctgggccatta-
ccttaatctcagtaaatgg
aatttttgtgatatgctgcctgacctactgctttgccccaagatgcagagagagaaggaggaatgagagattga-
gaagggaaagtgtacgcc ctgtataaatcgat 10A8 scFv-hmtIgG1-CD80 (amino
acid sequence) (SEQ ID NO: 54)
MDFQVQIFSFLLISASVIMSRGVDIQMTQSPSSLSASLGGKVTITCKASQDIKKYIGWYQH
KPGKGPRLLIYYTSTLQPGIPSRFSGSGSGRDYSLSIRNLEPEDIATYYCQQYDNLPLTFGS
GTKLEIKRGGGGSGGGGSGGGGSDVQLQESGPGLVKPSQSLSLTCSVTGYSITSGFYWN
WIRQFPGNKLEWMGHISHDGRNNYNPSLINRISITRDTSKNQFFLKLSSVTTEDTATYFC
ARHYGSSGAMDYWGQGTSVTVSSDLEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDT
LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV
LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTC
LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
VMHEALHNHYTQKSLSLSPGKADPSNLLPSWAITLISVNGIFVICCLTYCFAPRCRERRR
NERLRRESVRPV 500A2-hmtIgG1-CD80 (nucleotide sequence) (SEQ ID NO:
55)
atgttgtatacatctcagctccttgggcttttactcttctggatttcagcctccagaagtgacatagtgctgac-
tcagactccagccactctgtctc
taattcctggagaaagagtcacaatgacctgtaagaccagtcagaatattggcacaatcttacactggtatcac-
caaaaaccaaaggaggct
ccaagggctctcatcaagtatgcttcgcagtccattcctgggatcccctccagattcagtggcagtggttcgga-
aacagatttcactctcagca
tcaataacctggagcctgatgatatcggaatttattactgtcaacaaagtagaagctggcctgtcacgttcggt-
cctggcaccaagctggaga
taaaacggggtggcggtggctcgggcggaggtgggtcgggtggcggcggatctcaggtcaagctgcagcagtcc-
ggttctgaactagg
gaaacctggggcctcagtgaaactgtcctgcaagacttcaggctacatattcacagatcactatatttcttggg-
tgaaacagaagcctggaga
aagcctgcagtggataggaaatgtttatggtggaaatggtggtacaagctacaatcaaaaattccagggcaagg-
ccacactgactgtagata
aaatctctagcacagcctacatggaactcagcagcctgacatctgaggattctgccatctattactgtgcaaga-
aggccggtagcgacgggc
catgctatggactactggggtcaggggatccaagttaccgtctcctctgatctggagcccaaatcttctgacaa-
aactcacacatccccaccg
tccccagcacctgaactcctggggggatcgtcagtcttcctcttccccccaaaacccaaggacaccctcatgat-
ctcccggacccctgaggt
cacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggagg-
tgcataatgccaaga
caaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactgg-
ctgaatggcaagga
gtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaagggcagc-
cccgagaaccacag
gtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggctt-
ctatcccagcgacatcg
ccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggc-
tccttcttcctctaca
gcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctg-
cacaaccactacacgc
agaagagcctctccctgtctccgggtaaagcggatccttcgaacctgctcccatcctgggccattaccttaatc-
tcagtaaatggaatttttgtg
atatgctgcctgacctactgctttgccccaagatgcagagagagaaggaggaatgagagattgagaagggaaag-
tgtacgccctgtataaa tcgat 500A2-hmtIgG1-CD80 (amino acid sequence)
(SEQ ID NO: 56)
MLYTSQLLGLLLFWISASRSDIVLTQTPATLSLIPGERVTMTCKTSQNIGTILHWYHQKPK
EAPRALIKYASQSIPGIPSRFSGSGSETDFTLSINNLEPDDIGIYYCQQSRSWPVTFGPGTKL
EIKRGGGGSGGGGSGGGGSQVKLQQSGSELGKPGASVKLSCKTSGYIFTDHYISWVKQK
PGESLQWIGNVYGGNGGTSYNQKFQGKATLTVDKISSTAYMELSSLTSEDSAIYYCARR
PVATGHAMDYWGQGIQVTVSSDLEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDTL
MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL
HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCL
VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV
MHEALHNHYTQKSLSLSPGKADPSNLLPSWAITLISVNGIFVICCLTYCFAPRCRERRRNE
RLRRESVRPV 2H7 scFv MTH(SSS)WTCH2CH3 (nucleotide sequence) (SEQ ID
NO: 57)
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagctggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaggagcccaaatcttctg
acaaaactcacacatccccaccgtccccagcacctgaactcctggggggaccgtcagtcttcctcttcccccca-
aaacccaaggacaccct
catgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttca-
actggtacgtggacgg
cgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcc-
tcaccgtcctgcacc
aggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaca-
atctccaaagccaaa
gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcct-
gacctgcctggtca
aaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacg-
cctcccgtgctgga
ctccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttct-
catgctccgtgatgcatg
aggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga 2H7
scFv MTH(SSS)WTCH2CH3 (amino acid sequence) (SEQ ID NO: 58)
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAELVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQEPKSSDKTHTSPPSPAPELLGGPSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK 2H7 scFv IgAH IGG WT CH2CH3 (2H7 scFv
with IgA hinge and WT CH2 and CH3) (nucleotide sequence) (SEQ ID
NO: 59)
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagctggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctctgatca-
gccagttccctcaactccac
ctaccccatctccctcaactccacctaccccatctccctcatgcgcacctgaactcctggggggaccgtcagtc-
ttcctcttccccccaaaac
ccaaggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccct-
gaggtcaagttcaact
ggtacgtggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgt-
gtggtcagcgtcct
caccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagccc-
ccatcgagaaaacaa
tctccaaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaag-
aaccaggtcagcct
gacctgcctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaaca-
actacaagaccacg
cctcccgtgctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagca-
ggggaacgtcttctcat
gctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatct-
aga 2H7 scFv IgAH IGG WT CH2CH3 (amino acid sequence) (SEQ ID NO:
60) MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAELVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSDQPVPSTPPTPSPSTPPTPSPSCAPELLGGP
SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 2H7 scFv IgAH IgACH2CH3 (2H7 scFv
IgAhinge and IgA CH2 and CH3) (nucleotide sequence) (SEQ ID NO: 61)
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctctccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagctggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcagccagttccctcaactcc
acctaccccatctccctcaactccacctaccccatctccctcatgctgccacccccgactgtcactgcaccgac-
cggccctcgaggacctgc
tcttaggttcagaagcgatcctcacgtgcacactgaccggcctgagagatgcctcaggtgtcaccttcacctgg-
acgccctcaagtgggaa
gagcgctgttcaaggaccacctgaccgtgacctctgtggctgctacagcgtgtccagtgtcctgccgggctgtg-
ccgagccatggaaccat
gggaagaccttcacttgcactgctgcctaccccgagtccaagaccccgctaaccgccaccctctcaaaatccgg-
aaacacattccggccc
gaggtccacctgctgccgccgccgtcggaggagctggccctgaacgagctggtgacgctgacgtgcctggcacg-
tggcttcagccccaa
ggatgtgctggttcgctggctgcaggggtcacaggagctgccccgcgagaagtacctgacttgggcatcccggc-
aggagcccagccag
ggcaccaccaccttcgctgtgaccagcatactgcgcgtggcagccgaggactggaagaagggggacaccttctc-
ctgcatggtgggcca
cgaggccctgccgctggccttcacacagaagaccatcgaccgcttggcgggtaaacccacccatgtcaatgtgt-
ctgttgtcatggcggag gtggacggcacctgctactgataatctaga 2H7 scFv IgAH
IgACH2CH3 (2H7 scFv IgA hinge and IgA CH2 and CH3) (amino acid
sequence) (SEQ ID NO: 62)
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAELVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQPVPSTPPTPSPSTPPTPSPSCCHPRLSL
HRPALEDLLLGSEAILTCTLTGLRDASGVTFTWTPSSGKSAVQGPPDRDLCGCYSVSSVL
PGCAEPWNHGKTFTCTAAYPESKTPLTATLSKSGNTFRPEVHLLPPPSEELALNELVTLT
CLARGFSPKDVLVRWLQGSQELPREKYLTWASRQEPSQGTTTFAVTSILRVAAEDWKK
GDTFSCMVGHEALPLAFTQKTIDRLAGKPTHVNVSVVMAEVDGTCY IgA hinge-CH2--CH3
(Human IgA tail, full length) (nucleotide sequence) (SEQ ID NO: 63)
tgatcagccagttccctcaactccacctaccccatctccctcaactccacctaccccatctccctcatgctgcc-
acccccgactgtcactgcac
cgaccggccctcgaggacctgctcttaggttcagaagcgatcctcacgtgcacactgaccggcctgagagatgc-
ctcaggtgtcaccttca
cctggacgccctcaagtgggaagagcgctgttcaaggaccacctgaccgtgacctctgtggctgctacagcgtg-
tccagtgtcctgccgg
gctgtgccgagccatggaaccatgggaagaccttcacttgcactgctgcctaccccgagtccaagaccccgcta-
accgccaccctctcaaa
atccggaaacacattccggcccgaggtccacctgctgccgccgccgtcggaggagctggccctgaacgagctgg-
tgacgctgacgtgcc
tggcacgtggcttcagccccaaggatgtgctggttcgctggctgcaggggtcacaggagctgccccgcgagaag-
tacctgacttgggcat
cccggcaggagcccagccagggcaccaccaccttcgctgtgaccagcatactgcgcgtggcagccgaggactgg-
aagaagggggaca
ccttctcctgcatggtgggccacgaggccctgccgctggccttcacacagaagaccatcgaccgcttggcgggt-
aaacccacccatgtca
atgtgtctgttgtcatggcggaggtggacggcacctgctactgataatctaga IgA
hinge-CH2--CH3 (Human IgA tail, full length) (amino acid sequence)
(SEQ ID NO: 64)
DQPVPSTPPTPSPSTPPTPSPSCCHPRLSLHRPALEDLLLGSEAILTCTLTGLRDASGVTFT
WTPSSGKSAVQGPPDRDLCGCYSVSSVLPGCAEPWNHGKTFTCTAAYPESKTPLTATLS
KSGNTFRPEVHLLPPPSEELALNELVTLTCLARGFSPKDVLVRWLQGSQELPREKYLTW
ASRQEPSQGTTTFAVTSILRVAAEDWKKGDTFSCMVGHEALPLAFTQKTIDRLAGKPTH
VNVSVVMAEVDGTCY Human J Chain (nucleotide sequence) (SEQ ID NO: 65)
agatctcaagaagatgaaaggattgttcttgttgacaacaaatgtaagtgtgcccggattacttccaggatcat-
ccgttatccgaagatcctaa
tgaggacattgtggagagaaacatccgaattattgttcctctgaacaacagggagaatatctctgatcccacct-
caccattgagaaccagattt
gtgtaccatttgtctgacctcagctgtaaaaaatgtgatcctacagaagtggagctggataatcagatagttac-
tgctacccagagcaatatct
gtgatgaagacagtgctacagagacctgctacacttatgacagaaacaagtgctacacagctgtggtcccactc-
gtatatggtggtgagacc
aaaatggtggaaacagccttaaccccagatgcctgctatcctgactaatctaga Human J
Chain (amino acid sequence) (SEQ ID NO: 66)
RSQEDERIVLVDNKCKCARITSRIIRSSEDPNEDIVERNIRIIVPLNNRENISDPTSPLRTRFV
YHLSDLSCKKCDPTEVELDNQIVTATQSNICDEDSATETCYTYDRNKCYTAVVPLVYGG
ETKMVETALTPDACYP 4 carboxy terminal amino acids deleted from IgA
CH3 (amino acid sequence) (SEQ ID NO: 67) GTCY IgAH IgAT4 (human
IgA tail, truncated (3T1)-(missing last 4 amino acids from carboxy
terminus) (nucleotide sequence) (SEQ ID NO: 68)
tgatcagccagttccctcaactccacctaccccatctccctcaactccacctaccccatctccctcatgctgcc-
acccccgactgtcactgcac
cgaccggccctcgaggacctgctcttaggttcagaagcgatcctcacgtgcacactgaccggcctgagagatgc-
ctcaggtgtcaccttca
cctggacgccctcaagtgggaagagcgctgttcaaggaccacctgaccgtgacctctgtggctgctacagcgtg-
tccagtgtcctgccgg
gctgtgccgagccatggaaccatgggaagaccttcacttgcactgctgcctaccccgagtccaagaccccgcta-
accgccaccctctcaaa
atccggaaacacattccggcccgaggtccacctgctgccgccgccgtcggaggagctggccctgaacgagctgg-
tgacgctgacgtgcc
tggcacgtggcttcagccccaaggatgtgctggttcgctggctgcaggggtcacaggagctgccccgcgagaag-
tacctgacttgggcat
cccggcaggagcccagccagggcaccaccaccttcgctgtgaccagcatactgcgcgtggcagccgaggactgg-
aagaagggggaca
ccttctcctgcatggtgggccacgaggccctgccgctggccttcacacagaagaccatcgaccgcttggcgggt-
aaacccacccatgtca atgtgtctgttgtcatggcggaggtggactgataatctaga IgAH
IgAT4 (amino acid sequence) (SEQ ID NO: 69)
DQPVPSTPPTPSPSTPPTPSPSCCHPRLSLHRPALEDLLLGSEAILTCTLTGLRDASGVTFT
WTPSSGKSAVQGPPDRDLCGCYSVSSVLPGCAEPWNHGKTFTCTAAYPESKTPLTATLS
KSGNTFRPEVHLLPPPSEELALNELVTLTCLARGFSPKDVLVRWLQGSQELPREKYLTW
ASRQEPSQGTTTFAVTSILRVAAEDWKKGDTFSCMVGHEALPLAFTQKTIDRLAGKPTH
VNVSVVMAEVD 2H7 scFv IgAH IgAT4 (2H7 scFv IgA 3T1 construct;
truncates the CH3 domain at the 3'end) (nucleotide sequence) (SEQ
ID NO: 70)
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagctggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcagccagttccctcaactcc
acctaccccatctccctcaactccacctaccccatctccctcatgctgccacccccgactgtcactgcaccgac-
cggccctcgaggacctgc
tcttaggttcagaagcgatcctcacgtgcacactgaccggcctgagagatgcctcaggtgtcaccttcacctgg-
acgccctcaagtgggaa
gagcgctgttcaaggaccacctgaccgtgacctctgtggctgctacagcgtgtccagtgtcctgccgggctgtg-
ccgagccatggaaccat
gggaagaccttcacttgcactgctgcctaccccgagtccaagaccccgctaaccgccaccctctcaaaatccgg-
aaacacattccggccc
gaggtccacctgctgccgccgccgtcggaggagctggccctgaacgagctggtgacgctgacgtgcctggcacg-
tggcttcagccccaa
ggatgtgctggttcgctggctgcaggggtcacaggagctgccccgcgagaagtacctgacttgggcatcccggc-
aggagcccagccag
ggcaccaccaccttcgctgtgaccagcatactgcgcgtggcagccgaggactggaagaagggggacaccttctc-
ctgcatggtgggcca
cgaggccctgccgctggccttcacacagaagaccatcgaccgcttggcgggtaaacccacccatgtcaatgtgt-
ctgttgtcatggcggag gtggactgataatctaga 2H7 scFv IgAH-T4 (amino acid
sequence) (SEQ ID NO: 71)
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAELVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQPVPSTPPTPSPSTPPTPSPSCCHPRLSL
HRPALEDLLLGSEAILTCTLTGLRDASGVTFTWTPSSGKSAVQGPPDRDLCGCYSVSSVL
PGCAEPWNHGKTFTCTAAYPESKTPLTATLSKSGNTFRPEVHLLPPPSEELALNELVTLT
CLARGFSPKDVLVRWLQGSQELPREKYLTWASRQEPSQGTTTFAVTSILRVAAEDWKK
GDTFSCMVGHEALPLAFTQKTIDRLAGKPTHVNVSVVMAEVD 14 amino acids deleted
from IgAH-T4 (so that total of 18 amino acids deleted from wild
type IgA CH3) (amino acid sequence) (SEQ ID NO: 72) PTHVNVSVVMAEVD
IgAH IgA-T18 (human IgA Tail truncated, 3T2) (nucleotide sequence)
(SEQ ID NO: 73)
tgatcagccagttccctcaactccacctaccccatctccctcaactccacctaccccatctccctcatgctgcc-
acccccgactgtcactgcac
cgaccggccctcgaggacctgctcttaggttcagaagcgatcctcacgtgcacactgaccggcctgagagatgc-
ctcaggtgtcaccttca
cctggacgccctcaagtgggaagagcgctgttcaaggaccacctgaccgtgacctctgtggctgctacagcgtg-
tccagtgtcctgccgg
gctgtgccgagccatggaaccatgggaagaccttcacttgcactgctgcctaccccgagtccaagaccccgcta-
accgccaccctctcaaa
atccggaaacacattccggcccgaggtccacctgctgccgccgccgtcggaggagctggccctgaacgagctgg-
tgacgctgacgtgcc
tggcacgtggcttcagccccaaggatgtgctggttcgctggctgcaggggtcacaggagctgccccgcgagaag-
tacctgacttgggcat
cccggcaggagcccagccagggcaccaccaccttcgctgtgaccagcatactgcgcgtggcagccgaggactgg-
aagaagggggaca
ccttctcctgcatggtgggccacgaggccctgccgctggccttcacacagaagaccatcgaccgcttggcgggt-
aaa IgAH IgA-T18 (amino acid sequence) (SEQ ID NO: 74)
DQPVPSTPPTPSPSTPPTPSPSCCHPRLSLHRPALEDLLLGSEAILTCTLTGLRDASGVTFT
WTPSSGKSAVQGPPDRDLCGCYSVSSVLPGCAEPWNHGKTFTCTAAYPESKTPLTATLS
KSGNTFRPEVHLLPPPSEELALNELVTLTCLARGFSPKDVLVRWLQGSQELPREKYLTW
ASRQEPSQGTTTFAVTSILRVAAEDWKKGDTFSCMVGHEALPLAFTQKTIDRLAGK 2H7 scFv
IgAH IgAT18 (human IgA Tail truncated, 3T2) (nucleotide sequence)
(SEQ ID NO: 75)
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagctggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcagccagttccctcaactcc
acctaccccatctccctcaactccacctaccccatctccctcatgctgccacccccgactgtcactgcaccgac-
cggccctcgaggacctgc
tcttaggttcagaagcgatcctcacgtgcacactgaccggcctgagagatgcctcaggtgtcaccttcacctgg-
acgccctcaagtgggaa
gagcgctgttcaaggaccacctgaccgtgacctctgtggctgctacagcgtgtccagtgtcctgccgggctgtg-
ccgagccatggaaccat
gggaagaccttcacttgcactgctgcctaccccgagtccaagaccccgctaaccgccaccctctcaaaatccgg-
aaacacattccggccc
gaggtccacctgctgccgccgccgtcggaggagctggccctgaacgagctggtgacgctgacgtgcctggcacg-
tggcttcagccccaa
ggatgtgctggttcgctggctgcaggggtcacaggagctgccccgcgagaagtacctgacttgggcatcccggc-
aggagcccagccag
ggcaccaccaccttcgctgtgaccagcatactgcgcgtggcagccgaggactggaagaagggggacaccttctc-
ctgcatggtgggcca
cgaggccctgccgctggccttcacacagaagaccatcgaccgcttggcgggtaaa 2H7 scFv
IgAH IgAT18 (amino acid sequence) (SEQ ID NO: 76)
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAELVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQPVPSTPPTPSPSTPPTPSPSCCHPRLSL
HRPALEDLLLGSEAILTCTLTGLRDASGVTFTWTPSSGKSAVQGPPDRDLCGCYSVSSVL
PGCAEPWNHGKTFTCTAAYPESKTPLTATLSKSGNTFRPEVHLLPPPSEELALNELVTLT
CLARGFSPKDVLVRWLQGSQELPREKYLTWASRQEPSQGTTTFAVTSILRVAAEDWKK
GDTFSCMVGHEALPLAFTQKTIDRLAGK CTLA-4 IgG WTH WTCH2CH3
(human-oncoMLP-CTLA4EC-hIgGWT) (nucleotide sequence) (SEQ ID NO:
77)
gcaacctacatgatggggaatgagttgaccttcctagatgattccatctgcacgggcacctccagtggaaatca-
agtgaacctcactatccaa
ggactgagggccatggacacgggactctacatctgcaaggtggagctcatgtacccaccgccatactacctggg-
cataggcaacggaac
ccagatttatgtaattgatccagaaccgtgcccagattctgatcaacccaaatcttgtgacaaaactcacacat-
gcccaccgtgcccagcacc
tgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggaccc-
ctgaggtcacatgcgtg
gtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatgc-
caagacaaagccgcg
ggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggca-
aggagtacaagtgca
aggtctccaacaaagccctcccagcccccatcgagaaaacaatctccaaagccaaagggcagccccgagaacca-
caggtgtacaccctg
cccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatcccagcga-
catcgccgtggagtgg
gagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcct-
ctacagcaagctcacc
gtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccacta-
cacgcagaagagcctc tccctgtctccgggtaaatga CTLA-4 IgG WTH WTCH2CH3
(amino acid sequence) (SEQ ID NO: 78)
MGVLLTQRTLLSLVLALLFPSMASMAMHVAQPAVVLASSRGIASFVCEYASPGKATEV
RVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLY
ICKVELMYPPPYYLGIGNGTQIYVIDPEPCPDSDQPKSCDKTHTCPPCPAPELLGGPSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK Human OncoM leader Peptide + CTLA4 EC
(BclI) (nucleotide sequence) (SEQ ID NO: 79)
atgggggtactgctcacacagaggacgctgctcagtctggtccttgcactcctgtttccaagcatggcgagcat-
ggcaatgcacgtggccc
agcctgctgtggtactggccagcagccgaggcatcgccagctttgtgtgtgagtatgcatctccaggcaaagcc-
actgaggtccgggtgac
agtgcttcggcaggctgacagccaggtgactgaagtctgtgcggcaacctacatgatggggaatgagttgacct-
tcctagatgattccatct
gcacgggcacctccagtggaaatcaagtgaacctcactatccaaggactgagggccatggacacgggactctac-
atctgcaaggtggag
ctcatgtacccaccgccatactacctgggcataggcaacggaacccagatttatgtaattgatccagaaccgtg-
cccagattctgatcaa Human OncoM leader Peptide + CTLA4 EC (amino acid
sequence) (SEQ ID NO: 80)
MGVLLTQRTLLSLVLALLFPSMASMAMHVAQPAVVLASSRGIASFVCEYASPGKATEV
RVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLY
ICKVELMYPPPYYLGIGNGTQIYVIDPEPCPDSDQ Human OncoM leader (nucleotide
sequence) (SEQ ID NO: 81)
atgggggtactgctcacacagaggacgctgctcagtctggtccttgcactcctgtttccaagcatggcgagcat-
g Human OncoM leader (amino acid sequence) (SEQ ID NO: 82)
MGVLLTQRTLLSLVLALLFPSM Human CTLA4 EC (no LP) (nucleotide sequence)
(SEQ ID NO: 83)
gcaatgcacgtggcccagcctgctgtggtactggccagcagccgaggcatcgccagctttgtgtgtgagtatgc-
atctccaggcaaagcca
ctgaggtccgggtgacagtgcttcggcaggctgacagccaggtgactgaagtctgtgcggcaacctacatgacg-
gggaatgagttgacct
tcctagatgattccatctgcacgggcacctccagtggaaatcaagtgaacctcactatccaaggactgagggcc-
atggacacgggactcta
catctgcaaggtggagctcatgtacccaccgccatactacctgggcataggcaacggaacccagatttatgtaa-
ttgatccagaaccgtgcc cagattct Human CTLA4 EC (no LP) (amino acid
sequence) (SEQ ID NO: 84)
AMHVAQPAVVLASSRGIASFVCEYASPGKATEVRVTVLRQADSQVTEVCAATYMTGN
ELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDP
EPCPDS Human CTLA4 IgG MTH (SSS) MTCH2CH3 (nucleotide sequence)
(SEQ ID NO: 85)
atgggggtactgctcacacagaggacgctgctcagtctggtccttgcactcctgtttccaagcatggcgagcat-
ggcaatgcacgtggccc
agcctgctgtggtactggccagcagccgaggcatcgccagctttgtgtgtgagtatgcatctccaggcaaagcc-
actgaggtccgggtgac
agtgcttcggcaggctgacagccaggtgactgaagtctgtgcggcaacctacatgatggggaatgagttgacct-
tcctagatgattccatct
gcacgggcacctccagtggaaatcaagtgaacctcactatccaaggactgagggccatggacacgggactctac-
atctgcaaggtggag
ctcatgtacccaccgccatactacctgggcataggcaacggaacccagatttatgtaattgatccagaaccgtg-
cccagattctgatcaaccc
aaatcttctgacaaaactcacacatccccaccgtccccagcacctgaactcctggggggatcgtcagtcttcct-
cttccccccaaaacccaa
ggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgagg-
tcaagttcaactggta
cgtggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtgg-
tcagcgtcctcacc
gtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccat-
cgagaaaacaatctcc
aaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaacca-
ggtcagcctgacct
gcctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactac-
aagaccacgcctccc
gtgctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaa-
cgtcttctcatgctccgt
gatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatga
Human CTLA4 IgG MTH (SSS) MTCH2CH3 (amino acid sequence) (SEQ ID
NO: 86) MGVLLTQRTLLSLVLALLFPSMASMAMHVAQPAVVLASSRGIASFVCEYASPGKATEV
RVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLY
ICKVELMYPPPYYLGIGNGTQIYVIDPEPCPDSDQPKSSDKTHTSPPSPAPELLGGSSVFLF
PPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR
VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTK
NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ
GNVFSCSVMHEALHNHYTQKSLSLSPGK CTLA-4 IgAH IgACH2CH3
(human-oncoMLP-CTLA4EC-IgA) (nucleotide sequence) (SEQ ID NO: 87)
atgggggtactgctcacacagaggacgctgctcagtctggtccttgcactcctgtttccaagcatggcgagcat-
ggcaatgcacgtggccc
agcctgctgtggtactggccagcagccgaggcatcgccagctttgtgtgtgagtatgcatctccaggcaaagcc-
actgaggtccgggtgac
agtgcttcggcaggctgacagccaggtgactgaagtctgtgcggcaacctacatgatggggaatgagttgacct-
tcctagatgattccatct
gcacgggcacctccagtggaaatcaagtgaacctcactatccaaggactgagggccatggacacgggactctac-
atctgcaaggtggag
ctcatgtacccaccgccatactacctgggcataggcaacggaacccagatttatgtaattgatccagaaccgtg-
cccagattctgatcagcca
gttccctcaactccacctaccccatctccctcaactccacctaccccatctccctcatgctgccacccccgact-
gtcactgcaccgaccggcc
ctcgaggacctgctcttaggttcagaagcgatcctcacgtgcacactgaccggcctgagagatgcctcaggtgt-
caccttcacctggacgc
cctcaagtgggaagagcgctgttcaaggaccacctgaccgtgacctctgtggctgctacagcgtgtccagtgtc-
ctgccgggctgtgccga
gccatggaaccatgggaagaccttcacttgcactgctgcctaccccgagtccaagaccccgctaaccgccaccc-
tctcaaaatccggaaa
cacattccggcccgaggtccacctgctgccgccgccgtcggaggagctggccctgaacgagctggtgacgctga-
cgtgcctggcacgtg
gcttcagccccaaggatgtgctggttcgctggctgcaggggtcacaggagctgccccgcgagaagtacctgact-
tgggcatcccggcag
gagcccagccagggcaccaccaccttcgctgtgaccagcatactgcgcgtggcagccgaggactggaagaaggg-
ggacaccttctcct
gcatggtgggccacgaggccctgccgctggccttcacacagaagaccatcgaccgcttggcgggtaaacccacc-
catgtcaatgtgtctg ttgtcatggcggaggtggacggcacctgctactgataatctaga
CTLA-4 IgAH IgACH2CH3 (amino acid sequence) (SEQ ID NO: 88)
MGVLLTQRTLLSLVLALLFPSMASMAMHVAQPAVVLASSRGIASFVCEYASPGKATEV
RVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLY
ICKVELMYPPPYYLGIGNGTQIYVIDPEPCPDSDQPVPSTPPTPSPSTPPTPSPSCCHPRLSL
HRPALEDLLLGSEAILTCTLTGLRDASGVTFTWTPSSGKSAVQGPPDRDLCGCYSVSSVL
PGCAEPWNHGKTFTCTAAYPESKTPLTATLSKSGNTFRPEVHLLPPPSEELALNELVTLT
CLARGFSPKDVLVRWLQGSQELPREKYLTWASRQEPSQGTTTFAVTSILRVAAEDWKK
GDTFSCMVGHEALPLAFTQKTIDRLAGKPTHVNVSVVMAEVDGTCY CTLA-4 IgAH IgA-T4
(human-oncoMLP-CTLA4EC-IgA3T1) (nucleotide sequence) (SEQ ID NO:
89)
atgggggtactgctcacacagaggacgctgctcagtctggtccttgcactcctgtttccaagcatggcgagcat-
ggcaatgcacgtggccc
agcctgctgtggtactggccagcagccgaggcatcgccagctttgtgtgtgagtatgcatctccaggcaaagcc-
actgaggtccgggtgac
agtgcttcggcaggctgacagccaggtgactgaagtctgtgcggcaacctacatgatggggaatgagttgacct-
tcctagatgattccatct
gcacgggcacctccagtggaaatcaagtgaacctcactatccaaggactgagggccatggacacgggactctac-
atctgcaaggtggag
ctcatgtacccaccgccatactacctgggcataggcaacggaacccagatttatgtaattgatccagaaccgtg-
cccagattctgatcagcca
gttccctcaactccacctaccccatctccctcaactccacctaccccatctccctcatgctgccacccccgact-
gtcactgcaccgaccggcc
ctcgaggacctgctcttaggttcagaagcgatcctcacgtgcacactgaccggcctgagagatgcctcaggtgt-
caccttcacctggacgc
cctcaagtgggaagagcgctgttcaaggaccacctgaccgtgacctctgtggctgctacagcgtgtccagtgtc-
ctgccgggctgtgccga
gccatggaaccatgggaagaccttcacttgcactgctgcctaccccgagtccaagaccccgctaaccgccaccc-
tctcaaaatccggaaa
cacattccggcccgaggtccacctgctgccgccgccgtcggaggagctggccctgaacgagctggtgacgctga-
cgtgcctggcacgtg
gcttcagccccaaggatgtgctggttcgctggctgcaggggtcacaggagctgccccgcgagaagtacctgact-
tgggcatcccggcag
gagcccagccagggcaccaccaccttcgctgtgaccagcatactgcgcgtggcagccgaggactggaagaaggg-
ggacaccttctcct
gcatggtgggccacgaggccctgccgctggccttcacacagaagaccatcgaccgcttggcgggtaaacccacc-
catgtcaatgtgtctg ttgtcatggcggaggtggactgataatctaga CTLA-4 IgAH
IgA-T4 (amino acid sequence) (SEQ ID NO: 90)
MGVLLTQRTLLSLVLALLFPSMASMAMHVAQPAVVLASSRGIASFVCEYASPGKATEV
RVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLY
ICKVELMYPPPYYLGIGNGTQIYVIDPEPCPDSDQPVPSTPPTPSPSTPPTPSPSCCHPRLSL
HRPALEDLLLGSEAILTCTLTGLRDASGVTFTWTPSSGKSAVQGPPDRDLCGCYSVSSVL
PGCAEPWNHGKTFTCTAAYPESKTPLTATLSKSGNTFRPEVHLLPPPSEELALNELVTLT
CLARGFSPKDVLVRWLQGSQELPREKYLTWASRQEPSQGTTTFAVTSILRVAAEDWKK
GDTFSCMVGHEALPLAFTQKTIDRLAGKPTHVNVSVVMAEVD human IgG1 CH2 with 238
mutation pro.fwdarw.ser (nucleotide sequence) (SEQ ID NO: 91)
cctgaactcctggggggatcgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggac-
ccctgaggtcacatgcgt
ggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatg-
ccaagacaaagccgc
gggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggc-
aaggagtacaagtgc
aaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaag human
IgG1 CH2 with 238 mutation pro.fwdarw.ser (amino acid sequence)
(SEQ ID NO: 92)
PELLGGSSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK Amino acids
surrounding Pro to Ser in CH2 (amino acid sequence) (SEQ ID NO: 93)
PAPELLGGPS Amino acids surrounding Pro to Ser in CH2 (amino acid
sequence) (SEQ ID NO: 94) PAPELLGGSS hIgE3BB (leaves an open
reading frame at end of gene to read into transmembrane and
cytoplasmic tail domain attached at either the BamHI or SfuI sites)
(nucleotide sequence) (SEQ ID NO: 95) gtt gtt ttc gaa gga tcc gct
tta ccg gga ttt aca gac acc gct cgc tgg human IgE Fc
(CH2--CH3--CH4) ORF (nucleotide sequence) (SEQ ID NO: 96)
tgatcacgtctgctccagggacttcaccccgcccaccgtgaagatcttacagtcgtcctgcgacggcggcgggc-
acttccccccgaccatc
cagctcctgtgcctcgtctctgggtacaccccagggactatcaacatcacctggctggaggacgggcaggtcat-
ggacgtggacttgtcca
ccgcctctaccacgcaggagggtgagctggcctccacacaaagcgagctcaccctcagccagaagcactggctg-
tcagaccgcacctac
acctgccaggtcacctatcaaggtcacacctttgaggacagcaccaagaagtgtgcagattccaacccgagagg-
ggtgagcgcctaccta
agccggcccagcccgttcgacctgttcatccgcaagtcgcccacgatcacctgtctggtggtggacctggcacc-
cagcaaggggaccgtg
aacctgacctggtcccgggccagtgggaagcctgtgaaccactccaccagaaaggaggagaagcagcgcaatgg-
cacgttaaccgtca
cgtccaccctgccggtgggcacccgagactggatcgagggggagacctaccagtgcagggtgacccacccccac-
ctgcccagggccct
catgcggtccacgaccaagaccagcggcccgcgtgctgccccggaagtctatgcgtttgcgacgccggagtggc-
cggggagccggga
caagcgcaccctcgcctgcctgatccagaacttcatgcctgaggacatctcggtgcagtggctgcacaacgagg-
tgcagctcccggacgc
ccggcacagcacgacgcagccccgcaagaccaagggctccggcttcttcgtcttcagccgcctggaggtgacca-
gggccgaatgggag
cagaaagatgagttcatctgccgtgcagtccatgaggcagcgagcccctcacagaccgtccagcgagcggtgtc-
tgtaaatcccggtaaa gcggatccttcgaa human IgE Fc (CH2--CH3--CH4) ORF
(amino acid sequence) (SEQ ID NO: 97)
DHVCSRDFTPPTVKILQSSCDGGGHFPPTIQLLCLVSGYTPGTINITWLEDGQVMDVDLS
TASTTQEGELASTQSELTLSQKHWLSDRTYTCQVTYQGHTFEDSTKKCADSNPRGVSAY
LSRPSPFDLFIRKSPTITCLVVDLAPSKGTVNLTWSRASGKPVNHSTRKEEKQRNGTLTV
TSTLPVGTRDWIEGETYQCRVTHPHLPRALMRSTTKTSGPRAAPEVYAFATPEWPGSRD
KRTLACLIQNFMPEDISVQWLHNEVQLPDARHSTTQPRKTKGSGFFVFSRLEVTRAEWE
QKDEFICRAVHEAASPSQTVQRAVSVNPGKADPS IFhIgGwtBcl5 (nucleotide
sequence) (SEQ ID NO: 98) gtt gtt tga tca gga gcc caa atc ttg tga
caa aac tca cac atg ccc acc gtg ccc agc acc (63 mer) HuIgGMHWC
(sense, 5' primer for mutating wild type hinge CCC to mutant SSS)
(nucleotide sequence) (SEQ ID NO: 99) gtt gtt gat cag gag ccc aaa
tct tct gac aaa act cac aca tct cca ccg tcc cca gca cct gaa ctc ctg
ggt gga ccg tca gtc ttc c 1D8 VH (nucleotide sequence) (SEQ ID NO:
100)
caggtgcagctgaaggaggcaggacctggcctggtgcaaccgacacagaccctgtccctcacatgcactgtctc-
tgggttctcattaacca
gcgatggtgtacactggattcgacagcctccaggaaagggtctggaatggatgggaataatatattatgatgga-
ggcacagattataattca
gcaattaaatccagactgagcatcagcagggacacctccaagagccaagttttcttaaaaatcaacagtctgca-
aactgatgacacagccat
gtattactgtgccagaatccactttgattactggggccaaggagtcatggtcacagtctcctct
1D8 VH (no leader) (amino acid sequence) (SEQ ID NO: 101)
QVQLKEAGPGLVQPTQTLSLTCTVSGFSLTSDGVHWIRQPPGKGLEWMGIIYYDGGTDY
NSAIKSRLSISRDTSKSQVFLKINSLQTDDTAMYYCARIHFDYWGQGVMVTVSS 1D8 VL (no
leader) (nucleotide sequence) (SEQ ID NO: 102)
gacattgtgctcactcagtctccaacaaccatagctgcatctccaggggagaaggtcaccatcacctgccgtgc-
cagctccagtgtaagtta
catgtactggtaccagcagaagtcaggcgcctcccctaaactctggatttatgacacatccaagctggcttctg-
gagttccaaatcgcttcagt
ggcagtgggtctgggacctcttattctctcgcaatcaacaccatggagactgaagatgctgccacttattactg-
tcagcagtggagtagtactc cgctcacgttcgggtctgggaccaagctggagatcaaacgg 1D8
VL (amino acid sequence) (SEQ ID NO: 103)
DIVLTQSPTTIAASPGEKVTITCRASSSVSYMYWYQQKSGASPKLWIYDTSKLASGVPNR
FSGSGSGTSYSLAINTMETEDAATYYCQQWSSTPLTFGSGTKLEIKR 1D8 scFv
(nucleotide sequence) (SEQ ID NO: 104)
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcactcagtctc
caacaaccatagctgcatctccaggggagaaggtcaccatcacctgccgtgccagctccagtgtaagttacatg-
tactggtaccagcagaa
gtcaggcgcctcccctaaactctggatttatgacacatccaagctggcttctggagttccaaatcgcttcagtg-
gcagtgggtctgggacctct
tattctctcgcaatcaacaccatggagactgaagatgctgccacttattactgtcagcagtggagtagtactcc-
gctcacgttcgggtctggga
ccaagctggagatcaaacggggtggcggtggctcgggcggtggtgggtcgggtggcggcggatctcaggtgcag-
ctgaaggaggcag
gacctggcctggtgcaaccgacacagaccctgtccctcacatgcactgtctctgggttctcattaaccagcgat-
ggtgtacactggattcgac
agcctccaggaaagggtctggaatggatgggaataatatattatgatggaggcacagattataattcagcaatt-
aaatccagactgagcatca
gcagggacacctccaagagccaagttttcttaaaaatcaacagtctgcaaactgatgacacagccatgtattac-
tgtgccagaatccactttg attactggggccaaggagtcatggtcacagtctcctctgatca 1D8
scFv (amino acid sequence) (SEQ ID NO: 105)
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPTTIAASPGEKVTITCRASSSVSYMYWYQQK
SGASPKLWIYDTSKLASGVPNRFSGSGSGTSYSLAINTMETEDAATYYCQQWSSTPLTFG
SGTKLEIKRGGGGSGGGGSGGGGSQVQLKEAGPGLVQPTQTLSLTCTVSGFSLTSDGVH
WIRQPPGKGLEWMGIIYYDGGTDYNSAIKSRLSISRDTSKSQVFLKINSLQTDDTAMYYC
ARIHFDYWGQGVMVTVSS 1D8 scFv IgG WTH WTCH2CH3 (nucleotide sequence)
(SEQ ID NO: 106)
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcactcagtctc
caacaaccatagctgcatctccaggggagaaggtcaccatcacctgccgtgccagctccagtgtaagttacatg-
tactggtaccagcagaa
gtcaggcgcctcccctaaactctggatttatgacacatccaagctggcttctggagttccaaatcgcttcagtg-
gcagtgggtctgggacctct
tattctctcgcaatcaacaccatggagactgaagatgctgccacttattactgtcagcagtggagtagtactcc-
gctcacgttcgggtctggga
ccaagctggagatcaaacggggtggcggtggctcgggcggtggtgggtcgggtggcggcggatctcaggtgcag-
ctgaaggaggcag
gacctggcctggtgcaaccgacacagaccctgtccctcacatgcactgtctctgggttctcattaaccagcgat-
ggtgtacactggattcgac
agcctccaggaaagggtctggaatggatgggaataatatattatgatggaggcacagattataattcagcaatt-
aaatccagactgagcatca
gcagggacacctccaagagccaagttttcttaaaaatcaacagtctgcaaactgatgacacagccatgtattac-
tgtgccagaatccactttg
attactggggccaaggagtcatggtcacagtctcctctgatcaggagcccaaatcttgtgacaaaactcacaca-
tgcccaccgtgcccagca
cctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggac-
ccctgaggtcacatgcgt
ggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatg-
ccaagacaaagccgc
gggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggc-
aaggagtacaagtgc
aaggtctccaacaaagccctcccagcccccatcgagaaaacaatctccaaagccaaagggcagccccgagaacc-
acaggtgtacaccct
gcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatcccagcg-
acatcgccgtggagtg
ggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcc-
tctacagcaagctcac
cgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccact-
acacgcagaagagcct ctccctgtctccgggtaaatgatctaga 1D8 scFv IgG WTH
WTCH2CH3 (amino acid sequence) (SEQ ID NO: 107)
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPTTIAASPGEKVTITCRASSSVSYMYWYQQK
SGASPKLWIYDTSKLASGVPNRFSGSGSGTSYSLAINTMETEDAATYYCQQWSSTPLTFG
SGTKLEIKRGGGGSGGGGSGGGGSQVQLKEAGPGLVQPTQTLSLTCTVSGFSLTSDGVH
WIRQPPGKGLEWMGIIYYDGGTDYNSAIKSRLSISRDTSKSQVFLKINSLQTDDTAMYYC
ARIHFDYWGQGVMVTVSSDQEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR
TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKG
FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
ALHNHYTQKSLSLSPGK 1D8 scFv IgG MTH MTCH2CH3-CD80 (nucleotide
sequence) (SEQ ID NO: 108)
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcactcagtctc
caacaaccatagctgcatctccaggggagaaggtcaccatcacctgccgtgccagctccagtgtaagttacatg-
tactggtaccagcagaa
gtcaggcgcctcccctaaactctggatttatgacacatccaagctggcttctggagttccaaatcgcttcagtg-
gcagtgggtctgggacctct
tattctctcgcaatcaacaccatggagactgaagatgctgccacttattactgtcagcagtggagtagtactcc-
gctcacgttcgggtctggga
ccaagctggagatcaaacggggtggcggtggctcgggcggtggtgggtcgggtggcggcggatctcaggtgcag-
ctgaaggaggcag
gacctggcctggtgcaaccgacacagaccctgtccctcacatgcactgtctctgggttctcattaaccagcgat-
ggtgtacactggattcgac
agcctccaggaaagggtctggaatggatgggaataatatattatgatggaggcacagattataattcagcaatt-
aaatccagactgagcatca
gcagggacacctccaagagccaagttttcttaaaaatcaacagtctgcaaactgatgacacagccatgtattac-
tgtgccagaatccactttg
attactggggccaaggagtcatggtcacagtctcctctgatctggagcccaaatcttctgacaaaactcacaca-
agcccaccgagcccagc
acctgaactcctggggggatcgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccgga-
cccctgaggtcacatgcg
tggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataat-
gccaagacaaagccg
cgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatgg-
caaggagtacaagtg
caaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaagggcagccccgagaac-
cacaggtgtacacc
ctgcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatcccag-
cgacatcgccgtggag
tgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttctt-
cctctacagcaagctc
accgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaacca-
ctacacgcagaagag
cctctccctgtctccgggtaaagcggatccttcgaacctgctcccatcctgggccattaccttaatctcagtaa-
atggaatttttgtgatatgctg
cctgacctactgctttgccccaagatgcagagagagaaggaggaatgagagattgagaagggaaagtgtacgcc-
ctgtataaatcgata 1D8 scFv IgG MTH MTCH2CH3-CD80 (amino acid
sequence) (SEQ ID NO: 109)
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPTTIAASPGEKVTITCRASSSVSYMYWYQQK
SGASPKLWIYDTSKLASGVPNRFSGSGSGTSYSLAINTMETEDAATYYCQQWSSTPLTFG
SGTKLEIKRGGGGSGGGGSGGGGSQVQLKEAGPGLVQPTQTLSLTCTVSGFSLTSDGVH
WIRQPPGKGLEWMGIIYYDGGTDYNSAIKSRLSISRDTSKSQVFLKINSLQTDDTAMYYC
ARIHFDYWGQGVMVTVSSDLEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDTLMISR
TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKG
FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
ALHNHYTQKSLSLSPGKADPSNLLPSWAITLISVNGIFVICCLTYCFAPRCRERRRNERLR
RESVRPV 1D8 scFv IgG WTH WTCH2CH3-CD80 (nucleotide sequence) (SEQ
ID NO: 110)
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcactcagtctc
caacaaccatagctgcatctccaggggagaaggtcaccatcacctgccgtgccagctccagtgtaagttacatg-
tactggtaccagcagaa
gtcaggcgcctcccctaaactctggatttatgacacatccaagctggcttctggagttccaaatcgcttcagtg-
gcagtgggtctgggacctct
tattctctcgcaatcaacaccatggagactgaagatgctgccacttattactgtcagcagtggagtagtactcc-
gctcacgttcgggtctggga
ccaagctggagatcaaacggggtggcggtggctcgggcggtggtgggtcgggtggcggcggatctcaggtgcag-
ctgaaggaggcag
gacctggcctggtgcaaccgacacagaccctgtccctcacatgcactgtctctgggttctcattaaccagcgat-
ggtgtacactggattcgac
agcctccaggaaagggtctggaatggatgggaataatatattatgatggaggcacagattataattcagcaatt-
aaatccagactgagcatca
gcagggacacctccaagagccaagttttcttaaaaatcaacagtctgcaaactgatgacacagccatgtattac-
tgtgccagaatccactttg
attactggggccaaggagtcatggtcacagtctcctctgatctggagcccaaatcttgtgacaaaactcacaca-
tgcccaccgtgcccagca
cctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggac-
ccctgaggtcacatgcgt
ggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatg-
ccaagacaaagccgc
gggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggc-
aaggagtacaagtgc
aaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaagggcagccccgagaacc-
acaggtgtacaccct
gcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatcccagcg-
acatcgccgtggagtg
ggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcc-
tctacagcaagctcac
cgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccact-
acacgcagaagagcct
ctccctgtctccgggtaaagcggatccttcgaacctgctcccatcctgggccattaccttaatctcagtaaatg-
gaatttttgtgatatgctgcct
gacctactgctttgccccaagatgcagagagagaaggaggaatgagagattgagaagggaaagtgtacgccctg-
tataaatcgata 1D8 scFv IgG WTH WTCH2CH3-CD80 (amino acid sequence)
(SEQ ID NO: 111)
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPTTIAASPGEKVTITCRASSSVSYMYWYQQK
SGASPKLWIYDTSKLASGVPNRFSGSGSGTSYSLAINTMETEDAATYYCQQWSSTPLTFG
SGTKLEIKRGGGGSGGGGSGGGGSQVQLKEAGPGLVQPTQTLSLTCTVSGFSLTSDGVH
WIRQPPGKGLEWMGIIYYDGGTDYNSAIKSRLSISRDTSKSQVFLKINSLQTDDTAMYYC
ARIHFDYWGQGVMVTVSSDLEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR
TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKG
FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
ALHNHYTQKSLSLSPGKADPSNLLPSWAITLISVNGIFVICCLTYCFAPRCRERRRNERLR
RESVRPV Anti-human CD3 scFv WTH WTCH2CH3 (nucleotide sequence) (SEQ
ID NO: 112)
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacatccagatgacacagac
tacatcctccctgtctgcctctctgggagacagagtcaccatcagttgcagggcaagtcaggacattcgcaatt-
atttaaactggtatcagcag
aaaccagatggaactgttaaactcctgatctactacacatcaagattacactcaggagtcccatcaaggttcag-
tggcagtgggtctggaaca
gattattctctcaccattgccaacctgcaaccagaagatattgccacttacttttgccaacagggtaatacgct-
tccgtggacgttcggtggag
gcaccaaactggtaaccaaacgggagctcggtggcggtggctcgggcggtggtgggtcgggtggcggcggatct-
atcgatgaggtcca
gctgcaacagtctggacctgaactggtgaagcctggagcttcaatgtcctgcaaggcctctggttactcattca-
ctggctacatcgtgaactg
gctgaagcagagccatggaaagaaccttgagtggattggacttattaatccatacaaaggtcttactacctaca-
accagaaattcaagggca
aggccacattaactgtagacaagtcatccagcacagcctacatggagctcctcagtctgacatctgaagactct-
gcagtctattactgtgcaa
gatctgggtactatggtgactcggactggtacttcgatgtctggggcgcagggaccacggtcaccgtctcctct-
gatcaggagcccaaatct
tgtgacaaaactcacacatgcccaccgtgcccagcacctgaactcctggggggaccgtcagtcttcctcttccc-
cccaaaacccaaggaca
ccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaag-
ttcaactggtacgtgga
cggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcg-
tcctcaccgtcctgc
accaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaa-
acaatctccaaagcc
aaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcag-
cctgacctgcctgg
tcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagacc-
acgcctcccgtgctg
gactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtctt-
ctcatgctccgtgatgc
atgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga
Anti-human CD3 scFv WTH WTCH2CH3 (amino acid sequence) (SEQ ID NO:
113) MDFQVQIFSFLLISASVIMSRGVDIQMTQTTSSLSASLGDRVTISCRASQDIRNYLNWYQ
QKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTIANLQPEDIATYFCQQGNTLPWT
FGGGTKLVTKRELGGGGSGGGGSGGGGSIDEVQLQQSGPELVKPGASMSCKASGYSFT
GYIVNWLKQSHGKNLEWIGLINPYKGLTTYNQKFKGKATLTVDKSSSTAYMELLSLTSE
DSAVYYCARSGYYGDSDWYFDVWGAGTTVTVSSDQEPKSCDKTHTCPPCPAPELLGGP
SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 2H7-antiCD40 scFv MTH (SSS)
MTCH2WTCH3 (2h7-40.2.220Ig + restriction sites) (nucleotide
sequence) (SEQ ID NO: 114)
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaaggtggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagctggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaatccaactctgaagaag
caaagaaagaggaggccaaaaaggaggaagccaagaaatctaacagcgtcgacattgttctgactcagtctcca-
gccaccctgtctgtga
ctccaggagatagagtctctctttcctgcagggccagccagagtattagcgactacttacactggtatcaacaa-
aaatcacatgagtctccaa
ggcttctcatcaaatatgcttcccattccatctctgggatcccctccaggttcagtggcagtggatcagggtca-
gatttcactctcagtatcaac
agtgtggaacctgaagatgttggaatttattactgtcaacatggtcacagctttccgtggacgttcggtggagg-
caccaagctggaaatcaaa
cggggtggcggtggctcgggcggaggtgggtcgggtggcggcggatctcagatccagttggtgcaatctggacc-
tgagctgaagaagc
ctggagagacagtcaggatctcctgcaaggcttctgggtatgccttcacaactactggaatgcagtgggtgcaa-
gagatgccaggaaagg
gtttgaagtggattggctggataaacaccccactctggagtgccaaaatatgtagaagacttcaaggacggttt-
gccttctctttggaaacctct
gccaacactgcatatttacagataagcaacctcaaagatgaggacacggctacgtatttctgtgtgagatccgg-
gaatggtaactatgacctg
gcctactttgcttactggggccaagggacactggtcactgtctctgatcaggagcccaaatcttctgacaaaac-
tcacacatccccaccgtcc
ccagcacctgaactcctggggggatcgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctc-
ccggacccctgaggtca
catgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtg-
cataatgccaagaca
aagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggct-
gaatggcaaggagta
caagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaacaatctccaaagccaaagggcagcccc-
gagaaccacaggtg
tacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttcta-
tcccagcgacatcgcc
gtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctc-
cttcttcctctacagc
aagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgca-
caaccactacacgcag aagagcctctccctgtctccgggtaaatgatctaga 2H7-antiCD40
scFv MTH (SSS) MTCH2WTCH3 (2H7-40.2.220Ig) (amino acid sequence)
(SEQ ID NO: 115)
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKGGGGSGGGGSGGGGSSQAYLQQSGAELVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQSNSEEAKKEEAKKEEAKKSNSVDIVL
TQSPATLSVTPGDRVSLSCRASQSISDYLHWYQQKSHESPRLLIKYASHSISGIPSRFSGSG
SGSDFTLSINSVEPEDVGIYYCQHGHSFPWTFGGGTKLEIKRGGGGSGGGGSGGGGSQIQ
LVQSGPELKKPGETVRISCKASGYAFTTTGMQWVQEMPGKGLKWIGWINTPLWSAKIC
RRLQGRFAFSLETSANTAYLQISNLKDEDTATYFCVRSGNGNYDLAYFAYWGQGTLVT
VSDQEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPE
VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL
PAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPE
NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 5B9 VH
(includes the VH leader peptide) (nucleotide sequence) (SEQ ID NO:
116)
atggctgtcttggggctgctcttctgcctggtgacatttccaagctgtgtcctatcccaggtgcagctgaagca-
gtcaggacctggcctagtgc
agtcctcacagagcctgtccatcacctgcacagtctctggtttctcattaactacctatgctgtacactgggtt-
cgccagtctccaggaaagggt
ctggagtggctgggagtgatatggagtggtggaatcacagactataatgcagctttcatatccagactgagcat-
caccaaggacgattccaa
gagccaagttttctttaaaatgaacagtctgcaacctaatgacacagccatttattactgtgccagaaatgggg-
gtgataactacccttattacta
tgctatggactactggggtcaaggaacctcagtcaccgtctcctca 5B9 VH (minus the
leader) (nucleotide sequence) (SEQ ID NO: 117)
caggtgcagctgaagcagtcaggacctggcctagtgcagtcctcacagagcctgtccatcacctgcacagtctc-
tggtttctcattaactacc
tatgctgtacactgggttcgccagtctccaggaaagggtctggagtggctgggagtgatatggagtggtggaat-
cacagactataatgcagc
tttcatatccagactgagcatcaccaaggacgattccaagagccaagttttctttaaaatgaacagtctgcaac-
ctaatgacacagccatttatt
actgtgccagaaatgggggtgataactacccttattactatgctatggactactggggtcaaggaacctcagtc-
accgtctcctca 5B9 VH (includes leader peptide) (amino acid sequence)
(SEQ ID NO: 118)
MAVLGLLFCLVTFPSCVLSQVQLKQSGPGLVQSSQSLSITCTVSGFSLTTYAVHWVRQSP
GKGLEWLGVIWSGGITDYNAAFISRLSITKDDSKSQVFFKMNSLQPNDTAIYYCARNGG
DNYPYYYAMDYWGQGTSVTVSS 5B9 VH (no leader peptide) (amino acid
sequence) (SEQ ID NO: 119)
QVQLKQSGPGLVQSSQSLSITCTVSGFSLTTYAVHWVRQSPGKGLEWLGVIWSGGITDY
NAAFISRLSITKDDSKSQVFFKMNSLQPNDTAIYYCARNGGDNYPYYYAMDYWGQGTS VTVSS
5B9 VL (nucleotide sequence) (SEQ ID NO: 120)
atgaggttctctgctcagcttctggggctgcttgtgctctggatccctggatccactgcagatattgtgatgac-
gcaggctgcattctccaatcc
agtcactcttggaacatcagcttccatctcctgcaggtctagtaagagtctcctacatagtaatggcatcactt-
atttgtattggtatctgcagaag
ccaggccagtctcctcagctcctgatttatcagatgtccaaccttgcctcaggagtcccagacaggttcagtag-
cagtgggtcaggaactgat
ttcacactgagaatcagcagagtggaggctgaggatgtgggtgtttattactgtgctcaaaatctagaacttcc-
gctcacgttcggtgctggga ccaagctggagctgaaacgg
5B9 VL (amino acid sequence) (SEQ ID NO: 121)
MRFSAQLLGLLVLWIPGSTADIVMTQAAFSNPVTLGTSASISCRSSKSLLHSNGITYLYW
YLQKPGQSPQLLIYQMSNLASGVPDRFSSSGSGTDFTLRISRVEAEDVGVYYCAQNLELP
LTFGAGTKLELKR 5B9 scFv (nucleotide sequence) (SEQ ID NO: 122)
aagcttgccgccatgaggttctctgctcagcttctggggctgatgtgctctggatccctggatccactgcagat-
attgtgatgacgcaggctg
cattctccaatccagtcactcttggaacatcagcttccatctcctgcaggtctagtaagagtctcctacatagt-
aatggcatcacttatttgtattg
gtatctgcagaagccaggccagtctcctcagctcctgatttatcagatgtccaaccttgcctcaggagtcccag-
acaggttcagtagcagtgg
gtcaggaactgatttcacactgagaatcagcagagtggaggctgaggatgtgggtgtttattactgtgctcaaa-
atctagaacttccgctcac
gttcggtgctgggaccaagctggagctgaaacggggtggcggtggctcgggcggtggtgggtcgggtggcggcg-
gatcgtcacaggtg
cagctgaagcagtcaggacctggcctagtgcagtcctcacagagcctgtccatcacctgcacagtctctggttt-
ctcattaactacctatgctg
tacactgggttcgccagtctccaggaaagggtctggagtggctgggagtgatatggagtggtggaatcacagac-
tataatgcagctttcatat
ccagactgagcatcaccaaggacgattccaagagccaagttttctttaaaatgaacagtctgcaacctaatgac-
acagccatttattactgtgc
cagaaatgggggtgataactacccttattactatgctatggactactggggtcaaggaacctcagtcaccgtct-
cctct 5B9 scFv (amino acid sequence) (SEQ ID NO: 123)
MRFSAQLLGLLVLWIPGSTADIVMTQAAFSNPVTLGTSASISCRSSKSLLHSNGITYLYW
YLQKPGQSPQLLIYQMSNLASGVPDRFSSSGSGTDFTLRISRVEAEDVGVYYCAQNLELP
LTFGAGTKLELKRGGGGSGGGGSGGGGSSQVQLKQSGPGLVQSSQSLSITCTVSGFSLTT
YAVHWVRQSPGKGLEWLGVIWSGGITDYNAAFISRLSITKDDSKSQVFFKMNSLQPNDT
AIYYCARNGGDNYPYYYAMDYWGQGTSVTVSS 5B9 scFv-hmtIgG1-hCD80 (nucleotide
sequence) (SEQ ID NO: 124)
aagcttgccgccatgaggttctctgctcagcttctggggctgatgtgctctggatccctggatccactgcagat-
attgtgatgacgcaggctg
cattctccaatccagtcactcttggaacatcagcttccatctcctgcaggtctagtaagagtctcctacatagt-
aatggcatcacttatttgtattg
gtatctgcagaagccaggccagtctcctcagctcctgatttatcagatgtccaaccttgcctcaggagtcccag-
acaggttcagtagcagtgg
gtcaggaactgatttcacactgagaatcagcagagtggaggctgaggatgtgggtgtttattactgtgctcaaa-
atctagaacttccgctcac
gttcggtgctgggaccaagctggagctgaaacggggtggcggtggctcgggcggtggtgggtcgggtggcggcg-
gatcgtcacaggtg
cagctgaagcagtcaggacctggcctagtgcagtcctcacagagcctgtccatcacctgcacagtctctggttt-
ctcattaactacctatgctg
tacactgggttcgccagtctccaggaaagggtctggagtggctgggagtgatatggagtggtggaatcacagac-
tataatgcagctttcatat
ccagactgagcatcaccaaggacgattccaagagccaagttttctttaaaatgaacagtctgcaacctaatgac-
acagccatttattactgtgc
cagaaatgggggtgataactacccttattactatgctatggactactggggtcaaggaacctcagtcaccgtct-
cctctgatctggagcccaa
atcttctgacaaaactcacacaagcccaccgagcccagcacctgaactcctggggggatcgtcagtcttcctct-
tccccccaaaacccaag
gacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggt-
caagttcaactggtac
gtggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggt-
cagcgtcctcaccg
tcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatc-
gagaaaaccatctcca
aagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccag-
gtcagcctgacctg
cctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactaca-
agaccacgcctcccg
tgctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaac-
gtcttctcatgctccgtg
atgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaagcggatccttcgaa-
cctgctcccatcctggg
ccattaccttaatctcagtaaatggaatttttgtgatatgctgcctgacctactgctttgccccaagatgcaga-
gagagaaggaggaatgagag attgagaagggaaagtgtacgccctgtataaatcgatactcgag
5B9 scFv-hmtIgG1-hCD80 (amino acid sequence) (SEQ ID NO: 125)
MRFSAQLLGLLVLWIPGSTADIVMTQAAFSNPVTLGTSASISCRSSKSLLHSNGITYLYW
YLQKPGQSPQLLIYQMSNLASGVPDRFSSSGSGTDFTLRISRVEAEDVGVYYCAQNLELP
LTFGAGTKLELKRGGGGSGGGGSGGGGSSQVQLKQSGPGLVQSSQSLSITCTVSGFSLTT
YAVHWVRQSPGKGLEWLGVIWSGGITDYNAAFISRLSITKDDSKSQVFFKMNSLQPNDT
AIYYCARNGGDNYPYYYAMDYWGQGTSVTVSSDLEPKSSDKTHTSPPSPAPELLGGSS
VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN
STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD
ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS
RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKADPSNLLPSWAITLISVNGIFVICCLTY
CFAPRCRERRRNERLRRESVRPV 2e12 scFv WTH CH2 CH3 (2e12
scFv-WthIgG-CD80) (nucleotide sequence) (SEQ ID NO: 126)
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcacccaatctc
cagcttctttggctgtgtctctaggtcagagagccaccatctcctgcagagccagtgaaagtgttgaatattat-
gtcacaagtttaatgcagtgg
taccaacagaaaccaggacagccacccaaactcctcatctctgctgcatccaacgtagaatctggggtccctgc-
caggtttagtggcagtg
ggtctgggacagacttcagcctcaacatccatcctgtggaggaggatgatattgcaatgtatttctgtcagcaa-
agtaggaaggttccttgga
cgttcggtggaggcaccaagctggaaatcaaacggggtggcggtggctcgggcggaggtgggtcgggtggcggc-
ggatctcaggtgc
agctgaaggagtcaggacctggcctggtggcgccctcacagagcctgtccatcacatgcaccgtctcagggttc-
tcattaaccggctatggt
gtaaactgggttcgccagcctccaggaaagggtctggagtggctgggaatgatatggggtgatggaagcacaga-
ctataattcagctctca
aatccagactgagcatcaccaaggacaactccaagagccaagttttcttaaaaatgaacagtctgcaaactgat-
gacacagccagatactac
tgtgccagagatggttatagtaatttcattactatgttatggactactggggtcaaggaacctcagtcaccgtc-
tcctcagatctggagcccaa
atcttgtgacaaaactcacacatgcccaccgtgcccagcacctgaactcctggggggaccgtcagtcttcctct-
tccccccaaaacccaagg
acaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtc-
aagttcaactggtacgt
ggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtca-
gcgtcctcaccgtc
ctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcga-
gaaaaccatctccaa
agccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccagg-
tcagcctgacctgc
ctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaa-
gaccacgcctcccgt
gctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacg-
tcttctcatgctccgtg
atgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaagcggatccttcgaa-
cctgctcccatcctggg
ccattaccttaatctcagtaaatggaatttttgtgatatgctgcctgacctactgctttgccccaagatgcaga-
gagagaaggaggaatgagag attgagaagggaaagtgtacgccctgtataaatcgat 2e12
scFv WTH CH2 CH3 (2e12 scFv-WthIgG-CD80) (amino acid sequence) (SEQ
ID NO: 127)
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPASLAVSLGQRATISCRASESVEYYVTSLMQ
WYQQKPGQPPKLLISAASNVESGVPARFSGSGSGTDFSLNIHPVEEDDIAMYFCQQSRKV
PWTFGGGTKLEIKRGGGGSGGGGSGGGGSQVQLKESGPGLVAPSQSLSITCTVSGFSLT
GYGVNWVRQPPGKGLEWLGMIWGDGSTDYNSALKSRLSITKDNSKSQVFLKMNSLQT
DDTARYYCARDGYSNFHYYVMDYWGQGTSVTVSSDLEPKSCDKTHTCPPCPAPELLG
GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ
YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS
RDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD
KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKADPSNLLPSWAITLISVNGIFVICCL
TYCFAPRCRERRRNERLRRESVRPV 2H7-human IgE Fc (CH2--CH3--CH4)
(nucleotide sequence) (SEQ ID NO: 128)
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaaggtggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagctggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctctgatca-
cgtctgctccagggacttca
ccccgcccaccgtgaagatcttacagtcgtcctgcgacggcggcgggcacttccccccgaccatccagctcctg-
tgcctcgtctctgggta
caccccagggactatcaacatcacctggctggaggacgggcaggtcatggacgtggacttgtccaccgcctcta-
ccacgcaggagggtg
agctggcctccacacaaagcgagctcaccctcagccagaagcactggctgtcagaccgcacctacacctgccag-
gtcacctatcaaggtc
acacctttgaggacagcaccaagaagtgtgcagattccaacccgagaggggtgagcgcctacctaagccggccc-
agcccgttcgacctg
ttcatccgcaagtcgcccacgatcacctgtctggtggtggacctggcacccagcaaggggaccgtgaacctgac-
ctggtcccgggccagt
gggaagcctgtgaaccactccaccagaaaggaggagaagcagcgcaatggcacgttaaccgtcacgtccaccct-
gccggtgggcaccc
gagactggatcgagggggagacctaccagtgcagggtgacccacccccacctgcccagggccctcatgcggtcc-
acgaccaagacca
gcggcccgcgtgctgccccggaagtctatgcgtttgcgacgccggagtggccggggagccgggacaagcgcacc-
ctcgcctgcctgat
ccagaacttcatgcctgaggacatctcggtgcagtggctgcacaacgaggtgcagctcccggacgcccggcaca-
gcacgacgcagccc
cgcaagaccaagggctccggcttcttcgtcttcagccgcctggaggtgaccagggccgaatgggagcagaaaga-
tgagttcatctgccgt
gcagtccatgaggcagcgagcccctcacagaccgtccagcgagcggtgtctgtaaatcccggtaaatgataatc-
taga 2H7 scFv IgE (CH2--CH3--CH4) (amino acid sequence) (SEQ ID NO:
129) MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKGGGGSGGGGSGGGGSSQAYLQQSGAELVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSDHVCSRDFTPPTVKILQSSCDGGGHFPPTI
QLLCLVSGYTPGTINITWLEDGQVMDVDLSTASTTQEGELASTQSELTLSQKHWLSDRT
YTCQVTYQGHTFEDSTKKCADSNPRGVSAYLSRPSPFDLFIRKSPTITCLVVDLAPSKGT
VNLTWSRASGKPVNHSTRKEEKQRNGTLTVTSTLPVGTRDWIEGETYQCRVTHPHLPR
ALMRSTTKTSGPRAAPEVYAFATPEWPGSRDKRTLACLIQNFMPEDISVQWLHNEVQLP
DARHSTTQPRKTKGSGFFVFSRLEVTRAEWEQKDEFICRAVHEAASPSQTVQRAVSVNP GK 2H7
scFv MH (SSS) MCH2WTCH3 (nucleotide sequence) (SEQ ID NO: 130)
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagctggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaggagcccaaatcttctg
acaaaactcacacatccccaccgtccccagcacctgaactcctggggggatcgtcagtcttcctcttcccccca-
aaacccaaggacaccct
catgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttca-
actggtacgtggacgg
cgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcc-
tcaccgtcctgcacc
aggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaca-
atctccaaagccaaa
gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcct-
gacctgcctggtca
aaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacg-
cctcccgtgctgga
ctccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttct-
catgctccgtgatgcatg
aggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga 2H7
scFv MH (SSS) MCH2WTCH3 (amino acid sequence) (SEQ ID NO: 131)
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAELVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQEPKSSDKTHTSPPSPAPELLGGSSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK 5B9 scFv MTHWTCH2CH3 (nucleotide
sequence) (SEQ ID NO: 132)
aagcttgccgccatgaggttctctgctcagcttctggggctgcttgtgctctggatccctggatccactgcaga-
tattgtgatgacgcaggctg
cattctccaatccagtcactcttggaacatcagcttccatctcctgcaggtctagtaagagtctcctacatagt-
aatggcatcacttatttgtattg
gtatctgcagaagccaggccagtctcctcagctcctgatttatcagatgtccaaccttgcctcaggagtcccag-
acaggttcagtagcagtgg
gtcaggaactgatttcacactgagaatcagcagagtggaggctgaggatgtgggtgtttattactgtgctcaaa-
atctagaacttccgctcac
gttcggtgctgggaccaagctggagctgaaacggggtggcggtggctcgggcggtggtgggtcgggtggcggcg-
gatcgtcacaggtg
cagctgaagcagtcaggacctggcctagtgcagtcctcacagagcctgtccatcacctgcacagtctctggttt-
ctcattaactacctatgctg
tacactgggttcgccagtctccaggaaagggtctggagtggctgggagtgatatggagtggtggaatcacagac-
tataatgcagctttcatat
ccagactgagcatcaccaaggacgattccaagagccaagttttctttaaaatgaacagtctgcaacctaatgac-
acagccatttattactgtgc
cagaaatgggggtgataactacccttattactatgctatggactactggggtcaaggaacctcagtcaccgtct-
cctctgatcaggagcccaa
atcttctgacaaaactcacacatccccaccgtccccagcacctgaactcctggggggaccgtcagtcttcctct-
tccccccaaaacccaagg
acaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtc-
aagttcaactggtacgt
ggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtca-
gcgtcctcaccgtc
ctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcga-
gaaaacaatctccaa
agccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccagg-
tcagcctgacctgc
ctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaa-
gaccacgcctcccgt
gctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacg-
tcttctcatgctccgtg
atgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga
5B9 scFv MTHWTCH2CH3 (amino acid sequence) (SEQ ID NO: 133)
MRFSAQLLGLLVLWIPGSTADIVMTQAAFSNPVTLGTSASISCRSSKSLLHSNGITYLYW
YLQKPGQSPQLLIYQMSNLASGVPDRFSSSGSGTDFTLRISRVEAEDVGVYYCAQNLELP
LTFGAGTKLELKRGGGGSGGGGSGGGGSSQVQLKQSGPGLVQSSQSLSITCTVSGFSLTT
YAVHWVRQSPGKGLEWLGVIWSGGITDYNAAFISRLSITKDDSKSQVFFKMNSLQPNDT
AIYYCARNGGDNYPYYYAMDYWGQGTSVTVSSDQEPKSSDKTHTSPPSPAPELLGGPS
VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN
STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD
ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS
RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Human IgG1 hinge mutations 2H7
scFv-MTH (CSS) WTCH2CH3 (nucleotide sequence) (SEQ ID NO: 134)
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctctactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttta-
acccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagctggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaggagcccaaatcttgtg
acaaaactcacacatccccaccgtccccagcacctgaactcctggggggaccgtcagtcttcctcttcccccca-
aaacccaaggacaccct
catgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttca-
actggtacgtggacgg
cgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcc-
tcaccgtcctgcacc
aggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaca-
atctccaaagccaaa
gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcct-
gacctgcctggtca
aaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacg-
cctcccgtgctgga
ctccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttct-
catgctccgtgatgcatg
aggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga 2H7
scFv-MTH (CSS) WTCH2CH3 (amino acid sequence) (SEQ ID NO: 135)
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAELVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQEPKSCDKTHTSPPSPAPELLGGPSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK 2H7 scFv-MTH (SCS) WTCH2CH3
(nucleotide sequence) (SEQ ID NO: 136)
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagctggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaggagcccaaatcttctg
acaaaactcacacatgcccaccgtccccagcacctgaactcctggggggaccgtcagtcttcctcttcccccca-
aaacccaaggacaccct
catgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttca-
actggtacgtggacgg
cgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcc-
tcaccgtcctgcacc
aggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaca-
atctccaaagccaaa
gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcct-
gacctgcctggtca
aaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacg-
cctcccgtgctgga
ctccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttct-
catgctccgtgatgcatg
aggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga 2H7
scFv-MTH (SCS) WTCH2CH3 (amino acid sequence) (SEQ ID NO: 137)
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAELVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQEPKSSDKTHTCPPSPAPELLGGPSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK 2H7 scFv-MTH (SSC) WTCH2CH3
(nucleotide sequence) (SEQ ID NO: 138)
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagctggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaggagcccaaatcttctg
acaaaactcacacatccccaccgtgcccagcacctgaactcctggggggaccgtcagtcttcctcttcccccca-
aaacccaaggacaccct
catgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttca-
actggtacgtggacgg
cgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcc-
tcaccgtcctgcacc
aggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaca-
atctccaaagccaaa
gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcct-
gacctgcctggtca
aaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacg-
cctcccgtgctgga
ctccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttct-
catgctccgtgatgcatg
aggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga 2H7
scFv-MTH (SSC) WTCH2CH3 (amino acid sequence) (SEQ ID NO: 139)
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAELVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQEPKSSDKTHTSPPCPAPELLGGPSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK HIgGMHcys1 (nucleotide sequence) (SEQ
ID NO: 140) gtt gtt gat cag gag ccc aaa tct tct gac aaa act cac aca
tg HIgGMHcys2 (nucleotide sequence) (SEQ ID NO: 141) gtt gtt gat
cag gag ccc aaa tct tgt gac aaa act cac aca tct cca ccg tgc
HIgGMHcys3 (nucleotide sequence) (SEQ ID NO: 142) gtt gtt gat cag
gag ccc aaa tct tgt gac aaa act cac aca tgt cca ccg tcc cca gca cct
HuIgG1 MTCH3Y405 (nucleotide sequence) (SEQ ID NO: 143)
gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggaggagatgaccaagaaccaggtcagcct-
gacctgcctggtca
aaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacg-
cctcccgtgctgga
ctccgacggctccttctacctctatagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttct-
catgctccgtgatgcatg
aggctctgcacaaccactacacgcagaagagcctctccctgtccccgggtaaatga HuIgG1
MTCH3Y405 (amino acid sequence) (SEQ ID NO: 144)
GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD
SDGSFYLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK HuIgG1 MTCH3A405
(nucleotide sequence) (SEQ ID NO: 145)
gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggaggagatgaccaagaaccaggtcagcct-
gacctgcctggtca
aaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacg-
cctcccgtgctgga
ctccgacggctccttcgccctctatagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttct-
catgctccgtgatgcat
gaggctctgcacaaccactacacgcagaagagcctctccctgtccccgggtaaatga HuIgG1
MTCH3A405 (amino acid sequence) (SEQ ID NO: 146)
GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD
SDGSFALYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK HuIgG1 MTCH3A407
(nucleotide sequence) (SEQ ID NO: 147)
Gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggaggagatgaccaagaaccaggtcagcct-
gacctgcctggtc
aaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccac-
gcctcccgtgctgg
actccgacggctccttcttcctcgccagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttc-
tcatgctccgtgatgca
tgaggctctgcacaaccactacacgcagaagagcctctccctgtccccgggtaaatga HuIgG1
MTCH3A407 (amino acid sequence) (SEQ ID NO: 148)
GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD
SDGSFFLASKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK HuIgG1
MTCH3Y405A407 (nucleotide sequence) (SEQ ID NO: 149)
gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggaggagatgaccaagaaccaggtcagcct-
gacctgcctggtca
aaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacg-
cctcccgtgctgga
ctccgacggctccttctacctcgccagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttct-
catgctccgtgatgcat
gaggctctgcacaaccactacacgcagaagagcctctccctgtccccgggtaaatga HuIgG1
MTCH3Y405A407 (amino acid sequence) (SEQ ID NO: 150)
GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD
SDGSFYLASKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK HuIgG1
MTCH3A405A407 (nucleotide sequence) (SEQ ID NO: 151)
gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggaggagatgaccaagaaccaggtcagcct-
gacctgcctggtca
aaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacg-
cctcccgtgctgga
ctccgacggctccttcgccctcgccagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttct-
catgctccgtgatgca
tgaggctctgcacaaccactacacgcagaagagcctctccctgtccccgggtaaatga HuIgG1
MTCH3A405A407 (amino acid sequence) (SEQ ID NO: 152)
GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD
SDGSFALASKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 2H7 scFv MTH (SSS)
WTCH2MTCH3Y405 (nucleotide sequence) (SEQ ID NO: 153)
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagctggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaggagcccaaatcttctg
acaaaactcacacatccccaccgtccccagcacctgaactcctggggggaccgtcagtcttcctcttcccccca-
aaacccaaggacaccct
catgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttca-
actggtacgtggacgg
cgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcc-
tcaccgtcctgcacc
aggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaca-
atctccaaagccaaa
gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggaggagatgaccaagaaccaggtcagcct-
gacctgcctggtca
aaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacg-
cctcccgtgctgga
ctccgacggctccttctacctctatagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttct-
catgctccgtgatgcatg
aggctctgcacaaccactacacgcagaagagcctctccctgtccccgggtaaatgatctaga 2H7
scFv MTH (SSS) WTCH2MTCH3Y405 (amino acid sequence) (SEQ ID NO:
154) MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAELVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQEPKSSDKTHTSPPSPAPELLGGPSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFYLYSKLTVDKSRW
QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 2H7 scFv MTH (SSS) WTCH2MTCH3A405
(nucleotide sequence) (SEQ ID NO: 155)
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagctggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaggagcccaaatcttctg
acaaaactcacacatccccaccgtccccagcacctgaactcctggggggaccgtcagtcttcctcttcccccca-
aaacccaaggacaccct
catgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttca-
actggtacgtggacgg
cgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcc-
tcaccgtcctgcacc
aggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaca-
atctccaaagccaaa
gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggaggagatgaccaagaaccaggtcagcct-
gacctgcctggtca
aaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacg-
cctcccgtgctgga
ctccgacggctccttcgccctctatagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttct-
catgctccgtgatgcat
gaggctctgcacaaccactacacgcagaagagcctctccctgtccccgggtaaatga 2H7 scFv
MTH (SSS) WTCH2MTCH3A405 (nucleotide sequence) (SEQ ID NO: 156)
mdfqvqifsfllisasviiargqivlsqspailsaspgekvtmtcrasssvsymhwyqqkpgsspkpwiyapsn-
lasgyparfsgsgsg
tsysltisrveaedaatyycqqwsfnpptfgagtklelkdgggsggggsggggssqaylqqsgaelvrpgasvk-
msckasgytftsyn
mhwvkqtprqglewigaiypgngdtsynqkfkgkatltvdkssstaymqlssltsedsavyfcarvvyysnsyw-
yfdvwgtgttvtv
ssdqepkssdkthtsppspapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevh-
naktkpreeqyns
tyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgf-
ypsdiavewesngq
pennykttppvldsdgsfalyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk 2H7
scFv MTH (SSS) WTCH2MTCH3A407 (nucleotide sequence) (SEQ ID NO:
157)
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagctggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaggagcccaaatcttctg
acaaaactcacacatccccaccgtccccagcacctgaactcctggggggaccgtcagtcttcctcttcccccca-
aaacccaaggacaccct
catgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttca-
actggtacgtggacgg
cgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcc-
tcaccgtcctgcacc
aggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaca-
atctccaaagccaaa
gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggaggagatgaccaagaaccaggtcagcct-
gacctgcctggtca
aaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacg-
cctcccgtgctgga
ctccgacggctccttcttcctcgccagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttct-
catgctccgtgatgcat
gaggctctgcacaaccactacacgcagaagagcctctccctgtccccgggtaaatga 2H7 scFv
MTH (SSS) WTCH2MTCH3A407 (amino acid sequence) (SEQ ID NO: 158)
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAELVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQEPKSSDKTHTSPPSPAPELLGGPSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLASKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK 2H7 scFv MTH (SSS) WTCH2MTCH3Y405A407
(nucleotide sequence) (SEQ ID NO: 159)
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagctggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaggagcccaaatcttctg
acaaaactcacacatccccaccgtccccagcacctgaactcctggggggaccgtcagtcttcctcttcccccca-
aaacccaaggacaccct
catgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttca-
actggtacgtggacgg
cgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcc-
tcaccgtcctgcacc
aggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaca-
atctccaaagccaaa
gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggaggagatgaccaagaaccaggtcagcct-
gacctgcctggtca
aaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacg-
cctcccgtgctgga
ctccgacggctccttctacctcgccagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttct-
catgctccgtgatgcat
gaggctctgcacaaccactacacgcagaagagcctctccctgtccccgggtaaatga 2H7 scFv
MTH (SSS) WTCH2MTCH3Y405A407 (amino acid sequence) (SEQ ID NO: 160)
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAELVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQEPKSSDKTHTSPPSPAPELLGGPSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFYLASKLTVDKSRW
QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 2H7 scFv MTH (SSS)
WTCH2MTCH3A405A407 (nucleotide sequence) (SEQ ID NO: 161)
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagctggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaggagcccaaatcttctg
acaaaactcacacatccccaccgtccccagcacctgaactcctggggggaccgtcagtcttcctcttcccccca-
aaacccaaggacaccct
catgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttca-
actggtacgtggacgg
cgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcc-
tcaccgtcctgcacc
aggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaca-
atctccaaagccaaa
gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggaggagatgaccaagaaccaggtcagcct-
gacctgcctggtca
aaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacg-
cctcccgtgctgga
ctccgacggctccttcgccctcgccagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttct-
catgctccgtgatgca
tgaggctctgcacaaccactacacgcagaagagcctctccctgtccccgggtaaatga 2H7 scFv
MTH (SSS) WTCH2MTCH3A405A407 (amino acid sequence) (SEQ ID NO: 162)
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAELVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQEPKSSDKTHTSPPSPAPELLGGPSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFALASKLTVDKSRW
QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 2H7 scFv MTH (SCC) WTCH2CH3
(nucleotide sequence) (SEQ ID NO: 163)
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagctggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaggagcccaaatcttctg
acaaaactcacacatgcccaccgtgcccagcacctgaactcctggggggaccgtcagtcttcctcttcccccca-
aaacccaaggacaccct
catgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttca-
actggtacgtggacgg
cgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcc-
tcaccgtcctgcacc
aggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaca-
atctccaaagccaaa
gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcct-
gacctgcctggtca
aaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacg-
cctcccgtgctgga
ctccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttct-
catgctccgtgatgcatg
aggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga 2H7
scFv MTH (SCC) WTCH2CH3 (amino acid sequence) (SEQ ID NO: 164)
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAELVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQEPKSSDKTHTCPPCPAPELLGGPSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK 2H7 scFv MTH (CSC) WTCH2CH3
(nucleotide sequence) (SEQ ID NO: 165)
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagctggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaggagcccaaatcttgtg
acaaaactcacacatctccaccgtgcccagcacctgaactcctggggggaccgtcagtcttcctcttcccccca-
aaacccaaggacaccct
catgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttca-
actggtacgtggacgg
cgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcc-
tcaccgtcctgcacc
aggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaca-
atctccaaagccaaa
gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcct-
gacctgcctggtca
aaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacg-
cctcccgtgctgga
ctccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttct-
catgctccgtgatgcatg
aggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga 2H7
scFv MTH (CSC) WTCH2CH3 (amino acid sequence) (SEQ ID NO: 166)
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAELVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQEPKSCDKTHTSPPCPAPELLGGPSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK 2H7 scFv MTH (CCS) WTCH2CH3
(nucleotide sequence) (SEQ ID NO: 167)
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagctggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaggagcccaaatcttgtg
acaaaactcacacatgtccaccgtccccagcacctgaactcctggggggaccgtcagtcttcctcttcccccca-
aaacccaaggacaccct
catgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttca-
actggtacgtggacgg
cgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcc-
tcaccgtcctgcacc
aggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaca-
atctccaaagccaaa
gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcct-
gacctgcctggtca
aaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacg-
cctcccgtgctgga
ctccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttct-
catgctccgtgatgcatg
aggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga 2H7
scFv MTH (CCS) WTCH2CH3 (amino acid sequence) (SEQ ID NO: 168)
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAELVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQEPKSCDKTHTCPPSPAPELLGGPSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK HuIgAHIgA-T4-ORF (nucleotide
sequence) (SEQ ID NO: 169)
tgatcagccagttccctcaactccacctaccccatctccctcaactccacctaccccatctccctcatgctgcc-
acccccgactgtcactgcac
cgaccggccctcgaggacctgctcttaggttcagaagcgatcctcacgtgcacactgaccggcctgagagatgc-
ctcaggtgtcaccttca
cctggacgccctcaagtgggaagagcgctgttcaaggaccacctgaccgtgacctctgtggctgctacagcgtg-
tccagtgtcctgccgg
gctgtgccgagccatggaaccatgggaagaccttcacttgcactgctgcctaccccgagtccaagaccccgcta-
accgccaccctctcaaa
atccggaaacacattccggcccgaggtccacctgctgccgccgccgtcggaggagctggccctgaacgagctgg-
tgacgctgacgtgcc
tggcacgtggcttcagccccaaggatgtgctggttcgctggctgcaggggtcacaggagctgccccgcgagaag-
tacctgacttgggcat
cccggcaggagcccagccagggcaccaccaccttcgctgtgaccagcatactgcgcgtggcagccgaggactgg-
aagaagggggaca
ccttctcctgcatggtgggccacgaggccctgccgctggccttcacacagaagaccatcgaccgcttggcgggt-
aaacccacccatgtca atgtgtctgttgtcatggcggaggtggacgcggatccttcgaac
HuIgAHIgA-T4-ORF (amino acid sequence) (SEQ ID NO: 170)
DQPVPSTPPTPSPSTPPTPSPSCCHPRLSLHRPALEDLLLGSEAILTCTLTGLRDASGVTFT
WTPSSGKSAVQGPPDRDLCGCYSVSSVLPGCAEPWNHGKTFTCTAAYPESKTPLTATLS
KSGNTFRPEVHLLPPPSEELALNELVTLTCLARGFSPKDVLVRWLQGSQELPREKYLTW
ASRQEPSQGTTTFAVTSILRVAAEDWKKGDTFSCMVGHEALPLAFTQKTIDRLAGKPTH
VNVSVVMAEVDADPSN 1D8-IgAH IgA-T4-CD80 (nucleotide sequence) (SEQ ID
NO: 171)
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcactcagtctc
caacaaccatagctgcatctccaggggagaaggtcaccatcacctgccgtgccagctccagtgtaagttacatg-
tactggtaccagcagaa
gtcaggcgcctcccctaaactctggatttatgacacatccaagctggcttctggagttccaaatcgcttcagtg-
gcagtgggtctgggacctct
tattctctcgcaatcaacaccatggagactgaagatgctgccacttattactgtcagcagtggagtagtactcc-
gctcacgttcgggtctggga
ccaagctggagatcaaacggggtggcggtggctcgggcggtggtgggtcgggtggcggcggatctcaggtgcag-
ctgaaggaggcag
gacctggcctggtgcaaccgacacagaccctgtccctcacatgcactgtctctgggttctcattaaccagcgat-
ggtgtacactggattcgac
agcctccaggaaagggtctggaatggatgggaataatatattatgatggaggcacagattataattcagcaatt-
aaatccagactgagcatca
gcagggacacctccaagagccaagttttcttaaaaatcaacagtctgcaaactgatgacacagccatgtattac-
tgtgccagaatccactttg
attactggggccaaggagtcatggtcacagtctcctctgatcagccagttccctcaactccacctaccccatct-
ccctcaactccacctacccc
atctccctcatgctgccacccccgactgtcactgcaccgaccggccctcgaggacctgctcttaggttcagaag-
cgatcctcacgtgcacac
tgaccggcctgagagatgcctcaggtgtcaccttcacctggacgccctcaagtgggaagagcgctgttcaagga-
ccacctgaccgtgacc
tctgtggctgctacagcgtgtccagtgtcctgccgggctgtgccgagccatggaaccatgggaagaccttcact-
tgcactgctgcctacccc
gagtccaagaccccgctaaccgccaccctctcaaaatccggaaacacattccggcccgaggtccacctgctgcc-
gccgccgtcggagga
gctggccctgaacgagctggtgacgctgacgtgcctggcacgtggcttcagccccaaggatgtgctggttcgct-
ggctgcaggggtcaca
ggagctgccccgcgagaagtacctgacttgggcatcccggcaggagcccagccagggcaccaccaccttcgctg-
tgaccagcatactgc
gcgtggcagccgaggactggaagaagggggacaccttctcctgcatggtgggccacgaggccctgccgctggcc-
ttcacacagaagac
catcgaccgcttggcgggtaaacccacccatgtcaatgtgtctgttgtcatggcggaggtggacgcggatcctt-
cgaacaacctgctcccat
cctgggccattaccttaatctcagtaaatggaatttttgtgatatgctgcctgacctactgctttgccccaaga-
tgcagagagagaaggaggaa tgagagattgagaagggaaagtgtacgccctgtataaatcgatac
AA 1D8 scFv IgAH IgA-T4-CD80 (amino acid sequence) (SEQ ID NO: 172)
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPTTIAASPGEKVTITCRASSSVSYMYWYQQK
SGASPKLWIYDTSKLASGVPNRFSGSGSGTSYSLAINTMETEDAATYYCQQWSSTPLTFG
SGTKLEIKRGGGGSGGGGSGGGGSQVQLKEAGPGLVQPTQTLSLTCTVSGFSLTSDGVH
WIRQPPGKGLEWMGIIYYDGGTDYNSAIKSRLSISRDTSKSQVFLKINSLQTDDTAMYYC
ARIHFDYWGQGVMVTVSSDQPVPSTPPTPSPSTPPTPSPSCCHPRLSLHRPALEDLLLGSE
AILTCTLTGLRDASGVTFTWTPSSGKSAVQGPPDRDLCGCYSVSSVLPGCAEPWNHGKT
FTCTAAYPESKTPLTATLSKSGNTFRPEVHLLPPPSEELALNELVTLTCLARGFSPKDVLV
RWLQGSQELPREKYLTWASRQEPSQGTTTFAVTSILRVAAEDWKKGDTFSCMVGHEAL
PLAFTQKTIDRLAGKPTHVNVSVVMAEVDADPSNNLLPSWAITLISVNGIFVICCLTYCF
APRCRERRRNERLRRESVRPV human IgE Fc (CH2--CH3--CH4) ORF (nucleotide
sequence) (SEQ ID NO: 173)
tgatcacgtctgctccagggacttcaccccgcccaccgtgaagatcttacagtcgtcctgcgacggcggcgggc-
acttccccccgaccatc
cagctcctgtgcctcgtctctgggtacaccccagggactatcaacatcacctggctggaggacgggcaggtcat-
ggacgtggacttgtcca
ccgcctctaccacgcaggagggtgagctggcctccacacaaagcgagctcaccctcagccagaagcactggctg-
tcagaccgcacctac
acctgccaggtcacctatcaaggtcacacctttgaggacagcaccaagaagtgtgcagattccaacccgagagg-
ggtgagcgcctaccta
agccggcccagcccgttcgacctgttcatccgcaagtcgcccacgatcacctgtctggtggtggacctggcacc-
cagcaaggggaccgtg
aacctgacctggtcccgggccagtgggaagcctgtgaaccactccaccagaaaggaggagaagcagcgcaatgg-
cacgttaaccgtca
cgtccaccctgccggtgggcacccgagactggatcgagggggagacctaccagtgcagggtgacccacccccac-
ctgcccagggccct
catgcggtccacgaccaagaccagcggcccgcgtgctgccccggaagtctatgcgtttgcgacgccggagtggc-
cggggagccggga
caagcgcaccctcgcctgcctgatccagaacttcatgcctgaggacatctcggtgcagtggctgcacaacgagg-
tgcagctcccggacgc
ccggcacagcacgacgcagccccgcaagaccaagggctccggcttcttcgtcttcagccgcctggaggtgacca-
gggccgaatgggag
cagaaagatgagttcatctgccgtgcagtccatgaggcagcgagcccctcacagaccgtccagcgagcggtgtc-
tgtaaatcccggtaaa gcggatccttcgaa AA human IgE Fc (CH2--CH3--CH4) ORF
(amino acid sequence) (SEQ ID NO: 174)
DHVCSRDFTPPTVKILQSSCDGGGHFPPTIQLLCLVSGYTPGTINITWLEDGQVMDVDLS
TASTTQEGELASTQSELTLSQKHWLSDRTYTCQVTYQGHTFEDSTKKCADSNPRGVSAY
LSRPSPFDLFIRKSPTITCLVVDLAPSKGTVNLTWSRASGKPVNHSTRKEEKQRNGTLTV
TSTLPVGTRDWIEGETYQCRVTHPHLPRALMRSTTKTSGPRAAPEVYAFATPEWPGSRD
KRTLACLIQNFMPEDISVQWLHNEVQLPDARHSTTQPRKTKGSGFFVFSRLEVTRAEWE
QKDEFICRAVHEAASPSQTVQRAVSVNPGKADPS 1D8 scFv-human IgE Fc
(CH2--CH3--CH4)-CD80 (nucleotide sequence) (SEQ ID NO: 175)
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcactcagtctc
caacaaccatagctgcatctccaggggagaaggtcaccatcacctgccgtgccagctccagtgtaagttacatg-
tactggtaccagcagaa
gtcaggcgcctcccctaaactctggatttatgacacatccaagctggcttctggagttccaaatcgcttcagtg-
gcagtgggtctgggacctct
tattctctcgcaatcaacaccatggagactgaagatgctgccacttattactgtcagcagtggagtagtactcc-
gctcacgttcgggtctggga
ccaagctggagatcaaacggggtggcggtggctcgggcggtggtgggtcgggtggcggcggatctcaggtgcag-
ctgaaggaggcag
gacctggcctggtgcaaccgacacagaccctgtccctcacatgcactgtctctgggttctcattaaccagcgat-
ggtgtacactggattcgac
agcctccaggaaagggtctggaatggatgggaataatatattatgatggaggcacagattataattcagcaatt-
aaatccagactgagcatca
gcagggacacctccaagagccaagttttcttaaaaatcaacagtctgcaaactgatgacacagccatgtattac-
tgtgccagaatccactttg
attactggggccaaggagtcatggtcacagtctcctctgatcacgtctgctccagggacttcaccccgcccacc-
gtgaagatcttacagtcgt
cctgcgacggcggcgggcacttccccccgaccatccagctcctgtgcctcgtctctgggtacaccccagggact-
atcaacatcacctggct
ggaggacgggcaggtcatggacgtggacttgtccaccgcctctaccacgcaggagggtgagctggcctccacac-
aaagcgagctcacc
ctcagccagaagcactggctgtcagaccgcacctacacctgccaggtcacctatcaaggtcacacctttgagga-
cagcaccaagaagtgt
gcagattccaacccgagaggggtgagcgcctacctaagccggcccagcccgttcgacctgttcatccgcaagtc-
gcccacgatcacctgt
ctggtggtggacctggcacccagcaaggggaccgtgaacctgacctggtcccgggccagtgggaagcctgtgaa-
ccactccaccagaa
aggaggagaagcagcgcaatggcacgttaaccgtcacgtccaccctgccggtgggcacccgagactggatcgag-
ggggagacctacc
agtgcagggtgacccacccccacctgcccagggccctcatgcggtccacgaccaagaccagcggcccgcgtgct-
gccccggaagtcta
tgcgtttgcgacgccggagtggccggggagccgggacaagcgcaccctcgcctgcctgatccagaacttcatgc-
ctgaggacatctcggt
gcagtggctgcacaacgaggtgcagctcccggacgcccggcacagcacgacgcagccccgcaagaccaagggct-
ccggcttcttcgtc
ttcagccgcctggaggtgaccagggccgaatgggagcagaaagatgagttcatctgccgtgcagtccatgaggc-
agcgagcccctcaca
gaccgtccagcgagcggtgtctgtaaatcccggtaaagcggatccttcgaagctcccatcctgggccattacct-
taatctcagtaaatggaat
ttttgtgatatgctgcctgacctactgctttgccccaagatgcagagagagaaggaggaatgagagattgagaa-
gggaaagtgtacgccctg tataaatcgata 1D8-scFv-human IgE Fc
(CH2--CH3--CH4)-CD80 (amino acid sequence) (SEQ ID NO: 176)
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPTTIAASPGEKVTITCRASSSVSYMYWYQQK
SGASPKLWIYDTSKLASGVPNRFSGSGSGTSYSLAINTMETEDAATYYCQQWSSTPLTFG
SGTKLEIKRGGGGSGGGGSGGGGSQVQLKEAGPGLVQPTQTLSLTCTVSGFSLTSDGVH
WIRQPPGKGLEWMGIIYYDGGTDYNSAIKSRLSISRDTSKSQVFLKINSLQTDDTAMYYC
ARIHFDYWGQGVMVTVSSDHVCSRDFTPPTVKILQSSCDGGGHFPPTIQLLCLVSGYTPG
TINITWLEDGQVMDVDLSTASTTQEGELASTQSELTLSQKHWLSDRTYTCQVTYQGHTF
EDSTKKCADSNPRGVSAYLSRPSPFDLFIRKSPTITCLVVDLAPSKGTVNLTWSRASGKP
VNHSTRKEEKQRNGTLTVTSTLPVGTRDWIEGETYQCRVTHPHLPRALMRSTTKTSGPR
AAPEVYAFATPEWPGSRDKRTLACLIQNFMPEDISVQWLHNEVQLPDARHSTTQPRKTK
GSGFFVFSRLEVTRAEWEQKDEFICRAVHEAASPSQTVQRAVSVNPGKADPSKLPSWAI
TLISVNGIFVICCLTYCFAPRCRERRRNERLRRESVRPV 5B9-IgAH IgA-T4-CD80
(nucleotide sequence) (SEQ ID NO: 177)
aagcttgccgccatgaggttctctgctcagcttctggggctgcttgtgctctggatccctggatccactgcaga-
tattgtgatgacgcaggctg
cattctccaatccagtcactcttggaacatcagcttccatctcctgcaggtctagtaagagtctcctacatagt-
aatggcatcacttatttgtattg
gtatctgcagaagccaggccagtctcctcagctcctgatttatcagatgtccaaccttgcctcaggagtcccag-
acaggttcagtagcagtgg
gtcaggaactgatttcacactgagaatcagcagagtggaggctgaggatgtgggtgtttattactgtgctcaaa-
atctagaacttccgctcac
gttcggtgctgggaccaagctggagctgaaacggggtggcggtggctcgggcggtggtgggtcgggtggcggcg-
gatcgtcacaggtg
cagctgaagcagtcaggacctggcctagtgcagtcctcacagagcctgtccatcacctgcacagtctctggttt-
ctcattaactacctatgctg
tacactgggttcgccagtctccaggaaagggtctggagtggctgggagtgatatggagtggtggaatcacagac-
tataatgcagctttcatat
ccagactgagcatcaccaaggacgattccaagagccaagttttctttaaaatgaacagtctgcaacctaatgac-
acagccatttattactgtgc
cagaaatgggggtgataactacccttattactatgctatggactactggggtcaaggaacctcagtcaccgtct-
cctctgatcagccagttccc
tcaactccacctaccccatctccctcaactccacctaccccatctccctcatgctgccacccccgactgtcact-
gcaccgaccggccctcga
ggacctgctcttaggttcagaagcgatcctcacgtgcacactgaccggcctgagagatgcctcaggtgtcacct-
tcacctggacgccctcaa
gtgggaagagcgctgttcaaggaccacctgaccgtgacctctgtggctgctacagcgtgtccagtgtcctgccg-
ggctgtgccgagccatg
gaaccatgggaagaccttcacttgcactgctgcctaccccgagtccaagaccccgctaaccgccaccctctcaa-
aatccggaaacacattc
cggcccgaggtccacctgctgccgccgccgtcggaggagctggccctgaacgagctggtgacgctgacgtgcct-
ggcacgtggcttca
gccccaaggatgtgctggttcgctggctgcaggggtcacaggagctgccccgcgagaagtacctgacttgggca-
tcccggcaggagccc
agccagggcaccaccaccttcgctgtgaccagcatactgcgcgtggcagccgaggactggaagaagggggacac-
cttctcctgcatggt
gggccacgaggccctgccgctggccttcacacagaagaccatcgaccgcttggcgggtaaacccacccatgtca-
atgtgtctgttgtcatg
gcggaggtggacgcggatccttcgaacaacctgctcccatcctgggccattaccttaatctcagtaaatggaat-
ttttgtgatatgctgcctga
cctactgctttgccccaagatgcagagagagaaggaggaatgagagattgagaagggaaagtgtacgccctgta-
taaatcgatac 5B9-IgAH IgA-T4-CD80 (amino acid sequence) (SEQ ID NO:
178) MRFSAQLLGLLVLWIPGSTADIVMTQAAFSNPVTLGTSASISCRSSKSLLHSNGITYLYW
YLQKPGQSPQLLIYQMSNLASGVPDRFSSSGSGTDFTLRISRVEAEDVGVYYCAQNLELP
LTFGAGTKLELKRGGGGSGGGGSGGGGSSQVQLKQSGPGLVQSSQSLSITCTVSGFSLTT
YAVHWVRQSPGKGLEWLGVIWSGGITDYNAAFISRLSITKDDSKSQVFFKMNSLQPNDT
AIYYCARNGGDNYPYYYAMDYWGQGTSVTVSSDQPVPSTPPTPSPSTPPTPSPSCCHPRL
SLHRPALEDLLLGSEAILTCTLTGLRDASGVTFTWTPSSGKSAVQGPPDRDLCGCYSVSS
VLPGCAEPWNHGKTFTCTAAYPESKTPLTATLSKSGNTFRPEVHLLPPPSEELALNELVT
LTCLARGFSPKDVLVRWLQGSQELPREKYLTWASRQEPSQGTTTFAVTSILRVAAEDWK
KGDTFSCMVGHEALPLAFTQKTIDRLAGKPTHVNVSVVMAEVDADPSNNLLPSWAITLI
SVNGIFVICCLTYCFAPRCRERRRNERLRRESVRPV 5B9-scFv-human IgE Fc
(CH2--CH3--CH4)-CD80 (nucleotide sequence) (SEQ ID NO: 179)
aagcttgccgccatgaggttctctgctcagcttctggggctgcttgtgctctggatccctggatccactgcaga-
tattgtgatgacgcaggctg
cattctccaatccagtcactcttggaacatcagcttccatctcctgcaggtctagtaagagtctcctacatagt-
aatggcatcacttatttgtattg
gtatctgcagaagccaggccagtctcctcagctcctgatttatcagatgtccaaccttgcctcaggagtcccag-
acaggttcagtagcagtgg
gtcaggaactgatttcacactgagaatcagcagagtggaggctgaggatgtgggtgtttattactgtgctcaaa-
atctagaacttccgctcac
gttcggtgctgggaccaagctggagctgaaacggggtggcggtggctcgggcggtggtgggtcgggtggcggcg-
gatcgtcacaggtg
cagctgaagcagtcaggacctggcctagtgcagtcctcacagagcctgtccatcacctgcacagtctctggttt-
ctcattaactacctatgctg
tacactgggttcgccagtctccaggaaagggtctggagtggctgggagtgatatggagtggtggaatcacagac-
tataatgcagctttcatat
ccagactgagcatcaccaaggacgattccaagagccaagttttctttaaaatgaacagtctgcaacctaatgac-
acagccatttattactgtgc
cagaaatgggggtgataactacccttattactatgctatggactactggggtcaaggaacctcagtcaccgtct-
cctctgatcacgtctgctcc
agggacttcaccccgcccaccgtgaagatcttacagtcgtcctgcgacggcggcgggcacttccccccgaccat-
ccagctcctgtgcctc
gtctctgggtacaccccagggactatcaacatcacctggctggaggacgggcaggtcatggacgtggacttgtc-
caccgcctctaccacg
caggagggtgagctggcctccacacaaagcgagctcaccctcagccagaagcactggctgtcagaccgcaccta-
cacctgccaggtcac
ctatcaaggtcacacctttgaggacagcaccaagaagtgtgcagattccaacccgagaggggtgagcgcctacc-
taagccggcccagcc
cgttcgacctgttcatccgcaagtcgcccacgatcacctgtctggtggtggacctggcacccagcaaggggacc-
gtgaacctgacctggtc
ccgggccagtgggaagcctgtgaaccactccaccagaaaggaggagaagcagcgcaatggcacgttaaccgtca-
cgtccaccctgccg
gtgggcacccgagactggatcgagggggagacctaccagtgcagggtgacccacccccacctgcccagggccct-
catgcggtccacg
accaagaccagcggcccgcgtgctgccccggaagtctatgcgtttgcgacgccggagtggccggggagccggga-
caagcgcaccctc
gcctgcctgatccagaacttcatgcctgaggacatctcggtgcagtggctgcacaacgaggtgcagctcccgga-
cgcccggcacagcac
gacgcagccccgcaagaccaagggctccggcttcttcgtcttcagccgcctggaggtgaccagggccgaatggg-
agcagaaagatgag
ttcatctgccgtgcagtccatgaggcagcgagcccctcacagaccgtccagcgagcggtgtctgtaaatcccgg-
taaagcggatccttcga
agctcccatcctgggccattaccttaatctcagtaaatggaatttttgtgatatgctgcctgacctactgcttt-
gccccaagatgcagagagaga
aggaggaatgagagattgagaagggaaagtgtacgccctgtataaatcgata 5B9-scFv-human
IgE Fc (CH2--CH3--CH4)-CD80 (amino acid sequence) (SEQ ID NO: 180)
MRFSAQLLGLLVLWIPGSTADIVMTQAAFSNPVTLGTSASISCRSSKSLLHSNGITYLYW
YLQKPGQSPQLLIYQMSNLASGVPDRFSSSGSGTDFTLRISRVEAEDVGVYYCAQNLELP
LTFGAGTKLELKRGGGGSGGGGSGGGGSSQVQLKQSGPGLVQSSQSLSITCTVSGFSLTT
YAVHWVRQSPGKGLEWLGVIWSGGITDYNAAFISRLSITKDDSKSQVFFKMNSLQPNDT
AIYYCARNGGDNYPYYYAMDYWGQGTSVTVSSDHVCSRDFTPPTVKILQSSCDGGGHF
PPTIQLLCLVSGYTPGTINITWLEDGQVMDVDLSTASTTQEGELASTQSELTLSQKHWLS
DRTYTCQVTYQGHTFEDSTKKCADSNPRGVSAYLSRPSPFDLFIRKSPTITCLVVDLAPS
KGTVNLTWSRASGKPVNHSTRKEEKQRNGTLTVTSTLPVGTRDWIEGETYQCRVTHPH
LPRALMRSTTKTSGPRAAPEVYAFATPEWPGSRDKRTLACLIQNFMPEDISVQWLHNEV
QLPDARHSTTQPRKTKGSGFFVFSRLEVTRAEWEQKDEFICRAVHEAASPSQTVQRAVS
VNPGKADPSKLPSWAITLISVNGIFVICCLTYCFAPRCRERRRNERLRRESVRPV
2e12-scFv-IgAH IgA-T4-CD80 (nucleotide sequence) (SEQ ID NO: 181)
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcacccaatctc
cagcttctttggctgtgtctctaggtcagagagccaccatctcctgcagagccagtgaaagtgttgaatattat-
gtcacaagtttaatgcagtgg
taccaacagaaaccaggacagccacccaaactcctcatctctgctgcatccaacgtagaatctggggtccctgc-
caggtttagtggcagtg
ggtctgggacagacttcagcctcaacatccatcctgtggaggaggatgatattgcaatgtatttctgtcagcaa-
agtaggaaggttccttgga
cgttcggtggaggcaccaagctggaaatcaaacggggtggcggtggctcgggcggaggtgggtcgggtggcggc-
ggatctcaggtgc
agctgaaggagtcaggacctggcctggtggcgccctcacagagcctgtccatcacatgcaccgtctcagggttc-
tcattaaccggctatggt
gtaaactgggttcgccagcctccaggaaagggtctggagtggctgggaatgatatggggtgatggaagcacaga-
ctataattcagctctca
aatccagactgagcatcaccaaggacaactccaagagccaagttttcttaaaaatgaacagtctgcaaactgat-
gacacagccagatactac
tgtgccagagatggttatagtaactttcattactatgttatggactactggggtcaaggaacctcagtcaccgt-
ctcctcagatcagccagttcc
ctcaactccacctaccccatctccctcaactccacctaccccatctccctcatgctgccacccccgactgtcac-
tgcaccgaccggccctcga
ggacctgctcttaggttcagaagcgatcctcacgtgcacactgaccggcctgagagatgcctcaggtgtcacct-
tcacctggacgccctcaa
gtgggaagagcgctgttcaaggaccacctgaccgtgacctctgtggctgctacagcgtgtccagtgtcctgccg-
ggctgtgccgagccatg
gaaccatgggaagaccttcacttgcactgctgcctaccccgagtccaagaccccgctaaccgccaccctctcaa-
aatccggaaacacattc
cggcccgaggtccacctgctgccgccgccgtcggaggagctggccctgaacgagctggtgacgctgacgtgcct-
ggcacgtggcttca
gccccaaggatgtgctggttcgctggctgcaggggtcacaggagctgccccgcgagaagtacctgacttgggca-
tcccggcaggagccc
agccagggcaccaccaccttcgctgtgaccagcatactgcgcgtggcagccgaggactggaagaagggggacac-
cttctcctgcatggt
gggccacgaggccctgccgctggccttcacacagaagaccatcgaccgcttggcgggtaaacccacccatgtca-
atgtgtctgttgtcatg
gcggaggtggacgcggatccttcgaacaacctgctcccatcctgggccattaccttaatctcagtaaatggaat-
ttttgtgatatgctgcctga
cctactgctttgccccaagatgcagagagagaaggaggaatgagagattgagaagggaaagtgtacgccctgta-
taaatcgatac 2e12-scFv-IgAH IgA-T4-CD80 (amino acid sequence) (SEQ
ID NO: 182)
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPASLAVSLGQRATISCRASESVEYYVTSLMQ
WYQQKPGQPPKLLISAASNVESGVPARFSGSGSGTDFSLNIHPVEEDDIAMYFCQQSRKV
PWTFGGGTKLEIKRGGGGSGGGGSGGGGSQVQLKESGPGLVAPSQSLSITCTVSGFSLT
GYGVNWVRQPPGKGLEWLGMIWGDGSTDYNSALKSRLSITKDNSKSQVFLKMNSLQT
DDTARYYCARDGYSNFHYYVMDYWGQGTSVTVSSDQPVPSTPPTPSPSTPPTPSPSCCH
PRLSLHRPALEDLLLGSEAILTCTLTGLRDASGVTFTWTPSSGKSAVQGPPDRDLCGCYS
VSSVLPGCAEPWNHGKTFTCTAAYPESKTPLTATLSKSGNTFRPEVHLLPPPSEELALNE
LVTLTCLARGFSPKDVLVRWLQGSQELPREKYLTWASRQEPSQGTTTFAVTSILRVAAE
DWKKGDTFSCMVGHEALPLAFTQKTIDRLAGKPTHVNVSVVMAEVDADPSNNLLPSW
AITLISVNGIFVICCLTYCFAPRCRERRRNERLRRESVRPV 2e12-scFv-human IgE Fc
(CH2--CH3--CH4)-CD80 (nucleotide sequence) (SEQ ID NO: 183)
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcacccaatctc
cagcttctttggctgtgtctctaggtcagagagccaccatctcctgcagagccagtgaaagtgttgaatattat-
gtcacaagtttaatgcagtgg
taccaacagaaaccaggacagccacccaaactcctcatctctgctgcatccaacgtagaatctggggtccctgc-
caggtttagtggcagtg
ggtctgggacagacttcagcctcaacatccatcctgtggaggaggatgatattgcaatgtatttctgtcagcaa-
agtaggaaggttccttgga
cgttcggtggaggcaccaagctggaaatcaaacggggtggcggtggctcgggcggaggtgggtcgggtggcggc-
ggatctcaggtgc
agctgaaggagtcaggacctggcctggtggcgccctcacagagcctgtccatcacatgcaccgtctcagggttc-
tcattaaccggctatggt
gtaaactgggttcgccagcctccaggaaagggtctggagtggctgggaatgatatggggtgatggaagcacaga-
ctataattcagctctca
aatccagactgagcatcaccaaggacaactccaagagccaagttttcttaaaaatgaacagtctgcaaactgat-
gacacagccagatactac
tgtgccagagatggttatagtaactttcattactatgttatggactactggggtcaaggaacctcagtcaccgt-
ctcctcagatcacgtctgctcc
agggacttcaccccgcccaccgtgaagatcttacagtcgtcctgcgacggcggcgggcacttccccccgaccat-
ccagctcctgtgcctc
gtctctgggtacaccccagggactatcaacatcacctggctggaggacgggcaggtcatggacgtggacttgtc-
caccgcctctaccacg
caggagggtgagctggcctccacacaaagcgagctcaccctcagccagaagcactggctgtcagaccgcaccta-
cacctgccaggtcac
ctatcaaggtcacacctttgaggacagcaccaagaagtgtgcagattccaacccgagaggggtgagcgcctacc-
taagccggcccagcc
cgttcgacctgttcatccgcaagtcgcccacgatcacctgtctggtggtggacctggcacccagcaaggggacc-
gtgaacctgacctggtc
ccgggccagtgggaagcctgtgaaccactccaccagaaaggaggagaagcagcgcaatggcacgttaaccgtca-
cgtccaccctgccg
gtgggcacccgagactggatcgagggggagacctaccagtgcagggtgacccacccccacctgcccagggccct-
catgcggtccacg
accaagaccagcggcccgcgtgctgccccggaagtctatgcgtttgcgacgccggagtggccggggagccggga-
caagcgcaccctc
gcctgcctgatccagaacttcatgcctgaggacatctcggtgcagtggctgcacaacgaggtgcagctcccgga-
cgcccggcacagcac
gacgcagccccgcaagaccaagggctccggcttcttcgtcttcagccgcctggaggtgaccagggccgaatggg-
agcagaaagatgag
ttcatctgccgtgcagtccatgaggcagcgagcccctcacagaccgtccagcgagcggtgtctgtaaatcccgg-
taaagcggatccttcga
agctcccatcctgggccattaccttaatctcagtaaatggaatttttgtgatatgctgcctgacctactgcttt-
gccccaagatgcagagagaga
aggaggaatgagagattgagaagggaaagtgtacgccctgtataaatcgata
2e12-scFv-human IgE Fc (CH2--CH3--CH4)-CD80 (amino acid sequence)
(SEQ ID NO: 184)
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPASLAVSLGQRATISCRASESVEYYVTSLMQ
WYQQKPGQPPKLLISAASNVESGVPARFSGSGSGTDFSLNIHPVEEDDIAMYFCQQSRKV
PWTFGGGTKLEIKRGGGGSGGGGSGGGGSQVQLKESGPGLVAPSQSLSITCTVSGFSLT
GYGVNWVRQPPGKGLEWLGMIWGDGSTDYNSALKSRLSITKDNSKSQVFLKMNSLQT
DDTARYYCARDGYSNFHYYVMDYWGQGTSVTVSSDHVCSRDFTPPTVKILQSSCDGG
GHFPPTIQLLCLVSGYTPGTINITWLEDGQVMDVDLSTASTTQEGELASTQSELTLSQKH
WLSDRTYTCQVTYQGHTFEDSTKKCADSNPRGVSAYLSRPSPFDLFIRKSPTITCLVVDL
APSKGTVNLTWSRASGKPVNHSTRKEEKQRNGTLTVTSTLPVGTRDWIEGETYQCRVT
HPHLPRALMRSTTKTSGPRAAPEVYAFATPEWPGSRDKRTLACLIQNFMPEDISVQWLH
NEVQLPDARHSTTQPRKTKGSGFFVFSRLEVTRAEWEQKDEFICRAVHEAASPSQTVQR
AVSVNPGKADPSKLPSWAITLISVNGIFVICCLTYCFAPRCRERRRNERLRRESVRPV 500A2
scFv (nucleotide sequence) (SEQ ID NO: 185)
atgttgtatacatctcagctccttgggcttttactcttctggatttcagcctccagaagtgacatagtgctgac-
tcagactccagccactctgtctc
taattcctggagaaagagtcacaatgacctgtaagaccagtcagaatattggcacaatcttacactggtatcac-
caaaaaccaaaggaggct
ccaagggctctcatcaagtatgcttcgcagtccattcctgggatcccctccagattcagtggcagtggttcgga-
aacagatttcactctcagca
tcaataacctggagcctgatgatatcggaatttattactgtcaacaaagtagaagctggcctgtcacgttcggt-
cctggcaccaagctggaga
taaaacggggtggcggtggctcgggcggaggtgggtcgggtggcggcggatctcaggtcaagctgcagcagtcc-
ggttctgaactagg
gaaacctggggcctcagtgaaactgtcctgcaagacttcaggctacatattcacagatcactatatttcttggg-
tgaaacagaagcctggaga
aagcctgcagtggataggaaatgtttatggtggaaatggtggtacaagctacaatcaaaaattccagggcaagg-
ccacactgactgtagata
aaatctctagcacagcctacatggaactcagcagcctgacatctgaggattctgccatctattactgtgcaaga-
aggccggtagcgacgggc
catgctatggactactggggtcaggggatccaagttaccgtctcctctgatc 500A2 scFv
(amino acid sequence) (SEQ ID NO: 186)
MLYTSQLLGLLLFWISASRSDIVLTQTPATLSLIPGERVTMTCKTSQNIGTILHWYHQKPK
EAPRALIKYASQSIPGIPSRFSGSGSETDFTLSINNLEPDDIGIYYCQQSRSWPVTFGPGTKL
EIKRGGGGSGGGGSGGGGSQVKLQQSGSELGKPGASVKLSCKTSGYIFTDHYISWVKQK
PGESLQWIGNVYGGNGGTSYNQKFQGKATLTVDKISSTAYMELSSLTSEDSAIYYCARR
PVATGHAMDYWGQGIQVTVSSD NT 5' oligo: Name: IgGWT3 (SEQ ID NO: 187)
GTTGTTTTCGAAGGATCCGCTTTACCCGGAGACAGGGAGAGGCTCTT NT 3' oligo: Name:
hIgGWT5 (SEQ ID NO: 188)
GTTGTTAGATCTGGAGCCCAAATCTTGTGACAAAACTCACACATG NT 5' oligo: Name:
FADD5 (SEQ ID NO: 189) Sequence:
GTTGTGGATCCTTCGAACCCGTTCCTGGTGCTGCTGCACTCGGTGTCG NT 3' oligo: Name:
FADD3 (SEQ ID NO: 190) Sequence:
GTTGTTATCGATCTCGAGTTATCAGGACGCTTCGGAGGTAGATGCGTC NT FADD-CSSCFV
(nucleotide sequence) (SEQ ID NO: 191)
gtggatccttcgaacccgttcctggtgctgctgcactcggtgtcgtccagcctgtcgagcagcgagctgaccga-
gctcaagttcctatgcctc
gggcgcgtgggcaagcgcaagctggagcgcgtgcagagcggcctagacctcttctccatgctgctggagcagaa-
cgacctggagcccg
ggcacaccgagctcctgcgcgagctgctcgcctccctgcggcgccacgacctgctgcggcgcgtcgacgacttc-
gaggcgggggcgg
cggccggggccgcgcctggggaagaagacctgtgtgcagcatttaacgtcatatgtgataatgtggggaaagat-
tggagaaggctggctc
gtcagctcaaagtctcagacaccaagatcgacagcatcgaggacagatacccccgcaacctgacagagcgtgtg-
cgggagtcactgaga
atctggaagaacacagagaaggagaacgcaacagtggcccacctggtgggggctctcaggtcctgccagatgaa-
cctggtggctgacct
ggtacaagaggttcagcaggcccgtgacctccagaacaggagtggggccatgtccccgatgtcatggaactcag-
acgcatctacctccga agcgtcctgataactcgagatcgataacaac FADD-CSSCFV (amino
acid sequence) (SEQ ID NO: 192)
VDPSNPFLVLLHSVSSSLSSSELTELKFLCLGRVGKRKLERVQSGLDLFSMLLEQNDLEP
GHTELLRELLASLRRHDLLRRVDDFEAGAAAGAAPGEEDLCAAFNVICDNVGKDWRRL
ARQLKVSDTKIDSIEDRYPRNLTERVRESLRIWKNTEKENATVAHLVGALRSCQMNLVA
DLVQEVQQARDLQNRSGAMSPMSWNSDASTSEAS HCD28tm5B (nucleotide sequence)
(SEQ ID NO: 193)
GTTGTGGATCCTCCCTTTTGGGTGCTGGTGGTGGTTGGTGTCCTGGCTTGCTATAGCT TG
HCD28tm3S (nucleotide sequence) (SEQ ID NO: 194)
GTTGTTTCGAACCCAGAAAATAATAAAGGCCACTGTTACTAGCAAGCTATAGCAAG CCAG
HCD28tm5' (nucleotide sequence) (SEQ ID NO: 195)
GTTGTGGATCCTCCCTTTTGGGTGCTGGTGGT HCD28tm3' (nucleotide sequence)
(SEQ ID NO: 196) GTTGTTTCGAACCCAGAAAATAATAAAGGCCAC
HCD80tm5' (nucleotide sequence) (SEQ ID NO: 197)
GTTGTGGATCCTCCTGCTCCCATCCTGG HCD80tm3' (nucleotide sequence) (SEQ
ID NO: 198) GTTGTTTCGAACGGCAAAGCAGTAGGTCAGGC MFADD5BB (nucleotide
sequence) (SEQ ID NO: 199)
GTTGTGGATCCTTCGAACCCATTCCTGGTGCTGCTGCACTCGCTG MFADD3XC (nucleotide
sequence) (SEQ ID NO: 200)
GTTGTTATCGATCTCGAGTCAGGGTGTTTCTGAGGAAGACAC Murine FADD nucleotide
sequence (full length, but without flanking --Ig or transmembrane
sequences) (nucleotide sequence) (SEQ ID NO: 201)
gtggatccttcgaacatggacccattcctggtgctgctgcactcgctgtccggcagcctgtcgggcaacgatct-
gatggagctcaagttcttg
tgccgcgagcgcgtgagcaaacgaaagctggagcgcgtgcagagtggcctggacctgttcacggtgctgctgga-
gcagaacgacctgg
agcgcgggcacaccgggctgctgcgcgagttgctggcctcgctgcgccgacacgatctactgcagcgcctggac-
gacttcgaggcggg
gacggcgaccgctgcgcccccgggggaggcagatctgcaggtggcatttgacattgtgtgtgacaatgtgggga-
gagactggaaaagac
tggcccgcgagctgaaggtgtctgaggccaagatggatgggattgaggagaagtacccccgaagtctgagtgag-
cgggtaagggagag
tctgaaagtctggaagaatgctgagaagaagaacgcctcggtggccggactggtcaaggcgctgcggacctgca-
ggctgaatctggtgg
ctgacctggtggaagaagcccaggaatctgtgagcaagagtgagaatatgtccccagtactaagggattcaact-
gtgtcttcctcagaaaca ccctgactcgagatcgat Murine FADD (amino acid
sequence) (SEQ ID NO: 202)
VDPSNMDPFLVLLHSLSGSLSGNDLMELKFLCRERVSKRKLERVQSGLDLFTVLLEQND
LERGHTGLLRELLASLRRHDLLQRLDDFEAGTATAAPPGEADLQVAFDIVCDNVGRDW
KRLARELKVSEAKMDGIEEKYPRSLSERVRESLKVWKNAEKKNASVAGLVKALRTCRL
NLVADLVEEAQESVSKSENMSPVLRDSTVSSSETP MCASP3-5 (nucleotide sequence)
(SEQ ID NO: 203) GTTGTGGATCCTTCGAACATGGAGAACAACAAAACCTCAGTGGATTCA
MCASP3-3 (nucleotide sequence) (SEQ ID NO: 204)
GTTGTTATCGATCTCGAGCTAGTGATAAAAGTACAGTTCTTTCGT MCASP8-5 (nucleotide
sequence) (SEQ ID NO: 205)
GTTGTTTCGAACATGGATTTCCAGAGTTGTCTTTATGCTATTGCTG MCASP8-3 (nucleotide
sequence) (SEQ ID NO: 206)
GTTGTTATCGATCTCGAGTCATTAGGGAGGGAAGAAGAGCTTCTTCCG
hcasp3-5(nucleotide sequence) (SEQ ID NO: 207)
GTTGTGGATCCTTCGAACATGGAGAACACTGAAAACTCAGTGGAT hcasp3-3 (nucleotide
sequence) (SEQ ID NO: 208)
GTTGTTATCGATCTCGAGTTAGTGATAAAAATAGAGTTCTTTTGTGAG hcasp8-5
(nucleotide sequence) (SEQ ID NO: 209)
GTTGTGGATCCTTCGAACATGGACTTCAGCAGAAATCTTTATGAT hcasp8-3 (nucleotide
sequence) (SEQ ID NO: 210)
GTTGTTATCGATGCATGCTCAATCAGAAGGGAAGACAAGTTTTTTTCT 1. 2H7 scFv with
alternative VHL11 mutations (SEQ ID NO: 211): Nucleotide sequence
Aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccag
tctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagtta-
catgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt ctggggctgag (one of the following: tcn, acn, gan,
can, aan, cgn, agn)
gtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagttacaatatgcactg-
ggtaaagcagacacctag
acagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatcagaagttcaagggca-
aggccacactgactgtag
acaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcggtctatttctgtgca-
agagtggtgtactatagta
actcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctgatcag
Amino acid sequence (SEQ ID NO: 212)
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAE (one of the following: S, T, D,
E, Q, N, R, K, H)
VRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKA
TLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQ 2. VHL11
deletion (SEQ ID NO: 213) Nucleotide sequence:
Aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccag
tctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagtta-
catgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgaggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagttac-
aatatgcactgggtaaag
cagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatcagaa-
gttcaagggcaaggcca
cactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcggtc-
tatttctgtgcaagagtgg
tgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctgatcag
Amino acid sequence (SEQ ID NO: 214):
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAEVRPGASVKMSCKASGYTFTSYNMH
WVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAV
YFCARVVYYSNSYWYFDVWGTGTTVTVSSDQ 3. 2H7 VL L106 with alternative
mutations Nucleotide sequence (SEQ ID NO: 215):
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc tgggaccaagctggag (tcn, agn, aan, cgn, can,
gan, and non-natural derivatives of these codons)
aaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctc Amino acid
sequence (SEQ ID NO: 216):
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA GTKLE
(S, T, R, K, H, Q, N, D, E, and non-natural derivatives of these
amino acids at position 106)KDGGGSGGGGSGGGGSS 4. VL L106 deletion
(SEQ ID NO: 217) Nucleotide sequence:
Aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccag
tctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagtta-
catgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctc
Amino acid sequence (SEQ ID NO: 218):
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLEKDGGGSGGGGSGGGGSS 5. IgE CH3 CH4 (SEQ ID NO: 219) Nucleotide
sequence:
tccaacccgagaggggtgagcgcctacctaagccggcccagcccgttcgacctgttcatccgcaagtcgcccac-
gatcacctgtctggtg
gtggacctggcacccagcaaggggaccgtgaacctgacctggtcccgggccagtgggaagcctgtgaaccactc-
caccagaaaggag
gagaagcagcgcaatggcacgttaaccgtcacgtccaccctgccggtgggcacccgagactggatcgaggggga-
gacctaccagtgca
gggtgacccacccccacctgcccagggccctcatgcggtccacgaccaagaccagcggcccgcgtgctgccccg-
gaagtctatgcgttt
gcgacgccggagtggccggggagccgggacaagcgcaccctcgcctgcctgatccagaacttcatgcctgagga-
catctcggtgcagt
ggctgcacaacgaggtgcagctcccggacgcccggcacagcacgacgcagccccgcaagaccaagggctccggc-
ttcttcgtcttcag
ccgcctggaggtgaccagggccgaatgggagcagaaagatgagttcatctgccgtgcagtccatgaggcagcga-
gcccctcacagacc gtccagcgagcggtgtctgtaaatcccggtaaatgataatctagaa Amino
acid sequence (SEQ ID NO: 220):
SNPRGVSAYLSRPSPFDLFIRKSPTITCLVVDLAPSKGTVNLTWSRASGKPVNHSTRKEE
KQRNGTLTVTSTLPVGTRDWIEGETYQCRVTHPHLPRALMRSTTKTSGPRAAPEVYAFA
TPEWPGSRDKRTLACLIQNFMPEDISVQWLHNEVQLPDARHSTTQPRKTKGSGFFVFSR
LEVTRAEWEQKDEFICRAVHEAASPSQTVQRAVSVNPGK 6. hIgG1H/IgE WCH3 WCH4
(SEQ ID NO: 221) Nucleotide sequence:
tgatcaggagcccaaatcttctgacaaaactcacacatccccaccgtccccagcatccaacccgagaggggtga-
gcgcctacctaagccg
gcccagcccgttcgacctgttcatccgcaagtcgcccacgatcacctgtctggtggtggacctggcacccagca-
aggggaccgtgaacct
gacctggtcccgggccagtgggaagcctgtgaaccactccaccagaaaggaggagaagcagcgcaatggcacgt-
taaccgtcacgtcc
accctgccggtgggcacccgagactggatcgagggggagacctaccagtgcagggtgacccacccccacctgcc-
cagggccctcatgc
ggtccacgaccaagaccagcggcccgcgtgctgccccggaagtctatgcgtttgcgacgccggagtggccgggg-
agccgggacaagc
gcaccctcgcctgcctgatccagaacttcatgcctgaggacatctcggtgcagtggctgcacaacgaggtgcag-
ctcccggacgcccggc
acagcacgacgcagccccgcaagaccaagggctccggcttcttcgtcttcagccgcctggaggtgaccagggcc-
gaatgggagcagaa
agatgagttcatctgccgtgcagtccatgaggcagcgagcccctcacagaccgtccagcgagcggtgtctgtaa-
atcccggtaaatgataa tctagaa Amino acid sequence (SEQ ID NO: 222):
DQEPKSSDKTHTSPPSPASNPRGVSAYLSRPSPFDLFIRKSPTITCLVVDLAPSKGTVNLT
WSRASGKPVNHSTRKEEKQRNGTLTVTSTLPVGTRDWIEGETYQCRVTHPHLPRALMR
STTKTSGPRAAPEVYAFATPEWPGSRDKRTLACLIQNFMPEDISVQWLHNEVQLPDARH
STTQPRKTKGSGFFVFSRLEVTRAEWEQKDEFICRAVHEAASPSQTVQRAVSVNPGK 7. IgE
WCH2 WCH3 WCH4 (SEQ ID NO: 223) Nucleotide sequence:
Tgatcacgtctgctccagggacttcaccccgcccaccgtgaagatcttacagtcgtcctgcgacggcggcgggc-
acttccccccgaccat
ccagctcctgtgcctcgtctctgggtacaccccagggactatcaacatcacctggctggaggacgggcaggtca-
tggacgtggacttgtcc
accgcctctaccacgcaggagggtgagctggcctccacacaaagcgagctcaccctcagccagaagcactggct-
gtcagaccgcaccta
cacctgccaggtcacctatcaaggtcacacctttgaggacagcaccaagaagtgtgcagattccaacccgagag-
gggtgagcgcctacct
aagccggcccagcccgttcgacctgttcatccgcaagtcgcccacgatcacctgtctggtggtggacctggcac-
ccagcaaggggaccgt
gaacctgacctggtcccgggccagtgggaagcctgtgaaccactccaccagaaaggaggagaagcagcgcaatg-
gcacgttaaccgtc
acgtccaccctgccggtgggcacccgagactggatcgagggggagacctaccagtgcagggtgacccaccccca-
cctgcccagggcc
ctcatgcggtccacgaccaagaccagcggcccgcgtgctgccccggaagtctatgcgtttgcgacgccggagtg-
gccggggagccggg
acaagcgcaccctcgcctgcctgatccagaacttcatgcctgaggacatctcggtgcagtggctgcacaacgag-
gtgcagctcccggacg
cccggcacagcacgacgcagccccgcaagaccaagggctccggcttcttcgtcttcagccgcctggaggtgacc-
agggccgaatggga
gcagaaagatgagttcatctgccgtgcagtccatgaggcagcgagcccctcacagaccgtccagcgagcggtgt-
ctgtaaatcccggtaa atgataatctaga Amino acid sequence (SEQ ID NO:
224): DHVCSRDFTPPTVKILQSSCDGGGHFPPTIQLLCLVSGYTPGTINITWLEDGQVMDVDLS
TASTTQEGELASTQSELTLSQKHWLSDRTYTCQVTYQGHTFEDSTKKCADSNPRGVSAY
LSRPSPFDLFIRKSPTITCLVVDLAPSKGTVNLTWSRASGKPVNHSTRKEEKQRNGTLTV
TSTLPVGTRDWIEGETYQCRVTHPHLPRALMRSTTKTSGPRAAPEVYAFATPEWPGSRD
KRTLACLIQNFMPEDISVQWLHNEVQLPDARHSTTQPRKTKGSGFFVFSRLEVTRAEWE
QKDEFICRAVHEAASPSQTVQRAVSVNPGK 8. hIgG1H/IgE CH3 CH4 (ORF) (SEQ ID
NO: 225) Nucleotide sequence:
tgatcaggagcccaaatcttctgacaaaactcacacatccccaccgtccccagcatccaacccgagaggggtga-
gcgcctacctaagccg
gcccagcccgttcgacctgttcatccgcaagtcgcccacgatcacctgtctggtggtggacctggcacccagca-
aggggaccgtgaacct
gacctggtcccgggccagtgggaagcctgtgaaccactccaccagaaaggaggagaagcagcgcaatggcacgt-
taaccgtcacgtcc
accctgccggtgggcacccgagactggatcgagggggagacctaccagtgcagggtgacccacccccacctgcc-
cagggccctcatgc
ggtccacgaccaagaccagcggcccgcgtgctgccccggaagtctatgcgtttgcgacgccggagtggccgggg-
agccgggacaagc
gcaccctcgcctgcctgatccagaacttcatgcctgaggacatctcggtgcagtggctgcacaacgaggtgcag-
ctcccggacgcccggc
acagcacgacgcagccccgcaagaccaagggctccggcttcttcgtcttcagccgcctggaggtgaccagggcc-
gaatgggagcagaa
agatgagttcatctgccgtgcagtccatgaggcagcgagcccctcacagaccgtccagcgagcggtgtctgtaa-
atcccggtaaagcgga tccttcgaa Amino acid sequence (SEQ ID NO: 226):
DQEPKSSDKTHTSPPSPASNPRGVSAYLSRPSPFDLFIRKSPTITCLVVDLAPSKGTVNLT
WSRASGKPVNHSTRKEEKQRNGTLTVTSTLPVGTRDWIEGETYQCRVTHPHLPRALMR
STTKTSGPRAAPEVYAFATPEWPGSRDKRTLACLIQNFMPEDISVQWLHNEVQLPDARH
STTQPRKTKGSGFFVFSRLEVTRAEWEQKDEFICRAVHEAASPSQTVQRAVSVNPGKSG SFE 9.
2H7 VHL11S scFv hIgG1(SSS-S)H hIgE WCH3 WCH4 (SEQ ID NO: 227)
Nucleotide sequence:
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagtcggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaggagcccaaatcttctg
acaaaactcacacatccccaccgtcctcagcatccaacccgagaggggtgagcgcctacctaagccggcccagc-
ccgttcgacctgttca
tccgcaagtcgcccacgatcacctgtctggtggtggacctggcacccagcaaggggaccgtgaacctgacctgg-
tcccgggccagtggg
aagcctgtgaaccactccaccagaaaggaggagaagcagcgcaatggcacgttaaccgtcacgtccaccctgcc-
ggtgggcacccgag
actggatcgagggggagacctaccagtgcagggtgacccacccccacctgcccagggccctcatgcggtccacg-
accaagaccagcg
gcccgcgtgctgccccggaagtctatgcgtttgcgacgccggagtggccggggagccgggacaagcgcaccctc-
gcctgcctgatcca
gaacttcatgcctgaggacatctcggtgcagtggctgcacaacgaggtgcagctcccggacgcccggcacagca-
cgacgcagccccgc
aagaccaagggctccggcttcttcgtcttcagccgcctggaggtgaccagggccgaatgggagcagaaagatga-
gttcatctgccgtgca
gtccatgaggcagcgagcccctcacagaccgtccagcgagcggtgtctgtaaatcccggtaaatgataatctag-
a Amino acid sequence (SEQ ID NO: 228):
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAESVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQEPKSSDKTHTSPPSSASNPRGVSAYL
SRPSPFDLFIRKSPTITCLVVDLAPSKGTVNLTWSRASGKPVNHSTRKEEKQRNGTLTVT
STLPVGTRDWIEGETYQCRVTHPHLPRALMRSTTKTSGPRAAPEVYAFATPEWPGSRDK
RTLACLIQNFMPEDISVQWLHNEVQLPDARHSTTQPRKTKGSGFFVFSRLEVTRAEWEQ
KDEFICRAVHEAASPSQTVQRAVSVNPGK 10. 2H7 VHL11S scFv hIgG1(SSS-P)H
hIgE WCH3 WCH4 (SEQ ID NO: 229) Nucleotide sequence:
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagtcggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaggagcccaaatcttctg
acaaaactcacacatccccaccgtccccagcatccaacccgagaggggtgagcgcctacctaagccggcccagc-
ccgttcgacctgttca
tccgcaagtcgcccacgatcacctgtctggtggtggacctggcacccagcaaggggaccgtgaacctgacctgg-
tcccgggccagtggg
aagcctgtgaaccactccaccagaaaggaggagaagcagcgcaatggcacgttaaccgtcacgtccaccctgcc-
ggtgggcacccgag
actggatcgagggggagacctaccagtgcagggtgacccacccccacctgcccagggccctcatgcggtccacg-
accaagaccagcg
gcccgcgtgctgccccggaagtctatgcgtttgcgacgccggagtggccggggagccgggacaagcgcaccctc-
gcctgcctgatcca
gaacttcatgcctgaggacatctcggtgcagtggctgcacaacgaggtgcagctcccggacgcccggcacagca-
cgacgcagccccgc
aagaccaagggctccggcttcttcgtcttcagccgcctggaggtgaccagggccgaatgggagcagaaagatga-
gttcatctgccgtgca
gtccatgaggcagcgagcccctcacagaccgtccagcgagcggtgtctgtaaatcccggtaaatgataatctag-
a Amino acid sequence (SEQ ID NO: 230):
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAESVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQEPKSSDKTHTSPPSPASNPRGVSAYL
SRPSPFDLFIRKSPTITCLVVDLAPSKGTVNLTWSRASGKPVNHSTRKEEKQRNGTLTVT
STLPVGTRDWIEGETYQCRVTHPHLPRALMRSTTKTSGPRAAPEVYAFATPEWPGSRDK
RTLACLIQNFMPEDISVQWLHNEVQLPDARHSTTQPRKTKGSGFFVFSRLEVTRAEWEQ
KDEFICRAVHEAASPSQTVQRAVSVNPGK 10. 2H7 VL L106S (SEQ ID NO: 231)
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctc
Amino acid sequence (SEQ ID NO: 232):
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLESKDGGGSGGGGSGGGGSS 11. 2H7 VL L106S scFv (SEQ ID NO: 233)
Nucleotide sequence:
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagtctaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagtc
tggggctgagctggtgaggcctggggcctcagtgaagatgtcctgcaaggatctggctacacatttaccagtta-
caatatgcactgggtaa
agcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatcag-
aagttcaagggcaaggc
cacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcgg-
tctatttctgtgcaagagt
ggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctgatc-
ag Amino acid sequence (SEQ ID NO: 234):
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLESKDGGGSGGGGSGGGGSSQAYLQQSGAELVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQ 12. 2H7 scFv VL L106S VHL11S scFv
(SEQ ID NO: 235) Nucleotide sequence:
Aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccag
tctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagtta-
catgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctatactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttta-
acccacccacgttcggtgc
tgggaccaagctggagtctaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagtc
tggggctgagtcggtgaggcctggggcctcagtgaagatgtcctgcaaggatctggctacacatttaccagtta-
caatatgcactgggtaa
agcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatcag-
aagttcaagggcaaggc
cacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcgg-
tctatttctgtgcaagagt
ggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctgatc-
ag Amino acid sequence (SEQ ID NO: 236):
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLESKDGGGSGGGGSGGGGSSQAYLQQSGAESVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQ 10. Human IgD hinge linker with
attached restriction sites (SEQ ID NO: 237) Nucleotide:
gtggatccaggttcgaagtctccaaaggcacaggcctcctccgtgcccactgcacaaccccaagcagagggcag-
cctcgccaaggcaac
cacagccccagccaccacccgtaacacaggaagaggaggagaagagaagaagaaggagaaggagaaagaggaac-
aagaagagag agagacaaagaccggtgcagtcgacg Amino acid (SEQ ID NO: 238):
VDPGSKSPKAQASSVPTAQPQAEGSLAKATTAPATTRNTGRGGEEKKKEKEKEEQEERE TKTGAVD
sequence of Native IgD hinge domain (SEQ ID NO: 239): (includes a
cysteine residue--we truncated the hinge prior to that residue for
these constructs:) Nucleotide:
gagtctccaaaggcacaggcctcctccgtgcccactgcacaaccccaagcagagggcagcctcgccaaggcaac-
cacagccccagcc
accacccgtaacacaggaagaggaggagaagagaagaagaaggagaaggagaaagaggaacaagaagagagaga-
gacaaagaca ccagagtgtccgagccacacccagcctcttggcgtctacctgctaacccct
Amino acid sequence (SEQ ID NO: 240):
ESPKAQASSVPTAQPQAEGSLAKATTAPATTRNTGRGGEEKKKEKEKEEQEERETKTPE
CPSHTQPLGVYLLTP 12. 2H7 VH L11S (SEQ ID NO: 241) Nucleotide
sequence:
caggcttatctacagcagtctggggctgagtcggtgaggcctggggcctcagtgaagatgtcctgcaaggcttc-
tggctacacatttaccag
ttacaatatgcactgggtaaagcagacacctagacagggcctggaatggattggagctatttatccaggaaatg-
gtgatacttcctacaatca
gaagttcaagggcaaggccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctga-
catctgaagactctgc
ggtctatttctgtgcaagagtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggacca-
cggtcaccgtctcttct Amino acid sequence (SEQ ID NO: 242):
QAYLQQSGAESVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGD
TSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGT GTTVTVSS
13. 2H7 VH L11S scFv (SEQ ID NO: 243) Nucleotide sequence:
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctatactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttta-
acccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagtcggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcag Amino acid sequence (SEQ ID NO: 244):
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAESVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQ 14. 2H7 scFv VH L11S hIgG1
(CSC-S)H WCH2 WCH3 (SEQ ID NO: 245) Nucleotide sequence:
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctatactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttta-
acccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagtctgtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggtaa
agcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatcag-
aagttcaagggcaaggc
cacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcgg-
tctatttctgtgcaagagt
ggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctgatc-
aggagcccaaatcttgtgac
aaaactcacacatctccaccgtgctcagcacctgaactcctgggtggaccgtcagtcttcctcttccccccaaa-
acccaaggacaccctcat
gatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaact-
ggtacgtggacggcgt
ggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctca-
ccgtcctgcaccag
gactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaacaat-
ctccaaagccaaagg
gcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcctga-
cctgcctggtcaaag
gcttctatccaagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcct-
cccgtgctggactcc
gacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatg-
ctccgtgatgcatgagg
ctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga Amino
acid sequence (SEQ ID NO: 246):
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAESVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQEPKSCDKTHTSPPCSAPELLGGPSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK 15. 2H7 scFv VH L11S IgE WCH2 WCH3
WCH4 (SEQ ID NO: 247) Nucleotide sequence:
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagtctgtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggtaa
agcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatcag-
aagttcaagggcaaggc
cacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcgg-
tctatttctgtgcaagagt
ggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctgatc-
acgtctgctccagggacttc
accccgcccaccgtgaagatcttacagtcgtcctgcgacggcggcgggcacttccccccgaccatccagctcct-
gtgcctcgtctctgggt
acaccccagggactatcaacatcacctggctggaggacgggcaggtcatggacgtggacttgtccaccgcctct-
accacgcaggagggt
gagctggcctccacacaaagcgagctcaccctcagccagaagcactggctgtcagaccgcacctacacctgcca-
ggtcacctatcaaggt
cacacctttgaggacagcaccaagaagtgtgcagattccaacccgagaggggtgagcgcctacctaagccggcc-
cagcccgttcgacct
gttcatccgcaagtcgcccacgatcacctgtctggtggtggacctggcacccagcaaggggaccgtgaacctga-
cctggtcccgggcca
gtgggaagcctgtgaaccactccaccagaaaggaggagaagcagcgcaatggcacgttaaccgtcacgtccacc-
ctgccggtgggcac
ccgagactggatcgagggggagacctaccagtgcagggtgacccacccccacctgcccagggccctcatgcggt-
ccacgaccaagac
cagcggcccgcgtgctgccccggaagtctatgcgtttgcgacgccggagtggccggggagccgggacaagcgca-
ccctcgcctgcctg
atccagaacttcatgcctgaggacatctcggtgcagtggctgcacaacgaggtgcagctcccggacgcccggca-
cagcacgacgcagcc
ccgcaagaccaagggctccggcttcttcgtcttcagccgcctggaggtgaccagggccgaatgggagcagaaag-
atgagttcatctgccg
tgcagtccatgaggcagcgagcccctcacagaccgtccagcgagcggtgtctgtaaatcccggtaaatgataat-
ctaga Amino acid sequence (SEQ ID NO: 248):
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAESVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDHVCSRDFTPPTVKILQSSCDGGGHFPP
TIQLLCLVSGYTPGTINITWLEDGQVMDVDLSTASTTQEGELASTQSELTLSQKHWLSDR
TYTCQVTYQGHTFEDSTKKCADSNPRGVSAYLSRPSPFDLFIRKSPTITCLVVDLAPSKG
TVNLTWSRASGKPVNHSTRKEEKQRNGTLTVTSTLPVGTRDWIEGETYQCRVTHPHLPR
ALMRSTTKTSGPRAAPEVYAFATPEWPGSRDKRTLACLIQNFMPEDISVQWLHNEVQLP
DARHSTTQPRKTKGSGFFVFSRLEVTRAEWEQKDEFICRAVHEAASPSQTVQRAVSVNP GK 16.
2H7 scFv VH L11S mIgE WCH2 WCH3 WCH4 (SEQ ID NO: 249) Nucleotide
sequence:
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagtctgtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggtaa
agcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatcag-
aagttcaagggcaaggc
cacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcgg-
tctatttctgtgcaagagt
ggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctgatc-
acgttcgacctgtcaacatca
ctgagcccaccttggagctactccattcatcctgcgaccccaatgcattccactccaccatccagctgtactgc-
ttcatttatggccacatccta
aatgatgtctctgtcagctggctaatggacgatcgggagataactgatacacttgcacaaactgttctaatcaa-
ggaggaaggcaaactagc
ctctacctgcagtaaactcaacatcactgagcagcaatggatgtctgaaagcaccttcacctgcaaggtcacct-
cccaaggcgtagactattt
ggcccacactcggagatgcccagatcatgagccacggggtgtgattacctacctgatcccacccagccccctgg-
acctgtatcaaaacggt
gctcccaagcttacctgtctggtggtggacctggaaagcgagaagaatgtcaatgtgacgtggaaccaagagaa-
gaagacttcagtctcag
catcccagtggtacactaagcaccacaataacgccacaactagtatcacctccatcctgcctgtagttgccaag-
gactggattgaaggctac
ggctatcagtgcatagtggaccaccctgattttcccaagcccattgtgcgttccatcaccaagaccccaggcca-
gcgctcagcccccgagg
tatatgtgttcccaccaccagaggaggagagcgaggacaaacgcacactcacctgtttgatccagaacttcttc-
cctgaggatatctctgtgc
agtggctgggggatggcaaactgatctcaaacagccagcacagtaccacaacacccctgaaatccaatggctcc-
aatcaaggcttcttcat
cttcagtcgcctagaggtcgccaagacactctggacacagagaaaacagttcacctgccaagtgatccatgagg-
cacttcagaaacccag
gaaactggagaaaacaatatccacaagccttggtaacacctccctccgtccatcctagtaatctagag
Amino acid sequence (SEQ ID NO: 250):
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAESVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDHVRPVNITEPTLELLHSSCDPNAFHSTI
QLYCFIYGHILNDVSVSWLMDDREITDTLAQTVLIKEEGKLASTCSKLNITEQQWMSEST
FTCKVTSQGVDYLAHTRRCPDHEPRGVITYLIPPSPLDLYQNGAPKLTCLVVDLESEKNV
NVTWNQEKKTSVSASQWYTKHHNNATTSITSILPVVAKDWIEGYGYQCIVDHPDFPKPI
VRSITKTPGQRSAPEVYVFPPPEEESEDKRTLTCLIQNFFPEDISVQWLGDGKLISNSQHST
TTPLKSNGSNQGFFIFSRLEVAKTLWTQRKQFTCQVIHEALQKPRKLEKTISTSLGNTSLR PS
17. 2H7 scFv VH L11S hIgA WH WCH2 T4CH3 (SEQ ID NO: 251) Nucleotide
sequence:
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagtctgtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggtaa
agcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatcag-
aagttcaagggcaaggc
cacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcgg-
tctatttctgtgcaagagt
ggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctgatc-
agccagttccctcaactcca
cctaccccatctccctcaactccacctaccccatctccctcatgctgccacccccgactgtcactgcaccgacc-
ggccctcgaggacctgct
cttaggttcagaagcgatcctcacgtgcacactgaccggcctgagagatgcctcaggtgtcaccttcacctgga-
cgccctcaagtgggaag
agcgctgttcaaggaccacctgaccgtgacctctgtggctgctacagcgtgtccagtgtcctgccgggctgtgc-
cgagccatggaaccatg
ggaagaccttcacttgcactgctgcctaccccgagtccaagaccccgctaaccgccaccctctcaaaatccgga-
aacacattccggcccga
ggtccacctgctgccgccgccgtcggaggagctggccctgaacgagctggtgacgctgacgtgcctggcacgtg-
gcttcagccccaagg
atgtgctggttcgctggctgcaggggtcacaggagctgccccgcgagaagtacctgacttgggcatcccggcag-
gagcccagccaggg
caccaccaccttcgctgtgaccagcatactgcgcgtggcagccgaggactggaagaagggggacaccttctcct-
gcatggtgggccacg
aggccctgccgctggccttcacacagaagaccatcgaccgcttggcgggtaaacccacccatgtcaatgtgtct-
gttgtcatggcggaggt ggactgataatctaga Amino acid sequence (SEQ ID NO:
252):
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAESVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQPVPSTPPTPSPSTPPTPSPSCCHPRLSL
HRPALEDLLLGSEAILTCTLTGLRDASGVTFTWTPSSGKSAVQGPPDRDLCGCYSVSSVL
PGCAEPWNHGKTFTCTAAYPESKTPLTATLSKSGNTFRPEVHLLPPPSEELALNELVTLT
CLARGFSPKDVLVRWLQGSQELPREKYLTWASRQEPSQGTTTFAVTSILRVAAEDWKK
GDTFSCMVGHEALPLAFTQKTIDRLAGKPTHVNVSVVMAEVD 18. 2H7 scFv VH L11S
mIgA WH WCH2 T4 CH3 (SEQ ID NO: 253) Nucleotide sequence:
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagtctgtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggtaa
agcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatcag-
aagttcaagggcaaggc
cacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcgg-
tctatttctgtgcaagagt
ggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctgatc-
acatctgttctcctcctactac
tcctcctccaccttcctgccagcccagcctgtcactgcagcggccagctcttgaggacctgctcctgggttcag-
atgccagcatcacatgtac
tctgaatggcctgagagatcctgagggagctgtcttcacctgggagccctccactgggaaggatgcagtgcaga-
agaaagctgtgcagaa
ttcctgcggctgctacagtgtgtccagcgtcctgcctggctgtgctgagcgctggaacagtggcgcatcattca-
agtgcacagttacccatcc
tgagtctgacaccttaactggcacaattgccaaagtcacagtgaacaccttcccaccccaggtccacctgctac-
cgccgccgtcggaggag
ctggccctgaatgagctcgtgtccctgacatgcctggtgcgagctttcaaccctaaagaagtgctggtgcgatg-
gctgcatggaaatgagga
gctgtccccagaaagctacctagtgtttgagcccctaaaggagccaggcgagggagccaccacctacctggtga-
caagcgtgttgcgtgt
atcagctgaaatctggaaacagggtgaccagtactcctgcatggtgggccacgaggccttgcccatgaacttca-
cccagaagaccatcga
ccgtctgtcgggtaaacccaccaatgtcagcgtgtctgtgatcatgtcagagggagattgataatctagat
Amino acid sequence (SEQ ID NO: 254):
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAESVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDHICSPPTTPPPPSCQPSLSLQRPALEDLL
LGSDASITCTLNGLRDPEGAVFTWEPSTGKDAVQKKAVQNSCGCYSVSSVLPGCAERW
NSGASFKCTVTHPESDTLTGTIAKVTVNTFPPQVHLLPPPSEELALNELVSLTCLVRAFNP
KEVLVRWLHGNEELSPESYLVFEPLKEPGEGATTYLVTSVLRVSAEIWKQGDQYSCMV
GHEALPMNFTQKTIDRLSGKPTNVSVSVIMSEGD A. mIgA WCH2 T4CH3 (SEQ ID NO:
255) Nucleotide sequence:
Gttgttgatcacatctgttctcctcctactactcctcctccaccttcctgccagcccagcctgtcactgcagcg-
gccagctcttgaggacctgct
cctgggttcagatgccagcatcacatgtactctgaatggcctgagagatcctgagggagctgtcttcacctggg-
agccctccactgggaag
gatgcagtgcagaagaaagctgtgcagaattcctgcggctgctacagtgtgtccagcgtcctgcctggctgtgc-
tgagcgctggaacagtg
gcgcatcattcaagtgcacagttacccatcctgagtctgacaccttaactggcacaattgccaaagtcacagtg-
aacaccttcccaccccag
gtccacctgctaccgccgccgtcggaggagctggccctgaatgagctcgtgtccctgacatgcctggtgcgagc-
tttcaaccctaaagaag
tgctggtgcgatggctgcatggaaatgaggagctgtccccagaaagctacctagtgtttgagcccctaaaggag-
ccaggcgagggagcc
accacctacctggtgacaagcgtgttgcgtgtatcagctgaaatctggaaacagggtgaccagtactcctgcat-
ggtgggccacgaggcct
tgcccatgaacttcacccagaagaccatcgaccgtctgtcgggtaaacccaccaatgtcagcgtgtctgtgatc-
atgtcagagggagattga taatctagat Amino acid sequence (SEQ ID NO: 256):
DHICSPPTTPPPPSCQPSLSLQRPALEDLLLGSDASITCTLNGLRDPEGAVFTWEPSTGKD
AVQKKAVQNSCGCYSVSSVLPGCAERWNSGASFKCTVTHPESDTLTGTIAKVTVNTFPP
QVHLLPPPSEELALNELVSLTCLVRAFNPKEVLVRWLHGNEELSPESYLVFEPLKEPGEG
ATTYLVTSVLRVSAEIWKQGDQYSCMVGHEALPMNFTQKTIDRLSGKPTNVSVSVIMSE GD 20.
K322S CH2 region (SEQ ID NO: 257) Nucleotide sequence:
cctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggac-
ccctgaggtcacatgcgt
ggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatg-
ccaagacaaagccgc
gggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggc-
aaggagtacaagtgc
tcggtctccaacaaagccctcccagcccccatcgagaaaacaatctccaaagccaaa Amino
acid sequence (SEQ ID NO: 258):
PELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCSVSNKALPAPIEKTISKAK 21. K322S CH2
WCH3 (SEQ ID NO: 259) Nucleotide sequence:
cctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggac-
ccctgaggtcacatgcgt
ggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatg-
ccaagacaaagccgc
gggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggc-
aaggagtacaagtgc
tcggtctccaacaaagccctcccagcccccatcgagaaaacaatctccaaagccaaagggcagccccgagaacc-
acaggtgtacaccct
gcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatcccagcg-
acatcgccgtggagtg
ggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcc-
tctacagcaagctcac
cgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccact-
acacgcagaagagcct ctccctgtctccgggtaaatgatctaga Amino acid sequence
(SEQ ID NO: 260):
PELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCSVSNKALPAPIEKTISKAKGQPREPQVY
TLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSK
LTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 1. K322L CH2 WCH3 (SEQ ID
NO: 261) Nucleotide sequence:
tgatcaggagcccaaatcttctgacaaaactcacacatccccaccgtcctcagcacctgaactcctggggggac-
cgtcagtcttcctcttccc
cccaaaacccaaggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacg-
aagaccctgaggtca
agttcaactggtacgtggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagc-
acgtaccgtgtggtc
agcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcctggtctccaacaaagccct-
cccagcccccatcgag
aaaacaatctccaaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagct-
gaccaagaaccagg
tcagcctgacctgcctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccg-
gagaacaactacaag
accacgcctcccgtgctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtg-
gcagcaggggaacgtc
ttctcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaa-
atgatctaga Amino acid sequence (SEQ ID NO: 262):
DQEPKSSDKTHTSPPSSAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK
FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCLVSNKALPAP
IEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY
KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 22. 2H7
scFv VHL11S hIgG1 (SSS-S)H K322SCH2 WCH3 (SEQ ID NO: 263)
Nucleotide sequence:
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagtcggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaggagcccaaatcttctg
acaaaactcacacatccccaccgtcctcagcacctgaactcctggggggaccgtcagtcttcctcttcccccca-
aaacccaaggacaccct
catgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttca-
actggtacgtggacgg
cgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcc-
tcaccgtcctgcacc
aggactggctgaatggcaaggagtacaagtgctcggtctccaacaaagccctcccagcccccatcgagaaaaca-
atctccaaagccaaa
gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcct-
gacctgcctggtca
aaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacg-
cctcccgtgctgga
ctccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttct-
catgctccgtgatgcatg
aggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga
Amino acid sequence (SEQ ID NO: 264):
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAESVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQEPKSSDKTHTSPPSSAPELLGGPSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCSVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK 23. 2H7 scFv VHL11S hIgG1 (SSS-S)H
K322LCH2 WCH3 (SEQ ID NO: 265) Nucleotide sequence:
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctatactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttta-
acccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagtcggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaggagcccaaatcttctg
acaaaactcacacatccccaccgtcctcagcacctgaactcctggggggaccgtcagtcttcctcttcccccca-
aaacccaaggacaccct
catgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttca-
actggtacgtggacgg
cgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcc-
tcaccgtcctgcacc
aggactggctgaatggcaaggagtacaagtgcctggtctccaacaaagccctcccagcccccatcgagaaaaca-
atctccaaagccaaa
gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcct-
gacctgcctggtca
aaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacg-
cctcccgtgctgga
ctccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttct-
catgctccgtgatgcatg
aggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga
Amino acid sequence (SEQ ID NO: 266):
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAESVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQEPKSSDKTHTSPPSSAPELLGGPSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCLVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK 24. 2H7 scFv VHL11S hIgG1 (CSS-S)H
K322SCH2 WCH3 (SEQ ID NO: 267) Nucleotide sequence:
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctatactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttta-
acccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagtcggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaggagcccaaatcttgtg
acaaaactcacacatccccaccgtcctcagcacctgaactcctggggggaccgtcagtcttcctcttcccccca-
aaacccaaggacaccct
catgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttca-
actggtacgtggacgg
cgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcc-
tcaccgtcctgcacc
aggactggctgaatggcaaggagtacaagtgctcggtctccaacaaagccctcccagcccccatcgagaaaaca-
atctccaaagccaaa
gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcct-
gacctgcctggtca
aaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacg-
cctcccgtgctgga
ctccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttct-
catgctccgtgatgcatg
aggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga
Amino acid sequence (SEQ ID NO: 268):
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAESVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQEPKSCDKTHTSPPSSAPELLGGPSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCSVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK 25. P331S CH2 (SEQ ID NO: 269)
Nucleotide sequence:
cctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggac-
ccctgaggtcacatgcgt
ggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatg-
ccaagacaaagccgc
gggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggc-
aaggagtacaagtgc
aaggtctccaacaaagccctcccagcctccatcgagaaaacaatctccaaagccaaa Amino
acid sequence (SEQ ID NO: 270)
PELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAK 26. P331S CH2
WCH3 (SEQ ID NO: 271) Nucleotide sequence:
cctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggac-
ccctgaggtcacatgcgt
ggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatg-
ccaagacaaagccgc
gggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggc-
aaggagtacaagtgc
aaggtctccaacaaagccctcccagcctccatcgagaaaacaatctccaaagccaaagggcagccccgagaacc-
acaggtgtacaccct
gcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatcccagcg-
acatcgccgtggagtg
ggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcc-
tctacagcaagctcac
cgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccact-
acacgcagaagagcct ctccctgtctccgggtaaatgatctaga Amino acid sequence
(SEQ ID NO: 272)
PELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPREPQV
YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYS
KLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 27. 2H7 scFv VH L11S
(SSS-S)H P331S CH2 WCH3 (SEQ ID NO: 273) Nucleotide sequence:
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctatactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttta-
acccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagtcggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaggagcccaaatcttctg
acaaaactcacacatccccaccgtcctcagcacctgaactcctggggggaccgtcagtcttcctcttcccccca-
aaacccaaggacaccct
catgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttca-
actggtacgtggacgg
cgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcc-
tcaccgtcctgcacc
aggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcctccatcgagaaaaca-
atctccaaagccaaa
gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcct-
gacctgcctggtca
aaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacg-
cctcccgtgctgga
ctccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttct-
catgctccgtgatgcatg
aggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga
Amino acid sequence (SEQ ID NO: 274)
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAESVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQEPKSSDKTHTSPPSSAPELLGGPSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPREPQVYTLPPSRDELT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK 28. 2H7 scFv VH L11S (CSS-S)H P331S
CH2 WCH3 (SEQ ID NO: 275) Nucleotide sequence:
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctatactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttta-
acccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagtcggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaggagcccaaatcttgtg
acaaaactcacacatccccaccgtcctcagcacctgaactcctggggggaccgtcagtcttcctcttcccccca-
aaacccaaggacaccct
catgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttca-
actggtacgtggacgg
cgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcc-
tcaccgtcctgcacc
aggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcctccatcgagaaaaca-
atctccaaagccaaa
gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcct-
gacctgcctggtca
aaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacg-
cctcccgtgctgga
ctccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttct-
catgctccgtgatgcatg
aggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga
Amino acid sequence (SEQ ID NO: 276)
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAESVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQEPKSCDKTHTSPPSSAPELLGGPSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPREPQVYTLPPSRDELT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK 29. T256N CH2 region (SEQ ID NO: 277)
Nucleotide sequence:
Cctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggaa-
ccctgaggtcacatgcg
tggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataat-
gccaagacaaagccg
cgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatgg-
caaggagtacaagtg
caaggtctccaacaaagccctcccagcccccatcgagaaaacaatctccaaagccaaa Amino
acid sequence (SEQ ID NO: 278)
PELLGGPSVFLFPPKPKDTLMISRNPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT
KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 30. T256N CH2
WCH3 (SEQ ID NO: 279) Nucleotide sequence:
cctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggaa-
ccctgaggtcacatgcgt
ggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatg-
ccaagacaaagccgc
gggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggc-
aaggagtacaagtgc
aaggtctccaacaaagccctcccagcccccatcgagaaaacaatctccaaagccaaagggcagccccgagaacc-
acaggtgtacaccct
gcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatcccagcg-
acatcgccgtggagtg
ggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcc-
tctacagcaagctcac
cgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccact-
acacgcagaagagcct ctccctgtctccgggtaaatgatctaga Amino acid sequence
(SEQ ID NO: 280)
PELLGGPSVFLFPPKPKDTLMISRNPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT
KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ
VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY
SKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 31. 2H7 scFv VH L11S
(SSS-S)H T256N CH2 WCH3 (SEQ ID NO: 281) Nucleotide sequence:
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagtcggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaggagcccaaatcttctg
acaaaactcacacatccccaccgtcctcagcacctgaactcctggggggaccgtcagtcttcctcttcccccca-
aaacccaaggacaccct
catgatctcccggaaccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttca-
actggtacgtggacgg
cgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcc-
tcaccgtcctgcacc
aggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaca-
atctccaaagccaaa
gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcct-
gacctgcctggtca
aaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacg-
cctcccgtgctgga
ctccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttct-
catgctccgtgatgcatg
aggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga
Amino acid sequence (SEQ ID NO: 282)
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAESVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQEPKSSDKTHTSPPSSAPELLGGPSVFL
FPPKPKDTLMISRNPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK 32. 2H7 scFv VH L11S (CSS-S)H T256N
CH2 WCH3 (SEQ ID NO: 283) Nucleotide sequence:
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagtcggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaggagcccaaatcttgtg
acaaaactcacacatccccaccgtcctcagcacctgaactcctggggggaccgtcagtcttcctcttcccccca-
aaacccaaggacaccct
catgatctcccggaaccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttca-
actggtacgtggacgg
cgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcc-
tcaccgtcctgcacc
aggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaca-
atctccaaagccaaa
gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcct-
gacctgcctggtca
aaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacg-
cctcccgtgctgga
ctccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttct-
catgctccgtgatgcatg
aggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga
Amino acid sequence (SEQ ID NO: 284)
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAESVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQEPKSCDKTHTSPPSSAPELLGGPSVFL
FPPKPKDTLMISRNPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK 33. RTPE/QNAK (255-258) CH2 (SEQ ID
NO: 285) Nucleotide sequence:
cctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccagaa-
cgctaaggtcacatgcgt
ggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatg-
ccaagacaaagccgc
gggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggc-
aaggagtacaagtgc
aaggtctccaacaaagccctcccagcccccatcgagaaaacaatctccaaagccaaa Amino
acid sequence (SEQ ID NO: 286)
PELLGGPSVFLFPPKPKDTLMISQNAKVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT
KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 34. RTPE/QNAK
(255-258)CH2 WCH3 (SEQ ID NO: 287) Nucleotide sequence:
cctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccagaa-
cgctaaggtcacatgcgt
ggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatg-
ccaagacaaagccgc
gggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggc-
aaggagtacaagtgc
aaggtctccaacaaagccctcccagcccccatcgagaaaacaatctccaaagccaaagggcagccccgagaacc-
acaggtgtacaccct
gcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatcccagcg-
acatcgccgtggagtg
ggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcc-
tctacagcaagctcac
cgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccact-
acacgcagaagagcct ctccctgtctccgggtaaatgatctaga Amino acid sequence
(SEQ ID NO: 288)
PELLGGPSVFLFPPKPKDTLMISQNAKVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT
KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ
VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY
SKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 35. 2H7 scFv VH L11S
(SSS-S)H RTPE/QNAK (255-258)CH2 WCH3 (SEQ ID NO: 289) Nucleotide
sequence:
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagtcggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaggagcccaaatcttctg
acaaaactcacacatccccaccgtcctcagcacctgaactcctggggggaccgtcagtcttcctcttcccccca-
aaacccaaggacaccct
catgatctcccagaacgctaaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttca-
actggtacgtggacgg
cgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcc-
tcaccgtcctgcacc
aggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaca-
atctccaaagccaaa
gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcct-
gacctgcctggtca
aaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacg-
cctcccgtgctgga
ctccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttct-
catgctccgtgatgcatg
aggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga
Amino acid sequence (SEQ ID NO: 290)
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAESVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQEPKSSDKTHTSPPSSAPELLGGPSVFL
FPPKPKDTLMISQNAKVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST
YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL
TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW
QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 36. 2H7 scFv VH L11S (CSS-S)H
RTPE/QNAK (255-258)CH2 WCH3 (SEQ ID NO: 291) Nucleotide sequence:
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagtcggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaggagcccaaatcttgtg
acaaaactcacacatccccaccgtcctcagcacctgaactcctggggggaccgtcagtcttcctcttcccccca-
aaacccaaggacaccct
catgatctcccagaacgctaaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttca-
actggtacgtggacgg
cgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcc-
tcaccgtcctgcacc
aggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaca-
atctccaaagccaaa
gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcct-
gacctgcctggtca
aaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacg-
cctcccgtgctgga
ctccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttct-
catgctccgtgatgcatg
aggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga
Amino acid sequence (SEQ ID NO: 292)
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAESVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQEPKSCDKTHTSPPSSAPELLGGPSVFL
FPPKPKDTLMISQNAKVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST
YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL
TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW
QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 36. K290Q CH2 region (SEQ ID NO:
293) Nucleotide sequence:
cctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggac-
ccctgaggtcacatgcgt
ggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatg-
ccaagacacagccgc
gggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggc-
aaggagtacaagtgc
aaggtctccaacaaagccctcccagcccccatcgagaaaacaatctccaaagccaaa Amino
acid sequence (SEQ ID NO: 294):
PELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTQ
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 37. K290Q CH2
WCH3 (SEQ ID NO: 295) Nucleotide sequence:
Cctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggac-
ccctgaggtcacatgcg
tggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataat-
gccaagacacagccg
cgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatgg-
caaggagtacaagtg
caaggtctccaacaaagccctcccagcccccatcgagaaaacaatctccaaagccaaagggcagccccgagaac-
cacaggtgtacacc
ctgcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatcccag-
cgacatcgccgtggag
tgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttctt-
cctctacagcaagctc
accgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaacca-
ctacacgcagaagag cctctccctgtctccgggtaaatgatctaga Amino acid sequence
(SEQ ID NO: 296):
PELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTQ
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQV
YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYS
KLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 38. 2H7 scFv VH L11S
(SSS-S)H K290Q CH2 WCH3 (SEQ ID NO: 297) Nucleotide sequence:
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagtcggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaggagcccaaatcttctg
acaaaactcacacatccccaccgtcctcagcacctgaactcctggggggaccgtcagtcttcctcttcccccca-
aaacccaaggacaccct
catgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttca-
actggtacgtggacgg
cgtggaggtgcataatgccaagacacagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcc-
tcaccgtcctgcacc
aggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaca-
atctccaaagccaaa
gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcct-
gacctgcctggtca
aaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacg-
cctcccgtgctgga
ctccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttct-
catgctccgtgatgcatg
aggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga
Amino acid sequence (SEQ ID NO: 298):
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAESVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQEPKSSDKTHTSPPSSAPELLGGPSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTQPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK 39. 2H7 scfv VH L11S (CSS-S)H K290Q
CH2 WCH3 (SEQ ID NO: 299) Nucleotide sequence:
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagtcggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaggagcccaaatcttgtg
acaaaactcacacatccccaccgtcctcagcacctgaactcctggggggaccgtcagtcttcctcttcccccca-
aaacccaaggacaccct
catgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttca-
actggtacgtggacgg
cgtggaggtgcataatgccaagacacagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcc-
tcaccgtcctgcacc
aggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaca-
atctccaaagccaaa
gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcct-
gacctgcctggtca
aaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacg-
cctcccgtgctgga
ctccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttct-
catgctccgtgatgcatg
aggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga
Amino acid sequence (SEQ ID NO: 300):
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAESVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQEPKSCDKTHTSPPSSAPELLGGPSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTQPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK 40. A339PCH2 (SEQ ID NO: 301)
Nucleotide sequence:
cctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggac-
ccctgaggtcacatgcgt
ggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatg-
ccaagacaaagccgc
gggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggc-
aaggagtacaagtgc
aaggtctccaacaaagccctcccagcccccatcgagaaaacaatctccaaacccaaa Amino
acid sequence (SEQ ID NO: 302):
PELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKPK 41. A339P CH2
WCH3 (SEQ ID NO: 303) Nucleotide sequence:
cctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggac-
ccctgaggtcacatgcgt
ggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatg-
ccaagacaaagccgc
gggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggc-
aaggagtacaagtgc
aaggtctccaacaaagccctcccagcccccatcgagaaaacaatctccaaacccaaagggcagccccgagaacc-
acaggtgtacaccct
gcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatcccagcg-
acatcgccgtggagtg
ggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcc-
tctacagcaagctcac
cgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccact-
acacgcagaagagcct ctccctgtctccgggtaaatgatctaga Amino acid sequence
(SEQ ID NO: 304):
PELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKPKGQPREPQVY
TLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSK
LTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
42. 2H7 scFv VHL11S (SSS-S)H A339P CH2 WCH3 (SEQ ID NO: 305)
Nucleotide sequence:
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagtcggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaggagcccaaatcttctg
acaaaactcacacatccccaccgtcctcagcacctgaactcctggggggaccgtcagtcttcctcttcccccca-
aaacccaaggacaccct
catgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttca-
actggtacgtggacgg
cgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcc-
tcaccgtcctgcacc
aggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaca-
atctccaaacccaaa
gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcct-
gacctgcctggtca
aaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacg-
cctcccgtgctgga
ctccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttct-
catgctccgtgatgcatg
aggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga
Amino acid sequence (SEQ ID NO: 306):
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAESVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQEPKSSDKTHTSPPSSAPELLGGPSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKPKGQPREPQVYTLPPSRDELT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK 43. 2H7 scFv VHL11S (CSS-S)H A339P
CH2 WCH3 (SEQ ID NO: 307) Nucleotide sequence:
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagtcggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaggagcccaaatcttgtg
acaaaactcacacatccccaccgtcctcagcacctgaactcctggggggaccgtcagtcttcctcttcccccca-
aaacccaaggacaccct
catgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttca-
actggtacgtggacgg
cgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcc-
tcaccgtcctgcacc
aggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaca-
atctccaaacccaaa
gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcct-
gacctgcctggtca
aaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacg-
cctcccgtgctgga
ctccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttct-
catgctccgtgatgcatg
aggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga
Amino acid sequence (SEQ ID NO: 308):
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAESVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQEPKSCDKTHTSPPSSAPELLGGPSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKPKGQPREPQVYTLPPSRDELT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK 44. G28-1VH (SEQ ID NO: 309)
Nucleotide sequence:
gcggtccagctgcagcagtctggacctgagctggaaaagcctggcgcttcagtgaagatttcctgcaaggcttc-
tggttactcattcactggc
tacaatatgaactgggtgaagcagaataatggaaagagccttgagtggattggaaatattgatccttattatgg-
tggtactacctacaaccgga
agttcaagggcaaggccacattgactgtagacaaatcctccagcacagcctacatgcagctcaagagtctgaca-
tctgaggactctgcagt
ctattactgtgcaagatcggtcggccctatggactactggggtcaaggaacctcagtcaccgtctcttctgatc-
ag Amino acid sequence (SEQ ID NO: 310):
AVQLQQSGPELEKPGASVKISCKASGYSFTGYNMNWVKQNNGKSLEWIGNIDPYYGGT
TYNRKFKGKATLTVDKSSSTAYMQLKSLTSEDSAVYYCARSVGPMDYWGQGTSVTVS SDQ 45.
G28-1VL (SEQ ID NO: 311) Nucleotide sequence:
aagcttgccgccatggtatccacagctcagttccttgggttgctgctgctgtggcttacaggtggcagatgtga-
catccagatgactcagtctc
cagcctccctatctgcatctgtgggagagactgtcaccatcacatgtcgaacaagtgaaaatgtttacagttat-
ttggcttggtatcag cagaa
acagggaaaatctcctcagctcctggtctcttttgcaaaaaccttagcagaaggtgtgccatcaaggttcagtg-
gcagtggatcaggcacac
agttttctctgaagatcagcagcctgcagcctgaagattctggaagttatttctgtcaacatcattccgataat-
ccgtggacgttcggtggaggc
accgaactggagatcaaaggtggcggtggctcgggcggtggtgggtcgggtggcggcggatcgtca
Amino acid sequence (SEQ ID NO: 312):
MVSTAQFLGLLLLWLTGGRCDIQMTQSPASLSASVGETVTITCRTSENVYSYLAWYQQK
QGKSPQLLVSFAKTLAEGVPSRFSGSGSGTQFSLKISSLQPEDSGSYFCQHHSDNPWTFG
GGTELEIKGGGGSGGGGSGGGGSS 46. G28-1 scFv (SEQ ID NO: 313) Nucleotide
sequence:
aagcttgccgccatggtatccacagctcagttccttgggttgctgctgctgtggcttacaggtggcagatgtga-
catccagatgactcagtctc
cagcctccctatctgcatctgtgggagagactgtcaccatcacatgtcgaacaagtgaaaatgtttacagttat-
ttggcttggtatcag cagaa
acagggaaaatctcctcagctcctggtctcttttgcaaaaaccttagcagaaggtgtgccatcaaggttcagtg-
gcagtggatcaggcacac
agttttctctgaagatcagcagcctgcagcctgaagattctggaagttatttctgtcaacatcattccgataat-
ccgtggacgttcggtggaggc
accgaactggagatcaaaggtggcggtggctcgggcggtggtgggtcgggtggcggcggatcgtcagcggtcca-
gctgcagcagtctg
gacctgagctggaaaagcctggcgcttcagtgaagatttcctgcaaggcttctggttactcattcactggctac-
aatatgaactgggtgaagc
agaataatggaaagagccttgagtggattggaaatattgatccttattatggtggtactacctacaaccggaag-
ttcaagggcaaggccacat
tgactgtagacaaatcctccagcacagcctacatgcagctcaagagtctgacatctgaggactctgcagtctat-
tactgtgcaagatcggtcg
gccctatggactactggggtcaaggaacctcagtcaccgtctcttctgatcag Amino acid
sequence (SEQ ID NO: 314):
MVSTAQFLGLLLLWLTGGRCDIQMTQSPASLSASVGETVTITCRTSENVYSYLAWYQQK
QGKSPQLLVSFAKTLAEGVPSRFSGSGSGTQFSLKISSLQPEDSGSYFCQHHSDNPWTFG
GGTELEIKGGGGSGGGGSGGGGSSAVQLQQSGPELEKPGASVKISCKASGYSFTGYNMN
WVKQNNGKSLEWIGNIDPYYGGTTYNRKFKGKATLTVDKSSSTAYMQLKSLTSEDSAV
YYCARSVGPMDYWGQGTSVTVSSDQ 47. G28-1 VHL11S (SEQ ID NO: 315)
Nucleotide sequence:
gcggtccagctgcagcagtctggacctgagtcggaaaagcctggcgcttcagtgaagatttcctgcaaggcttc-
tggttactcattcactggc
tacaatatgaactgggtgaagcagaataatggaaagagccttgagtggattggaaatattgatccttattatgg-
tggtactacctacaaccgga
agttcaagggcaaggccacattgactgtagacaaatcctccagcacagcctacatgcagctcaagagtctgaca-
tctgaggactctgcagt
ctattactgtgcaagatcggtcggccctatggactactggggtcaaggaacctcagtcaccgtctcttctgatc-
ag Amino acid sequence (SEQ ID NO: 316):
AVQLQQSGPESEKPGASVKISCKASGYSFTGYNMNWVKQNNGKSLEWIGNIDPYYGGT
TYNRKFKGKATLTVDKSSSTAYMQLKSLTSEDSAVYYCARSVGPMDYWGQGTSVTVS SDQ 48.
G28-1 VHL11S scFv (SEQ ID NO: 317) Nucleotide sequence:
aagcttgccgccatggtatccacagctcagttccttgggttgctgctgctgtggcttacaggtggcagatgtga-
catccagatgactcagtctc
cagcctccctatctgcatctgtgggagagactgtcaccatcacatgtcgaacaagtgaaaatgtttacagttat-
ttggcttggtatcagcagaa
acagggaaaatctcctcagctcctggtctcttttgcaaaaaccttagcagaaggtgtgccatcaaggttcagtg-
gcagtggatcaggcacac
agttttctctgaagatcagcagcctgcagcctgaagattctggaagttatttctgtcaacatcattccgataat-
ccgtggacgttcggtggaggc
accgaactggagatcaaaggtggcggtggctcgggcggtggtgggtcgggtggcggcggatcgtcagcggtcca-
gctgcagcagtctg
gacctgagtcggaaaagcctggcgcttcagtgaagatttcctgcaaggcttctggttactcattcactggctac-
aatatgaactgggtgaagc
agaataatggaaagagccttgagtggattggaaatattgatccttattatggtggtactacctacaaccggaag-
ttcaagggcaaggccacat
tgactgtagacaaatcctccagcacagcctacatgcagctcaagagtctgacatctgaggactctgcagtctat-
tactgtgcaagatcggtcg
gccctatggactactggggtcaaggaacctcagtcaccgtctcttctgatcag Amino acid
sequence (SEQ ID NO: 318):
MVSTAQFLGLLLLWLTGGRCDIQMTQSPASLSASVGETVTITCRTSENVYSYLAWYQQK
QGKSPQLLVSFAKTLAEGVPSRFSGSGSGTQFSLKISSLQPEDSGSYFCQHHSDNPWTFG
GGTELEIKGGGGSGGGGSGGGGSSAVQLQQSGPESEKPGASVKISCKASGYSFTGYNMN
WVKQNNGKSLEWIGNIDPYYGGTTYNRKFKGKATLTVDKSSSTAYMQLKSLTSEDSAV
YYCARSVGPMDYWGQGTSVTVSSDQ 49. G28-1 scFv (SSS-S)H WCH2 WCH3 (SEQ ID
NO: 319) Nucleotide sequence:
aagcttgccgccatggtatccacagctcagttccttgggttgctgctgctgtggcttacaggtggcagatgtga-
catccagatgactcagtctc
cagcctccctatctgcatctgtgggagagactgtcaccatcacatgtcgaacaagtgaaaatgtttacagttat-
ttggcttggtatcagcagaa
acagggaaaatctcctcagctcctggtctcttttgcaaaaaccttagcagaaggtgtgccatcaaggttcagtg-
gcagtggatcaggcacac
agttttctctgaagatcagcagcctgcagcctgaagattctggaagttatttctgtcaacatcattccgataat-
ccgtggacgttcggtggaggc
accgaactggagatcaaaggtggcggtggctcgggcggtggtgggtcgggtggcggcggatcgtcagcggtcca-
gctgcagcagtctg
gacctgagctggaaaagcctggcgcttcagtgaagatttcctgcaaggcttctggttactcattcactggctac-
aatatgaactgggtgaagc
agaataatggaaagagccttgagtggattggaaatattgatccttattatggtggtactacctacaaccggaag-
ttcaagggcaaggccacat
tgactgtagacaaatcctccagcacagcctacatgcagctcaagagtctgacatctgaggactctgcagtctat-
tactgtgcaagatcggtcg
gccctatggactactggggtcaaggaacctcagtcaccgtctcttctgatcatgatcaggagcccaaatcttct-
gacaaaactcacacatccc
caccgtcctcagcacctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaaggacaccctc-
atgatctcccggacccct
gaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgt-
ggaggtgcataatgc
caagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccagg-
actggctgaatggc
aaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaacaatctccaaagccaaagg-
gcagccccgagaac
cacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaa-
ggcttctatcccagcg
acatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactcc-
gacggctccttcttc
ctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatga-
ggctctgcacaaccact acacgcagaagagcctctccctgtctccgggtaaatgatctaga
Amino acid sequence (SEQ ID NO: 320):
MVSTAQFLGLLLLWLTGGRCDIQMTQSPASLSASVGETVTITCRTSENVYSYLAWYQQK
QGKSPQLLVSFAKTLAEGVPSRFSGSGSGTQFSLKISSLQPEDSGSYFCQHHSDNPWTFG
GGTELEIKGGGGSGGGGSGGGGSSAVQLQQSGPELEKPGASVKISCKASGYSFTGYNMN
WVKQNNGKSLEWIGNIDPYYGGTTYNRKFKGKATLTVDKSSSTAYMQLKSLTSEDSAV
YYCARSVGPMDYWGQGTSVTVSSDHDQEPKSSDKTHTSPPSSAPELLGGPSVFLFPPKP
KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVS
VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQV
SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV
FSCSVMHEALHNHYTQKSLSLSPGK 50. G28-1 scFv IgAW H IgG1WCH2 WCH3 (SEQ
ID NO: 321) Nucleotide sequence:
aagcttgccgccatggtatccacagctcagttccttgggttgctgctgctgtggcttacaggtggcagatgtga-
catccagatgactcagtctc
cagcctccctatctgcatctgtgggagagactgtcaccatcacatgtcgaacaagtgaaaatgtttacagttat-
ttggcttggtatcagcagaa
acagggaaaatctcctcagctcctggtctcttttgcaaaaaccttagcagaaggtgtgccatcaaggttcagtg-
gcagtggatcaggcacac
agttttctctgaagatcagcagcctgcagcctgaagattctggaagttatttctgtcaacatcattccgataat-
ccgtggacgttcggtggaggc
accgaactggagatcaaaggtggcggtggctcgggcggtggtgggtcgggtggcggcggatcgtcagcggtcca-
gctgcagcagtctg
gacctgagctggaaaagcctggcgcttcagtgaagatttcctgcaaggcttctggttactcattcactggctac-
aatatgaactgggtgaagc
agaataatggaaagagccttgagtggattggaaatattgatccttattatggtggtactacctacaaccggaag-
ttcaagggcaaggccacat
tgactgtagacaaatcctccagcacagcctacatgcagctcaagagtctgacatctgaggactctgcagtctat-
tactgtgcaagatcggtcg
gccctatggactactggggtcaaggaacctcagtcaccgtctcttctgatcagccagttccctcaactccacct-
accccatctccctcaactcc
acctaccccatctccctcatgcgcacctgaactcctggggggaccgtcagtcttcctcttccccccaaaaccca-
aggacaccctcatgatctc
ccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacg-
tggacggcgtggagg
tgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtc-
ctgcaccaggactgg
ctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaacaatctccaa-
agccaaagggcagcc
ccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcc-
tggtcaaaggcttcta
tcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgc-
tggactccgacggc
tccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgt-
gatgcatgaggctctgca
caaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga Amino acid
sequence (SEQ ID NO: 322):
MVSTAQFLGLLLLWLTGGRCDIQMTQSPASLSASVGETVTITCRTSENVYSYLAWYQQK
QGKSPQLLVSFAKTLAEGVPSRFSGSGSGTQFSLKISSLQPEDSGSYFCQHHSDNPWTFG
GGTELEIKGGGGSGGGGSGGGGSSAVQLQQSGPELEKPGASVKISCKASGYSFTGYNMN
WVKQNNGKSLEWIGNIDPYYGGTTYNRKFKGKATLTVDKSSSTAYMQLKSLTSEDSAV
YYCARSVGPMDYWGQGTSVTVSSDQPVPSTPPTPSPSTPPTPSPSCAPELLGGPSVFLFPP
KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV
VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKN
QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG
NVFSCSVMHEALHNHYTQKSLSLSPGK 51. G28-1 scFv VHL11S (SSS-S)H WCH2
WCH3 (SEQ ID NO: 323) Nucleotide sequence:
aagcttgccgccatggtatccacagctcagttccttgggttgctgctgctgtggcttacaggtggcagatgtga-
catccagatgactcagtctc
cagcctccctatctgcatctgtgggagagactgtcaccatcacatgtcgaacaagtgaaaatgtttacagttat-
ttggcttggtatcagcagaa
acagggaaaatctcctcagctcctggtctcttttgcaaaaaccttagcagaaggtgtgccatcaaggttcagtg-
gcagtggatcaggcacac
agttttctctgaagatcagcagcctgcagcctgaagattctggaagttatttctgtcaacatcattccgataat-
ccgtggacgttcggtggaggc
accgaactggagatcaaaggtggcggtggctcgggcggtggtgggtcgggtggcggcggatcgtcagcggtcca-
gctgcagcagtctg
gacctgagtcggaaaagcctggcgcttcagtgaagatttcctgcaaggcttctggttactcattcactggctac-
aatatgaactgggtgaagc
agaataatggaaagagccttgagtggattggaaatattgatccttattatggtggtactacctacaaccggaag-
ttcaagggcaaggccacat
tgactgtagacaaatcctccagcacagcctacatgcagctcaagagtctgacatctgaggactctgcagtctat-
tactgtgcaagatcggtcg
gccctatggactactggggtcaaggaacctcagtcaccgtctcttctgatcaggagcccaaatcttctgacaaa-
actcacacatccccaccgt
cctcagcacctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatc-
tcccggacccctgaggt
cacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggagg-
tgcataatgccaaga
caaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactgg-
ctgaatggcaagga
gtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaacaatctccaaagccaaagggcagc-
cccgagaaccacag
gtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggctt-
ctatcccagcgacatcg
ccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggc-
tcctcttcctctaca
gcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctg-
cacaaccactacacgc agaagagcctctccctgtctccgggtaaatgatctaga Amino acid
sequence (SEQ ID NO: 324):
MVSTAQFLGLLLLWLTGGRCDIQMTQSPASLSASVGETVTITCRTSENVYSYLAWYQQK
QGKSPQLLVSFAKTLAEGVPSRFSGSGSGTQFSLKISSLQPEDSGSYFCQHHSDNPWTFG
GGTELEIKGGGGSGGGGSGGGGSSAVQLQQSGPESEKPGASVKISCKASGYSFTGYNMN
WVKQNNGKSLEWIGNIDPYYGGTTYNRKFKGKATLTVDKSSSTAYMQLKSLTSEDSAV
YYCARSVGPMDYWGQGTSVTVSSDHDQEPKSSDKTHTSPPSSAPELLGGPSVFLFPPKP
KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVS
VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQV
SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV
FSCSVMHEALHNHYTQKSLSLSPGK 52. G28-1 scFv VHL11S (CSS-S)H WCH2 WCH3
(SEQ ID NO: 325) Nucleotide sequence:
aagcttgccgccatggtatccacagctcagttccttgggttgctgctgctgtggcttacaggtggcagatgtga-
catccagatgactcagtctc
cagcctccctatctgcatctgtgggagagactgtcaccatcacatgtcgaacaagtgaaaatgtttacagttat-
ttggcttggtatcagcagaa
acagggaaaatctcctcagctcctggtctcttttgcaaaaaccttagcagaaggtgtgccatcaaggttcagtg-
gcagtggatcaggcacac
agttttctctgaagatcagcagcctgcagcctgaagattctggaagttatttctgtcaacatcattccgataat-
ccgtggacgttcggtggaggc
accgaactggagatcaaaggtggcggtggctcgggcggtggtgggtcgggtggcggcggatcgtcagcggtcca-
gctgcagcagtctg
gacctgagtcggaaaagcctggcgcttcagtgaagatttcctgcaaggcttctggttactcattcactggctac-
aatatgaactgggtgaagc
agaataatggaaagagccttgagtggattggaaatattgatccttattatggtggtactacctacaaccggaag-
ttcaagggcaaggccacat
tgactgtagacaaatcctccagcacagcctacatgcagctcaagagtctgacatctgaggactctgcagtctat-
tactgtgcaagatcggtcg
gccctatggactactggggtcaaggaacctcagtcaccgtctcttctgatcaggagcccaaatcttgtgacaaa-
actcacacatccccaccgt
cctcagcacctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatc-
tcccggacccctgaggt
cacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggagg-
tgcataatgccaaga
caaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactgg-
ctgaatggcaagga
gtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaacaatctccaaagccaaagggcagc-
cccgagaaccacag
gtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggctt-
ctatcccagcgacatcg
ccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggc-
tccttcttcctctaca
gcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctg-
cacaaccactacacgc agaagagcctctccctgtctccgggtaaatgatctaga Amino acid
sequence (SEQ ID NO: 326):
MVSTAQFLGLLLLWLTGGRCDIQMTQSPASLSASVGETVTITCRTSENVYSYLAWYQQK
QGKSPQLLVSFAKTLAEGVPSRFSGSGSGTQFSLKISSLQPEDSGSYFCQHHSDNPWTFG
GGTELEIKGGGGSGGGGSGGGGSSAVQLQQSGPESEKPGASVKISCKASGYSFTGYNMN
WVKQNNGKSLEWIGNIDPYYGGTTYNRKFKGKATLTVDKSSSTAYMQLKSLTSEDSAV
YYCARSVGPMDYWGQGTSVTVSSDQEPKSCDKTHTSPPSSAPELLGGPSVFLFPPKPKD
TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT
VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC
SVMHEALHNHYTQKSLSLSPGK 53. G28-1 scFv VH L11S (CSC-S)H WCH2 WCH3
(SEQ ID NO: 327) Nucleotide sequence:
aagcttgccgccatggtatccacagctcagttccttgggttgctgctgctgtggcttacaggtggcagatgtga-
catccagatgactcagtctc
cagcctccctatctgcatctgtgggagagactgtcaccatcacatgtcgaacaagtgaaaatgtttacagttat-
ttggcttggtatcagcagaa
acagggaaaatctcctcagctcctggtctcttttgcaaaaaccttagcagaaggtgtgccatcaaggttcagtg-
gcagtggatcaggcacac
agttttctctgaagatcagcagcctgcagcctgaagattctggaagttatttctgtcaacatcattccgataat-
ccgtggacgttcggtggaggc
accgaactggagatcaaaggtggcggtggctcgggcggtggtgggtcgggtggcggcggatcgtcagcggtcca-
gctgcagcagtctg
gacctgagtcggaaaagcctggcgcttcagtgaagatttcctgcaaggcttctggttactcattcactggctac-
aatatgaactgggtgaagc
agaataatggaaagagccttgagtggattggaaatattgatccttattatggtggtactacctacaaccggaag-
ttcaagggcaaggccacat
tgactgtagacaaatcctccagcacagcctacatgcagctcaagagtctgacatctgaggactctgcagtctat-
tactgtgcaagatcggtcg
gccctatggactactggggtcaaggaacctcagtcaccgtctcttctgatcaggagcccaaatcttgtgacaaa-
actcacacatctccaccgt
gctcagcacctgaactcctgggtggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatc-
tcccggacccctgaggtc
acatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggt-
gcataatgccaagac
aaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggc-
tgaatggcaaggagt
acaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaacaatctccaaagccaaagggcagccc-
cgagaaccacaggt
gtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttct-
atccaagcgacatcgc
cgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggct-
ccttcttcctctacag
caagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgc-
acaaccactacacgca gaagagcctctccctgtctccgggtaaatgatctaga Amino acid
sequence (SEQ ID NO: 328):
MVSTAQFLGLLLLWLTGGRCDIQMTQSPASLSASVGETVTITCRTSENVYSYLAWYQQK
QGKSPQLLVSFAKTLAEGVPSRFSGSGSGTQFSLKISSLQPEDSGSYFCQHHSDNPWTFG
GGTELEIKGGGGSGGGGSGGGGSSAVQLQQSGPESEKPGASVKISCKASGYSFTGYNMN
WVKQNNGKSLEWIGNIDPYYGGTTYNRKFKGKATLTVDKSSSTAYMQLKSLTSEDSAV
YYCARSVGPMDYWGQGTSVTVSSDQEPKSCDKTHTSPPCSAPELLGGPSVFLFPPKPKD
TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT
VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC
SVMHEALHNHYTQKSLSLSPGK 54. G28-1 scFv VH L11S (SSC-P)H WCH2 WCH3
(SEQ ID NO: 329) Nucleotide sequence:
aagcttgccgccatggtatccacagctcagttccttgggttgctgctgctgtggcttacaggtggcagatgtga-
catccagatgactcagtctc
cagcctccctatctgcatctgtgggagagactgtcaccatcacatgtcgaacaagtgaaaatgtttacagttat-
ttggcttggtatcagcagaa
acagggaaaatctcctcagctcctggtctcttttgcaaaaaccttagcagaaggtgtgccatcaaggttcagtg-
gcagtggatcaggcacac
agttttctctgaagatcagcagcctgcagcctgaagattctggaagttatttctgtcaacatcattccgataat-
ccgtggacgttcggtggaggc
accgaactggagatcaaaggtggcggtggctcgggcggtggtgggtcgggtggcggcggatcgtcagcggtcca-
gctgcagcagtctg
gacctgagtcggaaaagcctggcgcttcagtgaagatttcctgcaaggcttctggttactcattcactggctac-
aatatgaactgggtgaagc
agaataatggaaagagccttgagtggattggaaatattgatccttattatggtggtactacctacaaccggaag-
ttcaagggcaaggccacat
tgactgtagacaaatcctccagcacagcctacatgcagctcaagagtctgacatctgaggactctgcagtctat-
tactgtgcaagatcggtcg
gccctatggactactggggtcaaggaacctcagtcaccgtctcttctgatcaggagcccaaatcttctgacaaa-
actcacacatccccaccgt
gcccagcacctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatc-
tcccggacccctgaggt
cacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggagg-
tgcataatgccaaga
caaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactgg-
ctgaatggcaagga
gtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaacaatctccaaagccaaagggcagc-
cccgagaaccacag
gtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggctt-
ctatcccagcgacatcg
ccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggc-
tccttcttcctctaca
gcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctg-
cacaaccactacacgc agaagagcctctccctgtctccgggtaaatgatctaga Amino acid
sequence (SEQ ID NO: 330):
MVSTAQFLGLLLLWLTGGRCDIQMTQSPASLSASVGETVTITCRTSENVYSYLAWYQQK
QGKSPQLLVSFAKTLAEGVPSRFSGSGSGTQFSLKISSLQPEDSGSYFCQHHSDNPWTFG
GGTELEIKGGGGSGGGGSGGGGSSAVQLQQSGPESEKPGASVKISCKASGYSFTGYNMN
WVKQNNGKSLEWIGNIDPYYGGTTYNRKFKGKATLTVDKSSSTAYMQLKSLTSEDSAV
YYCARSVGPMDYWGQGTSVTVSSDQEPKSSDKTHTSPPCPAPELLGGPSVFLFPPKPKD
TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT
VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC
SVMHEALHNHYTQKSLSLSPGK II. 54. HCTLA4 HIGG1 (SSS-S)H P238SCH2 WCH3
(SEQ ID NO: 331) Nucleotide sequence:
atggcttgccttggatttcagcggcacaaggctcagctgaacctggctgccaggacctggccctgcactctcct-
gttttttcttctcttcatccct
gtcttctgcaaagcaatgcacgtggcccagcctgctgtggtactggccagcagccgaggcatcgccagctttgt-
gtgtgagtatgcatctcc
aggcaaagccactgaggtccgggtgacagtgcttcggcaggctgacagccaggtgactgaagtctgtgcggcaa-
cctacatgacgggga
atgagttgaccttcctagatgattccatctgcacgggcacctccagtggaaatcaagtgaacctcactatccaa-
ggactgagggccatggac
acgggactctacatctgcaaggtggagctcatgtacccaccgccatactacctgggcataggcaacggaaccca-
gatttatgtaattgatcc
agaaccgtgcccagattctgatcaacccaaatcttctgacaaaactcacacatccccaccgtcctcagcacctg-
aactcctggggggatcgt
cagtcttcctcttcccccaaaacccaaggacaccctcatgatctcccggacccctgaggtcacatgcgtggtgg-
tggacgtgagccacga
agaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatgccaagacaaagccgcgggagg-
agcagtacaacagc
acgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggt-
ctccaacaaagccctc
ccagcccccatcgagaaaacaatctccaaagccaaagggcagccccgagaaccacaggtgtacaccctgccccc-
atcccgggatgagc
tgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatcccagcgacatcgccgtggagtgggag-
agcaatgggcagccg
gagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcctctacagcaagctcaccgt-
ggacaagagcaggtgg
cagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctc-
cctgtctccgggtaaatga
Amino acid sequence (SEQ ID NO: 332):
MACLGFQRHKAQLNLAARTWPCTLLFFLLFIPVFCKAMHVAQPAVVLASSRGIASFVCE
YASPGKATEVRVTVLRQADSQVTEVCAATYMTGNELTFLDDSICTGTSSGNQVNLTIQG
LRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPEPCPDSDQPKSSDKTHTSPPSSAPE
LLGGSSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPR
EEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTL
PPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLT
VDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 55. Fc2-2 VL (SEQ ID NO: 333)
Nucleotide sequence:
gttgttaagcttgccgccatggattcacaggcccaggttcttatgttactgctgctatgggtatctggtacctg-
tggggacattgtgatgtcaca
gtctccatcctccctagctgtgtcagttggagagaaggtttctatgagctgcaagtccagtcagagccttttat-
ataatcacaatcaaaagaact
acttggcctggtaccagcagataccagggcagtctcctaaactgctgatttactgggcatccactagggaatct-
ggggtccctgatcgcttca
caggcagtggatctgggacagatttcactctcaccatcagcagagtgaaggctgaagacctggcagtttattac-
tgtcagcaatattataccta
tcctcccacgttcggaggtggcaccaagctggaaataaaaggtggcggtggctcgggcggtggtgggtcgggtg-
gcggcgggagctcg Amino acid sequence (SEQ ID NO: 334):
MDSQAQVLMLLLLWVSGTCGDIVMSQSPSSLAVSVGEKVSMSCKSSQSLLYNHNQKN
YLAWYQQIPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISRVKAEDLAVYYCQQ
YYTYPPTFGGGTKLEIKGGGGSGGGGSGGGGSS 56. FC2-2VH (SEQ ID NO: 335)
Nucleotide sequence:
Gggagctcgcaggtgcagttgaaggagtcaggacctggcctggtggcgccctcacagagcctgtccatcacatg-
caccgtctcagggtt
ctcattaaccgtctatggtgttaactgggttcgccagcctccaggaaagggtctggactggctgggaatgatat-
ggggtgatggaagcacag
actataattcagctctcaaatccagactgagcatcagtaaggacaactccaagagccaagttttcttaaaaatg-
gacagtctacaaactgatga
cacagccaggtactactgtgccagagatcactatggtacccactatgctatggactactggggtcaaggaacct-
cagtcaccgtctcctctga tcag Amino acid sequence (SEQ ID NO: 336):
GSSQVQLKESGPGLVAPSQSLSITCTVSGFSLTVYGVNWVRQPPGKGLDWLGMIWGDG
STDYNSALKSRLSISKDNSKSQVFLKMDSLQTDDTARYYCARDHYGTHYAMDYWGQG TSVTVSSDQ
57. FC2-2scFv (SEQ ID NO: 337) Nucleotide sequence:
gttgttaagcttgccgccatggattcacaggcccaggttcttatgttactgctgctatgggtatctggtacctg-
tggggacattgtgatgtcaca
gtctccatcctccctagctgtgtcagttggagagaaggtttctatgagctgcaagtccagtcagagccttttat-
ataatcacaatcaaaagaact
acttggcctggtaccagcagataccagggcagtctcctaaactgctgatttactgggcatccactagggaatct-
ggggtccctgatcgcttca
caggcagtggatctgggacagatttcactctcaccatcagcagagtgaaggctgaagacctggcagtttattac-
tgtcagcaatattataccta
tcctcccacgttcggaggtggcaccaagctggaaataaaaggtggcggtggctcgggcggtggtgggtcgggtg-
gcggcgggagctct
caggtgcagttgaaggagtcaggacctggcctggtggcgccctcacagagcctgtccatcacatgcaccgtctc-
agggttctcattaaccgt
ctatggtgttaactgggttcgccagcctccaggaaagggtctggactggctgggaatgatatggggtgatggaa-
gcacagactataattcag
ctctcaaatccagactgagcatcagtaaggacaactccaagagccaagttttcttaaaaatggacagtctacaa-
actgatgacacagccagg
tactactgtgccagagatcactatggtacccactatgctatggactactggggtcaaggaacctcagtcaccgt-
ctcctctgatcag Amino acid sequence (SEQ ID NO: 338):
MDSQAQVLMLLLLWVSGTCGDIVMSQSPSSLAVSVGEKVSMSCKSSQSLLYNHNQKN
YLAWYQQIPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISRVKAEDLAVYYCQQ
YYTYPPTFGGGTKLEIKGGGGSGGGGSGGGGSSQVQLKESGPGLVAPSQSLSITCTVSGF
SLTVYGVNWVRQPPGKGLDWLGMIWGDGSTDYNSALKSRLSISKDNSKSQVFLKMDS
LQTDDTARYYCARDHYGTHYAMDYWGQGTSVTVSSDQ 58. FC2-2 VHL11S (SEQ ID NO:
339) Nucleotide sequence:
gggagctctcaggtgcagttgaaggagtcaggacctggctcggtggcgccctcacagagcctgtccatcacatg-
caccgtctcagggttct
cattaaccgtctatggtgttaactgggttcgccagcctccaggaaagggtctggactggctgggaatgatatgg-
ggtgatggaagcacaga
ctataattcagctctcaaatccagactgagcatcagtaaggacaactccaagagccaagttttcttaaaaatgg-
acagtctacaaactgatgac
acagccaggtactactgtgccagagatcactatggtacccactatgctatggactactggggtcaaggaacctc-
agtcaccgtctcctctgat cag Amino acid sequence (SEQ ID NO: 340):
(GSS)QVQLKESGPGSVAPSQSLSITCTVSGFSLTVYGVNWVRQPPGKGLDWLGMIWGD
GSTDYNSALKSRLSISKDNSKSQVFLKMDSLQTDDTARYYCARDHYGTHYAMDYWGQ
GTSVTVSSDQ 59. FC2-2 VH L11S scFv (SEQ ID NO: 341) Nucleotide
sequence:
gttgttaagcttgccgccatggattcacaggcccaggttcttatgttactgctgctatgggtatctggtacctg-
tggggacattgtgatgtcaca
gtctccatcctccctagctgtgtcagttggagagaaggtttctatgagctgcaagtccagtcagagccttttat-
ataatcacaatcaaaagaact
acttggcctggtaccagcagataccagggcagtctcctaaactgctgatttactgggcatccactagggaatct-
ggggtccctgatcgcttca
caggcagtggatctgggacagatttcactctcaccatcagcagagtgaaggctgaagacctggcagtttattac-
tgtcagcaatattataccta
tcctcccacgttcggaggtggcaccaagctggaaataaaaggtggcggtggctcgggcggtggtgggtcgggtg-
gcggcgggagctct
caggtgcagttgaaggagtcaggacctggctcggtggcgccctcacagagcctgtccatcacatgcaccgtctc-
agggttctcattaaccgt
ctatggtgttaactgggttcgccagcctccaggaaagggtctggactggctgggaatgatatggggtgatggaa-
gcacagactataattcag
ctctcaaatccagactgagcatcagtaaggacaactccaagagccaagttttcttaaaaatggacagtctacaa-
actgatgacacagccagg
tactactgtgccagagatcactatggtacccactatgctatggactactggggtcaaggaacctcagtcaccgt-
ctcctctgatcag Amino acid sequence (SEQ ID NO: 342):
MDSQAQVLMLLLLWVSGTCGDIVMSQSPSSLAVSVGEKVSMSCKSSQSLLYNHNQKN
YLAWYQQIPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISRVKAEDLAVYYCQQ
YYTYPPTFGGGTKLEIKGGGGSGGGGSGGGGSSQVQLKESGPGSVAPSQSLSITCTVSGF
SLTVYGVNWVRQPPGKGLDWLGMIWGDGSTDYNSALKSRLSISKDNSKSQVFLKMDS
LQTDDTARYYCARDHYGTHYAMDYWGQGTSVTVSSDQ 60. FC2-2 (SSS-S)H WCH2 WCH3
(SEQ ID NO: 343) Nucleotide sequence:
gttgttaagcttgccgccatggattcacaggcccaggttcttatgttactgctgctatgggtatctggtacctg-
tggggacattgtgatgtcaca
gtctccatcctccctagctgtgtcagttggagagaaggtttctatgagctgcaagtccagtcagagccttttat-
ataatcacaatcaaaagaact
acttggcctggtaccagcagataccagggcagtctcctaaactgctgatttactgggcatccactagggaatct-
ggggtccctgatcgcttca
caggcagtggatctgggacagatttcactctcaccatcagcagagtgaaggctgaagacctggcagtttattac-
tgtcagcaatattataccta
tcctcccacgttcggaggtggcaccaagctggaaataaaaggtggcggtggctcgggcggtggtgggtcgggtg-
gcggcgggagctct
caggtgcagttgaaggagtcaggacctggcctggtggcgccctcacagagcctgtccatcacatgcaccgtctc-
agggttctcattaaccgt
ctatggtgttaactgggttcgccagcctccaggaaagggtctggactggctgggaatgatatggggtgatggaa-
gcacagactataattcag
ctctcaaatccagactgagcatcagtaaggacaactccaagagccaagttttcttaaaaatggacagtctacaa-
actgatgacacagccagg
tactactgtgccagagatcactatggtacccactatgctatggactactggggtcaaggaacctcagtcaccgt-
ctcctctgatcaggagccc
aaatcttctgacaaaactcacacatccccaccgtcctcagcacctgaactcctgggtggaccgtcagtcttcct-
cttccccccaaaacccaag
gacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggt-
caagttcaactggtac
gtggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggt-
cagcgtcctcaccg
tcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatc-
gagaaaaccatctcca
aagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccag-
gtcagcctgacctg
cctggtcaaaggcttctatccaagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactaca-
agaccacgcctcccg
tgctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaac-
gtcttctcatgctccgtg
atgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga
Amino acid sequence (SEQ ID NO: 344):
MDSQAQVLMLLLLWVSGTCGDIVMSQSPSSLAVSVGEKVSMSCKSSQSLLYNHNQKN
YLAWYQQIPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISRVKAEDLAVYYCQQ
YYTYPPTFGGGTKLEIKGGGGSGGGGSGGGGSSQVQLKESGPGLVAPSQSLSITCTVSGF
SLTVYGVNWVRQPPGKGLDWLGMIWGDGSTDYNSALKSRLSISKDNSKSQVFLKMDS
LQTDDTARYYCARDHYGTHYAMDYWGQGTSVTVSSDQEPKSSDKTHTSPPSSAPELLG
GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ
YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS
RDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD
KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 61. FC2-2 VHL11S (SSS-S)H WCH2
WCH3 (SEQ ID NO: 345) Nucleotide sequence:
gttgttaagcttgccgccatggattcacaggcccaggttcttatgttactgctgctatgggtatctggtacctg-
tggggacattgtgatgtcaca
gtctccatcctccctagctgtgtcagttggagagaaggtttctatgagctgcaagtccagtcagagccttttat-
ataatcacaatcaaaagaact
acttggcctggtaccagcagataccagggcagtctcctaaactgctgatttactgggcatccactagggaatct-
ggggtccctgatcgcttca
caggcagtggatctgggacagatttcactctcaccatcagcagagtgaaggctgaagacctggcagtttattac-
tgtcagcaatattataccta
tcctcccacgttcggaggtggcaccaagctggaaataaaaggtggcggtggctcgggcggtggtgggtcgggtg-
gcggcgggagctct
caggtgcagttgaaggagtcaggacctggctcggtggcgccctcacagagcctgtccatcacatgcaccgtctc-
agggttctcattaaccgt
ctatggtgttaactgggttcgccagcctccaggaaagggtctggactggctgggaatgatatggggtgatggaa-
gcacagactataattcag
ctctcaaatccagactgagcatcagtaaggacaactccaagagccaagttttcttaaaaatggacagtctacaa-
actgatgacacagccagg
tactactgtgccagagatcactatggtacccactatgctatggactactggggtcaaggaacctcagtcaccgt-
ctcctctgatcaggagccc
aaatcttctgacaaaactcacacatccccaccgtcctcagcacctgaactcctgggtggaccgtcagtcttcct-
cttccccccaaaacccaag
gacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggt-
caagttcaactggtac
gtggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggt-
cagcgtcctcaccg
tcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatc-
gagaaaaccatctcca
aagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccag-
gtcagcctgacctg
cctggtcaaaggcttctatccaagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactaca-
agaccacgcctcccg
tgctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaac-
gtcttctcatgctccgtg
atgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga
Amino acid sequence (SEQ ID NO: 346):
MDSQAQVLMLLLLWVSGTCGDIVMSQSPSSLAVSVGEKVSMSCKSSQSLLYNHNQKN
YLAWYQQIPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISRVKAEDLAVYYCQQ
YYTYPPTFGGGTKLEIKGGGGSGGGGSGGGGSSQVQLKESGPGSVAPSQSLSITCTVSGF
SLTVYGVNWVRQPPGKGLDWLGMIWGDGSTDYNSALKSRLSISKDNSKSQVFLKMDS
LQTDDTARYYCARDHYGTHYAMDYWGQGTSVTVSSDQEPKSSDKTHTSPPSSAPELLG
GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ
YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS
RDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD
KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 62. UCHL-1 VH (SEQ ID NO: 347)
Nucleotide sequence:
atgggcaggcttacttcttcattcctgctactgattgttcctgcatatgtcctctcccagattactctgaaaga-
gtctggccctgggatcttgcagc
cctcccagaccctcagtctgacttgttctttctctgggttttcactgaccacttatggtataggagtaggttgg-
attcgtcagcctccagggaagg
gtctggagtggctgacacacatttggtggaatgataataagtactataacacagccctgaggagccggctcaca-
atctccaaggattcctcc
aacaaccaagtactcctcaagatcgccaatgtggacactgcagataccgccacatactactgtctctacggcta-
cacttactggggccaagg gactctggtcactgtctctgca Amino acid sequence (SEQ
ID NO: 348):
MGRLTSSFLLLIVPAYVLSQITLKESGPGILQPSQTLSLTCSFSGFSLTTYGIGVGWIRQPP
GKGLEWLTHIWWNDNKYYNTALRSRLTISKDSSNNQVLLKIANVDTADTATYYCLYGY
TYWGQGTLVTVSA 63. UCHL-1 VL (SEQ ID NO: 349) Nucleotide sequence:
atgaagttgcctgttaggctgttggtgctgatgttctggattcctgcttccatcagtgatgttgtgatgaccca-
aactccactctccctgcctgtca
gtcttggagatcaggcctccatctatgcagatctagtcagagccttctttacagtaatggaaacacctatttac-
attggtacctgcagaagcca
ggccagtctccaaaactcctgatctacaaactttccaaccgattttctggggtcccagacaggttcagtggcag-
tggatcagggacagatttc
acactcaagatcagcagagtggaggctgaggatctgggagtttatttctgctctcaaagtacacatgttccgtg-
gacgttcggtggaggcac caagctggaaatcaaa Amino acid sequence (SEQ ID NO:
350): MKLPVRLLVLMFWIPASISDVVMTQTPLSLPVSLGDQASISCRSSQSLLYSNGNTYLHW
YLQKPGQSPKLLIYKLSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVP
WTFGGGTKLEIK 64. UCHL-1 scFv (SEQ ID NO: 351) Nucleotide sequence:
gttgttaagcttgccgccatgaagttgcctgttaggctgttggtgctgatgttctggattcctgcttccatcag-
tgatgttgtgatgacccaaactc
cactctccctgcctgtcagtcttggagatcaggcctccatctcttgcagatctagtcagagccttctttacagt-
aatggaaacacctatttacatt
ggtacctgcagaagccaggccagtctccaaaactcctgatctacaaactttccaaccgattttctggggtccca-
gacaggttcagtggcagt
ggatcagggacagatttcacactcaagatcagcagagtggaggctgaggatctgggagtttatttctgctctca-
aagtacacatgttccgtgg
acgttcggtggaggcaccaagctggaaatcaaagatggcggtggctcgggcggtggtggatctggaggaggtgg-
gagctctcagattac
tctgaaagagtctggccctgggatcttgcagccctcccagaccctcagtctgacttgttctttctctgggtttt-
cactgaccacttatggtatagg
agtaggttggattcgtcagcctccagggaagggtctggagtggctgacacacatttggtggaatgataataagt-
actataacacagccctga
ggagccggctcacaatctccaaggattcctccaacaaccaagtactcctcaagatcgccaatgtggacactgca-
gataccgccacatacta
ctgtctctacggctacacttactggggccaagggactctggtcactgtctctgctgatca Amino
acid sequence (SEQ ID NO: 352):
MKLPVRLLVLMFWIPASISDVVMTQTPLSLPVSLGDQASISCRSSQSLLYSNGNTYLHW
YLQKPGQSPKLLIYKLSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVP
WTFGGGTKLEIKDGGGSGGGGSGGGGSSQITLKESGPGILQPSQTLSLTCSFSGFSLTTYG
IGVGWIRQPPGKGLEWLTHIWWNDNKYYNTALRSRLTISKDSSNNQVLLKIANVDTAD
TATYYCLYGYTYWGQGTLVTVSAD 65. UCHL-1 VH I11SL12S (SEQ ID NO: 353)
Nucleotide sequence:
gggagctctcagattactctgaaagagtctggccctgggatcttgcagccctcccagaccctcagtctgacttg-
ttctttctctgggttttcactg
accacttatggtataggagtaggttggattcgtcagcctccagggaagggtctggagtggctgacacacatttg-
gtggaatgataataagtac
tataacacagccctgaggagccggctcacaatctccaaggattcctccaacaaccaagtactcctcaagatcgc-
caatgtggacactgcag
ataccgccacatactactgtctctacggctacacttactggggccaagggactctggtcactgtctctgctgat-
ca Amino acid sequence (SEQ ID NO: 354):
(GSS)QITLKESGPGSSQPSQTLSLTCSFSGFSLTTYGIGVGWIRQPPGKGLEWLTHIWWN
DNKYYNTALRSRLTISKDSSNNQVLLKIANVDTADTATYYCLYGYTYWGQGTLVTVSAD 66.
UCHL-1 scFv VH L11S (SEQ ID NO: 355) Nucleotide sequence:
gttgttaagcttgccgccatgaagttgcctgttaggctgttggtgctgatgttctggattcctgcttccatcag-
tgatgttgtgatgacccaaactc
cactctccctgcctgtcagtcttggagatcaggcctccatctcttgcagatctagtcagagccttctttacagt-
aatggaaacacctatttacatt
ggtacctgcagaagccaggccagtctccaaaactcctgatctacaaactttccaaccgattttctggggtccca-
gacaggttcagtggcagt
ggatcagggacagatttcacactcaagatcagcagagtggaggctgaggatctgggagtttatttctgctctca-
aagtacacatgttccgtgg
acgttcggtggaggcaccaagctggaaatcaaagatggcggtggctcgggcggtggtggatctggaggaggtgg-
gagctctcagattac
tctgaaagagtctggccctgggagctcccagccctcccagaccctcagtctgacttgttctttctctgggtttt-
cactgaccacttatggtatag
gagtaggttggattcgtcagcctccagggaagggtctggagtggctgacacacatttggtggaatgataataag-
tactataacacagccctg
aggagccggctcacaatctccaaggattcctccaacaaccaagtactcctcaagatcgccaatgtggacactgc-
agataccgccacatact
actgtctctacggctacacttactggggccaagggactctggtcactgtctctgctgatca Amino
acid sequence (SEQ ID NO: 356):
MKLPVRLLVLMFWIPASISDVVMTQTPLSLPVSLGDQASISCRSSQSLLYSNGNTYLHW
YLQKPGQSPKLLIYKLSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVP
WTFGGGTKLEIKDGGGSGGGGSGGGGSSQITLKESGPGSSQPSQTLSLTCSFSGFSLTTY
GIGVGWIRQPPGKGLEWLTHIWWNDNKYYNTALRSRLTISKDSSNNQVLLKIANVDTA
DTATYYCLYGYTYWGQGTLVTVSAD 67. UCHL-1 scFv (SSS-S)H WCH2 WCH3 (SEQ
ID NO: 357) Nucleotide sequence:
gttgttaagcttgccgccatgaagttgcctgttaggctgttggtgctgatgttctggattcctgcttccatcag-
tgatgttgtgatgacccaaactc
cactctccctgcctgtcagtcttggagatcaggcctccatctcttgcagatctagtcagagccttctttacagt-
aatggaaacacctatttacatt
ggtacctgcagaagccaggccagtctccaaaactcctgatctacaaactttccaaccgattttctggggtccca-
gacaggttcagtggcagt
ggatcagggacagatttcacactcaagatcagcagagtggaggctgaggatctgggagtttatttctgctctca-
aagtacacatgttccgtgg
acgttcggtggaggcaccaagctggaaatcaaagatggcggtggctcgggcggtggtggatctggaggaggtgg-
gagctctcagattac
tctgaaagagtctggccctgggatcttgcagccctcccagaccctcagtctgacttgttctttctctgggtttt-
cactgaccacttatggtatagg
agtaggttggattcgtcagcctccagggaagggtctggagtggctgacacacatttggtggaatgataataagt-
actataacacagccctga
ggagccggctcacaatctccaaggattcctccaacaaccaagtactcctcaagatcgccaatgtggacactgca-
gataccgccacatacta
ctgtctctacggctacacttactggggccaagggactctggtcactgtctctgctgatcaggagcccaaatctt-
ctgacaaaactcacacatcc
ccaccgtcctcagcacctgaactcctgggtggaccgtcagtcttcctcttccccccaaaacccaaggacaccct-
catgatctcccggacccc
tgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcg-
tggaggtgcataatgc
caagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccagg-
actggctgaatggc
aaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaagg-
gcagccccgagaac
cacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaa-
ggcttctatccaagcg
acatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactcc-
gacggctccttcttc
ctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatga-
ggctctgcacaaccact acacgcagaagagcctctccctgtctccgggtaaatgatctaga
Amino acid sequence (SEQ ID NO: 358):
MKLPVRLLVLMFWIPASISDVVMTQTPLSLPVSLGDQASISCRSSQSLLYSNGNTYLHW
YLQKPGQSPKLLIYKLSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVP
WTFGGGTKLEIKDGGGSGGGGSGGGGSSQITLKESGPGILQPSQTLSLTCSFSGFSLTTYG
IGVGWIRQPPGKGLEWLTHIWWNDNKYYNTALRSRLTISKDSSNNQVLLKIANVDTAD
TATYYCLYGYTYWGQGTLVTVSADQEPKSSDKTHTSPPSSAPELLGGPSVFLFPPKPKD
TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT
VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC
SVMHEALHNHYTQKSLSLSPGK 68. UCHL-1 scFv VHL11S (SSS-S)H WCH2 WCH3
(SEQ ID NO: 359) Nucleotide sequence:
gttgttaagcttgccgccatgaagttgcctgttaggctgttggtgctgatgttctggattcctgcttccatcag-
tgatgttgtgatgacccaaactc
cactctccctgcctgtcagtcttggagatcaggcctccatctcttgcagatctagtcagagccttctttacagt-
aatggaaacacctatttacatt
ggtacctgcagaagccaggccagtctccaaaactcctgatctacaaactttccaaccgattttctggggtccca-
gacaggttcagtggcagt
ggatcagggacagatttcacactcaagatcagcagagtggaggctgaggatctgggagtttatttctgctctca-
aagtacacatgttccgtgg
acgttcggtggaggcaccaagctggaaatcaaagatggcggtggctcgggcggtggtggatctggaggaggtgg-
gagctctcagattac
tctgaaagagtctggccctgggagctcccagccctcccagaccctcagtctgacttgttctttctctgggtttt-
cactgaccacttatggtatag
gagtaggttggattcgtcagcctccagggaagggtctggagtggctgacacacatttggtggaatgataataag-
tactataacacagccctg
aggagccggctcacaatctccaaggattcctccaacaaccaagtactcctcaagatcgccaatgtggacactgc-
agataccgccacatact
actgtctctacggctacacttactggggccaagggactctggtcactgtctctgctgatcaggagcccaaatct-
tctgacaaaactcacacatc
cccaccgtcctcagcacctgaactcctgggtggaccgtcagtcttcctcttccccccaaaacccaaggacaccc-
tcatgatctcccggaccc
ctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggc-
gtggaggtgcataatg
ccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccag-
gactggctgaatgg
caaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaag-
ggcagccccgagaa
ccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaa-
aggcttctatccaagc
gacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactc-
cgacggctccttctt
cctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatg-
aggctctgcacaacca ctacacgcagaagagcctctccctgtctccgggtaaatgatctagaa
Amino acid sequence (SEQ ID NO: 360):
MKLPVRLLVLMFWIPASISDVVMTQTPLSLPVSLGDQASISCRSSQSLLYSNGNTYLHW
YLQKPGQSPKLLIYKLSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVP
WTFGGGTKLEIKDGGGSGGGGSGGGGSSQITLKESGPGSSQPSQTLSLTCSFSGFSLTTY
GIGVGWIRQPPGKGLEWLTHIWWNDNKYYNTALRSRLTISKDSSNNQVLLKIANVDTA
DTATYYCLYGYTYWGQGTLVTVSADQEPKSSDKTHTSPPSSAPELLGGPSVFLFPPKPK
DTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVL
TVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSL
TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS
CSVMHEALHNHYTQKSLSLSPGK 69. 5B9 VH L11S (SEQ ID NO: 361) Nucleotide
sequence:
gggagctctcaggtgcagctgaagcagtcaggacctggctcagtgcagtcctcacagagcctgtccatcacctg-
cacagtctctggtttctc
attaactacctatgctgtacactgggttcgccagtctccaggaaagggtctggagtggctgggagtgatatgga-
gtggtggaatcacagact
ataatgcagctttcatatccagactgagcatcaccaaggacgattccaagagccaagttttctttaaaatgaac-
agtctgcaacctaatgacac
agccatttattactgtgccagaaatgggggtgataactacccttattactatgctatggactactggggtcaag-
gaacctcagtcaccgtctcct cag Amino acid sequence (SEQ ID NO: 362):
(GSS)QVQLKQSGPGSVQSSQSLSITCTVSGFSLTTYAVHWVRQSPGKGLEWLGVIWSGG
ITDYNAAFISRLSITKDDSKSQVFFKMNSLQPNDTAIYYCARNGGDNYPYYYAMDYWG
QGTSVTVSS 73. 5B9 VH L11S scFv (SEQ ID NO: 363) Nucleotide
sequence:
aagcttgccgccatgaggttctctgctcagcttctggggctgcttgtgctctggatccctggatccactgcaga-
tattgtgatgacgcaggctg
cattctccaatccagtcactcttggaacatcagcttccatctcctgcaggtctagtaagagtctcctacatagt-
aatggcatcacttatttgtattg
gtatctgcagaagccaggccagtctcctcagctcctgatttatcagatgtccaaccttgcctcaggagtcccag-
acaggttcagtagcagtgg
gtcaggaactgatttcacactgagaatcagcagagtggaggctgaggatgtgggtgtttattactgtgctcaaa-
atctagaacttccgctcac
gttcggtgctgggaccaagctggagctgaaacggggtggcggtggctcgggcggtggtgggtcgggtggcggcg-
ggagctctcaggtg
cagctgaagcagtcaggacctggctcagtgcagtcctcacagagcctgtccatcacctgcacagtctctggttt-
ctcattaactacctatgctg
tacactgggttcgccagtctccaggaaagggtctggagtggctgggagtgatatggagtggtggaatcacagac-
tataatgcagctttcatat
ccagactgagcatcaccaaggacgattccaagagccaagttttctttaaaatgaacagtctgcaacctaatgac-
acagccatttattactgtgc
cagaaatgggggtgataactacccttattactatgctatggactactggggtcaaggaacctcagtcaccgtct-
cctcag Amino acid sequence (SEQ ID NO: 364):
MRFSAQLLGLLVLWIPGSTADIVMTQAAFSNPVTLGTSASISCRSSKSLLHSNGITYLYW
YLQKPGQSPQLLIYQMSNLASGVPDRFSSSGSGTDFTLRISRVEAEDVGVYYCAQNLELP
LTFGAGTKLELKRGGGGSGGGGSGGGGSSQVQLKQSGPGSVQSSQSLSITCTVSGFSLTT
YAVHWVRQSPGKGLEWLGVIWSGGITDYNAAFISRLSITKDDSKSQVFFKMNSLQPNDT
AIYYCARNGGDNYPYYYAMDYWGQGTSVTVSS 70. 5B9 scFv VHL11S (SSS-S)H WCH2
WCH3 (SEQ ID NO: 365) Nucleotide sequence:
aagcttgccgccatgaggttctctgctcagcttctggggctgcttgtgctctggatccctggatccactgcaga-
tattgtgatgacgcaggctg
cattctccaatccagtcactcttggaacatcagcttccatctcctgcaggtctagtaagagtctcctacatagt-
aatggcatcacttatttgtattg
gtatctgcagaagccaggccagtctcctcagctcctgatttatcagatgtccaaccttgcctcaggagtcccag-
acaggttcagtagcagtgg
gtcaggaactgatttcacactgagaatcagcagagtggaggctgaggatgtgggtgtttattactgtgctcaaa-
atctagaacttccgctcac
gttcggtgctgggaccaagctggagctgaaacggggtggcggtggctcgggcggtggtgggtcgggtggcggcg-
ggagctctcaggtg
cagctgaagcagtcaggacctggctcagtgcagtcctcacagagcctgtccatcacctgcacagtctctggttt-
ctcattaactacctatgctg
tacactgggttcgccagtctccaggaaagggtctggagtggctgggagtgatatggagtggtggaatcacagac-
tataatgcagctttcatat
ccagactgagcatcaccaaggacgattccaagagccaagttttctttaaaatgaacagtctgcaacctaatgac-
acagccatttattactgtgc
cagaaatgggggtgataactacccttattactatgctatggactactggggtcaaggaacctcagtcaccgtct-
cctctgatcaggagcccaa
atcttctgacaaaactcacacatccccaccgtcctcagcacctgaactcctgggtggaccgtcagtcttcctct-
tcccccaaaacccaagga
caccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtca-
agttcaactggtacgtg
gacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcag-
cgtcctcaccgtcct
gcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgaga-
aaaccatctccaaag
ccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtc-
agcctgacctgcct
ggtcaaaggcttctatccaagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaaga-
ccacgcctcccgtg
ctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgt-
cttctcatgctccgtgat
gcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctagag
Amino acid sequence (SEQ ID NO: 366):
MRFSAQLLGLLVLWIPGSTADIVMTQAAFSNPVTLGTSASISCRSSKSLLHSNGITYLYW
YLQKPGQSPQLLIYQMSNLASGVPDRFSSSGSGTDFTLRISRVEAEDVGVYYCAQNLELP
LTFGAGTKLELKRGGGGSGGGGSGGGGSSQVQLKQSGPGSVQSSQSLSITCTVSGFSLTT
YAVHWVRQSPGKGLEWLGVIWSGGITDYNAAFISRLSITKDDSKSQVFFKMNSLQPNDT
AIYYCARNGGDNYPYYYAMDYWGQGTSVTVSSDQEPKSSDKTHTSPPSSAPELLGGPS
VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN
STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD
ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS
RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 76. 2H7 scFv VH L11S (SSS-S)H
P238SCH2 WCH3 (SEQ ID NO: 367) Nucleotide sequence:
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagtcggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaggagcccaaatcttctg
acaaaactcacacatccccaccgtcctcagcacctgaactcctggggggatcgtcagtcttcctcttcccccca-
aaacccaaggacaccctc
atgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaa-
ctggtacgtggacggc
gtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcct-
caccgtcctgcacca
ggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaacaa-
tctccaaagccaaag
ggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcctg-
acctgcctggtcaaa
ggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcc-
tcccgtgctggactc
cgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcat-
gctccgtgatgcatgag
gctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga Amino
acid sequence (SEQ ID NO: 368):
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAESVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQEPKSSDKTHTSPPSSAPELLGGSSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK 78. 2H7 scFv VH L11S (SSS-S)H WCH2
WCH3 (SEQ ID NO: 369) Nucleotide sequence:
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagtcggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaggagcccaaatcttctg
acaaaactcacacatccccaccgtcctcagcacctgaactcctggggggaccgtcagtcttcctcttcccccca-
aaacccaaggacaccct
catgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttca-
actggtacgtggacgg
cgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcc-
tcaccgtcctgcacc
aggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaca-
atctccaaagccaaa
gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcct-
gacctgcctggtca
aaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacg-
cctcccgtgctgga
ctccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttct-
catgctccgtgatgcatg
aggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga
Amino acid sequence (SEQ ID NO: 370):
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAESVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQEPKSSDKTHTSPPSSAPELLGGPSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK 79. 2H7 scFv VH L11S (CSS-S)H WCH2
WCH3 (SEQ ID NO: 371) Nucleotide sequence:
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagtcggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tcaggagcccaaatcttgtg
acaaaactcacacatccccaccgtcctcagcacctgaactcctggggggaccgtcagtcttcctcttcccccca-
aaacccaaggacaccct
catgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttca-
actggtacgtggacgg
cgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcc-
tcaccgtcctgcacc
aggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaca-
atctccaaagccaaa
gggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcct-
gacctgcctggtca
aaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacg-
cctcccgtgctgga
ctccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttct-
catgctccgtgatgcatg
aggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga
Amino acid sequence (SEQ ID NO: 372):
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAESVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDQEPKSCDKTHTSPPSSAPELLGGPSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK 77. G8-1 scFv VHL11S (SCS-S)H WCH2
WCH3 (SEQ ID NO: 373) Nucleotide sequence:
gttgttaagcttgccgccatggtatccacagctcagttccttgggttgctgctgctgtggcttacaggtggcag-
atgtgacatccagatgactc
agtctccagcctccctatctgcatctgtgggagagactgtcaccatcacatgtcgaacaagtgaaaatgtttac-
agttatttggcttggtatcag
cagaaacagggaaaatctcctcagctcctggtctcttttgcaaaaaccttagcagaaggtgtgccatcaaggtt-
cagtggcagtggatcagg
cacacagttttctctgaagatcagcagcctgcagcctgaagattctggaagttatttctgtcaacatcattccg-
ataatccgtggacgttcggtg
gaggcaccgaactggagatcaaaggtggcggtggctcgggcggtggtgggtcgggtggcggcggatcgtcagcg-
gtccagctgcagc
agtctggacctgagtcggaaaagcctggcgcttcagtgaagatttcctgcaaggcttctggttactcattcact-
ggctacaatatgaactgggt
gaagcagaataatggaaagagccttgagtggattggaaatattgatccttattatggtggtactacctacaacc-
ggaagttcaagggcaagg
ccacattgactgtagacaaatcctccagcacagcctacatgcagctcaagagtctgacatctgaggactctgca-
gtctattactgtgcaagat
cggtcggccctatggactactggggtcaaggaacctcagtcaccgtctcttctgatcaggagcccaaatcttct-
gacaaaactcacacatgc
ccaccgtcctcagcacctgaactcctgggtggaccgtcagtcttcctcttccccccaaaacccaaggacaccct-
catgatctcccggacccc
tgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcg-
tggaggtgcataatgc
caagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccagg-
actggctgaatggc
aaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaacaatctccaaagccaaagg-
gcagccccgagaac
cacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaa-
ggcttctatccaagcg
acatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactcc-
gacggctccttcttc
ctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatga-
ggctctgcacaaccact acacgcagaagagcctctccctgtctccgggtaaatgatctagag
Amino acid sequence (SEQ ID NO: 374):
MVSTAQFLGLLLLWLTGGRCDIQMTQSPASLSASVGETVTITCRTSENVYSYLAWYQQK
QGKSPQLLVSFAKTLAEGVPSRFSGSGSGTQFSLKISSLQPEDSGSYFCQHHSDNPWTFG
GGTELEIKGGGGSGGGGSGGGGSSAVQLQQSGPESEKPGASVKISCKASGYSFTGYNMN
WVKQNNGKSLEWIGNIDPYYGGTTYNRKFKGKATLTVDKSSSTAYMQLKSLTSEDSAV
YYCARSVGPMDYWGQGTSVTVSSDQEPKSSDKTHTCPPSSAPELLGGPSVFLFPPKPKD
TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT
VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC
SVMHEALHNHYTQKSLSLSPGK 79.. G28-1 scFv VHL11S (CCS-P)H WCH2 WCH3
(SEQ ID NO: 375) Nucleotide sequence:
gttgttaagcttgccgccatggtatccacagctcagttccttgggttgctgctgctgtggcttacaggtggcag-
atgtgacatccagatgactc
agtctccagcctccctatctgcatctgtgggagagactgtcaccatcacatgtcgaacaagtgaaaatgtttac-
agttatttggcttggtatcag
cagaaacagggaaaatctcctcagctcctggtctcttttgcaaaaaccttagcagaaggtgtgccatcaaggtt-
cagtggcagtggatcagg
cacacagttttctctgaagatcagcagcctgcagcctgaagattctggaagttatttctgtcaacatcattccg-
ataatccgtggacgttcggtg
gaggcaccgaactggagatcaaaggtggcggtggctcgggcggtggtgggtcgggtggcggcggatcgtcagcg-
gtccagctgcagc
agtctggacctgagtcggaaaagcctggcgcttcagtgaagatttcctgcaaggcttctggttactcattcact-
ggctacaatatgaactgggt
gaagcagaataatggaaagagccttgagtggattggaaatattgatccttattatggtggtactacctacaacc-
ggaagttcaagggcaagg
ccacattgactgtagacaaatcctccagcacagcctacatgcagctcaagagtctgacatctgaggactctgca-
gtctattactgtgcaagat
cggtcggccctatggactactggggtcaaggaacctcagtcaccgtctcttctgatcaggagcccaaatcttgt-
gacaaaactcacacatgtc
caccgtccccagcacctgaactcctgggtggaccgtcagtcttcctcttccccccaaaacccaaggacaccctc-
atgatctcccggacccct
gaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgt-
ggaggtgcataatgc
caagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccagg-
actggctgaatggc
aaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaacaatctccaaagccaaagg-
gcagccccgagaac
cacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaa-
ggcttctatccaagcg
acatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactcc-
gacggctccttcttc
ctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatga-
ggctctgcacaaccact acacgcagaagagcctctccctgtctccgggtaaatgatctaga
Amino acid sequence (SEQ ID NO: 376):
MVSTAQFLGLLLLWLTGGRCDIQMTQSPASLSASVGETVTITCRTSENVYSYLAWYQQK
QGKSPQLLVSFAKTLAEGVPSRFSGSGSGTQFSLKISSLQPEDSGSYFCQHHSDNPWTFG
GGTELEIKGGGGSGGGGSGGGGSSAVQLQQSGPESEKPGASVKISCKASGYSFTGYNMN
WVKQNNGKSLEWIGNIDPYYGGTTYNRKFKGKATLTVDKSSSTAYMQLKSLTSEDSAV
YYCARSVGPMDYWGQGTSVTVSSDQEPKSCDKTHTCPPSPAPELLGGPSVFLFPPKPKD
TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT
VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC
SVMHEALHNHYTQKSLSLSPGK 80. G28-1 scFv VH L11S (SCC-P)H WCH2 WCH3
(SEQ ID NO: 377) Nucleotide sequence:
gttgttaagcttgccgccatggtatccacagctcagttccttgggttgctgctgctgtggcttacaggtggcag-
atgtgacatccagatgactc
agtctccagcctccctatctgcatctgtgggagagactgtcaccatcacatgtcgaacaagtgaaaatgtttac-
agttatttggcttggtatcag
cagaaacagggaaaatctcctcagctcctggtctcttttgcaaaaaccttagcagaaggtgtgccatcaaggtt-
cagtggcagtggatcagg
cacacagttttctctgaagatcagcagcctgcagcctgaagattctggaagttatttctgtcaacatcattccg-
ataatccgtggacgttcggtg
gaggcaccgaactggagatcaaaggtggcggtggctcgggcggtggtgggtcgggtggcggcggatcgtcagcg-
gtccagctgcagc
agtctggacctgagtcggaaaagcctggcgcttcagtgaagatttcctgcaaggcttctggttactcattcact-
ggctacaatatgaactgggt
gaagcagaataatggaaagagccttgagtggattggaaatattgatccttattatggtggtactacctacaacc-
ggaagttcaagggcaagg
ccacattgactgtagacaaatcctccagcacagcctacatgcagctcaagagtctgacatctgaggactctgca-
gtctattactgtgcaagat
cggtcggccctatggactactggggtcaaggaacctcagtcaccgtctcttctgatcaggagcccaaatcttct-
gacaaaactcacacatgc
ccaccgtgcccagcacctgaactcctgggtggaccgtcagtcttcctcttccccccaaaacccaaggacaccct-
catgatctcccggaccc
ctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggc-
gtggaggtgcataatg
ccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccag-
gactggctgaatgg
caaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaacaatctccaaagccaaag-
ggcagccccgagaa
ccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaa-
aggcttctatccaagc
gacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactc-
cgacggctccttctt
cctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatg-
aggctctgcacaacca ctacacgcagaagagcctctccctgtctccgggtaaatgatctaga
Amino acid sequence (SEQ ID NO: 378):
MVSTAQFLGLLLLWLTGGRCDIQMTQSPASLSASVGETVTITCRTSENVYSYLAWYQQK
QGKSPQLLVSFAKTLAEGVPSRFSGSGSGTQFSLKISSLQPEDSGSYFCQHHSDNPWTFG
GGTELEIKGGGGSGGGGSGGGGSSAVQLQQSGPESEKPGASVKISCKASGYSFTGYNMN
WVKQNNGKSLEWIGNIDPYYGGTTYNRKFKGKATLTVDKSSSTAYMQLKSLTSEDSAV
YYCARSVGPMDYWGQGTSVTVSSDQEPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKD
TLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT
VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLT
CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC
SVMHEALHNHYTQKSLSLSPGK 81. G28-1 scFv VH L11S mIgE CH2 CH3 CH4 (SEQ
ID NO: 379) Nucleotide sequence:
aagcttgccgccatggtatccacagctcagttccttgggttgctgctgctgtggcttacaggtggcagatgtga-
catccagatgactcagtctc
cagcctccctatctgcatctgtgggagagactgtcaccatcacatgtcgaacaagtgaaaatgtttacagttat-
ttggcttggtatcagcagaa
acagggaaaatctcctcagctcctggtctcttttgcaaaaaccttagcagaaggtgtgccatcaaggttcagtg-
gcagtggatcaggcacac
agttttctctgaagatcagcagcctgcagcctgaagattctggaagttatttctgtcaacatcattccgataat-
ccgtggacgttcggtggaggc
accgaactggagatcaaaggtggcggtggctcgggcggtggtgggtcgggtggcggcggatcgtcagcggtcca-
gctgcagcagtctg
gacctgagtcggaaaagcctggcgcttcagtgaagatttcctgcaaggcttctggttactcattcactggctac-
aatatgaactgggtgaagc
agaataatggaaagagccttgagtggattggaaatattgatccttattatggtggtactacctacaaccggaag-
ttcaagggcaaggccacat
tgactgtagacaaatcctccagcacagcctacatgcagctcaagagtctgacatctgaggactctgcagtctat-
tactgtgcaagatcggtcg
gccctatggactactggggtcaaggaacctcagtcaccgtctcttctgatcacgttcgacctgtcaacatcact-
gagcccaccttggagctac
tccattcatcctgcgaccccaatgcattccactccaccatccagctgtactgcttcatttatggccacatccta-
aatgatgtctctgtcagctggc
taatggacgatcgggagataactgatacacttgcacaaactgttctaatcaaggaggaaggcaaactagcctct-
acctgcagtaaactcaac
atcactgagcagcaatggatgtctgaaagcaccttcacctgcaaggtcacctcccaaggcgtagactatttggc-
ccacacteggagatgcc
cagatcatgagccacggggtgtgattacctacctgatcccacccagccccctggacctgtatcaaaacggtgct-
cccaagcttacctgtctg
gtggtggacctggaaagcgagaagaatgtcaatgtgacgtggaaccaagagaagaagacttcagtctcagcatc-
ccagtggtacactaag
caccacaataacgccacaactagtatcacctccatcctgcctgtagttgccaaggactggattgaaggctacgg-
ctatcagtgcatagtgga
ccaccctgattttcccaagcccattgtgcgttccatcaccaagaccccaggccagcgctcagcccccgaggtat-
atgtgttcccaccaccag
aggaggagagcgaggacaaacgcacactcacctgtttgatccagaacttcttccctgaggatatctctgtgcag-
tggctgggggatggcaa
actgatctcaaacagccagcacagtaccacaacacccctgaaatccaatggctccaatcaaggcttcttcatct-
tcagtcgcctagaggtcgc
caagacactctggacacagagaaaacagttcacctgccaagtgatccatgaggcacttcagaaacccaggaaac-
tggagaaaacaatatc cacaagccttggtaacacctccctccgtccatcctagtaatctagagg
Amino acid sequence (SEQ ID NO: 380):
MVSTAQFLGLLLLWLTGGRCDIQMTQSPASLSASVGETVTITCRTSENVYSYLAWYQQK
QGKSPQLLVSFAKTLAEGVPSRFSGSGSGTQFSLKISSLQPEDSGSYFCQHHSDNPWTFG
GGTELEIKGGGGSGGGGSGGGGSSAVQLQQSGPESEKPGASVKISCKASGYSFTGYNMN
WVKQNNGKSLEWIGNIDPYYGGTTYNRKFKGKATLTVDKSSSTAYMQLKSLTSEDSAV
YYCARSVGPMDYWGQGTSVTVSSDHVRPVNITEPTLELLHSSCDPNAFHSTIQLYCFIYG
HILNDVSVSWLMDDREITDTLAQTVLIKEEGKLASTCSKLNITEQQWMSESTFTCKVTSQ
GVDYLAHTRRCPDHEPRGVITYLIPPSPLDLYQNGAPKLTCLVVDLESEKNVNVTWNQE
KKTSVSASQWYTKHHNNATTSITSILPVVAKDWIEGYGYQCIVDHPDFPKPIVRSITKTP
GQRSAPEVYVFPPPEEESEDKRTLTCLIQNFFPEDISVQWLGDGKLISNSQHSTTTPLKSN
GSNQGFFIFSRLEVAKTLWTQRKQFTCQVIHEALQKPRKLEKTISTSLGNTSLRPS 82. G28-1
scFv VH L11S mIgA WH WCH2 T4CH3 (SEQ ID NO: 381) Nucleotide
sequence:
aagcttgccgccatggtatccacagctcagttccttgggttgctgctgctgtggcttacaggtggcagatgtga-
catccagatgactcagtctc
cagcctccctatctgcatctgtgggagagactgtcaccatcacatgtcgaacaagtgaaaatgtttacagttat-
ttggcttggtatcagcagaa
acagggaaaatctcctcagctcctggtctcttttgcaaaaaccttagcagaaggtgtgccatcaaggttcagtg-
gcagtggatcaggcacac
agttttctctgaagatcagcagcctgcagcctgaagattctggaagttatttctgtcaacatcattccgataat-
ccgtggacgttcggtggaggc
accgaactggagatcaaaggtggcggtggctcgggcggtggtgggtcgggtggcggcggatcgtcagcggtcca-
gctgcagcagtctg
gacctgagtcggaaaagcctggcgcttcagtgaagatttcctgcaaggcttctggttactcattcactggctac-
aatatgaactgggtgaagc
agaataatggaaagagccttgagtggattggaaatattgatccttattatggtggtactacctacaaccggaag-
ttcaagggcaaggccacat
tgactgtagacaaatcctccagcacagcctacatgcagctcaagagtctgacatctgaggactctgcagtctat-
tactgtgcaagatcggtcg
gccctatggactactggggtcaaggaacctcagtcaccgtctcttctgatcacatctgttctcctcctactact-
cctcctccaccttcctgccagc
ccagcctgtcactgcagcggccagacttgaggacctgacctgggttcagatgccagcatcacatgtactctgaa-
tggcctgagagatcct
gagggagctgtcttcacctgggagccctccactgggaaggatgcagtgcagaagaaagctgtgcagaattcctg-
cggctgctacagtgtgt
ccagcgtcctgcctggctgtgctgagcgctggaacagtggcgcatcattcaagtgcacagttacccatcctgag-
tctgacaccttaactggc
acaattgccaaagtcacagtgaacaccttcccaccccaggtccacctgctaccgccgccgtcggaggagctggc-
cctgaatgagctcgtgt
ccctgacatgcctggtgcgagctttcaaccctaaagaagtgctggtgcgatggctgcatggaaatgaggagctg-
tccccagaaagctacct
agtgtttgagcccctaaaggagccaggcgagggagccaccacctacctggtgacaagcgtgttgcgtgtatcag-
ctgaaatctggaaaca
gggtgaccagtactcctgcatggtgggccacgaggccttgcccatgaacttcacccagaagaccatcgaccgtc-
tgtcgggtaaacccac caatgtcagcgtgtctgtgatcatgtcagagggagattgataatctagat
Amino acid sequence (SEQ ID NO: 382):
MVSTAQFLGLLLLWLTGGRCDIQMTQSPASLSASVGETVTITCRTSENVYSYLAWYQQK
QGKSPQLLVSFAKTLAEGVPSRFSGSGSGTQFSLKISSLQPEDSGSYFCQHHSDNPWTFG
GGTELEIKGGGGSGGGGSGGGGSSAVQLQQSGPESEKPGASVKISCKASGYSFTGYNMN
WVKQNNGKSLEWIGNIDPYYGGTTYNRKFKGKATLTVDKSSSTAYMQLKSLTSEDSAV
YYCARSVGPMDYWGQGTSVTVSSDHICSPPTTPPPPSCQPSLSLQRPALEDLLLGSDASIT
CTLNGLRDPEGAVFTWEPSTGKDAVQKKAVQNSCGCYSVSSVLPGCAERWNSGASFKC
TVTHPESDTLTGTIAKVTVNTFPPQVHLLPPPSEELALNELVSLTCLVRAFNPKEVLVRW
LHGNEELSPESYLVFEPLKEPGEGATTYLVTSVLRVSAEIWKQGDQYSCMVGHEALPMN
FTQKTIDRLSGKPTNVSVSVIMSEGD 83. G28-1 scFv Vh L11S hIgE CH2 CH3 CH4
(SEQ ID NO: 383) Nucleotide sequence:
aagcttgccgccatggtatccacagctcagttccttgggttgctgctgctgtggcttacaggtggcagatgtga-
catccagatgactcagtctc
cagcctccctatctgcatctgtgggagagactgtcaccatcacatgtcgaacaagtgaaaatgtttacagttat-
ttggcttggtatcagcagaa
acagggaaaatctcctcagctcctggtctctttgcaaaaaccttagcagaaggtgtgccatcaaggttcagtgg-
cagtggatcaggcacac
agttttctctgaagatcagcagcctgcagcctgaagattctggaagttatttctgtcaacatcattccgataat-
ccgtggacgttcggtggaggc
accgaactggagatcaaaggtggcggtggctcgggcggtggtgggtcgggtggcggcggatcgtcagcggtcca-
gctgcagcagtctg
gacctgagtcggaaaagcctggcgcttcagtgaagatttcctgcaaggcttctggttactcattcactggctac-
aatatgaactgggtgaagc
agaataatggaaagagccttgagtggattggaaatattgatccttattatggtggtactacctacaaccggaag-
ttcaagggcaaggccacat
tgactgtagacaaatcctccagcacagcctacatgcagctcaagagtctgacatctgaggactctgcagtctat-
tactgtgcaagatcggtcg
gccctatggactactggggtcaaggaacctcagtcaccgtctcttctgatcacgtctgctccagggacttcacc-
ccgcccaccgtgaagatct
tacagtcgtcctgcgacggcggcgggcacttccccccgaccatccagctcctgtgcctcgtctctgggtacacc-
ccagggactatcaacat
cacctggctggaggacgggcaggtcatggacgtggacttgtccaccgcctctaccacgcaggagggtgagctgg-
cctccacacaaagc
gagctcaccctcagccagaagcactggctgtcagaccgcacctacacctgccaggtcacctatcaaggtcacac-
ctttgaggacagcacc
aagaagtgtgcagattccaacccgagaggggtgagcgcctacctaagccggcccagcccgttcgacctgttcat-
ccgcaagtcgcccac
gatcacctgtctggtggtggacctggcacccagcaaggggaccgtgaacctgacctggtcccgggccagtggga-
agcctgtgaaccact
ccaccagaaaggaggagaagcagcgcaatggcacgttaaccgtcacgtccaccctgccggtgggcacccgagac-
tggatcgaggggg
agacctaccagtgcagggtgacccacccccacctgcccagggccctcatgcggtccacgaccaagaccagcggc-
ccgcgtgctgcccc
ggaagtctatgcgtttgcgacgccggagtggccggggagccgggacaagcgcaccctcgcctgcctgatccaga-
acttcatgcctgagg
acatctcggtgcagtggctgcacaacgaggtgcagctcccggacgcccggcacagcacgacgcagccccgcaag-
accaagggctccg
gcttcttcgtcttcagccgcctggaggtgaccagggccgaatgggagcagaaagatgagttcatctgccgtgca-
gtccatgaggcagcga
gcccctcacagaccgtccagcgagcggtgtctgtaaatcccggtaaatgataatctaga Amino
acid sequence (SEQ ID NO: 384):
MVSTAQFLGLLLLWLTGGRCDIQMTQSPASLSASVGETVTITCRTSENVYSYLAWYQQK
QGKSPQLLVSFAKTLAEGVPSRFSGSGSGTQFSLKISSLQPEDSGSYFCQHHSDNPWTFG
GGTELEIKGGGGSGGGGSGGGGSSAVQLQQSGPESEKPGASVKISCKASGYSFTGYNMN
WVKQNNGKSLEWIGNIDPYYGGTTYNRKFKGKATLTVDKSSSTAYMQLKSLTSEDSAV
YYCARSVGPMDYWGQGTSVTVSSDHVCSRDFTPPTVKILQSSCDGGGHFPPTIQLLCLV
SGYTPGTINITWLEDGQVMDVDLSTASTTQEGELASTQSELTLSQKHWLSDRTYTCQVT
YQGHTFEDSTKKCADSNPRGVSAYLSRPSPFDLFIRKSPTITCLVVDLAPSKGTVNLTWS
RASGKPVNHSTRKEEKQRNGTLTVTSTLPVGTRDWIEGETYQCRVTHPHLPRALMRSTT
KTSGPRAAPEVYAFATPEWPGSRDKRTLACLIQNFMPEDISVQWLHNEVQLPDARHSTT
QPRKTKGSGFFVFSRLEVTRAEWEQKDEFICRAVHEAASPSQTVQRAVSVNPGK 84. G28-1
scFv VH L11S hIgA WH WCH2 T4CH3 (SEQ ID NO: 385) Nucleotide
sequence:
atggtatccacagctcagttccttgggttgctgctgctgtggcttacaggtggcagatgtgacatccagatgac-
tcagtctccagcctccctat
ctgcatctgtgggagagactgtcaccatcacatgtcgaacaagtgaaaatgtttacagttatttggcttggtat-
cagcagaaacagggaaaat
ctcctcagctcctggtctcttttgcaaaaaccttagcagaaggtgtgccatcaaggttcagtggcagtggatca-
ggcacacagttttctctgaa
gatcagcagcctgcagcctgaagattctggaagttatttctgtcaacatcattccgataatccgtggacgttcg-
gtggaggcaccgaactgga
gatcaaaggtggcggtggctcgggcggtggtgggtcgggtggcggcggatcgtcagcggtccagctgcagcagt-
ctggacctgagtcg
gaaaagcctggcgcttcagtgaagatttcctgcaaggcttctggttactcattcactggctacaatatgaactg-
ggtgaagcagaataatgga
aagagccttgagtggattggaaatattgatccttattatggtggtactacctacaaccggaagttcaagggcaa-
ggccacattgactgtagac
aaatcctccagcacagcctacatgcagctcaagagtctgacatctgaggactctgcagtctattactgtgcaag-
atcggtcggccctatggac
tactggggtcaaggaacctcagtcaccgtctcttctgatcagccagttccctcaactccacctaccccatctcc-
ctcaactccacctaccccat
ctccctcatgctgccacccccgactgtcactgcaccgaccggccctcgaggacctgctcttaggttcagaagcg-
atcctcacgtgcacactg
accggcctgagagatgcctcaggtgtcaccttcacctggacgccctcaagtgggaagagcgctgttcaaggacc-
acctgaccgtgacctct
gtggctgctacagcgtgtccagtgtcctgccgggctgtgccgagccatggaaccatgggaagaccttcacttgc-
actgctgcctaccccga
gtccaagaccccgctaaccgccaccctctcaaaatccggaaacacattccggcccgaggtccacctgctgccgc-
cgccgtcggaggagc
tggccctgaacgagctggtgacgctgacgtgcctggcacgtggcttcagccccaaggatgtgctggttcgctgg-
ctgcaggggtcacagg
agctgccccgcgagaagtacctgacttgggcatcccggcaggagcccagccagggcaccaccaccttcgctgtg-
accagcatactgcgc
gtggcagccgaggactggaagaagggggacaccttctcctgcatggtgggccacgaggccctgccgctggcctt-
cacacagaagacca
tcgaccgcttggcgggtaaacccacccatgtcaatgtgtctgttgtcatggcggaggtggactgataatctaga
Amino acid sequence (SEQ ID NO: 386):
MVSTAQFLGLLLLWLTGGRCDIQMTQSPASLSASVGETVTITCRTSENVYSYLAWYQQK
QGKSPQLLVSFAKTLAEGVPSRFSGSGSGTQFSLKISSLQPEDSGSYFCQHHSDNPWTFG
GGTELEIKGGGGSGGGGSGGGGSSAVQLQQSGPESEKPGASVKISCKASGYSFTGYNMN
WVKQNNGKSLEWIGNIDPYYGGTTYNRKFKGKATLTVDKSSSTAYMQLKSLTSEDSAV
YYCARSVGPMDYWGQGTSVTVSSDQPVPSTPPTPSPSTPPTPSPSCCHPRLSLHRPALED 85.
HD37 VL (SEQ ID NO: 387) Nucleotide sequence:
aagcttgccgccatggagacagacacactcctgctatgggtgctgctgctctgggttccaggctccactggtga-
cattgtgctgacccaatct
ccagcttctttggctgtgtctctagggcagagggccaccatctcctgcaaggccagccaaagtgttgattatga-
tggtgatagttatttgaactg
gtaccaacagattccaggacagccacccaaactcctcatctatgatgcatccaatctagtttctgggatcccac-
ccaggtttagtggcagtgg
gtctgggacagacttcaccctcaacatccatcctgtggagaaggtggatgctgcaacctatcactgtcagcaaa-
gtactgaggatccgtgga
cgttcggtggaggcaccaagctggaaatcaaaggtggcggtggctcgggcggtggtgggtcgggtggcggcggg-
agctcg Amino acid sequence (SEQ ID NO: 388):
METDTLLLWVLLLWVPGSTGDIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLN
WYQQIPGQPPKLLIYDASNLVSGIPPRFSGSGSGTDFTLNIHPVEKVDAATYHCQQSTED
PWTFGGGTKLEIKGGGGSGGGGSGGGGSS 86. HD37 VH (SEQ ID NO: 389)
Nucleotide sequence:
gggagctcgcaggttcagctgcagcagtctggggctgagctggtgaggcctgggtcctcagtgaagatttcctg-
caaggcttctggctatg
cattcagtagctactggatgaactgggtgaagcagaggcctggacagggtcttgagtggattggacagatttgg-
cctggagatggtgatact
aactacaatggaaagttcaagggtaaagccactctgactgcagacgaatcctccagcacagcctacatgcaact-
cagcagcctagcatctg
aggactctgcggtctatttctgtgcaagacgggagactacgacggtaggccgttattactatgctatggactac-
tggggtcaaggaacctca gtcaccgtctcctctgatcag Amino acid sequence (SEQ
ID NO: 390):
(GSS)QVQLQQSGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIWPG
DGDTNYNGKFKGKATLTADESSSTAYMQLSSLASEDSAVYFCARRETTTVGRYYYAM
DYWGQGTSVTVSSDQ 87. HD37 scFv (SEQ ID NO: 391) Nucleotide sequence:
aagcttgccgccatggagacagacacactcctgctatgggtgctgctgctctgggttccaggctccactggtga-
cattgtgctgacccaatct
ccagcttctttggctgtgtctctagggcagagggccaccatctcctgcaaggccagccaaagtgttgattatga-
tggtgatagttatttgaactg
gtaccaacagattccaggacagccacccaaactcctcatctatgatgcatccaatctagtttctgggatcccac-
ccaggtttagtggcagtgg
gtctgggacagacttcaccctcaacatccatcctgtggagaaggtggatgctgcaacctatcactgtcagcaaa-
gtactgaggatccgtgga
cgttcggtggaggcaccaagctggaaatcaaaggtggcggtggctcgggcggtggtgggtcgggtggcggcgga-
tcgtcacaggttca
gctgcagcagtctggggctgagctggtgaggcctgggtcctcagtgaagatttcctgcaaggcttctggctatg-
cattcagtagctactggat
gaactgggtgaagcagaggcctggacagggtcttgagtggattggacagatttggcctggagatggtgatacta-
actacaatggaaagttc
aagggtaaagccactctgactgcagacgaatcctccagcacagcctacatgcaactcagcagcctagcatctga-
ggactctgcggtctattt
ctgtgcaagacgggagactacgacggtaggccgttattactatgctatggactactggggtcaaggaacctcag-
tcaccgtctcctctgatc ag Amino acid sequence (SEQ ID NO: 392):
METDTLLLWVLLLWVPGSTGDIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLN
WYQQIPGQPPKLLIYDASNLVSGIPPRFSGSGSGTDFTLNIHPVEKVDAATYHCQQSTED
PWTFGGGTKLEIKGGGGSGGGGSGGGGSSQVQLQQSGAELVRPGSSVKISCKASGYAFS
SYWMNWVKQRPGQGLEWIGQIWPGDGDTNYNGKFKGKATLTADESSSTAYMQLSSLA
SEDSAVYFCARRETTTVGRYYYAMDYWGQGTSVTVSSDQ 88. HD37 VHL11S (SEQ ID NO:
393): Nucleotide sequence:
gggagctcgcaggttcagctgcagcagtctggggctgagtcggtgaggcctgggtcctcagtgaagatttcctg-
caaggcttctggctatg
cattcagtagctactggatgaactgggtgaagcagaggcctggacagggtcttgagtggattggacagatttgg-
cctggagatggtgatact
aactacaatggaaagttcaagggtaaagccactctgactgcagacgaatcctccagcacagcctacatgcaact-
cagcagcctagcatctg
aggactctgcggtctatttctgtgcaagacgggagactacgacggtaggccgttattactatgctatggactac-
tggggtcaaggaacctca gtcaccgtctcctctgatcag Amino acid sequence (SEQ
ID NO: 394):
(GSS)QVQLQQSGAESVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIWPG
DGDTNYNGKFKGKATLTADESSSTAYMQLSSLASEDSAVYFCARRETTTVGRYYYAM
DYWGQGTSVTVSSDQ 89. HD37 scFv VHL11S (SEQ ID NO: 395): Nucleotide
sequence:
Aagcttgccgccatggagacagacacactcctgctatgggtgctgctgctctgggttccaggctccactggtga-
cattgtgctgacccaatc
tccagcttctttggctgtgtctctagggcagagggccaccatctcctgcaaggccagccaaagtgttgattatg-
atggtgatagttatttgaact
ggtaccaacagattccaggacagccacccaaactcctcatctatgatgcatccaatctagtttctgggatccca-
cccaggtttagtggcagtg
ggtctgggacagacttcaccctcaacatccatcctgtggagaaggtggatgctgcaacctatcactgtcagcaa-
agtactgaggatccgtgg
acgttcggtggaggcaccaagctggaaatcaaaggtggcggtggctcgggcggtggtgggtcgggtggcggcgg-
gagctcgcaggttc
agctgcagcagtctggggctgagtcggtgaggcctgggtcctcagtgaagatttcctgcaaggcttctggctat-
gcattcagtagctactgg
atgaactgggtgaagcagaggcctggacagggtcttgagtggattggacagatttggcctggagatggtgatac-
taactacaatggaaagtt
caagggtaaagccactctgactgcagacgaatcctccagcacagcctacatgcaactcagcagcctagcatctg-
aggactctgcggtctatt
tctgtgcaagacgggagactacgacggtaggccgttattactatgctatggactactggggtcaaggaacctca-
gtcaccgtctcctctgatc ag Amino acid sequence (SEQ ID NO: 396):
METDTLLLWVLLLWVPGSTGDIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLN
WYQQIPGQPPKLLIYDASNLVSGIPPRFSGSGSGTDFTLNIHPVEKVDAATYHCQQSTED
PWTFGGGTKLEIKGGGGSGGGGSGGGGSSQVQLQQSGAESVRPGSSVKISCKASGYAFS
SYWMNWVKQRPGQGLEWIGQIWPGDGDTNYNGKFKGKATLTADESSSTAYMQLSSLA
SEDSAVYFCARRETTTVGRYYYAMDYWGQGTSVTVSSDQ 90. HD37 scFv IgAH hIgG1
WCH2 T4CH3 (SEQ ID NO: 397) Nucleotide sequence
aagcttgccgccatggagacagacacactcctgctatgggtgctgctgctctgggttccaggctccactggtga-
cattgtgctgacccaatct
ccagcttctttggctgtgtctctagggcagagggccaccatctcctgcaaggccagccaaagtgttgattatga-
tggtgatagttatttgaactg
gtaccaacagattccaggacagccacccaaactcctcatctatgatgcatccaatctagtttctgggatcccac-
ccaggtttagtggcagtgg
gtctgggacagacttcaccctcaacatccatcctgtggagaaggtggatgctgcaacctatcactgtcagcaaa-
gtactgaggatccgtgga
cgttcggtggaggcaccaagctggaaatcaaaggtggcggtggctcgggcggtggtgggtcgggtggcggcggg-
agctcgcaggttca
gctgcagcagtctggggctgagtcggtgaggcctgggtcctcagtgaagatttcctgcaaggcttctggctatg-
cattcagtagctactggat
gaactgggtgaagcagaggcctggacagggtcttgagtggattggacagatttggcctggagatggtgatacta-
actacaatggaaagttc
aagggtaaagccactctgactgcagacgaatcctccagcacagcctacatgcaactcagcagcctagcatctga-
ggactctgcggtctattt
ctgtgcaagacgggagactacgacggtaggccgttattactatgctatggactactggggtcaaggaacctcag-
tcaccgtctcctctgatc
agccagttccctcaactccacctaccccatctccctcaactccacctaccccatctccctcatgctgccacccc-
cgactgtcactgcaccgac
cggccctcgaggacctgctcttaggttcagaagcgatcctcacgtgcacactgaccggcctgagagatgcctca-
ggtgtcaccttcacctg
gacgccctcaagtgggaagagcgctgttcaaggaccacctgaccgtgacctctgtggctgctacagcgtgtcca-
gtgtcctgccgggctgt
gccgagccatggaaccatgggaagaccttcacttgcactgctgcctaccccgagtccaagaccccgctaaccgc-
caccctctcaaaatcc
ggaaacacattccggcccgaggtccacctgctgccgccgccgtcggaggagctggccctgaacgagctggtgac-
gctgacgtgcctgg
cacgtggcttcagccccaaggatgtgctggttcgctggctgcaggggtcacaggagctgccccgcgagaagtac-
ctgacttgggcatccc
ggcaggagcccagccagggcaccaccaccttcgctgtgaccagcatactgcgcgtggcagccgaggactggaag-
aagggggacacct
tctcctgcatggtgggccacgaggccctgccgctggccttcacacagaagaccatcgaccgcttggcgggtaaa-
cccacccatgtcaatgt gtctgttgtcatggcggaggtggactgataatctaga Amino acid
sequence (SEQ ID NO: 398)
METDTLLLWVLLLWVPGSTGDIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLN
WYQQIPGQPPKLLIYDASNLVSGIPPRFSGSGSGTDFTLNIHPVEKVDAATYHCQQSTED
PWTFGGGTKLEIKGGGGSGGGGSGGGGSSQVQLQQSGAESVRPGSSVKISCKASGYAFS
SYWMNWVKQRPGQGLEWIGQIWPGDGDTNYNGKFKGKATLTADESSSTAYMQLSSLA
SEDSAVYFCARRETTTVGRYYYAMDYWGQGTSVTVSSDQPVPSTPPTPSPSTPPTPSPSC
CHPRLSLHRPALEDLLLGSEAILTCTLTGLRDASGVTFTWTPSSGKSAVQGPPDRDLCGC
YSVSSVLPGCAEPWNHGKTFTCTAAYPESKTPLTATLSKSGNTFRPEVHLLPPPSEELAL
NELVTLTCLARGFSPKDVLVRWLQGSQELPREKYLTWASRQEPSQGTTTFAVTSILRVA
AEDWKKGDTFSCMVGHEALPLAFTQKTIDRLAGKPTHVNVSVVMAEVD 91. HD37 scFv
(SSS-S)H WCH2 WCH3 (SEQ ID NO: 399) Nucleotide sequence:
aagcttgccgccatggagacagacacactcctgctatgggtgctgctgctctgggttccaggctccactggtga-
cattgtgctgacccaatct
ccagcttctttggctgtgtctctagggcagagggccaccatctcctgcaaggccagccaaagtgttgattatga-
tggtgatagttatttgaactg
gtaccaacagattccaggacagccacccaaactcctcatctatgatgcatccaatctagtttctgggatcccac-
ccaggtttagtggcagtgg
gtctgggacagacttcaccctcaacatccatcctgtggagaaggtggatgctgcaacctatcactgtcagcaaa-
gtactgaggatccgtgga
cgttcggtggaggcaccaagctggaaatcaaaggtggcggtggctcgggcggtggtgggtcgggtggcggcgga-
tcgtcacaggttca
gctgcagcagtctggggctgagctggtgaggcctgggtcctcagtgaagatttcctgcaaggcttctggctatg-
cattcagtagctactggat
gaactgggtgaagcagaggcctggacagggtcttgagtggattggacagatttggcctggagatggtgatacta-
actacaatggaaagttc
aagggtaaagccactctgactgcagacgaatcctccagcacagcctacatgcaactcagcagcctagcatctga-
ggactctgcggtctattt
ctgtgcaagacgggagactacgacggtaggccgttattactatgctatggactactggggtcaaggaacctcag-
tcaccgtctcctctgatc
aggagcccaaatcttctgacaaaactcacacatccccaccgtcctcagcacctgaactcctgggtggaccgtca-
gtcttcctcttccccccaa
aacccaaggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagac-
cctgaggtcaagttca
actggtacgtggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtac-
cgtgtggtcagcgt
cctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccag-
cccccatcgagaaaa
ccatctccaaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgacc-
aagaaccaggtcag
cctgacctgcctggtcaaaggcttctatccaagcgacatcgccgtggagtgggagagcaatgggcagccggaga-
acaactacaagacca
cgcctcccgtgctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcag-
caggggaacgtcttctc
atgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgat-
ctaga Amino acid sequence (SEQ ID NO: 400):
METDTLLLWVLLLWVPGSTGDIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLN
WYQQIPGQPPKLLIYDASNLVSGIPPRFSGSGSGTDFTLNIHPVEKVDAATYHCQQSTED
PWTFGGGTKLEIKGGGGSGGGGSGGGGSSQVQLQQSGAELVRPGSSVKISCKASGYAFS
SYWMNWVKQRPGQGLEWIGQIWPGDGDTNYNGKFKGKATLTADESSSTAYMQLSSLA
SEDSAVYFCARRETTTVGRYYYAMDYWGQGTSVTVSSDQEPKSSDKTHTSPPSSAPELL
GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE
QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPP
SRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV
DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 92. HD37 scFv VH L11S (SSS-S)H
WCH2 WCH3 (SEQ ID NO: 401) Nucleotide sequence:
aagcttgccgccatggagacagacacactcctgctatgggtgctgctgctctgggttccaggctccactggtga-
cattgtgctgacccaatct
ccagcttctttggctgtgtctctagggcagagggccaccatctcctgcaaggccagccaaagtgttgattatga-
tggtgatagttatttgaactg
gtaccaacagattccaggacagccacccaaactcctcatctatgatgcatccaatctagtttctgggatcccac-
ccaggtttagtggcagtgg
gtctgggacagacttcaccctcaacatccatcctgtggagaaggtggatgctgcaacctatcactgtcagcaaa-
gtactgaggatccgtgga
cgttcggtggaggcaccaagctggaaatcaaaggtggcggtggctcgggcggtggtgggtcgggtggcggcggg-
agctcgcaggttca
gctgcagcagtctggggctgagtcggtgaggcctgggtcctcagtgaagatttcctgcaaggcttctggctatg-
cattcagtagctactggat
gaactgggtgaagcagaggcctggacagggtcttgagtggattggacagatttggcctggagatggtgatacta-
actacaatggaaagttc
aagggtaaagccactctgactgcagacgaatcctccagcacagcctacatgcaactcagcagcctagcatctga-
ggactctgcggtctattt
ctgtgcaagacgggagactacgacggtaggccgttattactatgctatggactactggggtcaaggaacctcag-
tcaccgtctcctctgatc
aggagcccaaatcttctgacaaaactcacacatccccaccgtcctcagcacctgaactcctggggggaccgtca-
gtcttcctcttcccccca
aaacccaaggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaaga-
ccctgaggtcaagttc
aactggtacgtggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgta-
ccgtgtggtcagcg
tcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctccca-
gcccccatcgagaaaa
caatctccaaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgacc-
aagaaccaggtcag
cctgacctgcctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggaga-
acaactacaagacca
cgcctcccgtgctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcag-
caggggaacgtcttctc
atgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgat-
ctaga Amino acid sequence (SEQ ID NO: 402):
METDTLLLWVLLLWVPGSTGDIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLN
WYQQIPGQPPKLLIYDASNLVSGIPPRFSGSGSGTDFTLNIHPVEKVDAATYHCQQSTED
PWTFGGGTKLEIKGGGGSGGGGSGGGGSSQVQLQQSGAESVRPGSSVKISCKASGYAFS
SYWMNWVKQRPGQGLEWIGQIWPGDGDTNYNGKFKGKATLTADESSSTAYMQLSSLA
SEDSAVYFCARRETTTVGRYYYAMDYWGQGTSVTVSSDQEPKSSDKTHTSPPSSAPELL
GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE
QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPP
SRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV
DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 91. L6 VL (SEQ ID NO: 403)
Nucleotide sequence:
atggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggacaaattgt-
tctctcccagtctccagcaatcc
tgtctgcatctccaggggagaaggtcacattgacttgcagggccagctcaagtgtaagtttcatgaactggtac-
cagcagaagccaggatcc
tcccccaaaccctggatttatgccacatccaatttggcttctgagttccctggtcgcttcagtggcgagtggtc-
tgggacctcttactctctcgca
atcagcagagtggaggctgaagatgctgccacttattactgccagcagtggaatagtaacccactcacgttcgg-
tgctgggaccaagctgg
agctgaaagagctctctggtggcggtggctcgggcggtggtgggtcgggtggcggcggatct
Amino acid sequence (SEQ ID NO: 404):
MDFQVQIFSFLLISASVIMSRGQIVLSQSPAILSASPGEKVTLTCRASSSVSFMNWYQQKP
GSSPKPWIYATSNLASEFPGRFSGEWSGTSYSLAISRVEAEDAATYYCQQWNSNPLTFG
AGTKLELKELSGGGGSGGGGSGGGGS 92. L6 VH (SEQ ID NO: 405) Nucleotide
sequence:
cagatccagttggtgcagtctggacctgagctgaagaagcctggagagacagtcaagatctcctgcaaggcttc-
tgggtataccttcacaaa
ctatggaatgaactgggtgaagcaggctccaggaaagggtttaaagtggatgggctggataaacacctacactg-
gacagccaacatatgct
gatgacttcaagggacggtttgccttctattggaaacctctgcctacactgcctatttgcagatcaacaacctc-
aaaaatgaggacatggcta
catatttctgtgcaagatttagctatggtaactcacgttacgctgactactggggccaaggcaccactctcaca-
gtacctctgatca Amino acid sequence (SEQ ID NO: 406):
QIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNWVKQAPGKGLKWMGWINTYTGQ
PTYADDFKGRFAFSLETSAYTAYLQINNLKNEDMATYFCARFSYGNSRYADYWGQGTT LTVSSD
93. L6 scFv (SEQ ID NO: 407) Nucleotide sequence:
atggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggacaaattgt-
tctctcccagtctccagcaatcc
tgtctgcatctccaggggagaaggtcacattgacttgcagggccagctcaagtgtaagtttcatgaactggtac-
cagcagaagccaggatcc
tcccccaaaccctggatttatgccacatccaatttggcttctgagttccctggtcgcttcagtggcgagtggtc-
tgggacctcttactctctcgca
atcagcagagtggaggctgaagatgctgccacttattactgccagcagtggaatagtaacccactcacgttcgg-
tgctgggaccaagctgg
agctgaaagagctctctggtggcggtggctcgggcggtggtgggtcgggtggcggcggatctctgcagatccag-
ttggtgcagtctggac
ctgagctgaagaagcctggagagacagtcaagatctcctgcaaggcttctgggtataccttcacaaactatgga-
atgaactgggtgaagca
ggctccaggaaagggtttaaagtggatgggctggataaacacctacactggacagccaacatatgctgatgact-
tcaagggacggtttgcc
ttctattggaaacctctgcctacactgcctatttgcagatcaacaacctcaaaaatgaggacatggctacatat-
ttctgtgcaagatttagctatg
gtaactcacgttacgctgactactggggccaaggcaccactctcacagtctcctctgatca Amino
acid sequence (SEQ ID NO: 408):
MDFQVQIFSFLLISASVIMSRGQIVLSQSPAILSASPGEKVTLTCRASSSVSFMNWYQQKP
GSSPKPWIYATSNLASEFPGRFSGEWSGTSYSLAISRVEAEDAATYYCQQWNSNPLTFG
AGTKLELKELSGGGGSGGGGSGGGGSLQIQLVQSGPELKKPGETVKISCKASGYTFTNY
GMNWVKQAPGKGLKWMGWINTYTGQPTYADDFKGRFAFSLETSAYTAYLQINNLKNE
DMATYFCARFSYGNSRYADYWGQGTTLTVSSD 94. L6 VHL11S (SEQ ID NO: 409)
Nucleotide sequence:
ctgcagatccagttggtgcagtctggacctgagtcgaagaagcctggagagacagtcaagatctcctgcaaggc-
ttctgggtataccttcac
aaactatggaatgaactgggtgaagcaggctccaggaaagggtttaaagtggatgggctggataaacacctaca-
ctggacagccaacata
tgctgatgacttcaagggacggtttgccttctctttggaaacctctgcctacactgcctatttgcagatcaaca-
acctcaaaaatgaggacatgg
ctacatatttctgtgcaagatttagctatggtaactcacgttacgctgactactggggccaaggcaccactctc-
acagtctcctctgatca Amino acid sequence (SEQ ID NO: 410):
QIQLVQSGPESKKPGETVKISCKASGYTFTNYGMNWVKQAPGKGLKWMGWINTYTGQ
PTYADDFKGRFAFSLETSAYTAYLQINNLKNEDMATYFCARFSYGNSRYADYWGQGTT LTVSSD
95. L6 VH L11S scFv (SEQ ID NO: 411) Nucleotide sequence;
Aagcttgttgttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacattgacttgcagggccagctcaagtgtaagtttc-
atgaactggtaccagcag
aagccaggatcctcccccaaaccctggatttatgccacatccaatttggcttctgagttccctggtcgcttcag-
tggcgagtggtctgggacct
cttactctctcgcaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggaatagtaac-
ccactcacgttcggtgctg
ggaccaagctggagctgaaagagctctctggtggcggtggctcgggcggtggtgggtcgggtggcggcggatct-
ctgcagatccagttg
gtgcagtctggacctgagtcgaagaagcctggagagacagtcaagatctcctgcaaggcttctgggtatacctt-
cacaaactatggaatgaa
ctgggtgaagcaggctccaggaaagggtttaaagtggatgggctggataaacacctacactggacagccaacat-
atgctgatgacttcaag
ggacggtttgccttctctttggaaacctctgcctacactgcctatttgcagatcaacaacctcaaaaatgagga-
catggctacatatttctgtgca
agatttagctatggtaactcacgttacgctgactactggggccaaggcaccactctcacagtctcctctgatca
Amino acid sequence (SEQ ID NO: 412):
MDFQVQIFSFLLISASVIMSRGQIVLSQSPAILSASPGEKVTLTCRASSSVSFMNWYQQKP
GSSPKPWIYATSNLASEFPGRFSGEWSGTSYSLAISRVEAEDAATYYCQQWNSNPLTFG
AGTKLELKELSGGGGSGGGGSGGGGSLQIQLVQSGPESKKPGETVKISCKASGYTFTNY
GMNWVKQAPGKGLKWMGWINTYTGQPTYADDFKGRFAFSLETSAYTAYLQINNLKNE
DMATYFCARFSYGNSRYADYWGQGTTLTVSSD 96. L6 Or L6 VHL11S scFv IgAH
hIgG1 WCH2 WCH3 (SEQ ID NO: 413) Nucleotide sequence: (L6 VHL11S is
shown)
aagcttgttgttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccag-
aggacaaattgttctctcccagtc
tccagcaatcctgtctgcatctccaggggagaaggtcacattgacttgcagggccagctcaagtgtaagtttca-
tgaactggtaccagcaga
agccaggatcctcccccaaaccctggatttatgccacatccaatttggcttctgagttccctggtcgcttcagt-
ggcgagtggtctgggacctc
ttactctctcgcaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggaatagtaacc-
cactcacgttcggtgctgg
gaccaagctggagctgaaagagctctctggtggcggtggctcgggcggtggtgggtcgggtggcggcggatctc-
tgcagatccagttgg
tgcagtctggacctgagtcgaagaagcctggagagacagtcaagatctcctgcaaggcttctgggtataccttc-
acaaactatggaatgaac
tgggtgaagcaggctccaggaaagggtttaaagtggatgggctggataaacacctacactggacagccaacata-
tgctgatgacttcaagg
gacggtttgccttctctttggaaacctctgcctacactgcctatttgcagatcaacaacctcaaaaatgaggac-
atggctacatatttctgtgcaa
gatttagctatggtaactcacgttacgctgactactggggccaaggcaccactctcacagtctcctctgatcag-
ccagttccctcaactccacc
taccccatctccctcaactccacctaccccatctccctcatgcgcacctgaactcctggggggaccgtcagtct-
tcctcttccccccaaaacc
caaggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctg-
aggtcaagttcaactg
gtacgtggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtg-
tggtcagcgtcctc
accgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccc-
catcgagaaaacaat
ctccaaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaaga-
accaggtcagcctg
acctgcctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaa-
ctacaagaccacgcc
tcccgtgctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcagg-
ggaacgtcttctcatgct
ccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga
Amino acid sequence (SEQ ID NO: 414):
MDFQVQIFSFLLISASVIMSRGQIVLSQSPAILSASPGEKVTLTCRASSSVSFMNWYQQKP
GSSPKPWIYATSNLASEFPGRFSGEWSGTSYSLAISRVEAEDAATYYCQQWNSNPLTFG
AGTKLELKELSGGGGSGGGGSGGGGSLQIQLVQSGPESKKPGETVKISCKASGYTFTNY
GMNWVKQAPGKGLKWMGWINTYTGQPTYADDFKGRFAFSLETSAYTAYLQINNLKNE
DMATYFCARFSYGNSRYADYWGQGTTLTVSSDQPVPSTPPTPSPSTPPTPSPSCAPELLG
GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ
YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS
RDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD
KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 97. L6 scFv VHL11S (SSS-S)H WCH2
WCH3 (SEQ ID NO: 415) Nucleotide sequence:
aagcttgttgttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccag-
aggacaaattgttctctcccagtc
tccagcaatcctgtctgcatctccaggggagaaggtcacattgacttgcagggccagctcaagtgtaagtttca-
tgaactggtaccagcaga
agccaggatcctcccccaaaccctggatttatgccacatccaatttggcttctgagttccctggtcgcttcagt-
ggcgagtggtctgggacctc
ttactctctcgcaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggaatagtaacc-
cactcacgttcggtgctgg
gaccaagctggagctgaaagagctctctggtggcggtggctcgggcggtggtgggtcgggtggcggcggatctc-
tgcagatccagttgg
tgcagtctggacctgagtcgaagaagcctggagagacagtcaagatctcctgcaaggcttctgggtataccttc-
acaaactatggaatgaac
tgggtgaagcaggctccaggaaagggtttaaagtggatgggctggataaacacctacactggacagccaacata-
tgctgatgacttcaagg
gacggtttgccttctctttggaaacctctgcctacactgcctatttgcagatcaacaacctcaaaaatgaggac-
atggctacatatttctgtgcaa
gatttagctatggtaactcacgttacgctgactactggggccaaggcaccactctcacagtctcctctgatcag-
gagcccaaatcttctgacaa
aactcacacatccccaccgtcctcagcacctgaactcctggggggaccgtcagtcttcctcttccccccaaaac-
ccaaggacaccctcatga
tctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactgg-
tacgtggacggcgtgg
aggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcacc-
gtcctgcaccaggac
tggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaacaatctc-
caaagccaaagggca
gccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcctgacct-
gcctggtcaaaggct
tctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctccc-
gtgctggactccgac
ggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctc-
cgtgatgcatgaggctct
gcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga Amino acid
sequence (SEQ ID NO: 416):
MDFQVQIFSFLLISASVIMSRGQIVLSQSPAILSASPGEKVTLTCRASSSVSFMNWYQQKP
GSSPKPWIYATSNLASEFPGRFSGEWSGTSYSLAISRVEAEDAATYYCQQWNSNPLTFG
AGTKLELKELSGGGGSGGGGSGGGGSLQIQLVQSGPESKKPGETVKISCKASGYTFTNY
GMNWVKQAPGKGLKWMGWINTYTGQPTYADDFKGRFAFSLETSAYTAYLQINNLKNE
DMATYFCARFSYGNSRYADYWGQGTTLTVSSDQEPKSSDKTHTSPPSSAPELLGGPSVF
LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST
YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL
TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW
QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 98. P238 CH2 WCH3 a. P238S CH2 WCH3
(SEQ ID NO: 417) Nucleotide sequence:
cctgaactcctggggggatcgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggac-
ccctgaggtcacatgcgt
ggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatg-
ccaagacaaagccgc
gggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggc-
aaggagtacaagtgc
aaggtctccaacaaagccctcccagcccccatcgagaaaacaatctccaaagccaaagggcagccccgagaacc-
acaggtgtacaccct
gcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatcccagcg-
acatcgccgtggagtg
ggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcc-
tctacagcaagctcac
cgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccact-
acacgcagaagagcct ctccctgtctccgggtaaatgatctaga Amino acid sequence
(SEQ ID NO: 418):
PELLGGSSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQV
YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYS
KLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK b. (SSS-S)H P238S CH2 WCH3
(SEQ ID NO: 419) Nucleotide sequence:
tgatcaggagcccaaatcttctgacaaaactcacacatccccaccgtcctcagcacctgaactcctggggggat-
cgtcagtcttcctcttccc
cccaaaacccaaggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacg-
aagaccctgaggtca
agttcaactggtacgtggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagc-
acgtaccgtgtggtc
agcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccct-
cccagcccccatcga
gaaaacaatctccaaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagc-
tgaccaagaaccag
gtcagcctgacctgcctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagcc-
ggagaacaactacaa
gaccacgcctcccgtgctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggt-
ggcagcaggggaacgt
cttctcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggta-
aatgatctaga Amino acid sequence (SEQ ID NO: 420):
DQEPKSSDKTHTSPPSSAPELLGGSSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK
FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA
PIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK* 99. a.
CD16-6 low (ED) + NL + (SSS-S)H P238S CH2 WCH3 (SEQ ID NO: 421)
Nucleotide sequence:
ggagcccaaatcttctgacaaaactcacacatccccaccgtcctcagcacctgaactcctggggggatcgtcag-
tcttcctcttccccccaaa
acccaaggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagacc-
ctgaggtcaagttcaa
ctggtacgtggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtacc-
gtgtggtcagcgtc
ctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagc-
ccccatcgagaaaac
aatctccaaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgacca-
agaaccaggtcagc
ctgacctgcctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaa-
caactacaagaccac
gcctcccgtgctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagc-
aggggaacgtcttctca
tgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatc-
taga Amino acid sequence (SEQ ID NO: 422):
MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNST
QWFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWV
FKEEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGL
VGSKNVSSETVNITITQGLADQEPKSSDKTHTSPPSSAPELLGGSSVFLFPPKPKDTLMISR
TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKG
FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
ALHNHYTQKSLSLSPGK 100. b. CD16-6 low (ED) + HE4LP + (SSS-S)H P238S
CH2 WCH3 (SEQ ID NO: 423) Nucleotide sequence:
aagcttgccgccatgcctgcttgtcgcctaggcccgctagccgccgccctcctcctcagcctgctgctgttcgg-
cttcaccctagtctcaggc
accggtgcaatgcggactgaagatctcccaaaggctgtggtgttcctggagcctcaatggtacagggtgctcga-
gaaggacagtgtgactc
tgaagtgccagggagcctactcccctgaggacaattccacacagtggtttcacaatgagagcctcatctcaagc-
caggcctcgagctacttc
attgacgctgccacagtcgacgacagtggagagtacaggtgccagacaaacctctccaccctcagtgacccggt-
gcagctagaagtccat
atcggctggctgttgctccaggcccctcggtgggtgttcaaggaggaagaccctattcacctgaggtgtcacag-
ctggaagaacactgctct
gcataaggtcacatatttacagaatggcaaaggcaggaagtattttcatcataattctgacttctacattccaa-
aagccacactcaaagacagc
ggctcctacttctgcagggggcttgttgggagtaaaaatgtgtcttcagagactgtgaacatcaccatcactca-
aggtttggctgatcaggag
cccaaatcttctgacaaaactcacacatccccaccgtcctcagcacctgaactcctggggggatcgtcagtctt-
cctcttccccccaaaaccc
aaggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctga-
ggtcaagttcaactgg
tacgtggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgt-
ggtcagcgtcctca
ccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagccccc-
atcgagaaaacaatct
ccaaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaac-
caggtcagcctgac
ctgcctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaact-
acaagaccacgcctc
ccgtgctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcagggg-
aacgtcttctcatgctc
cgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctagaa-
a Amino acid sequence (SEQ ID NO: 424):
MPACRLGPLAAALLLSLLLFGFTLVSGTGAMRTEDLPKAVVFLEPQWYRVLEKDSVTL
KCQGAYSPEDNSTQWFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVH
IGWLLLQAPRWVFKEEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKAT
LKDSGSYFCRGLVGSKNVSSETVNITITQGLADQEPKSSDKTHTSPPSSAPELLGGSSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK 101. CD16-9 high (ED) (SSS-S)H P238S
CH2 CH3 a. CD16-9 high (ED)NL + (SSS-S)H P238S CH2 CH3 (SEQ ID NO:
425) Nucleotide sequence:
gttgttaagcttgccgccatgtggcagctgctcctcccaactgctctgctacttctagtttcagctggcatgcg-
gactgaagatctcccaaagg
ctgtggtgttcctggagcctcaatggtacagggtgctcgagaaggacagtgtgactctgaagtgccagggagcc-
tactcccctgaggacaa
ttccacacagtggtttcacaatgagagcctcatctcaagccaggcctcgagctacttcattgacgctgccacag-
tcgacgacagtggagagt
acaggtgccagacaaacctctccaccctcagtgacccggtgcagctagaagtccatatcggctggctgttgctc-
caggcccctcggtgggt
gttcaaggaggaagaccctattcacctgaggtgtcacagctggaagaacactgctctgcataaggtcacatatt-
tacagaatggcaaaggca
ggaagtattttcatcataattctgacttctacattccaaaagccacactcaaagacagcggctcctacttctgc-
agggggctttttgggagtaaa
aatgtgtcttcagagactgtgaacatcaccatcactcaaggtttggctgatcaggagcccaaatcttctgacaa-
aactcacacatccccaccgt
cctcagcacctgaactcctggggggatcgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatc-
tcccggacccctgaggtc
acatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggt-
gcataatgccaagac
aaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggc-
tgaatggcaaggagt
acaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaacaatctccaaagccaaagggcagccc-
cgagaaccacaggt
gtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttct-
atcccagcgacatcgc
cgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggct-
ccttcttcctctacag
caagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgc-
acaaccactacacgca gaagagcctctccctgtctccgggtaaatgatctagaaa Amino acid
sequence (SEQ ID NO: 426):
MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNST
QWFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWV
FKEEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLF
GSKNVSSETVNITITQGLADQEPKSSDKTHTSPPSSAPELLGGSSVFLFPPKPKDTLMISRT
PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW
LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFY
PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA
LHNHYTQKSLSLSPGK CD16-9 high (ED) + HE4LP + hIgG1 (SSS-S)H P238S
CH2 CH3 (SEQ ID NO: 427) Nucleotide sequence:
aagcttgccgccatgcctgcttgtcgcctaggcccgctagccgccgccctcctcctcagcctgctgctgttcgg-
cttcaccctagtctcaggc
accggtgcaatgcggactgaagatctcccaaaggctgtggtgttcctggagcctcaatggtacagggtgctcga-
gaaggacagtgtgactc
tgaagtgccagggagcctactcccctgaggacaattccacacagtggtttcacaatgagagcctcatctcaagc-
caggcctcgagctacttc
attgacgctgccacagtcgacgacagtggagagtacaggtgccagacaaacctctccaccctcagtgacccggt-
gcagctagaagtccat
atcggctggctgttgctccaggcccctcggtgggtgttcaaggaggaagaccctattcacctgaggtgtcacag-
ctggaagaacactgctct
gcataaggtcacatatttacagaatggcaaaggcaggaagtattttcatcataattctgacttctacattccaa-
aagccacactcaaagacagc
ggctcctacttctgcagggggctttttgggagtaaaaatgtgtcttcagagactgtgaacatcaccatcactca-
aggtttggctgatcaggagc
ccaaatcttctgacaaaactcacacatccccaccgtcctcagcacctgaactcctggggggatcgtcagtcttc-
ctcttccccccaaaaccca
aggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgag-
gtcaagttcaactggt
acgtggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtg-
gtcagcgtcctcac
cgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagccccca-
tcgagaaaacaatctc
caaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaacc-
aggtcagcctgacc
tgcctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaacta-
caagaccacgcctcc
cgtgctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcagggga-
acgtcttctcatgctcc
gtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctagaaa
Amino acid sequence (SEQ ID NO: 428):
MPACRLGPLAAALLLSLLLFGFTLVSGTGAMRTEDLPKAVVFLEPQWYRVLEKDSVTL
KCQGAYSPEDNSTQWFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVH
IGWLLLQAPRWVFKEEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKAT
LKDSGSYFCRGLFGSKNVSSETVNITITQGLADQEPKSSDKTHTSPPSSAPELLGGSSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK 102. a. CD16 ED low (native leader)
(SEQ ID NO: 429) Nucleotide sequence:
aagcttgccgccatgtggcagctgctcctcccaactgctctgctacttctagtttcagctggcatgcggactga-
agatctcccaaaggctgtg
gtgttcctggagcctcaatggtacagggtgctcgagaaggacagtgtgactctgaagtgccagggagcctactc-
ccctgaggacaattcca
cacagtggtttcacaatgagagcctcatctcaagccaggcctcgagctacttcattgacgctgccacagtcgac-
gacagtggagagtacag
gtgccagacaaacctctccaccctcagtgacccggtgcagctagaagtccatatcggctggctgttgctccagg-
cccctcggtgggtgttca
aggaggaagaccctattcacctgaggtgtcacagctggaagaacactgctctgcataaggtcacatatttacag-
aatggcaaaggcaggaa
gtattttcatcataattctgacttctacattccaaaagccacactcaaagacagcggctcctacttctgcaggg-
ggcttgttgggagtaaaaatg
tgtcttcagagactgtgaacatcaccatcactcaaggtttggctgatcaaaa Amino acid
sequence (SEQ ID NO: 430):
mwqlllptallllvsagmrtedlpkavvflepqwyrvlekdsvtlkcqgayspednstqwfhneslissqassy-
fidaatvddsgeyrc
qtnlstlsdpvqlevhigwlllqaprwvfkeedpihlrchswkntalhkvtylqngkgrkyfhhnsdfyipkat-
lkdsgsyfcrglvgsk nvssetvnititqgladq b. CD16 ED low (HE4 leader)
(SEQ ID NO: 431) Nucleotide sequence
aagcttgccgccatgcctgcttgtcgcctaggcccgctagccgccgccctcctcctcagcctgctgctgttcgg-
cttcaccctagtctcaggc
accggtgcaatgcggactgaagatctcccaaaggctgtggtgttcctggagcctcaatggtacagggtgctcga-
gaaggacagtgtgactc
tgaagtgccagggagcctactcccctgaggacaattccacacagtggtttcacaatgagagcctcatctcaagc-
caggcctcgagctacttc
attgacgctgccacagtcgacgacagtggagagtacaggtgccagacaaacctctccaccctcagtgacccggt-
gcagctagaagtccat
atcggctggctgttgctccaggcccctcggtgggtgttcaaggaggaagaccctattcacctgaggtgtcacag-
ctggaagaacactgctct
gcataaggtcacatatttacagaatggcaaaggcaggaagtattttcatcataattctgacttctacattccaa-
aagccacactcaaagacagc
ggctcctacttctgcagggggcttgttgggagtaaaaatgtgtcttcagagactgtgaacatcaccatcactca-
aggtttggctgatcaaa Amino acid sequence (SEQ ID NO: 432)
mpacrlgplaaalllslllfgftlvsgtgamrtedlpkavvflepqwyrvlekdsvtlkcqgayspednstqwf-
hneslissqassyfidaa
tvddsgeyrcqtnlstlsdpvqlevhigwlllqaprwvfkeedpihlrchswkntalhkvtylqngkgrkyfhh-
nsdfyipkatlkdsgs yfcrglvgsknvssetvnititqgladq 103. a. CD16 ED high
(native leader) (SEQ ID NO: 433) Nucleotide sequence:
gttgttaagcttgccgccatgtggcagctgctcctcccaactgctctgctacttctagtttcagctggcatgcg-
gactgaagatctcccaaagg
ctgtggtgttcctggagcctcaatggtacagggtgctcgagaaggacagtgtgactctgaagtgccagggagcc-
tactcccctgaggacaa
ttccacacagtggtttcacaatgagagcctcatctcaagccaggcctcgagctacttcattgacgctgccacag-
tcgacgacagtggagagt
acaggtgccagacaaacctctccaccctcagtgacccggtgcagctagaagtccatatcggctggctgttgctc-
caggcccctcggtgggt
gttcaaggaggaagaccctattcacctgaggtgtcacagctggaagaacactgctctgcataaggtcacatatt-
tacagaatggcaaaggca
ggaagtattttcatcataattctgacttctacattccaaaagccacactcaaagacagcggctcctacttctgc-
agggggctttttgggagtaaa
aatgtgtcttcagagactgtgaacatcaccatcactcaaggtttggctgatcaaa Amino acid
sequence (SEQ ID NO: 434):
mwqlllptallllvsagmrtedlpkavvflepqwyrvlekdsvtlkcqgayspednstqwfhneslissqassy-
fidaatvddsgeyrc
qtnlstlsdpvqlevhigwlllqaprwvfkeedpihlrchswkntalhkvtylqngkgrkyfhhnsdfyipkat-
lkdsgsyfcrglfgsk nvssetvnititqgladq
b. CD16 ED high (HE4 leader) (SEQ ID NO: 435) Nucleotide sequence:
aagcttgccgccatgcctgcttgtcgcctaggcccgctagccgccgccctcctcctcagcctgctgctgttcgg-
cttcaccctagtctcaggc
accggtgcaatgcggactgaagatctcccaaaggctgtggtgttcctggagcctcaatggtacagggtgctcga-
gaaggacagtgtgactc
tgaagtgccagggagcctactcccctgaggacaattccacacagtggtttcacaatgagagcctcatctcaagc-
caggcctcgagctacttc
attgacgctgccacagtcgacgacagtggagagtacaggtgccagacaaacctctccaccctcagtgacccggt-
gcagctagaagtccat
atcggctggctgttgctccaggcccctcggtgggtgttcaaggaggaagaccctattcacctgaggtgtcacag-
ctggaagaacactgctct
gcataaggtcacatatttacagaatggcaaaggcaggaagtattttcatcataattctgacttctacattccaa-
aagccacactcaaagacagc
ggctcctacttctgcagggggctttttgggagtaaaaatgtgtcttcagagactgtgaacatcaccatcactca-
aggtttggctgatcaaa Amino acid sequence (SEQ ID NO: 436):
MPACRLGPLAAALLLSLLLFGFTLVSGTGAMRTEDLPKAVVFLEPQWYRVLEKDSVTL
KCQGAYSPEDNSTQWFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVH
IGWLLLQAPRWVFKEEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKAT
LKDSGSYFCRGLFGSKNVSSETVNITITQGLADQ 104. 2e12 scFv (SSS-S)H P238S
CH2 WCH3-hCD80TM/CT (SEQ ID NO: 437) Nucleotide sequence:
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcacccaatctc
cagcttctttggctgtgtctctaggtcagagagccaccatctcctgcagagccagtgaaagtgttgaatattat-
gtcacaagtttaatgcagtgg
taccaacagaaaccaggacagccacccaaactcctcatctctgctgcatccaacgtagaatctggggtccctgc-
caggtttagtggcagtg
ggtctgggacagacttcagcctcaacatccatcctgtggaggaggatgatattgcaatgtatttctgtcagcaa-
agtaggaaggttccttgga
cgttcggtggaggcaccaagctggaaatcaaacggggtggcggtggctcgggcggaggtgggtcgggtggcggc-
ggatctcaggtgc
agctgaaggagtcaggacctggcctggtggcgccctcacagagcctgtccatcacatgcaccgtctcagggttc-
tcattaaccggctatggt
gtaaactgggttcgccagcctccaggaaagggtctggagtggctgggaatgatatggggtgatggaagcacaga-
ctataattcagctctca
aatccagactgagcatcaccaaggacaactccaagagccaagttttcttaaaaatgaacagtctgcaaactgat-
gacacagccagatactac
tgtgccagagatggttatagtaactttcattactatgttatggactactggggtcaaggaacctcagtcaccgt-
ctcctcagatctggagcccaa
atcttctgacaaaactcacacatccccaccgtccccagcacctgaactcctggggggatcgtcagtcttcctct-
tccccccaaaacccaagg
acaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtc-
aagttcaactggtacgt
ggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtca-
gcgtcctcaccgtc
ctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcga-
gaaaaccatctccaa
agccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccagg-
tcagcctgacctgc
ctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaa-
gaccacgcctcccgt
gctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacg-
tcttctcatgctccgtg
atgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaagcggatccttcgaa-
cctgctcccatcctggg
ccattaccttaatctcagtaaatggaatttttgtgatatgctgcctgacctactgctttgccccaagatgcaga-
gagagaaggaggaatgagag attgagaagggaaagtgtacgccctgtataaatcgat Amino
acid sequence (SEQ ID NO: 438):
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPASLAVSLGQRATISCRASESVEYYVTSLMQ
WYQQKPGQPPKLLISAASNVESGVPARFSGSGSGTDFSLNIHPVEEDDIAMYFCQQSRKV
PWTFGGGTKLEIKRGGGGSGGGGSGGGGSQVQLKESGPGLVAPSQSLSITCTVSGFSLT
GYGVNWVRQPPGKGLEWLGMIWGDGSTDYNSALKSRLSITKDNSKSQVFLKMNSLQT
DDTARYYCARDGYSNFHYYVMDYWGQGTSVTVSSDLEPKSSDKTHTSPPSPAPELLGG
SSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKADPSNLLPSWAITLISVNGIFVICCLT
YCFAPRCRERRRNERLRRESVRPV 105. 10A8 scFv (SSS-S)H P238SCH2
WCH3-hCD80TM/CT (SEQ ID NO: 439) Nucleotide sequence:
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacatccagatgacacagtct
ccatcctcactgtctgcatctctgggaggcaaagtcaccatcacttgcaaggcaagccaagacattaagaagta-
tataggttggtaccaaca
caagcctggaaaaggtcccaggctgctcatatattacacatctacattacagccaggcatcccatcaaggttca-
gtggaagtgggtctggga
gagattattccctcagcatcagaaacctggagcctgaagatattgcaacttattattgtcaacagtatgataat-
cttccattgacgttcggctcgg
ggacaaagttggaaataaaacggggtggcggtggctcgggcggtggtgggtcgggtggcggcggatctgatgta-
cagcttcaggagtca
ggacctggcctcgtgaaaccttctcagtctctgtctctcacctgctctgtcactggctactccatcaccagtgg-
tttctactggaactggatccg
acagtttccgggaaacaaactggaatggatgggccacataagccacgacggtaggaataactacaacccatctc-
tcataaatcgaatctcc
atcactcgtgacacatctaagaaccagtttttcctgaagttgagttctgtgactactgaggacacagctacata-
tttctgtgcaagacactacgg
tagtagcggagctatggactactggggtcaaggaacctcagtcaccgtctcctctgatctggagcccaaatctt-
ctgacaaaactcacacatc
cccaccgtccccagcacctgaactcctggggggatcgtcagtcttcctcttccccccaaaacccaaggacaccc-
tcatgatctcccggacc
cctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacgg-
cgtggaggtgcataat
gccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcacca-
ggactggctgaatg
gcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaa-
gggcagccccgaga
accacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtca-
aaggcttctatcccag
cgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggact-
ccgacggctccttct
tcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcat-
gaggctctgcacaacca
ctacacgcagaagagcctctccctgtctccgggtaaagcggatccttcgaacctgctcccatcctgggccatta-
ccttaatctcagtaaatgg
aatttttgtgatatgctgcctgacctactgctttgccccaagatgcagagagagaaggaggaatgagagattga-
gaagggaaagtgtacgcc ctgtataaatcgat Amino acid sequence (SEQ ID NO:
440): MDFQVQIFSFLLISASVIMSRGVDIQMTQSPSSLSASLGGKVTITCKASQDIKKYIGWYQH
KPGKGPRLLIYYTSTLQPGIPSRFSGSGSGRDYSLSIRNLEPEDIATYYCQQYDNLPLTFGS
GTKLEIKRGGGGSGGGGSGGGGSDVQLQESGPGLVKPSQSLSLTCSVTGYSITSGFYWN
WIRQFPGNKLEWMGHISHDGRNNYNPSLINRISITRDTSKNQFFLKLSSVTTEDTATYFC
ARHYGSSGAMDYWGQGTSVTVSSDLEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDT
LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV
LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTC
LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCS
VMHEALHNHYTQKSLSLSPGKADPSNLLPSWAITLISVNGIFVICCLTYCFAPRCRERRR
NERLRRESVRPV 106. 2H7 scFv VHL11S (SSS-P)H P238SCH2CH3-hCD80TM/CT
(SEQ ID NO: 441) Nucleotide sequence:
aagcttgccgccatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataattgccag-
aggacaaattgttctctcccagt
ctccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgcagggccagctcaagtgtaagttac-
atgcactggtaccagca
gaagccaggatcctcccccaaaccctggatttatgccccatccaacctggcttctggagtccctgctcgcttca-
gtggcagtgggtctggga
cctcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtggagtttt-
aacccacccacgttcggtgc
tgggaccaagctggagctgaaagatggcggtggctcgggcggtggtggatctggaggaggtgggagctctcagg-
cttatctacagcagt
ctggggctgagtcggtgaggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacatttaccagt-
tacaatatgcactgggta
aagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttcctacaatca-
gaagttcaagggcaagg
ccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg-
gtctatttctgtgcaaga
gtggtgtactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctcttctga-
tctggagcccaaatcttctga
caaaactcacacatccccaccgtccccagcacctgaactcctggggggatcgtcagtcttcctcttccccccaa-
aacccaaggacaccctc
atgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagttcaa-
ctggtacgtggacggc
gtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcct-
caccgtcctgcacca
ggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaacca-
tctccaaagccaaag
ggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagcctg-
acctgcctggtcaaa
ggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccacgcc-
tcccgtgctggactc
cgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcat-
gctccgtgatgcatgag
gctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaagcggatccttcgaacctgctccc-
atcctgggccattacctta
atctcagtaaatggaatttttgtgatatgctgcctgacctactgctttgccccaagatgcagagagagaaggag-
gaatgagagattgagaagg gaaagtgtacgccctgtataaatcgat Amino acid sequence
(SEQ ID NO: 442):
MDFQVQIFSFLLISASVIIARGQIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKP
GSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGA
GTKLELKDGGGSGGGGSGGGGSSQAYLQQSGAESVRPGASVKMSCKASGYTFTSYNM
HWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSA
VYFCARVVYYSNSYWYFDVWGTGTTVTVSSDLEPKSSDKTHTSPPSPAPELLGGSSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGKADPSNLLPSWAITLISVNGIFVICCLTYCFAP
RCRERRRNERLRRESVRPV 107. G19-4 scFv (SSS-P)H P238SCH2
WCH3-hCD80TM/CT (SEQ ID NO: 443) Nucleotide sequence:
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacatccagatgacacagac
tacatcctccctgtctgcctctctgggagacagagtcaccatcagttgcagggcaagtcaggacattcgcaatt-
atttaaactggtatcagcag
aaaccagatggaactgttaaactcctgatctactacacatcaagattacactcaggagtcccatcaaggttcag-
tggcagtgggtctggaaca
gattattctctcaccattgccaacctgcaaccagaagatattgccacttacttttgccaacagggtaatacgct-
tccgtggacgttcggtggag
gcaccaaactggtaaccaaacgggagctcggtggcggtggctcgggcggtggtgggtcgggtggcggcggatct-
atcgatgaggtcca
gctgcaacagtctggacctgaactggtgaagcctggagcttcaatgtcctgcaaggcctctggttactcattca-
ctggctacatcgtgaactg
gctgaagcagagccatggaaagaaccttgagtggattggacttattaatccatacaaaggtcttactacctaca-
accagaaattcaagggca
aggccacattaactgtagacaagtcatccagcacagcctacatggagctcctcagtctgacatctgaagactct-
gcagtctattactgtgcaa
gatctgggtactatggtgactcggactggtacttcgatgtctggggcgcagggaccacggtcaccgtctcctct-
gatctggagcccaaatctt
ctgacaaaactcacacaagcccaccgagcccagcacctgaactcctggggggatcgtcagtcttcctcttcccc-
ccaaaacccaaggaca
ccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaag-
ttcaactggtacgtgga
cggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcg-
tcctcaccgtcctgc
accaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaa-
accatctccaaagcc
aaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcag-
cctgacctgcctgg
tcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagacc-
acgcctcccgtgctg
gactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtctt-
ctcatgctccgtgatgc
atgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaagcggatccttcgaacctg-
ctcccatcctgggccatt
accttaatctcagtaaatggaatttttgatatgctgcctgacctactgctttgccccaagatgcagagagagaa-
ggaggaatgagagattga gaagggaaagtgtacgccctgtataaatcgatactcgag Amino
acid sequence (SEQ ID NO: 444):
MDFQVQIFSFLLISASVIMSRGVDIQMTQTTSSLSASLGDRVTISCRASQDIRNYLNWYQ
QKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTIANLQPEDIATYFCQQGNTLPWT
FGGGTKLVTKRELGGGGSGGGGSGGGGSIDEVQLQQSGPELVKPGASMSCKASGYSFT
GYIVNWLKQSHGKNLEWIGLINPYKGLTTYNQKFKGKATLTVDKSSSTAYMELLSLTSE
DSAVYYCARSGYYGDSDWYFDVWGAGTTVTVSSDLEPKSSDKTHTSPPSPAPELLGGS
SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKADPSNLLPSWAITLISVNGIFVICCLT
YCFAPRCRERRRNERLRRESVRPV 108. 2e12 scFv IgA WH WCH2 T4
CH3-hCD80TM/CT (SEQ ID NO: 445) Nucleotide sequence:
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcacccaatctc
cagcttctttggctgtgtctctaggtcagagagccaccatctcctgcagagccagtgaaagtgttgaatattat-
gtcacaagtttaatgcagtgg
taccaacagaaaccaggacagccacccaaactcctcatctctgctgcatccaacgtagaatctggggtccctgc-
caggtttagtggcagtg
ggtctgggacagacttcagcctcaacatccatcctgtggaggaggatgatattgcaatgtatttctgtcagcaa-
agtaggaaggttccttgga
cgttcggtggaggcaccaagctggaaatcaaacggggtggcggtggctcgggcggaggtgggtcgggtggcggc-
ggatctcaggtgc
agctgaaggagtcaggacctggcctggtggcgccctcacagagcctgtccatcacatgcaccgtctcagggttc-
tcattaaccggctatggt
gtaaactgggttcgccagcctccaggaaagggtctggagtggctgggaatgatatggggtgatggaagcacaga-
ctataattcagctctca
aatccagactgagcatcaccaaggacaactccaagagccaagttttcttaaaaatgaacagtctgcaaactgat-
gacacagccagatactac
tgtgccagagatggttatagtaactttcattactatgttatggactactggggtcaaggaacctcagtcaccgt-
ctcctcagatcagccagttcc
ctcaactccacctaccccatctccctcaactccacctaccccatctccctcatgctgccacccccgactgtcac-
tgcaccgaccggccctcga
ggacctgctcttaggttcagaagcgatcctcacgtgcacactgaccggcctgagagatgcctcaggtgtcacct-
tcacctggacgccctcaa
gtgggaagagcgctgttcaaggaccacctgaccgtgacctctgtggctgctacagcgtgtccagtgtcctgccg-
ggctgtgccgagccatg
gaaccatgggaagaccttcacttgcactgctgcctaccccgagtccaagaccccgctaaccgccaccctctcaa-
aatccggaaacacattc
cggcccgaggtccacctgctgccgccgccgtcggaggagctggccctgaacgagctggtgacgctgacgtgcct-
ggcacgtggcttca
gccccaaggatgtgctggttcgctggctgcaggggtcacaggagctgccccgcgagaagtacctgacttgggca-
tcccggcaggagccc
agccagggcaccaccaccttcgctgtgaccagcatactgcgcgtggcagccgaggactggaagaagggggacac-
cttctcctgcatggt
gggccacgaggccctgccgctggccttcacacagaagaccatcgaccgcttggcgggtaaacccacccatgtca-
atgtgtctgttgtcatg
gcggaggtggacgcggatccttcgaacaacctgctcccatcctgggccattaccttaatctcagtaaatggaat-
ttttgtgatatgctgcctga
cctactgctttgccccaagatgcagagagagaaggaggaatgagagattgagaagggaaagtgtacgccctgta-
taaatcgatac Amino acid sequence (SEQ ID NO: 446):
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPASLAVSLGQRATISCRASESVEYYVTSLMQ
WYQQKPGQPPKLLISAASNVESGVPARFSGSGSGTDFSLNIHPVEEDDIAMYFCQQSRKV
PWTFGGGTKLEIKRGGGGSGGGGSGGGGSQVQLKESGPGLVAPSQSLSITCTVSGFSLT
GYGVNWVRQPPGKGLEWLGMIWGDGSTDYNSALKSRLSITKDNSKSQVFLKMNSLQT
DDTARYYCARDGYSNFHYYVMDYWGQGTSVTVSSDQPVPSTPPTPSPSTPPTPSPSCCH
PRLSLHRPALEDLLLGSEAILTCTLTGLRDASGVTFTWTPSSGKSAVQGPPDRDLCGCYS
VSSVLPGCAEPWNHGKTFTCTAAYPESKTPLTATLSKSGNTFRPEVHLLPPPSEELALNE
LVTLTCLARGFSPKDVLVRWLQGSQELPREKYLTWASRQEPSQGTTTFAVTSILRVAAE
DWKKGDTFSCMVGHEALPLAFTQKTIDRLAGKPTHVNVSVVMAEVDADPSNNLLPSW
AITLISVNGIFVICCLTYCFAPRCRERRRNERLRRESVRPV 109. 2e12 scFV (SSS-P)H
P238S CH2 WCH3-mFADD-TM/CT (SEQ ID NO: 447) Nucleotide sequence:
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcacccaatctc
cagcttctttggctgtgtctctaggtcagagagccaccatctcctgcagagccagtgaaagtgttgaatattat-
gtcacaagtttaatgcagtgg
taccaacagaaaccaggacagccacccaaactcctcatctctgctgcatccaacgtagaatctggggtccctgc-
caggtttagtggcagtg
ggtctgggacagacttcagcctcaacatccatcctgtggaggaggatgatattgcaatgtatttctgtcagcaa-
agtaggaaggttccttgga
cgttcggtggaggcaccaagctggaaatcaaacggggtggcggtggctcgggcggaggtgggtcgggtggcggc-
ggatctcaggtgc
agctgaaggagtcaggacctggcctggtggcgccctcacagagcctgtccatcacatgcaccgtctcagggttc-
tcattaaccggctatggt
gtaaactgggttcgccagcctccaggaaagggtctggagtggctgggaatgatatggggtgatggaagcacaga-
ctataattcagctctca
aatccagactgagcatcaccaaggacaactccaagagccaagttttcttaaaaatgaacagtctgcaaactgat-
gacacagccagatactac
tgtgccagagatggttatagtaactttcattactatgttatggactactggggtcaaggaacctcagtcaccgt-
ctcctcagatctggagcccaa
atcttctgacaaaactcacacatccccaccgtccccagcacctgaactcctgggtggatcgtcagtcttcctct-
tccccccaaaacccaagga
caccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtca-
agttcaactggtacgtg
gacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcag-
cgtcctcaccgtcct
gcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgaga-
aaaccatctccaaag
ccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtc-
agcctgacctgcct
ggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaaga-
ccacgcctcccgtg
ctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgt-
cttctcatgctccgtgat
gcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaagcggatccttcgaaca-
tggacccattcctggtg
ctgctgcactcgctgtccggcagcctgtcgggcaacgatctgatggagctcaagttcttgtgccgcgagcgcgt-
gagcaaacgaaagctg
gagcgcgtgcagagtggcctggacctgttcacggtgctgctggagcagaacgacctggagcgcgggcacaccgg-
gctgctgcgcgagt
tgctggcctcgctgcgccgacacgatctactgcagcgcctggacgacttcgaggcggggacggcgaccgctgcg-
cccccgggggagg
cagatctgcaggtggcatttgacattgtgtgtgacaatgtggggagagactggaaaagactggcccgcgagctg-
aaggtgtctgaggcca
agatggatgggattgaggagaagtacccccgaagtctgagtgagcgggtaagggagagtctgaaagtctggaag-
aatgctgagaagaag
aacgcctcggtggccggactggtcaaggcgctgcggacctgcaggctgaatctggtggctgacctggtggaaga-
agcccaggaatctgt
gagcaagagtgagaatatgtccccagtactaagggattcaactgtgtcttcctcagaaacaccctgactcgaga-
tcgat
Amino acid sequence (SEQ ID NO: 448):
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPASLAVSLGQRATISCRASESVEYYVTSLMQ
WYQQKPGQPPKLLISAASNVESGVPARFSGSGSGTDFSLNIHPVEEDDIAMYFCQQSRKV
PWTFGGGTKLEIKRGGGGSGGGGSGGGGSQVQLKESGPGLVAPSQSLSITCTVSGFSLT
GYGVNWVRQPPGKGLEWLGMIWGDGSTDYNSALKSRLSITKDNSKSQVFLKMNSLQT
DDTARYYCARDGYSNFHYYVMDYWGQGTSVTVSSDLEPKSSDKTHTSPPSPAPELLGG
SSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKADPSNMDPFLVLLHSLSGSLSGNDL
MELKFLCRERVSKRKLERVQSGLDLFTVLLEQNDLERGHTGLLRELLASLRRHDLLQRL
DDFEAGTATAAPPGEADLQVAFDIVCDNVGRDWKRLARELKVSEAKMDGIEEKYPRSL
SERVRESLKVWKNAEKKNASVAGLVKALRTCRLNLVADLVEEAQESVSKSENMSPVLR
DSTVSSSETP 110. 2e12 scFv (SSS-P)H WCH2WCH3-mFADD-TM/CT (SEQ ID NO:
449) Nucleotide sequence:
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcacccaatctc
cagcttctttggctgtgtctctaggtcagagagccaccatctcctgcagagccagtgaaagtgttgaatattat-
gtcacaagtttaatgcagtgg
taccaacagaaaccaggacagccacccaaactcctcatctctgctgcatccaacgtagaatctggggtccctgc-
caggtttagtggcagtg
ggtctgggacagacttcagcctcaacatccatcctgtggaggaggatgatattgcaatgtatttctgtcagcaa-
agtaggaaggttccttgga
cgttcggtggaggcaccaagctggaaatcaaacggggtggcggtggctcgggcggaggtgggtcgggtggcggc-
ggatctcaggtgc
agctgaaggagtcaggacctggcctggtggcgccctcacagagcctgtccatcacatgcaccgtctcagggttc-
tcattaaccggctatggt
gtaaactgggttcgccagcctccaggaaagggtctggagtggctgggaatgatatggggtgatggaagcacaga-
ctataattcagctctca
aatccagactgagcatcaccaaggacaactccaagagccaagttttcttaaaaatgaacagtctgcaaactgat-
gacacagccagatactac
tgtgccagagatggttatagtaactttcattactatgttatggactactggggtcaaggaacctcagtcaccgt-
ctcctcagatctggagcccaa
atcttctgacaaaactcacacatccccaccgtccccagcacctgaactcctgggtggaccgtcagtcttcctct-
tccccccaaaacccaagg
acaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtc-
aagttcaactggtacgt
ggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtca-
gcgtcctcaccgtc
ctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcga-
gaaaaccatctccaa
agccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccagg-
tcagcctgacctgc
ctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaa-
gaccacgcctcccgt
gctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacg-
tcttctcatgctccgtg
atgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaagcggatccttcgaa-
catggacccattcctggt
gctgctgcactcgctgtccggcagcctgtcgggcaacgatctgatggagctcaagttcttgtgccgcgagcgcg-
tgagcaaacgaaagct
ggagcgcgtgcagagtggcctggacctgttcacggtgctgctggagcagaacgacctggagcgcgggcacaccg-
ggctgctgcgcga
gttgctggcctcgctgcgccgacacgatctactgcagcgcctggacgacttcgaggcggggacggcgaccgctg-
cgcccccgggggag
gcagatctgcaggtggcatttgacattgtgtgtgacaatgtggggagagactggaaaagactggcccgcgagct-
gaaggtgtctgaggcc
aagatggatgggattgaggagaagtacccccgaagtctgagtgagcgggtaagggagagtctgaaagtctggaa-
gaatgctgagaagaa
gaacgcctcggtggccggactggtcaaggcgctgcggacctgcaggctgaatctggtggctgacctggtggaag-
aagcccaggaatctg
tgagcaagagtgagaatatgtccccagtactaagggattcaactgtgtcttcctcagaaacaccctgactcgag-
atcgat Amino acid sequence (SEQ ID NO: 450):
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPASLAVSLGQRATISCRASESVEYYVTSLMQ
WYQQKPGQPPKLLISAASNVESGVPARFSGSGSGTDFSLNIHPVEEDDIAMYFCQQSRKV
PWTFGGGTKLEIKRGGGGSGGGGSGGGGSQVQLKESGPGLVAPSQSLSITCTVSGFSLT
GYGVNWVRQPPGKGLEWLGMIWGDGSTDYNSALKSRLSITKDNSKSQVFLKMNSLQT
DDTARYYCARDGYSNFHYYVMDYWGQGTSVTVSSDLEPKSSDKTHTSPPSPAPELLGG
PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKADPSNMDPFLVLLHSLSGSLSGNDL
MELKFLCRERVSKRKLERVQSGLDLFTVLLEQNDLERGHTGLLRELLASLRRHDLLQRL
DDFEAGTATAAPPGEADLQVAFDIVCDNVGRDWKRLARELKVSEAKMDGIEEKYPRSL
SERVRESLKVWKNAEKKNASVAGLVKALRTCRLNLVADLVEEAQESVSKSENMSPVLR
DSTVSSSETP 111. mcasp3-TM/CT (SEQ ID NO: 451) Nucleotide sequence:
Ggatccttcgaacatggagaacaacaaaacctcagtggattcaaaatccattaataattttgaagtaaagacca-
tacatgggagcaagtcag
tggactctgggatctatctggacagtagttacaaaatggattatcctgaaatgggcatatgcataataattaat-
aataagaacttccataagagc
actggaatgtcatctcgctctggtacggatgtggacgcagccaacctcagagagacattcatgggcctgaaata-
ccaagtcaggaataaaa
atgatcttactcgtgaagacattttggaattaatggatagtgtttctaaggaagatcatagcaaaaggagcagc-
tttgtgtgtgtgattctaagcc
atggtgatgaaggggtcatttatgggacaaatgggcctgttgaactgaaaaagttgactagcttcttcagaggc-
gactactgccggagtctga
ctggaaagccgaaactcttcatcattcaggcctgccggggtacggagctggactgtggcattgagacagacagt-
gggactgatgaggaga
tggcttgccagaagataccggtggaggctgacttcctgtatgcttactctacagcacctggttactattcctgg-
agaaattcaaaggacgggtc
gtggttcatccagtccctttgcagcatgctgaagctgtacgcgcacaagctagaatttatgcacattctcactc-
gcgttaacaggaaggtggc
aacggaattcgagtccttctccctggactccactttccacgcaaagaaacagatcccgtgtattgtgtccatgc-
tcacgaaagaactgtactttt atcactagctcgagatcgatg Amino acid sequence
(SEQ ID NO: 452):
DPSNMENNKTSVDSKSINNFEVKTIHGSKSVDSGIYLDSSYKMDYPEMGICIIINNKNFHK
STGMSSRSGTDVDAANLRETFMGLKYQVRNKNDLTREDILELMDSVSKEDHSKRSSFV
CVILSHGDEGVIYGTNGPVELKKLTSFFRGDYCRSLTGKPKLFIIQACRGTELDCGIETDS
GTDEEMACQKIPVEADFLYAYSTAPGYYSWRNSKDGSWFIQSLCSMLKLYAHKLEFMH
ILTRVNRKVATEFESFSLDSTFHAKKQIPCIVSMLTKELYFYH 112. 2e12 scFv (SSS-P)H
WCH2WCH3-mcasp3-TM/CT (SEQ ID NO: 453) Nucleotide sequence:
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcacccaatctc
cagcttctttggctgtgtctctaggtcagagagccaccatctcctgcagagccagtgaaagtgttgaatattat-
gtcacaagtttaatgcagtgg
taccaacagaaaccaggacagccacccaaactcctcatctctgctgcatccaacgtagaatctggggtccctgc-
caggtttagtggcagtg
ggtctgggacagacttcagcctcaacatccatcctgtggaggaggatgatattgcaatgtatttctgtcagcaa-
agtaggaaggttccttgga
cgttcggtggaggcaccaagctggaaatcaaacggggtggcggtggctcgggcggaggtgggtcgggtggcggc-
ggatctcaggtgc
agctgaaggagtcaggacctggcctggtggcgccctcacagagcctgtccatcacatgcaccgtctcagggttc-
tcattaaccggctatggt
gtaaactgggttcgccagcctccaggaaagggtctggagtggctgggaatgatatggggtgatggaagcacaga-
ctataattcagctctca
aatccagactgagcatcaccaaggacaactccaagagccaagttttcttaaaaatgaacagtctgcaaactgat-
gacacagccagatactac
tgtgccagagatggttatagtaactttcattactatgttatggactactggggtcaaggaacctcagtcaccgt-
ctcctcagatctggagcccaa
atcttctgacaaaactcacacatccccaccgtccccagcacctgaactcctgggtggaccgtcagtcttcctct-
tccccccaaaacccaagg
acaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtc-
aagttcaactggtacgt
ggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtca-
gcgtcctcaccgtc
ctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcga-
gaaaaccatctccaa
agccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccagg-
tcagcctgacctgc
ctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaa-
gaccacgcctcccgt
gctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacg-
tcttctcatgctccgtg
atgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaagcggatccttcgaa-
catggagaacaacaaa
acctcagtggattcaaaatccattaataattttgaagtaaagaccatacatgggagcaagtcagtggactctgg-
gatctatctggacagtagtt
acaaaatggattatcctgaaatgggcatatgcataataattaataataagaacttccataagagcactggaatg-
tcatctcgctctggtacggat
gtggacgcagccaacctcagagagacattcatgggcctgaaataccaagtcaggaataaaaatgatcttactcg-
tgaagacattttggaatta
atggatagtgtttctaaggaagatcatagcaaaaggagcagctttgtgtgtgtgattctaagccatggtgatga-
aggggtcatttatgggacaa
atgggcctgttgaactgaaaaagttgactagcttcttcagaggcgactactgccggagtctgactggaaagccg-
aaactcttcatcattcagg
cctgccggggtacggagctggactgtggcattgagacagacagtgggactgatgaggagatggcttgccagaag-
ataccggtggaggct
gacttcctgtatgcttactctacagcacctggttactattcctggagaaattcaaaggacgggtcgtggttcat-
ccagtccctttgcagcatgct
gaagctgtacgcgcacaagctagaatttatgcacattctcactcgcgttaacaggaaggtggcaacggaattcg-
agtccttctccctggactc
cactttccacgcaaagaaacagatcccgtgtattgtgtccatgctcacgaaagaactgtacttttatcactagc-
tcgagatcgatg Amino acid sequence (SEQ ID NO: 454):
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPASLAVSLGQRATISCRASESVEYYVTSLMQ
WYQQKPGQPPKLLISAASNVESGVPARFSGSGSGTDFSLNIHPVEEDDIAMYFCQQSRKV
PWTFGGGTKLEIKRGGGGSGGGGSGGGGSQVQLKESGPGLVAPSQSLSITCTVSGFSLT
GYGVNWVRQPPGKGLEWLGMIWGDGSTDYNSALKSRLSITKDNSKSQVFLKMNSLQT
DDTARYYCARDGYSNFHYYVMDYWGQGTSVTVSSDLEPKSSDKTHTSPPSPAPELLGG
PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKADPSNMENNKTSVDSKSINNFEVKTI
HGSKSVDSGIYLDSSYKMDYPEMGICIIINNKNFHKSTGMSSRSGTDVDAANLRETFMG
LKYQVRNKNDLTREDILELMDSVSKEDHSKRSSFVCVILSHGDEGVIYGTNGPVELKKL
TSFFRGDYCRSLTGKPKLFIIQACRGTELDCGIETDSGTDEEMACQKIPVEADFLYAYSTA
PGYYSWRNSKDGSWFIQSLCSMLKLYAHKLEFMHILTRVNRKVATEFESFSLDSTFHAK
KQIPCIVSMLTKELYFYH 113. 2e12 scFv (SSS-P)H
P238SCH2WCH3-mcasp3-TM/CT (SEQ ID NO: 455) Nucleotide sequence:
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcacccaatctc
cagcttctttggctgtgtctctaggtcagagagccaccatctcctgcagagccagtgaaagtgttgaatattat-
gtcacaagtttaatgcagtgg
taccaacagaaaccaggacagccacccaaactcctcatctctgctgcatccaacgtagaatctggggtccctgc-
caggtttagtggcagtg
ggtctgggacagacttcagcctcaacatccatcctgtggaggaggatgatattgcaatgtatttctgtcagcaa-
agtaggaaggttccttgga
cgttcggtggaggcaccaagctggaaatcaaacggggtggcggtggctcgggcggaggtgggtcgggtggcggc-
ggatctcaggtgc
agctgaaggagtcaggacctggcctggtggcgccctcacagagcctgtccatcacatgcaccgtctcagggttc-
tcattaaccggctatggt
gtaaactgggttcgccagcctccaggaaagggtctggagtggctgggaatgatatggggtgatggaagcacaga-
ctataattcagctctca
aatccagactgagcatcaccaaggacaactccaagagccaagttttcttaaaaatgaacagtctgcaaactgat-
gacacagccagatactac
tgtgccagagatggttatagtaactttcattactatgttatggactactggggtcaaggaacctcagtcaccgt-
ctcctcagatctggagcccaa
atcttctgacaaaactcacacatccccaccgtccccagcacctgaactcctgggtggatcgtcagtcttcctct-
tccccccaaaacccaagga
caccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtca-
agttcaactggtacgtg
gacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcag-
cgtcctcaccgtcct
gcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgaga-
aaaccatctccaaag
ccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtc-
agcctgacctgcct
ggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaaga-
ccacgcctcccgtg
ctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgt-
cttctcatgctccgtgat
gcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaagcggatccttcgaatt-
cgaacatggagaacaac
aaaacctcagtggattcaaaatccattaataattttgaagtaaagaccatacatgggagcaagtcagtggactc-
tgggatctatctggacagta
gttacaaaatggattatcctgaaatgggcatatgcataataattaataataagaacttccataagagcactgga-
atgtcatctcgctctggtacg
gatgtggacgcagccaacctcagagagacattcatgggcctgaaataccaagtcaggaataaaaatgatcttac-
tcgtgaagacattttgga
attaatggatagtgtttctaaggaagatcatagcaaaaggagcagctttgtgtgtgtgattctaagccatggtg-
atgaaggggtcatttatggga
caaatgggcctgttgaactgaaaaagttgactagcttcttcagaggcgactactgccggagtctgactggaaag-
ccgaaactcttcatcattc
aggcctgccggggtacggagctggactgtggcattgagacagacagtgggactgatgaggagatggcttgccag-
aagataccggtgga
ggctgacttcctgtatgcttactctacagcacctggttactattcctggagaaattcaaaggacgggtcgtggt-
tcatccagtccctttgcagca
tgctgaagctgtacgcgcacaagctagaatttatgcacattctcactcgcgttaacaggaaggtggcaacggaa-
ttcgagtccttctccctgg
actccactttccacgcaaagaaacagatcccgtgtattgtgtccatgctcacgaaagaactgtacttttatcac-
tagctcgagatcgatga Amino acid sequence (SEQ ID NO: 456):
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPASLAVSLGQRATISCRASESVEYYVTSLMQ
WYQQKPGQPPKLLISAASNVESGVPARFSGSGSGTDFSLNIHPVEEDDIAMYFCQQSRKV
PWTFGGGTKLEIKRGGGGSGGGGSGGGGSQVQLKESGPGLVAPSQSLSITCTVSGFSLT
GYGVNWVRQPPGKGLEWLGMIWGDGSTDYNSALKSRLSITKDNSKSQVFLKMNSLQT
DDTARYYCARDGYSNFHYYVMDYWGQGTSVTVSSDLEPKSSDKTHTSPPSPAPELLGG
SSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKADPSNSNMENNKTSVDSKSINNFEV
KTIHGSKSVDSGIYLDSSYKMDYPEMGICIIINNKNFHKSTGMSSRSGTDVDAANLRETF
MGLKYQVRNKNDLTREDILELMDSVSKEDHSKRSSFVCVILSHGDEGVIYGTNGPVELK
KLTSFFRGDYCRSLTGKPKLFIIQACRGTELDCGIETDSGTDEEMACQKIPVEADFLYAYS
TAPGYYSWRNSKDGSWFIQSLCSMLKLYAHKLEFMHILTRVNRKVATEFESFSLDSTFH
AKKQIPCIVSMLTKELYFYH 114. mcasp8-TM/CT (SEQ ID NO: 457) Nucleotide
sequence:
ttcgaacatggatttccagagttgtctttatgctattgctgaagaactgggcagtgaagacctggctgccctca-
agttcctgtgcttggactacat
cccacacaagaagcaggagaccatcgaggatgcccagaagctatttctgaggctgcgggaaaaggggatgttgg-
aggaaggcaatctgt
ctttcctgaaagagctgcttttccacatcagtcggtgggacctgctggtcaacttcctagactgcaaccgagag-
gagatggtgagagagctg
cgggatccagacaatgcccagatttctccctacagggtcatgctctttaagctctcagaagaagtgagcgagtt-
ggaattgagatcttttaagtt
ccttttgaacaatgagatccccaaatgtaagctggaagatgacttgagcctgcttgaaatttttgtagaaatgg-
agaagaggaccatgctggc
agaaaataacttggaaaccctaaaatcaatctgtgaccaggtcaacaagagcctgctggggaagatcgaggatt-
atgaaagatcaagcaca
gagagaagaatgagccttgaaggaagggaagagttgccaccttcagttttggatgagatgagcctcaaaatggc-
ggaactgtgtgactcgc
caagagaacaagacagtgagtcacggacttcagacaaagtttaccaaatgaagaacaaacctcggggatactgt-
ctgatcatcaacaatca
tgatttcagcaaggcccgggaagacataacccaactccgaaaaatgaaggacagaaaaggaacagactgtgata-
aagaggctctgagta
agacctttaaggagcttcattttgagatagtatcttacgacgactgcactgcaaatgaaatccacgagattcta-
gaaggctaccaaagcgcag
accacaagaacaaagactgcttcatctgctgtatcctatcccacggtgacaagggtgtcgtctatggaacggat-
gggaaggaggcctccat
ctatgacctgacatcttacttcactggttcaaagtgcccttccctgtctgggaaacccaagatctttttcattc-
aggcttgccaaggaagtaactt
ccagaaaggagtgcctgatgaggcaggcttcgagcaacagaaccacactttagaagtggattcatcatctcaca-
agaactatattccggatg
aggcagactttctgctgggaatggctacggtgaagaactgcgtttcctaccgagatcctgtgaatggaacctgg-
tatattcagtcactttgcca
gagcctgagggaaagatgtcctcaaggagatgacattcttagcatcctgactggcgtgaactatgacgtgagca-
ataaagacgacaggag
gaacaagggaaagcagatgccacagcccaccttcacactacggaagaagctcttcttccctccctaatgactcg-
agatcgatt Amino acid sequence (SEQ ID NO: 458):
SNMDFQSCLYAIAEELGSEDLAALKFLCLDYIPHKKQETIEDAQKLFLRLREKGMLEEGN
LSFLKELLFHISRWDLLVNFLDCNREEMVRELRDPDNAQISPYRVMLFKLSEEVSELELR
SFKFLLNNEIPKCKLEDDLSLLEIFVEMEKRTMLAENNLETLKSICDQVNKSLLGKIEDYE
RSSTERRMSLEGREELPPSVLDEMSLKMAELCDSPREQDSESRTSDKVYQMKNKPRGYC
LIINNHDFSKAREDITQLRKMKDRKGTDCDKEALSKTFKELHFEIVSYDDCTANEIHEILE
GYQSADHKNKDCFICCILSHGDKGVVYGTDGKEASIYDLTSYFTGSKCPSLSGKPKIFFIQ
ACQGSNFQKGVPDEAGFEQQNHTLEVDSSSHKNYIPDEADFLLGMATVKNCVSYRDPV
NGTWYIQSLCQSLRERCPQGDDILSILTGVNYDVSNKDDRRNKGKQMPQPTFTLRKKLF FPP
115. 2e12 scFv hIgG1 (SSS-P)H WCH2 WCH3-mcasp8-TM/CT (SEQ ID NO:
459) Nucleotide sequence:
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcacccaatctc
cagcttctttggctgtgtctctaggtcagagagccaccatctcctgcagagccagtgaaagtgttgaatattat-
gtcacaagtttaatgcagtgg
taccaacagaaaccaggacagccacccaaactcctcatctctgctgcatccaacgtagaatctggggtccctgc-
caggtttagtggcagtg
ggtctgggacagacttcagcctcaacatccatcctgtggaggaggatgatattgcaatgtatttctgtcagcaa-
agtaggaaggttccttgga
cgttcggtggaggcaccaagctggaaatcaaacggggtggcggtggctcgggcggaggtgggtcgggtggcggc-
ggatctcaggtgc
agctgaaggagtcaggacctggcctggtggcgccctcacagagcctgtccatcacatgcaccgtctcagggttc-
tcattaaccggctatggt
gtaaactgggttcgccagcctccaggaaagggtctggagtggctgggaatgatatggggtgatggaagcacaga-
ctataattcagctctca
aatccagactgagcatcaccaaggacaactccaagagccaagttttcttaaaaatgaacagtctgcaaactgat-
gacacagccagatactac
tgtgccagagatggttatagtaactttcattactatgttatggactactggggtcaaggaacctcagtcaccgt-
ctcctcagatctggagcccaa
atcttctgacaaaactcacacatccccaccgtccccagcacctgaactcctgggtggaccgtcagtcttcctct-
tccccccaaaacccaagg
acaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtc-
aagttcaactggtacgt
ggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtca-
gcgtcctcaccgtc
ctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcga-
gaaaaccatctccaa
agccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccagg-
tcagcctgacctgc
ctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaa-
gaccacgcctcccgt
gctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacg-
tcttctcatgctccgtg
atgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaagcggatccttcgaa-
catggatttccagagttg
tctttatgctattgctgaagaactgggcagtgaagacctggctgccctcaagttcctgtgcttggactacatcc-
cacacaagaagcaggagac
catcgaggatgcccagaagctatttctgaggctgcgggaaaaggggatgttggaggaaggcaatctgtctttcc-
tgaaagagctgcttttcc
acatcagtcggtgggacctgctggtcaacttcctagactgcaaccgagaggagatggtgagagagctgcgggat-
ccagacaatgcccag
atttctccctacagggtcatgctattaagctctcagaagaagtgagcgagttggaattgagatcttttaagttc-
cttttgaacaatgagatcccc
aaatgtaagctggaagatgacttgagcctgcttgaaatttttgtagaaatggagaagaggaccatgctggcaga-
aaataacttggaaacccta
aaatcaatctgtgaccaggtcaacaagagcctgctggggaagatcgaggattatgaaagatcaagcacagagag-
aagaatgagccttgaa
ggaagggaagagttgccaccttcagttttggatgagatgagcctcaaaatggcggaactgtgtgactcgccaag-
agaacaagacagtgag
tcacggacttcagacaaagtttaccaaatgaagaacaaacctcggggatactgtctgatcatcaacaatcatga-
tttcagcaaggcccggga
agacataacccaactccgaaaaatgaaggacagaaaaggaacagactgtgataaagaggctctgagtaagacct-
ttaaggagcttcatttt
gagatagtatcttacgacgactgcactgcaaatgaaatccacgagattctagaaggctaccaaagcgcagacca-
caagaacaaagactgct
tcatctgctgtatcctatcccacggtgacaagggtgtcgtctatggaacggatgggaaggaggcctccatctat-
gacctgacatcttacttcac
tggttcaaagtgcccttccctgtctgggaaacccaagatctttttcattcaggcttgccaaggaagtaacttcc-
agaaaggagtgcctgatgag
gcaggcttcgagcaacagaaccacactttagaagtggattcatcatctcacaagaactatattccggatgaggc-
agactttctgctgggaatg
gctacggtgaagaactgcgtttcctaccgagatcctgtgaatggaacctggtatattcagtcactttgccagag-
cctgagggaaagatgtcct
caaggagatgacattcttagcatcctgactggcgtgaactatgacgtgagcaataaagacgacaggaggaacaa-
gggaaagcagatgcc
acagcccaccttcacactacggaagaagctcttcttccctccctaatgactcgagatcgatt
Amino acid sequence (SEQ ID NO: 460):
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPASLAVSLGQRATISCRASESVEYYVTSLMQ
WYQQKPGQPPKLLISAASNVESGVPARFSGSGSGTDFSLNIHPVEEDDIAMYFCQQSRKV
PWTFGGGTKLEIKRGGGGSGGGGSGGGGSQVQLKESGPGLVAPSQSLSITCTVSGFSLT
GYGVNWVRQPPGKGLEWLGMIWGDGSTDYNSALKSRLSITKDNSKSQVFLKMNSLQT
DDTARYYCARDGYSNFHYYVMDYWGQGTSVTVSSDLEPKSSDKTHTSPPSPAPELLGG
PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKADPSNMDFQSCLYAIAEELGSEDLA
ALKFLCLDYIPHKKQETIEDAQKLFLRLREKGMLEEGNLSFLKELLFHISRWDLLVNFLD
CNREEMVRELRDPDNAQISPYRVMLFKLSEEVSELELRSFKFLLNNEIPKCKLEDDLSLL
EIFVEMEKRTMLAENNLETLKSICDQVNKSLLGKIEDYERSSTERRMSLEGREELPPSVL
DEMSLKMAELCDSPREQDSESRTSDKVYQMKNKPRGYCLIINNHDFSKAREDITQLRK
MKDRKGTDCDKEALSKTFKELHFEIVSYDDCTANEIHEILEGYQSADHKNKDCFICCILS
HGDKGVVYGTDGKEASIYDLTSYFTGSKCPSLSGKPKIFFIQACQGSNFQKGVPDEAGFE
QQNHTLEVDSSSHKNYIPDEADFLLGMATVKNCVSYRDPVNGTWYIQSLCQSLRERCP
QGDDILSILTGVNYDVSNKDDRRNKGKQMPQPTFTLRKKLFFPP 116. 2e12 scFv hIgG1
(SSS-P)H P238SCH2 WCH3-mcasp8-TM/CT (SEQ ID NO: 461) Nucleotide
sequence:
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcacccaatctc
cagcttctttggctgtgtctctaggtcagagagccaccatctcctgcagagccagtgaaagtgttgaatattat-
gtcacaagtttaatgcagtgg
taccaacagaaaccaggacagccacccaaactcctcatctctgctgcatccaacgtagaatctggggtccctgc-
caggtttagtggcagtg
ggtctgggacagacttcagcctcaacatccatcctgtggaggaggatgatattgcaatgtatttctgtcagcaa-
agtaggaaggttccttgga
cgttcggtggaggcaccaagctggaaatcaaacggggtggcggtggctcgggcggaggtgggtcgggtggcggc-
ggatctcaggtgc
agctgaaggagtcaggacctggcctggtggcgccctcacagagcctgtccatcacatgcaccgtctcagggttc-
tcattaaccggctatggt
gtaaactgggttcgccagcctccaggaaagggtctggagtggctgggaatgatatggggtgatggaagcacaga-
ctataattcagctctca
aatccagactgagcatcaccaaggacaactccaagagccaagttttcttaaaaatgaacagtctgcaaactgat-
gacacagccagatactac
tgtgccagagatggttatagtaactttcattactatgttatggactactggggtcaaggaacctcagtcaccgt-
ctcctcagatctggagcccaa
atcttctgacaaaactcacacatccccaccgtccccagcacctgaactcctgggtggatcgtcagtcttcctct-
tccccccaaaacccaagga
caccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtca-
agttcaactggtacgtg
gacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcag-
cgtcctcaccgtcct
gcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgaga-
aaaccatctccaaag
ccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtc-
agcctgacctgcct
ggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaaga-
ccacgcctcccgtg
ctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgt-
cttctcatgctccgtgat
gcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaagcggatccttcgaaca-
tggatttccagagttgtc
tttatgctattgctgaagaactgggcagtgaagacctggctgccctcaagttcctgtgcttggactacatccca-
cacaagaagcaggagacc
atcgaggatgcccagaagctatttctgaggctgcgggaaaaggggatgttggaggaaggcaatctgtattcctg-
aaagagctgcttttcca
catcagtcggtgggacctgctggtcaacttcctagactgcaaccgagaggagatggtgagagagctgcgggatc-
cagacaatgcccagat
ttctccctacagggtcatgctctttaagctctcagaagaagtgagcgagttggaattgagatcttttaagttcc-
ttttgaacaatgagatccccaa
atgtaagctggaagatgacttgagcctgcttgaaatttttgtagaaatggagaagaggaccatgctggcagaaa-
ataacttggaaaccctaaa
atcaatctgtgaccaggtcaacaagagcctgctggggaagatcgaggattatgaaagatcaagcacagagagaa-
gaatgagccttgaagg
aagggaagagttgccaccttcagttttggatgagatgagcctcaaaatggcggaactgtgtgactcgccaagag-
aacaagacagtgagtca
cggacttcagacaaagtttaccaaatgaagaacaaacctcggggatactgtctgatcatcaacaatcatgattt-
cagcaaggcccgggaaga
cataacccaactccgaaaaatgaaggacagaaaaggaacagactgtgataaagaggctctgagtaagaccttta-
aggagcttcattttgag
atagtatcttacgacgactgcactgcaaatgaaatccacgagattctagaaggctaccaaagcgcagaccacaa-
gaacaaagactgcttcat
ctgctgtatcctatcccacggtgacaagggtgtcgtctatggaacggatgggaaggaggcctccatctatgacc-
tgacatcttacttcactggt
tcaaagtgcccttccctgtctgggaaacccaagatctttttcattcaggcttgccaaggaagtaacttccagaa-
aggagtgcctgatgaggca
ggcttcgagcaacagaaccacactttagaagtggattcatcatctcacaagaactatattccggatgaggcaga-
ctttctgctgggaatggct
acggtgaagaactgcgtttcctaccgagatcctgtgaatggaacctggtatattcagtcactttgccagagcct-
gagggaaagatgtcctcaa
ggagatgacattcttagcatcctgactggcgtgaactatgacgtgagcaataaagacgacaggaggaacaaggg-
aaagcagatgccaca
gcccaccttcacactacggaagaagctcttcttccctccctaatgactcgagatcgattc Amino
acid sequence (SEQ ID NO: 462):
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPASLAVSLGQRATISCRASESVEYYVTSLMQ
WYQQKPGQPPKLLISAASNVESGVPARFSGSGSGTDFSLNIHPVEEDDIAMYFCQQSRKV
PWTFGGGTKLEIKRGGGGSGGGGSGGGGSQVQLKESGPGLVAPSQSLSITCTVSGFSLT
GYGVNWVRQPPGKGLEWLGMIWGDGSTDYNSALKSRLSITKDNSKSQVFLKMNSLQT
DDTARYYCARDGYSNFHYYVMDYWGQGTSVTVSSDLEPKSSDKTHTSPPSPAPELLGG
SSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKADPSNMDFQSCLYAIAEELGSEDLA
ALKFLCLDYIPHKKQETIEDAQKLFLRLREKGMLEEGNLSFLKELLFHISRWDLLVNFLD
CNREEMVRELRDPDNAQISPYRVMLFKLSEEVSELELRSFKFLLNNEIPKCKLEDDLSLL
EIFVEMEKRTMLAENNLETLKSICDQVNKSLLGKIEDYERSSTERRMSLEGREELPPSVL
DEMSLKMAELCDSPREQDSESRTSDKVYQMKNKPRGYCLIINNHDFSKAREDITQLRK
MKDRKGTDCDKEALSKTFKELHFEIVSYDDCTANEIHEILEGYQSADHKNKDCFICCILS
HGDKGVVYGTDGKEASIYDLTSYFTGSKCPSLSGKPKIFFIQACQGSNFQKGVPDEAGFE
QQNHTLEVDSSSHKNYIPDEADFLLGMATVKNCVSYRDPVNGTWYIQSLCQSLRERCP
QGDDILSILTGVNYDVSNKDDRRNKGKQMPQPTFTLRKKLFFPP 117. hcasp3-TM/CT (SEQ
ID NO: 463) Nucleotide sequence:
Ggatccttcgaacatggagaacactgaaaactcagtggattcaaaatccattaaaaatttggaaccaaagatca-
tacatggaagcgaatcaa
tggactctggaatatccctggacaacagttataaaatggattatcctgagatgggtttatgtataataattaat-
aataagaattttcataaaagcac
tggaatgacatctcggtctggtacagatgtcgatgcagcaaacctcagggaaacattcagaaacttgaaatatg-
aagtcaggaataaaaatg
atcttacacgtgaagaaattgtggaattgatgcgtgatgtttctaaagaagatcacagcaaaaggagcagtttt-
gtttgtgtgcttctgagccat
ggtgaagaaggaataatttttggaacaaatggacctgttgacctgaaaaaaataacaaactttttcagagggga-
tcgttgtagaagtctaactg
gaaaacccaaacttttcattattcaggcctgccgtggtacagaactggactgtggcattgagacagacagtggt-
gttgatgatgacatggcgt
gtcataaaataccagtggaggccgacttcttgtatgcatactccacagcacctggttattattcttggcgaaat-
tcaaaggatggctcctggttc
atccagtcgctttgtgccatgctgaaacagtatgccgacaagcttgaatttatgcacattcttacccgggttaa-
ccgaaaggtggcaacagaat
ttgagtccttttcctttgacgctacttttcatgcaaagaaacagattccatgtattgtttccatgctcacaaaa-
gaactctatttttatcactaactcga gatcgata Amino acid sequence (SEQ ID NO:
464): DPSNMENTENSVDSKSIKNLEPKIIHGSESMDSGISLDNSYKMDYPEMGLCIIINNKNFHK
STGMTSRSGTDVDAANLRETFRNLKYEVRNKNDLTREEIVELMRDVSKEDHSKRSSFVC
VLLSHGEEGIIFGTNGPVDLKKITNFFRGDRCRSLTGKPKLFIIQACRGTELDCGIETDSGV
DDDMACHKIPVEADFLYAYSTAPGYYSWRNSKDGSWFIQSLCAMLKQYADKLEFMHIL
TRVNRKVATEFESFSFDATFHAKKQIPCIVSMLTKELYFYH 118. 2e12 scFv hIgG1
(SSS-P)H WCH2 WCH3-hcasp3-TM/CT (SEQ ID NO: 465) Nucleotide
sequence:
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcacccaatctc
cagcttctttggctgtgtctctaggtcagagagccaccatctcctgcagagccagtgaaagtgttgaatattat-
gtcacaagtttaatgcagtgg
taccaacagaaaccaggacagccacccaaactcctcatctctgctgcatccaacgtagaatctggggtccctgc-
caggtttagtggcagtg
ggtctgggacagacttcagcctcaacatccatcctgtggaggaggatgatattgcaatgtatttctgtcagcaa-
agtaggaaggttccttgga
cgttcggtggaggcaccaagctggaaatcaaacggggtggcggtggctcgggcggaggtgggtcgggtggcggc-
ggatctcaggtgc
agctgaaggagtcaggacctggcctggtggcgccctcacagagcctgtccatcacatgcaccgtctcagggttc-
tcattaaccggctatggt
gtaaactgggttcgccagcctccaggaaagggtctggagtggctgggaatgatatggggtgatggaagcacaga-
ctataattcagctctca
aatccagactgagcatcaccaaggacaactccaagagccaagttttcttaaaaatgaacagtctgcaaactgat-
gacacagccagatactac
tgtgccagagatggttatagtaactttcattactatgttatggactactggggtcaaggaacctcagtcaccgt-
ctcctcagatctggagcccaa
atcttctgacaaaactcacacatccccaccgtccccagcacctgaactcctgggtggaccgtcagtcttcctct-
tccccccaaaacccaagg
acaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtc-
aagttcaactggtacgt
ggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtca-
gcgtcctcaccgtc
ctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcga-
gaaaaccatctccaa
agccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccagg-
tcagcctgacctgc
ctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaa-
gaccacgcctcccgt
gctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacg-
tcttctcatgctccgtg
atgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaagcggatccttcgaa-
catggagaacactgaaa
actcagtggattcaaaatccattaaaaatttggaaccaaagatcatacatggaagcgaatcaatggactctgga-
atatccctggacaacagtt
ataaaatggattatcctgagatgggtttatgtataataattaataataagaattttcataaaagcactggaatg-
acatctcggtctggtacagatgt
cgatgcagcaaacctcagggaaacattcagaaacttgaaatatgaagtcaggaataaaaatgatcttacacgtg-
aagaaattgtggaattgat
gcgtgatgtttctaaagaagatcacagcaaaaggagcagttttgtttgtgtgcttctgagccatggtgaagaag-
gaataatttttggaacaaatg
gacctgttgacctgaaaaaaataacaaactttttcagaggggatcgttgtagaagtctaactggaaaacccaaa-
cttttcattattcaggcctgc
cgtggtacagaactggactgtggcattgagacagacagtggtgttgatgatgacatggcgtgtcataaaatacc-
agtggaggccgacttctt
gtatgcatactccacagcacctggttattattcttggcgaaattcaaaggatggctcctggttcatccagtcgc-
tttgtgccatgctgaaacagta
tgccgacaagcttgaatttatgcacattcttacccgggttaaccgaaaggtggcaacagaatttgagtcctttt-
cctttgacgctacttttcatgca
aagaaacagattccatgtattgtttccatgctcacaaaagaactctatttttatcactaactcgagatcgata
Amino acid sequence (SEQ ID NO: 466):
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPASLAVSLGQRATISCRASESVEYYVTSLMQ
WYQQKPGQPPKLLISAASNVESGVPARFSGSGSGTDFSLNIHPVEEDDIAMYFCQQSRKV
PWTFGGGTKLEIKRGGGGSGGGGSGGGGSQVQLKESGPGLVAPSQSLSITCTVSGFSLT
GYGVNWVRQPPGKGLEWLGMIWGDGSTDYNSALKSRLSITKDNSKSQVFLKMNSLQT
DDTARYYCARDGYSNFHYYVMDYWGQGTSVTVSSDLEPKSSDKTHTSPPSPAPELLGG
PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKADPSNMENTENSVDSKSIKNLEPKII
HGSESMDSGISLDNSYKMDYPEMGLCIIINNKNFHKSTGMTSRSGTDVDAANLRETFRN
LKYEVRNKNDLTREEIVELMRDVSKEDHSKRSSFVCVLLSHGEEGIIFGTNGPVDLKKIT
NFFRGDRCRSLTGKPKLFIIQACRGTELDCGIETDSGVDDDMACHKIPVEADFLYAYSTA
PGYYSWRNSKDGSWFIQSLCAMLKQYADKLEFMHILTRVNRKVATEFESFSFDATFHA
KKQIPCIVSMLTKELYFYH 123. 2e12 scFv hIgG1 (SSS-P)H P238SCH2
WCH3-hcasp3-TM/CT (SEQ ID NO: 467) Nucleotide sequence:
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcacccaatctc
cagcttctttggctgtgtctctaggtcagagagccaccatctcctgcagagccagtgaaagtgttgaatattat-
gtcacaagtttaatgcagtgg
taccaacagaaaccaggacagccacccaaactcctcatctctgctgcatccaacgtagaatctggggtccctgc-
caggtttagtggcagtg
ggtctgggacagacttcagcctcaacatccatcctgtggaggaggatgatattgcaatgtatttctgtcagcaa-
agtaggaaggttccttgga
cgttcggtggaggcaccaagctggaaatcaaacggggtggcggtggctcgggcggaggtgggtcgggtggcggc-
ggatctcaggtgc
agctgaaggagtcaggacctggcctggtggcgccctcacagagcctgtccatcacatgcaccgtctcagggttc-
tcattaaccggctatggt
gtaaactgggttcgccagcctccaggaaagggtctggagtggctgggaatgatatggggtgatggaagcacaga-
ctataattcagctctca
aatccagactgagcatcaccaaggacaactccaagagccaagttttcttaaaaatgaacagtctgcaaactgat-
gacacagccagatactac
tgtgccagagatggttatagtaactttcattactatgttatggactactggggtcaaggaacctcagtcaccgt-
ctcctcagatctggagcccaa
atcttctgacaaaactcacacatccccaccgtccccagcacctgaactcctgggtggatcgtcagtcttcctct-
tccccccaaaacccaagga
caccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtca-
agttcaactggtacgtg
gacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcag-
cgtcctcaccgtcct
gcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgaga-
aaaccatctccaaag
ccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtc-
agcctgacctgcct
ggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaaga-
ccacgcctcccgtg
ctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgt-
cttctcatgctccgtgat
gcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaagcggatccttcgaaca-
tggagaacactgaaaa
ctcagtggattcaaaatccattaaaaatttggaaccaaagatcatacatggaagcgaatcaatggactctggaa-
tatccctggacaacagttat
aaaatggattatcctgagatgggtttatgtataataattaataataagaattttcataaaagcactggaatgac-
atctcggtctggtacagatgtc
gatgcagcaaacctcagggaaacattcagaaacttgaaatatgaagtcaggaataaaaatgatcttacacgtga-
agaaattgtggaattgatg
cgtgatgtttctaaagaagatcacagcaaaaggagcagttttgtttgtgtgcttctgagccatggtgaagaagg-
aataatttttggaacaaatgg
acctgttgacctgaaaaaaataacaaactttttcagaggggatcgttgtagaagtctaactggaaaacccaaac-
ttttcattattcaggcctgcc
gtggtacagaactggactgtggcattgagacagacagtggtgttgatgatgacatggcgtgtcataaaatacca-
gtggaggccgacttcttgt
atgcatactccacagcacctggttattattcttggcgaaattcaaaggatggctcctggttcatccagtcgctt-
tgtgccatgctgaaacagtatg
ccgacaagcttgaatttatgcacattcttacccgggttaaccgaaaggtggcaacagaatttgagtccttttcc-
tttgacgctacttttcatgcaa
agaaacagattccatgtattgtttccatgctcacaaaagaactctatttttatcactaactcgagatcgataa
Amino acid sequence (SEQ ID NO: 468):
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPASLAVSLGQRATISCRASESVEYYVTSLMQ
WYQQKPGQPPKLLISAASNVESGVPARFSGSGSGTDFSLNIHPVEEDDIAMYFCQQSRKV
PWTFGGGTKLEIKRGGGGSGGGGSGGGGSQVQLKESGPGLVAPSQSLSITCTVSGFSLT
GYGVNWVRQPPGKGLEWLGMIWGDGSTDYNSALKSRLSITKDNSKSQVFLKMNSLQT
DDTARYYCARDGYSNFHYYVMDYWGQGTSVTVSSDLEPKSSDKTHTSPPSPAPELLGG
SSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKADPSNMENTENSVDSKSIKNLEPKII
HGSESMDSGISLDNSYKMDYPEMGLCIIINNKNFHKSTGMTSRSGTDVDAANLRETFRN
LKYEVRNKNDLTREEIVELMRDVSKEDHSKRSSFVCVLLSHGEEGIIFGTNGPVDLKKIT
NFFRGDRCRSLTGKPKLFIIQACRGTELDCGIETDSGVDDDMACHKIPVEADFLYAYSTA
PGYYSWRNSKDGSWFIQSLCAMLKQYADKLEFMHILTRVNRKVATEFESFSFDATFHA
KKQIPCIVSMLTKELYFYH 124. hcasp8-TM/CT (SEQ ID NO: 469) hCaspase8B:
Nucleotide sequence:
ggatccttcgaacatggacttcagcagaaatctttatgatattggggaacaactggacagtgaagatctggcct-
ccctcaagttcctgagcct
ggactacattccgcaaaggaagcaagaacccatcaaggatgccttgatgttattccagagactccaggaaaaga-
gaatgttggaggaaag
caatctgtccttcctgaaggagctgctcttccgaattaatagactggatttgctgattacctacctaaacacta-
gaaaggaggagatggaaagg
gaacttcagacaccaggcagggctcaaatttctgcctacagggtcatgctctatcagatttcagaagaagtgag-
cagatcagaattgaggtct
tttaagtttcttttgcaagaggaaatctccaaatgcaaactggatgatgacatgaacctgctggatattttcat-
agagatggagaagagggtcat
cctgggagaaggaaagttggacatcctgaaaagagtctgtgcccaaatcaacaagagcctgctgaagataatca-
acgactatgaagaattc
agcaaagagagaagcagcagccttgaaggaagtcctgatgaattttcaaatggggaggagttgtgtggggtaat-
gacaatctcggactctc
caagagaacaggatagtgaatcacagactttggacaaagtttaccaaatgaaaagcaaacctcggggatactgt-
ctgatcatcaacaatcac
aattttgcaaaagcacgggagaaagtgcccaaacttcacagcattagggacaggaatggaacacacttggatgc-
aggggctttgaccacg
acctttgaagagcttcattttgagatcaagccccacgatgactgcacagtagagcaaatctatgagattttgaa-
aatctaccaactcatggacc
acagtaacatggactgatcatctgctgtatcctctcccatggagacaagggcatcatctatggcactgatggac-
aggaggcccccatctatg
agctgacatctcagttcactggtttgaagtgcccttcccttgctggaaaacccaaagtgttttttattcaggct-
tgtcagggggataactaccag
aaaggtatacctgttgagactgattcagaggagcaaccctatttagaaatggatttatcatcacctcaaacgag-
atatatcccggatgaggctg
actttctgctggggatggccactgtgaataactgtgtttcctaccgaaaccctgcagagggaacctggtacatc-
cagtcactttgccagagcc
tgagagagcgatgtcctcgaggcgatgatattctcaccatcctgactgaagtgaactatgaagtaagcaacaag-
gatgacaagaaaaacat
ggggaaacagatgcctcagcctactttcacactaagaaaaaaacttgtcttcccttctgattgagcatgcatcg-
ata Amino acid sequence (SEQ ID NO: 470):
DPSNMDFSRNLYDIGEQLDSEDLASLKFLSLDYIPQRKQEPIKDALMLFQRLQEKRMLEE
SNLSFLKELLFRINRLDLLITYLNTRKEEMERELQTPGRAQISAYRVMLYQISEEVSRSEL
RSFKFLLQEEISKCKLDDDMNLLDIFIEMEKRVILGEGKLDILKRVCAQINKSLLKIINDYE
EFSKERSSSLEGSPDEFSNGEELCGVMTISDSPREQDSESQTLDKVYQMKSKPRGYCLIIN
NHNFAKAREKVPKLHSIRDRNGTHLDAGALTTTFEELHFEIKPHDDCTVEQIYEILKIYQL
MDHSNMDCFICCILSHGDKGIIYGTDGQEAPIYELTSQFTGLKCPSLAGKPKVFFIQACQG
DNYQKGIPVETDSEEQPYLEMDLSSPQTRYIPDEADFLLGMATVNNCVSYRNPAEGTW
YIQSLCQSLRERCPRGDDILTILTEVNYEVSNKDDKKNMGKQMPQPTFTLRKKLVFPSD
hCaspase8C: Nucleotide sequence (SEQ ID NO: 471):
ggatccttcgaacatggacttcagcagaaatctttatgatattggggaacaactggacagtgaagatctggcct-
ccctcaagttcctgagcct
ggactacattccgcaaaggaagcaagaacccatcaaggatgccttgatgttattccagagactccaggaaaaga-
gaatgttggaggaaag
caatctgtccttcctgaaggagctgctcttccgaattaatagactggatttgctgattacctacctaaacacta-
gaaaggaggagatggaaagg
gaacttcagacaccaggcagggctcaaatttctgcctacagggtcatgctctatcagatttcagaagaagtgag-
cagatcagaattgaggtct
tttaagtttcttttgcaagaggaaatctccaaatgcaaactggatgatgacatgaacctgctggatattttcat-
agagatggagaagagggtcat
cctgggagaaggaaagttggacatcctgaaaagagtctgtgcccaaatcaacaagagcctgctgaagataatca-
acgactatgaagaattc
agcaaaggggaggagttgtgtggggtaatgacaatctcggactctccaagagaacaggatagtgaatcacagac-
tttggacaaagtttacc
aaatgaaaagcaaacctcggggatactgtctgatcatcaacaatcacaattttgcaaaagcacgggagaaagtg-
cccaaacttcacagcatt
agggacaggaatggaacacacttggatgcaggggctttgaccacgacctttgaagagcttcattttgagatcaa-
gccccacgatgactgca
cagtagagcaaatctatgagattttgaaaatctaccaactcatggaccacagtaacatggactgcttcatctgc-
tgtatcctctcccatggagac
aagggcatcatctatggcactgatggacaggaggcccccatctatgagctgacatctcagttcactggtttgaa-
gtgcccttcccttgctgga
aaacccaaagtgttttttattcaggcttgtcagggggataactaccagaaaggtatacctgttgagactgattc-
agaggagcaaccctatttag
aaatggatttatcatcacctcaaacgagatatatcccggatgaggctgactttctgctggggatggccactgtg-
aataactgtgtttcctaccga
aaccctgcagagggaacctggtacatccagtcactttgccagagcctgagagagcgatgtcctcgaggcgatga-
tattctcaccatcctgac
tgaagtgaactatgaagtaagcaacaaggatgacaagaaaaacatggggaaacagatgcctcagcctactttca-
cactaagaaaaaaactt gtcttcccttctgattgagcatgcatcgata Amino acid
sequence (SEQ ID NO: 472):
DPSNMDFSRNLYDIGEQLDSEDLASLKFLSLDYIPQRKQEPIKDALMLFQRLQEKRMLEE
SNLSFLKELLFRINRLDLLITYLNTRKEEMERELQTPGRAQISAYRVMLYQISEEVSRSEL
RSFKFLLQEEISKCKLDDDMNLLDIFIEMEKRVILGEGKLDILKRVCAQINKSLLKIINDYE
EFSKGEELCGVMTISDSPREQDSESQTLDKVYQMKSKPRGYCLIINNHNFAKAREKVPK
LHSIRDRNGTHLDAGALTTTFEELHFEIKPHDDCTVEQIYEILKIYQLMDHSNMDCFICCI
LSHGDKGIIYGTDGQEAPIYELTSQFTGLKCPSLAGKPKVFFIQACQGDNYQKGIPVETDS
EEQPYLEMDLSSPQTRYIPDEADFLLGMATVNNCVSYRNPAEGTWYIQSLCQSLRERCP
RGDDILTILTEVNYEVSNKDDKKNMGKQMPQPTFTLRKKLVFPSD 125. 2e12 scFv hIgG1
(SSS-P)H WCH2 WCH3-hcasp8-TM/CT Nucleotide sequence (SEQ ID NO:
473):
aagcttatggatttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagtc-
gacattgtgctcacccaatctc
cagcttctttggctgtgtctctaggtcagagagccaccatctcctgcagagccagtgaaagtgttgaatattat-
gtcacaagtttaatgcagtgg
taccaacagaaaccaggacagccacccaaactcctcatctctgctgcatccaacgtagaatctggggtccctgc-
caggtttagtggcagtg
ggtctgggacagacttcagcctcaacatccatcctgtggaggaggatgatattgcaatgtatttctgtcagcaa-
agtaggaaggttccttgga
cgttcggtggaggcaccaagctggaaatcaaacggggtggcggtggctcgggcggaggtgggtcgggtggcggc-
ggatctcaggtgc
agctgaaggagtcaggacctggcctggtggcgccctcacagagcctgtccatcacatgcaccgtctcagggttc-
tcattaaccggctatggt
gtaaactgggttcgccagcctccaggaaagggtctggagtggctgggaatgatatggggtgatggaagcacaga-
ctataattcagctctca
aatccagactgagcatcaccaaggacaactccaagagccaagttttcttaaaaatgaacagtctgcaaactgat-
gacacagccagatactac
tgtgccagagatggttatagtaactttcattactatgttatggactactggggtcaaggaacctcagtcaccgt-
ctcctcagatctggagcccaa
atcttctgacaaaactcacacatccccaccgtccccagcacctgaactcctgggtggaccgtcagtcttcctct-
tccccccaaaacccaagg
acaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtc-
aagttcaactggtacgt
ggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtca-
gcgtcctcaccgtc
ctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcga-
gaaaaccatctccaa
agccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccagg-
tcagcctgacctgc
ctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaa-
gaccacgcctcccgt
gctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacg-
tcttctcatgctccgtg
atgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaagcggatccttcgaa-
catggacttcagcagaa
atctttatgatattggggaacaactggacagtgaagatctggcctccctcaagttcctgagcctggactacatt-
ccgcaaaggaagcaagaa
cccatcaaggatgccttgatgttattccagagactccaggaaaagagaatgttggaggaaagcaatctgtcctt-
cctgaaggagctgctcttc
cgaattaatagactggatttgctgattacctacctaaacactagaaaggaggagatggaaagggaacttcagac-
accaggcagggctcaaa
tttctgcctacagggtcatgctctatcagatttcagaagaagtgagcagatcagaattgaggtcttttaagttt-
cttttgcaagaggaaatctcca
aatgcaaactggatgatgacatgaacctgctggatattttcatagagatggagaagagggtcatcctgggagaa-
ggaaagttggacatcctg
aaaagagtctgtgcccaaatcaacaagagcctgctgaagataatcaacgactatgaagaattcagcaaagagag-
aagcagcagccttgaa
ggaagtcctgatgaattttcaaatggggaggagttgtgtggggtaatgacaatctcggactctccaagagaaca-
ggatagtgaatcacagac
tttggacaaagtttaccaaatgaaaagcaaacctcggggatactgtctgatcatcaacaatcacaattttgcaa-
aagcacgggagaaagtgc
ccaaacttcacagcattagggacaggaatggaacacacttggatgcaggggctttgaccacgacctttgaagag-
cttcattttgagatcaag
ccccacgatgactgcacagtagagcaaatctatgagattttgaaaatctaccaactcatggaccacagtaacat-
ggactgcttcatctgctgta
tcctctcccatggagacaagggcatcatctatggcactgatggacaggaggcccccatctatgagctgacatct-
cagttcactggtttgaagt
gcccttcccttgctggaaaacccaaagtgttttttattcaggcttgtcagggggataactaccagaaaggtata-
cctgttgagactgattcagag
gagcaaccctatttagaaatggatttatcatcacctcaaacgagatatatcccggatgaggctgactttctgct-
ggggatggccactgtgaata
actgtgtttcctaccgaaaccctgcagagggaacctggtacatccagtcactttgccagagcctgagagagcga-
tgtcctcgaggcgatgat
attctcaccatcctgactgaagtgaactatgaagtaagcaacaaggatgacaagaaaaacatggggaaacagat-
gcctcagcctactttcac actaagaaaaaaacttgtcttcccttctgattgagcatgcatcgata
Amino acid sequence (SEQ ID NO: 474):
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPASLAVSLGQRATISCRASESVEYYVTSLMQ
WYQQKPGQPPKLLISAASNVESGVPARFSGSGSGTDFSLNIHPVEEDDIAMYFCQQSRKV
PWTFGGGTKLEIKRGGGGSGGGGSGGGGSQVQLKESGPGLVAPSQSLSITCTVSGFSLT
GYGVNWVRQPPGKGLEWLGMIWGDGSTDYNSALKSRLSITKDNSKSQVFLKMNSLQT
DDTARYYCARDGYSNFHYYVMDYWGQGTSVTVSSDLEPKSSDKTHTSPPSPAPELLGG
PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKADPSNMDFSRNLYDIGEQLDSEDLA
SLKFLSLDYIPQRKQEPIKDALMLFQRLQEKRMLEESNLSFLKELLFRINRLDLLITYLNT
RKEEMERELQTPGRAQISAYRVMLYQISEEVSRSELRSFKFLLQEEISKCKLDDDMNLLD
IFIEMEKRVILGEGKLDILKRVCAQINKSLLKIINDYEEFSKERSSSLEGSPDEFSNGEELCG
VMTISDSPREQDSESQTLDKVYQMKSKPRGYCLIINNHNFAKAREKVPKLHSIRDRNGT
HLDAGALTTTFEELHFEIKPHDDCTVEQIYEILKIYQLMDHSNMDCFICCILSHGDKGIIY
GTDGQEAPIYELTSQFTGLKCPSLAGKPKVFFIQACQGDNYQKGIPVETDSEEQPYLEMD
LSSPQTRYIPDEADFLLGMATVNNCVSYRNPAEGTWYIQSLCQSLRERCPRGDDILTILT
EVNYEVSNKDDKKNMGKQMPQPTFTLRKKLVFPSD
126. 2e12 scFv hIgG1 (SSS-P)H P238SCH2 WCH3-hcasp8B-TM/CT (other
caspase 8 isoforms are similar) Nucleotide sequence (SEQ ID NO:
475):
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcacccaatctc
cagcttctttggctgtgtctctaggtcagagagccaccatctcctgcagagccagtgaaagtgttgaatattat-
gtcacaagtttaatgcagtgg
taccaacagaaaccaggacagccacccaaactcctcatctctgctgcatccaacgtagaatctggggtccctgc-
caggtttagtggcagtg
ggtctgggacagacttcagcctcaacatccatcctgtggaggaggatgatattgcaatgtatttctgtcagcaa-
agtaggaaggttccttgga
cgttcggtggaggcaccaagctggaaatcaaacggggtggcggtggctcgggcggaggtgggtcgggtggcggc-
ggatctcaggtgc
agctgaaggagtcaggacctggcctggtggcgccctcacagagcctgtccatcacatgcaccgtctcagggttc-
tcattaaccggctatggt
gtaaactgggttcgccagcctccaggaaagggtctggagtggctgggaatgatatggggtgatggaagcacaga-
ctataattcagctctca
aatccagactgagcatcaccaaggacaactccaagagccaagttttcttaaaaatgaacagtctgcaaactgat-
gacacagccagatactac
tgtgccagagatggttatagtaactttcattactatgttatggactactggggtcaaggaacctcagtcaccgt-
ctcctcagatctggagcccaa
atcttctgacaaaactcacacatccccaccgtccccagcacctgaactcctgggtggatcgtcagtcttcctct-
tccccccaaaacccaagga
caccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtca-
agttcaactggtacgtg
gacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcag-
cgtcctcaccgtcct
gcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgaga-
aaaccatctccaaag
ccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtc-
agcctgacctgcct
ggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaaga-
ccacgcctcccgtg
ctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgt-
cttctcatgctccgtgat
gcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaagcggatccttcgaaca-
tggacttcagcagaaat
ctttatgatattggggaacaactggacagtgaagatctggcctccctcaagttcctgagcctggactacattcc-
gcaaaggaagcaagaacc
catcaaggatgccttgatgttattccagagactccaggaaaagagaatgttggaggaaagcaatctgtccttcc-
tgaaggagctgctcttccg
aattaatagactggatttgctgattacctacctaaacactagaaaggaggagatggaaagggaacttcagacac-
caggcagggctcaaattt
ctgcctacagggtcatgctctatcagatttcagaagaagtgagcagatcagaattgaggtcttttaagtttctt-
ttgcaagaggaaatctccaaat
gcaaactggatgatgacatgaacctgctggatattttcatagagatggagaagagggtcatcctgggagaagga-
aagttggacatcctgaa
aagagtctgtgcccaaatcaacaagagcctgctgaagataatcaacgactatgaagaattcagcaaagagagaa-
gcagcagccttgaagg
aagtcctgatgaattttcaaatggggaggagttgtgtggggtaatgacaatctcggactctccaagagaacagg-
atagtgaatcacagacttt
ggacaaagtttaccaaatgaaaagcaaacctcggggatactgtctgatcatcaacaatcacaattttgcaaaag-
cacgggagaaagtgccc
aaacttcacagcattagggacaggaatggaacacacttggatgcaggggattgaccacgacctttgaagagctt-
cattttgagatcaagcc
ccacgatgactgcacagtagagcaaatctatgagattttgaaaatctaccaactcatggaccacagtaacatgg-
actgcttcatctgctgtatc
ctctcccatggagacaagggcatcatctatggcactgatggacaggaggcccccatctatgagctgacatctca-
gttcactggtttgaagtgc
ccttcccttgctggaaaacccaaagtgttttttattcaggcttgtcagggggataactaccagaaaggtatacc-
tgttgagactgattcagagga
gcaaccctatttagaaatggatttatcatcacctcaaacgagatatatcccggatgaggctgactttctgctgg-
ggatggccactgtgaataac
tgtgtttcctaccgaaaccctgcagagggaacctggtacatccagtcactttgccagagcctgagagagcgatg-
tcctcgaggcgatgatat
tctcaccatcctgactgaagtgaactatgaagtaagcaacaaggatgacaagaaaaacatggggaaacagatgc-
ctcagcctactttcaca ctaagaaaaaaacttgtcttcccttctgattgagcatgcatcgataa
Amino acid sequence (SEQ ID NO: 476):
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPASLAVSLGQRATISCRASESVEYYVTSLMQ
WYQQKPGQPPKLLISAASNVESGVPARFSGSGSGTDFSLNIHPVEEDDIAMYFCQQSRKV
PWTFGGGTKLEIKRGGGGSGGGGSGGGGSQVQLKESGPGLVAPSQSLSITCTVSGFSLT
GYGVNWVRQPPGKGLEWLGMIWGDGSTDYNSALKSRLSITKDNSKSQVFLKMNSLQT
DDTARYYCARDGYSNFHYYVMDYWGQGTSVTVSSDLEPKSSDKTHTSPPSPAPELLGG
SSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKADPSNMDFSRNLYDIGEQLDSEDLA
SLKFLSLDYIPQRKQEPIKDALMLFQRLQEKRMLEESNLSFLKELLFRINRLDLLITYLNT
RKEEMERELQTPGRAQISAYRVMLYQISEEVSRSELRSFKFLLQEEISKCKLDDDMNLLD
IFIEMEKRVILGEGKLDILKRVCAQINKSLLKIINDYEEFSKERSSSLEGSPDEFSNGEELCG
VMTISDSPREQDSESQTLDKVYQMKSKPRGYCLIINNHNFAKAREKVPKLHSIRDRNGT
HLDAGALTTTFEELHFEIKPHDDCTVEQIYEILKIYQLMDHSNMDCFICCILSHGDKGIIY
GTDGQEAPIYELTSQFTGLKCPSLAGKPKVFFIQACQGDNYQKGIPVETDSEEQPYLEMD
LSSPQTRYIPDEADFLLGMATVNNCVSYRNPAEGTWYIQSLCQSLRERCPRGDDILTILT
EVNYEVSNKDDKKNMGKQMPQPTFTLRKKLVFPSD 128. 2e12 scFv-hIgG1 (SSS-P)H
WCH2 WCH3-hFADD-TM/CT Nucleotide sequence (SEQ ID NO: 477):
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcacccaatctc
cagcttctttggctgtgtctctaggtcagagagccaccatctcctgcagagccagtgaaagtgttgaatattat-
gtcacaagtttaatgcagtgg
taccaacagaaaccaggacagccacccaaactcctcatctctgctgcatccaacgtagaatctggggtccctgc-
caggtttagtggcagtg
ggtctgggacagacttcagcctcaacatccatcctgtggaggaggatgatattgcaatgtatttctgtcagcaa-
agtaggaaggttccttgga
cgttcggtggaggcaccaagctggaaatcaaacggggtggcggtggctcgggcggaggtgggtcgggtggcggc-
ggatctcaggtgc
agctgaaggagtcaggacctggcctggtggcgccctcacagagcctgtccatcacatgcaccgtctcagggttc-
tcattaaccggctatggt
gtaaactgggttcgccagcctccaggaaagggtctggagtggctgggaatgatatggggtgatggaagcacaga-
ctataattcagctctca
aatccagactgagcatcaccaaggacaactccaagagccaagttttcttaaaaatgaacagtctgcaaactgat-
gacacagccagatactac
tgtgccagagatggttatagtaactttcattactatgttatggactactggggtcaaggaacctcagtcaccgt-
ctcctcagatctggagcccaa
atcttctgacaaaactcacacatccccaccgtccccagcacctgaactcctgggtggaccgtcagtcttcctct-
tccccccaaaacccaagg
acaccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtc-
aagttcaactggtacgt
ggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtca-
gcgtcctcaccgtc
ctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcga-
gaaaaccatctccaa
agccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccagg-
tcagcctgacctgc
ctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaa-
gaccacgcctcccgt
gctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacg-
tcttctcatgctccgtg
atgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaagcggatccttcgaa-
cccgttcctggtgctgct
gcactcggtgtcgtccagcctgtcgagcagcgagctgaccgagctcaagttcctatgcctcgggcgcgtgggca-
agcgcaagctggagc
gcgtgcagagcggcctagacctcttctccatgctgctggagcagaacgacctggagcccgggcacaccgagctc-
ctgcgcgagctgctc
gcctccctgcggcgccacgacctgctgcggcgcgtcgacgacttcgaggcgggggcggcggccggggccgcgcc-
tggggaagaaga
cctgtgtgcagcatttaacgtcatatgtgataatgtggggaaagattggagaaggctggctcgtcagctcaaag-
tctcagacaccaagatcg
acagcatcgaggacagatacccccgcaacctgacagagcgtgtgcgggagtcactgagaatctggaagaacaca-
gagaaggagaacg
caacagtggcccacctggtgggggctctcaggtcctgccagatgaacctggtggctgacctggtacaagaggtt-
cagcaggcccgtgacc
tccagaacaggagtggggccatgtccccgatgtcatggaactcagacgcatctacctccgaagcgtcctgataa-
ctcgagatcgataacaac Amino acid sequence (SEQ ID NO: 478):
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPASLAVSLGQRATISCRASESVEYYVTSLMQ
WYQQKPGQPPKLLISAASNVESGVPARFSGSGSGTDFSLNIHPVEEDDIAMYFCQQSRKV
PWTFGGGTKLEIKRGGGGSGGGGSGGGGSQVQLKESGPGLVAPSQSLSITCTVSGFSLT
GYGVNWVRQPPGKGLEWLGMIWGDGSTDYNSALKSRLSITKDNSKSQVFLKMNSLQT
DDTARYYCARDGYSNFHYYVMDYWGQGTSVTVSSDLEPKSSDKTHTSPPSPAPELLGG
PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKADPSNPFLVLLHSVSSSLSSSELTELK
FLCLGRVGKRKLERVQSGLDLFSMLLEQNDLEPGHTELLRELLASLRRHDLLRRVDDFE
AGAAAGAAPGEEDLCAAFNVICDNVGKDWRRLARQLKVSDTKIDSIEDRYPRNLTERV
RESLRIWKNTEKENATVAHLVGALRSCQMNLVADLVQEVQQARDLQNRSGAMSPMS
WNSDASTSEAS 129. 2e12 scFv-hIgG1 (SSS-P)H P238SCH2 WCH3-hFADD-TM/CT
Nucleotide sequence (SEQ ID NO: 479):
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcacccaatctc
cagcttctttggctgtgtctctaggtcagagagccaccatctcctgcagagccagtgaaagtgttgaatattat-
gtcacaagtttaatgcagtgg
taccaacagaaaccaggacagccacccaaactcctcatctctgctgcatccaacgtagaatctggggtccctgc-
caggtttagtggcagtg
ggtctgggacagacttcagcctcaacatccatcctgtggaggaggatgatattgcaatgtatttctgtcagcaa-
agtaggaaggttccttgga
cgttcggtggaggcaccaagctggaaatcaaacggggtggcggtggctcgggcggaggtgggtcgggtggcggc-
ggatctcaggtgc
agctgaaggagtcaggacctggcctggtggcgccctcacagagcctgtccatcacatgcaccgtctcagggttc-
tcattaaccggctatggt
gtaaactgggttcgccagcctccaggaaagggtctggagtggctgggaatgatatggggtgatggaagcacaga-
ctataattcagctctca
aatccagactgagcatcaccaaggacaactccaagagccaagttttcttaaaaatgaacagtctgcaaactgat-
gacacagccagatactac
tgtgccagagatggttatagtaactttcattactatgttatggactactggggtcaaggaacctcagtcaccgt-
ctcctcagatctggagcccaa
atcttctgacaaaactcacacatccccaccgtccccagcacctgaactcctgggtggatcgtcagtcttcctct-
tccccccaaaacccaagga
caccctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtca-
agttcaactggtacgtg
gacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcag-
cgtcctcaccgtcct
gcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgaga-
aaaccatctccaaag
ccaaagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtc-
agcctgacctgcct
ggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaaga-
ccacgcctcccgtg
ctggactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgt-
cttctcatgctccgtgat
gcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaagcggatccttcgaacc-
cgttcctggtgctgctgc
actcggtgtcgtccagcctgtcgagcagcgagctgaccgagctcaagttcctatgcctcgggcgcgtgggcaag-
cgcaagctggagcgc
gtgcagagcggcctagacctcttctccatgctgctggagcagaacgacctggagcccgggcacaccgagctcct-
gcgcgagctgctcgc
ctccctgcggcgccacgacctgctgcggcgcgtcgacgacttcgaggcgggggcggcggccggggccgcgcctg-
gggaagaagacc
tgtgtgcagcatttaacgtcatatgtgataatgtggggaaagattggagaaggctggctcgtcagctcaaagtc-
tcagacaccaagatcgac
agcatcgaggacagatacccccgcaacctgacagagcgtgtgcgggagtcactgagaatctggaagaacacaga-
gaaggagaacgca
acagtggcccacctggtgggggctctcaggtcctgccagatgaacctggtggctgacctggtacaagaggttca-
gcaggcccgtgacctc
cagaacaggagtggggccatgtccccgatgtcatggaactcagacgcatctacctccgaagcgtcctgataact-
cgagatcgataacaac Amino acid sequence (SEQ ID NO: 480):
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPASLAVSLGQRATISCRASESVEYYVTSLMQ
WYQQKPGQPPKLLISAASNVESGVPARFSGSGSGTDFSLNIHPVEEDDIAMYFCQQSRKV
PWTFGGGTKLEIKRGGGGSGGGGSGGGGSQVQLKESGPGLVAPSQSLSITCTVSGFSLT
GYGVNWVRQPPGKGLEWLGMIWGDGSTDYNSALKSRLSITKDNSKSQVFLKMNSLQT
DDTARYYCARDGYSNFHYYVMDYWGQGTSVTVSSDLEPKSSDKTHTSPPSPAPELLGG
SSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKADPSNPFLVLLHSVSSSLSSSELTELK
FLCLGRVGKRKLERVQSGLDLFSMLLEQNDLEPGHTELLRELLASLRRHDLLRRVDDFE
AGAAAGAAPGEEDLCAAFNVICDNVGKDWRRLARQLKVSDTKIDSIEDRYPRNLTERV
RESLRIWKNTEKENATVAHLVGALRSCQMNLVADLVQEVQQARDLQNRSGAMSPMS
WNSDASTSEAS 130.1D8 scFv hIgG1 (SSS-P)H WCH2 WCH3-hCD80TM/CT
Nucleotide sequence (SEQ ID NO: 481)
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcacccaatctc
cagcttctttggctgtgtctctaggtcagagagccaccatctcctgcagagccagtgaaagtgttgaatattat-
gtcacaagtttaatgcagtgg
taccaacagaaaccaggacagccacccaaactcctcatctctgctgcatccaacgtagaatctggggtccctgc-
caggtttagtggcagtg
ggtctgggacagacttcagcctcaacatccatcctgtggaggaggatgatattgcaatgtatttctgtcagcaa-
agtaagcttatggattttcaa
gtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagtcgacattgtgctcactca-
gtctccaacaaccatagctgc
atctccaggggagaaggtcaccatcacctgccgtgccagctccagtgtaagttacatgtactggtaccagcaga-
agtcaggcgcctcccct
aaactctggatttatgacacatccaagctggcttctggagttccaaatcgcttcagtggcagtgggtctgggac-
ctcttattctctcgcaatcaa
caccatggagactgaagatgctgccacttattactgtcagcagtggagtagtactccgctcacgttcgggtctg-
ggaccaagctggagatca
aacggggtggcggtggctcgggcggtggtgggtcgggtggcggcggatctcaggtgcagctgaaggaggcagga-
cctggcctggtgc
aaccgacacagaccctgtccctcacatgcactgtctctgggttctcattaaccagcgatggtgtacactggatt-
cgacagcctccaggaaag
ggtctggaatggatgggaataatatattatgatggaggcacagattataattcagcaattaaatccagactgag-
catcagcagggacacctcc
aagagccaagttttcttaaaaatcaacagtctgcaaactgatgacacagccatgtattactgtgccagaatcca-
ctttgattactggggccaag
gagtcatggtcacagtctcctctgatctggagcccaaatcttctgacaaaactcacacatccccaccgtcccca-
gcacctgaactcctgggg
ggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggacccctgaggtcacatg-
cgtggtggtggacgtga
gccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatgccaagacaaagccg-
cgggaggagcagta
caacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagt-
gcaaggtctccaacaa
agccctcccagcccccatcgagaaaaccatctccaaagccaaagggcagccccgagaaccacaggtgtacaccc-
tgcccccatcccgg
gatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatcccagcgacatcgccgtgga-
gtgggagagcaatgg
gcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcctctacagcaagc-
tcaccgtggacaagag
caggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaaga-
gcctctccctgtctccg
ggtaaagcggatccttcgaacctgctcccatcctgggccattaccttaatctcagtaaatggaatttttgtgat-
atgctgcctgacctactgcttt
gccccaagatgcagagagagaaggaggaatgagagattgagaagggaaagtgtacgccctgtataaatcgat
Amino acid sequence (SEQ ID NO: 482):
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPASLAVSLGQRATISCRASESVEYYVTSLMQ
WYQQKPGQPPKLLISAASNVESGVPARFSGSGSGTDFSLNIHPVEEDDIAMYFCQQSKL
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPTTIAASPGEKVTITCRASSSVSYMYWYQQK
SGASPKLWIYDTSKLASGVPNRFSGSGSGTSYSLAINTMETEDAATYYCQQWSSTPLTFG
SGTKLEIKRGGGGSGGGGSGGGGSQVQLKEAGPGLVQPTQTLSLTCTVSGFSLTSDGVH
WIRQPPGKGLEWMGIIYYDGGTDYNSAIKSRLSISRDTSKSQVFLKINSLQTDDTAMYYC
ARIHFDYWGQGVMVTVSSDLEPKSSDKTHTSPPSPAPELLGGPSVFLFPPKPKDTLMISR
TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKG
FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
ALHNHYTQKSLSLSPGKADPSNLLPSWAITLISVNGIFVICCLTYCFAPRCRERRRNERLR
RESVRPV 131.1D8 scFv mIgAT4-hCD80TM/CT Nucleotide sequence (SEQ ID
NO: 483)
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcactcagtctc
caacaaccatagctgcatctccaggggagaaggtcaccatcacctgccgtgccagctccagtgtaagttacatg-
tactggtaccagcagaa
gtcaggcgcctcccctaaactctggatttatgacacatccaagctggcttctggagttccaaatcgcttcagtg-
gcagtgggtctgggacctct
tattctctcgcaatcaacaccatggagactgaagatgctgccacttattactgtcagcagtggagtagtactcc-
gctcacgttcgggtctggga
ccaagctggagatcaaacggggtggcggtggctcgggcggtggtgggtcgggtggcggcggatctcaggtgcag-
ctgaaggaggcag
gacctggcctggtgcaaccgacacagaccctgtccctcacatgcactgtctctgggttctcattaaccagcgat-
ggtgtacactggattcgac
agcctccaggaaagggtctggaatggatgggaataatatattatgatggaggcacagattataattcagcaatt-
aaatccagactgagcatca
gcagggacacctccaagagccaagttttcttaaaaatcaacagtctgcaaactgatgacacagccatgtattac-
tgtgccagaatccactttg
attactggggccaaggagtcatggtcacagtctcctctgatcacatctgttctcctcctactactcctcctcca-
ccttcctgccagcccagcctg
tcactgcagcggccagctcttgaggacctgctcctgggttcagatgccagcatcacatgtactctgaatggcct-
gagagatcctgagggag
ctgtcttcacctgggagccctccactgggaaggatgcagtgcagaagaaagctgtgcagaattcctgcggctgc-
tacagtgtgtccagcgt
cctgcctggctgtgctgagcgctggaacagtggcgcatcattcaagtgcacagttacccatcctgagtctgaca-
ccttaactggcacaattgc
caaagtcacagtgaacaccttcccaccccaggtccacctgctaccgccgccgtcggaggagctggccctgaatg-
agctcgtgtccctgac
atgcctggtgcgagctttcaaccctaaagaagtgctggtgcgatggctgcatggaaatgaggagctgtccccag-
aaagctacctagtgtttg
agcccctaaaggagccaggcgagggagccaccacctacctggtgacaagcgtgttgcgtgtatcagctgaaatc-
tggaaacagggtgac
cagtactcctgcatggtgggccacgaggccttgcccatgaacttcacccagaagaccatcgaccgtctgtcggg-
taaacccaccaatgtca
gcgtgtctgtgatcatgtcagagggagaggatccttcgaacaacctgctcccatcctgggccattaccttaatc-
tcagtaaatggaatttttgtg
atatgctgcctgacctactgctttgccccaagatgcagagagagaaggaggaatgagagattgagaagggaaag-
tgtacgccctgtataaa tcgatact Amino acid sequence (SEQ ID NO: 484):
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPTTIAASPGEKVTITCRASSSVSYMYWYQQK
SGASPKLWIYDTSKLASGVPNRFSGSGSGTSYSLAINTMETEDAATYYCQQWSSTPLTFG
SGTKLEIKRGGGGSGGGGSGGGGSQVQLKEAGPGLVQPTQTLSLTCTVSGFSLTSDGVH
WIRQPPGKGLEWMGIIYYDGGTDYNSAIKSRLSISRDTSKSQVFLKINSLQTDDTAMYYC
ARIHFDYWGQGVMVTVSSDHICSPPTTPPPPSCQPSLSLQRPALEDLLLGSDASITCTLNG
LRDPEGAVFTWEPSTGKDAVQKKAVQNSCGCYSVSSVLPGCAERWNSGASFKCTVTHP
ESDTLTGTIAKVTVNTFPPQVHLLPPPSEELALNELVSLTCLVRAFNPKEVLVRWLHGNE
ELSPESYLVFEPLKEPGEGATTYLVTSVLRVSAEIWKQGDQYSCMVGHEALPMNFTQKT
IDRLSGKPTNVSVSVIMSEGEDPSNNLLPSWAITLISVNGIFVICCLTYCFAPRCRERRRNE
RLRRESVRPV 132.1D8 scFv hIgG1 (SSS-P)H WCH2 WCH3-mFADD-TM/CT
Nucleotide sequence (SEQ ID NO: 485)
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcactcagtctc
caacaaccatagctgcatctccaggggagaaggtcaccatcacctgccgtgccagctccagtgtaagttacatg-
tactggtaccagcagaa
gtcaggcgcctcccctaaactctggatttatgacacatccaagctggcttctggagttccaaatcgcttcagtg-
gcagtgggtctgggacctct
tattctctcgcaatcaacaccatggagactgaagatgctgccacttattactgtcagcagtggagtagtactcc-
gctcacgttcgggtctggga
ccaagctggagatcaaacggggtggcggtggctcgggcggtggtgggtcgggtggcggcggatctcaggtgcag-
ctgaaggaggcag
gacctggcctggtgcaaccgacacagaccctgtccctcacatgcactgtctctgggttctcattaaccagcgat-
ggtgtacactggattcgac
agcctccaggaaagggtctggaatggatgggaataatatattatgatggaggcacagattataattcagcaatt-
aaatccagactgagcatca
gcagggacacctccaagagccaagttttcttaaaaatcaacagtctgcaaactgatgacacagccatgtattac-
tgtgccagaatccactttg
attactggggccaaggagtcatggtcacagtctcctctgatctggagcccaaatcttctgacaaaactcacaca-
tccccaccgtccccagca
cctgaactcctgggtggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggac-
ccctgaggtcacatgcgt
ggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatg-
ccaagacaaagccgc
gggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggc-
aaggagtacaagtgc
aaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaagggcagccccgagaacc-
acaggtgtacaccct
gcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatcccagcg-
acatcgccgtggagtg
ggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcc-
tctacagcaagctcac
cgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccact-
acacgcagaagagcct
ctccctgtctccgggtaaagcggatccttcgaacatggacccattcctggtgctgctgcactcgctgtccggca-
gcctgtcgggcaacgatc
tgatggagctcaagttcttgtgccgcgagcgcgtgagcaaacgaaagctggagcgcgtgcagagtggcctggac-
ctgttcacggtgctgc
tggagcagaacgacctggagcgcgggcacaccgggctgctgcgcgagttgctggcctcgctgcgccgacacgat-
ctactgcagcgcct
ggacgacttcgaggcggggacggcgaccgctgcgcccccgggggaggcagatctgcaggtggcatttgacattg-
tgtgtgacaatgtgg
ggagagactggaaaagactggcccgcgagctgaaggtgtctgaggccaagatggatgggattgaggagaagtac-
ccccgaagtctgag
tgagcgggtaagggagagtctgaaagtctggaagaatgctgagaagaagaacgcctcggtggccggactggtca-
aggcgctgcggacc
tgcaggctgaatctggtggctgacctggtggaagaagcccaggaatctgtgagcaagagtgagaatatgtcccc-
agtactaagggattcaa ctgtgtcttcctcagaaacaccctgactcgagatcgat Amino acid
sequence (SEQ ID NO: 486):
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPTTIAASPGEKVTITCRASSSVSYMYWYQQK
SGASPKLWIYDTSKLASGVPNRFSGSGSGTSYSLAINTMETEDAATYYCQQWSSTPLTFG
SGTKLEIKRGGGGSGGGGSGGGGSQVQLKEAGPGLVQPTQTLSLTCTVSGFSLTSDGVH
WIRQPPGKGLEWMGIIYYDGGTDYNSAIKSRLSISRDTSKSQVFLKINSLQTDDTAMYYC
ARIHFDYWGQGVMVTVSSDLEPKSSDKTHTSPPSPAPELLGGPSVFLFPPKPKDTLMISR
TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKG
FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
ALHNHYTQKSLSLSPGKADPSNMDPFLVLLHSLSGSLSGNDLMELKFLCRERVSKRKLE
RVQSGLDLFTVLLEQNDLERGHTGLLRELLASLRRHDLLQRLDDFEAGTATAAPPGEAD
LQVAFDIVCDNVGRDWKRLARELKVSEAKMDGIEEKYPRSLSERVRESLKVWKNAEKK
NASVAGLVKALRTCRLNLVADLVEEAQESVSKSENMSPVLRDSTVSSSETP 133.1D8 scFv
hIgG1 (SSS-P)H P238S CH2 WCH3-mFADD-TM/CT Nucleotide sequence (SEQ
ID NO: 487)
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcactcagtctc
caacaaccatagctgcatctccaggggagaaggtcaccatcacctgccgtgccagctccagtgtaagttacatg-
tactggtaccagcagaa
gtcaggcgcctcccctaaactctggatttatgacacatccaagctggcttctggagttccaaatcgcttcagtg-
gcagtgggtctgggacctct
tattctctcgcaatcaacaccatggagactgaagatgctgccacttattactgtcagcagtggagtagtactcc-
gctcacgttcgggtctggga
ccaagctggagatcaaacggggtggcggtggctcgggcggtggtgggtcgggtggcggcggatctcaggtgcag-
ctgaaggaggcag
gacctggcctggtgcaaccgacacagaccctgtccctcacatgcactgtctctgggttctcattaaccagcgat-
ggtgtacactggattcgac
agcctccaggaaagggtctggaatggatgggaataatatattatgatggaggcacagattataattcagcaatt-
aaatccagactgagcatca
gcagggacacctccaagagccaagttttcttaaaaatcaacagtctgcaaactgatgacacagccatgtattac-
tgtgccagaatccactttg
attactggggccaaggagtcatggtcacagtctcctctgatctggagcccaaatcttctgacaaaactcacaca-
tccccaccgtccccagca
cctgaactcctgggtggatcgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggac-
ccctgaggtcacatgcgt
ggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatg-
ccaagacaaagccgc
gggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggc-
aaggagtacaagtgc
aaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaagggcagccccgagaacc-
acaggtgtacaccct
gcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatcccagcg-
acatcgccgtggagtg
ggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcc-
tctacagcaagctcac
cgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccact-
acacgcagaagagcct
ctccctgtctccgggtaaagcggatccttcgaacatggacccattcctggtgctgctgcactcgctgtccggca-
gcctgtcgggcaacgatc
tgatggagctcaagttcttgtgccgcgagcgcgtgagcaaacgaaagctggagcgcgtgcagagtggcctggac-
ctgttcacggtgctgc
tggagcagaacgacctggagcgcgggcacaccgggctgctgcgcgagttgctggcctcgctgcgccgacacgat-
ctactgcagcgcct
ggacgacttcgaggcggggacggcgaccgctgcgcccccgggggaggcagatctgcaggtggcatttgacattg-
tgtgtgacaatgtgg
ggagagactggaaaagactggcccgcgagctgaaggtgtctgaggccaagatggatgggattgaggagaagtac-
ccccgaagtctgag
tgagcgggtaagggagagtctgaaagtctggaagaatgctgagaagaagaacgcctcggtggccggactggtca-
aggcgctgcggacc
tgcaggctgaatctggtggctgacctggtggaagaagcccaggaatctgtgagcaagagtgagaatatgtcccc-
agtactaagggattcaa ctgtgtcttcctcagaaacaccctgactcgagatcgat Amino acid
sequence (SEQ ID NO: 488):
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPTTIAASPGEKVTITCRASSSVSYMYWYQQK
SGASPKLWIYDTSKLASGVPNRFSGSGSGTSYSLAINTMETEDAATYYCQQWSSTPLTFG
SGTKLEIKRGGGGSGGGGSGGGGSQVQLKEAGPGLVQPTQTLSLTCTVSGFSLTSDGVH
WIRQPPGKGLEWMGIIYYDGGTDYNSAIKSRLSISRDTSKSQVFLKINSLQTDDTAMYYC
ARIHFDYWGQGVMVTVSSDLEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDTLMISR
TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKG
FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
ALHNHYTQKSLSLSPGKADPSNMDPFLVLLHSLSGSLSGNDLMELKFLCRERVSKRKLE
RVQSGLDLFTVLLEQNDLERGHTGLLRELLASLRRHDLLQRLDDFEAGTATAAPPGEAD
LQVAFDIVCDNVGRDWKRLARELKVSEAKMDGIEEKYPRSLSERVRESLKVWKNAEKK
NASVAGLVKALRTCRLNLVADLVEEAQESVSKSENMSPVLRDSTVSSSETP 134.1D8 scFv
hIgG1 (SSS-P)H WCH2 WCH3-mcasp3-TM/CT Nucleotide sequence (SEQ ID
NO: 489):
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcactcagtctc
caacaaccatagctgcatctccaggggagaaggtcaccatcacctgccgtgccagctccagtgtaagttacatg-
tactggtaccagcagaa
gtcaggcgcctcccctaaactctggatttatgacacatccaagctggcttctggagttccaaatcgcttcagtg-
gcagtgggtctgggacctct
tattctctcgcaatcaacaccatggagactgaagatgctgccacttattactgtcagcagtggagtagtactcc-
gctcacgttcgggtctggga
ccaagctggagatcaaacggggtggcggtggctcgggcggtggtgggtcgggtggcggcggatctcaggtgcag-
ctgaaggaggcag
gacctggcctggtgcaaccgacacagaccctgtccctcacatgcactgtctctgggttctcattaaccagcgat-
ggtgtacactggattcgac
agcctccaggaaagggtctggaatggatgggaataatatattatgatggaggcacagattataattcagcaatt-
aaatccagactgagcatca
gcagggacacctccaagagccaagttttcttaaaaatcaacagtctgcaaactgatgacacagccatgtattac-
tgtgccagaatccactttg
attactggggccaaggagtcatggtcacagtctcctctgatctggagcccaaatcttctgacaaaactcacaca-
tccccaccgtccccagca
cctgaactcctgggtggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggac-
ccctgaggtcacatgcgt
ggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatg-
ccaagacaaagccgc
gggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggc-
aaggagtacaagtgc
aaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaagggcagccccgagaacc-
acaggtgtacaccct
gcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatcccagcg-
acatcgccgtggagtg
ggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcc-
tctacagcaagctcac
cgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccact-
acacgcagaagagcct
ctccctgtctccgggtaaagcggatccttcgaacatggagaacaacaaaacctcagtggattcaaaatccatta-
ataattttgaagtaaagac
catacatgggagcaagtcagtggactctgggatctatctggacagtagttacaaaatggattatcctgaaatgg-
gcatatgcataataattaat
aataagaacttccataagagcactggaatgtcatctcgctctggtacggatgtggacgcagccaacctcagaga-
gacattcatgggcctgaa
ataccaagtcaggaataaaaatgatcttactcgtgaagacattttggaattaatggatagtgtttctaaggaag-
atcatagcaaaaggagcagc
tttgtgtgtgtgattctaagccatggtgatgaaggggtcatttatgggacaaatgggcctgttgaactgaaaaa-
gttgactagcttcttcagagg
cgactactgccggagtctgactggaaagccgaaactcttcatcattcaggcctgccggggtacggagctggact-
gtggcattgagacagac
agtgggactgatgaggagatggcttgccagaagataccggtggaggctgacttcctgtatgcttactctacagc-
acctggttactattcctgg
agaaattcaaaggacgggtcgtggttcatccagtccctttgcagcatgctgaagctgtacgcgcacaagctaga-
atttatgcacattctcactc
gcgttaacaggaaggtggcaacggaattcgagtccttctccctggactccactttccacgcaaagaaacagatc-
ccgtgtattgtgtccatgc tcacgaaagaactgtacttttatcactagctcgagatcgatg
Amino acid sequence (SEQ ID NO: 490):
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPTTIAASPGEKVTITCRASSSVSYMYWYQQK
SGASPKLWIYDTSKLASGVPNRFSGSGSGTSYSLAINTMETEDAATYYCQQWSSTPLTFG
SGTKLEIKRGGGGSGGGGSGGGGSQVQLKEAGPGLVQPTQTLSLTCTVSGFSLTSDGVH
WIRQPPGKGLEWMGIIYYDGGTDYNSAIKSRLSISRDTSKSQVFLKINSLQTDDTAMYYC
ARIHFDYWGQGVMVTVSSDLEPKSSDKTHTSPPSPAPELLGGPSVFLFPPKPKDTLMISR
TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKG
FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
ALHNHYTQKSLSLSPGKADPSNMENNKTSVDSKSINNFEVKTIHGSKSVDSGIYLDSSYK
MDYPEMGICIIINNKNFHKSTGMSSRSGTDVDAANLRETFMGLKYQVRNKNDLTREDIL
ELMDSVSKEDHSKRSSFVCVILSHGDEGVIYGTNGPVELKKLTSFFRGDYCRSLTGKPKL
FIIQACRGTELDCGIETDSGTDEEMACQKIPVEADFLYAYSTAPGYYSWRNSKDGSWFIQ
SLCSMLKLYAHKLEFMHILTRVNRKVATEFESFSLDSTFHAKKQIPCIVSMLTKELYFYH
135.1D8 scFv hIgG1 (SSS-P)H P238S CH2 WCH3-mcasp3-TM/CT Nucleotide
sequence (SEQ ID NO: 491):
Aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgatcagtcataatgtccagaggagtc-
gacattgtgctcactcagtct
ccaacaaccatagctgcatctccaggggagaaggtcaccatcacctgccgtgccagctccagtgtaagttacat-
gtactggtaccagcaga
agtcaggcgcctcccctaaactctggatttatgacacatccaagctggcttctggagttccaaatcgcttcagt-
ggcagtgggtctgggacct
cttattctctcgcaatcaacaccatggagactgaagatgctgccacttattactgtcagcagtggagtagtact-
ccgctcacgttcgggtctgg
gaccaagctggagatcaaacggggtggcggtggctcgggcggtggtgggtcgggtggcggcggatctcaggtgc-
agctgaaggaggc
aggacctggcctggtgcaaccgacacagaccctgtccctcacatgcactgtctctgggttctcattaaccagcg-
atggtgtacactggattcg
acagcctccaggaaagggtctggaatggatgggaataatatattatgatggaggcacagattataattcagcaa-
ttaaatccagactgagcat
cagcagggacacctccaagagccaagttttcttaaaaatcaacagtctgcaaactgatgacacagccatgtatt-
actgtgccagaatccacttt gattactggggccaaggagtcatggtcacagtctcctctga
Amino acid sequence (SEQ ID NO: 492):
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPTTIAASPGEKVTITCRASSSVSYMYWYQQK
SGASPKLWIYDTSKLASGVPNRFSGSGSGTSYSLAINTMETEDAATYYCQQWSSTPLTFG
SGTKLEIKRGGGGSGGGGSGGGGSQVQLKEAGPGLVQPTQTLSLTCTVSGFSLTSDGVH
WIRQPPGKGLEWMGIIYYDGGTDYNSAIKSRLSISRDTSKSQVFLKINSLQTDDTAMYYC
ARIHFDYWGQGVMVTVSSDLEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDTLMISR
TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKG
FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
ALHNHYTQKSLSLSPGKADPSNSNMENNKTSVDSKSINNFEVKTIHGSKSVDSGIYLDSS
YKMDYPEMGICIIINNKNFHKSTGMSSRSGTDVDAANLRETFMGLKYQVRNKNDLTRE
DILELMDSVSKEDHSKRSSFVCVILSHGDEGVIYGTNGPVELKKLTSFFRGDYCRSLTGK
PKLFIIQACRGTELDCGIETDSGTDEEMACQKIPVEADFLYAYSTAPGYYSWRNSKDGS
WFIQSLCSMLKLYAHKLEFMHILTRVNRKVATEFESFSLDSTFHAKKQIPCIVSMLTKEL YFYH
136.1D8 scFv hIgG1 (SSS-P)H WCH2 WCH3-mcasp8-TM/CT Nucleotide
sequence (SEQ ID NO: 493):
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcactcagtctc
caacaaccatagctgcatctccaggggagaaggtcaccatcacctgccgtgccagctccagtgtaagttacatg-
tactggtaccagcagaa
gtcaggcgcctcccctaaactctggatttatgacacatccaagctggcttctggagttccaaatcgcttcagtg-
gcagtgggtctgggacctct
tattctctcgcaatcaacaccatggagactgaagatgctgccacttattactgtcagcagtggagtagtactcc-
gctcacgttcgggtctggga
ccaagctggagatcaaacggggtggcggtggctcgggcggtggtgggtcgggtggcggcggatctcaggtgcag-
ctgaaggaggcag
gacctggcctggtgcaaccgacacagaccctgtccctcacatgcactgtctctgggttctcattaaccagcgat-
ggtgtacactggattcgac
agcctccaggaaagggtctggaatggatgggaataatatattatgatggaggcacagattataattcagcaatt-
aaatccagactgagcatca
gcagggacacctccaagagccaagttttcttaaaaatcaacagtctgcaaactgatgacacagccatgtattac-
tgtgccagaatccactttg
attactggggccaaggagtcatggtcacagtctcctctgatctggagcccaaatcttctgacaaaactcacaca-
tccccaccgtccccagca
cctgaactcctgggtggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggac-
ccctgaggtcacatgcgt
ggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatg-
ccaagacaaagccgc
gggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggc-
aaggagtacaagtgc
aaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaagggcagccccgagaacc-
acaggtgtacaccct
gcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatcccagcg-
acatcgccgtggagtg
ggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcc-
tctacagcaagctcac
cgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccact-
acacgcagaagagcct
ctccctgtctccgggtaaagcggatccttcgaacatggatttccagagttgtctttatgctattgctgaagaac-
tgggcagtgaagacctggct
gccctcaagttcctgtgcttggactacatcccacacaagaagcaggagaccatcgaggatgcccagaagctatt-
tctgaggctgcgggaaa
aggggatgttggaggaaggcaatctgtctttcctgaaagagctgcttttccacatcagtcggtgggacctgctg-
gtcaacttcctagactgca
accgagaggagatggtgagagagctgcgggatccagacaatgcccagatttctccctacagggtcatgctcttt-
aagctctcagaagaagt
gagcgagttggaattgagatcttttaagttccttttgaacaatgagatccccaaatgtaagctggaagatgact-
tgagcctgcttgaaatttttgt
agaaatggagaagaggaccatgctggcagaaaataacttggaaaccctaaaatcaatctgtgaccaggtcaaca-
agagcctgctggggaa
gatcgaggattatgaaagatcaagcacagagagaagaatgagccttgaaggaagggaagagttgccaccttcag-
ttttggatgagatgag
cctcaaaatggcggaactgtgtgactcgccaagagaacaagacagtgagtcacggacttcagacaaagtttacc-
aaatgaagaacaaacc
tcggggatactgtctgatcatcaacaatcatgatttcagcaaggcccgggaagacataacccaactccgaaaaa-
tgaaggacagaaaagg
aacagactgtgataaagaggctctgagtaagacctttaaggagcttcattttgagatagtatcttacgacgact-
gcactgcaaatgaaatccac
gagattctagaaggctaccaaagcgcagaccacaagaacaaagactgcttcatctgctgtatcctatcccacgg-
tgacaagggtgtcgtcta
tggaacggatgggaaggaggcctccatctatgacctgacatcttacttcactggttcaaagtgcccttccctgt-
ctgggaaacccaagatcttt
ttcattcaggcttgccaaggaagtaacttccagaaaggagtgcctgatgaggcaggcttcgagcaacagaacca-
cactttagaagtggattc
atcatctcacaagaactatattccggatgaggcagactttctgctgggaatggctacggtgaagaactgcgttt-
cctaccgagatcctgtgaat
ggaacctggtatattcagtcactttgccagagcctgagggaaagatgtcctcaaggagatgacattcttagcat-
cctgactggcgtgaactat
gacgtgagcaataaagacgacaggaggaacaagggaaagcagatgccacagcccaccttcacactacggaagaa-
gctcttcttccctcc ctaatgactcgagatcgatt Amino acid sequence (SEQ ID
NO: 494):
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPTTIAASPGEKVTITCRASSSVSYMYWYQQK
SGASPKLWIYDTSKLASGVPNRFSGSGSGTSYSLAINTMETEDAATYYCQQWSSTPLTFG
SGTKLEIKRGGGGSGGGGSGGGGSQVQLKEAGPGLVQPTQTLSLTCTVSGFSLTSDGVH
WIRQPPGKGLEWMGIIYYDGGTDYNSAIKSRLSISRDTSKSQVFLKINSLQTDDTAMYYC
ARIHFDYWGQGVMVTVSSDLEPKSSDKTHTSPPSPAPELLGGPSVFLFPPKPKDTLMISR
TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKG
FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
ALHNHYTQKSLSLSPGKADPSNMDFQSCLYAIAEELGSEDLAALKFLCLDYIPHKKQETI
EDAQKLFLRLREKGMLEEGNLSFLKELLFHISRWDLLVNFLDCNREEMVRELRDPDNAQ
ISPYRVMLFKLSEEVSELELRSFKFLLNNEIPKCKLEDDLSLLEIFVEMEKRTMLAENNLE
TLKSICDQVNKSLLGKIEDYERSSTERRMSLEGREELPPSVLDEMSLKMAELCDSPREQD
SESRTSDKVYQMKNKPRGYCLIINNHDFSKAREDITQLRKMKDRKGTDCDKEALSKTFK
ELHFEIVSYDDCTANEIHEILEGYQSADHKNKDCFICCILSHGDKGVVYGTDGKEASIYD
LTSYFTGSKCPSLSGKPKIFFIQACQGSNFQKGVPDEAGFEQQNHTLEVDSSSHKNYIPDE
ADFLLGMATVKNCVSYRDPVNGTWYIQSLCQSLRERCPQGDDILSILTGVNYDVSNKD
DRRNKGKQMPQPTFTLRKKLFFPP 137.1D8 scFv hIgG1 (SSS-P)H P238SCH2
WCH3-mcasp8-TM/CT
Nucleotide sequence (SEQ ID NO: 495):
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcactcagtctc
caacaaccatagctgcatctccaggggagaaggtcaccatcacctgccgtgccagctccagtgtaagttacatg-
tactggtaccagcagaa
gtcaggcgcctcccctaaactctggatttatgacacatccaagctggcttctggagttccaaatcgcttcagtg-
gcagtgggtctgggacctct
tattctctcgcaatcaacaccatggagactgaagatgctgccacttattactgtcagcagtggagtagtactcc-
gctcacgttcgggtctggga
ccaagctggagatcaaacggggtggcggtggctcgggcggtggtgggtcgggtggcggcggatctcaggtgcag-
ctgaaggaggcag
gacctggcctggtgcaaccgacacagaccctgtccctcacatgcactgtctctgggttctcattaaccagcgat-
ggtgtacactggattcgac
agcctccaggaaagggtctggaatggatgggaataatatattatgatggaggcacagattataattcagcaatt-
aaatccagactgagcatca
gcagggacacctccaagagccaagttttcttaaaaatcaacagtctgcaaactgatgacacagccatgtattac-
tgtgccagaatccactttg
attactggggccaaggagtcatggtcacagtctcctctgatctggagcccaaatcttctgacaaaactcacaca-
tccccaccgtccccagca
cctgaactcctgggtggatcgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggac-
ccctgaggtcacatgcgt
ggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatg-
ccaagacaaagccgc
gggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggc-
aaggagtacaagtgc
aaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaagggcagccccgagaacc-
acaggtgtacaccct
gcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatcccagcg-
acatcgccgtggagtg
ggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcc-
tctacagcaagctcac
cgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccact-
acacgcagaagagcct
ctccctgtctccgggtaaagcggatccttcgaacatggatttccagagttgtctttatgctattgctgaagaac-
tgggcagtgaagacctggct
gccctcaagttcctgtgcttggactacatcccacacaagaagcaggagaccatcgaggatgcccagaagctatt-
tctgaggctgcgggaaa
aggggatgttggaggaaggcaatctgtctttcctgaaagagctgcttttccacatcagtcggtgggacctgctg-
gtcaacttcctagactgca
accgagaggagatggtgagagagctgcgggatccagacaatgcccagatttctccctacagggtcatgctcttt-
aagctctcagaagaagt
gagcgagttggaattgagatcttttaagttccttttgaacaatgagatccccaaatgtaagctggaagatgact-
tgagcctgcttgaaatttttgt
agaaatggagaagaggaccatgctggcagaaaataacttggaaaccctaaaatcaatctgtgaccaggtcaaca-
agagcctgctggggaa
gatcgaggattatgaaagatcaagcacagagagaagaatgagccttgaaggaagggaagagttgccaccttcag-
ttttggatgagatgag
cctcaaaatggcggaactgtgtgactcgccaagagaacaagacagtgagtcacggacttcagacaaagtttacc-
aaatgaagaacaaacc
tcggggatactgtctgatcatcaacaatcatgatttcagcaaggcccgggaagacataacccaactccgaaaaa-
tgaaggacagaaaagg
aacagactgtgataaagaggctctgagtaagacctttaaggagcttcattttgagatagtatcttacgacgact-
gcactgcaaatgaaatccac
gagattctagaaggctaccaaagcgcagaccacaagaacaaagactgcttcatctgctgtatcctatcccacgg-
tgacaagggtgtcgtcta
tggaacggatgggaaggaggcctccatctatgacctgacatcttacttcactggttcaaagtgccatccctgtc-
tgggaaacccaagatcttt
ttcattcaggcttgccaaggaagtaacttccagaaaggagtgcctgatgaggcaggcttcgagcaacagaacca-
cactttagaagtggattc
atcatctcacaagaactatattccggatgaggcagactttctgctgggaatggctacggtgaagaactgcgttt-
cctaccgagatcctgtgaat
ggaacctggtatattcagtcactttgccagagcctgagggaaagatgtcctcaaggagatgacattcttagcat-
cctgactggcgtgaactat
gacgtgagcaataaagacgacaggaggaacaagggaaagcagatgccacagcccaccttcacactacggaagaa-
gctcttcttccctcc ctaatgactcgagatcgattc Amino acid sequence (SEQ ID
NO: 496):
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPTTIAASPGEKVTITCRASSSVSYMYWYQQK
SGASPKLWIYDTSKLASGVPNRFSGSGSGTSYSLAINTMETEDAATYYCQQWSSTPLTFG
SGTKLEIKRGGGGSGGGGSGGGGSQVQLKEAGPGLVQPTQTLSLTCTVSGFSLTSDGVH
WIRQPPGKGLEWMGIIYYDGGTDYNSAIKSRLSISRDTSKSQVFLKINSLQTDDTAMYYC
ARIHFDYWGQGVMVTVSSDLEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDTLMISR
TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKG
FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
ALHNHYTQKSLSLSPGKADPSNMDFQSCLYAIAEELGSEDLAALKFLCLDYIPHKKQETI
EDAQKLFLRLREKGMLEEGNLSFLKELLFHISRWDLLVNFLDCNREEMVRELRDPDNAQ
ISPYRVMLFKLSEEVSELELRSFKFLLNNEIPKCKLEDDLSLLEIFVEMEKRTMLAENNLE
TLKSICDQVNKSLLGKIEDYERSSTERRMSLEGREELPPSVLDEMSLKMAELCDSPREQD
SESRTSDKVYQMKNKPRGYCLIINNHDFSKAREDITQLRKMKDRKGTDCDKEALSKTFK
ELHFEIVSYDDCTANEIHEILEGYQSADHKNKDCFICCILSHGDKGVVYGTDGKEASIYD
LTSYFTGSKCPSLSGKPKIFFIQACQGSNFQKGVPDEAGFEQQNHTLEVDSSSHKNYIPDE
ADFLLGMATVKNCVSYRDPVNGTWYIQSLCQSLRERCPQGDDILSILTGVNYDVSNKD
DRRNKGKQMPQPTFTLRKKLFFPP 138.1D8 scFv hIgG1 (SSS-P)H WCH2
WCH3-hcasp3-TM/CT (SEQ ID NO: 497)
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcactcagtctc
caacaaccatagctgcatctccaggggagaaggtcaccatcacctgccgtgccagctccagtgtaagttacatg-
tactggtaccagcagaa
gtcaggcgcctcccctaaactctggatttatgacacatccaagctggcttctggagttccaaatcgcttcagtg-
gcagtgggtctgggacctct
tattctctcgcaatcaacaccatggagactgaagatgctgccacttattactgtcagcagtggagtagtactcc-
gctcacgttcgggtctggga
ccaagctggagatcaaacggggtggcggtggctcgggcggtggtgggtcgggtggcggcggatctcaggtgcag-
ctgaaggaggcag
gacctggcctggtgcaaccgacacagaccctgtccctcacatgcactgtctctgggttctcattaaccagcgat-
ggtgtacactggattcgac
agcctccaggaaagggtctggaatggatgggaataatatattatgatggaggcacagattataattcagcaatt-
aaatccagactgagcatca
gcagggacacctccaagagccaagttttcttaaaaatcaacagtctgcaaactgatgacacagccatgtattac-
tgtgccagaatccactttg
attactggggccaaggagtcatggtcacagtctcctctgatctggagcccaaatcttctgacaaaactcacaca-
tccccaccgtccccagca
cctgaactcctgggtggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggac-
ccctgaggtcacatgcgt
ggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatg-
ccaagacaaagccgc
gggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggc-
aaggagtacaagtgc
aaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaagggcagccccgagaacc-
acaggtgtacaccct
gcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatcccagcg-
acatcgccgtggagtg
ggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcc-
tctacagcaagctcac
cgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccact-
acacgcagaagagcct
ctccctgtctccgggtaaagcggatccttcgaacatggagaacactgaaaactcagtggattcaaaatccatta-
aaaatttggaaccaaagat
catacatggaagcgaatcaatggactctggaatatccctggacaacagttataaaatggattatcctgagatgg-
gtttatgtataataattaata
ataagaattttcataaaagcactggaatgacatctcggtctggtacagatgtcgatgcagcaaacctcagggaa-
acattcagaaacttgaaat
atgaagtcaggaataaaaatgatcttacacgtgaagaaattgtggaattgatgcgtgatgtttctaaagaagat-
cacagcaaaaggagcagtt
ttgtttgtgtgcttctgagccatggtgaagaaggaataatttttggaacaaatggacctgttgacctgaaaaaa-
ataacaaactttttcagaggg
gatcgttgtagaagtctaactggaaaacccaaacttttcattattcaggcctgccgtggtacagaactggactg-
tggcattgagacagacagt
ggtgttgatgatgacatggcgtgtcataaaataccagtggaggccgacttcttgtatgcatactccacagcacc-
tggttattattcttggcgaaa
ttcaaaggatggctcctggttcatccagtcgctttgtgccatgctgaaacagtatgccgacaagcttgaattta-
tgcacattcttacccgggttaa
ccgaaaggtggcaacagaatttgagtccttttcctttgacgctacttttcatgcaaagaaacagattccatgta-
ttgtttccatgctcacaaaaga actctatttttatcactaactcgagatcgata Amino acid
sequence (SEQ ID NO: 498):
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPTTIAASPGEKVTITCRASSSVSYMYWYQQK
SGASPKLWIYDTSKLASGVPNRFSGSGSGTSYSLAINTMETEDAATYYCQQWSSTPLTFG
SGTKLEIKRGGGGSGGGGSGGGGSQVQLKEAGPGLVQPTQTLSLTCTVSGFSLTSDGVH
WIRQPPGKGLEWMGIIYYDGGTDYNSAIKSRLSISRDTSKSQVFLKINSLQTDDTAMYYC
ARIHFDYWGQGVMVTVSSDLEPKSSDKTHTSPPSPAPELLGGPSVFLFPPKPKDTLMISR
TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKG
FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
ALHNHYTQKSLSLSPGKADPSNMENTENSVDSKSIKNLEPKIIHGSESMDSGISLDNSYK
MDYPEMGLCIIINNKNFHKSTGMTSRSGTDVDAANLRETFRNLKYEVRNKNDLTREEIV
ELMRDVSKEDHSKRSSFVCVLLSHGEEGIIFGTNGPVDLKKITNFFRGDRCRSLTGKPKL
FIIQACRGTELDCGIETDSGVDDDMACHKIPVEADFLYAYSTAPGYYSWRNSKDGSWFI
QSLCAMLKQYADKLEFMHILTRVNRKVATEFESFSFDATFHAKKQIPCIVSMLTKELYF YH 139.
1D8 scFv hIgG1 (SSS-P)H P238SCH2 WCH3-hcasp3-TM/CT Nucleotide
sequence (SEQ ID NO: 499):
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcactcagtctc
caacaaccatagctgcatctccaggggagaaggtcaccatcacctgccgtgccagctccagtgtaagttacatg-
tactggtaccagcagaa
gtcaggcgcctcccctaaactctggatttatgacacatccaagctggcttctggagttccaaatcgcttcagtg-
gcagtgggtctgggacctct
tattctctcgcaatcaacaccatggagactgaagatgctgccacttattactgtcagcagtggagtagtactcc-
gctcacgttcgggtctggga
ccaagctggagatcaaacggggtggcggtggctcgggcggtggtgggtcgggtggcggcggatctcaggtgcag-
ctgaaggaggcag
gacctggcctggtgcaaccgacacagaccctgtccctcacatgcactgtctctgggttctcattaaccagcgat-
ggtgtacactggattcgac
agcctccaggaaagggtctggaatggatgggaataatatattatgatggaggcacagattataattcagcaatt-
aaatccagactgagcatca
gcagggacacctccaagagccaagttttcttaaaaatcaacagtctgcaaactgatgacacagccatgtattac-
tgtgccagaatccactttg
attactggggccaaggagtcatggtcacagtctcctctgatctggagcccaaatcttctgacaaaactcacaca-
tccccaccgtccccagca
cctgaactcctgggtggatcgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggac-
ccctgaggtcacatgcgt
ggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatg-
ccaagacaaagccgc
gggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggc-
aaggagtacaagtgc
aaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaagggcagccccgagaacc-
acaggtgtacaccct
gcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatcccagcg-
acatcgccgtggagtg
ggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcc-
tctacagcaagctcac
cgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccact-
acacgcagaagagcct
ctccctgtctccgggtaaagcggatccttcgaacatggagaacactgaaaactcagtggattcaaaatccatta-
aaaatttggaaccaaagat
catacatggaagcgaatcaatggactctggaatatccctggacaacagttataaaatggattatcctgagatgg-
gtttatgtataataattaata
ataagaattttcataaaagcactggaatgacatctcggtctggtacagatgtcgatgcagcaaacctcagggaa-
acattcagaaacttgaaat
atgaagtcaggaataaaaatgatcttacacgtgaagaaattgtggaattgatgcgtgatgtttctaaagaagat-
cacagcaaaaggagcagtt
ttgtttgtgtgcttctgagccatggtgaagaaggaataatttttggaacaaatggacctgttgacctgaaaaaa-
ataacaaactttttcagaggg
gatcgttgtagaagtctaactggaaaacccaaacttttcattattcaggcctgccgtggtacagaactggactg-
tggcattgagacagacagt
ggtgttgatgatgacatggcgtgtcataaaataccagtggaggccgacttcttgtatgcatactccacagcacc-
tggttattattcttggcgaaa
ttcaaaggatggctcctggttcatccagtcgctttgtgccatgctgaaacagtatgccgacaagcttgaattta-
tgcacattcttacccgggttaa
ccgaaaggtggcaacagaatttgagtccttttcctttgacgctacttttcatgcaaagaaacagattccatgta-
ttgtttccatgctcacaaaaga actctatttttatcactaactcgagatcgataa Amino acid
sequence (SEQ ID NO: 500):
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPTTIAASPGEKVTITCRASSSVSYMYWYQQK
SGASPKLWIYDTSKLASGVPNRFSGSGSGTSYSLAINTMETEDAATYYCQQWSSTPLTFG
SGTKLEIKRGGGGSGGGGSGGGGSQVQLKEAGPGLVQPTQTLSLTCTVSGFSLTSDGVH
WIRQPPGKGLEWMGIIYYDGGTDYNSAIKSRLSISRDTSKSQVFLKINSLQTDDTAMYYC
ARIHFDYWGQGVMVTVSSDLEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDTLMISR
TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKG
FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
ALHNHYTQKSLSLSPGKADPSNMENTENSVDSKSIKNLEPKIIHGSESMDSGISLDNSYK
MDYPEMGLCIIINNKNFHKSTGMTSRSGTDVDAANLRETFRNLKYEVRNKNDLTREEIV
ELMRDVSKEDHSKRSSFVCVLLSHGEEGIIFGTNGPVDLKKITNFFRGDRCRSLTGKPKL
FIIQACRGTELDCGIETDSGVDDDMACHKIPVEADFLYAYSTAPGYYSWRNSKDGSWFI
QSLCAMLKQYADKLEFMHILTRVNRKVATEFESFSFDATFHAKKQIPCIVSMLTKELYF YH
140.1D8 scFv hIgG1 (SSS-S)H WCH2 WCH3-hcasp8-TM/CT Nucleotide
sequence (SEQ ID NO: 501):
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcactcagtctc
caacaaccatagctgcatctccaggggagaaggtcaccatcacctgccgtgccagctccagtgtaagttacatg-
tactggtaccagcagaa
gtcaggcgcctcccctaaactctggatttatgacacatccaagctggcttctggagttccaaatcgcttcagtg-
gcagtgggtctgggacctct
tattctctcgcaatcaacaccatggagactgaagatgctgccacttattactgtcagcagtggagtagtactcc-
gctcacgttcgggtctggga
ccaagctggagatcaaacggggtggcggtggctcgggcggtggtgggtcgggtggcggcggatctcaggtgcag-
ctgaaggaggcag
gacctggcctggtgcaaccgacacagaccctgtccctcacatgcactgtctctgggttctcattaaccagcgat-
ggtgtacactggattcgac
agcctccaggaaagggtctggaatggatgggaataatatattatgatggaggcacagattataattcagcaatt-
aaatccagactgagcatca
gcagggacacctccaagagccaagttttcttaaaaatcaacagtctgcaaactgatgacacagccatgtattac-
tgtgccagaatccactttg
attactggggccaaggagtcatggtcacagtctcctctgatctggagcccaaatcttctgacaaaactcacaca-
tccccaccgtccccagca
cctgaactcctgggtggaccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggac-
ccctgaggtcacatgcgt
ggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatg-
ccaagacaaagccgc
gggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggc-
aaggagtacaagtgc
aaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaagggcagccccgagaacc-
acaggtgtacaccct
gcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatcccagcg-
acatcgccgtggagtg
ggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcc-
tctacagcaagctcac
cgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccact-
acacgcagaagagcct
ctccctgtctccgggtaaagcggatccttcgaacatggacttcagcagaaatctttatgatattggggaacaac-
tggacagtgaagatctggc
ctccctcaagttcctgagcctggactacattccgcaaaggaagcaagaacccatcaaggatgccttgatgttat-
tccagagactccaggaaa
agagaatgttggaggaaagcaatctgtccttcctgaaggagctgctcttccgaattaatagactggatttgctg-
attacctacctaaacactag
aaaggaggagatggaaagggaacttcagacaccaggcagggctcaaatttctgcctacagggtcatgctctatc-
agatttcagaagaagtg
agcagatcagaattgaggtcttttaagtttcttttgcaagaggaaatctccaaatgcaaactggatgatgacat-
gaacctgctggatattttcata
gagatggagaagagggtcatcctgggagaaggaaagttggacatcctgaaaagagtctgtgcccaaatcaacaa-
gagcctgctgaagat
aatcaacgactatgaagaattcagcaaagagagaagcagcagccttgaaggaagtcctgatgaattttcaaatg-
gggaggagttgtgtggg
gtaatgacaatctcggactctccaagagaacaggatagtgaatcacagactttggacaaagtttaccaaatgaa-
aagcaaacctcggggata
ctgtctgatcatcaacaatcacaattttgcaaaagcacgggagaaagtgcccaaacttcacagcattagggaca-
ggaatggaacacacttgg
atgcaggggctttgaccacgacctttgaagagcttcattttgagatcaagccccacgatgactgcacagtagag-
caaatctatgagattttgaa
aatctaccaactcatggaccacagtaacatggactgcttcatctgctgtatcctctcccatggagacaagggca-
tcatctatggcactgatgga
caggaggcccccatctatgagctgacatctcagttcactggtttgaagtgcccttcccttgctggaaaacccaa-
agtgttttttattcaggcttgt
cagggggataactaccagaaaggtatacctgttgagactgattcagaggagcaaccctatttagaaatggattt-
atcatcacctcaaacgaga
tatatcccggatgaggctgactttctgctggggatggccactgtgaataactgtgtttcctaccgaaaccctgc-
agagggaacctggtacatc
cagtcactttgccagagcctgagagagcgatgtcctcgaggcgatgatattctcaccatcctgactgaagtgaa-
ctatgaagtaagcaacaa
ggatgacaagaaaaacatggggaaacagatgcctcagcctactttcacactaagaaaaaaacttgtcttccctt-
ctgattgagcatgcatcga ta Amino acid sequence (SEQ ID NO: 502):
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPTTIAASPGEKVTITCRASSSVSYMYWYQQK
SGASPKLWIYDTSKLASGVPNRFSGSGSGTSYSLAINTMETEDAATYYCQQWSSTPLTFG
SGTKLEIKRGGGGSGGGGSGGGGSQVQLKEAGPGLVQPTQTLSLTCTVSGFSLTSDGVH
WIRQPPGKGLEWMGIIYYDGGTDYNSAIKSRLSISRDTSKSQVFLKINSLQTDDTAMYYC
ARIHFDYWGQGVMVTVSSDLEPKSSDKTHTSPPSPAPELLGGPSVFLFPPKPKDTLMISR
TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKG
FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
ALHNHYTQKSLSLSPGKADPSNMDFSRNLYDIGEQLDSEDLASLKFLSLDYIPQRKQEPI
KDALMLFQRLQEKRMLEESNLSFLKELLFRINRLDLLITYLNTRKEEMERELQTPGRAQI
SAYRVMLYQISEEVSRSELRSFKFLLQEEISKCKLDDDMNLLDIFIEMEKRVILGEGKLDI
LKRVCAQINKSLLKIINDYEEFSKERSSSLEGSPDEFSNGEELCGVMTISDSPREQDSESQT
LDKVYQMKSKPRGYCLIINNHNFAKAREKVPKLHSIRDRNGTHLDAGALTTTFEELHFEI
KPHDDCTVEQIYEILKIYQLMDHSNMDCFICCILSHGDKGIIYGTDGQEAPIYELTSQFTG
LKCPSLAGKPKVFFIQACQGDNYQKGIPVETDSEEQPYLEMDLSSPQTRYIPDEADFLLG
MATVNNCVSYRNPAEGTWYIQSLCQSLRERCPRGDDILTILTEVNYEVSNKDDKKNMG
KQMPQPTFTLRKKLVFPSD 141.1D8 scFv hIgG1 (SSS-S)H P238SCH2
WCH3-hcasp8-TM/CT Nucleotide sequence (SEQ ID NO: 503):
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacattgtgctcactcagtctc
caacaaccatagctgcatctccaggggagaaggtcaccatcacctgccgtgccagctccagtgtaagttacatg-
tactggtaccagcagaa
gtcaggcgcctcccctaaactctggatttatgacacatccaagctggcttctggagttccaaatcgcttcagtg-
gcagtgggtctgggacctct
tattctctcgcaatcaacaccatggagactgaagatgctgccacttattactgtcagcagtggagtagtactcc-
gctcacgttcgggtctggga
ccaagctggagatcaaacggggtggcggtggctcgggcggtggtgggtcgggtggcggcggatctcaggtgcag-
ctgaaggaggcag
gacctggcctggtgcaaccgacacagaccctgtccctcacatgcactgtctctgggttctcattaaccagcgat-
ggtgtacactggattcgac
agcctccaggaaagggtctggaatggatgggaataatatattatgatggaggcacagattataattcagcaatt-
aaatccagactgagcatca
gcagggacacctccaagagccaagttttcttaaaaatcaacagtctgcaaactgatgacacagccatgtattac-
tgtgccagaatccactttg
attactggggccaaggagtcatggtcacagtctcctctgatctggagcccaaatcttctgacaaaactcacaca-
tccccaccgtccccagca
cctgaactcctgggtggatcgtcagtcttcctcttccccccaaaacccaaggacaccctcatgatctcccggac-
ccctgaggtcacatgcgt
ggtggtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatg-
ccaagacaaagccgc
gggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggc-
aaggagtacaagtgc
aaggtctccaacaaagccctcccagcccccatcgagaaaaccatctccaaagccaaagggcagccccgagaacc-
acaggtgtacaccct
gcccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctatcccagcg-
acatcgccgtggagtg
ggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttcttcc-
tctacagcaagctcac
cgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccact-
acacgcagaagagcct
ctccctgtctccgggtaaagcggatccttcgaacatggacttcagcagaaatctttatgatattggggaacaac-
tggacagtgaagatctggc
ctccctcaagttcctgagcctggactacattccgcaaaggaagcaagaacccatcaaggatgccttgatgttat-
tccagagactccaggaaa
agagaatgttggaggaaagcaatctgtccttcctgaaggagctgctcttccgaattaatagactggatttgctg-
attacctacctaaacactag
aaaggaggagatggaaagggaacttcagacaccaggcagggctcaaatttctgcctacagggtcatgctctatc-
agatttcagaagaagtg
agcagatcagaattgaggtcttttaagtttcttttgcaagaggaaatctccaaatgcaaactggatgatgacat-
gaacctgctggatattttcata
gagatggagaagagggtcatcctgggagaaggaaagttggacatcctgaaaagagtctgtgcccaaatcaacaa-
gagcctgctgaagat
aatcaacgactatgaagaattcagcaaagagagaagcagcagccttgaaggaagtcctgatgaattttcaaatg-
gggaggagttgtgtggg
gtaatgacaatctcggactctccaagagaacaggatagtgaatcacagactttggacaaagtttaccaaatgaa-
aagcaaacctcggggata
ctgtctgatcatcaacaatcacaattttgcaaaagcacgggagaaagtgcccaaacttcacagcattagggaca-
ggaatggaacacacttgg
atgcaggggctttgaccacgacctttgaagagcttcattttgagatcaagccccacgatgactgcacagtagag-
caaatctatgagattttgaa
aatctaccaactcatggaccacagtaacatggactgcttcatctgctgtatcctctcccatggagacaagggca-
tcatctatggcactgatgga
caggaggcccccatctatgagctgacatctcagttcactggtttgaagtgcccttcccttgctggaaaacccaa-
agtgttttttattcaggcttgt
cagggggataactaccagaaaggtatacctgttgagactgattcagaggagcaaccctatttagaaatggattt-
atcatcacctcaaacgaga
tatatcccggatgaggctgactttctgctggggatggccactgtgaataactgtgtttcctaccgaaaccctgc-
agagggaacctggtacatc
cagtcactttgccagagcctgagagagcgatgtcctcgaggcgatgatattctcaccatcctgactgaagtgaa-
ctatgaagtaagcaacaa
ggatgacaagaaaaacatggggaaacagatgcctcagcctactttcacactaagaaaaaaacttgtcttccctt-
ctgattgagcatgcatcga taa Amino acid sequence (SEQ ID NO: 504):
MDFQVQIFSFLLISASVIMSRGVDIVLTQSPTTIAASPGEKVTITCRASSSVSYMYWYQQK
SGASPKLWIYDTSKLASGVPNRFSGSGSGTSYSLAINTMETEDAATYYCQQWSSTPLTFG
SGTKLEIKRGGGGSGGGGSGGGGSQVQLKEAGPGLVQPTQTLSLTCTVSGFSLTSDGVH
WIRQPPGKGLEWMGIIYYDGGTDYNSAIKSRLSISRDTSKSQVFLKINSLQTDDTAMYYC
ARIHFDYWGQGVMVTVSSDLEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDTLMISR
TPEVTCVVVDVSHEDPEVKFNWWVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKG
FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
ALHNHYTQKSLSLSPGKADPSNMDFSRNLYDIGEQLDSEDLASLKFLSLDYIPQRKQEPI
KDALMLFQRLQEKRMLEESNLSFLKELLFRINRLDLLITYLNTRKEEMERELQTPGRAQI
SAYRVMLYQISEEVSRSELRSFKFLLQEEISKCKLDDDMNLLDIFIEMEKRVILGEGKLDI
LKRVCAQINKSLLKIINDYEEFSKERSSSLEGSPDEFSNGEELCGVMTISDSPREQDSESQT
LDKVYQMKSKPRGYCLIINNHNFAKAREKVPKLHSIRDRNGTHLDAGALTTTFEELHFEI
KPHDDCTVEQIYEILKIYQLMDHSNMDCFICCILSHGDKGIIYGTDGQEAPIYELTSQFTG
LKCPSLAGKPKVFFIQACQGDNYQKGIPVETDSEEQPYLEMDLSSPQTRYIPDEADFLLG
MATVNNCVSYRNPAEGTWYIQSLCQSLRERCPRGDDILTILTEVNYEVSNKDDKKNMG
KQMPQPTFTLRKKLVFPSD 145. hCTLA4 IgAH IgACH2CH3 Nucleotide sequence
(SEQ ID NO: 505):
atggcttgccttggatttcagcggcacaaggctcagctgaacctggctgccaggacctggccctgcactctcct-
gtttttcttctcttcatccct
gtcttctgcaaagcaatgcacgtggcccagcctgctgtggtactggccagcagccgaggcatcgccagctttgt-
gtgtgagtatgcatctcc
aggcaaagccactgaggtccgggtgacagtgcttcggcaggctgacagccaggtgactgaagtctgtgcggcaa-
cctacatgacgggga
atgagttgaccttcctagatgattccatctgcacgggcacctccagtggaaatcaagtgaacctcactatccaa-
ggactgagggccatggac
acgggactctacatctgcaaggtggagctcatgtacccaccgccatactacctgggcataggcaacggaaccca-
gatttatgtaattgatcc
agaaccgtgcccagattctgatcagccagttccctcaactccacctaccccatctccctcaactccacctaccc-
catctccctcatgctgccac
ccccgactgtcactgcaccgaccggccctcgaggacctgctcttaggttcagaagcgatcctcacgtgcacact-
gaccggcctgagagat
gcctcaggtgtcaccttcacctggacgccctcaagtgggaagagcgctgttcaaggaccacctgaccgtgacct-
ctgtggctgctacagcg
tgtccagtgtcctgccgggctgtgccgagccatggaaccatgggaagaccttcacttgcactgctgcctacccc-
gagtccaagaccccgct
aaccgccaccctctcaaaatccggaaacacattccggcccgaggtccacctgctgccgccgccgtcggaggagc-
tggccctgaacgagc
tggtgacgctgacgtgcctggcacgtggcttcagccccaaggatgtgctggttcgctggctgcaggggtcacag-
gagctgccccgcgag
aagtacctgacttgggcatcccggcaggagcccagccagggcaccaccaccttcgctgtgaccagcatactgcg-
cgtggcagccgagg
actggaagaagggggacaccttctcctgcatggtgggccacgaggccctgccgctggccttcacacagaagacc-
atcgaccgcttggcg
ggtaaacccacccatgtcaatgtgtctgttgtcatggcggaggtggacggcacctgctactgataatctaga
Amino acid sequence (SEQ ID NO: 506):
MACLGFQRHKAQLNLAARTWPCTLLFFLLFIPVFCKAMHVAQPAVVLASSRGIASFVCE
YASPGKATEVRVTVLRQADSQVTEVCAATYMTGNELTFLDDSICTGTSSGNQVNLTIQG
LRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPEPCPDSDQPVPSTPPTPSPSTPPTPS
PSCCHPRLSLHRPALEDLLLGSEAILTCTLTGLRDASGVTFTWTPSSGKSAVQGPPDRDL
CGCYSVSSVLPGCAEPWNHGKTFTCTAAYPESKTPLTATLSKSGNTFRPEVHLLPPPSEE
LALNELVTLTCLARGFSPKDVLVRWLQGSQELPREKYLTWASRQEPSQGTTTFAVTSIL
RVAAEDWKKGDTFSCMVGHEALPLAFTQKTIDRLAGKPTHVNVSVVMAEVDGTCY 146. hCTLA4
IgA WH WCH2 T4CH3 (hCTLA4 IgAH IgACH2CH3) Nucleotide sequence (SEQ
ID NO: 507):
atggcttgccttggatttcagcggcacaaggctcagctgaacctggctgccaggacctggccctgcactctcct-
gttttttcttctcttcatccct
gtcttctgcaaagcaatgcacgtggcccagcctgctgtggtactggccagcagccgaggcatcgccagctttgt-
gtgtgagtatgcatctcc
aggcaaagccactgaggtccgggtgacagtgcttcggcaggctgacagccaggtgactgaagtctgtgcggcaa-
cctacatgacgggga
atgagttgaccttcctagatgattccatctgcacgggcacctccagtggaaatcaagtgaacctcactatccaa-
ggactgagggccatggac
acgggactctacatctgcaaggtggagctcatgtacccaccgccatactacctgggcataggcaacggaaccca-
gatttatgtaattgatcc
agaaccgtgcccagattctgatcagccagttccctcaactccacctaccccatctccctcaactccacctaccc-
catctccctcatgctgccac
ccccgactgtcactgcaccgaccggccctcgaggacctgctcttaggttcagaagcgatcctcacgtgcacact-
gaccggcctgagagat
gcctcaggtgtcaccttcacctggacgccctcaagtgggaagagcgctgttcaaggaccacctgaccgtgacct-
ctgtggctgctacagcg
tgtccagtgtcctgccgggctgtgccgagccatggaaccatgggaagaccttcacttgcactgctgcctacccc-
gagtccaagaccccgct
aaccgccaccctctcaaaatccggaaacacattccggcccgaggtccacctgctgccgccgccgtcggaggagc-
tggccctgaacgagc
tggtgacgctgacgtgcctggcacgtggcttcagccccaaggatgtgctggttcgctggctgcaggggtcacag-
gagctgccccgcgag
aagtacctgacttgggcatcccggcaggagcccagccagggcaccaccaccttcgctgtgaccagcatactgcg-
cgtggcagccgagg
actggaagaagggggacaccttctcctgcatggtgggccacgaggccctgccgctggccttcacacagaagacc-
atcgaccgcttggcg
ggtaaacccacccatgtcaatgtgtctgttgtcatggcggaggtggactgataatctaga Amino
acid sequence (SEQ ID NO: 508):
MACLGFQRHKAQLNLAARTWPCTLLFFLLFIPVFCKAMHVAQPAVVLASSRGIASFVCE
YASPGKATEVRVTVLRQADSQVTEVCAATYMTGNELTFLDDSICTGTSSGNQVNLTIQG
LRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPEPCPDSDQPVPSTPPTPSPSTPPTPS
PSCCHPRLSLHRPALEDLLLGSEAILTCTLTGLRDASGVTFTWTPSSGKSAVQGPPDRDL
CGCYSVSSVLPGCAEPWNHGKTFTCTAAYPESKTPLTATLSKSGNTFRPEVHLLPPPSEE
LALNELVTLTCLARGFSPKDVLVRWLQGSQELPREKYLTWASRQEPSQGTTTFAVTSIL
RVAAEDWKKGDTFSCMVGHEALPLAFTQKTIDRLAGKPTHVNVSVVMAEVD 147. hIGA WH
WCH2 T18CH3 Nucleotide sequence (SEQ ID NO: 509):
Tgatcagccagttccctcaactccacctaccccatctccctcaactccacctaccccatctccctcatgctgcc-
acccccgactgtcactgca
ccgaccggccctcgaggacctgctcttaggttcagaagcgatcctcacgtgcacactgaccggcctgagagatg-
cctcaggtgtcaccttc
acctggacgccctcaagtgggaagagcgctgttcaaggaccacctgaccgtgacctctgtggctgctacagcgt-
gtccagtgtcctgccgg
gctgtgccgagccatggaaccatgggaagaccttcacttgcactgctgcctaccccgagtccaagaccccgcta-
accgccaccctctcaaa
atccggaaacacattccggcccgaggtccacctgctgccgccgccgtcggaggagctggccctgaacgagctgg-
tgacgctgacgtgcc
tggcacgtggcttcagccccaaggatgtgctggttcgctggctgcaggggtcacaggagctgccccgcgagaag-
tacctgacttgggcat
cccggcaggagcccagccagggcaccaccaccttcgctgtgaccagcatactgcgcgtggcagccgaggactgg-
aagaagggggaca
ccttctcctgcatggtgggccacgaggccctgccgctggccttcacacagaagaccatcgaccgcttggcgggt-
aaatgataatctaga Amino acid sequence (SEQ ID NO: 510):
DQPVPSTPPTPSPSTPPTPSPSCCHPRLSLHRPALEDLLLGSEAILTCTLTGLRDASGVTFT
WTPSSGKSAVQGPPDRDLCGCYSVSSVLPGCAEPWNHGKTFTCTAAYPESKTPLTATLS
KSGNTFRPEVHLLPPPSEELALNELVTLTCLARGFSPKDVLVRWLQGSQELPREKYLTW
ASRQEPSQGTTTFAVTSILRVAAEDWKKGDTFSCMVGHEALPLAFTQKTIDRLAGK 150. G19-4
scFv (SSS-P)WH WCH2 WCH3-hCD80TMCT Nucleotide sequence (SEQ ID NO:
511):
aagcttatggattttcaagtgcagattttcagcttcctgctaatcagtgcttcagtcataatgtccagaggagt-
cgacatccagatgacacagac
tacatcctccctgtctgcctctctgggagacagagtcaccatcagttgcagggcaagtcaggacattcgcaatt-
atttaaactggtatcagcag
aaaccagatggaactgttaaactcctgatctactacacatcaagattacactcaggagtcccatcaaggttcag-
tggcagtgggtctggaaca
gattattctctcaccattgccaacctgcaaccagaagatattgccacttacttttgccaacagggtaatacgct-
tccgtggacgttcggtggag
gcaccaaactggtaaccaaacgggagctcggtggcggtggctcgggcggtggtgggtcgggtggcggcggatct-
atcgatgaggtcca
gctgcaacagtctggacctgaactggtgaagcctggagcttcaatgtcctgcaaggcctctggttactcattca-
ctggctacatcgtgaactg
gctgaagcagagccatggaaagaaccttgagtggattggacttattaatccatacaaaggtcttactacctaca-
accagaaattcaagggca
aggccacattaactgtagacaagtcatccagcacagcctacatggagctcctcagtctgacatctgaagactct-
gcagtctattactgtgcaa
gatctgggtactatggtgactcggactggtacttcgatgtctggggcgcagggaccacggtcaccgtctcctct-
gatctggagcccaaatctt
ctgacaaaactcacacatccccaccgtccccagcacctgaactcctggggggaccgtcagtcttcctcttcccc-
ccaaaacccaaggacac
cctcatgatctcccggacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagt-
tcaactggtacgtggac
ggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgt-
cctcaccgtcctgca
ccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccccatcgagaaaa-
ccatctccaaagcca
aagggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtcagc-
ctgacctgcctggt
caaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagacca-
cgcctcccgtgctg
gactccgacggctccttcttcctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtctt-
ctcatgctccgtgatgc
atgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaagcggatccttcgaacctg-
ctcccatcctgggccatt
accttaatctcagtaaatggaatttttgtgatatgctgcctgacctactgctttgccccaagatgcagagagag-
aaggaggaatgagagattga gaagggaaagtgtacgccctgtataaatcgat Amino acid
sequence (SEQ ID NO: 512):
MDFQVQIFSFLLISASVIMSRGVDIQMTQTTSSLSASLGDRVTISCRASQDIRNYLNWYQ
QKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTIANLQPEDIATYFCQQGNTLPWT
FGGGTKLVTKRELGGGGSGGGGSGGGGSIDEVQLQQSGPELVKPGASMSCKASGYSFT
GYIVNWLKQSHGKNLEWIGLINPYKGLTTYNQKFKGKATLTVDKSSSTAYMELLSLTSE
DSAVYYCARSGYYGDSDWYFDVWGAGTTVTVSSDLEPKSSDKTHTSPPSPAPELLGGP
SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKADPSNLLPSWAITLISVNGIFVICCLT
YCFAPRCRERRRNERLRRESVRPV HCD16lowFL + NL Nucleotide sequence (SEQ
ID NO: 513):
aagcttgccgccatgtggcagctgctcctcccaactgctctgctacttctagtttcagctggcatgcggactga-
agatctcccaaaggctgtg
gtgttcctggagcctcaatggtacagggtgctcgagaaggacagtgtgactctgaagtgccagggagcctactc-
ccctgaggacaattcca
cacagtggtttcacaatgagagcctcatctcaagccaggcctcgagctacttcattgacgctgccacagtcgac-
gacagtggagagtacag
gtgccagacaaacctctccaccctcagtgacccggtgcagctagaagtccatatcggctggctgttgctccagg-
cccctcggtgggtgttca
aggaggaagaccctattcacctgaggtgtcacagctggaagaacactgctctgcataaggtcacatatttacag-
aatggcaaaggcaggaa
gtattttcatcataattctgacttctacattccaaaagccacactcaaagacagcggctcctacttctgcaggg-
ggcttgttgggagtaaaaatg
tgtcttcagagactgtgaacatcaccatcactcaaggtttggcagtgtcaaccatctcatcattctttccacct-
gggtaccaagtctctttctgctt
ggtgatggtactcctttttgcagtggacacaggactatatttctctgtgaagacaaacattcgaagctcaacaa-
gagactggaaggaccataa atttaaatggagaaaggaccctcaagacaaatgaccc Amino
acid sequence (SEQ ID NO: 514):
MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNST
QWFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWV
FKEEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGL
VGSKNVSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSS
TRDWKDHKFKWRKDPQDK
[0863] From the foregoing, it will be appreciated that, although
specific embodiments of the invention have been described herein
for the purpose of illustration, various modifications may be made
without deviating from the spirit and scope of the invention.
Accordingly, the present invention is not limited except as by the
appended claims.
[0864] All patents, patent applications, publications, scientific
articles, web sites, and other documents and materials referenced
or mentioned herein are indicative of the levels of skill of those
skilled in the art to which the invention pertains, and each such
referenced document and material is hereby incorporated by
reference to the same extent as if it had been incorporated by
reference in its entirety individually or set forth herein in its
entirety. Additionally, all claims in this application, and all
priority applications, including but not limited to original
claims, are hereby incorporated in their entirety into, and form a
part of, the written description of the invention. Applicants
reserve the right to physically incorporate into this specification
any and all materials and information from any such patents,
applications, publications, scientific articles, web sites,
electronically available information, and other referenced
materials or documents. Applicants reserve the right to physically
incorporate into any part of this document, including any part of
the written description, the claims referred to above including but
not limited to any original claims.
[0865] The specific methods and compositions described herein are
representative of preferred embodiments and are exemplary and not
intended as limitations on the scope of the invention. Other
objects, aspects, and embodiments will occur to those skilled in
the art upon consideration of this specification, and are
encompassed within the spirit of the invention as defined by the
scope of the claims. It will be readily apparent to one skilled in
the art that varying substitutions and modifications may be made to
the invention disclosed herein without departing from the scope and
spirit of the invention. The invention illustratively described
herein suitably may be practiced in the absence of any element or
elements, or limitation or limitations, which is not specifically
disclosed herein as essential. Thus, for example, in each instance
herein, in embodiments or examples of the present invention, any of
the terms "comprising", "consisting essentially of", and
"consisting of may be replaced with either of the other two terms
in the specification. Also, the terms "comprising", "including",
containing", etc. are to be read expansively and without
limitation. The methods and processes illustratively described
herein suitably may be practiced in differing orders of steps, and
that they are not necessarily restricted to the orders of steps
indicated herein or in the claims. It is also that as used herein
and in the appended claims, the singular forms "a," "an," and "the"
include plural reference unless the context clearly dictates
otherwise. Thus, for example, a reference to "a host cell" includes
a plurality (for example, a culture or population) of such host
cells, and so forth. Under no circumstances may the patent be
interpreted to be limited to the specific examples or embodiments
or methods specifically disclosed herein. Under no circumstances
may the patent be interpreted to be limited by any statement made
by any Examiner or any other official or employee of the Patent and
Trademark Office unless such statement is specifically and without
qualification or reservation expressly adopted in a responsive
writing by Applicants.
[0866] The terms and expressions that have been employed are used
as terms of description and not of limitation, and there is no
intent in the use of such terms and expressions to exclude any
equivalent of the features shown and described or portions thereof,
but it is recognized that various modifications are possible within
the scope of the invention as claimed. Thus, it will be understood
that although the present invention has been specifically disclosed
by preferred embodiments and optional features, modification and
variation of the concepts herein disclosed may be resorted to by
those skilled in the art, and that such modifications and
variations are considered to be within the scope of this invention
as defined by the appended claims.
[0867] The invention has been described broadly and generically
herein. Each of the narrower species and subgeneric groupings
falling within the generic disclosure also form part of the
invention. This includes the generic description of the invention
with a proviso or negative limitation removing any subject matter
from the genus, regardless of whether or not the excised material
is specifically recited herein. For example, the subject matter of
the instant invention may optionally exclude any of the subject
matter or sequences described or included in related application
published as U.S.S.N. 2003/0118592 A1 on Jun. 26, 2003 (and the
sequence listings of SEQ ID NOS: 1-427 published by USPTO), by
Ledbetter et al. entitled "Binding Domain-Immunoglobulin Fusion
Proteins".
[0868] Other embodiments are within the following claims. In
addition, where features or aspects of the invention are described
in terms of Markush groups, those skilled in the art will recognize
that the invention is also thereby described in terms of any
individual member or subgroup of members of the Markush group.
Sequence CWU 1
1
6991714DNAHomo sapiens 1tctgatcagg agcccaaatc ttgtgacaaa actcacacat
gcccaccgtg cccagcacct 60gaactcctgg ggggaccgtc agtcttcctc ttccccccaa
aacccaagga caccctcatg 120atctcccgga cccctgaggt cacatgcgtg
gtggtggacg tgagccacga agaccctgag 180gtcaagttca actggtacgt
ggacggcgtg gaggtgcata atgccaagac aaagccgcgg 240gaggagcagt
acaacagcac gtaccgtgtg gtcagcgtcc tcaccgtcct gcaccaggac
300tggctgaatg gcaaggagta caagtgcaag gtctccaaca aagccctccc
agcccccatc 360gagaaaacaa tctccaaagc caaagggcag ccccgagaac
cacaggtgta caccctgccc 420ccatcccggg atgagctgac caagaaccag
gtcagcctga cctgcctggt caaaggcttc 480tatcccagcg acatcgccgt
ggagtgggag agcaatgggc agccggagaa caactacaag 540accacgcctc
ccgtgctgga ctccgacggc tccttcttcc tctacagcaa gctcaccgtg
600gacaagagca ggtggcagca ggggaacgtc ttctcatgct ccgtgatgca
tgaggctctg 660cacaaccact acacgcagaa gagcctctcc ctgtctccgg
gtaaatgatc taga 7142235PRTHomo sapiens 2Ser Asp Gln Glu Pro Lys Ser
Cys Asp Lys Thr His Thr Cys Pro Pro1 5 10 15Cys Pro Ala Pro Glu Leu
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro 20 25 30Pro Lys Pro Lys Asp
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr 35 40 45Cys Val Val Val
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn 50 55 60Trp Tyr Val
Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg65 70 75 80Glu
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val 85 90
95Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser
100 105 110Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys
Ala Lys 115 120 125Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
Pro Ser Arg Asp 130 135 140Glu Leu Thr Lys Asn Gln Val Ser Leu Thr
Cys Leu Val Lys Gly Phe145 150 155 160Tyr Pro Ser Asp Ile Ala Val
Glu Trp Glu Ser Asn Gly Gln Pro Glu 165 170 175Asn Asn Tyr Lys Thr
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 180 185 190Phe Leu Tyr
Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly 195 200 205Asn
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 210 215
220Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys225 230
2353718DNALama glamamodified_base(34)..(34)n is a, c, g, or t
3tgatcaagaa ccacatggag gatgcacgtg cccncagtgc ccncaatgcc cngcnccnga
60actnccagga ggcccttctg tctttgtctt ccccccgaaa cccaaggacg tcctctccat
120ttttggaggc cgagtcacgt gcgttgtagt ggacgtcgga aagaaagacc
ccgaggtcaa 180tttcaactgg tatattgatg gcgttgaggt gcgaacggcc
aatacgaagc caaaagagga 240acagttcaac agcacgtacc gcgtggtcag
cgtcctgccc atccagcacc aggactggct 300gacggggaag gaattcaagt
gcaaggtcaa caacaaagct ctcccggccc ccatcgagag 360gaccatctcc
aaggccaaag ggcagacccg ggagccgcag gtgtacaccc tggccccaca
420ccgggaagaa ctggccaagg acaccgtgag cgtaacatgc ctggtcaaag
gcttctaccc 480agctgacatc aacgttgagt ggcagaggaa cggtcagccg
gagtcagagg gcacctacgc 540caacacgccg ccacagctgg acaacgacgg
gacctacttc ctctacagca agctctcggt 600gggaaagaac acgtggcagc
ggggagaaac cttaacctgt gtggtgatgc atgaggccct 660gcacaaccac
tacacccaga aatccatcac ccagtcttcg ggtaaatagt aatctaga 7184231PRTLama
glama 4Glu Pro His Gly Gly Cys Thr Cys Pro Gln Cys Pro Ala Pro Glu
Leu1 5 10 15Pro Gly Gly Pro Ser Val Phe Val Phe Pro Pro Lys Pro Lys
Asp Val 20 25 30Leu Ser Ile Ser Gly Arg Pro Glu Val Thr Cys Val Val
Val Asp Val 35 40 45Gly Lys Glu Asp Pro Glu Val Asn Phe Asn Trp Tyr
Ile Asp Gly Val 50 55 60Glu Val Arg Thr Ala Asn Thr Lys Pro Lys Glu
Glu Gln Phe Asn Ser65 70 75 80Thr Tyr Arg Val Val Ser Val Leu Pro
Ile Gln His Gln Asp Trp Leu 85 90 95Thr Gly Lys Glu Phe Lys Cys Lys
Val Asn Asn Lys Ala Leu Pro Ala 100 105 110Pro Ile Glu Arg Thr Ile
Ser Lys Ala Lys Gly Gln Thr Arg Glu Pro 115 120 125Gln Val Tyr Thr
Leu Ala Pro His Arg Glu Glu Leu Ala Lys Asp Thr 130 135 140Val Ser
Val Thr Cys Leu Val Lys Gly Phe Tyr Pro Ala Asp Ile Asn145 150 155
160Val Glu Trp Gln Arg Asn Gly Gln Pro Glu Ser Glu Gly Thr Tyr Ala
165 170 175Asn Thr Pro Pro Gln Leu Asp Asn Asp Gly Thr Tyr Phe Leu
Tyr Ser 180 185 190Arg Leu Ser Val Gly Lys Asn Thr Trp Gln Arg Gly
Glu Thr Leu Thr 195 200 205Gly Val Val Met His Glu Ala Leu His Asn
His Tyr Thr Gln Lys Ser 210 215 220Ile Thr Gln Ser Ser Gly Lys225
2305757DNALama glama 5tgatcaagaa cccaagacac caaaaccaca accacaacca
caaccacaac ccaatcctac 60aacagaatcc aagtgtccca aatgtccagc ccctgagctc
ctgggagggc cctcagtctt 120catcttcccc ccgaaaccca aggacgtcct
ctccatttct gggaggcccg aggtcacgtg 180cgttgtggta gacgtgggcc
aggaagaccc cgaggtcagt ttcaactggt acattgatgg 240cgctgaggtg
cgaacggcca acacgaggcc aaaagaggaa cagttcaaca gcacgtaccg
300cgtggtcagc gtcctgccca tccagcacca ggactggctg acggggaagg
aattcaagtg 360caaggtcaac aacaaagctc tcccggcccc catcgagaag
accatctcca aggccaaagg 420gcagacccgg gagccgcagg tgtacaccct
ggccccacac cgggaagagc tggccaagga 480caccgtgagc gtaacatgcc
tggtcaaagg cttctaccca cctgatatca acgttgagtg 540gcagaggaat
gggcagccgg agtcagaggg cacytacgcc accacgccac cccagctgga
600caacgacggg acctacttcc tctacagcaa gctctcggtg ggaaagaaca
cgtggcagca 660gggagaaacc ttcacctgtg tggtgatgca cgaggccctg
cacaaccact acacccagaa 720atccatcacc cagtcttcgg gtaaatagta atctaga
7576248PRTLama glama 6Asp Gln Glu Pro Lys Thr Pro Lys Pro Gln Pro
Gln Pro Gln Pro Gln1 5 10 15Pro Asn Pro Thr Thr Glu Ser Lys Cys Pro
Lys Cys Pro Ala Pro Glu 20 25 30Leu Leu Gly Gly Pro Ser Val Phe Ile
Phe Pro Pro Lys Pro Lys Asp 35 40 45Val Leu Ser Ile Ser Gly Arg Pro
Glu Val Thr Cys Val Val Val Asp 50 55 60Val Gly Gln Glu Asp Pro Glu
Val Ser Phe Asn Trp Tyr Ile Asp Gly65 70 75 80Ala Glu Val Arg Thr
Ala Asn Thr Arg Pro Lys Glu Glu Gln Phe Asn 85 90 95Ser Thr Tyr Arg
Val Val Ser Val Leu Pro Ile Gln His Gln Asp Trp 100 105 110Leu Thr
Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Ala Leu Pro 115 120
125Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Thr Arg Glu
130 135 140Pro Gln Val Tyr Thr Leu Ala Pro His Arg Glu Glu Leu Ala
Lys Asp145 150 155 160Thr Val Ser Val Thr Cys Leu Val Lys Gly Phe
Tyr Pro Pro Asp Ile 165 170 175Asn Val Glu Trp Gln Arg Asn Gly Gln
Pro Glu Ser Glu Gly Thr Tyr 180 185 190Ala Thr Thr Pro Pro Gln Leu
Asp Asn Asp Gly Thr Tyr Phe Leu Tyr 195 200 205Ser Lys Leu Ser Val
Gly Lys Asn Thr Trp Gln Gln Gly Glu Thr Phe 210 215 220Thr Cys Val
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys225 230 235
240Ser Ile Thr Gln Ser Ser Gly Lys 2457727DNALama glama 7tgatcaagcg
caccacagcg aagaccccag ctccaagtgt cccaaatgcc caggccctga 60actccttgga
gggcccacgg tcttcatctt ccccccgaaa gccaaggacg tcctctccat
120cacccgaaaa cctgaggtca cgtgcttgtg gtggacgtgg gtaaagaaga
ccctgagatc 180gagttcaagc tggtccgtgg atgacacaga ggtacacacg
gctgagacaa agccaaagga 240ggaacagttc aacagcacgt accgcgtggt
cagcgtcctg cccatccagc accaggactg 300gctgacgggg aaggaattca
agtgcaaggt caacaacaaa gctctcccag cccccatcga 360gaggaccatc
tccaaggcca aagggcagac ccgggagccg caggtgtaca ccctggcccc
420acaccgggaa gagctggcca aggacaccgt gagcgtaacc tgcctggtca
aaggcttctt 480cccagctgac atcaacgttg agtggcagag gaatgggcag
ccggagtcag agggcaccta 540cgccaacacg ccgccacagc tggacaacga
cgggacctac ttcctctaca gcaaactctc 600cgtgggaaag aacacgtggc
agcagggaga agtcttcacc tgtgtggtga tgcacgaggc 660tctacacaat
cactccaccc agaaatccat cacccagtct tcgggtaaat agtaatctag 720agggccc
7278236PRTLama glama 8Asp Gln Ala His His Ser Glu Asp Pro Ser Ser
Lys Cys Pro Lys Cys1 5 10 15Pro Gly Pro Glu Leu Leu Gly Gly Pro Thr
Val Phe Ile Phe Pro Pro 20 25 30Lys Ala Lys Asp Val Leu Ser Ile Thr
Arg Lys Pro Glu Val Thr Cys 35 40 45Leu Trp Trp Thr Trp Val Lys Lys
Thr Leu Arg Ser Ser Ser Ser Trp 50 55 60Ser Val Asp Asp Thr Glu Val
His Thr Ala Glu Thr Lys Pro Lys Glu65 70 75 80Glu Gln Phe Asn Ser
Thr Tyr Arg Val Val Ser Val Leu Pro Ile Gln 85 90 95His Gln Asp Trp
Leu Thr Gly Lys Glu Phe Lys Cys Lys Val Asn Asn 100 105 110Lys Ala
Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Ala Lys Gly 115 120
125Gln Thr Arg Glu Pro Gln Val Tyr Thr Leu Ala Pro His Arg Glu Glu
130 135 140Leu Ala Lys Asp Thr Val Ser Val Thr Cys Leu Val Lys Gly
Phe Phe145 150 155 160Pro Ala Asp Ile Asn Val Glu Trp Gln Arg Asn
Gly Gln Pro Glu Ser 165 170 175Glu Gly Thr Tyr Ala Asn Thr Pro Pro
Gln Leu Asp Asn Asp Gly Thr 180 185 190Tyr Phe Leu Tyr Ser Lys Leu
Ser Val Gly Lys Asn Thr Trp Gln Gln 195 200 205Gly Glu Val Phe Thr
Cys Val Val Met His Glu Ala Leu His Asn His 210 215 220Ser Thr Gln
Lys Ser Ile Thr Gln Ser Ser Gly Lys225 230 235954DNAHomo sapiens
9gatcaggagc ccaaatcttg tgacaaaact cacacatgcc caccgtgccc agca
541018PRTHomo sapiens 10Asp Gln Glu Pro Lys Ser Cys Asp Lys Thr His
Thr Cys Pro Pro Cys1 5 10 15Pro Ala1154DNAHomo sapiens 11gatctggagc
ccaaatcttg tgacaaaact cacacatgcc caccgtgccc agca 541218PRTHomo
sapiens 12Asp Leu Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro
Pro Cys1 5 10 15Pro Ala13327DNAHomo sapiens 13cctgaactcc tggggggacc
gtcagtcttc ctcttccccc caaaacccaa ggacaccctc 60atgatctccc ggacccctga
ggtcacatgc gtggtggtgg acgtgagcca cgaagaccct 120gaggtcaagt
tcaactggta cgtggacggc gtggaggtgc ataatgccaa gacaaagccg
180cgggaggagc agtacaacag cacgtaccgt gtggtcagcg tcctcaccgt
cctgcaccag 240gactggctga atggcaagga gtacaagtgc aaggtctcca
acaaagccct cccagccccc 300atcgagaaaa ccatctccaa agccaaa
32714109PRTHomo sapiens 14Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
Leu Phe Pro Pro Lys Pro1 5 10 15Lys Asp Thr Leu Met Ile Ser Arg Thr
Pro Glu Val Thr Cys Val Val 20 25 30Val Asp Val Ser His Glu Asp Pro
Glu Val Lys Phe Asn Trp Tyr Val 35 40 45Asp Gly Val Glu Val His Asn
Ala Lys Thr Lys Pro Arg Glu Glu Gln 50 55 60Tyr Asn Ser Thr Tyr Arg
Val Val Ser Val Leu Thr Val Leu His Gln65 70 75 80Asp Trp Leu Asn
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 85 90 95Leu Pro Ala
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 100 10515324DNAHomo sapiens
15gggcagcccc gagaaccaca ggtgtacacc ctgcccccat cccgggagga gatgaccaag
60aaccaggtca gcctgacctg cctggtcaaa ggcttctatc ccagcgacat cgccgtggag
120tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt
gctggactcc 180gacggctcct tcttcctcta tagcaagctc accgtggaca
agagcaggtg gcagcagggg 240aacgtcttct catgctccgt gatgcatgag
gctctgcaca accactacac gcagaagagc 300ctctccctgt ccccgggtaa atga
32416107PRTHomo sapiens 16Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
Leu Pro Pro Ser Arg Glu1 5 10 15Glu Met Thr Lys Asn Gln Val Ser Leu
Thr Cys Leu Val Lys Gly Phe 20 25 30Tyr Pro Ser Asp Ile Ala Val Glu
Trp Glu Ser Asn Gly Gln Pro Glu 35 40 45Asn Asn Tyr Lys Thr Thr Pro
Pro Val Leu Asp Ser Asp Gly Ser Phe 50 55 60Phe Leu Tyr Ser Lys Leu
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly65 70 75 80Asn Val Phe Ser
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 85 90 95Thr Gln Lys
Ser Leu Ser Leu Ser Pro Gly Lys 100 1051754DNAHomo sapiens
17gatcaggagc ccaaatcttc tgacaaaact cacacatccc caccgtcccc agca
541818PRTHomo sapiens 18Asp Gln Glu Pro Lys Ser Ser Asp Lys Thr His
Thr Ser Pro Pro Ser1 5 10 15Pro Ala19712DNAArtificial
SequenceDescription of Artificial Synthetic nucleotide sequence
19tgatcacccc aaatcttctg acaaaactca cacatctcca ccgtcctcag cacctgaact
60cctgggtgga ccgtcagtct tcctcttccc cccaaaaccc aaggacaccc tcatgatctc
120ccggacccct gaggtcacat gcgtggtggt ggacgtgagc cacgaagacc
ctgaggtcaa 180gttcaactgg tacgtggacg gcgtggaggt gcataatgcc
aagacaaagc cgcgggagga 240gcagtacaac agcacgtacc gtgtggtcag
cgtcctcacc gtcctgcacc aggactggct 300gaatggcaag gagtacaagt
gcaaggtctc caacaaagcc ctcccagccc ccatcgagaa 360aacaatctcc
aaagccaaag ggcagccccg agaaccacag gtgtacaccc tgcccccatc
420ccgggatgag ctgaccaaga accaggtcag cctgacctgc ctggtcaaag
gcttctatcc 480cagcgacatc gccgtggagt gggagagcaa tgggcagccg
gagaacaact acaagaccac 540gcctcccgtg ctggactccg acggctcctt
cttcctctac agcaagctca ccgtggacaa 600gagcaggtgg cagcagggga
acgtcttctc atgctccgtg atgcatgagg ctctgcacaa 660ccactacacg
cagaagagcc tctccctgtc tccgggtaaa tgataatcta ga
71220233PRTArtificial SequenceDescription of Artificial Synthetic
amino acid sequence 20Asp His Pro Lys Ser Ser Asp Lys Thr His Thr
Ser Pro Pro Ser Ser1 5 10 15Ala Pro Glu Leu Leu Gly Gly Pro Ser Val
Phe Leu Phe Pro Pro Lys 20 25 30Pro Lys Asp Thr Leu Met Ile Ser Arg
Thr Pro Glu Val Thr Cys Val 35 40 45Val Val Asp Val Ser His Glu Asp
Pro Glu Val Lys Phe Asn Trp Tyr 50 55 60Val Asp Gly Val Glu Val His
Asn Ala Lys Thr Lys Pro Arg Glu Glu65 70 75 80Gln Tyr Asn Ser Thr
Tyr Arg Val Val Ser Val Leu Thr Val Leu His 85 90 95Gln Asp Trp Leu
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 100 105 110Ala Leu
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln 115 120
125Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
130 135 140Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe
Tyr Pro145 150 155 160Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
Gln Pro Glu Asn Asn 165 170 175Tyr Lys Thr Thr Pro Pro Val Leu Asp
Ser Asp Gly Ser Phe Phe Leu 180 185 190Tyr Ser Lys Leu Thr Val Asp
Lys Ser Arg Trp Gln Gln Gly Asn Val 195 200 205Phe Ser Cys Ser Val
Met His Glu Ala Leu His Asn His Tyr Thr Gln 210 215 220Lys Ser Leu
Ser Leu Ser Pro Gly Lys225 230211527DNALama
glamamodified_base(843)..(843)n is a, c, g, or t 21aagcttgccg
ccatggattt tcaagtgcag attttcagct tcctgctaat cagtgcttca 60gtcataattg
ccagaggaca aattgttctc tcccagtctc cagcaatcct gtctgcatct
120ccaggggaga aggtcacaat gacttgcagg gccagctcaa gtgtaagtta
catgcactgg 180taccagcaga agccaggatc ctcccccaaa ccctggattt
atgccccatc caacctggct 240tctggagtcc ctgctcgctt cagtggcagt
gggtctggga cctcttactc tctcacaatc 300agcagagtgg aggctgaaga
tgctgccact tattactgcc agcagtggag ttttaaccca 360cccacgttcg
gtgctgggac caagctggag ctgaaagatg gcggtggctc gggcggtggt
420ggatctggag gaggtgggag ctctcaggct tatctacagc agtctggggc
tgagctggtg 480aggcctgggg cctcagtgaa gatgtcctgc aaggcttctg
gctacacatt taccagttac 540aatatgcact gggtaaagca gacacctaga
cagggcctgg aatggattgg agctatttat 600ccaggaaatg gtgatacttc
ctacaatcag aagttcaagg gcaaggccac actgactgta 660gacaaatcct
ccagcacagc ctacatgcag ctcagcagcc tgacatctga agactctgcg
720gtctatttct gtgcaagagt ggtgtactat agtaactctt actggtactt
cgatgtctgg 780ggcacaggga ccacggtcac cgtctcttct gatcaagaac
cacatggagg atgcacgtgc 840ccncagtgcc cncaatgccc ngcnccngaa
ctnccaggag gcccttctgt ctttgtcttc 900cccccgaaac ccaaggacgt
cctctccatt tttggaggcc gagtcacgtg cgttgtagtg 960gacgtcggaa
agaaagaccc cgaggtcaat ttcaactggt atattgatgg cgttgaggtg
1020cgaacggcca atacgaagcc aaaagaggaa cagttcaaca gcacgtaccg
cgtggtcagc
1080gtcctgccca tccagcacca ggactggctg acggggaagg aattcaagtg
caaggtcaac 1140aacaaagctc tcccggcccc catcgagagg accatctcca
aggccaaagg gcagacccgg 1200gagccgcagg tgtacaccct ggccccacac
cgggaagaac tggccaagga caccgtgagc 1260gtaacatgcc tggtcaaagg
cttctaccca gctgacatca acgttgagtg gcagaggaac 1320ggtcagccgg
agtcagaggg cacctacgcc aacacgccgc cacagctgga caacgacggg
1380acctacttcc tctacagcaa gctctcggtg ggaaagaaca cgtggcagcg
gggagaaacc 1440ttaacctgtg tggtgatgca tgaggccctg cacaaccact
acacccagaa atccatcacc 1500cagtcttcgg gtaaatagta atctaga
152722498PRTLama glama 22Met Asp Phe Gln Val Gln Ile Phe Ser Phe
Leu Leu Ile Ser Ala Ser1 5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val
Leu Ser Gln Ser Pro Ala Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys
Val Thr Met Thr Cys Arg Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His
Trp Tyr Gln Gln Lys Pro Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr
Ala Pro Ser Asn Leu Ala Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser
Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val
Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser
Phe Asn Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 115 120
125Asp Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser
130 135 140Gln Ala Tyr Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro
Gly Ala145 150 155 160Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr
Thr Phe Thr Ser Tyr 165 170 175Asn Met His Trp Val Lys Gln Thr Pro
Arg Gln Gly Leu Glu Trp Ile 180 185 190Gly Ala Ile Tyr Pro Gly Asn
Gly Asp Thr Ser Tyr Asn Gln Lys Phe 195 200 205Lys Gly Lys Ala Thr
Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 210 215 220Met Gln Leu
Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys225 230 235
240Ala Arg Val Val Tyr Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp
245 250 255Gly Thr Gly Thr Thr Val Thr Val Ser Ser Asp Gln Glu Pro
His Gly 260 265 270Gly Cys Thr Cys Pro Gln Cys Pro Ala Pro Glu Leu
Pro Gly Gly Pro 275 280 285Ser Val Phe Val Phe Pro Pro Lys Pro Lys
Asp Val Leu Ser Ile Phe 290 295 300Gly Gly Arg Val Thr Cys Val Val
Val Asp Val Gly Lys Lys Asp Pro305 310 315 320Glu Val Asn Phe Asn
Trp Tyr Ile Asp Gly Val Glu Val Arg Thr Ala 325 330 335Asn Thr Lys
Pro Lys Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val 340 345 350Ser
Val Leu Pro Ile Gln His Gln Asp Trp Leu Thr Gly Lys Glu Phe 355 360
365Lys Cys Lys Val Asn Asn Lys Ala Leu Pro Ala Pro Ile Glu Arg Thr
370 375 380Ile Ser Lys Ala Lys Gly Gln Thr Arg Glu Pro Gln Val Tyr
Thr Leu385 390 395 400Ala Pro His Arg Glu Glu Leu Ala Lys Asp Thr
Val Ser Val Thr Cys 405 410 415Leu Val Lys Gly Phe Tyr Pro Ala Asp
Ile Asn Val Glu Trp Gln Arg 420 425 430Asn Gly Gln Pro Glu Ser Glu
Gly Thr Tyr Ala Asn Thr Pro Pro Gln 435 440 445Leu Asp Asn Asp Gly
Thr Tyr Phe Leu Tyr Ser Lys Leu Ser Val Gly 450 455 460Lys Asn Thr
Trp Gln Arg Gly Glu Thr Leu Thr Cys Val Val Met His465 470 475
480Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Ile Thr Gln Ser Ser
485 490 495Gly Lys231566DNALama glama 23aagcttgccg ccatggattt
tcaagtgcag attttcagct tcctgctaat cagtgcttca 60gtcataattg ccagaggaca
aattgttctc tcccagtctc cagcaatcct gtctgcatct 120ccaggggaga
aggtcacaat gacttgcagg gccagctcaa gtgtaagtta catgcactgg
180taccagcaga agccaggatc ctcccccaaa ccctggattt atgccccatc
caacctggct 240tctggagtcc ctgctcgctt cagtggcagt gggtctggga
cctcttactc tctcacaatc 300agcagagtgg aggctgaaga tgctgccact
tattactgcc agcagtggag ttttaaccca 360cccacgttcg gtgctgggac
caagctggag ctgaaagatg gcggtggctc gggcggtggt 420ggatctggag
gaggtgggag ctctcaggct tatctacagc agtctggggc tgagctggtg
480aggcctgggg cctcagtgaa gatgtcctgc aaggcttctg gctacacatt
taccagttac 540aatatgcact gggtaaagca gacacctaga cagggcctgg
aatggattgg agctatttat 600ccaggaaatg gtgatacttc ctacaatcag
aagttcaagg gcaaggccac actgactgta 660gacaaatcct ccagcacagc
ctacatgcag ctcagcagcc tgacatctga agactctgcg 720gtctatttct
gtgcaagagt ggtgtactat agtaactctt actggtactt cgatgtctgg
780ggcacaggga ccacggtcac cgtctcttct gatcaagaac ccaagacacc
aaaaccacaa 840ccacaaccac aaccacaacc caatcctaca acagaatcca
agtgtcccaa atgtccagcc 900cctgagctcc tgggagggcc ctcagtcttc
atcttccccc cgaaacccaa ggacgtcctc 960tccatttctg ggaggcccga
ggtcacgtgc gttgtggtag acgtgggcca ggaagacccc 1020gaggtcagtt
tcaactggta cattgatggc gctgaggtgc gaacggccaa cacgaggcca
1080aaagaggaac agttcaacag cacgtaccgc gtggtcagcg tcctgcccat
ccagcaccag 1140gactggctga cggggaagga attcaagtgc aaggtcaaca
acaaagctct cccggccccc 1200atcgagaaga ccatctccaa ggccaaaggg
cagacccggg agccgcaggt gtacaccctg 1260gccccacacc gggaagagct
ggccaaggac accgtgagcg taacatgcct ggtcaaaggc 1320ttctacccac
ctgatatcaa cgttgagtgg cagaggaatg ggcagccgga gtcagagggc
1380acytacgcca ccacgccacc ccagctggac aacgacggga cctacttcct
ctacagcaag 1440ctctcggtgg gaaagaacac gtggcagcag ggagaaacct
tcacctgtgt ggtgatgcac 1500gaggccctgc acaaccacta cacccagaaa
tccatcaccc agtcttcggg taaatagtaa 1560tctaga 156624514PRTLama glama
24Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1
5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu Ser Gln Ser Pro Ala
Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg
Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro
Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala Pro Ser Asn Leu Ala
Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr
Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu Ala Glu Asp Ala Ala
Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe Asn Pro Pro Thr Phe
Gly Ala Gly Thr Lys Leu Glu Leu Lys 115 120 125Asp Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser 130 135 140Gln Ala Tyr
Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala145 150 155
160Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
165 170 175Asn Met His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Glu
Trp Ile 180 185 190Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr
Asn Gln Lys Phe 195 200 205Lys Gly Lys Ala Thr Leu Thr Val Asp Lys
Ser Ser Ser Thr Ala Tyr 210 215 220Met Gln Leu Ser Ser Leu Thr Ser
Glu Asp Ser Ala Val Tyr Phe Cys225 230 235 240Ala Arg Val Val Tyr
Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp 245 250 255Gly Thr Gly
Thr Thr Val Thr Val Ser Ser Asp Gln Glu Pro Lys Thr 260 265 270Pro
Lys Pro Gln Pro Gln Pro Gln Pro Gln Pro Asn Pro Thr Thr Glu 275 280
285Ser Lys Cys Pro Lys Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser
290 295 300Val Phe Ile Phe Pro Pro Lys Pro Lys Asp Val Leu Ser Ile
Ser Gly305 310 315 320Arg Pro Glu Val Thr Cys Val Val Val Asp Val
Gly Gln Glu Asp Pro 325 330 335Glu Val Ser Phe Asn Trp Tyr Ile Asp
Gly Ala Glu Val Arg Thr Ala 340 345 350Asn Thr Arg Pro Lys Glu Glu
Gln Phe Asn Ser Thr Tyr Arg Val Val 355 360 365Ser Val Leu Pro Ile
Gln His Gln Asp Trp Leu Thr Gly Lys Glu Phe 370 375 380Lys Cys Lys
Val Asn Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr385 390 395
400Ile Ser Lys Ala Lys Gly Gln Thr Arg Glu Pro Gln Val Tyr Thr Leu
405 410 415Ala Pro His Arg Glu Glu Leu Ala Lys Asp Thr Val Ser Val
Thr Cys 420 425 430Leu Val Lys Gly Phe Tyr Pro Pro Asp Ile Asn Val
Glu Trp Gln Arg 435 440 445Asn Gly Gln Pro Glu Ser Glu Gly Thr Tyr
Ala Thr Thr Pro Pro Gln 450 455 460Leu Asp Asn Asp Gly Thr Tyr Phe
Leu Tyr Ser Lys Leu Ser Val Gly465 470 475 480Lys Asn Thr Trp Gln
Gln Gly Glu Thr Phe Thr Cys Val Val Met His 485 490 495Glu Ala Leu
His Asn His Tyr Thr Gln Lys Ser Ile Thr Gln Ser Ser 500 505 510Gly
Lys251536DNALama glama 25aagcttgccg ccatggattt tcaagtgcag
attttcagct tcctgctaat cagtgcttca 60gtcataattg ccagaggaca aattgttctc
tcccagtctc cagcaatcct gtctgcatct 120ccaggggaga aggtcacaat
gacttgcagg gccagctcaa gtgtaagtta catgcactgg 180taccagcaga
agccaggatc ctcccccaaa ccctggattt atgccccatc caacctggct
240tctggagtcc ctgctcgctt cagtggcagt gggtctggga cctcttactc
tctcacaatc 300agcagagtgg aggctgaaga tgctgccact tattactgcc
agcagtggag ttttaaccca 360cccacgttcg gtgctgggac caagctggag
ctgaaagatg gcggtggctc gggcggtggt 420ggatctggag gaggtgggag
ctctcaggct tatctacagc agtctggggc tgagctggtg 480aggcctgggg
cctcagtgaa gatgtcctgc aaggcttctg gctacacatt taccagttac
540aatatgcact gggtaaagca gacacctaga cagggcctgg aatggattgg
agctatttat 600ccaggaaatg gtgatacttc ctacaatcag aagttcaagg
gcaaggccac actgactgta 660gacaaatcct ccagcacagc ctacatgcag
ctcagcagcc tgacatctga agactctgcg 720gtctatttct gtgcaagagt
ggtgtactat agtaactctt actggtactt cgatgtctgg 780ggcacaggga
ccacggtcac cgtctcttct gatcaagcga accacagcga agaccccagc
840tccaagtgtc ccaaatgccc aggccctgaa ctccttggag ggcccacggt
cttcatcttc 900cccccgaaag ccaaggacgt cctctccatc acccgaaaac
ctgaggtcac gtgcttgtgg 960tggacgtggg taaagaagac cctgagatcg
agttcaagct ggtccgtgga tgacacagag 1020gtacacacgg ctgagacaaa
gccaaaggag gaacagttca acagcacgta ccgcgtggtc 1080agcgtcctgc
ccatccagca ccaggactgg ctgacgggga aggaattcaa gtgcaaggtc
1140aacaacaaag ctctcccagc ccccatcgag aggaccatct ccaaggccaa
agggcagacc 1200cgggagccgc aggtgtacac cctggcccca caccgggaag
agctggccaa ggacaccgtg 1260agcgtaacct gcctggtcaa aggcttcttc
ccagctgaca tcaacgttga gtggcagagg 1320aatgggcagc cggagtcaga
gggcacctac gccaacacgc cgccacagct ggacaacgac 1380gggacctact
tcctctacag caaactctcc gtgggaaaga acacgtggca gcagggagaa
1440gtcttcacct gtgtggtgat gcacgaggct ctacacaatc actccaccca
gaaatccatc 1500acccagtctt cgggtaaata gtaatctaga gggccc
153626503PRTLama glama 26Met Asp Phe Gln Val Gln Ile Phe Ser Phe
Leu Leu Ile Ser Ala Ser1 5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val
Leu Ser Gln Ser Pro Ala Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys
Val Thr Met Thr Cys Arg Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His
Trp Tyr Gln Gln Lys Pro Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr
Ala Pro Ser Asn Leu Ala Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser
Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val
Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser
Phe Asn Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 115 120
125Asp Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser
130 135 140Gln Ala Tyr Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro
Gly Ala145 150 155 160Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr
Thr Phe Thr Ser Tyr 165 170 175Asn Met His Trp Val Lys Gln Thr Pro
Arg Gln Gly Leu Glu Trp Ile 180 185 190Gly Ala Ile Tyr Pro Gly Asn
Gly Asp Thr Ser Tyr Asn Gln Lys Phe 195 200 205Lys Gly Lys Ala Thr
Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 210 215 220Met Gln Leu
Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys225 230 235
240Ala Arg Val Val Tyr Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp
245 250 255Gly Thr Gly Thr Thr Val Thr Val Ser Ser Asp Gln Ala His
Ser His 260 265 270Ser Glu Asp Pro Ser Ser Lys Cys Pro Lys Cys Pro
Gly Pro Glu Leu 275 280 285Leu Gly Gly Pro Thr Val Phe Ile Phe Pro
Pro Lys Ala Lys Asp Val 290 295 300Leu Ser Ile Thr Arg Lys Pro Glu
Val Thr Cys Leu Trp Trp Thr Trp305 310 315 320Val Lys Lys Thr Leu
Arg Ser Ser Ser Ser Trp Ser Val Asp Asp Thr 325 330 335Glu Val His
Thr Ala Glu Thr Lys Pro Lys Glu Glu Gln Phe Asn Ser 340 345 350Thr
Tyr Arg Val Val Ser Val Leu Pro Ile Gln His Gln Asp Trp Leu 355 360
365Thr Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Ala Leu Pro Ala
370 375 380Pro Ile Glu Arg Thr Ile Ser Lys Ala Lys Gly Gln Thr Arg
Glu Pro385 390 395 400Gln Val Tyr Thr Leu Ala Pro His Arg Glu Glu
Leu Ala Lys Asp Thr 405 410 415Val Ser Val Thr Cys Leu Val Lys Gly
Phe Phe Pro Ala Asp Ile Asn 420 425 430Val Glu Trp Gln Arg Asn Gly
Gln Pro Glu Ser Glu Gly Thr Tyr Ala 435 440 445Asn Thr Pro Pro Gln
Leu Asp Asn Asp Gly Thr Tyr Phe Leu Tyr Ser 450 455 460Lys Leu Ser
Val Gly Lys Asn Thr Trp Gln Gln Gly Glu Val Phe Thr465 470 475
480Cys Val Val Met His Glu Ala Leu His Asn His Ser Thr Gln Lys Ser
485 490 495Ile Thr Gln Ser Ser Gly Lys 500271521DNAArtificial
sequenceDescription of Artificial Synthetic nucleotide sequence
27aagcttgccg ccatggattt tcaagtgcag attttcagct tcctgctaat cagtgcttca
60gtcataattg ccagaggaca aattgttctc tcccagtctc cagcaatcct gtctgcatct
120ccaggggaga aggtcacaat gacttgcagg gccagctcaa gtgtaagtta
catgcactgg 180taccagcaga agccaggatc ctcccccaaa ccctggattt
atgccccatc caacctggct 240tctggagtcc ctgctcgctt cagtggcagt
gggtctggga cctcttactc tctcacaatc 300agcagagtgg aggctgaaga
tgctgccact tattactgcc agcagtggag ttttaaccca 360cccacgttcg
gtgctgggac caagctggag ctgaaagatg gcggtggctc gggcggtggt
420ggatctggag gaggtgggag ctctcaggct tatctacagc agtctggggc
tgagctggtg 480aggcctgggg cctcagtgaa gatgtcctgc aaggcttctg
gctacacatt taccagttac 540aatatgcact gggtaaagca gacacctaga
cagggcctgg aatggattgg agctatttat 600ccaggaaatg gtgatacttc
ctacaatcag aagttcaagg gcaaggccac actgactgta 660gacaaatcct
ccagcacagc ctacatgcag ctcagcagcc tgacatctga agactctgcg
720gtctatttct gtgcaagagt ggtgtactat agtaactctt actggtactt
cgatgtctgg 780ggcacaggga ccacggtcac cgtctcttct gatcaggagc
ccaaatcttg tgacaaaact 840cacacatgcc caccgtgccc agcacctgaa
ctcctggggg gaccgtcagt cttcctcttc 900cccccaaaac ccaaggacac
cctcatgatc tcccggaccc ctgaggtcac atgcgtggtg 960gtggacgtga
gccacgaaga ccctgaggtc aagttcaact ggtacgtgga cggcgtggag
1020gtgcataatg ccaagacaaa gccgcgggag gagcagtaca acagcacgta
ccgtgtggtc 1080agcgtcctca ccgtcctgca ccaggactgg ctgaatggca
aggagtacaa gtgcaaggtc 1140tccaacaaag ccctcccagc ccccatcgag
aaaacaatct ccaaagccaa agggcagccc 1200cgagaaccac aggtgtacac
cctgccccca tcccgggatg agctgaccaa gaaccaggtc 1260agcctgacct
gcctggtcaa aggcttctat cccagcgaca tcgccgtgga gtgggagagc
1320aatgggcagc cggagaacaa ctacaagacc acgcctcccg tgctggactc
cgacggctcc 1380ttcttcctct acagcaagct caccgtggac aagagcaggt
ggcagcaggg gaacgtcttc 1440tcatgctccg tgatgcatga ggctctgcac
aaccactaca cgcagaagag cctctccctg 1500tctccgggta aatgatctag a
152128500PRTArtificial sequenceDescription of Artificial Synthetic
amino acid sequence 28Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu
Leu Ile Ser Ala Ser1 5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu
Ser Gln Ser Pro Ala Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val
Thr Met Thr Cys Arg Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp
Tyr Gln Gln Lys Pro Gly Ser Ser 50
55 60Pro Lys Pro Trp Ile Tyr Ala Pro Ser Asn Leu Ala Ser Gly Val
Pro65 70 75 80Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser
Leu Thr Ile 85 90 95Ser Arg Val Glu Ala Glu Asp Ala Ala Thr Tyr Tyr
Cys Gln Gln Trp 100 105 110Ser Phe Asn Pro Pro Thr Phe Gly Ala Gly
Thr Lys Leu Glu Leu Lys 115 120 125Asp Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Ser 130 135 140Gln Ala Tyr Leu Gln Gln
Ser Gly Ala Glu Leu Val Arg Pro Gly Ala145 150 155 160Ser Val Lys
Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 165 170 175Asn
Met His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Glu Trp Ile 180 185
190Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe
195 200 205Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr
Ala Tyr 210 215 220Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala
Val Tyr Phe Cys225 230 235 240Ala Arg Val Val Tyr Tyr Ser Asn Ser
Tyr Trp Tyr Phe Asp Val Trp 245 250 255Gly Thr Gly Thr Thr Val Thr
Val Ser Ser Asp Gln Glu Pro Lys Ser 260 265 270Cys Asp Lys Thr His
Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 275 280 285Gly Gly Pro
Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 290 295 300Met
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser305 310
315 320His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
Glu 325 330 335Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr
Asn Ser Thr 340 345 350Tyr Arg Val Val Ser Val Leu Thr Val Leu His
Gln Asp Trp Leu Asn 355 360 365Gly Lys Glu Tyr Lys Cys Lys Val Ser
Asn Lys Ala Leu Pro Ala Pro 370 375 380Ile Glu Lys Thr Ile Ser Lys
Ala Lys Gly Gln Pro Arg Glu Pro Gln385 390 395 400Val Tyr Thr Leu
Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val 405 410 415Ser Leu
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 420 425
430Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro
435 440 445Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
Leu Thr 450 455 460Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
Ser Cys Ser Val465 470 475 480Met His Glu Ala Leu His Asn His Tyr
Thr Gln Lys Ser Leu Ser Leu 485 490 495Ser Pro Gly Lys
50029162DNAArtificial sequenceDescription of Artificial Synthetic
nucleotide sequence 29gcggatcctt cgaacctgct cccatcctgg gccattacct
taatctcagt aaatggaatt 60tttgtgatat gctgcctgac ctactgcttt gccccaagat
gcagagagag aaggaggaat 120gagagattga gaagggaaag tgtacgccct
gtataaatcg at 1623051PRTArtificial sequenceDescription of
Artificial Synthetic amino acid sequence 30Ala Asp Pro Ser Asn Leu
Leu Pro Ser Trp Ala Ile Thr Leu Ile Ser1 5 10 15Val Asn Gly Ile Phe
Val Ile Cys Cys Leu Thr Tyr Cys Phe Ala Pro 20 25 30Arg Cys Arg Glu
Arg Arg Arg Asn Glu Arg Leu Arg Arg Glu Ser Val 35 40 45Arg Pro Val
5031399DNAArtificial sequenceDescription of Artificial Synthetic
nucleotide sequence 31aagcttatgg attttcaagt gcagattttc agcttcctgc
taatcagtgc ttcagtcata 60atgtccagag gagtcgacat tgttctgact cagtctccag
ccaccctgtc tgtgactcca 120ggagatagag tctctctttc ctgcagggcc
agccagagta ttagcgacta cttacactgg 180tatcaacaaa aatcacatga
gtctccaagg cttctcatca aatatgcttc ccattccatc 240tctgggatcc
cctccaggtt cagtggcagt ggatcagggt cagatttcac tctcagtatc
300aacagtgtgg aacctgaaga tgttggaatt tattactgtc aacatggtca
cagctttccg 360tggacgttcg gtggaggcac caagctggaa atcaaacgg
39932131PRTArtificial sequenceDescription of Artificial Synthetic
amino acid sequence 32Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu
Leu Ile Ser Ala Ser1 5 10 15Val Ile Met Ser Arg Gly Val Asp Ile Val
Leu Thr Gln Ser Pro Ala 20 25 30Thr Leu Ser Val Thr Pro Gly Asp Arg
Val Ser Leu Ser Cys Arg Ala 35 40 45Ser Gln Ser Ile Ser Asp Tyr Leu
His Trp Tyr Gln Gln Lys Ser His 50 55 60Glu Ser Pro Arg Leu Leu Ile
Lys Tyr Ala Ser His Ser Ile Ser Gly65 70 75 80Ile Pro Ser Arg Phe
Ser Gly Ser Gly Ser Gly Ser Asp Phe Thr Leu 85 90 95Ser Ile Asn Ser
Val Glu Pro Glu Asp Val Gly Ile Tyr Tyr Cys Gln 100 105 110His Gly
His Ser Phe Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu 115 120
125Ile Lys Arg 13033368DNAArtificial sequenceDescription of
Artificial Synthetic nucleotide sequence 33cagatccagt tggtgcaatc
tggacctgag ctgaagaagc ctggagagac agtcaggatc 60tcctgcaagg cttctgggta
tgccttcaca actactggaa tgcagtgggt gcaagagatg 120ccaggaaagg
gtttgaagtg gattggctgg ataaacaccc cactctggag tgccaaaata
180tgtagaagac ttcaaggacg gtttgccttc tctttggaaa cctctgccaa
cactgcatat 240ttacagataa gcaacctcaa agatgaggac acggctacgt
atttctgtgt gagatccggg 300aatggtaact atgacctggc ctactttgct
tactggggcc aagggacact ggtcactgtc 360tctgatca 36834121PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
34Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu1
5 10 15Thr Val Arg Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Thr
Thr 20 25 30Gly Met Gln Trp Val Gln Glu Met Pro Gly Lys Gly Leu Lys
Trp Ile 35 40 45Gly Trp Ile Asn Thr Pro Leu Trp Ser Ala Lys Ile Cys
Arg Arg Leu 50 55 60Gln Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala
Asn Thr Ala Tyr65 70 75 80Leu Gln Ile Ser Asn Leu Lys Asp Glu Asp
Thr Ala Thr Tyr Phe Cys 85 90 95Val Arg Ser Gly Asn Gly Asn Tyr Asp
Leu Ala Tyr Phe Ala Tyr Trp 100 105 110Gly Gln Gly Thr Leu Val Thr
Val Ser 115 12035812DNAArtificial sequenceDescription of Artificial
Synthetic nucleotide sequence 35aagcttatgg attttcaagt gcagattttc
agcttcctgc taatcagtgc ttcagtcata 60atgtccagag gagtcgacat tgttctgact
cagtctccag ccaccctgtc tgtgactcca 120ggagatagag tctctctttc
ctgcagggcc agccagagta ttagcgacta cttacactgg 180tatcaacaaa
aatcacatga gtctccaagg cttctcatca aatatgcttc ccattccatc
240tctgggatcc cctccaggtt cagtggcagt ggatcagggt cagatttcac
tctcagtatc 300aacagtgtgg aacctgaaga tgttggaatt tattactgtc
aacatggtca cagctttccg 360tggacgttcg gtggaggcac caagctggaa
atcaaacggg gtggcggtgg ctcgggcgga 420ggtgggtcgg gtggcggcgg
atctcagatc cagttggtgc aatctggacc tgagctgaag 480aagcctggag
agacagtcag gatctcctgc aaggcttctg ggtatgcctt cacaactact
540ggaatgcagt gggtgcaaga gatgccagga aagggtttga agtggattgg
ctggataaac 600accccactct ggagtgccaa aatatgtaga agacttcaag
gacggtttgc cttctctttg 660gaaacctctg ccaacactgc atatttacag
ataagcaacc tcaaagatga ggacacggct 720acgtatttct gtgtgagatc
cgggaatggt aactatgacc tggcctactt tgcttactgg 780ggccaaggga
cactggtcac tgtctctgat ca 81236267PRTArtificial sequenceDescription
of Artificial Synthetic amino acid sequence 36Met Asp Phe Gln Val
Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1 5 10 15Val Ile Met Ser
Arg Gly Val Asp Ile Val Leu Thr Gln Ser Pro Ala 20 25 30Thr Leu Ser
Val Thr Pro Gly Asp Arg Val Ser Leu Ser Cys Arg Ala 35 40 45Ser Gln
Ser Ile Ser Asp Tyr Leu His Trp Tyr Gln Gln Lys Ser His 50 55 60Glu
Ser Pro Arg Leu Leu Ile Lys Tyr Ala Ser His Ser Ile Ser Gly65 70 75
80Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Ser Asp Phe Thr Leu
85 90 95Ser Ile Asn Ser Val Glu Pro Glu Asp Val Gly Ile Tyr Tyr Cys
Gln 100 105 110His Gly His Ser Phe Pro Trp Thr Phe Gly Gly Gly Thr
Lys Leu Glu 115 120 125Ile Lys Arg Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly 130 135 140Gly Ser Gln Ile Gln Leu Val Gln Ser
Gly Pro Glu Leu Lys Lys Pro145 150 155 160Gly Glu Thr Val Arg Ile
Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr 165 170 175Thr Thr Gly Met
Gln Trp Val Gln Glu Met Pro Gly Lys Gly Leu Lys 180 185 190Trp Ile
Gly Trp Ile Asn Thr Pro Leu Trp Ser Ala Lys Ile Cys Arg 195 200
205Arg Leu Gln Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Asn Thr
210 215 220Ala Tyr Leu Gln Ile Ser Asn Leu Lys Asp Glu Asp Thr Ala
Thr Tyr225 230 235 240Phe Cys Val Arg Ser Gly Asn Gly Asn Tyr Asp
Leu Ala Tyr Phe Ala 245 250 255Tyr Trp Gly Gln Gly Thr Leu Val Thr
Val Ser 260 26537405DNAArtificial sequenceDescription of Artificial
Synthetic nucleotide sequence 37atggattttc aagtgcagat tttcagcttc
ctgctaatca gtgcttcagt cataatgtcc 60agaggagtcg acattgtgct cacccaatct
ccagcttctt tggctgtgtc tctaggtcag 120agagccacca tctcctgcag
agccagtgaa agtgttgaat attatgtcac aagtttaatg 180cagtggtacc
aacagaaacc aggacagcca cccaaactcc tcatctctgc tgcatccaac
240gtagaatctg gggtccctgc caggtttagt ggcagtgggt ctgggacaga
cttcagcctc 300aacatccatc ctgtggagga ggatgatatt gcaatgtatt
tctgtcagca aagtaggaag 360gttccttgga cgttcggtgg aggcaccaag
ctggaaatca aacgg 40538135PRTArtificial sequenceDescription of
Artificial Synthetic amino acid sequence 38Met Asp Phe Gln Val Gln
Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1 5 10 15Val Ile Met Ser Arg
Gly Val Asp Ile Val Leu Thr Gln Ser Pro Ala 20 25 30Ser Leu Ala Val
Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala 35 40 45Ser Glu Ser
Val Glu Tyr Tyr Val Thr Ser Leu Met Gln Trp Tyr Gln 50 55 60Gln Lys
Pro Gly Gln Pro Pro Lys Leu Leu Ile Ser Ala Ala Ser Asn65 70 75
80Val Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr
85 90 95Asp Phe Ser Leu Asn Ile His Pro Val Glu Glu Asp Asp Ile Ala
Met 100 105 110Tyr Phe Cys Gln Gln Ser Arg Lys Val Pro Trp Thr Phe
Gly Gly Gly 115 120 125Thr Lys Leu Glu Ile Lys Arg 130
13539369DNAArtificial sequenceDescription of Artificial Synthetic
nucleotide sequence 39caggtgcagc tgaaggagtc aggacctggc ctggtggcgc
cctcacagag cctgtccatc 60acatgcaccg tctcagggtt ctcattaacc ggctatggtg
taaactgggt tcgccagcct 120ccaggaaagg gtctggagtg gctgggaatg
atatggggtg atggaagcac agactataat 180tcagctctca aatccagact
gagcatcacc aaggacaact ccaagagcca agttttctta 240aaaatgaaca
gtctgcaaac tgatgacaca gccagatact actgtgccag agatggttat
300agtaactttc attactatgt tatggactac tggggtcaag gaacctcagt
caccgtctcc 360tcagatctg 36940121PRTArtificial sequenceDescription
of Artificial Synthetic amino acid sequence 40Gln Val Gln Leu Lys
Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln1 5 10 15Ser Leu Ser Ile
Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Gly Tyr 20 25 30Gly Val Asn
Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu 35 40 45Gly Met
Ile Trp Gly Asp Gly Ser Thr Asp Tyr Asn Ser Ala Leu Lys 50 55 60Ser
Arg Leu Ser Ile Thr Lys Asp Asn Ser Lys Ser Gln Val Phe Leu65 70 75
80Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Arg Tyr Tyr Cys Ala
85 90 95Arg Asp Gly Tyr Ser Asn Phe His Tyr Tyr Val Met Asp Tyr Trp
Gly 100 105 110Gln Gly Thr Ser Val Thr Val Ser Ser 115
12041825DNAArtificial sequenceDescription of Artificial Synthetic
nucleotide sequence 41aagcttatgg attttcaagt gcagattttc agcttcctgc
taatcagtgc ttcagtcata 60atgtccagag gagtcgacat tgtgctcacc caatctccag
cttctttggc tgtgtctcta 120ggtcagagag ccaccatctc ctgcagagcc
agtgaaagtg ttgaatatta tgtcacaagt 180ttaatgcagt ggtaccaaca
gaaaccagga cagccaccca aactcctcat ctctgctgca 240tccaacgtag
aatctggggt ccctgccagg tttagtggca gtgggtctgg gacagacttc
300agcctcaaca tccatcctgt ggaggaggat gatattgcaa tgtatttctg
tcagcaaagt 360aggaaggttc cttggacgtt cggtggaggc accaagctgg
aaatcaaacg gggtggcggt 420ggctcgggcg gaggtgggtc gggtggcggc
ggatctcagg tgcagctgaa ggagtcagga 480cctggcctgg tggcgccctc
acagagcctg tccatcacat gcaccgtctc agggttctca 540ttaaccggct
atggtgtaaa ctgggttcgc cagcctccag gaaagggtct ggagtggctg
600ggaatgatat ggggtgatgg aagcacagac tataattcag ctctcaaatc
cagactgagc 660atcaccaagg acaactccaa gagccaagtt ttcttaaaaa
tgaacagtct gcaaactgat 720gacacagcca gatactactg tgccagagat
ggttatagta actttcatta ctatgttatg 780gactactggg gtcaaggaac
ctcagtcacc gtctcctctg atcag 82542271PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
42Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1
5 10 15Val Ile Met Ser Arg Gly Val Asp Ile Val Leu Thr Gln Ser Pro
Ala 20 25 30Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys
Arg Ala 35 40 45Ser Glu Ser Val Glu Tyr Tyr Val Thr Ser Leu Met Gln
Trp Tyr Gln 50 55 60Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Ser
Ala Ala Ser Asn65 70 75 80Val Glu Ser Gly Val Pro Ala Arg Phe Ser
Gly Ser Gly Ser Gly Thr 85 90 95Asp Phe Ser Leu Asn Ile His Pro Val
Glu Glu Asp Asp Ile Ala Met 100 105 110Tyr Phe Cys Gln Gln Ser Arg
Lys Val Pro Trp Thr Phe Gly Gly Gly 115 120 125Thr Lys Leu Glu Ile
Lys Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly 130 135 140Ser Gly Gly
Gly Gly Ser Gln Val Gln Leu Lys Glu Ser Gly Pro Gly145 150 155
160Leu Val Ala Pro Ser Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly
165 170 175Phe Ser Leu Thr Gly Tyr Gly Val Asn Trp Val Arg Gln Pro
Pro Gly 180 185 190Lys Gly Leu Glu Trp Leu Gly Met Ile Trp Gly Asp
Gly Ser Thr Asp 195 200 205Tyr Asn Ser Ala Leu Lys Ser Arg Leu Ser
Ile Thr Lys Asp Asn Ser 210 215 220Lys Ser Gln Val Phe Leu Lys Met
Asn Ser Leu Gln Thr Asp Asp Thr225 230 235 240Ala Arg Tyr Tyr Cys
Ala Arg Asp Gly Tyr Ser Asn Phe His Tyr Tyr 245 250 255Val Met Asp
Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser 260 265
27043393DNAArtificial sequenceDescription of Artificial Synthetic
nucleotide sequence 43atggattttc aagtgcagat tttcagcttc ctgctaatca
gtgcttcagt cataatgtcc 60agaggagtcg acatccagat gacacagtct ccatcctcac
tgtctgcatc tctgggaggc 120aaagtcacca tcacttgcaa ggcaagccaa
gacattaaga agtatatagg ttggtaccaa 180cacaagcctg gaaaaggtcc
caggctgctc atatattaca catctacatt acagccaggc 240atcccatcaa
ggttcagtgg aagtgggtct gggagagatt attccctcag catcagaaac
300ctggagcctg aagatattgc aacttattat tgtcaacagt atgataatct
tccattgacg 360ttcggctcgg ggacaaagtt ggaaataaaa cgg
39344131PRTArtificial sequenceDescription of Artificial Synthetic
amino acid sequence 44Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu
Leu Ile Ser Ala Ser1 5 10 15Val Ile Met Ser Arg Gly Val Asp Ile Gln
Met Thr Gln Ser Pro Ser 20 25 30Ser Leu Ser Ala Ser Leu Gly Gly Lys
Val Thr Ile Thr Cys Lys Ala 35 40 45Ser Gln Asp Ile Lys Lys Tyr Ile
Gly Trp Tyr Gln His Lys Pro Gly 50 55 60Lys Gly Pro Arg Leu Leu Ile
Tyr Tyr Thr Ser Thr Leu Gln Pro Gly65 70 75
80Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Arg Asp Tyr Ser Leu
85 90 95Ser Ile Arg Asn Leu Glu Pro Glu Asp Ile Ala Thr Tyr Tyr Cys
Gln 100 105 110Gln Tyr Asp Asn Leu Pro Leu Thr Phe Gly Ser Gly Thr
Lys Leu Glu 115 120 125Ile Lys Arg 13045362DNAArtificial
sequenceDescription of Artificial Synthetic nucleotide sequence
45gatgtacagc ttcaggagtc aggacctggc ctcgtgaaac cttctcagtc tctgtctctc
60acctgctctg tcactggcta ctccatcacc agtggtttct actggaactg gatccgacag
120tttccgggaa acaaactgga atggatgggc cacataagcc acgacggtag
gaataactac 180aacccatctc tcataaatcg aatctccatc actcgtgaca
catctaagaa ccagtttttc 240ctgaagttga gttctgtgac tactgaggac
acagctacat atttctgtgc aagacactac 300ggtagtagcg gagctatgga
ctactggggt caaggaacct cagtcaccgt ctcctctgat 360ca
36246119PRTArtificial sequenceDescription of Artificial Synthetic
amino acid sequence 46Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu
Val Lys Pro Ser Gln1 5 10 15Ser Leu Ser Leu Thr Cys Ser Val Thr Gly
Tyr Ser Ile Thr Ser Gly 20 25 30Phe Tyr Trp Asn Trp Ile Arg Gln Phe
Pro Gly Asn Lys Leu Glu Trp 35 40 45Met Gly His Ile Ser His Asp Gly
Arg Asn Asn Tyr Asn Pro Ser Leu 50 55 60Ile Asn Arg Ile Ser Ile Thr
Arg Asp Thr Ser Lys Asn Gln Phe Phe65 70 75 80Leu Lys Leu Ser Ser
Val Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95Ala Arg His Tyr
Gly Ser Ser Gly Ala Met Asp Tyr Trp Gly Gln Gly 100 105 110Thr Ser
Val Thr Val Ser Ser 11547806DNAArtificial sequenceDescription of
Artificial Synthetic nucleotide sequence 47aagcttatgg attttcaagt
gcagattttc agcttcctgc taatcagtgc ttcagtcata 60atgtccagag gagtcgacat
ccagatgaca cagtctccat cctcactgtc tgcatctctg 120ggaggcaaag
tcaccatcac ttgcaaggca agccaagaca ttaagaagta tataggttgg
180taccaacaca agcctggaaa aggtcccagg ctgctcatat attacacatc
tacattacag 240ccaggcatcc catcaaggtt cagtggaagt gggtctggga
gagattattc cctcagcatc 300agaaacctgg agcctgaaga tattgcaact
tattattgtc aacagtatga taatcttcca 360ttgacgttcg gctcggggac
aaagttggaa ataaaacggg gtggcggtgg ctcgggcggt 420ggtgggtcgg
gtggcggcgg atctgatgta cagcttcagg agtcaggacc tggcctcgtg
480aaaccttctc agtctctgtc tctcacctgc tctgtcactg gctactccat
caccagtggt 540ttctactgga actggatccg acagtttccg ggaaacaaac
tggaatggat gggccacata 600agccacgacg gtaggaataa ctacaaccca
tctctcataa atcgaatctc catcactcgt 660gacacatcta agaaccagtt
tttcctgaag ttgagttctg tgactactga ggacacagct 720acatatttct
gtgcaagaca ctacggtagt agcggagcta tggactactg gggtcaagga
780acctcagtca ccgtctcctc tgatca 80648266PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
48Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1
5 10 15Val Ile Met Ser Arg Gly Val Asp Ile Gln Met Thr Gln Ser Pro
Ser 20 25 30Ser Leu Ser Ala Ser Leu Gly Gly Lys Val Thr Ile Thr Cys
Lys Ala 35 40 45Ser Gln Asp Ile Lys Lys Tyr Ile Gly Trp Tyr Gln His
Lys Pro Gly 50 55 60Lys Gly Pro Arg Leu Leu Ile Tyr Tyr Thr Ser Thr
Leu Gln Pro Gly65 70 75 80Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser
Gly Arg Asp Tyr Ser Leu 85 90 95Ser Ile Arg Asn Leu Glu Pro Glu Asp
Ile Ala Thr Tyr Tyr Cys Gln 100 105 110Gln Tyr Asp Asn Leu Pro Leu
Thr Phe Gly Ser Gly Thr Lys Leu Glu 115 120 125Ile Lys Arg Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 130 135 140Gly Ser Asp
Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro145 150 155
160Ser Gln Ser Leu Ser Leu Thr Cys Ser Val Thr Gly Tyr Ser Ile Thr
165 170 175Ser Gly Phe Tyr Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn
Lys Leu 180 185 190Glu Trp Met Gly His Ile Ser His Asp Gly Arg Asn
Asn Tyr Asn Pro 195 200 205Ser Leu Ile Asn Arg Ile Ser Ile Thr Arg
Asp Thr Ser Lys Asn Gln 210 215 220Phe Phe Leu Lys Leu Ser Ser Val
Thr Thr Glu Asp Thr Ala Thr Tyr225 230 235 240Phe Cys Ala Arg His
Tyr Gly Ser Ser Gly Ala Met Asp Tyr Trp Gly 245 250 255Gln Gly Thr
Ser Val Thr Val Ser Ser Asp 260 265491671DNAArtificial
sequenceDescription of Artificial Synthetic nucleotide sequence
49aagcttatgg attttcaagt gcagattttc agcttcctgc taatcagtgc ttcagtcata
60atgtccagag gagtcgacat tgttctgact cagtctccag ccaccctgtc tgtgactcca
120ggagatagag tctctctttc ctgcagggcc agccagagta ttagcgacta
cttacactgg 180tatcaacaaa aatcacatga gtctccaagg cttctcatca
aatatgcttc ccattccatc 240tctgggatcc cctccaggtt cagtggcagt
ggatcagggt cagatttcac tctcagtatc 300aacagtgtgg aacctgaaga
tgttggaatt tattactgtc aacatggtca cagctttccg 360tggacgttcg
gtggaggcac caagctggaa atcaaacggg gtggcggtgg ctcgggcgga
420ggtgggtcgg gtggcggcgg atctcagatc cagttggtgc aatctggacc
tgagctgaag 480aagcctggag agacagtcag gatctcctgc aaggcttctg
ggtatgcctt cacaactact 540ggaatgcagt gggtgcaaga gatgccagga
aagggtttga agtggattgg ctggataaac 600accccactct ggagtgccaa
aatatgtaga agacttcaag gacggtttgc cttctctttg 660gaaacctctg
ccaacactgc atatttacag ataagcaacc tcaaagatga ggacacggct
720acgtatttct gtgtgagatc cgggaatggt aactatgacc tggcctactt
tgcttactgg 780ggccaaggga cactggtcac tgtctctgat ctggagccca
aatcttctga caaaactcac 840acatccccac cgtccccagc acctgaactc
ctggggggat cgtcagtctt cctcttcccc 900ccaaaaccca aggacaccct
catgatctcc cggacccctg aggtcacatg cgtggtggtg 960gacgtgagcc
acgaagaccc tgaggtcaag ttcaactggt acgtggacgg cgtggaggtg
1020cataatgcca agacaaagcc gcgggaggag cagtacaaca gcacgtaccg
tgtggtcagc 1080gtcctcaccg tcctgcacca ggactggctg aatggcaagg
agtacaagtg caaggtctcc 1140aacaaagccc tcccagcccc catcgagaaa
accatctcca aagccaaagg gcagccccga 1200gaaccacagg tgtacaccct
gcccccatcc cgggatgagc tgaccaagaa ccaggtcagc 1260ctgacctgcc
tggtcaaagg cttctatccc agcgacatcg ccgtggagtg ggagagcaat
1320gggcagccgg agaacaacta caagaccacg cctcccgtgc tggactccga
cggctccttc 1380ttcctctaca gcaagctcac cgtggacaag agcaggtggc
agcaggggaa cgtcttctca 1440tgctccgtga tgcatgaggc tctgcacaac
cactacacgc agaagagcct ctccctgtct 1500ccgggtaaag cggatccttc
gaacctgctc ccatcctggg ccattacctt aatctcagta 1560aatggaattt
ttgtgatatg ctgcctgacc tactgctttg ccccaagatg cagagagaga
1620aggaggaatg agagattgag aagggaaagt gtacgccctg tataaatcga t
167150552PRTArtificial sequenceDescription of Artificial Synthetic
amino acid sequence 50Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu
Leu Ile Ser Ala Ser1 5 10 15Val Ile Met Ser Arg Gly Val Asp Ile Val
Leu Thr Gln Ser Pro Ala 20 25 30Thr Leu Ser Val Thr Pro Gly Asp Arg
Val Ser Leu Ser Cys Arg Ala 35 40 45Ser Gln Ser Ile Ser Asp Tyr Leu
His Trp Tyr Gln Gln Lys Ser His 50 55 60Glu Ser Pro Arg Leu Leu Ile
Lys Tyr Ala Ser His Ser Ile Ser Gly65 70 75 80Ile Pro Ser Arg Phe
Ser Gly Ser Gly Ser Gly Ser Asp Phe Thr Leu 85 90 95Ser Ile Asn Ser
Val Glu Pro Glu Asp Val Gly Ile Tyr Tyr Cys Gln 100 105 110His Gly
His Ser Phe Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu 115 120
125Ile Lys Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
130 135 140Gly Ser Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys
Lys Pro145 150 155 160Gly Glu Thr Val Arg Ile Ser Cys Lys Ala Ser
Gly Tyr Ala Phe Thr 165 170 175Thr Thr Gly Met Gln Trp Val Gln Glu
Met Pro Gly Lys Gly Leu Lys 180 185 190Trp Ile Gly Trp Ile Asn Thr
Pro Leu Trp Ser Ala Lys Ile Cys Arg 195 200 205Arg Leu Gln Gly Arg
Phe Ala Phe Ser Leu Glu Thr Ser Ala Asn Thr 210 215 220Ala Tyr Leu
Gln Ile Ser Asn Leu Lys Asp Glu Asp Thr Ala Thr Tyr225 230 235
240Phe Cys Val Arg Ser Gly Asn Gly Asn Tyr Asp Leu Ala Tyr Phe Ala
245 250 255Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Asp Leu Glu
Pro Lys 260 265 270Ser Ser Asp Lys Thr His Thr Ser Pro Pro Ser Pro
Ala Pro Glu Leu 275 280 285Leu Gly Gly Ser Ser Val Phe Leu Phe Pro
Pro Lys Pro Lys Asp Thr 290 295 300Leu Met Ile Ser Arg Thr Pro Glu
Val Thr Cys Val Val Val Asp Val305 310 315 320Ser His Glu Asp Pro
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 325 330 335Glu Val His
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser 340 345 350Thr
Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 355 360
365Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
370 375 380Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
Glu Pro385 390 395 400Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
Leu Thr Lys Asn Gln 405 410 415Val Ser Leu Thr Cys Leu Val Lys Gly
Phe Tyr Pro Ser Asp Ile Ala 420 425 430Val Glu Trp Glu Ser Asn Gly
Gln Pro Glu Asn Asn Tyr Lys Thr Thr 435 440 445Pro Pro Val Leu Asp
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 450 455 460Thr Val Asp
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser465 470 475
480Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
485 490 495Leu Ser Pro Gly Lys Ala Asp Pro Ser Asn Leu Leu Pro Ser
Trp Ala 500 505 510Ile Thr Leu Ile Ser Val Asn Gly Ile Phe Val Ile
Cys Cys Leu Thr 515 520 525Tyr Cys Phe Ala Pro Arg Cys Arg Glu Arg
Arg Arg Asn Glu Arg Leu 530 535 540Arg Arg Glu Ser Val Arg Pro
Val545 550511683DNAArtificial sequenceDescription of Artificial
Synthetic nucleotide sequence 51aagcttatgg attttcaagt gcagattttc
agcttcctgc taatcagtgc ttcagtcata 60atgtccagag gagtcgacat tgtgctcacc
caatctccag cttctttggc tgtgtctcta 120ggtcagagag ccaccatctc
ctgcagagcc agtgaaagtg ttgaatatta tgtcacaagt 180ttaatgcagt
ggtaccaaca gaaaccagga cagccaccca aactcctcat ctctgctgca
240tccaacgtag aatctggggt ccctgccagg tttagtggca gtgggtctgg
gacagacttc 300agcctcaaca tccatcctgt ggaggaggat gatattgcaa
tgtatttctg tcagcaaagt 360aggaaggttc cttggacgtt cggtggaggc
accaagctgg aaatcaaacg gggtggcggt 420ggctcgggcg gaggtgggtc
gggtggcggc ggatctcagg tgcagctgaa ggagtcagga 480cctggcctgg
tggcgccctc acagagcctg tccatcacat gcaccgtctc agggttctca
540ttaaccggct atggtgtaaa ctgggttcgc cagcctccag gaaagggtct
ggagtggctg 600ggaatgatat ggggtgatgg aagcacagac tataattcag
ctctcaaatc cagactgagc 660atcaccaagg acaactccaa gagccaagtt
ttcttaaaaa tgaacagtct gcaaactgat 720gacacagcca gatactactg
tgccagagat ggttatagta actttcatta ctatgttatg 780gactactggg
gtcaaggaac ctcagtcacc gtctcctcag atctggagcc caaatcttct
840gacaaaactc acacatcccc accgtcccca gcacctgaac tcctgggggg
atcgtcagtc 900ttcctcttcc ccccaaaacc caaggacacc ctcatgatct
cccggacccc tgaggtcaca 960tgcgtggtgg tggacgtgag ccacgaagac
cctgaggtca agttcaactg gtacgtggac 1020ggcgtggagg tgcataatgc
caagacaaag ccgcgggagg agcagtacaa cagcacgtac 1080cgtgtggtca
gcgtcctcac cgtcctgcac caggactggc tgaatggcaa ggagtacaag
1140tgcaaggtct ccaacaaagc cctcccagcc cccatcgaga aaaccatctc
caaagccaaa 1200gggcagcccc gagaaccaca ggtgtacacc ctgcccccat
cccgggatga gctgaccaag 1260aaccaggtca gcctgacctg cctggtcaaa
ggcttctatc ccagcgacat cgccgtggag 1320tgggagagca atgggcagcc
ggagaacaac tacaagacca cgcctcccgt gctggactcc 1380gacggctcct
tcttcctcta cagcaagctc accgtggaca agagcaggtg gcagcagggg
1440aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacac
gcagaagagc 1500ctctccctgt ctccgggtaa agcggatcct tcgaacctgc
tcccatcctg ggccattacc 1560ttaatctcag taaatggaat ttttgtgata
tgctgcctga cctactgctt tgccccaaga 1620tgcagagaga gaaggaggaa
tgagagattg agaagggaaa gtgtacgccc tgtataaatc 1680gat
168352556PRTArtificial sequenceDescription of Artificial Synthetic
amino acid sequence 52Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu
Leu Ile Ser Ala Ser1 5 10 15Val Ile Met Ser Arg Gly Val Asp Ile Val
Leu Thr Gln Ser Pro Ala 20 25 30Ser Leu Ala Val Ser Leu Gly Gln Arg
Ala Thr Ile Ser Cys Arg Ala 35 40 45Ser Glu Ser Val Glu Tyr Tyr Val
Thr Ser Leu Met Gln Trp Tyr Gln 50 55 60Gln Lys Pro Gly Gln Pro Pro
Lys Leu Leu Ile Ser Ala Ala Ser Asn65 70 75 80Val Glu Ser Gly Val
Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr 85 90 95Asp Phe Ser Leu
Asn Ile His Pro Val Glu Glu Asp Asp Ile Ala Met 100 105 110Tyr Phe
Cys Gln Gln Ser Arg Lys Val Pro Trp Thr Phe Gly Gly Gly 115 120
125Thr Lys Leu Glu Ile Lys Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly
130 135 140Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Lys Glu Ser Gly
Pro Gly145 150 155 160Leu Val Ala Pro Ser Gln Ser Leu Ser Ile Thr
Cys Thr Val Ser Gly 165 170 175Phe Ser Leu Thr Gly Tyr Gly Val Asn
Trp Val Arg Gln Pro Pro Gly 180 185 190Lys Gly Leu Glu Trp Leu Gly
Met Ile Trp Gly Asp Gly Ser Thr Asp 195 200 205Tyr Asn Ser Ala Leu
Lys Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser 210 215 220Lys Ser Gln
Val Phe Leu Lys Met Asn Ser Leu Gln Thr Asp Asp Thr225 230 235
240Ala Arg Tyr Tyr Cys Ala Arg Asp Gly Tyr Ser Asn Phe His Tyr Tyr
245 250 255Val Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser
Ser Asp 260 265 270Leu Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser
Pro Pro Ser Pro 275 280 285Ala Pro Glu Leu Leu Gly Gly Ser Ser Val
Phe Leu Phe Pro Pro Lys 290 295 300Pro Lys Asp Thr Leu Met Ile Ser
Arg Thr Pro Glu Val Thr Cys Val305 310 315 320Val Val Asp Val Ser
His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 325 330 335Val Asp Gly
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 340 345 350Gln
Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 355 360
365Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
370 375 380Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys
Gly Gln385 390 395 400Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
Ser Arg Asp Glu Leu 405 410 415Thr Lys Asn Gln Val Ser Leu Thr Cys
Leu Val Lys Gly Phe Tyr Pro 420 425 430Ser Asp Ile Ala Val Glu Trp
Glu Ser Asn Gly Gln Pro Glu Asn Asn 435 440 445Tyr Lys Thr Thr Pro
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 450 455 460Tyr Ser Lys
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val465 470 475
480Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
485 490 495Lys Ser Leu Ser Leu Ser Pro Gly Lys Ala Asp Pro Ser Asn
Leu Leu 500 505 510Pro Ser Trp Ala Ile Thr Leu Ile Ser Val Asn Gly
Ile Phe Val Ile 515 520 525Cys Cys Leu Thr Tyr Cys Phe Ala Pro Arg
Cys Arg Glu Arg Arg Arg 530 535 540Asn Glu Arg Leu Arg Arg Glu Ser
Val Arg Pro Val545 550 555531665DNAArtificial sequenceDescription
of Artificial Synthetic nucleotide sequence 53aagcttatgg attttcaagt
gcagattttc agcttcctgc taatcagtgc ttcagtcata 60atgtccagag gagtcgacat
ccagatgaca cagtctccat cctcactgtc tgcatctctg 120ggaggcaaag
tcaccatcac ttgcaaggca agccaagaca ttaagaagta tataggttgg
180taccaacaca agcctggaaa aggtcccagg ctgctcatat attacacatc
tacattacag 240ccaggcatcc catcaaggtt cagtggaagt gggtctggga
gagattattc cctcagcatc 300agaaacctgg agcctgaaga tattgcaact
tattattgtc aacagtatga taatcttcca 360ttgacgttcg gctcggggac
aaagttggaa ataaaacggg gtggcggtgg ctcgggcggt 420ggtgggtcgg
gtggcggcgg atctgatgta cagcttcagg agtcaggacc tggcctcgtg
480aaaccttctc agtctctgtc tctcacctgc tctgtcactg gctactccat
caccagtggt 540ttctactgga actggatccg acagtttccg ggaaacaaac
tggaatggat gggccacata 600agccacgacg gtaggaataa ctacaaccca
tctctcataa atcgaatctc catcactcgt 660gacacatcta agaaccagtt
tttcctgaag ttgagttctg tgactactga ggacacagct 720acatatttct
gtgcaagaca ctacggtagt agcggagcta tggactactg gggtcaagga
780acctcagtca ccgtctcctc tgatctggag cccaaatctt ctgacaaaac
tcacacatcc 840ccaccgtccc cagcacctga actcctgggg ggatcgtcag
tcttcctctt ccccccaaaa 900cccaaggaca ccctcatgat ctcccggacc
cctgaggtca catgcgtggt ggtggacgtg 960agccacgaag accctgaggt
caagttcaac tggtacgtgg acggcgtgga ggtgcataat 1020gccaagacaa
agccgcggga ggagcagtac aacagcacgt accgtgtggt cagcgtcctc
1080accgtcctgc accaggactg gctgaatggc aaggagtaca agtgcaaggt
ctccaacaaa 1140gccctcccag cccccatcga gaaaaccatc tccaaagcca
aagggcagcc ccgagaacca 1200caggtgtaca ccctgccccc atcccgggat
gagctgacca agaaccaggt cagcctgacc 1260tgcctggtca aaggcttcta
tcccagcgac atcgccgtgg agtgggagag caatgggcag 1320ccggagaaca
actacaagac cacgcctccc gtgctggact ccgacggctc cttcttcctc
1380tacagcaagc tcaccgtgga caagagcagg tggcagcagg ggaacgtctt
ctcatgctcc 1440gtgatgcatg aggctctgca caaccactac acgcagaaga
gcctctccct gtctccgggt 1500aaagcggatc cttcgaacct gctcccatcc
tgggccatta ccttaatctc agtaaatgga 1560atttttgtga tatgctgcct
gacctactgc tttgccccaa gatgcagaga gagaaggagg 1620aatgagagat
tgagaaggga aagtgtacgc cctgtataaa tcgat 166554550PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
54Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1
5 10 15Val Ile Met Ser Arg Gly Val Asp Ile Gln Met Thr Gln Ser Pro
Ser 20 25 30Ser Leu Ser Ala Ser Leu Gly Gly Lys Val Thr Ile Thr Cys
Lys Ala 35 40 45Ser Gln Asp Ile Lys Lys Tyr Ile Gly Trp Tyr Gln His
Lys Pro Gly 50 55 60Lys Gly Pro Arg Leu Leu Ile Tyr Tyr Thr Ser Thr
Leu Gln Pro Gly65 70 75 80Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser
Gly Arg Asp Tyr Ser Leu 85 90 95Ser Ile Arg Asn Leu Glu Pro Glu Asp
Ile Ala Thr Tyr Tyr Cys Gln 100 105 110Gln Tyr Asp Asn Leu Pro Leu
Thr Phe Gly Ser Gly Thr Lys Leu Glu 115 120 125Ile Lys Arg Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 130 135 140Gly Ser Asp
Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro145 150 155
160Ser Gln Ser Leu Ser Leu Thr Cys Ser Val Thr Gly Tyr Ser Ile Thr
165 170 175Ser Gly Phe Tyr Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn
Lys Leu 180 185 190Glu Trp Met Gly His Ile Ser His Asp Gly Arg Asn
Asn Tyr Asn Pro 195 200 205Ser Leu Ile Asn Arg Ile Ser Ile Thr Arg
Asp Thr Ser Lys Asn Gln 210 215 220Phe Phe Leu Lys Leu Ser Ser Val
Thr Thr Glu Asp Thr Ala Thr Tyr225 230 235 240Phe Cys Ala Arg His
Tyr Gly Ser Ser Gly Ala Met Asp Tyr Trp Gly 245 250 255Gln Gly Thr
Ser Val Thr Val Ser Ser Asp Leu Glu Pro Lys Ser Ser 260 265 270Asp
Lys Thr His Thr Ser Pro Pro Ser Pro Ala Pro Glu Leu Leu Gly 275 280
285Gly Ser Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
290 295 300Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
Ser His305 310 315 320Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
Asp Gly Val Glu Val 325 330 335His Asn Ala Lys Thr Lys Pro Arg Glu
Glu Gln Tyr Asn Ser Thr Tyr 340 345 350Arg Val Val Ser Val Leu Thr
Val Leu His Gln Asp Trp Leu Asn Gly 355 360 365Lys Glu Tyr Lys Cys
Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 370 375 380Glu Lys Thr
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val385 390 395
400Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
405 410 415Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
Val Glu 420 425 430Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
Thr Thr Pro Pro 435 440 445Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
Tyr Ser Lys Leu Thr Val 450 455 460Asp Lys Ser Arg Trp Gln Gln Gly
Asn Val Phe Ser Cys Ser Val Met465 470 475 480His Glu Ala Leu His
Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 485 490 495Pro Gly Lys
Ala Asp Pro Ser Asn Leu Leu Pro Ser Trp Ala Ile Thr 500 505 510Leu
Ile Ser Val Asn Gly Ile Phe Val Ile Cys Cys Leu Thr Tyr Cys 515 520
525Phe Ala Pro Arg Cys Arg Glu Arg Arg Arg Asn Glu Arg Leu Arg Arg
530 535 540Glu Ser Val Arg Pro Val545 550551653DNAArtificial
sequenceDescription of Artificial Synthetic nucleotide sequence
55atgttgtata catctcagct ccttgggctt ttactcttct ggatttcagc ctccagaagt
60gacatagtgc tgactcagac tccagccact ctgtctctaa ttcctggaga aagagtcaca
120atgacctgta agaccagtca gaatattggc acaatcttac actggtatca
ccaaaaacca 180aaggaggctc caagggctct catcaagtat gcttcgcagt
ccattcctgg gatcccctcc 240agattcagtg gcagtggttc ggaaacagat
ttcactctca gcatcaataa cctggagcct 300gatgatatcg gaatttatta
ctgtcaacaa agtagaagct ggcctgtcac gttcggtcct 360ggcaccaagc
tggagataaa acggggtggc ggtggctcgg gcggaggtgg gtcgggtggc
420ggcggatctc aggtcaagct gcagcagtcc ggttctgaac tagggaaacc
tggggcctca 480gtgaaactgt cctgcaagac ttcaggctac atattcacag
atcactatat ttcttgggtg 540aaacagaagc ctggagaaag cctgcagtgg
ataggaaatg tttatggtgg aaatggtggt 600acaagctaca atcaaaaatt
ccagggcaag gccacactga ctgtagataa aatctctagc 660acagcctaca
tggaactcag cagcctgaca tctgaggatt ctgccatcta ttactgtgca
720agaaggccgg tagcgacggg ccatgctatg gactactggg gtcaggggat
ccaagttacc 780gtctcctctg atctggagcc caaatcttct gacaaaactc
acacatcccc accgtcccca 840gcacctgaac tcctgggggg atcgtcagtc
ttcctcttcc ccccaaaacc caaggacacc 900ctcatgatct cccggacccc
tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac 960cctgaggtca
agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag
1020ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac
cgtcctgcac 1080caggactggc tgaatggcaa ggagtacaag tgcaaggtct
ccaacaaagc cctcccagcc 1140cccatcgaga aaaccatctc caaagccaaa
gggcagcccc gagaaccaca ggtgtacacc 1200ctgcccccat cccgggatga
gctgaccaag aaccaggtca gcctgacctg cctggtcaaa 1260ggcttctatc
ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac
1320tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta
cagcaagctc 1380accgtggaca agagcaggtg gcagcagggg aacgtcttct
catgctccgt gatgcatgag 1440gctctgcaca accactacac gcagaagagc
ctctccctgt ctccgggtaa agcggatcct 1500tcgaacctgc tcccatcctg
ggccattacc ttaatctcag taaatggaat ttttgtgata 1560tgctgcctga
cctactgctt tgccccaaga tgcagagaga gaaggaggaa tgagagattg
1620agaagggaaa gtgtacgccc tgtataaatc gat 165356548PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
56Met Leu Tyr Thr Ser Gln Leu Leu Gly Leu Leu Leu Phe Trp Ile Ser1
5 10 15Ala Ser Arg Ser Asp Ile Val Leu Thr Gln Thr Pro Ala Thr Leu
Ser 20 25 30Leu Ile Pro Gly Glu Arg Val Thr Met Thr Cys Lys Thr Ser
Gln Asn 35 40 45Ile Gly Thr Ile Leu His Trp Tyr His Gln Lys Pro Lys
Glu Ala Pro 50 55 60Arg Ala Leu Ile Lys Tyr Ala Ser Gln Ser Ile Pro
Gly Ile Pro Ser65 70 75 80Arg Phe Ser Gly Ser Gly Ser Glu Thr Asp
Phe Thr Leu Ser Ile Asn 85 90 95Asn Leu Glu Pro Asp Asp Ile Gly Ile
Tyr Tyr Cys Gln Gln Ser Arg 100 105 110Ser Trp Pro Val Thr Phe Gly
Pro Gly Thr Lys Leu Glu Ile Lys Arg 115 120 125Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln 130 135 140Val Lys Leu
Gln Gln Ser Gly Ser Glu Leu Gly Lys Pro Gly Ala Ser145 150 155
160Val Lys Leu Ser Cys Lys Thr Ser Gly Tyr Ile Phe Thr Asp His Tyr
165 170 175Ile Ser Trp Val Lys Gln Lys Pro Gly Glu Ser Leu Gln Trp
Ile Gly 180 185 190Asn Val Tyr Gly Gly Asn Gly Gly Thr Ser Tyr Asn
Gln Lys Phe Gln 195 200 205Gly Lys Ala Thr Leu Thr Val Asp Lys Ile
Ser Ser Thr Ala Tyr Met 210 215 220Glu Leu Ser Ser Leu Thr Ser Glu
Asp Ser Ala Ile Tyr Tyr Cys Ala225 230 235 240Arg Arg Pro Val Ala
Thr Gly His Ala Met Asp Tyr Trp Gly Gln Gly 245 250 255Ile Gln Val
Thr Val Ser Ser Asp Leu Glu Pro Lys Ser Ser Asp Lys 260 265 270Thr
His Thr Ser Pro Pro Ser Pro Ala Pro Glu Leu Leu Gly Gly Ser 275 280
285Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
290 295 300Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
Glu Asp305 310 315 320Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
Val Glu Val His Asn 325 330 335Ala Lys Thr Lys Pro Arg Glu Glu Gln
Tyr Asn Ser Thr Tyr Arg Val 340 345 350Val Ser Val Leu Thr Val Leu
His Gln Asp Trp Leu Asn Gly Lys Glu 355 360 365Tyr Lys Cys Lys Val
Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 370 375 380Thr Ile Ser
Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr385 390 395
400Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr
405 410 415Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
Trp Glu 420 425 430Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
Pro Pro Val Leu 435 440 445Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
Lys Leu Thr Val Asp Lys 450 455 460Ser Arg Trp Gln Gln Gly Asn Val
Phe Ser Cys Ser Val Met His Glu465 470 475 480Ala Leu His Asn His
Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 485 490 495Lys Ala Asp
Pro Ser Asn Leu Leu Pro Ser Trp Ala Ile Thr Leu Ile 500 505 510Ser
Val Asn Gly Ile Phe Val Ile Cys Cys Leu Thr Tyr Cys Phe Ala 515 520
525Pro Arg Cys Arg Glu Arg Arg Arg Asn Glu Arg Leu Arg Arg Glu Ser
530 535 540Val Arg Pro Val545571521DNAArtificial
sequenceDescription of Artificial Synthetic nucleotide sequence
57aagcttgccg ccatggattt tcaagtgcag attttcagct tcctgctaat cagtgcttca
60gtcataattg ccagaggaca aattgttctc tcccagtctc cagcaatcct gtctgcatct
120ccaggggaga aggtcacaat gacttgcagg gccagctcaa gtgtaagtta
catgcactgg 180taccagcaga agccaggatc ctcccccaaa ccctggattt
atgccccatc caacctggct 240tctggagtcc ctgctcgctt cagtggcagt
gggtctggga cctcttactc tctcacaatc 300agcagagtgg aggctgaaga
tgctgccact tattactgcc agcagtggag ttttaaccca 360cccacgttcg
gtgctgggac caagctggag ctgaaagatg gcggtggctc gggcggtggt
420ggatctggag gaggtgggag ctctcaggct tatctacagc agtctggggc
tgagctggtg 480aggcctgggg cctcagtgaa gatgtcctgc aaggcttctg
gctacacatt taccagttac 540aatatgcact gggtaaagca gacacctaga
cagggcctgg aatggattgg agctatttat 600ccaggaaatg gtgatacttc
ctacaatcag aagttcaagg gcaaggccac actgactgta 660gacaaatcct
ccagcacagc ctacatgcag ctcagcagcc tgacatctga agactctgcg
720gtctatttct gtgcaagagt ggtgtactat agtaactctt actggtactt
cgatgtctgg 780ggcacaggga ccacggtcac cgtctcttct gatcaggagc
ccaaatcttc tgacaaaact 840cacacatccc caccgtcccc agcacctgaa
ctcctggggg gaccgtcagt cttcctcttc 900cccccaaaac ccaaggacac
cctcatgatc tcccggaccc ctgaggtcac atgcgtggtg 960gtggacgtga
gccacgaaga ccctgaggtc aagttcaact ggtacgtgga cggcgtggag
1020gtgcataatg ccaagacaaa gccgcgggag gagcagtaca acagcacgta
ccgtgtggtc 1080agcgtcctca ccgtcctgca ccaggactgg ctgaatggca
aggagtacaa gtgcaaggtc 1140tccaacaaag ccctcccagc ccccatcgag
aaaacaatct ccaaagccaa agggcagccc 1200cgagaaccac aggtgtacac
cctgccccca tcccgggatg agctgaccaa gaaccaggtc 1260agcctgacct
gcctggtcaa aggcttctat cccagcgaca tcgccgtgga gtgggagagc
1320aatgggcagc cggagaacaa ctacaagacc acgcctcccg tgctggactc
cgacggctcc 1380ttcttcctct acagcaagct caccgtggac aagagcaggt
ggcagcaggg gaacgtcttc 1440tcatgctccg tgatgcatga ggctctgcac
aaccactaca cgcagaagag cctctccctg 1500tctccgggta aatgatctag a
152158500PRTArtificial sequenceDescription of Artificial Synthetic
amino acid sequence 58Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu
Leu Ile Ser Ala Ser1 5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu
Ser Gln Ser Pro Ala Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val
Thr Met Thr Cys Arg Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp
Tyr Gln Gln Lys Pro Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala
Pro Ser Asn Leu Ala Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly
Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu
Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe
Asn Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 115 120
125Asp Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser
130 135 140Gln Ala Tyr Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro
Gly Ala145 150 155 160Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr
Thr Phe Thr Ser Tyr 165 170 175Asn Met His Trp Val Lys Gln Thr Pro
Arg Gln Gly Leu Glu Trp Ile 180 185 190Gly Ala Ile Tyr Pro Gly Asn
Gly Asp Thr Ser Tyr Asn Gln Lys Phe 195 200 205Lys Gly Lys Ala Thr
Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 210 215 220Met Gln Leu
Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys225 230 235
240Ala Arg Val Val Tyr Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp
245 250 255Gly Thr Gly Thr Thr Val Thr Val Ser Ser Asp Gln Glu Pro
Lys Ser 260 265 270Ser Asp Lys Thr His Thr Ser Pro Pro Ser Pro Ala
Pro Glu Leu Leu 275 280 285Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
Lys Pro Lys Asp Thr Leu 290 295 300Met Ile Ser Arg Thr Pro Glu Val
Thr Cys Val Val Val Asp Val Ser305 310 315 320His Glu Asp Pro Glu
Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 325 330 335Val His Asn
Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 340 345 350Tyr
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 355 360
365Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro
370 375 380Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
Pro Gln385 390 395 400Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
Thr Lys Asn Gln Val 405 410 415Ser Leu Thr Cys Leu Val Lys Gly Phe
Tyr Pro Ser Asp Ile Ala Val 420 425 430Glu Trp Glu Ser Asn Gly Gln
Pro Glu Asn Asn Tyr Lys Thr Thr Pro 435 440 445Pro Val Leu Asp Ser
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 450 455 460Val Asp Lys
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val465 470 475
480Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
485 490 495Ser Pro Gly Lys 500591536DNAArtificial
sequenceDescription of Artificial Synthetic nucleotide sequence
59aagcttgccg ccatggattt tcaagtgcag attttcagct tcctgctaat cagtgcttca
60gtcataattg ccagaggaca aattgttctc tcccagtctc cagcaatcct gtctgcatct
120ccaggggaga aggtcacaat gacttgcagg gccagctcaa gtgtaagtta
catgcactgg 180taccagcaga agccaggatc ctcccccaaa ccctggattt
atgccccatc caacctggct 240tctggagtcc ctgctcgctt cagtggcagt
gggtctggga
cctcttactc tctcacaatc 300agcagagtgg aggctgaaga tgctgccact
tattactgcc agcagtggag ttttaaccca 360cccacgttcg gtgctgggac
caagctggag ctgaaagatg gcggtggctc gggcggtggt 420ggatctggag
gaggtgggag ctctcaggct tatctacagc agtctggggc tgagctggtg
480aggcctgggg cctcagtgaa gatgtcctgc aaggcttctg gctacacatt
taccagttac 540aatatgcact gggtaaagca gacacctaga cagggcctgg
aatggattgg agctatttat 600ccaggaaatg gtgatacttc ctacaatcag
aagttcaagg gcaaggccac actgactgta 660gacaaatcct ccagcacagc
ctacatgcag ctcagcagcc tgacatctga agactctgcg 720gtctatttct
gtgcaagagt ggtgtactat agtaactctt actggtactt cgatgtctgg
780ggcacaggga ccacggtcac cgtctctgat cagccagttc cctcaactcc
acctacccca 840tctccctcaa ctccacctac cccatctccc tcatgcgcac
ctgaactcct ggggggaccg 900tcagtcttcc tcttcccccc aaaacccaag
gacaccctca tgatctcccg gacccctgag 960gtcacatgcg tggtggtgga
cgtgagccac gaagaccctg aggtcaagtt caactggtac 1020gtggacggcg
tggaggtgca taatgccaag acaaagccgc gggaggagca gtacaacagc
1080acgtaccgtg tggtcagcgt cctcaccgtc ctgcaccagg actggctgaa
tggcaaggag 1140tacaagtgca aggtctccaa caaagccctc ccagccccca
tcgagaaaac aatctccaaa 1200gccaaagggc agccccgaga accacaggtg
tacaccctgc ccccatcccg ggatgagctg 1260accaagaacc aggtcagcct
gacctgcctg gtcaaaggct tctatcccag cgacatcgcc 1320gtggagtggg
agagcaatgg gcagccggag aacaactaca agaccacgcc tcccgtgctg
1380gactccgacg gctccttctt cctctacagc aagctcaccg tggacaagag
caggtggcag 1440caggggaacg tcttctcatg ctccgtgatg catgaggctc
tgcacaacca ctacacgcag 1500aagagcctct ccctgtctcc gggtaaatga tctaga
153660505PRTArtificial sequenceDescription of Artificial Synthetic
amino acid sequence 60Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu
Leu Ile Ser Ala Ser1 5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu
Ser Gln Ser Pro Ala Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val
Thr Met Thr Cys Arg Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp
Tyr Gln Gln Lys Pro Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala
Pro Ser Asn Leu Ala Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly
Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu
Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe
Asn Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 115 120
125Asp Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser
130 135 140Gln Ala Tyr Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro
Gly Ala145 150 155 160Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr
Thr Phe Thr Ser Tyr 165 170 175Asn Met His Trp Val Lys Gln Thr Pro
Arg Gln Gly Leu Glu Trp Ile 180 185 190Gly Ala Ile Tyr Pro Gly Asn
Gly Asp Thr Ser Tyr Asn Gln Lys Phe 195 200 205Lys Gly Lys Ala Thr
Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 210 215 220Met Gln Leu
Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys225 230 235
240Ala Arg Val Val Tyr Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp
245 250 255Gly Thr Gly Thr Thr Val Thr Val Ser Asp Gln Pro Val Pro
Ser Thr 260 265 270Pro Pro Thr Pro Ser Pro Ser Thr Pro Pro Thr Pro
Ser Pro Ser Cys 275 280 285Ala Pro Glu Leu Leu Gly Gly Pro Ser Val
Phe Leu Phe Pro Pro Lys 290 295 300Pro Lys Asp Thr Leu Met Ile Ser
Arg Thr Pro Glu Val Thr Cys Val305 310 315 320Val Val Asp Val Ser
His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 325 330 335Val Asp Gly
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 340 345 350Gln
Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 355 360
365Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
370 375 380Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys
Gly Gln385 390 395 400Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
Ser Arg Asp Glu Leu 405 410 415Thr Lys Asn Gln Val Ser Leu Thr Cys
Leu Val Lys Gly Phe Tyr Pro 420 425 430Ser Asp Ile Ala Val Glu Trp
Glu Ser Asn Gly Gln Pro Glu Asn Asn 435 440 445Tyr Lys Thr Thr Pro
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 450 455 460Tyr Ser Lys
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val465 470 475
480Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
485 490 495Lys Ser Leu Ser Leu Ser Pro Gly Lys 500
505611584DNAArtificial sequenceDescription of Artificial Synthetic
nucleotide sequence 61aagcttgccg ccatggattt tcaagtgcag attttcagct
tcctgctaat cagtgcttca 60gtcataattg ccagaggaca aattgttctc tcccagtctc
cagcaatcct gtctgcatct 120ccaggggaga aggtcacaat gacttgcagg
gccagctcaa gtgtaagtta catgcactgg 180taccagcaga agccaggatc
ctcccccaaa ccctggattt atgccccatc caacctggct 240tctggagtcc
ctgctcgctt cagtggcagt gggtctggga cctcttactc tctcacaatc
300agcagagtgg aggctgaaga tgctgccact tattactgcc agcagtggag
ttttaaccca 360cccacgttcg gtgctgggac caagctggag ctgaaagatg
gcggtggctc gggcggtggt 420ggatctggag gaggtgggag ctctcaggct
tatctacagc agtctggggc tgagctggtg 480aggcctgggg cctcagtgaa
gatgtcctgc aaggcttctg gctacacatt taccagttac 540aatatgcact
gggtaaagca gacacctaga cagggcctgg aatggattgg agctatttat
600ccaggaaatg gtgatacttc ctacaatcag aagttcaagg gcaaggccac
actgactgta 660gacaaatcct ccagcacagc ctacatgcag ctcagcagcc
tgacatctga agactctgcg 720gtctatttct gtgcaagagt ggtgtactat
agtaactctt actggtactt cgatgtctgg 780ggcacaggga ccacggtcac
cgtctcttct gatcagccag ttccctcaac tccacctacc 840ccatctccct
caactccacc taccccatct ccctcatgct gccacccccg actgtcactg
900caccgaccgg ccctcgagga cctgctctta ggttcagaag cgatcctcac
gtgcacactg 960accggcctga gagatgcctc aggtgtcacc ttcacctgga
cgccctcaag tgggaagagc 1020gctgttcaag gaccacctga ccgtgacctc
tgtggctgct acagcgtgtc cagtgtcctg 1080ccgggctgtg ccgagccatg
gaaccatggg aagaccttca cttgcactgc tgcctacccc 1140gagtccaaga
ccccgctaac cgccaccctc tcaaaatccg gaaacacatt ccggcccgag
1200gtccacctgc tgccgccgcc gtcggaggag ctggccctga acgagctggt
gacgctgacg 1260tgcctggcac gtggcttcag ccccaaggat gtgctggttc
gctggctgca ggggtcacag 1320gagctgcccc gcgagaagta cctgacttgg
gcatcccggc aggagcccag ccagggcacc 1380accaccttcg ctgtgaccag
catactgcgc gtggcagccg aggactggaa gaagggggac 1440accttctcct
gcatggtggg ccacgaggcc ctgccgctgg ccttcacaca gaagaccatc
1500gaccgcttgg cgggtaaacc cacccatgtc aatgtgtctg ttgtcatggc
ggaggtggac 1560ggcacctgct actgataatc taga 158462520PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
62Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1
5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu Ser Gln Ser Pro Ala
Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg
Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro
Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala Pro Ser Asn Leu Ala
Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr
Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu Ala Glu Asp Ala Ala
Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe Asn Pro Pro Thr Phe
Gly Ala Gly Thr Lys Leu Glu Leu Lys 115 120 125Asp Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser 130 135 140Gln Ala Tyr
Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala145 150 155
160Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
165 170 175Asn Met His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Glu
Trp Ile 180 185 190Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr
Asn Gln Lys Phe 195 200 205Lys Gly Lys Ala Thr Leu Thr Val Asp Lys
Ser Ser Ser Thr Ala Tyr 210 215 220Met Gln Leu Ser Ser Leu Thr Ser
Glu Asp Ser Ala Val Tyr Phe Cys225 230 235 240Ala Arg Val Val Tyr
Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp 245 250 255Gly Thr Gly
Thr Thr Val Thr Val Ser Ser Asp Gln Pro Val Pro Ser 260 265 270Thr
Pro Pro Thr Pro Ser Pro Ser Thr Pro Pro Thr Pro Ser Pro Ser 275 280
285Cys Cys His Pro Arg Leu Ser Leu His Arg Pro Ala Leu Glu Asp Leu
290 295 300Leu Leu Gly Ser Glu Ala Ile Leu Thr Cys Thr Leu Thr Gly
Leu Arg305 310 315 320Asp Ala Ser Gly Val Thr Phe Thr Trp Thr Pro
Ser Ser Gly Lys Ser 325 330 335Ala Val Gln Gly Pro Pro Asp Arg Asp
Leu Cys Gly Cys Tyr Ser Val 340 345 350Ser Ser Val Leu Pro Gly Cys
Ala Glu Pro Trp Asn His Gly Lys Thr 355 360 365Phe Thr Cys Thr Ala
Ala Tyr Pro Glu Ser Lys Thr Pro Leu Thr Ala 370 375 380Thr Leu Ser
Lys Ser Gly Asn Thr Phe Arg Pro Glu Val His Leu Leu385 390 395
400Pro Pro Pro Ser Glu Glu Leu Ala Leu Asn Glu Leu Val Thr Leu Thr
405 410 415Cys Leu Ala Arg Gly Phe Ser Pro Lys Asp Val Leu Val Arg
Trp Leu 420 425 430Gln Gly Ser Gln Glu Leu Pro Arg Glu Lys Tyr Leu
Thr Trp Ala Ser 435 440 445Arg Gln Glu Pro Ser Gln Gly Thr Thr Thr
Phe Ala Val Thr Ser Ile 450 455 460Leu Arg Val Ala Ala Glu Asp Trp
Lys Lys Gly Asp Thr Phe Ser Cys465 470 475 480Met Val Gly His Glu
Ala Leu Pro Leu Ala Phe Thr Gln Lys Thr Ile 485 490 495Asp Arg Leu
Ala Gly Lys Pro Thr His Val Asn Val Ser Val Val Met 500 505 510Ala
Glu Val Asp Gly Thr Cys Tyr 515 52063775DNAArtificial
SequenceDescription of Artificial Synthetic nucleotide sequence
63tgatcagcca gttccctcaa ctccacctac cccatctccc tcaactccac ctaccccatc
60tccctcatgc tgccaccccc gactgtcact gcaccgaccg gccctcgagg acctgctctt
120aggttcagaa gcgatcctca cgtgcacact gaccggcctg agagatgcct
caggtgtcac 180cttcacctgg acgccctcaa gtgggaagag cgctgttcaa
ggaccacctg accgtgacct 240ctgtggctgc tacagcgtgt ccagtgtcct
gccgggctgt gccgagccat ggaaccatgg 300gaagaccttc acttgcactg
ctgcctaccc cgagtccaag accccgctaa ccgccaccct 360ctcaaaatcc
ggaaacacat tccggcccga ggtccacctg ctgccgccgc cgtcggagga
420gctggccctg aacgagctgg tgacgctgac gtgcctggca cgtggcttca
gccccaagga 480tgtgctggtt cgctggctgc aggggtcaca ggagctgccc
cgcgagaagt acctgacttg 540ggcatcccgg caggagccca gccagggcac
caccaccttc gctgtgacca gcatactgcg 600cgtggcagcc gaggactgga
agaaggggga caccttctcc tgcatggtgg gccacgaggc 660cctgccgctg
gccttcacac agaagaccat cgaccgcttg gcgggtaaac ccacccatgt
720caatgtgtct gttgtcatgg cggaggtgga cggcacctgc tactgataat ctaga
77564254PRTArtificial SequenceDescription of Artificial Synthetic
amino acid sequence 64Asp Gln Pro Val Pro Ser Thr Pro Pro Thr Pro
Ser Pro Ser Thr Pro1 5 10 15Pro Thr Pro Ser Pro Ser Cys Cys His Pro
Arg Leu Ser Leu His Arg 20 25 30Pro Ala Leu Glu Asp Leu Leu Leu Gly
Ser Glu Ala Ile Leu Thr Cys 35 40 45Thr Leu Thr Gly Leu Arg Asp Ala
Ser Gly Val Thr Phe Thr Trp Thr 50 55 60Pro Ser Ser Gly Lys Ser Ala
Val Gln Gly Pro Pro Asp Arg Asp Leu65 70 75 80Cys Gly Cys Tyr Ser
Val Ser Ser Val Leu Pro Gly Cys Ala Glu Pro 85 90 95Trp Asn His Gly
Lys Thr Phe Thr Cys Thr Ala Ala Tyr Pro Glu Ser 100 105 110Lys Thr
Pro Leu Thr Ala Thr Leu Ser Lys Ser Gly Asn Thr Phe Arg 115 120
125Pro Glu Val His Leu Leu Pro Pro Pro Ser Glu Glu Leu Ala Leu Asn
130 135 140Glu Leu Val Thr Leu Thr Cys Leu Ala Arg Gly Phe Ser Pro
Lys Asp145 150 155 160Val Leu Val Arg Trp Leu Gln Gly Ser Gln Glu
Leu Pro Arg Glu Lys 165 170 175Tyr Leu Thr Trp Ala Ser Arg Gln Glu
Pro Ser Gln Gly Thr Thr Thr 180 185 190Phe Ala Val Thr Ser Ile Leu
Arg Val Ala Ala Glu Asp Trp Lys Lys 195 200 205Gly Asp Thr Phe Ser
Cys Met Val Gly His Glu Ala Leu Pro Leu Ala 210 215 220Phe Thr Gln
Lys Thr Ile Asp Arg Leu Ala Gly Lys Pro Thr His Val225 230 235
240Asn Val Ser Val Val Met Ala Glu Val Asp Gly Thr Cys Tyr 245
25065429DNAHomo sapiens 65agatctcaag aagatgaaag gattgttctt
gttgacaaca aatgtaagtg tgcccggatt 60acttccagga tcatccgttc ttccgaagat
cctaatgagg acattgtgga gagaaacatc 120cgaattattg ttcctctgaa
caacagggag aatatctctg atcccacctc accattgaga 180accagatttg
tgtaccattt gtctgacctc agctgtaaaa aatgtgatcc tacagaagtg
240gagctggata atcagatagt tactgctacc cagagcaata tctgtgatga
agacagtgct 300acagagacct gctacactta tgacagaaac aagtgctaca
cagctgtggt cccactcgta 360tatggtggtg agaccaaaat ggtggaaaca
gccttaaccc cagatgcctg ctatcctgac 420taatctaga 42966139PRTHomo
sapiens 66Arg Ser Gln Glu Asp Glu Arg Ile Val Leu Val Asp Asn Lys
Cys Lys1 5 10 15Cys Ala Arg Ile Thr Ser Arg Ile Ile Arg Ser Ser Glu
Asp Pro Asn 20 25 30Glu Asp Ile Val Glu Arg Asn Ile Arg Ile Ile Val
Pro Leu Asn Asn 35 40 45Arg Glu Asn Ile Ser Asp Pro Thr Ser Pro Leu
Arg Thr Arg Phe Val 50 55 60Tyr His Leu Ser Asp Leu Ser Cys Lys Lys
Cys Asp Pro Thr Glu Val65 70 75 80Glu Leu Asp Asn Gln Ile Val Thr
Ala Thr Gln Ser Asn Ile Cys Asp 85 90 95Glu Asp Ser Ala Thr Glu Thr
Cys Tyr Thr Tyr Asp Arg Asn Lys Cys 100 105 110Tyr Thr Ala Val Val
Pro Leu Val Tyr Gly Gly Glu Thr Lys Met Val 115 120 125Glu Thr Ala
Leu Thr Pro Asp Ala Cys Tyr Pro 130 135674PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
67Gly Thr Cys Tyr168763DNAArtificial sequenceDescription of
Artificial Synthetic nucleotide sequence 68tgatcagcca gttccctcaa
ctccacctac cccatctccc tcaactccac ctaccccatc 60tccctcatgc tgccaccccc
gactgtcact gcaccgaccg gccctcgagg acctgctctt 120aggttcagaa
gcgatcctca cgtgcacact gaccggcctg agagatgcct caggtgtcac
180cttcacctgg acgccctcaa gtgggaagag cgctgttcaa ggaccacctg
accgtgacct 240ctgtggctgc tacagcgtgt ccagtgtcct gccgggctgt
gccgagccat ggaaccatgg 300gaagaccttc acttgcactg ctgcctaccc
cgagtccaag accccgctaa ccgccaccct 360ctcaaaatcc ggaaacacat
tccggcccga ggtccacctg ctgccgccgc cgtcggagga 420gctggccctg
aacgagctgg tgacgctgac gtgcctggca cgtggcttca gccccaagga
480tgtgctggtt cgctggctgc aggggtcaca ggagctgccc cgcgagaagt
acctgacttg 540ggcatcccgg caggagccca gccagggcac caccaccttc
gctgtgacca gcatactgcg 600cgtggcagcc gaggactgga agaaggggga
caccttctcc tgcatggtgg gccacgaggc 660cctgccgctg gccttcacac
agaagaccat cgaccgcttg gcgggtaaac ccacccatgt 720caatgtgtct
gttgtcatgg cggaggtgga ctgataatct aga 76369250PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
69Asp Gln Pro Val Pro Ser Thr Pro Pro Thr Pro Ser Pro Ser Thr Pro1
5 10 15Pro Thr Pro Ser Pro Ser Cys Cys His Pro Arg Leu Ser Leu His
Arg 20 25 30Pro Ala Leu Glu Asp Leu Leu Leu Gly Ser Glu Ala Ile Leu
Thr Cys 35 40 45Thr Leu Thr Gly Leu Arg Asp Ala Ser Gly Val Thr Phe
Thr Trp Thr 50 55 60Pro Ser Ser Gly Lys Ser Ala Val Gln Gly Pro Pro
Asp Arg Asp Leu65 70 75 80Cys Gly Cys Tyr Ser Val Ser Ser Val Leu
Pro Gly Cys Ala Glu Pro 85 90 95Trp Asn His Gly Lys Thr Phe Thr Cys
Thr Ala Ala Tyr Pro Glu Ser 100 105 110Lys Thr Pro Leu Thr Ala Thr
Leu Ser Lys Ser Gly Asn Thr Phe Arg 115 120 125Pro Glu Val His Leu
Leu Pro
Pro Pro Ser Glu Glu Leu Ala Leu Asn 130 135 140Glu Leu Val Thr Leu
Thr Cys Leu Ala Arg Gly Phe Ser Pro Lys Asp145 150 155 160Val Leu
Val Arg Trp Leu Gln Gly Ser Gln Glu Leu Pro Arg Glu Lys 165 170
175Tyr Leu Thr Trp Ala Ser Arg Gln Glu Pro Ser Gln Gly Thr Thr Thr
180 185 190Phe Ala Val Thr Ser Ile Leu Arg Val Ala Ala Glu Asp Trp
Lys Lys 195 200 205Gly Asp Thr Phe Ser Cys Met Val Gly His Glu Ala
Leu Pro Leu Ala 210 215 220Phe Thr Gln Lys Thr Ile Asp Arg Leu Ala
Gly Lys Pro Thr His Val225 230 235 240Asn Val Ser Val Val Met Ala
Glu Val Asp 245 250701572DNAArtificial sequenceDescription of
Artificial Synthetic nucleotide sequence 70aagcttgccg ccatggattt
tcaagtgcag attttcagct tcctgctaat cagtgcttca 60gtcataattg ccagaggaca
aattgttctc tcccagtctc cagcaatcct gtctgcatct 120ccaggggaga
aggtcacaat gacttgcagg gccagctcaa gtgtaagtta catgcactgg
180taccagcaga agccaggatc ctcccccaaa ccctggattt atgccccatc
caacctggct 240tctggagtcc ctgctcgctt cagtggcagt gggtctggga
cctcttactc tctcacaatc 300agcagagtgg aggctgaaga tgctgccact
tattactgcc agcagtggag ttttaaccca 360cccacgttcg gtgctgggac
caagctggag ctgaaagatg gcggtggctc gggcggtggt 420ggatctggag
gaggtgggag ctctcaggct tatctacagc agtctggggc tgagctggtg
480aggcctgggg cctcagtgaa gatgtcctgc aaggcttctg gctacacatt
taccagttac 540aatatgcact gggtaaagca gacacctaga cagggcctgg
aatggattgg agctatttat 600ccaggaaatg gtgatacttc ctacaatcag
aagttcaagg gcaaggccac actgactgta 660gacaaatcct ccagcacagc
ctacatgcag ctcagcagcc tgacatctga agactctgcg 720gtctatttct
gtgcaagagt ggtgtactat agtaactctt actggtactt cgatgtctgg
780ggcacaggga ccacggtcac cgtctcttct gatcagccag ttccctcaac
tccacctacc 840ccatctccct caactccacc taccccatct ccctcatgct
gccacccccg actgtcactg 900caccgaccgg ccctcgagga cctgctctta
ggttcagaag cgatcctcac gtgcacactg 960accggcctga gagatgcctc
aggtgtcacc ttcacctgga cgccctcaag tgggaagagc 1020gctgttcaag
gaccacctga ccgtgacctc tgtggctgct acagcgtgtc cagtgtcctg
1080ccgggctgtg ccgagccatg gaaccatggg aagaccttca cttgcactgc
tgcctacccc 1140gagtccaaga ccccgctaac cgccaccctc tcaaaatccg
gaaacacatt ccggcccgag 1200gtccacctgc tgccgccgcc gtcggaggag
ctggccctga acgagctggt gacgctgacg 1260tgcctggcac gtggcttcag
ccccaaggat gtgctggttc gctggctgca ggggtcacag 1320gagctgcccc
gcgagaagta cctgacttgg gcatcccggc aggagcccag ccagggcacc
1380accaccttcg ctgtgaccag catactgcgc gtggcagccg aggactggaa
gaagggggac 1440accttctcct gcatggtggg ccacgaggcc ctgccgctgg
ccttcacaca gaagaccatc 1500gaccgcttgg cgggtaaacc cacccatgtc
aatgtgtctg ttgtcatggc ggaggtggac 1560tgataatcta ga
157271516PRTArtificial sequenceDescription of Artificial Synthetic
amino acid sequence 71Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu
Leu Ile Ser Ala Ser1 5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu
Ser Gln Ser Pro Ala Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val
Thr Met Thr Cys Arg Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp
Tyr Gln Gln Lys Pro Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala
Pro Ser Asn Leu Ala Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly
Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu
Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe
Asn Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 115 120
125Asp Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser
130 135 140Gln Ala Tyr Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro
Gly Ala145 150 155 160Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr
Thr Phe Thr Ser Tyr 165 170 175Asn Met His Trp Val Lys Gln Thr Pro
Arg Gln Gly Leu Glu Trp Ile 180 185 190Gly Ala Ile Tyr Pro Gly Asn
Gly Asp Thr Ser Tyr Asn Gln Lys Phe 195 200 205Lys Gly Lys Ala Thr
Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 210 215 220Met Gln Leu
Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys225 230 235
240Ala Arg Val Val Tyr Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp
245 250 255Gly Thr Gly Thr Thr Val Thr Val Ser Ser Asp Gln Pro Val
Pro Ser 260 265 270Thr Pro Pro Thr Pro Ser Pro Ser Thr Pro Pro Thr
Pro Ser Pro Ser 275 280 285Cys Cys His Pro Arg Leu Ser Leu His Arg
Pro Ala Leu Glu Asp Leu 290 295 300Leu Leu Gly Ser Glu Ala Ile Leu
Thr Cys Thr Leu Thr Gly Leu Arg305 310 315 320Asp Ala Ser Gly Val
Thr Phe Thr Trp Thr Pro Ser Ser Gly Lys Ser 325 330 335Ala Val Gln
Gly Pro Pro Asp Arg Asp Leu Cys Gly Cys Tyr Ser Val 340 345 350Ser
Ser Val Leu Pro Gly Cys Ala Glu Pro Trp Asn His Gly Lys Thr 355 360
365Phe Thr Cys Thr Ala Ala Tyr Pro Glu Ser Lys Thr Pro Leu Thr Ala
370 375 380Thr Leu Ser Lys Ser Gly Asn Thr Phe Arg Pro Glu Val His
Leu Leu385 390 395 400Pro Pro Pro Ser Glu Glu Leu Ala Leu Asn Glu
Leu Val Thr Leu Thr 405 410 415Cys Leu Ala Arg Gly Phe Ser Pro Lys
Asp Val Leu Val Arg Trp Leu 420 425 430Gln Gly Ser Gln Glu Leu Pro
Arg Glu Lys Tyr Leu Thr Trp Ala Ser 435 440 445Arg Gln Glu Pro Ser
Gln Gly Thr Thr Thr Phe Ala Val Thr Ser Ile 450 455 460Leu Arg Val
Ala Ala Glu Asp Trp Lys Lys Gly Asp Thr Phe Ser Cys465 470 475
480Met Val Gly His Glu Ala Leu Pro Leu Ala Phe Thr Gln Lys Thr Ile
485 490 495Asp Arg Leu Ala Gly Lys Pro Thr His Val Asn Val Ser Val
Val Met 500 505 510Ala Glu Val Asp 5157214PRTArtificial
sequenceDescription of Artificial Synthetic peptide 72Pro Thr His
Val Asn Val Ser Val Val Met Ala Glu Val Asp1 5 1073709DNAArtificial
sequenceDescription of Artificial Synthetic nucleotide sequence
73tgatcagcca gttccctcaa ctccacctac cccatctccc tcaactccac ctaccccatc
60tccctcatgc tgccaccccc gactgtcact gcaccgaccg gccctcgagg acctgctctt
120aggttcagaa gcgatcctca cgtgcacact gaccggcctg agagatgcct
caggtgtcac 180cttcacctgg acgccctcaa gtgggaagag cgctgttcaa
ggaccacctg accgtgacct 240ctgtggctgc tacagcgtgt ccagtgtcct
gccgggctgt gccgagccat ggaaccatgg 300gaagaccttc acttgcactg
ctgcctaccc cgagtccaag accccgctaa ccgccaccct 360ctcaaaatcc
ggaaacacat tccggcccga ggtccacctg ctgccgccgc cgtcggagga
420gctggccctg aacgagctgg tgacgctgac gtgcctggca cgtggcttca
gccccaagga 480tgtgctggtt cgctggctgc aggggtcaca ggagctgccc
cgcgagaagt acctgacttg 540ggcatcccgg caggagccca gccagggcac
caccaccttc gctgtgacca gcatactgcg 600cgtggcagcc gaggactgga
agaaggggga caccttctcc tgcatggtgg gccacgaggc 660cctgccgctg
gccttcacac agaagaccat cgaccgcttg gcgggtaaa 70974236PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
74Asp Gln Pro Val Pro Ser Thr Pro Pro Thr Pro Ser Pro Ser Thr Pro1
5 10 15Pro Thr Pro Ser Pro Ser Cys Cys His Pro Arg Leu Ser Leu His
Arg 20 25 30Pro Ala Leu Glu Asp Leu Leu Leu Gly Ser Glu Ala Ile Leu
Thr Cys 35 40 45Thr Leu Thr Gly Leu Arg Asp Ala Ser Gly Val Thr Phe
Thr Trp Thr 50 55 60Pro Ser Ser Gly Lys Ser Ala Val Gln Gly Pro Pro
Asp Arg Asp Leu65 70 75 80Cys Gly Cys Tyr Ser Val Ser Ser Val Leu
Pro Gly Cys Ala Glu Pro 85 90 95Trp Asn His Gly Lys Thr Phe Thr Cys
Thr Ala Ala Tyr Pro Glu Ser 100 105 110Lys Thr Pro Leu Thr Ala Thr
Leu Ser Lys Ser Gly Asn Thr Phe Arg 115 120 125Pro Glu Val His Leu
Leu Pro Pro Pro Ser Glu Glu Leu Ala Leu Asn 130 135 140Glu Leu Val
Thr Leu Thr Cys Leu Ala Arg Gly Phe Ser Pro Lys Asp145 150 155
160Val Leu Val Arg Trp Leu Gln Gly Ser Gln Glu Leu Pro Arg Glu Lys
165 170 175Tyr Leu Thr Trp Ala Ser Arg Gln Glu Pro Ser Gln Gly Thr
Thr Thr 180 185 190Phe Ala Val Thr Ser Ile Leu Arg Val Ala Ala Glu
Asp Trp Lys Lys 195 200 205Gly Asp Thr Phe Ser Cys Met Val Gly His
Glu Ala Leu Pro Leu Ala 210 215 220Phe Thr Gln Lys Thr Ile Asp Arg
Leu Ala Gly Lys225 230 235751518DNAArtificial SequenceDescription
of Artificial Synthetic nucleotide sequence 75aagcttgccg ccatggattt
tcaagtgcag attttcagct tcctgctaat cagtgcttca 60gtcataattg ccagaggaca
aattgttctc tcccagtctc cagcaatcct gtctgcatct 120ccaggggaga
aggtcacaat gacttgcagg gccagctcaa gtgtaagtta catgcactgg
180taccagcaga agccaggatc ctcccccaaa ccctggattt atgccccatc
caacctggct 240tctggagtcc ctgctcgctt cagtggcagt gggtctggga
cctcttactc tctcacaatc 300agcagagtgg aggctgaaga tgctgccact
tattactgcc agcagtggag ttttaaccca 360cccacgttcg gtgctgggac
caagctggag ctgaaagatg gcggtggctc gggcggtggt 420ggatctggag
gaggtgggag ctctcaggct tatctacagc agtctggggc tgagctggtg
480aggcctgggg cctcagtgaa gatgtcctgc aaggcttctg gctacacatt
taccagttac 540aatatgcact gggtaaagca gacacctaga cagggcctgg
aatggattgg agctatttat 600ccaggaaatg gtgatacttc ctacaatcag
aagttcaagg gcaaggccac actgactgta 660gacaaatcct ccagcacagc
ctacatgcag ctcagcagcc tgacatctga agactctgcg 720gtctatttct
gtgcaagagt ggtgtactat agtaactctt actggtactt cgatgtctgg
780ggcacaggga ccacggtcac cgtctcttct gatcagccag ttccctcaac
tccacctacc 840ccatctccct caactccacc taccccatct ccctcatgct
gccacccccg actgtcactg 900caccgaccgg ccctcgagga cctgctctta
ggttcagaag cgatcctcac gtgcacactg 960accggcctga gagatgcctc
aggtgtcacc ttcacctgga cgccctcaag tgggaagagc 1020gctgttcaag
gaccacctga ccgtgacctc tgtggctgct acagcgtgtc cagtgtcctg
1080ccgggctgtg ccgagccatg gaaccatggg aagaccttca cttgcactgc
tgcctacccc 1140gagtccaaga ccccgctaac cgccaccctc tcaaaatccg
gaaacacatt ccggcccgag 1200gtccacctgc tgccgccgcc gtcggaggag
ctggccctga acgagctggt gacgctgacg 1260tgcctggcac gtggcttcag
ccccaaggat gtgctggttc gctggctgca ggggtcacag 1320gagctgcccc
gcgagaagta cctgacttgg gcatcccggc aggagcccag ccagggcacc
1380accaccttcg ctgtgaccag catactgcgc gtggcagccg aggactggaa
gaagggggac 1440accttctcct gcatggtggg ccacgaggcc ctgccgctgg
ccttcacaca gaagaccatc 1500gaccgcttgg cgggtaaa
151876502PRTArtificial sequenceDescription of Artificial Synthetic
amino acid sequence 76Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu
Leu Ile Ser Ala Ser1 5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu
Ser Gln Ser Pro Ala Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val
Thr Met Thr Cys Arg Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp
Tyr Gln Gln Lys Pro Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala
Pro Ser Asn Leu Ala Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly
Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu
Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe
Asn Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 115 120
125Asp Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser
130 135 140Gln Ala Tyr Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro
Gly Ala145 150 155 160Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr
Thr Phe Thr Ser Tyr 165 170 175Asn Met His Trp Val Lys Gln Thr Pro
Arg Gln Gly Leu Glu Trp Ile 180 185 190Gly Ala Ile Tyr Pro Gly Asn
Gly Asp Thr Ser Tyr Asn Gln Lys Phe 195 200 205Lys Gly Lys Ala Thr
Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 210 215 220Met Gln Leu
Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys225 230 235
240Ala Arg Val Val Tyr Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp
245 250 255Gly Thr Gly Thr Thr Val Thr Val Ser Ser Asp Gln Pro Val
Pro Ser 260 265 270Thr Pro Pro Thr Pro Ser Pro Ser Thr Pro Pro Thr
Pro Ser Pro Ser 275 280 285Cys Cys His Pro Arg Leu Ser Leu His Arg
Pro Ala Leu Glu Asp Leu 290 295 300Leu Leu Gly Ser Glu Ala Ile Leu
Thr Cys Thr Leu Thr Gly Leu Arg305 310 315 320Asp Ala Ser Gly Val
Thr Phe Thr Trp Thr Pro Ser Ser Gly Lys Ser 325 330 335Ala Val Gln
Gly Pro Pro Asp Arg Asp Leu Cys Gly Cys Tyr Ser Val 340 345 350Ser
Ser Val Leu Pro Gly Cys Ala Glu Pro Trp Asn His Gly Lys Thr 355 360
365Phe Thr Cys Thr Ala Ala Tyr Pro Glu Ser Lys Thr Pro Leu Thr Ala
370 375 380Thr Leu Ser Lys Ser Gly Asn Thr Phe Arg Pro Glu Val His
Leu Leu385 390 395 400Pro Pro Pro Ser Glu Glu Leu Ala Leu Asn Glu
Leu Val Thr Leu Thr 405 410 415Cys Leu Ala Arg Gly Phe Ser Pro Lys
Asp Val Leu Val Arg Trp Leu 420 425 430Gln Gly Ser Gln Glu Leu Pro
Arg Glu Lys Tyr Leu Thr Trp Ala Ser 435 440 445Arg Gln Glu Pro Ser
Gln Gly Thr Thr Thr Phe Ala Val Thr Ser Ile 450 455 460Leu Arg Val
Ala Ala Glu Asp Trp Lys Lys Gly Asp Thr Phe Ser Cys465 470 475
480Met Val Gly His Glu Ala Leu Pro Leu Ala Phe Thr Gln Lys Thr Ile
485 490 495Asp Arg Leu Ala Gly Lys 50077924DNAArtificial
SequenceDescription of Artificial Synthetic nucleotide sequence
77gcaacctaca tgatggggaa tgagttgacc ttcctagatg attccatctg cacgggcacc
60tccagtggaa atcaagtgaa cctcactatc caaggactga gggccatgga cacgggactc
120tacatctgca aggtggagct catgtaccca ccgccatact acctgggcat
aggcaacgga 180acccagattt atgtaattga tccagaaccg tgcccagatt
ctgatcaacc caaatcttgt 240gacaaaactc acacatgccc accgtgccca
gcacctgaac tcctgggggg accgtcagtc 300ttcctcttcc ccccaaaacc
caaggacacc ctcatgatct cccggacccc tgaggtcaca 360tgcgtggtgg
tggacgtgag ccacgaagac cctgaggtca agttcaactg gtacgtggac
420ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagtacaa
cagcacgtac 480cgtgtggtca gcgtcctcac cgtcctgcac caggactggc
tgaatggcaa ggagtacaag 540tgcaaggtct ccaacaaagc cctcccagcc
cccatcgaga aaacaatctc caaagccaaa 600gggcagcccc gagaaccaca
ggtgtacacc ctgcccccat cccgggatga gctgaccaag 660aaccaggtca
gcctgacctg cctggtcaaa ggcttctatc ccagcgacat cgccgtggag
720tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt
gctggactcc 780gacggctcct tcttcctcta cagcaagctc accgtggaca
agagcaggtg gcagcagggg 840aacgtcttct catgctccgt gatgcatgag
gctctgcaca accactacac gcagaagagc 900ctctccctgt ctccgggtaa atga
92478382PRTArtificial sequenceDescription of Artificial Synthetic
amino acid sequence 78Met Gly Val Leu Leu Thr Gln Arg Thr Leu Leu
Ser Leu Val Leu Ala1 5 10 15Leu Leu Phe Pro Ser Met Ala Ser Met Ala
Met His Val Ala Gln Pro 20 25 30Ala Val Val Leu Ala Ser Ser Arg Gly
Ile Ala Ser Phe Val Cys Glu 35 40 45Tyr Ala Ser Pro Gly Lys Ala Thr
Glu Val Arg Val Thr Val Leu Arg 50 55 60Gln Ala Asp Ser Gln Val Thr
Glu Val Cys Ala Ala Thr Tyr Met Met65 70 75 80Gly Asn Glu Leu Thr
Phe Leu Asp Asp Ser Ile Cys Thr Gly Thr Ser 85 90 95Ser Gly Asn Gln
Val Asn Leu Thr Ile Gln Gly Leu Arg Ala Met Asp 100 105 110Thr Gly
Leu Tyr Ile Cys Lys Val Glu Leu Met Tyr Pro Pro Pro Tyr 115 120
125Tyr Leu Gly Ile Gly Asn Gly Thr Gln Ile Tyr Val Ile Asp Pro Glu
130 135 140Pro Cys Pro Asp Ser Asp Gln Pro Lys Ser Cys Asp Lys Thr
His Thr145 150 155 160Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
Gly Pro Ser Val Phe 165 170 175Leu Phe Pro Pro Lys Pro Lys
Asp Thr Leu Met Ile Ser Arg Thr Pro 180 185 190Glu Val Thr Cys Val
Val Val Asp Val Ser His Glu Asp Pro Glu Val 195 200 205Lys Phe Asn
Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr 210 215 220Lys
Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val225 230
235 240Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
Cys 245 250 255Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys
Thr Ile Ser 260 265 270Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
Tyr Thr Leu Pro Pro 275 280 285Ser Arg Asp Glu Leu Thr Lys Asn Gln
Val Ser Leu Thr Cys Leu Val 290 295 300Lys Gly Phe Tyr Pro Ser Asp
Ile Ala Val Glu Trp Glu Ser Asn Gly305 310 315 320Gln Pro Glu Asn
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp 325 330 335Gly Ser
Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp 340 345
350Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
355 360 365Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
370 375 38079453DNAHomo sapiens 79atgggggtac tgctcacaca gaggacgctg
ctcagtctgg tccttgcact cctgtttcca 60agcatggcga gcatggcaat gcacgtggcc
cagcctgctg tggtactggc cagcagccga 120ggcatcgcca gctttgtgtg
tgagtatgca tctccaggca aagccactga ggtccgggtg 180acagtgcttc
ggcaggctga cagccaggtg actgaagtct gtgcggcaac ctacatgatg
240gggaatgagt tgaccttcct agatgattcc atctgcacgg gcacctccag
tggaaatcaa 300gtgaacctca ctatccaagg actgagggcc atggacacgg
gactctacat ctgcaaggtg 360gagctcatgt acccaccgcc atactacctg
ggcataggca acggaaccca gatttatgta 420attgatccag aaccgtgccc
agattctgat caa 45380151PRTHomo sapiens 80Met Gly Val Leu Leu Thr
Gln Arg Thr Leu Leu Ser Leu Val Leu Ala1 5 10 15Leu Leu Phe Pro Ser
Met Ala Ser Met Ala Met His Val Ala Gln Pro 20 25 30Ala Val Val Leu
Ala Ser Ser Arg Gly Ile Ala Ser Phe Val Cys Glu 35 40 45Tyr Ala Ser
Pro Gly Lys Ala Thr Glu Val Arg Val Thr Val Leu Arg 50 55 60Gln Ala
Asp Ser Gln Val Thr Glu Val Cys Ala Ala Thr Tyr Met Met65 70 75
80Gly Asn Glu Leu Thr Phe Leu Asp Asp Ser Ile Cys Thr Gly Thr Ser
85 90 95Ser Gly Asn Gln Val Asn Leu Thr Ile Gln Gly Leu Arg Ala Met
Asp 100 105 110Thr Gly Leu Tyr Ile Cys Lys Val Glu Leu Met Tyr Pro
Pro Pro Tyr 115 120 125Tyr Leu Gly Ile Gly Asn Gly Thr Gln Ile Tyr
Val Ile Asp Pro Glu 130 135 140Pro Cys Pro Asp Ser Asp Gln145
1508175DNAHomo sapiens 81atgggggtac tgctcacaca gaggacgctg
ctcagtctgg tccttgcact cctgtttcca 60agcatggcga gcatg 758222PRTHomo
sapiens 82Met Gly Val Leu Leu Thr Gln Arg Thr Leu Leu Ser Leu Val
Leu Ala1 5 10 15Leu Leu Phe Pro Ser Met 2083372DNAHomo sapiens
83gcaatgcacg tggcccagcc tgctgtggta ctggccagca gccgaggcat cgccagcttt
60gtgtgtgagt atgcatctcc aggcaaagcc actgaggtcc gggtgacagt gcttcggcag
120gctgacagcc aggtgactga agtctgtgcg gcaacctaca tgacggggaa
tgagttgacc 180ttcctagatg attccatctg cacgggcacc tccagtggaa
atcaagtgaa cctcactatc 240caaggactga gggccatgga cacgggactc
tacatctgca aggtggagct catgtaccca 300ccgccatact acctgggcat
aggcaacgga acccagattt atgtaattga tccagaaccg 360tgcccagatt ct
37284124PRTHomo sapiens 84Ala Met His Val Ala Gln Pro Ala Val Val
Leu Ala Ser Ser Arg Gly1 5 10 15Ile Ala Ser Phe Val Cys Glu Tyr Ala
Ser Pro Gly Lys Ala Thr Glu 20 25 30Val Arg Val Thr Val Leu Arg Gln
Ala Asp Ser Gln Val Thr Glu Val 35 40 45Cys Ala Ala Thr Tyr Met Thr
Gly Asn Glu Leu Thr Phe Leu Asp Asp 50 55 60Ser Ile Cys Thr Gly Thr
Ser Ser Gly Asn Gln Val Asn Leu Thr Ile65 70 75 80Gln Gly Leu Arg
Ala Met Asp Thr Gly Leu Tyr Ile Cys Lys Val Glu 85 90 95Leu Met Tyr
Pro Pro Pro Tyr Tyr Leu Gly Ile Gly Asn Gly Thr Gln 100 105 110Ile
Tyr Val Ile Asp Pro Glu Pro Cys Pro Asp Ser 115 120851149DNAHomo
sapiens 85atgggggtac tgctcacaca gaggacgctg ctcagtctgg tccttgcact
cctgtttcca 60agcatggcga gcatggcaat gcacgtggcc cagcctgctg tggtactggc
cagcagccga 120ggcatcgcca gctttgtgtg tgagtatgca tctccaggca
aagccactga ggtccgggtg 180acagtgcttc ggcaggctga cagccaggtg
actgaagtct gtgcggcaac ctacatgatg 240gggaatgagt tgaccttcct
agatgattcc atctgcacgg gcacctccag tggaaatcaa 300gtgaacctca
ctatccaagg actgagggcc atggacacgg gactctacat ctgcaaggtg
360gagctcatgt acccaccgcc atactacctg ggcataggca acggaaccca
gatttatgta 420attgatccag aaccgtgccc agattctgat caacccaaat
cttctgacaa aactcacaca 480tccccaccgt ccccagcacc tgaactcctg
gggggatcgt cagtcttcct cttcccccca 540aaacccaagg acaccctcat
gatctcccgg acccctgagg tcacatgcgt ggtggtggac 600gtgagccacg
aagaccctga ggtcaagttc aactggtacg tggacggcgt ggaggtgcat
660aatgccaaga caaagccgcg ggaggagcag tacaacagca cgtaccgtgt
ggtcagcgtc 720ctcaccgtcc tgcaccagga ctggctgaat ggcaaggagt
acaagtgcaa ggtctccaac 780aaagccctcc cagcccccat cgagaaaaca
atctccaaag ccaaagggca gccccgagaa 840ccacaggtgt acaccctgcc
cccatcccgg gatgagctga ccaagaacca ggtcagcctg 900acctgcctgg
tcaaaggctt ctatcccagc gacatcgccg tggagtggga gagcaatggg
960cagccggaga acaactacaa gaccacgcct cccgtgctgg actccgacgg
ctccttcttc 1020ctctacagca agctcaccgt ggacaagagc aggtggcagc
aggggaacgt cttctcatgc 1080tccgtgatgc atgaggctct gcacaaccac
tacacgcaga agagcctctc cctgtctccg 1140ggtaaatga 114986382PRTHomo
sapiens 86Met Gly Val Leu Leu Thr Gln Arg Thr Leu Leu Ser Leu Val
Leu Ala1 5 10 15Leu Leu Phe Pro Ser Met Ala Ser Met Ala Met His Val
Ala Gln Pro 20 25 30Ala Val Val Leu Ala Ser Ser Arg Gly Ile Ala Ser
Phe Val Cys Glu 35 40 45Tyr Ala Ser Pro Gly Lys Ala Thr Glu Val Arg
Val Thr Val Leu Arg 50 55 60Gln Ala Asp Ser Gln Val Thr Glu Val Cys
Ala Ala Thr Tyr Met Met65 70 75 80Gly Asn Glu Leu Thr Phe Leu Asp
Asp Ser Ile Cys Thr Gly Thr Ser 85 90 95Ser Gly Asn Gln Val Asn Leu
Thr Ile Gln Gly Leu Arg Ala Met Asp 100 105 110Thr Gly Leu Tyr Ile
Cys Lys Val Glu Leu Met Tyr Pro Pro Pro Tyr 115 120 125Tyr Leu Gly
Ile Gly Asn Gly Thr Gln Ile Tyr Val Ile Asp Pro Glu 130 135 140Pro
Cys Pro Asp Ser Asp Gln Pro Lys Ser Ser Asp Lys Thr His Thr145 150
155 160Ser Pro Pro Ser Pro Ala Pro Glu Leu Leu Gly Gly Ser Ser Val
Phe 165 170 175Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
Arg Thr Pro 180 185 190Glu Val Thr Cys Val Val Val Asp Val Ser His
Glu Asp Pro Glu Val 195 200 205Lys Phe Asn Trp Tyr Val Asp Gly Val
Glu Val His Asn Ala Lys Thr 210 215 220Lys Pro Arg Glu Glu Gln Tyr
Asn Ser Thr Tyr Arg Val Val Ser Val225 230 235 240Leu Thr Val Leu
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys 245 250 255Lys Val
Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser 260 265
270Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
275 280 285Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys
Leu Val 290 295 300Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
Glu Ser Asn Gly305 310 315 320Gln Pro Glu Asn Asn Tyr Lys Thr Thr
Pro Pro Val Leu Asp Ser Asp 325 330 335Gly Ser Phe Phe Leu Tyr Ser
Lys Leu Thr Val Asp Lys Ser Arg Trp 340 345 350Gln Gln Gly Asn Val
Phe Ser Cys Ser Val Met His Glu Ala Leu His 355 360 365Asn His Tyr
Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 370 375
380871221DNAArtificial SequenceDescription of Artificial Synthetic
nucleotide sequence 87atgggggtac tgctcacaca gaggacgctg ctcagtctgg
tccttgcact cctgtttcca 60agcatggcga gcatggcaat gcacgtggcc cagcctgctg
tggtactggc cagcagccga 120ggcatcgcca gctttgtgtg tgagtatgca
tctccaggca aagccactga ggtccgggtg 180acagtgcttc ggcaggctga
cagccaggtg actgaagtct gtgcggcaac ctacatgatg 240gggaatgagt
tgaccttcct agatgattcc atctgcacgg gcacctccag tggaaatcaa
300gtgaacctca ctatccaagg actgagggcc atggacacgg gactctacat
ctgcaaggtg 360gagctcatgt acccaccgcc atactacctg ggcataggca
acggaaccca gatttatgta 420attgatccag aaccgtgccc agattctgat
cagccagttc cctcaactcc acctacccca 480tctccctcaa ctccacctac
cccatctccc tcatgctgcc acccccgact gtcactgcac 540cgaccggccc
tcgaggacct gctcttaggt tcagaagcga tcctcacgtg cacactgacc
600ggcctgagag atgcctcagg tgtcaccttc acctggacgc cctcaagtgg
gaagagcgct 660gttcaaggac cacctgaccg tgacctctgt ggctgctaca
gcgtgtccag tgtcctgccg 720ggctgtgccg agccatggaa ccatgggaag
accttcactt gcactgctgc ctaccccgag 780tccaagaccc cgctaaccgc
caccctctca aaatccggaa acacattccg gcccgaggtc 840cacctgctgc
cgccgccgtc ggaggagctg gccctgaacg agctggtgac gctgacgtgc
900ctggcacgtg gcttcagccc caaggatgtg ctggttcgct ggctgcaggg
gtcacaggag 960ctgccccgcg agaagtacct gacttgggca tcccggcagg
agcccagcca gggcaccacc 1020accttcgctg tgaccagcat actgcgcgtg
gcagccgagg actggaagaa gggggacacc 1080ttctcctgca tggtgggcca
cgaggccctg ccgctggcct tcacacagaa gaccatcgac 1140cgcttggcgg
gtaaacccac ccatgtcaat gtgtctgttg tcatggcgga ggtggacggc
1200acctgctact gataatctag a 122188403PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
88Met Gly Val Leu Leu Thr Gln Arg Thr Leu Leu Ser Leu Val Leu Ala1
5 10 15Leu Leu Phe Pro Ser Met Ala Ser Met Ala Met His Val Ala Gln
Pro 20 25 30Ala Val Val Leu Ala Ser Ser Arg Gly Ile Ala Ser Phe Val
Cys Glu 35 40 45Tyr Ala Ser Pro Gly Lys Ala Thr Glu Val Arg Val Thr
Val Leu Arg 50 55 60Gln Ala Asp Ser Gln Val Thr Glu Val Cys Ala Ala
Thr Tyr Met Met65 70 75 80Gly Asn Glu Leu Thr Phe Leu Asp Asp Ser
Ile Cys Thr Gly Thr Ser 85 90 95Ser Gly Asn Gln Val Asn Leu Thr Ile
Gln Gly Leu Arg Ala Met Asp 100 105 110Thr Gly Leu Tyr Ile Cys Lys
Val Glu Leu Met Tyr Pro Pro Pro Tyr 115 120 125Tyr Leu Gly Ile Gly
Asn Gly Thr Gln Ile Tyr Val Ile Asp Pro Glu 130 135 140Pro Cys Pro
Asp Ser Asp Gln Pro Val Pro Ser Thr Pro Pro Thr Pro145 150 155
160Ser Pro Ser Thr Pro Pro Thr Pro Ser Pro Ser Cys Cys His Pro Arg
165 170 175Leu Ser Leu His Arg Pro Ala Leu Glu Asp Leu Leu Leu Gly
Ser Glu 180 185 190Ala Ile Leu Thr Cys Thr Leu Thr Gly Leu Arg Asp
Ala Ser Gly Val 195 200 205Thr Phe Thr Trp Thr Pro Ser Ser Gly Lys
Ser Ala Val Gln Gly Pro 210 215 220Pro Asp Arg Asp Leu Cys Gly Cys
Tyr Ser Val Ser Ser Val Leu Pro225 230 235 240Gly Cys Ala Glu Pro
Trp Asn His Gly Lys Thr Phe Thr Cys Thr Ala 245 250 255Ala Tyr Pro
Glu Ser Lys Thr Pro Leu Thr Ala Thr Leu Ser Lys Ser 260 265 270Gly
Asn Thr Phe Arg Pro Glu Val His Leu Leu Pro Pro Pro Ser Glu 275 280
285Glu Leu Ala Leu Asn Glu Leu Val Thr Leu Thr Cys Leu Ala Arg Gly
290 295 300Phe Ser Pro Lys Asp Val Leu Val Arg Trp Leu Gln Gly Ser
Gln Glu305 310 315 320Leu Pro Arg Glu Lys Tyr Leu Thr Trp Ala Ser
Arg Gln Glu Pro Ser 325 330 335Gln Gly Thr Thr Thr Phe Ala Val Thr
Ser Ile Leu Arg Val Ala Ala 340 345 350Glu Asp Trp Lys Lys Gly Asp
Thr Phe Ser Cys Met Val Gly His Glu 355 360 365Ala Leu Pro Leu Ala
Phe Thr Gln Lys Thr Ile Asp Arg Leu Ala Gly 370 375 380Lys Pro Thr
His Val Asn Val Ser Val Val Met Ala Glu Val Asp Gly385 390 395
400Thr Cys Tyr891209DNAArtificial SequenceDescription of Artificial
Synthetic nucleotide sequence 89atgggggtac tgctcacaca gaggacgctg
ctcagtctgg tccttgcact cctgtttcca 60agcatggcga gcatggcaat gcacgtggcc
cagcctgctg tggtactggc cagcagccga 120ggcatcgcca gctttgtgtg
tgagtatgca tctccaggca aagccactga ggtccgggtg 180acagtgcttc
ggcaggctga cagccaggtg actgaagtct gtgcggcaac ctacatgatg
240gggaatgagt tgaccttcct agatgattcc atctgcacgg gcacctccag
tggaaatcaa 300gtgaacctca ctatccaagg actgagggcc atggacacgg
gactctacat ctgcaaggtg 360gagctcatgt acccaccgcc atactacctg
ggcataggca acggaaccca gatttatgta 420attgatccag aaccgtgccc
agattctgat cagccagttc cctcaactcc acctacccca 480tctccctcaa
ctccacctac cccatctccc tcatgctgcc acccccgact gtcactgcac
540cgaccggccc tcgaggacct gctcttaggt tcagaagcga tcctcacgtg
cacactgacc 600ggcctgagag atgcctcagg tgtcaccttc acctggacgc
cctcaagtgg gaagagcgct 660gttcaaggac cacctgaccg tgacctctgt
ggctgctaca gcgtgtccag tgtcctgccg 720ggctgtgccg agccatggaa
ccatgggaag accttcactt gcactgctgc ctaccccgag 780tccaagaccc
cgctaaccgc caccctctca aaatccggaa acacattccg gcccgaggtc
840cacctgctgc cgccgccgtc ggaggagctg gccctgaacg agctggtgac
gctgacgtgc 900ctggcacgtg gcttcagccc caaggatgtg ctggttcgct
ggctgcaggg gtcacaggag 960ctgccccgcg agaagtacct gacttgggca
tcccggcagg agcccagcca gggcaccacc 1020accttcgctg tgaccagcat
actgcgcgtg gcagccgagg actggaagaa gggggacacc 1080ttctcctgca
tggtgggcca cgaggccctg ccgctggcct tcacacagaa gaccatcgac
1140cgcttggcgg gtaaacccac ccatgtcaat gtgtctgttg tcatggcgga
ggtggactga 1200taatctaga 120990399PRTArtificial sequenceDescription
of Artificial Synthetic amino acid sequence 90Met Gly Val Leu Leu
Thr Gln Arg Thr Leu Leu Ser Leu Val Leu Ala1 5 10 15Leu Leu Phe Pro
Ser Met Ala Ser Met Ala Met His Val Ala Gln Pro 20 25 30Ala Val Val
Leu Ala Ser Ser Arg Gly Ile Ala Ser Phe Val Cys Glu 35 40 45Tyr Ala
Ser Pro Gly Lys Ala Thr Glu Val Arg Val Thr Val Leu Arg 50 55 60Gln
Ala Asp Ser Gln Val Thr Glu Val Cys Ala Ala Thr Tyr Met Met65 70 75
80Gly Asn Glu Leu Thr Phe Leu Asp Asp Ser Ile Cys Thr Gly Thr Ser
85 90 95Ser Gly Asn Gln Val Asn Leu Thr Ile Gln Gly Leu Arg Ala Met
Asp 100 105 110Thr Gly Leu Tyr Ile Cys Lys Val Glu Leu Met Tyr Pro
Pro Pro Tyr 115 120 125Tyr Leu Gly Ile Gly Asn Gly Thr Gln Ile Tyr
Val Ile Asp Pro Glu 130 135 140Pro Cys Pro Asp Ser Asp Gln Pro Val
Pro Ser Thr Pro Pro Thr Pro145 150 155 160Ser Pro Ser Thr Pro Pro
Thr Pro Ser Pro Ser Cys Cys His Pro Arg 165 170 175Leu Ser Leu His
Arg Pro Ala Leu Glu Asp Leu Leu Leu Gly Ser Glu 180 185 190Ala Ile
Leu Thr Cys Thr Leu Thr Gly Leu Arg Asp Ala Ser Gly Val 195 200
205Thr Phe Thr Trp Thr Pro Ser Ser Gly Lys Ser Ala Val Gln Gly Pro
210 215 220Pro Asp Arg Asp Leu Cys Gly Cys Tyr Ser Val Ser Ser Val
Leu Pro225 230 235 240Gly Cys Ala Glu Pro Trp Asn His Gly Lys Thr
Phe Thr Cys Thr Ala 245 250 255Ala Tyr Pro Glu Ser Lys Thr Pro Leu
Thr Ala Thr Leu Ser Lys Ser 260 265 270Gly Asn Thr Phe Arg Pro Glu
Val His Leu Leu Pro Pro Pro Ser Glu 275 280 285Glu Leu Ala Leu Asn
Glu Leu Val Thr Leu Thr Cys Leu Ala Arg Gly 290 295 300Phe Ser Pro
Lys Asp Val Leu Val Arg Trp Leu Gln Gly Ser Gln Glu305 310 315
320Leu Pro Arg Glu Lys Tyr Leu Thr Trp Ala Ser Arg Gln Glu Pro Ser
325 330 335Gln Gly Thr Thr Thr Phe Ala Val Thr Ser Ile Leu
Arg Val Ala Ala 340 345 350Glu Asp Trp Lys Lys Gly Asp Thr Phe Ser
Cys Met Val Gly His Glu 355 360 365Ala Leu Pro Leu Ala Phe Thr Gln
Lys Thr Ile Asp Arg Leu Ala Gly 370 375 380Lys Pro Thr His Val Asn
Val Ser Val Val Met Ala Glu Val Asp385 390 39591328DNAHomo sapiens
91cctgaactcc tggggggatc gtcagtcttc ctcttccccc caaaacccaa ggacaccctc
60atgatctccc ggacccctga ggtcacatgc gtggtggtgg acgtgagcca cgaagaccct
120gaggtcaagt tcaactggta cgtggacggc gtggaggtgc ataatgccaa
gacaaagccg 180cgggaggagc agtacaacag cacgtaccgt gtggtcagcg
tcctcaccgt cctgcaccag 240gactggctga atggcaagga gtacaagtgc
aaggtctcca acaaagccct cccagccccc 300atcgagaaaa ccatctccaa agccaaag
32892109PRTHomo sapiens 92Pro Glu Leu Leu Gly Gly Ser Ser Val Phe
Leu Phe Pro Pro Lys Pro1 5 10 15Lys Asp Thr Leu Met Ile Ser Arg Thr
Pro Glu Val Thr Cys Val Val 20 25 30Val Asp Val Ser His Glu Asp Pro
Glu Val Lys Phe Asn Trp Tyr Val 35 40 45Asp Gly Val Glu Val His Asn
Ala Lys Thr Lys Pro Arg Glu Glu Gln 50 55 60Tyr Asn Ser Thr Tyr Arg
Val Val Ser Val Leu Thr Val Leu His Gln65 70 75 80Asp Trp Leu Asn
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 85 90 95Leu Pro Ala
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 100 1059310PRTArtificial
sequenceDescription of Artificial Synthetic peptide 93Pro Ala Pro
Glu Leu Leu Gly Gly Pro Ser1 5 109410PRTArtificial
sequenceDescription of Artificial Synthetic peptide 94Pro Ala Pro
Glu Leu Leu Gly Gly Ser Ser1 5 109551DNAArtificial
sequenceDescription of Artificial Synthetic nucleotide sequence
95gttgttttcg aaggatccgc tttaccggga tttacagaca ccgctcgctg g
5196996DNAHomo sapiens 96tgatcacgtc tgctccaggg acttcacccc
gcccaccgtg aagatcttac agtcgtcctg 60cgacggcggc gggcacttcc ccccgaccat
ccagctcctg tgcctcgtct ctgggtacac 120cccagggact atcaacatca
cctggctgga ggacgggcag gtcatggacg tggacttgtc 180caccgcctct
accacgcagg agggtgagct ggcctccaca caaagcgagc tcaccctcag
240ccagaagcac tggctgtcag accgcaccta cacctgccag gtcacctatc
aaggtcacac 300ctttgaggac agcaccaaga agtgtgcaga ttccaacccg
agaggggtga gcgcctacct 360aagccggccc agcccgttcg acctgttcat
ccgcaagtcg cccacgatca cctgtctggt 420ggtggacctg gcacccagca
aggggaccgt gaacctgacc tggtcccggg ccagtgggaa 480gcctgtgaac
cactccacca gaaaggagga gaagcagcgc aatggcacgt taaccgtcac
540gtccaccctg ccggtgggca cccgagactg gatcgagggg gagacctacc
agtgcagggt 600gacccacccc cacctgccca gggccctcat gcggtccacg
accaagacca gcggcccgcg 660tgctgccccg gaagtctatg cgtttgcgac
gccggagtgg ccggggagcc gggacaagcg 720caccctcgcc tgcctgatcc
agaacttcat gcctgaggac atctcggtgc agtggctgca 780caacgaggtg
cagctcccgg acgcccggca cagcacgacg cagccccgca agaccaaggg
840ctccggcttc ttcgtcttca gccgcctgga ggtgaccagg gccgaatggg
agcagaaaga 900tgagttcatc tgccgtgcag tccatgaggc agcgagcccc
tcacagaccg tccagcgagc 960ggtgtctgta aatcccggta aagcggatcc ttcgaa
99697331PRTHomo sapiens 97Asp His Val Cys Ser Arg Asp Phe Thr Pro
Pro Thr Val Lys Ile Leu1 5 10 15Gln Ser Ser Cys Asp Gly Gly Gly His
Phe Pro Pro Thr Ile Gln Leu 20 25 30Leu Cys Leu Val Ser Gly Tyr Thr
Pro Gly Thr Ile Asn Ile Thr Trp 35 40 45Leu Glu Asp Gly Gln Val Met
Asp Val Asp Leu Ser Thr Ala Ser Thr 50 55 60Thr Gln Glu Gly Glu Leu
Ala Ser Thr Gln Ser Glu Leu Thr Leu Ser65 70 75 80Gln Lys His Trp
Leu Ser Asp Arg Thr Tyr Thr Cys Gln Val Thr Tyr 85 90 95Gln Gly His
Thr Phe Glu Asp Ser Thr Lys Lys Cys Ala Asp Ser Asn 100 105 110Pro
Arg Gly Val Ser Ala Tyr Leu Ser Arg Pro Ser Pro Phe Asp Leu 115 120
125Phe Ile Arg Lys Ser Pro Thr Ile Thr Cys Leu Val Val Asp Leu Ala
130 135 140Pro Ser Lys Gly Thr Val Asn Leu Thr Trp Ser Arg Ala Ser
Gly Lys145 150 155 160Pro Val Asn His Ser Thr Arg Lys Glu Glu Lys
Gln Arg Asn Gly Thr 165 170 175Leu Thr Val Thr Ser Thr Leu Pro Val
Gly Thr Arg Asp Trp Ile Glu 180 185 190Gly Glu Thr Tyr Gln Cys Arg
Val Thr His Pro His Leu Pro Arg Ala 195 200 205Leu Met Arg Ser Thr
Thr Lys Thr Ser Gly Pro Arg Ala Ala Pro Glu 210 215 220Val Tyr Ala
Phe Ala Thr Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg225 230 235
240Thr Leu Ala Cys Leu Ile Gln Asn Phe Met Pro Glu Asp Ile Ser Val
245 250 255Gln Trp Leu His Asn Glu Val Gln Leu Pro Asp Ala Arg His
Ser Thr 260 265 270Thr Gln Pro Arg Lys Thr Lys Gly Ser Gly Phe Phe
Val Phe Ser Arg 275 280 285Leu Glu Val Thr Arg Ala Glu Trp Glu Gln
Lys Asp Glu Phe Ile Cys 290 295 300Arg Ala Val His Glu Ala Ala Ser
Pro Ser Gln Thr Val Gln Arg Ala305 310 315 320Val Ser Val Asn Pro
Gly Lys Ala Asp Pro Ser 325 3309863DNAArtificial
sequenceDescription of Artificial Synthetic nucleotide sequence
98gttgtttgat caggagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc
60acc 639991DNAArtificial sequenceDescription of Artificial
Synthetic nucleotide sequence 99gttgttgatc aggagcccaa atcttctgac
aaaactcaca catctccacc gtccccagca 60cctgaactcc tgggtggacc gtcagtcttc
c 91100339DNAArtificial sequenceDescription of Artificial Synthetic
nucleotide sequence 100caggtgcagc tgaaggaggc aggacctggc ctggtgcaac
cgacacagac cctgtccctc 60acatgcactg tctctgggtt ctcattaacc agcgatggtg
tacactggat tcgacagcct 120ccaggaaagg gtctggaatg gatgggaata
atatattatg atggaggcac agattataat 180tcagcaatta aatccagact
gagcatcagc agggacacct ccaagagcca agttttctta 240aaaatcaaca
gtctgcaaac tgatgacaca gccatgtatt actgtgccag aatccacttt
300gattactggg gccaaggagt catggtcaca gtctcctct
339101113PRTArtificial sequenceDescription of Artificial Synthetic
amino acid sequence 101Gln Val Gln Leu Lys Glu Ala Gly Pro Gly Leu
Val Gln Pro Thr Gln1 5 10 15Thr Leu Ser Leu Thr Cys Thr Val Ser Gly
Phe Ser Leu Thr Ser Asp 20 25 30Gly Val His Trp Ile Arg Gln Pro Pro
Gly Lys Gly Leu Glu Trp Met 35 40 45Gly Ile Ile Tyr Tyr Asp Gly Gly
Thr Asp Tyr Asn Ser Ala Ile Lys 50 55 60Ser Arg Leu Ser Ile Ser Arg
Asp Thr Ser Lys Ser Gln Val Phe Leu65 70 75 80Lys Ile Asn Ser Leu
Gln Thr Asp Asp Thr Ala Met Tyr Tyr Cys Ala 85 90 95Arg Ile His Phe
Asp Tyr Trp Gly Gln Gly Val Met Val Thr Val Ser 100 105
110Ser102321DNAArtificial sequenceDescription of Artificial
Synthetic nucleotide sequence 102gacattgtgc tcactcagtc tccaacaacc
atagctgcat ctccagggga gaaggtcacc 60atcacctgcc gtgccagctc cagtgtaagt
tacatgtact ggtaccagca gaagtcaggc 120gcctccccta aactctggat
ttatgacaca tccaagctgg cttctggagt tccaaatcgc 180ttcagtggca
gtgggtctgg gacctcttat tctctcgcaa tcaacaccat ggagactgaa
240gatgctgcca cttattactg tcagcagtgg agtagtactc cgctcacgtt
cgggtctggg 300accaagctgg agatcaaacg g 321103107PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
103Asp Ile Val Leu Thr Gln Ser Pro Thr Thr Ile Ala Ala Ser Pro Gly1
5 10 15Glu Lys Val Thr Ile Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr
Met 20 25 30Tyr Trp Tyr Gln Gln Lys Ser Gly Ala Ser Pro Lys Leu Trp
Ile Tyr 35 40 45Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Asn Arg Phe
Ser Gly Ser 50 55 60Gly Ser Gly Thr Ser Tyr Ser Leu Ala Ile Asn Thr
Met Glu Thr Glu65 70 75 80Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp
Ser Ser Thr Pro Leu Thr 85 90 95Phe Gly Ser Gly Thr Lys Leu Glu Ile
Lys Arg 100 105104785DNAArtificial sequenceDescription of
Artificial Synthetic nucleotide sequence 104aagcttatgg attttcaagt
gcagattttc agcttcctgc taatcagtgc ttcagtcata 60atgtccagag gagtcgacat
tgtgctcact cagtctccaa caaccatagc tgcatctcca 120ggggagaagg
tcaccatcac ctgccgtgcc agctccagtg taagttacat gtactggtac
180cagcagaagt caggcgcctc ccctaaactc tggatttatg acacatccaa
gctggcttct 240ggagttccaa atcgcttcag tggcagtggg tctgggacct
cttattctct cgcaatcaac 300accatggaga ctgaagatgc tgccacttat
tactgtcagc agtggagtag tactccgctc 360acgttcgggt ctgggaccaa
gctggagatc aaacggggtg gcggtggctc gggcggtggt 420gggtcgggtg
gcggcggatc tcaggtgcag ctgaaggagg caggacctgg cctggtgcaa
480ccgacacaga ccctgtccct cacatgcact gtctctgggt tctcattaac
cagcgatggt 540gtacactgga ttcgacagcc tccaggaaag ggtctggaat
ggatgggaat aatatattat 600gatggaggca cagattataa ttcagcaatt
aaatccagac tgagcatcag cagggacacc 660tccaagagcc aagttttctt
aaaaatcaac agtctgcaaa ctgatgacac agccatgtat 720tactgtgcca
gaatccactt tgattactgg ggccaaggag tcatggtcac agtctcctct 780gatca
785105258PRTArtificial sequenceDescription of Artificial Synthetic
amino acid sequence 105Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu
Leu Ile Ser Ala Ser1 5 10 15Val Ile Met Ser Arg Gly Val Asp Ile Val
Leu Thr Gln Ser Pro Thr 20 25 30Thr Ile Ala Ala Ser Pro Gly Glu Lys
Val Thr Ile Thr Cys Arg Ala 35 40 45Ser Ser Ser Val Ser Tyr Met Tyr
Trp Tyr Gln Gln Lys Ser Gly Ala 50 55 60Ser Pro Lys Leu Trp Ile Tyr
Asp Thr Ser Lys Leu Ala Ser Gly Val65 70 75 80Pro Asn Arg Phe Ser
Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Ala 85 90 95Ile Asn Thr Met
Glu Thr Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln 100 105 110Trp Ser
Ser Thr Pro Leu Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile 115 120
125Lys Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
130 135 140Ser Gln Val Gln Leu Lys Glu Ala Gly Pro Gly Leu Val Gln
Pro Thr145 150 155 160Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly
Phe Ser Leu Thr Ser 165 170 175Asp Gly Val His Trp Ile Arg Gln Pro
Pro Gly Lys Gly Leu Glu Trp 180 185 190Met Gly Ile Ile Tyr Tyr Asp
Gly Gly Thr Asp Tyr Asn Ser Ala Ile 195 200 205Lys Ser Arg Leu Ser
Ile Ser Arg Asp Thr Ser Lys Ser Gln Val Phe 210 215 220Leu Lys Ile
Asn Ser Leu Gln Thr Asp Asp Thr Ala Met Tyr Tyr Cys225 230 235
240Ala Arg Ile His Phe Asp Tyr Trp Gly Gln Gly Val Met Val Thr Val
245 250 255Ser Ser1061491DNAArtificial sequenceDescription of
Artificial Synthetic nucleotide sequence 106aagcttatgg attttcaagt
gcagattttc agcttcctgc taatcagtgc ttcagtcata 60atgtccagag gagtcgacat
tgtgctcact cagtctccaa caaccatagc tgcatctcca 120ggggagaagg
tcaccatcac ctgccgtgcc agctccagtg taagttacat gtactggtac
180cagcagaagt caggcgcctc ccctaaactc tggatttatg acacatccaa
gctggcttct 240ggagttccaa atcgcttcag tggcagtggg tctgggacct
cttattctct cgcaatcaac 300accatggaga ctgaagatgc tgccacttat
tactgtcagc agtggagtag tactccgctc 360acgttcgggt ctgggaccaa
gctggagatc aaacggggtg gcggtggctc gggcggtggt 420gggtcgggtg
gcggcggatc tcaggtgcag ctgaaggagg caggacctgg cctggtgcaa
480ccgacacaga ccctgtccct cacatgcact gtctctgggt tctcattaac
cagcgatggt 540gtacactgga ttcgacagcc tccaggaaag ggtctggaat
ggatgggaat aatatattat 600gatggaggca cagattataa ttcagcaatt
aaatccagac tgagcatcag cagggacacc 660tccaagagcc aagttttctt
aaaaatcaac agtctgcaaa ctgatgacac agccatgtat 720tactgtgcca
gaatccactt tgattactgg ggccaaggag tcatggtcac agtctcctct
780gatcaggagc ccaaatcttg tgacaaaact cacacatgcc caccgtgccc
agcacctgaa 840ctcctggggg gaccgtcagt cttcctcttc cccccaaaac
ccaaggacac cctcatgatc 900tcccggaccc ctgaggtcac atgcgtggtg
gtggacgtga gccacgaaga ccctgaggtc 960aagttcaact ggtacgtgga
cggcgtggag gtgcataatg ccaagacaaa gccgcgggag 1020gagcagtaca
acagcacgta ccgtgtggtc agcgtcctca ccgtcctgca ccaggactgg
1080ctgaatggca aggagtacaa gtgcaaggtc tccaacaaag ccctcccagc
ccccatcgag 1140aaaacaatct ccaaagccaa agggcagccc cgagaaccac
aggtgtacac cctgccccca 1200tcccgggatg agctgaccaa gaaccaggtc
agcctgacct gcctggtcaa aggcttctat 1260cccagcgaca tcgccgtgga
gtgggagagc aatgggcagc cggagaacaa ctacaagacc 1320acgcctcccg
tgctggactc cgacggctcc ttcttcctct acagcaagct caccgtggac
1380aagagcaggt ggcagcaggg gaacgtcttc tcatgctccg tgatgcatga
ggctctgcac 1440aaccactaca cgcagaagag cctctccctg tctccgggta
aatgatctag a 1491107492PRTArtificial sequenceDescription of
Artificial Synthetic amino acid sequence 107Met Asp Phe Gln Val Gln
Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1 5 10 15Val Ile Met Ser Arg
Gly Val Asp Ile Val Leu Thr Gln Ser Pro Thr 20 25 30Thr Ile Ala Ala
Ser Pro Gly Glu Lys Val Thr Ile Thr Cys Arg Ala 35 40 45Ser Ser Ser
Val Ser Tyr Met Tyr Trp Tyr Gln Gln Lys Ser Gly Ala 50 55 60Ser Pro
Lys Leu Trp Ile Tyr Asp Thr Ser Lys Leu Ala Ser Gly Val65 70 75
80Pro Asn Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Ala
85 90 95Ile Asn Thr Met Glu Thr Glu Asp Ala Ala Thr Tyr Tyr Cys Gln
Gln 100 105 110Trp Ser Ser Thr Pro Leu Thr Phe Gly Ser Gly Thr Lys
Leu Glu Ile 115 120 125Lys Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly 130 135 140Ser Gln Val Gln Leu Lys Glu Ala Gly
Pro Gly Leu Val Gln Pro Thr145 150 155 160Gln Thr Leu Ser Leu Thr
Cys Thr Val Ser Gly Phe Ser Leu Thr Ser 165 170 175Asp Gly Val His
Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp 180 185 190Met Gly
Ile Ile Tyr Tyr Asp Gly Gly Thr Asp Tyr Asn Ser Ala Ile 195 200
205Lys Ser Arg Leu Ser Ile Ser Arg Asp Thr Ser Lys Ser Gln Val Phe
210 215 220Leu Lys Ile Asn Ser Leu Gln Thr Asp Asp Thr Ala Met Tyr
Tyr Cys225 230 235 240Ala Arg Ile His Phe Asp Tyr Trp Gly Gln Gly
Val Met Val Thr Val 245 250 255Ser Ser Asp Gln Glu Pro Lys Ser Cys
Asp Lys Thr His Thr Cys Pro 260 265 270Pro Cys Pro Ala Pro Glu Leu
Leu Gly Gly Pro Ser Val Phe Leu Phe 275 280 285Pro Pro Lys Pro Lys
Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 290 295 300Thr Cys Val
Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe305 310 315
320Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
325 330 335Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
Leu Thr 340 345 350Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
Lys Cys Lys Val 355 360 365Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu
Lys Thr Ile Ser Lys Ala 370 375 380Lys Gly Gln Pro Arg Glu Pro Gln
Val Tyr Thr Leu Pro Pro Ser Arg385 390 395 400Asp Glu Leu Thr Lys
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 405 410 415Phe Tyr Pro
Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 420 425 430Glu
Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 435 440
445Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
450 455 460Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
Asn His465 470 475 480Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
Lys 485 4901081645DNAArtificial sequenceDescription of Artificial
Synthetic nucleotide sequence 108aagcttatgg attttcaagt gcagattttc
agcttcctgc taatcagtgc ttcagtcata 60atgtccagag gagtcgacat tgtgctcact
cagtctccaa caaccatagc tgcatctcca
120ggggagaagg tcaccatcac ctgccgtgcc agctccagtg taagttacat
gtactggtac 180cagcagaagt caggcgcctc ccctaaactc tggatttatg
acacatccaa gctggcttct 240ggagttccaa atcgcttcag tggcagtggg
tctgggacct cttattctct cgcaatcaac 300accatggaga ctgaagatgc
tgccacttat tactgtcagc agtggagtag tactccgctc 360acgttcgggt
ctgggaccaa gctggagatc aaacggggtg gcggtggctc gggcggtggt
420gggtcgggtg gcggcggatc tcaggtgcag ctgaaggagg caggacctgg
cctggtgcaa 480ccgacacaga ccctgtccct cacatgcact gtctctgggt
tctcattaac cagcgatggt 540gtacactgga ttcgacagcc tccaggaaag
ggtctggaat ggatgggaat aatatattat 600gatggaggca cagattataa
ttcagcaatt aaatccagac tgagcatcag cagggacacc 660tccaagagcc
aagttttctt aaaaatcaac agtctgcaaa ctgatgacac agccatgtat
720tactgtgcca gaatccactt tgattactgg ggccaaggag tcatggtcac
agtctcctct 780gatctggagc ccaaatcttc tgacaaaact cacacaagcc
caccgagccc agcacctgaa 840ctcctggggg gatcgtcagt cttcctcttc
cccccaaaac ccaaggacac cctcatgatc 900tcccggaccc ctgaggtcac
atgcgtggtg gtggacgtga gccacgaaga ccctgaggtc 960aagttcaact
ggtacgtgga cggcgtggag gtgcataatg ccaagacaaa gccgcgggag
1020gagcagtaca acagcacgta ccgtgtggtc agcgtcctca ccgtcctgca
ccaggactgg 1080ctgaatggca aggagtacaa gtgcaaggtc tccaacaaag
ccctcccagc ccccatcgag 1140aaaaccatct ccaaagccaa agggcagccc
cgagaaccac aggtgtacac cctgccccca 1200tcccgggatg agctgaccaa
gaaccaggtc agcctgacct gcctggtcaa aggcttctat 1260cccagcgaca
tcgccgtgga gtgggagagc aatgggcagc cggagaacaa ctacaagacc
1320acgcctcccg tgctggactc cgacggctcc ttcttcctct acagcaagct
caccgtggac 1380aagagcaggt ggcagcaggg gaacgtcttc tcatgctccg
tgatgcatga ggctctgcac 1440aaccactaca cgcagaagag cctctccctg
tctccgggta aagcggatcc ttcgaacctg 1500ctcccatcct gggccattac
cttaatctca gtaaatggaa tttttgtgat atgctgcctg 1560acctactgct
ttgccccaag atgcagagag agaaggagga atgagagatt gagaagggaa
1620agtgtacgcc ctgtataaat cgata 1645109543PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
109Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1
5 10 15Val Ile Met Ser Arg Gly Val Asp Ile Val Leu Thr Gln Ser Pro
Thr 20 25 30Thr Ile Ala Ala Ser Pro Gly Glu Lys Val Thr Ile Thr Cys
Arg Ala 35 40 45Ser Ser Ser Val Ser Tyr Met Tyr Trp Tyr Gln Gln Lys
Ser Gly Ala 50 55 60Ser Pro Lys Leu Trp Ile Tyr Asp Thr Ser Lys Leu
Ala Ser Gly Val65 70 75 80Pro Asn Arg Phe Ser Gly Ser Gly Ser Gly
Thr Ser Tyr Ser Leu Ala 85 90 95Ile Asn Thr Met Glu Thr Glu Asp Ala
Ala Thr Tyr Tyr Cys Gln Gln 100 105 110Trp Ser Ser Thr Pro Leu Thr
Phe Gly Ser Gly Thr Lys Leu Glu Ile 115 120 125Lys Arg Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 130 135 140Ser Gln Val
Gln Leu Lys Glu Ala Gly Pro Gly Leu Val Gln Pro Thr145 150 155
160Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser
165 170 175Asp Gly Val His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu
Glu Trp 180 185 190Met Gly Ile Ile Tyr Tyr Asp Gly Gly Thr Asp Tyr
Asn Ser Ala Ile 195 200 205Lys Ser Arg Leu Ser Ile Ser Arg Asp Thr
Ser Lys Ser Gln Val Phe 210 215 220Leu Lys Ile Asn Ser Leu Gln Thr
Asp Asp Thr Ala Met Tyr Tyr Cys225 230 235 240Ala Arg Ile His Phe
Asp Tyr Trp Gly Gln Gly Val Met Val Thr Val 245 250 255Ser Ser Asp
Leu Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser Pro 260 265 270Pro
Ser Pro Ala Pro Glu Leu Leu Gly Gly Ser Ser Val Phe Leu Phe 275 280
285Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
290 295 300Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
Lys Phe305 310 315 320Asn Trp Tyr Val Asp Gly Val Glu Val His Asn
Ala Lys Thr Lys Pro 325 330 335Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
Arg Val Val Ser Val Leu Thr 340 345 350Val Leu His Gln Asp Trp Leu
Asn Gly Lys Glu Tyr Lys Cys Lys Val 355 360 365Ser Asn Lys Ala Leu
Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala 370 375 380Lys Gly Gln
Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg385 390 395
400Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
405 410 415Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
Gln Pro 420 425 430Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
Ser Asp Gly Ser 435 440 445Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
Lys Ser Arg Trp Gln Gln 450 455 460Gly Asn Val Phe Ser Cys Ser Val
Met His Glu Ala Leu His Asn His465 470 475 480Tyr Thr Gln Lys Ser
Leu Ser Leu Ser Pro Gly Lys Ala Asp Pro Ser 485 490 495Asn Leu Leu
Pro Ser Trp Ala Ile Thr Leu Ile Ser Val Asn Gly Ile 500 505 510Phe
Val Ile Cys Cys Leu Thr Tyr Cys Phe Ala Pro Arg Cys Arg Glu 515 520
525Arg Arg Arg Asn Glu Arg Leu Arg Arg Glu Ser Val Arg Pro Val 530
535 5401101645DNAArtificial sequenceDescription of Artificial
Synthetic nucleotide sequence 110aagcttatgg attttcaagt gcagattttc
agcttcctgc taatcagtgc ttcagtcata 60atgtccagag gagtcgacat tgtgctcact
cagtctccaa caaccatagc tgcatctcca 120ggggagaagg tcaccatcac
ctgccgtgcc agctccagtg taagttacat gtactggtac 180cagcagaagt
caggcgcctc ccctaaactc tggatttatg acacatccaa gctggcttct
240ggagttccaa atcgcttcag tggcagtggg tctgggacct cttattctct
cgcaatcaac 300accatggaga ctgaagatgc tgccacttat tactgtcagc
agtggagtag tactccgctc 360acgttcgggt ctgggaccaa gctggagatc
aaacggggtg gcggtggctc gggcggtggt 420gggtcgggtg gcggcggatc
tcaggtgcag ctgaaggagg caggacctgg cctggtgcaa 480ccgacacaga
ccctgtccct cacatgcact gtctctgggt tctcattaac cagcgatggt
540gtacactgga ttcgacagcc tccaggaaag ggtctggaat ggatgggaat
aatatattat 600gatggaggca cagattataa ttcagcaatt aaatccagac
tgagcatcag cagggacacc 660tccaagagcc aagttttctt aaaaatcaac
agtctgcaaa ctgatgacac agccatgtat 720tactgtgcca gaatccactt
tgattactgg ggccaaggag tcatggtcac agtctcctct 780gatctggagc
ccaaatcttg tgacaaaact cacacatgcc caccgtgccc agcacctgaa
840ctcctggggg gaccgtcagt cttcctcttc cccccaaaac ccaaggacac
cctcatgatc 900tcccggaccc ctgaggtcac atgcgtggtg gtggacgtga
gccacgaaga ccctgaggtc 960aagttcaact ggtacgtgga cggcgtggag
gtgcataatg ccaagacaaa gccgcgggag 1020gagcagtaca acagcacgta
ccgtgtggtc agcgtcctca ccgtcctgca ccaggactgg 1080ctgaatggca
aggagtacaa gtgcaaggtc tccaacaaag ccctcccagc ccccatcgag
1140aaaaccatct ccaaagccaa agggcagccc cgagaaccac aggtgtacac
cctgccccca 1200tcccgggatg agctgaccaa gaaccaggtc agcctgacct
gcctggtcaa aggcttctat 1260cccagcgaca tcgccgtgga gtgggagagc
aatgggcagc cggagaacaa ctacaagacc 1320acgcctcccg tgctggactc
cgacggctcc ttcttcctct acagcaagct caccgtggac 1380aagagcaggt
ggcagcaggg gaacgtcttc tcatgctccg tgatgcatga ggctctgcac
1440aaccactaca cgcagaagag cctctccctg tctccgggta aagcggatcc
ttcgaacctg 1500ctcccatcct gggccattac cttaatctca gtaaatggaa
tttttgtgat atgctgcctg 1560acctactgct ttgccccaag atgcagagag
agaaggagga atgagagatt gagaagggaa 1620agtgtacgcc ctgtataaat cgata
1645111543PRTArtificial sequenceDescription of Artificial Synthetic
amino acid sequence 111Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu
Leu Ile Ser Ala Ser1 5 10 15Val Ile Met Ser Arg Gly Val Asp Ile Val
Leu Thr Gln Ser Pro Thr 20 25 30Thr Ile Ala Ala Ser Pro Gly Glu Lys
Val Thr Ile Thr Cys Arg Ala 35 40 45Ser Ser Ser Val Ser Tyr Met Tyr
Trp Tyr Gln Gln Lys Ser Gly Ala 50 55 60Ser Pro Lys Leu Trp Ile Tyr
Asp Thr Ser Lys Leu Ala Ser Gly Val65 70 75 80Pro Asn Arg Phe Ser
Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Ala 85 90 95Ile Asn Thr Met
Glu Thr Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln 100 105 110Trp Ser
Ser Thr Pro Leu Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile 115 120
125Lys Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
130 135 140Ser Gln Val Gln Leu Lys Glu Ala Gly Pro Gly Leu Val Gln
Pro Thr145 150 155 160Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly
Phe Ser Leu Thr Ser 165 170 175Asp Gly Val His Trp Ile Arg Gln Pro
Pro Gly Lys Gly Leu Glu Trp 180 185 190Met Gly Ile Ile Tyr Tyr Asp
Gly Gly Thr Asp Tyr Asn Ser Ala Ile 195 200 205Lys Ser Arg Leu Ser
Ile Ser Arg Asp Thr Ser Lys Ser Gln Val Phe 210 215 220Leu Lys Ile
Asn Ser Leu Gln Thr Asp Asp Thr Ala Met Tyr Tyr Cys225 230 235
240Ala Arg Ile His Phe Asp Tyr Trp Gly Gln Gly Val Met Val Thr Val
245 250 255Ser Ser Asp Leu Glu Pro Lys Ser Cys Asp Lys Thr His Thr
Cys Pro 260 265 270Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser
Val Phe Leu Phe 275 280 285Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
Ser Arg Thr Pro Glu Val 290 295 300Thr Cys Val Val Val Asp Val Ser
His Glu Asp Pro Glu Val Lys Phe305 310 315 320Asn Trp Tyr Val Asp
Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 325 330 335Arg Glu Glu
Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 340 345 350Val
Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 355 360
365Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala
370 375 380Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
Ser Arg385 390 395 400Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr
Cys Leu Val Lys Gly 405 410 415Phe Tyr Pro Ser Asp Ile Ala Val Glu
Trp Glu Ser Asn Gly Gln Pro 420 425 430Glu Asn Asn Tyr Lys Thr Thr
Pro Pro Val Leu Asp Ser Asp Gly Ser 435 440 445Phe Phe Leu Tyr Ser
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln 450 455 460Gly Asn Val
Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His465 470 475
480Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Ala Asp Pro Ser
485 490 495Asn Leu Leu Pro Ser Trp Ala Ile Thr Leu Ile Ser Val Asn
Gly Ile 500 505 510Phe Val Ile Cys Cys Leu Thr Tyr Cys Phe Ala Pro
Arg Cys Arg Glu 515 520 525Arg Arg Arg Asn Glu Arg Leu Arg Arg Glu
Ser Val Arg Pro Val 530 535 5401121527DNAArtificial
sequenceDescription of Artificial Synthetic nucleotide sequence
112aagcttatgg attttcaagt gcagattttc agcttcctgc taatcagtgc
ttcagtcata 60atgtccagag gagtcgacat ccagatgaca cagactacat cctccctgtc
tgcctctctg 120ggagacagag tcaccatcag ttgcagggca agtcaggaca
ttcgcaatta tttaaactgg 180tatcagcaga aaccagatgg aactgttaaa
ctcctgatct actacacatc aagattacac 240tcaggagtcc catcaaggtt
cagtggcagt gggtctggaa cagattattc tctcaccatt 300gccaacctgc
aaccagaaga tattgccact tacttttgcc aacagggtaa tacgcttccg
360tggacgttcg gtggaggcac caaactggta accaaacggg agctcggtgg
cggtggctcg 420ggcggtggtg ggtcgggtgg cggcggatct atcgatgagg
tccagctgca acagtctgga 480cctgaactgg tgaagcctgg agcttcaatg
tcctgcaagg cctctggtta ctcattcact 540ggctacatcg tgaactggct
gaagcagagc catggaaaga accttgagtg gattggactt 600attaatccat
acaaaggtct tactacctac aaccagaaat tcaagggcaa ggccacatta
660actgtagaca agtcatccag cacagcctac atggagctcc tcagtctgac
atctgaagac 720tctgcagtct attactgtgc aagatctggg tactatggtg
actcggactg gtacttcgat 780gtctggggcg cagggaccac ggtcaccgtc
tcctctgatc aggagcccaa atcttgtgac 840aaaactcaca catgcccacc
gtgcccagca cctgaactcc tggggggacc gtcagtcttc 900ctcttccccc
caaaacccaa ggacaccctc atgatctccc ggacccctga ggtcacatgc
960gtggtggtgg acgtgagcca cgaagaccct gaggtcaagt tcaactggta
cgtggacggc 1020gtggaggtgc ataatgccaa gacaaagccg cgggaggagc
agtacaacag cacgtaccgt 1080gtggtcagcg tcctcaccgt cctgcaccag
gactggctga atggcaagga gtacaagtgc 1140aaggtctcca acaaagccct
cccagccccc atcgagaaaa caatctccaa agccaaaggg 1200cagccccgag
aaccacaggt gtacaccctg cccccatccc gggatgagct gaccaagaac
1260caggtcagcc tgacctgcct ggtcaaaggc ttctatccca gcgacatcgc
cgtggagtgg 1320gagagcaatg ggcagccgga gaacaactac aagaccacgc
ctcccgtgct ggactccgac 1380ggctccttct tcctctacag caagctcacc
gtggacaaga gcaggtggca gcaggggaac 1440gtcttctcat gctccgtgat
gcatgaggct ctgcacaacc actacacgca gaagagcctc 1500tccctgtctc
cgggtaaatg atctaga 1527113504PRTArtificial sequenceDescription of
Artificial Synthetic amino acid sequence 113Met Asp Phe Gln Val Gln
Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1 5 10 15Val Ile Met Ser Arg
Gly Val Asp Ile Gln Met Thr Gln Thr Thr Ser 20 25 30Ser Leu Ser Ala
Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala 35 40 45Ser Gln Asp
Ile Arg Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp 50 55 60Gly Thr
Val Lys Leu Leu Ile Tyr Tyr Thr Ser Arg Leu His Ser Gly65 70 75
80Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu
85 90 95Thr Ile Ala Asn Leu Gln Pro Glu Asp Ile Ala Thr Tyr Phe Cys
Gln 100 105 110Gln Gly Asn Thr Leu Pro Trp Thr Phe Gly Gly Gly Thr
Lys Leu Val 115 120 125Thr Lys Arg Glu Leu Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly 130 135 140Gly Gly Gly Ser Ile Asp Glu Val Gln
Leu Gln Gln Ser Gly Pro Glu145 150 155 160Leu Val Lys Pro Gly Ala
Ser Met Ser Cys Lys Ala Ser Gly Tyr Ser 165 170 175Phe Thr Gly Tyr
Ile Val Asn Trp Leu Lys Gln Ser His Gly Lys Asn 180 185 190Leu Glu
Trp Ile Gly Leu Ile Asn Pro Tyr Lys Gly Leu Thr Thr Tyr 195 200
205Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser
210 215 220Ser Thr Ala Tyr Met Glu Leu Leu Ser Leu Thr Ser Glu Asp
Ser Ala225 230 235 240Val Tyr Tyr Cys Ala Arg Ser Gly Tyr Tyr Gly
Asp Ser Asp Trp Tyr 245 250 255Phe Asp Val Trp Gly Ala Gly Thr Thr
Val Thr Val Ser Ser Asp Gln 260 265 270Glu Pro Lys Ser Cys Asp Lys
Thr His Thr Cys Pro Pro Cys Pro Ala 275 280 285Pro Glu Leu Leu Gly
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 290 295 300Lys Asp Thr
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val305 310 315
320Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
325 330 335Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
Glu Gln 340 345 350Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
Val Leu His Gln 355 360 365Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
Lys Val Ser Asn Lys Ala 370 375 380Leu Pro Ala Pro Ile Glu Lys Thr
Ile Ser Lys Ala Lys Gly Gln Pro385 390 395 400Arg Glu Pro Gln Val
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr 405 410 415Lys Asn Gln
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 420 425 430Asp
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 435 440
445Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
450 455 460Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
Val Phe465 470 475 480Ser Cys Ser Val Met His Glu Ala Leu His Asn
His Tyr Thr Gln Lys 485 490 495Ser Leu Ser Leu Ser Pro Gly Lys
5001142325DNAArtificial sequenceDescription of Artificial Synthetic
nucleotide sequence 114aagcttgccg ccatggattt tcaagtgcag attttcagct
tcctgctaat cagtgcttca 60gtcataattg ccagaggaca aattgttctc tcccagtctc
cagcaatcct gtctgcatct
120ccaggggaga aggtcacaat gacttgcagg gccagctcaa gtgtaagtta
catgcactgg 180taccagcaga agccaggatc ctcccccaaa ccctggattt
atgccccatc caacctggct 240tctggagtcc ctgctcgctt cagtggcagt
gggtctggga cctcttactc tctcacaatc 300agcagagtgg aggctgaaga
tgctgccact tattactgcc agcagtggag ttttaaccca 360cccacgttcg
gtgctgggac caagctggag ctgaaaggtg gcggtggctc gggcggtggt
420ggatctggag gaggtgggag ctctcaggct tatctacagc agtctggggc
tgagctggtg 480aggcctgggg cctcagtgaa gatgtcctgc aaggcttctg
gctacacatt taccagttac 540aatatgcact gggtaaagca gacacctaga
cagggcctgg aatggattgg agctatttat 600ccaggaaatg gtgatacttc
ctacaatcag aagttcaagg gcaaggccac actgactgta 660gacaaatcct
ccagcacagc ctacatgcag ctcagcagcc tgacatctga agactctgcg
720gtctatttct gtgcaagagt ggtgtactat agtaactctt actggtactt
cgatgtctgg 780ggcacaggga ccacggtcac cgtctcttct gatcaatcca
actctgaaga agcaaagaaa 840gaggaggcca aaaaggagga agccaagaaa
tctaacagcg tcgacattgt tctgactcag 900tctccagcca ccctgtctgt
gactccagga gatagagtct ctctttcctg cagggccagc 960cagagtatta
gcgactactt acactggtat caacaaaaat cacatgagtc tccaaggctt
1020ctcatcaaat atgcttccca ttccatctct gggatcccct ccaggttcag
tggcagtgga 1080tcagggtcag atttcactct cagtatcaac agtgtggaac
ctgaagatgt tggaatttat 1140tactgtcaac atggtcacag ctttccgtgg
acgttcggtg gaggcaccaa gctggaaatc 1200aaacggggtg gcggtggctc
gggcggaggt gggtcgggtg gcggcggatc tcagatccag 1260ttggtgcaat
ctggacctga gctgaagaag cctggagaga cagtcaggat ctcctgcaag
1320gcttctgggt atgccttcac aactactgga atgcagtggg tgcaagagat
gccaggaaag 1380ggtttgaagt ggattggctg gataaacacc ccactctgga
gtgccaaaat atgtagaaga 1440cttcaaggac ggtttgcctt ctctttggaa
acctctgcca acactgcata tttacagata 1500agcaacctca aagatgagga
cacggctacg tatttctgtg tgagatccgg gaatggtaac 1560tatgacctgg
cctactttgc ttactggggc caagggacac tggtcactgt ctctgatcag
1620gagcccaaat cttctgacaa aactcacaca tccccaccgt ccccagcacc
tgaactcctg 1680gggggatcgt cagtcttcct cttcccccca aaacccaagg
acaccctcat gatctcccgg 1740acccctgagg tcacatgcgt ggtggtggac
gtgagccacg aagaccctga ggtcaagttc 1800aactggtacg tggacggcgt
ggaggtgcat aatgccaaga caaagccgcg ggaggagcag 1860tacaacagca
cgtaccgtgt ggtcagcgtc ctcaccgtcc tgcaccagga ctggctgaat
1920ggcaaggagt acaagtgcaa ggtctccaac aaagccctcc cagcccccat
cgagaaaaca 1980atctccaaag ccaaagggca gccccgagaa ccacaggtgt
acaccctgcc cccatcccgg 2040gatgagctga ccaagaacca ggtcagcctg
acctgcctgg tcaaaggctt ctatcccagc 2100gacatcgccg tggagtggga
gagcaatggg cagccggaga acaactacaa gaccacgcct 2160cccgtgctgg
actccgacgg ctccttcttc ctctacagca agctcaccgt ggacaagagc
2220aggtggcagc aggggaacgt cttctcatgc tccgtgatgc atgaggctct
gcacaaccac 2280tacacgcaga agagcctctc cctgtctccg ggtaaatgat ctaga
2325115768PRTArtificial sequenceDescription of Artificial Synthetic
amino acid sequence 115Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu
Leu Ile Ser Ala Ser1 5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu
Ser Gln Ser Pro Ala Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val
Thr Met Thr Cys Arg Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp
Tyr Gln Gln Lys Pro Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala
Pro Ser Asn Leu Ala Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly
Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu
Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe
Asn Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 115 120
125Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser
130 135 140Gln Ala Tyr Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro
Gly Ala145 150 155 160Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr
Thr Phe Thr Ser Tyr 165 170 175Asn Met His Trp Val Lys Gln Thr Pro
Arg Gln Gly Leu Glu Trp Ile 180 185 190Gly Ala Ile Tyr Pro Gly Asn
Gly Asp Thr Ser Tyr Asn Gln Lys Phe 195 200 205Lys Gly Lys Ala Thr
Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 210 215 220Met Gln Leu
Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys225 230 235
240Ala Arg Val Val Tyr Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp
245 250 255Gly Thr Gly Thr Thr Val Thr Val Ser Ser Asp Gln Ser Asn
Ser Glu 260 265 270Glu Ala Lys Lys Glu Glu Ala Lys Lys Glu Glu Ala
Lys Lys Ser Asn 275 280 285Ser Val Asp Ile Val Leu Thr Gln Ser Pro
Ala Thr Leu Ser Val Thr 290 295 300Pro Gly Asp Arg Val Ser Leu Ser
Cys Arg Ala Ser Gln Ser Ile Ser305 310 315 320Asp Tyr Leu His Trp
Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu 325 330 335Leu Ile Lys
Tyr Ala Ser His Ser Ile Ser Gly Ile Pro Ser Arg Phe 340 345 350Ser
Gly Ser Gly Ser Gly Ser Asp Phe Thr Leu Ser Ile Asn Ser Val 355 360
365Glu Pro Glu Asp Val Gly Ile Tyr Tyr Cys Gln His Gly His Ser Phe
370 375 380Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg
Gly Gly385 390 395 400Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gln Ile Gln 405 410 415Leu Val Gln Ser Gly Pro Glu Leu Lys
Lys Pro Gly Glu Thr Val Arg 420 425 430Ile Ser Cys Lys Ala Ser Gly
Tyr Ala Phe Thr Thr Thr Gly Met Gln 435 440 445Trp Val Gln Glu Met
Pro Gly Lys Gly Leu Lys Trp Ile Gly Trp Ile 450 455 460Asn Thr Pro
Leu Trp Ser Ala Lys Ile Cys Arg Arg Leu Gln Gly Arg465 470 475
480Phe Ala Phe Ser Leu Glu Thr Ser Ala Asn Thr Ala Tyr Leu Gln Ile
485 490 495Ser Asn Leu Lys Asp Glu Asp Thr Ala Thr Tyr Phe Cys Val
Arg Ser 500 505 510Gly Asn Gly Asn Tyr Asp Leu Ala Tyr Phe Ala Tyr
Trp Gly Gln Gly 515 520 525Thr Leu Val Thr Val Ser Asp Gln Glu Pro
Lys Ser Ser Asp Lys Thr 530 535 540His Thr Ser Pro Pro Ser Pro Ala
Pro Glu Leu Leu Gly Gly Ser Ser545 550 555 560Val Phe Leu Phe Pro
Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 565 570 575Thr Pro Glu
Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 580 585 590Glu
Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 595 600
605Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
610 615 620Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
Glu Tyr625 630 635 640Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
Pro Ile Glu Lys Thr 645 650 655Ile Ser Lys Ala Lys Gly Gln Pro Arg
Glu Pro Gln Val Tyr Thr Leu 660 665 670Pro Pro Ser Arg Asp Glu Leu
Thr Lys Asn Gln Val Ser Leu Thr Cys 675 680 685Leu Val Lys Gly Phe
Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 690 695 700Asn Gly Gln
Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp705 710 715
720Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
725 730 735Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
Glu Ala 740 745 750Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
Ser Pro Gly Lys 755 760 765116423DNAArtificial sequenceDescription
of Artificial Synthetic nucleotide sequence 116atggctgtct
tggggctgct cttctgcctg gtgacatttc caagctgtgt cctatcccag 60gtgcagctga
agcagtcagg acctggccta gtgcagtcct cacagagcct gtccatcacc
120tgcacagtct ctggtttctc attaactacc tatgctgtac actgggttcg
ccagtctcca 180ggaaagggtc tggagtggct gggagtgata tggagtggtg
gaatcacaga ctataatgca 240gctttcatat ccagactgag catcaccaag
gacgattcca agagccaagt tttctttaaa 300atgaacagtc tgcaacctaa
tgacacagcc atttattact gtgccagaaa tgggggtgat 360aactaccctt
attactatgc tatggactac tggggtcaag gaacctcagt caccgtctcc 420tca
423117366DNAArtificial sequenceDescription of Artificial Synthetic
nucleotide sequence 117caggtgcagc tgaagcagtc aggacctggc ctagtgcagt
cctcacagag cctgtccatc 60acctgcacag tctctggttt ctcattaact acctatgctg
tacactgggt tcgccagtct 120ccaggaaagg gtctggagtg gctgggagtg
atatggagtg gtggaatcac agactataat 180gcagctttca tatccagact
gagcatcacc aaggacgatt ccaagagcca agttttcttt 240aaaatgaaca
gtctgcaacc taatgacaca gccatttatt actgtgccag aaatgggggt
300gataactacc cttattacta tgctatggac tactggggtc aaggaacctc
agtcaccgtc 360tcctca 366118141PRTArtificial sequenceDescription of
Artificial Synthetic amino acid sequence 118Met Ala Val Leu Gly Leu
Leu Phe Cys Leu Val Thr Phe Pro Ser Cys1 5 10 15Val Leu Ser Gln Val
Gln Leu Lys Gln Ser Gly Pro Gly Leu Val Gln 20 25 30Ser Ser Gln Ser
Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu 35 40 45Thr Thr Tyr
Ala Val His Trp Val Arg Gln Ser Pro Gly Lys Gly Leu 50 55 60Glu Trp
Leu Gly Val Ile Trp Ser Gly Gly Ile Thr Asp Tyr Asn Ala65 70 75
80Ala Phe Ile Ser Arg Leu Ser Ile Thr Lys Asp Asp Ser Lys Ser Gln
85 90 95Val Phe Phe Lys Met Asn Ser Leu Gln Pro Asn Asp Thr Ala Ile
Tyr 100 105 110Tyr Cys Ala Arg Asn Gly Gly Asp Asn Tyr Pro Tyr Tyr
Tyr Ala Met 115 120 125Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val
Ser Ser 130 135 140119122PRTArtificial sequenceDescription of
Artificial Synthetic amino acid sequence 119Gln Val Gln Leu Lys Gln
Ser Gly Pro Gly Leu Val Gln Ser Ser Gln1 5 10 15Ser Leu Ser Ile Thr
Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 20 25 30Ala Val His Trp
Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Leu 35 40 45Gly Val Ile
Trp Ser Gly Gly Ile Thr Asp Tyr Asn Ala Ala Phe Ile 50 55 60Ser Arg
Leu Ser Ile Thr Lys Asp Asp Ser Lys Ser Gln Val Phe Phe65 70 75
80Lys Met Asn Ser Leu Gln Pro Asn Asp Thr Ala Ile Tyr Tyr Cys Ala
85 90 95Arg Asn Gly Gly Asp Asn Tyr Pro Tyr Tyr Tyr Ala Met Asp Tyr
Trp 100 105 110Gly Gln Gly Thr Ser Val Thr Val Ser Ser 115
120120399DNAArtificial sequenceDescription of Artificial Synthetic
nucleotide sequence 120atgaggttct ctgctcagct tctggggctg cttgtgctct
ggatccctgg atccactgca 60gatattgtga tgacgcaggc tgcattctcc aatccagtca
ctcttggaac atcagcttcc 120atctcctgca ggtctagtaa gagtctccta
catagtaatg gcatcactta tttgtattgg 180tatctgcaga agccaggcca
gtctcctcag ctcctgattt atcagatgtc caaccttgcc 240tcaggagtcc
cagacaggtt cagtagcagt gggtcaggaa ctgatttcac actgagaatc
300agcagagtgg aggctgagga tgtgggtgtt tattactgtg ctcaaaatct
agaacttccg 360ctcacgttcg gtgctgggac caagctggag ctgaaacgg
399121133PRTArtificial sequenceDescription of Artificial Synthetic
amino acid sequence 121Met Arg Phe Ser Ala Gln Leu Leu Gly Leu Leu
Val Leu Trp Ile Pro1 5 10 15Gly Ser Thr Ala Asp Ile Val Met Thr Gln
Ala Ala Phe Ser Asn Pro 20 25 30Val Thr Leu Gly Thr Ser Ala Ser Ile
Ser Cys Arg Ser Ser Lys Ser 35 40 45Leu Leu His Ser Asn Gly Ile Thr
Tyr Leu Tyr Trp Tyr Leu Gln Lys 50 55 60Pro Gly Gln Ser Pro Gln Leu
Leu Ile Tyr Gln Met Ser Asn Leu Ala65 70 75 80Ser Gly Val Pro Asp
Arg Phe Ser Ser Ser Gly Ser Gly Thr Asp Phe 85 90 95Thr Leu Arg Ile
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr 100 105 110Cys Ala
Gln Asn Leu Glu Leu Pro Leu Thr Phe Gly Ala Gly Thr Lys 115 120
125Leu Glu Leu Lys Arg 130122825DNAArtificial sequenceDescription
of Artificial Synthetic nucleotide sequence 122aagcttgccg
ccatgaggtt ctctgctcag cttctggggc tgcttgtgct ctggatccct 60ggatccactg
cagatattgt gatgacgcag gctgcattct ccaatccagt cactcttgga
120acatcagctt ccatctcctg caggtctagt aagagtctcc tacatagtaa
tggcatcact 180tatttgtatt ggtatctgca gaagccaggc cagtctcctc
agctcctgat ttatcagatg 240tccaaccttg cctcaggagt cccagacagg
ttcagtagca gtgggtcagg aactgatttc 300acactgagaa tcagcagagt
ggaggctgag gatgtgggtg tttattactg tgctcaaaat 360ctagaacttc
cgctcacgtt cggtgctggg accaagctgg agctgaaacg gggtggcggt
420ggctcgggcg gtggtgggtc gggtggcggc ggatcgtcac aggtgcagct
gaagcagtca 480ggacctggcc tagtgcagtc ctcacagagc ctgtccatca
cctgcacagt ctctggtttc 540tcattaacta cctatgctgt acactgggtt
cgccagtctc caggaaaggg tctggagtgg 600ctgggagtga tatggagtgg
tggaatcaca gactataatg cagctttcat atccagactg 660agcatcacca
aggacgattc caagagccaa gttttcttta aaatgaacag tctgcaacct
720aatgacacag ccatttatta ctgtgccaga aatgggggtg ataactaccc
ttattactat 780gctatggact actggggtca aggaacctca gtcaccgtct cctct
825123271PRTArtificial sequenceDescription of Artificial Synthetic
amino acid sequence 123Met Arg Phe Ser Ala Gln Leu Leu Gly Leu Leu
Val Leu Trp Ile Pro1 5 10 15Gly Ser Thr Ala Asp Ile Val Met Thr Gln
Ala Ala Phe Ser Asn Pro 20 25 30Val Thr Leu Gly Thr Ser Ala Ser Ile
Ser Cys Arg Ser Ser Lys Ser 35 40 45Leu Leu His Ser Asn Gly Ile Thr
Tyr Leu Tyr Trp Tyr Leu Gln Lys 50 55 60Pro Gly Gln Ser Pro Gln Leu
Leu Ile Tyr Gln Met Ser Asn Leu Ala65 70 75 80Ser Gly Val Pro Asp
Arg Phe Ser Ser Ser Gly Ser Gly Thr Asp Phe 85 90 95Thr Leu Arg Ile
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr 100 105 110Cys Ala
Gln Asn Leu Glu Leu Pro Leu Thr Phe Gly Ala Gly Thr Lys 115 120
125Leu Glu Leu Lys Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
130 135 140Gly Gly Gly Ser Ser Gln Val Gln Leu Lys Gln Ser Gly Pro
Gly Leu145 150 155 160Val Gln Ser Ser Gln Ser Leu Ser Ile Thr Cys
Thr Val Ser Gly Phe 165 170 175Ser Leu Thr Thr Tyr Ala Val His Trp
Val Arg Gln Ser Pro Gly Lys 180 185 190Gly Leu Glu Trp Leu Gly Val
Ile Trp Ser Gly Gly Ile Thr Asp Tyr 195 200 205Asn Ala Ala Phe Ile
Ser Arg Leu Ser Ile Thr Lys Asp Asp Ser Lys 210 215 220Ser Gln Val
Phe Phe Lys Met Asn Ser Leu Gln Pro Asn Asp Thr Ala225 230 235
240Ile Tyr Tyr Cys Ala Arg Asn Gly Gly Asp Asn Tyr Pro Tyr Tyr Tyr
245 250 255Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser
Ser 260 265 2701241696DNAArtificial sequenceDescription of
Artificial Synthetic nucleotide sequence 124aagcttgccg ccatgaggtt
ctctgctcag cttctggggc tgcttgtgct ctggatccct 60ggatccactg cagatattgt
gatgacgcag gctgcattct ccaatccagt cactcttgga 120acatcagctt
ccatctcctg caggtctagt aagagtctcc tacatagtaa tggcatcact
180tatttgtatt ggtatctgca gaagccaggc cagtctcctc agctcctgat
ttatcagatg 240tccaaccttg cctcaggagt cccagacagg ttcagtagca
gtgggtcagg aactgatttc 300acactgagaa tcagcagagt ggaggctgag
gatgtgggtg tttattactg tgctcaaaat 360ctagaacttc cgctcacgtt
cggtgctggg accaagctgg agctgaaacg gggtggcggt 420ggctcgggcg
gtggtgggtc gggtggcggc ggatcgtcac aggtgcagct gaagcagtca
480ggacctggcc tagtgcagtc ctcacagagc ctgtccatca cctgcacagt
ctctggtttc 540tcattaacta cctatgctgt acactgggtt cgccagtctc
caggaaaggg tctggagtgg 600ctgggagtga tatggagtgg tggaatcaca
gactataatg cagctttcat atccagactg 660agcatcacca aggacgattc
caagagccaa gttttcttta aaatgaacag tctgcaacct 720aatgacacag
ccatttatta ctgtgccaga aatgggggtg ataactaccc ttattactat
780gctatggact actggggtca aggaacctca gtcaccgtct cctctgatct
ggagcccaaa 840tcttctgaca aaactcacac aagcccaccg agcccagcac
ctgaactcct ggggggatcg 900tcagtcttcc tcttcccccc aaaacccaag
gacaccctca tgatctcccg gacccctgag 960gtcacatgcg tggtggtgga
cgtgagccac gaagaccctg aggtcaagtt caactggtac 1020gtggacggcg
tggaggtgca taatgccaag acaaagccgc gggaggagca gtacaacagc
1080acgtaccgtg tggtcagcgt cctcaccgtc ctgcaccagg actggctgaa
tggcaaggag 1140tacaagtgca aggtctccaa
caaagccctc ccagccccca tcgagaaaac catctccaaa 1200gccaaagggc
agccccgaga accacaggtg tacaccctgc ccccatcccg ggatgagctg
1260accaagaacc aggtcagcct gacctgcctg gtcaaaggct tctatcccag
cgacatcgcc 1320gtggagtggg agagcaatgg gcagccggag aacaactaca
agaccacgcc tcccgtgctg 1380gactccgacg gctccttctt cctctacagc
aagctcaccg tggacaagag caggtggcag 1440caggggaacg tcttctcatg
ctccgtgatg catgaggctc tgcacaacca ctacacgcag 1500aagagcctct
ccctgtctcc gggtaaagcg gatccttcga acctgctccc atcctgggcc
1560attaccttaa tctcagtaaa tggaattttt gtgatatgct gcctgaccta
ctgctttgcc 1620ccaagatgca gagagagaag gaggaatgag agattgagaa
gggaaagtgt acgccctgta 1680taaatcgata ctcgag 1696125556PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
125Met Arg Phe Ser Ala Gln Leu Leu Gly Leu Leu Val Leu Trp Ile Pro1
5 10 15Gly Ser Thr Ala Asp Ile Val Met Thr Gln Ala Ala Phe Ser Asn
Pro 20 25 30Val Thr Leu Gly Thr Ser Ala Ser Ile Ser Cys Arg Ser Ser
Lys Ser 35 40 45Leu Leu His Ser Asn Gly Ile Thr Tyr Leu Tyr Trp Tyr
Leu Gln Lys 50 55 60Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Gln Met
Ser Asn Leu Ala65 70 75 80Ser Gly Val Pro Asp Arg Phe Ser Ser Ser
Gly Ser Gly Thr Asp Phe 85 90 95Thr Leu Arg Ile Ser Arg Val Glu Ala
Glu Asp Val Gly Val Tyr Tyr 100 105 110Cys Ala Gln Asn Leu Glu Leu
Pro Leu Thr Phe Gly Ala Gly Thr Lys 115 120 125Leu Glu Leu Lys Arg
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 130 135 140Gly Gly Gly
Ser Ser Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu145 150 155
160Val Gln Ser Ser Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe
165 170 175Ser Leu Thr Thr Tyr Ala Val His Trp Val Arg Gln Ser Pro
Gly Lys 180 185 190Gly Leu Glu Trp Leu Gly Val Ile Trp Ser Gly Gly
Ile Thr Asp Tyr 195 200 205Asn Ala Ala Phe Ile Ser Arg Leu Ser Ile
Thr Lys Asp Asp Ser Lys 210 215 220Ser Gln Val Phe Phe Lys Met Asn
Ser Leu Gln Pro Asn Asp Thr Ala225 230 235 240Ile Tyr Tyr Cys Ala
Arg Asn Gly Gly Asp Asn Tyr Pro Tyr Tyr Tyr 245 250 255Ala Met Asp
Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Asp 260 265 270Leu
Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser Pro Pro Ser Pro 275 280
285Ala Pro Glu Leu Leu Gly Gly Ser Ser Val Phe Leu Phe Pro Pro Lys
290 295 300Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr
Cys Val305 310 315 320Val Val Asp Val Ser His Glu Asp Pro Glu Val
Lys Phe Asn Trp Tyr 325 330 335Val Asp Gly Val Glu Val His Asn Ala
Lys Thr Lys Pro Arg Glu Glu 340 345 350Gln Tyr Asn Ser Thr Tyr Arg
Val Val Ser Val Leu Thr Val Leu His 355 360 365Gln Asp Trp Leu Asn
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 370 375 380Ala Leu Pro
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln385 390 395
400Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
405 410 415Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe
Tyr Pro 420 425 430Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
Pro Glu Asn Asn 435 440 445Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
Asp Gly Ser Phe Phe Leu 450 455 460Tyr Ser Lys Leu Thr Val Asp Lys
Ser Arg Trp Gln Gln Gly Asn Val465 470 475 480Phe Ser Cys Ser Val
Met His Glu Ala Leu His Asn His Tyr Thr Gln 485 490 495Lys Ser Leu
Ser Leu Ser Pro Gly Lys Ala Asp Pro Ser Asn Leu Leu 500 505 510Pro
Ser Trp Ala Ile Thr Leu Ile Ser Val Asn Gly Ile Phe Val Ile 515 520
525Cys Cys Leu Thr Tyr Cys Phe Ala Pro Arg Cys Arg Glu Arg Arg Arg
530 535 540Asn Glu Arg Leu Arg Arg Glu Ser Val Arg Pro Val545 550
5551261683DNAArtificial sequenceDescription of Artificial Synthetic
nucleotide sequence 126aagcttatgg attttcaagt gcagattttc agcttcctgc
taatcagtgc ttcagtcata 60atgtccagag gagtcgacat tgtgctcacc caatctccag
cttctttggc tgtgtctcta 120ggtcagagag ccaccatctc ctgcagagcc
agtgaaagtg ttgaatatta tgtcacaagt 180ttaatgcagt ggtaccaaca
gaaaccagga cagccaccca aactcctcat ctctgctgca 240tccaacgtag
aatctggggt ccctgccagg tttagtggca gtgggtctgg gacagacttc
300agcctcaaca tccatcctgt ggaggaggat gatattgcaa tgtatttctg
tcagcaaagt 360aggaaggttc cttggacgtt cggtggaggc accaagctgg
aaatcaaacg gggtggcggt 420ggctcgggcg gaggtgggtc gggtggcggc
ggatctcagg tgcagctgaa ggagtcagga 480cctggcctgg tggcgccctc
acagagcctg tccatcacat gcaccgtctc agggttctca 540ttaaccggct
atggtgtaaa ctgggttcgc cagcctccag gaaagggtct ggagtggctg
600ggaatgatat ggggtgatgg aagcacagac tataattcag ctctcaaatc
cagactgagc 660atcaccaagg acaactccaa gagccaagtt ttcttaaaaa
tgaacagtct gcaaactgat 720gacacagcca gatactactg tgccagagat
ggttatagta actttcatta ctatgttatg 780gactactggg gtcaaggaac
ctcagtcacc gtctcctcag atctggagcc caaatcttgt 840gacaaaactc
acacatgccc accgtgccca gcacctgaac tcctgggggg accgtcagtc
900ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc
tgaggtcaca 960tgcgtggtgg tggacgtgag ccacgaagac cctgaggtca
agttcaactg gtacgtggac 1020ggcgtggagg tgcataatgc caagacaaag
ccgcgggagg agcagtacaa cagcacgtac 1080cgtgtggtca gcgtcctcac
cgtcctgcac caggactggc tgaatggcaa ggagtacaag 1140tgcaaggtct
ccaacaaagc cctcccagcc cccatcgaga aaaccatctc caaagccaaa
1200gggcagcccc gagaaccaca ggtgtacacc ctgcccccat cccgggatga
gctgaccaag 1260aaccaggtca gcctgacctg cctggtcaaa ggcttctatc
ccagcgacat cgccgtggag 1320tgggagagca atgggcagcc ggagaacaac
tacaagacca cgcctcccgt gctggactcc 1380gacggctcct tcttcctcta
cagcaagctc accgtggaca agagcaggtg gcagcagggg 1440aacgtcttct
catgctccgt gatgcatgag gctctgcaca accactacac gcagaagagc
1500ctctccctgt ctccgggtaa agcggatcct tcgaacctgc tcccatcctg
ggccattacc 1560ttaatctcag taaatggaat ttttgtgata tgctgcctga
cctactgctt tgccccaaga 1620tgcagagaga gaaggaggaa tgagagattg
agaagggaaa gtgtacgccc tgtataaatc 1680gat 1683127556PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
127Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1
5 10 15Val Ile Met Ser Arg Gly Val Asp Ile Val Leu Thr Gln Ser Pro
Ala 20 25 30Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys
Arg Ala 35 40 45Ser Glu Ser Val Glu Tyr Tyr Val Thr Ser Leu Met Gln
Trp Tyr Gln 50 55 60Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Ser
Ala Ala Ser Asn65 70 75 80Val Glu Ser Gly Val Pro Ala Arg Phe Ser
Gly Ser Gly Ser Gly Thr 85 90 95Asp Phe Ser Leu Asn Ile His Pro Val
Glu Glu Asp Asp Ile Ala Met 100 105 110Tyr Phe Cys Gln Gln Ser Arg
Lys Val Pro Trp Thr Phe Gly Gly Gly 115 120 125Thr Lys Leu Glu Ile
Lys Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly 130 135 140Ser Gly Gly
Gly Gly Ser Gln Val Gln Leu Lys Glu Ser Gly Pro Gly145 150 155
160Leu Val Ala Pro Ser Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly
165 170 175Phe Ser Leu Thr Gly Tyr Gly Val Asn Trp Val Arg Gln Pro
Pro Gly 180 185 190Lys Gly Leu Glu Trp Leu Gly Met Ile Trp Gly Asp
Gly Ser Thr Asp 195 200 205Tyr Asn Ser Ala Leu Lys Ser Arg Leu Ser
Ile Thr Lys Asp Asn Ser 210 215 220Lys Ser Gln Val Phe Leu Lys Met
Asn Ser Leu Gln Thr Asp Asp Thr225 230 235 240Ala Arg Tyr Tyr Cys
Ala Arg Asp Gly Tyr Ser Asn Phe His Tyr Tyr 245 250 255Val Met Asp
Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Asp 260 265 270Leu
Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro 275 280
285Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
290 295 300Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr
Cys Val305 310 315 320Val Val Asp Val Ser His Glu Asp Pro Glu Val
Lys Phe Asn Trp Tyr 325 330 335Val Asp Gly Val Glu Val His Asn Ala
Lys Thr Lys Pro Arg Glu Glu 340 345 350Gln Tyr Asn Ser Thr Tyr Arg
Val Val Ser Val Leu Thr Val Leu His 355 360 365Gln Asp Trp Leu Asn
Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 370 375 380Ala Leu Pro
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln385 390 395
400Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
405 410 415Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe
Tyr Pro 420 425 430Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
Pro Glu Asn Asn 435 440 445Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
Asp Gly Ser Phe Phe Leu 450 455 460Tyr Ser Lys Leu Thr Val Asp Lys
Ser Arg Trp Gln Gln Gly Asn Val465 470 475 480Phe Ser Cys Ser Val
Met His Glu Ala Leu His Asn His Tyr Thr Gln 485 490 495Lys Ser Leu
Ser Leu Ser Pro Gly Lys Ala Asp Pro Ser Asn Leu Leu 500 505 510Pro
Ser Trp Ala Ile Thr Leu Ile Ser Val Asn Gly Ile Phe Val Ile 515 520
525Cys Cys Leu Thr Tyr Cys Phe Ala Pro Arg Cys Arg Glu Arg Arg Arg
530 535 540Asn Glu Arg Leu Arg Arg Glu Ser Val Arg Pro Val545 550
5551281800DNAArtificial SequenceDescription of Artificial Synthetic
nucleotide sequence 128aagcttgccg ccatggattt tcaagtgcag attttcagct
tcctgctaat cagtgcttca 60gtcataattg ccagaggaca aattgttctc tcccagtctc
cagcaatcct gtctgcatct 120ccaggggaga aggtcacaat gacttgcagg
gccagctcaa gtgtaagtta catgcactgg 180taccagcaga agccaggatc
ctcccccaaa ccctggattt atgccccatc caacctggct 240tctggagtcc
ctgctcgctt cagtggcagt gggtctggga cctcttactc tctcacaatc
300agcagagtgg aggctgaaga tgctgccact tattactgcc agcagtggag
ttttaaccca 360cccacgttcg gtgctgggac caagctggag ctgaaaggtg
gcggtggctc gggcggtggt 420ggatctggag gaggtgggag ctctcaggct
tatctacagc agtctggggc tgagctggtg 480aggcctgggg cctcagtgaa
gatgtcctgc aaggcttctg gctacacatt taccagttac 540aatatgcact
gggtaaagca gacacctaga cagggcctgg aatggattgg agctatttat
600ccaggaaatg gtgatacttc ctacaatcag aagttcaagg gcaaggccac
actgactgta 660gacaaatcct ccagcacagc ctacatgcag ctcagcagcc
tgacatctga agactctgcg 720gtctatttct gtgcaagagt ggtgtactat
agtaactctt actggtactt cgatgtctgg 780ggcacaggga ccacggtcac
cgtctctgat cacgtctgct ccagggactt caccccgccc 840accgtgaaga
tcttacagtc gtcctgcgac ggcggcgggc acttcccccc gaccatccag
900ctcctgtgcc tcgtctctgg gtacacccca gggactatca acatcacctg
gctggaggac 960gggcaggtca tggacgtgga cttgtccacc gcctctacca
cgcaggaggg tgagctggcc 1020tccacacaaa gcgagctcac cctcagccag
aagcactggc tgtcagaccg cacctacacc 1080tgccaggtca cctatcaagg
tcacaccttt gaggacagca ccaagaagtg tgcagattcc 1140aacccgagag
gggtgagcgc ctacctaagc cggcccagcc cgttcgacct gttcatccgc
1200aagtcgccca cgatcacctg tctggtggtg gacctggcac ccagcaaggg
gaccgtgaac 1260ctgacctggt cccgggccag tgggaagcct gtgaaccact
ccaccagaaa ggaggagaag 1320cagcgcaatg gcacgttaac cgtcacgtcc
accctgccgg tgggcacccg agactggatc 1380gagggggaga cctaccagtg
cagggtgacc cacccccacc tgcccagggc cctcatgcgg 1440tccacgacca
agaccagcgg cccgcgtgct gccccggaag tctatgcgtt tgcgacgccg
1500gagtggccgg ggagccggga caagcgcacc ctcgcctgcc tgatccagaa
cttcatgcct 1560gaggacatct cggtgcagtg gctgcacaac gaggtgcagc
tcccggacgc ccggcacagc 1620acgacgcagc cccgcaagac caagggctcc
ggcttcttcg tcttcagccg cctggaggtg 1680accagggccg aatgggagca
gaaagatgag ttcatctgcc gtgcagtcca tgaggcagcg 1740agcccctcac
agaccgtcca gcgagcggtg tctgtaaatc ccggtaaatg ataatctaga
1800129592PRTArtificial sequenceDescription of Artificial Synthetic
amino acid sequence 129Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu
Leu Ile Ser Ala Ser1 5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu
Ser Gln Ser Pro Ala Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val
Thr Met Thr Cys Arg Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp
Tyr Gln Gln Lys Pro Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala
Pro Ser Asn Leu Ala Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly
Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu
Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe
Asn Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 115 120
125Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser
130 135 140Gln Ala Tyr Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro
Gly Ala145 150 155 160Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr
Thr Phe Thr Ser Tyr 165 170 175Asn Met His Trp Val Lys Gln Thr Pro
Arg Gln Gly Leu Glu Trp Ile 180 185 190Gly Ala Ile Tyr Pro Gly Asn
Gly Asp Thr Ser Tyr Asn Gln Lys Phe 195 200 205Lys Gly Lys Ala Thr
Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 210 215 220Met Gln Leu
Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys225 230 235
240Ala Arg Val Val Tyr Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp
245 250 255Gly Thr Gly Thr Thr Val Thr Val Ser Asp His Val Cys Ser
Arg Asp 260 265 270Phe Thr Pro Pro Thr Val Lys Ile Leu Gln Ser Ser
Cys Asp Gly Gly 275 280 285Gly His Phe Pro Pro Thr Ile Gln Leu Leu
Cys Leu Val Ser Gly Tyr 290 295 300Thr Pro Gly Thr Ile Asn Ile Thr
Trp Leu Glu Asp Gly Gln Val Met305 310 315 320Asp Val Asp Leu Ser
Thr Ala Ser Thr Thr Gln Glu Gly Glu Leu Ala 325 330 335Ser Thr Gln
Ser Glu Leu Thr Leu Ser Gln Lys His Trp Leu Ser Asp 340 345 350Arg
Thr Tyr Thr Cys Gln Val Thr Tyr Gln Gly His Thr Phe Glu Asp 355 360
365Ser Thr Lys Lys Cys Ala Asp Ser Asn Pro Arg Gly Val Ser Ala Tyr
370 375 380Leu Ser Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser
Pro Thr385 390 395 400Ile Thr Cys Leu Val Val Asp Leu Ala Pro Ser
Lys Gly Thr Val Asn 405 410 415Leu Thr Trp Ser Arg Ala Ser Gly Lys
Pro Val Asn His Ser Thr Arg 420 425 430Lys Glu Glu Lys Gln Arg Asn
Gly Thr Leu Thr Val Thr Ser Thr Leu 435 440 445Pro Val Gly Thr Arg
Asp Trp Ile Glu Gly Glu Thr Tyr Gln Cys Arg 450 455 460Val Thr His
Pro His Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys465 470 475
480Thr Ser Gly Pro Arg Ala Ala Pro Glu Val Tyr Ala Phe Ala Thr Pro
485 490 495Glu Trp Pro Gly Ser Arg Asp Lys Arg Thr Leu Ala Cys Leu
Ile Gln 500 505 510Asn Phe Met Pro Glu Asp Ile Ser Val Gln Trp Leu
His Asn Glu Val 515 520 525Gln Leu Pro Asp Ala Arg His Ser Thr Thr
Gln Pro Arg Lys Thr Lys 530 535 540Gly Ser Gly Phe Phe Val Phe Ser
Arg Leu Glu Val Thr Arg Ala Glu545 550 555 560Trp Glu Gln Lys Asp
Glu Phe Ile Cys Arg Ala Val His Glu Ala Ala 565 570 575Ser Pro Ser
Gln Thr Val Gln Arg Ala Val Ser Val Asn Pro Gly Lys 580 585
5901301521DNAArtificial sequenceDescription of Artificial Synthetic
nucleotide sequence 130aagcttgccg ccatggattt tcaagtgcag attttcagct
tcctgctaat cagtgcttca 60gtcataattg ccagaggaca aattgttctc
tcccagtctc
cagcaatcct gtctgcatct 120ccaggggaga aggtcacaat gacttgcagg
gccagctcaa gtgtaagtta catgcactgg 180taccagcaga agccaggatc
ctcccccaaa ccctggattt atgccccatc caacctggct 240tctggagtcc
ctgctcgctt cagtggcagt gggtctggga cctcttactc tctcacaatc
300agcagagtgg aggctgaaga tgctgccact tattactgcc agcagtggag
ttttaaccca 360cccacgttcg gtgctgggac caagctggag ctgaaagatg
gcggtggctc gggcggtggt 420ggatctggag gaggtgggag ctctcaggct
tatctacagc agtctggggc tgagctggtg 480aggcctgggg cctcagtgaa
gatgtcctgc aaggcttctg gctacacatt taccagttac 540aatatgcact
gggtaaagca gacacctaga cagggcctgg aatggattgg agctatttat
600ccaggaaatg gtgatacttc ctacaatcag aagttcaagg gcaaggccac
actgactgta 660gacaaatcct ccagcacagc ctacatgcag ctcagcagcc
tgacatctga agactctgcg 720gtctatttct gtgcaagagt ggtgtactat
agtaactctt actggtactt cgatgtctgg 780ggcacaggga ccacggtcac
cgtctcttct gatcaggagc ccaaatcttc tgacaaaact 840cacacatccc
caccgtcccc agcacctgaa ctcctggggg gatcgtcagt cttcctcttc
900cccccaaaac ccaaggacac cctcatgatc tcccggaccc ctgaggtcac
atgcgtggtg 960gtggacgtga gccacgaaga ccctgaggtc aagttcaact
ggtacgtgga cggcgtggag 1020gtgcataatg ccaagacaaa gccgcgggag
gagcagtaca acagcacgta ccgtgtggtc 1080agcgtcctca ccgtcctgca
ccaggactgg ctgaatggca aggagtacaa gtgcaaggtc 1140tccaacaaag
ccctcccagc ccccatcgag aaaacaatct ccaaagccaa agggcagccc
1200cgagaaccac aggtgtacac cctgccccca tcccgggatg agctgaccaa
gaaccaggtc 1260agcctgacct gcctggtcaa aggcttctat cccagcgaca
tcgccgtgga gtgggagagc 1320aatgggcagc cggagaacaa ctacaagacc
acgcctcccg tgctggactc cgacggctcc 1380ttcttcctct acagcaagct
caccgtggac aagagcaggt ggcagcaggg gaacgtcttc 1440tcatgctccg
tgatgcatga ggctctgcac aaccactaca cgcagaagag cctctccctg
1500tctccgggta aatgatctag a 1521131500PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
131Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1
5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu Ser Gln Ser Pro Ala
Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg
Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro
Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala Pro Ser Asn Leu Ala
Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr
Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu Ala Glu Asp Ala Ala
Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe Asn Pro Pro Thr Phe
Gly Ala Gly Thr Lys Leu Glu Leu Lys 115 120 125Asp Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser 130 135 140Gln Ala Tyr
Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala145 150 155
160Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
165 170 175Asn Met His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Glu
Trp Ile 180 185 190Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr
Asn Gln Lys Phe 195 200 205Lys Gly Lys Ala Thr Leu Thr Val Asp Lys
Ser Ser Ser Thr Ala Tyr 210 215 220Met Gln Leu Ser Ser Leu Thr Ser
Glu Asp Ser Ala Val Tyr Phe Cys225 230 235 240Ala Arg Val Val Tyr
Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp 245 250 255Gly Thr Gly
Thr Thr Val Thr Val Ser Ser Asp Gln Glu Pro Lys Ser 260 265 270Ser
Asp Lys Thr His Thr Ser Pro Pro Ser Pro Ala Pro Glu Leu Leu 275 280
285Gly Gly Ser Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
290 295 300Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
Val Ser305 310 315 320His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
Val Asp Gly Val Glu 325 330 335Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln Tyr Asn Ser Thr 340 345 350Tyr Arg Val Val Ser Val Leu
Thr Val Leu His Gln Asp Trp Leu Asn 355 360 365Gly Lys Glu Tyr Lys
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 370 375 380Ile Glu Lys
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln385 390 395
400Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
405 410 415Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
Ala Val 420 425 430Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
Lys Thr Thr Pro 435 440 445Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
Leu Tyr Ser Lys Leu Thr 450 455 460Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn Val Phe Ser Cys Ser Val465 470 475 480Met His Glu Ala Leu
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 485 490 495Ser Pro Gly
Lys 5001321536DNAArtificial sequenceDescription of Artificial
Synthetic nucleotide sequence 132aagcttgccg ccatgaggtt ctctgctcag
cttctggggc tgcttgtgct ctggatccct 60ggatccactg cagatattgt gatgacgcag
gctgcattct ccaatccagt cactcttgga 120acatcagctt ccatctcctg
caggtctagt aagagtctcc tacatagtaa tggcatcact 180tatttgtatt
ggtatctgca gaagccaggc cagtctcctc agctcctgat ttatcagatg
240tccaaccttg cctcaggagt cccagacagg ttcagtagca gtgggtcagg
aactgatttc 300acactgagaa tcagcagagt ggaggctgag gatgtgggtg
tttattactg tgctcaaaat 360ctagaacttc cgctcacgtt cggtgctggg
accaagctgg agctgaaacg gggtggcggt 420ggctcgggcg gtggtgggtc
gggtggcggc ggatcgtcac aggtgcagct gaagcagtca 480ggacctggcc
tagtgcagtc ctcacagagc ctgtccatca cctgcacagt ctctggtttc
540tcattaacta cctatgctgt acactgggtt cgccagtctc caggaaaggg
tctggagtgg 600ctgggagtga tatggagtgg tggaatcaca gactataatg
cagctttcat atccagactg 660agcatcacca aggacgattc caagagccaa
gttttcttta aaatgaacag tctgcaacct 720aatgacacag ccatttatta
ctgtgccaga aatgggggtg ataactaccc ttattactat 780gctatggact
actggggtca aggaacctca gtcaccgtct cctctgatca ggagcccaaa
840tcttctgaca aaactcacac atccccaccg tccccagcac ctgaactcct
ggggggaccg 900tcagtcttcc tcttcccccc aaaacccaag gacaccctca
tgatctcccg gacccctgag 960gtcacatgcg tggtggtgga cgtgagccac
gaagaccctg aggtcaagtt caactggtac 1020gtggacggcg tggaggtgca
taatgccaag acaaagccgc gggaggagca gtacaacagc 1080acgtaccgtg
tggtcagcgt cctcaccgtc ctgcaccagg actggctgaa tggcaaggag
1140tacaagtgca aggtctccaa caaagccctc ccagccccca tcgagaaaac
aatctccaaa 1200gccaaagggc agccccgaga accacaggtg tacaccctgc
ccccatcccg ggatgagctg 1260accaagaacc aggtcagcct gacctgcctg
gtcaaaggct tctatcccag cgacatcgcc 1320gtggagtggg agagcaatgg
gcagccggag aacaactaca agaccacgcc tcccgtgctg 1380gactccgacg
gctccttctt cctctacagc aagctcaccg tggacaagag caggtggcag
1440caggggaacg tcttctcatg ctccgtgatg catgaggctc tgcacaacca
ctacacgcag 1500aagagcctct ccctgtctcc gggtaaatga tctaga
1536133505PRTArtificial sequenceDescription of Artificial Synthetic
amino acid sequence 133Met Arg Phe Ser Ala Gln Leu Leu Gly Leu Leu
Val Leu Trp Ile Pro1 5 10 15Gly Ser Thr Ala Asp Ile Val Met Thr Gln
Ala Ala Phe Ser Asn Pro 20 25 30Val Thr Leu Gly Thr Ser Ala Ser Ile
Ser Cys Arg Ser Ser Lys Ser 35 40 45Leu Leu His Ser Asn Gly Ile Thr
Tyr Leu Tyr Trp Tyr Leu Gln Lys 50 55 60Pro Gly Gln Ser Pro Gln Leu
Leu Ile Tyr Gln Met Ser Asn Leu Ala65 70 75 80Ser Gly Val Pro Asp
Arg Phe Ser Ser Ser Gly Ser Gly Thr Asp Phe 85 90 95Thr Leu Arg Ile
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr 100 105 110Cys Ala
Gln Asn Leu Glu Leu Pro Leu Thr Phe Gly Ala Gly Thr Lys 115 120
125Leu Glu Leu Lys Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
130 135 140Gly Gly Gly Ser Ser Gln Val Gln Leu Lys Gln Ser Gly Pro
Gly Leu145 150 155 160Val Gln Ser Ser Gln Ser Leu Ser Ile Thr Cys
Thr Val Ser Gly Phe 165 170 175Ser Leu Thr Thr Tyr Ala Val His Trp
Val Arg Gln Ser Pro Gly Lys 180 185 190Gly Leu Glu Trp Leu Gly Val
Ile Trp Ser Gly Gly Ile Thr Asp Tyr 195 200 205Asn Ala Ala Phe Ile
Ser Arg Leu Ser Ile Thr Lys Asp Asp Ser Lys 210 215 220Ser Gln Val
Phe Phe Lys Met Asn Ser Leu Gln Pro Asn Asp Thr Ala225 230 235
240Ile Tyr Tyr Cys Ala Arg Asn Gly Gly Asp Asn Tyr Pro Tyr Tyr Tyr
245 250 255Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser
Ser Asp 260 265 270Gln Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser
Pro Pro Ser Pro 275 280 285Ala Pro Glu Leu Leu Gly Gly Pro Ser Val
Phe Leu Phe Pro Pro Lys 290 295 300Pro Lys Asp Thr Leu Met Ile Ser
Arg Thr Pro Glu Val Thr Cys Val305 310 315 320Val Val Asp Val Ser
His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr 325 330 335Val Asp Gly
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 340 345 350Gln
Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 355 360
365Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
370 375 380Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys
Gly Gln385 390 395 400Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
Ser Arg Asp Glu Leu 405 410 415Thr Lys Asn Gln Val Ser Leu Thr Cys
Leu Val Lys Gly Phe Tyr Pro 420 425 430Ser Asp Ile Ala Val Glu Trp
Glu Ser Asn Gly Gln Pro Glu Asn Asn 435 440 445Tyr Lys Thr Thr Pro
Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu 450 455 460Tyr Ser Lys
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val465 470 475
480Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
485 490 495Lys Ser Leu Ser Leu Ser Pro Gly Lys 500
5051341521DNAArtificial SequenceDescription of Artificial Synthetic
nucleotide sequence 134aagcttgccg ccatggattt tcaagtgcag attttcagct
tcctgctaat cagtgcttca 60gtcataattg ccagaggaca aattgttctc tcccagtctc
cagcaatcct gtctgcatct 120ccaggggaga aggtcacaat gacttgcagg
gccagctcaa gtgtaagtta catgcactgg 180taccagcaga agccaggatc
ctcccccaaa ccctggattt atgccccatc caacctggct 240tctggagtcc
ctgctcgctt cagtggcagt gggtctggga cctcttactc tctcacaatc
300agcagagtgg aggctgaaga tgctgccact tattactgcc agcagtggag
ttttaaccca 360cccacgttcg gtgctgggac caagctggag ctgaaagatg
gcggtggctc gggcggtggt 420ggatctggag gaggtgggag ctctcaggct
tatctacagc agtctggggc tgagctggtg 480aggcctgggg cctcagtgaa
gatgtcctgc aaggcttctg gctacacatt taccagttac 540aatatgcact
gggtaaagca gacacctaga cagggcctgg aatggattgg agctatttat
600ccaggaaatg gtgatacttc ctacaatcag aagttcaagg gcaaggccac
actgactgta 660gacaaatcct ccagcacagc ctacatgcag ctcagcagcc
tgacatctga agactctgcg 720gtctatttct gtgcaagagt ggtgtactat
agtaactctt actggtactt cgatgtctgg 780ggcacaggga ccacggtcac
cgtctcttct gatcaggagc ccaaatcttg tgacaaaact 840cacacatccc
caccgtcccc agcacctgaa ctcctggggg gaccgtcagt cttcctcttc
900cccccaaaac ccaaggacac cctcatgatc tcccggaccc ctgaggtcac
atgcgtggtg 960gtggacgtga gccacgaaga ccctgaggtc aagttcaact
ggtacgtgga cggcgtggag 1020gtgcataatg ccaagacaaa gccgcgggag
gagcagtaca acagcacgta ccgtgtggtc 1080agcgtcctca ccgtcctgca
ccaggactgg ctgaatggca aggagtacaa gtgcaaggtc 1140tccaacaaag
ccctcccagc ccccatcgag aaaacaatct ccaaagccaa agggcagccc
1200cgagaaccac aggtgtacac cctgccccca tcccgggatg agctgaccaa
gaaccaggtc 1260agcctgacct gcctggtcaa aggcttctat cccagcgaca
tcgccgtgga gtgggagagc 1320aatgggcagc cggagaacaa ctacaagacc
acgcctcccg tgctggactc cgacggctcc 1380ttcttcctct acagcaagct
caccgtggac aagagcaggt ggcagcaggg gaacgtcttc 1440tcatgctccg
tgatgcatga ggctctgcac aaccactaca cgcagaagag cctctccctg
1500tctccgggta aatgatctag a 1521135500PRTArtificial
SequenceDescription of Artificial Synthetic amino acid sequence
135Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1
5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu Ser Gln Ser Pro Ala
Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg
Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro
Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala Pro Ser Asn Leu Ala
Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr
Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu Ala Glu Asp Ala Ala
Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe Asn Pro Pro Thr Phe
Gly Ala Gly Thr Lys Leu Glu Leu Lys 115 120 125Asp Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser 130 135 140Gln Ala Tyr
Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala145 150 155
160Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
165 170 175Asn Met His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Glu
Trp Ile 180 185 190Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr
Asn Gln Lys Phe 195 200 205Lys Gly Lys Ala Thr Leu Thr Val Asp Lys
Ser Ser Ser Thr Ala Tyr 210 215 220Met Gln Leu Ser Ser Leu Thr Ser
Glu Asp Ser Ala Val Tyr Phe Cys225 230 235 240Ala Arg Val Val Tyr
Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp 245 250 255Gly Thr Gly
Thr Thr Val Thr Val Ser Ser Asp Gln Glu Pro Lys Ser 260 265 270Cys
Asp Lys Thr His Thr Ser Pro Pro Ser Pro Ala Pro Glu Leu Leu 275 280
285Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
290 295 300Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
Val Ser305 310 315 320His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
Val Asp Gly Val Glu 325 330 335Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln Tyr Asn Ser Thr 340 345 350Tyr Arg Val Val Ser Val Leu
Thr Val Leu His Gln Asp Trp Leu Asn 355 360 365Gly Lys Glu Tyr Lys
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 370 375 380Ile Glu Lys
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln385 390 395
400Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
405 410 415Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
Ala Val 420 425 430Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
Lys Thr Thr Pro 435 440 445Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
Leu Tyr Ser Lys Leu Thr 450 455 460Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn Val Phe Ser Cys Ser Val465 470 475 480Met His Glu Ala Leu
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 485 490 495Ser Pro Gly
Lys 5001361521DNAArtificial SequenceDescription of Artificial
Synthetic nucleotide sequence 136aagcttgccg ccatggattt tcaagtgcag
attttcagct tcctgctaat cagtgcttca 60gtcataattg ccagaggaca aattgttctc
tcccagtctc cagcaatcct gtctgcatct 120ccaggggaga aggtcacaat
gacttgcagg gccagctcaa gtgtaagtta catgcactgg 180taccagcaga
agccaggatc ctcccccaaa ccctggattt atgccccatc caacctggct
240tctggagtcc ctgctcgctt cagtggcagt gggtctggga cctcttactc
tctcacaatc 300agcagagtgg aggctgaaga tgctgccact tattactgcc
agcagtggag ttttaaccca 360cccacgttcg gtgctgggac caagctggag
ctgaaagatg gcggtggctc gggcggtggt 420ggatctggag gaggtgggag
ctctcaggct tatctacagc agtctggggc tgagctggtg 480aggcctgggg
cctcagtgaa gatgtcctgc aaggcttctg gctacacatt taccagttac
540aatatgcact gggtaaagca gacacctaga cagggcctgg aatggattgg
agctatttat 600ccaggaaatg gtgatacttc ctacaatcag aagttcaagg
gcaaggccac actgactgta 660gacaaatcct ccagcacagc ctacatgcag
ctcagcagcc tgacatctga agactctgcg 720gtctatttct gtgcaagagt
ggtgtactat agtaactctt actggtactt cgatgtctgg 780ggcacaggga
ccacggtcac cgtctcttct gatcaggagc ccaaatcttc tgacaaaact
840cacacatgcc caccgtcccc agcacctgaa ctcctggggg gaccgtcagt
cttcctcttc 900cccccaaaac ccaaggacac cctcatgatc tcccggaccc
ctgaggtcac atgcgtggtg 960gtggacgtga gccacgaaga ccctgaggtc
aagttcaact ggtacgtgga cggcgtggag 1020gtgcataatg ccaagacaaa
gccgcgggag gagcagtaca acagcacgta ccgtgtggtc 1080agcgtcctca
ccgtcctgca ccaggactgg ctgaatggca aggagtacaa gtgcaaggtc
1140tccaacaaag ccctcccagc ccccatcgag aaaacaatct ccaaagccaa
agggcagccc 1200cgagaaccac aggtgtacac cctgccccca tcccgggatg
agctgaccaa gaaccaggtc 1260agcctgacct gcctggtcaa aggcttctat
cccagcgaca tcgccgtgga gtgggagagc 1320aatgggcagc cggagaacaa
ctacaagacc acgcctcccg tgctggactc cgacggctcc 1380ttcttcctct
acagcaagct caccgtggac aagagcaggt ggcagcaggg gaacgtcttc
1440tcatgctccg tgatgcatga ggctctgcac aaccactaca cgcagaagag
cctctccctg 1500tctccgggta aatgatctag a 1521137500PRTArtificial
SequenceDescription of Artificial Synthetic amino acid sequence
137Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1
5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu Ser Gln Ser Pro Ala
Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg
Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro
Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala Pro Ser Asn Leu Ala
Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr
Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu Ala Glu Asp Ala Ala
Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe Asn Pro Pro Thr Phe
Gly Ala Gly Thr Lys Leu Glu Leu Lys 115 120 125Asp Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser 130 135 140Gln Ala Tyr
Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala145 150 155
160Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
165 170 175Asn Met His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Glu
Trp Ile 180 185 190Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr
Asn Gln Lys Phe 195 200 205Lys Gly Lys Ala Thr Leu Thr Val Asp Lys
Ser Ser Ser Thr Ala Tyr 210 215 220Met Gln Leu Ser Ser Leu Thr Ser
Glu Asp Ser Ala Val Tyr Phe Cys225 230 235 240Ala Arg Val Val Tyr
Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp 245 250 255Gly Thr Gly
Thr Thr Val Thr Val Ser Ser Asp Gln Glu Pro Lys Ser 260 265 270Ser
Asp Lys Thr His Thr Cys Pro Pro Ser Pro Ala Pro Glu Leu Leu 275 280
285Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
290 295 300Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
Val Ser305 310 315 320His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
Val Asp Gly Val Glu 325 330 335Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln Tyr Asn Ser Thr 340 345 350Tyr Arg Val Val Ser Val Leu
Thr Val Leu His Gln Asp Trp Leu Asn 355 360 365Gly Lys Glu Tyr Lys
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 370 375 380Ile Glu Lys
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln385 390 395
400Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
405 410 415Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
Ala Val 420 425 430Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
Lys Thr Thr Pro 435 440 445Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
Leu Tyr Ser Lys Leu Thr 450 455 460Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn Val Phe Ser Cys Ser Val465 470 475 480Met His Glu Ala Leu
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 485 490 495Ser Pro Gly
Lys 5001381521DNAArtificial SequenceDescription of Artificial
Synthetic nucleotide sequence 138aagcttgccg ccatggattt tcaagtgcag
attttcagct tcctgctaat cagtgcttca 60gtcataattg ccagaggaca aattgttctc
tcccagtctc cagcaatcct gtctgcatct 120ccaggggaga aggtcacaat
gacttgcagg gccagctcaa gtgtaagtta catgcactgg 180taccagcaga
agccaggatc ctcccccaaa ccctggattt atgccccatc caacctggct
240tctggagtcc ctgctcgctt cagtggcagt gggtctggga cctcttactc
tctcacaatc 300agcagagtgg aggctgaaga tgctgccact tattactgcc
agcagtggag ttttaaccca 360cccacgttcg gtgctgggac caagctggag
ctgaaagatg gcggtggctc gggcggtggt 420ggatctggag gaggtgggag
ctctcaggct tatctacagc agtctggggc tgagctggtg 480aggcctgggg
cctcagtgaa gatgtcctgc aaggcttctg gctacacatt taccagttac
540aatatgcact gggtaaagca gacacctaga cagggcctgg aatggattgg
agctatttat 600ccaggaaatg gtgatacttc ctacaatcag aagttcaagg
gcaaggccac actgactgta 660gacaaatcct ccagcacagc ctacatgcag
ctcagcagcc tgacatctga agactctgcg 720gtctatttct gtgcaagagt
ggtgtactat agtaactctt actggtactt cgatgtctgg 780ggcacaggga
ccacggtcac cgtctcttct gatcaggagc ccaaatcttc tgacaaaact
840cacacatccc caccgtgccc agcacctgaa ctcctggggg gaccgtcagt
cttcctcttc 900cccccaaaac ccaaggacac cctcatgatc tcccggaccc
ctgaggtcac atgcgtggtg 960gtggacgtga gccacgaaga ccctgaggtc
aagttcaact ggtacgtgga cggcgtggag 1020gtgcataatg ccaagacaaa
gccgcgggag gagcagtaca acagcacgta ccgtgtggtc 1080agcgtcctca
ccgtcctgca ccaggactgg ctgaatggca aggagtacaa gtgcaaggtc
1140tccaacaaag ccctcccagc ccccatcgag aaaacaatct ccaaagccaa
agggcagccc 1200cgagaaccac aggtgtacac cctgccccca tcccgggatg
agctgaccaa gaaccaggtc 1260agcctgacct gcctggtcaa aggcttctat
cccagcgaca tcgccgtgga gtgggagagc 1320aatgggcagc cggagaacaa
ctacaagacc acgcctcccg tgctggactc cgacggctcc 1380ttcttcctct
acagcaagct caccgtggac aagagcaggt ggcagcaggg gaacgtcttc
1440tcatgctccg tgatgcatga ggctctgcac aaccactaca cgcagaagag
cctctccctg 1500tctccgggta aatgatctag a 1521139500PRTArtificial
SequenceDescription of Artificial Synthetic amino acid sequence
139Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1
5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu Ser Gln Ser Pro Ala
Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg
Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro
Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala Pro Ser Asn Leu Ala
Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr
Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu Ala Glu Asp Ala Ala
Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe Asn Pro Pro Thr Phe
Gly Ala Gly Thr Lys Leu Glu Leu Lys 115 120 125Asp Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser 130 135 140Gln Ala Tyr
Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala145 150 155
160Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
165 170 175Asn Met His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Glu
Trp Ile 180 185 190Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr
Asn Gln Lys Phe 195 200 205Lys Gly Lys Ala Thr Leu Thr Val Asp Lys
Ser Ser Ser Thr Ala Tyr 210 215 220Met Gln Leu Ser Ser Leu Thr Ser
Glu Asp Ser Ala Val Tyr Phe Cys225 230 235 240Ala Arg Val Val Tyr
Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp 245 250 255Gly Thr Gly
Thr Thr Val Thr Val Ser Ser Asp Gln Glu Pro Lys Ser 260 265 270Ser
Asp Lys Thr His Thr Ser Pro Pro Cys Pro Ala Pro Glu Leu Leu 275 280
285Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
290 295 300Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
Val Ser305 310 315 320His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
Val Asp Gly Val Glu 325 330 335Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln Tyr Asn Ser Thr 340 345 350Tyr Arg Val Val Ser Val Leu
Thr Val Leu His Gln Asp Trp Leu Asn 355 360 365Gly Lys Glu Tyr Lys
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 370 375 380Ile Glu Lys
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln385 390 395
400Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
405 410 415Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
Ala Val 420 425 430Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
Lys Thr Thr Pro 435 440 445Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
Leu Tyr Ser Lys Leu Thr 450 455 460Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn Val Phe Ser Cys Ser Val465 470 475 480Met His Glu Ala Leu
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 485 490 495Ser Pro Gly
Lys 50014044DNAArtificial sequenceDescription of Artificial
Synthetic primer 140gttgttgatc aggagcccaa atcttctgac aaaactcaca
catg 4414154DNAArtificial sequenceDescription of Artificial
Synthetic primer 141gttgttgatc aggagcccaa atcttgtgac aaaactcaca
catctccacc gtgc 5414263DNAArtificial sequenceDescription of
Artificial Synthetic primer 142gttgttgatc aggagcccaa atcttgtgac
aaaactcaca catgtccacc gtccccagca 60cct 63143324DNAArtificial
SequenceDescription of Artificial Synthetic nucleotide sequence
143gggcagcccc gagaaccaca ggtgtacacc ctgcccccat cccgggagga
gatgaccaag 60aaccaggtca gcctgacctg cctggtcaaa ggcttctatc ccagcgacat
cgccgtggag 120tgggagagca atgggcagcc ggagaacaac tacaagacca
cgcctcccgt gctggactcc 180gacggctcct tctacctcta tagcaagctc
accgtggaca agagcaggtg gcagcagggg 240aacgtcttct catgctccgt
gatgcatgag gctctgcaca accactacac gcagaagagc 300ctctccctgt
ccccgggtaa atga 324144107PRTArtificial SequenceDescription of
Artificial Synthetic amino acid sequence 144Gly Gln Pro Arg Glu Pro
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu1 5 10 15Glu Met Thr Lys Asn
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe 20 25 30Tyr Pro Ser Asp
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 35 40 45Asn Asn Tyr
Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 50 55 60Tyr Leu
Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly65 70 75
80Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr
85 90 95Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 100
105145324DNAArtificial SequenceDescription of Artificial Synthetic
nucleotide sequence 145gggcagcccc gagaaccaca ggtgtacacc ctgcccccat
cccgggagga gatgaccaag 60aaccaggtca gcctgacctg cctggtcaaa ggcttctatc
ccagcgacat cgccgtggag 120tgggagagca atgggcagcc ggagaacaac
tacaagacca cgcctcccgt gctggactcc 180gacggctcct tcgccctcta
tagcaagctc accgtggaca agagcaggtg gcagcagggg 240aacgtcttct
catgctccgt gatgcatgag gctctgcaca accactacac gcagaagagc
300ctctccctgt ccccgggtaa atga 324146107PRTArtificial
SequenceDescription of Artificial Synthetic amino acid sequence
146Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu1
5 10 15Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
Phe 20 25 30Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
Pro Glu 35 40 45Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
Gly Ser Phe 50 55 60Ala Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
Trp Gln Gln Gly65 70 75 80Asn Val Phe Ser Cys Ser Val Met His Glu
Ala Leu His Asn His Tyr 85 90 95Thr Gln Lys Ser Leu Ser Leu Ser Pro
Gly Lys 100 105147324DNAArtificial SequenceDescription of
Artificial Synthetic nucleotide sequence 147gggcagcccc gagaaccaca
ggtgtacacc ctgcccccat cccgggagga gatgaccaag 60aaccaggtca gcctgacctg
cctggtcaaa ggcttctatc ccagcgacat cgccgtggag 120tgggagagca
atgggcagcc ggagaacaac tacaagacca cgcctcccgt gctggactcc
180gacggctcct tcttcctcgc cagcaagctc accgtggaca agagcaggtg
gcagcagggg 240aacgtcttct catgctccgt gatgcatgag gctctgcaca
accactacac gcagaagagc 300ctctccctgt ccccgggtaa atga
324148107PRTArtificial SequenceDescription of Artificial Synthetic
amino acid sequence 148Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
Pro Pro Ser Arg Glu1 5 10 15Glu Met Thr Lys Asn Gln Val Ser Leu Thr
Cys Leu Val Lys Gly Phe 20 25 30Tyr Pro Ser Asp Ile Ala Val Glu Trp
Glu Ser Asn Gly Gln Pro Glu 35 40 45Asn Asn Tyr Lys Thr Thr Pro Pro
Val Leu Asp Ser Asp Gly Ser Phe 50 55 60Phe Leu Ala Ser Lys Leu Thr
Val Asp Lys Ser Arg Trp Gln Gln Gly65 70 75 80Asn Val Phe Ser Cys
Ser Val Met His Glu Ala Leu His Asn His Tyr 85 90 95Thr Gln Lys Ser
Leu Ser Leu Ser Pro Gly Lys 100 105149324DNAArtificial
SequenceDescription of Artificial Synthetic nucleotide sequence
149gggcagcccc gagaaccaca ggtgtacacc ctgcccccat cccgggagga
gatgaccaag 60aaccaggtca gcctgacctg cctggtcaaa ggcttctatc ccagcgacat
cgccgtggag 120tgggagagca atgggcagcc ggagaacaac tacaagacca
cgcctcccgt gctggactcc 180gacggctcct tctacctcgc cagcaagctc
accgtggaca agagcaggtg gcagcagggg 240aacgtcttct catgctccgt
gatgcatgag gctctgcaca accactacac gcagaagagc 300ctctccctgt
ccccgggtaa atga 324150107PRTArtificial SequenceDescription of
Artificial Synthetic amino acid sequence 150Gly Gln Pro Arg Glu Pro
Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu1 5 10 15Glu Met Thr Lys Asn
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe 20 25 30Tyr Pro Ser Asp
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu 35 40 45Asn Asn Tyr
Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 50 55 60Tyr Leu
Ala Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly65 70 75
80Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr
85 90 95Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 100
105151324DNAArtificial SequenceDescription of Artificial Synthetic
nucleotide sequence 151gggcagcccc gagaaccaca ggtgtacacc ctgcccccat
cccgggagga gatgaccaag 60aaccaggtca gcctgacctg cctggtcaaa ggcttctatc
ccagcgacat cgccgtggag 120tgggagagca atgggcagcc ggagaacaac
tacaagacca cgcctcccgt gctggactcc 180gacggctcct tcgccctcgc
cagcaagctc accgtggaca agagcaggtg gcagcagggg 240aacgtcttct
catgctccgt gatgcatgag gctctgcaca accactacac gcagaagagc
300ctctccctgt ccccgggtaa atga 324152107PRTArtificial
SequenceDescription of Artificial Synthetic amino acid sequence
152Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu1
5 10 15Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
Phe 20 25 30Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
Pro Glu 35 40 45Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
Gly Ser Phe 50 55 60Ala Leu Ala Ser Lys Leu Thr Val Asp Lys Ser Arg
Trp Gln Gln Gly65 70 75 80Asn Val Phe Ser Cys Ser Val Met His Glu
Ala Leu His Asn His Tyr 85 90 95Thr Gln Lys Ser Leu Ser Leu Ser Pro
Gly Lys 100 1051531521DNAArtificial SequenceDescription of
Artificial Synthetic nucleotide sequence 153aagcttgccg ccatggattt
tcaagtgcag attttcagct tcctgctaat cagtgcttca 60gtcataattg ccagaggaca
aattgttctc tcccagtctc
cagcaatcct gtctgcatct 120ccaggggaga aggtcacaat gacttgcagg
gccagctcaa gtgtaagtta catgcactgg 180taccagcaga agccaggatc
ctcccccaaa ccctggattt atgccccatc caacctggct 240tctggagtcc
ctgctcgctt cagtggcagt gggtctggga cctcttactc tctcacaatc
300agcagagtgg aggctgaaga tgctgccact tattactgcc agcagtggag
ttttaaccca 360cccacgttcg gtgctgggac caagctggag ctgaaagatg
gcggtggctc gggcggtggt 420ggatctggag gaggtgggag ctctcaggct
tatctacagc agtctggggc tgagctggtg 480aggcctgggg cctcagtgaa
gatgtcctgc aaggcttctg gctacacatt taccagttac 540aatatgcact
gggtaaagca gacacctaga cagggcctgg aatggattgg agctatttat
600ccaggaaatg gtgatacttc ctacaatcag aagttcaagg gcaaggccac
actgactgta 660gacaaatcct ccagcacagc ctacatgcag ctcagcagcc
tgacatctga agactctgcg 720gtctatttct gtgcaagagt ggtgtactat
agtaactctt actggtactt cgatgtctgg 780ggcacaggga ccacggtcac
cgtctcttct gatcaggagc ccaaatcttc tgacaaaact 840cacacatccc
caccgtcccc agcacctgaa ctcctggggg gaccgtcagt cttcctcttc
900cccccaaaac ccaaggacac cctcatgatc tcccggaccc ctgaggtcac
atgcgtggtg 960gtggacgtga gccacgaaga ccctgaggtc aagttcaact
ggtacgtgga cggcgtggag 1020gtgcataatg ccaagacaaa gccgcgggag
gagcagtaca acagcacgta ccgtgtggtc 1080agcgtcctca ccgtcctgca
ccaggactgg ctgaatggca aggagtacaa gtgcaaggtc 1140tccaacaaag
ccctcccagc ccccatcgag aaaacaatct ccaaagccaa agggcagccc
1200cgagaaccac aggtgtacac cctgccccca tcccgggagg agatgaccaa
gaaccaggtc 1260agcctgacct gcctggtcaa aggcttctat cccagcgaca
tcgccgtgga gtgggagagc 1320aatgggcagc cggagaacaa ctacaagacc
acgcctcccg tgctggactc cgacggctcc 1380ttctacctct atagcaagct
caccgtggac aagagcaggt ggcagcaggg gaacgtcttc 1440tcatgctccg
tgatgcatga ggctctgcac aaccactaca cgcagaagag cctctccctg
1500tccccgggta aatgatctag a 1521154500PRTArtificial
SequenceDescription of Artificial Synthetic amino acid sequence
154Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1
5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu Ser Gln Ser Pro Ala
Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg
Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro
Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala Pro Ser Asn Leu Ala
Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr
Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu Ala Glu Asp Ala Ala
Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe Asn Pro Pro Thr Phe
Gly Ala Gly Thr Lys Leu Glu Leu Lys 115 120 125Asp Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser 130 135 140Gln Ala Tyr
Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala145 150 155
160Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
165 170 175Asn Met His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Glu
Trp Ile 180 185 190Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr
Asn Gln Lys Phe 195 200 205Lys Gly Lys Ala Thr Leu Thr Val Asp Lys
Ser Ser Ser Thr Ala Tyr 210 215 220Met Gln Leu Ser Ser Leu Thr Ser
Glu Asp Ser Ala Val Tyr Phe Cys225 230 235 240Ala Arg Val Val Tyr
Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp 245 250 255Gly Thr Gly
Thr Thr Val Thr Val Ser Ser Asp Gln Glu Pro Lys Ser 260 265 270Ser
Asp Lys Thr His Thr Ser Pro Pro Ser Pro Ala Pro Glu Leu Leu 275 280
285Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
290 295 300Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
Val Ser305 310 315 320His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
Val Asp Gly Val Glu 325 330 335Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln Tyr Asn Ser Thr 340 345 350Tyr Arg Val Val Ser Val Leu
Thr Val Leu His Gln Asp Trp Leu Asn 355 360 365Gly Lys Glu Tyr Lys
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 370 375 380Ile Glu Lys
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln385 390 395
400Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val
405 410 415Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
Ala Val 420 425 430Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
Lys Thr Thr Pro 435 440 445Pro Val Leu Asp Ser Asp Gly Ser Phe Tyr
Leu Tyr Ser Lys Leu Thr 450 455 460Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn Val Phe Ser Cys Ser Val465 470 475 480Met His Glu Ala Leu
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 485 490 495Ser Pro Gly
Lys 5001551515DNAArtificial SequenceDescription of Artificial
Synthetic nucleotide sequence 155aagcttgccg ccatggattt tcaagtgcag
attttcagct tcctgctaat cagtgcttca 60gtcataattg ccagaggaca aattgttctc
tcccagtctc cagcaatcct gtctgcatct 120ccaggggaga aggtcacaat
gacttgcagg gccagctcaa gtgtaagtta catgcactgg 180taccagcaga
agccaggatc ctcccccaaa ccctggattt atgccccatc caacctggct
240tctggagtcc ctgctcgctt cagtggcagt gggtctggga cctcttactc
tctcacaatc 300agcagagtgg aggctgaaga tgctgccact tattactgcc
agcagtggag ttttaaccca 360cccacgttcg gtgctgggac caagctggag
ctgaaagatg gcggtggctc gggcggtggt 420ggatctggag gaggtgggag
ctctcaggct tatctacagc agtctggggc tgagctggtg 480aggcctgggg
cctcagtgaa gatgtcctgc aaggcttctg gctacacatt taccagttac
540aatatgcact gggtaaagca gacacctaga cagggcctgg aatggattgg
agctatttat 600ccaggaaatg gtgatacttc ctacaatcag aagttcaagg
gcaaggccac actgactgta 660gacaaatcct ccagcacagc ctacatgcag
ctcagcagcc tgacatctga agactctgcg 720gtctatttct gtgcaagagt
ggtgtactat agtaactctt actggtactt cgatgtctgg 780ggcacaggga
ccacggtcac cgtctcttct gatcaggagc ccaaatcttc tgacaaaact
840cacacatccc caccgtcccc agcacctgaa ctcctggggg gaccgtcagt
cttcctcttc 900cccccaaaac ccaaggacac cctcatgatc tcccggaccc
ctgaggtcac atgcgtggtg 960gtggacgtga gccacgaaga ccctgaggtc
aagttcaact ggtacgtgga cggcgtggag 1020gtgcataatg ccaagacaaa
gccgcgggag gagcagtaca acagcacgta ccgtgtggtc 1080agcgtcctca
ccgtcctgca ccaggactgg ctgaatggca aggagtacaa gtgcaaggtc
1140tccaacaaag ccctcccagc ccccatcgag aaaacaatct ccaaagccaa
agggcagccc 1200cgagaaccac aggtgtacac cctgccccca tcccgggagg
agatgaccaa gaaccaggtc 1260agcctgacct gcctggtcaa aggcttctat
cccagcgaca tcgccgtgga gtgggagagc 1320aatgggcagc cggagaacaa
ctacaagacc acgcctcccg tgctggactc cgacggctcc 1380ttcgccctct
atagcaagct caccgtggac aagagcaggt ggcagcaggg gaacgtcttc
1440tcatgctccg tgatgcatga ggctctgcac aaccactaca cgcagaagag
cctctccctg 1500tccccgggta aatga 1515156500PRTArtificial
SequenceDescription of Artificial Synthetic amino acid sequence
156Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1
5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu Ser Gln Ser Pro Ala
Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg
Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro
Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala Pro Ser Asn Leu Ala
Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr
Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu Ala Glu Asp Ala Ala
Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe Asn Pro Pro Thr Phe
Gly Ala Gly Thr Lys Leu Glu Leu Lys 115 120 125Asp Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser 130 135 140Gln Ala Tyr
Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala145 150 155
160Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
165 170 175Asn Met His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Glu
Trp Ile 180 185 190Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr
Asn Gln Lys Phe 195 200 205Lys Gly Lys Ala Thr Leu Thr Val Asp Lys
Ser Ser Ser Thr Ala Tyr 210 215 220Met Gln Leu Ser Ser Leu Thr Ser
Glu Asp Ser Ala Val Tyr Phe Cys225 230 235 240Ala Arg Val Val Tyr
Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp 245 250 255Gly Thr Gly
Thr Thr Val Thr Val Ser Ser Asp Gln Glu Pro Lys Ser 260 265 270Ser
Asp Lys Thr His Thr Ser Pro Pro Ser Pro Ala Pro Glu Leu Leu 275 280
285Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
290 295 300Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
Val Ser305 310 315 320His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
Val Asp Gly Val Glu 325 330 335Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln Tyr Asn Ser Thr 340 345 350Tyr Arg Val Val Ser Val Leu
Thr Val Leu His Gln Asp Trp Leu Asn 355 360 365Gly Lys Glu Tyr Lys
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 370 375 380Ile Glu Lys
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln385 390 395
400Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val
405 410 415Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
Ala Val 420 425 430Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
Lys Thr Thr Pro 435 440 445Pro Val Leu Asp Ser Asp Gly Ser Phe Ala
Leu Tyr Ser Lys Leu Thr 450 455 460Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn Val Phe Ser Cys Ser Val465 470 475 480Met His Glu Ala Leu
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 485 490 495Ser Pro Gly
Lys 5001571515DNAArtificial SequenceDescription of Artificial
Synthetic nucleotide sequence 157aagcttgccg ccatggattt tcaagtgcag
attttcagct tcctgctaat cagtgcttca 60gtcataattg ccagaggaca aattgttctc
tcccagtctc cagcaatcct gtctgcatct 120ccaggggaga aggtcacaat
gacttgcagg gccagctcaa gtgtaagtta catgcactgg 180taccagcaga
agccaggatc ctcccccaaa ccctggattt atgccccatc caacctggct
240tctggagtcc ctgctcgctt cagtggcagt gggtctggga cctcttactc
tctcacaatc 300agcagagtgg aggctgaaga tgctgccact tattactgcc
agcagtggag ttttaaccca 360cccacgttcg gtgctgggac caagctggag
ctgaaagatg gcggtggctc gggcggtggt 420ggatctggag gaggtgggag
ctctcaggct tatctacagc agtctggggc tgagctggtg 480aggcctgggg
cctcagtgaa gatgtcctgc aaggcttctg gctacacatt taccagttac
540aatatgcact gggtaaagca gacacctaga cagggcctgg aatggattgg
agctatttat 600ccaggaaatg gtgatacttc ctacaatcag aagttcaagg
gcaaggccac actgactgta 660gacaaatcct ccagcacagc ctacatgcag
ctcagcagcc tgacatctga agactctgcg 720gtctatttct gtgcaagagt
ggtgtactat agtaactctt actggtactt cgatgtctgg 780ggcacaggga
ccacggtcac cgtctcttct gatcaggagc ccaaatcttc tgacaaaact
840cacacatccc caccgtcccc agcacctgaa ctcctggggg gaccgtcagt
cttcctcttc 900cccccaaaac ccaaggacac cctcatgatc tcccggaccc
ctgaggtcac atgcgtggtg 960gtggacgtga gccacgaaga ccctgaggtc
aagttcaact ggtacgtgga cggcgtggag 1020gtgcataatg ccaagacaaa
gccgcgggag gagcagtaca acagcacgta ccgtgtggtc 1080agcgtcctca
ccgtcctgca ccaggactgg ctgaatggca aggagtacaa gtgcaaggtc
1140tccaacaaag ccctcccagc ccccatcgag aaaacaatct ccaaagccaa
agggcagccc 1200cgagaaccac aggtgtacac cctgccccca tcccgggagg
agatgaccaa gaaccaggtc 1260agcctgacct gcctggtcaa aggcttctat
cccagcgaca tcgccgtgga gtgggagagc 1320aatgggcagc cggagaacaa
ctacaagacc acgcctcccg tgctggactc cgacggctcc 1380ttcttcctcg
ccagcaagct caccgtggac aagagcaggt ggcagcaggg gaacgtcttc
1440tcatgctccg tgatgcatga ggctctgcac aaccactaca cgcagaagag
cctctccctg 1500tccccgggta aatga 1515158500PRTArtificial
SequenceDescription of Artificial Synthetic amino acid sequence
158Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1
5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu Ser Gln Ser Pro Ala
Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg
Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro
Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala Pro Ser Asn Leu Ala
Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr
Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu Ala Glu Asp Ala Ala
Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe Asn Pro Pro Thr Phe
Gly Ala Gly Thr Lys Leu Glu Leu Lys 115 120 125Asp Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser 130 135 140Gln Ala Tyr
Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala145 150 155
160Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
165 170 175Asn Met His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Glu
Trp Ile 180 185 190Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr
Asn Gln Lys Phe 195 200 205Lys Gly Lys Ala Thr Leu Thr Val Asp Lys
Ser Ser Ser Thr Ala Tyr 210 215 220Met Gln Leu Ser Ser Leu Thr Ser
Glu Asp Ser Ala Val Tyr Phe Cys225 230 235 240Ala Arg Val Val Tyr
Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp 245 250 255Gly Thr Gly
Thr Thr Val Thr Val Ser Ser Asp Gln Glu Pro Lys Ser 260 265 270Ser
Asp Lys Thr His Thr Ser Pro Pro Ser Pro Ala Pro Glu Leu Leu 275 280
285Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
290 295 300Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
Val Ser305 310 315 320His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
Val Asp Gly Val Glu 325 330 335Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln Tyr Asn Ser Thr 340 345 350Tyr Arg Val Val Ser Val Leu
Thr Val Leu His Gln Asp Trp Leu Asn 355 360 365Gly Lys Glu Tyr Lys
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 370 375 380Ile Glu Lys
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln385 390 395
400Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val
405 410 415Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
Ala Val 420 425 430Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
Lys Thr Thr Pro 435 440 445Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
Leu Ala Ser Lys Leu Thr 450 455 460Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn Val Phe Ser Cys Ser Val465 470 475 480Met His Glu Ala Leu
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 485 490 495Ser Pro Gly
Lys 5001591515DNAArtificial SequenceDescription of Artificial
Synthetic nucleotide sequence 159aagcttgccg ccatggattt tcaagtgcag
attttcagct tcctgctaat cagtgcttca 60gtcataattg ccagaggaca aattgttctc
tcccagtctc cagcaatcct gtctgcatct 120ccaggggaga aggtcacaat
gacttgcagg gccagctcaa gtgtaagtta catgcactgg 180taccagcaga
agccaggatc ctcccccaaa ccctggattt atgccccatc caacctggct
240tctggagtcc ctgctcgctt cagtggcagt gggtctggga cctcttactc
tctcacaatc 300agcagagtgg aggctgaaga tgctgccact tattactgcc
agcagtggag ttttaaccca 360cccacgttcg gtgctgggac caagctggag
ctgaaagatg gcggtggctc gggcggtggt 420ggatctggag gaggtgggag
ctctcaggct tatctacagc agtctggggc tgagctggtg 480aggcctgggg
cctcagtgaa gatgtcctgc aaggcttctg gctacacatt taccagttac
540aatatgcact gggtaaagca gacacctaga cagggcctgg aatggattgg
agctatttat 600ccaggaaatg gtgatacttc ctacaatcag aagttcaagg
gcaaggccac actgactgta 660gacaaatcct ccagcacagc ctacatgcag
ctcagcagcc tgacatctga agactctgcg 720gtctatttct gtgcaagagt
ggtgtactat agtaactctt actggtactt cgatgtctgg 780ggcacaggga
ccacggtcac cgtctcttct gatcaggagc ccaaatcttc tgacaaaact
840cacacatccc caccgtcccc agcacctgaa ctcctggggg
gaccgtcagt cttcctcttc 900cccccaaaac ccaaggacac cctcatgatc
tcccggaccc ctgaggtcac atgcgtggtg 960gtggacgtga gccacgaaga
ccctgaggtc aagttcaact ggtacgtgga cggcgtggag 1020gtgcataatg
ccaagacaaa gccgcgggag gagcagtaca acagcacgta ccgtgtggtc
1080agcgtcctca ccgtcctgca ccaggactgg ctgaatggca aggagtacaa
gtgcaaggtc 1140tccaacaaag ccctcccagc ccccatcgag aaaacaatct
ccaaagccaa agggcagccc 1200cgagaaccac aggtgtacac cctgccccca
tcccgggagg agatgaccaa gaaccaggtc 1260agcctgacct gcctggtcaa
aggcttctat cccagcgaca tcgccgtgga gtgggagagc 1320aatgggcagc
cggagaacaa ctacaagacc acgcctcccg tgctggactc cgacggctcc
1380ttctacctcg ccagcaagct caccgtggac aagagcaggt ggcagcaggg
gaacgtcttc 1440tcatgctccg tgatgcatga ggctctgcac aaccactaca
cgcagaagag cctctccctg 1500tccccgggta aatga 1515160500PRTArtificial
SequenceDescription of Artificial Synthetic amino acid sequence
160Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1
5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu Ser Gln Ser Pro Ala
Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg
Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro
Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala Pro Ser Asn Leu Ala
Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr
Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu Ala Glu Asp Ala Ala
Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe Asn Pro Pro Thr Phe
Gly Ala Gly Thr Lys Leu Glu Leu Lys 115 120 125Asp Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser 130 135 140Gln Ala Tyr
Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala145 150 155
160Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
165 170 175Asn Met His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Glu
Trp Ile 180 185 190Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr
Asn Gln Lys Phe 195 200 205Lys Gly Lys Ala Thr Leu Thr Val Asp Lys
Ser Ser Ser Thr Ala Tyr 210 215 220Met Gln Leu Ser Ser Leu Thr Ser
Glu Asp Ser Ala Val Tyr Phe Cys225 230 235 240Ala Arg Val Val Tyr
Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp 245 250 255Gly Thr Gly
Thr Thr Val Thr Val Ser Ser Asp Gln Glu Pro Lys Ser 260 265 270Ser
Asp Lys Thr His Thr Ser Pro Pro Ser Pro Ala Pro Glu Leu Leu 275 280
285Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
290 295 300Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
Val Ser305 310 315 320His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
Val Asp Gly Val Glu 325 330 335Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln Tyr Asn Ser Thr 340 345 350Tyr Arg Val Val Ser Val Leu
Thr Val Leu His Gln Asp Trp Leu Asn 355 360 365Gly Lys Glu Tyr Lys
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 370 375 380Ile Glu Lys
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln385 390 395
400Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val
405 410 415Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
Ala Val 420 425 430Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
Lys Thr Thr Pro 435 440 445Pro Val Leu Asp Ser Asp Gly Ser Phe Tyr
Leu Ala Ser Lys Leu Thr 450 455 460Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn Val Phe Ser Cys Ser Val465 470 475 480Met His Glu Ala Leu
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 485 490 495Ser Pro Gly
Lys 5001611515DNAArtificial SequenceDescription of Artificial
Synthetic nucleotide sequence 161aagcttgccg ccatggattt tcaagtgcag
attttcagct tcctgctaat cagtgcttca 60gtcataattg ccagaggaca aattgttctc
tcccagtctc cagcaatcct gtctgcatct 120ccaggggaga aggtcacaat
gacttgcagg gccagctcaa gtgtaagtta catgcactgg 180taccagcaga
agccaggatc ctcccccaaa ccctggattt atgccccatc caacctggct
240tctggagtcc ctgctcgctt cagtggcagt gggtctggga cctcttactc
tctcacaatc 300agcagagtgg aggctgaaga tgctgccact tattactgcc
agcagtggag ttttaaccca 360cccacgttcg gtgctgggac caagctggag
ctgaaagatg gcggtggctc gggcggtggt 420ggatctggag gaggtgggag
ctctcaggct tatctacagc agtctggggc tgagctggtg 480aggcctgggg
cctcagtgaa gatgtcctgc aaggcttctg gctacacatt taccagttac
540aatatgcact gggtaaagca gacacctaga cagggcctgg aatggattgg
agctatttat 600ccaggaaatg gtgatacttc ctacaatcag aagttcaagg
gcaaggccac actgactgta 660gacaaatcct ccagcacagc ctacatgcag
ctcagcagcc tgacatctga agactctgcg 720gtctatttct gtgcaagagt
ggtgtactat agtaactctt actggtactt cgatgtctgg 780ggcacaggga
ccacggtcac cgtctcttct gatcaggagc ccaaatcttc tgacaaaact
840cacacatccc caccgtcccc agcacctgaa ctcctggggg gaccgtcagt
cttcctcttc 900cccccaaaac ccaaggacac cctcatgatc tcccggaccc
ctgaggtcac atgcgtggtg 960gtggacgtga gccacgaaga ccctgaggtc
aagttcaact ggtacgtgga cggcgtggag 1020gtgcataatg ccaagacaaa
gccgcgggag gagcagtaca acagcacgta ccgtgtggtc 1080agcgtcctca
ccgtcctgca ccaggactgg ctgaatggca aggagtacaa gtgcaaggtc
1140tccaacaaag ccctcccagc ccccatcgag aaaacaatct ccaaagccaa
agggcagccc 1200cgagaaccac aggtgtacac cctgccccca tcccgggagg
agatgaccaa gaaccaggtc 1260agcctgacct gcctggtcaa aggcttctat
cccagcgaca tcgccgtgga gtgggagagc 1320aatgggcagc cggagaacaa
ctacaagacc acgcctcccg tgctggactc cgacggctcc 1380ttcgccctcg
ccagcaagct caccgtggac aagagcaggt ggcagcaggg gaacgtcttc
1440tcatgctccg tgatgcatga ggctctgcac aaccactaca cgcagaagag
cctctccctg 1500tccccgggta aatga 1515162500PRTArtificial
SequenceDescription of Artificial Synthetic amino acid sequence
162Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1
5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu Ser Gln Ser Pro Ala
Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg
Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro
Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala Pro Ser Asn Leu Ala
Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr
Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu Ala Glu Asp Ala Ala
Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe Asn Pro Pro Thr Phe
Gly Ala Gly Thr Lys Leu Glu Leu Lys 115 120 125Asp Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser 130 135 140Gln Ala Tyr
Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala145 150 155
160Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
165 170 175Asn Met His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Glu
Trp Ile 180 185 190Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr
Asn Gln Lys Phe 195 200 205Lys Gly Lys Ala Thr Leu Thr Val Asp Lys
Ser Ser Ser Thr Ala Tyr 210 215 220Met Gln Leu Ser Ser Leu Thr Ser
Glu Asp Ser Ala Val Tyr Phe Cys225 230 235 240Ala Arg Val Val Tyr
Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp 245 250 255Gly Thr Gly
Thr Thr Val Thr Val Ser Ser Asp Gln Glu Pro Lys Ser 260 265 270Ser
Asp Lys Thr His Thr Ser Pro Pro Ser Pro Ala Pro Glu Leu Leu 275 280
285Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
290 295 300Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
Val Ser305 310 315 320His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
Val Asp Gly Val Glu 325 330 335Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln Tyr Asn Ser Thr 340 345 350Tyr Arg Val Val Ser Val Leu
Thr Val Leu His Gln Asp Trp Leu Asn 355 360 365Gly Lys Glu Tyr Lys
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 370 375 380Ile Glu Lys
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln385 390 395
400Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val
405 410 415Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
Ala Val 420 425 430Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
Lys Thr Thr Pro 435 440 445Pro Val Leu Asp Ser Asp Gly Ser Phe Ala
Leu Ala Ser Lys Leu Thr 450 455 460Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn Val Phe Ser Cys Ser Val465 470 475 480Met His Glu Ala Leu
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 485 490 495Ser Pro Gly
Lys 5001631521DNAArtificial SequenceDescription of Artificial
Synthetic nucleotide sequence 163aagcttgccg ccatggattt tcaagtgcag
attttcagct tcctgctaat cagtgcttca 60gtcataattg ccagaggaca aattgttctc
tcccagtctc cagcaatcct gtctgcatct 120ccaggggaga aggtcacaat
gacttgcagg gccagctcaa gtgtaagtta catgcactgg 180taccagcaga
agccaggatc ctcccccaaa ccctggattt atgccccatc caacctggct
240tctggagtcc ctgctcgctt cagtggcagt gggtctggga cctcttactc
tctcacaatc 300agcagagtgg aggctgaaga tgctgccact tattactgcc
agcagtggag ttttaaccca 360cccacgttcg gtgctgggac caagctggag
ctgaaagatg gcggtggctc gggcggtggt 420ggatctggag gaggtgggag
ctctcaggct tatctacagc agtctggggc tgagctggtg 480aggcctgggg
cctcagtgaa gatgtcctgc aaggcttctg gctacacatt taccagttac
540aatatgcact gggtaaagca gacacctaga cagggcctgg aatggattgg
agctatttat 600ccaggaaatg gtgatacttc ctacaatcag aagttcaagg
gcaaggccac actgactgta 660gacaaatcct ccagcacagc ctacatgcag
ctcagcagcc tgacatctga agactctgcg 720gtctatttct gtgcaagagt
ggtgtactat agtaactctt actggtactt cgatgtctgg 780ggcacaggga
ccacggtcac cgtctcttct gatcaggagc ccaaatcttc tgacaaaact
840cacacatgcc caccgtgccc agcacctgaa ctcctggggg gaccgtcagt
cttcctcttc 900cccccaaaac ccaaggacac cctcatgatc tcccggaccc
ctgaggtcac atgcgtggtg 960gtggacgtga gccacgaaga ccctgaggtc
aagttcaact ggtacgtgga cggcgtggag 1020gtgcataatg ccaagacaaa
gccgcgggag gagcagtaca acagcacgta ccgtgtggtc 1080agcgtcctca
ccgtcctgca ccaggactgg ctgaatggca aggagtacaa gtgcaaggtc
1140tccaacaaag ccctcccagc ccccatcgag aaaacaatct ccaaagccaa
agggcagccc 1200cgagaaccac aggtgtacac cctgccccca tcccgggatg
agctgaccaa gaaccaggtc 1260agcctgacct gcctggtcaa aggcttctat
cccagcgaca tcgccgtgga gtgggagagc 1320aatgggcagc cggagaacaa
ctacaagacc acgcctcccg tgctggactc cgacggctcc 1380ttcttcctct
acagcaagct caccgtggac aagagcaggt ggcagcaggg gaacgtcttc
1440tcatgctccg tgatgcatga ggctctgcac aaccactaca cgcagaagag
cctctccctg 1500tctccgggta aatgatctag a 1521164500PRTArtificial
SequenceDescription of Artificial Synthetic amino acid sequence
164Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1
5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu Ser Gln Ser Pro Ala
Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg
Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro
Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala Pro Ser Asn Leu Ala
Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr
Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu Ala Glu Asp Ala Ala
Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe Asn Pro Pro Thr Phe
Gly Ala Gly Thr Lys Leu Glu Leu Lys 115 120 125Asp Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser 130 135 140Gln Ala Tyr
Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala145 150 155
160Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
165 170 175Asn Met His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Glu
Trp Ile 180 185 190Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr
Asn Gln Lys Phe 195 200 205Lys Gly Lys Ala Thr Leu Thr Val Asp Lys
Ser Ser Ser Thr Ala Tyr 210 215 220Met Gln Leu Ser Ser Leu Thr Ser
Glu Asp Ser Ala Val Tyr Phe Cys225 230 235 240Ala Arg Val Val Tyr
Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp 245 250 255Gly Thr Gly
Thr Thr Val Thr Val Ser Ser Asp Gln Glu Pro Lys Ser 260 265 270Ser
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu 275 280
285Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
290 295 300Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
Val Ser305 310 315 320His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
Val Asp Gly Val Glu 325 330 335Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln Tyr Asn Ser Thr 340 345 350Tyr Arg Val Val Ser Val Leu
Thr Val Leu His Gln Asp Trp Leu Asn 355 360 365Gly Lys Glu Tyr Lys
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 370 375 380Ile Glu Lys
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln385 390 395
400Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
405 410 415Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
Ala Val 420 425 430Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
Lys Thr Thr Pro 435 440 445Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
Leu Tyr Ser Lys Leu Thr 450 455 460Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn Val Phe Ser Cys Ser Val465 470 475 480Met His Glu Ala Leu
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 485 490 495Ser Pro Gly
Lys 5001651521DNAArtificial SequenceDescription of Artificial
Synthetic nucleotide sequence 165aagcttgccg ccatggattt tcaagtgcag
attttcagct tcctgctaat cagtgcttca 60gtcataattg ccagaggaca aattgttctc
tcccagtctc cagcaatcct gtctgcatct 120ccaggggaga aggtcacaat
gacttgcagg gccagctcaa gtgtaagtta catgcactgg 180taccagcaga
agccaggatc ctcccccaaa ccctggattt atgccccatc caacctggct
240tctggagtcc ctgctcgctt cagtggcagt gggtctggga cctcttactc
tctcacaatc 300agcagagtgg aggctgaaga tgctgccact tattactgcc
agcagtggag ttttaaccca 360cccacgttcg gtgctgggac caagctggag
ctgaaagatg gcggtggctc gggcggtggt 420ggatctggag gaggtgggag
ctctcaggct tatctacagc agtctggggc tgagctggtg 480aggcctgggg
cctcagtgaa gatgtcctgc aaggcttctg gctacacatt taccagttac
540aatatgcact gggtaaagca gacacctaga cagggcctgg aatggattgg
agctatttat 600ccaggaaatg gtgatacttc ctacaatcag aagttcaagg
gcaaggccac actgactgta 660gacaaatcct ccagcacagc ctacatgcag
ctcagcagcc tgacatctga agactctgcg 720gtctatttct gtgcaagagt
ggtgtactat agtaactctt actggtactt cgatgtctgg 780ggcacaggga
ccacggtcac cgtctcttct gatcaggagc ccaaatcttg tgacaaaact
840cacacatctc caccgtgccc agcacctgaa ctcctggggg gaccgtcagt
cttcctcttc 900cccccaaaac ccaaggacac cctcatgatc tcccggaccc
ctgaggtcac atgcgtggtg 960gtggacgtga gccacgaaga ccctgaggtc
aagttcaact ggtacgtgga cggcgtggag 1020gtgcataatg ccaagacaaa
gccgcgggag gagcagtaca acagcacgta ccgtgtggtc 1080agcgtcctca
ccgtcctgca ccaggactgg ctgaatggca aggagtacaa gtgcaaggtc
1140tccaacaaag ccctcccagc ccccatcgag aaaacaatct ccaaagccaa
agggcagccc 1200cgagaaccac aggtgtacac cctgccccca tcccgggatg
agctgaccaa gaaccaggtc 1260agcctgacct gcctggtcaa aggcttctat
cccagcgaca tcgccgtgga gtgggagagc 1320aatgggcagc cggagaacaa
ctacaagacc acgcctcccg tgctggactc cgacggctcc 1380ttcttcctct
acagcaagct caccgtggac aagagcaggt ggcagcaggg gaacgtcttc
1440tcatgctccg tgatgcatga ggctctgcac aaccactaca cgcagaagag
cctctccctg 1500tctccgggta aatgatctag a 1521166500PRTArtificial
SequenceDescription of Artificial Synthetic amino acid sequence
166Met Asp Phe Gln Val Gln
Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1 5 10 15Val Ile Ile Ala Arg
Gly Gln Ile Val Leu Ser Gln Ser Pro Ala Ile 20 25 30Leu Ser Ala Ser
Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser 35 40 45Ser Ser Val
Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Ser Ser 50 55 60Pro Lys
Pro Trp Ile Tyr Ala Pro Ser Asn Leu Ala Ser Gly Val Pro65 70 75
80Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile
85 90 95Ser Arg Val Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln
Trp 100 105 110Ser Phe Asn Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu
Glu Leu Lys 115 120 125Asp Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Ser 130 135 140Gln Ala Tyr Leu Gln Gln Ser Gly Ala
Glu Leu Val Arg Pro Gly Ala145 150 155 160Ser Val Lys Met Ser Cys
Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 165 170 175Asn Met His Trp
Val Lys Gln Thr Pro Arg Gln Gly Leu Glu Trp Ile 180 185 190Gly Ala
Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe 195 200
205Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
210 215 220Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr
Phe Cys225 230 235 240Ala Arg Val Val Tyr Tyr Ser Asn Ser Tyr Trp
Tyr Phe Asp Val Trp 245 250 255Gly Thr Gly Thr Thr Val Thr Val Ser
Ser Asp Gln Glu Pro Lys Ser 260 265 270Cys Asp Lys Thr His Thr Ser
Pro Pro Cys Pro Ala Pro Glu Leu Leu 275 280 285Gly Gly Pro Ser Val
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 290 295 300Met Ile Ser
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser305 310 315
320His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
325 330 335Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
Ser Thr 340 345 350Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
Asp Trp Leu Asn 355 360 365Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
Lys Ala Leu Pro Ala Pro 370 375 380Ile Glu Lys Thr Ile Ser Lys Ala
Lys Gly Gln Pro Arg Glu Pro Gln385 390 395 400Val Tyr Thr Leu Pro
Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val 405 410 415Ser Leu Thr
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 420 425 430Glu
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 435 440
445Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
450 455 460Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
Ser Val465 470 475 480Met His Glu Ala Leu His Asn His Tyr Thr Gln
Lys Ser Leu Ser Leu 485 490 495Ser Pro Gly Lys
5001671521DNAArtificial SequenceDescription of Artificial Synthetic
nucleotide sequence 167aagcttgccg ccatggattt tcaagtgcag attttcagct
tcctgctaat cagtgcttca 60gtcataattg ccagaggaca aattgttctc tcccagtctc
cagcaatcct gtctgcatct 120ccaggggaga aggtcacaat gacttgcagg
gccagctcaa gtgtaagtta catgcactgg 180taccagcaga agccaggatc
ctcccccaaa ccctggattt atgccccatc caacctggct 240tctggagtcc
ctgctcgctt cagtggcagt gggtctggga cctcttactc tctcacaatc
300agcagagtgg aggctgaaga tgctgccact tattactgcc agcagtggag
ttttaaccca 360cccacgttcg gtgctgggac caagctggag ctgaaagatg
gcggtggctc gggcggtggt 420ggatctggag gaggtgggag ctctcaggct
tatctacagc agtctggggc tgagctggtg 480aggcctgggg cctcagtgaa
gatgtcctgc aaggcttctg gctacacatt taccagttac 540aatatgcact
gggtaaagca gacacctaga cagggcctgg aatggattgg agctatttat
600ccaggaaatg gtgatacttc ctacaatcag aagttcaagg gcaaggccac
actgactgta 660gacaaatcct ccagcacagc ctacatgcag ctcagcagcc
tgacatctga agactctgcg 720gtctatttct gtgcaagagt ggtgtactat
agtaactctt actggtactt cgatgtctgg 780ggcacaggga ccacggtcac
cgtctcttct gatcaggagc ccaaatcttg tgacaaaact 840cacacatgtc
caccgtcccc agcacctgaa ctcctggggg gaccgtcagt cttcctcttc
900cccccaaaac ccaaggacac cctcatgatc tcccggaccc ctgaggtcac
atgcgtggtg 960gtggacgtga gccacgaaga ccctgaggtc aagttcaact
ggtacgtgga cggcgtggag 1020gtgcataatg ccaagacaaa gccgcgggag
gagcagtaca acagcacgta ccgtgtggtc 1080agcgtcctca ccgtcctgca
ccaggactgg ctgaatggca aggagtacaa gtgcaaggtc 1140tccaacaaag
ccctcccagc ccccatcgag aaaacaatct ccaaagccaa agggcagccc
1200cgagaaccac aggtgtacac cctgccccca tcccgggatg agctgaccaa
gaaccaggtc 1260agcctgacct gcctggtcaa aggcttctat cccagcgaca
tcgccgtgga gtgggagagc 1320aatgggcagc cggagaacaa ctacaagacc
acgcctcccg tgctggactc cgacggctcc 1380ttcttcctct acagcaagct
caccgtggac aagagcaggt ggcagcaggg gaacgtcttc 1440tcatgctccg
tgatgcatga ggctctgcac aaccactaca cgcagaagag cctctccctg
1500tctccgggta aatgatctag a 1521168500PRTArtificial
SequenceDescription of Artificial Synthetic amino acid sequence
168Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1
5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu Ser Gln Ser Pro Ala
Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg
Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro
Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala Pro Ser Asn Leu Ala
Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr
Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu Ala Glu Asp Ala Ala
Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe Asn Pro Pro Thr Phe
Gly Ala Gly Thr Lys Leu Glu Leu Lys 115 120 125Asp Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser 130 135 140Gln Ala Tyr
Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala145 150 155
160Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
165 170 175Asn Met His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Glu
Trp Ile 180 185 190Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr
Asn Gln Lys Phe 195 200 205Lys Gly Lys Ala Thr Leu Thr Val Asp Lys
Ser Ser Ser Thr Ala Tyr 210 215 220Met Gln Leu Ser Ser Leu Thr Ser
Glu Asp Ser Ala Val Tyr Phe Cys225 230 235 240Ala Arg Val Val Tyr
Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp 245 250 255Gly Thr Gly
Thr Thr Val Thr Val Ser Ser Asp Gln Glu Pro Lys Ser 260 265 270Cys
Asp Lys Thr His Thr Cys Pro Pro Ser Pro Ala Pro Glu Leu Leu 275 280
285Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
290 295 300Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
Val Ser305 310 315 320His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
Val Asp Gly Val Glu 325 330 335Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln Tyr Asn Ser Thr 340 345 350Tyr Arg Val Val Ser Val Leu
Thr Val Leu His Gln Asp Trp Leu Asn 355 360 365Gly Lys Glu Tyr Lys
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 370 375 380Ile Glu Lys
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln385 390 395
400Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
405 410 415Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
Ala Val 420 425 430Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
Lys Thr Thr Pro 435 440 445Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
Leu Tyr Ser Lys Leu Thr 450 455 460Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn Val Phe Ser Cys Ser Val465 470 475 480Met His Glu Ala Leu
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 485 490 495Ser Pro Gly
Lys 500169766DNAArtificial SequenceDescription of Artificial
Synthetic nucleotide sequence 169tgatcagcca gttccctcaa ctccacctac
cccatctccc tcaactccac ctaccccatc 60tccctcatgc tgccaccccc gactgtcact
gcaccgaccg gccctcgagg acctgctctt 120aggttcagaa gcgatcctca
cgtgcacact gaccggcctg agagatgcct caggtgtcac 180cttcacctgg
acgccctcaa gtgggaagag cgctgttcaa ggaccacctg accgtgacct
240ctgtggctgc tacagcgtgt ccagtgtcct gccgggctgt gccgagccat
ggaaccatgg 300gaagaccttc acttgcactg ctgcctaccc cgagtccaag
accccgctaa ccgccaccct 360ctcaaaatcc ggaaacacat tccggcccga
ggtccacctg ctgccgccgc cgtcggagga 420gctggccctg aacgagctgg
tgacgctgac gtgcctggca cgtggcttca gccccaagga 480tgtgctggtt
cgctggctgc aggggtcaca ggagctgccc cgcgagaagt acctgacttg
540ggcatcccgg caggagccca gccagggcac caccaccttc gctgtgacca
gcatactgcg 600cgtggcagcc gaggactgga agaaggggga caccttctcc
tgcatggtgg gccacgaggc 660cctgccgctg gccttcacac agaagaccat
cgaccgcttg gcgggtaaac ccacccatgt 720caatgtgtct gttgtcatgg
cggaggtgga cgcggatcct tcgaac 766170255PRTArtificial
SequenceDescription of Artificial Synthetic amino acid sequence
170Asp Gln Pro Val Pro Ser Thr Pro Pro Thr Pro Ser Pro Ser Thr Pro1
5 10 15Pro Thr Pro Ser Pro Ser Cys Cys His Pro Arg Leu Ser Leu His
Arg 20 25 30Pro Ala Leu Glu Asp Leu Leu Leu Gly Ser Glu Ala Ile Leu
Thr Cys 35 40 45Thr Leu Thr Gly Leu Arg Asp Ala Ser Gly Val Thr Phe
Thr Trp Thr 50 55 60Pro Ser Ser Gly Lys Ser Ala Val Gln Gly Pro Pro
Asp Arg Asp Leu65 70 75 80Cys Gly Cys Tyr Ser Val Ser Ser Val Leu
Pro Gly Cys Ala Glu Pro 85 90 95Trp Asn His Gly Lys Thr Phe Thr Cys
Thr Ala Ala Tyr Pro Glu Ser 100 105 110Lys Thr Pro Leu Thr Ala Thr
Leu Ser Lys Ser Gly Asn Thr Phe Arg 115 120 125Pro Glu Val His Leu
Leu Pro Pro Pro Ser Glu Glu Leu Ala Leu Asn 130 135 140Glu Leu Val
Thr Leu Thr Cys Leu Ala Arg Gly Phe Ser Pro Lys Asp145 150 155
160Val Leu Val Arg Trp Leu Gln Gly Ser Gln Glu Leu Pro Arg Glu Lys
165 170 175Tyr Leu Thr Trp Ala Ser Arg Gln Glu Pro Ser Gln Gly Thr
Thr Thr 180 185 190Phe Ala Val Thr Ser Ile Leu Arg Val Ala Ala Glu
Asp Trp Lys Lys 195 200 205Gly Asp Thr Phe Ser Cys Met Val Gly His
Glu Ala Leu Pro Leu Ala 210 215 220Phe Thr Gln Lys Thr Ile Asp Arg
Leu Ala Gly Lys Pro Thr His Val225 230 235 240Asn Val Ser Val Val
Met Ala Glu Val Asp Ala Asp Pro Ser Asn 245 250
2551711697DNAArtificial sequenceDescription of Artificial Synthetic
nucleotide sequence 171aagcttatgg attttcaagt gcagattttc agcttcctgc
taatcagtgc ttcagtcata 60atgtccagag gagtcgacat tgtgctcact cagtctccaa
caaccatagc tgcatctcca 120ggggagaagg tcaccatcac ctgccgtgcc
agctccagtg taagttacat gtactggtac 180cagcagaagt caggcgcctc
ccctaaactc tggatttatg acacatccaa gctggcttct 240ggagttccaa
atcgcttcag tggcagtggg tctgggacct cttattctct cgcaatcaac
300accatggaga ctgaagatgc tgccacttat tactgtcagc agtggagtag
tactccgctc 360acgttcgggt ctgggaccaa gctggagatc aaacggggtg
gcggtggctc gggcggtggt 420gggtcgggtg gcggcggatc tcaggtgcag
ctgaaggagg caggacctgg cctggtgcaa 480ccgacacaga ccctgtccct
cacatgcact gtctctgggt tctcattaac cagcgatggt 540gtacactgga
ttcgacagcc tccaggaaag ggtctggaat ggatgggaat aatatattat
600gatggaggca cagattataa ttcagcaatt aaatccagac tgagcatcag
cagggacacc 660tccaagagcc aagttttctt aaaaatcaac agtctgcaaa
ctgatgacac agccatgtat 720tactgtgcca gaatccactt tgattactgg
ggccaaggag tcatggtcac agtctcctct 780gatcagccag ttccctcaac
tccacctacc ccatctccct caactccacc taccccatct 840ccctcatgct
gccacccccg actgtcactg caccgaccgg ccctcgagga cctgctctta
900ggttcagaag cgatcctcac gtgcacactg accggcctga gagatgcctc
aggtgtcacc 960ttcacctgga cgccctcaag tgggaagagc gctgttcaag
gaccacctga ccgtgacctc 1020tgtggctgct acagcgtgtc cagtgtcctg
ccgggctgtg ccgagccatg gaaccatggg 1080aagaccttca cttgcactgc
tgcctacccc gagtccaaga ccccgctaac cgccaccctc 1140tcaaaatccg
gaaacacatt ccggcccgag gtccacctgc tgccgccgcc gtcggaggag
1200ctggccctga acgagctggt gacgctgacg tgcctggcac gtggcttcag
ccccaaggat 1260gtgctggttc gctggctgca ggggtcacag gagctgcccc
gcgagaagta cctgacttgg 1320gcatcccggc aggagcccag ccagggcacc
accaccttcg ctgtgaccag catactgcgc 1380gtggcagccg aggactggaa
gaagggggac accttctcct gcatggtggg ccacgaggcc 1440ctgccgctgg
ccttcacaca gaagaccatc gaccgcttgg cgggtaaacc cacccatgtc
1500aatgtgtctg ttgtcatggc ggaggtggac gcggatcctt cgaacaacct
gctcccatcc 1560tgggccatta ccttaatctc agtaaatgga atttttgtga
tatgctgcct gacctactgc 1620tttgccccaa gatgcagaga gagaaggagg
aatgagagat tgagaaggga aagtgtacgc 1680cctgtataaa tcgatac
1697172560PRTArtificial sequenceDescription of Artificial Synthetic
amino acid sequence 172Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu
Leu Ile Ser Ala Ser1 5 10 15Val Ile Met Ser Arg Gly Val Asp Ile Val
Leu Thr Gln Ser Pro Thr 20 25 30Thr Ile Ala Ala Ser Pro Gly Glu Lys
Val Thr Ile Thr Cys Arg Ala 35 40 45Ser Ser Ser Val Ser Tyr Met Tyr
Trp Tyr Gln Gln Lys Ser Gly Ala 50 55 60Ser Pro Lys Leu Trp Ile Tyr
Asp Thr Ser Lys Leu Ala Ser Gly Val65 70 75 80Pro Asn Arg Phe Ser
Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Ala 85 90 95Ile Asn Thr Met
Glu Thr Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln 100 105 110Trp Ser
Ser Thr Pro Leu Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile 115 120
125Lys Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
130 135 140Ser Gln Val Gln Leu Lys Glu Ala Gly Pro Gly Leu Val Gln
Pro Thr145 150 155 160Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly
Phe Ser Leu Thr Ser 165 170 175Asp Gly Val His Trp Ile Arg Gln Pro
Pro Gly Lys Gly Leu Glu Trp 180 185 190Met Gly Ile Ile Tyr Tyr Asp
Gly Gly Thr Asp Tyr Asn Ser Ala Ile 195 200 205Lys Ser Arg Leu Ser
Ile Ser Arg Asp Thr Ser Lys Ser Gln Val Phe 210 215 220Leu Lys Ile
Asn Ser Leu Gln Thr Asp Asp Thr Ala Met Tyr Tyr Cys225 230 235
240Ala Arg Ile His Phe Asp Tyr Trp Gly Gln Gly Val Met Val Thr Val
245 250 255Ser Ser Asp Gln Pro Val Pro Ser Thr Pro Pro Thr Pro Ser
Pro Ser 260 265 270Thr Pro Pro Thr Pro Ser Pro Ser Cys Cys His Pro
Arg Leu Ser Leu 275 280 285His Arg Pro Ala Leu Glu Asp Leu Leu Leu
Gly Ser Glu Ala Ile Leu 290 295 300Thr Cys Thr Leu Thr Gly Leu Arg
Asp Ala Ser Gly Val Thr Phe Thr305 310 315 320Trp Thr Pro Ser Ser
Gly Lys Ser Ala Val Gln Gly Pro Pro Asp Arg 325 330 335Asp Leu Cys
Gly Cys Tyr Ser Val Ser Ser Val Leu Pro Gly Cys Ala 340 345 350Glu
Pro Trp Asn His Gly Lys Thr Phe Thr Cys Thr Ala Ala Tyr Pro 355 360
365Glu Ser Lys Thr Pro Leu Thr Ala Thr Leu Ser Lys Ser Gly Asn Thr
370 375 380Phe Arg Pro Glu Val His Leu Leu Pro Pro Pro Ser Glu Glu
Leu Ala385 390 395 400Leu Asn Glu Leu Val Thr Leu Thr Cys Leu Ala
Arg Gly Phe Ser Pro 405 410 415Lys Asp Val Leu Val Arg Trp Leu Gln
Gly Ser Gln Glu Leu Pro Arg 420 425 430Glu Lys Tyr Leu Thr Trp Ala
Ser Arg Gln Glu Pro Ser Gln Gly Thr 435 440 445Thr Thr Phe Ala Val
Thr Ser Ile Leu Arg Val Ala Ala Glu Asp Trp 450 455 460Lys Lys Gly
Asp Thr Phe Ser Cys Met Val Gly His Glu Ala Leu Pro465
470 475 480Leu Ala Phe Thr Gln Lys Thr Ile Asp Arg Leu Ala Gly Lys
Pro Thr 485 490 495His Val Asn Val Ser Val Val Met Ala Glu Val Asp
Ala Asp Pro Ser 500 505 510Asn Asn Leu Leu Pro Ser Trp Ala Ile Thr
Leu Ile Ser Val Asn Gly 515 520 525Ile Phe Val Ile Cys Cys Leu Thr
Tyr Cys Phe Ala Pro Arg Cys Arg 530 535 540Glu Arg Arg Arg Asn Glu
Arg Leu Arg Arg Glu Ser Val Arg Pro Val545 550 555 560173996DNAHomo
sapiens 173tgatcacgtc tgctccaggg acttcacccc gcccaccgtg aagatcttac
agtcgtcctg 60cgacggcggc gggcacttcc ccccgaccat ccagctcctg tgcctcgtct
ctgggtacac 120cccagggact atcaacatca cctggctgga ggacgggcag
gtcatggacg tggacttgtc 180caccgcctct accacgcagg agggtgagct
ggcctccaca caaagcgagc tcaccctcag 240ccagaagcac tggctgtcag
accgcaccta cacctgccag gtcacctatc aaggtcacac 300ctttgaggac
agcaccaaga agtgtgcaga ttccaacccg agaggggtga gcgcctacct
360aagccggccc agcccgttcg acctgttcat ccgcaagtcg cccacgatca
cctgtctggt 420ggtggacctg gcacccagca aggggaccgt gaacctgacc
tggtcccggg ccagtgggaa 480gcctgtgaac cactccacca gaaaggagga
gaagcagcgc aatggcacgt taaccgtcac 540gtccaccctg ccggtgggca
cccgagactg gatcgagggg gagacctacc agtgcagggt 600gacccacccc
cacctgccca gggccctcat gcggtccacg accaagacca gcggcccgcg
660tgctgccccg gaagtctatg cgtttgcgac gccggagtgg ccggggagcc
gggacaagcg 720caccctcgcc tgcctgatcc agaacttcat gcctgaggac
atctcggtgc agtggctgca 780caacgaggtg cagctcccgg acgcccggca
cagcacgacg cagccccgca agaccaaggg 840ctccggcttc ttcgtcttca
gccgcctgga ggtgaccagg gccgaatggg agcagaaaga 900tgagttcatc
tgccgtgcag tccatgaggc agcgagcccc tcacagaccg tccagcgagc
960ggtgtctgta aatcccggta aagcggatcc ttcgaa 996174331PRTHomo sapiens
174Asp His Val Cys Ser Arg Asp Phe Thr Pro Pro Thr Val Lys Ile Leu1
5 10 15Gln Ser Ser Cys Asp Gly Gly Gly His Phe Pro Pro Thr Ile Gln
Leu 20 25 30Leu Cys Leu Val Ser Gly Tyr Thr Pro Gly Thr Ile Asn Ile
Thr Trp 35 40 45Leu Glu Asp Gly Gln Val Met Asp Val Asp Leu Ser Thr
Ala Ser Thr 50 55 60Thr Gln Glu Gly Glu Leu Ala Ser Thr Gln Ser Glu
Leu Thr Leu Ser65 70 75 80Gln Lys His Trp Leu Ser Asp Arg Thr Tyr
Thr Cys Gln Val Thr Tyr 85 90 95Gln Gly His Thr Phe Glu Asp Ser Thr
Lys Lys Cys Ala Asp Ser Asn 100 105 110Pro Arg Gly Val Ser Ala Tyr
Leu Ser Arg Pro Ser Pro Phe Asp Leu 115 120 125Phe Ile Arg Lys Ser
Pro Thr Ile Thr Cys Leu Val Val Asp Leu Ala 130 135 140Pro Ser Lys
Gly Thr Val Asn Leu Thr Trp Ser Arg Ala Ser Gly Lys145 150 155
160Pro Val Asn His Ser Thr Arg Lys Glu Glu Lys Gln Arg Asn Gly Thr
165 170 175Leu Thr Val Thr Ser Thr Leu Pro Val Gly Thr Arg Asp Trp
Ile Glu 180 185 190Gly Glu Thr Tyr Gln Cys Arg Val Thr His Pro His
Leu Pro Arg Ala 195 200 205Leu Met Arg Ser Thr Thr Lys Thr Ser Gly
Pro Arg Ala Ala Pro Glu 210 215 220Val Tyr Ala Phe Ala Thr Pro Glu
Trp Pro Gly Ser Arg Asp Lys Arg225 230 235 240Thr Leu Ala Cys Leu
Ile Gln Asn Phe Met Pro Glu Asp Ile Ser Val 245 250 255Gln Trp Leu
His Asn Glu Val Gln Leu Pro Asp Ala Arg His Ser Thr 260 265 270Thr
Gln Pro Arg Lys Thr Lys Gly Ser Gly Phe Phe Val Phe Ser Arg 275 280
285Leu Glu Val Thr Arg Ala Glu Trp Glu Gln Lys Asp Glu Phe Ile Cys
290 295 300Arg Ala Val His Glu Ala Ala Ser Pro Ser Gln Thr Val Gln
Arg Ala305 310 315 320Val Ser Val Asn Pro Gly Lys Ala Asp Pro Ser
325 3301751921DNAHomo sapiens 175aagcttatgg attttcaagt gcagattttc
agcttcctgc taatcagtgc ttcagtcata 60atgtccagag gagtcgacat tgtgctcact
cagtctccaa caaccatagc tgcatctcca 120ggggagaagg tcaccatcac
ctgccgtgcc agctccagtg taagttacat gtactggtac 180cagcagaagt
caggcgcctc ccctaaactc tggatttatg acacatccaa gctggcttct
240ggagttccaa atcgcttcag tggcagtggg tctgggacct cttattctct
cgcaatcaac 300accatggaga ctgaagatgc tgccacttat tactgtcagc
agtggagtag tactccgctc 360acgttcgggt ctgggaccaa gctggagatc
aaacggggtg gcggtggctc gggcggtggt 420gggtcgggtg gcggcggatc
tcaggtgcag ctgaaggagg caggacctgg cctggtgcaa 480ccgacacaga
ccctgtccct cacatgcact gtctctgggt tctcattaac cagcgatggt
540gtacactgga ttcgacagcc tccaggaaag ggtctggaat ggatgggaat
aatatattat 600gatggaggca cagattataa ttcagcaatt aaatccagac
tgagcatcag cagggacacc 660tccaagagcc aagttttctt aaaaatcaac
agtctgcaaa ctgatgacac agccatgtat 720tactgtgcca gaatccactt
tgattactgg ggccaaggag tcatggtcac agtctcctct 780gatcacgtct
gctccaggga cttcaccccg cccaccgtga agatcttaca gtcgtcctgc
840gacggcggcg ggcacttccc cccgaccatc cagctcctgt gcctcgtctc
tgggtacacc 900ccagggacta tcaacatcac ctggctggag gacgggcagg
tcatggacgt ggacttgtcc 960accgcctcta ccacgcagga gggtgagctg
gcctccacac aaagcgagct caccctcagc 1020cagaagcact ggctgtcaga
ccgcacctac acctgccagg tcacctatca aggtcacacc 1080tttgaggaca
gcaccaagaa gtgtgcagat tccaacccga gaggggtgag cgcctaccta
1140agccggccca gcccgttcga cctgttcatc cgcaagtcgc ccacgatcac
ctgtctggtg 1200gtggacctgg cacccagcaa ggggaccgtg aacctgacct
ggtcccgggc cagtgggaag 1260cctgtgaacc actccaccag aaaggaggag
aagcagcgca atggcacgtt aaccgtcacg 1320tccaccctgc cggtgggcac
ccgagactgg atcgaggggg agacctacca gtgcagggtg 1380acccaccccc
acctgcccag ggccctcatg cggtccacga ccaagaccag cggcccgcgt
1440gctgccccgg aagtctatgc gtttgcgacg ccggagtggc cggggagccg
ggacaagcgc 1500accctcgcct gcctgatcca gaacttcatg cctgaggaca
tctcggtgca gtggctgcac 1560aacgaggtgc agctcccgga cgcccggcac
agcacgacgc agccccgcaa gaccaagggc 1620tccggcttct tcgtcttcag
ccgcctggag gtgaccaggg ccgaatggga gcagaaagat 1680gagttcatct
gccgtgcagt ccatgaggca gcgagcccct cacagaccgt ccagcgagcg
1740gtgtctgtaa atcccggtaa agcggatcct tcgaagctcc catcctgggc
cattacctta 1800atctcagtaa atggaatttt tgtgatatgc tgcctgacct
actgctttgc cccaagatgc 1860agagagagaa ggaggaatga gagattgaga
agggaaagtg tacgccctgt ataaatcgat 1920a 1921176635PRTHomo sapiens
176Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1
5 10 15Val Ile Met Ser Arg Gly Val Asp Ile Val Leu Thr Gln Ser Pro
Thr 20 25 30Thr Ile Ala Ala Ser Pro Gly Glu Lys Val Thr Ile Thr Cys
Arg Ala 35 40 45Ser Ser Ser Val Ser Tyr Met Tyr Trp Tyr Gln Gln Lys
Ser Gly Ala 50 55 60Ser Pro Lys Leu Trp Ile Tyr Asp Thr Ser Lys Leu
Ala Ser Gly Val65 70 75 80Pro Asn Arg Phe Ser Gly Ser Gly Ser Gly
Thr Ser Tyr Ser Leu Ala 85 90 95Ile Asn Thr Met Glu Thr Glu Asp Ala
Ala Thr Tyr Tyr Cys Gln Gln 100 105 110Trp Ser Ser Thr Pro Leu Thr
Phe Gly Ser Gly Thr Lys Leu Glu Ile 115 120 125Lys Arg Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 130 135 140Ser Gln Val
Gln Leu Lys Glu Ala Gly Pro Gly Leu Val Gln Pro Thr145 150 155
160Gln Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Ser
165 170 175Asp Gly Val His Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu
Glu Trp 180 185 190Met Gly Ile Ile Tyr Tyr Asp Gly Gly Thr Asp Tyr
Asn Ser Ala Ile 195 200 205Lys Ser Arg Leu Ser Ile Ser Arg Asp Thr
Ser Lys Ser Gln Val Phe 210 215 220Leu Lys Ile Asn Ser Leu Gln Thr
Asp Asp Thr Ala Met Tyr Tyr Cys225 230 235 240Ala Arg Ile His Phe
Asp Tyr Trp Gly Gln Gly Val Met Val Thr Val 245 250 255Ser Ser Asp
His Val Cys Ser Arg Asp Phe Thr Pro Pro Thr Val Lys 260 265 270Ile
Leu Gln Ser Ser Cys Asp Gly Gly Gly His Phe Pro Pro Thr Ile 275 280
285Gln Leu Leu Cys Leu Val Ser Gly Tyr Thr Pro Gly Thr Ile Asn Ile
290 295 300Thr Trp Leu Glu Asp Gly Gln Val Met Asp Val Asp Leu Ser
Thr Ala305 310 315 320Ser Thr Thr Gln Glu Gly Glu Leu Ala Ser Thr
Gln Ser Glu Leu Thr 325 330 335Leu Ser Gln Lys His Trp Leu Ser Asp
Arg Thr Tyr Thr Cys Gln Val 340 345 350Thr Tyr Gln Gly His Thr Phe
Glu Asp Ser Thr Lys Lys Cys Ala Asp 355 360 365Ser Asn Pro Arg Gly
Val Ser Ala Tyr Leu Ser Arg Pro Ser Pro Phe 370 375 380Asp Leu Phe
Ile Arg Lys Ser Pro Thr Ile Thr Cys Leu Val Val Asp385 390 395
400Leu Ala Pro Ser Lys Gly Thr Val Asn Leu Thr Trp Ser Arg Ala Ser
405 410 415Gly Lys Pro Val Asn His Ser Thr Arg Lys Glu Glu Lys Gln
Arg Asn 420 425 430Gly Thr Leu Thr Val Thr Ser Thr Leu Pro Val Gly
Thr Arg Asp Trp 435 440 445Ile Glu Gly Glu Thr Tyr Gln Cys Arg Val
Thr His Pro His Leu Pro 450 455 460Arg Ala Leu Met Arg Ser Thr Thr
Lys Thr Ser Gly Pro Arg Ala Ala465 470 475 480Pro Glu Val Tyr Ala
Phe Ala Thr Pro Glu Trp Pro Gly Ser Arg Asp 485 490 495Lys Arg Thr
Leu Ala Cys Leu Ile Gln Asn Phe Met Pro Glu Asp Ile 500 505 510Ser
Val Gln Trp Leu His Asn Glu Val Gln Leu Pro Asp Ala Arg His 515 520
525Ser Thr Thr Gln Pro Arg Lys Thr Lys Gly Ser Gly Phe Phe Val Phe
530 535 540Ser Arg Leu Glu Val Thr Arg Ala Glu Trp Glu Gln Lys Asp
Glu Phe545 550 555 560Ile Cys Arg Ala Val His Glu Ala Ala Ser Pro
Ser Gln Thr Val Gln 565 570 575Arg Ala Val Ser Val Asn Pro Gly Lys
Ala Asp Pro Ser Lys Leu Pro 580 585 590Ser Trp Ala Ile Thr Leu Ile
Ser Val Asn Gly Ile Phe Val Ile Cys 595 600 605Cys Leu Thr Tyr Cys
Phe Ala Pro Arg Cys Arg Glu Arg Arg Arg Asn 610 615 620Glu Arg Leu
Arg Arg Glu Ser Val Arg Pro Val625 630 6351771742DNAArtificial
sequenceDescription of Artificial Synthetic nucleotide sequence
177aagcttgccg ccatgaggtt ctctgctcag cttctggggc tgcttgtgct
ctggatccct 60ggatccactg cagatattgt gatgacgcag gctgcattct ccaatccagt
cactcttgga 120acatcagctt ccatctcctg caggtctagt aagagtctcc
tacatagtaa tggcatcact 180tatttgtatt ggtatctgca gaagccaggc
cagtctcctc agctcctgat ttatcagatg 240tccaaccttg cctcaggagt
cccagacagg ttcagtagca gtgggtcagg aactgatttc 300acactgagaa
tcagcagagt ggaggctgag gatgtgggtg tttattactg tgctcaaaat
360ctagaacttc cgctcacgtt cggtgctggg accaagctgg agctgaaacg
gggtggcggt 420ggctcgggcg gtggtgggtc gggtggcggc ggatcgtcac
aggtgcagct gaagcagtca 480ggacctggcc tagtgcagtc ctcacagagc
ctgtccatca cctgcacagt ctctggtttc 540tcattaacta cctatgctgt
acactgggtt cgccagtctc caggaaaggg tctggagtgg 600ctgggagtga
tatggagtgg tggaatcaca gactataatg cagctttcat atccagactg
660agcatcacca aggacgattc caagagccaa gttttcttta aaatgaacag
tctgcaacct 720aatgacacag ccatttatta ctgtgccaga aatgggggtg
ataactaccc ttattactat 780gctatggact actggggtca aggaacctca
gtcaccgtct cctctgatca gccagttccc 840tcaactccac ctaccccatc
tccctcaact ccacctaccc catctccctc atgctgccac 900ccccgactgt
cactgcaccg accggccctc gaggacctgc tcttaggttc agaagcgatc
960ctcacgtgca cactgaccgg cctgagagat gcctcaggtg tcaccttcac
ctggacgccc 1020tcaagtggga agagcgctgt tcaaggacca cctgaccgtg
acctctgtgg ctgctacagc 1080gtgtccagtg tcctgccggg ctgtgccgag
ccatggaacc atgggaagac cttcacttgc 1140actgctgcct accccgagtc
caagaccccg ctaaccgcca ccctctcaaa atccggaaac 1200acattccggc
ccgaggtcca cctgctgccg ccgccgtcgg aggagctggc cctgaacgag
1260ctggtgacgc tgacgtgcct ggcacgtggc ttcagcccca aggatgtgct
ggttcgctgg 1320ctgcaggggt cacaggagct gccccgcgag aagtacctga
cttgggcatc ccggcaggag 1380cccagccagg gcaccaccac cttcgctgtg
accagcatac tgcgcgtggc agccgaggac 1440tggaagaagg gggacacctt
ctcctgcatg gtgggccacg aggccctgcc gctggccttc 1500acacagaaga
ccatcgaccg cttggcgggt aaacccaccc atgtcaatgt gtctgttgtc
1560atggcggagg tggacgcgga tccttcgaac aacctgctcc catcctgggc
cattacctta 1620atctcagtaa atggaatttt tgtgatatgc tgcctgacct
actgctttgc cccaagatgc 1680agagagagaa ggaggaatga gagattgaga
agggaaagtg tacgccctgt ataaatcgat 1740ac 1742178573PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
178Met Arg Phe Ser Ala Gln Leu Leu Gly Leu Leu Val Leu Trp Ile Pro1
5 10 15Gly Ser Thr Ala Asp Ile Val Met Thr Gln Ala Ala Phe Ser Asn
Pro 20 25 30Val Thr Leu Gly Thr Ser Ala Ser Ile Ser Cys Arg Ser Ser
Lys Ser 35 40 45Leu Leu His Ser Asn Gly Ile Thr Tyr Leu Tyr Trp Tyr
Leu Gln Lys 50 55 60Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Gln Met
Ser Asn Leu Ala65 70 75 80Ser Gly Val Pro Asp Arg Phe Ser Ser Ser
Gly Ser Gly Thr Asp Phe 85 90 95Thr Leu Arg Ile Ser Arg Val Glu Ala
Glu Asp Val Gly Val Tyr Tyr 100 105 110Cys Ala Gln Asn Leu Glu Leu
Pro Leu Thr Phe Gly Ala Gly Thr Lys 115 120 125Leu Glu Leu Lys Arg
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 130 135 140Gly Gly Gly
Ser Ser Gln Val Gln Leu Lys Gln Ser Gly Pro Gly Leu145 150 155
160Val Gln Ser Ser Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe
165 170 175Ser Leu Thr Thr Tyr Ala Val His Trp Val Arg Gln Ser Pro
Gly Lys 180 185 190Gly Leu Glu Trp Leu Gly Val Ile Trp Ser Gly Gly
Ile Thr Asp Tyr 195 200 205Asn Ala Ala Phe Ile Ser Arg Leu Ser Ile
Thr Lys Asp Asp Ser Lys 210 215 220Ser Gln Val Phe Phe Lys Met Asn
Ser Leu Gln Pro Asn Asp Thr Ala225 230 235 240Ile Tyr Tyr Cys Ala
Arg Asn Gly Gly Asp Asn Tyr Pro Tyr Tyr Tyr 245 250 255Ala Met Asp
Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Asp 260 265 270Gln
Pro Val Pro Ser Thr Pro Pro Thr Pro Ser Pro Ser Thr Pro Pro 275 280
285Thr Pro Ser Pro Ser Cys Cys His Pro Arg Leu Ser Leu His Arg Pro
290 295 300Ala Leu Glu Asp Leu Leu Leu Gly Ser Glu Ala Ile Leu Thr
Cys Thr305 310 315 320Leu Thr Gly Leu Arg Asp Ala Ser Gly Val Thr
Phe Thr Trp Thr Pro 325 330 335Ser Ser Gly Lys Ser Ala Val Gln Gly
Pro Pro Asp Arg Asp Leu Cys 340 345 350Gly Cys Tyr Ser Val Ser Ser
Val Leu Pro Gly Cys Ala Glu Pro Trp 355 360 365Asn His Gly Lys Thr
Phe Thr Cys Thr Ala Ala Tyr Pro Glu Ser Lys 370 375 380Thr Pro Leu
Thr Ala Thr Leu Ser Lys Ser Gly Asn Thr Phe Arg Pro385 390 395
400Glu Val His Leu Leu Pro Pro Pro Ser Glu Glu Leu Ala Leu Asn Glu
405 410 415Leu Val Thr Leu Thr Cys Leu Ala Arg Gly Phe Ser Pro Lys
Asp Val 420 425 430Leu Val Arg Trp Leu Gln Gly Ser Gln Glu Leu Pro
Arg Glu Lys Tyr 435 440 445Leu Thr Trp Ala Ser Arg Gln Glu Pro Ser
Gln Gly Thr Thr Thr Phe 450 455 460Ala Val Thr Ser Ile Leu Arg Val
Ala Ala Glu Asp Trp Lys Lys Gly465 470 475 480Asp Thr Phe Ser Cys
Met Val Gly His Glu Ala Leu Pro Leu Ala Phe 485 490 495Thr Gln Lys
Thr Ile Asp Arg Leu Ala Gly Lys Pro Thr His Val Asn 500 505 510Val
Ser Val Val Met Ala Glu Val Asp Ala Asp Pro Ser Asn Asn Leu 515 520
525Leu Pro Ser Trp Ala Ile Thr Leu Ile Ser Val Asn Gly Ile Phe Val
530 535 540Ile Cys Cys Leu Thr Tyr Cys Phe Ala Pro Arg Cys Arg Glu
Arg Arg545 550 555 560Arg Asn Glu Arg Leu Arg Arg Glu Ser Val Arg
Pro Val 565 5701791966DNAHomo sapiens 179aagcttgccg ccatgaggtt
ctctgctcag cttctggggc tgcttgtgct ctggatccct 60ggatccactg cagatattgt
gatgacgcag gctgcattct ccaatccagt cactcttgga
120acatcagctt ccatctcctg caggtctagt aagagtctcc tacatagtaa
tggcatcact 180tatttgtatt ggtatctgca gaagccaggc cagtctcctc
agctcctgat ttatcagatg 240tccaaccttg cctcaggagt cccagacagg
ttcagtagca gtgggtcagg aactgatttc 300acactgagaa tcagcagagt
ggaggctgag gatgtgggtg tttattactg tgctcaaaat 360ctagaacttc
cgctcacgtt cggtgctggg accaagctgg agctgaaacg gggtggcggt
420ggctcgggcg gtggtgggtc gggtggcggc ggatcgtcac aggtgcagct
gaagcagtca 480ggacctggcc tagtgcagtc ctcacagagc ctgtccatca
cctgcacagt ctctggtttc 540tcattaacta cctatgctgt acactgggtt
cgccagtctc caggaaaggg tctggagtgg 600ctgggagtga tatggagtgg
tggaatcaca gactataatg cagctttcat atccagactg 660agcatcacca
aggacgattc caagagccaa gttttcttta aaatgaacag tctgcaacct
720aatgacacag ccatttatta ctgtgccaga aatgggggtg ataactaccc
ttattactat 780gctatggact actggggtca aggaacctca gtcaccgtct
cctctgatca cgtctgctcc 840agggacttca ccccgcccac cgtgaagatc
ttacagtcgt cctgcgacgg cggcgggcac 900ttccccccga ccatccagct
cctgtgcctc gtctctgggt acaccccagg gactatcaac 960atcacctggc
tggaggacgg gcaggtcatg gacgtggact tgtccaccgc ctctaccacg
1020caggagggtg agctggcctc cacacaaagc gagctcaccc tcagccagaa
gcactggctg 1080tcagaccgca cctacacctg ccaggtcacc tatcaaggtc
acacctttga ggacagcacc 1140aagaagtgtg cagattccaa cccgagaggg
gtgagcgcct acctaagccg gcccagcccg 1200ttcgacctgt tcatccgcaa
gtcgcccacg atcacctgtc tggtggtgga cctggcaccc 1260agcaagggga
ccgtgaacct gacctggtcc cgggccagtg ggaagcctgt gaaccactcc
1320accagaaagg aggagaagca gcgcaatggc acgttaaccg tcacgtccac
cctgccggtg 1380ggcacccgag actggatcga gggggagacc taccagtgca
gggtgaccca cccccacctg 1440cccagggccc tcatgcggtc cacgaccaag
accagcggcc cgcgtgctgc cccggaagtc 1500tatgcgtttg cgacgccgga
gtggccgggg agccgggaca agcgcaccct cgcctgcctg 1560atccagaact
tcatgcctga ggacatctcg gtgcagtggc tgcacaacga ggtgcagctc
1620ccggacgccc ggcacagcac gacgcagccc cgcaagacca agggctccgg
cttcttcgtc 1680ttcagccgcc tggaggtgac cagggccgaa tgggagcaga
aagatgagtt catctgccgt 1740gcagtccatg aggcagcgag cccctcacag
accgtccagc gagcggtgtc tgtaaatccc 1800ggtaaagcgg atccttcgaa
gctcccatcc tgggccatta ccttaatctc agtaaatgga 1860atttttgtga
tatgctgcct gacctactgc tttgccccaa gatgcagaga gagaaggagg
1920aatgagagat tgagaaggga aagtgtacgc cctgtataaa tcgata
1966180648PRTHomo sapiens 180Met Arg Phe Ser Ala Gln Leu Leu Gly
Leu Leu Val Leu Trp Ile Pro1 5 10 15Gly Ser Thr Ala Asp Ile Val Met
Thr Gln Ala Ala Phe Ser Asn Pro 20 25 30Val Thr Leu Gly Thr Ser Ala
Ser Ile Ser Cys Arg Ser Ser Lys Ser 35 40 45Leu Leu His Ser Asn Gly
Ile Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys 50 55 60Pro Gly Gln Ser Pro
Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu Ala65 70 75 80Ser Gly Val
Pro Asp Arg Phe Ser Ser Ser Gly Ser Gly Thr Asp Phe 85 90 95Thr Leu
Arg Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr 100 105
110Cys Ala Gln Asn Leu Glu Leu Pro Leu Thr Phe Gly Ala Gly Thr Lys
115 120 125Leu Glu Leu Lys Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly 130 135 140Gly Gly Gly Ser Ser Gln Val Gln Leu Lys Gln Ser
Gly Pro Gly Leu145 150 155 160Val Gln Ser Ser Gln Ser Leu Ser Ile
Thr Cys Thr Val Ser Gly Phe 165 170 175Ser Leu Thr Thr Tyr Ala Val
His Trp Val Arg Gln Ser Pro Gly Lys 180 185 190Gly Leu Glu Trp Leu
Gly Val Ile Trp Ser Gly Gly Ile Thr Asp Tyr 195 200 205Asn Ala Ala
Phe Ile Ser Arg Leu Ser Ile Thr Lys Asp Asp Ser Lys 210 215 220Ser
Gln Val Phe Phe Lys Met Asn Ser Leu Gln Pro Asn Asp Thr Ala225 230
235 240Ile Tyr Tyr Cys Ala Arg Asn Gly Gly Asp Asn Tyr Pro Tyr Tyr
Tyr 245 250 255Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val
Ser Ser Asp 260 265 270His Val Cys Ser Arg Asp Phe Thr Pro Pro Thr
Val Lys Ile Leu Gln 275 280 285Ser Ser Cys Asp Gly Gly Gly His Phe
Pro Pro Thr Ile Gln Leu Leu 290 295 300Cys Leu Val Ser Gly Tyr Thr
Pro Gly Thr Ile Asn Ile Thr Trp Leu305 310 315 320Glu Asp Gly Gln
Val Met Asp Val Asp Leu Ser Thr Ala Ser Thr Thr 325 330 335Gln Glu
Gly Glu Leu Ala Ser Thr Gln Ser Glu Leu Thr Leu Ser Gln 340 345
350Lys His Trp Leu Ser Asp Arg Thr Tyr Thr Cys Gln Val Thr Tyr Gln
355 360 365Gly His Thr Phe Glu Asp Ser Thr Lys Lys Cys Ala Asp Ser
Asn Pro 370 375 380Arg Gly Val Ser Ala Tyr Leu Ser Arg Pro Ser Pro
Phe Asp Leu Phe385 390 395 400Ile Arg Lys Ser Pro Thr Ile Thr Cys
Leu Val Val Asp Leu Ala Pro 405 410 415Ser Lys Gly Thr Val Asn Leu
Thr Trp Ser Arg Ala Ser Gly Lys Pro 420 425 430Val Asn His Ser Thr
Arg Lys Glu Glu Lys Gln Arg Asn Gly Thr Leu 435 440 445Thr Val Thr
Ser Thr Leu Pro Val Gly Thr Arg Asp Trp Ile Glu Gly 450 455 460Glu
Thr Tyr Gln Cys Arg Val Thr His Pro His Leu Pro Arg Ala Leu465 470
475 480Met Arg Ser Thr Thr Lys Thr Ser Gly Pro Arg Ala Ala Pro Glu
Val 485 490 495Tyr Ala Phe Ala Thr Pro Glu Trp Pro Gly Ser Arg Asp
Lys Arg Thr 500 505 510Leu Ala Cys Leu Ile Gln Asn Phe Met Pro Glu
Asp Ile Ser Val Gln 515 520 525Trp Leu His Asn Glu Val Gln Leu Pro
Asp Ala Arg His Ser Thr Thr 530 535 540Gln Pro Arg Lys Thr Lys Gly
Ser Gly Phe Phe Val Phe Ser Arg Leu545 550 555 560Glu Val Thr Arg
Ala Glu Trp Glu Gln Lys Asp Glu Phe Ile Cys Arg 565 570 575Ala Val
His Glu Ala Ala Ser Pro Ser Gln Thr Val Gln Arg Ala Val 580 585
590Ser Val Asn Pro Gly Lys Ala Asp Pro Ser Lys Leu Pro Ser Trp Ala
595 600 605Ile Thr Leu Ile Ser Val Asn Gly Ile Phe Val Ile Cys Cys
Leu Thr 610 615 620Tyr Cys Phe Ala Pro Arg Cys Arg Glu Arg Arg Arg
Asn Glu Arg Leu625 630 635 640Arg Arg Glu Ser Val Arg Pro Val
6451811736DNAArtificial sequenceDescription of Artificial Synthetic
nucleotide sequence 181aagcttatgg attttcaagt gcagattttc agcttcctgc
taatcagtgc ttcagtcata 60atgtccagag gagtcgacat tgtgctcacc caatctccag
cttctttggc tgtgtctcta 120ggtcagagag ccaccatctc ctgcagagcc
agtgaaagtg ttgaatatta tgtcacaagt 180ttaatgcagt ggtaccaaca
gaaaccagga cagccaccca aactcctcat ctctgctgca 240tccaacgtag
aatctggggt ccctgccagg tttagtggca gtgggtctgg gacagacttc
300agcctcaaca tccatcctgt ggaggaggat gatattgcaa tgtatttctg
tcagcaaagt 360aggaaggttc cttggacgtt cggtggaggc accaagctgg
aaatcaaacg gggtggcggt 420ggctcgggcg gaggtgggtc gggtggcggc
ggatctcagg tgcagctgaa ggagtcagga 480cctggcctgg tggcgccctc
acagagcctg tccatcacat gcaccgtctc agggttctca 540ttaaccggct
atggtgtaaa ctgggttcgc cagcctccag gaaagggtct ggagtggctg
600ggaatgatat ggggtgatgg aagcacagac tataattcag ctctcaaatc
cagactgagc 660atcaccaagg acaactccaa gagccaagtt ttcttaaaaa
tgaacagtct gcaaactgat 720gacacagcca gatactactg tgccagagat
ggttatagta actttcatta ctatgttatg 780gactactggg gtcaaggaac
ctcagtcacc gtctcctcag atcagccagt tccctcaact 840ccacctaccc
catctccctc aactccacct accccatctc cctcatgctg ccacccccga
900ctgtcactgc accgaccggc cctcgaggac ctgctcttag gttcagaagc
gatcctcacg 960tgcacactga ccggcctgag agatgcctca ggtgtcacct
tcacctggac gccctcaagt 1020gggaagagcg ctgttcaagg accacctgac
cgtgacctct gtggctgcta cagcgtgtcc 1080agtgtcctgc cgggctgtgc
cgagccatgg aaccatggga agaccttcac ttgcactgct 1140gcctaccccg
agtccaagac cccgctaacc gccaccctct caaaatccgg aaacacattc
1200cggcccgagg tccacctgct gccgccgccg tcggaggagc tggccctgaa
cgagctggtg 1260acgctgacgt gcctggcacg tggcttcagc cccaaggatg
tgctggttcg ctggctgcag 1320gggtcacagg agctgccccg cgagaagtac
ctgacttggg catcccggca ggagcccagc 1380cagggcacca ccaccttcgc
tgtgaccagc atactgcgcg tggcagccga ggactggaag 1440aagggggaca
ccttctcctg catggtgggc cacgaggccc tgccgctggc cttcacacag
1500aagaccatcg accgcttggc gggtaaaccc acccatgtca atgtgtctgt
tgtcatggcg 1560gaggtggacg cggatccttc gaacaacctg ctcccatcct
gggccattac cttaatctca 1620gtaaatggaa tttttgtgat atgctgcctg
acctactgct ttgccccaag atgcagagag 1680agaaggagga atgagagatt
gagaagggaa agtgtacgcc ctgtataaat cgatac 1736182573PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
182Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1
5 10 15Val Ile Met Ser Arg Gly Val Asp Ile Val Leu Thr Gln Ser Pro
Ala 20 25 30Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys
Arg Ala 35 40 45Ser Glu Ser Val Glu Tyr Tyr Val Thr Ser Leu Met Gln
Trp Tyr Gln 50 55 60Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Ser
Ala Ala Ser Asn65 70 75 80Val Glu Ser Gly Val Pro Ala Arg Phe Ser
Gly Ser Gly Ser Gly Thr 85 90 95Asp Phe Ser Leu Asn Ile His Pro Val
Glu Glu Asp Asp Ile Ala Met 100 105 110Tyr Phe Cys Gln Gln Ser Arg
Lys Val Pro Trp Thr Phe Gly Gly Gly 115 120 125Thr Lys Leu Glu Ile
Lys Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly 130 135 140Ser Gly Gly
Gly Gly Ser Gln Val Gln Leu Lys Glu Ser Gly Pro Gly145 150 155
160Leu Val Ala Pro Ser Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly
165 170 175Phe Ser Leu Thr Gly Tyr Gly Val Asn Trp Val Arg Gln Pro
Pro Gly 180 185 190Lys Gly Leu Glu Trp Leu Gly Met Ile Trp Gly Asp
Gly Ser Thr Asp 195 200 205Tyr Asn Ser Ala Leu Lys Ser Arg Leu Ser
Ile Thr Lys Asp Asn Ser 210 215 220Lys Ser Gln Val Phe Leu Lys Met
Asn Ser Leu Gln Thr Asp Asp Thr225 230 235 240Ala Arg Tyr Tyr Cys
Ala Arg Asp Gly Tyr Ser Asn Phe His Tyr Tyr 245 250 255Val Met Asp
Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Asp 260 265 270Gln
Pro Val Pro Ser Thr Pro Pro Thr Pro Ser Pro Ser Thr Pro Pro 275 280
285Thr Pro Ser Pro Ser Cys Cys His Pro Arg Leu Ser Leu His Arg Pro
290 295 300Ala Leu Glu Asp Leu Leu Leu Gly Ser Glu Ala Ile Leu Thr
Cys Thr305 310 315 320Leu Thr Gly Leu Arg Asp Ala Ser Gly Val Thr
Phe Thr Trp Thr Pro 325 330 335Ser Ser Gly Lys Ser Ala Val Gln Gly
Pro Pro Asp Arg Asp Leu Cys 340 345 350Gly Cys Tyr Ser Val Ser Ser
Val Leu Pro Gly Cys Ala Glu Pro Trp 355 360 365Asn His Gly Lys Thr
Phe Thr Cys Thr Ala Ala Tyr Pro Glu Ser Lys 370 375 380Thr Pro Leu
Thr Ala Thr Leu Ser Lys Ser Gly Asn Thr Phe Arg Pro385 390 395
400Glu Val His Leu Leu Pro Pro Pro Ser Glu Glu Leu Ala Leu Asn Glu
405 410 415Leu Val Thr Leu Thr Cys Leu Ala Arg Gly Phe Ser Pro Lys
Asp Val 420 425 430Leu Val Arg Trp Leu Gln Gly Ser Gln Glu Leu Pro
Arg Glu Lys Tyr 435 440 445Leu Thr Trp Ala Ser Arg Gln Glu Pro Ser
Gln Gly Thr Thr Thr Phe 450 455 460Ala Val Thr Ser Ile Leu Arg Val
Ala Ala Glu Asp Trp Lys Lys Gly465 470 475 480Asp Thr Phe Ser Cys
Met Val Gly His Glu Ala Leu Pro Leu Ala Phe 485 490 495Thr Gln Lys
Thr Ile Asp Arg Leu Ala Gly Lys Pro Thr His Val Asn 500 505 510Val
Ser Val Val Met Ala Glu Val Asp Ala Asp Pro Ser Asn Asn Leu 515 520
525Leu Pro Ser Trp Ala Ile Thr Leu Ile Ser Val Asn Gly Ile Phe Val
530 535 540Ile Cys Cys Leu Thr Tyr Cys Phe Ala Pro Arg Cys Arg Glu
Arg Arg545 550 555 560Arg Asn Glu Arg Leu Arg Arg Glu Ser Val Arg
Pro Val 565 5701831960DNAHomo sapiens 183aagcttatgg attttcaagt
gcagattttc agcttcctgc taatcagtgc ttcagtcata 60atgtccagag gagtcgacat
tgtgctcacc caatctccag cttctttggc tgtgtctcta 120ggtcagagag
ccaccatctc ctgcagagcc agtgaaagtg ttgaatatta tgtcacaagt
180ttaatgcagt ggtaccaaca gaaaccagga cagccaccca aactcctcat
ctctgctgca 240tccaacgtag aatctggggt ccctgccagg tttagtggca
gtgggtctgg gacagacttc 300agcctcaaca tccatcctgt ggaggaggat
gatattgcaa tgtatttctg tcagcaaagt 360aggaaggttc cttggacgtt
cggtggaggc accaagctgg aaatcaaacg gggtggcggt 420ggctcgggcg
gaggtgggtc gggtggcggc ggatctcagg tgcagctgaa ggagtcagga
480cctggcctgg tggcgccctc acagagcctg tccatcacat gcaccgtctc
agggttctca 540ttaaccggct atggtgtaaa ctgggttcgc cagcctccag
gaaagggtct ggagtggctg 600ggaatgatat ggggtgatgg aagcacagac
tataattcag ctctcaaatc cagactgagc 660atcaccaagg acaactccaa
gagccaagtt ttcttaaaaa tgaacagtct gcaaactgat 720gacacagcca
gatactactg tgccagagat ggttatagta actttcatta ctatgttatg
780gactactggg gtcaaggaac ctcagtcacc gtctcctcag atcacgtctg
ctccagggac 840ttcaccccgc ccaccgtgaa gatcttacag tcgtcctgcg
acggcggcgg gcacttcccc 900ccgaccatcc agctcctgtg cctcgtctct
gggtacaccc cagggactat caacatcacc 960tggctggagg acgggcaggt
catggacgtg gacttgtcca ccgcctctac cacgcaggag 1020ggtgagctgg
cctccacaca aagcgagctc accctcagcc agaagcactg gctgtcagac
1080cgcacctaca cctgccaggt cacctatcaa ggtcacacct ttgaggacag
caccaagaag 1140tgtgcagatt ccaacccgag aggggtgagc gcctacctaa
gccggcccag cccgttcgac 1200ctgttcatcc gcaagtcgcc cacgatcacc
tgtctggtgg tggacctggc acccagcaag 1260gggaccgtga acctgacctg
gtcccgggcc agtgggaagc ctgtgaacca ctccaccaga 1320aaggaggaga
agcagcgcaa tggcacgtta accgtcacgt ccaccctgcc ggtgggcacc
1380cgagactgga tcgaggggga gacctaccag tgcagggtga cccaccccca
cctgcccagg 1440gccctcatgc ggtccacgac caagaccagc ggcccgcgtg
ctgccccgga agtctatgcg 1500tttgcgacgc cggagtggcc ggggagccgg
gacaagcgca ccctcgcctg cctgatccag 1560aacttcatgc ctgaggacat
ctcggtgcag tggctgcaca acgaggtgca gctcccggac 1620gcccggcaca
gcacgacgca gccccgcaag accaagggct ccggcttctt cgtcttcagc
1680cgcctggagg tgaccagggc cgaatgggag cagaaagatg agttcatctg
ccgtgcagtc 1740catgaggcag cgagcccctc acagaccgtc cagcgagcgg
tgtctgtaaa tcccggtaaa 1800gcggatcctt cgaagctccc atcctgggcc
attaccttaa tctcagtaaa tggaattttt 1860gtgatatgct gcctgaccta
ctgctttgcc ccaagatgca gagagagaag gaggaatgag 1920agattgagaa
gggaaagtgt acgccctgta taaatcgata 1960184648PRTHomo sapiens 184Met
Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1 5 10
15Val Ile Met Ser Arg Gly Val Asp Ile Val Leu Thr Gln Ser Pro Ala
20 25 30Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg
Ala 35 40 45Ser Glu Ser Val Glu Tyr Tyr Val Thr Ser Leu Met Gln Trp
Tyr Gln 50 55 60Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Ser Ala
Ala Ser Asn65 70 75 80Val Glu Ser Gly Val Pro Ala Arg Phe Ser Gly
Ser Gly Ser Gly Thr 85 90 95Asp Phe Ser Leu Asn Ile His Pro Val Glu
Glu Asp Asp Ile Ala Met 100 105 110Tyr Phe Cys Gln Gln Ser Arg Lys
Val Pro Trp Thr Phe Gly Gly Gly 115 120 125Thr Lys Leu Glu Ile Lys
Arg Gly Gly Gly Gly Ser Gly Gly Gly Gly 130 135 140Ser Gly Gly Gly
Gly Ser Gln Val Gln Leu Lys Glu Ser Gly Pro Gly145 150 155 160Leu
Val Ala Pro Ser Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly 165 170
175Phe Ser Leu Thr Gly Tyr Gly Val Asn Trp Val Arg Gln Pro Pro Gly
180 185 190Lys Gly Leu Glu Trp Leu Gly Met Ile Trp Gly Asp Gly Ser
Thr Asp 195 200 205Tyr Asn Ser Ala Leu Lys Ser Arg Leu Ser Ile Thr
Lys Asp Asn Ser 210 215 220Lys Ser Gln Val Phe Leu Lys Met Asn Ser
Leu Gln Thr Asp Asp Thr225 230 235 240Ala Arg Tyr Tyr Cys Ala Arg
Asp Gly Tyr Ser Asn Phe His Tyr Tyr 245 250 255Val Met Asp Tyr Trp
Gly Gln Gly Thr Ser Val Thr Val Ser Ser Asp 260 265 270His Val Cys
Ser Arg Asp Phe Thr Pro Pro Thr Val Lys Ile Leu Gln 275 280 285Ser
Ser Cys Asp Gly Gly Gly His Phe Pro Pro Thr Ile Gln Leu Leu 290
295
300Cys Leu Val Ser Gly Tyr Thr Pro Gly Thr Ile Asn Ile Thr Trp
Leu305 310 315 320Glu Asp Gly Gln Val Met Asp Val Asp Leu Ser Thr
Ala Ser Thr Thr 325 330 335Gln Glu Gly Glu Leu Ala Ser Thr Gln Ser
Glu Leu Thr Leu Ser Gln 340 345 350Lys His Trp Leu Ser Asp Arg Thr
Tyr Thr Cys Gln Val Thr Tyr Gln 355 360 365Gly His Thr Phe Glu Asp
Ser Thr Lys Lys Cys Ala Asp Ser Asn Pro 370 375 380Arg Gly Val Ser
Ala Tyr Leu Ser Arg Pro Ser Pro Phe Asp Leu Phe385 390 395 400Ile
Arg Lys Ser Pro Thr Ile Thr Cys Leu Val Val Asp Leu Ala Pro 405 410
415Ser Lys Gly Thr Val Asn Leu Thr Trp Ser Arg Ala Ser Gly Lys Pro
420 425 430Val Asn His Ser Thr Arg Lys Glu Glu Lys Gln Arg Asn Gly
Thr Leu 435 440 445Thr Val Thr Ser Thr Leu Pro Val Gly Thr Arg Asp
Trp Ile Glu Gly 450 455 460Glu Thr Tyr Gln Cys Arg Val Thr His Pro
His Leu Pro Arg Ala Leu465 470 475 480Met Arg Ser Thr Thr Lys Thr
Ser Gly Pro Arg Ala Ala Pro Glu Val 485 490 495Tyr Ala Phe Ala Thr
Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg Thr 500 505 510Leu Ala Cys
Leu Ile Gln Asn Phe Met Pro Glu Asp Ile Ser Val Gln 515 520 525Trp
Leu His Asn Glu Val Gln Leu Pro Asp Ala Arg His Ser Thr Thr 530 535
540Gln Pro Arg Lys Thr Lys Gly Ser Gly Phe Phe Val Phe Ser Arg
Leu545 550 555 560Glu Val Thr Arg Ala Glu Trp Glu Gln Lys Asp Glu
Phe Ile Cys Arg 565 570 575Ala Val His Glu Ala Ala Ser Pro Ser Gln
Thr Val Gln Arg Ala Val 580 585 590Ser Val Asn Pro Gly Lys Ala Asp
Pro Ser Lys Leu Pro Ser Trp Ala 595 600 605Ile Thr Leu Ile Ser Val
Asn Gly Ile Phe Val Ile Cys Cys Leu Thr 610 615 620Tyr Cys Phe Ala
Pro Arg Cys Arg Glu Arg Arg Arg Asn Glu Arg Leu625 630 635 640Arg
Arg Glu Ser Val Arg Pro Val 645185793DNAArtificial
sequenceDescription of Artificial Synthetic nucleotide sequence
185atgttgtata catctcagct ccttgggctt ttactcttct ggatttcagc
ctccagaagt 60gacatagtgc tgactcagac tccagccact ctgtctctaa ttcctggaga
aagagtcaca 120atgacctgta agaccagtca gaatattggc acaatcttac
actggtatca ccaaaaacca 180aaggaggctc caagggctct catcaagtat
gcttcgcagt ccattcctgg gatcccctcc 240agattcagtg gcagtggttc
ggaaacagat ttcactctca gcatcaataa cctggagcct 300gatgatatcg
gaatttatta ctgtcaacaa agtagaagct ggcctgtcac gttcggtcct
360ggcaccaagc tggagataaa acggggtggc ggtggctcgg gcggaggtgg
gtcgggtggc 420ggcggatctc aggtcaagct gcagcagtcc ggttctgaac
tagggaaacc tggggcctca 480gtgaaactgt cctgcaagac ttcaggctac
atattcacag atcactatat ttcttgggtg 540aaacagaagc ctggagaaag
cctgcagtgg ataggaaatg tttatggtgg aaatggtggt 600acaagctaca
atcaaaaatt ccagggcaag gccacactga ctgtagataa aatctctagc
660acagcctaca tggaactcag cagcctgaca tctgaggatt ctgccatcta
ttactgtgca 720agaaggccgg tagcgacggg ccatgctatg gactactggg
gtcaggggat ccaagttacc 780gtctcctctg atc 793186264PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
186Met Leu Tyr Thr Ser Gln Leu Leu Gly Leu Leu Leu Phe Trp Ile Ser1
5 10 15Ala Ser Arg Ser Asp Ile Val Leu Thr Gln Thr Pro Ala Thr Leu
Ser 20 25 30Leu Ile Pro Gly Glu Arg Val Thr Met Thr Cys Lys Thr Ser
Gln Asn 35 40 45Ile Gly Thr Ile Leu His Trp Tyr His Gln Lys Pro Lys
Glu Ala Pro 50 55 60Arg Ala Leu Ile Lys Tyr Ala Ser Gln Ser Ile Pro
Gly Ile Pro Ser65 70 75 80Arg Phe Ser Gly Ser Gly Ser Glu Thr Asp
Phe Thr Leu Ser Ile Asn 85 90 95Asn Leu Glu Pro Asp Asp Ile Gly Ile
Tyr Tyr Cys Gln Gln Ser Arg 100 105 110Ser Trp Pro Val Thr Phe Gly
Pro Gly Thr Lys Leu Glu Ile Lys Arg 115 120 125Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln 130 135 140Val Lys Leu
Gln Gln Ser Gly Ser Glu Leu Gly Lys Pro Gly Ala Ser145 150 155
160Val Lys Leu Ser Cys Lys Thr Ser Gly Tyr Ile Phe Thr Asp His Tyr
165 170 175Ile Ser Trp Val Lys Gln Lys Pro Gly Glu Ser Leu Gln Trp
Ile Gly 180 185 190Asn Val Tyr Gly Gly Asn Gly Gly Thr Ser Tyr Asn
Gln Lys Phe Gln 195 200 205Gly Lys Ala Thr Leu Thr Val Asp Lys Ile
Ser Ser Thr Ala Tyr Met 210 215 220Glu Leu Ser Ser Leu Thr Ser Glu
Asp Ser Ala Ile Tyr Tyr Cys Ala225 230 235 240Arg Arg Pro Val Ala
Thr Gly His Ala Met Asp Tyr Trp Gly Gln Gly 245 250 255Ile Gln Val
Thr Val Ser Ser Asp 26018747DNAArtificial sequenceDescription of
Artificial Synthetic oligonucleotide 187gttgttttcg aaggatccgc
tttacccgga gacagggaga ggctctt 4718845DNAArtificial
sequenceDescription of Artificial Synthetic oligonucleotide
188gttgttagat ctggagccca aatcttgtga caaaactcac acatg
4518948DNAArtificial sequenceDescription of Artificial Synthetic
oligonucleotide 189gttgtggatc cttcgaaccc gttcctggtg ctgctgcact
cggtgtcg 4819048DNAArtificial sequenceDescription of Artificial
Synthetic oligonucleotide 190gttgttatcg atctcgagtt atcaggacgc
ttcggaggta gatgcgtc 48191657DNAArtificial sequenceDescription of
Artificial Synthetic nucleotide sequence 191gtggatcctt cgaacccgtt
cctggtgctg ctgcactcgg tgtcgtccag cctgtcgagc 60agcgagctga ccgagctcaa
gttcctatgc ctcgggcgcg tgggcaagcg caagctggag 120cgcgtgcaga
gcggcctaga cctcttctcc atgctgctgg agcagaacga cctggagccc
180gggcacaccg agctcctgcg cgagctgctc gcctccctgc ggcgccacga
cctgctgcgg 240cgcgtcgacg acttcgaggc gggggcggcg gccggggccg
cgcctgggga agaagacctg 300tgtgcagcat ttaacgtcat atgtgataat
gtggggaaag attggagaag gctggctcgt 360cagctcaaag tctcagacac
caagatcgac agcatcgagg acagataccc ccgcaacctg 420acagagcgtg
tgcgggagtc actgagaatc tggaagaaca cagagaagga gaacgcaaca
480gtggcccacc tggtgggggc tctcaggtcc tgccagatga acctggtggc
tgacctggta 540caagaggttc agcaggcccg tgacctccag aacaggagtg
gggccatgtc cccgatgtca 600tggaactcag acgcatctac ctccgaagcg
tcctgataac tcgagatcga taacaac 657192211PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
192Val Asp Pro Ser Asn Pro Phe Leu Val Leu Leu His Ser Val Ser Ser1
5 10 15Ser Leu Ser Ser Ser Glu Leu Thr Glu Leu Lys Phe Leu Cys Leu
Gly 20 25 30Arg Val Gly Lys Arg Lys Leu Glu Arg Val Gln Ser Gly Leu
Asp Leu 35 40 45Phe Ser Met Leu Leu Glu Gln Asn Asp Leu Glu Pro Gly
His Thr Glu 50 55 60Leu Leu Arg Glu Leu Leu Ala Ser Leu Arg Arg His
Asp Leu Leu Arg65 70 75 80Arg Val Asp Asp Phe Glu Ala Gly Ala Ala
Ala Gly Ala Ala Pro Gly 85 90 95Glu Glu Asp Leu Cys Ala Ala Phe Asn
Val Ile Cys Asp Asn Val Gly 100 105 110Lys Asp Trp Arg Arg Leu Ala
Arg Gln Leu Lys Val Ser Asp Thr Lys 115 120 125Ile Asp Ser Ile Glu
Asp Arg Tyr Pro Arg Asn Leu Thr Glu Arg Val 130 135 140Arg Glu Ser
Leu Arg Ile Trp Lys Asn Thr Glu Lys Glu Asn Ala Thr145 150 155
160Val Ala His Leu Val Gly Ala Leu Arg Ser Cys Gln Met Asn Leu Val
165 170 175Ala Asp Leu Val Gln Glu Val Gln Gln Ala Arg Asp Leu Gln
Asn Arg 180 185 190Ser Gly Ala Met Ser Pro Met Ser Trp Asn Ser Asp
Ala Ser Thr Ser 195 200 205Glu Ala Ser 21019360DNAArtificial
sequenceDescription of Artificial Synthetic primer 193gttgtggatc
ctcccttttg ggtgctggtg gtggttggtg tcctggcttg ctatagcttg
6019460DNAArtificial sequenceDescription of Artificial Synthetic
primer 194gttgtttcga acccagaaaa taataaaggc cactgttact agcaagctat
agcaagccag 6019532DNAArtificial sequenceDescription of Artificial
Synthetic primer 195gttgtggatc ctcccttttg ggtgctggtg gt
3219633DNAArtificial sequenceDescription of Artificial Synthetic
primer 196gttgtttcga acccagaaaa taataaaggc cac 3319728DNAArtificial
sequenceDescription of Artificial Synthetic primer 197gttgtggatc
ctcctgctcc catcctgg 2819832DNAArtificial sequenceDescription of
Artificial Synthetic primer 198gttgtttcga acggcaaagc agtaggtcag gc
3219945DNAArtificial sequenceDescription of Artificial Synthetic
primer 199gttgtggatc cttcgaaccc attcctggtg ctgctgcact cgctg
4520042DNAArtificial sequenceDescription of Artificial Synthetic
primer 200gttgttatcg atctcgagtc agggtgtttc tgaggaagac ac
42201645DNAMus sp. 201gtggatcctt cgaacatgga cccattcctg gtgctgctgc
actcgctgtc cggcagcctg 60tcgggcaacg atctgatgga gctcaagttc ttgtgccgcg
agcgcgtgag caaacgaaag 120ctggagcgcg tgcagagtgg cctggacctg
ttcacggtgc tgctggagca gaacgacctg 180gagcgcgggc acaccgggct
gctgcgcgag ttgctggcct cgctgcgccg acacgatcta 240ctgcagcgcc
tggacgactt cgaggcgggg acggcgaccg ctgcgccccc gggggaggca
300gatctgcagg tggcatttga cattgtgtgt gacaatgtgg ggagagactg
gaaaagactg 360gcccgcgagc tgaaggtgtc tgaggccaag atggatggga
ttgaggagaa gtacccccga 420agtctgagtg agcgggtaag ggagagtctg
aaagtctgga agaatgctga gaagaagaac 480gcctcggtgg ccggactggt
caaggcgctg cggacctgca ggctgaatct ggtggctgac 540ctggtggaag
aagcccagga atctgtgagc aagagtgaga atatgtcccc agtactaagg
600gattcaactg tgtcttcctc agaaacaccc tgactcgaga tcgat
645202210PRTMus sp. 202Val Asp Pro Ser Asn Met Asp Pro Phe Leu Val
Leu Leu His Ser Leu1 5 10 15Ser Gly Ser Leu Ser Gly Asn Asp Leu Met
Glu Leu Lys Phe Leu Cys 20 25 30Arg Glu Arg Val Ser Lys Arg Lys Leu
Glu Arg Val Gln Ser Gly Leu 35 40 45Asp Leu Phe Thr Val Leu Leu Glu
Gln Asn Asp Leu Glu Arg Gly His 50 55 60Thr Gly Leu Leu Arg Glu Leu
Leu Ala Ser Leu Arg Arg His Asp Leu65 70 75 80Leu Gln Arg Leu Asp
Asp Phe Glu Ala Gly Thr Ala Thr Ala Ala Pro 85 90 95Pro Gly Glu Ala
Asp Leu Gln Val Ala Phe Asp Ile Val Cys Asp Asn 100 105 110Val Gly
Arg Asp Trp Lys Arg Leu Ala Arg Glu Leu Lys Val Ser Glu 115 120
125Ala Lys Met Asp Gly Ile Glu Glu Lys Tyr Pro Arg Ser Leu Ser Glu
130 135 140Arg Val Arg Glu Ser Leu Lys Val Trp Lys Asn Ala Glu Lys
Lys Asn145 150 155 160Ala Ser Val Ala Gly Leu Val Lys Ala Leu Arg
Thr Cys Arg Leu Asn 165 170 175Leu Val Ala Asp Leu Val Glu Glu Ala
Gln Glu Ser Val Ser Lys Ser 180 185 190Glu Asn Met Ser Pro Val Leu
Arg Asp Ser Thr Val Ser Ser Ser Glu 195 200 205Thr Pro
21020348DNAMus sp. 203gttgtggatc cttcgaacat ggagaacaac aaaacctcag
tggattca 4820445DNAMus sp. 204gttgttatcg atctcgagct agtgataaaa
gtacagttct ttcgt 4520546DNAMus sp. 205gttgtttcga acatggattt
ccagagttgt ctttatgcta ttgctg 4620648DNAMus sp. 206gttgttatcg
atctcgagtc attagggagg gaagaagagc ttcttccg 4820745DNAHomo sapiens
207gttgtggatc cttcgaacat ggagaacact gaaaactcag tggat 4520848DNAHomo
sapiens 208gttgttatcg atctcgagtt agtgataaaa atagagttct tttgtgag
4820945DNAHomo sapiens 209gttgtggatc cttcgaacat ggacttcagc
agaaatcttt atgat 4521048DNAHomo sapiens 210gttgttatcg atgcatgctc
aatcagaagg gaagacaagt ttttttct 48211816DNAArtificial
sequenceDescription of Artificial Synthetic nucleotide sequence
211aagcttgccg ccatggattt tcaagtgcag attttcagct tcctgctaat
cagtgcttca 60gtcataattg ccagaggaca aattgttctc tcccagtctc cagcaatcct
gtctgcatct 120ccaggggaga aggtcacaat gacttgcagg gccagctcaa
gtgtaagtta catgcactgg 180taccagcaga agccaggatc ctcccccaaa
ccctggattt atgccccatc caacctggct 240tctggagtcc ctgctcgctt
cagtggcagt gggtctggga cctcttactc tctcacaatc 300agcagagtgg
aggctgaaga tgctgccact tattactgcc agcagtggag ttttaaccca
360cccacgttcg gtgctgggac caagctggag ctgaaagatg gcggtggctc
gggcggtggt 420ggatctggag gaggtgggag ctctcaggct tatctacagc
agtctggggc tgagnnngtg 480aggcctgggg cctcagtgaa gatgtcctgc
aaggcttctg gctacacatt taccagttac 540aatatgcact gggtaaagca
gacacctaga cagggcctgg aatggattgg agctatttat 600ccaggaaatg
gtgatacttc ctacaatcag aagttcaagg gcaaggccac actgactgta
660gacaaatcct ccagcacagc ctacatgcag ctcagcagcc tgacatctga
agactctgcg 720gtctatttct gtgcaagagt ggtgtactat agtaactctt
actggtactt cgatgtctgg 780ggcacaggga ccacggtcac cgtctcttct gatcag
816212268PRTArtificial sequenceDescription of Artificial Synthetic
amino acid sequence 212Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu
Leu Ile Ser Ala Ser1 5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu
Ser Gln Ser Pro Ala Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val
Thr Met Thr Cys Arg Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp
Tyr Gln Gln Lys Pro Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala
Pro Ser Asn Leu Ala Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly
Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu
Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe
Asn Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 115 120
125Asp Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser
130 135 140Gln Ala Tyr Leu Gln Gln Ser Gly Ala Glu Xaa Val Arg Pro
Gly Ala145 150 155 160Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr
Thr Phe Thr Ser Tyr 165 170 175Asn Met His Trp Val Lys Gln Thr Pro
Arg Gln Gly Leu Glu Trp Ile 180 185 190Gly Ala Ile Tyr Pro Gly Asn
Gly Asp Thr Ser Tyr Asn Gln Lys Phe 195 200 205Lys Gly Lys Ala Thr
Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 210 215 220Met Gln Leu
Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys225 230 235
240Ala Arg Val Val Tyr Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp
245 250 255Gly Thr Gly Thr Thr Val Thr Val Ser Ser Asp Gln 260
265213813DNAArtificial sequenceDescription of Artificial Synthetic
nucleotide sequence 213aagcttgccg ccatggattt tcaagtgcag attttcagct
tcctgctaat cagtgcttca 60gtcataattg ccagaggaca aattgttctc tcccagtctc
cagcaatcct gtctgcatct 120ccaggggaga aggtcacaat gacttgcagg
gccagctcaa gtgtaagtta catgcactgg 180taccagcaga agccaggatc
ctcccccaaa ccctggattt atgccccatc caacctggct 240tctggagtcc
ctgctcgctt cagtggcagt gggtctggga cctcttactc tctcacaatc
300agcagagtgg aggctgaaga tgctgccact tattactgcc agcagtggag
ttttaaccca 360cccacgttcg gtgctgggac caagctggag ctgaaagatg
gcggtggctc gggcggtggt 420ggatctggag gaggtgggag ctctcaggct
tatctacagc agtctggggc tgaggtgagg 480cctggggcct cagtgaagat
gtcctgcaag gcttctggct acacatttac cagttacaat 540atgcactggg
taaagcagac acctagacag ggcctggaat ggattggagc tatttatcca
600ggaaatggtg atacttccta caatcagaag ttcaagggca aggccacact
gactgtagac 660aaatcctcca gcacagccta catgcagctc agcagcctga
catctgaaga ctctgcggtc 720tatttctgtg caagagtggt gtactatagt
aactcttact ggtacttcga tgtctggggc 780acagggacca cggtcaccgt
ctcttctgat cag 813214267PRTArtificial sequenceDescription of
Artificial Synthetic amino acid sequence 214Met Asp Phe Gln Val Gln
Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1 5 10 15Val Ile Ile Ala Arg
Gly Gln Ile Val Leu Ser Gln Ser Pro Ala Ile 20 25 30Leu Ser Ala Ser
Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser 35 40 45Ser Ser Val
Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Ser Ser 50 55 60Pro Lys
Pro Trp Ile Tyr Ala Pro Ser Asn Leu Ala
Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr
Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu Ala Glu Asp Ala Ala
Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe Asn Pro Pro Thr Phe
Gly Ala Gly Thr Lys Leu Glu Leu Lys 115 120 125Asp Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser 130 135 140Gln Ala Tyr
Leu Gln Gln Ser Gly Ala Glu Val Arg Pro Gly Ala Ser145 150 155
160Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Asn
165 170 175Met His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Glu Trp
Ile Gly 180 185 190Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn
Gln Lys Phe Lys 195 200 205Gly Lys Ala Thr Leu Thr Val Asp Lys Ser
Ser Ser Thr Ala Tyr Met 210 215 220Gln Leu Ser Ser Leu Thr Ser Glu
Asp Ser Ala Val Tyr Phe Cys Ala225 230 235 240Arg Val Val Tyr Tyr
Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp Gly 245 250 255Thr Gly Thr
Thr Val Thr Val Ser Ser Asp Gln 260 265215443DNAArtificial
sequenceDescription of Artificial Synthetic nucleotide sequence
215aagcttgccg ccatggattt tcaagtgcag attttcagct tcctgctaat
cagtgcttca 60gtcataattg ccagaggaca aattgttctc tcccagtctc cagcaatcct
gtctgcatct 120ccaggggaga aggtcacaat gacttgcagg gccagctcaa
gtgtaagtta catgcactgg 180taccagcaga agccaggatc ctcccccaaa
ccctggattt atgccccatc caacctggct 240tctggagtcc ctgctcgctt
cagtggcagt gggtctggga cctcttactc tctcacaatc 300agcagagtgg
aggctgaaga tgctgccact tattactgcc agcagtggag ttttaaccca
360cccacgttcg gtgctgggac caagctggag nnnaaagatg gcggtggctc
gggcggtggt 420ggatctggag gaggtgggag ctc 443216144PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
216Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1
5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu Ser Gln Ser Pro Ala
Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg
Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro
Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala Pro Ser Asn Leu Ala
Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr
Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu Ala Glu Asp Ala Ala
Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe Asn Pro Pro Thr Phe
Gly Ala Gly Thr Lys Leu Glu Xaa Lys 115 120 125Asp Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser 130 135
140217440DNAArtificial sequenceDescription of Artificial Synthetic
nucleotide sequence 217aagcttgccg ccatggattt tcaagtgcag attttcagct
tcctgctaat cagtgcttca 60gtcataattg ccagaggaca aattgttctc tcccagtctc
cagcaatcct gtctgcatct 120ccaggggaga aggtcacaat gacttgcagg
gccagctcaa gtgtaagtta catgcactgg 180taccagcaga agccaggatc
ctcccccaaa ccctggattt atgccccatc caacctggct 240tctggagtcc
ctgctcgctt cagtggcagt gggtctggga cctcttactc tctcacaatc
300agcagagtgg aggctgaaga tgctgccact tattactgcc agcagtggag
ttttaaccca 360cccacgttcg gtgctgggac caagctggag aaagatggcg
gtggctcggg cggtggtgga 420tctggaggag gtgggagctc
440218143PRTArtificial sequenceDescription of Artificial Synthetic
amino acid sequence 218Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu
Leu Ile Ser Ala Ser1 5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu
Ser Gln Ser Pro Ala Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val
Thr Met Thr Cys Arg Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp
Tyr Gln Gln Lys Pro Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala
Pro Ser Asn Leu Ala Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly
Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu
Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe
Asn Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu Glu Lys Asp 115 120
125Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser 130
135 140219664DNAArtificial sequenceDescription of Artificial
Synthetic nucleotide sequence 219tccaacccga gaggggtgag cgcctaccta
agccggccca gcccgttcga cctgttcatc 60cgcaagtcgc ccacgatcac ctgtctggtg
gtggacctgg cacccagcaa ggggaccgtg 120aacctgacct ggtcccgggc
cagtgggaag cctgtgaacc actccaccag aaaggaggag 180aagcagcgca
atggcacgtt aaccgtcacg tccaccctgc cggtgggcac ccgagactgg
240atcgaggggg agacctacca gtgcagggtg acccaccccc acctgcccag
ggccctcatg 300cggtccacga ccaagaccag cggcccgcgt gctgccccgg
aagtctatgc gtttgcgacg 360ccggagtggc cggggagccg ggacaagcgc
accctcgcct gcctgatcca gaacttcatg 420cctgaggaca tctcggtgca
gtggctgcac aacgaggtgc agctcccgga cgcccggcac 480agcacgacgc
agccccgcaa gaccaagggc tccggcttct tcgtcttcag ccgcctggag
540gtgaccaggg ccgaatggga gcagaaagat gagttcatct gccgtgcagt
ccatgaggca 600gcgagcccct cacagaccgt ccagcgagcg gtgtctgtaa
atcccggtaa atgataatct 660agaa 664220217PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
220Ser Asn Pro Arg Gly Val Ser Ala Tyr Leu Ser Arg Pro Ser Pro Phe1
5 10 15Asp Leu Phe Ile Arg Lys Ser Pro Thr Ile Thr Cys Leu Val Val
Asp 20 25 30Leu Ala Pro Ser Lys Gly Thr Val Asn Leu Thr Trp Ser Arg
Ala Ser 35 40 45Gly Lys Pro Val Asn His Ser Thr Arg Lys Glu Glu Lys
Gln Arg Asn 50 55 60Gly Thr Leu Thr Val Thr Ser Thr Leu Pro Val Gly
Thr Arg Asp Trp65 70 75 80Ile Glu Gly Glu Thr Tyr Gln Cys Arg Val
Thr His Pro His Leu Pro 85 90 95Arg Ala Leu Met Arg Ser Thr Thr Lys
Thr Ser Gly Pro Arg Ala Ala 100 105 110Pro Glu Val Tyr Ala Phe Ala
Thr Pro Glu Trp Pro Gly Ser Arg Asp 115 120 125Lys Arg Thr Leu Ala
Cys Leu Ile Gln Asn Phe Met Pro Glu Asp Ile 130 135 140Ser Val Gln
Trp Leu His Asn Glu Val Gln Leu Pro Asp Ala Arg His145 150 155
160Ser Thr Thr Gln Pro Arg Lys Thr Lys Gly Ser Gly Phe Phe Val Phe
165 170 175Ser Arg Leu Glu Val Thr Arg Ala Glu Trp Glu Gln Lys Asp
Glu Phe 180 185 190Ile Cys Arg Ala Val His Glu Ala Ala Ser Pro Ser
Gln Thr Val Gln 195 200 205Arg Ala Val Ser Val Asn Pro Gly Lys 210
215221719DNAArtificial sequenceDescription of Artificial Synthetic
nucleotide sequence 221tgatcaggag cccaaatctt ctgacaaaac tcacacatcc
ccaccgtccc cagcatccaa 60cccgagaggg gtgagcgcct acctaagccg gcccagcccg
ttcgacctgt tcatccgcaa 120gtcgcccacg atcacctgtc tggtggtgga
cctggcaccc agcaagggga ccgtgaacct 180gacctggtcc cgggccagtg
ggaagcctgt gaaccactcc accagaaagg aggagaagca 240gcgcaatggc
acgttaaccg tcacgtccac cctgccggtg ggcacccgag actggatcga
300gggggagacc taccagtgca gggtgaccca cccccacctg cccagggccc
tcatgcggtc 360cacgaccaag accagcggcc cgcgtgctgc cccggaagtc
tatgcgtttg cgacgccgga 420gtggccgggg agccgggaca agcgcaccct
cgcctgcctg atccagaact tcatgcctga 480ggacatctcg gtgcagtggc
tgcacaacga ggtgcagctc ccggacgccc ggcacagcac 540gacgcagccc
cgcaagacca agggctccgg cttcttcgtc ttcagccgcc tggaggtgac
600cagggccgaa tgggagcaga aagatgagtt catctgccgt gcagtccatg
aggcagcgag 660cccctcacag accgtccagc gagcggtgtc tgtaaatccc
ggtaaatgat aatctagaa 719222235PRTArtificial sequenceDescription of
Artificial Synthetic amino acid sequence 222Asp Gln Glu Pro Lys Ser
Ser Asp Lys Thr His Thr Ser Pro Pro Ser1 5 10 15Pro Ala Ser Asn Pro
Arg Gly Val Ser Ala Tyr Leu Ser Arg Pro Ser 20 25 30Pro Phe Asp Leu
Phe Ile Arg Lys Ser Pro Thr Ile Thr Cys Leu Val 35 40 45Val Asp Leu
Ala Pro Ser Lys Gly Thr Val Asn Leu Thr Trp Ser Arg 50 55 60Ala Ser
Gly Lys Pro Val Asn His Ser Thr Arg Lys Glu Glu Lys Gln65 70 75
80Arg Asn Gly Thr Leu Thr Val Thr Ser Thr Leu Pro Val Gly Thr Arg
85 90 95Asp Trp Ile Glu Gly Glu Thr Tyr Gln Cys Arg Val Thr His Pro
His 100 105 110Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Thr Ser
Gly Pro Arg 115 120 125Ala Ala Pro Glu Val Tyr Ala Phe Ala Thr Pro
Glu Trp Pro Gly Ser 130 135 140Arg Asp Lys Arg Thr Leu Ala Cys Leu
Ile Gln Asn Phe Met Pro Glu145 150 155 160Asp Ile Ser Val Gln Trp
Leu His Asn Glu Val Gln Leu Pro Asp Ala 165 170 175Arg His Ser Thr
Thr Gln Pro Arg Lys Thr Lys Gly Ser Gly Phe Phe 180 185 190Val Phe
Ser Arg Leu Glu Val Thr Arg Ala Glu Trp Glu Gln Lys Asp 195 200
205Glu Phe Ile Cys Arg Ala Val His Glu Ala Ala Ser Pro Ser Gln Thr
210 215 220Val Gln Arg Ala Val Ser Val Asn Pro Gly Lys225 230
235223994DNAArtificial sequenceDescription of Artificial Synthetic
nucleotide sequence 223tgatcacgtc tgctccaggg acttcacccc gcccaccgtg
aagatcttac agtcgtcctg 60cgacggcggc gggcacttcc ccccgaccat ccagctcctg
tgcctcgtct ctgggtacac 120cccagggact atcaacatca cctggctgga
ggacgggcag gtcatggacg tggacttgtc 180caccgcctct accacgcagg
agggtgagct ggcctccaca caaagcgagc tcaccctcag 240ccagaagcac
tggctgtcag accgcaccta cacctgccag gtcacctatc aaggtcacac
300ctttgaggac agcaccaaga agtgtgcaga ttccaacccg agaggggtga
gcgcctacct 360aagccggccc agcccgttcg acctgttcat ccgcaagtcg
cccacgatca cctgtctggt 420ggtggacctg gcacccagca aggggaccgt
gaacctgacc tggtcccggg ccagtgggaa 480gcctgtgaac cactccacca
gaaaggagga gaagcagcgc aatggcacgt taaccgtcac 540gtccaccctg
ccggtgggca cccgagactg gatcgagggg gagacctacc agtgcagggt
600gacccacccc cacctgccca gggccctcat gcggtccacg accaagacca
gcggcccgcg 660tgctgccccg gaagtctatg cgtttgcgac gccggagtgg
ccggggagcc gggacaagcg 720caccctcgcc tgcctgatcc agaacttcat
gcctgaggac atctcggtgc agtggctgca 780caacgaggtg cagctcccgg
acgcccggca cagcacgacg cagccccgca agaccaaggg 840ctccggcttc
ttcgtcttca gccgcctgga ggtgaccagg gccgaatggg agcagaaaga
900tgagttcatc tgccgtgcag tccatgaggc agcgagcccc tcacagaccg
tccagcgagc 960ggtgtctgta aatcccggta aatgataatc taga
994224327PRTArtificial sequenceDescription of Artificial Synthetic
amino acid sequence 224Asp His Val Cys Ser Arg Asp Phe Thr Pro Pro
Thr Val Lys Ile Leu1 5 10 15Gln Ser Ser Cys Asp Gly Gly Gly His Phe
Pro Pro Thr Ile Gln Leu 20 25 30Leu Cys Leu Val Ser Gly Tyr Thr Pro
Gly Thr Ile Asn Ile Thr Trp 35 40 45Leu Glu Asp Gly Gln Val Met Asp
Val Asp Leu Ser Thr Ala Ser Thr 50 55 60Thr Gln Glu Gly Glu Leu Ala
Ser Thr Gln Ser Glu Leu Thr Leu Ser65 70 75 80Gln Lys His Trp Leu
Ser Asp Arg Thr Tyr Thr Cys Gln Val Thr Tyr 85 90 95Gln Gly His Thr
Phe Glu Asp Ser Thr Lys Lys Cys Ala Asp Ser Asn 100 105 110Pro Arg
Gly Val Ser Ala Tyr Leu Ser Arg Pro Ser Pro Phe Asp Leu 115 120
125Phe Ile Arg Lys Ser Pro Thr Ile Thr Cys Leu Val Val Asp Leu Ala
130 135 140Pro Ser Lys Gly Thr Val Asn Leu Thr Trp Ser Arg Ala Ser
Gly Lys145 150 155 160Pro Val Asn His Ser Thr Arg Lys Glu Glu Lys
Gln Arg Asn Gly Thr 165 170 175Leu Thr Val Thr Ser Thr Leu Pro Val
Gly Thr Arg Asp Trp Ile Glu 180 185 190Gly Glu Thr Tyr Gln Cys Arg
Val Thr His Pro His Leu Pro Arg Ala 195 200 205Leu Met Arg Ser Thr
Thr Lys Thr Ser Gly Pro Arg Ala Ala Pro Glu 210 215 220Val Tyr Ala
Phe Ala Thr Pro Glu Trp Pro Gly Ser Arg Asp Lys Arg225 230 235
240Thr Leu Ala Cys Leu Ile Gln Asn Phe Met Pro Glu Asp Ile Ser Val
245 250 255Gln Trp Leu His Asn Glu Val Gln Leu Pro Asp Ala Arg His
Ser Thr 260 265 270Thr Gln Pro Arg Lys Thr Lys Gly Ser Gly Phe Phe
Val Phe Ser Arg 275 280 285Leu Glu Val Thr Arg Ala Glu Trp Glu Gln
Lys Asp Glu Phe Ile Cys 290 295 300Arg Ala Val His Glu Ala Ala Ser
Pro Ser Gln Thr Val Gln Arg Ala305 310 315 320Val Ser Val Asn Pro
Gly Lys 325225720DNAArtificial sequenceDescription of Artificial
Synthetic nucleotide sequence 225tgatcaggag cccaaatctt ctgacaaaac
tcacacatcc ccaccgtccc cagcatccaa 60cccgagaggg gtgagcgcct acctaagccg
gcccagcccg ttcgacctgt tcatccgcaa 120gtcgcccacg atcacctgtc
tggtggtgga cctggcaccc agcaagggga ccgtgaacct 180gacctggtcc
cgggccagtg ggaagcctgt gaaccactcc accagaaagg aggagaagca
240gcgcaatggc acgttaaccg tcacgtccac cctgccggtg ggcacccgag
actggatcga 300gggggagacc taccagtgca gggtgaccca cccccacctg
cccagggccc tcatgcggtc 360cacgaccaag accagcggcc cgcgtgctgc
cccggaagtc tatgcgtttg cgacgccgga 420gtggccgggg agccgggaca
agcgcaccct cgcctgcctg atccagaact tcatgcctga 480ggacatctcg
gtgcagtggc tgcacaacga ggtgcagctc ccggacgccc ggcacagcac
540gacgcagccc cgcaagacca agggctccgg cttcttcgtc ttcagccgcc
tggaggtgac 600cagggccgaa tgggagcaga aagatgagtt catctgccgt
gcagtccatg aggcagcgag 660cccctcacag accgtccagc gagcggtgtc
tgtaaatccc ggtaaagcgg atccttcgaa 720226240PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
226Asp Gln Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser Pro Pro Ser1
5 10 15Pro Ala Ser Asn Pro Arg Gly Val Ser Ala Tyr Leu Ser Arg Pro
Ser 20 25 30Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr Ile Thr Cys
Leu Val 35 40 45Val Asp Leu Ala Pro Ser Lys Gly Thr Val Asn Leu Thr
Trp Ser Arg 50 55 60Ala Ser Gly Lys Pro Val Asn His Ser Thr Arg Lys
Glu Glu Lys Gln65 70 75 80Arg Asn Gly Thr Leu Thr Val Thr Ser Thr
Leu Pro Val Gly Thr Arg 85 90 95Asp Trp Ile Glu Gly Glu Thr Tyr Gln
Cys Arg Val Thr His Pro His 100 105 110Leu Pro Arg Ala Leu Met Arg
Ser Thr Thr Lys Thr Ser Gly Pro Arg 115 120 125Ala Ala Pro Glu Val
Tyr Ala Phe Ala Thr Pro Glu Trp Pro Gly Ser 130 135 140Arg Asp Lys
Arg Thr Leu Ala Cys Leu Ile Gln Asn Phe Met Pro Glu145 150 155
160Asp Ile Ser Val Gln Trp Leu His Asn Glu Val Gln Leu Pro Asp Ala
165 170 175Arg His Ser Thr Thr Gln Pro Arg Lys Thr Lys Gly Ser Gly
Phe Phe 180 185 190Val Phe Ser Arg Leu Glu Val Thr Arg Ala Glu Trp
Glu Gln Lys Asp 195 200 205Glu Phe Ile Cys Arg Ala Val His Glu Ala
Ala Ser Pro Ser Gln Thr 210 215 220Val Gln Arg Ala Val Ser Val Asn
Pro Gly Lys Ser Gly Ser Phe Glu225 230 235 2402271527DNAArtificial
sequenceDescription of Artificial Synthetic nucleotide sequence
227aagcttgccg ccatggattt tcaagtgcag attttcagct tcctgctaat
cagtgcttca 60gtcataattg ccagaggaca aattgttctc tcccagtctc cagcaatcct
gtctgcatct 120ccaggggaga aggtcacaat gacttgcagg gccagctcaa
gtgtaagtta catgcactgg 180taccagcaga agccaggatc ctcccccaaa
ccctggattt atgccccatc caacctggct 240tctggagtcc ctgctcgctt
cagtggcagt gggtctggga cctcttactc tctcacaatc 300agcagagtgg
aggctgaaga tgctgccact tattactgcc agcagtggag ttttaaccca
360cccacgttcg gtgctgggac caagctggag ctgaaagatg gcggtggctc
gggcggtggt 420ggatctggag gaggtgggag ctctcaggct tatctacagc
agtctggggc tgagtcggtg 480aggcctgggg cctcagtgaa gatgtcctgc
aaggcttctg gctacacatt taccagttac 540aatatgcact gggtaaagca
gacacctaga cagggcctgg aatggattgg agctatttat 600ccaggaaatg
gtgatacttc ctacaatcag aagttcaagg gcaaggccac actgactgta
660gacaaatcct ccagcacagc ctacatgcag ctcagcagcc tgacatctga
agactctgcg 720gtctatttct gtgcaagagt ggtgtactat agtaactctt
actggtactt cgatgtctgg
780ggcacaggga ccacggtcac cgtctcttct gatcaggagc ccaaatcttc
tgacaaaact 840cacacatccc caccgtcctc agcatccaac ccgagagggg
tgagcgccta cctaagccgg 900cccagcccgt tcgacctgtt catccgcaag
tcgcccacga tcacctgtct ggtggtggac 960ctggcaccca gcaaggggac
cgtgaacctg acctggtccc gggccagtgg gaagcctgtg 1020aaccactcca
ccagaaagga ggagaagcag cgcaatggca cgttaaccgt cacgtccacc
1080ctgccggtgg gcacccgaga ctggatcgag ggggagacct accagtgcag
ggtgacccac 1140ccccacctgc ccagggccct catgcggtcc acgaccaaga
ccagcggccc gcgtgctgcc 1200ccggaagtct atgcgtttgc gacgccggag
tggccgggga gccgggacaa gcgcaccctc 1260gcctgcctga tccagaactt
catgcctgag gacatctcgg tgcagtggct gcacaacgag 1320gtgcagctcc
cggacgcccg gcacagcacg acgcagcccc gcaagaccaa gggctccggc
1380ttcttcgtct tcagccgcct ggaggtgacc agggccgaat gggagcagaa
agatgagttc 1440atctgccgtg cagtccatga ggcagcgagc ccctcacaga
ccgtccagcg agcggtgtct 1500gtaaatcccg gtaaatgata atctaga
1527228501PRTArtificial sequenceDescription of Artificial Synthetic
amino acid sequence 228Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu
Leu Ile Ser Ala Ser1 5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu
Ser Gln Ser Pro Ala Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val
Thr Met Thr Cys Arg Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp
Tyr Gln Gln Lys Pro Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala
Pro Ser Asn Leu Ala Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly
Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu
Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe
Asn Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 115 120
125Asp Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser
130 135 140Gln Ala Tyr Leu Gln Gln Ser Gly Ala Glu Ser Val Arg Pro
Gly Ala145 150 155 160Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr
Thr Phe Thr Ser Tyr 165 170 175Asn Met His Trp Val Lys Gln Thr Pro
Arg Gln Gly Leu Glu Trp Ile 180 185 190Gly Ala Ile Tyr Pro Gly Asn
Gly Asp Thr Ser Tyr Asn Gln Lys Phe 195 200 205Lys Gly Lys Ala Thr
Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 210 215 220Met Gln Leu
Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys225 230 235
240Ala Arg Val Val Tyr Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp
245 250 255Gly Thr Gly Thr Thr Val Thr Val Ser Ser Asp Gln Glu Pro
Lys Ser 260 265 270Ser Asp Lys Thr His Thr Ser Pro Pro Ser Ser Ala
Ser Asn Pro Arg 275 280 285Gly Val Ser Ala Tyr Leu Ser Arg Pro Ser
Pro Phe Asp Leu Phe Ile 290 295 300Arg Lys Ser Pro Thr Ile Thr Cys
Leu Val Val Asp Leu Ala Pro Ser305 310 315 320Lys Gly Thr Val Asn
Leu Thr Trp Ser Arg Ala Ser Gly Lys Pro Val 325 330 335Asn His Ser
Thr Arg Lys Glu Glu Lys Gln Arg Asn Gly Thr Leu Thr 340 345 350Val
Thr Ser Thr Leu Pro Val Gly Thr Arg Asp Trp Ile Glu Gly Glu 355 360
365Thr Tyr Gln Cys Arg Val Thr His Pro His Leu Pro Arg Ala Leu Met
370 375 380Arg Ser Thr Thr Lys Thr Ser Gly Pro Arg Ala Ala Pro Glu
Val Tyr385 390 395 400Ala Phe Ala Thr Pro Glu Trp Pro Gly Ser Arg
Asp Lys Arg Thr Leu 405 410 415Ala Cys Leu Ile Gln Asn Phe Met Pro
Glu Asp Ile Ser Val Gln Trp 420 425 430Leu His Asn Glu Val Gln Leu
Pro Asp Ala Arg His Ser Thr Thr Gln 435 440 445Pro Arg Lys Thr Lys
Gly Ser Gly Phe Phe Val Phe Ser Arg Leu Glu 450 455 460Val Thr Arg
Ala Glu Trp Glu Gln Lys Asp Glu Phe Ile Cys Arg Ala465 470 475
480Val His Glu Ala Ala Ser Pro Ser Gln Thr Val Gln Arg Ala Val Ser
485 490 495Val Asn Pro Gly Lys 5002291527DNAArtificial
sequenceDescription of Artificial Synthetic nucleotide sequence
229aagcttgccg ccatggattt tcaagtgcag attttcagct tcctgctaat
cagtgcttca 60gtcataattg ccagaggaca aattgttctc tcccagtctc cagcaatcct
gtctgcatct 120ccaggggaga aggtcacaat gacttgcagg gccagctcaa
gtgtaagtta catgcactgg 180taccagcaga agccaggatc ctcccccaaa
ccctggattt atgccccatc caacctggct 240tctggagtcc ctgctcgctt
cagtggcagt gggtctggga cctcttactc tctcacaatc 300agcagagtgg
aggctgaaga tgctgccact tattactgcc agcagtggag ttttaaccca
360cccacgttcg gtgctgggac caagctggag ctgaaagatg gcggtggctc
gggcggtggt 420ggatctggag gaggtgggag ctctcaggct tatctacagc
agtctggggc tgagtcggtg 480aggcctgggg cctcagtgaa gatgtcctgc
aaggcttctg gctacacatt taccagttac 540aatatgcact gggtaaagca
gacacctaga cagggcctgg aatggattgg agctatttat 600ccaggaaatg
gtgatacttc ctacaatcag aagttcaagg gcaaggccac actgactgta
660gacaaatcct ccagcacagc ctacatgcag ctcagcagcc tgacatctga
agactctgcg 720gtctatttct gtgcaagagt ggtgtactat agtaactctt
actggtactt cgatgtctgg 780ggcacaggga ccacggtcac cgtctcttct
gatcaggagc ccaaatcttc tgacaaaact 840cacacatccc caccgtcccc
agcatccaac ccgagagggg tgagcgccta cctaagccgg 900cccagcccgt
tcgacctgtt catccgcaag tcgcccacga tcacctgtct ggtggtggac
960ctggcaccca gcaaggggac cgtgaacctg acctggtccc gggccagtgg
gaagcctgtg 1020aaccactcca ccagaaagga ggagaagcag cgcaatggca
cgttaaccgt cacgtccacc 1080ctgccggtgg gcacccgaga ctggatcgag
ggggagacct accagtgcag ggtgacccac 1140ccccacctgc ccagggccct
catgcggtcc acgaccaaga ccagcggccc gcgtgctgcc 1200ccggaagtct
atgcgtttgc gacgccggag tggccgggga gccgggacaa gcgcaccctc
1260gcctgcctga tccagaactt catgcctgag gacatctcgg tgcagtggct
gcacaacgag 1320gtgcagctcc cggacgcccg gcacagcacg acgcagcccc
gcaagaccaa gggctccggc 1380ttcttcgtct tcagccgcct ggaggtgacc
agggccgaat gggagcagaa agatgagttc 1440atctgccgtg cagtccatga
ggcagcgagc ccctcacaga ccgtccagcg agcggtgtct 1500gtaaatcccg
gtaaatgata atctaga 1527230501PRTArtificial sequenceDescription of
Artificial Synthetic amino acid sequence 230Met Asp Phe Gln Val Gln
Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1 5 10 15Val Ile Ile Ala Arg
Gly Gln Ile Val Leu Ser Gln Ser Pro Ala Ile 20 25 30Leu Ser Ala Ser
Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser 35 40 45Ser Ser Val
Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Ser Ser 50 55 60Pro Lys
Pro Trp Ile Tyr Ala Pro Ser Asn Leu Ala Ser Gly Val Pro65 70 75
80Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile
85 90 95Ser Arg Val Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln
Trp 100 105 110Ser Phe Asn Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu
Glu Leu Lys 115 120 125Asp Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Ser 130 135 140Gln Ala Tyr Leu Gln Gln Ser Gly Ala
Glu Ser Val Arg Pro Gly Ala145 150 155 160Ser Val Lys Met Ser Cys
Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 165 170 175Asn Met His Trp
Val Lys Gln Thr Pro Arg Gln Gly Leu Glu Trp Ile 180 185 190Gly Ala
Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe 195 200
205Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
210 215 220Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr
Phe Cys225 230 235 240Ala Arg Val Val Tyr Tyr Ser Asn Ser Tyr Trp
Tyr Phe Asp Val Trp 245 250 255Gly Thr Gly Thr Thr Val Thr Val Ser
Ser Asp Gln Glu Pro Lys Ser 260 265 270Ser Asp Lys Thr His Thr Ser
Pro Pro Ser Pro Ala Ser Asn Pro Arg 275 280 285Gly Val Ser Ala Tyr
Leu Ser Arg Pro Ser Pro Phe Asp Leu Phe Ile 290 295 300Arg Lys Ser
Pro Thr Ile Thr Cys Leu Val Val Asp Leu Ala Pro Ser305 310 315
320Lys Gly Thr Val Asn Leu Thr Trp Ser Arg Ala Ser Gly Lys Pro Val
325 330 335Asn His Ser Thr Arg Lys Glu Glu Lys Gln Arg Asn Gly Thr
Leu Thr 340 345 350Val Thr Ser Thr Leu Pro Val Gly Thr Arg Asp Trp
Ile Glu Gly Glu 355 360 365Thr Tyr Gln Cys Arg Val Thr His Pro His
Leu Pro Arg Ala Leu Met 370 375 380Arg Ser Thr Thr Lys Thr Ser Gly
Pro Arg Ala Ala Pro Glu Val Tyr385 390 395 400Ala Phe Ala Thr Pro
Glu Trp Pro Gly Ser Arg Asp Lys Arg Thr Leu 405 410 415Ala Cys Leu
Ile Gln Asn Phe Met Pro Glu Asp Ile Ser Val Gln Trp 420 425 430Leu
His Asn Glu Val Gln Leu Pro Asp Ala Arg His Ser Thr Thr Gln 435 440
445Pro Arg Lys Thr Lys Gly Ser Gly Phe Phe Val Phe Ser Arg Leu Glu
450 455 460Val Thr Arg Ala Glu Trp Glu Gln Lys Asp Glu Phe Ile Cys
Arg Ala465 470 475 480Val His Glu Ala Ala Ser Pro Ser Gln Thr Val
Gln Arg Ala Val Ser 485 490 495Val Asn Pro Gly Lys
500231443DNAArtificial sequenceDescription of Artificial Synthetic
nucleotide sequence 231aagcttgccg ccatggattt tcaagtgcag attttcagct
tcctgctaat cagtgcttca 60gtcataattg ccagaggaca aattgttctc tcccagtctc
cagcaatcct gtctgcatct 120ccaggggaga aggtcacaat gacttgcagg
gccagctcaa gtgtaagtta catgcactgg 180taccagcaga agccaggatc
ctcccccaaa ccctggattt atgccccatc caacctggct 240tctggagtcc
ctgctcgctt cagtggcagt gggtctggga cctcttactc tctcacaatc
300agcagagtgg aggctgaaga tgctgccact tattactgcc agcagtggag
ttttaaccca 360cccacgttcg gtgctgggac caagctggag ctgaaagatg
gcggtggctc gggcggtggt 420ggatctggag gaggtgggag ctc
443232144PRTArtificial sequenceDescription of Artificial Synthetic
amino acid sequence 232Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu
Leu Ile Ser Ala Ser1 5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu
Ser Gln Ser Pro Ala Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val
Thr Met Thr Cys Arg Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp
Tyr Gln Gln Lys Pro Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala
Pro Ser Asn Leu Ala Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly
Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu
Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe
Asn Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu Glu Ser Lys 115 120
125Asp Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser
130 135 140233816DNAArtificial sequenceDescription of Artificial
Synthetic nucleotide sequence 233aagcttgccg ccatggattt tcaagtgcag
attttcagct tcctgctaat cagtgcttca 60gtcataattg ccagaggaca aattgttctc
tcccagtctc cagcaatcct gtctgcatct 120ccaggggaga aggtcacaat
gacttgcagg gccagctcaa gtgtaagtta catgcactgg 180taccagcaga
agccaggatc ctcccccaaa ccctggattt atgccccatc caacctggct
240tctggagtcc ctgctcgctt cagtggcagt gggtctggga cctcttactc
tctcacaatc 300agcagagtgg aggctgaaga tgctgccact tattactgcc
agcagtggag ttttaaccca 360cccacgttcg gtgctgggac caagctggag
tctaaagatg gcggtggctc gggcggtggt 420ggatctggag gaggtgggag
ctctcaggct tatctacagc agtctggggc tgagctggtg 480aggcctgggg
cctcagtgaa gatgtcctgc aaggcttctg gctacacatt taccagttac
540aatatgcact gggtaaagca gacacctaga cagggcctgg aatggattgg
agctatttat 600ccaggaaatg gtgatacttc ctacaatcag aagttcaagg
gcaaggccac actgactgta 660gacaaatcct ccagcacagc ctacatgcag
ctcagcagcc tgacatctga agactctgcg 720gtctatttct gtgcaagagt
ggtgtactat agtaactctt actggtactt cgatgtctgg 780ggcacaggga
ccacggtcac cgtctcttct gatcag 816234268PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
234Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1
5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu Ser Gln Ser Pro Ala
Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg
Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro
Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala Pro Ser Asn Leu Ala
Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr
Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu Ala Glu Asp Ala Ala
Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe Asn Pro Pro Thr Phe
Gly Ala Gly Thr Lys Leu Glu Ser Lys 115 120 125Asp Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser 130 135 140Gln Ala Tyr
Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala145 150 155
160Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
165 170 175Asn Met His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Glu
Trp Ile 180 185 190Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr
Asn Gln Lys Phe 195 200 205Lys Gly Lys Ala Thr Leu Thr Val Asp Lys
Ser Ser Ser Thr Ala Tyr 210 215 220Met Gln Leu Ser Ser Leu Thr Ser
Glu Asp Ser Ala Val Tyr Phe Cys225 230 235 240Ala Arg Val Val Tyr
Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp 245 250 255Gly Thr Gly
Thr Thr Val Thr Val Ser Ser Asp Gln 260 265235816DNAArtificial
sequenceDescription of Artificial Synthetic nucleotide sequence
235aagcttgccg ccatggattt tcaagtgcag attttcagct tcctgctaat
cagtgcttca 60gtcataattg ccagaggaca aattgttctc tcccagtctc cagcaatcct
gtctgcatct 120ccaggggaga aggtcacaat gacttgcagg gccagctcaa
gtgtaagtta catgcactgg 180taccagcaga agccaggatc ctcccccaaa
ccctggattt atgccccatc caacctggct 240tctggagtcc ctgctcgctt
cagtggcagt gggtctggga cctcttactc tctcacaatc 300agcagagtgg
aggctgaaga tgctgccact tattactgcc agcagtggag ttttaaccca
360cccacgttcg gtgctgggac caagctggag tctaaagatg gcggtggctc
gggcggtggt 420ggatctggag gaggtgggag ctctcaggct tatctacagc
agtctggggc tgagtcggtg 480aggcctgggg cctcagtgaa gatgtcctgc
aaggcttctg gctacacatt taccagttac 540aatatgcact gggtaaagca
gacacctaga cagggcctgg aatggattgg agctatttat 600ccaggaaatg
gtgatacttc ctacaatcag aagttcaagg gcaaggccac actgactgta
660gacaaatcct ccagcacagc ctacatgcag ctcagcagcc tgacatctga
agactctgcg 720gtctatttct gtgcaagagt ggtgtactat agtaactctt
actggtactt cgatgtctgg 780ggcacaggga ccacggtcac cgtctcttct gatcag
816236268PRTArtificial sequenceDescription of Artificial Synthetic
amino acid sequence 236Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu
Leu Ile Ser Ala Ser1 5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu
Ser Gln Ser Pro Ala Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val
Thr Met Thr Cys Arg Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp
Tyr Gln Gln Lys Pro Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala
Pro Ser Asn Leu Ala Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly
Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu
Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe
Asn Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu Glu Ser Lys 115 120
125Asp Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser
130 135 140Gln Ala Tyr Leu Gln Gln Ser Gly Ala Glu Ser Val Arg Pro
Gly Ala145 150 155 160Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr
Thr Phe Thr Ser Tyr 165 170 175Asn Met His Trp Val Lys Gln Thr Pro
Arg Gln Gly Leu Glu Trp Ile 180 185 190Gly Ala Ile Tyr Pro Gly Asn
Gly Asp Thr Ser Tyr Asn Gln
Lys Phe 195 200 205Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser
Ser Thr Ala Tyr 210 215 220Met Gln Leu Ser Ser Leu Thr Ser Glu Asp
Ser Ala Val Tyr Phe Cys225 230 235 240Ala Arg Val Val Tyr Tyr Ser
Asn Ser Tyr Trp Tyr Phe Asp Val Trp 245 250 255Gly Thr Gly Thr Thr
Val Thr Val Ser Ser Asp Gln 260 265237199DNAHomo sapiens
237gtggatccag gttcgaagtc tccaaaggca caggcctcct ccgtgcccac
tgcacaaccc 60caagcagagg gcagcctcgc caaggcaacc acagccccag ccaccacccg
taacacagga 120agaggaggag aagagaagaa gaaggagaag gagaaagagg
aacaagaaga gagagagaca 180aagaccggtg cagtcgacg 19923866PRTHomo
sapiens 238Val Asp Pro Gly Ser Lys Ser Pro Lys Ala Gln Ala Ser Ser
Val Pro1 5 10 15Thr Ala Gln Pro Gln Ala Glu Gly Ser Leu Ala Lys Ala
Thr Thr Ala 20 25 30Pro Ala Thr Thr Arg Asn Thr Gly Arg Gly Gly Glu
Glu Lys Lys Lys 35 40 45Glu Lys Glu Lys Glu Glu Gln Glu Glu Arg Glu
Thr Lys Thr Gly Ala 50 55 60Val Asp65239222DNAArtificial
sequenceDescription of Artificial Synthetic nucleotide sequence
239gagtctccaa aggcacaggc ctcctccgtg cccactgcac aaccccaagc
agagggcagc 60ctcgccaagg caaccacagc cccagccacc acccgtaaca caggaagagg
aggagaagag 120aagaagaagg agaaggagaa agaggaacaa gaagagagag
agacaaagac accagagtgt 180ccgagccaca cccagcctct tggcgtctac
ctgctaaccc ct 22224074PRTArtificial sequenceDescription of
Artificial Synthetic amino acid sequence 240Glu Ser Pro Lys Ala Gln
Ala Ser Ser Val Pro Thr Ala Gln Pro Gln1 5 10 15Ala Glu Gly Ser Leu
Ala Lys Ala Thr Thr Ala Pro Ala Thr Thr Arg 20 25 30Asn Thr Gly Arg
Gly Gly Glu Glu Lys Lys Lys Glu Lys Glu Lys Glu 35 40 45Glu Gln Glu
Glu Arg Glu Thr Lys Thr Pro Glu Cys Pro Ser His Thr 50 55 60Gln Pro
Leu Gly Val Tyr Leu Leu Thr Pro65 70241366DNAArtificial
sequenceDescription of Artificial Synthetic nucleotide sequence
241caggcttatc tacagcagtc tggggctgag tcggtgaggc ctggggcctc
agtgaagatg 60tcctgcaagg cttctggcta cacatttacc agttacaata tgcactgggt
aaagcagaca 120cctagacagg gcctggaatg gattggagct atttatccag
gaaatggtga tacttcctac 180aatcagaagt tcaagggcaa ggccacactg
actgtagaca aatcctccag cacagcctac 240atgcagctca gcagcctgac
atctgaagac tctgcggtct atttctgtgc aagagtggtg 300tactatagta
actcttactg gtacttcgat gtctggggca cagggaccac ggtcaccgtc 360tcttct
366242122PRTArtificial sequenceDescription of Artificial Synthetic
amino acid sequence 242Gln Ala Tyr Leu Gln Gln Ser Gly Ala Glu Ser
Val Arg Pro Gly Ala1 5 10 15Ser Val Lys Met Ser Cys Lys Ala Ser Gly
Tyr Thr Phe Thr Ser Tyr 20 25 30Asn Met His Trp Val Lys Gln Thr Pro
Arg Gln Gly Leu Glu Trp Ile 35 40 45Gly Ala Ile Tyr Pro Gly Asn Gly
Asp Thr Ser Tyr Asn Gln Lys Phe 50 55 60Lys Gly Lys Ala Thr Leu Thr
Val Asp Lys Ser Ser Ser Thr Ala Tyr65 70 75 80Met Gln Leu Ser Ser
Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95Ala Arg Val Val
Tyr Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp 100 105 110Gly Thr
Gly Thr Thr Val Thr Val Ser Ser 115 120243816DNAArtificial
sequenceDescription of Artificial Synthetic nucleotide sequence
243aagcttgccg ccatggattt tcaagtgcag attttcagct tcctgctaat
cagtgcttca 60gtcataattg ccagaggaca aattgttctc tcccagtctc cagcaatcct
gtctgcatct 120ccaggggaga aggtcacaat gacttgcagg gccagctcaa
gtgtaagtta catgcactgg 180taccagcaga agccaggatc ctcccccaaa
ccctggattt atgccccatc caacctggct 240tctggagtcc ctgctcgctt
cagtggcagt gggtctggga cctcttactc tctcacaatc 300agcagagtgg
aggctgaaga tgctgccact tattactgcc agcagtggag ttttaaccca
360cccacgttcg gtgctgggac caagctggag ctgaaagatg gcggtggctc
gggcggtggt 420ggatctggag gaggtgggag ctctcaggct tatctacagc
agtctggggc tgagtcggtg 480aggcctgggg cctcagtgaa gatgtcctgc
aaggcttctg gctacacatt taccagttac 540aatatgcact gggtaaagca
gacacctaga cagggcctgg aatggattgg agctatttat 600ccaggaaatg
gtgatacttc ctacaatcag aagttcaagg gcaaggccac actgactgta
660gacaaatcct ccagcacagc ctacatgcag ctcagcagcc tgacatctga
agactctgcg 720gtctatttct gtgcaagagt ggtgtactat agtaactctt
actggtactt cgatgtctgg 780ggcacaggga ccacggtcac cgtctcttct gatcag
816244268PRTArtificial sequenceDescription of Artificial Synthetic
amino acid sequence 244Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu
Leu Ile Ser Ala Ser1 5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu
Ser Gln Ser Pro Ala Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val
Thr Met Thr Cys Arg Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp
Tyr Gln Gln Lys Pro Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala
Pro Ser Asn Leu Ala Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly
Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu
Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe
Asn Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 115 120
125Asp Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser
130 135 140Gln Ala Tyr Leu Gln Gln Ser Gly Ala Glu Ser Val Arg Pro
Gly Ala145 150 155 160Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr
Thr Phe Thr Ser Tyr 165 170 175Asn Met His Trp Val Lys Gln Thr Pro
Arg Gln Gly Leu Glu Trp Ile 180 185 190Gly Ala Ile Tyr Pro Gly Asn
Gly Asp Thr Ser Tyr Asn Gln Lys Phe 195 200 205Lys Gly Lys Ala Thr
Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 210 215 220Met Gln Leu
Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys225 230 235
240Ala Arg Val Val Tyr Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp
245 250 255Gly Thr Gly Thr Thr Val Thr Val Ser Ser Asp Gln 260
2652451521DNAArtificial sequenceDescription of Artificial Synthetic
nucleotide sequence 245aagcttgccg ccatggattt tcaagtgcag attttcagct
tcctgctaat cagtgcttca 60gtcataattg ccagaggaca aattgttctc tcccagtctc
cagcaatcct gtctgcatct 120ccaggggaga aggtcacaat gacttgcagg
gccagctcaa gtgtaagtta catgcactgg 180taccagcaga agccaggatc
ctcccccaaa ccctggattt atgccccatc caacctggct 240tctggagtcc
ctgctcgctt cagtggcagt gggtctggga cctcttactc tctcacaatc
300agcagagtgg aggctgaaga tgctgccact tattactgcc agcagtggag
ttttaaccca 360cccacgttcg gtgctgggac caagctggag ctgaaagatg
gcggtggctc gggcggtggt 420ggatctggag gaggtgggag ctctcaggct
tatctacagc agtctggggc tgagtctgtg 480aggcctgggg cctcagtgaa
gatgtcctgc aaggcttctg gctacacatt taccagttac 540aatatgcact
gggtaaagca gacacctaga cagggcctgg aatggattgg agctatttat
600ccaggaaatg gtgatacttc ctacaatcag aagttcaagg gcaaggccac
actgactgta 660gacaaatcct ccagcacagc ctacatgcag ctcagcagcc
tgacatctga agactctgcg 720gtctatttct gtgcaagagt ggtgtactat
agtaactctt actggtactt cgatgtctgg 780ggcacaggga ccacggtcac
cgtctcttct gatcaggagc ccaaatcttg tgacaaaact 840cacacatctc
caccgtgctc agcacctgaa ctcctgggtg gaccgtcagt cttcctcttc
900cccccaaaac ccaaggacac cctcatgatc tcccggaccc ctgaggtcac
atgcgtggtg 960gtggacgtga gccacgaaga ccctgaggtc aagttcaact
ggtacgtgga cggcgtggag 1020gtgcataatg ccaagacaaa gccgcgggag
gagcagtaca acagcacgta ccgtgtggtc 1080agcgtcctca ccgtcctgca
ccaggactgg ctgaatggca aggagtacaa gtgcaaggtc 1140tccaacaaag
ccctcccagc ccccatcgag aaaacaatct ccaaagccaa agggcagccc
1200cgagaaccac aggtgtacac cctgccccca tcccgggatg agctgaccaa
gaaccaggtc 1260agcctgacct gcctggtcaa aggcttctat ccaagcgaca
tcgccgtgga gtgggagagc 1320aatgggcagc cggagaacaa ctacaagacc
acgcctcccg tgctggactc cgacggctcc 1380ttcttcctct acagcaagct
caccgtggac aagagcaggt ggcagcaggg gaacgtcttc 1440tcatgctccg
tgatgcatga ggctctgcac aaccactaca cgcagaagag cctctccctg
1500tctccgggta aatgatctag a 1521246500PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
246Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1
5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu Ser Gln Ser Pro Ala
Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg
Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro
Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala Pro Ser Asn Leu Ala
Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr
Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu Ala Glu Asp Ala Ala
Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe Asn Pro Pro Thr Phe
Gly Ala Gly Thr Lys Leu Glu Leu Lys 115 120 125Asp Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser 130 135 140Gln Ala Tyr
Leu Gln Gln Ser Gly Ala Glu Ser Val Arg Pro Gly Ala145 150 155
160Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
165 170 175Asn Met His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Glu
Trp Ile 180 185 190Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr
Asn Gln Lys Phe 195 200 205Lys Gly Lys Ala Thr Leu Thr Val Asp Lys
Ser Ser Ser Thr Ala Tyr 210 215 220Met Gln Leu Ser Ser Leu Thr Ser
Glu Asp Ser Ala Val Tyr Phe Cys225 230 235 240Ala Arg Val Val Tyr
Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp 245 250 255Gly Thr Gly
Thr Thr Val Thr Val Ser Ser Asp Gln Glu Pro Lys Ser 260 265 270Cys
Asp Lys Thr His Thr Ser Pro Pro Cys Ser Ala Pro Glu Leu Leu 275 280
285Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
290 295 300Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
Val Ser305 310 315 320His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
Val Asp Gly Val Glu 325 330 335Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln Tyr Asn Ser Thr 340 345 350Tyr Arg Val Val Ser Val Leu
Thr Val Leu His Gln Asp Trp Leu Asn 355 360 365Gly Lys Glu Tyr Lys
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro 370 375 380Ile Glu Lys
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln385 390 395
400Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
405 410 415Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
Ala Val 420 425 430Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
Lys Thr Thr Pro 435 440 445Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
Leu Tyr Ser Lys Leu Thr 450 455 460Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn Val Phe Ser Cys Ser Val465 470 475 480Met His Glu Ala Leu
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 485 490 495Ser Pro Gly
Lys 5002471803DNAArtificial sequenceDescription of Artificial
Synthetic nucleotide sequence 247aagcttgccg ccatggattt tcaagtgcag
attttcagct tcctgctaat cagtgcttca 60gtcataattg ccagaggaca aattgttctc
tcccagtctc cagcaatcct gtctgcatct 120ccaggggaga aggtcacaat
gacttgcagg gccagctcaa gtgtaagtta catgcactgg 180taccagcaga
agccaggatc ctcccccaaa ccctggattt atgccccatc caacctggct
240tctggagtcc ctgctcgctt cagtggcagt gggtctggga cctcttactc
tctcacaatc 300agcagagtgg aggctgaaga tgctgccact tattactgcc
agcagtggag ttttaaccca 360cccacgttcg gtgctgggac caagctggag
ctgaaagatg gcggtggctc gggcggtggt 420ggatctggag gaggtgggag
ctctcaggct tatctacagc agtctggggc tgagtctgtg 480aggcctgggg
cctcagtgaa gatgtcctgc aaggcttctg gctacacatt taccagttac
540aatatgcact gggtaaagca gacacctaga cagggcctgg aatggattgg
agctatttat 600ccaggaaatg gtgatacttc ctacaatcag aagttcaagg
gcaaggccac actgactgta 660gacaaatcct ccagcacagc ctacatgcag
ctcagcagcc tgacatctga agactctgcg 720gtctatttct gtgcaagagt
ggtgtactat agtaactctt actggtactt cgatgtctgg 780ggcacaggga
ccacggtcac cgtctcttct gatcacgtct gctccaggga cttcaccccg
840cccaccgtga agatcttaca gtcgtcctgc gacggcggcg ggcacttccc
cccgaccatc 900cagctcctgt gcctcgtctc tgggtacacc ccagggacta
tcaacatcac ctggctggag 960gacgggcagg tcatggacgt ggacttgtcc
accgcctcta ccacgcagga gggtgagctg 1020gcctccacac aaagcgagct
caccctcagc cagaagcact ggctgtcaga ccgcacctac 1080acctgccagg
tcacctatca aggtcacacc tttgaggaca gcaccaagaa gtgtgcagat
1140tccaacccga gaggggtgag cgcctaccta agccggccca gcccgttcga
cctgttcatc 1200cgcaagtcgc ccacgatcac ctgtctggtg gtggacctgg
cacccagcaa ggggaccgtg 1260aacctgacct ggtcccgggc cagtgggaag
cctgtgaacc actccaccag aaaggaggag 1320aagcagcgca atggcacgtt
aaccgtcacg tccaccctgc cggtgggcac ccgagactgg 1380atcgaggggg
agacctacca gtgcagggtg acccaccccc acctgcccag ggccctcatg
1440cggtccacga ccaagaccag cggcccgcgt gctgccccgg aagtctatgc
gtttgcgacg 1500ccggagtggc cggggagccg ggacaagcgc accctcgcct
gcctgatcca gaacttcatg 1560cctgaggaca tctcggtgca gtggctgcac
aacgaggtgc agctcccgga cgcccggcac 1620agcacgacgc agccccgcaa
gaccaagggc tccggcttct tcgtcttcag ccgcctggag 1680gtgaccaggg
ccgaatggga gcagaaagat gagttcatct gccgtgcagt ccatgaggca
1740gcgagcccct cacagaccgt ccagcgagcg gtgtctgtaa atcccggtaa
atgataatct 1800aga 1803248593PRTArtificial sequenceDescription of
Artificial Synthetic amino acid sequence 248Met Asp Phe Gln Val Gln
Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1 5 10 15Val Ile Ile Ala Arg
Gly Gln Ile Val Leu Ser Gln Ser Pro Ala Ile 20 25 30Leu Ser Ala Ser
Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser 35 40 45Ser Ser Val
Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Ser Ser 50 55 60Pro Lys
Pro Trp Ile Tyr Ala Pro Ser Asn Leu Ala Ser Gly Val Pro65 70 75
80Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile
85 90 95Ser Arg Val Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln
Trp 100 105 110Ser Phe Asn Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu
Glu Leu Lys 115 120 125Asp Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Ser 130 135 140Gln Ala Tyr Leu Gln Gln Ser Gly Ala
Glu Ser Val Arg Pro Gly Ala145 150 155 160Ser Val Lys Met Ser Cys
Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 165 170 175Asn Met His Trp
Val Lys Gln Thr Pro Arg Gln Gly Leu Glu Trp Ile 180 185 190Gly Ala
Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe 195 200
205Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
210 215 220Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr
Phe Cys225 230 235 240Ala Arg Val Val Tyr Tyr Ser Asn Ser Tyr Trp
Tyr Phe Asp Val Trp 245 250 255Gly Thr Gly Thr Thr Val Thr Val Ser
Ser Asp His Val Cys Ser Arg 260 265 270Asp Phe Thr Pro Pro Thr Val
Lys Ile Leu Gln Ser Ser Cys Asp Gly 275 280 285Gly Gly His Phe Pro
Pro Thr Ile Gln Leu Leu Cys Leu Val Ser Gly 290 295 300Tyr Thr Pro
Gly Thr Ile Asn Ile Thr Trp Leu Glu Asp Gly Gln Val305 310 315
320Met Asp Val Asp Leu Ser Thr Ala Ser Thr Thr Gln Glu Gly Glu Leu
325 330 335Ala Ser Thr Gln Ser Glu Leu Thr Leu Ser Gln Lys His Trp
Leu Ser 340 345 350Asp Arg Thr Tyr Thr Cys Gln Val Thr Tyr Gln Gly
His Thr Phe Glu 355 360 365Asp Ser Thr Lys Lys Cys Ala Asp Ser Asn
Pro Arg Gly Val Ser Ala 370 375 380Tyr Leu Ser Arg Pro Ser Pro Phe
Asp Leu Phe Ile Arg Lys Ser Pro385 390
395 400Thr Ile Thr Cys Leu Val Val Asp Leu Ala Pro Ser Lys Gly Thr
Val 405 410 415Asn Leu Thr Trp Ser Arg Ala Ser Gly Lys Pro Val Asn
His Ser Thr 420 425 430Arg Lys Glu Glu Lys Gln Arg Asn Gly Thr Leu
Thr Val Thr Ser Thr 435 440 445Leu Pro Val Gly Thr Arg Asp Trp Ile
Glu Gly Glu Thr Tyr Gln Cys 450 455 460Arg Val Thr His Pro His Leu
Pro Arg Ala Leu Met Arg Ser Thr Thr465 470 475 480Lys Thr Ser Gly
Pro Arg Ala Ala Pro Glu Val Tyr Ala Phe Ala Thr 485 490 495Pro Glu
Trp Pro Gly Ser Arg Asp Lys Arg Thr Leu Ala Cys Leu Ile 500 505
510Gln Asn Phe Met Pro Glu Asp Ile Ser Val Gln Trp Leu His Asn Glu
515 520 525Val Gln Leu Pro Asp Ala Arg His Ser Thr Thr Gln Pro Arg
Lys Thr 530 535 540Lys Gly Ser Gly Phe Phe Val Phe Ser Arg Leu Glu
Val Thr Arg Ala545 550 555 560Glu Trp Glu Gln Lys Asp Glu Phe Ile
Cys Arg Ala Val His Glu Ala 565 570 575Ala Ser Pro Ser Gln Thr Val
Gln Arg Ala Val Ser Val Asn Pro Gly 580 585
590Lys2491822DNAArtificial sequenceDescription of Artificial
Synthetic nucleotide sequence 249aagcttgccg ccatggattt tcaagtgcag
attttcagct tcctgctaat cagtgcttca 60gtcataattg ccagaggaca aattgttctc
tcccagtctc cagcaatcct gtctgcatct 120ccaggggaga aggtcacaat
gacttgcagg gccagctcaa gtgtaagtta catgcactgg 180taccagcaga
agccaggatc ctcccccaaa ccctggattt atgccccatc caacctggct
240tctggagtcc ctgctcgctt cagtggcagt gggtctggga cctcttactc
tctcacaatc 300agcagagtgg aggctgaaga tgctgccact tattactgcc
agcagtggag ttttaaccca 360cccacgttcg gtgctgggac caagctggag
ctgaaagatg gcggtggctc gggcggtggt 420ggatctggag gaggtgggag
ctctcaggct tatctacagc agtctggggc tgagtctgtg 480aggcctgggg
cctcagtgaa gatgtcctgc aaggcttctg gctacacatt taccagttac
540aatatgcact gggtaaagca gacacctaga cagggcctgg aatggattgg
agctatttat 600ccaggaaatg gtgatacttc ctacaatcag aagttcaagg
gcaaggccac actgactgta 660gacaaatcct ccagcacagc ctacatgcag
ctcagcagcc tgacatctga agactctgcg 720gtctatttct gtgcaagagt
ggtgtactat agtaactctt actggtactt cgatgtctgg 780ggcacaggga
ccacggtcac cgtctcttct gatcacgttc gacctgtcaa catcactgag
840cccaccttgg agctactcca ttcatcctgc gaccccaatg cattccactc
caccatccag 900ctgtactgct tcatttatgg ccacatccta aatgatgtct
ctgtcagctg gctaatggac 960gatcgggaga taactgatac acttgcacaa
actgttctaa tcaaggagga aggcaaacta 1020gcctctacct gcagtaaact
caacatcact gagcagcaat ggatgtctga aagcaccttc 1080acctgcaagg
tcacctccca aggcgtagac tatttggccc acactcggag atgcccagat
1140catgagccac ggggtgtgat tacctacctg atcccaccca gccccctgga
cctgtatcaa 1200aacggtgctc ccaagcttac ctgtctggtg gtggacctgg
aaagcgagaa gaatgtcaat 1260gtgacgtgga accaagagaa gaagacttca
gtctcagcat cccagtggta cactaagcac 1320cacaataacg ccacaactag
tatcacctcc atcctgcctg tagttgccaa ggactggatt 1380gaaggctacg
gctatcagtg catagtggac caccctgatt ttcccaagcc cattgtgcgt
1440tccatcacca agaccccagg ccagcgctca gcccccgagg tatatgtgtt
cccaccacca 1500gaggaggaga gcgaggacaa acgcacactc acctgtttga
tccagaactt cttccctgag 1560gatatctctg tgcagtggct gggggatggc
aaactgatct caaacagcca gcacagtacc 1620acaacacccc tgaaatccaa
tggctccaat caaggcttct tcatcttcag tcgcctagag 1680gtcgccaaga
cactctggac acagagaaaa cagttcacct gccaagtgat ccatgaggca
1740cttcagaaac ccaggaaact ggagaaaaca atatccacaa gccttggtaa
cacctccctc 1800cgtccatcct agtaatctag ag 1822250599PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
250Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1
5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu Ser Gln Ser Pro Ala
Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg
Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro
Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala Pro Ser Asn Leu Ala
Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr
Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu Ala Glu Asp Ala Ala
Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe Asn Pro Pro Thr Phe
Gly Ala Gly Thr Lys Leu Glu Leu Lys 115 120 125Asp Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser 130 135 140Gln Ala Tyr
Leu Gln Gln Ser Gly Ala Glu Ser Val Arg Pro Gly Ala145 150 155
160Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
165 170 175Asn Met His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Glu
Trp Ile 180 185 190Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr
Asn Gln Lys Phe 195 200 205Lys Gly Lys Ala Thr Leu Thr Val Asp Lys
Ser Ser Ser Thr Ala Tyr 210 215 220Met Gln Leu Ser Ser Leu Thr Ser
Glu Asp Ser Ala Val Tyr Phe Cys225 230 235 240Ala Arg Val Val Tyr
Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp 245 250 255Gly Thr Gly
Thr Thr Val Thr Val Ser Ser Asp His Val Arg Pro Val 260 265 270Asn
Ile Thr Glu Pro Thr Leu Glu Leu Leu His Ser Ser Cys Asp Pro 275 280
285Asn Ala Phe His Ser Thr Ile Gln Leu Tyr Cys Phe Ile Tyr Gly His
290 295 300Ile Leu Asn Asp Val Ser Val Ser Trp Leu Met Asp Asp Arg
Glu Ile305 310 315 320Thr Asp Thr Leu Ala Gln Thr Val Leu Ile Lys
Glu Glu Gly Lys Leu 325 330 335Ala Ser Thr Cys Ser Lys Leu Asn Ile
Thr Glu Gln Gln Trp Met Ser 340 345 350Glu Ser Thr Phe Thr Cys Lys
Val Thr Ser Gln Gly Val Asp Tyr Leu 355 360 365Ala His Thr Arg Arg
Cys Pro Asp His Glu Pro Arg Gly Val Ile Thr 370 375 380Tyr Leu Ile
Pro Pro Ser Pro Leu Asp Leu Tyr Gln Asn Gly Ala Pro385 390 395
400Lys Leu Thr Cys Leu Val Val Asp Leu Glu Ser Glu Lys Asn Val Asn
405 410 415Val Thr Trp Asn Gln Glu Lys Lys Thr Ser Val Ser Ala Ser
Gln Trp 420 425 430Tyr Thr Lys His His Asn Asn Ala Thr Thr Ser Ile
Thr Ser Ile Leu 435 440 445Pro Val Val Ala Lys Asp Trp Ile Glu Gly
Tyr Gly Tyr Gln Cys Ile 450 455 460Val Asp His Pro Asp Phe Pro Lys
Pro Ile Val Arg Ser Ile Thr Lys465 470 475 480Thr Pro Gly Gln Arg
Ser Ala Pro Glu Val Tyr Val Phe Pro Pro Pro 485 490 495Glu Glu Glu
Ser Glu Asp Lys Arg Thr Leu Thr Cys Leu Ile Gln Asn 500 505 510Phe
Phe Pro Glu Asp Ile Ser Val Gln Trp Leu Gly Asp Gly Lys Leu 515 520
525Ile Ser Asn Ser Gln His Ser Thr Thr Thr Pro Leu Lys Ser Asn Gly
530 535 540Ser Asn Gln Gly Phe Phe Ile Phe Ser Arg Leu Glu Val Ala
Lys Thr545 550 555 560Leu Trp Thr Gln Arg Lys Gln Phe Thr Cys Gln
Val Ile His Glu Ala 565 570 575Leu Gln Lys Pro Arg Lys Leu Glu Lys
Thr Ile Ser Thr Ser Leu Gly 580 585 590Asn Thr Ser Leu Arg Pro Ser
5952511572DNAArtificial sequenceDescription of Artificial Synthetic
nucleotide sequence 251aagcttgccg ccatggattt tcaagtgcag attttcagct
tcctgctaat cagtgcttca 60gtcataattg ccagaggaca aattgttctc tcccagtctc
cagcaatcct gtctgcatct 120ccaggggaga aggtcacaat gacttgcagg
gccagctcaa gtgtaagtta catgcactgg 180taccagcaga agccaggatc
ctcccccaaa ccctggattt atgccccatc caacctggct 240tctggagtcc
ctgctcgctt cagtggcagt gggtctggga cctcttactc tctcacaatc
300agcagagtgg aggctgaaga tgctgccact tattactgcc agcagtggag
ttttaaccca 360cccacgttcg gtgctgggac caagctggag ctgaaagatg
gcggtggctc gggcggtggt 420ggatctggag gaggtgggag ctctcaggct
tatctacagc agtctggggc tgagtctgtg 480aggcctgggg cctcagtgaa
gatgtcctgc aaggcttctg gctacacatt taccagttac 540aatatgcact
gggtaaagca gacacctaga cagggcctgg aatggattgg agctatttat
600ccaggaaatg gtgatacttc ctacaatcag aagttcaagg gcaaggccac
actgactgta 660gacaaatcct ccagcacagc ctacatgcag ctcagcagcc
tgacatctga agactctgcg 720gtctatttct gtgcaagagt ggtgtactat
agtaactctt actggtactt cgatgtctgg 780ggcacaggga ccacggtcac
cgtctcttct gatcagccag ttccctcaac tccacctacc 840ccatctccct
caactccacc taccccatct ccctcatgct gccacccccg actgtcactg
900caccgaccgg ccctcgagga cctgctctta ggttcagaag cgatcctcac
gtgcacactg 960accggcctga gagatgcctc aggtgtcacc ttcacctgga
cgccctcaag tgggaagagc 1020gctgttcaag gaccacctga ccgtgacctc
tgtggctgct acagcgtgtc cagtgtcctg 1080ccgggctgtg ccgagccatg
gaaccatggg aagaccttca cttgcactgc tgcctacccc 1140gagtccaaga
ccccgctaac cgccaccctc tcaaaatccg gaaacacatt ccggcccgag
1200gtccacctgc tgccgccgcc gtcggaggag ctggccctga acgagctggt
gacgctgacg 1260tgcctggcac gtggcttcag ccccaaggat gtgctggttc
gctggctgca ggggtcacag 1320gagctgcccc gcgagaagta cctgacttgg
gcatcccggc aggagcccag ccagggcacc 1380accaccttcg ctgtgaccag
catactgcgc gtggcagccg aggactggaa gaagggggac 1440accttctcct
gcatggtggg ccacgaggcc ctgccgctgg ccttcacaca gaagaccatc
1500gaccgcttgg cgggtaaacc cacccatgtc aatgtgtctg ttgtcatggc
ggaggtggac 1560tgataatcta ga 1572252516PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
252Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1
5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu Ser Gln Ser Pro Ala
Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg
Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro
Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala Pro Ser Asn Leu Ala
Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr
Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu Ala Glu Asp Ala Ala
Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe Asn Pro Pro Thr Phe
Gly Ala Gly Thr Lys Leu Glu Leu Lys 115 120 125Asp Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser 130 135 140Gln Ala Tyr
Leu Gln Gln Ser Gly Ala Glu Ser Val Arg Pro Gly Ala145 150 155
160Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
165 170 175Asn Met His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Glu
Trp Ile 180 185 190Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr
Asn Gln Lys Phe 195 200 205Lys Gly Lys Ala Thr Leu Thr Val Asp Lys
Ser Ser Ser Thr Ala Tyr 210 215 220Met Gln Leu Ser Ser Leu Thr Ser
Glu Asp Ser Ala Val Tyr Phe Cys225 230 235 240Ala Arg Val Val Tyr
Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp 245 250 255Gly Thr Gly
Thr Thr Val Thr Val Ser Ser Asp Gln Pro Val Pro Ser 260 265 270Thr
Pro Pro Thr Pro Ser Pro Ser Thr Pro Pro Thr Pro Ser Pro Ser 275 280
285Cys Cys His Pro Arg Leu Ser Leu His Arg Pro Ala Leu Glu Asp Leu
290 295 300Leu Leu Gly Ser Glu Ala Ile Leu Thr Cys Thr Leu Thr Gly
Leu Arg305 310 315 320Asp Ala Ser Gly Val Thr Phe Thr Trp Thr Pro
Ser Ser Gly Lys Ser 325 330 335Ala Val Gln Gly Pro Pro Asp Arg Asp
Leu Cys Gly Cys Tyr Ser Val 340 345 350Ser Ser Val Leu Pro Gly Cys
Ala Glu Pro Trp Asn His Gly Lys Thr 355 360 365Phe Thr Cys Thr Ala
Ala Tyr Pro Glu Ser Lys Thr Pro Leu Thr Ala 370 375 380Thr Leu Ser
Lys Ser Gly Asn Thr Phe Arg Pro Glu Val His Leu Leu385 390 395
400Pro Pro Pro Ser Glu Glu Leu Ala Leu Asn Glu Leu Val Thr Leu Thr
405 410 415Cys Leu Ala Arg Gly Phe Ser Pro Lys Asp Val Leu Val Arg
Trp Leu 420 425 430Gln Gly Ser Gln Glu Leu Pro Arg Glu Lys Tyr Leu
Thr Trp Ala Ser 435 440 445Arg Gln Glu Pro Ser Gln Gly Thr Thr Thr
Phe Ala Val Thr Ser Ile 450 455 460Leu Arg Val Ala Ala Glu Asp Trp
Lys Lys Gly Asp Thr Phe Ser Cys465 470 475 480Met Val Gly His Glu
Ala Leu Pro Leu Ala Phe Thr Gln Lys Thr Ile 485 490 495Asp Arg Leu
Ala Gly Lys Pro Thr His Val Asn Val Ser Val Val Met 500 505 510Ala
Glu Val Asp 5152531546DNAArtificial sequenceDescription of
Artificial Synthetic nucleotide sequence 253aagcttgccg ccatggattt
tcaagtgcag attttcagct tcctgctaat cagtgcttca 60gtcataattg ccagaggaca
aattgttctc tcccagtctc cagcaatcct gtctgcatct 120ccaggggaga
aggtcacaat gacttgcagg gccagctcaa gtgtaagtta catgcactgg
180taccagcaga agccaggatc ctcccccaaa ccctggattt atgccccatc
caacctggct 240tctggagtcc ctgctcgctt cagtggcagt gggtctggga
cctcttactc tctcacaatc 300agcagagtgg aggctgaaga tgctgccact
tattactgcc agcagtggag ttttaaccca 360cccacgttcg gtgctgggac
caagctggag ctgaaagatg gcggtggctc gggcggtggt 420ggatctggag
gaggtgggag ctctcaggct tatctacagc agtctggggc tgagtctgtg
480aggcctgggg cctcagtgaa gatgtcctgc aaggcttctg gctacacatt
taccagttac 540aatatgcact gggtaaagca gacacctaga cagggcctgg
aatggattgg agctatttat 600ccaggaaatg gtgatacttc ctacaatcag
aagttcaagg gcaaggccac actgactgta 660gacaaatcct ccagcacagc
ctacatgcag ctcagcagcc tgacatctga agactctgcg 720gtctatttct
gtgcaagagt ggtgtactat agtaactctt actggtactt cgatgtctgg
780ggcacaggga ccacggtcac cgtctcttct gatcacatct gttctcctcc
tactactcct 840cctccacctt cctgccagcc cagcctgtca ctgcagcggc
cagctcttga ggacctgctc 900ctgggttcag atgccagcat cacatgtact
ctgaatggcc tgagagatcc tgagggagct 960gtcttcacct gggagccctc
cactgggaag gatgcagtgc agaagaaagc tgtgcagaat 1020tcctgcggct
gctacagtgt gtccagcgtc ctgcctggct gtgctgagcg ctggaacagt
1080ggcgcatcat tcaagtgcac agttacccat cctgagtctg acaccttaac
tggcacaatt 1140gccaaagtca cagtgaacac cttcccaccc caggtccacc
tgctaccgcc gccgtcggag 1200gagctggccc tgaatgagct cgtgtccctg
acatgcctgg tgcgagcttt caaccctaaa 1260gaagtgctgg tgcgatggct
gcatggaaat gaggagctgt ccccagaaag ctacctagtg 1320tttgagcccc
taaaggagcc aggcgaggga gccaccacct acctggtgac aagcgtgttg
1380cgtgtatcag ctgaaatctg gaaacagggt gaccagtact cctgcatggt
gggccacgag 1440gccttgccca tgaacttcac ccagaagacc atcgaccgtc
tgtcgggtaa acccaccaat 1500gtcagcgtgt ctgtgatcat gtcagaggga
gattgataat ctagat 1546254507PRTArtificial sequenceDescription of
Artificial Synthetic amino acid sequence 254Met Asp Phe Gln Val Gln
Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1 5 10 15Val Ile Ile Ala Arg
Gly Gln Ile Val Leu Ser Gln Ser Pro Ala Ile 20 25 30Leu Ser Ala Ser
Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser 35 40 45Ser Ser Val
Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Ser Ser 50 55 60Pro Lys
Pro Trp Ile Tyr Ala Pro Ser Asn Leu Ala Ser Gly Val Pro65 70 75
80Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile
85 90 95Ser Arg Val Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln
Trp 100 105 110Ser Phe Asn Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu
Glu Leu Lys 115 120 125Asp Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Ser 130 135 140Gln Ala Tyr Leu Gln Gln Ser Gly Ala
Glu Ser Val Arg Pro Gly Ala145 150 155 160Ser Val Lys Met Ser Cys
Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 165 170 175Asn Met His Trp
Val Lys Gln Thr Pro Arg Gln Gly Leu Glu Trp Ile 180 185 190Gly Ala
Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe 195 200
205Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
210 215 220Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr
Phe Cys225 230 235 240Ala Arg Val Val Tyr Tyr Ser Asn Ser Tyr Trp
Tyr Phe Asp Val Trp 245 250 255Gly Thr Gly
Thr Thr Val Thr Val Ser Ser Asp His Ile Cys Ser Pro 260 265 270Pro
Thr Thr Pro Pro Pro Pro Ser Cys Gln Pro Ser Leu Ser Leu Gln 275 280
285Arg Pro Ala Leu Glu Asp Leu Leu Leu Gly Ser Asp Ala Ser Ile Thr
290 295 300Cys Thr Leu Asn Gly Leu Arg Asp Pro Glu Gly Ala Val Phe
Thr Trp305 310 315 320Glu Pro Ser Thr Gly Lys Asp Ala Val Gln Lys
Lys Ala Val Gln Asn 325 330 335Ser Cys Gly Cys Tyr Ser Val Ser Ser
Val Leu Pro Gly Cys Ala Glu 340 345 350Arg Trp Asn Ser Gly Ala Ser
Phe Lys Cys Thr Val Thr His Pro Glu 355 360 365Ser Asp Thr Leu Thr
Gly Thr Ile Ala Lys Val Thr Val Asn Thr Phe 370 375 380Pro Pro Gln
Val His Leu Leu Pro Pro Pro Ser Glu Glu Leu Ala Leu385 390 395
400Asn Glu Leu Val Ser Leu Thr Cys Leu Val Arg Ala Phe Asn Pro Lys
405 410 415Glu Val Leu Val Arg Trp Leu His Gly Asn Glu Glu Leu Ser
Pro Glu 420 425 430Ser Tyr Leu Val Phe Glu Pro Leu Lys Glu Pro Gly
Glu Gly Ala Thr 435 440 445Thr Tyr Leu Val Thr Ser Val Leu Arg Val
Ser Ala Glu Ile Trp Lys 450 455 460Gln Gly Asp Gln Tyr Ser Cys Met
Val Gly His Glu Ala Leu Pro Met465 470 475 480Asn Phe Thr Gln Lys
Thr Ile Asp Arg Leu Ser Gly Lys Pro Thr Asn 485 490 495Val Ser Val
Ser Val Ile Met Ser Glu Gly Asp 500 505255742DNAArtificial
sequenceDescription of Artificial Synthetic nucleotide sequence
255gttgttgatc acatctgttc tcctcctact actcctcctc caccttcctg
ccagcccagc 60ctgtcactgc agcggccagc tcttgaggac ctgctcctgg gttcagatgc
cagcatcaca 120tgtactctga atggcctgag agatcctgag ggagctgtct
tcacctggga gccctccact 180gggaaggatg cagtgcagaa gaaagctgtg
cagaattcct gcggctgcta cagtgtgtcc 240agcgtcctgc ctggctgtgc
tgagcgctgg aacagtggcg catcattcaa gtgcacagtt 300acccatcctg
agtctgacac cttaactggc acaattgcca aagtcacagt gaacaccttc
360ccaccccagg tccacctgct accgccgccg tcggaggagc tggccctgaa
tgagctcgtg 420tccctgacat gcctggtgcg agctttcaac cctaaagaag
tgctggtgcg atggctgcat 480ggaaatgagg agctgtcccc agaaagctac
ctagtgtttg agcccctaaa ggagccaggc 540gagggagcca ccacctacct
ggtgacaagc gtgttgcgtg tatcagctga aatctggaaa 600cagggtgacc
agtactcctg catggtgggc cacgaggcct tgcccatgaa cttcacccag
660aagaccatcg accgtctgtc gggtaaaccc accaatgtca gcgtgtctgt
gatcatgtca 720gagggagatt gataatctag at 742256241PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
256Asp His Ile Cys Ser Pro Pro Thr Thr Pro Pro Pro Pro Ser Cys Gln1
5 10 15Pro Ser Leu Ser Leu Gln Arg Pro Ala Leu Glu Asp Leu Leu Leu
Gly 20 25 30Ser Asp Ala Ser Ile Thr Cys Thr Leu Asn Gly Leu Arg Asp
Pro Glu 35 40 45Gly Ala Val Phe Thr Trp Glu Pro Ser Thr Gly Lys Asp
Ala Val Gln 50 55 60Lys Lys Ala Val Gln Asn Ser Cys Gly Cys Tyr Ser
Val Ser Ser Val65 70 75 80Leu Pro Gly Cys Ala Glu Arg Trp Asn Ser
Gly Ala Ser Phe Lys Cys 85 90 95Thr Val Thr His Pro Glu Ser Asp Thr
Leu Thr Gly Thr Ile Ala Lys 100 105 110Val Thr Val Asn Thr Phe Pro
Pro Gln Val His Leu Leu Pro Pro Pro 115 120 125Ser Glu Glu Leu Ala
Leu Asn Glu Leu Val Ser Leu Thr Cys Leu Val 130 135 140Arg Ala Phe
Asn Pro Lys Glu Val Leu Val Arg Trp Leu His Gly Asn145 150 155
160Glu Glu Leu Ser Pro Glu Ser Tyr Leu Val Phe Glu Pro Leu Lys Glu
165 170 175Pro Gly Glu Gly Ala Thr Thr Tyr Leu Val Thr Ser Val Leu
Arg Val 180 185 190Ser Ala Glu Ile Trp Lys Gln Gly Asp Gln Tyr Ser
Cys Met Val Gly 195 200 205His Glu Ala Leu Pro Met Asn Phe Thr Gln
Lys Thr Ile Asp Arg Leu 210 215 220Ser Gly Lys Pro Thr Asn Val Ser
Val Ser Val Ile Met Ser Glu Gly225 230 235
240Asp257327DNAArtificial sequenceDescription of Artificial
Synthetic nucleotide sequence 257cctgaactcc tggggggacc gtcagtcttc
ctcttccccc caaaacccaa ggacaccctc 60atgatctccc ggacccctga ggtcacatgc
gtggtggtgg acgtgagcca cgaagaccct 120gaggtcaagt tcaactggta
cgtggacggc gtggaggtgc ataatgccaa gacaaagccg 180cgggaggagc
agtacaacag cacgtaccgt gtggtcagcg tcctcaccgt cctgcaccag
240gactggctga atggcaagga gtacaagtgc tcggtctcca acaaagccct
cccagccccc 300atcgagaaaa caatctccaa agccaaa 327258109PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
258Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro1
5 10 15Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
Val 20 25 30Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
Tyr Val 35 40 45Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln 50 55 60Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
Val Leu His Gln65 70 75 80Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
Ser Val Ser Asn Lys Ala 85 90 95Leu Pro Ala Pro Ile Glu Lys Thr Ile
Ser Lys Ala Lys 100 105259657DNAArtificial sequenceDescription of
Artificial Synthetic nucleotide sequence 259cctgaactcc tggggggacc
gtcagtcttc ctcttccccc caaaacccaa ggacaccctc 60atgatctccc ggacccctga
ggtcacatgc gtggtggtgg acgtgagcca cgaagaccct 120gaggtcaagt
tcaactggta cgtggacggc gtggaggtgc ataatgccaa gacaaagccg
180cgggaggagc agtacaacag cacgtaccgt gtggtcagcg tcctcaccgt
cctgcaccag 240gactggctga atggcaagga gtacaagtgc tcggtctcca
acaaagccct cccagccccc 300atcgagaaaa caatctccaa agccaaaggg
cagccccgag aaccacaggt gtacaccctg 360cccccatccc gggatgagct
gaccaagaac caggtcagcc tgacctgcct ggtcaaaggc 420ttctatccca
gcgacatcgc cgtggagtgg gagagcaatg ggcagccgga gaacaactac
480aagaccacgc ctcccgtgct ggactccgac ggctccttct tcctctacag
caagctcacc 540gtggacaaga gcaggtggca gcaggggaac gtcttctcat
gctccgtgat gcatgaggct 600ctgcacaacc actacacgca gaagagcctc
tccctgtctc cgggtaaatg atctaga 657260216PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
260Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro1
5 10 15Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
Val 20 25 30Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
Tyr Val 35 40 45Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln 50 55 60Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
Val Leu His Gln65 70 75 80Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
Ser Val Ser Asn Lys Ala 85 90 95Leu Pro Ala Pro Ile Glu Lys Thr Ile
Ser Lys Ala Lys Gly Gln Pro 100 105 110Arg Glu Pro Gln Val Tyr Thr
Leu Pro Pro Ser Arg Asp Glu Leu Thr 115 120 125Lys Asn Gln Val Ser
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 130 135 140Asp Ile Ala
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr145 150 155
160Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
165 170 175Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
Val Phe 180 185 190Ser Cys Ser Val Met His Glu Ala Leu His Asn His
Tyr Thr Gln Lys 195 200 205Ser Leu Ser Leu Ser Pro Gly Lys 210
215261712DNAArtificial sequenceDescription of Artificial Synthetic
nucleotide sequence 261tgatcaggag cccaaatctt ctgacaaaac tcacacatcc
ccaccgtcct cagcacctga 60actcctgggg ggaccgtcag tcttcctctt ccccccaaaa
cccaaggaca ccctcatgat 120ctcccggacc cctgaggtca catgcgtggt
ggtggacgtg agccacgaag accctgaggt 180caagttcaac tggtacgtgg
acggcgtgga ggtgcataat gccaagacaa agccgcggga 240ggagcagtac
aacagcacgt accgtgtggt cagcgtcctc accgtcctgc accaggactg
300gctgaatggc aaggagtaca agtgcctggt ctccaacaaa gccctcccag
cccccatcga 360gaaaacaatc tccaaagcca aagggcagcc ccgagaacca
caggtgtaca ccctgccccc 420atcccgggat gagctgacca agaaccaggt
cagcctgacc tgcctggtca aaggcttcta 480tcccagcgac atcgccgtgg
agtgggagag caatgggcag ccggagaaca actacaagac 540cacgcctccc
gtgctggact ccgacggctc cttcttcctc tacagcaagc tcaccgtgga
600caagagcagg tggcagcagg ggaacgtctt ctcatgctcc gtgatgcatg
aggctctgca 660caaccactac acgcagaaga gcctctccct gtctccgggt
aaatgatcta ga 712262234PRTArtificial sequenceDescription of
Artificial Synthetic amino acid sequence 262Asp Gln Glu Pro Lys Ser
Ser Asp Lys Thr His Thr Ser Pro Pro Ser1 5 10 15Ser Ala Pro Glu Leu
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 20 25 30Lys Pro Lys Asp
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 35 40 45Val Val Val
Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 50 55 60Tyr Val
Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu65 70 75
80Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
85 90 95His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Leu Val Ser
Asn 100 105 110Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys
Ala Lys Gly 115 120 125Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
Pro Ser Arg Asp Glu 130 135 140Leu Thr Lys Asn Gln Val Ser Leu Thr
Cys Leu Val Lys Gly Phe Tyr145 150 155 160Pro Ser Asp Ile Ala Val
Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 165 170 175Asn Tyr Lys Thr
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 180 185 190Leu Tyr
Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 195 200
205Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
210 215 220Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys225
2302631521DNAArtificial sequenceDescription of Artificial Synthetic
nucleotide sequence 263aagcttgccg ccatggattt tcaagtgcag attttcagct
tcctgctaat cagtgcttca 60gtcataattg ccagaggaca aattgttctc tcccagtctc
cagcaatcct gtctgcatct 120ccaggggaga aggtcacaat gacttgcagg
gccagctcaa gtgtaagtta catgcactgg 180taccagcaga agccaggatc
ctcccccaaa ccctggattt atgccccatc caacctggct 240tctggagtcc
ctgctcgctt cagtggcagt gggtctggga cctcttactc tctcacaatc
300agcagagtgg aggctgaaga tgctgccact tattactgcc agcagtggag
ttttaaccca 360cccacgttcg gtgctgggac caagctggag ctgaaagatg
gcggtggctc gggcggtggt 420ggatctggag gaggtgggag ctctcaggct
tatctacagc agtctggggc tgagtcggtg 480aggcctgggg cctcagtgaa
gatgtcctgc aaggcttctg gctacacatt taccagttac 540aatatgcact
gggtaaagca gacacctaga cagggcctgg aatggattgg agctatttat
600ccaggaaatg gtgatacttc ctacaatcag aagttcaagg gcaaggccac
actgactgta 660gacaaatcct ccagcacagc ctacatgcag ctcagcagcc
tgacatctga agactctgcg 720gtctatttct gtgcaagagt ggtgtactat
agtaactctt actggtactt cgatgtctgg 780ggcacaggga ccacggtcac
cgtctcttct gatcaggagc ccaaatcttc tgacaaaact 840cacacatccc
caccgtcctc agcacctgaa ctcctggggg gaccgtcagt cttcctcttc
900cccccaaaac ccaaggacac cctcatgatc tcccggaccc ctgaggtcac
atgcgtggtg 960gtggacgtga gccacgaaga ccctgaggtc aagttcaact
ggtacgtgga cggcgtggag 1020gtgcataatg ccaagacaaa gccgcgggag
gagcagtaca acagcacgta ccgtgtggtc 1080agcgtcctca ccgtcctgca
ccaggactgg ctgaatggca aggagtacaa gtgctcggtc 1140tccaacaaag
ccctcccagc ccccatcgag aaaacaatct ccaaagccaa agggcagccc
1200cgagaaccac aggtgtacac cctgccccca tcccgggatg agctgaccaa
gaaccaggtc 1260agcctgacct gcctggtcaa aggcttctat cccagcgaca
tcgccgtgga gtgggagagc 1320aatgggcagc cggagaacaa ctacaagacc
acgcctcccg tgctggactc cgacggctcc 1380ttcttcctct acagcaagct
caccgtggac aagagcaggt ggcagcaggg gaacgtcttc 1440tcatgctccg
tgatgcatga ggctctgcac aaccactaca cgcagaagag cctctccctg
1500tctccgggta aatgatctag a 1521264500PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
264Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1
5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu Ser Gln Ser Pro Ala
Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg
Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro
Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala Pro Ser Asn Leu Ala
Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr
Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu Ala Glu Asp Ala Ala
Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe Asn Pro Pro Thr Phe
Gly Ala Gly Thr Lys Leu Glu Leu Lys 115 120 125Asp Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser 130 135 140Gln Ala Tyr
Leu Gln Gln Ser Gly Ala Glu Ser Val Arg Pro Gly Ala145 150 155
160Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
165 170 175Asn Met His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Glu
Trp Ile 180 185 190Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr
Asn Gln Lys Phe 195 200 205Lys Gly Lys Ala Thr Leu Thr Val Asp Lys
Ser Ser Ser Thr Ala Tyr 210 215 220Met Gln Leu Ser Ser Leu Thr Ser
Glu Asp Ser Ala Val Tyr Phe Cys225 230 235 240Ala Arg Val Val Tyr
Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp 245 250 255Gly Thr Gly
Thr Thr Val Thr Val Ser Ser Asp Gln Glu Pro Lys Ser 260 265 270Ser
Asp Lys Thr His Thr Ser Pro Pro Ser Ser Ala Pro Glu Leu Leu 275 280
285Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
290 295 300Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
Val Ser305 310 315 320His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
Val Asp Gly Val Glu 325 330 335Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln Tyr Asn Ser Thr 340 345 350Tyr Arg Val Val Ser Val Leu
Thr Val Leu His Gln Asp Trp Leu Asn 355 360 365Gly Lys Glu Tyr Lys
Cys Ser Val Ser Asn Lys Ala Leu Pro Ala Pro 370 375 380Ile Glu Lys
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln385 390 395
400Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
405 410 415Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
Ala Val 420 425 430Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
Lys Thr Thr Pro 435 440 445Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
Leu Tyr Ser Lys Leu Thr 450 455 460Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn Val Phe Ser Cys Ser Val465 470 475 480Met His Glu Ala Leu
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 485 490 495Ser Pro Gly
Lys 5002651521DNAArtificial sequenceDescription of Artificial
Synthetic nucleotide sequence 265aagcttgccg ccatggattt tcaagtgcag
attttcagct tcctgctaat cagtgcttca 60gtcataattg ccagaggaca aattgttctc
tcccagtctc cagcaatcct gtctgcatct 120ccaggggaga aggtcacaat
gacttgcagg gccagctcaa gtgtaagtta catgcactgg 180taccagcaga
agccaggatc ctcccccaaa ccctggattt atgccccatc caacctggct
240tctggagtcc ctgctcgctt cagtggcagt gggtctggga cctcttactc
tctcacaatc 300agcagagtgg aggctgaaga tgctgccact tattactgcc
agcagtggag ttttaaccca 360cccacgttcg gtgctgggac caagctggag
ctgaaagatg gcggtggctc gggcggtggt 420ggatctggag gaggtgggag
ctctcaggct tatctacagc agtctggggc tgagtcggtg 480aggcctgggg
cctcagtgaa gatgtcctgc aaggcttctg gctacacatt taccagttac
540aatatgcact gggtaaagca gacacctaga cagggcctgg aatggattgg
agctatttat 600ccaggaaatg gtgatacttc ctacaatcag aagttcaagg
gcaaggccac actgactgta 660gacaaatcct ccagcacagc ctacatgcag
ctcagcagcc
tgacatctga agactctgcg 720gtctatttct gtgcaagagt ggtgtactat
agtaactctt actggtactt cgatgtctgg 780ggcacaggga ccacggtcac
cgtctcttct gatcaggagc ccaaatcttc tgacaaaact 840cacacatccc
caccgtcctc agcacctgaa ctcctggggg gaccgtcagt cttcctcttc
900cccccaaaac ccaaggacac cctcatgatc tcccggaccc ctgaggtcac
atgcgtggtg 960gtggacgtga gccacgaaga ccctgaggtc aagttcaact
ggtacgtgga cggcgtggag 1020gtgcataatg ccaagacaaa gccgcgggag
gagcagtaca acagcacgta ccgtgtggtc 1080agcgtcctca ccgtcctgca
ccaggactgg ctgaatggca aggagtacaa gtgcctggtc 1140tccaacaaag
ccctcccagc ccccatcgag aaaacaatct ccaaagccaa agggcagccc
1200cgagaaccac aggtgtacac cctgccccca tcccgggatg agctgaccaa
gaaccaggtc 1260agcctgacct gcctggtcaa aggcttctat cccagcgaca
tcgccgtgga gtgggagagc 1320aatgggcagc cggagaacaa ctacaagacc
acgcctcccg tgctggactc cgacggctcc 1380ttcttcctct acagcaagct
caccgtggac aagagcaggt ggcagcaggg gaacgtcttc 1440tcatgctccg
tgatgcatga ggctctgcac aaccactaca cgcagaagag cctctccctg
1500tctccgggta aatgatctag a 1521266500PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
266Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1
5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu Ser Gln Ser Pro Ala
Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg
Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro
Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala Pro Ser Asn Leu Ala
Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr
Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu Ala Glu Asp Ala Ala
Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe Asn Pro Pro Thr Phe
Gly Ala Gly Thr Lys Leu Glu Leu Lys 115 120 125Asp Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser 130 135 140Gln Ala Tyr
Leu Gln Gln Ser Gly Ala Glu Ser Val Arg Pro Gly Ala145 150 155
160Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
165 170 175Asn Met His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Glu
Trp Ile 180 185 190Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr
Asn Gln Lys Phe 195 200 205Lys Gly Lys Ala Thr Leu Thr Val Asp Lys
Ser Ser Ser Thr Ala Tyr 210 215 220Met Gln Leu Ser Ser Leu Thr Ser
Glu Asp Ser Ala Val Tyr Phe Cys225 230 235 240Ala Arg Val Val Tyr
Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp 245 250 255Gly Thr Gly
Thr Thr Val Thr Val Ser Ser Asp Gln Glu Pro Lys Ser 260 265 270Ser
Asp Lys Thr His Thr Ser Pro Pro Ser Ser Ala Pro Glu Leu Leu 275 280
285Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
290 295 300Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
Val Ser305 310 315 320His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
Val Asp Gly Val Glu 325 330 335Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln Tyr Asn Ser Thr 340 345 350Tyr Arg Val Val Ser Val Leu
Thr Val Leu His Gln Asp Trp Leu Asn 355 360 365Gly Lys Glu Tyr Lys
Cys Leu Val Ser Asn Lys Ala Leu Pro Ala Pro 370 375 380Ile Glu Lys
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln385 390 395
400Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
405 410 415Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
Ala Val 420 425 430Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
Lys Thr Thr Pro 435 440 445Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
Leu Tyr Ser Lys Leu Thr 450 455 460Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn Val Phe Ser Cys Ser Val465 470 475 480Met His Glu Ala Leu
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 485 490 495Ser Pro Gly
Lys 5002671521DNAArtificial sequenceDescription of Artificial
Synthetic nucleotide sequence 267aagcttgccg ccatggattt tcaagtgcag
attttcagct tcctgctaat cagtgcttca 60gtcataattg ccagaggaca aattgttctc
tcccagtctc cagcaatcct gtctgcatct 120ccaggggaga aggtcacaat
gacttgcagg gccagctcaa gtgtaagtta catgcactgg 180taccagcaga
agccaggatc ctcccccaaa ccctggattt atgccccatc caacctggct
240tctggagtcc ctgctcgctt cagtggcagt gggtctggga cctcttactc
tctcacaatc 300agcagagtgg aggctgaaga tgctgccact tattactgcc
agcagtggag ttttaaccca 360cccacgttcg gtgctgggac caagctggag
ctgaaagatg gcggtggctc gggcggtggt 420ggatctggag gaggtgggag
ctctcaggct tatctacagc agtctggggc tgagtcggtg 480aggcctgggg
cctcagtgaa gatgtcctgc aaggcttctg gctacacatt taccagttac
540aatatgcact gggtaaagca gacacctaga cagggcctgg aatggattgg
agctatttat 600ccaggaaatg gtgatacttc ctacaatcag aagttcaagg
gcaaggccac actgactgta 660gacaaatcct ccagcacagc ctacatgcag
ctcagcagcc tgacatctga agactctgcg 720gtctatttct gtgcaagagt
ggtgtactat agtaactctt actggtactt cgatgtctgg 780ggcacaggga
ccacggtcac cgtctcttct gatcaggagc ccaaatcttg tgacaaaact
840cacacatccc caccgtcctc agcacctgaa ctcctggggg gaccgtcagt
cttcctcttc 900cccccaaaac ccaaggacac cctcatgatc tcccggaccc
ctgaggtcac atgcgtggtg 960gtggacgtga gccacgaaga ccctgaggtc
aagttcaact ggtacgtgga cggcgtggag 1020gtgcataatg ccaagacaaa
gccgcgggag gagcagtaca acagcacgta ccgtgtggtc 1080agcgtcctca
ccgtcctgca ccaggactgg ctgaatggca aggagtacaa gtgctcggtc
1140tccaacaaag ccctcccagc ccccatcgag aaaacaatct ccaaagccaa
agggcagccc 1200cgagaaccac aggtgtacac cctgccccca tcccgggatg
agctgaccaa gaaccaggtc 1260agcctgacct gcctggtcaa aggcttctat
cccagcgaca tcgccgtgga gtgggagagc 1320aatgggcagc cggagaacaa
ctacaagacc acgcctcccg tgctggactc cgacggctcc 1380ttcttcctct
acagcaagct caccgtggac aagagcaggt ggcagcaggg gaacgtcttc
1440tcatgctccg tgatgcatga ggctctgcac aaccactaca cgcagaagag
cctctccctg 1500tctccgggta aatgatctag a 1521268500PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
268Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1
5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu Ser Gln Ser Pro Ala
Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg
Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro
Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala Pro Ser Asn Leu Ala
Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr
Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu Ala Glu Asp Ala Ala
Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe Asn Pro Pro Thr Phe
Gly Ala Gly Thr Lys Leu Glu Leu Lys 115 120 125Asp Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser 130 135 140Gln Ala Tyr
Leu Gln Gln Ser Gly Ala Glu Ser Val Arg Pro Gly Ala145 150 155
160Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
165 170 175Asn Met His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Glu
Trp Ile 180 185 190Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr
Asn Gln Lys Phe 195 200 205Lys Gly Lys Ala Thr Leu Thr Val Asp Lys
Ser Ser Ser Thr Ala Tyr 210 215 220Met Gln Leu Ser Ser Leu Thr Ser
Glu Asp Ser Ala Val Tyr Phe Cys225 230 235 240Ala Arg Val Val Tyr
Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp 245 250 255Gly Thr Gly
Thr Thr Val Thr Val Ser Ser Asp Gln Glu Pro Lys Ser 260 265 270Cys
Asp Lys Thr His Thr Ser Pro Pro Ser Ser Ala Pro Glu Leu Leu 275 280
285Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu
290 295 300Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
Val Ser305 310 315 320His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
Val Asp Gly Val Glu 325 330 335Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln Tyr Asn Ser Thr 340 345 350Tyr Arg Val Val Ser Val Leu
Thr Val Leu His Gln Asp Trp Leu Asn 355 360 365Gly Lys Glu Tyr Lys
Cys Ser Val Ser Asn Lys Ala Leu Pro Ala Pro 370 375 380Ile Glu Lys
Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln385 390 395
400Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val
405 410 415Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
Ala Val 420 425 430Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
Lys Thr Thr Pro 435 440 445Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
Leu Tyr Ser Lys Leu Thr 450 455 460Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn Val Phe Ser Cys Ser Val465 470 475 480Met His Glu Ala Leu
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 485 490 495Ser Pro Gly
Lys 500269327DNAArtificial sequenceDescription of Artificial
Synthetic nucleotide sequence 269cctgaactcc tggggggacc gtcagtcttc
ctcttccccc caaaacccaa ggacaccctc 60atgatctccc ggacccctga ggtcacatgc
gtggtggtgg acgtgagcca cgaagaccct 120gaggtcaagt tcaactggta
cgtggacggc gtggaggtgc ataatgccaa gacaaagccg 180cgggaggagc
agtacaacag cacgtaccgt gtggtcagcg tcctcaccgt cctgcaccag
240gactggctga atggcaagga gtacaagtgc aaggtctcca acaaagccct
cccagcctcc 300atcgagaaaa caatctccaa agccaaa 327270109PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
270Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro1
5 10 15Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
Val 20 25 30Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
Tyr Val 35 40 45Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln 50 55 60Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
Val Leu His Gln65 70 75 80Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
Lys Val Ser Asn Lys Ala 85 90 95Leu Pro Ala Ser Ile Glu Lys Thr Ile
Ser Lys Ala Lys 100 105271657DNAArtificial sequenceDescription of
Artificial Synthetic nucleotide sequence 271cctgaactcc tggggggacc
gtcagtcttc ctcttccccc caaaacccaa ggacaccctc 60atgatctccc ggacccctga
ggtcacatgc gtggtggtgg acgtgagcca cgaagaccct 120gaggtcaagt
tcaactggta cgtggacggc gtggaggtgc ataatgccaa gacaaagccg
180cgggaggagc agtacaacag cacgtaccgt gtggtcagcg tcctcaccgt
cctgcaccag 240gactggctga atggcaagga gtacaagtgc aaggtctcca
acaaagccct cccagcctcc 300atcgagaaaa caatctccaa agccaaaggg
cagccccgag aaccacaggt gtacaccctg 360cccccatccc gggatgagct
gaccaagaac caggtcagcc tgacctgcct ggtcaaaggc 420ttctatccca
gcgacatcgc cgtggagtgg gagagcaatg ggcagccgga gaacaactac
480aagaccacgc ctcccgtgct ggactccgac ggctccttct tcctctacag
caagctcacc 540gtggacaaga gcaggtggca gcaggggaac gtcttctcat
gctccgtgat gcatgaggct 600ctgcacaacc actacacgca gaagagcctc
tccctgtctc cgggtaaatg atctaga 657272216PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
272Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro1
5 10 15Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
Val 20 25 30Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
Tyr Val 35 40 45Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln 50 55 60Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
Val Leu His Gln65 70 75 80Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
Lys Val Ser Asn Lys Ala 85 90 95Leu Pro Ala Ser Ile Glu Lys Thr Ile
Ser Lys Ala Lys Gly Gln Pro 100 105 110Arg Glu Pro Gln Val Tyr Thr
Leu Pro Pro Ser Arg Asp Glu Leu Thr 115 120 125Lys Asn Gln Val Ser
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 130 135 140Asp Ile Ala
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr145 150 155
160Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
165 170 175Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
Val Phe 180 185 190Ser Cys Ser Val Met His Glu Ala Leu His Asn His
Tyr Thr Gln Lys 195 200 205Ser Leu Ser Leu Ser Pro Gly Lys 210
2152731521DNAArtificial sequenceDescription of Artificial Synthetic
nucleotide sequence 273aagcttgccg ccatggattt tcaagtgcag attttcagct
tcctgctaat cagtgcttca 60gtcataattg ccagaggaca aattgttctc tcccagtctc
cagcaatcct gtctgcatct 120ccaggggaga aggtcacaat gacttgcagg
gccagctcaa gtgtaagtta catgcactgg 180taccagcaga agccaggatc
ctcccccaaa ccctggattt atgccccatc caacctggct 240tctggagtcc
ctgctcgctt cagtggcagt gggtctggga cctcttactc tctcacaatc
300agcagagtgg aggctgaaga tgctgccact tattactgcc agcagtggag
ttttaaccca 360cccacgttcg gtgctgggac caagctggag ctgaaagatg
gcggtggctc gggcggtggt 420ggatctggag gaggtgggag ctctcaggct
tatctacagc agtctggggc tgagtcggtg 480aggcctgggg cctcagtgaa
gatgtcctgc aaggcttctg gctacacatt taccagttac 540aatatgcact
gggtaaagca gacacctaga cagggcctgg aatggattgg agctatttat
600ccaggaaatg gtgatacttc ctacaatcag aagttcaagg gcaaggccac
actgactgta 660gacaaatcct ccagcacagc ctacatgcag ctcagcagcc
tgacatctga agactctgcg 720gtctatttct gtgcaagagt ggtgtactat
agtaactctt actggtactt cgatgtctgg 780ggcacaggga ccacggtcac
cgtctcttct gatcaggagc ccaaatcttc tgacaaaact 840cacacatccc
caccgtcctc agcacctgaa ctcctggggg gaccgtcagt cttcctcttc
900cccccaaaac ccaaggacac cctcatgatc tcccggaccc ctgaggtcac
atgcgtggtg 960gtggacgtga gccacgaaga ccctgaggtc aagttcaact
ggtacgtgga cggcgtggag 1020gtgcataatg ccaagacaaa gccgcgggag
gagcagtaca acagcacgta ccgtgtggtc 1080agcgtcctca ccgtcctgca
ccaggactgg ctgaatggca aggagtacaa gtgcaaggtc 1140tccaacaaag
ccctcccagc ctccatcgag aaaacaatct ccaaagccaa agggcagccc
1200cgagaaccac aggtgtacac cctgccccca tcccgggatg agctgaccaa
gaaccaggtc 1260agcctgacct gcctggtcaa aggcttctat cccagcgaca
tcgccgtgga gtgggagagc 1320aatgggcagc cggagaacaa ctacaagacc
acgcctcccg tgctggactc cgacggctcc 1380ttcttcctct acagcaagct
caccgtggac aagagcaggt ggcagcaggg gaacgtcttc 1440tcatgctccg
tgatgcatga ggctctgcac aaccactaca cgcagaagag cctctccctg
1500tctccgggta aatgatctag a 1521274500PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
274Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1
5 10 15Val Ile Ile Ala Arg Gly Gln Ile Val Leu Ser Gln Ser Pro Ala
Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg
Ala Ser 35 40 45Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro
Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala Pro Ser Asn Leu Ala
Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr
Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu Ala Glu Asp Ala Ala
Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Phe Asn Pro Pro Thr Phe
Gly Ala Gly Thr Lys Leu Glu Leu Lys 115 120 125Asp Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser 130 135 140Gln Ala Tyr
Leu Gln Gln Ser Gly Ala Glu Ser Val Arg Pro Gly Ala145 150 155
160Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
165 170 175Asn Met His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Glu
Trp Ile 180 185 190Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr
Asn Gln Lys Phe 195 200 205Lys Gly Lys Ala
Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 210 215 220Met Gln
Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys225 230 235
240Ala Arg Val Val Tyr Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp
245 250 255Gly Thr Gly Thr Thr Val Thr Val Ser Ser Asp Gln Glu Pro
Lys Ser 260 265 270Ser Asp Lys Thr His Thr Ser Pro Pro Ser Ser Ala
Pro Glu Leu Leu 275 280 285Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
Lys Pro Lys Asp Thr Leu 290 295 300Met Ile Ser Arg Thr Pro Glu Val
Thr Cys Val Val Val Asp Val Ser305 310 315 320His Glu Asp Pro Glu
Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu 325 330 335Val His Asn
Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr 340 345 350Tyr
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 355 360
365Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Ser
370 375 380Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
Pro Gln385 390 395 400Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
Thr Lys Asn Gln Val 405 410 415Ser Leu Thr Cys Leu Val Lys Gly Phe
Tyr Pro Ser Asp Ile Ala Val 420 425 430Glu Trp Glu Ser Asn Gly Gln
Pro Glu Asn Asn Tyr Lys Thr Thr Pro 435 440 445Pro Val Leu Asp Ser
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 450 455 460Val Asp Lys
Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val465 470 475
480Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu
485 490 495Ser Pro Gly Lys 5002751521DNAArtificial
sequenceDescription of Artificial Synthetic nucleotide sequence
275aagcttgccg ccatggattt tcaagtgcag attttcagct tcctgctaat
cagtgcttca 60gtcataattg ccagaggaca aattgttctc tcccagtctc cagcaatcct
gtctgcatct 120ccaggggaga aggtcacaat gacttgcagg gccagctcaa
gtgtaagtta catgcactgg 180taccagcaga agccaggatc ctcccccaaa
ccctggattt atgccccatc caacctggct 240tctggagtcc ctgctcgctt
cagtggcagt gggtctggga cctcttactc tctcacaatc 300agcagagtgg
aggctgaaga tgctgccact tattactgcc agcagtggag ttttaaccca
360cccacgttcg gtgctgggac caagctggag ctgaaagatg gcggtggctc
gggcggtggt 420ggatctggag gaggtgggag ctctcaggct tatctacagc
agtctggggc tgagtcggtg 480aggcctgggg cctcagtgaa gatgtcctgc
aaggcttctg gctacacatt taccagttac 540aatatgcact gggtaaagca
gacacctaga cagggcctgg aatggattgg agctatttat 600ccaggaaatg
gtgatacttc ctacaatcag aagttcaagg gcaaggccac actgactgta
660gacaaatcct ccagcacagc ctacatgcag ctcagcagcc tgacatctga
agactctgcg 720gtctatttct gtgcaagagt ggtgtactat agtaactctt
actggtactt cgatgtctgg 780ggcacaggga ccacggtcac cgtctcttct
gatcaggagc ccaaatcttg tgacaaaact 840cacacatccc caccgtcctc
agcacctgaa ctcctggggg gaccgtcagt cttcctcttc 900cccccaaaac
ccaaggacac cctcatgatc tcccggaccc ctgaggtcac atgcgtggtg
960gtggacgtga gccacgaaga ccctgaggtc aagttcaact ggtacgtgga
cggcgtggag 1020gtgcataatg ccaagacaaa gccgcgggag gagcagtaca
acagcacgta ccgtgtggtc 1080agcgtcctca ccgtcctgca ccaggactgg
ctgaatggca aggagtacaa gtgcaaggtc 1140tccaacaaag ccctcccagc
ctccatcgag aaaacaatct ccaaagccaa agggcagccc 1200cgagaaccac
aggtgtacac cctgccccca tcccgggatg agctgaccaa gaaccaggtc
1260agcctgacct gcctggtcaa aggcttctat cccagcgaca tcgccgtgga
gtgggagagc 1320aatgggcagc cggagaacaa ctacaagacc acgcctcccg
tgctggactc cgacggctcc 1380ttcttcctct acagcaagct caccgtggac
aagagcaggt ggcagcaggg gaacgtcttc 1440tcatgctccg tgatgcatga
ggctctgcac aaccactaca cgcagaagag cctctccctg 1500tctccgggta
aatgatctag a 1521276500PRTArtificial sequenceDescription of
Artificial Synthetic amino acid sequence 276Met Asp Phe Gln Val Gln
Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1 5 10 15Val Ile Ile Ala Arg
Gly Gln Ile Val Leu Ser Gln Ser Pro Ala Ile 20 25 30Leu Ser Ala Ser
Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser 35 40 45Ser Ser Val
Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Ser Ser 50 55 60Pro Lys
Pro Trp Ile Tyr Ala Pro Ser Asn Leu Ala Ser Gly Val Pro65 70 75
80Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile
85 90 95Ser Arg Val Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln
Trp 100 105 110Ser Phe Asn Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu
Glu Leu Lys 115 120 125Asp Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Ser 130 135 140Gln Ala Tyr Leu Gln Gln Ser Gly Ala
Glu Ser Val Arg Pro Gly Ala145 150 155 160Ser Val Lys Met Ser Cys
Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 165 170 175Asn Met His Trp
Val Lys Gln Thr Pro Arg Gln Gly Leu Glu Trp Ile 180 185 190Gly Ala
Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe 195 200
205Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
210 215 220Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr
Phe Cys225 230 235 240Ala Arg Val Val Tyr Tyr Ser Asn Ser Tyr Trp
Tyr Phe Asp Val Trp 245 250 255Gly Thr Gly Thr Thr Val Thr Val Ser
Ser Asp Gln Glu Pro Lys Ser 260 265 270Cys Asp Lys Thr His Thr Ser
Pro Pro Ser Ser Ala Pro Glu Leu Leu 275 280 285Gly Gly Pro Ser Val
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 290 295 300Met Ile Ser
Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser305 310 315
320His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu
325 330 335Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
Ser Thr 340 345 350Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
Asp Trp Leu Asn 355 360 365Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
Lys Ala Leu Pro Ala Ser 370 375 380Ile Glu Lys Thr Ile Ser Lys Ala
Lys Gly Gln Pro Arg Glu Pro Gln385 390 395 400Val Tyr Thr Leu Pro
Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val 405 410 415Ser Leu Thr
Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 420 425 430Glu
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 435 440
445Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr
450 455 460Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
Ser Val465 470 475 480Met His Glu Ala Leu His Asn His Tyr Thr Gln
Lys Ser Leu Ser Leu 485 490 495Ser Pro Gly Lys
500277327DNAArtificial sequenceDescription of Artificial Synthetic
nucleotide sequence 277cctgaactcc tggggggacc gtcagtcttc ctcttccccc
caaaacccaa ggacaccctc 60atgatctccc ggaaccctga ggtcacatgc gtggtggtgg
acgtgagcca cgaagaccct 120gaggtcaagt tcaactggta cgtggacggc
gtggaggtgc ataatgccaa gacaaagccg 180cgggaggagc agtacaacag
cacgtaccgt gtggtcagcg tcctcaccgt cctgcaccag 240gactggctga
atggcaagga gtacaagtgc aaggtctcca acaaagccct cccagccccc
300atcgagaaaa caatctccaa agccaaa 327278109PRTArtificial
sequenceDescription of Artificial Synthetic amino acid sequence
278Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro1
5 10 15Lys Asp Thr Leu Met Ile Ser Arg Asn Pro Glu Val Thr Cys Val
Val 20 25 30Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
Tyr Val 35 40 45Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln 50 55 60Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
Val Leu His Gln65 70
* * * * *
References